PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10733100-6	2000	Furthermore, cycloheximide greatly reduced LPS-induced TSG-14 mRNA up-regulation in macrophages but not in 3T3 cells.	Cycloheximide	13-26	pentraxin related gene	Mus musculus	55-61
10733100-10	2000	Inhibition of LPS-induced TSG-14 mRNA expression by IFN-gamma in macrophages was also observed in the presence of cycloheximide and in cells from STAT1 null mice, suggesting that IFN-gamma inhibits TSG-14 expression through an unconventional mechanism.	Cycloheximide	114-127	pentraxin related gene	Mus musculus	26-32
10733100-10	2000	Inhibition of LPS-induced TSG-14 mRNA expression by IFN-gamma in macrophages was also observed in the presence of cycloheximide and in cells from STAT1 null mice, suggesting that IFN-gamma inhibits TSG-14 expression through an unconventional mechanism.	Cycloheximide	114-127	interferon gamma	Mus musculus	52-61
10733100-10	2000	Inhibition of LPS-induced TSG-14 mRNA expression by IFN-gamma in macrophages was also observed in the presence of cycloheximide and in cells from STAT1 null mice, suggesting that IFN-gamma inhibits TSG-14 expression through an unconventional mechanism.	Cycloheximide	114-127	interferon gamma	Mus musculus	179-188
10688617-2	2000	Temporary inhibition of protein synthesis by cycloheximide resulted in superinduction of oxidized tryptophan-inducible CYP1A1 mRNA, protein, and 7-ethoxyresorufin O-deethylase activity in Hepa-1 cells.	Cycloheximide	45-58	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	119-125
10688617-5	2000	Temporary inhibition of protein synthesis by cycloheximide further induced oxidized tryptophan-inducible CYP1A2 mRNA as well as the protein in Hepa-1 cells.	Cycloheximide	45-58	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	105-111
10700251-4	2000	Low doses of cycloheximide, which reduce elongation rate independently of eEF2 phosphorylation, decreased overall protein synthesis but increased alphaCaMK II synthesis.	Cycloheximide	13-26	eukaryotic translation elongation factor 2	Rattus norvegicus	74-78
10731036-3	2000	Our experiments demonstrate that the rapid prostaglandin E2 (PGE2) synthesis induced by IL-1beta is abolished by cycloheximide, suggesting the involvement of protein synthesis.	Cycloheximide	113-126	interleukin 1 beta	Homo sapiens	88-96
10709910-6	2000	A protein synthesis inhibitor, cycloheximide, amplified the LPS-induced uPA mRNA, suggesting that LPS induces uPA by activating the gene expression in which de novo protein synthesis is not necessary.	Cycloheximide	31-44	plasminogen activator, urokinase	Homo sapiens	72-75
10709910-6	2000	A protein synthesis inhibitor, cycloheximide, amplified the LPS-induced uPA mRNA, suggesting that LPS induces uPA by activating the gene expression in which de novo protein synthesis is not necessary.	Cycloheximide	31-44	plasminogen activator, urokinase	Homo sapiens	110-113
10737714-9	2000	In contrast to other oncogenes like c-myc, MAT1/PEA-15 mRNA was extremely stable after actinomycin D and cycloheximide treatments suggesting that other protein expression is prerequisite for degradation of MAT1/PEA-15 mRNA.	Cycloheximide	105-118	proliferation and apoptosis adaptor protein 15A	Mus musculus	43-47
10737714-9	2000	In contrast to other oncogenes like c-myc, MAT1/PEA-15 mRNA was extremely stable after actinomycin D and cycloheximide treatments suggesting that other protein expression is prerequisite for degradation of MAT1/PEA-15 mRNA.	Cycloheximide	105-118	proliferation and apoptosis adaptor protein 15A	Mus musculus	48-54
10657593-8	2000	The repression of CFTR up-regulation by cycloheximide (35.5 microM) suggests the participation of a de novo synthesized protein.	Cycloheximide	40-53	CF transmembrane conductance regulator	Homo sapiens	18-22
10679284-4	2000	Brefeldin A as well as cycloheximide inhibited biliary secretion of apo A-I (-52%; -68%), however, not of PL.	Cycloheximide	23-36	apolipoprotein A1	Rattus norvegicus	68-75
10640397-2	2000	Fibronectin can provide sufficient signals for all three processes, even when protein synthesis is prevented by cycloheximide.	Cycloheximide	112-125	fibronectin 1	Homo sapiens	0-11
10706374-0	2000	Changes of caspase activities involved in apoptosis of a macrophage-like cell line J774.1/JA-4 treated with lipopolysaccharide (LPS) and cycloheximide.	Cycloheximide	137-150	caspase 1	Mus musculus	11-18
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	55-68	deoxynucleotidyltransferase, terminal	Mus musculus	164-201
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	55-68	deoxynucleotidyltransferase, terminal	Mus musculus	203-206
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	55-68	poly (ADP-ribose) polymerase family, member 1	Mus musculus	345-349
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	70-73	deoxynucleotidyltransferase, terminal	Mus musculus	164-201
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	70-73	deoxynucleotidyltransferase, terminal	Mus musculus	203-206
10706374-1	2000	The addition of lipopolysaccharide (LPS) together with cycloheximide (CHX) induced apoptosis in a subline of a J774.1 macrophage-like cell line, JA-4, as judged by terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL)-staining and poly(adenosine 5"-diphosphate (ADP)-ribose) polymerase (PARP)-cleavage.	Cycloheximide	70-73	poly (ADP-ribose) polymerase family, member 1	Mus musculus	345-349
10676636-6	2000	Biochemical analysis of the signaling events induced by TRAIL revealed that PK could be sensitized for TRAIL and, similarly, for TRAIL-R1- and TRAIL-R2-specific apoptosis by pretreatment of the cells with cycloheximide (CHX).	Cycloheximide	205-218	TNF receptor superfamily member 10a	Homo sapiens	129-137
10676636-6	2000	Biochemical analysis of the signaling events induced by TRAIL revealed that PK could be sensitized for TRAIL and, similarly, for TRAIL-R1- and TRAIL-R2-specific apoptosis by pretreatment of the cells with cycloheximide (CHX).	Cycloheximide	205-218	TNF receptor superfamily member 10b	Homo sapiens	143-151
10676636-6	2000	Biochemical analysis of the signaling events induced by TRAIL revealed that PK could be sensitized for TRAIL and, similarly, for TRAIL-R1- and TRAIL-R2-specific apoptosis by pretreatment of the cells with cycloheximide (CHX).	Cycloheximide	220-223	TNF receptor superfamily member 10b	Homo sapiens	143-151
10676636-8	2000	These data indicate that an early block of TRAIL-induced apoptosis was present in PK compared with TK or PK treated with CHX.	Cycloheximide	121-124	TNF superfamily member 10	Homo sapiens	43-48
10738943-8	2000	Moreover, MMP-9 levels in blood and peritoneal neutrophils were reduced to 30-45% of non-treated controls by actinomycin D (500 microg/kg) or cycloheximide (10 mg/kg)-treatment (p<0.05).	Cycloheximide	142-155	matrix metalloproteinase-9	Cavia porcellus	10-15
10670586-7	2000	The 2.6-kb sgk mRNA was induced rapidly (within 30 min) by GM-CSF and remained at high levels for at least 12 h. Up-regulation was blocked completely by the transcription inhibitor, actinomycin D, but not by the translation inhibitor, cycloheximide, nor by the tyrosine kinase inhibitor, genistein.	Cycloheximide	235-248	serum/glucocorticoid regulated kinase 1	Homo sapiens	11-14
10673748-5	2000	The proteolytic processing of procaspases-8 and -3 to produce active fragments, caspases-8 (p18) and -3 (p17), respectively, was observed after treatment with 2CdA, and suppressed by cycloheximide.	Cycloheximide	183-196	caspase 3	Homo sapiens	30-50
10673748-5	2000	The proteolytic processing of procaspases-8 and -3 to produce active fragments, caspases-8 (p18) and -3 (p17), respectively, was observed after treatment with 2CdA, and suppressed by cycloheximide.	Cycloheximide	183-196	H3 histone pseudogene 12	Homo sapiens	92-95
10673748-5	2000	The proteolytic processing of procaspases-8 and -3 to produce active fragments, caspases-8 (p18) and -3 (p17), respectively, was observed after treatment with 2CdA, and suppressed by cycloheximide.	Cycloheximide	183-196	family with sequence similarity 72 member B	Homo sapiens	105-108
10810453-6	2000	The translation blocker cycloheximide (CHM) (10 mg/mL) superinduced COX-2 mRNA during 2 hr of incubation and further stabilized the COX-2 mRNA (T1/2 > 4 hr).	Cycloheximide	24-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	68-73
10810453-6	2000	The translation blocker cycloheximide (CHM) (10 mg/mL) superinduced COX-2 mRNA during 2 hr of incubation and further stabilized the COX-2 mRNA (T1/2 > 4 hr).	Cycloheximide	24-37	prostaglandin-endoperoxide synthase 2	Homo sapiens	132-137
10678754-8	2000	BDNF-induced neuroprotection, but not NGF-induced neuroprotection, was inhibited by a protein synthesis inhibitor cycloheximide.	Cycloheximide	114-127	brain-derived neurotrophic factor	Rattus norvegicus	0-4
11193846-3	2000	The number of VIP binding sites was reduced 66% on treatment with E2 for 72 h. Experiments with cycloheximide suggested that the effect was independent (at least partly so) of protein synthesis.	Cycloheximide	96-109	vasoactive intestinal peptide	Homo sapiens	14-17
10651020-5	2000	Viability assay performed after exposure to soluble APO2L for 16 h showed that DAOY medulloblastoma cells were the most sensitive and that apoptosis induced by APO2L was greatly enhanced when protein synthesis was inhibited by cycloheximide.	Cycloheximide	227-240	TNF superfamily member 10	Homo sapiens	52-57
10651020-5	2000	Viability assay performed after exposure to soluble APO2L for 16 h showed that DAOY medulloblastoma cells were the most sensitive and that apoptosis induced by APO2L was greatly enhanced when protein synthesis was inhibited by cycloheximide.	Cycloheximide	227-240	TNF superfamily member 10	Homo sapiens	160-165
11154046-7	2000	Furthermore, the induction of MnSOD by PSK could be blocked by cycloheximide and actinomycin D.	Cycloheximide	63-76	superoxide dismutase 2, mitochondrial	Mus musculus	30-35
10731674-7	2000	Administration of the inhibitors together with cycloheximide stabilized the amount of TPH with no appreciable increase or decrease.	Cycloheximide	47-60	tryptophan hydroxylase 1	Rattus norvegicus	86-89
11012093-7	2000	Additionally, evidence was obtained for a cycloheximide-sensitive regulator of H-ferritin gene expression, since the presence of this protein synthesis inhibitor increased H-ferritin message levels, and in combination with TGF-beta1, cooperated in an additive manner to augment H-ferritin gene expression.	Cycloheximide	42-55	ferritin heavy polypeptide 1	Mus musculus	79-89
11012093-7	2000	Additionally, evidence was obtained for a cycloheximide-sensitive regulator of H-ferritin gene expression, since the presence of this protein synthesis inhibitor increased H-ferritin message levels, and in combination with TGF-beta1, cooperated in an additive manner to augment H-ferritin gene expression.	Cycloheximide	42-55	ferritin heavy polypeptide 1	Mus musculus	172-182
11012093-7	2000	Additionally, evidence was obtained for a cycloheximide-sensitive regulator of H-ferritin gene expression, since the presence of this protein synthesis inhibitor increased H-ferritin message levels, and in combination with TGF-beta1, cooperated in an additive manner to augment H-ferritin gene expression.	Cycloheximide	42-55	transforming growth factor, beta 1	Mus musculus	223-232
11012093-7	2000	Additionally, evidence was obtained for a cycloheximide-sensitive regulator of H-ferritin gene expression, since the presence of this protein synthesis inhibitor increased H-ferritin message levels, and in combination with TGF-beta1, cooperated in an additive manner to augment H-ferritin gene expression.	Cycloheximide	42-55	ferritin heavy polypeptide 1	Mus musculus	172-182
10642314-6	2000	Cycloheximide blocked the atRA-induced decrease in AT(1)-R mRNA expression, suggesting that this process requires de novo protein synthesis.	Cycloheximide	0-13	angiotensin II receptor, type 1b	Rattus norvegicus	51-58
10653982-3	2000	We show that increased activity of several metalloproteases on the HeLa cell surface occurs after stresses due to UVC, actinomycin D, cycloheximide, and cisplatinum, which induce the release of transforming growth factor-alpha (TGFalpha) and other bioactive molecules.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	194-226
10653982-3	2000	We show that increased activity of several metalloproteases on the HeLa cell surface occurs after stresses due to UVC, actinomycin D, cycloheximide, and cisplatinum, which induce the release of transforming growth factor-alpha (TGFalpha) and other bioactive molecules.	Cycloheximide	134-147	transforming growth factor alpha	Homo sapiens	228-236
10961438-6	2000	In other experiments the protein synthesis of Cerebrolysin treated and untreated cells was blocked with cycloheximide at that moment when all cells exhibited the same MAP2 content.	Cycloheximide	104-117	microtubule associated protein 2	Gallus gallus	167-171
10620119-10	2000	Tumor necrosis factor-alpha induced production of C3 and interferon-gamma induced production of factor B were inhibited by cycloheximide.	Cycloheximide	123-136	tumor necrosis factor	Homo sapiens	0-27
10620119-10	2000	Tumor necrosis factor-alpha induced production of C3 and interferon-gamma induced production of factor B were inhibited by cycloheximide.	Cycloheximide	123-136	interferon gamma	Homo sapiens	57-73
10608813-13	1999	Inhibiting protein degradation with MG132 caused the constitutive activation of SAPK2/p38, which was blocked by a pretreatment with either cycloheximide or heat shock.	Cycloheximide	139-152	mitogen-activated protein kinase 11	Homo sapiens	80-85
10617117-5	2000	The protein synthesis inhibitor cycloheximide blocked the induction of AP-1, consistent with a requirement for induction of expression of AP-1 family members.	Cycloheximide	32-45	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-75
10617117-5	2000	The protein synthesis inhibitor cycloheximide blocked the induction of AP-1, consistent with a requirement for induction of expression of AP-1 family members.	Cycloheximide	32-45	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	138-142
10567848-6	2000	Furthermore, coincubation with cycloheximide (20 microg/ml) for 16 h inhibited both EGF- and TPA-stimulated increases in L-alanine transport to a great extent.	Cycloheximide	31-44	epidermal growth factor	Sus scrofa	84-87
10594010-5	2000	In addition, the ability of cycloheximide to block the activation-induced alternative splicing of CD45 suggests a requirement for de novo protein synthesis.	Cycloheximide	28-41	protein tyrosine phosphatase receptor type C	Homo sapiens	98-102
10660069-5	2000	Deletion of RRD1 caused pleiotropic phenotypes under a wide range of conditions, including sensitivity to Ca2+, vanadate, ketoconazole, cycloheximide and Calcofluor white, and resistance to caffeine and rapamycin.	Cycloheximide	136-149	peptidylprolyl isomerase RRD1	Saccharomyces cerevisiae S288C	12-16
11098108-8	2000	Prior treatment of the protein synthesis inhibitor cycloheximide prevented the expression of immunoreactivities to the anti-c-Fos antibody detected on two-dimensional electrophoresis in hippocampal nuclear fractions obtained 2h after administration.These results suggest that in vivo kainate signals may lead to persistent expression of the transcription factor activator protein-1 that consists of different Fos family members, as well as of c-Fos protein phosphorylated on serine and/or tyrosine residues, at an early stage after administration.	Cycloheximide	51-64	FBJ osteosarcoma oncogene	Mus musculus	124-129
11098108-8	2000	Prior treatment of the protein synthesis inhibitor cycloheximide prevented the expression of immunoreactivities to the anti-c-Fos antibody detected on two-dimensional electrophoresis in hippocampal nuclear fractions obtained 2h after administration.These results suggest that in vivo kainate signals may lead to persistent expression of the transcription factor activator protein-1 that consists of different Fos family members, as well as of c-Fos protein phosphorylated on serine and/or tyrosine residues, at an early stage after administration.	Cycloheximide	51-64	jun proto-oncogene	Mus musculus	362-381
11098108-8	2000	Prior treatment of the protein synthesis inhibitor cycloheximide prevented the expression of immunoreactivities to the anti-c-Fos antibody detected on two-dimensional electrophoresis in hippocampal nuclear fractions obtained 2h after administration.These results suggest that in vivo kainate signals may lead to persistent expression of the transcription factor activator protein-1 that consists of different Fos family members, as well as of c-Fos protein phosphorylated on serine and/or tyrosine residues, at an early stage after administration.	Cycloheximide	51-64	FBJ osteosarcoma oncogene	Mus musculus	126-129
11098108-8	2000	Prior treatment of the protein synthesis inhibitor cycloheximide prevented the expression of immunoreactivities to the anti-c-Fos antibody detected on two-dimensional electrophoresis in hippocampal nuclear fractions obtained 2h after administration.These results suggest that in vivo kainate signals may lead to persistent expression of the transcription factor activator protein-1 that consists of different Fos family members, as well as of c-Fos protein phosphorylated on serine and/or tyrosine residues, at an early stage after administration.	Cycloheximide	51-64	FBJ osteosarcoma oncogene	Mus musculus	443-448
10608813-13	1999	Inhibiting protein degradation with MG132 caused the constitutive activation of SAPK2/p38, which was blocked by a pretreatment with either cycloheximide or heat shock.	Cycloheximide	139-152	mitogen-activated protein kinase 14	Homo sapiens	86-89
10716204-7	1999	However, unlike dbcAMP and staurosporine, which also induce fra-1, HMBA repressed cycloheximide-induced fra-1 gene expression.	Cycloheximide	82-95	FOS like 1, AP-1 transcription factor subunit	Rattus norvegicus	104-109
10618717-3	1999	Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis.	Cycloheximide	228-241	proline/serine-rich coiled-coil 1	Mus musculus	16-20
10618717-3	1999	Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis.	Cycloheximide	228-241	proline/serine-rich coiled-coil 1	Mus musculus	143-147
10618717-3	1999	Upregulation of DDA3 could be detected within 2 h after down-shifting the temperature to 32.5 degrees C; upon shifting back to 38.5 degrees C, DDA3 mRNA rapidly degraded with a half-life of less than 2 h. Actinomycin D, but not cycloheximide, inhibited the p53 dependent DDA3 induction, suggesting that the activation is through transcriptional regulation and does not require de novo protein synthesis.	Cycloheximide	228-241	proline/serine-rich coiled-coil 1	Mus musculus	143-147
10622740-5	1999	Induction of E16/CD98LC/hLAT1 mRNA by TCDD did not require de novo protein synthesis as revealed by the experiment using cycloheximide.	Cycloheximide	121-134	solute carrier family 7 member 5	Homo sapiens	13-16
10585391-6	1999	This process was dependent on both Pex5p and the targeting signal, and, most importantly, occurred even in the presence of cycloheximide, a protein synthesis inhibitor.	Cycloheximide	123-136	peroxisomal biogenesis factor 5	Homo sapiens	35-40
10622740-5	1999	Induction of E16/CD98LC/hLAT1 mRNA by TCDD did not require de novo protein synthesis as revealed by the experiment using cycloheximide.	Cycloheximide	121-134	solute carrier family 7 member 5	Homo sapiens	24-29
10572065-11	1999	The IL-16 expression induced by histamine and combined cytokines was significantly inhibited by pretreatment with the protein synthesis inhibitor cycloheximide (10 microg/ml).	Cycloheximide	146-159	interleukin 16	Homo sapiens	4-9
10600885-7	1999	Lipoxygenase inhibitors and cycloheximide inhibited the release of both NCA and MCA.	Cycloheximide	28-41	CEA cell adhesion molecule 4	Homo sapiens	72-75
10600887-1	1999	Transforming growth factor-beta (TGF-beta) stimulates alpha(1)(I) collagen mRNA synthesis in human lung fibroblasts through a mechanism that is partially sensitive to cycloheximide and that may involve synthesis of connective tissue growth factor (CTGF).	Cycloheximide	167-180	transforming growth factor beta 1	Homo sapiens	0-31
10600887-1	1999	Transforming growth factor-beta (TGF-beta) stimulates alpha(1)(I) collagen mRNA synthesis in human lung fibroblasts through a mechanism that is partially sensitive to cycloheximide and that may involve synthesis of connective tissue growth factor (CTGF).	Cycloheximide	167-180	transforming growth factor beta 1	Homo sapiens	33-41
10637438-5	1999	Although cycloheximide can activate the JNK or p38 MAP kinases in some cells, neither was implicated here.	Cycloheximide	9-22	mitogen-activated protein kinase 14	Homo sapiens	47-50
10698258-3	1999	During inhibition of protein synthesis with cycloheximide, the D123 protein level in 3Y1tsD123 decreased markedly depending on the incubation temperature, compared with that in 3Y1, indicating that the lowered levels of D123 protein in 3Y1tsD123 are due to its degradation.	Cycloheximide	44-57	cell division cycle 123	Rattus norvegicus	63-67
10698258-3	1999	During inhibition of protein synthesis with cycloheximide, the D123 protein level in 3Y1tsD123 decreased markedly depending on the incubation temperature, compared with that in 3Y1, indicating that the lowered levels of D123 protein in 3Y1tsD123 are due to its degradation.	Cycloheximide	44-57	cell division cycle 123	Rattus norvegicus	90-94
10619557-4	1999	The CNTF has to be added more than half an hour before the insult for the effect to occur and its effect is eliminated by the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	170-183	ciliary neurotrophic factor	Homo sapiens	4-8
10569731-10	1999	The addition of cycloheximide at 2 h before IL-1alpha stimulation almost completely inhibited the accumulation of CD26 mRNA.	Cycloheximide	16-29	dipeptidyl peptidase 4	Homo sapiens	114-118
10528234-10	1999	Inhibition of protein synthesis with cycloheximide caused an increase in basal collagenase-3 expression but blocked the effect of PTH, suggesting that an inhibitory factor prevents basal expression while an inductive factor is involved with PTH action.	Cycloheximide	37-50	matrix metallopeptidase 13	Rattus norvegicus	79-92
10616203-8	1999	Inhibition of protein synthesis by cycloheximide resulted in increased sensitivity to agonistic anti-CD95 antibodies, suggesting a role for short-lived apoptosis-protective proteins in the resistance of RCC to CD95-mediated apoptosis.	Cycloheximide	35-48	Fas cell surface death receptor	Homo sapiens	101-105
10616218-7	1999	Addition of cycloheximide (CX) enhanced apoptotic cell death by increasing iNOS activity.	Cycloheximide	12-25	nitric oxide synthase 2	Homo sapiens	75-79
10616218-7	1999	Addition of cycloheximide (CX) enhanced apoptotic cell death by increasing iNOS activity.	Cycloheximide	27-29	nitric oxide synthase 2	Homo sapiens	75-79
10616218-12	1999	TNF-alpha sensitivity and NO2 production were completely restored by the addition of CX.	Cycloheximide	85-87	tumor necrosis factor	Homo sapiens	0-9
10613653-11	1999	Actinomycin D partially whereas cycloheximide completely prevented the serum-induced increased expression of TFPI synthesis by these cells, suggesting control primarily at the translational but some at the transcriptional level as well.	Cycloheximide	32-45	tissue factor pathway inhibitor	Homo sapiens	109-113
10611446-4	1999	When the isolation procedure was performed in the presence of cycloheximide, the mRNA for the alpha(1A)-adrenoceptor did not diminish and the induction of the alpha(1D)-adrenoceptor mRNA was even more evident.	Cycloheximide	62-75	alpha-1A adrenergic receptor	Cavia porcellus	94-116
10581397-8	1999	However, cycloheximide blocked both hemin- and dopamine-induced HO-1 expression, suggesting that both pathways may involve proteins with short half-lives.	Cycloheximide	9-22	heme oxygenase 1	Homo sapiens	64-68
10564823-7	1999	However, in all cells tested, Rbtg3 was proved to be one of the primary response genes superinduced by TPA (50ng/ml)+cycloheximide (CHX, 10 microgram/ml).	Cycloheximide	117-130	BTG anti-proliferation factor 3	Rattus norvegicus	30-35
10564823-7	1999	However, in all cells tested, Rbtg3 was proved to be one of the primary response genes superinduced by TPA (50ng/ml)+cycloheximide (CHX, 10 microgram/ml).	Cycloheximide	132-135	BTG anti-proliferation factor 3	Rattus norvegicus	30-35
10556191-5	1999	CD10 was newly synthesized by the apoptosing cells because its expression was inhibited by exposure to cycloheximide and CD10 mRNA became detectable by reverse transcription-polymerase chain reaction in T cells cultured under conditions favoring apoptosis.	Cycloheximide	103-116	membrane metalloendopeptidase	Homo sapiens	0-4
10554012-4	1999	The inhibitory effects of flavopiridol on VEGF mRNA induction also occurred in the presence of cycloheximide.	Cycloheximide	95-108	vascular endothelial growth factor A	Homo sapiens	42-46
10559009-4	1999	Both actinomycin D and cycloheximide blocked PDGF-stimulated HO-1 mRNA and protein.	Cycloheximide	23-36	heme oxygenase 1	Rattus norvegicus	61-65
10547273-9	1999	The stimulatory effects of IL-1 on SPI-3 mRNA expression were decreased by co-incubation with an inhibitor of gene transcription (actinomycin D), an inhibitor of protein synthesis (cycloheximide) or an inhibitor of NF-kappaB activation (PDTC).	Cycloheximide	181-194	serine (or cysteine) peptidase inhibitor, clade A, member 3N	Rattus norvegicus	35-40
10628429-10	1999	The restoration of leptin expression by insulin was blocked by cycloheximide treatment.	Cycloheximide	63-76	leptin	Sus scrofa	19-25
10628429-10	1999	The restoration of leptin expression by insulin was blocked by cycloheximide treatment.	Cycloheximide	63-76	insulin	Sus scrofa	40-47
10537148-8	1999	This time difference in cAMP-responsive expression of the PR and PACAP genes is due, at least in part, to the requirement of ongoing protein synthesis for PACAP expression, as demonstrated by the inhibitory effect of cycloheximide on cAMP-induced PACAP, but not PR, mRNA levels.	Cycloheximide	217-230	progesterone receptor	Rattus norvegicus	58-60
10537148-8	1999	This time difference in cAMP-responsive expression of the PR and PACAP genes is due, at least in part, to the requirement of ongoing protein synthesis for PACAP expression, as demonstrated by the inhibitory effect of cycloheximide on cAMP-induced PACAP, but not PR, mRNA levels.	Cycloheximide	217-230	adenylate cyclase activating polypeptide 1	Rattus norvegicus	65-70
10537148-8	1999	This time difference in cAMP-responsive expression of the PR and PACAP genes is due, at least in part, to the requirement of ongoing protein synthesis for PACAP expression, as demonstrated by the inhibitory effect of cycloheximide on cAMP-induced PACAP, but not PR, mRNA levels.	Cycloheximide	217-230	adenylate cyclase activating polypeptide 1	Rattus norvegicus	155-160
10537148-8	1999	This time difference in cAMP-responsive expression of the PR and PACAP genes is due, at least in part, to the requirement of ongoing protein synthesis for PACAP expression, as demonstrated by the inhibitory effect of cycloheximide on cAMP-induced PACAP, but not PR, mRNA levels.	Cycloheximide	217-230	adenylate cyclase activating polypeptide 1	Rattus norvegicus	155-160
10537148-8	1999	This time difference in cAMP-responsive expression of the PR and PACAP genes is due, at least in part, to the requirement of ongoing protein synthesis for PACAP expression, as demonstrated by the inhibitory effect of cycloheximide on cAMP-induced PACAP, but not PR, mRNA levels.	Cycloheximide	217-230	progesterone receptor	Rattus norvegicus	262-264
10583443-12	1999	Anti-PR-3 antibody induced endothelial IL-8 expression could be inhibited by cycloheximide.	Cycloheximide	77-90	C-X-C motif chemokine ligand 8	Homo sapiens	39-43
10602388-6	1999	Time-course experiments showed a NaF-induced IL-6 response at 5 h, whereas an IL-8 response was observed after 10 h. Cycloheximide treatment completely abolished the NaF-induced cytokine responses.	Cycloheximide	117-130	interleukin 6	Homo sapiens	45-49
10602388-6	1999	Time-course experiments showed a NaF-induced IL-6 response at 5 h, whereas an IL-8 response was observed after 10 h. Cycloheximide treatment completely abolished the NaF-induced cytokine responses.	Cycloheximide	117-130	C-X-C motif chemokine ligand 8	Homo sapiens	78-82
10536167-4	1999	The initial transient cell arrest at the G1 checkpoint seen at 8-16 h of treatment with 0.15 microM CPT was accompanied by the rapid accumulation of p53 (preventable by cycloheximide) in the nucleus; the rise (>20-fold) in p53 was maximal for S phase cells.	Cycloheximide	169-182	tumor protein p53	Homo sapiens	149-152
10550743-9	1999	The transcription inhibitor actinomycin D, the nuclear factor kappaB (NFkappaB) inhibitor N-CBZ-Leu-Leu-Leu-AL, the protein synthesis inhibitor cycloheximide, and the protein kinase C inhibitor H7 significantly decreased MMP-9 activity in TNF-alpha-treated cells.	Cycloheximide	144-157	matrix metallopeptidase 9	Homo sapiens	221-226
10497315-9	1999	Consistent with c-jun, their mRNA expressions were simultaneously superinduced by cycloheximide (1 microg/ml), suggesting that de novo protein synthesis is involved their transcriptions.	Cycloheximide	82-95	jun proto-oncogene	Mus musculus	16-21
10547370-4	1999	The translocation of ZnBP to the nucleus can be inhibited or abolished by inhibitors of protein synthesis (cycloheximide) or transcription (actinomycin D).	Cycloheximide	107-120	parathymosin	Rattus norvegicus	21-25
10547370-5	1999	Moreover, cycloheximide can induce a relocation of ZnBP to the cytoplasm when applied after the appearance of ZnBP in the nuclei.	Cycloheximide	10-23	parathymosin	Rattus norvegicus	51-55
10547370-5	1999	Moreover, cycloheximide can induce a relocation of ZnBP to the cytoplasm when applied after the appearance of ZnBP in the nuclei.	Cycloheximide	10-23	parathymosin	Rattus norvegicus	110-114
10493750-5	1999	Treatment of muscle cells with cycloheximide to inhibit c-JUN synthesis at the protein level and suppression of c-JUN function by a dominant-negative mutant blocked neuregulin-induced expression of the epsilon-subunit gene, indicating an essential role of c-JUN in neuregulin signaling.	Cycloheximide	31-44	jun proto-oncogene	Mus musculus	56-61
10537047-6	1999	Forskolin-induced elevation of AA-NAT mRNA levels was enhanced by cycloheximide, which decreased the degradation of the transcript in cells treated with actinomycin D.	Cycloheximide	66-79	aralkylamine N-acetyltransferase	Gallus gallus	31-37
10541325-10	1999	The up-regulation of FcepsilonRI was completely inhibited by cycloheximide, indicating that it was dependent on de novo protein synthesis.	Cycloheximide	61-74	Fc epsilon receptor Ia	Homo sapiens	21-32
10510285-12	1999	Trolox decreased the rate of loss of CYP2E1 protein when the cells were treated with cycloheximide.	Cycloheximide	85-98	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	37-43
10491655-7	1999	Inhibitors of protein synthesis (cycloheximide) and RNA synthesis (actinomycin D, and 5,6-dichloro-1-beta-ribofuranosyl benzimidazole) completely abrogated the EGF-induced LDH A mRNA expression, indicating that EGF increased LDH A mRNA levels through a transcriptional mechanism, which probably involves protein synthesis.	Cycloheximide	33-46	epidermal growth factor	Homo sapiens	160-163
10491655-7	1999	Inhibitors of protein synthesis (cycloheximide) and RNA synthesis (actinomycin D, and 5,6-dichloro-1-beta-ribofuranosyl benzimidazole) completely abrogated the EGF-induced LDH A mRNA expression, indicating that EGF increased LDH A mRNA levels through a transcriptional mechanism, which probably involves protein synthesis.	Cycloheximide	33-46	lactate dehydrogenase A	Homo sapiens	172-177
10521370-9	1999	In the presence of cycloheximide, Cox-2 mRNA levels were induced by HDL and inhibited by dexamethasone, suggesting that HDL and dexamethasone work in the absence of de novo protein synthesis.	Cycloheximide	19-32	prostaglandin G/H synthase 2	Oryctolagus cuniculus	34-39
10562909-11	1999	Accumulation of u-PA was inhibited by cycloheximide, implying that there was a requirement for protein synthesis.	Cycloheximide	38-51	plasminogen activator, urokinase	Homo sapiens	16-20
10547161-8	1999	Studies with cycloheximide, a protein synthesis inhibitor, demonstrated that de novo protein synthesis is required for IL-1beta induced MMP-9 expression.	Cycloheximide	13-26	interleukin 1 beta	Homo sapiens	119-127
10547161-8	1999	Studies with cycloheximide, a protein synthesis inhibitor, demonstrated that de novo protein synthesis is required for IL-1beta induced MMP-9 expression.	Cycloheximide	13-26	matrix metallopeptidase 9	Homo sapiens	136-141
10537278-3	1999	Forced expression of the dominant negative HOSdeltaF construct inhibited IkappaB degradation and led to sensitization of melanoma cells to apoptosis induced by tumor necrosis factor alpha with cycloheximide, as well as by cisplatin and ionizing and UV irradiation.	Cycloheximide	193-206	tumor necrosis factor	Homo sapiens	160-187
10523409-3	1999	Cycloheximide (10 microg ml-1, 6 h) blocked IL-1beta-induced COX-2 protein expression and super-induced COX-2 mRNA expression.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	44-52
10523409-3	1999	Cycloheximide (10 microg ml-1, 6 h) blocked IL-1beta-induced COX-2 protein expression and super-induced COX-2 mRNA expression.	Cycloheximide	0-13	prostaglandin-endoperoxide synthase 2	Homo sapiens	61-66
10523409-3	1999	Cycloheximide (10 microg ml-1, 6 h) blocked IL-1beta-induced COX-2 protein expression and super-induced COX-2 mRNA expression.	Cycloheximide	0-13	prostaglandin-endoperoxide synthase 2	Homo sapiens	104-109
10506215-12	1999	Furthermore, adenovirus-mediated delivery of an IkappaBalpha mutant to prevent NFkappaB activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes.	Cycloheximide	177-190	NFKB inhibitor alpha	Homo sapiens	48-60
10506215-12	1999	Furthermore, adenovirus-mediated delivery of an IkappaBalpha mutant to prevent NFkappaB activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes.	Cycloheximide	177-190	nuclear factor kappa B subunit 1	Homo sapiens	79-87
10506215-12	1999	Furthermore, adenovirus-mediated delivery of an IkappaBalpha mutant to prevent NFkappaB activation impaired the ability of Bcl-2 to suppress apoptosis provoked by TNFalpha plus cycloheximide in ventricular myocytes.	Cycloheximide	177-190	BCL2 apoptosis regulator	Homo sapiens	123-128
10504447-4	1999	The increase of activator protein-2 mRNA was detected at 30 min after stimulation and that of activator protein-2 protein was at 2 h. Their levels were lower than the control levels at 24 h. The interleukin-6-dependent induction of activator protein-2 mRNA was completely blocked by adding actinomycin D, whereas it was approximately 50% affected by cycloheximide.	Cycloheximide	350-363	transcription factor AP-2 alpha	Homo sapiens	16-35
10504447-4	1999	The increase of activator protein-2 mRNA was detected at 30 min after stimulation and that of activator protein-2 protein was at 2 h. Their levels were lower than the control levels at 24 h. The interleukin-6-dependent induction of activator protein-2 mRNA was completely blocked by adding actinomycin D, whereas it was approximately 50% affected by cycloheximide.	Cycloheximide	350-363	transcription factor AP-2 alpha	Homo sapiens	94-113
10504447-4	1999	The increase of activator protein-2 mRNA was detected at 30 min after stimulation and that of activator protein-2 protein was at 2 h. Their levels were lower than the control levels at 24 h. The interleukin-6-dependent induction of activator protein-2 mRNA was completely blocked by adding actinomycin D, whereas it was approximately 50% affected by cycloheximide.	Cycloheximide	350-363	interleukin 6	Homo sapiens	195-208
10504447-4	1999	The increase of activator protein-2 mRNA was detected at 30 min after stimulation and that of activator protein-2 protein was at 2 h. Their levels were lower than the control levels at 24 h. The interleukin-6-dependent induction of activator protein-2 mRNA was completely blocked by adding actinomycin D, whereas it was approximately 50% affected by cycloheximide.	Cycloheximide	350-363	transcription factor AP-2 alpha	Homo sapiens	94-113
10576142-7	1999	IL-10 produced a decrease in the stability of KC mRNA, and CA-stimulated macrophages with cycloheximide blocked the suppressive effect of IL-10.	Cycloheximide	90-103	interleukin 10	Mus musculus	138-143
10576415-6	1999	The simultaneous incubation of brefeldin A with cycloheximide or dopamine diminished the released prolactin concomitant with a lower (cycloheximide) or greater (dopamine) hormonal intracellular prolactin content with respect to brefeldin A.	Cycloheximide	48-61	prolactin	Rattus norvegicus	98-107
10576415-6	1999	The simultaneous incubation of brefeldin A with cycloheximide or dopamine diminished the released prolactin concomitant with a lower (cycloheximide) or greater (dopamine) hormonal intracellular prolactin content with respect to brefeldin A.	Cycloheximide	48-61	prolactin	Rattus norvegicus	194-203
10576415-7	1999	The combined treatment cycloheximide-dopamine inhibited prolactin secretion.	Cycloheximide	23-36	prolactin	Rattus norvegicus	56-65
10576415-9	1999	These results revealed that prolactin release in vitro in the presence or not of brefeldin A is dependent on either: the neosynthesized hormone that can be inhibited by cycloheximide, and the hormone stored in granules, the exocytosis of which was blocked by dopamine, indicates the contribution of both constitutive and regulated pathways in the secretory process.	Cycloheximide	169-182	prolactin	Rattus norvegicus	28-37
10516755-8	1999	Cycloheximide, but not actinomycin D or brefeldin A, increased CD95-specific cell death only in IFNgamma-treated RS4;11 cells by approximately 12%.	Cycloheximide	0-13	Fas cell surface death receptor	Homo sapiens	63-67
10516755-8	1999	Cycloheximide, but not actinomycin D or brefeldin A, increased CD95-specific cell death only in IFNgamma-treated RS4;11 cells by approximately 12%.	Cycloheximide	0-13	interferon gamma	Homo sapiens	96-104
10471325-6	1999	Concurrent addition of the protein synthesis inhibitor, cycloheximide, or the endonuclease inhibitor, aurintricarboxylic acid, to PARP-inhibited cells further delayed the onset and attenuated the extent of H(2)O(2)-induced cell lysis, consistent with an active mode of cell death.	Cycloheximide	56-69	poly(ADP-ribose) polymerase 1	Homo sapiens	130-134
10493518-9	1999	However, steady-state levels of cyclin D1 mRNA display a significant decrease by 4 h of flavopiridol treatment, with total disappearance by 8 h. This mRNA decline is not abrogated by the presence of cycloheximide.	Cycloheximide	199-212	cyclin D1	Homo sapiens	32-41
10440872-7	1999	The ability of RNA (actinomycin-D, Act-D) and protein synthesis inhibitors (cyclohexamide (CHX), emetine) to block drug-mediated sensitization to Fas-L killing was analyzed.	Cycloheximide	91-94	Fas ligand	Homo sapiens	146-151
10440923-8	1999	In addition, 24 h of cycloheximide treatment caused depletion of RhoA from the membrane (active) fraction in neo cells, but in the cells overexpressing cyclin E, RhoA remained in the active (membrane-associated) fraction.	Cycloheximide	21-34	ras homolog family member A	Mus musculus	65-69
10440923-8	1999	In addition, 24 h of cycloheximide treatment caused depletion of RhoA from the membrane (active) fraction in neo cells, but in the cells overexpressing cyclin E, RhoA remained in the active (membrane-associated) fraction.	Cycloheximide	21-34	ras homolog family member A	Mus musculus	162-166
10580840-7	1999	Basal expression of Peg3 mRNA was almost completely abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	97-110	paternally expressed 3	Homo sapiens	20-24
10479292-0	1999	Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties.	Cycloheximide	38-51	FK506 binding protein 1a	Mus musculus	91-97
10479292-1	1999	On the basis of the new finding that the protein synthesis inhibitor cycloheximide (1, 4-[2-(3, 5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]-2,6-piperidinedione) is able to competitively inhibit hFKBP12 (K(i) = 3.4 microM) and homologous enzymes, a series of derivatives has been synthesized.	Cycloheximide	69-82	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	194-201
10479292-3	1999	As a result, several less toxic or nontoxic cycloheximide derivatives were identified by N-substitution of the glutarimide moiety and exhibit IC(50) values in the range of 22.0-4.4 microM for inhibition of hFKBP12.	Cycloheximide	44-57	FKBP prolyl isomerase 1A pseudogene 4	Homo sapiens	206-213
10479292-4	1999	Among these compounds cycloheximide-N-(ethyl ethanoate) (10, K(i) = 4.1 microM), which exerted FKBP12 inhibition to an extent comparable to that of cycloheximide (1), was found to cause an approximately 1000-fold weaker inhibitory effect on eukaryotic protein synthesis (IC(50) = 115 microM).	Cycloheximide	22-35	FK506 binding protein 1a	Mus musculus	95-101
10512636-14	1999	When incubated with HF and cycloheximide or HF and heparin, the cell growth was inhibited, suggesting that the mechanism of action of HF is similar to that of VEGF.	Cycloheximide	27-40	vascular endothelial growth factor A	Rattus norvegicus	159-163
10484459-3	1999	We now show that E1A-dependent induction of interleukin-8 expression is specific to LPS, superinduced by cycloheximide, and not observed after tumor necrosis factor or phorbol 12-myristate 13-acetate stimulation.	Cycloheximide	105-118	C-X-C motif chemokine ligand 8	Homo sapiens	44-57
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	140-153	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	84-89
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	140-153	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	197-202
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	286-289
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	155-158	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	84-89
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	155-158	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	197-202
10484519-5	1999	Moreover, a posttranscriptional mechanism(s) appears to contribute significantly to COX-2 mRNA accumulation as pretreatment for 15 min with cycloheximide (CHX, 1 microM) caused a superinduction of COX-2 mRNA accumulation in unstimulated cells as well as in cells challenged with either TNF or PMA.	Cycloheximide	155-158	tumor necrosis factor	Homo sapiens	286-289
10457374-5	1999	In addition, stimulation of NGF but not S-100beta release was substantially reduced in cultures treated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	141-154	nerve growth factor	Rattus norvegicus	28-31
10454511-10	1999	The role of protein synthesis in maintaining PHM activity in blood was demonstrated by treatment with cycloheximide, which reduced serum PHM activity and retarded the recovery of PHM activity after PBA administration.	Cycloheximide	102-115	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	45-48
10454511-10	1999	The role of protein synthesis in maintaining PHM activity in blood was demonstrated by treatment with cycloheximide, which reduced serum PHM activity and retarded the recovery of PHM activity after PBA administration.	Cycloheximide	102-115	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	137-140
10454511-10	1999	The role of protein synthesis in maintaining PHM activity in blood was demonstrated by treatment with cycloheximide, which reduced serum PHM activity and retarded the recovery of PHM activity after PBA administration.	Cycloheximide	102-115	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	137-140
10458930-6	1999	In response to cycloheximide pretreatment, cPLA(2) mRNA was superinduced.	Cycloheximide	15-28	phospholipase A2 group IVA	Homo sapiens	43-50
10576546-7	1999	This enhancement of DA uptake induced by EGF or bFGF was significantly inhibited when the cells were cultured with actinomycin D, cycloheximide, or brefeldin A.	Cycloheximide	130-143	epidermal growth factor like 1	Rattus norvegicus	41-44
10576546-7	1999	This enhancement of DA uptake induced by EGF or bFGF was significantly inhibited when the cells were cultured with actinomycin D, cycloheximide, or brefeldin A.	Cycloheximide	130-143	fibroblast growth factor 2	Rattus norvegicus	48-52
10503713-2	1999	Along these lines, our laboratory has shown that testosterone increased androgen receptor (AR) protein levels and binding in the castrated rat ventral prostate within 1 h. Ongoing protein synthesis was required for the testosterone effect, as the protein synthesis inhibitor cycloheximide blocked this effect.	Cycloheximide	275-288	androgen receptor	Rattus norvegicus	72-89
10503713-2	1999	Along these lines, our laboratory has shown that testosterone increased androgen receptor (AR) protein levels and binding in the castrated rat ventral prostate within 1 h. Ongoing protein synthesis was required for the testosterone effect, as the protein synthesis inhibitor cycloheximide blocked this effect.	Cycloheximide	275-288	androgen receptor	Rattus norvegicus	91-93
10509718-7	1999	Furthermore, we found that drugs including cycloheximide, genistein and EDTA either prevented the decline in Mcl-1 levels or blocked the intense DNA laddering pattern.	Cycloheximide	43-56	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	109-114
10521580-5	1999	The TGF-beta1, GGF(2) and forskolin dependent reduction in NT-3 mRNA levels involved a destabilization of transcripts which was antagonised by co-treatment with cycloheximide.	Cycloheximide	161-174	transforming growth factor beta 1	Homo sapiens	4-13
10521580-5	1999	The TGF-beta1, GGF(2) and forskolin dependent reduction in NT-3 mRNA levels involved a destabilization of transcripts which was antagonised by co-treatment with cycloheximide.	Cycloheximide	161-174	neuregulin 1	Homo sapiens	15-21
10521580-5	1999	The TGF-beta1, GGF(2) and forskolin dependent reduction in NT-3 mRNA levels involved a destabilization of transcripts which was antagonised by co-treatment with cycloheximide.	Cycloheximide	161-174	neurotrophin 3	Rattus norvegicus	59-63
10438953-7	1999	Cytokine-mediated I kappa B alpha reappearance was completely blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	105-118	NFKB inhibitor alpha	Homo sapiens	18-33
10465793-7	1999	These proteins, which we refer to as p33(ringo) (rapid inducer of G(2)/M progression in oocytes), induce very rapid MPF activation in cycloheximide-treated oocytes.	Cycloheximide	134-147	centromere protein K L homeolog	Xenopus laevis	37-40
10441477-5	1999	The MDR1 mRNA half-life was prolonged to >20 h upon treatment with the protein synthesis inhibitor cycloheximide.	Cycloheximide	102-115	ATP binding cassette subfamily B member 1	Homo sapiens	4-8
10441511-5	1999	In addition, in EoL-1 cells, p21 protein was induced by troglitazone treatment and the induction was inhibited by protein synthesis inhibitor, cycloheximide.	Cycloheximide	143-156	cyclin dependent kinase inhibitor 1A	Homo sapiens	29-32
10428830-8	1999	In addition, we have identified the CD95 high expressing cell line Boe(R) as a CD95 apoptosis-resistant type II cell that can be sensitized by treatment with cycloheximide without affecting formation of the DISC.	Cycloheximide	158-171	Fas cell surface death receptor	Homo sapiens	36-40
10428830-8	1999	In addition, we have identified the CD95 high expressing cell line Boe(R) as a CD95 apoptosis-resistant type II cell that can be sensitized by treatment with cycloheximide without affecting formation of the DISC.	Cycloheximide	158-171	Fas cell surface death receptor	Homo sapiens	79-83
10428830-9	1999	This also places the effects of cycloheximide in the mitochondrial branch of the type II CD95 pathway.	Cycloheximide	32-45	Fas cell surface death receptor	Homo sapiens	89-93
10421655-9	1999	Actinomycin and cycloheximide inhibited the MMP2 activation induced by concanavalin A. Recombinant tissue inhibitor of metalloproteinase-2 and the MMP inhibitor BB-3103, but not PMSF, blocked MMP2 activation induced by collagen I or concanavalin A, and MT1-MMP processing to its Mr-43 kd form.	Cycloheximide	16-29	matrix metallopeptidase 2	Homo sapiens	44-48
10421655-9	1999	Actinomycin and cycloheximide inhibited the MMP2 activation induced by concanavalin A. Recombinant tissue inhibitor of metalloproteinase-2 and the MMP inhibitor BB-3103, but not PMSF, blocked MMP2 activation induced by collagen I or concanavalin A, and MT1-MMP processing to its Mr-43 kd form.	Cycloheximide	16-29	matrix metallopeptidase 2	Homo sapiens	192-196
10421655-9	1999	Actinomycin and cycloheximide inhibited the MMP2 activation induced by concanavalin A. Recombinant tissue inhibitor of metalloproteinase-2 and the MMP inhibitor BB-3103, but not PMSF, blocked MMP2 activation induced by collagen I or concanavalin A, and MT1-MMP processing to its Mr-43 kd form.	Cycloheximide	16-29	matrix metallopeptidase 14	Homo sapiens	253-260
10428050-7	1999	Further, cycloheximide (0.2 microg/ml) completely protected the cells from MK-801-induced apoptotic cell death and caspase-3 activation.	Cycloheximide	9-22	caspase 3	Rattus norvegicus	115-124
10428052-2	1999	Actinomycin D and cycloheximide inhibit induction of caspase-3 and prevent death.	Cycloheximide	18-31	caspase 3	Rattus norvegicus	53-62
10409681-9	1999	We also demonstrated that basal degradation of IG in the presence of cycloheximide is inhibited by such mutations, suggesting that basal degradation of IkappaBalpha also requires phosphorylation as the signal for degradation.	Cycloheximide	69-82	NFKB inhibitor alpha	Homo sapiens	152-164
10427101-6	1999	Both beta-catenin and cadherin were more rapidly downregulated in cad7-29 than in Ncad-1 cells treated with cycloheximide, suggesting a higher turnover rate for cadherin-7-mediated cell-cell contacts than for those mediated by N-cadherin.	Cycloheximide	108-121	catenin (cadherin associated protein), beta 1	Mus musculus	5-17
10427101-6	1999	Both beta-catenin and cadherin were more rapidly downregulated in cad7-29 than in Ncad-1 cells treated with cycloheximide, suggesting a higher turnover rate for cadherin-7-mediated cell-cell contacts than for those mediated by N-cadherin.	Cycloheximide	108-121	cadherin 7, type 2	Mus musculus	161-171
10427101-6	1999	Both beta-catenin and cadherin were more rapidly downregulated in cad7-29 than in Ncad-1 cells treated with cycloheximide, suggesting a higher turnover rate for cadherin-7-mediated cell-cell contacts than for those mediated by N-cadherin.	Cycloheximide	108-121	cadherin 2	Mus musculus	227-237
10573164-4	1999	U19 and U18/20 were beta genes; their transcription was inhibited by cycloheximide but not by phosphonoacetate, an inhibitor of DNA synthesis.	Cycloheximide	69-82	small nucleolar RNA, H/ACA box 74A	Homo sapiens	0-3
10460759-5	1999	The upregulation was blocked by cycloheximide, indicating that it requires new protein synthesis, and was accompanied by an increase in both the stability of NK(2) receptor mRNA and the rate of NK(2) receptor gene transcription.	Cycloheximide	32-45	tachykinin receptor 2	Homo sapiens	158-172
10460759-5	1999	The upregulation was blocked by cycloheximide, indicating that it requires new protein synthesis, and was accompanied by an increase in both the stability of NK(2) receptor mRNA and the rate of NK(2) receptor gene transcription.	Cycloheximide	32-45	tachykinin receptor 2	Homo sapiens	194-208
10484362-5	1999	Cycloheximide prevented the stimulatory effect of T3 on collagenase-3 but not on gelatinase B transcripts.	Cycloheximide	0-13	matrix metallopeptidase 13	Mus musculus	56-69
10467171-6	1999	Actinomycin D, cycloheximide, indomethacin, and NS-398 (COX-2 inhibitor) suppressed the production of IL-6 and PGE(2).	Cycloheximide	15-28	interleukin 6	Homo sapiens	102-106
10400702-5	1999	The inhibition appears to be due to an endoribonucleolytic activity of perchloric acid-soluble protein because L-PSP directly affects mRNA template activity and induces disaggregation of the reticulocyte polysomes into 80 S ribosomes, even in the presence of cycloheximide.	Cycloheximide	259-272	reactive intermediate imine deaminase A homolog	Rattus norvegicus	71-102
10397723-9	1999	C/EBPalphaWT-ER induced endogenous PU.1 mRNA within 8 hours in both 32D cl3 and Ba/F3 cells, even in the presence of cycloheximide, indicating that C/EBPalpha directly activates the PU.1 gene.	Cycloheximide	117-130	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	0-10
10397725-11	1999	Cycloheximide, but not actinomycin-D, treatment inhibited the serum and bFGF/heparin-induced increase in TFPI activity in PASMC.	Cycloheximide	0-13	fibroblast growth factor 2	Homo sapiens	72-76
10397725-11	1999	Cycloheximide, but not actinomycin-D, treatment inhibited the serum and bFGF/heparin-induced increase in TFPI activity in PASMC.	Cycloheximide	0-13	tissue factor pathway inhibitor	Homo sapiens	105-109
10448891-2	1999	Stimulation of the cells with interleukin-1beta (2.5 ng/ml) resulted in a great increase of prostacyclin production, which was abolished by indomethacin (1 microM) or cycloheximide (2 microM).	Cycloheximide	167-180	interleukin 1 beta	Rattus norvegicus	30-47
10385601-7	1999	In contrast, RNI-induced TGF-beta1 release was unaffected by DRB and blunted by the protein synthesis inhibitor cycloheximide, suggesting the involvement of translational and post-translational mechanisms.	Cycloheximide	112-125	transforming growth factor beta 1	Homo sapiens	25-34
10377024-5	1999	IVF and A23187+CHX induced similar changes: cyclin B1 was destroyed shortly after activation followed by accumulation of cyclin B1, phosphorylation of cdc2, and dephosphorylation of ERK2 at pronuclear formation 15 h after activation.	Cycloheximide	15-18	cyclin B1	Bos taurus	44-53
10377024-5	1999	IVF and A23187+CHX induced similar changes: cyclin B1 was destroyed shortly after activation followed by accumulation of cyclin B1, phosphorylation of cdc2, and dephosphorylation of ERK2 at pronuclear formation 15 h after activation.	Cycloheximide	15-18	cyclin B1	Bos taurus	121-130
10377024-5	1999	IVF and A23187+CHX induced similar changes: cyclin B1 was destroyed shortly after activation followed by accumulation of cyclin B1, phosphorylation of cdc2, and dephosphorylation of ERK2 at pronuclear formation 15 h after activation.	Cycloheximide	15-18	cyclin dependent kinase 1	Bos taurus	151-155
10377024-5	1999	IVF and A23187+CHX induced similar changes: cyclin B1 was destroyed shortly after activation followed by accumulation of cyclin B1, phosphorylation of cdc2, and dephosphorylation of ERK2 at pronuclear formation 15 h after activation.	Cycloheximide	15-18	mitogen-activated protein kinase 1	Bos taurus	182-186
10384149-5	1999	IL-5 effects persisted for 24 h and were abolished by cycloheximide and actinomycin D.	Cycloheximide	54-67	interleukin 5	Homo sapiens	0-4
10386954-7	1999	The cAMP-induced increase in BHSP binding was preceded by an increase in levels of mRNA for NK1 receptor and was attenuated by pretreatment with cycloheximide.	Cycloheximide	145-158	tachykinin receptor 1	Rattus norvegicus	92-104
10386968-7	1999	In control cells incubated with 100 microM puromycin or 20 microM cycloheximide for 3 days, the level of catalytically active TH protein failed to decline and exhibited a half-life of > or = 250 h. This finding indicated that TH protein was stabilized.	Cycloheximide	66-79	tyrosine hydroxylase	Bos taurus	126-128
10386968-7	1999	In control cells incubated with 100 microM puromycin or 20 microM cycloheximide for 3 days, the level of catalytically active TH protein failed to decline and exhibited a half-life of > or = 250 h. This finding indicated that TH protein was stabilized.	Cycloheximide	66-79	tyrosine hydroxylase	Bos taurus	229-231
10386968-10	1999	In contrast, the increased amount of TH induced by DMPP was not stabilized but instead underwent a decline to the basal level following addition of puromycin or cycloheximide.	Cycloheximide	161-174	tyrosine hydroxylase	Bos taurus	37-39
10373511-6	1999	Cycloheximide treatment, like anti-cyclin D1 microinjection, was inhibitory throughout G1 phase (which lasts a total of 4 to 5 h in these cells).	Cycloheximide	0-13	cyclin D1	Mus musculus	35-44
10381373-5	1999	Furthermore, this stimulatory effect of BMP-4 was attenuated by treatment with actinomycin D, but not with cycloheximide.	Cycloheximide	107-120	bone morphogenetic protein 4	Mus musculus	40-45
10391681-1	1999	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3.	Cycloheximide	32-45	mitogen-activated protein kinase 8	Homo sapiens	54-77
10391681-1	1999	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3.	Cycloheximide	32-45	mitogen-activated protein kinase 8	Homo sapiens	79-83
10391681-1	1999	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3.	Cycloheximide	32-45	mitogen-activated protein kinase 9	Homo sapiens	89-93
10391681-1	1999	Fas ligation in the presence of cycloheximide induced Jun N-terminal kinase 1 (JNK1) and JNK2 phosphorylation, caspase activation and cell death in the IL-3-dependent cell line BAF3.	Cycloheximide	32-45	interleukin 3	Homo sapiens	152-156
10364265-6	1999	In parallel, transmembrane TNF-expressing HeLa cells display high sensitivity to cycloheximide or interferon-gamma, similar to untransfected cells treated with these agents in combination with sTNF.	Cycloheximide	81-94	tumor necrosis factor	Homo sapiens	27-30
10364265-7	1999	Moreover, cycloheximide-induced apoptosis in transmembrane TNF transfectants can be blocked by the caspase inhibitor zVAD-fmk and does not necessarily need cell to cell contact, indicating a critical role of constitutive autotropic signaling of TNF.TNF receptor complexes.	Cycloheximide	10-23	tumor necrosis factor	Homo sapiens	59-62
10364265-7	1999	Moreover, cycloheximide-induced apoptosis in transmembrane TNF transfectants can be blocked by the caspase inhibitor zVAD-fmk and does not necessarily need cell to cell contact, indicating a critical role of constitutive autotropic signaling of TNF.TNF receptor complexes.	Cycloheximide	10-23	tumor necrosis factor	Homo sapiens	245-248
10364265-7	1999	Moreover, cycloheximide-induced apoptosis in transmembrane TNF transfectants can be blocked by the caspase inhibitor zVAD-fmk and does not necessarily need cell to cell contact, indicating a critical role of constitutive autotropic signaling of TNF.TNF receptor complexes.	Cycloheximide	10-23	tumor necrosis factor	Homo sapiens	245-248
10361124-3	1999	Upon stimulation with RA, mRNA levels of RARalpha and beta transiently increased in parallel with the induction of uPA, and this increase was inhibited by cycloheximide.	Cycloheximide	155-168	retinoic acid receptor alpha	Homo sapiens	41-49
10361124-3	1999	Upon stimulation with RA, mRNA levels of RARalpha and beta transiently increased in parallel with the induction of uPA, and this increase was inhibited by cycloheximide.	Cycloheximide	155-168	plasminogen activator, urokinase	Homo sapiens	115-118
10383144-5	1999	The observed HRG stimulation of paxillin mRNA expression was completely blocked by actinomycin D (a transcriptional inhibitor) as well as by cycloheximide (a protein synthesis inhibitor), suggesting the involvement of an inducible protein factor(s) and transcriptional regulation of paxillin mRNA by HRG.	Cycloheximide	141-154	paxillin	Homo sapiens	32-40
10344722-6	1999	Inhibition of BRCA1/2 expression by ADR and HN2 was blocked by cycloheximide, suggesting that this requires new protein synthesis, while inhibition by CPT, SLN, and UV did not require protein synthesis.	Cycloheximide	63-76	BRCA1 DNA repair associated	Homo sapiens	14-21
10344722-6	1999	Inhibition of BRCA1/2 expression by ADR and HN2 was blocked by cycloheximide, suggesting that this requires new protein synthesis, while inhibition by CPT, SLN, and UV did not require protein synthesis.	Cycloheximide	63-76	MT-RNR2 like 2 (pseudogene)	Homo sapiens	44-47
10354507-4	1999	Consistent with the inhibition by the protein synthesis inhibitor cycloheximide, SB 203580 and PD 98059 inhibited MIP-2 production at 4 h either when added simultaneously with staurosporine or 2 h after stimulation with staurosporine.	Cycloheximide	66-79	C-X-C motif chemokine ligand 2	Rattus norvegicus	114-119
10347228-3	1999	High levels of iron induce degradation of TfR mRNA; the translation inhibitor cycloheximide prevents this.	Cycloheximide	78-91	transferrin receptor	Homo sapiens	42-45
10347228-9	1999	Cycloheximide prevented the destabilization of TfR mRNA only in the presence of active IRPs.	Cycloheximide	0-13	transferrin receptor	Homo sapiens	47-50
10347228-10	1999	Inhibition of IRP inactivation by cycloheximide or by the specific proteasome inhibitor MG132 correlated with the stabilization of TfR mRNA.	Cycloheximide	34-47	Wnt family member 2	Homo sapiens	14-17
10347228-10	1999	Inhibition of IRP inactivation by cycloheximide or by the specific proteasome inhibitor MG132 correlated with the stabilization of TfR mRNA.	Cycloheximide	34-47	transferrin receptor	Homo sapiens	131-134
10347228-11	1999	These observations suggest that inhibition of translation by cycloheximide interferes with the rate-limiting step of iron-induced TfR mRNA decay in a trans-acting mechanism by blocking IRP inactivation.	Cycloheximide	61-74	transferrin receptor	Homo sapiens	130-133
10347228-11	1999	These observations suggest that inhibition of translation by cycloheximide interferes with the rate-limiting step of iron-induced TfR mRNA decay in a trans-acting mechanism by blocking IRP inactivation.	Cycloheximide	61-74	Wnt family member 2	Homo sapiens	185-188
10362664-5	1999	CX markedly attenuated the loss in contractile function and prevented the increase in iNOS and XO activities and dityrosine level.	Cycloheximide	0-2	nitric oxide synthase 2	Rattus norvegicus	86-90
10333489-5	1999	Subsequent cycloheximide chase revealed that the CYP2E1 half-life increased to 26 h. Neither the degradation rates of total protein, CYP2B1 and NADPH-cytochrome P450 reductase nor the cellular ATP level were affected by DPI under the conditions employed.	Cycloheximide	11-24	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	49-55
10547059-8	1999	The heat-induced accumulations of Hsp27 and alphaB-crystallin were also stimulated by cycloheximide, another stimulator of p38 MAP kinase.	Cycloheximide	86-99	heat shock protein family B (small) member 1	Rattus norvegicus	34-39
10547059-8	1999	The heat-induced accumulations of Hsp27 and alphaB-crystallin were also stimulated by cycloheximide, another stimulator of p38 MAP kinase.	Cycloheximide	86-99	crystallin, alpha B	Rattus norvegicus	44-61
10547059-8	1999	The heat-induced accumulations of Hsp27 and alphaB-crystallin were also stimulated by cycloheximide, another stimulator of p38 MAP kinase.	Cycloheximide	86-99	mitogen activated protein kinase 14	Rattus norvegicus	123-126
10554162-8	1999	Enhanced Bcl-2 expression was inhibited by cycloheximide, actinomycin D, or antisense oligonucleotide directed against bcl-2 mRNA.	Cycloheximide	43-56	BCL2 apoptosis regulator	Homo sapiens	9-14
10342860-9	1999	By comparison, the antiapoptotic effects of insulin-like growth factor I on germ cells in cultured fetal ovaries were significantly attenuated by cotreating ovaries with LY294002 (P < 0.05) but not with alpha-amanitin or cycloheximide (P > 0.05).	Cycloheximide	224-237	insulin-like growth factor 1	Mus musculus	44-72
10366413-5	1999	Cycloheximide is able to inhibit both basal and TGF-stimulated release of IGF-I and a similar effect was elicited by octreotide, the somatostatin analog, known to directly affect hepatic IGF-I gene expression.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	74-79
10366413-5	1999	Cycloheximide is able to inhibit both basal and TGF-stimulated release of IGF-I and a similar effect was elicited by octreotide, the somatostatin analog, known to directly affect hepatic IGF-I gene expression.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	187-192
10389635-9	1999	Induction was blocked by cordycepin as well as by cycloheximide indicating that both, mRNA and protein synthesis, are required for UVA-induction of hsp72.	Cycloheximide	50-63	heat shock protein family A (Hsp70) member 1A	Homo sapiens	148-153
10349860-6	1999	Hypoxia-mediated induction of this splice variant was blocked by pretreatment of neuroblastoma cells with the protein synthesis inhibitor cycloheximide or antioxidants such as N-acetylcysteine and diphenyl iodonium, suggesting that hypoxia-mediated oxidant stress might, at least in part, underlie the alternative splicing of PS-2 mRNA through de novo protein synthesis.	Cycloheximide	138-151	presenilin 2	Homo sapiens	326-330
10395406-12	1999	Administration of cycloheximide to hypergastrinemic rats (undergoing omeprazole treatment) resulted in a rapid decline of the HDC activity (estimated half-life 1 h and 50 min).	Cycloheximide	18-31	histidine decarboxylase	Rattus norvegicus	126-129
10408258-3	1999	The increase in VEGF concentrations in the supernatants containing 10 U/ml rHuEpo was abolished by incubation with 10 microg/ml of anti-human rHuEPO antiserum, 0.2 microg/ml actinomycin D or 10 microg/ml cycloheximide.	Cycloheximide	204-217	vascular endothelial growth factor A	Homo sapiens	16-20
10229670-4	1999	PGE generation by goldfish macrophages was similarly inhibited by the glucocorticoid, dexamethasone, and an inhibitor of protein synthesis, cycloheximide, suggesting that this stimulation may be due to an inducible enzyme equivalent to mammalian COX-2.	Cycloheximide	140-153	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	246-251
10320796-3	1999	Pretreatment with cycloheximide, an inhibitor of protein synthesis, or simultaneous treatment with Dex, an inhibitor of AP-1, suppressed the TPA-mediated downregulation of NT-3 gene expression.	Cycloheximide	18-31	neurotrophin 3	Rattus norvegicus	172-176
10397172-5	1999	This block in IL-2 mRNA splicing is relieved by the translation inhibitor, cycloheximide (CHX), which does not stimulate transcription [Gerez et al., J. Biol.	Cycloheximide	75-88	interleukin 2	Homo sapiens	14-18
10397172-5	1999	This block in IL-2 mRNA splicing is relieved by the translation inhibitor, cycloheximide (CHX), which does not stimulate transcription [Gerez et al., J. Biol.	Cycloheximide	90-93	interleukin 2	Homo sapiens	14-18
10397172-8	1999	We show that suppression of IL-2 mRNA expression, whether by CD8 cells, soluble mediators derived from them, or IL-10, is relieved completely by CHX.	Cycloheximide	145-148	interleukin 2	Homo sapiens	28-32
10397172-8	1999	We show that suppression of IL-2 mRNA expression, whether by CD8 cells, soluble mediators derived from them, or IL-10, is relieved completely by CHX.	Cycloheximide	145-148	CD8a molecule	Homo sapiens	61-64
10397172-8	1999	We show that suppression of IL-2 mRNA expression, whether by CD8 cells, soluble mediators derived from them, or IL-10, is relieved completely by CHX.	Cycloheximide	145-148	interleukin 10	Homo sapiens	112-117
10233014-6	1999	On the contrary, treatment with cycloheximide resulted in a decrease in the stability of Cx32 mRNA without an apparent change of the poly(A) tail size.	Cycloheximide	32-45	gap junction protein, beta 1	Rattus norvegicus	89-93
10470105-6	1999	Incubation with TNF alpha (+/- cycloheximide) led to activation of the caspase cascade and was followed by apoptosis.	Cycloheximide	31-44	tumor necrosis factor	Homo sapiens	16-25
10216102-7	1999	A potent activation of caspase-8 was also induced by cycloheximide, indicating that it was independent of protein synthesis.	Cycloheximide	53-66	caspase 8	Homo sapiens	23-32
10233014-7	1999	The effect of cycloheximide on Cx32 mRNA stability seems to be due indirectly to the induction of an inflammatory response by this drug.	Cycloheximide	14-27	gap junction protein, beta 1	Rattus norvegicus	31-35
10385262-6	1999	IL-1alpha-dependent receptor induction was blocked by cycloheximide.	Cycloheximide	54-67	interleukin 1 alpha	Homo sapiens	0-9
10222064-5	1999	Cycloheximide (protein synthesis inhibitor), tunicamycin (N-linked glycosylation inhibitor), and beta-d-xyloside (chondroitin sulfation inhibitor) all inhibited IL-4-mediated downregulation of TNFalpha-induced monocyte HA binding.	Cycloheximide	0-13	interleukin 4	Homo sapiens	161-165
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cycloheximide	15-28	mitogen-activated protein kinase 3	Homo sapiens	73-79
10353733-7	1999	Treatment with cycloheximide resulted in inhibition of cisplatin-induced ERK1/2 activation, demonstrating that ERK1/2 activity induced by cisplatin was dependent on de novo protein synthesis.	Cycloheximide	15-28	mitogen-activated protein kinase 3	Homo sapiens	111-117
10222064-5	1999	Cycloheximide (protein synthesis inhibitor), tunicamycin (N-linked glycosylation inhibitor), and beta-d-xyloside (chondroitin sulfation inhibitor) all inhibited IL-4-mediated downregulation of TNFalpha-induced monocyte HA binding.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	193-201
10340762-7	1999	The decrease was not observed when IkappaBalpha resynthesis was inhibited by cycloheximide.	Cycloheximide	77-90	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	35-47
10320526-2	1999	Treatment of MC3T3-E1 cells with PTH(1-34) (10-8M) or forskolin (FSK; 10-5M) transiently increased a 7 kb FGF-2 transcript with a peak at 2 h. The PTH increase in FGF-2 mRNA was maintained in the presence of cycloheximide.	Cycloheximide	208-221	fibroblast growth factor 2	Mus musculus	106-111
10360689-19	1999	Blocking RNA synthesis with actinomycin D or preventing protein synthesis with cycloheximide abolished or decreased particle-induced release of TNF-alpha and IL-6 from the macrophages.	Cycloheximide	79-92	tumor necrosis factor	Homo sapiens	144-153
10360689-19	1999	Blocking RNA synthesis with actinomycin D or preventing protein synthesis with cycloheximide abolished or decreased particle-induced release of TNF-alpha and IL-6 from the macrophages.	Cycloheximide	79-92	interleukin 6	Homo sapiens	158-162
10228004-6	1999	In fact, anti-CD95L mAb inhibited partially (50%) T cell-mediated XS52 cell death, and coupling of surface CD95 with anti-CD95 mAb triggered significant XS52 cell death, but only in the presence of cycloheximide.	Cycloheximide	198-211	Fas (TNF receptor superfamily member 6)	Mus musculus	107-111
10331497-2	1999	MCP-1 mRNA was first detected by Northern analysis at 8 h, and the peak level was detected at 16 h and sustained until 72 h. Cycloheximide and genistein, but not pertussis toxin, inhibited the expression of MCP-1 mRNA.	Cycloheximide	125-138	C-C motif chemokine ligand 2	Homo sapiens	0-5
10331497-2	1999	MCP-1 mRNA was first detected by Northern analysis at 8 h, and the peak level was detected at 16 h and sustained until 72 h. Cycloheximide and genistein, but not pertussis toxin, inhibited the expression of MCP-1 mRNA.	Cycloheximide	125-138	C-C motif chemokine ligand 2	Homo sapiens	207-212
10215633-4	1999	In the RA and CM, functional iNOS induction was blocked by both actinomycin D and cycloheximide; actinomycin D also blocked the appearance of iNOS mRNA in both tissues.	Cycloheximide	82-95	nitric oxide synthase 2	Rattus norvegicus	29-33
10215633-5	1999	In contrast, cycloheximide blocked CM (but not RA) iNOS mRNA induction.	Cycloheximide	13-26	nitric oxide synthase 2	Rattus norvegicus	51-55
10231432-8	1999	The increase in 2DOG uptake by TGF-beta 1 was completely abolished by the addition of 1 microgram/ml cycloheximide, and kinetic analysis of 2DOG or 3OMG uptake revealed an increase in Vmax by TGF-beta 1.	Cycloheximide	101-114	transforming growth factor beta-1 proprotein	Canis lupus familiaris	31-41
10231432-8	1999	The increase in 2DOG uptake by TGF-beta 1 was completely abolished by the addition of 1 microgram/ml cycloheximide, and kinetic analysis of 2DOG or 3OMG uptake revealed an increase in Vmax by TGF-beta 1.	Cycloheximide	101-114	transforming growth factor beta-1 proprotein	Canis lupus familiaris	192-202
10393506-7	1999	In addition, TNF-alpha reduced eNOS mRNA levels and this was prevented by coincubation with cycloheximide.	Cycloheximide	92-105	tumor necrosis factor	Homo sapiens	13-22
10393506-11	1999	Cycloheximide prevented the binding activity of the cytosolic protein to 3"-UTR eNOS mRNA related to TNF-alpha; this effect was associated with greater eNOS mRNA levels.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	101-110
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	263-276	interferon gamma	Homo sapiens	69-78
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	263-276	interferon gamma	Homo sapiens	152-161
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	263-276	interferon gamma	Homo sapiens	152-161
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	278-281	interferon gamma	Homo sapiens	69-78
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	278-281	interferon gamma	Homo sapiens	152-161
10320641-5	1999	An increase in H mRNA was observed as early as 2 h after addition of IFN-gamma; the response peaked at 24 h. The half-life of H mRNA in the presence of IFN-gamma was 3.8 +/- 0.8 h. The increase in H mRNA by IFN-gamma was partly dependent on protein synthesis, as cycloheximide (CHX) reduced the response by 40% and the level of H mRNA decreased in a dose-dependent manner with increasing concentrations of CHX.	Cycloheximide	278-281	interferon gamma	Homo sapiens	152-161
10355595-1	1999	Treatment of neutrophils with tumor necrosis factor-alpha (TNF-alpha) in the presence of cycloheximide induced apoptosis within 3 h, as evaluated by the occurrence of morphological nuclear changes characteristic of apoptosis.	Cycloheximide	89-102	tumor necrosis factor	Homo sapiens	30-57
10355595-1	1999	Treatment of neutrophils with tumor necrosis factor-alpha (TNF-alpha) in the presence of cycloheximide induced apoptosis within 3 h, as evaluated by the occurrence of morphological nuclear changes characteristic of apoptosis.	Cycloheximide	89-102	tumor necrosis factor	Homo sapiens	59-68
10355595-2	1999	Pretreatment of neutrophils with dibutyryl cyclic AMP (dbcAMP) suppressed the TNF-alpha/cycloheximide-induced apoptosis in neutrophils in a concentration-dependent manner, while dbcAMP by itself did not induce any morphological changes.	Cycloheximide	88-101	tumor necrosis factor	Homo sapiens	78-87
10355595-5	1999	DbcAMP also inhibited the TNF-alpha/cycloheximide-induced activation of caspase-3, but it had no effect on the activation of caspase-8 in human neutrophils.	Cycloheximide	36-49	tumor necrosis factor	Homo sapiens	26-35
10355595-5	1999	DbcAMP also inhibited the TNF-alpha/cycloheximide-induced activation of caspase-3, but it had no effect on the activation of caspase-8 in human neutrophils.	Cycloheximide	36-49	caspase 3	Homo sapiens	72-81
10189355-5	1999	Cycloheximide prolonged the increase in Egr-1 and c-jun mRNA and caused superinduction of both.	Cycloheximide	0-13	early growth response 1	Rattus norvegicus	40-45
10199399-4	1999	We provide functional and mechanistic evidence that SRA acts as an RNA transcript; transfected SRA, unlike other steroid receptor coregulators, functions in the presence of cycloheximide, and SRA mutants containing multiple translational stop signals retain their ability to activate steroid receptor-dependent gene expression.	Cycloheximide	173-186	steroid receptor RNA activator 1	Homo sapiens	52-55
10199399-4	1999	We provide functional and mechanistic evidence that SRA acts as an RNA transcript; transfected SRA, unlike other steroid receptor coregulators, functions in the presence of cycloheximide, and SRA mutants containing multiple translational stop signals retain their ability to activate steroid receptor-dependent gene expression.	Cycloheximide	173-186	steroid receptor RNA activator 1	Homo sapiens	95-98
10199399-4	1999	We provide functional and mechanistic evidence that SRA acts as an RNA transcript; transfected SRA, unlike other steroid receptor coregulators, functions in the presence of cycloheximide, and SRA mutants containing multiple translational stop signals retain their ability to activate steroid receptor-dependent gene expression.	Cycloheximide	173-186	steroid receptor RNA activator 1	Homo sapiens	95-98
10230502-3	1999	The expression of mGBP3 protein was also apparent by 4 and 6 h after the treatment of cells with IFN-gamma (100 U/ml) or LPS (1 microgram/ml), and remained at plateau for at least 24 h. Cycloheximide (10 micrograms/ml) had no effect on the IFN-gamma- or LPS-induced mGBP3 expression, suggesting that the mGBP3 induction did not require further protein synthesis.	Cycloheximide	186-199	guanylate binding protein 3	Mus musculus	18-23
10401681-7	1999	Membrane translocation of c-Src occurred in the presence of 100 microM cycloheximide and was observed after treatment with 1 nM TCDD or 50 nM 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin.	Cycloheximide	71-84	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	26-31
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	caspase 3	Homo sapiens	131-155
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	cytochrome c, somatic	Homo sapiens	194-206
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	BCL2 like 1	Homo sapiens	221-227
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	BCL2 apoptosis regulator	Homo sapiens	257-262
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	264-269
10381626-5	1999	Exposure of TPA-differentiated U937 cells to 0.8 microg/ml cycloheximide for 24 h, that triggers apoptosis in 50% cells, activates procaspase-2L, -3 and -8, induces the mitochondrial release of cytochrome c and decreases Bcl-xL expression without modifying Bcl-2, Mcl-1 and Bax protein levels.	Cycloheximide	59-72	BCL2 associated X, apoptosis regulator	Homo sapiens	274-277
10098503-7	1999	In contrast, the induction of 3beta-HSD mRNA by GH is altered by cycloheximide treatment.	Cycloheximide	65-78	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	30-39
10098511-10	1999	Inhibition of protein synthesis by cycloheximide (CHX) drastically diminished the hCG-induced StAR protein content, indicating the requirement for on-going protein synthesis for hCG action.	Cycloheximide	35-48	hypertrichosis 2 (generalised, congenital)	Homo sapiens	82-85
10098511-10	1999	Inhibition of protein synthesis by cycloheximide (CHX) drastically diminished the hCG-induced StAR protein content, indicating the requirement for on-going protein synthesis for hCG action.	Cycloheximide	35-48	steroidogenic acute regulatory protein	Mus musculus	94-98
10098511-10	1999	Inhibition of protein synthesis by cycloheximide (CHX) drastically diminished the hCG-induced StAR protein content, indicating the requirement for on-going protein synthesis for hCG action.	Cycloheximide	50-53	hypertrichosis 2 (generalised, congenital)	Homo sapiens	82-85
10098511-10	1999	Inhibition of protein synthesis by cycloheximide (CHX) drastically diminished the hCG-induced StAR protein content, indicating the requirement for on-going protein synthesis for hCG action.	Cycloheximide	50-53	steroidogenic acute regulatory protein	Mus musculus	94-98
10460009-7	1999	Furthermore, this c-fos expression is not inhibited by cycloheximide, but is completely abolished by pretreatment with TPA, so that the c-fos gene is a direct target of TGF-beta1 signalling and PKC is involved in this c-fos induction.	Cycloheximide	55-68	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	18-23
10460009-7	1999	Furthermore, this c-fos expression is not inhibited by cycloheximide, but is completely abolished by pretreatment with TPA, so that the c-fos gene is a direct target of TGF-beta1 signalling and PKC is involved in this c-fos induction.	Cycloheximide	55-68	transforming growth factor, beta 1	Rattus norvegicus	169-178
10084996-12	1999	In addition, a protein synthesis inhibitor, cycloheximide, inhibited VEGF mRNA accumulation in response to LPS.	Cycloheximide	44-57	vascular endothelial growth factor A	Homo sapiens	69-73
10201951-7	1999	Further, EMSA with human fibroblast nuclear extracts demonstrated enhanced binding of a single, specific complex within 5 min of TNF-alpha stimulation, which reached a plateau by 1 h and was not affected by preincubation of cells with cycloheximide.	Cycloheximide	235-248	tumor necrosis factor	Homo sapiens	129-138
10086995-6	1999	An enhanced gene transcription is the most likely mechanism involved in the tretinoin-induced stimulation of MC antioxidant defense systems because 1) preincubation of MCs with actinomycin D or cycloheximide fully abolished it; 2) tretinoin-incubated MCs showed increased levels of catalase mRNA and gamma-glutamyl-cysteine synthetase (catalytic subunit) mRNA, the latter being the rate-limiting step in de novo reduced glutathione synthesis; and 3) the stability of both mRNA was unchanged by tretinoin.	Cycloheximide	194-207	catalase	Rattus norvegicus	282-290
10200990-11	1999	Estradiol-enhanced binding of nuclear extracts to the AP-1 oligonucleotide was reversed by cycloheximide.	Cycloheximide	91-104	jun proto-oncogene	Mus musculus	54-58
10082548-6	1999	Following microinjection of HaeIII into lactacystin-treated normal fibroblasts, lactacystin-induced p53 protein is phosphorylated at serine 15 and stabilized even in the presence of cycloheximide.	Cycloheximide	182-195	tumor protein p53	Homo sapiens	100-103
10101022-4	1999	The response was cycloheximide-sensitive, because the protein synthesis inhibitor caused a GC-dependent superinduction of ALDH3 mRNA levels.	Cycloheximide	17-30	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	122-127
10074163-10	1999	However, RANTES mRNA was superinduced by measles virus in the presence of cycloheximide.	Cycloheximide	74-87	C-C motif chemokine ligand 5	Homo sapiens	9-15
10074167-14	1999	However, EBNA-1 protein levels showed no detectable change during the cell cycle, most likely due to the protein"s long half-life as estimated by inhibition of protein synthesis by cycloheximide.	Cycloheximide	181-194	EBNA-1	Human gammaherpesvirus 4	9-15
10085077-4	1999	TWEAK is a weak inducer of apoptosis in transformed cells when administered with interferon-gamma or cycloheximide (Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu Y. M., Scott, H., Hession, C., Garcia, I., and Browning, J. L. (1997) J. Biol.	Cycloheximide	101-114	TNF superfamily member 12	Homo sapiens	0-5
10085100-4	1999	GC-induced IL-1R2 gene transcription displayed features characteristic of a classical immediate early gene response, including a signal transduction function, a relatively low basal abundance, a rapid, transient induction, cycloheximide superinduction, actinomycin D suppression, and a rapid decay of IL-1R2 RNA message.	Cycloheximide	223-236	interleukin 1 receptor type 2	Homo sapiens	11-17
10375015-8	1999	Experiments with actinomycin D and cycloheximide suggested that estrogen induction of VEGF mRNA is dependent on the synthesis of new mRNA and increased mRNA half-life.	Cycloheximide	35-48	vascular endothelial growth factor A	Homo sapiens	86-90
10051448-5	1999	Treatment of IEC-18 cells with actinomycin D or cycloheximide attenuated mucin-enhanced ITF binding.	Cycloheximide	48-61	solute carrier family 13 member 2	Rattus norvegicus	73-78
10051448-5	1999	Treatment of IEC-18 cells with actinomycin D or cycloheximide attenuated mucin-enhanced ITF binding.	Cycloheximide	48-61	trefoil factor 3	Rattus norvegicus	88-91
10074923-10	1999	The treatment of tumor cells with cycloheximide reduced the activity in alpha-MSH-stimulated CM.	Cycloheximide	34-47	pro-opiomelanocortin-alpha	Mus musculus	72-81
10066786-1	1999	Cycloheximide (CHX) can contribute to apoptotic processes, either in conjunction with another agent (e.g. tumor necrosis factor-alpha) or on its own.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	106-133
10066786-1	1999	Cycloheximide (CHX) can contribute to apoptotic processes, either in conjunction with another agent (e.g. tumor necrosis factor-alpha) or on its own.	Cycloheximide	15-18	tumor necrosis factor	Homo sapiens	106-133
10066786-4	1999	In T-cells undergoing CHX-induced apoptosis (Jurkat), but not in T-cells resistant to the effects of CHX (CEM C7), caspase-8 and caspase-3 were activated.	Cycloheximide	22-25	caspase 3	Homo sapiens	129-138
10339655-3	1999	Results showed that APC and beta-actin mRNA levels were significantly increased in a dose-dependent manner after CHX treatment.	Cycloheximide	113-116	POTE ankyrin domain family member F	Homo sapiens	28-38
10030848-9	1999	LPS-induced PGHS-2 expression, TXB2 release, and pulmonary hypertension were inhibited by actinomycin D (an inhibitor of transcription) and cycloheximide (an inhibitor of protein synthesis).	Cycloheximide	140-153	prostaglandin G/H synthase 2	Oryctolagus cuniculus	12-18
10070056-11	1999	Addition of cycloheximide during ASN and ASN plus EGF treatment completely inhibited ODC activity without affecting the level of ODC protein.	Cycloheximide	12-25	ornithine decarboxylase 1	Rattus norvegicus	85-88
10070162-4	1999	Our results indicate that although C2 ceramide was toxic to mesangial cells, the cell death it induced differed both morphologically and biochemically from that induced by TNF-alpha in the presence of cycloheximide (CHX).	Cycloheximide	216-219	tumor necrosis factor	Rattus norvegicus	172-181
10204691-5	1999	Prior administration of the protein synthesis inhibitor cycloheximide blocked the haloperidol- and (-)-sulpiride-mediated induction of NGF mRNA.	Cycloheximide	56-69	nerve growth factor	Homo sapiens	135-138
10070162-9	1999	Furthermore, the cleavage of cytosolic phospholipase A2 during cell death induced by C2 ceramide and by TNF-alpha in the presence of CHX showed distinctive patterns.	Cycloheximide	133-136	phospholipase A2 group IVA	Rattus norvegicus	29-55
10070162-9	1999	Furthermore, the cleavage of cytosolic phospholipase A2 during cell death induced by C2 ceramide and by TNF-alpha in the presence of CHX showed distinctive patterns.	Cycloheximide	133-136	tumor necrosis factor	Rattus norvegicus	104-113
10228559-10	1999	The increase in AP-1 DNA-binding activity and the increase in ERCC-1 mRNA expression were prevented by pretreatment with cycloheximide.	Cycloheximide	121-134	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-20
10228559-10	1999	The increase in AP-1 DNA-binding activity and the increase in ERCC-1 mRNA expression were prevented by pretreatment with cycloheximide.	Cycloheximide	121-134	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	62-68
10029562-5	1999	The in vitro angiotensin II effects were abolished by candesartan cilexetil, an inhibitor of the membrane-bound AT1 receptor, and also by actinomycin D, an RNA synthesis inhibitor, and cycloheximide, a protein synthesis inhibitor, indicating that endothelin-1 release depended on AT1 receptor subtype and de novo protein synthesis.	Cycloheximide	185-198	angiotensinogen	Homo sapiens	13-27
10029562-5	1999	The in vitro angiotensin II effects were abolished by candesartan cilexetil, an inhibitor of the membrane-bound AT1 receptor, and also by actinomycin D, an RNA synthesis inhibitor, and cycloheximide, a protein synthesis inhibitor, indicating that endothelin-1 release depended on AT1 receptor subtype and de novo protein synthesis.	Cycloheximide	185-198	endothelin 1	Homo sapiens	247-259
10067826-8	1999	Moreover, competitive RT-PCR analysis revealed that 1-h treatment with CT reduced the level of CTR heterogeneous nuclear RNA to 10% in a cycloheximide-independent manner.	Cycloheximide	137-150	calcitonin receptor	Mus musculus	95-98
10067827-7	1999	The stimulation of HGF/SF mRNA expression by FGF-2 was blocked by cycloheximide, a protein synthesis inhibitor, but not by DNA or prostaglandin synthesis inhibitors.	Cycloheximide	66-79	hepatocyte growth factor	Mus musculus	19-25
10067827-7	1999	The stimulation of HGF/SF mRNA expression by FGF-2 was blocked by cycloheximide, a protein synthesis inhibitor, but not by DNA or prostaglandin synthesis inhibitors.	Cycloheximide	66-79	fibroblast growth factor 2	Mus musculus	45-50
10067845-6	1999	In response to 1,25-(OH)2D3, AR mRNA levels were first detected to rise at 8 h and reached a maximal induction of 10-fold over the untreated control at 48 h; the effect was sustained at 72 h. Furthermore, the induction of AR mRNA by 1,25-(OH)2D3 was completely abolished by incubation of cells with cycloheximide, a protein synthesis inhibitor.	Cycloheximide	299-312	androgen receptor	Homo sapiens	29-31
10067845-6	1999	In response to 1,25-(OH)2D3, AR mRNA levels were first detected to rise at 8 h and reached a maximal induction of 10-fold over the untreated control at 48 h; the effect was sustained at 72 h. Furthermore, the induction of AR mRNA by 1,25-(OH)2D3 was completely abolished by incubation of cells with cycloheximide, a protein synthesis inhibitor.	Cycloheximide	299-312	androgen receptor	Homo sapiens	222-224
9971806-4	1999	An immediate-early gene, Rta (open reading frame 50 [ORF50]), was induced within 4 h of the addition of n-butyrate, and its 3.6-kb mRNA was resistant to inhibition by cycloheximide.	Cycloheximide	167-180	MAS related GPR family member F	Homo sapiens	25-28
9927311-6	1999	Treatment with cycloheximide or alpha-amanitin abolished LH-induced PACAP transcripts, indicating that new protein synthesis and transcription are necessary.	Cycloheximide	15-28	adenylate cyclase activating polypeptide 1	Rattus norvegicus	68-73
9927313-5	1999	Messenger RNA for C/EBP beta and delta were induced by inhibition of protein synthesis with cycloheximide and cycloheximide acted synergistically with cAMP.	Cycloheximide	92-105	CCAAT/enhancer binding protein beta	Rattus norvegicus	18-28
9927313-5	1999	Messenger RNA for C/EBP beta and delta were induced by inhibition of protein synthesis with cycloheximide and cycloheximide acted synergistically with cAMP.	Cycloheximide	110-123	CCAAT/enhancer binding protein beta	Rattus norvegicus	18-28
9927318-8	1999	IGF-I inhibition of PTH/PTHrP receptor mRNA expression in UMR-106 cells was abrogated completely by pretreatment with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	118-131	insulin-like growth factor 1	Rattus norvegicus	0-5
9927318-8	1999	IGF-I inhibition of PTH/PTHrP receptor mRNA expression in UMR-106 cells was abrogated completely by pretreatment with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	118-131	parathyroid hormone	Rattus norvegicus	20-23
9927318-8	1999	IGF-I inhibition of PTH/PTHrP receptor mRNA expression in UMR-106 cells was abrogated completely by pretreatment with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	118-131	parathyroid hormone-like hormone	Rattus norvegicus	24-29
9927334-6	1999	Furthermore, the addition of cycloheximide inhibited expression of IGFBP-1 in cytochalasin D-treated cells.	Cycloheximide	29-42	insulin-like growth factor-binding protein 1	Papio anubis	67-74
9927334-9	1999	In these studies, IGFBP-1 expression was also inhibited by cycloheximide.	Cycloheximide	59-72	insulin-like growth factor-binding protein 1	Papio anubis	18-25
10334298-8	1999	PPAR-gamma reporter assays showed that PPAR-gamma activation by troglitazone was completely blocked by actinomycin D and cycloheximide.	Cycloheximide	121-134	peroxisome proliferator-activated receptor gamma	Cricetulus griseus	0-10
10334298-8	1999	PPAR-gamma reporter assays showed that PPAR-gamma activation by troglitazone was completely blocked by actinomycin D and cycloheximide.	Cycloheximide	121-134	peroxisome proliferator-activated receptor gamma	Cricetulus griseus	39-49
10334301-6	1999	Cycloheximide treatment did not significantly affect ob mRNA accumulation, but it reduced total secreted leptin.	Cycloheximide	0-13	leptin	Rattus norvegicus	105-111
10082623-3	1999	T3 stimulation of 3beta-HSD activity could be blocked by cycloheximide indicating the involvement of T3-induced protein (TIP) isolated and purified earlier from this laboratory.	Cycloheximide	57-70	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	18-27
9917505-10	1999	In addition, the induction of MMP-9 expression by TNF-alpha was completely abrogated in the presence of cycloheximide, a protein synthesis inhibitor, suggesting that de novo protein synthesis may be required.	Cycloheximide	104-117	matrix metallopeptidase 9	Homo sapiens	30-35
9917505-10	1999	In addition, the induction of MMP-9 expression by TNF-alpha was completely abrogated in the presence of cycloheximide, a protein synthesis inhibitor, suggesting that de novo protein synthesis may be required.	Cycloheximide	104-117	tumor necrosis factor	Homo sapiens	50-59
10195376-12	1999	Incubation of cultured GH secreting tumors with cycloheximide during 5 days blocked both basal and TRH stimulated GH secretion, thus indicating dependency on protein synthesis during the chronic, secondary phase.	Cycloheximide	48-61	growth hormone 1	Homo sapiens	23-25
10195376-12	1999	Incubation of cultured GH secreting tumors with cycloheximide during 5 days blocked both basal and TRH stimulated GH secretion, thus indicating dependency on protein synthesis during the chronic, secondary phase.	Cycloheximide	48-61	thyrotropin releasing hormone	Homo sapiens	99-102
10195376-12	1999	Incubation of cultured GH secreting tumors with cycloheximide during 5 days blocked both basal and TRH stimulated GH secretion, thus indicating dependency on protein synthesis during the chronic, secondary phase.	Cycloheximide	48-61	growth hormone 1	Homo sapiens	114-116
10101098-3	1999	Several protein synthesis inhibitors, cycloheximide, puromycin, and emetine, induced 10 to 15% apoptosis in hepatocytes after 4 h, as was determined by changes in nuclear morphology and flow cytometric analysis of Annexin V-positive cells.	Cycloheximide	38-51	annexin A5	Rattus norvegicus	214-223
10049759-4	1999	Actinomycin D and cycloheximide blocked the IGF-I effect, but not the insulin effect, suggesting that IGF-I stimulated the synthesis of IRS-1.	Cycloheximide	18-31	insulin like growth factor 1	Homo sapiens	44-49
10049759-4	1999	Actinomycin D and cycloheximide blocked the IGF-I effect, but not the insulin effect, suggesting that IGF-I stimulated the synthesis of IRS-1.	Cycloheximide	18-31	insulin like growth factor 1	Homo sapiens	102-107
10049759-4	1999	Actinomycin D and cycloheximide blocked the IGF-I effect, but not the insulin effect, suggesting that IGF-I stimulated the synthesis of IRS-1.	Cycloheximide	18-31	insulin receptor substrate 1	Homo sapiens	136-141
10195463-4	1999	However, the significant increase in the enzyme activity was found after 1 ng/ml PMA treatment for 1 h, while increasing MMP-9 mRNA transcription was only obvious after 1 ng/ml PMA treatment for 3 h. Moreover, secretion of MMP-9 protein was not inhibited by actinomycin D and cycloheximide.	Cycloheximide	276-289	matrix metallopeptidase 9	Bos taurus	121-126
10195463-4	1999	However, the significant increase in the enzyme activity was found after 1 ng/ml PMA treatment for 1 h, while increasing MMP-9 mRNA transcription was only obvious after 1 ng/ml PMA treatment for 3 h. Moreover, secretion of MMP-9 protein was not inhibited by actinomycin D and cycloheximide.	Cycloheximide	276-289	matrix metallopeptidase 9	Bos taurus	223-228
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	36-49	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	51-54	ATP binding cassette subfamily B member 1	Homo sapiens	57-61
10026303-3	1999	After treatment of MCF-7 cells with cycloheximide (CHX), MDR1 mRNA reached detectable levels, suggesting that MDR1 mRNA expression might be controlled by a labile negative regulatory protein(s) in MCF-7 cells.	Cycloheximide	51-54	ATP binding cassette subfamily B member 1	Homo sapiens	110-114
9973525-4	1999	The ability of Tat to up-regulate CXCR4 expression was abrogated by the protein synthesis inhibitor cycloheximide, clearly indicating the requirement of de novo synthesis.	Cycloheximide	100-113	tyrosine aminotransferase	Homo sapiens	15-18
9973525-4	1999	The ability of Tat to up-regulate CXCR4 expression was abrogated by the protein synthesis inhibitor cycloheximide, clearly indicating the requirement of de novo synthesis.	Cycloheximide	100-113	C-X-C motif chemokine receptor 4	Homo sapiens	34-39
10036222-9	1999	Further, liver CYP1A4 and 1A5 mRNAs had the same half lives and were both superinduced by cycloheximide, whereas mRNA half lives differ for CYP1A1 and 1A2, and cycloheximide superinduces only CYP1A1.	Cycloheximide	90-103	cytochrome P450 1A2	Gallus gallus	15-29
9933632-6	1999	Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappaB may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	67-76
9933632-6	1999	Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappaB may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	nuclear factor kappa B subunit 1	Homo sapiens	196-205
9933632-6	1999	Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappaB may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	304-313
9933632-6	1999	Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappaB may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	131-144	nuclear factor kappa B subunit 1	Homo sapiens	196-205
10076048-5	1999	Protective effects of cycloheximide, which enhances the expression of Bcl-2 protein, may further confirm our hypothesis that the megamitochondria formation is a cellular response to an increased ROS generation and raise a possibility that antiapoptotic action of the drug is exerted via the protection of the mitochondria functions.	Cycloheximide	22-35	BCL2, apoptosis regulator	Rattus norvegicus	70-75
9895307-4	1999	The increase in p21/CIP1 mRNA upon addition of EGF was rapid, and was enhanced in the presence of cycloheximide.	Cycloheximide	98-111	cyclin dependent kinase inhibitor 1A	Homo sapiens	16-19
9895307-4	1999	The increase in p21/CIP1 mRNA upon addition of EGF was rapid, and was enhanced in the presence of cycloheximide.	Cycloheximide	98-111	cyclin dependent kinase inhibitor 1A	Homo sapiens	20-24
9895307-4	1999	The increase in p21/CIP1 mRNA upon addition of EGF was rapid, and was enhanced in the presence of cycloheximide.	Cycloheximide	98-111	epidermal growth factor	Homo sapiens	47-50
9891045-4	1999	Induction of c-Myc mRNA by Raf was an immediate-early response, whereas the induction of cyclin D1 mRNA was delayed and inhibited by cycloheximide.	Cycloheximide	133-146	cyclin D1	Homo sapiens	89-98
10100302-8	1999	The regulation of UGT1A1 and UGT2B1 by dexamethasone was dose and time dependent, and the induction of dexamethasone in the expression of UGT1A1 and UGT2B1 was blocked by cycloheximide but not dichloro-1-D-ribofuranosylbenzimidazole.	Cycloheximide	171-184	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	18-24
10100302-8	1999	The regulation of UGT1A1 and UGT2B1 by dexamethasone was dose and time dependent, and the induction of dexamethasone in the expression of UGT1A1 and UGT2B1 was blocked by cycloheximide but not dichloro-1-D-ribofuranosylbenzimidazole.	Cycloheximide	171-184	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	29-35
10100302-8	1999	The regulation of UGT1A1 and UGT2B1 by dexamethasone was dose and time dependent, and the induction of dexamethasone in the expression of UGT1A1 and UGT2B1 was blocked by cycloheximide but not dichloro-1-D-ribofuranosylbenzimidazole.	Cycloheximide	171-184	UDP glucuronosyltransferase family 1 member A1	Rattus norvegicus	138-144
10100302-8	1999	The regulation of UGT1A1 and UGT2B1 by dexamethasone was dose and time dependent, and the induction of dexamethasone in the expression of UGT1A1 and UGT2B1 was blocked by cycloheximide but not dichloro-1-D-ribofuranosylbenzimidazole.	Cycloheximide	171-184	UDP glucuronosyltransferase family 2 member B17	Rattus norvegicus	149-155
10202812-3	1999	Cycloheximide inhibited the CO2 stress-induced ethylene production but superinduced the accumulation of CS-ACS1 transcript.	Cycloheximide	0-13	1-aminocyclopropane-1-carboxylate synthase CMW33	Cucumis sativus	104-111
10202812-4	1999	At higher concentrations, cycloheximide also induced the accumulation of CS-ACS2 and CS-ACS3 transcripts.	Cycloheximide	26-39	1-aminocyclopropane-1-carboxylate synthase-like	Cucumis sativus	73-80
10202812-4	1999	At higher concentrations, cycloheximide also induced the accumulation of CS-ACS2 and CS-ACS3 transcripts.	Cycloheximide	26-39	1-aminocyclopropane-1-carboxylate synthase CMA101	Cucumis sativus	85-92
10202812-5	1999	In the presence of CO2 and cycloheximide, the accumulation of CS-ACS2 transcript occurred within 1 h, disappeared after 3 h and increased greatly upon withdrawal of CO2.	Cycloheximide	27-40	1-aminocyclopropane-1-carboxylate synthase-like	Cucumis sativus	62-69
10202812-7	1999	The results presented here identify CS-ACS1 as the main ACC synthase gene responsible for the increased ethylene biosynthesis in cucumber fruit under CO2 stress and suggest that this gene is a primary response gene and its expression is under negative control since it is expressed by treatment with cycloheximide.	Cycloheximide	300-313	1-aminocyclopropane-1-carboxylate synthase CMA101	Cucumis sativus	39-43
10195688-7	1999	Cycloheximide (10 microg/ml) did not alter transcription rate following GH addition but blocked GHR/GHBP gene transcription in T3 treated cells indicating that up-regulation of GHR/GHBP gene transcription caused by T3 requires new protein synthesis and is, therefore, dependent on indirect mechanisms.	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	96-99
10195688-7	1999	Cycloheximide (10 microg/ml) did not alter transcription rate following GH addition but blocked GHR/GHBP gene transcription in T3 treated cells indicating that up-regulation of GHR/GHBP gene transcription caused by T3 requires new protein synthesis and is, therefore, dependent on indirect mechanisms.	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	100-104
10195688-7	1999	Cycloheximide (10 microg/ml) did not alter transcription rate following GH addition but blocked GHR/GHBP gene transcription in T3 treated cells indicating that up-regulation of GHR/GHBP gene transcription caused by T3 requires new protein synthesis and is, therefore, dependent on indirect mechanisms.	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	177-180
10195688-7	1999	Cycloheximide (10 microg/ml) did not alter transcription rate following GH addition but blocked GHR/GHBP gene transcription in T3 treated cells indicating that up-regulation of GHR/GHBP gene transcription caused by T3 requires new protein synthesis and is, therefore, dependent on indirect mechanisms.	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	181-185
9878697-4	1999	The enzymatic activity of iNOS was not changed by CsA, since it failed to affect NO production in cells in which iNOS had already been induced with IFN-gamma and any further induction was blocked by protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	227-240	nitric oxide synthase 2	Rattus norvegicus	26-30
9878697-4	1999	The enzymatic activity of iNOS was not changed by CsA, since it failed to affect NO production in cells in which iNOS had already been induced with IFN-gamma and any further induction was blocked by protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	242-245	nitric oxide synthase 2	Rattus norvegicus	26-30
9880508-12	1999	Northern analysis demonstrates that cycloheximide treatment abrogates the capacity of GM-CSF to decrease beta5 mRNA levels.	Cycloheximide	36-49	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	86-92
9880508-12	1999	Northern analysis demonstrates that cycloheximide treatment abrogates the capacity of GM-CSF to decrease beta5 mRNA levels.	Cycloheximide	36-49	integrin beta 5	Mus musculus	105-110
9864335-2	1999	Overexpression of any of the three FCR genes in the pdr1 pdr3 mutant resulted in increased resistance of the cells to FCZ and cycloheximide and in increased expression of PDR5, a gene coding for a drug efflux transporter of the ATP-binding cassette superfamily and whose transcription is under the control of Pdr1p and Pdr3p.	Cycloheximide	126-139	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	52-56
9864335-2	1999	Overexpression of any of the three FCR genes in the pdr1 pdr3 mutant resulted in increased resistance of the cells to FCZ and cycloheximide and in increased expression of PDR5, a gene coding for a drug efflux transporter of the ATP-binding cassette superfamily and whose transcription is under the control of Pdr1p and Pdr3p.	Cycloheximide	126-139	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	57-61
9864335-2	1999	Overexpression of any of the three FCR genes in the pdr1 pdr3 mutant resulted in increased resistance of the cells to FCZ and cycloheximide and in increased expression of PDR5, a gene coding for a drug efflux transporter of the ATP-binding cassette superfamily and whose transcription is under the control of Pdr1p and Pdr3p.	Cycloheximide	126-139	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	309-314
9864335-2	1999	Overexpression of any of the three FCR genes in the pdr1 pdr3 mutant resulted in increased resistance of the cells to FCZ and cycloheximide and in increased expression of PDR5, a gene coding for a drug efflux transporter of the ATP-binding cassette superfamily and whose transcription is under the control of Pdr1p and Pdr3p.	Cycloheximide	126-139	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	319-324
9924183-10	1999	Indeed, DEX also enhanced the RA-dependent increase in RARbeta mRNA in a cycloheximide-sensitive manner.	Cycloheximide	73-86	retinoic acid receptor, beta	Rattus norvegicus	55-62
9916736-5	1999	While actinomycin-D (1 microg/ml) had little influence on the generation of IL-8 during chemotaxis, the protein synthesis inhibitor cycloheximide (10 microg/ml) markedly blunted the accumulation of cell-associated IL-8, suggesting that new protein synthesis from preexisting mRNA was responsible for the effect.	Cycloheximide	132-145	C-X-C motif chemokine ligand 8	Homo sapiens	214-218
9918687-8	1999	In contrast, the ability of PAF to maintain sIgM and VLA-4 expression at control levels was inhibited by cycloheximide (7.	Cycloheximide	105-118	PCNA clamp associated factor	Homo sapiens	28-31
9920768-4	1999	Inhibition of protein synthesis by cycloheximide abolished the MG132- or lactacystin-induced hyperphosphorylation and DNA-binding activity of HSF1.	Cycloheximide	35-48	heat shock transcription factor 1	Homo sapiens	142-146
9873014-9	1999	The sustained synthesis of SCFm at low pH was no longer observed in the presence of cycloheximide, suggesting that SCF exon 6 skipping requires de novo protein synthesis.	Cycloheximide	84-97	kit ligand	Mus musculus	27-30
9874786-6	1999	Immunoprecipitation analysis showed that both CED-4 and CED-4 (K165R) bind directly to Drosophila caspase drICE, and the overexpression of CED-4 (K165R) inhibits CED-4-, ecdysone-, or cycloheximide-dependent caspase activation in S2 cells.	Cycloheximide	184-197	Cell death protein 4	Caenorhabditis elegans	46-51
9874786-6	1999	Immunoprecipitation analysis showed that both CED-4 and CED-4 (K165R) bind directly to Drosophila caspase drICE, and the overexpression of CED-4 (K165R) inhibits CED-4-, ecdysone-, or cycloheximide-dependent caspase activation in S2 cells.	Cycloheximide	184-197	Cell death protein 4	Caenorhabditis elegans	56-61
9874786-6	1999	Immunoprecipitation analysis showed that both CED-4 and CED-4 (K165R) bind directly to Drosophila caspase drICE, and the overexpression of CED-4 (K165R) inhibits CED-4-, ecdysone-, or cycloheximide-dependent caspase activation in S2 cells.	Cycloheximide	184-197	Death caspase-1	Drosophila melanogaster	98-105
9874786-6	1999	Immunoprecipitation analysis showed that both CED-4 and CED-4 (K165R) bind directly to Drosophila caspase drICE, and the overexpression of CED-4 (K165R) inhibits CED-4-, ecdysone-, or cycloheximide-dependent caspase activation in S2 cells.	Cycloheximide	184-197	Cell death protein 4	Caenorhabditis elegans	56-61
9874786-6	1999	Immunoprecipitation analysis showed that both CED-4 and CED-4 (K165R) bind directly to Drosophila caspase drICE, and the overexpression of CED-4 (K165R) inhibits CED-4-, ecdysone-, or cycloheximide-dependent caspase activation in S2 cells.	Cycloheximide	184-197	Cell death protein 4	Caenorhabditis elegans	56-61
9878766-5	1999	Pre-treatment with the protein synthesis inhibitor cycloheximide, as well as pre-incubation with PAb421, a p53 monoclonal antibody, significantly attenuated p53 DNA-binding activity induced by KA treatment.	Cycloheximide	51-64	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	157-160
9974134-9	1999	However, the effect of BDNF was blocked by the inhibitors of translation, cycloheximide or anisomycin.	Cycloheximide	74-87	brain derived neurotrophic factor	Homo sapiens	23-27
10592837-1	1999	In this study, we investigated the effects of Pai-Hui by acupuncture on cycloheximide (CXM)-induced impairment of the passive avoidance response in rats.	Cycloheximide	72-85	serpin family E member 1	Rattus norvegicus	46-49
10592837-1	1999	In this study, we investigated the effects of Pai-Hui by acupuncture on cycloheximide (CXM)-induced impairment of the passive avoidance response in rats.	Cycloheximide	87-90	serpin family E member 1	Rattus norvegicus	46-49
10592837-2	1999	Acupuncture at Pai-Hui (Go-20) treated 15 min before or immediately after training trial for 15 min significantly attenuated CXM-induced impairment of passive avoidance response in rats, but did not have the same effect 30 and 60 min before or 30 min after the training trial or before the retention trial.	Cycloheximide	125-128	serpin family E member 1	Rattus norvegicus	15-18
10592837-3	1999	Acupuncture at Pai-Hui 15 min before the training trial for 15, 30 and 60 min significantly attenuated CXM-induced impairment of passive avoidance response in rats, and its efficacy paralleled the acupuncture duration.	Cycloheximide	103-106	serpin family E member 1	Rattus norvegicus	15-18
10592837-6	1999	These results suggest that acupuncture at Pai-Hui mainly affects the memory storage process and has preventive and immediate therapeutic effects on CXM-induced impairment of passive avoidance response.	Cycloheximide	148-151	serpin family E member 1	Rattus norvegicus	42-45
10592837-8	1999	The preventive effect of acupuncture at Pai-Hui on CXM-induced impairment is significantly reduced by serotonergic 5-HT releaser, and slightly by cholinergic manipulations.	Cycloheximide	51-54	serpin family E member 1	Rattus norvegicus	40-43
9886918-8	1999	Exposure to 25 nM thrombin for >60 min prevented rapid cycloheximide-insensitive PAR-1 reappearance.	Cycloheximide	58-71	coagulation factor II, thrombin	Homo sapiens	18-26
9886918-9	1999	Cycloheximide-sensitive recovery of cell surface PAR-1 expression required 18 h. Therefore, both duration and concentration of thrombin exposure regulate the time course of recovery of HPAEC surface PAR-1 expression.	Cycloheximide	0-13	coagulation factor II thrombin receptor	Homo sapiens	49-54
9886918-9	1999	Cycloheximide-sensitive recovery of cell surface PAR-1 expression required 18 h. Therefore, both duration and concentration of thrombin exposure regulate the time course of recovery of HPAEC surface PAR-1 expression.	Cycloheximide	0-13	coagulation factor II, thrombin	Homo sapiens	127-135
9886918-9	1999	Cycloheximide-sensitive recovery of cell surface PAR-1 expression required 18 h. Therefore, both duration and concentration of thrombin exposure regulate the time course of recovery of HPAEC surface PAR-1 expression.	Cycloheximide	0-13	coagulation factor II thrombin receptor	Homo sapiens	199-204
14517426-5	1999	Upon exposure to estradiol, an increase in beta1, alpha5 and alpha6 integrin mRNA was observed in subconfluent cells which was abrogated by treatment with cycloheximide.	Cycloheximide	155-168	integrin subunit beta 1	Homo sapiens	43-76
10226577-2	1999	We now show that the protein synthesis inhibitors, anisomycin and cycloheximide, arrest WT cells in the G1 phase of the cell cycle and induce apoptosis in Y8 cells via a p53-independent mechanism.	Cycloheximide	66-79	transformation related protein 53, pseudogene	Mus musculus	170-173
9920290-13	1999	Cycloheximide inhibited A(II)-induced cell death, indicating that its toxicity requires de novo protein synthesis.	Cycloheximide	0-13	NLR family pyrin domain containing 3	Homo sapiens	24-29
10092954-4	1999	The level of early induction of c-myc mRNA after castration was increased in ventral prostate treated with cycloheximide, but it was almost reduced by actinomycin-D pretreatment.	Cycloheximide	107-120	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	32-37
9884348-6	1999	Finally, unlike IL-12 p40 mRNA, the constitutive accumulation of IL-18 transcripts by unstimulated cells was amplified in the presence of the translational blocker cycloheximide, which also caused a superinduction of IL-18 expression after Staphylococcus aureus stimulation.	Cycloheximide	164-177	interleukin 18	Homo sapiens	65-70
9884348-6	1999	Finally, unlike IL-12 p40 mRNA, the constitutive accumulation of IL-18 transcripts by unstimulated cells was amplified in the presence of the translational blocker cycloheximide, which also caused a superinduction of IL-18 expression after Staphylococcus aureus stimulation.	Cycloheximide	164-177	interleukin 18	Homo sapiens	217-222
9914482-6	1999	Overexpression of GTS1 considerably reduced, and disruption of GTS1 slightly decreased, cellular resistance to cycloheximide, cadmium, cisplatin and 1-chloro-2,4-dinitrophenol, which (except for cycloheximide) are all substrates of Ycf1p.	Cycloheximide	111-124	Gts1p	Saccharomyces cerevisiae S288C	18-22
9914482-6	1999	Overexpression of GTS1 considerably reduced, and disruption of GTS1 slightly decreased, cellular resistance to cycloheximide, cadmium, cisplatin and 1-chloro-2,4-dinitrophenol, which (except for cycloheximide) are all substrates of Ycf1p.	Cycloheximide	111-124	Gts1p	Saccharomyces cerevisiae S288C	63-67
9914482-6	1999	Overexpression of GTS1 considerably reduced, and disruption of GTS1 slightly decreased, cellular resistance to cycloheximide, cadmium, cisplatin and 1-chloro-2,4-dinitrophenol, which (except for cycloheximide) are all substrates of Ycf1p.	Cycloheximide	195-208	Gts1p	Saccharomyces cerevisiae S288C	18-22
10462919-2	1999	The cytotoxic effect of EDTA, methanol, DMSO, and cycloheximide on serum-free McCoy-Plovdiv cell culture (SF) was detected visually on inverted microscope and quantitatively by tests for viability (NR) and total protein (KBP).	Cycloheximide	50-63	kinesin family binding protein	Mus musculus	221-224
10588052-4	1999	The pdr3-9 allele conferred resistance of transformed cells to cycloheximide, chloramphenicol, mucidin and oligomycin both in the absence and in the presence of a chromosomal copy of the PDR3 gene.	Cycloheximide	63-76	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	4-8
9867823-12	1999	This unassembled pool, but not the assembled one, was greatly diminished following treatment of cycloheximide for 5 h, indicating that the rapidly degraded pool of NR1 is not assembled with NR2.	Cycloheximide	96-109	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	164-167
9867869-4	1999	Suppression of translation relative to ER protein processing (cycloheximide) produced approximately 50% ADP-ribosylation of GRP78 within 90 min without eIF-2 phosphorylation.	Cycloheximide	62-75	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	124-129
9867869-6	1999	Cycloheximide sharply reduced eIF-2 phosphorylation in response to ER stressors for about 30 min; sensitivity returned as GRP78 became increasingly ADP-ribosylated.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	122-127
9867869-8	1999	Prolonged (24 h) incubations with cycloheximide resulted in the selective loss of the ADP-ribosylated form of GRP78 and increased sensitivity of eIF-2 phosphorylation in response to ER stressors.	Cycloheximide	34-47	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	110-115
9934685-4	1999	Treatment of HCMV-infected cells with cycloheximide followed by treatment with actinomycin D allowed virus immediate-early gene expression but inhibited hsp70 nuclear localization.	Cycloheximide	38-51	heat shock protein family A (Hsp70) member 4	Homo sapiens	153-158
9915882-6	1999	Moreover, super-induction of HFE mRNA in the presence of cycloheximide suggests that HFE gene expression may be controlled by a short-lived repressor protein.	Cycloheximide	57-70	homeostatic iron regulator	Homo sapiens	29-32
9915882-6	1999	Moreover, super-induction of HFE mRNA in the presence of cycloheximide suggests that HFE gene expression may be controlled by a short-lived repressor protein.	Cycloheximide	57-70	homeostatic iron regulator	Homo sapiens	85-88
10462083-7	1999	Forskolin (0.1 to 3 microM), an activator of adenylyl cyclase, induced a concentration-dependent positive inotropism which was also inhibited by (R)p-cAMPS, actinomycin D and cycloheximide.	Cycloheximide	175-188	calmodulin 2, pseudogene 1	Rattus norvegicus	150-155
10462083-10	1999	As it was inhibited by a protein kinase A inhibitor ((R)p-cAMPS) and similarly to isoproterenol, the positive inotropism induced by forskolin, which increases cytosolic cAMP, was also inhibited by actinomycin D and cycloheximide.	Cycloheximide	215-228	calmodulin 2, pseudogene 1	Rattus norvegicus	58-63
10704075-4	1999	Treatment of the endothelial cells with TNFalpha and cycloheximide for 6 h induced nuclear fragmentation in a TNFalpha dose-dependent manner (1-10 ng/ml).	Cycloheximide	53-66	tumor necrosis factor	Bos taurus	110-118
9892011-4	1999	JAK2 signaling to STAT5b at the conclusion of a GH pulse could be sustained by the protein synthesis inhibitor cycloheximide or by the proteasome inhibitor MG132, indicating that termination of this JAK2-catalyzed STAT activation loop requires synthesis of a labile or GH-inducible protein factor and is facilitated by the proteasome pathway.	Cycloheximide	111-124	Janus kinase 2	Rattus norvegicus	0-4
9892011-4	1999	JAK2 signaling to STAT5b at the conclusion of a GH pulse could be sustained by the protein synthesis inhibitor cycloheximide or by the proteasome inhibitor MG132, indicating that termination of this JAK2-catalyzed STAT activation loop requires synthesis of a labile or GH-inducible protein factor and is facilitated by the proteasome pathway.	Cycloheximide	111-124	signal transducer and activator of transcription 5B	Rattus norvegicus	18-24
9892011-4	1999	JAK2 signaling to STAT5b at the conclusion of a GH pulse could be sustained by the protein synthesis inhibitor cycloheximide or by the proteasome inhibitor MG132, indicating that termination of this JAK2-catalyzed STAT activation loop requires synthesis of a labile or GH-inducible protein factor and is facilitated by the proteasome pathway.	Cycloheximide	111-124	Janus kinase 2	Rattus norvegicus	199-203
9892011-8	1999	These are proposed to include the down-regulation of JAK2 signaling to STAT5b via a cycloheximide- and H7-sensitive step, proteasome-dependent degradation of a key component or regulatory factor, and dephosphorylation leading to deactivation of the receptor-kinase signaling complex and its STAT5b substrate via the action of a phosphotyrosine phosphatase.	Cycloheximide	84-97	Janus kinase 2	Rattus norvegicus	53-57
9892011-8	1999	These are proposed to include the down-regulation of JAK2 signaling to STAT5b via a cycloheximide- and H7-sensitive step, proteasome-dependent degradation of a key component or regulatory factor, and dephosphorylation leading to deactivation of the receptor-kinase signaling complex and its STAT5b substrate via the action of a phosphotyrosine phosphatase.	Cycloheximide	84-97	signal transducer and activator of transcription 5B	Rattus norvegicus	71-77
10338309-7	1999	Intraperitoneal injection of cycloheximide blocked the expression of SNAP-25, thus suggesting de novo SNAP-25 protein synthesis following kainate administration.	Cycloheximide	29-42	synaptosome associated protein 25	Rattus norvegicus	69-76
10338309-7	1999	Intraperitoneal injection of cycloheximide blocked the expression of SNAP-25, thus suggesting de novo SNAP-25 protein synthesis following kainate administration.	Cycloheximide	29-42	synaptosome associated protein 25	Rattus norvegicus	102-109
10080689-6	1999	Additional characterization of ACS6 gene expression indicated that the gene is also induced by wounding, and by treatment with LiCl, NaCl, CuCl2, auxin, cycloheximide (CHX), aminooxyacetic acid (AOA) and ethylene.	Cycloheximide	153-166	1-aminocyclopropane-1-carboxylic acid (acc) synthase 6	Arabidopsis thaliana	31-35
10080689-6	1999	Additional characterization of ACS6 gene expression indicated that the gene is also induced by wounding, and by treatment with LiCl, NaCl, CuCl2, auxin, cycloheximide (CHX), aminooxyacetic acid (AOA) and ethylene.	Cycloheximide	168-171	1-aminocyclopropane-1-carboxylic acid (acc) synthase 6	Arabidopsis thaliana	31-35
9845540-6	1998	First, LPS-induced IP-10 mRNA expression was blocked in cells cotreated with cycloheximide.	Cycloheximide	77-90	chemokine (C-X-C motif) ligand 10	Mus musculus	19-24
9833770-4	1998	E2-induced ER down-regulation was partly blocked by actinomycin D (AMD), okadaic acid (OK) and cycloheximide (CHX) when assessed by these 2 methods.	Cycloheximide	95-108	estrogen receptor 1	Homo sapiens	11-13
9833770-4	1998	E2-induced ER down-regulation was partly blocked by actinomycin D (AMD), okadaic acid (OK) and cycloheximide (CHX) when assessed by these 2 methods.	Cycloheximide	110-113	estrogen receptor 1	Homo sapiens	11-13
9879998-6	1998	Treatment of serum-starved or cycloheximide-treated cells with Z-VAD.FMK or Z-DEVD.FMK, which inhibit caspases required for apoptosis, protects eIF4G from degradation and blocks the appearance of the ca.	Cycloheximide	30-43	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	144-149
9846978-5	1998	The release of NCA and MCA was inhibited by cycloheximide and lipoxygenase inhibitors (P < 0.01).	Cycloheximide	44-57	CEA cell adhesion molecule 6	Homo sapiens	15-18
9846980-8	1998	Lipoxygenase inhibitors and cycloheximide inhibited the release of NCA and MCA.	Cycloheximide	28-41	CEA cell adhesion molecule 4	Homo sapiens	67-70
9918113-8	1998	One of the bischolesteryl oligos was nearly as effective as cycloheximide at decreasing synthesis of p75.	Cycloheximide	60-73	nerve growth factor receptor	Rattus norvegicus	101-104
9820807-6	1998	Hyperosmolarity increases SMIT gene expression as evidenced by the inhibition of hyperosmotic induction of SMIT mRNA levels by actinomycin D, and of myo-inositol accumulation by actinomycin D and cycloheximide.	Cycloheximide	196-209	solute carrier family 5 member 3	Homo sapiens	26-30
9884076-7	1998	PDBu (1 microM) exposure caused a time-dependent reduction in the steady-state levels of histamine H1-receptor mRNA, which was inhibited by pre-incubation with GF 109203X and by cycloheximide, a protein synthesis inhibitor.	Cycloheximide	178-191	histamine H1 receptor	Bos taurus	89-110
9832422-3	1998	This report shows that murine granulosa cells are initially resistant to antibody-induced Fas-mediated apoptosis, but will undergo apoptosis when cotreated with TNF and interferon-gamma (IFN) or cycloheximide (CX).	Cycloheximide	210-212	tumor necrosis factor	Mus musculus	161-164
9832422-3	1998	This report shows that murine granulosa cells are initially resistant to antibody-induced Fas-mediated apoptosis, but will undergo apoptosis when cotreated with TNF and interferon-gamma (IFN) or cycloheximide (CX).	Cycloheximide	210-212	interferon gamma	Mus musculus	169-185
9832422-12	1998	Experiments were performed as described above, except that cells were treated with 0.5 microg/ml CX in conjunction with other treatments at 48 h. Fas mAb treatment in the presence of CX induced 25% cell death without IFN pretreatment and 38% with IFN (P < 0.05).	Cycloheximide	97-99	interferon gamma	Mus musculus	247-250
9832422-12	1998	Experiments were performed as described above, except that cells were treated with 0.5 microg/ml CX in conjunction with other treatments at 48 h. Fas mAb treatment in the presence of CX induced 25% cell death without IFN pretreatment and 38% with IFN (P < 0.05).	Cycloheximide	183-185	interferon gamma	Mus musculus	247-250
9832422-13	1998	TNF treatment in the presence of CX had no effect alone, but potentiated the effects of Fas mAb, resulting in 56% killing in the absence of IFN and 86% killing in the presence of IFN (P < 0.05).	Cycloheximide	33-35	tumor necrosis factor	Mus musculus	0-3
9832422-25	1998	Granulosa cells appear to have inhibitors of the Fas antigen pathway, as treatment with CX potentiates Fas-mediated death.	Cycloheximide	88-90	Fas (TNF receptor superfamily member 6)	Mus musculus	49-60
9828212-6	1998	An equally rapid loss of PC-1 protein and mRNA could also be provoked in normal livers by the administration of the translational inhibitor, cycloheximide, but the transcriptional inhibitors, actinomycin D and alpha-amanitin, did not show these effects.	Cycloheximide	141-154	ectonucleotide pyrophosphatase/phosphodiesterase 1	Rattus norvegicus	25-29
9828212-7	1998	Nuclear run-on assays revealed that the loss of PC-1 mRNA after hepatectomy or after the administration of cycloheximide was not caused by a decreased transcription of the PC-1 gene, suggesting that the level of PC-1 is controlled by an mRNA-stabilizing protein that is lost after hepatectomy and has a high turnover.	Cycloheximide	107-120	ectonucleotide pyrophosphatase/phosphodiesterase 1	Rattus norvegicus	48-52
9848782-8	1998	Upregulation of MCP-1 protein production could be blocked by preincubation with actinomycin D or cycloheximide, suggesting that MCP-1 mRNA and protein expression in response to HA are based on de novo synthesis.	Cycloheximide	97-110	chemokine (C-C motif) ligand 2	Mus musculus	16-21
9848782-8	1998	Upregulation of MCP-1 protein production could be blocked by preincubation with actinomycin D or cycloheximide, suggesting that MCP-1 mRNA and protein expression in response to HA are based on de novo synthesis.	Cycloheximide	97-110	chemokine (C-C motif) ligand 2	Mus musculus	128-133
9831079-5	1998	In the presence cycloheximide (10 microg/ml), the liganded VDR protein was degraded with a half-life of approximately 8 h, and this rate of degradation was completely blocked by 0.05 mM MG132.	Cycloheximide	16-29	vitamin D receptor	Rattus norvegicus	59-62
9844102-5	1998	In MC3T3-E1 cells, PTH induced ICER mRNA levels, which peaked at 2 h and declined to baseline by 8 h. Cycloheximide caused superinduction of ICER mRNA in response to PTH.	Cycloheximide	102-115	parathyroid hormone	Mus musculus	19-22
9844102-5	1998	In MC3T3-E1 cells, PTH induced ICER mRNA levels, which peaked at 2 h and declined to baseline by 8 h. Cycloheximide caused superinduction of ICER mRNA in response to PTH.	Cycloheximide	102-115	cAMP responsive element modulator	Mus musculus	31-35
9844102-5	1998	In MC3T3-E1 cells, PTH induced ICER mRNA levels, which peaked at 2 h and declined to baseline by 8 h. Cycloheximide caused superinduction of ICER mRNA in response to PTH.	Cycloheximide	102-115	cAMP responsive element modulator	Mus musculus	141-145
9844102-5	1998	In MC3T3-E1 cells, PTH induced ICER mRNA levels, which peaked at 2 h and declined to baseline by 8 h. Cycloheximide caused superinduction of ICER mRNA in response to PTH.	Cycloheximide	102-115	parathyroid hormone	Mus musculus	166-169
9880003-5	1998	However, Env expression in stressed cells treated with a protein synthesis inhibitor (cycloheximide) indicates the effect is mediated through increased translation of viral Env protein.	Cycloheximide	86-99	endogenous retrovirus group K member 20	Homo sapiens	9-12
9880003-5	1998	However, Env expression in stressed cells treated with a protein synthesis inhibitor (cycloheximide) indicates the effect is mediated through increased translation of viral Env protein.	Cycloheximide	86-99	endogenous retrovirus group K member 20	Homo sapiens	173-176
10426546-8	1999	In addition, the cycloheximide treatment increased the cytosolic phospholipase A2 messenger RNA level in the same cell populations originally possessing messenger RNA signals.	Cycloheximide	17-30	phospholipase A2 group IVA	Rattus norvegicus	55-81
9850158-4	1998	Depletion of PMN intracellular Ca2+ stores with thapsigargin caused membrane depolarization and significantly delayed CHX-induced apoptosis based on both morphological and annexin-V-fluorescein isothiocyanate binding criteria.	Cycloheximide	118-121	annexin A5	Homo sapiens	172-181
9851744-5	1998	PBL-induced TF activity was inhibited by cycloheximide or actinomycin D, indicating active protein synthesis that was confirmed by the increase in TF mRNA detected by reverse transcription-polymerase chain reaction.	Cycloheximide	41-54	coagulation factor III, tissue factor	Homo sapiens	12-14
9869416-1	1998	A cDNA of tobacco BY-2 cells corresponding to an mRNA species which was rapidly induced by methyl jasmonate (MeJA) in the presence of cycloheximide (CHX) was found to encode ornithine decarboxylase (ODC).	Cycloheximide	134-147	ornithine decarboxylase	Nicotiana tabacum	174-197
9869416-1	1998	A cDNA of tobacco BY-2 cells corresponding to an mRNA species which was rapidly induced by methyl jasmonate (MeJA) in the presence of cycloheximide (CHX) was found to encode ornithine decarboxylase (ODC).	Cycloheximide	134-147	ornithine decarboxylase	Nicotiana tabacum	199-202
9844728-2	1998	We found that AA acted synergistically with cycloheximide to suppress insulin-stimulated glucose transport, although it alone was without effect.	Cycloheximide	44-57	insulin	Homo sapiens	70-77
9844728-4	1998	Immunoblot analysis indicated that the increase in plasma membranes of the insulin-regulated glucose transporter (GLUT4) in response to insulin was decreased in cells pretreated with cycloheximide for a prolonged time, while total amount of GLUT4 was not altered.	Cycloheximide	183-196	insulin	Homo sapiens	75-82
9844728-4	1998	Immunoblot analysis indicated that the increase in plasma membranes of the insulin-regulated glucose transporter (GLUT4) in response to insulin was decreased in cells pretreated with cycloheximide for a prolonged time, while total amount of GLUT4 was not altered.	Cycloheximide	183-196	solute carrier family 2 member 4	Homo sapiens	114-119
9844728-4	1998	Immunoblot analysis indicated that the increase in plasma membranes of the insulin-regulated glucose transporter (GLUT4) in response to insulin was decreased in cells pretreated with cycloheximide for a prolonged time, while total amount of GLUT4 was not altered.	Cycloheximide	183-196	insulin	Homo sapiens	136-143
9842902-8	1998	In the fibroblast cell line SV80 both CD40 and the p55TNFR trigger apoptosis when protein synthesis is blocked with cycloheximide (CHX).	Cycloheximide	116-129	CD40 molecule	Homo sapiens	38-42
9842902-8	1998	In the fibroblast cell line SV80 both CD40 and the p55TNFR trigger apoptosis when protein synthesis is blocked with cycloheximide (CHX).	Cycloheximide	131-134	CD40 molecule	Homo sapiens	38-42
9792910-5	1998	Time-course analysis of the effects of actinomycin D demonstrated that the increase in iNOS transcripts is the result of an accompanying great increase in iNOS gene transcription and lower iNOS mRNA stability; also blockage by cycloheximide suggests that it is dependent on de novo protein synthesis.	Cycloheximide	227-240	nitric oxide synthase 2, inducible	Mus musculus	87-91
9792910-5	1998	Time-course analysis of the effects of actinomycin D demonstrated that the increase in iNOS transcripts is the result of an accompanying great increase in iNOS gene transcription and lower iNOS mRNA stability; also blockage by cycloheximide suggests that it is dependent on de novo protein synthesis.	Cycloheximide	227-240	nitric oxide synthase 2, inducible	Mus musculus	155-159
9792910-5	1998	Time-course analysis of the effects of actinomycin D demonstrated that the increase in iNOS transcripts is the result of an accompanying great increase in iNOS gene transcription and lower iNOS mRNA stability; also blockage by cycloheximide suggests that it is dependent on de novo protein synthesis.	Cycloheximide	227-240	nitric oxide synthase 2, inducible	Mus musculus	155-159
9798919-4	1998	The action of TGF-beta1 on PAI-1 mRNA was inhibited by cycloheximide, indicating a requirement for de novo protein synthesis.	Cycloheximide	55-68	transforming growth factor, beta 1	Rattus norvegicus	14-23
9798919-4	1998	The action of TGF-beta1 on PAI-1 mRNA was inhibited by cycloheximide, indicating a requirement for de novo protein synthesis.	Cycloheximide	55-68	serpin family E member 1	Rattus norvegicus	27-32
9798919-5	1998	In contrast, cycloheximide potentiated the action of bFGF.	Cycloheximide	13-26	fibroblast growth factor 2	Rattus norvegicus	53-57
9817599-5	1998	Studies of the estrogenic regulation of EBBP expression demonstrated that the E-dependent increase in EBBP mRNA levels in the ER-transfected HMEC is an early, ER-mediated, and cycloheximide-insensitive process.	Cycloheximide	176-189	tripartite motif containing 16	Homo sapiens	102-106
9817599-5	1998	Studies of the estrogenic regulation of EBBP expression demonstrated that the E-dependent increase in EBBP mRNA levels in the ER-transfected HMEC is an early, ER-mediated, and cycloheximide-insensitive process.	Cycloheximide	176-189	estrogen receptor 1	Homo sapiens	126-128
9862498-5	1998	Transformed colonies were selected for restoration of C-8,7 sterol isomerase activity (i.e. wild-type ergosterol production) by enhanced resistance to the antibiotic cycloheximide.	Cycloheximide	166-179	C-8,7 sterol isomerase	Arabidopsis thaliana	54-76
9830682-3	1998	Addition of cycloheximide (CHX) to the incubation medium eliminated the potential interference of E2-induced ER loss.	Cycloheximide	12-25	estrogen receptor 1	Homo sapiens	109-111
9830682-3	1998	Addition of cycloheximide (CHX) to the incubation medium eliminated the potential interference of E2-induced ER loss.	Cycloheximide	27-30	estrogen receptor 1	Homo sapiens	109-111
9790974-0	1998	PAP gene transcription induced by cycloheximide in AR4-2J cells involves ADP-ribosylation.	Cycloheximide	34-47	regenerating family member 3 beta	Rattus norvegicus	0-3
9790974-1	1998	We report in this paper that cycloheximide induces PAP mRNA expression in the pancreatic acinar cell line AR4-2J in a dose- and time-dependent manner.	Cycloheximide	29-42	regenerating family member 3 beta	Rattus norvegicus	51-54
9790974-5	1998	PAP mRNA concentration remained unchanged for 4 h and then decreased in both cycloheximide-treated and control cells, ruling out a significant contribution of posttranscriptional regulation in cycloheximide induction.	Cycloheximide	77-90	regenerating family member 3 beta	Rattus norvegicus	0-3
10894765-0	1999	Superinduction of Oxidized Tryptophan-Inducible Cytochrome P450 1A1 by Cycloheximide in Hepa lclc7 Cells.	Cycloheximide	71-84	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	48-67
10894765-2	1999	In the present study, we have examined the effect of temporary inhibition of protein synthesis by cycloheximide on oxidized tryptophan inducible CYP1A1 mRNA, protein, and EROD activity in Hepa-1 cells.	Cycloheximide	98-111	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	145-151
10894765-3	1999	The results demonstrate that combined exposure of wild-type Hepa-1 cells to either UV- or ozone-oxidized tryptophan and cycloheximide causes an increase in CYP1A1 mRNA, protein, and EROD activity, which is greater than the sum of the increases that were observed by exposure to each compound alone.	Cycloheximide	120-133	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	156-162
9869416-1	1998	A cDNA of tobacco BY-2 cells corresponding to an mRNA species which was rapidly induced by methyl jasmonate (MeJA) in the presence of cycloheximide (CHX) was found to encode ornithine decarboxylase (ODC).	Cycloheximide	149-152	ornithine decarboxylase	Nicotiana tabacum	174-197
9869416-1	1998	A cDNA of tobacco BY-2 cells corresponding to an mRNA species which was rapidly induced by methyl jasmonate (MeJA) in the presence of cycloheximide (CHX) was found to encode ornithine decarboxylase (ODC).	Cycloheximide	149-152	ornithine decarboxylase	Nicotiana tabacum	199-202
9822695-6	1998	Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide significantly abrogated the effect of UVB on AP-1 DNA binding, indicating that transcription and translation were required for AP-1 activation.	Cycloheximide	88-101	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	147-151
9822695-6	1998	Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide significantly abrogated the effect of UVB on AP-1 DNA binding, indicating that transcription and translation were required for AP-1 activation.	Cycloheximide	88-101	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	229-233
9822711-7	1998	This dexamethasone-dependent repression involved a reduced COX-2 mRNA half-life, was blocked by actinomycin D or cycloheximide, and was antagonized by the steroid antagonist RU38486.	Cycloheximide	113-126	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	59-64
9828112-10	1998	Increased FGF-2 release occurred via a cycloheximide-insensitive pathway.	Cycloheximide	39-52	fibroblast growth factor 2	Homo sapiens	10-15
9813034-1	1998	Most normal and neoplastic cell types are resistant to tumor necrosis factor (TNF) cytotoxicity unless cotreated with protein or RNA synthesis inhibitors, such as cycloheximide and actinomycin D.	Cycloheximide	163-176	tumor necrosis factor	Homo sapiens	55-76
9813034-1	1998	Most normal and neoplastic cell types are resistant to tumor necrosis factor (TNF) cytotoxicity unless cotreated with protein or RNA synthesis inhibitors, such as cycloheximide and actinomycin D.	Cycloheximide	163-176	tumor necrosis factor	Homo sapiens	78-81
9813175-5	1998	Recovery of the cyclic GMP response was blocked in the presence of cycloheximide (10 microM) suggesting that de novo protein synthesis is necessary for tolerance reversal.	Cycloheximide	67-80	5'-nucleotidase, cytosolic II	Homo sapiens	23-26
9827565-5	1998	Cycloheximide-induced enhanced transcription suggests the immediate early response of the p62 gene.	Cycloheximide	0-13	nucleoporin 62	Homo sapiens	90-93
9820166-4	1998	Both effects of thrombin and PMA on PCA in SW-480 cells were blocked by pretreatment of cells with cycloheximide or actinomycin D, indicating that the response required de novo protein and RNA synthesis.	Cycloheximide	99-112	coagulation factor II, thrombin	Homo sapiens	16-24
9863663-8	1998	COX substrate arachidonic acid time- and concentration-dependently mimicked IL-1beta induced attenuation and the effect was prevented by the non-selective COX inhibitors Ind and flurbiprofen, but not by NS-398, CHX and Dex.	Cycloheximide	211-214	interleukin 1 beta	Homo sapiens	76-84
9763560-8	1998	Enforced overexpression of either A1 or A20 inhibits LPS and cycloheximide-initiated apoptosis.	Cycloheximide	61-74	TNF alpha induced protein 3	Homo sapiens	40-43
9809812-8	1998	In fed rats the increase was slower, reaching a plateau after 24 h that lasted for 6 days (twofold increase); (4) The translation inhibitor cycloheximide blocked the activation of HDC induced by gastrin (4 h infusion of 5 nmol kg(-1) h(-1)), while the transcription inhibitor actinomycin D, which suppressed the increase in HDC mRNA expression, did not.	Cycloheximide	140-153	histidine decarboxylase	Rattus norvegicus	180-183
9784597-2	1998	PreproET-1 mRNA levels reached a plateau within 1 h after the addition of 0.5 microM LPA and declined after 2 h. The induction was superinduced by cycloheximide and was blocked by actinomycin D.	Cycloheximide	147-160	endothelin 1	Rattus norvegicus	0-10
9780210-2	1998	Incubation of peripheral blood neutrophils with thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-sequestering-ATPase, causes a dose-dependent induction of IL-8 synthesis that continues for up to 8 h. Cycloheximide inhibits the thapsigargin-induced IL-8 production, suggesting the induction of protein synthesis de novo.	Cycloheximide	212-225	C-X-C motif chemokine ligand 8	Homo sapiens	167-171
9809812-8	1998	In fed rats the increase was slower, reaching a plateau after 24 h that lasted for 6 days (twofold increase); (4) The translation inhibitor cycloheximide blocked the activation of HDC induced by gastrin (4 h infusion of 5 nmol kg(-1) h(-1)), while the transcription inhibitor actinomycin D, which suppressed the increase in HDC mRNA expression, did not.	Cycloheximide	140-153	gastrin	Rattus norvegicus	195-202
9809812-8	1998	In fed rats the increase was slower, reaching a plateau after 24 h that lasted for 6 days (twofold increase); (4) The translation inhibitor cycloheximide blocked the activation of HDC induced by gastrin (4 h infusion of 5 nmol kg(-1) h(-1)), while the transcription inhibitor actinomycin D, which suppressed the increase in HDC mRNA expression, did not.	Cycloheximide	140-153	histidine decarboxylase	Rattus norvegicus	324-327
9790906-5	1998	Furthermore, it was revealed that cycloheximide suppressed expression of both p53 and Bax.	Cycloheximide	34-47	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	78-81
9790906-5	1998	Furthermore, it was revealed that cycloheximide suppressed expression of both p53 and Bax.	Cycloheximide	34-47	BCL2 associated X, apoptosis regulator	Rattus norvegicus	86-89
9821819-0	1998	Structure-activity relationships of lipopolysaccharide (LPS) in tumor necrosis factor-alpha (TNF-alpha) production and induction of macrophage cell death in the presence of cycloheximide (CHX) in a murine macrophage-like cell line, J774.1.	Cycloheximide	173-186	toll-like receptor 4	Mus musculus	56-59
9821819-0	1998	Structure-activity relationships of lipopolysaccharide (LPS) in tumor necrosis factor-alpha (TNF-alpha) production and induction of macrophage cell death in the presence of cycloheximide (CHX) in a murine macrophage-like cell line, J774.1.	Cycloheximide	188-191	toll-like receptor 4	Mus musculus	56-59
9821819-1	1998	The structure-activity relationships of lipopolysaccharide (LPS) in tumor necrosis factor-alpha (TNF-alpha) production and induction of macrophage cell death in the presence of cycloheximide (CHX) were examined in a murine macrophage-like cell line, J774.1.	Cycloheximide	192-195	toll-like receptor 4	Mus musculus	60-63
9757037-2	1998	The proENK mRNA level was significantly increased about 3.3-fold 4 h after PGE2 (10 microM) treatment and this increase was potentiated by the pre-treatment with cycloheximide (CHX; 15 microM) about 1.7-fold as much as PGE2 alone treated cells.	Cycloheximide	162-175	proenkephalin	Rattus norvegicus	4-10
9757037-2	1998	The proENK mRNA level was significantly increased about 3.3-fold 4 h after PGE2 (10 microM) treatment and this increase was potentiated by the pre-treatment with cycloheximide (CHX; 15 microM) about 1.7-fold as much as PGE2 alone treated cells.	Cycloheximide	177-180	proenkephalin	Rattus norvegicus	4-10
10100886-0	1998	Effect of cycloheximide and tunicamycin on the gonadotrophin-releasing hormone stimulated distal glycosylation of luteinizing hormone by rat pituitary cells.	Cycloheximide	10-23	gonadotropin releasing hormone 1	Homo sapiens	47-78
9755111-6	1998	Actinomycin D and cycloheximide abrogated protective effects of KGF.	Cycloheximide	18-31	fibroblast growth factor 7	Rattus norvegicus	64-67
10100886-2	1998	In the present report, we have further examined the GnRH-induced [3H]Gal-LH synthesis and release by treating anterior pituitary cells with polypeptide synthesis and glycosylation inhibitors (cycloheximide and tunicamycin, respectively).	Cycloheximide	192-205	gonadotropin releasing hormone 1	Homo sapiens	52-56
10100886-7	1998	Cycloheximide totally blocked synthesis and release of [14C]Leu-LH and greatly reduced those of [3H]Man-LH, resulting in the loss of cellular responsiveness to GnRH.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Homo sapiens	160-164
9796909-4	1998	We found that the IL-2 mRNA level in T cells from young but not from old mice increased up to 6- to 10-fold by addition of cycloheximide (CHX) while the stability of IL-2 mRNA is not affected.	Cycloheximide	123-136	interleukin 2	Mus musculus	18-22
10228901-8	1998	In contrast, treatment of cells with cycloheximide not only resulted in decreasing cell numbers but also in a complete inhibition of CA 125 production by surviving cells.	Cycloheximide	37-50	mucin 16, cell surface associated	Homo sapiens	133-139
9731749-5	1998	AII-stimulated transport was also blocked when cells were incubated with cycloheximide for 6 hr, suggesting that protein synthesis is required for the long-term effects of AII on glucose transport.	Cycloheximide	73-86	angiotensinogen	Homo sapiens	0-3
9731749-5	1998	AII-stimulated transport was also blocked when cells were incubated with cycloheximide for 6 hr, suggesting that protein synthesis is required for the long-term effects of AII on glucose transport.	Cycloheximide	73-86	angiotensinogen	Homo sapiens	172-175
9764849-4	1998	Prior treatment of cells with cycloheximide or actinomycin D abolished the p53 increase and apoptosis induced by curcumin, suggesting that either de novo p53 protein synthesis or some proteins synthesis for stabilization of p53 is required for apoptosis.	Cycloheximide	30-43	tumor protein p53	Homo sapiens	75-78
9764849-4	1998	Prior treatment of cells with cycloheximide or actinomycin D abolished the p53 increase and apoptosis induced by curcumin, suggesting that either de novo p53 protein synthesis or some proteins synthesis for stabilization of p53 is required for apoptosis.	Cycloheximide	30-43	tumor protein p53	Homo sapiens	154-157
9764849-4	1998	Prior treatment of cells with cycloheximide or actinomycin D abolished the p53 increase and apoptosis induced by curcumin, suggesting that either de novo p53 protein synthesis or some proteins synthesis for stabilization of p53 is required for apoptosis.	Cycloheximide	30-43	tumor protein p53	Homo sapiens	154-157
9795219-7	1998	Caspase-3 activation and morphological changes were prevented by cycloheximide treatment.	Cycloheximide	65-78	caspase 3	Mus musculus	0-9
9808457-3	1998	In contrast, microinjection of cytochrome c rapidly induced a caspase-dependent death in NGF-deprived, Bax-deficient or NGF-deprived, cycloheximide-treated neurons.	Cycloheximide	134-147	cytochrome c, somatic	Homo sapiens	31-43
9743330-6	1998	Furthermore, inactivation of Cat S as well as blockade of protein neosynthesis by cycloheximide strongly reduced IgE/Fc epsilon RI-mediated Ag presentation by DC.	Cycloheximide	82-95	Fc epsilon receptor Ia	Homo sapiens	117-130
9722543-2	1998	The repression of MMP-1 up-regulation in RCG by cycloheximide suggested the participation in the regulation process of a de novo synthesized intermediary component.	Cycloheximide	48-61	matrix metallopeptidase 1	Homo sapiens	18-23
9722570-7	1998	AKAP121 mRNA accumulated in the presence of cycloheximide, suggesting that transcription of the anchor protein gene is directly controlled by cAMP and PKA.	Cycloheximide	44-57	A-kinase anchoring protein 1	Rattus norvegicus	0-7
9796909-4	1998	We found that the IL-2 mRNA level in T cells from young but not from old mice increased up to 6- to 10-fold by addition of cycloheximide (CHX) while the stability of IL-2 mRNA is not affected.	Cycloheximide	138-141	interleukin 2	Mus musculus	18-22
9728056-5	1998	PMA-induced eotaxin mRNA expression was inhibited by cycloheximide (10 microg/ml), whereas TNF-alpha-induced expression was not.	Cycloheximide	53-66	C-C motif chemokine ligand 11	Homo sapiens	12-19
9721193-12	1998	We show that the protein synthesis inhibitor cycloheximide prolonged the CYP7A1 mRNA half-life, suggesting that translation is required for mRNA decay.	Cycloheximide	45-58	cytochrome P450 family 7 subfamily A member 1	Homo sapiens	73-79
9734646-4	1998	Moreover, the binding was specific for surface bound but not soluble TSP and appeared to be divalent cation dependent, was not significantly inhibited by heparin and was sensitive to cycloheximide (CHX) treatment of senescent PMN (>90%) inhibition at 10 microM CHX).	Cycloheximide	183-196	thrombospondin 1	Homo sapiens	69-72
9734646-4	1998	Moreover, the binding was specific for surface bound but not soluble TSP and appeared to be divalent cation dependent, was not significantly inhibited by heparin and was sensitive to cycloheximide (CHX) treatment of senescent PMN (>90%) inhibition at 10 microM CHX).	Cycloheximide	198-201	thrombospondin 1	Homo sapiens	69-72
9747510-5	1998	Cycloheximide and actinomycin D inhibited the increases in the HO-1 mRNA level produced by hyperoxia, indicating that response to hyperoxia is dependent on de novo protein synthesis and mRNA transcription.	Cycloheximide	0-13	heme oxygenase 1	Homo sapiens	63-67
9737666-8	1998	Actinomycin D, cycloheximide, and brefeldin A inhibited the increase in DAF release induced by IL-4 and IL-1beta stimulation.	Cycloheximide	15-28	CD55 molecule (Cromer blood group)	Homo sapiens	72-75
9737666-8	1998	Actinomycin D, cycloheximide, and brefeldin A inhibited the increase in DAF release induced by IL-4 and IL-1beta stimulation.	Cycloheximide	15-28	interleukin 4	Homo sapiens	95-99
9737666-8	1998	Actinomycin D, cycloheximide, and brefeldin A inhibited the increase in DAF release induced by IL-4 and IL-1beta stimulation.	Cycloheximide	15-28	interleukin 1 beta	Homo sapiens	104-112
9794606-7	1998	The inhibitory activity of IL-13 was abrogated, however, in the presence of cycloheximide, suggesting that IL-13"s effect was via synthesis of de novo repressor protein(s).	Cycloheximide	76-89	interleukin 13	Homo sapiens	27-32
9794606-7	1998	The inhibitory activity of IL-13 was abrogated, however, in the presence of cycloheximide, suggesting that IL-13"s effect was via synthesis of de novo repressor protein(s).	Cycloheximide	76-89	interleukin 13	Homo sapiens	107-112
9725242-9	1998	The down-regulatory effect of IFN-gamma on IL-1beta-induced COX-2 expression was abrogated with cycloheximide.	Cycloheximide	96-109	interferon gamma	Homo sapiens	30-39
9725242-9	1998	The down-regulatory effect of IFN-gamma on IL-1beta-induced COX-2 expression was abrogated with cycloheximide.	Cycloheximide	96-109	interleukin 1 beta	Homo sapiens	43-51
9725242-9	1998	The down-regulatory effect of IFN-gamma on IL-1beta-induced COX-2 expression was abrogated with cycloheximide.	Cycloheximide	96-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	60-65
9725250-11	1998	Both the BK- and arachidonic acid-induced IL-8 production was inhibited by the protein synthesis inhibitors cycloheximide and actinomycin D and by the steroid dexamethasone.	Cycloheximide	108-121	kininogen 1	Homo sapiens	9-11
9725250-11	1998	Both the BK- and arachidonic acid-induced IL-8 production was inhibited by the protein synthesis inhibitors cycloheximide and actinomycin D and by the steroid dexamethasone.	Cycloheximide	108-121	C-X-C motif chemokine ligand 8	Homo sapiens	42-46
9696804-10	1998	The phosphorylation of virion-associated VP13/14, VP16, and VP22 was demonstrated in cells infected in the presence of cycloheximide.	Cycloheximide	119-132	host cell factor C1	Homo sapiens	50-54
9720586-6	1998	The protein synthesis inhibitor cycloheximide inhibited basal and stretch-induced PTHrP secretion.	Cycloheximide	32-45	parathyroid hormone like hormone	Homo sapiens	82-87
9749837-5	1998	This autoregulation of AR was confirmed by Western blot, and seems to involve transcription and protein synthesis, since it was suppressed by actinomycin D and cycloheximide.	Cycloheximide	160-173	androgen receptor	Homo sapiens	23-25
9728043-12	1998	Cycloheximide (10 microg/ml for 24 h), an inhibitor of protein synthesis, also abolished the effects of IL-1beta on Iso-induced cell stiffness changes and cAMP formation.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	104-112
9693113-6	1998	Cycloheximide lowered the cGMP-dependent induction of HO-1 mRNA to about one half.	Cycloheximide	0-13	heme oxygenase 1	Rattus norvegicus	54-58
9721872-9	1998	Paclitaxel-induced c-Mos gene expression was completely abrogated by cycloheximide and actinomycin D.	Cycloheximide	69-82	MOS proto-oncogene, serine/threonine kinase	Homo sapiens	19-24
9648916-6	1998	Assessment of the metabolic requirements for CD-induced PAI-1 expression by using the protein synthesis inhibitors puromycin and cycloheximide indicated that PAI-1 transcripts were regulated in a complex manner in response to CD.	Cycloheximide	129-142	serpin family E member 2	Rattus norvegicus	56-61
9648916-6	1998	Assessment of the metabolic requirements for CD-induced PAI-1 expression by using the protein synthesis inhibitors puromycin and cycloheximide indicated that PAI-1 transcripts were regulated in a complex manner in response to CD.	Cycloheximide	129-142	serpin family E member 2	Rattus norvegicus	158-163
9648931-8	1998	Actinomycin D had no effect at 9, 90, 270, or 720 min, but there was a small decrease in E2-stimulated PKC in RC treated with cycloheximide at 90 and 270 min and in GC treated for 90 min.	Cycloheximide	126-139	protein kinase C, alpha	Rattus norvegicus	103-106
9691096-2	1998	We have found that the antimalarial and antiinflammatory drug, chloroquine, is able to stimulate NO synthase (NOS) activity in murine, porcine, and human endothelial cells in vitro: the increase of enzyme activity is dependent on a de novo synthesis of some regulatory protein, as it is inhibited by cycloheximide but is not accompanied by an increased expression of inducible or constitutive NOS isoforms.	Cycloheximide	300-313	nitric oxide synthase 1, neuronal	Mus musculus	97-108
9686620-0	1998	Sustained phosphorylation of cytosolic phospholipase A2 accompanies cycloheximide- and adenovirus-induced susceptibility to TNF.	Cycloheximide	68-81	phospholipase A2 group IVA	Homo sapiens	29-55
9686620-0	1998	Sustained phosphorylation of cytosolic phospholipase A2 accompanies cycloheximide- and adenovirus-induced susceptibility to TNF.	Cycloheximide	68-81	tumor necrosis factor	Homo sapiens	124-127
9686620-1	1998	In this report we examine the phosphorylation state of cytosolic phospholipase A2 (cPLA2) in C3HA fibroblasts that have been treated with TNF, cycloheximide (CHI), or a combination of both compounds.	Cycloheximide	143-156	phospholipase A2 group IVA	Homo sapiens	55-81
9686620-1	1998	In this report we examine the phosphorylation state of cytosolic phospholipase A2 (cPLA2) in C3HA fibroblasts that have been treated with TNF, cycloheximide (CHI), or a combination of both compounds.	Cycloheximide	143-156	phospholipase A2 group IVA	Homo sapiens	83-88
9686620-1	1998	In this report we examine the phosphorylation state of cytosolic phospholipase A2 (cPLA2) in C3HA fibroblasts that have been treated with TNF, cycloheximide (CHI), or a combination of both compounds.	Cycloheximide	158-161	phospholipase A2 group IVA	Homo sapiens	55-81
9686620-1	1998	In this report we examine the phosphorylation state of cytosolic phospholipase A2 (cPLA2) in C3HA fibroblasts that have been treated with TNF, cycloheximide (CHI), or a combination of both compounds.	Cycloheximide	158-161	phospholipase A2 group IVA	Homo sapiens	83-88
9881864-10	1998	Finally, it was also found that cycloheximide, an inhibitor of protein synthesis, overinduces CREM/ICER gene expression.	Cycloheximide	32-45	cAMP responsive element modulator	Rattus norvegicus	94-98
9881864-10	1998	Finally, it was also found that cycloheximide, an inhibitor of protein synthesis, overinduces CREM/ICER gene expression.	Cycloheximide	32-45	cAMP responsive element modulator	Rattus norvegicus	99-103
10375811-11	1998	Cycloheximide and dactinomycin also suppressed enhancement of NOS activity stimulated by LPS/dBcAMP, both in nitrite production and citrulline assay, indicating that the enhancement of NOS activity was due to the expression of inducible NOS (iNOS) gene and protein.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	227-240
10375811-11	1998	Cycloheximide and dactinomycin also suppressed enhancement of NOS activity stimulated by LPS/dBcAMP, both in nitrite production and citrulline assay, indicating that the enhancement of NOS activity was due to the expression of inducible NOS (iNOS) gene and protein.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	242-246
9712850-9	1998	Cycloheximide pretreatment abolished the post-transcriptional effect of NGF, indicating that de novo protein synthesis was required for the observed increase in m4 mRNA stability.	Cycloheximide	0-13	nerve growth factor	Rattus norvegicus	72-75
9729434-7	1998	jun-D, ssat and A02-1 expressions were superinduced in the presence of cycloheximide, which indicates that they belong to the immediate early gene family.	Cycloheximide	71-84	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	7-11
9748607-2	1998	Cycloheximide suppresses these effects of IL-13 suggesting that de novo protein synthesis is involved.	Cycloheximide	0-13	interleukin 13	Mus musculus	42-47
9709006-7	1998	Moreover, beta 2m mRNA remained undetectable in MCF-7/Adr cells following cycloheximide treatment.	Cycloheximide	74-87	beta-2-microglobulin	Homo sapiens	10-17
9709006-8	1998	However, in MCF-7 cells, increased beta 2m mRNA was observed after 12 h, and a similar level of increased mRNA expression was observed after 36 h of cycloheximide treatment in MCF-7/Adr-5 cells; these results suggest that one of the mechanisms controlling beta 2m mRNA expression might be a negative regulatory protein in MCF-7/Adr-5 cells.	Cycloheximide	149-162	beta-2-microglobulin	Homo sapiens	256-263
9685415-3	1998	Pretreatment of Jurkat T-cells with 8-bromo cAMP (8-Br-cAMP) or prostaglandin E2 increased PDE3 and PDE4 activity in an actinomycin D- and cycloheximide-sensitive manner.	Cycloheximide	139-152	phosphodiesterase 4A	Homo sapiens	100-104
9688686-5	1998	Circulating and myocardial TNF-alpha increased at 1 and 2 h, whereas myocardial contractility was depressed at 4 and 6 h. Pretreatment with cycloheximide or dexamethasone abolished the increase in circulating and myocardial TNF-alpha and preserved myocardial contractile function.	Cycloheximide	140-153	tumor necrosis factor	Rattus norvegicus	27-36
9688686-5	1998	Circulating and myocardial TNF-alpha increased at 1 and 2 h, whereas myocardial contractility was depressed at 4 and 6 h. Pretreatment with cycloheximide or dexamethasone abolished the increase in circulating and myocardial TNF-alpha and preserved myocardial contractile function.	Cycloheximide	140-153	tumor necrosis factor	Rattus norvegicus	224-233
9719063-8	1998	p67phox, a cytosolic factor, appears to be affected at both the level of transcription and protein synthesis because actinomycin and cycloheximide individually inhibited the observed effect.	Cycloheximide	133-146	neutrophil cytosol factor 2	Oryctolagus cuniculus	0-7
9717846-5	1998	Induction of PR mRNA by forskolin is blocked by the A-kinase inhibitor H89 and cycloheximide but not by the E antagonist, ICI 164,384.	Cycloheximide	79-92	progesterone receptor	Rattus norvegicus	13-15
9716376-7	1998	The HSF activation by proteasome inhibitors was completely blocked in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	118-131	interleukin 6	Homo sapiens	4-7
9655919-3	1998	Cycloheximide (CHI) at 10 microg/ml, which inhibited protein synthesis for 80%, caused a 80-fold induction of IL-6 mRNA level which was due predominantly to a stabilization of IL-6 mRNA (20-fold) early on.	Cycloheximide	0-13	interleukin 6	Homo sapiens	110-114
9655919-3	1998	Cycloheximide (CHI) at 10 microg/ml, which inhibited protein synthesis for 80%, caused a 80-fold induction of IL-6 mRNA level which was due predominantly to a stabilization of IL-6 mRNA (20-fold) early on.	Cycloheximide	0-13	interleukin 6	Homo sapiens	176-180
9655919-3	1998	Cycloheximide (CHI) at 10 microg/ml, which inhibited protein synthesis for 80%, caused a 80-fold induction of IL-6 mRNA level which was due predominantly to a stabilization of IL-6 mRNA (20-fold) early on.	Cycloheximide	15-18	interleukin 6	Homo sapiens	110-114
9655919-3	1998	Cycloheximide (CHI) at 10 microg/ml, which inhibited protein synthesis for 80%, caused a 80-fold induction of IL-6 mRNA level which was due predominantly to a stabilization of IL-6 mRNA (20-fold) early on.	Cycloheximide	15-18	interleukin 6	Homo sapiens	176-180
9855686-7	1998	The IFN-c-mediated increase in CB gene transcription and steady-state mRNA level was blocked by a-amanitin or cycloheximide, suggesting the involvement of RNA polymerase II and the requirement of de novo protein synthesis.	Cycloheximide	110-123	cathepsin B	Homo sapiens	31-33
9713511-8	1998	It occurs mostly through type I (p55) TNF receptors, probably involves a calphostin-C sensitive protein kinase C activity and requires synthesis of proteins (it is inhibited by actinomycin D or cycloheximide) and of inducible nitric oxide (NO) synthase (it is inhibited by NG-methyl-L-arginine or aminoguanidine).	Cycloheximide	194-207	TNF receptor superfamily member 1A	Homo sapiens	33-36
9713511-8	1998	It occurs mostly through type I (p55) TNF receptors, probably involves a calphostin-C sensitive protein kinase C activity and requires synthesis of proteins (it is inhibited by actinomycin D or cycloheximide) and of inducible nitric oxide (NO) synthase (it is inhibited by NG-methyl-L-arginine or aminoguanidine).	Cycloheximide	194-207	tumor necrosis factor	Homo sapiens	38-41
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cycloheximide	103-116	matrix metallopeptidase 14	Homo sapiens	251-259
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cycloheximide	103-116	matrix metallopeptidase 1	Homo sapiens	254-259
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cycloheximide	103-116	matrix metallopeptidase 2	Homo sapiens	268-273
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cycloheximide	103-116	TIMP metallopeptidase inhibitor 1	Homo sapiens	275-281
9639398-5	1998	Activation induced by GRGDSP and cytochalasin B, but not cell rounding, was inhibited by herbimycin A, cycloheximide and actinomycin D, suggesting a role for tyrosine kinases, protein and RNA synthesis, but was not associated with changes in mRNA for MT-MMP-1, MMP-1, MMP-2, TIMP-1 or TIMP-2.	Cycloheximide	103-116	TIMP metallopeptidase inhibitor 2	Homo sapiens	285-291
9688852-9	1998	Furthermore, the LPS-IFN-gamma-induced NOS-II mRNA accumulation was sensitive to cycloheximide, suggesting that, in addition to NF-kappaB, transcriptional factors that require new protein synthesis are involved in NOS-II induction.	Cycloheximide	81-94	interferon gamma	Bos taurus	21-30
9688852-9	1998	Furthermore, the LPS-IFN-gamma-induced NOS-II mRNA accumulation was sensitive to cycloheximide, suggesting that, in addition to NF-kappaB, transcriptional factors that require new protein synthesis are involved in NOS-II induction.	Cycloheximide	81-94	nitric oxide synthase 2	Bos taurus	39-45
9688852-9	1998	Furthermore, the LPS-IFN-gamma-induced NOS-II mRNA accumulation was sensitive to cycloheximide, suggesting that, in addition to NF-kappaB, transcriptional factors that require new protein synthesis are involved in NOS-II induction.	Cycloheximide	81-94	nitric oxide synthase 2	Bos taurus	214-220
9688858-6	1998	A twofold increase in Iir and a hyperpolarization (-41.3 +/- 3.7 mV, n = 16) were abolished by pretreatment of THP-1 cells with cycloheximide, a protein synthesis inhibitor, or herbimycin A, a tyrosine kinase inhibitor, or by pretreatment of the LPS-treated HUVECs with anti-VCAM-1.	Cycloheximide	128-141	GLI family zinc finger 2	Homo sapiens	111-116
9688858-6	1998	A twofold increase in Iir and a hyperpolarization (-41.3 +/- 3.7 mV, n = 16) were abolished by pretreatment of THP-1 cells with cycloheximide, a protein synthesis inhibitor, or herbimycin A, a tyrosine kinase inhibitor, or by pretreatment of the LPS-treated HUVECs with anti-VCAM-1.	Cycloheximide	128-141	vascular cell adhesion molecule 1	Homo sapiens	275-281
9655920-5	1998	The inhibitory effect of 1,25(OH)2D3 on transgene mRNA was maintained in the presence of the protein synthesis inhibitor cycloheximide, suggesting that the inhibitory effect on Col1a1 gene transcription does not require de novo protein synthesis.	Cycloheximide	121-134	collagen, type I, alpha 1	Mus musculus	177-183
9661070-8	1998	Cycloheximide enhanced effects of both IL-1 and PMA, suggesting that de novo protein synthesis is not required for induction of PGHS-2.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	39-51
9671378-17	1998	Prior treatment of rats with the protein synthesis inhibitor, cycloheximide, also blunted LPS-induced iNOS mRNA expression.	Cycloheximide	62-75	nitric oxide synthase 2	Rattus norvegicus	102-106
9671378-19	1998	LPS-induced iNOS expression is blunted by pretreating rats with dexamethasone or cycloheximide.	Cycloheximide	81-94	nitric oxide synthase 2	Rattus norvegicus	12-16
9712367-2	1998	The time courses of the inhibition of IFN-gamma-induced kynurenine synthesis by actinomycin D and cycloheximide showed that the indoleamine dioxygenase gene was transcribed as early as 2 h and translated as early as 5 h after initiation of IFN treatment.	Cycloheximide	98-111	interferon gamma	Homo sapiens	38-47
9618150-2	1998	At physiological doses, either insulin-like growth factor I (IGF-I) or insulin turned out to be as potent as dibutyryl cAMP (dbcAMP) in increasing UCP1 gene transcription rate (1 h) and also UCP1 mRNA accumulation (3 h), their maximal effect (15-fold increase) reached upon treatment for 24 h. Upon treatment with either IGF-I or insulin for 48 h, a 7-fold increase in the UCP1 protein content relative to levels in the control cells was found, this induction being abolished in the presence of cycloheximide.	Cycloheximide	495-508	insulin like growth factor 1	Homo sapiens	31-59
9618150-2	1998	At physiological doses, either insulin-like growth factor I (IGF-I) or insulin turned out to be as potent as dibutyryl cAMP (dbcAMP) in increasing UCP1 gene transcription rate (1 h) and also UCP1 mRNA accumulation (3 h), their maximal effect (15-fold increase) reached upon treatment for 24 h. Upon treatment with either IGF-I or insulin for 48 h, a 7-fold increase in the UCP1 protein content relative to levels in the control cells was found, this induction being abolished in the presence of cycloheximide.	Cycloheximide	495-508	insulin like growth factor 1	Homo sapiens	61-66
9618150-2	1998	At physiological doses, either insulin-like growth factor I (IGF-I) or insulin turned out to be as potent as dibutyryl cAMP (dbcAMP) in increasing UCP1 gene transcription rate (1 h) and also UCP1 mRNA accumulation (3 h), their maximal effect (15-fold increase) reached upon treatment for 24 h. Upon treatment with either IGF-I or insulin for 48 h, a 7-fold increase in the UCP1 protein content relative to levels in the control cells was found, this induction being abolished in the presence of cycloheximide.	Cycloheximide	495-508	insulin	Homo sapiens	31-38
9632721-6	1998	However, addition of fumonisin B1, a selective ceramide synthase inhibitor, attenuated TNF-alpha/CHX-induced intracellular ceramide elevation and BCEC death.	Cycloheximide	97-100	tumor necrosis factor	Bos taurus	87-96
9624173-4	1998	Exploiting this translation dependence, we show that pharmacologic inhibition of translation with cycloheximide abolishes the down-regulation of regulated MYC and globin-MYC mRNAs and induces their levels in differentiating C2C12 cells.	Cycloheximide	98-111	myelocytomatosis oncogene	Mus musculus	155-158
9624173-4	1998	Exploiting this translation dependence, we show that pharmacologic inhibition of translation with cycloheximide abolishes the down-regulation of regulated MYC and globin-MYC mRNAs and induces their levels in differentiating C2C12 cells.	Cycloheximide	98-111	myelocytomatosis oncogene	Mus musculus	170-173
9624173-9	1998	Finally, using cycloheximide induction to examine mRNA half-lives, we show that mRNA turnover is increased sufficiently by mechanisms targeting the exon 2 and 3 regulatory elements to account for the magnitude of c-myc mRNA down-regulation during differentiation.	Cycloheximide	15-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	213-218
9662427-5	1998	The response to NGF was maximal in the presence of cycloheximide, and RA also reduced the superinduction of NGFI-B and c-fos mRNA levels.	Cycloheximide	51-64	nerve growth factor	Rattus norvegicus	16-19
9637506-6	1998	The protein synthesis inhibitor, cycloheximide, increased TNF-induced cPLA2 activity and cytotoxicity in both CEM and CEM/VLB100 cell lines.	Cycloheximide	33-46	tumor necrosis factor	Homo sapiens	58-61
9637506-6	1998	The protein synthesis inhibitor, cycloheximide, increased TNF-induced cPLA2 activity and cytotoxicity in both CEM and CEM/VLB100 cell lines.	Cycloheximide	33-46	phospholipase A2 group IVA	Homo sapiens	70-75
9637507-3	1998	The inhibitory activity of IL-10 was abrogated by cycloheximide (CHX), suggesting the involvement of a newly synthesized protein(s).	Cycloheximide	50-63	interleukin 10	Homo sapiens	27-32
9637507-3	1998	The inhibitory activity of IL-10 was abrogated by cycloheximide (CHX), suggesting the involvement of a newly synthesized protein(s).	Cycloheximide	65-68	interleukin 10	Homo sapiens	27-32
9637703-3	1998	Both the protein translation inhibitor cycloheximide and the specific inhibitor of proteasome function, lactacystin, prevented intracellular degradation of Z alpha1AT.	Cycloheximide	39-52	serpin family A member 1	Homo sapiens	158-166
9626179-6	1998	Conversely, the accumulation of both PAI-1 and collagen induced by IL-1 was inhibited with an IL-1 receptor antagonist (200 ng/mL; n = 6) and with cycloheximide (10 micrograms/mL; n = 6), implying that protein synthesis was a requirement for the effect.	Cycloheximide	147-160	serpin family E member 2	Rattus norvegicus	37-42
9609725-8	1998	Phorbol 12-myristate 13-acetate, lipopolysaccharide, transforming growth factor-beta, tumor necrosis factor-alpha, or cycloheximide induced uPAR and uPAR mRNA expression in cultured rabbit pleural mesothelial cells and lung fibroblasts and concurrently reduced the uPAR mRNA-uPAR mRNABP interaction.	Cycloheximide	118-131	plasminogen activator, urokinase receptor	Homo sapiens	140-144
9609725-8	1998	Phorbol 12-myristate 13-acetate, lipopolysaccharide, transforming growth factor-beta, tumor necrosis factor-alpha, or cycloheximide induced uPAR and uPAR mRNA expression in cultured rabbit pleural mesothelial cells and lung fibroblasts and concurrently reduced the uPAR mRNA-uPAR mRNABP interaction.	Cycloheximide	118-131	plasminogen activator, urokinase receptor	Homo sapiens	149-153
9609725-8	1998	Phorbol 12-myristate 13-acetate, lipopolysaccharide, transforming growth factor-beta, tumor necrosis factor-alpha, or cycloheximide induced uPAR and uPAR mRNA expression in cultured rabbit pleural mesothelial cells and lung fibroblasts and concurrently reduced the uPAR mRNA-uPAR mRNABP interaction.	Cycloheximide	118-131	plasminogen activator, urokinase receptor	Homo sapiens	149-153
9609725-8	1998	Phorbol 12-myristate 13-acetate, lipopolysaccharide, transforming growth factor-beta, tumor necrosis factor-alpha, or cycloheximide induced uPAR and uPAR mRNA expression in cultured rabbit pleural mesothelial cells and lung fibroblasts and concurrently reduced the uPAR mRNA-uPAR mRNABP interaction.	Cycloheximide	118-131	plasminogen activator, urokinase receptor	Homo sapiens	149-153
9841496-7	1998	Moreover, enhanced expression of Hsp110 and Osp94 was subsequent to induction of Hsp70 and was suppressed by inhibition of protein synthesis by cycloheximide.	Cycloheximide	144-157	heat shock protein 4	Mus musculus	33-39
9841496-7	1998	Moreover, enhanced expression of Hsp110 and Osp94 was subsequent to induction of Hsp70 and was suppressed by inhibition of protein synthesis by cycloheximide.	Cycloheximide	144-157	heat shock protein 4 like	Mus musculus	44-49
9667646-6	1998	Cycloheximide blocked the apoptosis of 7-4 cells in a dose-dependent manner, indicating that specific protein regulating apoptosis may be synthesized through Ha-ras overexpression.	Cycloheximide	0-13	Harvey rat sarcoma virus oncogene	Mus musculus	158-164
9649118-5	1998	In the presence of cycloheximide, virally induced IFN-beta gene expression of C-76 cells was suppressed, whereas R1 and R2 cells produced IFN-beta 7.5- and 2.2-fold higher than C-76 cells respectively.	Cycloheximide	19-32	interferon beta 1	Homo sapiens	50-58
9649118-5	1998	In the presence of cycloheximide, virally induced IFN-beta gene expression of C-76 cells was suppressed, whereas R1 and R2 cells produced IFN-beta 7.5- and 2.2-fold higher than C-76 cells respectively.	Cycloheximide	19-32	interferon beta 1	Homo sapiens	138-146
9689490-0	1998	On the inhibition of camel retina acetylcholinesterase activity by cycloheximide in vitro.	Cycloheximide	67-80	acetylcholinesterase	Camelus bactrianus	34-54
9689490-1	1998	The kinetic parameters of inhibition of camel retinal acetylcholinesterase (AChE) activity by cycloheximide (CH) were investigated.	Cycloheximide	94-107	acetylcholinesterase	Camelus bactrianus	54-74
9689490-1	1998	The kinetic parameters of inhibition of camel retinal acetylcholinesterase (AChE) activity by cycloheximide (CH) were investigated.	Cycloheximide	94-107	acetylcholinesterase	Camelus bactrianus	76-80
9747450-5	1998	RESULTS: PCR analysis showed the presence of mRNA for iNOS in stimulated samples which could be inhibited by cycloheximide.	Cycloheximide	109-122	nitric oxide synthase 2	Homo sapiens	54-58
9923963-10	1998	The decay rates of uridine kinase were examined in rats injected with a high dose of cycloheximide, which inhibits protein biosynthesis by 90%.	Cycloheximide	85-98	uridine-cytidine kinase 2	Homo sapiens	19-33
9618150-2	1998	At physiological doses, either insulin-like growth factor I (IGF-I) or insulin turned out to be as potent as dibutyryl cAMP (dbcAMP) in increasing UCP1 gene transcription rate (1 h) and also UCP1 mRNA accumulation (3 h), their maximal effect (15-fold increase) reached upon treatment for 24 h. Upon treatment with either IGF-I or insulin for 48 h, a 7-fold increase in the UCP1 protein content relative to levels in the control cells was found, this induction being abolished in the presence of cycloheximide.	Cycloheximide	495-508	insulin	Homo sapiens	71-78
9712367-2	1998	The time courses of the inhibition of IFN-gamma-induced kynurenine synthesis by actinomycin D and cycloheximide showed that the indoleamine dioxygenase gene was transcribed as early as 2 h and translated as early as 5 h after initiation of IFN treatment.	Cycloheximide	98-111	interferon alpha 1	Homo sapiens	38-41
9607773-4	1998	The ionomycin inhibitory effect on GnRH cytoplasmic mRNA levels was significantly inhibited in the presence of cycloheximide or the RNA synthesis inhibitor 5,6-dichloro-1beta-ribofuranosylbenzimidazole, indicating that novel protein/RNA synthesis is obligatory for this effect.	Cycloheximide	111-124	gonadotropin releasing hormone 1	Mus musculus	35-39
9660180-4	1998	There was an up to fivefold increase in 5-LO primary transcripts by TGFbeta and calcitriol, which could be inhibited by cycloheximide.	Cycloheximide	120-133	transforming growth factor beta 1	Homo sapiens	68-75
9660180-7	1998	Addition of cycloheximide together with the second inducer inhibited only the TGFbeta but not the calcitriol effects, which indicated that there is a direct stimulation of 5-LO transcription by calcitriol in the presence of TGFbeta-induced proteins.	Cycloheximide	12-25	transforming growth factor beta 1	Homo sapiens	78-85
9660180-7	1998	Addition of cycloheximide together with the second inducer inhibited only the TGFbeta but not the calcitriol effects, which indicated that there is a direct stimulation of 5-LO transcription by calcitriol in the presence of TGFbeta-induced proteins.	Cycloheximide	12-25	transforming growth factor beta 1	Homo sapiens	224-231
9660180-12	1998	The effects of both TGFbeta and calcitriol on transcript elongation and maturation were inhibited by cycloheximide.	Cycloheximide	101-114	transforming growth factor beta 1	Homo sapiens	20-27
9660181-10	1998	Clusterin mRNA levels were strongly induced in pancreatic acinar AR4-2J cells in response to various apoptotic stimuli (i.e., cycloheximide, staurosporine, ceramide and H2O2) but not with interleukin (IL)-1, IL-4 or IL-6 or heat shock, which do not induce apoptosis in AR4-2J cells.	Cycloheximide	126-139	clusterin	Rattus norvegicus	0-9
9596701-3	1998	SLPI mRNA was detectable in macrophages by Northern blot analysis within 30 min of exposure to LPS but levels peaked only at 24 to 36 h and remained elevated at 72 h. Despite the slowly mounting and prolonged response, early expression of SLPI mRNA was cycloheximide resistant.	Cycloheximide	253-266	secretory leukocyte peptidase inhibitor	Mus musculus	0-4
9632527-2	1998	IFN-gamma specific transcripts were clearly detected in rat astrocytes and were upregulated after treatment with IFN-gamma itself or cycloheximide.	Cycloheximide	133-146	interferon gamma	Rattus norvegicus	0-9
9632527-3	1998	In microglial cells, IFN-gamma transcripts were barely detectable in basal conditions and were upregulated by lipopolysaccharide and, to a lesser extent, by IFN-gamma or cycloheximide.	Cycloheximide	170-183	interferon gamma	Rattus norvegicus	21-30
9754910-4	1998	The ability of IFNgamma to stimulate increased bradykinin receptor expression was abrogated by treatment with either the transcription inhibitor actinomycin D or the protein synthesis inhibitor cycloheximide.	Cycloheximide	194-207	interferon gamma	Homo sapiens	15-23
9754910-4	1998	The ability of IFNgamma to stimulate increased bradykinin receptor expression was abrogated by treatment with either the transcription inhibitor actinomycin D or the protein synthesis inhibitor cycloheximide.	Cycloheximide	194-207	kininogen 1	Homo sapiens	47-57
9590541-6	1998	Furthermore, SPIN from cycloheximide-treated oocytes that lack detectable MAP kinase activity is only partially phosphorylated, indicating that SPIN may be phosphorylated by the MOS/MAP kinase pathway.	Cycloheximide	23-36	spindlin 1	Mus musculus	13-17
9590541-6	1998	Furthermore, SPIN from cycloheximide-treated oocytes that lack detectable MAP kinase activity is only partially phosphorylated, indicating that SPIN may be phosphorylated by the MOS/MAP kinase pathway.	Cycloheximide	23-36	spindlin 1	Mus musculus	144-148
9614208-4	1998	The action of TGF-beta2 could be abolished by cycloheximide or EGTA, suggesting the requirement of a newly synthesized protein and extracellular Ca2+.	Cycloheximide	46-59	transforming growth factor, beta 2	Rattus norvegicus	14-23
9626660-3	1998	The kinetics of appearance and reversal of the RU-dependent ER mislocalization in the presence or absence of cycloheximide demonstrated 1) that this effect was reversed by RU withdrawal or estradiol (E2) treatment, and 2) that cycloheximide with RU inhibited and reversed the ER cytoplasmic mislocalization induced by RU alone.	Cycloheximide	109-122	estrogen receptor 1	Homo sapiens	60-62
9626660-3	1998	The kinetics of appearance and reversal of the RU-dependent ER mislocalization in the presence or absence of cycloheximide demonstrated 1) that this effect was reversed by RU withdrawal or estradiol (E2) treatment, and 2) that cycloheximide with RU inhibited and reversed the ER cytoplasmic mislocalization induced by RU alone.	Cycloheximide	109-122	estrogen receptor 1	Homo sapiens	276-278
9626660-3	1998	The kinetics of appearance and reversal of the RU-dependent ER mislocalization in the presence or absence of cycloheximide demonstrated 1) that this effect was reversed by RU withdrawal or estradiol (E2) treatment, and 2) that cycloheximide with RU inhibited and reversed the ER cytoplasmic mislocalization induced by RU alone.	Cycloheximide	227-240	estrogen receptor 1	Homo sapiens	60-62
9675902-6	1998	Repression of CPD transcription by brassinosteroids is sensitive to the protein synthesis inhibitor cycloheximide, indicating a requirement for de novo synthesis of a regulatory factor.	Cycloheximide	100-113	Cytochrome P450 superfamily protein	Arabidopsis thaliana	14-17
9596701-3	1998	SLPI mRNA was detectable in macrophages by Northern blot analysis within 30 min of exposure to LPS but levels peaked only at 24 to 36 h and remained elevated at 72 h. Despite the slowly mounting and prolonged response, early expression of SLPI mRNA was cycloheximide resistant.	Cycloheximide	253-266	secretory leukocyte peptidase inhibitor	Mus musculus	239-243
9622592-14	1998	Cycloheximide abolished completely the release of sPLA2 and markedly reduced the release of PGE2 from cytokine-stimulated FRCO, regardless of whether growth factors were present or not.	Cycloheximide	0-13	phospholipase A2 group X	Homo sapiens	50-55
9627221-10	1998	Moreover, when cycloheximide was used for 72 h to suppress protein synthesis, surface P-gp expression showed no decrease, whereas total P-gp was considerably lowered.	Cycloheximide	15-28	phosphoglycolate phosphatase	Homo sapiens	86-90
9627221-10	1998	Moreover, when cycloheximide was used for 72 h to suppress protein synthesis, surface P-gp expression showed no decrease, whereas total P-gp was considerably lowered.	Cycloheximide	15-28	phosphoglycolate phosphatase	Homo sapiens	136-140
9576849-10	1998	The induction of p53 by H2O2 was abolished by the iron chelator deferoxamine and the protein synthesis inhibitor cycloheximide.	Cycloheximide	113-126	tumor protein p53	Homo sapiens	17-20
9633998-5	1998	The expression of mRNA for COX-2 induced by catalase was blocked completely by actinomycin D (ACT) or cycloheximide (CHX).	Cycloheximide	102-115	catalase	Rattus norvegicus	44-52
9633998-5	1998	The expression of mRNA for COX-2 induced by catalase was blocked completely by actinomycin D (ACT) or cycloheximide (CHX).	Cycloheximide	117-120	catalase	Rattus norvegicus	44-52
9578594-5	1998	Comparative analyses of immunodetectable protein levels following treatment with cycloheximide showed that DMSO clearly decreased the rate of CYP3A protein turnover but not that of CYP2B.	Cycloheximide	81-94	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	142-147
9593144-7	1998	The resulting erg6 strains were shown to be hypersusceptible to a number of sterol synthesis and metabolic inhibitors, including terbinafine, tridemorph, fenpropiomorph, fluphenazine, cycloheximide, cerulenin, and brefeldin A.	Cycloheximide	184-197	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	14-18
9562439-4	1998	This increase in GM-CSF mRNA levels in response to shear stress depended on protein synthesis, because it was blocked by cycloheximide.	Cycloheximide	121-134	colony stimulating factor 2	Homo sapiens	17-23
9593711-6	1998	Whereas immortalized PARP +/+ fibroblasts showed the early burst of poly(ADP-ribosyl)ation and a rapid apoptotic response when exposed to anti-Fas and cycloheximide, PARP -/- fibroblasts exhibited neither the early poly (ADP-ribosyl)ation nor any of the biochemical or morphological changes characteristic of apoptosis when similarly treated.	Cycloheximide	151-164	poly(ADP-ribose) polymerase 1	Homo sapiens	21-25
9620452-5	1998	Cycloheximide (35.5 microM) had no effect on basal mRNA levels for the exchanger but steady-state levels were diminished in cells treated with TGF-beta1.	Cycloheximide	0-13	transforming growth factor, beta 1	Rattus norvegicus	143-152
9572795-6	1998	The release of ECA in response to ACh and SP was inhibited by nonspecific and 5-specific lipoxygenase inhibitors and by cycloheximide (P < 0.01).	Cycloheximide	120-133	tachykinin precursor 1	Bos taurus	42-44
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	72-77
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	angiotensinogen	Homo sapiens	179-182
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	268-272
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	274-279
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	327-331
9589661-11	1998	Inhibition of protein synthesis with cycloheximide blocked induction of CYP21 as well as type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSDII) mRNA expression in response to AII, forskolin, and dibutyryl cAMP, but had no effect on 17 alpha-hydroxylase cytochrome P450 (CYP17) or cholesterol side-chain cleavage cytochrome P450 (CYP11A) mRNA.	Cycloheximide	37-50	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	333-339
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cycloheximide	188-201	Fas cell surface death receptor	Homo sapiens	21-25
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cycloheximide	188-201	Fas ligand	Homo sapiens	26-32
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cycloheximide	188-201	Fas cell surface death receptor	Homo sapiens	26-30
9574534-4	1998	The critical role of CD95/CD95-L interaction was supported by complete inhibition in the presence of the antagonist CD95 mAb ZB4 and by blocking CD95-L synthesis and surface expression by cycloheximide, cyclosporin A, EGTA, or cytochalasin B.	Cycloheximide	188-201	Fas cell surface death receptor	Homo sapiens	26-30
9557667-3	1998	U41, U53, U31, and U19 are beta genes since their expression is inhibited by cycloheximide but not by phosphonoacetate, an inhibitor of DNA synthesis.	Cycloheximide	77-90	small nucleolar RNA, C/D box 41	Homo sapiens	0-3
9557667-3	1998	U41, U53, U31, and U19 are beta genes since their expression is inhibited by cycloheximide but not by phosphonoacetate, an inhibitor of DNA synthesis.	Cycloheximide	77-90	small nucleolar RNA, C/D box 53	Homo sapiens	5-8
9557667-3	1998	U41, U53, U31, and U19 are beta genes since their expression is inhibited by cycloheximide but not by phosphonoacetate, an inhibitor of DNA synthesis.	Cycloheximide	77-90	small nucleolar RNA, C/D box 31	Homo sapiens	10-13
9557667-3	1998	U41, U53, U31, and U19 are beta genes since their expression is inhibited by cycloheximide but not by phosphonoacetate, an inhibitor of DNA synthesis.	Cycloheximide	77-90	small nucleolar RNA, H/ACA box 74A	Homo sapiens	19-22
9557675-4	1998	Although all three transcripts accumulate to high levels in cells infected in the presence of cycloheximide, kinetic analysis demonstrates that TR5/6 and TR6 are either early or late transcripts that leak through the cycloheximide block.	Cycloheximide	94-107	TNF receptor superfamily member 6b	Homo sapiens	144-149
9557675-4	1998	Although all three transcripts accumulate to high levels in cells infected in the presence of cycloheximide, kinetic analysis demonstrates that TR5/6 and TR6 are either early or late transcripts that leak through the cycloheximide block.	Cycloheximide	94-107	TNF receptor superfamily member 6b	Homo sapiens	154-157
9557675-4	1998	Although all three transcripts accumulate to high levels in cells infected in the presence of cycloheximide, kinetic analysis demonstrates that TR5/6 and TR6 are either early or late transcripts that leak through the cycloheximide block.	Cycloheximide	217-230	TNF receptor superfamily member 6b	Homo sapiens	144-149
9557675-4	1998	Although all three transcripts accumulate to high levels in cells infected in the presence of cycloheximide, kinetic analysis demonstrates that TR5/6 and TR6 are either early or late transcripts that leak through the cycloheximide block.	Cycloheximide	217-230	TNF receptor superfamily member 6b	Homo sapiens	154-157
9605178-4	1998	Pretreatment of synovial fibroblasts with cycloheximide prevented SAA-mediated MMP-2 and MMP-3 secretion.	Cycloheximide	42-55	serum amyloid A1 cluster	Homo sapiens	66-69
9605178-4	1998	Pretreatment of synovial fibroblasts with cycloheximide prevented SAA-mediated MMP-2 and MMP-3 secretion.	Cycloheximide	42-55	matrix metallopeptidase 2	Homo sapiens	79-84
9605178-4	1998	Pretreatment of synovial fibroblasts with cycloheximide prevented SAA-mediated MMP-2 and MMP-3 secretion.	Cycloheximide	42-55	matrix metallopeptidase 3	Homo sapiens	89-94
9597689-4	1998	Actinomycin D and cycloheximide inhibited MIP-1 alpha production completely, but glucocorticoids did not completely inhibit MIP-1 alpha production, with a maximum inhibition of 70%.	Cycloheximide	18-31	C-C motif chemokine ligand 3	Homo sapiens	42-53
9553092-2	1998	They are made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide or vanadate.	Cycloheximide	99-112	tumor necrosis factor	Rattus norvegicus	53-62
9605472-2	1998	The respiratory control ratio, which is an index of oxidative phosphorylation and therefore reflects the ability of mitochondria to produce ATP, is reduced by 50% within the first 2 h after the beginning of apoptosis, insulin-like growth factor I (IGF-I), actinomicin D or cycloheximide, previously reported to inhibit apoptosis, fully prevent the impairment of cellular respiration while scavengers of reactive oxygen species partially inhibit apoptosis and restore cellular respiration.	Cycloheximide	273-286	insulin-like growth factor 1	Rattus norvegicus	218-246
9605472-2	1998	The respiratory control ratio, which is an index of oxidative phosphorylation and therefore reflects the ability of mitochondria to produce ATP, is reduced by 50% within the first 2 h after the beginning of apoptosis, insulin-like growth factor I (IGF-I), actinomicin D or cycloheximide, previously reported to inhibit apoptosis, fully prevent the impairment of cellular respiration while scavengers of reactive oxygen species partially inhibit apoptosis and restore cellular respiration.	Cycloheximide	273-286	insulin-like growth factor 1	Rattus norvegicus	248-253
9525952-7	1998	Experiments with cycloheximide indicated that the effect of IL-1beta was independent of protein synthesis.	Cycloheximide	17-30	interleukin 1 beta	Homo sapiens	60-68
9575827-2	1998	We have defined elements in the SgII promoter that mediate regulation by cycloheximide (CHX) and forskolin (FSK) and characterized the nuclear proteins that interact with them.	Cycloheximide	73-86	secretogranin II	Rattus norvegicus	32-36
9575827-2	1998	We have defined elements in the SgII promoter that mediate regulation by cycloheximide (CHX) and forskolin (FSK) and characterized the nuclear proteins that interact with them.	Cycloheximide	88-91	secretogranin II	Rattus norvegicus	32-36
9512490-7	1998	CYP1A1 mRNA is also induced when hepatocytes are treated with metyrapone in combination with the protein synthesis inhibitor cycloheximide but not with dexamethasone in combination with cycloheximide, indicating that CYP1A1 mRNA induction is strictly dependent on the presence of metyrapone and suggesting that the metyrapone-associated induction of CYP1A1 mRNA is dependent on a loss of a constitutively expressed protein that functions to suppress CYP1A1 gene expression.	Cycloheximide	125-138	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	0-6
9606981-4	1998	The protein synthesis inhibitor, cycloheximide, blunted the diurnal and fructose driven increase in GLUT5 mRNA expression in the morning, but had minimal effect on the pattern of expression in the evening.	Cycloheximide	33-46	solute carrier family 2 member 5	Rattus norvegicus	100-105
9606981-6	1998	Following vehicle gavage, Cycloheximide was more effective in reducing GLUT5 protein expression levels in the morning when compared to the evening.	Cycloheximide	26-39	solute carrier family 2 member 5	Rattus norvegicus	71-76
9512490-7	1998	CYP1A1 mRNA is also induced when hepatocytes are treated with metyrapone in combination with the protein synthesis inhibitor cycloheximide but not with dexamethasone in combination with cycloheximide, indicating that CYP1A1 mRNA induction is strictly dependent on the presence of metyrapone and suggesting that the metyrapone-associated induction of CYP1A1 mRNA is dependent on a loss of a constitutively expressed protein that functions to suppress CYP1A1 gene expression.	Cycloheximide	125-138	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	217-223
9512490-7	1998	CYP1A1 mRNA is also induced when hepatocytes are treated with metyrapone in combination with the protein synthesis inhibitor cycloheximide but not with dexamethasone in combination with cycloheximide, indicating that CYP1A1 mRNA induction is strictly dependent on the presence of metyrapone and suggesting that the metyrapone-associated induction of CYP1A1 mRNA is dependent on a loss of a constitutively expressed protein that functions to suppress CYP1A1 gene expression.	Cycloheximide	125-138	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	217-223
9512490-7	1998	CYP1A1 mRNA is also induced when hepatocytes are treated with metyrapone in combination with the protein synthesis inhibitor cycloheximide but not with dexamethasone in combination with cycloheximide, indicating that CYP1A1 mRNA induction is strictly dependent on the presence of metyrapone and suggesting that the metyrapone-associated induction of CYP1A1 mRNA is dependent on a loss of a constitutively expressed protein that functions to suppress CYP1A1 gene expression.	Cycloheximide	125-138	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	217-223
10022753-8	1998	Half-lives of the polymorphic mEH proteins were determined in transiently transfected COS-1 cells treated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	143-156	epoxide hydrolase 1, microsomal	Mus musculus	30-33
9605550-9	1998	Maintaining slices in the protein synthesis inhibitor cycloheximide (1 microM), to prevent COX-2 induction, had no effect on the potentiation action of DFU (10 microM).	Cycloheximide	54-67	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	91-96
9512490-14	1998	The dependence of CYP1A1 induction on dexamethasone or cycloheximide suggests that derepression by a glucocorticoid receptor-modulated negative-acting factor of CYP1A1 gene expression might be critical to induction by metyrapone.	Cycloheximide	55-68	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	18-24
9512490-14	1998	The dependence of CYP1A1 induction on dexamethasone or cycloheximide suggests that derepression by a glucocorticoid receptor-modulated negative-acting factor of CYP1A1 gene expression might be critical to induction by metyrapone.	Cycloheximide	55-68	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	101-124
9512490-14	1998	The dependence of CYP1A1 induction on dexamethasone or cycloheximide suggests that derepression by a glucocorticoid receptor-modulated negative-acting factor of CYP1A1 gene expression might be critical to induction by metyrapone.	Cycloheximide	55-68	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	161-167
9528960-4	1998	hCYR61 messenger RNA (mRNA) steady-state levels were stimulated 11-fold by 10 nM 1,25-(OH)2D3 by 1 h and declined to control levels by 4 h. This transient stimulation of hCYR61 mRNA was not inhibited by cycloheximide but was prevented by actinomycin D, indicating that the 1,25-(OH)2D3 effect involves transcriptional events and does not require de novo protein synthesis.	Cycloheximide	203-216	cellular communication network factor 1	Homo sapiens	0-6
9528960-5	1998	hCYR61 mRNA stability was not influenced by 1,25(OH)2D3, whereas cycloheximide treatment stabilized hCYR61 mRNA.	Cycloheximide	65-78	cellular communication network factor 1	Homo sapiens	100-106
9528967-10	1998	However, Jak2 tyrosine phosphorylation and Stat5 DNA-binding activity were prolonged for at least 4 h in the presence of cycloheximide, which suggests that the maintenance of desensitization requires ongoing protein synthesis.	Cycloheximide	121-134	Janus kinase 2	Rattus norvegicus	9-13
9528967-10	1998	However, Jak2 tyrosine phosphorylation and Stat5 DNA-binding activity were prolonged for at least 4 h in the presence of cycloheximide, which suggests that the maintenance of desensitization requires ongoing protein synthesis.	Cycloheximide	121-134	signal transducer and activator of transcription 5A	Rattus norvegicus	43-48
9578515-5	1998	The stimulatory effect of IGF-I was completely abolished by the presence of cycloheximide; in contrast the effect of vitamin K2 was still observed in the presence of cycloheximide.	Cycloheximide	76-89	insulin like growth factor 1	Homo sapiens	26-31
9607608-3	1998	The GPx mimic BXT-51072 strongly inhibits the TNFalpha-induced and cycloheximide-sensitive expression of ICAM-1 and VCAM-1.	Cycloheximide	67-80	intercellular adhesion molecule 1	Homo sapiens	105-111
9607608-3	1998	The GPx mimic BXT-51072 strongly inhibits the TNFalpha-induced and cycloheximide-sensitive expression of ICAM-1 and VCAM-1.	Cycloheximide	67-80	vascular cell adhesion molecule 1	Homo sapiens	116-122
9749794-4	1998	The protein synthesis inhibitor cycloheximide blocked all these phenomena, whereas RNA synthesis inhibitor actinomycin-D, survival factor such as insulin-like growth factor-1, brain-derived neurotrophic factor, high K+ (25 mM) and overproduced antiapoptotic protein Bcl-2, prevented deltapsi, loss, caspase activation, and nuclear change, but not an increase in active c-Jun.	Cycloheximide	32-45	B cell leukemia/lymphoma 2	Mus musculus	266-271
9749794-4	1998	The protein synthesis inhibitor cycloheximide blocked all these phenomena, whereas RNA synthesis inhibitor actinomycin-D, survival factor such as insulin-like growth factor-1, brain-derived neurotrophic factor, high K+ (25 mM) and overproduced antiapoptotic protein Bcl-2, prevented deltapsi, loss, caspase activation, and nuclear change, but not an increase in active c-Jun.	Cycloheximide	32-45	jun proto-oncogene	Mus musculus	369-374
9491783-8	1998	Cycloheximide inhibited moderately the OP-1-induced increase in IGF-I mRNA, suggesting partial dependency on protein synthesis.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	64-69
9491783-14	1998	The level of IGFBP-5 mRNA was barely detectable in the presence of cycloheximide, and further suppressive effect of OP-1 on IGFBP-5 mRNA could not be determined.	Cycloheximide	67-80	insulin-like growth factor binding protein 5	Rattus norvegicus	13-20
9554800-4	1998	Aspirin and SQ29548 inhibited and cycloheximide and actinomycin D reduced the time-dependent enhanced response to angiotensin II in rings with endothelium from SHRs.	Cycloheximide	34-47	angiotensinogen	Rattus norvegicus	114-128
9584837-6	1998	Induction of PGHS-2 expression proceeded in the presence of 10 microg/ml cycloheximide which agrees with the classification of PGHS-2 as an immediate early gene.	Cycloheximide	73-86	prostaglandin-endoperoxide synthase 2	Homo sapiens	13-19
9650640-6	1998	CdCl2 (10 microM) caused an accumulation of c-fos mRNA over 30 min that was sustained for at least 8 h. Cycloheximide inhibits turnover of c-fos mRNA and shows a synergistic effect with Cd2+ on transcript levels.	Cycloheximide	104-117	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
9650640-6	1998	CdCl2 (10 microM) caused an accumulation of c-fos mRNA over 30 min that was sustained for at least 8 h. Cycloheximide inhibits turnover of c-fos mRNA and shows a synergistic effect with Cd2+ on transcript levels.	Cycloheximide	104-117	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	139-144
9650640-6	1998	CdCl2 (10 microM) caused an accumulation of c-fos mRNA over 30 min that was sustained for at least 8 h. Cycloheximide inhibits turnover of c-fos mRNA and shows a synergistic effect with Cd2+ on transcript levels.	Cycloheximide	104-117	CD2 molecule	Homo sapiens	186-189
9482780-10	1998	If protein synthesis was inhibited by cycloheximide, AChE mRNA levels in 3-d-old regenerating muscle, still containing myoblasts, increased approximately twofold.	Cycloheximide	38-51	acetylcholinesterase	Rattus norvegicus	53-57
9497363-2	1998	Cycloheximide blocked most of the TIGR mRNA induction, suggesting a requirement for ongoing protein synthesis.	Cycloheximide	0-13	myocilin	Homo sapiens	34-38
9580415-8	1998	Pre-stress microinjections of cycloheximide increased exploration of open arms in the elevated plus maze (percentage of entries, SAL = 10.3 +/- 2.7, CHX 4 microg = 24.5 +/- 4.6, CHX 8 microg = 28.2 +/- 4.8, percentage of time spent, SAL = 2.0 +/- 0.6, CHX 4 microg = 8.4 +/- 2.3, CHX 8 microg = 9.6 +/- 2.6, Duncan test, P < 0.05).	Cycloheximide	30-43	UNC homeobox	Rattus norvegicus	149-154
9580415-8	1998	Pre-stress microinjections of cycloheximide increased exploration of open arms in the elevated plus maze (percentage of entries, SAL = 10.3 +/- 2.7, CHX 4 microg = 24.5 +/- 4.6, CHX 8 microg = 28.2 +/- 4.8, percentage of time spent, SAL = 2.0 +/- 0.6, CHX 4 microg = 8.4 +/- 2.3, CHX 8 microg = 9.6 +/- 2.6, Duncan test, P < 0.05).	Cycloheximide	30-43	UNC homeobox	Rattus norvegicus	252-257
9555062-2	1998	The proENK mRNA level was elevated at 4 h after the treatment of PMA (2.5 microM) without altering the intracellular proENK protein level, and this increase was attenuated by pre-treatment with cycloheximide (CHX; 15 microM), a protein synthesis inhibitor.	Cycloheximide	194-207	proenkephalin	Rattus norvegicus	4-10
9606035-3	1998	This effect was blocked by 1 microM dactinomycin or 10 microM cycloheximide, i.e. the stimulatory effect of IL-1beta depended on de-novo synthesis.	Cycloheximide	62-75	interleukin 1 beta	Homo sapiens	108-116
10200470-3	1998	We report here that rapid apoptosis induced by TNF in U937 cells or anti-Fas in Jurkat cells, in the presence of cycloheximide, induced only a very low increase (<20%) in the cell ceramide content.	Cycloheximide	113-126	tumor necrosis factor	Homo sapiens	47-50
9510850-5	1998	Moreover, the amount of PSA transcript in MCF-7, a PSA-negative breast line, increased after incubation with cycloheximide.	Cycloheximide	109-122	kallikrein related peptidase 3	Homo sapiens	24-27
9510850-5	1998	Moreover, the amount of PSA transcript in MCF-7, a PSA-negative breast line, increased after incubation with cycloheximide.	Cycloheximide	109-122	kallikrein related peptidase 3	Homo sapiens	51-54
9518257-6	1998	Dexamethasone at 10 nM repress induction of PEPCK mRNA by 1 microM BRL 49653, 0.32 mM oleate, or 1 mM clofibrate, in a cycloheximide-independent manner.	Cycloheximide	119-132	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	44-49
9488429-2	1998	The ATP binding cassette transporter-encoding genes regulated by Pdrlp include PDR5 and YOR1, which are required for normal cycloheximide and oligomycin tolerances, respectively.	Cycloheximide	124-137	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	79-83
9488429-2	1998	The ATP binding cassette transporter-encoding genes regulated by Pdrlp include PDR5 and YOR1, which are required for normal cycloheximide and oligomycin tolerances, respectively.	Cycloheximide	124-137	ATP-binding cassette transporter YOR1	Saccharomyces cerevisiae S288C	88-92
9550631-4	1998	When measured by nuclear run-on assay, the rate of PTH/PTHrP receptor gene transcription was increased twofold at 24 h. PTH/PTHrP receptor mRNA expression was blocked completely after 24 h of treatment with cycloheximide.	Cycloheximide	207-220	parathyroid hormone	Rattus norvegicus	51-54
9550631-4	1998	When measured by nuclear run-on assay, the rate of PTH/PTHrP receptor gene transcription was increased twofold at 24 h. PTH/PTHrP receptor mRNA expression was blocked completely after 24 h of treatment with cycloheximide.	Cycloheximide	207-220	parathyroid hormone-like hormone	Rattus norvegicus	55-60
9550631-4	1998	When measured by nuclear run-on assay, the rate of PTH/PTHrP receptor gene transcription was increased twofold at 24 h. PTH/PTHrP receptor mRNA expression was blocked completely after 24 h of treatment with cycloheximide.	Cycloheximide	207-220	parathyroid hormone	Rattus norvegicus	55-58
9550631-4	1998	When measured by nuclear run-on assay, the rate of PTH/PTHrP receptor gene transcription was increased twofold at 24 h. PTH/PTHrP receptor mRNA expression was blocked completely after 24 h of treatment with cycloheximide.	Cycloheximide	207-220	parathyroid hormone-like hormone	Rattus norvegicus	124-129
9769910-10	1998	However, TNF can cause apoptosis of EC when cells are co-treated with either the protein synthesis inhibitor cycloheximide (CHX) or the lipid mediator ceramide (cer).	Cycloheximide	109-122	tumor necrosis factor	Homo sapiens	9-12
9769910-10	1998	However, TNF can cause apoptosis of EC when cells are co-treated with either the protein synthesis inhibitor cycloheximide (CHX) or the lipid mediator ceramide (cer).	Cycloheximide	124-127	tumor necrosis factor	Homo sapiens	9-12
9531044-5	1998	Furthermore, inhibition of the ongoing protein synthesis with cycloheximide abrogated completely the PMA-induced uPAR mRNA accumulation but only partially the induction by PMA plus cAMP, whereas the induction by cAMP alone was rather amplified, indicating that the de novo protein synthesis is necessary in the induction by PMA but not in the induction by cAMP and that the cAMP pathway may be dominant in uPAR gene expression in the PL-21 cells as compared to the PMA pathway.	Cycloheximide	62-75	plasminogen activator, urokinase receptor	Homo sapiens	113-117
9516462-8	1998	Whereas the protein synthesis inhibitor cycloheximide did not block IRP1 inactivation during hypoxia, it completely blocked IRP1 reactivation during subsequent reoxygenation.	Cycloheximide	40-53	aconitase 1	Rattus norvegicus	124-128
9559891-6	1998	Cycloheximide (1 microM), a protein synthesis inhibitor, prevented iNOS protein expression, nitrite accumulation and the suppression of contractility by IL-1beta on the isolated aortic rings.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	67-71
9559891-6	1998	Cycloheximide (1 microM), a protein synthesis inhibitor, prevented iNOS protein expression, nitrite accumulation and the suppression of contractility by IL-1beta on the isolated aortic rings.	Cycloheximide	0-13	interleukin 1 beta	Rattus norvegicus	153-161
9539105-8	1998	The levels of G0S24 RNA and both intermediates were increased by the protein synthesis inhibitor cycloheximide, consistent with regulation by a labile repressor.	Cycloheximide	97-110	ZFP36 ring finger protein	Homo sapiens	14-19
9578040-9	1998	Nissl staining confirmed previously reported prevention of KA-induced neuronal loss in CA3 and CA1 areas of the hippocampus by cycloheximide pretreatment.	Cycloheximide	127-140	carbonic anhydrase 3	Rattus norvegicus	87-90
9578040-9	1998	Nissl staining confirmed previously reported prevention of KA-induced neuronal loss in CA3 and CA1 areas of the hippocampus by cycloheximide pretreatment.	Cycloheximide	127-140	carbonic anhydrase 1	Rattus norvegicus	95-98
9500714-10	1998	The blockade of protein translation before hemorrhage by cycloheximide reduced upregulation of HO-1/hsp32 mRNA significantly (65.4% reduction, P < .05), whereas the inducibility of hsp70 transcript was maintained.	Cycloheximide	57-70	heme oxygenase 1	Rattus norvegicus	95-99
9500714-10	1998	The blockade of protein translation before hemorrhage by cycloheximide reduced upregulation of HO-1/hsp32 mRNA significantly (65.4% reduction, P < .05), whereas the inducibility of hsp70 transcript was maintained.	Cycloheximide	57-70	heme oxygenase 1	Rattus norvegicus	100-105
9627795-6	1998	After treatment of CD34+ cells with cycloheximide, Tie mRNA levels were decreased in the presence or absence of LIF or SLF at 24 hours.	Cycloheximide	36-49	CD34 molecule	Homo sapiens	19-23
9627795-6	1998	After treatment of CD34+ cells with cycloheximide, Tie mRNA levels were decreased in the presence or absence of LIF or SLF at 24 hours.	Cycloheximide	36-49	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	51-54
9627795-6	1998	After treatment of CD34+ cells with cycloheximide, Tie mRNA levels were decreased in the presence or absence of LIF or SLF at 24 hours.	Cycloheximide	36-49	LIF interleukin 6 family cytokine	Homo sapiens	112-115
9627795-6	1998	After treatment of CD34+ cells with cycloheximide, Tie mRNA levels were decreased in the presence or absence of LIF or SLF at 24 hours.	Cycloheximide	36-49	KIT ligand	Homo sapiens	119-122
9506750-12	1998	Our results also demonstrated that induction of steady state TF mRNA by MPA was abolished by treating cells with E2 plus MPA in conjunction with the protein synthesis inhibitor cycloheximide.	Cycloheximide	177-190	inhibitor of carbonic anhydrase pseudogene	Homo sapiens	61-63
9535110-3	1998	The decrease in the night-time NAT activity evoked by a 1-min pulse of UV-A light (as well as by a 15-s pulse of broad-band visible light) gradually deepened during the first 40 min of treatment of animals with constant darkness, then the enzyme activity began to rise reaching control values by 3 h. Treatment of rats with a protein synthesis inhibitor, cycloheximide, attenuated this night-driven reactivation of the pineal NAT activity.	Cycloheximide	355-368	N-acetyltransferase 1	Rattus norvegicus	31-34
9468526-12	1998	Induction of PAP-2a mRNA was not affected by the protein synthesis inhibitor cycloheximide and was accompanied by a marked increase in PAP-2 activity as measured by the conversion of phosphatidic acid into diacylglycerol in membrane fractions of LNCaP.	Cycloheximide	77-90	phospholipid phosphatase 1	Homo sapiens	13-19
9468526-12	1998	Induction of PAP-2a mRNA was not affected by the protein synthesis inhibitor cycloheximide and was accompanied by a marked increase in PAP-2 activity as measured by the conversion of phosphatidic acid into diacylglycerol in membrane fractions of LNCaP.	Cycloheximide	77-90	phospholipid phosphatase 1	Homo sapiens	13-18
9484773-3	1998	We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling.	Cycloheximide	62-75	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	23-27
9484773-3	1998	We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling.	Cycloheximide	62-75	mitogen activated protein kinase 1	Rattus norvegicus	162-166
9484773-3	1998	We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling.	Cycloheximide	62-75	mitogen activated protein kinase 1	Rattus norvegicus	168-172
9484773-3	1998	We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling.	Cycloheximide	62-75	AKT serine/threonine kinase 1	Rattus norvegicus	205-212
9461519-10	1998	Pretreatment by actinomycin D or cycloheximide completely inhibited the up-regulation of I-BABP expression by bile acid.	Cycloheximide	33-46	fatty acid binding protein 6	Homo sapiens	89-95
9461531-5	1998	This increase in BKB1R mRNA level is protein synthesis-independent as indicated by treatment of cells with cycloheximide (CHX) or puromycin (PUR).	Cycloheximide	107-120	bradykinin receptor B1	Homo sapiens	17-22
9461531-5	1998	This increase in BKB1R mRNA level is protein synthesis-independent as indicated by treatment of cells with cycloheximide (CHX) or puromycin (PUR).	Cycloheximide	122-125	bradykinin receptor B1	Homo sapiens	17-22
9461540-4	1998	Cycloheximide (CHI, 10 microg/ml), an inhibitor of protein synthesis, maximally increased IL-8 mRNA levels 30-fold in H292 cells.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
9461540-4	1998	Cycloheximide (CHI, 10 microg/ml), an inhibitor of protein synthesis, maximally increased IL-8 mRNA levels 30-fold in H292 cells.	Cycloheximide	15-18	C-X-C motif chemokine ligand 8	Homo sapiens	90-94
9461593-2	1998	In this report we show that the cells can be made susceptible to the apoptotic effect of TNF-alpha when pretreated with actinomycin D, cycloheximide, or vanadate.	Cycloheximide	135-148	tumor necrosis factor	Rattus norvegicus	89-98
9461593-6	1998	However, when the cells were pretreated with actinomycin D or cycloheximide, TNF-alpha stimulated a second sustained JNK activity peak.	Cycloheximide	62-75	tumor necrosis factor	Homo sapiens	77-86
9461593-6	1998	However, when the cells were pretreated with actinomycin D or cycloheximide, TNF-alpha stimulated a second sustained JNK activity peak.	Cycloheximide	62-75	mitogen-activated protein kinase 8	Homo sapiens	117-120
9499794-7	1998	(iv) Fragmentation of the microtubules at the periphery of the cell near the plasma membrane was observed in untreated or cycloheximide-treated cells 2 h after infection with syn- virus HSV-1(MP) or syn+ HSV-1(mP) but not in mock-infected cells.	Cycloheximide	122-135	synemin	Homo sapiens	175-178
9499794-7	1998	(iv) Fragmentation of the microtubules at the periphery of the cell near the plasma membrane was observed in untreated or cycloheximide-treated cells 2 h after infection with syn- virus HSV-1(MP) or syn+ HSV-1(mP) but not in mock-infected cells.	Cycloheximide	122-135	synemin	Homo sapiens	199-202
9531974-3	1998	VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction was superinduced by cycloheximide and blocked by actinomycin D.	Cycloheximide	131-144	vascular endothelial growth factor A	Rattus norvegicus	0-4
9531974-3	1998	VEGF mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 4 h. The induction was superinduced by cycloheximide and blocked by actinomycin D.	Cycloheximide	131-144	angiotensinogen	Rattus norvegicus	68-71
9486123-3	1998	GAPDH was induced in cells by the transition metals cobalt, nickel, and manganese and by deferoxamine, and GAPDH mRNA induction by hypoxia was blocked by cycloheximide.	Cycloheximide	154-167	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	0-5
9486123-3	1998	GAPDH was induced in cells by the transition metals cobalt, nickel, and manganese and by deferoxamine, and GAPDH mRNA induction by hypoxia was blocked by cycloheximide.	Cycloheximide	154-167	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	107-112
9486138-5	1998	Ets-1 mRNA was superinduced by PDGF-BB and ET-1 in the presence of cycloheximide.	Cycloheximide	67-80	ETS proto-oncogene 1, transcription factor	Rattus norvegicus	0-5
9458101-9	1998	Phorbol 12-myristate 13-acetate inhibited CD95-mediated apoptosis by counteracting the IFNgamma-, actinomycin D-, and cycloheximide-mediated but not the brefeldin A-mediated sensitization.	Cycloheximide	118-131	Fas cell surface death receptor	Homo sapiens	42-46
9526053-3	1998	Pretreatment with cycloheximide prevented the induction of FOS, but not CREB phosphorylation, normally seen in response to acute ether exposure, and significantly attenuated the stress-induced rise in AVP, but not CRF, heteronuclear RNA expression in the parvocellular division of the PVH.	Cycloheximide	18-31	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	59-62
9555062-2	1998	The proENK mRNA level was elevated at 4 h after the treatment of PMA (2.5 microM) without altering the intracellular proENK protein level, and this increase was attenuated by pre-treatment with cycloheximide (CHX; 15 microM), a protein synthesis inhibitor.	Cycloheximide	194-207	proenkephalin	Rattus norvegicus	117-123
9555062-2	1998	The proENK mRNA level was elevated at 4 h after the treatment of PMA (2.5 microM) without altering the intracellular proENK protein level, and this increase was attenuated by pre-treatment with cycloheximide (CHX; 15 microM), a protein synthesis inhibitor.	Cycloheximide	209-212	proenkephalin	Rattus norvegicus	4-10
9555062-3	1998	Both AP-1 and ENKCRE-2 DNA binding activities were markedly increased at 1-4 h by PMA treatment and these PMA-induced responses were inhibited by pre-treatment with CHX, showing that the increase of proENK mRNA level was well correlated with the AP-1 and ENKCRE-2 DNA binding activities.	Cycloheximide	165-168	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	5-9
9555062-3	1998	Both AP-1 and ENKCRE-2 DNA binding activities were markedly increased at 1-4 h by PMA treatment and these PMA-induced responses were inhibited by pre-treatment with CHX, showing that the increase of proENK mRNA level was well correlated with the AP-1 and ENKCRE-2 DNA binding activities.	Cycloheximide	165-168	proenkephalin	Rattus norvegicus	199-205
9555062-3	1998	Both AP-1 and ENKCRE-2 DNA binding activities were markedly increased at 1-4 h by PMA treatment and these PMA-induced responses were inhibited by pre-treatment with CHX, showing that the increase of proENK mRNA level was well correlated with the AP-1 and ENKCRE-2 DNA binding activities.	Cycloheximide	165-168	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	246-250
9449635-7	1998	The increase in DIII mRNA in response to aFGF, bFGF, and EGF requires gene transcription and protein synthesis, as the inductive effect on mRNA is completely blocked by actinomycin D or cycloheximide.	Cycloheximide	186-199	fibroblast growth factor 1	Rattus norvegicus	41-45
9449635-7	1998	The increase in DIII mRNA in response to aFGF, bFGF, and EGF requires gene transcription and protein synthesis, as the inductive effect on mRNA is completely blocked by actinomycin D or cycloheximide.	Cycloheximide	186-199	fibroblast growth factor 2	Rattus norvegicus	47-51
9449635-7	1998	The increase in DIII mRNA in response to aFGF, bFGF, and EGF requires gene transcription and protein synthesis, as the inductive effect on mRNA is completely blocked by actinomycin D or cycloheximide.	Cycloheximide	186-199	epidermal growth factor like 1	Rattus norvegicus	57-60
9449644-9	1998	TNF reduced NIS mRNA levels in young cells grown with TSH at t1/2 = 0.62 days, a cycloheximide inhibitable effect.	Cycloheximide	81-94	tumor necrosis factor-like	Rattus norvegicus	0-3
9490031-9	1998	Ornithine decarboxylase activity was completely suppressed but that of aspartate transcarbamoylase was further increased by cycloheximide treatment.	Cycloheximide	124-137	ornithine decarboxylase 1	Rattus norvegicus	0-23
9501479-3	1998	Treatment of C. parasitica with low levels of the protein synthesis inhibitor cycloheximide caused cpc-1 transcript levels to undergo a rapid, transient increase similar to that reported for the mammalian b-ZIP transactivators, c-Jun and c-Fos.	Cycloheximide	78-91	death associated protein kinase 3	Homo sapiens	207-210
9501479-3	1998	Treatment of C. parasitica with low levels of the protein synthesis inhibitor cycloheximide caused cpc-1 transcript levels to undergo a rapid, transient increase similar to that reported for the mammalian b-ZIP transactivators, c-Jun and c-Fos.	Cycloheximide	78-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	228-233
9501479-3	1998	Treatment of C. parasitica with low levels of the protein synthesis inhibitor cycloheximide caused cpc-1 transcript levels to undergo a rapid, transient increase similar to that reported for the mammalian b-ZIP transactivators, c-Jun and c-Fos.	Cycloheximide	78-91	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	238-243
9537840-6	1998	Cycloheximide did not block the effects of TGF-beta1 or FGF-2 on GFAP mRNA levels, but blocked the inhibitory effects of FGF-2 on the TGF-beta1-mediated increase in GFAP expression.	Cycloheximide	0-13	fibroblast growth factor 2	Homo sapiens	121-126
9606992-4	1998	GM1-enhanced apoptosis was blocked by common apoptotic pathway inhibitors including aurintricarboxylic acid (inhibitor of endonuclease activity), actinomycin D (inhibitor of RNA transcription), and cycloheximide (inhibitor of protein synthesis).	Cycloheximide	198-211	coenzyme Q10A	Mus musculus	0-3
9527395-9	1998	The production of RANTES was both dose- and time-dependent and was inhibited by cycloheximide, indicating that de novo protein synthesis is required.	Cycloheximide	80-93	C-C motif chemokine ligand 5	Homo sapiens	18-24
9493500-15	1998	Western blotting using an antibody specific for inducible nitric oxide synthase (NOS) revealed that 17beta-oestradiol (10 micromol/L for 24 h) treatment induced the formation of inducible NOS protein in the aorta, an effect blocked by cycloheximide.	Cycloheximide	235-248	nitric oxide synthase 2	Rattus norvegicus	48-79
9537840-6	1998	Cycloheximide did not block the effects of TGF-beta1 or FGF-2 on GFAP mRNA levels, but blocked the inhibitory effects of FGF-2 on the TGF-beta1-mediated increase in GFAP expression.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	134-143
9537840-6	1998	Cycloheximide did not block the effects of TGF-beta1 or FGF-2 on GFAP mRNA levels, but blocked the inhibitory effects of FGF-2 on the TGF-beta1-mediated increase in GFAP expression.	Cycloheximide	0-13	glial fibrillary acidic protein	Homo sapiens	165-169
9475274-11	1998	The desArg9-bradykinin-induced contraction also was inhibited by the protein-synthesis inhibitor cycloheximide.	Cycloheximide	97-110	kininogen 1	Homo sapiens	12-22
9538196-1	1998	Expression of a luciferase reporter gene by Chinese hamster ovary cells under the control of the human heat shock protein (hsp) 70 gene promoter was suppressed by incubation at 37 degrees C after treatment with cycloheximide (CHX) during 42 degrees C heat shock exposure.	Cycloheximide	211-224	heat shock protein family A (Hsp70) member 4	Homo sapiens	103-130
9616381-8	1998	Preincubation with cycloheximide inhibited IL-6 but not IL-8 transcription, and incubation of stimulated cells with actinomycin D stabilized IL-8 and also IL-6 mRNA.	Cycloheximide	19-32	interleukin 6	Homo sapiens	43-47
9457913-0	1998	Cycloheximide facilitates the identification of aberrant transcripts resulting from a novel splice-site mutation in COL17A1 in a patient with generalized atrophic benign epidermolysis bullosa.	Cycloheximide	0-13	collagen type XVII alpha 1 chain	Homo sapiens	116-123
9457913-5	1998	Based on our recent finding that cycloheximide stabilized mutant COL17A1 transcripts in keratinocytes homozygous for a frameshift mutation, the effects of the splice-site mutation on splicing of COL17A1 transcripts were determined using reverse transcriptase polymerase chain reaction of total RNA from keratinocytes incubated for 2.5 h in the presence or absence of 10 microg cycloheximide per ml.	Cycloheximide	33-46	collagen type XVII alpha 1 chain	Homo sapiens	65-72
9457913-5	1998	Based on our recent finding that cycloheximide stabilized mutant COL17A1 transcripts in keratinocytes homozygous for a frameshift mutation, the effects of the splice-site mutation on splicing of COL17A1 transcripts were determined using reverse transcriptase polymerase chain reaction of total RNA from keratinocytes incubated for 2.5 h in the presence or absence of 10 microg cycloheximide per ml.	Cycloheximide	33-46	collagen type XVII alpha 1 chain	Homo sapiens	195-202
9484835-6	1998	were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G1/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C.	Cycloheximide	128-141	tumor protein p53	Homo sapiens	176-179
9484835-6	1998	were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G1/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C.	Cycloheximide	128-141	tumor protein p53	Homo sapiens	320-323
9484835-6	1998	were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G1/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C.	Cycloheximide	143-146	tumor protein p53	Homo sapiens	176-179
9484835-6	1998	were slow requiring at least 1 h and slowly increasing thereafter with full activation observed at 6 h. Treatment of cells with cycloheximide (CHX) prevented the activation of p53 in all phases of the cell cycle and its accumulation in G1/S and S. However, removing CHX-block allowed full activation and accumulation of p53 with fast kinetics even if 4 h had lapsed since the initial U.V.C.	Cycloheximide	143-146	tumor protein p53	Homo sapiens	320-323
9477164-2	1998	HGF (1 and 5 ng/ml) rapidly stimulated the expression of beta2-adrenergic responses and significantly increased alpha2-adrenergic responses with a maximal response at 21 h. The stimulatory effects of HGF were reduced dependent on the initial plating density and were completely blocked by cycloheximide (5 microM).	Cycloheximide	289-302	hepatocyte growth factor	Rattus norvegicus	0-3
9477164-2	1998	HGF (1 and 5 ng/ml) rapidly stimulated the expression of beta2-adrenergic responses and significantly increased alpha2-adrenergic responses with a maximal response at 21 h. The stimulatory effects of HGF were reduced dependent on the initial plating density and were completely blocked by cycloheximide (5 microM).	Cycloheximide	289-302	hepatocyte growth factor	Rattus norvegicus	200-203
9467571-6	1998	Undetectable in quiescent stromal cells, messenger ribonucleic acid for COX-2 was induced 30 min after IL-1 beta treatment, reached a maximum at 4 h, and decreased after 15 h. Protein synthesis was not required for induction of the COX-2 gene, as it was blocked by actinomycin D but not by cycloheximide.	Cycloheximide	290-303	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	72-77
9559563-0	1998	An mRNA of tobacco cell, which is rapidly inducible by methyl jasmonate in the presence of cycloheximide, codes for a putative glycosyltransferase.	Cycloheximide	91-104	probable beta-1,4-xylosyltransferase IRX9	Nicotiana tabacum	127-146
9473527-9	1998	Administration of the protein synthesis inhibitor, CHX (15 mg/kg ip), 5 min after T-2 toxin (1.75 mg/kg ip) inhibited the induction of apoptosis in thymocytes, suggesting that the de novo protein synthesis was necessary.	Cycloheximide	51-54	brachyury 2	Mus musculus	82-85
9489703-3	1998	Here, AP3/PI function was put under posttranslational control to analyze its immediate effect on the floral mRNA population, with indirect effects blocked by cycloheximide.	Cycloheximide	158-171	K-box region and MADS-box transcription factor family protein	Arabidopsis thaliana	6-9
9417076-10	1998	After correcting for the specific activity of the 18O-enriched free palmitic acid pool, 7.6% of the PLP molecules were found to acquire palmitic acid in 6 h. This value is not only too large to be the result of the palmitoylation of newly synthesized PLP molecules, it was also unchanged upon the inhibition of protein synthesis with cycloheximide.	Cycloheximide	334-347	proteolipid protein 1	Rattus norvegicus	100-103
9460994-5	1998	The increase in PBGD activity and PPIX fluorescence was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	101-114	hydroxymethylbilane synthase	Homo sapiens	16-20
9538196-1	1998	Expression of a luciferase reporter gene by Chinese hamster ovary cells under the control of the human heat shock protein (hsp) 70 gene promoter was suppressed by incubation at 37 degrees C after treatment with cycloheximide (CHX) during 42 degrees C heat shock exposure.	Cycloheximide	226-229	heat shock protein family A (Hsp70) member 4	Homo sapiens	103-130
9538196-2	1998	The CHX-induced suppression of hsp gene expression induced no development of thermotolerance.	Cycloheximide	4-7	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	31-34
9515165-6	1998	Both the PMA- and the anti-CD3 antibody-mediated increases in PDE-4 activity were blocked by treatment with either cycloheximide or actinomycin D.	Cycloheximide	115-128	CD3 antigen, epsilon polypeptide	Mus musculus	27-30
9929743-4	1998	This induction of HA-binding as well as the increase in CD44 expression are prevented by cycloheximide, suggesting a requirement for new additional CD44 molecules on the cell surface and/or cooperating proteins.	Cycloheximide	89-102	CD44 antigen	Mus musculus	56-60
10524760-4	1998	The radish SAUR transcript was accumulated by auxin and cycloheximide treatments in the same way as that in other plant species.	Cycloheximide	56-69	auxin-responsive protein SAUR21-like	Raphanus sativus	11-15
9459148-6	1998	Furthermore, the induction of TSC-22 by vesnarinone was inhibited by treatment with cycloheximide.	Cycloheximide	84-97	TSC22 domain family member 1	Homo sapiens	30-36
9832332-6	1998	Inhibition of protein synthesis (with cycloheximide) raised basal GMCSF mRNA transcripts to detectable levels, augmented IL-1-induced increases in GMCSF mRNA levels, and exhibited negative regulation by cAMP.	Cycloheximide	38-51	colony stimulating factor 2	Homo sapiens	66-71
9832332-6	1998	Inhibition of protein synthesis (with cycloheximide) raised basal GMCSF mRNA transcripts to detectable levels, augmented IL-1-induced increases in GMCSF mRNA levels, and exhibited negative regulation by cAMP.	Cycloheximide	38-51	colony stimulating factor 2	Homo sapiens	147-152
9929743-4	1998	This induction of HA-binding as well as the increase in CD44 expression are prevented by cycloheximide, suggesting a requirement for new additional CD44 molecules on the cell surface and/or cooperating proteins.	Cycloheximide	89-102	CD44 antigen	Mus musculus	148-152
9453158-7	1998	cycloheximide, chloramphenicol, fluconazole and o-phenanthroline, to which CDR1 confers resistance, could also prevent efflux and enhance accumulation to some extent.	Cycloheximide	0-13	cerebellar degeneration related protein 1	Homo sapiens	75-79
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	67-76
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	endothelin 1	Homo sapiens	102-106
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	endothelin 1	Homo sapiens	118-122
9436611-10	1998	In rat hepatoma H4IIE cells the induction of catalase mRNA by H2O2 was prevented by the addition of actinomycin D or cycloheximide.	Cycloheximide	117-130	catalase	Rattus norvegicus	45-53
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	140-149
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	endothelin 1	Homo sapiens	118-122
9533826-8	1998	Cycloheximide (9 micron), a protein synthesis inhibitor, decreased TNF-alpha-stimulated levels for ir-ET-1 and ir-Big ET-1, suggesting that TNF-alpha may be directly regulating ET-1 expression at the ET-1 gene.	Cycloheximide	0-13	endothelin 1	Homo sapiens	118-122
9440083-4	1998	NPR-C mRNA levels increased four- to eightfold within 6 h after treatment with the protein synthesis inhibitor cycloheximide, but simultaneous treatment with PMA or PDGF still decreased the level of NPR-C mRNA despite the presence of cycloheximide.	Cycloheximide	111-124	natriuretic peptide receptor 3	Rattus norvegicus	0-5
9450900-9	1998	Using cycloheximide (3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide) inhibition of de novo protein synthesis, GALT enzyme activity, and its dimeric protein had a biological T1/2 of approximately 24 hours in N314D/N314D cell lines as compared to 50 hours for WT/WT lymphoblasts.	Cycloheximide	6-19	galactose-1-phosphate uridylyltransferase	Homo sapiens	126-130
9450900-9	1998	Using cycloheximide (3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide) inhibition of de novo protein synthesis, GALT enzyme activity, and its dimeric protein had a biological T1/2 of approximately 24 hours in N314D/N314D cell lines as compared to 50 hours for WT/WT lymphoblasts.	Cycloheximide	21-83	galactose-1-phosphate uridylyltransferase	Homo sapiens	126-130
9495580-4	1998	Dexamethasone (DEX) or nordihydroguaiaretic acid (NDGA) were used to assess possible involvement of tumour necrosis factor-alpha (TNF) in sensitisation to CX.	Cycloheximide	155-157	tumor necrosis factor	Mus musculus	130-133
9495580-7	1998	CONCLUSION: AMG protection indicates the essential role of iNOS in CX-precipitated fatalities.	Cycloheximide	67-69	nitric oxide synthase 2, inducible	Mus musculus	59-63
9440083-6	1998	Treatment with cycloheximide induces NPR-C mRNA, but downregulation of this mRNA by either PDGF or PMA does not depend on synthesis of new protein.	Cycloheximide	15-28	natriuretic peptide receptor 3	Rattus norvegicus	37-42
9469590-6	1998	Treatment with cycloheximide prevented the induction of apoB mRNA by IL-1beta, but not by IL-6.	Cycloheximide	15-28	apolipoprotein B	Homo sapiens	56-60
9407310-8	1998	Inhibition of protein synthesis by cycloheximide did not affect this early stimulation of dye coupling, but it significantly inhibited the sustained effect of PTH and forskolin on cell coupling.	Cycloheximide	35-48	parathyroid hormone	Rattus norvegicus	159-162
9407317-6	1998	Time-course studies indicated that RA elevated MMP-2 activity levels in the cultures within 16 h. This increase was inhibited by cycloheximide and was enhanced by forskolin.	Cycloheximide	129-142	matrix metallopeptidase 2	Gallus gallus	47-52
9407317-7	1998	The increase in MMP-2 activity induced by RA was accompanied by an increase in MMP-2 mRNA levels and was abolished by treatment with cycloheximide.	Cycloheximide	133-146	matrix metallopeptidase 2	Gallus gallus	16-21
9469590-6	1998	Treatment with cycloheximide prevented the induction of apoB mRNA by IL-1beta, but not by IL-6.	Cycloheximide	15-28	interleukin 1 beta	Homo sapiens	69-77
9569007-10	1998	HEM45 mRNA expression in cultured cells was increased by estrogen in the presence of cycloheximide, indicating direct ER-regulation of HEM45.	Cycloheximide	85-98	interferon stimulated exonuclease gene 20	Homo sapiens	0-5
9569007-10	1998	HEM45 mRNA expression in cultured cells was increased by estrogen in the presence of cycloheximide, indicating direct ER-regulation of HEM45.	Cycloheximide	85-98	interferon stimulated exonuclease gene 20	Homo sapiens	135-140
9418853-6	1998	Cycloheximide treatment of cells decreased PKR activity, coincident with an increase in Alu RNA.	Cycloheximide	0-13	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	43-46
9443930-8	1998	The NF kappa B, AP-1, and OCT-1 changes were attenuated both by the N-methyl-D-aspartate receptor antagonist MK-801 and the protein synthesis inhibitor cycloheximide.	Cycloheximide	152-165	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	16-20
9443930-8	1998	The NF kappa B, AP-1, and OCT-1 changes were attenuated both by the N-methyl-D-aspartate receptor antagonist MK-801 and the protein synthesis inhibitor cycloheximide.	Cycloheximide	152-165	POU class 2 homeobox 1	Rattus norvegicus	26-31
9704334-11	1998	However, cycloheximide (0.1 microM), a protein synthesis inhibitor, was only effective to protect CCE cells from apoptosis induced by aFGF, bFGF or VEGF withdrawal, but not that induced by the introduction of TGF-beta 1.	Cycloheximide	9-22	fibroblast growth factor 1	Mus musculus	134-138
9704334-11	1998	However, cycloheximide (0.1 microM), a protein synthesis inhibitor, was only effective to protect CCE cells from apoptosis induced by aFGF, bFGF or VEGF withdrawal, but not that induced by the introduction of TGF-beta 1.	Cycloheximide	9-22	fibroblast growth factor 2	Mus musculus	140-144
9704334-11	1998	However, cycloheximide (0.1 microM), a protein synthesis inhibitor, was only effective to protect CCE cells from apoptosis induced by aFGF, bFGF or VEGF withdrawal, but not that induced by the introduction of TGF-beta 1.	Cycloheximide	9-22	vascular endothelial growth factor A	Mus musculus	148-152
10223621-3	1998	A deoxyadenosine-resistant L1210 cell line (Y8) derived from the parental WT cells had previously been shown to lack the expression of p53 but to respond to cycloheximide (CHX) treatment by superinduction of p53 mRNA.	Cycloheximide	157-170	transformation related protein 53, pseudogene	Mus musculus	208-211
10223621-3	1998	A deoxyadenosine-resistant L1210 cell line (Y8) derived from the parental WT cells had previously been shown to lack the expression of p53 but to respond to cycloheximide (CHX) treatment by superinduction of p53 mRNA.	Cycloheximide	172-175	transformation related protein 53, pseudogene	Mus musculus	208-211
9786178-7	1998	Dexamethasone (0.5 mg/kg, s.c., 4 h) or cycloheximide (1.5 mg/kg, s.c., 6 h) significantly prevented the edema caused by des-Arg9-bradykinin (100 nmol) in rats treated with IL-1beta (81 +/- 5% and 59 +/- 3%) or TNF alpha (78 +/- 4% and 43 +/- 2%).	Cycloheximide	40-53	interleukin 1 beta	Rattus norvegicus	173-181
9395239-7	1997	Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis.	Cycloheximide	17-30	tumor protein p53	Homo sapiens	86-89
9581561-1	1997	The effect of cycloheximide (CHX) on the mRNA expression of the cytokine-inducible, calcium-independent nitric oxide synthase (iNOS) was investigated in fetal hepatocytes stimulated with lipopolysaccharide (LPS) or pro-inflammatory cytokines.	Cycloheximide	14-27	nitric oxide synthase 2	Homo sapiens	84-125
9581561-1	1997	The effect of cycloheximide (CHX) on the mRNA expression of the cytokine-inducible, calcium-independent nitric oxide synthase (iNOS) was investigated in fetal hepatocytes stimulated with lipopolysaccharide (LPS) or pro-inflammatory cytokines.	Cycloheximide	14-27	nitric oxide synthase 2	Homo sapiens	127-131
9581561-1	1997	The effect of cycloheximide (CHX) on the mRNA expression of the cytokine-inducible, calcium-independent nitric oxide synthase (iNOS) was investigated in fetal hepatocytes stimulated with lipopolysaccharide (LPS) or pro-inflammatory cytokines.	Cycloheximide	29-32	nitric oxide synthase 2	Homo sapiens	84-125
9581561-1	1997	The effect of cycloheximide (CHX) on the mRNA expression of the cytokine-inducible, calcium-independent nitric oxide synthase (iNOS) was investigated in fetal hepatocytes stimulated with lipopolysaccharide (LPS) or pro-inflammatory cytokines.	Cycloheximide	29-32	nitric oxide synthase 2	Homo sapiens	127-131
9394805-10	1997	Moreover, when transcription was blocked with actinomycin D, an increment of the CD40L transcript levels induced by PMA or dbcAMP on ionomycin-treated cells was observed in the presence of cycloheximide.	Cycloheximide	189-202	CD40 ligand	Homo sapiens	81-86
9418190-4	1997	In vivo inhibition of ERK2 dephosphorylation observed after preincubation with translation or transcription inhibitors (cycloheximide or actinomycin, respectively) indicates the involvement of at least one inducible phosphatase, the best candidate for which is the dual-specificity phosphatase PAC-1.	Cycloheximide	120-133	mitogen activated protein kinase 1	Rattus norvegicus	22-26
9484441-9	1998	Cycloheximide induced the accumulation of the ZmFAD7 transcript in roots.	Cycloheximide	0-13	fatty acid desaturase 7	Zea mays	46-52
9680973-6	1998	JA activation via this pathway was blocked in the A. thaliana JA-insensitive mutants jin1, jin4 and coi1, and by exogenous application of cycloheximide or auxins.	Cycloheximide	138-151	RNI-like superfamily protein	Arabidopsis thaliana	100-104
12168008-6	1998	Cycloheximide, a well-known inhibitor of protein synthesis, showed an effect similar to the inhibition of protein kinases;it not only inhibited the basal activity of GnT-V, but also abolished the inducing stimulation of GnT-V by EGF of PMA.	Cycloheximide	0-13	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	166-171
12168008-6	1998	Cycloheximide, a well-known inhibitor of protein synthesis, showed an effect similar to the inhibition of protein kinases;it not only inhibited the basal activity of GnT-V, but also abolished the inducing stimulation of GnT-V by EGF of PMA.	Cycloheximide	0-13	alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase	Homo sapiens	220-225
12168008-6	1998	Cycloheximide, a well-known inhibitor of protein synthesis, showed an effect similar to the inhibition of protein kinases;it not only inhibited the basal activity of GnT-V, but also abolished the inducing stimulation of GnT-V by EGF of PMA.	Cycloheximide	0-13	epidermal growth factor	Homo sapiens	229-232
9459350-6	1998	The levels of TFPI antigen and mRNA were decreased to 72% and 38%, respectively, by the incubation with 50 microM LPC for 24 h. The down-regulation by LPC of TFPI mRNA expression was not observed in the presence of cycloheximide, suggesting that protein synthesis was involved in the suppression of TFPI mRNA expression.	Cycloheximide	215-228	tissue factor pathway inhibitor	Homo sapiens	14-18
9459350-6	1998	The levels of TFPI antigen and mRNA were decreased to 72% and 38%, respectively, by the incubation with 50 microM LPC for 24 h. The down-regulation by LPC of TFPI mRNA expression was not observed in the presence of cycloheximide, suggesting that protein synthesis was involved in the suppression of TFPI mRNA expression.	Cycloheximide	215-228	tissue factor pathway inhibitor	Homo sapiens	158-162
9459350-6	1998	The levels of TFPI antigen and mRNA were decreased to 72% and 38%, respectively, by the incubation with 50 microM LPC for 24 h. The down-regulation by LPC of TFPI mRNA expression was not observed in the presence of cycloheximide, suggesting that protein synthesis was involved in the suppression of TFPI mRNA expression.	Cycloheximide	215-228	tissue factor pathway inhibitor	Homo sapiens	158-162
9407130-6	1997	Both activation of AP-1 binding and elevation of Glut1 mRNA were prevented by cycloheximide.	Cycloheximide	78-91	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	19-23
9407130-6	1997	Both activation of AP-1 binding and elevation of Glut1 mRNA were prevented by cycloheximide.	Cycloheximide	78-91	solute carrier family 2 member 1	Homo sapiens	49-54
9509417-5	1997	Activation of this factor, named NF-IL-4/CD23, occurred within 5 min after IL-4 treatment in a cycloheximide-insensitive manner.	Cycloheximide	95-108	interleukin 4	Homo sapiens	36-40
9509417-5	1997	Activation of this factor, named NF-IL-4/CD23, occurred within 5 min after IL-4 treatment in a cycloheximide-insensitive manner.	Cycloheximide	95-108	Fc epsilon receptor II	Homo sapiens	41-45
9434628-9	1997	The de novo protein synthesis was required to promote the survival effect of ECM, since cycloheximide completely abolished the protective effect of collagen I and protection from apoptosis by ECM or by anti-beta 1 antibody was associated with the increased expression of bcl-2.	Cycloheximide	88-101	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	207-213
9434639-3	1997	Accumulation of heme oxygenase-1 mRNA by glutathione depletors was canceled by simultaneous treatment with cycloheximide, an inhibitor of protein synthesis; however, the inhibitory effect decreased when the inhibitor was added 30 min later.	Cycloheximide	107-120	heme oxygenase 1	Homo sapiens	16-32
9452013-5	1997	Since the increase of A-current density induced by TNF is inhibited by both the anti-TNF receptor antibody and cycloheximide treatment, the effect of TNF might be mediated through receptors and by de novo synthesis of the channel protein itself and/or modulating proteins associated with the channel activities.	Cycloheximide	111-124	tumor necrosis factor	Rattus norvegicus	51-54
9437188-7	1997	The reduction in PDGF-BB-induced GAPDH expression by SB is probably caused by a cycloheximide-insensitive transcriptional mechanism.	Cycloheximide	80-93	glyceraldehyde-3-phosphate dehydrogenase	Rattus norvegicus	33-38
9437196-7	1997	Cycloheximide, actinomycin D, and dexamethasone downregulated HDL-induced PGI2 synthesis; therefore, HDL induced de novo synthesis of protein and Cox-2 mRNA.	Cycloheximide	0-13	prostaglandin G/H synthase 2	Oryctolagus cuniculus	146-151
9408241-7	1997	The stimulatory effect of progestin was inhibited by RU-486 and by cycloheximide, suggesting that the up-regulation requires ligand binding to PR and de novo protein synthesis.	Cycloheximide	67-80	progesterone receptor	Homo sapiens	143-145
9422802-8	1997	This effect was solely due to de novo synthesis and release of kininogen (35 pg bradykinin h-1 mg-1 protein) since it could be suppressed by cycloheximide.	Cycloheximide	141-154	kininogen 2-like 1	Rattus norvegicus	63-72
9389508-4	1997	IL-6 and IL-6sR increased immunoreactive IGF-I levels by 2.4-fold after 24 h and 6.4-fold after 48 h. Cycloheximide prevented, and indomethacin markedly decreased, the effect of IL-6 and IL-6sR on IGF-I mRNA levels, but hydroxyurea did not.	Cycloheximide	102-115	interleukin 6	Rattus norvegicus	0-4
9389508-4	1997	IL-6 and IL-6sR increased immunoreactive IGF-I levels by 2.4-fold after 24 h and 6.4-fold after 48 h. Cycloheximide prevented, and indomethacin markedly decreased, the effect of IL-6 and IL-6sR on IGF-I mRNA levels, but hydroxyurea did not.	Cycloheximide	102-115	insulin-like growth factor 1	Rattus norvegicus	41-46
9389508-4	1997	IL-6 and IL-6sR increased immunoreactive IGF-I levels by 2.4-fold after 24 h and 6.4-fold after 48 h. Cycloheximide prevented, and indomethacin markedly decreased, the effect of IL-6 and IL-6sR on IGF-I mRNA levels, but hydroxyurea did not.	Cycloheximide	102-115	interleukin 6	Rattus norvegicus	9-13
9389508-4	1997	IL-6 and IL-6sR increased immunoreactive IGF-I levels by 2.4-fold after 24 h and 6.4-fold after 48 h. Cycloheximide prevented, and indomethacin markedly decreased, the effect of IL-6 and IL-6sR on IGF-I mRNA levels, but hydroxyurea did not.	Cycloheximide	102-115	insulin-like growth factor 1	Rattus norvegicus	197-202
9389509-11	1997	The decrease in PAM mRNA is blocked by cycloheximide, indicating that its requires new protein synthesis.	Cycloheximide	39-52	peptidylglycine alpha-amidating monooxygenase	Rattus norvegicus	16-19
9428739-3	1997	Despite the significant loss of the mRNA, reduction of NPR-C-specific ANP-binding activity after PMA exposure (4 h) was accompanied by a slight decrease in total NPR-C protein (with a 5% loss) and was also produced in the presence of actinomycin D or cycloheximide.	Cycloheximide	251-264	natriuretic peptide receptor 3	Homo sapiens	55-60
9389742-3	1997	TNF-alpha treatment of 3T3-L1 adipocytes resulted in rapid stimulation of leptin accumulation in the media, with a maximum effect at 6 h. This stimulation was insensitive to cycloheximide, a protein synthesis inhibitor, but was completely inhibited by the secretion inhibitor brefeldin A, indicating a posttranslational effect.	Cycloheximide	174-187	tumor necrosis factor	Mus musculus	0-9
9389742-3	1997	TNF-alpha treatment of 3T3-L1 adipocytes resulted in rapid stimulation of leptin accumulation in the media, with a maximum effect at 6 h. This stimulation was insensitive to cycloheximide, a protein synthesis inhibitor, but was completely inhibited by the secretion inhibitor brefeldin A, indicating a posttranslational effect.	Cycloheximide	174-187	leptin	Mus musculus	74-80
9444616-4	1997	The increase in TNF alpha caused by stimulation of J774.2 macrophages was abolished by pretreatment of cells with (i) the protein synthesis inhibitor cycloheximide, (ii) with the selective ETA-receptor antagonists BQ-123 or BQ-485 (but not the selective ETB-receptor antagonist BQ-788), (iii) the tyrosine kinase inhibitors genistein or tyrphostin AG126, or (iv) with the glucocorticoid, dexamethasone.	Cycloheximide	150-163	tumor necrosis factor	Rattus norvegicus	16-25
9396780-7	1997	Western analysis of Bcl-2 protein obtained from overexpressing cells treated with bryostatin 1, staurosporine, or UCN-01 revealed the appearance of a slowly migrating species and a general broadening of the protein band, effects that were insensitive to the protein synthesis inhibitor cycloheximide.	Cycloheximide	286-299	BCL2 apoptosis regulator	Homo sapiens	20-25
9398670-7	1997	Notably, cycloheximide resistance was also detected for other proteolytically deficient proteasome mutants (pre1-1, pre2-1, pre3-1, pre4-1).	Cycloheximide	9-22	proteasome core particle subunit beta 4	Saccharomyces cerevisiae S288C	108-114
9398670-7	1997	Notably, cycloheximide resistance was also detected for other proteolytically deficient proteasome mutants (pre1-1, pre2-1, pre3-1, pre4-1).	Cycloheximide	9-22	proteasome core particle subunit beta 1	Saccharomyces cerevisiae S288C	124-128
9374498-2	1997	Treatment of these cells with TNF in the presence of actinomycin D or cycloheximide induces cyclic changes in the intracellular ATP content preceding cell death.	Cycloheximide	70-83	tumor necrosis factor	Mus musculus	30-33
9374498-7	1997	The mechanism by which TNF/actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP synthesis and related to the cytotoxic effect of TNF, since blockade of mitochondrial electron transport prevented the increase in cellular ATP, the formation of reactive oxygen species, and the apoptotic cell death caused by TNF.	Cycloheximide	48-61	tumor necrosis factor	Mus musculus	44-47
9374498-7	1997	The mechanism by which TNF/actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP synthesis and related to the cytotoxic effect of TNF, since blockade of mitochondrial electron transport prevented the increase in cellular ATP, the formation of reactive oxygen species, and the apoptotic cell death caused by TNF.	Cycloheximide	48-61	tumor necrosis factor	Mus musculus	44-47
9374498-7	1997	The mechanism by which TNF/actinomycin D or TNF/cycloheximide increased cellular ATP seemed to be dependent on the mitochondrial ATP synthesis and related to the cytotoxic effect of TNF, since blockade of mitochondrial electron transport prevented the increase in cellular ATP, the formation of reactive oxygen species, and the apoptotic cell death caused by TNF.	Cycloheximide	48-61	tumor necrosis factor	Mus musculus	44-47
9374498-8	1997	We suggest that the TNF/actinomycin D- or TNF/cycloheximide-induced changes in intracellular ATP levels may be involved in the cytotoxic effect of TNF in metabolically inhibited L929 cells.	Cycloheximide	46-59	tumor necrosis factor	Mus musculus	42-45
9374498-8	1997	We suggest that the TNF/actinomycin D- or TNF/cycloheximide-induced changes in intracellular ATP levels may be involved in the cytotoxic effect of TNF in metabolically inhibited L929 cells.	Cycloheximide	46-59	tumor necrosis factor	Mus musculus	42-45
9417863-8	1997	hsp90 does not bind p53 in a spatial-specific manner because it remains bound to p53 when induced to translocate to the nucleus by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	163-176	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
9417863-8	1997	hsp90 does not bind p53 in a spatial-specific manner because it remains bound to p53 when induced to translocate to the nucleus by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	163-176	tumor protein p53	Homo sapiens	81-84
9417863-8	1997	hsp90 does not bind p53 in a spatial-specific manner because it remains bound to p53 when induced to translocate to the nucleus by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	178-181	heat shock protein 90 alpha family class A member 1	Homo sapiens	0-5
9417863-8	1997	hsp90 does not bind p53 in a spatial-specific manner because it remains bound to p53 when induced to translocate to the nucleus by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	178-181	tumor protein p53	Homo sapiens	81-84
9414112-0	1997	Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation.	Cycloheximide	32-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	18-23
9414112-0	1997	Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation.	Cycloheximide	32-45	mitogen-activated protein kinase 8	Homo sapiens	145-148
9414112-1	1997	Many primary response genes, including cyclooxygenase-2 (COX-2), exhibit mRNA superinduction following agonist stimulation in the presence of translational blockers such as cycloheximide.	Cycloheximide	173-186	prostaglandin-endoperoxide synthase 2	Homo sapiens	39-55
9414112-1	1997	Many primary response genes, including cyclooxygenase-2 (COX-2), exhibit mRNA superinduction following agonist stimulation in the presence of translational blockers such as cycloheximide.	Cycloheximide	173-186	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-62
9414112-3	1997	However, superinduction of IL-1beta-induced COX-2 mRNA levels by cycloheximide in pulmonary type II A549 cells occurred by increased transcription and not by mRNA stabilisation.	Cycloheximide	65-78	interleukin 1 beta	Homo sapiens	27-35
9414112-3	1997	However, superinduction of IL-1beta-induced COX-2 mRNA levels by cycloheximide in pulmonary type II A549 cells occurred by increased transcription and not by mRNA stabilisation.	Cycloheximide	65-78	prostaglandin-endoperoxide synthase 2	Homo sapiens	44-49
9414112-6	1997	These data are consistent with negative feed-back involving down-regulation of NF-kappaB by de novo IkappaB alpha synthesis and suggest that JNK activation may also be down-regulated by a cycloheximide sensitive process.	Cycloheximide	188-201	mitogen-activated protein kinase 8	Homo sapiens	141-144
9366409-7	1997	TNF-alpha-induced hepatocyte spreading was blocked by cytochalasin D, Arg-Gly-Asp peptides, cycloheximide, or anti-integrin beta1 Ab.	Cycloheximide	92-105	tumor necrosis factor	Mus musculus	0-9
9439833-8	1997	Experiments with the translational inhibitor, cycloheximide, showed that CCh mediated a direct effect on the VIP gene expression.	Cycloheximide	46-59	vasoactive intestinal peptide	Homo sapiens	109-112
9455997-4	1997	Western blot analysis demonstrated that the lipopolysaccharide (10 ng/ml)-induced expression of inducible NO synthase protein was inhibited by auranofin as well as by the protein synthesis inhibitor cycloheximide.	Cycloheximide	199-212	nitric oxide synthase 2, inducible	Mus musculus	96-117
9374724-6	1997	Inhibition of the NO-induced HO-1 mRNA expression by cycloheximide suggests that new protein synthesis is required for increased HO-1 gene expression.	Cycloheximide	53-66	heme oxygenase 1	Homo sapiens	29-33
9374724-6	1997	Inhibition of the NO-induced HO-1 mRNA expression by cycloheximide suggests that new protein synthesis is required for increased HO-1 gene expression.	Cycloheximide	53-66	heme oxygenase 1	Homo sapiens	129-133
9374730-8	1997	In addition, cycloheximide, a protein synthesis inhibitor, completely blocked the potentiating effect of TNF-alpha on Ca2+ signals.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	105-114
9786178-7	1998	Dexamethasone (0.5 mg/kg, s.c., 4 h) or cycloheximide (1.5 mg/kg, s.c., 6 h) significantly prevented the edema caused by des-Arg9-bradykinin (100 nmol) in rats treated with IL-1beta (81 +/- 5% and 59 +/- 3%) or TNF alpha (78 +/- 4% and 43 +/- 2%).	Cycloheximide	40-53	tumor necrosis factor	Rattus norvegicus	211-220
9786178-12	1998	injection of the IL-1beta or TNF alpha, produced up-regulation of B1 receptor-mediated paw edema, being this effect sensitive to dexamethasone and cycloheximide and to cyclo-oxygenase pathway.	Cycloheximide	147-160	interleukin 1 beta	Rattus norvegicus	17-25
9786178-12	1998	injection of the IL-1beta or TNF alpha, produced up-regulation of B1 receptor-mediated paw edema, being this effect sensitive to dexamethasone and cycloheximide and to cyclo-oxygenase pathway.	Cycloheximide	147-160	tumor necrosis factor	Rattus norvegicus	29-38
9349553-2	1997	Here we show that NGF withdrawal induces actinomycin D- and cycloheximide-sensitive caspase (ICE-like) activity.	Cycloheximide	60-73	nerve growth factor	Rattus norvegicus	18-21
9536288-10	1997	However, repression of ILA in fibroblasts and dedifferentiated chondrocytes was overcome by cycloheximide and IL-1 further increased ILA mRNA levels in the presence of cycloheximide.	Cycloheximide	168-181	interleukin 1 beta	Homo sapiens	110-114
9389316-4	1997	Thus, inhibition of CD97 surface expression by cycloheximide was not noticeable or insignificant for 15 min to 4 h after stimulation.	Cycloheximide	47-60	adhesion G protein-coupled receptor E5	Homo sapiens	20-24
9321398-6	1997	We show that cytoplasmic lysates made from S2 cells undergoing apoptosis induced by either reaper (rpr) expression or cycloheximide treatment contain a caspase activity with DEVD specificity which can cleave p35, lamin DmO, drICE and DCP-1 in vitro, and which can trigger chromatin condensation in isolated nuclei.	Cycloheximide	118-131	Death caspase-1	Drosophila melanogaster	152-159
9357930-0	1997	Platelet-activating factor (PAF) up-regulates plasma and tissue PAF-acetylhydrolase activity in the rat: effect of cycloheximide.	Cycloheximide	115-128	PCNA clamp associated factor	Rattus norvegicus	0-26
9357930-0	1997	Platelet-activating factor (PAF) up-regulates plasma and tissue PAF-acetylhydrolase activity in the rat: effect of cycloheximide.	Cycloheximide	115-128	PCNA clamp associated factor	Rattus norvegicus	28-31
9351654-2	1997	Furthermore, pretreatment with the protein synthesis inhibitor, cycloheximide (CHX), prevents de novo ITF protein expression 1 h post-injury.	Cycloheximide	64-77	trefoil factor 3	Rattus norvegicus	102-105
9351654-2	1997	Furthermore, pretreatment with the protein synthesis inhibitor, cycloheximide (CHX), prevents de novo ITF protein expression 1 h post-injury.	Cycloheximide	79-82	trefoil factor 3	Rattus norvegicus	102-105
9351654-3	1997	Here, we further characterize the effects of a single pretreatment dose of CHX on injury-induced expression of Krox-24 and show that CHX pretreatment phase-shifts (delays), but does not prevent, de novo expression of Krox-24 in hippocampal dentate gyrus neurons following injury.	Cycloheximide	75-78	early growth response 1	Rattus norvegicus	111-118
9351654-3	1997	Here, we further characterize the effects of a single pretreatment dose of CHX on injury-induced expression of Krox-24 and show that CHX pretreatment phase-shifts (delays), but does not prevent, de novo expression of Krox-24 in hippocampal dentate gyrus neurons following injury.	Cycloheximide	133-136	early growth response 1	Rattus norvegicus	217-224
9355887-6	1997	Actinomycin D and cycloheximide inhibited the HUVEC response to Lp(a), indicating that protein and RNA synthesis were required.	Cycloheximide	18-31	lipoprotein(a)	Homo sapiens	64-69
9334215-6	1997	The ability of cells to phosphorylate old prothymosin alpha molecules was established by demonstrating equivalent labeling of the protein with [32P]orthophosphate in the presence and absence of cycloheximide.	Cycloheximide	194-207	prothymosin alpha pseudogene 9	Homo sapiens	42-59
9359399-11	1997	This rapid turnover of the osmotic-stress-induced HSF-binding activity was inhibited by cycloheximide, a potent inhibitor of protein synthesis.	Cycloheximide	88-101	interleukin 6	Homo sapiens	50-53
9321398-6	1997	We show that cytoplasmic lysates made from S2 cells undergoing apoptosis induced by either reaper (rpr) expression or cycloheximide treatment contain a caspase activity with DEVD specificity which can cleave p35, lamin DmO, drICE and DCP-1 in vitro, and which can trigger chromatin condensation in isolated nuclei.	Cycloheximide	118-131	Cdk5 activator-like protein	Drosophila melanogaster	208-211
9321398-6	1997	We show that cytoplasmic lysates made from S2 cells undergoing apoptosis induced by either reaper (rpr) expression or cycloheximide treatment contain a caspase activity with DEVD specificity which can cleave p35, lamin DmO, drICE and DCP-1 in vitro, and which can trigger chromatin condensation in isolated nuclei.	Cycloheximide	118-131	Lamin	Drosophila melanogaster	213-222
9321398-6	1997	We show that cytoplasmic lysates made from S2 cells undergoing apoptosis induced by either reaper (rpr) expression or cycloheximide treatment contain a caspase activity with DEVD specificity which can cleave p35, lamin DmO, drICE and DCP-1 in vitro, and which can trigger chromatin condensation in isolated nuclei.	Cycloheximide	118-131	Death caspase-1	Drosophila melanogaster	234-239
9345268-0	1997	Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells.	Cycloheximide	181-194	ATP binding cassette subfamily C member 3	Homo sapiens	34-37
9378983-5	1997	IGF-I and IGF-II (but not basic fibroblast growth factor) were also able to protect cells from apoptosis induced by etoposide or cycloheximide.	Cycloheximide	129-142	insulin like growth factor 1	Homo sapiens	0-5
9378983-5	1997	IGF-I and IGF-II (but not basic fibroblast growth factor) were also able to protect cells from apoptosis induced by etoposide or cycloheximide.	Cycloheximide	129-142	insulin like growth factor 2	Homo sapiens	10-16
9344602-0	1997	Influence of cycloheximide-mediated downregulation of glucose transport on TNF alpha-induced apoptosis.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	75-84
9344602-1	1997	Enhancement of cellular sensitivity to TNF alpha-induced apoptosis by cycloheximide (CX) has been attributed to its quality as an inhibitor of protein synthesis, presumably by prevention of the synthesis of short-lived death antagonists.	Cycloheximide	70-83	tumor necrosis factor	Homo sapiens	39-48
9344602-1	1997	Enhancement of cellular sensitivity to TNF alpha-induced apoptosis by cycloheximide (CX) has been attributed to its quality as an inhibitor of protein synthesis, presumably by prevention of the synthesis of short-lived death antagonists.	Cycloheximide	85-87	tumor necrosis factor	Homo sapiens	39-48
9344602-10	1997	In conclusion, CX is proposed to contribute to TNF alpha-induced apoptosis predominantly by interference with glucose transport; the exact nature of this effect remains to be elucidated.	Cycloheximide	15-17	tumor necrosis factor	Homo sapiens	47-56
9345268-0	1997	Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells.	Cycloheximide	181-194	ATP binding cassette subfamily C member 1	Homo sapiens	38-42
9345268-0	1997	Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells.	Cycloheximide	181-194	glutamate-cysteine ligase catalytic subunit	Homo sapiens	52-85
9345268-6	1997	However, CHX alone could induce accumulation of gamma-GCS mRNA, also by posttranscriptional mechanism.	Cycloheximide	9-12	glutamate-cysteine ligase catalytic subunit	Homo sapiens	48-57
9312114-6	1997	The induction of HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcription inhibitor actinomycin D.	Cycloheximide	88-101	high mobility group AT-hook 2	Rattus norvegicus	17-23
9369245-1	1997	Cycloheximide in sublethal doses caused apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and accumulation of sphingosine, a toxic product of the sphingomyelin cycle.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	83-88
9369245-1	1997	Cycloheximide in sublethal doses caused apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and accumulation of sphingosine, a toxic product of the sphingomyelin cycle.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-95
9369245-1	1997	Cycloheximide in sublethal doses caused apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and accumulation of sphingosine, a toxic product of the sphingomyelin cycle.	Cycloheximide	0-13	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
9369245-1	1997	Cycloheximide in sublethal doses caused apoptosis in liver cells in vivo, inducing c-myc, c-fos, c-jun and p53 genes and accumulation of sphingosine, a toxic product of the sphingomyelin cycle.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	107-110
9357766-3	1997	L-Thyroxine (T4), 3,5,3"-L-triiodothyronine (T3), and milrinone enhanced the antiviral activity of IFN-gamma up to 100-fold, a potentiation blocked by cycloheximide.	Cycloheximide	151-164	interferon gamma	Homo sapiens	99-108
9357830-7	1997	Cycloheximide abolished IGFBP-5 mRNA.	Cycloheximide	0-13	insulin-like growth factor binding protein 5	Rattus norvegicus	24-31
9312202-6	1997	24,25-(OH)2D3-dependent plasma membrane PKC was sensitive to both actinomycin D and cycloheximide at early time points, but by 12 hours, no effect of the inhibitors was seen.	Cycloheximide	84-97	protein kinase C, gamma	Rattus norvegicus	40-43
9360546-8	1997	Analysis of the constitutive turnover of cellular hGHR and soluble GHBP showed that incubation of CHO/hGHR cells with cycloheximide caused parallel disappearance of hGHR and GHBP.	Cycloheximide	118-131	growth hormone receptor	Homo sapiens	50-54
9360546-8	1997	Analysis of the constitutive turnover of cellular hGHR and soluble GHBP showed that incubation of CHO/hGHR cells with cycloheximide caused parallel disappearance of hGHR and GHBP.	Cycloheximide	118-131	growth hormone receptor	Homo sapiens	102-106
9360546-8	1997	Analysis of the constitutive turnover of cellular hGHR and soluble GHBP showed that incubation of CHO/hGHR cells with cycloheximide caused parallel disappearance of hGHR and GHBP.	Cycloheximide	118-131	growth hormone receptor	Homo sapiens	102-106
9314569-6	1997	This increase was not detectable until 6 h after the addition of TNF alpha and was totally abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	136-149	tumor necrosis factor	Bos taurus	65-74
9328323-0	1997	Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes.	Cycloheximide	80-93	ATP binding cassette subfamily C member 2	Rattus norvegicus	13-17
9322956-4	1997	The blockade of synthesis of proteins with either cycloheximide or puromycin for 24 h prevented the inhibitory effect of TGFbeta1 on somatostatin mRNA.	Cycloheximide	50-63	transforming growth factor beta 1	Homo sapiens	121-129
9322956-4	1997	The blockade of synthesis of proteins with either cycloheximide or puromycin for 24 h prevented the inhibitory effect of TGFbeta1 on somatostatin mRNA.	Cycloheximide	50-63	somatostatin	Homo sapiens	133-145
9549041-6	1997	An inhibitory study showed that the presence of cycloheximide (3 micrograms/mL) or actinomycin D (1 microgram/mL) blocked both the stimulatory effect of IGF-II on progesterone accumulation and the amplification of GH on IGF-II induced production (P > 0.01), suggesting GH amplification of IGF-II-induced progesterone accumulation is a process involving gene transcription and translation.	Cycloheximide	48-61	insulin like growth factor 2	Homo sapiens	153-159
9549041-6	1997	An inhibitory study showed that the presence of cycloheximide (3 micrograms/mL) or actinomycin D (1 microgram/mL) blocked both the stimulatory effect of IGF-II on progesterone accumulation and the amplification of GH on IGF-II induced production (P > 0.01), suggesting GH amplification of IGF-II-induced progesterone accumulation is a process involving gene transcription and translation.	Cycloheximide	48-61	insulin like growth factor 2	Homo sapiens	220-226
9549041-6	1997	An inhibitory study showed that the presence of cycloheximide (3 micrograms/mL) or actinomycin D (1 microgram/mL) blocked both the stimulatory effect of IGF-II on progesterone accumulation and the amplification of GH on IGF-II induced production (P > 0.01), suggesting GH amplification of IGF-II-induced progesterone accumulation is a process involving gene transcription and translation.	Cycloheximide	48-61	insulin like growth factor 2	Homo sapiens	220-226
9328316-4	1997	When fetal hepatocytes were incubated in the presence of cycloheximide, a specific protein synthesis inhibitor, TGF-beta-induced apoptosis was completely blocked.	Cycloheximide	57-70	transforming growth factor, beta 1	Rattus norvegicus	112-120
9328323-0	1997	Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximide in rat hepatocytes.	Cycloheximide	80-93	ATP binding cassette subfamily C member 2	Rattus norvegicus	18-23
9328323-5	1997	Treatment with the chemical carcinogen 2-acetylaminofluorene (2-AAF), the antineoplastic drug cisplatin, and the protein-synthesis inhibitor cycloheximide led to a dose-dependent and time-dependent increase in cmrp gene expression.	Cycloheximide	141-154	ATP binding cassette subfamily C member 2	Rattus norvegicus	210-214
9328323-6	1997	A 347-base pair cmrp complementary DNA (cDNA) probe served to demonstrate the induction of cmrp messenger RNA (mRNA) with 40 micromol/L 2-AAF, 5 micromol/L cisplatin, or 5 micromol/L cycloheximide.	Cycloheximide	183-196	ATP binding cassette subfamily C member 2	Rattus norvegicus	91-95
9415030-8	1997	Northern blot analysis demonstrated that cycloheximide and actinomycin D abolished the effect of IL-1.	Cycloheximide	41-54	interleukin 1 beta	Homo sapiens	97-101
9312180-6	1997	Cycloheximide superinduced IL-6 transcripts and did not prevent the effect of IL-6 and sIL-6R.	Cycloheximide	0-13	interleukin 6	Rattus norvegicus	27-31
9335381-9	1997	dBSA influenced MCP-1 expression at the level of transcription and probably translation, as evidenced by abrogation of MCP-1 by actinomycin D and superinduction with the protein synthesis inhibitor cycloheximide.	Cycloheximide	198-211	chemokine (C-C motif) ligand 2	Mus musculus	16-21
9380504-9	1997	The ZnF20 cDNA hybridized to multiple transcripts in a thyroid cancer cell line (8.0, 4.5 and 2 kb) that increased after cycloheximide treatment and decayed <2 h after addition of actinomycin D.	Cycloheximide	121-134	zinc finger protein 20	Homo sapiens	4-9
9349634-10	1997	Cycloheximide (a protein biosynthesis inhibitor) (35 mg/kg, s.c.) suppressed the response of VEGF (1 ng/site).	Cycloheximide	0-13	vascular endothelial growth factor A	Mus musculus	93-97
9380021-9	1997	In contrast, EROD induction by hemin, biliverdin, or bilirubin was completely blocked by cycloheximide treatment, indicating that the increase in enzyme activity is dependent on increased Cyp1a1 apoprotein synthesis.	Cycloheximide	89-102	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	188-194
9308965-4	1997	TDF is selectively inactivated during protein synthesis inhibition by cycloheximide and at a late stage of adenovirus infection, thus accounting for the loss of RNA Pol III-mediated transcription of the tRNA and VA RNA genes under these conditions.	Cycloheximide	70-83	sex determining region Y	Homo sapiens	0-3
9299125-8	1997	Apoptosis induced by cycloheximide or alpha-amanitin was blocked by injection of RNA encoding Xenopus Bcl-2, suggesting that this maternal program is normally blocked by expression of an apoptotic inhibitor.	Cycloheximide	21-34	B-cell CLL/lymphoma 2 S homeolog	Xenopus laevis	102-107
9278545-8	1997	Protein synthesis is necessary for GDNF-induced neuroprotective effects because cycloheximide pretreatment that inhibits protein synthesis also blocks neuroprotection.	Cycloheximide	80-93	glial cell derived neurotrophic factor	Rattus norvegicus	35-39
9281587-9	1997	Cdc25B, but not Cdc25C, immunoprecipitated from the extract directly activated the p34(cdc2)/cyclin B of cycloheximide-treated cells as well as that of nontreated cells, although Cdc25C immunoprecipitated from the extract of mitotic cells activated the p34(cdc2)/cyclin B within the extract of cycloheximide-treated cells.	Cycloheximide	105-118	M-phase inducer phosphatase 2	Mesocricetus auratus	0-6
9281587-9	1997	Cdc25B, but not Cdc25C, immunoprecipitated from the extract directly activated the p34(cdc2)/cyclin B of cycloheximide-treated cells as well as that of nontreated cells, although Cdc25C immunoprecipitated from the extract of mitotic cells activated the p34(cdc2)/cyclin B within the extract of cycloheximide-treated cells.	Cycloheximide	105-118	M-phase inducer phosphatase 3	Mesocricetus auratus	179-185
9281587-9	1997	Cdc25B, but not Cdc25C, immunoprecipitated from the extract directly activated the p34(cdc2)/cyclin B of cycloheximide-treated cells as well as that of nontreated cells, although Cdc25C immunoprecipitated from the extract of mitotic cells activated the p34(cdc2)/cyclin B within the extract of cycloheximide-treated cells.	Cycloheximide	294-307	M-phase inducer phosphatase 2	Mesocricetus auratus	0-6
9309325-7	1997	Both the NGF- and bFGF-mediated neuroprotection required protein and RNA synthesis, because actinomycin D (RNA synthesis inhibitor) and cycloheximide (protein synthesis inhibitor) blocked their neuroprotective effects.	Cycloheximide	136-149	fibroblast growth factor 2	Rattus norvegicus	18-22
9332450-10	1997	Cycloheximide, an inhibitor of protein synthesis, enhanced BKR-2 mRNA expression.	Cycloheximide	0-13	bradykinin receptor B2	Homo sapiens	59-64
9283005-7	1997	Pretreatment with cycloheximide prevented FSH induction of StAR and P450scc mRNA, implicating intermediate protein synthesis in expression of both genes.	Cycloheximide	18-31	steroidogenic acute regulatory protein	Homo sapiens	59-63
9316506-6	1997	IL-1 beta-induced increases in Bmax with IL-1 beta were associated with approximately threefold increases in beta 2 AR mRNA and were blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	176-189	interleukin 1 beta	Homo sapiens	0-9
9316506-6	1997	IL-1 beta-induced increases in Bmax with IL-1 beta were associated with approximately threefold increases in beta 2 AR mRNA and were blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	176-189	interleukin 1 beta	Homo sapiens	41-50
9316506-6	1997	IL-1 beta-induced increases in Bmax with IL-1 beta were associated with approximately threefold increases in beta 2 AR mRNA and were blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	176-189	adrenoceptor beta 2	Homo sapiens	109-118
9322624-8	1997	Coincubation of cells with interleukin-1 alpha (10 ng/ml) and cycloheximide caused superinduction of cyclooxygenase-2 messenger ribonucleic acid but had no effect on the expression of cyclooxygenase-1 messenger ribonucleic acid.	Cycloheximide	62-75	prostaglandin-endoperoxide synthase 2	Homo sapiens	101-117
9322624-8	1997	Coincubation of cells with interleukin-1 alpha (10 ng/ml) and cycloheximide caused superinduction of cyclooxygenase-2 messenger ribonucleic acid but had no effect on the expression of cyclooxygenase-1 messenger ribonucleic acid.	Cycloheximide	62-75	prostaglandin-endoperoxide synthase 1	Homo sapiens	184-200
9283005-7	1997	Pretreatment with cycloheximide prevented FSH induction of StAR and P450scc mRNA, implicating intermediate protein synthesis in expression of both genes.	Cycloheximide	18-31	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	68-75
9275072-6	1997	Characterization of EET-1 expression in the uterus showed that estrogen treatment resulted in a rapid and transient increase in EET-1 messenger RNA; steady state levels peaked between 2-3 h, returning to basal levels by 6 h. This increase was not abolished by pretreatment with cycloheximide, indicating that induction of EET-1 is a primary response to estrogen.	Cycloheximide	278-291	lipopolysaccharide-induced TNF factor	Rattus norvegicus	20-25
9300182-8	1997	FGF-1.D mRNA is uniquely superinduced by serum in the presence of cycloheximide and displays delayed early kinetics, suggesting that this mRNA does not require de novo protein synthesis for expression.	Cycloheximide	66-79	fibroblast growth factor 1	Homo sapiens	0-5
9368672-7	1997	Cycloheximide (Cx) (0.35 mM) largely blocked IgM synthesis of the B1 B cells but inhibition of the B2 B cells was incomplete, possibly due to shedding of cytophilic antibodies as well as to the presence of B1 phenotype with loss of CD5 expression.	Cycloheximide	0-13	CD5 molecule	Homo sapiens	232-235
9368672-7	1997	Cycloheximide (Cx) (0.35 mM) largely blocked IgM synthesis of the B1 B cells but inhibition of the B2 B cells was incomplete, possibly due to shedding of cytophilic antibodies as well as to the presence of B1 phenotype with loss of CD5 expression.	Cycloheximide	15-17	CD5 molecule	Homo sapiens	232-235
9275040-7	1997	PTH could induce PG synthase-2 messenger RNA accumulation and PG synthase-2 transcription in the presence of cycloheximide.	Cycloheximide	109-122	parathyroid hormone	Mus musculus	0-3
9275040-8	1997	In addition, PTH-stimulated PG synthase-2 transcription was maintained at a high level at 2 h in the presence of cycloheximide.	Cycloheximide	113-126	parathyroid hormone	Mus musculus	13-16
9275047-6	1997	Interleukin-1beta (IL-1beta) elevated Cox-2 mRNA steady state levels in a concentration-dependent manner, and kinetic studies showed that Cox-2 mRNA levels were already induced at the 2 h point and returned to the basal level after incubation for 24 h. The protein synthesis inhibitor, cycloheximide, induced Cox-2 mRNA expression and potentiated the effect of IL-1beta.	Cycloheximide	286-299	interleukin 1 beta	Homo sapiens	0-17
9275047-6	1997	Interleukin-1beta (IL-1beta) elevated Cox-2 mRNA steady state levels in a concentration-dependent manner, and kinetic studies showed that Cox-2 mRNA levels were already induced at the 2 h point and returned to the basal level after incubation for 24 h. The protein synthesis inhibitor, cycloheximide, induced Cox-2 mRNA expression and potentiated the effect of IL-1beta.	Cycloheximide	286-299	interleukin 1 beta	Homo sapiens	19-27
9275047-6	1997	Interleukin-1beta (IL-1beta) elevated Cox-2 mRNA steady state levels in a concentration-dependent manner, and kinetic studies showed that Cox-2 mRNA levels were already induced at the 2 h point and returned to the basal level after incubation for 24 h. The protein synthesis inhibitor, cycloheximide, induced Cox-2 mRNA expression and potentiated the effect of IL-1beta.	Cycloheximide	286-299	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	138-143
9275047-6	1997	Interleukin-1beta (IL-1beta) elevated Cox-2 mRNA steady state levels in a concentration-dependent manner, and kinetic studies showed that Cox-2 mRNA levels were already induced at the 2 h point and returned to the basal level after incubation for 24 h. The protein synthesis inhibitor, cycloheximide, induced Cox-2 mRNA expression and potentiated the effect of IL-1beta.	Cycloheximide	286-299	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	138-143
9276725-5	1997	HSF1 activation was completely blocked by hemoglobin, dithiothreitol, and cycloheximide, suggesting that the protein damage and nascent polypeptide formation induced by NO may initiate this activation.	Cycloheximide	74-87	heat shock transcription factor 1	Homo sapiens	0-4
9278308-8	1997	In addition, fLC and Mo-DC incubated with anti-CD43 mAb increased expression of HLA-DR, ICAM-1, B7-1, B7-2, CD40, and CD83 after 24 h, and this was partially prevented by culturing cells in the presence of cycloheximide.	Cycloheximide	206-219	sialophorin	Homo sapiens	47-51
9261438-4	1997	Making use of a sequential combination of transcription and protein synthesis inhibitors (actinomycin D and cycloheximide, respectively), we demonstrated the immediate-early nature of the ORF4 gene product, which can thus be named IE4.	Cycloheximide	108-121	cortactin binding protein 2	Homo sapiens	188-192
9314949-2	1997	However, the combination of TNF and the protein synthesis inhibitor cycloheximide (CHX) induces apoptosis in up to 50% of EC within 24 hours.	Cycloheximide	83-86	tumor necrosis factor	Homo sapiens	28-31
9271421-6	1997	Loss of HXT11 and/or HXT9 confers cycloheximide, sulfomethuron methyl, and 4-NQO (4-nitroquinoline-N-oxide) resistance.	Cycloheximide	34-47	hexose transporter HXT11	Saccharomyces cerevisiae S288C	8-13
9271421-6	1997	Loss of HXT11 and/or HXT9 confers cycloheximide, sulfomethuron methyl, and 4-NQO (4-nitroquinoline-N-oxide) resistance.	Cycloheximide	34-47	hexose transporter HXT9	Saccharomyces cerevisiae S288C	21-25
9351242-7	1997	Induction of AtP5CS1 mRNA accumulation in salt-treated seedlings involves an immediate early transcriptional response regulated by ABA signalling that is not inhibited by cycloheximide, but abolished by the deficiency of ABA biosynthesis in the aba1 Arabidopsis mutant.	Cycloheximide	171-184	delta1-pyrroline-5-carboxylate synthase 1	Arabidopsis thaliana	13-20
9351242-8	1997	However, inhibition of protein synthesis by cycloheximide prevents the induction of AtP5CS2 mRNA accumulation, and blocks further increase of AtP5CS1 mRNA levels during the second, slow phase of salt-induction.	Cycloheximide	44-57	delta 1-pyrroline-5-carboxylate synthase 2	Arabidopsis thaliana	84-91
9355246-8	1997	Regeneration of the BVDV receptor to a normal level took about 4 h as indicated by flow cytometric analysis and this process was inhibited in the presence of cycloheximide, a protein synthesis inhibitor.	Cycloheximide	158-171	BVDV	Bos taurus	20-24
9268319-7	1997	Continuous presence of IFN-alpha was necessary for maintaining prolonged activation of ISGF3 and of Janus kinases, an activity that was blocked by antibodies to IFN-alpha or by cycloheximide.	Cycloheximide	177-190	interferon alpha 1	Homo sapiens	23-32
9259594-7	1997	Actinomycin D and cycloheximide blocked the ability of NO to decrease sGC subunit mRNA levels.	Cycloheximide	18-31	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	70-73
9242685-5	1997	Actinomycin D blocked COX-2 mRNA increase by hypotonic stress, while cycloheximide enhanced COX-2 mRNA expression.	Cycloheximide	69-82	prostaglandin-endoperoxide synthase 2	Homo sapiens	92-97
9290641-3	1997	When placed under GALA regulation, the Z. mays cDNA functionally complemented the erg6 mutation, restoring ergosterol production and conferring resistance to cycloheximide.	Cycloheximide	158-171	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	82-86
9276477-6	1997	We show here that expression of the NTH1 gene and its product, neutral trehalase (Nthlp), are also induced by other stressors such as H2O2, CuSO4, NaAsO2, and cycloheximide (CHX).	Cycloheximide	159-172	alpha,alpha-trehalase NTH1	Saccharomyces cerevisiae S288C	36-40
9276477-6	1997	We show here that expression of the NTH1 gene and its product, neutral trehalase (Nthlp), are also induced by other stressors such as H2O2, CuSO4, NaAsO2, and cycloheximide (CHX).	Cycloheximide	174-177	alpha,alpha-trehalase NTH1	Saccharomyces cerevisiae S288C	36-40
9256961-7	1997	The protein synthesis inhibitors, actinomycin D and cycloheximide, suppressed apoA-I accumulation in the medium in dose-dependent manner.	Cycloheximide	52-65	APOAI	Bos taurus	78-84
9276525-7	1997	Patients with mild disease showing high inducibility of IFN-gamma mRNA in their PBMC not only had the highest frequency of responders, but also the highest extent of an individual response, defined by superinduction of mRNA, to agents that relieve suppression (gamma-irradiation) or post-transcriptional down-regulation (cycloheximide).	Cycloheximide	321-334	interferon gamma	Homo sapiens	56-65
9260909-6	1997	Cycloheximide prevented UCN-01-induced DNA fragmentation in HT-29 cells, but not in HL60 and K562 cells, suggesting that macromolecular synthesis is selectively required for apoptotic DNA fragmentation in HT29 cells.	Cycloheximide	0-13	urocortin	Homo sapiens	24-27
9378495-5	1997	Cycloheximide superinduced c-fos and c-jun induction by IFN-gamma, thus indicating that both act as immediate early genes.	Cycloheximide	0-13	FBJ osteosarcoma oncogene	Mus musculus	27-32
9378495-5	1997	Cycloheximide superinduced c-fos and c-jun induction by IFN-gamma, thus indicating that both act as immediate early genes.	Cycloheximide	0-13	jun proto-oncogene	Mus musculus	37-42
9378495-5	1997	Cycloheximide superinduced c-fos and c-jun induction by IFN-gamma, thus indicating that both act as immediate early genes.	Cycloheximide	0-13	interferon gamma	Mus musculus	56-65
9600114-9	1997	When either 2 micrograms/ml actinomycin D or 20 micrograms/ml cycloheximide was added simultaneously with TPA to the culture, the repressive effect of TPA on CD30 was abolished.	Cycloheximide	62-75	TNF receptor superfamily member 8	Homo sapiens	158-162
9235926-2	1997	This gene encodes a protein highly homologous to S. cerevisiae yAP-1, a bZip transcription factor known to mediate cellular resistance to toxicants such as cycloheximide (CYH), 4-nitroquinoline N-oxide (4-NQO), cadmium, and hydrogen peroxide.	Cycloheximide	156-169	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	63-68
9235926-2	1997	This gene encodes a protein highly homologous to S. cerevisiae yAP-1, a bZip transcription factor known to mediate cellular resistance to toxicants such as cycloheximide (CYH), 4-nitroquinoline N-oxide (4-NQO), cadmium, and hydrogen peroxide.	Cycloheximide	171-174	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	63-68
9235926-6	1997	Overexpression of either CAP1 or YAP1 in a wild-type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance.	Cycloheximide	90-93	Cap1p	Saccharomyces cerevisiae S288C	25-29
9235926-6	1997	Overexpression of either CAP1 or YAP1 in a wild-type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance.	Cycloheximide	90-93	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	33-37
9235926-6	1997	Overexpression of either CAP1 or YAP1 in a wild-type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance.	Cycloheximide	163-166	Cap1p	Saccharomyces cerevisiae S288C	25-29
9235926-6	1997	Overexpression of either CAP1 or YAP1 in a wild-type strain results in resistance to FCZ, CYH, and 4-NQO, whereas such resistance is completely abrogated (FCZ and CYH) or strongly reduced (4-NQO) in a ybr008c deletion mutant, demonstrating that YBR008c is involved in YAP1- and CAP1-mediated multidrug resistance.	Cycloheximide	163-166	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	33-37
9258340-11	1997	Simultaneous treatment with Chs and cycloheximide (Cxm) resulted in a superinduction of TGF-beta 1 mRNA by 88 +/- 23% (n = 4, P < 0.05), which was abrogated by preexposure to Act D. In contrast, the induction of collagenase mRNA by Chs was totally blocked by Cxm, indicating that the Cxm-mediated superinduction is selective and that protein synthesis is required for induction of this mRNA.	Cycloheximide	36-49	transforming growth factor beta 1	Homo sapiens	88-98
9258340-11	1997	Simultaneous treatment with Chs and cycloheximide (Cxm) resulted in a superinduction of TGF-beta 1 mRNA by 88 +/- 23% (n = 4, P < 0.05), which was abrogated by preexposure to Act D. In contrast, the induction of collagenase mRNA by Chs was totally blocked by Cxm, indicating that the Cxm-mediated superinduction is selective and that protein synthesis is required for induction of this mRNA.	Cycloheximide	51-54	transforming growth factor beta 1	Homo sapiens	88-98
9259353-10	1997	Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins.	Cycloheximide	12-25	PCNA clamp associated factor	Homo sapiens	70-73
9259353-10	1997	Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins.	Cycloheximide	12-25	fibronectin 1	Homo sapiens	82-93
9259353-10	1997	Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins.	Cycloheximide	12-25	PCNA clamp associated factor	Homo sapiens	128-131
9259353-10	1997	Addition of cycloheximide, a protein synthesis inhibitor, upregulated PAF-induced fibronectin mRNA expression but downregulated PAF-induced TGF-beta1 gene expression, suggesting the existence of different regulatory transcriptional factors of the two proteins.	Cycloheximide	12-25	transforming growth factor beta 1	Homo sapiens	140-149
9261339-6	1997	Cycloheximide inhibited the production of both forms of TNF-alpha at similar concentrations.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	56-65
9274858-4	1997	The accumulation of intracellular Abeta was enhanced by chloroquine and blocked by cycloheximide and brefeldin A and pretreatment with trypsin, suggesting that the internalization of Abeta occurs by receptor-mediated endocytosis.	Cycloheximide	83-96	amyloid beta precursor protein	Homo sapiens	34-39
9274858-4	1997	The accumulation of intracellular Abeta was enhanced by chloroquine and blocked by cycloheximide and brefeldin A and pretreatment with trypsin, suggesting that the internalization of Abeta occurs by receptor-mediated endocytosis.	Cycloheximide	83-96	amyloid beta precursor protein	Homo sapiens	183-188
9292957-10	1997	Treatment for 8 hours with cycloheximide (5 or 10 micrograms/mL) had no effect on the D1 mRNA level, but blocked the TNF-induced reduction of this mRNA.	Cycloheximide	27-40	tumor necrosis factor	Rattus norvegicus	117-120
9228016-5	1997	Six hours following NGF treatment, COX-1 mRNA levels were elevated in PC12 cells, reaching nearly 5-fold above basal levels at 12 h. This increase was blocked by cycloheximide and was accompanied by concomitant increases in COX-1 protein and enzyme activity.	Cycloheximide	162-175	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	35-40
9228060-5	1997	The induction of DP5 gene expression was blocked when cell death was rescued by treatment with cycloheximide, KCl, or the cyclic AMP analogue CPTcAMP.	Cycloheximide	95-108	harakiri, BCL2 interacting protein	Homo sapiens	17-20
9245737-7	1997	Protein synthesis inhibitors cycloheximide and puromycin induced RBM3 transcripts, but cadmium chloride, H2O2, ethanol, and osmotic shock had no effect.	Cycloheximide	29-42	RNA binding motif protein 3	Homo sapiens	65-69
9294038-7	1997	Furthermore, MAG1 and DDI1 respond differently in the presence of the protein synthesis inhibitor cycloheximide, suggesting that these two genes are regulated by different mechanisms in the absence of de novo protein synthesis.	Cycloheximide	98-111	DNA-3-methyladenine glycosylase II	Saccharomyces cerevisiae S288C	13-17
9294038-7	1997	Furthermore, MAG1 and DDI1 respond differently in the presence of the protein synthesis inhibitor cycloheximide, suggesting that these two genes are regulated by different mechanisms in the absence of de novo protein synthesis.	Cycloheximide	98-111	Ddi1p	Saccharomyces cerevisiae S288C	22-26
9247301-4	1997	Blocking of macromolecular synthesis by cycloheximide or actinomycin D or modulation of CD95 expression by cytokines (TNF-alpha and/or gamma-interferon) restored sensitivity to anti-APO-1-induced cell death.	Cycloheximide	40-53	Fas cell surface death receptor	Homo sapiens	182-187
9242380-7	1997	VEGF expression induced by SNAP was inhibited by guanylate cyclase inhibitors, methylene blue (10 microM) and LY-83583 (1 microM), and by the protein synthesis inhibitor, cycloheximide (25 microg/ml).	Cycloheximide	171-184	vascular endothelial growth factor A	Homo sapiens	0-4
9224725-5	1997	Cycloheximide (10 microg/ml) ablated the induction of OPN mRNA by TPA.	Cycloheximide	0-13	secreted phosphoprotein 1	Homo sapiens	54-57
9207045-7	1997	Expression of mouse SnoN and SnoN2 mRNAs is induced with immediate early kinetics upon serum stimulation of quiescent fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, while Ski is not.	Cycloheximide	187-200	SKI-like	Mus musculus	20-24
9212746-7	1997	Either splenectomy or pretreatment with cycloheximide resulted in an attenuated TNF-induced increase in sICAM-1, without affecting mICAM-1 expression.	Cycloheximide	40-53	tumor necrosis factor	Mus musculus	80-83
9249506-4	1997	Both actinomycin D and cycloheximide blocked the basal expression of HO-1 mRNA and protein and prevented the cAMP-mediated induction of HO-1.	Cycloheximide	23-36	heme oxygenase 1	Rattus norvegicus	69-73
9249506-4	1997	Both actinomycin D and cycloheximide blocked the basal expression of HO-1 mRNA and protein and prevented the cAMP-mediated induction of HO-1.	Cycloheximide	23-36	cathelicidin antimicrobial peptide	Rattus norvegicus	109-113
9249506-4	1997	Both actinomycin D and cycloheximide blocked the basal expression of HO-1 mRNA and protein and prevented the cAMP-mediated induction of HO-1.	Cycloheximide	23-36	heme oxygenase 1	Rattus norvegicus	136-140
9221929-0	1997	The effect of cycloheximide on the regulation of proenkephalin and prodynorphin gene expressions induced by kainic acid in rat hippocampus.	Cycloheximide	14-27	proenkephalin	Rattus norvegicus	49-62
9221929-0	1997	The effect of cycloheximide on the regulation of proenkephalin and prodynorphin gene expressions induced by kainic acid in rat hippocampus.	Cycloheximide	14-27	prodynorphin	Rattus norvegicus	67-79
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	14-27	proenkephalin	Rattus norvegicus	87-100
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	14-27	proenkephalin	Rattus norvegicus	102-108
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	14-27	prodynorphin	Rattus norvegicus	114-126
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	14-27	prodynorphin	Rattus norvegicus	128-134
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	29-32	proenkephalin	Rattus norvegicus	87-100
9221929-1	1997	The effect of cycloheximide (CHX), a protein synthesis inhibitor, on the regulation of proenkephalin (proENK) and prodynorphin (proDYN) mRNA levels, proto-oncogenes, such as c-fos, 35-kDa fra and c-jun mRNA, and the levels of their products induced by kainic acid (KA) in rat hippocampus was studied.	Cycloheximide	29-32	prodynorphin	Rattus norvegicus	114-126
9221929-5	1997	The elevations of both proENK and proDYN mRNA levels induced by KA were inhibited by pre-administration of CHX (15 mg/kg i.p.).	Cycloheximide	107-110	proenkephalin	Rattus norvegicus	23-29
9221929-5	1997	The elevations of both proENK and proDYN mRNA levels induced by KA were inhibited by pre-administration of CHX (15 mg/kg i.p.).	Cycloheximide	107-110	prodynorphin	Rattus norvegicus	34-40
9182610-6	1997	The thrombin-mediated increase in NGF secretion was prevented by actinomycin D and cycloheximide, suggesting that RNA transcription and protein synthesis are required.	Cycloheximide	83-96	coagulation factor II	Rattus norvegicus	4-12
9237106-6	1997	IL-5 expression induced by either IL-2 or PHA was completely abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	106-119	interleukin 5	Homo sapiens	0-4
9237106-6	1997	IL-5 expression induced by either IL-2 or PHA was completely abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	106-119	interleukin 2	Homo sapiens	34-38
9215530-7	1997	Cycloheximide at 3.6 microM decreased IGFBP-6 transcripts and prevented the effect of TGF beta 1.	Cycloheximide	0-13	insulin-like growth factor binding protein 6	Rattus norvegicus	38-45
9215530-7	1997	Cycloheximide at 3.6 microM decreased IGFBP-6 transcripts and prevented the effect of TGF beta 1.	Cycloheximide	0-13	transforming growth factor, beta 1	Rattus norvegicus	86-96
9408080-1	1997	In MCF-7 cells, estrogen receptor (ER) elimination occurs rapidly under stimulation with estradiol (E2) at 1 nM ("ER processing"); cycloheximide (CHX) at 50 microM impedes this phenomenon.	Cycloheximide	146-149	estrogen receptor 1	Homo sapiens	35-37
9408080-8	1997	In the presence of CHX, such ER isoforms persist, confirming the absence of interference of the drug with the activation step.	Cycloheximide	19-22	estrogen receptor 1	Homo sapiens	29-31
9200735-5	1997	Insulin-like growth factor-I delayed the onset of a laddered DNA fragmentation pattern for 24 h and provided continuing protection against hyperosmotic exposure for 72 h. Amino acid uptake was decreased in hyperosmotic medium even in the presence of insulin-like growth factor-I; the protein synthesis inhibitor cycloheximide neither prevented the induction of programmed cell death nor interfered with the ability of insulin-like growth factor-I to act as an osmoprotectant in hyperosmotic medium.	Cycloheximide	312-325	insulin like growth factor 1	Homo sapiens	0-28
9195964-7	1997	Cycloheximide prevented the expected loss of Sp1 mediated by EGF and okadaic acid suggesting that the synthesis of a protease may mediate these events.	Cycloheximide	0-13	epidermal growth factor like 1	Rattus norvegicus	61-64
9207201-6	1997	Although both JAK2 and Stat5 were phosphorylated on tyrosine upon PRL treatment, the PRL mediated inhibition of 20alpha-HSD was not reversed by either tyrosine kinase inhibitors, AG18 and genistein, but was largely reversed by the protein synthesis inhibitor cycloheximide.	Cycloheximide	259-272	Janus kinase 2	Rattus norvegicus	14-18
9207201-6	1997	Although both JAK2 and Stat5 were phosphorylated on tyrosine upon PRL treatment, the PRL mediated inhibition of 20alpha-HSD was not reversed by either tyrosine kinase inhibitors, AG18 and genistein, but was largely reversed by the protein synthesis inhibitor cycloheximide.	Cycloheximide	259-272	aldo-keto reductase family 1, member C3	Rattus norvegicus	112-123
9223624-3	1997	TSP-1 mRNA levels reached a plateau within 2 h after the addition of AII and decreased after 5 h. The induction was superinduced by cycloheximide and blocked by actinomycin D.	Cycloheximide	132-145	thrombospondin 1	Rattus norvegicus	0-5
9224956-6	1997	Other regulatory mechanisms contribute to the elevated expression of the transcripts in rho0 cells, as suggested by cycloheximide enhancement of the accumulation of the mRNAs for EF-1 alpha and beta-actin in rho0 cells, but not in parental rho+ cells.	Cycloheximide	116-129	eukaryotic translation elongation factor 1 alpha 1	Gallus gallus	179-189
9224956-6	1997	Other regulatory mechanisms contribute to the elevated expression of the transcripts in rho0 cells, as suggested by cycloheximide enhancement of the accumulation of the mRNAs for EF-1 alpha and beta-actin in rho0 cells, but not in parental rho+ cells.	Cycloheximide	116-129	actin, beta	Gallus gallus	194-204
9225004-4	1997	The adhesion induced by MRC OX44 was inhibited by cycloheximide and actinomycin D, suggesting that de novo protein synthesis was required for this effect.	Cycloheximide	50-63	Cd53 molecule	Rattus norvegicus	28-32
9178100-6	1997	Moreover, the effects of TGF-beta 1 were indirect, since the increase in BSP mRNA was abrogated by cycloheximide (28 micrograms/ml).	Cycloheximide	99-112	transforming growth factor, beta 1	Rattus norvegicus	25-35
9178100-6	1997	Moreover, the effects of TGF-beta 1 were indirect, since the increase in BSP mRNA was abrogated by cycloheximide (28 micrograms/ml).	Cycloheximide	99-112	integrin-binding sialoprotein	Rattus norvegicus	73-76
9202172-5	1997	The increase in the level of Grp75 was completely blocked by cycloheximide, but only partially blocked by the inhibitors of mRNA synthesis actinomycin D and alpha-amanitin.	Cycloheximide	61-74	stress-70 protein, mitochondrial	Cricetulus griseus	29-34
9176392-8	1997	When C3H/HeN mice were pretreated with cycloheximide before hepatectomy, the early peak of Bcl-x mRNA at 4 hours was essentially abrogated whereas the immediate-early gene c-myc was hyperinduced, thus implicating Bcl-x as a delayed early response gene during liver regeneration.	Cycloheximide	39-52	BCL2-like 1	Mus musculus	91-96
9176392-8	1997	When C3H/HeN mice were pretreated with cycloheximide before hepatectomy, the early peak of Bcl-x mRNA at 4 hours was essentially abrogated whereas the immediate-early gene c-myc was hyperinduced, thus implicating Bcl-x as a delayed early response gene during liver regeneration.	Cycloheximide	39-52	jun proto-oncogene	Mus musculus	151-166
9176392-8	1997	When C3H/HeN mice were pretreated with cycloheximide before hepatectomy, the early peak of Bcl-x mRNA at 4 hours was essentially abrogated whereas the immediate-early gene c-myc was hyperinduced, thus implicating Bcl-x as a delayed early response gene during liver regeneration.	Cycloheximide	39-52	BCL2-like 1	Mus musculus	213-218
9227468-3	1997	Both of these effects were abolished with cycloheximide, implying a role for protein synthesis in mediating IL-1 beta"s effect.	Cycloheximide	42-55	interleukin-1 beta	Oryctolagus cuniculus	108-117
9227521-5	1997	However, cycloheximide treatment of the BEAS-2B cells before the conditioning process does preclude development of mast cell inhibitor activity in ECM, suggesting that this activity depends on protein synthesis.	Cycloheximide	9-22	multimerin 1	Homo sapiens	147-150
9179403-15	1997	The glucocorticosteroid dexamethasone and protein synthesis inhibitors, cycloheximide and actinomycin D, not only markedly inhibited IL-1 beta-stimulated PGE2 release and COX activity but also suppressed IL-1 beta-induced COX-2 induction.	Cycloheximide	72-85	interleukin 1 beta	Homo sapiens	133-142
9179403-15	1997	The glucocorticosteroid dexamethasone and protein synthesis inhibitors, cycloheximide and actinomycin D, not only markedly inhibited IL-1 beta-stimulated PGE2 release and COX activity but also suppressed IL-1 beta-induced COX-2 induction.	Cycloheximide	72-85	interleukin 1 beta	Homo sapiens	204-213
9179403-15	1997	The glucocorticosteroid dexamethasone and protein synthesis inhibitors, cycloheximide and actinomycin D, not only markedly inhibited IL-1 beta-stimulated PGE2 release and COX activity but also suppressed IL-1 beta-induced COX-2 induction.	Cycloheximide	72-85	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	222-227
9253159-0	1997	Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide.	Cycloheximide	58-71	Fas (TNF receptor superfamily member 6)	Mus musculus	19-30
9253159-1	1997	The effect of administration into rats of cycloheximide on the expression of genes, such as tissue transglutaminase, testosterone-repressed prostate message-2, Fas antigen, bcl-2, DNase I, and poly(ADP-ribose) polymerase, which were believed to be involved in the mechanism of apoptosis, was studied.	Cycloheximide	42-55	clusterin	Rattus norvegicus	117-158
9253159-1	1997	The effect of administration into rats of cycloheximide on the expression of genes, such as tissue transglutaminase, testosterone-repressed prostate message-2, Fas antigen, bcl-2, DNase I, and poly(ADP-ribose) polymerase, which were believed to be involved in the mechanism of apoptosis, was studied.	Cycloheximide	42-55	Fas (TNF receptor superfamily member 6)	Mus musculus	160-171
9253159-1	1997	The effect of administration into rats of cycloheximide on the expression of genes, such as tissue transglutaminase, testosterone-repressed prostate message-2, Fas antigen, bcl-2, DNase I, and poly(ADP-ribose) polymerase, which were believed to be involved in the mechanism of apoptosis, was studied.	Cycloheximide	42-55	BCL2, apoptosis regulator	Rattus norvegicus	173-178
9253159-1	1997	The effect of administration into rats of cycloheximide on the expression of genes, such as tissue transglutaminase, testosterone-repressed prostate message-2, Fas antigen, bcl-2, DNase I, and poly(ADP-ribose) polymerase, which were believed to be involved in the mechanism of apoptosis, was studied.	Cycloheximide	42-55	deoxyribonuclease 1	Rattus norvegicus	180-187
9253159-1	1997	The effect of administration into rats of cycloheximide on the expression of genes, such as tissue transglutaminase, testosterone-repressed prostate message-2, Fas antigen, bcl-2, DNase I, and poly(ADP-ribose) polymerase, which were believed to be involved in the mechanism of apoptosis, was studied.	Cycloheximide	42-55	poly (ADP-ribose) polymerase 1	Rattus norvegicus	193-220
9253159-3	1997	A possible direct effect of cycloheximide on cells per se to induce Fas antigen mRNA expression was demonstrated by the tissue culture study using L929 fibroblast cells, although the magnitude of the induction detected in vitro was small compared with that in vivo.	Cycloheximide	28-41	Fas (TNF receptor superfamily member 6)	Mus musculus	68-79
9253159-4	1997	This induction of Fas antigen mRNA by cycloheximide is a first report on the modulation of Fas antigen mRNA expression in vivo.	Cycloheximide	38-51	Fas (TNF receptor superfamily member 6)	Mus musculus	18-29
9253159-4	1997	This induction of Fas antigen mRNA by cycloheximide is a first report on the modulation of Fas antigen mRNA expression in vivo.	Cycloheximide	38-51	Fas (TNF receptor superfamily member 6)	Mus musculus	91-102
9185777-10	1997	Pretreatment of hepatocytes with cycloheximide also blocked TGF-beta1-induced apoptosis and the increase in CPP32-like activity.	Cycloheximide	33-46	transforming growth factor, beta 1	Rattus norvegicus	60-69
9185777-10	1997	Pretreatment of hepatocytes with cycloheximide also blocked TGF-beta1-induced apoptosis and the increase in CPP32-like activity.	Cycloheximide	33-46	caspase 3	Rattus norvegicus	108-113
9185777-12	1997	Thus, cycloheximide may block apoptosis by inhibiting the synthesis of a protein, which is involved in the upstream events responsible for the activation of the CPP32-like protease activity.	Cycloheximide	6-19	caspase 3	Rattus norvegicus	161-166
9169858-12	1997	Experiments in the presence of cycloheximide showed that protein synthesis is necessary for GFAP transcription.	Cycloheximide	31-44	glial fibrillary acidic protein	Rattus norvegicus	92-96
9176134-7	1997	The protein synthesis inhibitor cycloheximide led to a superinduction of egr-1 with preservation of the pH dependency of expression.	Cycloheximide	32-45	early growth response 1	Mus musculus	73-78
9146896-15	1997	LPS increased the release of 6-keto PGF1 alpha and PGE2 but not of TXB2, an effect that was inhibited by the protein synthesis inhibitor cycloheximide (1 microM), the anti-inflammatory steroid dexamethason (1 microM), the nonsteroidal anti-inflammatory drug indomethacin (30 microM) and, where tested, the selective COX-2 inhibitor NS-398 (30 microM).	Cycloheximide	137-150	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	316-321
9154334-9	1997	The potentiating effect of CsA on AVP-elicited InsP formation and 45Ca2+ efflux was inhibited by co-incubation with the protein synthesis inhibitors actinomycin D and cycloheximide, indicating that CsA acted on gene expression.	Cycloheximide	167-180	chorionic somatomammotropin hormone 1	Homo sapiens	27-30
9154334-9	1997	The potentiating effect of CsA on AVP-elicited InsP formation and 45Ca2+ efflux was inhibited by co-incubation with the protein synthesis inhibitors actinomycin D and cycloheximide, indicating that CsA acted on gene expression.	Cycloheximide	167-180	chorionic somatomammotropin hormone 1	Homo sapiens	198-201
9163601-7	1997	Rechallenge with thrombin induced rapid surface re-expression of P-selectin, which was independent of de novo protein synthesis, since cycloheximide did not inhibit re-expression.	Cycloheximide	135-148	coagulation factor II, thrombin	Homo sapiens	17-25
9163601-7	1997	Rechallenge with thrombin induced rapid surface re-expression of P-selectin, which was independent of de novo protein synthesis, since cycloheximide did not inhibit re-expression.	Cycloheximide	135-148	selectin P	Homo sapiens	65-75
9174164-1	1997	RGS1 and RGS2 are members of a new class of regulators of G-protein signaling identified by their selective mRNA expression either in phorbol ester (TPA)-stimulated human B lymphocytes (RGS1/1R20/BL34) or in blood mononuclear cells treated with the T-cell lectin concanavalin A (ConA) and cycloheximide (RGS2/G0S8).	Cycloheximide	289-302	regulator of G protein signaling 1	Homo sapiens	0-4
9174164-1	1997	RGS1 and RGS2 are members of a new class of regulators of G-protein signaling identified by their selective mRNA expression either in phorbol ester (TPA)-stimulated human B lymphocytes (RGS1/1R20/BL34) or in blood mononuclear cells treated with the T-cell lectin concanavalin A (ConA) and cycloheximide (RGS2/G0S8).	Cycloheximide	289-302	regulator of G protein signaling 2	Homo sapiens	9-13
9203943-7	1997	Cycloheximide prevented the effects of IEL supernatant and of rIFN gamma on TER.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	62-72
9130007-8	1997	The LPS and IFN-gamma induced CB increases were abolished by cycloheximide or actinomycin D in the cultures, indicating that the increases in CB required increased RNA transcription and de novo protein synthesis.	Cycloheximide	61-74	interferon gamma	Homo sapiens	12-21
9130007-8	1997	The LPS and IFN-gamma induced CB increases were abolished by cycloheximide or actinomycin D in the cultures, indicating that the increases in CB required increased RNA transcription and de novo protein synthesis.	Cycloheximide	61-74	cathepsin B	Homo sapiens	30-32
9152412-1	1997	Rat peritoneal macrophages were incubated in the presence of cycloheximide or dexamethasone to inhibit the induction of cyclooxygenase (COX)-2 protein synthesis.	Cycloheximide	61-74	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	120-142
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	37-50	interleukin 4	Homo sapiens	147-150
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	37-50	interleukin 4	Homo sapiens	168-171
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	37-50	complement C3d receptor 2	Homo sapiens	237-241
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	52-55	interleukin 4	Homo sapiens	147-150
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	52-55	interleukin 4	Homo sapiens	168-171
9250823-4	1997	Inhibition of protein synthesis with cycloheximide (CXM) had no effect on the expression of CD21 molecules, but abrogated their down-regulation by IL4, suggesting that IL4 induced the synthesis of proteins which modify the processing of CD21 molecules.	Cycloheximide	52-55	complement C3d receptor 2	Homo sapiens	237-241
9145908-8	1997	The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression.	Cycloheximide	28-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	82-88
9145908-8	1997	The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression.	Cycloheximide	28-41	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	93-99
9145908-8	1997	The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression.	Cycloheximide	28-41	transforming growth factor beta 1	Homo sapiens	155-164
9145908-8	1997	The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression.	Cycloheximide	28-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	82-86
9145908-8	1997	The treatment of cells with cycloheximide led to a superinduction of TCDD-induced CYP1A1 and CYP1B1 mRNA expression and abolished the inhibitory effect of TGF-beta1 on basal as well as TCDD-induced CYP1 and AHR mRNA expression.	Cycloheximide	28-41	aryl hydrocarbon receptor	Homo sapiens	207-210
9145917-9	1997	The down-regulation of CRF-R1 mRNA was dependent on de novo protein synthesis, as it was blocked by pretreatment with cycloheximide.	Cycloheximide	118-131	corticotropin releasing hormone receptor 1	Mus musculus	23-29
9094251-10	1997	This finding suggests that the cycloheximide-sensitive step of the action of insulin is related to Na+ delivery to the pump.	Cycloheximide	31-44	insulin	Homo sapiens	77-84
9160089-7	1997	Phorbol myristate acetate (PMA) induced a time- and dose-dependent up-regulation of CD11a, CD11b, CD11c, CD18 and CD54 that was inhibited by cycloheximide, suggesting a dependence on de novo protein synthesis.	Cycloheximide	141-154	integrin subunit alpha L	Homo sapiens	84-89
9160089-7	1997	Phorbol myristate acetate (PMA) induced a time- and dose-dependent up-regulation of CD11a, CD11b, CD11c, CD18 and CD54 that was inhibited by cycloheximide, suggesting a dependence on de novo protein synthesis.	Cycloheximide	141-154	integrin subunit alpha M	Homo sapiens	91-96
9160089-7	1997	Phorbol myristate acetate (PMA) induced a time- and dose-dependent up-regulation of CD11a, CD11b, CD11c, CD18 and CD54 that was inhibited by cycloheximide, suggesting a dependence on de novo protein synthesis.	Cycloheximide	141-154	integrin subunit alpha X	Homo sapiens	98-103
9160089-7	1997	Phorbol myristate acetate (PMA) induced a time- and dose-dependent up-regulation of CD11a, CD11b, CD11c, CD18 and CD54 that was inhibited by cycloheximide, suggesting a dependence on de novo protein synthesis.	Cycloheximide	141-154	integrin subunit beta 2	Homo sapiens	105-109
9160089-7	1997	Phorbol myristate acetate (PMA) induced a time- and dose-dependent up-regulation of CD11a, CD11b, CD11c, CD18 and CD54 that was inhibited by cycloheximide, suggesting a dependence on de novo protein synthesis.	Cycloheximide	141-154	intercellular adhesion molecule 1	Homo sapiens	114-118
9331268-7	1997	Stereoselective inhibitors of NOS and cycloheximide inhibited LPS-IFN-gamma-induced nitrite release in both cells, whereas transforming growth factor-beta (TGF-beta) slightly potentiated it.	Cycloheximide	38-51	interferon gamma	Bos taurus	66-75
9233375-4	1997	In addition, the superinduction of CYP1A1 in wildtype hepa1c1c7 cells, which is AHR-dependent, resulted from PBO and cycloheximide treatment of the cells.	Cycloheximide	117-130	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	35-41
9233375-4	1997	In addition, the superinduction of CYP1A1 in wildtype hepa1c1c7 cells, which is AHR-dependent, resulted from PBO and cycloheximide treatment of the cells.	Cycloheximide	117-130	aryl-hydrocarbon receptor	Mus musculus	80-83
9248621-6	1997	This increased expression of IRF-1 mRNA by IFN-gamma was not blocked by treatment with cycloheximide, but was abolished by treatment with actinomycin D.	Cycloheximide	87-100	interferon regulatory factor 1	Homo sapiens	29-34
9165006-9	1997	Pretreatment of mice with cycloheximide (400 microg/g), an inhibitor of protein synthesis, potentiated the increase in 24-OHase mRNA abundance, but blocked the increase in 24-OHase activity, induced by 1,25-(OH)2D3 in kidney and duodenum, suggesting that 24-OHase gene expression may be regulated not only by the vitamin D receptor but also by a short-lived repressor protein.	Cycloheximide	26-39	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	119-127
9165006-9	1997	Pretreatment of mice with cycloheximide (400 microg/g), an inhibitor of protein synthesis, potentiated the increase in 24-OHase mRNA abundance, but blocked the increase in 24-OHase activity, induced by 1,25-(OH)2D3 in kidney and duodenum, suggesting that 24-OHase gene expression may be regulated not only by the vitamin D receptor but also by a short-lived repressor protein.	Cycloheximide	26-39	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	172-180
9165006-9	1997	Pretreatment of mice with cycloheximide (400 microg/g), an inhibitor of protein synthesis, potentiated the increase in 24-OHase mRNA abundance, but blocked the increase in 24-OHase activity, induced by 1,25-(OH)2D3 in kidney and duodenum, suggesting that 24-OHase gene expression may be regulated not only by the vitamin D receptor but also by a short-lived repressor protein.	Cycloheximide	26-39	cytochrome P450, family 24, subfamily a, polypeptide 1	Mus musculus	172-180
9165006-9	1997	Pretreatment of mice with cycloheximide (400 microg/g), an inhibitor of protein synthesis, potentiated the increase in 24-OHase mRNA abundance, but blocked the increase in 24-OHase activity, induced by 1,25-(OH)2D3 in kidney and duodenum, suggesting that 24-OHase gene expression may be regulated not only by the vitamin D receptor but also by a short-lived repressor protein.	Cycloheximide	26-39	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	313-331
9241531-4	1997	Here, by means of cytofluorimetric analysis evidence is provided, that the induction of APN surface expression is partially resistent to the action of the inhibitors of protein biosynthesis, puromycin and cycloheximide, and is not prevented by tunicamycin, an inhibitor of glycosylation.	Cycloheximide	205-218	alanyl aminopeptidase, membrane	Homo sapiens	88-91
9138095-2	1997	The increase in LO mRNA was prevented by the presence of cycloheximide, indicative of controlling events at the level of protein synthesis.	Cycloheximide	57-70	lysyl oxidase	Rattus norvegicus	16-18
9154802-4	1997	Presence of CHES1 but not a control vector resulted in G2 delay after UV irradiation in checkpoint-defective strains, with kinetics, nuclear morphology, and cycloheximide resistance similar to those of a wild-type strain.	Cycloheximide	157-170	forkhead box N3	Homo sapiens	12-17
9185594-7	1997	However, transcription of three other early genes (39k, p35, and lef-3), which are known to be dependent on IE1 transactivation, was significantly reduced by the addition of 250 microg/ml cycloheximide.	Cycloheximide	188-201	interleukin 12a	Mus musculus	56-59
9185594-9	1997	Synthesis of IE1, IE2, and IE0 was resistant to cycloheximide treatment, while translation of SSB/LEF-3 and pp31 was strongly inhibited even at the lower concentration of cycloheximide.	Cycloheximide	171-184	Sjogren syndrome antigen B	Mus musculus	94-97
9148952-3	1997	Cycloheximide also potentiated ERK1 activation in Rat-1 cells expressing DeltaRaf-1:ER, an estradiol-regulated form of the oncogenic, human Raf-1.	Cycloheximide	0-13	mitogen activated protein kinase 3	Rattus norvegicus	31-35
9148952-3	1997	Cycloheximide also potentiated ERK1 activation in Rat-1 cells expressing DeltaRaf-1:ER, an estradiol-regulated form of the oncogenic, human Raf-1.	Cycloheximide	0-13	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	78-83
9148952-4	1997	Since cycloheximide did not potentiate MEK activity but abrogated the expression of mitogen-activated protein kinase phosphatase (MKP-1) normally seen in response to EGF and LPA, we speculated that the level of MKP-1 expression may be an important regulator of ERK1 activity in Rat-1 cells.	Cycloheximide	6-19	dual specificity phosphatase 1	Rattus norvegicus	130-135
9148952-4	1997	Since cycloheximide did not potentiate MEK activity but abrogated the expression of mitogen-activated protein kinase phosphatase (MKP-1) normally seen in response to EGF and LPA, we speculated that the level of MKP-1 expression may be an important regulator of ERK1 activity in Rat-1 cells.	Cycloheximide	6-19	dual specificity phosphatase 1	Rattus norvegicus	211-216
9180213-0	1997	Protein synthesis inhibitor cycloheximide dose-dependently decreases formalin-induced c-Fos protein and behavioral hyperalgesia in rats.	Cycloheximide	28-41	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	86-91
9180213-2	1997	To test whether de novo protein synthesis is required for the development of persistent pain after peripheral inflammation, we observed formalin-induced spinal c-Fos protein and nociceptive behaviors following pretreatment with cycloheximide, a protein synthesis inhibitor.	Cycloheximide	228-241	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	160-165
9180213-3	1997	Cycloheximide dose-dependently inhibited formalin-induced spinal c-Fos protein and tonic nociceptive responses.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	65-70
9143349-2	1997	Two methods were used to study the CYP2E1 turnover; after addition of cycloheximide, the half-life of the CYP2E1 in the intact cells was about 6 h as detected by PNP catalytic activity assay and immunoblot analysis of apoprotein content.	Cycloheximide	70-83	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	35-41
9143349-2	1997	Two methods were used to study the CYP2E1 turnover; after addition of cycloheximide, the half-life of the CYP2E1 in the intact cells was about 6 h as detected by PNP catalytic activity assay and immunoblot analysis of apoprotein content.	Cycloheximide	70-83	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	106-112
9143349-5	1997	The half-life of CYP2E1 was about 2.5 h, and the various substrates or ligands modified the turnover process within intact cells as described for the cycloheximide experiments.	Cycloheximide	150-163	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	17-23
9133556-9	1997	The increase in PAI-1 mRNA was followed by an increase in PAI-1 antigen in the conditioned medium that was suppressed by treatment with cycloheximide.	Cycloheximide	136-149	serpin family E member 1	Homo sapiens	16-21
9133556-9	1997	The increase in PAI-1 mRNA was followed by an increase in PAI-1 antigen in the conditioned medium that was suppressed by treatment with cycloheximide.	Cycloheximide	136-149	serpin family E member 1	Homo sapiens	58-63
9136832-8	1997	Cycloheximide treatment resulted in superinduction of IL-8 mRNA; however, dexamethasone inhibited E. histolytica-induced IL-8 gene expression.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	54-58
9126988-8	1997	Treatment of WT mice with cycloheximide plus rIFN-gamma superinduced IRF-1 mRNA expression, but partially inhibited CIITA mRNA expression, indicating that IRF-1 mRNA induction is not dependent on new protein synthesis, unlike CIITA.	Cycloheximide	26-39	interferon regulatory factor 1	Mus musculus	69-74
9126988-8	1997	Treatment of WT mice with cycloheximide plus rIFN-gamma superinduced IRF-1 mRNA expression, but partially inhibited CIITA mRNA expression, indicating that IRF-1 mRNA induction is not dependent on new protein synthesis, unlike CIITA.	Cycloheximide	26-39	class II transactivator	Mus musculus	116-121
9126988-8	1997	Treatment of WT mice with cycloheximide plus rIFN-gamma superinduced IRF-1 mRNA expression, but partially inhibited CIITA mRNA expression, indicating that IRF-1 mRNA induction is not dependent on new protein synthesis, unlike CIITA.	Cycloheximide	26-39	interferon regulatory factor 1	Mus musculus	155-160
9126988-8	1997	Treatment of WT mice with cycloheximide plus rIFN-gamma superinduced IRF-1 mRNA expression, but partially inhibited CIITA mRNA expression, indicating that IRF-1 mRNA induction is not dependent on new protein synthesis, unlike CIITA.	Cycloheximide	26-39	class II transactivator	Mus musculus	226-231
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Cycloheximide	89-102	BCL6 transcription repressor	Homo sapiens	4-9
9180294-4	1997	The BCL-6 transcripts in TPA-treated U-937 cells were superinduced by the treatment with cycloheximide (CHX) and the half-life of the BCL-6 mRNA was apparently prolonged when TPA-treated U-937 cells were exposed to CHX in the presence of actinomycin D (ACD).	Cycloheximide	104-107	BCL6 transcription repressor	Homo sapiens	4-9
9247974-4	1997	On the other hand, cyclooxygenase (COX) activity was increased (1.6-fold) within 2 h after the EGF-treatment and the induced activity was inhibited by cycloheximide.	Cycloheximide	151-164	epidermal growth factor	Homo sapiens	95-98
9144567-0	1997	Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF-kappaB.	Cycloheximide	29-42	interleukin 6	Homo sapiens	65-78
9144567-3	1997	Furthermore, IL-6 mRNA accumulation stimulated by cycloheximide or anisomycin is almost completely inhibited in the presence of actinomycin D, indicating that this effect occurs mainly through the activation of the transcriptional machinery.	Cycloheximide	50-63	interleukin 6	Homo sapiens	13-17
9186586-4	1997	Cycloheximide inhibited PDGF-B but not ICAM-1 mRNA induction by lyso-PC, suggesting the dependence on de novo protein synthesis for PDGF-B, but not ICAM-1.	Cycloheximide	0-13	platelet derived growth factor subunit B	Homo sapiens	24-30
9186586-4	1997	Cycloheximide inhibited PDGF-B but not ICAM-1 mRNA induction by lyso-PC, suggesting the dependence on de novo protein synthesis for PDGF-B, but not ICAM-1.	Cycloheximide	0-13	platelet derived growth factor subunit B	Homo sapiens	132-138
9108035-6	1997	Inhibition of apoptosis with cycloheximide inhibits the movement of Bax and Bcl-X(L) in thymocytes from the cytosol into membranes induced by dexamethasone treatment.	Cycloheximide	29-42	BCL2-associated X protein	Mus musculus	68-71
9108035-6	1997	Inhibition of apoptosis with cycloheximide inhibits the movement of Bax and Bcl-X(L) in thymocytes from the cytosol into membranes induced by dexamethasone treatment.	Cycloheximide	29-42	BCL2-like 1	Mus musculus	76-84
9142910-3	1997	When protein synthesis was blocked by addition of cycloheximide, the MP mRNA level remained unchanged in the presence of CCK.	Cycloheximide	50-63	serine peptidase inhibitor, Kazal type 1	Rattus norvegicus	69-71
9150261-3	1997	We observed that the steady-state mRNA level of mlip15 drastically increased after cycloheximide treatment.	Cycloheximide	83-96	low temperature-induced protein15	Zea mays	48-54
9150261-4	1997	In addition to mlip15, cycloheximide elevates the transcript levels of two other low temperature-induced genes, ZmCDPK1, and Adh1, which encodes alcohol dehydrogenase 1.	Cycloheximide	23-36	calcium dependent protein kinase 1	Zea mays	112-119
9150261-4	1997	In addition to mlip15, cycloheximide elevates the transcript levels of two other low temperature-induced genes, ZmCDPK1, and Adh1, which encodes alcohol dehydrogenase 1.	Cycloheximide	23-36	alcohol dehydrogenase 1	Zea mays	125-129
9150261-4	1997	In addition to mlip15, cycloheximide elevates the transcript levels of two other low temperature-induced genes, ZmCDPK1, and Adh1, which encodes alcohol dehydrogenase 1.	Cycloheximide	23-36	alcohol dehydrogenase 1	Zea mays	145-168
9150261-6	1997	The accumulation of the mlip15 transcript at low temperatures and in response to cycloheximide was significantly reduced by pretreatment with a calcium chelator, suggesting that calcium is involved in both cases of mlip15 induction.	Cycloheximide	81-94	low temperature-induced protein15	Zea mays	24-30
9150261-6	1997	The accumulation of the mlip15 transcript at low temperatures and in response to cycloheximide was significantly reduced by pretreatment with a calcium chelator, suggesting that calcium is involved in both cases of mlip15 induction.	Cycloheximide	81-94	low temperature-induced protein15	Zea mays	215-221
9109445-8	1997	Finally, the protein synthesis inhibitor cycloheximide, which completely blocks the effect of CT on prostaglandin synthesis, also blocked that of PAF, suggesting that PAF also mediates protein synthesis-dependent prostaglandin formation.	Cycloheximide	41-54	PCNA clamp associated factor	Homo sapiens	146-149
9109445-8	1997	Finally, the protein synthesis inhibitor cycloheximide, which completely blocks the effect of CT on prostaglandin synthesis, also blocked that of PAF, suggesting that PAF also mediates protein synthesis-dependent prostaglandin formation.	Cycloheximide	41-54	PCNA clamp associated factor	Homo sapiens	167-170
9092517-7	1997	The 60-min nadir is due to a rapid IkappaBalpha resynthesis that reassociates with Rel A and completely inhibits its DNA binding activity; the 60-min nadir is not observed when IkappaBalpha resynthesis is prevented by cycloheximide treatment.	Cycloheximide	218-231	NFKB inhibitor alpha	Homo sapiens	35-47
9141628-5	1997	Cells treated with cycloheximide and monensin, to limit the synthesis and secretion of endogenous fibronectin, attached as well as untreated cells.	Cycloheximide	19-32	fibronectin 1	Homo sapiens	98-109
9113273-6	1997	Upon the addition of cycloheximide to stop protein synthesis, CYP2E1 content and activity decreased with apparent half-lives of 6 and 4 hr, respectively.	Cycloheximide	21-34	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	62-68
9108352-6	1997	The vitamin D3 suppression of HES-1 mRNA level was blocked by actinomycin D as well as cycloheximide, suggesting the involvement of transcriptional control, which requires new protein synthesis.	Cycloheximide	87-100	hes family bHLH transcription factor 1	Rattus norvegicus	30-35
9118487-3	1997	Both actinomycin D and cycloheximide blocked NO-stimulated HO-1 mRNA and protein expression.	Cycloheximide	23-36	heme oxygenase 1	Rattus norvegicus	59-63
9144567-0	1997	Protein synthesis inhibitors cycloheximide and anisomycin induce interleukin-6 gene expression and activate transcription factor NF-kappaB.	Cycloheximide	29-42	nuclear factor kappa B subunit 1	Homo sapiens	129-138
9144567-1	1997	In two human cell lines, MDA-MB-231 and HeLa, the inducible expression of the interleukin-6 (IL-6) gene by two protein synthesis inhibitors, cycloheximide and anisomycin, was compared with the induction by the most potent physiological inducer of IL-6 described to date, interleukin-1beta (IL-1beta).	Cycloheximide	141-154	interleukin 6	Homo sapiens	78-91
9144567-2	1997	In cycloheximide or anisomycin treated cells, the accumulation of the IL-6 message and the activation of transcription factors required for IL-6 gene expression occurs at an extent similar to that obtained with IL-1beta.	Cycloheximide	3-16	interleukin 6	Homo sapiens	70-74
9144567-2	1997	In cycloheximide or anisomycin treated cells, the accumulation of the IL-6 message and the activation of transcription factors required for IL-6 gene expression occurs at an extent similar to that obtained with IL-1beta.	Cycloheximide	3-16	interleukin 6	Homo sapiens	140-144
9075706-10	1997	The down-regulation of TSHR gene expression induced by TSH/cAMP in 3T3-L1 cells is cycloheximide-insensitive, suggesting that continuous protein synthesis is not required for this process.	Cycloheximide	83-96	thyroid stimulating hormone receptor	Mus musculus	23-27
9075706-11	1997	In contrast, the down-regulation of TSHR gene expression observed in FRTL-5 cells is sensitive to cycloheximide.	Cycloheximide	98-111	thyroid stimulating hormone receptor	Rattus norvegicus	36-40
9119888-10	1997	A reduction in Cx32 mRNA and polypeptide in the liver was observed in cycloheximide treated animals.	Cycloheximide	70-83	gap junction protein, beta 1	Rattus norvegicus	15-19
9209893-7	1997	Cycloheximide treatment blocked this TGF-beta 1 protein induction indicating de novo protein synthesis of TGF-beta 1 from keratinocytes induced by UVB.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	37-47
9209893-7	1997	Cycloheximide treatment blocked this TGF-beta 1 protein induction indicating de novo protein synthesis of TGF-beta 1 from keratinocytes induced by UVB.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	106-116
9178036-3	1997	Treatment with lead acetate and cycloheximide superinduced c-fos mRNA.	Cycloheximide	32-45	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	59-64
9184928-6	1997	In contrast, cycloheximide stimulated the induction; this suggests that de nova protein synthesis is important in the regulation of the ESP-induced expression of iNOS mRNA.	Cycloheximide	13-26	protein tyrosine phosphatase, receptor type, V	Mus musculus	136-139
9184928-6	1997	In contrast, cycloheximide stimulated the induction; this suggests that de nova protein synthesis is important in the regulation of the ESP-induced expression of iNOS mRNA.	Cycloheximide	13-26	nitric oxide synthase 2, inducible	Mus musculus	162-166
9119894-9	1997	Cycloheximide but not actinomycin D blocked the FAC-induced increase in 125I-Lf binding, indicating that the increase in the number of Lf binding sites required translation but not transcription.	Cycloheximide	0-13	lactotransferrin	Rattus norvegicus	77-79
9119894-9	1997	Cycloheximide but not actinomycin D blocked the FAC-induced increase in 125I-Lf binding, indicating that the increase in the number of Lf binding sites required translation but not transcription.	Cycloheximide	0-13	lactotransferrin	Rattus norvegicus	135-137
9120022-5	1997	TNFalpha- and IL-1beta-induced increases in eotaxin mRNA were diminished in a dose-dependent manner by the glucocorticoid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	190-203	tumor necrosis factor	Homo sapiens	0-8
9120022-5	1997	TNFalpha- and IL-1beta-induced increases in eotaxin mRNA were diminished in a dose-dependent manner by the glucocorticoid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	190-203	interleukin 1 beta	Homo sapiens	14-22
9120022-5	1997	TNFalpha- and IL-1beta-induced increases in eotaxin mRNA were diminished in a dose-dependent manner by the glucocorticoid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	190-203	C-C motif chemokine ligand 11	Homo sapiens	44-51
9163517-4	1997	A protein synthesis inhibitor, cycloheximide, significantly inhibited cell death, implying that IFN-gamma induces de novo proteins involved in the death of hepatocytes.	Cycloheximide	31-44	interferon gamma	Homo sapiens	96-105
9077475-9	1997	Incubating keratinocytes with cycloheximide increased BPAG2 mRNA to a level detectable by northern analysis.	Cycloheximide	30-43	collagen type XVII alpha 1 chain	Homo sapiens	54-59
9142651-5	1997	In C32 cells, an IRF-2 mRNA of 2.4 kb is constitutively expressed in very low amounts but is inducible by Ch-IFN in the absence or presence of cycloheximide.	Cycloheximide	143-156	interferon regulatory factor 2	Gallus gallus	17-22
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	56-69	PCNA clamp associated factor	Homo sapiens	95-98
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	56-69	interleukin 6	Homo sapiens	183-187
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	56-69	interleukin 6	Homo sapiens	228-232
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	56-69	PCNA clamp associated factor	Homo sapiens	254-257
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	56-69	interleukin 6	Homo sapiens	228-232
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	130-143	PCNA clamp associated factor	Homo sapiens	95-98
9187959-8	1997	Pretreatment of EC with the protein synthesis inhibitor cycloheximide before their exposure to PAF resulted, after washout of the cycloheximide, in a markedly augmented production of IL-6, suggesting a synergy between augmented IL-6 mRNA accumulation by PAF and IL-6 mRNA superinduction by cycloheximide.	Cycloheximide	130-143	PCNA clamp associated factor	Homo sapiens	95-98
9328213-6	1997	When Se cells were treated with cycloheximide before T3 administration, the increase in ER was completely blocked.	Cycloheximide	32-45	estrogen receptor 1	Rattus norvegicus	88-90
9060638-8	1997	Ad infection also inhibited cPLA2 translocation in response to the Ca2+ ionophore A23187 and to cycloheximide, but this inhibition did not require E3-10.4K/14.5K.	Cycloheximide	96-109	phospholipase A2 group IVA	Homo sapiens	28-33
9092801-5	1997	Progestin induction of PRG1 mRNA was also inhibited by actinomycin D but not by cycloheximide.	Cycloheximide	80-93	PRG1	Homo sapiens	23-27
9106617-10	1997	The overexpression of GAPDH mRNA and protein was completely blocked by cycloheximide, actinomycin-D, and its antisense but not sense oligonucleotides.	Cycloheximide	71-84	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	22-27
9106619-6	1997	Camptothecin-induced expression of beta-globin or ALAS-E transcript levels was inhibited in the presence of cycloheximide or vanadate.	Cycloheximide	108-121	5'-aminolevulinate synthase 2	Homo sapiens	50-56
12223667-4	1997	More interesting is that a brief treatment with cycloheximide, a cytoplasmic translation inhibitor, also prevents the light activation of SPS without any effect on the amount of SPS protein.	Cycloheximide	48-61	sucrose-phosphate synthase	Solanum lycopersicum	138-141
9110412-7	1997	Concurrent treatment of the vessels with LPS plus 50 microM cycloheximide caused PKC alpha, -epsilon, and -zeta, but not -delta, isotypes to rapidly decrease in abundance while blunting the increase in PKC isotype mRNA.	Cycloheximide	60-73	protein kinase C, alpha	Rattus norvegicus	81-111
9110412-7	1997	Concurrent treatment of the vessels with LPS plus 50 microM cycloheximide caused PKC alpha, -epsilon, and -zeta, but not -delta, isotypes to rapidly decrease in abundance while blunting the increase in PKC isotype mRNA.	Cycloheximide	60-73	protein kinase C, alpha	Rattus norvegicus	81-84
9102211-9	1997	Possible involvement of negative regulators is suggested by the presence of a negative regulatory element in the 5" flanking region of the CYP1A1 gene and the observed superinduction of CYP1A1 mRNA by cycloheximide in TCDD-treated HepG2 cells.	Cycloheximide	201-214	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	139-145
9102211-9	1997	Possible involvement of negative regulators is suggested by the presence of a negative regulatory element in the 5" flanking region of the CYP1A1 gene and the observed superinduction of CYP1A1 mRNA by cycloheximide in TCDD-treated HepG2 cells.	Cycloheximide	201-214	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	186-192
9094091-8	1997	We also investigated the effects of cycloheximide (CHX), a protein synthesis inhibitor, on cyclin D1 and D3 gene expressions.	Cycloheximide	36-49	cyclin D1	Mus musculus	91-100
9094091-8	1997	We also investigated the effects of cycloheximide (CHX), a protein synthesis inhibitor, on cyclin D1 and D3 gene expressions.	Cycloheximide	51-54	cyclin D1	Mus musculus	91-100
9106470-2	1997	The protein synthesis inhibitor cycloheximide decreased GnRH primary transcript levels, indicating a protein synthesis requirement for basal GnRH transcription.	Cycloheximide	32-45	gonadotropin releasing hormone 1	Homo sapiens	56-60
9106470-2	1997	The protein synthesis inhibitor cycloheximide decreased GnRH primary transcript levels, indicating a protein synthesis requirement for basal GnRH transcription.	Cycloheximide	32-45	gonadotropin releasing hormone 1	Homo sapiens	141-145
9106470-4	1997	In contrast, the PMA-inhibitory effect on GnRH cytoplasmic mRNA levels was significantly reduced or inhibited in the presence of cycloheximide or RNA synthesis inhibitors given within 4 h of PMA, suggesting a protein/RNA synthesis-dependent mechanism for the regulation of GnRH mRNA levels by PMA.	Cycloheximide	129-142	gonadotropin releasing hormone 1	Homo sapiens	42-46
9106470-4	1997	In contrast, the PMA-inhibitory effect on GnRH cytoplasmic mRNA levels was significantly reduced or inhibited in the presence of cycloheximide or RNA synthesis inhibitors given within 4 h of PMA, suggesting a protein/RNA synthesis-dependent mechanism for the regulation of GnRH mRNA levels by PMA.	Cycloheximide	129-142	gonadotropin releasing hormone 1	Homo sapiens	273-277
9089293-6	1997	Cycloheximide strongly increased IL-1beta-induced TNF-alpha mRNA concentration indicating that de novo protein synthesis is not required for TNF-alpha gene expression.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	33-41
9130244-8	1997	NGF maintained catalase mRNA levels of actinomycin D (ACT-D) treated PC12 cells at twice that of cells exposed to ACT-D alone, delaying the rate of decay for catalase mRNA for 24 h. The NGF induction of GSH-Px and catalase mRNA was inhibited by cycloheximide (CHX) treatment with a slight decrease in their mRNA levels due to prolonged exposure to CHX.	Cycloheximide	245-258	nerve growth factor	Rattus norvegicus	0-3
9089293-6	1997	Cycloheximide strongly increased IL-1beta-induced TNF-alpha mRNA concentration indicating that de novo protein synthesis is not required for TNF-alpha gene expression.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	50-59
9130244-8	1997	NGF maintained catalase mRNA levels of actinomycin D (ACT-D) treated PC12 cells at twice that of cells exposed to ACT-D alone, delaying the rate of decay for catalase mRNA for 24 h. The NGF induction of GSH-Px and catalase mRNA was inhibited by cycloheximide (CHX) treatment with a slight decrease in their mRNA levels due to prolonged exposure to CHX.	Cycloheximide	245-258	nerve growth factor	Rattus norvegicus	186-189
9130244-8	1997	NGF maintained catalase mRNA levels of actinomycin D (ACT-D) treated PC12 cells at twice that of cells exposed to ACT-D alone, delaying the rate of decay for catalase mRNA for 24 h. The NGF induction of GSH-Px and catalase mRNA was inhibited by cycloheximide (CHX) treatment with a slight decrease in their mRNA levels due to prolonged exposure to CHX.	Cycloheximide	260-263	nerve growth factor	Rattus norvegicus	0-3
9122225-6	1997	B cells, but not T cells or mast cells, express Fig1 in response to IL-4 within 2 hr in a cycloheximide resistant manner.	Cycloheximide	90-103	interleukin 4	Mus musculus	68-72
9130244-8	1997	NGF maintained catalase mRNA levels of actinomycin D (ACT-D) treated PC12 cells at twice that of cells exposed to ACT-D alone, delaying the rate of decay for catalase mRNA for 24 h. The NGF induction of GSH-Px and catalase mRNA was inhibited by cycloheximide (CHX) treatment with a slight decrease in their mRNA levels due to prolonged exposure to CHX.	Cycloheximide	260-263	nerve growth factor	Rattus norvegicus	186-189
9054437-7	1997	Western blot analysis showed that treatment of UMSCC2 cells with cycloheximide, serum, epidermal growth factor, or vanadate resulted in the disappearance of the p80 form and conversion into p85.	Cycloheximide	65-78	coilin	Homo sapiens	161-164
9054437-7	1997	Western blot analysis showed that treatment of UMSCC2 cells with cycloheximide, serum, epidermal growth factor, or vanadate resulted in the disappearance of the p80 form and conversion into p85.	Cycloheximide	65-78	phosphoinositide-3-kinase regulatory subunit 2	Homo sapiens	190-193
9060477-0	1997	Neuroprotective action of cycloheximide involves induction of bcl-2 and antioxidant pathways.	Cycloheximide	26-39	BCL2, apoptosis regulator	Rattus norvegicus	62-67
9058812-7	1997	Concomitant treatment of cells with cycloheximide abolished the increases in both T beta RE-binding activity and expression of PAF receptor mRNA, indicating that de novo protein synthesis is required to exert TGF-beta 2 effect.	Cycloheximide	36-49	platelet activating factor receptor	Homo sapiens	127-139
9058812-7	1997	Concomitant treatment of cells with cycloheximide abolished the increases in both T beta RE-binding activity and expression of PAF receptor mRNA, indicating that de novo protein synthesis is required to exert TGF-beta 2 effect.	Cycloheximide	36-49	transforming growth factor beta 2	Homo sapiens	209-219
9060477-5	1997	Neuroprotective concentrations of CHX caused only a moderate (20-40%) reduction in overall protein synthesis, and induced an increase in c-fos, c-jun, and bcl-2 mRNAs and protein levels as determined by reverse transcription-PCR analysis and immunocytochemistry, respectively.	Cycloheximide	34-37	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	137-142
9060477-5	1997	Neuroprotective concentrations of CHX caused only a moderate (20-40%) reduction in overall protein synthesis, and induced an increase in c-fos, c-jun, and bcl-2 mRNAs and protein levels as determined by reverse transcription-PCR analysis and immunocytochemistry, respectively.	Cycloheximide	34-37	BCL2, apoptosis regulator	Rattus norvegicus	155-160
9060477-8	1997	Treatment of cultures with an antisense oligodeoxynucleotide directed against bcl-2 mRNA decreased Bcl-2 protein levels and significantly reduced the neuroprotective action of CHX, suggesting that induction of Bcl-2 expression was mechanistically involved in the neuroprotective actions of CHX.	Cycloheximide	176-179	BCL2, apoptosis regulator	Rattus norvegicus	78-83
9060477-8	1997	Treatment of cultures with an antisense oligodeoxynucleotide directed against bcl-2 mRNA decreased Bcl-2 protein levels and significantly reduced the neuroprotective action of CHX, suggesting that induction of Bcl-2 expression was mechanistically involved in the neuroprotective actions of CHX.	Cycloheximide	176-179	BCL2, apoptosis regulator	Rattus norvegicus	210-215
9060477-8	1997	Treatment of cultures with an antisense oligodeoxynucleotide directed against bcl-2 mRNA decreased Bcl-2 protein levels and significantly reduced the neuroprotective action of CHX, suggesting that induction of Bcl-2 expression was mechanistically involved in the neuroprotective actions of CHX.	Cycloheximide	290-293	BCL2, apoptosis regulator	Rattus norvegicus	78-83
9060477-8	1997	Treatment of cultures with an antisense oligodeoxynucleotide directed against bcl-2 mRNA decreased Bcl-2 protein levels and significantly reduced the neuroprotective action of CHX, suggesting that induction of Bcl-2 expression was mechanistically involved in the neuroprotective actions of CHX.	Cycloheximide	290-293	BCL2, apoptosis regulator	Rattus norvegicus	210-215
9126704-11	1997	The mechanisms that contribute to TNF mRNA accumulation also may differ in the two CD4+ T cell subsets, because cycloheximide superinduced TNF mRNA in Th2 cells, but not in Th1 cells.	Cycloheximide	112-125	tumor necrosis factor	Mus musculus	34-37
9065457-6	1997	Stimulation of intact cells with Ca2+ or Ang II led to a marked, cycloheximide-sensitive increase in cholesterol in CS (to 143 +/- 3.	Cycloheximide	65-78	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	41-47
9065457-8	1997	Western blot analysis revealed a cycloheximide-sensitive increase in StAR protein in mitochondrial extracts of Ca2+-clamped glomerulosa cells (to 159 +/- 23% of controls).	Cycloheximide	33-46	steroidogenic acute regulatory protein	Mus musculus	69-73
9065457-10	1997	Similarly, Ang II increased StAR protein in IM, and this effect was prevented by cycloheximide.	Cycloheximide	81-94	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	11-17
9065457-10	1997	Similarly, Ang II increased StAR protein in IM, and this effect was prevented by cycloheximide.	Cycloheximide	81-94	steroidogenic acute regulatory protein	Mus musculus	28-32
9117018-4	1997	COX-2 expression and PGE2 formation were inhibited by dexamethasone (2 microM), cycloheximide (10 microM), and IL-1-receptor antagonist (IL-1 ra) (250 ng/ml), independently.	Cycloheximide	80-93	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	0-5
9126704-11	1997	The mechanisms that contribute to TNF mRNA accumulation also may differ in the two CD4+ T cell subsets, because cycloheximide superinduced TNF mRNA in Th2 cells, but not in Th1 cells.	Cycloheximide	112-125	CD4 antigen	Mus musculus	83-86
9048615-4	1997	Actinomycin D and cycloheximide inhibited the effects of TNF alpha on PAI-1 mRNA, suggesting that ongoing RNA and protein syntheses were required.	Cycloheximide	18-31	tumor necrosis factor	Rattus norvegicus	57-66
9126704-11	1997	The mechanisms that contribute to TNF mRNA accumulation also may differ in the two CD4+ T cell subsets, because cycloheximide superinduced TNF mRNA in Th2 cells, but not in Th1 cells.	Cycloheximide	112-125	tumor necrosis factor	Mus musculus	139-142
9048615-4	1997	Actinomycin D and cycloheximide inhibited the effects of TNF alpha on PAI-1 mRNA, suggesting that ongoing RNA and protein syntheses were required.	Cycloheximide	18-31	serpin family E member 1	Rattus norvegicus	70-75
9126704-11	1997	The mechanisms that contribute to TNF mRNA accumulation also may differ in the two CD4+ T cell subsets, because cycloheximide superinduced TNF mRNA in Th2 cells, but not in Th1 cells.	Cycloheximide	112-125	heart and neural crest derivatives expressed 2	Mus musculus	151-154
9049198-7	1997	Inhibition of protein synthesis with cycloheximide rapidly induced p21 expression, primarily by post-transcriptional stabilization of the transcript.	Cycloheximide	37-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	67-70
9045811-1	1997	When Saccharomyces cerevisiae cells growing on galactose are transferred onto glucose medium containing cycloheximide, an inhibitor of protein synthesis, a rapid reduction of Gal2p-mediated galactose uptake is observed.	Cycloheximide	104-117	galactose permease GAL2	Saccharomyces cerevisiae S288C	175-180
9048649-6	1997	However, both E-selectin mRNA and gene transcription were dramatically induced by TNF-alpha in the same cells pretreated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	158-171	selectin E	Homo sapiens	14-24
9048649-6	1997	However, both E-selectin mRNA and gene transcription were dramatically induced by TNF-alpha in the same cells pretreated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	158-171	tumor necrosis factor	Homo sapiens	82-91
9048649-8	1997	Furthermore, E-selectin was detected on the cell surface of HASMCs after washing out of cycloheximide.	Cycloheximide	88-101	selectin E	Homo sapiens	13-23
9048649-9	1997	Cycloheximide pretreatment enabled immortalized human dermal microvascular endothelial cells that have lost the ability to express E-selectin to induce both E-selectin mRNA and gene transcription in response to TNF-alpha.	Cycloheximide	0-13	selectin E	Homo sapiens	131-141
9048649-9	1997	Cycloheximide pretreatment enabled immortalized human dermal microvascular endothelial cells that have lost the ability to express E-selectin to induce both E-selectin mRNA and gene transcription in response to TNF-alpha.	Cycloheximide	0-13	selectin E	Homo sapiens	157-167
9048649-9	1997	Cycloheximide pretreatment enabled immortalized human dermal microvascular endothelial cells that have lost the ability to express E-selectin to induce both E-selectin mRNA and gene transcription in response to TNF-alpha.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	211-220
9048649-10	1997	Induction of E-selectin mRNA by lipopolysaccharide or TNF-alpha in cycloheximide-treated HASMCs was inhibited by the antioxidant pyrrolidinedithiocarbamate and the serine protease inhibitor N alpha-L-tosyl-L-phenylalanine chloromethyl ketone, suggesting that a nuclear factor-kappa B-like mechanism may play an important role in E-selectin gene expression in HASMCs.	Cycloheximide	67-80	selectin E	Homo sapiens	13-23
9048649-10	1997	Induction of E-selectin mRNA by lipopolysaccharide or TNF-alpha in cycloheximide-treated HASMCs was inhibited by the antioxidant pyrrolidinedithiocarbamate and the serine protease inhibitor N alpha-L-tosyl-L-phenylalanine chloromethyl ketone, suggesting that a nuclear factor-kappa B-like mechanism may play an important role in E-selectin gene expression in HASMCs.	Cycloheximide	67-80	tumor necrosis factor	Homo sapiens	54-63
9048649-10	1997	Induction of E-selectin mRNA by lipopolysaccharide or TNF-alpha in cycloheximide-treated HASMCs was inhibited by the antioxidant pyrrolidinedithiocarbamate and the serine protease inhibitor N alpha-L-tosyl-L-phenylalanine chloromethyl ketone, suggesting that a nuclear factor-kappa B-like mechanism may play an important role in E-selectin gene expression in HASMCs.	Cycloheximide	67-80	selectin E	Homo sapiens	329-339
9049422-7	1997	The B13R protein does, however, block apoptosis mediated by anti-Fas antibodies or by tumour necrosis factor (TNF) and cycloheximide.	Cycloheximide	119-132	SPI-2/CrmA inhibits Fas-mediated apoptosis, IL-1 convertase, lipoxygenase pathway	Vaccinia virus	4-8
9125673-3	1997	Cycloheximide (35 microM), an inhibitor of protein synthesis, significantly reduced the incorporation of L-U-[(14)C]phenylalanine and 2-[(14)C]uridine into cellular protein and RNA, respectively, under control conditions and in response to ET-1.	Cycloheximide	0-13	endothelin-1	Oryctolagus cuniculus	240-244
9155746-10	1997	Addition of epidermal growth factor to cycloheximide-inhibited oocytes was without effect.	Cycloheximide	39-52	LOC521832	Bos taurus	12-35
9032234-1	1997	Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate acetate (PMA) and cycloheximide results in 17- and 10-fold, respectively, increases in steady-state expression of urokinase-type plasminogen activator receptor (uPAR) mRNA.	Cycloheximide	94-107	plasminogen activator, urokinase receptor	Homo sapiens	190-235
9079763-0	1997	Discrete cleavage patterns of pseudorabies virus immediate early protein (IE180) seen in some cell lines upon extraction after cycloheximide reversal.	Cycloheximide	127-140	transcriptional regulator ICP4	Suid alphaherpesvirus 1	74-79
9079763-2	1997	In this study, IE180 was examined in lysates from various cell lines infected at high multiplicities under cycloheximide inhibition of protein synthesis and subsequent reversal.	Cycloheximide	107-120	transcriptional regulator ICP4	Suid alphaherpesvirus 1	15-20
9032234-1	1997	Treatment of human pleural mesothelioma (MS-1) cells with phorbol myristate acetate (PMA) and cycloheximide results in 17- and 10-fold, respectively, increases in steady-state expression of urokinase-type plasminogen activator receptor (uPAR) mRNA.	Cycloheximide	94-107	plasminogen activator, urokinase receptor	Homo sapiens	237-241
9056761-5	1997	A significant fraction of the CYH2 pre-mRNA that accumulated in the presence of cycloheximide was associated with polysomes, but disappeared from that fraction when decay resumed in the absence of the drug.	Cycloheximide	80-93	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	30-34
9038227-7	1997	Incubation of PC12 cells with a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximide) attenuated the ability of NGF to decrease sGC subunit mRNA levels.	Cycloheximide	119-132	nerve growth factor	Rattus norvegicus	160-163
9038227-7	1997	Incubation of PC12 cells with a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximide) attenuated the ability of NGF to decrease sGC subunit mRNA levels.	Cycloheximide	119-132	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	176-179
9083783-8	1997	On the other hand, continuous exposure to the anti-inflammatory steroid dexamethasone (100 microM) or to the protein synthesis inhibitor cycloheximide (70 microM) largely prevented the sensitization to des-Arg9-bradykinin in incubated human umbilical vein rings.	Cycloheximide	137-150	kininogen 1	Homo sapiens	211-221
9034145-5	1997	In vitro studies indicate that the IgE-dependent upregulation of mouse mast cell Fc(epsilon)RI expression has two components: an early cycloheximide-insensitive phase, followed by a later and more sustained component that is highly sensitive to inhibition by cycloheximide.	Cycloheximide	135-148	Fc receptor, IgE, high affinity I, gamma polypeptide	Mus musculus	81-94
9034145-5	1997	In vitro studies indicate that the IgE-dependent upregulation of mouse mast cell Fc(epsilon)RI expression has two components: an early cycloheximide-insensitive phase, followed by a later and more sustained component that is highly sensitive to inhibition by cycloheximide.	Cycloheximide	259-272	Fc receptor, IgE, high affinity I, gamma polypeptide	Mus musculus	81-94
9078254-5	1997	T3-mediated changes in leptin and beta 3-adrenergic receptor mRNAs were blocked by cycloheximide, suggesting the involvement of short-lived proteins in these effects.	Cycloheximide	83-96	leptin	Rattus norvegicus	23-29
9078254-5	1997	T3-mediated changes in leptin and beta 3-adrenergic receptor mRNAs were blocked by cycloheximide, suggesting the involvement of short-lived proteins in these effects.	Cycloheximide	83-96	adrenoceptor beta 3	Rattus norvegicus	34-60
9123849-2	1997	It is shown that transfection of K562 cells with the ASFV A179L gene protects these cells from apoptotic cell death induced by a combination of cycloheximide and actinomycin D or by treatment with cytosine arabinoside.	Cycloheximide	144-157	bcl-2/bax homolog	African swine fever virus	58-63
9070291-5	1997	In the presence of cycloheximide, all-trans retinoic acid superinduced NOR-1 mRNA, whereas all-trans and 9-cis retinoic acids strongly suppressed the NGFI-B mRNA accumulation.	Cycloheximide	19-32	nuclear receptor subfamily 4 group A member 3	Homo sapiens	71-76
9070253-5	1997	Pretreatment of synovial fibroblasts with cycloheximide, an inhibitor of protein synthesis, prevented MMP-3 secretion from rheumatoid synovial cells suggesting that protein synthesis was required for SEA-induced MMP-3 secretion after SEA binding to MHC class II molecules.	Cycloheximide	42-55	matrix metallopeptidase 3	Homo sapiens	102-107
9070253-5	1997	Pretreatment of synovial fibroblasts with cycloheximide, an inhibitor of protein synthesis, prevented MMP-3 secretion from rheumatoid synovial cells suggesting that protein synthesis was required for SEA-induced MMP-3 secretion after SEA binding to MHC class II molecules.	Cycloheximide	42-55	matrix metallopeptidase 3	Homo sapiens	212-217
9068283-11	1997	IL-1 beta was ineffective in upregulating steady state cathepsin-B mRNA in chondrocytes; however, it upregulated the intracellular enzyme, and this was blocked with cycloheximide.	Cycloheximide	165-178	interleukin-1 beta	Oryctolagus cuniculus	0-9
9081687-6	1997	This stimulation of IL-8 production was time and dose dependent and could be blocked by cycloheximide.	Cycloheximide	88-101	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
9051287-6	1997	The release of GM-CSF elicited by the cytokine mixture was inhibited by cycloheximide and dexamethasone.	Cycloheximide	72-85	colony stimulating factor 2	Homo sapiens	15-21
8995203-8	1997	Continuous accumulation of fluorescent label was observed by CLSM in the presence of the protein synthesis inhibitor cycloheximide, suggesting that the gastrin receptor is recycled back to the cell membrane after hormone delivery to intracellular compartments.	Cycloheximide	117-130	cholecystokinin B receptor	Homo sapiens	152-168
9113384-4	1997	The results suggested that the cycloheximide inhibition of gene expression is specific to hsp gene expression induced by limited stress doses.	Cycloheximide	31-44	10 kDa heat shock protein, mitochondrial	Cricetulus griseus	90-93
9113384-5	1997	Furthermore, a prior 42 degrees C heat shock treatment for 30 minutes induced a decreased responsiveness (tolerance) to a second 42 degrees C heat treatment for hsp gene expression, but tolerance did not develop in cells exposed to the first heat shock in the presence of cycloheximide.	Cycloheximide	272-285	10 kDa heat shock protein, mitochondrial	Cricetulus griseus	161-164
9024798-5	1997	When the feedback repression of polyamine uptake was blocked with cycloheximide, C55.7 cells transfected with either ODC construct accumulated very high levels of putrescine from the medium, and underwent apoptosis in a putrescine dose-dependent manner.	Cycloheximide	66-79	ornithine decarboxylase, structural 1	Mus musculus	117-120
9021944-11	1997	This was reversed by cycloheximide, thus suggesting the indirect hepatotoxic effect of MIP2.	Cycloheximide	21-34	C-X-C motif chemokine ligand 2	Rattus norvegicus	87-91
9081220-1	1997	Previously, we have shown that IGF-1, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and aurintricarboxylic acid (ATA) protected MCF-7 cells against death induced by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	212-225	insulin like growth factor 1	Homo sapiens	31-36
9081220-1	1997	Previously, we have shown that IGF-1, the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and aurintricarboxylic acid (ATA) protected MCF-7 cells against death induced by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	227-230	insulin like growth factor 1	Homo sapiens	31-36
9003041-7	1997	Because pretreatment with protein (cycloheximide) or RNA synthesis (amanitin and actinomycin D) inhibitors eliminated the inductive effect of aFGF and TPA, we conclude that de novo transcription and translation are necessary for the expression of TH after convergence of both PKC and growth factor pathways.	Cycloheximide	35-48	fibroblast growth factor 1	Homo sapiens	142-146
9089489-7	1997	Most of the stimulation was blocked by Cx, indicating that the regulation of decorin gene expression by IL-1 beta may be via an indirect pathway, requiring new protein synthesis which regulates the promoter.	Cycloheximide	39-41	decorin	Homo sapiens	77-84
9089489-7	1997	Most of the stimulation was blocked by Cx, indicating that the regulation of decorin gene expression by IL-1 beta may be via an indirect pathway, requiring new protein synthesis which regulates the promoter.	Cycloheximide	39-41	interleukin 1 beta	Homo sapiens	104-113
9051715-5	1997	Pretreatment of SMC with cycloheximide and actinomycin not only inhibited IL-1 beta-induced eicosanoid synthesis and phospholipid breakdown but also diminished TXB2 production when co-incubated with platelets.	Cycloheximide	25-38	interleukin 1 beta	Homo sapiens	74-83
8993008-4	1997	Cell surface E-selectin is internalized more slowly on HDMEC than on HUVEC (t1/2 = 4.3 vs 1.6 h, respectively) as measured by serial FACS analyses in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	198-211	selectin E	Homo sapiens	13-23
8993011-4	1997	Within 10 min of addition, TNF stimulated a significant increase in total cellular G alpha(i2), as determined by pertussis toxin-catalyzed ADP ribosylation, which was blocked by the translation inhibitor cycloheximide.	Cycloheximide	204-217	tumor necrosis factor	Homo sapiens	27-30
8993011-7	1997	Pretreatment with cycloheximide prevented the TNF-induced reduction in steady state alpha(i2) mRNA levels.	Cycloheximide	18-31	tumor necrosis factor	Homo sapiens	46-49
9031634-10	1997	Northern blot analysis of an embryonic carcinoma cell line P19 showed that the steady-state level of Rabggtb mRNA expression was increased dramatically by cycloheximide (CHX) treatment as early as 2 h, suggesting a role of post-transcriptional regulation of Rab GGTase beta gene expression.	Cycloheximide	155-168	Rab geranylgeranyl transferase, b subunit	Mus musculus	101-108
9031634-10	1997	Northern blot analysis of an embryonic carcinoma cell line P19 showed that the steady-state level of Rabggtb mRNA expression was increased dramatically by cycloheximide (CHX) treatment as early as 2 h, suggesting a role of post-transcriptional regulation of Rab GGTase beta gene expression.	Cycloheximide	155-168	Rab geranylgeranyl transferase, b subunit	Mus musculus	258-273
9031634-10	1997	Northern blot analysis of an embryonic carcinoma cell line P19 showed that the steady-state level of Rabggtb mRNA expression was increased dramatically by cycloheximide (CHX) treatment as early as 2 h, suggesting a role of post-transcriptional regulation of Rab GGTase beta gene expression.	Cycloheximide	170-173	Rab geranylgeranyl transferase, b subunit	Mus musculus	101-108
9031634-10	1997	Northern blot analysis of an embryonic carcinoma cell line P19 showed that the steady-state level of Rabggtb mRNA expression was increased dramatically by cycloheximide (CHX) treatment as early as 2 h, suggesting a role of post-transcriptional regulation of Rab GGTase beta gene expression.	Cycloheximide	170-173	Rab geranylgeranyl transferase, b subunit	Mus musculus	258-273
9032234-2	1997	Studies of transcriptional inhibition by actinomycin D showed four- and sixfold extensions of uPAR mRNA half-life in MS-1 cells treated with PMA and cycloheximide, respectively, suggesting that uPAR gene expression involves a posttranscriptional regulatory mechanism.	Cycloheximide	149-162	plasminogen activator, urokinase receptor	Homo sapiens	94-98
9032234-2	1997	Studies of transcriptional inhibition by actinomycin D showed four- and sixfold extensions of uPAR mRNA half-life in MS-1 cells treated with PMA and cycloheximide, respectively, suggesting that uPAR gene expression involves a posttranscriptional regulatory mechanism.	Cycloheximide	149-162	plasminogen activator, urokinase receptor	Homo sapiens	194-198
9032234-7	1997	Binding of uPAR mRNABp to uPAR mRNA was abolished after treatment with cycloheximide and rapidly down-regulated by PMA.	Cycloheximide	71-84	plasminogen activator, urokinase receptor	Homo sapiens	11-15
9032234-7	1997	Binding of uPAR mRNABp to uPAR mRNA was abolished after treatment with cycloheximide and rapidly down-regulated by PMA.	Cycloheximide	71-84	plasminogen activator, urokinase receptor	Homo sapiens	26-30
9032234-8	1997	These data suggest that the 51-nt protein binding fragment of uPAR mRNA may be involved in mRNA turnover as well as in cycloheximide-induced uPAR message stabilization.	Cycloheximide	119-132	plasminogen activator, urokinase receptor	Homo sapiens	62-66
9032234-8	1997	These data suggest that the 51-nt protein binding fragment of uPAR mRNA may be involved in mRNA turnover as well as in cycloheximide-induced uPAR message stabilization.	Cycloheximide	119-132	plasminogen activator, urokinase receptor	Homo sapiens	141-145
9009219-7	1997	This very rapid synthesis of PKC-epsilon is not blocked by the transcription inhibitor actinomycin D but is inhibited by cycloheximide.	Cycloheximide	121-134	protein kinase C, epsilon	Mus musculus	29-40
9381980-15	1997	These alterations are in line with the rapid t1/2 degradation rates (12 min) of PI and PIP kinases observed in studies with cycloheximide.	Cycloheximide	124-137	prolactin induced protein	Homo sapiens	87-90
9020026-3	1997	The time-dependent accumulation of IL-8 inhibited by cycloheximide and the evaluation of the IL-8 mRNA levels by reverse transcriptase-polymerase chain reaction suggested that its action occurred in the posttranscriptional processes.	Cycloheximide	53-66	C-X-C motif chemokine ligand 8	Homo sapiens	35-39
9131782-9	1997	But activation of MDH in later stages of the response was inhibited by actinomycin D and cycloheximide, indicating that MDH might be regulated by JH at the transcriptional and/or translational level.	Cycloheximide	89-102	Malate dehydrogenase 1	Drosophila melanogaster	18-21
9131782-9	1997	But activation of MDH in later stages of the response was inhibited by actinomycin D and cycloheximide, indicating that MDH might be regulated by JH at the transcriptional and/or translational level.	Cycloheximide	89-102	Malate dehydrogenase 1	Drosophila melanogaster	120-123
9012653-4	1997	In the presence of cycloheximide, induction of syndecan-4 mRNA was enhanced.	Cycloheximide	19-32	syndecan 4	Rattus norvegicus	47-57
14646563-2	1997	Here we show that the onset of cell death after IL-3 withdrawal can be strongly delayed by either cycloheximide or actinomycin D, indicating that de novo protein synthesis is required.	Cycloheximide	98-111	interleukin 3	Mus musculus	48-52
9012653-6	1997	In contrast, syndecan-1 mRNA expression in response to serum was completely blocked in the presence of cycloheximide.	Cycloheximide	103-116	syndecan 1	Rattus norvegicus	13-23
8977420-8	1997	Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1 beta to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity.	Cycloheximide	15-28	interleukin 1 beta	Rattus norvegicus	115-124
8977420-8	1997	Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1 beta to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity.	Cycloheximide	15-28	phospholipase A2 group IIA	Rattus norvegicus	140-145
8977420-8	1997	Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1 beta to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity.	Cycloheximide	15-28	phospholipase A2 group IVA	Rattus norvegicus	150-155
8977420-8	1997	Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1 beta to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity.	Cycloheximide	15-28	phospholipase A2 group IB	Rattus norvegicus	141-145
9012782-6	1997	On the other hand, a prior incubation with cycloheximide, DRB, genistein, herbimycin A, and BAPTA/AM completely blocked the egr-1 gene level enhanced by shaking the culture dishes.	Cycloheximide	43-56	early growth response 1	Mus musculus	124-129
9024925-4	1997	Inhibition of RNA-(actinomycin D) of protein-synthesis (cycloheximide) prior to heat treatment completely inhibits the expression of HSP72 on the cell surface of both tumour cells, thus indicating that de novo protein synthesis is required for HSP72 cell surface expression.	Cycloheximide	56-69	heat shock protein family A (Hsp70) member 1A	Homo sapiens	133-138
9024925-4	1997	Inhibition of RNA-(actinomycin D) of protein-synthesis (cycloheximide) prior to heat treatment completely inhibits the expression of HSP72 on the cell surface of both tumour cells, thus indicating that de novo protein synthesis is required for HSP72 cell surface expression.	Cycloheximide	56-69	heat shock protein family A (Hsp70) member 1A	Homo sapiens	244-249
9479630-4	1997	EGF did not affect DNA synthesis by the cells for 4 h. Pretreatment of the cells with cycloheximide (10 micrograms/ml) for 1.5 h before EGF treatment significantly attenuated the cytoprotective effect of EGF by > 50%.	Cycloheximide	86-99	epidermal growth factor like 1	Rattus norvegicus	0-3
9479630-4	1997	EGF did not affect DNA synthesis by the cells for 4 h. Pretreatment of the cells with cycloheximide (10 micrograms/ml) for 1.5 h before EGF treatment significantly attenuated the cytoprotective effect of EGF by > 50%.	Cycloheximide	86-99	epidermal growth factor like 1	Rattus norvegicus	136-139
9479630-4	1997	EGF did not affect DNA synthesis by the cells for 4 h. Pretreatment of the cells with cycloheximide (10 micrograms/ml) for 1.5 h before EGF treatment significantly attenuated the cytoprotective effect of EGF by > 50%.	Cycloheximide	86-99	epidermal growth factor like 1	Rattus norvegicus	136-139
8977194-7	1997	In HT-29 cells stimulated with IL-1beta, IkappaB alpha was phosphorylated and when cycloheximide blocked new protein synthesis, IkappaB alpha was partially degraded.	Cycloheximide	83-96	interleukin 1 beta	Homo sapiens	31-39
8980292-5	1997	Stimulation by EGF was an actinomycin D- and cycloheximide-sensitive process.	Cycloheximide	45-58	epidermal growth factor	Homo sapiens	15-18
8977194-7	1997	In HT-29 cells stimulated with IL-1beta, IkappaB alpha was phosphorylated and when cycloheximide blocked new protein synthesis, IkappaB alpha was partially degraded.	Cycloheximide	83-96	NFKB inhibitor alpha	Homo sapiens	41-54
8977194-7	1997	In HT-29 cells stimulated with IL-1beta, IkappaB alpha was phosphorylated and when cycloheximide blocked new protein synthesis, IkappaB alpha was partially degraded.	Cycloheximide	83-96	NFKB inhibitor alpha	Homo sapiens	128-141
8985363-6	1997	Moreover, interleukin-8 (IL-8) mRNA accumulation was evident at 20 min postinfection and was induced even in the presence of cycloheximide.	Cycloheximide	125-138	C-X-C motif chemokine ligand 8	Homo sapiens	10-23
8989665-6	1997	The retinoic acid-induced increase in 125I-CNTF binding could be prevented by administration of either cycloheximide or actinomycin D, whereas neither agent altered the TPA-induced decrease in 125I-CNTF binding.	Cycloheximide	103-116	ciliary neurotrophic factor	Homo sapiens	43-47
8985363-6	1997	Moreover, interleukin-8 (IL-8) mRNA accumulation was evident at 20 min postinfection and was induced even in the presence of cycloheximide.	Cycloheximide	125-138	C-X-C motif chemokine ligand 8	Homo sapiens	25-29
9284085-4	1997	Pre-incubation with cycloheximide or aminoguanidine blocked IGF-1-stimulated NO release.	Cycloheximide	20-33	insulin like growth factor 1	Homo sapiens	60-65
9075824-4	1997	Increases in alpha-thrombin-induced TGF-beta1 message expression were insensitive to cycloheximide, but sensitive to actinomycin D.	Cycloheximide	85-98	transforming growth factor beta 1	Homo sapiens	36-45
9698933-4	1997	The eosinophil accumulation induced by LPs is not affected by inhibitors of cyclo or lipoxygenase nor by PAF antagonists but can be blocked by dexamethasone or the protein synthesis inhibitor cycloheximide.	Cycloheximide	192-205	toll-like receptor 4	Mus musculus	39-42
9061044-3	1997	A protein synthesis inhibitor cycloheximide also diminished the enhancement of the [3H]glucosamine incorporation by bFGF.	Cycloheximide	30-43	fibroblast growth factor 2	Homo sapiens	116-120
18472820-3	1997	The release of MNF was inhibited by the pretreatment of the macrophages with cycloheximide, a protein synthesis inhibitor, or with the glucocorticoid dexamethasone.	Cycloheximide	77-90	forkhead box K1	Mus musculus	15-18
18472868-3	1997	Dexamethasone (0.05-5 mug) and cycloheximide (6 ng), injected 2 h before LPS into the pouches, inhibited the neutrophil recruitment and the generation of the TNFalpha-like activity, while the H1-receptor antagonist mepyramine (1 and 4 mg/kg, i.p., 0.5 h before LPS) and the PAF-receptor antagonist WEB 2170 (0.05 and 1 mg/kg, i.p., 0.5 h before LPS) had no effect.	Cycloheximide	31-44	tumor necrosis factor	Rattus norvegicus	158-166
9029709-8	1997	Depletion of StAR by cycloheximide inhibits cholesterol transfer but is overcome by uptake of Ca2+ into the matrix.	Cycloheximide	21-34	steroidogenic acute regulatory protein	Rattus norvegicus	13-17
8990384-7	1996	CIITA induction by IFN-gamma was partially sensitive to cycloheximide, suggesting that another protein is required for CIITA induction.	Cycloheximide	56-69	class II transactivator	Mus musculus	0-5
9029737-6	1997	The down-regulation of aromatase, SF-1, and RII beta by each kinase activator and alpha-amanitin was prevented by cycloheximide when the drug was added in combination with the activator.	Cycloheximide	114-127	splicing factor 1	Rattus norvegicus	34-38
8990384-7	1996	CIITA induction by IFN-gamma was partially sensitive to cycloheximide, suggesting that another protein is required for CIITA induction.	Cycloheximide	56-69	interferon gamma	Mus musculus	19-28
8955085-10	1996	Cycloheximide abolished the TNF-alpha and IL-1beta effect, suggesting that de novo protein synthesis is required for receptor down-regulation.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	28-37
8955085-10	1996	Cycloheximide abolished the TNF-alpha and IL-1beta effect, suggesting that de novo protein synthesis is required for receptor down-regulation.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	42-50
8943275-3	1996	We now report that 2-cyclopenten-1-one selectively induces the expression of the 70-kDa HSP (HSP70) in human cells, through cycloheximide-sensitive activation of heat shock transcription factor 1 (HSF1).	Cycloheximide	124-137	heat shock transcription factor 1	Homo sapiens	162-195
8954973-2	1996	Using primary cultures of rat hippocampal neurons, we found that exposing the cells to cycloheximide allowed subsequent activation of BDNF mRNA expression, although activation of AP-1 DNA-binding activity resulting from the c-fos induction was abolished.	Cycloheximide	87-100	brain-derived neurotrophic factor	Rattus norvegicus	134-138
8954973-3	1996	Super-induction of BDNF gene was also caused by cycloheximide.	Cycloheximide	48-61	brain-derived neurotrophic factor	Rattus norvegicus	19-23
8978503-6	1996	Cycloheximide (100 microM), however, partially but significantly reversed the inhibitory effect of ET-3 on CNP-induced cGMP from 48.2 to 73.3% of the control value.	Cycloheximide	0-13	endothelin 3	Mus musculus	99-103
8978503-6	1996	Cycloheximide (100 microM), however, partially but significantly reversed the inhibitory effect of ET-3 on CNP-induced cGMP from 48.2 to 73.3% of the control value.	Cycloheximide	0-13	natriuretic peptide type C	Mus musculus	107-110
8943275-3	1996	We now report that 2-cyclopenten-1-one selectively induces the expression of the 70-kDa HSP (HSP70) in human cells, through cycloheximide-sensitive activation of heat shock transcription factor 1 (HSF1).	Cycloheximide	124-137	heat shock transcription factor 1	Homo sapiens	197-201
8940133-6	1996	The decreased abundance of frameshifted Pcy1 mRNA is attributed to increased degradation rather than decreased synthesis, since the mRNAs can be stabilized by treatment of cells with cycloheximide or anisomycin.	Cycloheximide	183-196	uncharacterized protein	Chlamydomonas reinhardtii	40-44
9034205-7	1997	We have also demonstrated, using cycloheximide as a inhibitor of protein synthesis, that the marked increase in LDL-R protein observed in LDL-IC-stimulated THP-1 cells resulted from de novo synthesis of LDL-R protein.	Cycloheximide	33-46	low density lipoprotein receptor	Homo sapiens	112-117
9034205-7	1997	We have also demonstrated, using cycloheximide as a inhibitor of protein synthesis, that the marked increase in LDL-R protein observed in LDL-IC-stimulated THP-1 cells resulted from de novo synthesis of LDL-R protein.	Cycloheximide	33-46	low density lipoprotein receptor	Homo sapiens	203-208
8997270-2	1996	Effects of KGF were dose dependent, were detected within 4 h of treatment, and were blocked by cycloheximide but not by actinomycin D, indicating that de novo protein synthesis mediated the response.	Cycloheximide	95-108	fibroblast growth factor 7	Mus musculus	11-14
8949903-9	1996	Human cyclin B1 protein microinjected into cycloheximide-treated bovine oocytes triggered meiotic resumption.	Cycloheximide	43-56	cyclin B1	Homo sapiens	6-15
8959339-3	1996	The decrease of pRB mRNA is blocked by cycloheximide, suggesting the requirement of ongoing protein synthesis.	Cycloheximide	39-52	RB transcriptional corepressor 1	Homo sapiens	16-19
8985116-1	1996	G0S3 is a member of a set of putative G0/G1 switch regulatory genes (G0S genes) selected by screening cDNA libraries prepared from human blood mononuclear cells cultured for 2 hr with lectin and cycloheximide.	Cycloheximide	195-208	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-4
8985116-8	1996	In freshly isolated cells, both FOS and FOSB mRNAs increase dramatically in response to the protein synthesis inhibitor cycloheximide.	Cycloheximide	120-133	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-35
8985116-8	1996	In freshly isolated cells, both FOS and FOSB mRNAs increase dramatically in response to the protein synthesis inhibitor cycloheximide.	Cycloheximide	120-133	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	40-44
8985116-9	1996	In preincubated cells, the cycloheximide response is decreased, especially in the case of FOSB.	Cycloheximide	27-40	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
21153085-4	1996	Cycloheximide (10 mug/mL) abolished the sodium butyrate-induced increase in CCK-LI content.	Cycloheximide	0-13	cholecystokinin	Homo sapiens	76-79
9025717-7	1996	Retinoic acid caused a rapid up-regulation of beta 1-AR mRNA levels that was blocked by cycloheximide.	Cycloheximide	88-101	adrenoceptor beta 1	Homo sapiens	46-55
9014820-8	1996	Cycloheximide analysis demonstrated that protein synthesis may be required for TNF-alpha-mediated MT-MMP expression on synovial fibroblasts.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	79-88
9014820-8	1996	Cycloheximide analysis demonstrated that protein synthesis may be required for TNF-alpha-mediated MT-MMP expression on synovial fibroblasts.	Cycloheximide	0-13	matrix metallopeptidase 14	Homo sapiens	98-104
9172015-3	1996	In THP-1 cells, the stimulation of IL-1 beta mRNA expression by Y-25510 was suppressed by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	90-103	interleukin 1 beta	Homo sapiens	35-44
9172015-5	1996	In contrast, the stimulation of mRNA expression for IL-6 by Y-25510 was not suppressed by cycloheximide but suppressed by N alpha-p-tosyl-L-phenylalanine chloromethyl ketone (TPCK), an inhibitor of nuclear transcription factor-kappa B (NF-kappa B) activation, in the presence of LPS, suggesting that the stimulation requires NF-kappa activation.	Cycloheximide	90-103	interleukin 6	Homo sapiens	52-56
8994394-5	1996	The effect was time-dependent and was first observed within 12 h and peaked at 24 h. The TGF beta effect was blocked by cycloheximide, while no effect on scleraxis mRNA stability was observed.	Cycloheximide	120-133	transforming growth factor, beta 1	Rattus norvegicus	89-97
8941674-7	1996	Cycloheximide increased basal TN mRNA expression and induced TN mRNA in IL-4-treated fibroblasts, suggesting that repressor protein(s) may regulate transcription of the TN gene.	Cycloheximide	0-13	tenascin C	Homo sapiens	30-32
8941674-7	1996	Cycloheximide increased basal TN mRNA expression and induced TN mRNA in IL-4-treated fibroblasts, suggesting that repressor protein(s) may regulate transcription of the TN gene.	Cycloheximide	0-13	tenascin C	Homo sapiens	61-63
8941674-7	1996	Cycloheximide increased basal TN mRNA expression and induced TN mRNA in IL-4-treated fibroblasts, suggesting that repressor protein(s) may regulate transcription of the TN gene.	Cycloheximide	0-13	interleukin 4	Homo sapiens	72-76
8941674-7	1996	Cycloheximide increased basal TN mRNA expression and induced TN mRNA in IL-4-treated fibroblasts, suggesting that repressor protein(s) may regulate transcription of the TN gene.	Cycloheximide	0-13	tenascin C	Homo sapiens	61-63
9011084-4	1996	Also, LiCl represses the cycloheximide (CHX)-induced accumulation of the ACS2 mRNA.	Cycloheximide	25-38	1-amino-cyclopropane-1-carboxylate synthase 2	Arabidopsis thaliana	73-77
9011084-4	1996	Also, LiCl represses the cycloheximide (CHX)-induced accumulation of the ACS2 mRNA.	Cycloheximide	40-43	1-amino-cyclopropane-1-carboxylate synthase 2	Arabidopsis thaliana	73-77
9027330-2	1996	We have demonstrated that testosterone increases AR protein and binding within 1 h in the ventral prostate of adult rats castrated for 24 h. Cycloheximide administered with testosterone reduces AR and AR mRNA levels.	Cycloheximide	141-154	androgen receptor	Rattus norvegicus	49-51
9027330-2	1996	We have demonstrated that testosterone increases AR protein and binding within 1 h in the ventral prostate of adult rats castrated for 24 h. Cycloheximide administered with testosterone reduces AR and AR mRNA levels.	Cycloheximide	141-154	androgen receptor	Rattus norvegicus	194-196
9027330-4	1996	c-fos mRNA levels were decreased 1 h after testosterone treatment in the ventral prostate, whereas they were increased in cycloheximide alone or cycloheximide-testosterone treated groups as compared to vehicle control.	Cycloheximide	145-158	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
9027330-5	1996	c-fos protein was also increased in the testosterone-cycloheximide treated group as compared to testosterone alone or cycloheximide alone groups at 1 h. By 3 h, the tissue recovers from the inhibitory effect of cycloheximide as evidenced by restoration of AR and an increase in AR mRNA levels.	Cycloheximide	53-66	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
9027330-5	1996	c-fos protein was also increased in the testosterone-cycloheximide treated group as compared to testosterone alone or cycloheximide alone groups at 1 h. By 3 h, the tissue recovers from the inhibitory effect of cycloheximide as evidenced by restoration of AR and an increase in AR mRNA levels.	Cycloheximide	53-66	androgen receptor	Rattus norvegicus	256-258
9027330-5	1996	c-fos protein was also increased in the testosterone-cycloheximide treated group as compared to testosterone alone or cycloheximide alone groups at 1 h. By 3 h, the tissue recovers from the inhibitory effect of cycloheximide as evidenced by restoration of AR and an increase in AR mRNA levels.	Cycloheximide	53-66	androgen receptor	Rattus norvegicus	278-280
9027330-5	1996	c-fos protein was also increased in the testosterone-cycloheximide treated group as compared to testosterone alone or cycloheximide alone groups at 1 h. By 3 h, the tissue recovers from the inhibitory effect of cycloheximide as evidenced by restoration of AR and an increase in AR mRNA levels.	Cycloheximide	118-131	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
9027330-6	1996	At this time c-fos protein levels were reduced after treatment with cycloheximide and testosterone and c-fos mRNA levels were comparable to the controls.	Cycloheximide	68-81	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	13-18
8939918-4	1996	Here we demonstrate that cat-1 is a classic delayed early growth response gene in the regenerating liver, since induction of its expression is sensitive to cycloheximide, indicating that protein synthesis is required.	Cycloheximide	156-169	solute carrier family 7 member 1	Rattus norvegicus	25-30
8939918-13	1996	Treatment of rats with cycloheximide superinduces the level of the 7.9-kb cat-1 mRNA in the kidney, spleen, and brain, but not in the liver, suggesting that cell type-specific labile factors are involved in its regulation.	Cycloheximide	23-36	solute carrier family 7 member 1	Rattus norvegicus	74-79
8910434-6	1996	The induction of IRF-1 mRNA by IFN-gamma in HT-29 cells reaches a maximum at 6 h and is superinduced by cycloheximide.	Cycloheximide	104-117	interferon regulatory factor 1	Homo sapiens	17-22
8910434-6	1996	The induction of IRF-1 mRNA by IFN-gamma in HT-29 cells reaches a maximum at 6 h and is superinduced by cycloheximide.	Cycloheximide	104-117	interferon gamma	Homo sapiens	31-40
8910434-7	1996	Four mRNA species for BGP are induced by IFN-gamma, the major band of which is inhibited by cycloheximide.	Cycloheximide	92-105	CEA cell adhesion molecule 1	Homo sapiens	22-25
8903482-6	1996	Pre-treatment with either actinomycin D or cycloheximide inhibited the induction of MnSOD mRNA by OK432.	Cycloheximide	43-56	superoxide dismutase 2	Homo sapiens	84-89
8981419-0	1996	Cycloheximide inhibits kainic acid-induced GAP-43 mRNA in dentate granule cells in rats.	Cycloheximide	0-13	growth associated protein 43	Rattus norvegicus	43-49
8981419-2	1996	To determine whether this effect was dependent on the synthesis of proteins activated under these experimental conditions we examined the effect of cycloheximide, a protein synthesis inhibitor, on kainic acid-induced GAP-43 mRNA.	Cycloheximide	148-161	growth associated protein 43	Rattus norvegicus	217-223
8981419-3	1996	Cycloheximide, injected s.c. 2 h but not 8 h after kainic acid, markedly reduced the increased expression of GAP-43 mRNA in granule cells.	Cycloheximide	0-13	growth associated protein 43	Rattus norvegicus	109-115
8981458-5	1996	This long-term SNP-induced increase in PS2 at high Istim was reduced by pretreatment with cycloheximide (5 mg kg-1, i.p.).	Cycloheximide	90-103	trefoil factor 1	Rattus norvegicus	39-42
8910434-7	1996	Four mRNA species for BGP are induced by IFN-gamma, the major band of which is inhibited by cycloheximide.	Cycloheximide	92-105	interferon gamma	Homo sapiens	41-50
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	0-13	jun proto-oncogene	Mus musculus	91-96
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	0-13	jun B proto-oncogene	Mus musculus	98-103
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	0-13	transformation related protein 53, pseudogene	Mus musculus	117-120
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	0-13	unconventional SNARE in the ER 1 homolog (S. cerevisiae)	Mus musculus	136-139
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	15-18	jun proto-oncogene	Mus musculus	91-96
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	15-18	jun B proto-oncogene	Mus musculus	98-103
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	15-18	transformation related protein 53, pseudogene	Mus musculus	117-120
9042210-5	1996	Cycloheximide (CHX) treatment of the cells resulted in the increase in the mRNA levels for c-jun, jun B, krox 24 and p53 in the Y-8 and ED2 cell lines.	Cycloheximide	15-18	unconventional SNARE in the ER 1 homolog (S. cerevisiae)	Mus musculus	136-139
9014756-5	1996	In MDA-MB-231 cells, low concentrations of MMP1 protein were detected in medium from treated cells and was only significantly increased after 24 h but it was inhibited by cycloheximide.	Cycloheximide	171-184	matrix metallopeptidase 1	Homo sapiens	43-47
8944708-11	1996	De novo protein and RNA synthesis were required, since cycloheximide and actinomycin D also inhibited LPS-stimulated TNF-alpha release.	Cycloheximide	55-68	tumor necrosis factor	Rattus norvegicus	117-126
8955877-0	1996	Effect of cycloheximide on the expression of LPS-inducible iNOS, IFN-beta, and IRF-1 genes in J774 macrophages.	Cycloheximide	10-23	toll-like receptor 4	Mus musculus	45-48
8955877-0	1996	Effect of cycloheximide on the expression of LPS-inducible iNOS, IFN-beta, and IRF-1 genes in J774 macrophages.	Cycloheximide	10-23	nitric oxide synthase 2, inducible	Mus musculus	59-63
8955877-0	1996	Effect of cycloheximide on the expression of LPS-inducible iNOS, IFN-beta, and IRF-1 genes in J774 macrophages.	Cycloheximide	10-23	interferon beta 1, fibroblast	Mus musculus	65-73
8955877-0	1996	Effect of cycloheximide on the expression of LPS-inducible iNOS, IFN-beta, and IRF-1 genes in J774 macrophages.	Cycloheximide	10-23	interferon regulatory factor 1	Mus musculus	79-84
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	14-27	nitric oxide synthase 2, inducible	Mus musculus	61-82
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	14-27	nitric oxide synthase 2, inducible	Mus musculus	84-88
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	14-27	interferon regulatory factor 1	Mus musculus	118-147
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	14-27	toll-like receptor 4	Mus musculus	164-167
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	29-32	nitric oxide synthase 2, inducible	Mus musculus	61-82
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	29-32	nitric oxide synthase 2, inducible	Mus musculus	84-88
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	29-32	interferon beta 1, fibroblast	Mus musculus	91-112
8955877-1	1996	The effect of cycloheximide (CHX) on the gene expression for inducible NO synthase (iNOS), interferon (IFN)-beta, and IFN regulatory factor (IRF)-1 was examined in LPS-stimulated J774 macrophages.	Cycloheximide	29-32	interferon regulatory factor 1	Mus musculus	118-147
9014756-7	1996	Treatment with cycloheximide for longer periods produced increased transcripts of MMP1, TGF alpha and EGF-receptor, suggesting the activation of processes for tissue breakdown and subsequent repair may occur on prolonged inhibition of protein synthesis.	Cycloheximide	15-28	matrix metallopeptidase 1	Homo sapiens	82-86
9014756-7	1996	Treatment with cycloheximide for longer periods produced increased transcripts of MMP1, TGF alpha and EGF-receptor, suggesting the activation of processes for tissue breakdown and subsequent repair may occur on prolonged inhibition of protein synthesis.	Cycloheximide	15-28	transforming growth factor alpha	Homo sapiens	88-114
8933170-6	1996	While the enhancing SLO effect on NAT could not be neutralized by the inhibitor of transcription actinomycin D, NAT stimulation by IFN gamma was abolished by actinomycin D and by the inhibitor of translation, cycloheximide.	Cycloheximide	209-222	N-acetyltransferase 1	Rattus norvegicus	112-115
8933170-6	1996	While the enhancing SLO effect on NAT could not be neutralized by the inhibitor of transcription actinomycin D, NAT stimulation by IFN gamma was abolished by actinomycin D and by the inhibitor of translation, cycloheximide.	Cycloheximide	209-222	interferon gamma	Rattus norvegicus	131-140
8874201-8	1996	IL-13 production was blocked by actinomycin D and cycloheximide and conditions leading to IL-13 release also lead to the induction of IL-13 mRNA.	Cycloheximide	50-63	interleukin 13	Homo sapiens	0-5
8912727-7	1996	We have found that, when the HaCaT cells were sensitized by the translation inhibitor cycloheximide, TNF-alpha induced apoptosis, as evidenced by nuclear disintegration, DNA fragmentation ("DNA laddering"), and the appearance of soluble DNA/histone complexes.	Cycloheximide	86-99	tumor necrosis factor	Homo sapiens	101-110
8910368-9	1996	Cycloheximide and actinomycin D, which respectively inhibited protein and RNA synthesis, suppressed basal and PGE2 induction of MMP-9 production by HSB.2 cells.	Cycloheximide	0-13	matrix metallopeptidase 9	Homo sapiens	128-133
8875957-8	1996	Dexamethasone, actinomycin D, and cycloheximide abolished the effect of IL-1beta on HODEs biosynthesis.	Cycloheximide	34-47	interleukin 1 beta	Homo sapiens	72-80
8948504-3	1996	Inhibitors of RNA and protein synthesis (actinomycin D and cycloheximide, respectively) completely blocked TNF-alpha-stimulated PGF2 alpha production.	Cycloheximide	59-72	tumor necrosis factor	Bos taurus	107-116
8900184-12	1996	In addition, MAPKK6 was activated strongly by tumor necrosis factor-alpha, H2O2, and okadaic acid and moderately by cycloheximide in KB cells.	Cycloheximide	116-129	mitogen-activated protein kinase kinase 6	Mus musculus	13-19
8943275-3	1996	We now report that 2-cyclopenten-1-one selectively induces the expression of the 70-kDa HSP (HSP70) in human cells, through cycloheximide-sensitive activation of heat shock transcription factor 1 (HSF1).	Cycloheximide	124-137	heat shock protein family A (Hsp70) member 4	Homo sapiens	88-91
8943275-3	1996	We now report that 2-cyclopenten-1-one selectively induces the expression of the 70-kDa HSP (HSP70) in human cells, through cycloheximide-sensitive activation of heat shock transcription factor 1 (HSF1).	Cycloheximide	124-137	heat shock protein family A (Hsp70) member 4	Homo sapiens	93-98
8910396-5	1996	The incorporation of preformed alphagamma and betagamma complexes into secreted fibrinogen did not require concurrent protein synthesis, as shown by experiments employing cycloheximide.	Cycloheximide	171-184	fibrinogen beta chain	Homo sapiens	80-90
8903323-5	1996	Whereas cycloheximide and actinomycin D both inhibited BK-induced IL-1beta synthesis, results from Northern blot and nuclear run-on assays suggested that BK acted primarily at the transcription level which led to the accumulation of IL-1beta message in stimulated cells.	Cycloheximide	8-21	kininogen 1	Homo sapiens	55-57
8903323-5	1996	Whereas cycloheximide and actinomycin D both inhibited BK-induced IL-1beta synthesis, results from Northern blot and nuclear run-on assays suggested that BK acted primarily at the transcription level which led to the accumulation of IL-1beta message in stimulated cells.	Cycloheximide	8-21	interleukin 1 beta	Homo sapiens	66-74
8892646-0	1996	Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology.	Cycloheximide	154-167	heat shock protein 90 alpha family class A member 1	Homo sapiens	10-31
8892646-0	1996	Increased heat shock protein 90 (hsp90) expression leads to increased apoptosis in the monoblastoid cell line U937 following induction with TNF-alpha and cycloheximide: a possible role in immunopathology.	Cycloheximide	154-167	heat shock protein 90 alpha family class A member 1	Homo sapiens	33-38
8892646-5	1996	We showed that apoptosis does occur in the monoblast/mononuclear phagocyte lineage, and that it could be induced in vitro by serum deprivation, UV light, or TNF-alpha in combination with cycloheximide (cx).	Cycloheximide	202-204	tumor necrosis factor	Homo sapiens	157-166
8892646-7	1996	This was complemented by the finding that reduced hsp90 levels correlate with protection against apoptosis in the TNF-alpha- and cx-treated cells.	Cycloheximide	129-131	heat shock protein 90 alpha family class A member 1	Homo sapiens	50-55
8892648-6	1996	The enhancement was first observed at 6 h and reached a plateau at 12 to 18 h. The effect of IL-5 was abolished in the presence of cycloheximide or actinomycin D.	Cycloheximide	131-144	interleukin 5	Homo sapiens	93-97
8914021-9	1996	Stimulation of TGF-beta 1 synthesis by IL-1 beta in D-glucose primed cells was inhibited by cycloheximide but not by actinomycin-D.	Cycloheximide	92-105	transforming growth factor beta 1	Homo sapiens	15-25
8914021-9	1996	Stimulation of TGF-beta 1 synthesis by IL-1 beta in D-glucose primed cells was inhibited by cycloheximide but not by actinomycin-D.	Cycloheximide	92-105	interleukin 1 beta	Homo sapiens	39-48
8938409-2	1996	We have used liquid callus cultures and a cycloheximide-synchronized suspension culture of Arabidopsis to investigate changes in cyclin transcript levels in response to exogenous auxin, cytokinin, and nutrients, and during the cell cycle.	Cycloheximide	42-55	cyclin	Arabidopsis thaliana	129-135
8824209-8	1996	Inhibition of translation, by the addition of cycloheximide, slows the nucleolytic degradation of the OLE1 mRNA and blocks the unsaturated fatty acid-triggered reduction in its half-life.	Cycloheximide	46-59	stearoyl-CoA 9-desaturase	Saccharomyces cerevisiae S288C	102-106
8912685-5	1996	Preincubation of FAO cells with cycloheximide prevented the oleate-mediated induction of L-FABP mRNA, showing that protein synthesis was required for the action of fatty acids.	Cycloheximide	32-45	fatty acid binding protein 1	Rattus norvegicus	89-95
8798777-8	1996	Furthermore, cycloheximide blocked the rise in beta1-subunit mRNA levels.	Cycloheximide	13-26	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	47-52
8895509-4	1996	Cycloheximide blocked the estrogen effect implying that estrogen induces synthesis of an unidentified estrogen-responsive protein(s) that then result in the elevation of BRCA1 and BRCA2 mRNAs.	Cycloheximide	0-13	BRCA1 DNA repair associated	Homo sapiens	170-175
8895509-4	1996	Cycloheximide blocked the estrogen effect implying that estrogen induces synthesis of an unidentified estrogen-responsive protein(s) that then result in the elevation of BRCA1 and BRCA2 mRNAs.	Cycloheximide	0-13	BRCA2 DNA repair associated	Homo sapiens	180-185
8878553-5	1996	Inhibition of protein synthesis by cycloheximide demonstrated increased p21 protein half-life in the presence of LC in mutant p53 containing cells.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	72-75
8878553-5	1996	Inhibition of protein synthesis by cycloheximide demonstrated increased p21 protein half-life in the presence of LC in mutant p53 containing cells.	Cycloheximide	35-48	tumor protein p53	Homo sapiens	126-129
8871604-3	1996	The inhibition of protein synthesis with cycloheximide (CXM) diminished the down-regulation of CD38 induced by IL4.	Cycloheximide	41-54	CD38 molecule	Homo sapiens	95-99
8871604-3	1996	The inhibition of protein synthesis with cycloheximide (CXM) diminished the down-regulation of CD38 induced by IL4.	Cycloheximide	41-54	interleukin 4	Homo sapiens	111-114
8871604-3	1996	The inhibition of protein synthesis with cycloheximide (CXM) diminished the down-regulation of CD38 induced by IL4.	Cycloheximide	56-59	CD38 molecule	Homo sapiens	95-99
8871604-3	1996	The inhibition of protein synthesis with cycloheximide (CXM) diminished the down-regulation of CD38 induced by IL4.	Cycloheximide	56-59	interleukin 4	Homo sapiens	111-114
8905323-0	1996	Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice.	Cycloheximide	64-77	prodynorphin	Mus musculus	27-44
8905323-1	1996	The effects of systemic or intracerebroventricular injection of dynorphin A-(1-13), a kappa-selective opioid receptor agonist, on cycloheximide-induced amnesia were investigated by using a step-down-type passive avoidance task in mice.	Cycloheximide	130-143	prodynorphin	Mus musculus	64-81
8905323-4	1996	before training or retention tests markedly inhibited the cycloheximide (30 mg/kg, s.c.)-induced shortening of step-down latency, indicating antiamnesic effects of dynorphin A-(1-13).	Cycloheximide	58-71	prodynorphin	Mus musculus	164-181
8798747-11	1996	The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide.	Cycloheximide	171-184	heat shock transcription factor 1	Homo sapiens	95-99
8798747-11	1996	The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide.	Cycloheximide	171-184	heat shock protein family A (Hsp70) member 1A	Homo sapiens	118-123
8828465-6	1996	Cycloheximide induced PDGF-B transcripts and decreased the effect of TGF beta 1.	Cycloheximide	0-13	platelet derived growth factor subunit B	Rattus norvegicus	22-28
8828465-6	1996	Cycloheximide induced PDGF-B transcripts and decreased the effect of TGF beta 1.	Cycloheximide	0-13	transforming growth factor, beta 1	Rattus norvegicus	69-79
8828493-1	1996	The effects of a calcium channel blocker (nifedipine) and a protein synthesis inhibitor (cycloheximide) on the induction of four steroidogenic cytochromes P450 (CYP11B2, CYP11B1, CYP11A1, and CYP21A1) by an elevated extracellular potassium concentration were studied in cultured rat zona glomerulosa cells.	Cycloheximide	89-102	cytochrome P450, family 11, subfamily b, polypeptide 2	Rattus norvegicus	161-168
8828493-1	1996	The effects of a calcium channel blocker (nifedipine) and a protein synthesis inhibitor (cycloheximide) on the induction of four steroidogenic cytochromes P450 (CYP11B2, CYP11B1, CYP11A1, and CYP21A1) by an elevated extracellular potassium concentration were studied in cultured rat zona glomerulosa cells.	Cycloheximide	89-102	cytochrome P450, family 11, subfamily a, polypeptide 1	Rattus norvegicus	179-186
8841418-9	1996	Cycloheximide at 3.6 microM slightly decreased IGFBP-6 transcripts but did not prevent the stimulatory effect of retinoic acid.	Cycloheximide	0-13	insulin-like growth factor binding protein 6	Rattus norvegicus	47-54
8943730-7	1996	The effects of long-term incubation with SCF, but not the short-term effects, were blocked by cycloheximide.	Cycloheximide	94-107	KIT ligand	Rattus norvegicus	41-44
8833917-7	1996	Cycloheximide prevented the ROI-associated increases in VEGF mRNA.	Cycloheximide	0-13	vascular endothelial growth factor A	Homo sapiens	56-60
8943778-8	1996	In addition, cycloheximide, used to prevent protein synthesis, abolished the inhibitory effects of dexamethasone on steady-state CCK mRNA levels.	Cycloheximide	13-26	cholecystokinin	Rattus norvegicus	129-132
8858921-6	1996	Stimulatory effects of insulin on [3H]-STX binding and veratridine-induced 22Na+ influx were nullified by simultaneous treatment with either 5,6-dichlorobenzimidazole riboside, an inhibitor of RNA synthesis, or cycloheximide, an inhibitor of protein synthesis, whereas insulin treatment did not appreciably increase the level of mRNA encoding the Na+ channel alpha-subunit.	Cycloheximide	211-224	insulin	Bos taurus	23-30
8805627-3	1996	Nuclear expression of phosphorylated STAT1 alpha was abrogated by co-incubation of anti-Ig-treated B cells with the protein synthesis inhibitor cycloheximide (CHX), with the protein kinase inhibitor H-7, or with the immunosuppressive drug rapamycin.	Cycloheximide	144-157	signal transducer and activator of transcription 1	Homo sapiens	37-42
8805627-3	1996	Nuclear expression of phosphorylated STAT1 alpha was abrogated by co-incubation of anti-Ig-treated B cells with the protein synthesis inhibitor cycloheximide (CHX), with the protein kinase inhibitor H-7, or with the immunosuppressive drug rapamycin.	Cycloheximide	159-162	signal transducer and activator of transcription 1	Homo sapiens	37-42
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 10	Mus musculus	66-71
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	134-138
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	229-233
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 10	Mus musculus	254-259
8703029-6	1996	The addition of cycloheximide to BMMC after stimulation with KL + IL-10 with or without IL-1beta increased the levels of steady-state IL-6 mRNA compared to levels in cells without drug, indicating that in addition to stimulating IL-6 transcription, KL + IL-10 induces a protein factor that destabilizes IL-6 mRNA.	Cycloheximide	16-29	interleukin 6	Mus musculus	229-233
8790349-11	1996	Additionally, the activation of SCD1 mRNA by clofibrate was inhibited 77% by cycloheximide administration.	Cycloheximide	77-90	stearoyl-Coenzyme A desaturase 1	Mus musculus	32-36
8853343-6	1996	This augmentation is correlated with a threefold increase in the endothelial constitutive NO synthase (ecNOS) transcript, which is time dependent and maximal at 24 h. The CsA-induced increase in ecNOS mRNA expression was blocked by actinomycin D but unaltered by cycloheximide.	Cycloheximide	263-276	nitric oxide synthase 3	Bos taurus	103-108
8853343-6	1996	This augmentation is correlated with a threefold increase in the endothelial constitutive NO synthase (ecNOS) transcript, which is time dependent and maximal at 24 h. The CsA-induced increase in ecNOS mRNA expression was blocked by actinomycin D but unaltered by cycloheximide.	Cycloheximide	263-276	nitric oxide synthase 3	Bos taurus	195-200
8886420-14	1996	Experiments using cycloheximide demonstrated that this synergistic effect of IL-13 and IL-1 alpha on IL-8 secretion was not through de novo protein synthesis.	Cycloheximide	18-31	interleukin 13	Homo sapiens	77-82
8886420-14	1996	Experiments using cycloheximide demonstrated that this synergistic effect of IL-13 and IL-1 alpha on IL-8 secretion was not through de novo protein synthesis.	Cycloheximide	18-31	interleukin 1 alpha	Homo sapiens	87-97
8886420-14	1996	Experiments using cycloheximide demonstrated that this synergistic effect of IL-13 and IL-1 alpha on IL-8 secretion was not through de novo protein synthesis.	Cycloheximide	18-31	C-X-C motif chemokine ligand 8	Homo sapiens	101-105
8756574-9	1996	Cycloheximide (20 micrograms/ml) caused a parallel disappearance of cellular GHR and secreted GHBP with a half-life of about 50 min, but increased GHR messenger RNA expression (superinduction).	Cycloheximide	0-13	growth hormone receptor	Oryctolagus cuniculus	77-80
8756574-9	1996	Cycloheximide (20 micrograms/ml) caused a parallel disappearance of cellular GHR and secreted GHBP with a half-life of about 50 min, but increased GHR messenger RNA expression (superinduction).	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	94-98
8756574-9	1996	Cycloheximide (20 micrograms/ml) caused a parallel disappearance of cellular GHR and secreted GHBP with a half-life of about 50 min, but increased GHR messenger RNA expression (superinduction).	Cycloheximide	0-13	growth hormone receptor	Oryctolagus cuniculus	147-150
8814273-5	1996	Burkitt lymphoma (BL)-derived, Bcl-2- B cells were induced into apoptosis either by the Ca(2+)-ionophore ionomycin or by the inhibitor of protein synthesis cycloheximide.	Cycloheximide	156-169	BCL2 apoptosis regulator	Homo sapiens	31-36
8814146-3	1996	The mechanism of upregulation by IL-1 beta was studied further with respect to proto-oncogene expression and under the treatment of cycloheximide and actinomycin D.	Cycloheximide	132-145	interleukin 1 beta	Homo sapiens	33-42
8816904-7	1996	Cycloheximide or actinomycin D markedly reduced the protection offered by IGF-I.	Cycloheximide	0-13	insulin-like growth factor 1	Mus musculus	74-79
9064318-10	1996	The influence of H/R on PMN transmigration was protein synthesis-dependent (> 80% decreased in the presence of cycloheximide) and could be inhibited by addition of functionally inhibitory antibodies to the PMN beta 2 integrin CD11b/18 (> 80% attenuated) and to CD47 (> 90% decreased compared to control).	Cycloheximide	114-127	integrin subunit alpha M	Homo sapiens	229-234
8819536-5	1996	Cycloheximide 10(-6) M and actinomycin 2 micrograms/ml abolished IL-5 production and mRNA expression.	Cycloheximide	0-13	interleukin 5	Mus musculus	65-69
8709223-8	1996	Block of protein synthesis does not abolish transcription: treatment with cycloheximide greatly induces stpC/tip mRNA levels.	Cycloheximide	74-87	integrin alpha FG-GAP repeat containing 1	Homo sapiens	109-112
8811088-4	1996	This reverse two-hybrid system utilizes a yeast strain which is resistant to cycloheximide due to the presence of a mutant cyh2 gene.	Cycloheximide	77-90	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	123-127
8811088-6	1996	Expression of the wild-type Gal4 protein is sufficient to restore growth sensitivity to cycloheximide.	Cycloheximide	88-101	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	28-32
8811088-7	1996	Growth sensitivity towards cycloheximide is also restored by the coexpression of the avian c-Rel protein and its I kappa B alpha counterpart, p40, as Gal4 fusion proteins.	Cycloheximide	27-40	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	150-154
8811088-8	1996	Restoration of growth sensitivity towards cycloheximide requires the association of c-Rel and p40 at the Gal1 promoter and correlates with the ability of the c-Rel/p40 interaction to activate expression from the Gal1 promoter.	Cycloheximide	42-55	galactokinase	Saccharomyces cerevisiae S288C	105-109
8811088-8	1996	Restoration of growth sensitivity towards cycloheximide requires the association of c-Rel and p40 at the Gal1 promoter and correlates with the ability of the c-Rel/p40 interaction to activate expression from the Gal1 promoter.	Cycloheximide	42-55	galactokinase	Saccharomyces cerevisiae S288C	212-216
8902879-3	1996	Both actinomycin D and cycloheximide inhibited the TNF-alpha mediated increase in L-arginine transport, indicating that de novo RNA and protein synthesis were required.	Cycloheximide	23-36	tumor necrosis factor	Bos taurus	51-60
8795714-5	1996	The kinetics of induction of factor H mRNA were slow, with the response reaching near maximal levels at 24 h. The increase in factor H mRNA by IFN-gamma was dependent on protein synthesis, as cycloheximide abolished the response.	Cycloheximide	192-205	interferon gamma	Mus musculus	143-152
8874185-4	1996	Translational inhibition by cycloheximide (CHX) significantly increased GM-CSF mRNA accumulation and half-life by three-fold in activated cord MNC, but had a minimal effect in activated adult MNC as compared with PMA + PHA alone.	Cycloheximide	28-41	colony stimulating factor 2	Homo sapiens	72-78
8874185-4	1996	Translational inhibition by cycloheximide (CHX) significantly increased GM-CSF mRNA accumulation and half-life by three-fold in activated cord MNC, but had a minimal effect in activated adult MNC as compared with PMA + PHA alone.	Cycloheximide	43-46	colony stimulating factor 2	Homo sapiens	72-78
8863818-7	1996	Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect.	Cycloheximide	138-151	angiotensinogen	Rattus norvegicus	0-6
8863818-7	1996	Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect.	Cycloheximide	138-151	angiotensin II receptor, type 1a	Rattus norvegicus	15-20
8863818-7	1996	Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect.	Cycloheximide	138-151	angiotensinogen	Rattus norvegicus	169-175
8863818-7	1996	Ang II-induced AT1-R mRNA destabilization is prevented by pretreatment with transcriptional inhibitors or the protein synthesis inhibitor cycloheximide, suggesting that Ang II-induced AT1-R mRNA destabilization requires the induction of an unknown factor or factors that are postulated to mediate this effect.	Cycloheximide	138-151	angiotensin II receptor, type 1a	Rattus norvegicus	184-189
8855240-4	1996	VDR half-life studies performed with cycloheximide-translational blocked rat osteoblast-like ROS 17/2.8 cells demonstrated that, in the absence of ligand, VDR levels rapidly decreased.	Cycloheximide	37-50	vitamin D receptor	Rattus norvegicus	0-3
8798494-2	1996	The homologous zinc finger transcription factors Pdr1p and Pdr3p both elevate resistance to many drugs, including cycloheximide.	Cycloheximide	114-127	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	49-54
8798494-2	1996	The homologous zinc finger transcription factors Pdr1p and Pdr3p both elevate resistance to many drugs, including cycloheximide.	Cycloheximide	114-127	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	59-64
8798494-3	1996	This elevation in cycloheximide tolerance only occurs in the presence of an intact copy of the PDR5 gene that encodes a plasma membrane-localized ATP binding cassette transporter protein.	Cycloheximide	18-31	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	95-99
8798446-6	1996	The increase in PGHS-2 mRNA levels is partially blocked by cycloheximide, suggesting de novo synthesis of an intermediate protein may be required for a maximal leukoregulin response.	Cycloheximide	59-72	prostaglandin-endoperoxide synthase 2	Homo sapiens	16-22
8804426-3	1996	Using the protein synthesis inhibitor cycloheximide and the antioxidant PDTC, that have an opposite effect on NF-kappa B and AP-1 activation, we showed that uPA mRNA induction by TNF-alpha and PMA in the A549 cell line is mainly due to NF-kappa B activation.	Cycloheximide	38-51	nuclear factor kappa B subunit 1	Homo sapiens	110-120
8804426-3	1996	Using the protein synthesis inhibitor cycloheximide and the antioxidant PDTC, that have an opposite effect on NF-kappa B and AP-1 activation, we showed that uPA mRNA induction by TNF-alpha and PMA in the A549 cell line is mainly due to NF-kappa B activation.	Cycloheximide	38-51	proline rich acidic protein 1	Homo sapiens	157-160
8804426-3	1996	Using the protein synthesis inhibitor cycloheximide and the antioxidant PDTC, that have an opposite effect on NF-kappa B and AP-1 activation, we showed that uPA mRNA induction by TNF-alpha and PMA in the A549 cell line is mainly due to NF-kappa B activation.	Cycloheximide	38-51	tumor necrosis factor	Homo sapiens	179-188
8804426-3	1996	Using the protein synthesis inhibitor cycloheximide and the antioxidant PDTC, that have an opposite effect on NF-kappa B and AP-1 activation, we showed that uPA mRNA induction by TNF-alpha and PMA in the A549 cell line is mainly due to NF-kappa B activation.	Cycloheximide	38-51	nuclear factor kappa B subunit 1	Homo sapiens	236-246
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	Cycloheximide	24-37	interleukin 6	Mus musculus	141-145
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	Cycloheximide	24-37	interleukin 1 beta	Mus musculus	224-232
8703029-4	1996	The exposure of BMMC to cycloheximide 0.5 h before the addition of the three exogenous cytokines inhibited by approximately 50% the level of IL-6 mRNA generated but did not inhibit the effects of KL + IL-10, indicating that IL-1beta induces the synthesis of a protein that stabilizes IL-6 mRNA.	Cycloheximide	24-37	interleukin 6	Mus musculus	284-288
8806678-8	1996	In addition, CrmA can block cycloheximide-induced amino-terminal processing of I kappa B-alpha in spleen cells transformed by wild-type v-Rel.	Cycloheximide	28-41	NFKB inhibitor alpha	Gallus gallus	79-94
8879343-9	1996	Thus, IL-1 beta controls iNOS gene expression at the transcriptional level, and an intermediate labile protein, whose synthesis is inhibited by cycloheximide, is required for IL-1 beta stimulated induction of iNOS mRNA transcription in WKY cells but not in SHR.	Cycloheximide	144-157	interleukin 1 beta	Rattus norvegicus	175-184
8879343-9	1996	Thus, IL-1 beta controls iNOS gene expression at the transcriptional level, and an intermediate labile protein, whose synthesis is inhibited by cycloheximide, is required for IL-1 beta stimulated induction of iNOS mRNA transcription in WKY cells but not in SHR.	Cycloheximide	144-157	nitric oxide synthase 2	Rattus norvegicus	209-213
8914344-9	1996	Following exposure of cells to combinations of drugs and IFN alpha, the percentage inhibition for Class I and ICAM-1 in the case of SKV14 and 5367 lines in the presence of cycloheximide (10 micrograms/mL) were 82%, 85% and 57%, 45% respectively.	Cycloheximide	172-185	interferon alpha 1	Homo sapiens	57-66
8914344-9	1996	Following exposure of cells to combinations of drugs and IFN alpha, the percentage inhibition for Class I and ICAM-1 in the case of SKV14 and 5367 lines in the presence of cycloheximide (10 micrograms/mL) were 82%, 85% and 57%, 45% respectively.	Cycloheximide	172-185	intercellular adhesion molecule 1	Homo sapiens	110-116
8952883-5	1996	In the presence of elastin peptides lymphocytes show increased proliferation and increased production of an elastase type serine protease apparently identical to PMN-elastase, inhibited by cycloheximide and by anti-PMN elastase antibodies.	Cycloheximide	189-202	elastin	Homo sapiens	19-26
8952883-5	1996	In the presence of elastin peptides lymphocytes show increased proliferation and increased production of an elastase type serine protease apparently identical to PMN-elastase, inhibited by cycloheximide and by anti-PMN elastase antibodies.	Cycloheximide	189-202	coagulation factor II, thrombin	Homo sapiens	122-137
8952883-5	1996	In the presence of elastin peptides lymphocytes show increased proliferation and increased production of an elastase type serine protease apparently identical to PMN-elastase, inhibited by cycloheximide and by anti-PMN elastase antibodies.	Cycloheximide	189-202	elastase, neutrophil expressed	Homo sapiens	162-174
8756533-7	1996	PTHrP mRNA levels were also induced by cycloheximide, another feature common to early response genes.	Cycloheximide	39-52	parathyroid hormone-like hormone	Rattus norvegicus	0-5
8756574-10	1996	Indeed, 4 h after removal of cycloheximide, GHR and GHBP were increased by 181% and 369%, respectively, compared to the control value.	Cycloheximide	29-42	growth hormone receptor	Oryctolagus cuniculus	44-47
8756574-10	1996	Indeed, 4 h after removal of cycloheximide, GHR and GHBP were increased by 181% and 369%, respectively, compared to the control value.	Cycloheximide	29-42	growth hormone receptor	Homo sapiens	52-56
8756579-2	1996	By Northern blotting of total RNA isolated from PD cells that had been stimulated in the presence of cycloheximide (10 micrograms/ml), PT cell-conditioned medium was shown to induce a significant increase in the expression of the early response gene, c-fos, above both PD cell-conditioned and nonconditioned medium control levels (P < 0.05).	Cycloheximide	101-114	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	251-256
8949656-7	1996	Pretreatment with cycloheximide blocked IL 1 beta induced inhibition of ACh stimulated jejunal contraction, suggesting that a newly synthesised protein was involved in the effect.	Cycloheximide	18-31	interleukin 1 beta	Rattus norvegicus	40-49
8816919-6	1996	Transforming growth factor beta caused a sustained 5- to 7-fold increase in the accumulation of PAI-1 mRNA that was maximal after 2 to 4 h. The IL-1 induction of PAI-1 was inhibited by actinomycin D, but not by cycloheximide.	Cycloheximide	211-224	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	96-101
8816919-6	1996	Transforming growth factor beta caused a sustained 5- to 7-fold increase in the accumulation of PAI-1 mRNA that was maximal after 2 to 4 h. The IL-1 induction of PAI-1 was inhibited by actinomycin D, but not by cycloheximide.	Cycloheximide	211-224	interleukin 1 complex	Mus musculus	144-148
8816919-6	1996	Transforming growth factor beta caused a sustained 5- to 7-fold increase in the accumulation of PAI-1 mRNA that was maximal after 2 to 4 h. The IL-1 induction of PAI-1 was inhibited by actinomycin D, but not by cycloheximide.	Cycloheximide	211-224	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	162-167
8816927-4	1996	The IL-1-mediated MeAIB uptake is independent of protein synthesis, since cycloheximide (CHX) did not inhibit MeAIB uptake, and characterized by a decrease in the Michaelis constant K(m) (0.147 vs. 0.270 mmol/l, IL-1 vs. control) and a slight increase in maximal velocity (Vmax) (4.59 vs. 3.89 nmol/mg prot/10 min, IL-1 vs. control).	Cycloheximide	74-87	interleukin 1 beta	Homo sapiens	4-8
8816927-4	1996	The IL-1-mediated MeAIB uptake is independent of protein synthesis, since cycloheximide (CHX) did not inhibit MeAIB uptake, and characterized by a decrease in the Michaelis constant K(m) (0.147 vs. 0.270 mmol/l, IL-1 vs. control) and a slight increase in maximal velocity (Vmax) (4.59 vs. 3.89 nmol/mg prot/10 min, IL-1 vs. control).	Cycloheximide	89-92	interleukin 1 beta	Homo sapiens	4-8
8830798-6	1996	The GHSA-induced chemokine secretion by hRPE was almost completely inhibited by actinomycin D and cycloheximide, suggesting that de novo mRNA and protein synthesis are necessary for the GHSA-induced IL-8 and MCP-1 production.	Cycloheximide	98-111	ribulose-5-phosphate-3-epimerase	Homo sapiens	40-44
8830798-6	1996	The GHSA-induced chemokine secretion by hRPE was almost completely inhibited by actinomycin D and cycloheximide, suggesting that de novo mRNA and protein synthesis are necessary for the GHSA-induced IL-8 and MCP-1 production.	Cycloheximide	98-111	C-X-C motif chemokine ligand 8	Homo sapiens	199-203
8830798-6	1996	The GHSA-induced chemokine secretion by hRPE was almost completely inhibited by actinomycin D and cycloheximide, suggesting that de novo mRNA and protein synthesis are necessary for the GHSA-induced IL-8 and MCP-1 production.	Cycloheximide	98-111	C-C motif chemokine ligand 2	Homo sapiens	208-213
8752129-12	1996	Cycloheximide blocked the effects of dexamethasone on PNMT mRNA expression in NE-rich cells but had little effect in E-rich cells.	Cycloheximide	0-13	phenylethanolamine N-methyltransferase	Bos taurus	54-58
8794894-7	1996	Treatment with anisomycin and cycloheximide also potentiated 0.1 microM 3-MC-induced coumarin 7-hydroxylase activity, induced c-fos and jun-D mRNA expression, and activated AP-1-dependent gene transcription in the hepatocytes.	Cycloheximide	30-43	proto-oncogene c-Fos	Mesocricetus auratus	126-131
8794894-7	1996	Treatment with anisomycin and cycloheximide also potentiated 0.1 microM 3-MC-induced coumarin 7-hydroxylase activity, induced c-fos and jun-D mRNA expression, and activated AP-1-dependent gene transcription in the hepatocytes.	Cycloheximide	30-43	transcription factor jun-D	Mesocricetus auratus	136-141
8695842-3	1996	In M1mycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60), treatment with estrogen and cycloheximide results in induction of ODC transcripts.	Cycloheximide	147-160	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	34-39
8702776-3	1996	In mouse RAW 264.7 macrophages, IGTP mRNA levels were almost undetectable but increased within 1 h of exposure to interferon gamma, peaked at very high levels within 3 h, and remained at high levels to at least 48 h; pretreatment of the cells with cycloheximide blocked the majority of mRNA accumulation.	Cycloheximide	248-261	interferon gamma induced GTPase	Mus musculus	32-36
8695842-3	1996	In M1mycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60), treatment with estrogen and cycloheximide results in induction of ODC transcripts.	Cycloheximide	147-160	interleukin 6	Homo sapiens	96-109
8695842-3	1996	In M1mycer cells, when endogenous c-myc expression has been suppressed following stimulation by interleukin-6 (IL-60), treatment with estrogen and cycloheximide results in induction of ODC transcripts.	Cycloheximide	147-160	ornithine decarboxylase 1	Homo sapiens	185-188
8754788-5	1996	A maximal increase of 2.5-fold was observed with 100 nM Ang II in an actinomycin- and cycloheximide-dependent process.	Cycloheximide	86-99	angiotensinogen	Rattus norvegicus	56-62
8759721-3	1996	Cell activation resulted in a delayed induction of STAT DNA-binding activity, which was sustained for several days, was composed predominantly of Stat1 and Stat3, and was blocked by cycloheximide and actinomycin D.	Cycloheximide	182-195	signal transducer and activator of transcription 1	Homo sapiens	146-151
8759721-3	1996	Cell activation resulted in a delayed induction of STAT DNA-binding activity, which was sustained for several days, was composed predominantly of Stat1 and Stat3, and was blocked by cycloheximide and actinomycin D.	Cycloheximide	182-195	signal transducer and activator of transcription 3	Homo sapiens	156-161
8706937-2	1996	We have found that treatment of MALME-3M human melanoma cells for 6 h with 10 micrograms/ml cycloheximide (CHX) increases ODC and SSAT mRNA 6-9-fold.	Cycloheximide	92-105	ornithine decarboxylase 1	Homo sapiens	122-125
8706937-2	1996	We have found that treatment of MALME-3M human melanoma cells for 6 h with 10 micrograms/ml cycloheximide (CHX) increases ODC and SSAT mRNA 6-9-fold.	Cycloheximide	92-105	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	130-134
8706937-2	1996	We have found that treatment of MALME-3M human melanoma cells for 6 h with 10 micrograms/ml cycloheximide (CHX) increases ODC and SSAT mRNA 6-9-fold.	Cycloheximide	107-110	ornithine decarboxylase 1	Homo sapiens	122-125
8706937-2	1996	We have found that treatment of MALME-3M human melanoma cells for 6 h with 10 micrograms/ml cycloheximide (CHX) increases ODC and SSAT mRNA 6-9-fold.	Cycloheximide	107-110	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	130-134
8706937-3	1996	When cells containing CHX-induced SSAT mRNA were washed and post-incubated for an additional 6 h in drug free media, enzyme activity increased only 2-fold above that in untreated cells despite the > 6-fold increase in accumulated mRNA.	Cycloheximide	22-25	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	34-38
8806719-6	1996	Inhibition of protein synthesis by cycloheximide resulted in moderate stabilization of osteocalcin mRNA (t1/2 = 7.7 h in the absence and 14.0 h in the presence of cycloheximide) in ROS 17/2.8 cells.	Cycloheximide	35-48	bone gamma-carboxyglutamate protein	Rattus norvegicus	87-98
8806719-6	1996	Inhibition of protein synthesis by cycloheximide resulted in moderate stabilization of osteocalcin mRNA (t1/2 = 7.7 h in the absence and 14.0 h in the presence of cycloheximide) in ROS 17/2.8 cells.	Cycloheximide	163-176	bone gamma-carboxyglutamate protein	Rattus norvegicus	87-98
8806719-7	1996	However, osteocalcin mRNA half-life in cells that had been treated with 1,25(OH)2D3 was not further prolonged in the presence of cycloheximide (t1/2 = 22.1 h in the absence and 22.6 h in the presence of cycloheximide).	Cycloheximide	203-216	bone gamma-carboxyglutamate protein	Rattus norvegicus	9-20
8774705-5	1996	The protein synthesis inhibitor cycloheximide is also a fairly strong inducer of IL-6 in these cells.	Cycloheximide	32-45	interleukin 6	Homo sapiens	81-85
8774705-9	1996	Finally, when MCF-7 cells were treated with IL-1 beta or TNF-alpha in the presence of cycloheximide, transcription of IL-6 mRNA from the endogenous IL-6 gene was observed.	Cycloheximide	86-99	interleukin 1 beta	Homo sapiens	44-53
8774705-9	1996	Finally, when MCF-7 cells were treated with IL-1 beta or TNF-alpha in the presence of cycloheximide, transcription of IL-6 mRNA from the endogenous IL-6 gene was observed.	Cycloheximide	86-99	tumor necrosis factor	Homo sapiens	57-66
8753710-7	1996	The production of TNF-alpha was inhibited in a dose-dependent manner by the translational inhibitor cycloheximide and the transcriptional inhibitor actinomycin D, indicating the requirement for both mRNA (messenger RNA) and protein synthesis for the induction of cytokine synthesis by titanium particles.	Cycloheximide	100-113	tumor necrosis factor	Homo sapiens	18-27
8774705-9	1996	Finally, when MCF-7 cells were treated with IL-1 beta or TNF-alpha in the presence of cycloheximide, transcription of IL-6 mRNA from the endogenous IL-6 gene was observed.	Cycloheximide	86-99	interleukin 6	Homo sapiens	118-122
8774705-9	1996	Finally, when MCF-7 cells were treated with IL-1 beta or TNF-alpha in the presence of cycloheximide, transcription of IL-6 mRNA from the endogenous IL-6 gene was observed.	Cycloheximide	86-99	interleukin 6	Homo sapiens	148-152
8877727-3	1996	This enhanced expression of IL-8 was inhibited by cycloheximide or actinomycin-D.	Cycloheximide	50-63	C-X-C motif chemokine ligand 8	Homo sapiens	28-32
8908616-7	1996	Inhibition of de novo protein synthesis with cycloheximide increased c-fos mRNA stability but not abrogated PGJ2-induced c-fos transcription.	Cycloheximide	45-58	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
8764657-2	1996	Using a fluorogenic substrate for interleukin-1beta converting enzyme (ICE), we show that K+ deprivation of cerebellar granule neurons induces cycloheximide-sensitive ICE-like protease activity.	Cycloheximide	143-156	caspase 1	Homo sapiens	34-69
8764657-2	1996	Using a fluorogenic substrate for interleukin-1beta converting enzyme (ICE), we show that K+ deprivation of cerebellar granule neurons induces cycloheximide-sensitive ICE-like protease activity.	Cycloheximide	143-156	caspase 1	Homo sapiens	71-74
8764657-2	1996	Using a fluorogenic substrate for interleukin-1beta converting enzyme (ICE), we show that K+ deprivation of cerebellar granule neurons induces cycloheximide-sensitive ICE-like protease activity.	Cycloheximide	143-156	caspase 1	Homo sapiens	167-170
8764657-5	1996	Using fluorescent assays, we show that ROS production after K+ deprivation is blocked by actinomycin D, cycloheximide, and Ac-YVAD-CMK, suggesting that ROS act downstream of gene transcription, mRNA translation, and ICE activation.	Cycloheximide	104-117	caspase 1	Homo sapiens	216-219
8918980-3	1996	However, concomitant administration of testosterone and cycloheximide blocked the testosterone-induced nuclear AR accumulation after 1 h. To determine if changes in AR binding reflected changes in AR protein levels, immunocytochemical studies were conducted on individually dissected ventral prostatic ducts.	Cycloheximide	56-69	androgen receptor	Rattus norvegicus	111-113
8918980-6	1996	Cycloheximide alone did not change AR immunostaining when compared to castrated vehicle-treated rats, yet it significantly decreased the nuclear AR staining induced by testosterone.	Cycloheximide	0-13	androgen receptor	Rattus norvegicus	145-147
8918980-10	1996	The inhibition of protein synthesis by cycloheximide did not change AR mRNA, but, when cycloheximide was administered in conjunction with testosterone, AR mRNA levels were significantly decreased.	Cycloheximide	87-100	androgen receptor	Rattus norvegicus	152-154
8918980-12	1996	Whereas simultaneous administration of testosterone and cycloheximide modified AR mRNA and AR protein levels, concomitant administration of testosterone with actinomycin D did not alter these levels.	Cycloheximide	56-69	androgen receptor	Rattus norvegicus	79-81
8918980-12	1996	Whereas simultaneous administration of testosterone and cycloheximide modified AR mRNA and AR protein levels, concomitant administration of testosterone with actinomycin D did not alter these levels.	Cycloheximide	56-69	androgen receptor	Rattus norvegicus	91-93
8763993-8	1996	In contrast, TNF treatment induced cytolysis and 3H-AA release in uninfected cells sensitized to TNF by treatment with cycloheximide and also in infected cells sensitized to TNF by expression of E1A.	Cycloheximide	119-132	tumor necrosis factor	Mus musculus	13-16
8763993-8	1996	In contrast, TNF treatment induced cytolysis and 3H-AA release in uninfected cells sensitized to TNF by treatment with cycloheximide and also in infected cells sensitized to TNF by expression of E1A.	Cycloheximide	119-132	tumor necrosis factor	Mus musculus	97-100
8763993-8	1996	In contrast, TNF treatment induced cytolysis and 3H-AA release in uninfected cells sensitized to TNF by treatment with cycloheximide and also in infected cells sensitized to TNF by expression of E1A.	Cycloheximide	119-132	tumor necrosis factor	Mus musculus	97-100
8763993-12	1996	E3-14.7K expressed in two stably transfected C127 cell lines prevented both TNF-cycloheximide-induced cytolysis and release of 3H-AA.	Cycloheximide	80-93	tumor necrosis factor	Mus musculus	76-79
8843948-3	1996	Treatment with the protein synthesis inhibitor, cycloheximide (CHX), also caused induction of IS10a mRNA to comparable levels, but the IS10a mRNA continued to accumulate after 3 h of induction.	Cycloheximide	48-61	scopoletin glucosyltransferase-like	Nicotiana tabacum	94-99
8843948-3	1996	Treatment with the protein synthesis inhibitor, cycloheximide (CHX), also caused induction of IS10a mRNA to comparable levels, but the IS10a mRNA continued to accumulate after 3 h of induction.	Cycloheximide	63-66	scopoletin glucosyltransferase-like	Nicotiana tabacum	94-99
8663337-9	1996	Treatment with the protein synthesis inhibitor cycloheximide gradually induced, whereas simultaneous addition of cAMP and cycloheximide superinduced LPL mRNA levels.	Cycloheximide	122-135	lipoprotein lipase	Homo sapiens	149-152
8703992-6	1996	In contrast, after inhibition of RNA synthesis with actinomycin D and protein synthesis with cycloheximide, the HsRAD51 protein level decreased rapidly.	Cycloheximide	93-106	RAD51 recombinase	Homo sapiens	112-119
8865166-0	1996	Cycloheximide enhances ACTH-receptor mRNA through transcriptional and post-transcriptional mechanisms in bovine adrenocortical cells.	Cycloheximide	0-13	melanocortin 2 receptor	Bos taurus	23-36
8865166-3	1996	The results show that cycloheximide alone, an inhibitor of protein synthesis, induced a time- and dose-dependent increase in the constitutive level of the ACTH-R major transcript of 3.6 kb in BAC.	Cycloheximide	22-35	melanocortin 2 receptor	Bos taurus	155-161
8865166-6	1996	The effect of cycloheximide involved an increase in the half-life and the transcription rate of the major transcript of ACTH-R (2- and 8.4-fold respectively).	Cycloheximide	14-27	melanocortin 2 receptor	Bos taurus	120-126
8695801-3	1996	Here, we show that the protein synthesis inhibitor, cycloheximide completely blocks the induction of t-PA by RA, which points to the need of an intermediary protein in t-PA stimulation.	Cycloheximide	52-65	plasminogen activator, tissue type	Homo sapiens	101-105
8695801-3	1996	Here, we show that the protein synthesis inhibitor, cycloheximide completely blocks the induction of t-PA by RA, which points to the need of an intermediary protein in t-PA stimulation.	Cycloheximide	52-65	plasminogen activator, tissue type	Homo sapiens	168-172
8695817-9	1996	The addition of TNF alpha to either cycloheximide or of actinomycin D-treated PMN overcame the inhibition, indicating that the effect was specific for TNF alpha.	Cycloheximide	36-49	tumor necrosis factor	Homo sapiens	16-25
8706726-5	1996	Induction of MT-MMP-1 by phorbol 12-myristate 13-acetate (PMA) required protein synthesis as shown by cycloheximide inhibition.	Cycloheximide	102-115	matrix metallopeptidase 14	Homo sapiens	13-21
8706754-9	1996	In addition, the induction of apoA-I gene transcription by dexamethasone was blocked by the protein-synthesis inhibitor cycloheximide, which suggests the presence of a labile protein involved in apoA-I gene activation by dexamethasone.	Cycloheximide	120-133	apolipoprotein A1	Rattus norvegicus	30-36
8706754-9	1996	In addition, the induction of apoA-I gene transcription by dexamethasone was blocked by the protein-synthesis inhibitor cycloheximide, which suggests the presence of a labile protein involved in apoA-I gene activation by dexamethasone.	Cycloheximide	120-133	apolipoprotein A1	Rattus norvegicus	195-201
8706820-2	1996	The results of morphological chase experiments involving cycloheximide demonstrated that gp160 was retained in the Golgi apparatus for longer than the half-life of the molecule.	Cycloheximide	57-70	glutamyl aminopeptidase	Homo sapiens	89-94
8660890-4	1996	Like the chromosomal Mix.1 gene, microinjected Mix.2 gene plasmids respond to activin in the presence of cycloheximide in animal cap assays and also respond to the embryonic inductive signal in Nieuwkoop recombinants.	Cycloheximide	105-118	Mix paired homeobox L homeolog	Xenopus laevis	21-26
8660890-4	1996	Like the chromosomal Mix.1 gene, microinjected Mix.2 gene plasmids respond to activin in the presence of cycloheximide in animal cap assays and also respond to the embryonic inductive signal in Nieuwkoop recombinants.	Cycloheximide	105-118	Mix paired homeobox L homeolog	Xenopus laevis	47-52
8663179-5	1996	The suppressive effect of dexamethasone on IL-1beta-induced IL-8 mRNA was not observed in the presence of cycloheximide (5 microg/ml), indicating that the dexamethasone-mediated repression of IL-8 gene expression also depends on new protein synthesis.	Cycloheximide	106-119	interleukin 1 beta	Homo sapiens	43-51
8663202-6	1996	Cycloheximide pretreatment completely inhibited the Delta12-PGJ2-induced expression of the BiP gene, suggesting that the effects on nascent protein synthesis are involved in the signaling mechanism.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 5	Homo sapiens	91-94
8663307-4	1996	In this work, we examined the effect of BCL-2 overexpression on acidification mediated by cycloheximide treatment or Fas ligation in Jurkat T-lymphoblasts.	Cycloheximide	90-103	BCL2 apoptosis regulator	Homo sapiens	40-45
8660686-2	1996	Treatment of rats with cycloheximide, a protein synthetic inhibitor, suppresses basal as well as phenobarbitone-induced levels of CYP2B1/B2 mRNA and its run-on transcription.	Cycloheximide	23-36	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	130-136
8694753-17	1996	When BFA was withdrawn and protein synthesis was blocked with cycloheximide, LPL in normal cells was transferred to Golgi within 30 min and disappeared within 60 min, whereas LPL in cld/cld cells was retained in large vesicles and ER.	Cycloheximide	62-75	lipoprotein lipase	Mus musculus	77-80
8694789-6	1996	Cycloheximide, which partly inhibited rapid ODC degradation caused by hypertonic shock, also part inhibited the increase in the ratio of ODC-antizyme complex total ODC.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	44-47
8757764-9	1996	The synthesis of p105 was inhibited by cycloheximide.	Cycloheximide	39-52	nuclear factor kappa B subunit 1	Homo sapiens	17-21
8818355-16	1996	Monocyte PGE2 and 8-epi-PGF2 alpha production was largely prevented by dexamethasone (2 microM) and cycloheximide (10 micrograms ml-1) in association with suppression of PGHS-2 but not of PGHS-1 expression.	Cycloheximide	100-113	prostaglandin-endoperoxide synthase 2	Homo sapiens	170-176
8818355-16	1996	Monocyte PGE2 and 8-epi-PGF2 alpha production was largely prevented by dexamethasone (2 microM) and cycloheximide (10 micrograms ml-1) in association with suppression of PGHS-2 but not of PGHS-1 expression.	Cycloheximide	100-113	prostaglandin-endoperoxide synthase 1	Homo sapiens	188-194
8690043-4	1996	In Northern blot experiments, expression of IL-11 mRNA was reduced in the presence of INF-alpha; this inhibiton was prevented by the addition of cycloheximide.	Cycloheximide	145-158	interleukin 11	Homo sapiens	44-49
8690043-4	1996	In Northern blot experiments, expression of IL-11 mRNA was reduced in the presence of INF-alpha; this inhibiton was prevented by the addition of cycloheximide.	Cycloheximide	145-158	interferon alpha 17	Homo sapiens	86-95
8770893-3	1996	Up-regulation of EGFR mRNA is most likely due to a direct effect of ER on the EGFR gene, with no involvement of protein synthesis, as it was not inhibited in the presence of cycloheximide; however, the subsequent down-regulation of EGFR required de novo protein synthesis.	Cycloheximide	174-187	epidermal growth factor receptor	Homo sapiens	17-21
8647916-7	1996	Cycloheximide treatment of MC3T3-E1 cells up-regulated CSF-1 mRNA, and compared to either agent alone, cycloheximide and TNF-alpha in combination resulted in augmentation of CSF-1 expression.	Cycloheximide	0-13	colony stimulating factor 1 (macrophage)	Mus musculus	55-60
8647916-7	1996	Cycloheximide treatment of MC3T3-E1 cells up-regulated CSF-1 mRNA, and compared to either agent alone, cycloheximide and TNF-alpha in combination resulted in augmentation of CSF-1 expression.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	121-130
8647916-7	1996	Cycloheximide treatment of MC3T3-E1 cells up-regulated CSF-1 mRNA, and compared to either agent alone, cycloheximide and TNF-alpha in combination resulted in augmentation of CSF-1 expression.	Cycloheximide	0-13	colony stimulating factor 1 (macrophage)	Mus musculus	174-179
8647916-7	1996	Cycloheximide treatment of MC3T3-E1 cells up-regulated CSF-1 mRNA, and compared to either agent alone, cycloheximide and TNF-alpha in combination resulted in augmentation of CSF-1 expression.	Cycloheximide	103-116	colony stimulating factor 1 (macrophage)	Mus musculus	174-179
8683130-1	1996	Previously we have shown that treatment of ML-1a cells with TNF in the presence of cycloheximide triggers apoptosis within 90 min.	Cycloheximide	83-96	tumor necrosis factor	Homo sapiens	60-63
8796788-5	1996	The action of IL-1 was greatly potentiated by the protein kinase C-activating phorbol ester, TPA, and inhibited by actinomycin D and cycloheximide.	Cycloheximide	133-146	interleukin 1 alpha	Homo sapiens	14-18
8753870-6	1996	Thus, the effect of gp120 was abolished by the NMDA receptor antagonist APV and partially reduced by cycloheximide.	Cycloheximide	101-114	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	20-25
8764381-4	1996	Moreover, a GAPDH antisense oligodeoxyribonucleotide arrested this cortical neuronal death for about 4 to 5 days and thus was more effective than cycloheximide.	Cycloheximide	146-159	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	12-17
8694789-6	1996	Cycloheximide, which partly inhibited rapid ODC degradation caused by hypertonic shock, also part inhibited the increase in the ratio of ODC-antizyme complex total ODC.	Cycloheximide	0-13	ornithine decarboxylase 1	Homo sapiens	137-140
8694789-6	1996	Cycloheximide, which partly inhibited rapid ODC degradation caused by hypertonic shock, also part inhibited the increase in the ratio of ODC-antizyme complex total ODC.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	137-140
8829212-5	1996	This stimulatory action of renin is enhanced rather than reduced by arachidonic acid treatment but abolished by treatment with cycloheximide or actinomycin D.	Cycloheximide	127-140	renin	Homo sapiens	27-32
8807578-7	1996	The increase in PAI-1:Ag by rHuEPO was suppressed by pre-incubation with 10 micrograms/ml cycloheximide (P < 0.01) or 0.2 microgram/ml actinomycin D (P < 0.01).	Cycloheximide	90-103	serpin family E member 1	Homo sapiens	16-21
8764176-6	1996	At both sites, c-fos expression was transient, prolonged by cycloheximide, and was strongly stimulated even in the presence of indomethacin.	Cycloheximide	60-73	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	15-20
8647946-11	1996	Medium P did not alter PTH mRNA in this system, but cycloheximide (10 microg/ml) abolished the effect of P on PTH secretion.	Cycloheximide	52-65	parathyroid hormone	Rattus norvegicus	110-113
8655604-3	1996	Actinomycin D and cycloheximide inhibited the up-regulation of both uPA and uPA-R, as determined by immunohistochemistry, indicating that RNA and protein syntheses are required for their induction in migrating keratinocytes.	Cycloheximide	18-31	plasminogen activator, urokinase	Homo sapiens	68-71
8655604-3	1996	Actinomycin D and cycloheximide inhibited the up-regulation of both uPA and uPA-R, as determined by immunohistochemistry, indicating that RNA and protein syntheses are required for their induction in migrating keratinocytes.	Cycloheximide	18-31	plasminogen activator, urokinase receptor	Homo sapiens	76-81
8707871-5	1996	Inhibition of protein synthesis by cycloheximide (100 microM) completely abolished the increase of EPO mRNA in response to hypoxia.	Cycloheximide	35-48	erythropoietin	Rattus norvegicus	99-102
8662924-3	1996	This T3 effect was abolished by the treatment with cycloheximide, indicating the possibility that gene ZAKI-4 is regulated by T3 in an indirect fashion, through an intermediate product of T3, rather directly by T3 itself.	Cycloheximide	51-64	regulator of calcineurin 2	Homo sapiens	103-109
8662783-6	1996	However, protein synthesis was not required, as treatment with cycloheximide did not block but rather superinduced the PDGF-induced increase in B2 receptor mRNA.	Cycloheximide	63-76	bradykinin receptor B2	Homo sapiens	144-155
8649769-2	1996	Okadaic acid increased AP-1 binding to a consensus TPA responsive element (TRE) within 2 h; maximum stimulation was observed at 6 h followed by a gradual decrease to basal levels within 24 h. Jun B, Jun D and Fos B proteins were identified as the major components of the AP-1 complex binding to the TRE element at 6 h. Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide abrogated the okadaic acid effect on AP-1 DNA binding, indicating that transcription and translation are required for okadaic acid increased TRE binding activity.	Cycloheximide	407-420	jun proto-oncogene	Mus musculus	23-27
8652672-1	1996	During the course of the study to examine the effect of cycloheximide on apoptosis-related genes, the variant rat testosterone-repressed prostate message-2 (TRPM-2) mRNA deficient of the exon 5 was found.	Cycloheximide	56-69	clusterin	Rattus norvegicus	114-155
8652672-1	1996	During the course of the study to examine the effect of cycloheximide on apoptosis-related genes, the variant rat testosterone-repressed prostate message-2 (TRPM-2) mRNA deficient of the exon 5 was found.	Cycloheximide	56-69	clusterin	Rattus norvegicus	157-163
8674541-2	1996	This complex (HIF-D) resembled mammalian hypoxia inducible factor (HIF-1) in DNA sequence specificity, abrogation of induction by cycloheximide, induction by desferrioxamine and redox sensitivity of DNA binding.	Cycloheximide	130-143	hypoxia inducible factor 1 subunit alpha	Homo sapiens	67-72
8799562-15	1996	Tranilast still had an inhibitory effect on the induction of c-myc mRNA when de novo protein synthesis was inhibited by cycloheximide and did not shorten the degradation of c-myc mRNA at the post-transcriptional level, demonstrating that tranilast directly inhibited c-myc mRNA expression at the transcriptional level.	Cycloheximide	120-133	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	61-66
8653710-7	1996	The transcriptional inhibitor actinomycin D, various protein kinase C inhibitors, and the calmodulin inhibitor W-7 strongly reduced PRG1 induction by PACAP, whereas the translational inhibitor cycloheximide potently increased PRG1 mRNA levels in unstimulated and PACAP-stimulated cells.	Cycloheximide	193-206	immediate early response 3	Rattus norvegicus	226-230
8670569-6	1996	Proteoglycan-degrading activity related to the 40 kDa Fn fragment was decreased up to 66% by fetal calf serum (10%), but was not prevented by protein synthesis inhibitors (cycloheximide or actinomycin D).	Cycloheximide	172-185	fibronectin 1	Homo sapiens	54-56
8809420-10	1996	Importantly, culturing these monocytes overnight in conventional medium containing 2 micrograms/mL IgE induced a cycloheximide insensitive accumulation of IgE bound to Fc epsilon RI and, in addition, led to cell activation.	Cycloheximide	113-126	immunoglobulin heavy constant epsilon	Homo sapiens	99-102
21153284-11	1996	The addition of cycloheximide to the culture of FRTL-5 cells abolished the effect of bTSH, but not that of 8-bromo-cAMP, on the expression of the Gsalpha gene.	Cycloheximide	16-29	GNAS complex locus	Homo sapiens	146-153
8675182-0	1996	The translational inhibitor cycloheximide represses growth factor depletion-induced apoptosis in an alb-SV40T transgenic rat liver cell line.	Cycloheximide	28-41	albumin	Rattus norvegicus	100-103
8675186-6	1996	Treatment of Kupffer cells with actinomycin D or cycloheximide inhibited PAF- and LPS-stimulated nitrite and nitric oxide synthase protein formation confirming that de novo synthesis of the enzyme occurred.	Cycloheximide	49-62	PCNA clamp associated factor	Rattus norvegicus	73-76
8675186-9	1996	PAF and LPS individually and in combination induced a time-dependent uptake of L-[3H]-arginine into the Kupffer cell, and this response was sensitive to cycloheximide.	Cycloheximide	153-166	PCNA clamp associated factor	Rattus norvegicus	0-3
8836162-8	1996	The TPA-induced decrease in ER mRNA was unaffected by the simultaneous administration of the protein synthesis inhibitor cycloheximide, whereas the increase in EGF-R mRNA was inhibited by co-incubation with cycloheximide.	Cycloheximide	207-220	epidermal growth factor receptor	Homo sapiens	160-165
8650251-6	1996	The accumulation of c-fos; mRNA in the cultured mammary tissues was also increased by human GH, recombinant bovine PRL, cycloheximide, and phorbol 12-myristate 13-acetate (TPA).	Cycloheximide	120-133	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-25
8658534-11	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4+ cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	CD4 antigen	Mus musculus	65-68
8658534-11	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4+ cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 2	Mus musculus	107-111
8658534-11	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4+ cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 4	Mus musculus	120-124
8661368-10	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4(+) cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	CD4 antigen	Mus musculus	65-68
8661368-10	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4(+) cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 2	Mus musculus	109-113
8661368-10	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4(+) cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	interleukin 4	Mus musculus	122-126
8659123-4	1996	Using Northern blot analysis we have determined that the UL105 transcript is a 3.4-kb message that can be detected as early as 24 hr postinfection in the presence of phosphonoformic acid but not in the presence of cycloheximide.	Cycloheximide	214-227	helicase-primase helicase subunit	Human betaherpesvirus 5	57-62
8647873-6	1996	Furthermore, cycloheximide inhibition experiments reveal that the fraction of p18 that resides in the outer nuclear membrane does not represent nascent chains en route to the inner nuclear membrane, but rather material in equilibrium with the p18 that partitions with the inner nuclear membrane.	Cycloheximide	13-26	H3 histone pseudogene 12	Homo sapiens	78-81
8645217-4	1996	Cycloheximide was found to be a strong inducer of AdoMetDC mRNA transcription and the effects of insulin and cycloheximide were additive, suggesting that they increase expression by separate mechanisms.	Cycloheximide	0-13	adenosylmethionine decarboxylase 1	Rattus norvegicus	50-58
8626670-8	1996	Release of human growth hormone from syntaxin 1A-expressing cells was maintained during a blockade of protein synthesis, suggesting that the hormone was being released from a pool of stored vesicles which accumulated before the addition of cycloheximide.	Cycloheximide	240-253	growth hormone 1	Homo sapiens	17-31
8626686-6	1996	Death was accompanied by characteristic markers of apoptosis with more than 90% of cells showing DNA fragmentation within 12-16 h. Myoblast death was prevented by IGF-I, des [1-3] IGF-I, IGF-II, and insulin with a dose potency consistent with activation of the IGF-I receptor; death also could be blocked by the protein synthesis inhibitor, cycloheximide.	Cycloheximide	341-354	insulin-like growth factor 1	Mus musculus	163-168
8690465-6	1996	The rhTNF-alpha induced CD4 expression on human eosinophils in a dose- and time-dependent fashion; rhTNF-alpha-induced CD4 expression was significantly inhibited by 10(-6) M cycloheximide, 10(-8) M dexamethasone, or 10(-6) M herbimycin A.	Cycloheximide	174-187	CD4 molecule	Homo sapiens	24-27
8690465-6	1996	The rhTNF-alpha induced CD4 expression on human eosinophils in a dose- and time-dependent fashion; rhTNF-alpha-induced CD4 expression was significantly inhibited by 10(-6) M cycloheximide, 10(-8) M dexamethasone, or 10(-6) M herbimycin A.	Cycloheximide	174-187	CD4 molecule	Homo sapiens	119-122
8844029-1	1996	Cycloheximide (20 mg/kg body wt, given intraperitoneally at-1 and 3 h after withdrawal of an ethanol-containing liquid diet) prevents the activation of liver tryptophan pyrrolase, the consequent inhibition of synthesis of brain 5-hydroxytryptamine, and the audiogenic seizures observed at 7 h after alcohol withdrawal.	Cycloheximide	0-13	tryptophan 2,3-dioxygenase	Rattus norvegicus	158-178
8612502-8	1996	Cycloheximide at 3.6 microM decreased IGFBP-6 transcripts and prevented the stimulatory effect of cortisol.	Cycloheximide	0-13	insulin-like growth factor binding protein 6	Rattus norvegicus	38-45
8612545-4	1996	The presence of cycloheximide abolished the effect of TSH to increase IGF-I-induced DNA synthesis.	Cycloheximide	16-29	insulin-like growth factor 1	Rattus norvegicus	70-75
8647108-5	1996	The protein-synthesis inhibitor cycloheximide led to a derepression of the CYP1A1 gene transcription, and to a superinduction when combined with either beta-naphthoflavone or benzimidazoles.	Cycloheximide	32-45	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	75-81
8647111-7	1996	Northern blot analysis using rat EC iNOS cDNA as a probe revealed that cycloheximide treatment led to a marked accumulation of iNOS mRNA in the presence and absence of interleukin-1 beta.	Cycloheximide	71-84	nitric oxide synthase 2	Rattus norvegicus	36-40
8647111-7	1996	Northern blot analysis using rat EC iNOS cDNA as a probe revealed that cycloheximide treatment led to a marked accumulation of iNOS mRNA in the presence and absence of interleukin-1 beta.	Cycloheximide	71-84	nitric oxide synthase 2	Rattus norvegicus	127-131
8647111-7	1996	Northern blot analysis using rat EC iNOS cDNA as a probe revealed that cycloheximide treatment led to a marked accumulation of iNOS mRNA in the presence and absence of interleukin-1 beta.	Cycloheximide	71-84	interleukin 1 beta	Rattus norvegicus	168-186
8632147-2	1996	Preincubation of the cells with cycloheximide inhibited induction of proenkephalin mRNA levels by each of these agents, indicating that newly synthesized transcription factors are involved.	Cycloheximide	32-45	proenkephalin	Bos taurus	69-82
8621263-8	1996	Protective effects of IFN-gamma on target cell sensitivity to lysis were blocked by pre-treatment of target cells with actinomycin-D or cycloheximide.	Cycloheximide	136-149	interferon gamma	Homo sapiens	22-31
8782859-6	1996	Both the PMA-induced decrease and increase of the CNTF-mRNA levels were canceled by treatment with cycloheximide, an inhibitor of protein synthesis, suggesting that protein synthesis-dependent mechanisms participate in both the PMA-induced decrease and increase of CNTF-mRNA levels.	Cycloheximide	99-112	ciliary neurotrophic factor	Rattus norvegicus	50-54
8782859-6	1996	Both the PMA-induced decrease and increase of the CNTF-mRNA levels were canceled by treatment with cycloheximide, an inhibitor of protein synthesis, suggesting that protein synthesis-dependent mechanisms participate in both the PMA-induced decrease and increase of CNTF-mRNA levels.	Cycloheximide	99-112	ciliary neurotrophic factor	Rattus norvegicus	265-269
8610904-8	1996	In addition, cycloheximide, an inhibitor of inducible NO synthase, prevented the attenuation of NE-induced contractions caused by LTA.	Cycloheximide	13-26	nitric oxide synthase 2	Homo sapiens	44-65
8621982-5	1996	An increase in new protein synthesis appeared to account for part of the increased fibronectin, because the inhibitor of protein synthesis, cycloheximide, inhibited the increase in total production of fibronectin.	Cycloheximide	140-153	fibronectin 1	Homo sapiens	83-94
8621982-5	1996	An increase in new protein synthesis appeared to account for part of the increased fibronectin, because the inhibitor of protein synthesis, cycloheximide, inhibited the increase in total production of fibronectin.	Cycloheximide	140-153	fibronectin 1	Homo sapiens	201-212
8667502-9	1996	Inhibitor studies revealed that PAI-1 decreased to approximately one third of control values when cycloheximide or actinomycin D were added to the media, indicating that active synthesis of PAI-1 had occurred.	Cycloheximide	98-111	serpin family E member 1	Homo sapiens	32-37
8667502-9	1996	Inhibitor studies revealed that PAI-1 decreased to approximately one third of control values when cycloheximide or actinomycin D were added to the media, indicating that active synthesis of PAI-1 had occurred.	Cycloheximide	98-111	serpin family E member 1	Homo sapiens	190-195
8622626-8	1996	Cycloheximide (10 micrograms/ml) pretreatment abolished the TGF-beta 1 effect, indicating that de novo protein synthesis was required for receptor downregulation.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	60-70
8631130-8	1996	Hepatocytes isolated from all three strains of rats showed an equivalent induction of mdr1b after treatment with cycloheximide.	Cycloheximide	113-126	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	86-91
8642312-6	1996	Furthermore, our data show that ERK and JNK activities are restored when anergy is induced in the presence of the protein synthesis inhibitor cycloheximide, or when anergic T cells are allowed to proliferate in response to exogenous IL-2.	Cycloheximide	142-155	mitogen-activated protein kinase 1	Mus musculus	32-35
8642312-6	1996	Furthermore, our data show that ERK and JNK activities are restored when anergy is induced in the presence of the protein synthesis inhibitor cycloheximide, or when anergic T cells are allowed to proliferate in response to exogenous IL-2.	Cycloheximide	142-155	mitogen-activated protein kinase 8	Mus musculus	40-43
8642312-6	1996	Furthermore, our data show that ERK and JNK activities are restored when anergy is induced in the presence of the protein synthesis inhibitor cycloheximide, or when anergic T cells are allowed to proliferate in response to exogenous IL-2.	Cycloheximide	142-155	interleukin 2	Mus musculus	233-237
8737408-10	1996	The effect of chromogranin A was dose dependent, inhibited by N omega-nitro-L-arginine methyl ester, a competitive inhibitor of nitric oxide synthase, and by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	158-171	chromogranin A	Homo sapiens	14-28
28306084-6	1996	Studies in the presence of cycloheximide have established that Urbain is a secondary response gene.	Cycloheximide	27-40	urbain	Bombyx mori	63-69
8738804-8	1996	Both proteinase 3-and elastase-mediated production of IL-8 was inhibited by cycloheximide, indicating de novo synthesis.	Cycloheximide	76-89	proteinase 3	Homo sapiens	5-30
8738804-8	1996	Both proteinase 3-and elastase-mediated production of IL-8 was inhibited by cycloheximide, indicating de novo synthesis.	Cycloheximide	76-89	C-X-C motif chemokine ligand 8	Homo sapiens	54-58
8615830-5	1996	UTP also stimulated expression of MAP kinase phosphatase-1 and this was abolished after pretreatment with cycloheximide.	Cycloheximide	106-119	dual specificity phosphatase 1	Homo sapiens	34-58
8619843-1	1996	This study shows that induction of heme oxygenase-1 (HO-1) gene expression by a glutathione (GSH) depletor, phorone, is inhibited by cycloheximide pretreatment and involves changes in c-jun, not c-fos, mRNA.	Cycloheximide	133-146	heme oxygenase 1	Rattus norvegicus	35-51
8619843-1	1996	This study shows that induction of heme oxygenase-1 (HO-1) gene expression by a glutathione (GSH) depletor, phorone, is inhibited by cycloheximide pretreatment and involves changes in c-jun, not c-fos, mRNA.	Cycloheximide	133-146	heme oxygenase 1	Rattus norvegicus	53-57
8619843-1	1996	This study shows that induction of heme oxygenase-1 (HO-1) gene expression by a glutathione (GSH) depletor, phorone, is inhibited by cycloheximide pretreatment and involves changes in c-jun, not c-fos, mRNA.	Cycloheximide	133-146	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	195-200
8621509-8	1996	Experiments with cycloheximide and actinomycin D indicated that IL-10 induces expression of a trans-acting factor(s) that stabilizes the mMCP-2 transcript or facilitates its processing.	Cycloheximide	17-30	interleukin 10	Mus musculus	64-69
8621509-8	1996	Experiments with cycloheximide and actinomycin D indicated that IL-10 induces expression of a trans-acting factor(s) that stabilizes the mMCP-2 transcript or facilitates its processing.	Cycloheximide	17-30	mast cell protease 2	Mus musculus	137-143
8621551-5	1996	IGFBP-5 transcripts were markedly decreased by cycloheximide, and further suppressive effects of cortisol could not be determined.	Cycloheximide	47-60	insulin-like growth factor binding protein 5	Rattus norvegicus	0-7
8611404-5	1996	The enhanced adhesion was significantly inhibited by complexing of thrombin with its inhibitor hirudin, or by serine proteinase inhibition with 3,4-DCI, but was unaffected by pretreatment of tumour cells with actinomycin D or cycloheximide.	Cycloheximide	226-239	coagulation factor II, thrombin	Homo sapiens	67-75
8603415-5	1996	Cycloheximide treatment of the cells showed that the low level of p53 mRNA in non-BL lymphoid cells can not be attributed to posttranscriptional regulation by a labile protein.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	66-69
9052991-6	1996	The TPA-induced change in mobility of NFI-DNA complexes in OCI/AML-3 cells was blocked by an inhibitor of protein synthesis, cycloheximide.	Cycloheximide	125-138	nuclear factor I C	Homo sapiens	38-41
8846917-8	1996	Protein synthesis inhibition by cycloheximide (CHX) treatment indicated that the half-life of p21/SDI-1 in dividing HT1 cells was approximately 30 min.	Cycloheximide	32-45	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-97
8846917-8	1996	Protein synthesis inhibition by cycloheximide (CHX) treatment indicated that the half-life of p21/SDI-1 in dividing HT1 cells was approximately 30 min.	Cycloheximide	32-45	cyclin dependent kinase inhibitor 1A	Homo sapiens	98-103
8846917-8	1996	Protein synthesis inhibition by cycloheximide (CHX) treatment indicated that the half-life of p21/SDI-1 in dividing HT1 cells was approximately 30 min.	Cycloheximide	47-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	94-97
8846917-8	1996	Protein synthesis inhibition by cycloheximide (CHX) treatment indicated that the half-life of p21/SDI-1 in dividing HT1 cells was approximately 30 min.	Cycloheximide	47-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	98-103
8666343-6	1996	The increases in steady-state PAI-1 mRNA caused by exposure to n-butyrate can be blocked by cycloheximide.	Cycloheximide	92-105	serpin family E member 1	Homo sapiens	30-35
8718665-0	1996	Cycloheximide-induced activation of mouse eggs: effects on cdc2/cyclin B and MAP kinase activities.	Cycloheximide	0-13	cyclin-dependent kinase 1	Mus musculus	59-63
8718665-3	1996	However, it is not known if cycloheximide treatment results in the same temporal changes in cdc2/cyclin B kinase and MAP kinase activities that are intimately associated with resumption of meiosis.	Cycloheximide	28-41	cyclin-dependent kinase 1	Mus musculus	92-96
8718665-4	1996	We report that cycloheximide-treated mouse eggs manifest similar temporal changes in the decrease in both cdc2/cyclin B kinase and MAP kinase activities that occur following fertilization, although cortical granule exocytosis is not stimulated.	Cycloheximide	15-28	cyclin-dependent kinase 1	Mus musculus	106-110
8726354-6	1996	Cycloheximide completely abolished the increase in synthesis of PAF by macrophages exposed to alpha 2M-methylamine.	Cycloheximide	0-13	PCNA clamp associated factor	Homo sapiens	64-67
8726354-6	1996	Cycloheximide completely abolished the increase in synthesis of PAF by macrophages exposed to alpha 2M-methylamine.	Cycloheximide	0-13	alpha-2-macroglobulin	Homo sapiens	94-102
8666909-9	1996	Both PAF- and 5(S)-HETE-induced lipid body formation were inhibited by protein kinase C (PKC) inhibitors staurosporine and chelerythrine, the phospholipase C (PLC) inhibitors D609 and U-73122, and by actinomycin D and cycloheximide.	Cycloheximide	218-231	patchy fur	Mus musculus	5-8
8666909-11	1996	Furthermore, pretreatment of cells with actinomycin D or cycloheximide inhibited not only the induction of lipid body formation by PAF, but also the PAF-induced "priming" for enhanced PGE2 and LTB4 in PMN.	Cycloheximide	57-70	patchy fur	Mus musculus	131-134
8666909-11	1996	Furthermore, pretreatment of cells with actinomycin D or cycloheximide inhibited not only the induction of lipid body formation by PAF, but also the PAF-induced "priming" for enhanced PGE2 and LTB4 in PMN.	Cycloheximide	57-70	patchy fur	Mus musculus	149-152
8786314-4	1996	Enhanced LT synthesis required a minimum of 6 h of GM-CSF pretreatment, suggesting that protein synthesis was required for enhanced LT production; indeed, cycloheximide completely abolished the GM-CSF effect on LT synthesis.	Cycloheximide	155-168	colony stimulating factor 2	Homo sapiens	194-200
8613710-7	1996	Cycloheximide enhanced the IL-1 beta mRNA accumulation by GM-CSF at the level of mRNA stabilization, but blocked IL-1 beta mRNA expression by TNF.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	27-36
8613710-7	1996	Cycloheximide enhanced the IL-1 beta mRNA accumulation by GM-CSF at the level of mRNA stabilization, but blocked IL-1 beta mRNA expression by TNF.	Cycloheximide	0-13	colony stimulating factor 2	Homo sapiens	58-64
8613710-7	1996	Cycloheximide enhanced the IL-1 beta mRNA accumulation by GM-CSF at the level of mRNA stabilization, but blocked IL-1 beta mRNA expression by TNF.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	113-122
8613710-7	1996	Cycloheximide enhanced the IL-1 beta mRNA accumulation by GM-CSF at the level of mRNA stabilization, but blocked IL-1 beta mRNA expression by TNF.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	142-145
8627337-3	1996	It was found that cycloheximide, a protein synthesis inhibitor, prevented the forskolin-induced decrease in CREB mRNA levels in CATH.a cells.	Cycloheximide	18-31	cAMP responsive element binding protein 1	Mus musculus	108-112
8627337-3	1996	It was found that cycloheximide, a protein synthesis inhibitor, prevented the forskolin-induced decrease in CREB mRNA levels in CATH.a cells.	Cycloheximide	18-31	cathepsin H	Mus musculus	128-132
8609829-10	1996	The effects of PRL on both citrate utilization and m-aconitase of RLP and RVP were abolished by cycloheximide and actinomycin.	Cycloheximide	96-109	prolactin	Rattus norvegicus	15-18
8602397-7	1996	TGFbeta1 or cycloheximide each increased bFGF mRNA about 3-fold.	Cycloheximide	12-25	fibroblast growth factor 2	Homo sapiens	41-45
8631819-11	1996	Reduction in macrophage scavenger receptor message in response to TNF-alpha was dependent on new protein synthesis because it was blocked by cycloheximide.	Cycloheximide	141-154	tumor necrosis factor	Homo sapiens	66-75
8645293-5	1996	Cycloheximide by itself strongly induced the PDI mRNA, but did not inhibit the effect of delta 12-PGJ2, suggesting that the pathway of delta 12-PGJ2-induced PDI gene expression does not involve unfolded protein accumulation.	Cycloheximide	0-13	prolyl 4-hydroxylase subunit beta	Homo sapiens	45-48
8645293-5	1996	Cycloheximide by itself strongly induced the PDI mRNA, but did not inhibit the effect of delta 12-PGJ2, suggesting that the pathway of delta 12-PGJ2-induced PDI gene expression does not involve unfolded protein accumulation.	Cycloheximide	0-13	prolyl 4-hydroxylase subunit beta	Homo sapiens	157-160
8640839-4	1996	Myelomas are antibody-secreting tumor cells derived from terminally differentiated B lymphocytes, and previous work from our laboratory showed that murine SP2/0 myeloma cells and derived B-cell hybridomas were highly sensitive to apoptosis induction by a block of gene expression (cycloheximide).	Cycloheximide	281-294	Sp2 transcription factor	Mus musculus	155-158
8610440-8	1996	Besides this entry-induced eIF4E dephosphorylation, dephosphorylation was also induced by blocking protein synthesis with the initiation inhibitor pactamycin, or with the elongation inhibitor cycloheximide.	Cycloheximide	192-205	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
8707886-8	1996	P120 mRNA accumulates in resting cells in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	90-103	NOP2 nucleolar protein	Homo sapiens	0-4
8707886-9	1996	Furthermore, the steady-state level of P120 mRNA increases in the presence of cycloheximide after PHA-stimulation; this level does not increase in cells not treated with this protein synthesis inhibitor.	Cycloheximide	78-91	NOP2 nucleolar protein	Homo sapiens	39-43
8707886-10	1996	The presence of cycloheximide increases both the transcription rate of the P120 gene and the stability of P120 mRNA.	Cycloheximide	16-29	NOP2 nucleolar protein	Homo sapiens	75-79
8707886-10	1996	The presence of cycloheximide increases both the transcription rate of the P120 gene and the stability of P120 mRNA.	Cycloheximide	16-29	NOP2 nucleolar protein	Homo sapiens	106-110
8707896-8	1996	Evidence was also obtained for a cycloheximide-sensitive regulator of ornithine decarboxylase gene expression whose effect, in combination with bFGF, resulted in a further augmentation of ornithine decarboxylase gene expression.	Cycloheximide	33-46	ornithine decarboxylase, structural 1	Mus musculus	70-93
8707896-8	1996	Evidence was also obtained for a cycloheximide-sensitive regulator of ornithine decarboxylase gene expression whose effect, in combination with bFGF, resulted in a further augmentation of ornithine decarboxylase gene expression.	Cycloheximide	33-46	fibroblast growth factor 2	Mus musculus	144-148
8707896-8	1996	Evidence was also obtained for a cycloheximide-sensitive regulator of ornithine decarboxylase gene expression whose effect, in combination with bFGF, resulted in a further augmentation of ornithine decarboxylase gene expression.	Cycloheximide	33-46	ornithine decarboxylase, structural 1	Mus musculus	188-211
8709977-4	1996	Addition of cycloheximide plus lovastatin to cells in culture abolished the observed increase in 24 kDa GTP-binding protein.	Cycloheximide	12-25	hydroxycarboxylic acid receptor 3	Homo sapiens	104-123
8709978-5	1996	Induction of Egr-1 mRNA by IL-1 beta and TNF-alpha was completely inhibited by H-7 suggesting the mediation of protein kinase C. The induction by IL-1 beta and TNF-alpha of Egr-1 mRNA was independent of de novo protein synthesis since this induction was also observed in the presence of protein synthesis inhibitor cycloheximide.	Cycloheximide	315-328	early growth response 1	Homo sapiens	13-18
8709978-5	1996	Induction of Egr-1 mRNA by IL-1 beta and TNF-alpha was completely inhibited by H-7 suggesting the mediation of protein kinase C. The induction by IL-1 beta and TNF-alpha of Egr-1 mRNA was independent of de novo protein synthesis since this induction was also observed in the presence of protein synthesis inhibitor cycloheximide.	Cycloheximide	315-328	tumor necrosis factor	Homo sapiens	41-50
8709978-5	1996	Induction of Egr-1 mRNA by IL-1 beta and TNF-alpha was completely inhibited by H-7 suggesting the mediation of protein kinase C. The induction by IL-1 beta and TNF-alpha of Egr-1 mRNA was independent of de novo protein synthesis since this induction was also observed in the presence of protein synthesis inhibitor cycloheximide.	Cycloheximide	315-328	interleukin 1 beta	Homo sapiens	146-155
8709978-5	1996	Induction of Egr-1 mRNA by IL-1 beta and TNF-alpha was completely inhibited by H-7 suggesting the mediation of protein kinase C. The induction by IL-1 beta and TNF-alpha of Egr-1 mRNA was independent of de novo protein synthesis since this induction was also observed in the presence of protein synthesis inhibitor cycloheximide.	Cycloheximide	315-328	tumor necrosis factor	Homo sapiens	160-169
8709978-6	1996	Fetal bovine serum and cycloheximide also independently induced the Egr-1 mRNA.	Cycloheximide	23-36	early growth response 1	Homo sapiens	68-73
8638712-6	1996	Furthermore, cycloheximide (0.1-10 microM) inhibited the gastrin-induced stimulation of HDC activity, whereas actinomycin D (up to 10 microM) was without effect.	Cycloheximide	13-26	gastrin	Oryctolagus cuniculus	57-64
8638712-6	1996	Furthermore, cycloheximide (0.1-10 microM) inhibited the gastrin-induced stimulation of HDC activity, whereas actinomycin D (up to 10 microM) was without effect.	Cycloheximide	13-26	histidine decarboxylase	Oryctolagus cuniculus	88-91
8780259-5	1996	Complete inhibition of AQP-2 biosynthesis by cycloheximide was verified by immuno-precipitation.	Cycloheximide	45-58	aquaporin 2	Sus scrofa	23-28
8882591-4	1996	The exaggerated release of PGE2 was attenuated by cycloheximide, an inhibitor of protein synthesis or by dexamethasone, a steroid known to inhibit the induction of cyclo-oxygenase (COX-2).	Cycloheximide	50-63	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	181-186
8882591-6	1996	This was reduced to 200 +/- 30 pg ml-1 min-1 in kidneys infused with cycloheximide (1 microM) and to 250 +/- 40 pg ml-1 min-1 in kidneys infused with dexamethasone (n = 8).	Cycloheximide	69-82	interleukin 17F	Homo sapiens	34-44
8603591-7	1996	The present study, however, indicates that IL-1 induced expression of Fos and Jun does not seem to participate in the regulation of iNOS and mRNA expression, because: 1) cycloheximide (1 microM) completely inhibited Fos expression but had no inhibitory effect on iNOS mRNA levels; and 2) tyrosine kinase inhibitors genistein and herbimycin A completely inhibited IL-1 induced iNOS expression but did not block c-fos and c-jun expression.	Cycloheximide	170-183	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	216-219
8603605-7	1996	Administration of cycloheximide (5-100 microM) abolished the OST-PTP and collagenase responses to PTH.	Cycloheximide	18-31	protein tyrosine phosphatase, receptor type, V	Rattus norvegicus	61-68
8603605-7	1996	Administration of cycloheximide (5-100 microM) abolished the OST-PTP and collagenase responses to PTH.	Cycloheximide	18-31	parathyroid hormone	Rattus norvegicus	98-101
8605941-5	1996	Appearance of the STAT1 factor is significantly reduced in the presence of cyclosporin A, and blocked by cycloheximide, indicating that its activation is dependent upon a protein(s) synthesized in response to initial signaling events.	Cycloheximide	105-118	signal transducer and activator of transcription 1	Homo sapiens	18-23
8833191-11	1996	These effects were blocked by cycloheximide, indicating that new synthesis of both receptor protein and G protein might occur during 24 h pretreatment with ET-1.	Cycloheximide	30-43	endothelin 1	Homo sapiens	156-160
8603611-8	1996	Cycloheximide abolished the RA-stimulated increase in IGFBP-6 mRNA and reduced baseline IGFBP-5 mRNA levels, but did not affect RA-modulated mRNA levels of the other IGFBPs.	Cycloheximide	0-13	insulin like growth factor binding protein 6	Homo sapiens	54-61
8603611-8	1996	Cycloheximide abolished the RA-stimulated increase in IGFBP-6 mRNA and reduced baseline IGFBP-5 mRNA levels, but did not affect RA-modulated mRNA levels of the other IGFBPs.	Cycloheximide	0-13	insulin like growth factor binding protein 5	Homo sapiens	88-95
8833191-7	1996	Cycloheximide (0.5 mu M) blocked the increase in (3H)BK binding, indicating that new synthesis of receptor protein might occur during 24 h pretreatment with dBcAMP.	Cycloheximide	0-13	kininogen 1	Homo sapiens	53-55
8617779-7	1996	ORP150 expression in hypoxic astrocytes resulted from de novo protein synthesis, as shown by inhibition in the presence of cycloheximide.	Cycloheximide	123-136	hypoxia up-regulated 1	Rattus norvegicus	0-6
8830049-3	1996	The administration of cycloheximide, a protein synthesis inhibitor, led rather to an increase in C/EBP beta mRNA, which suggested that a labile negative protein factor(s) is involved in regulation of the C/EBP beta mRNA level.	Cycloheximide	22-35	CCAAT/enhancer binding protein beta	Rattus norvegicus	97-107
8830049-3	1996	The administration of cycloheximide, a protein synthesis inhibitor, led rather to an increase in C/EBP beta mRNA, which suggested that a labile negative protein factor(s) is involved in regulation of the C/EBP beta mRNA level.	Cycloheximide	22-35	CCAAT/enhancer binding protein beta	Rattus norvegicus	204-214
8830049-4	1996	Cycloheximide further augmented the increases in C/EBP beta mRNA by dexamethasone and/or glucagon.	Cycloheximide	0-13	CCAAT/enhancer binding protein beta	Rattus norvegicus	49-59
8852946-6	1996	The inhibition of PGHS-2 and cPLA2 mRNA expression by IL-4 (10 ng/ml) was present at 1 h, reached a maximum at 4 h, and persisted for 24 h. The effects were maintained in the presence of cycloheximide.	Cycloheximide	187-200	prostaglandin-endoperoxide synthase 2	Mus musculus	18-24
8852946-6	1996	The inhibition of PGHS-2 and cPLA2 mRNA expression by IL-4 (10 ng/ml) was present at 1 h, reached a maximum at 4 h, and persisted for 24 h. The effects were maintained in the presence of cycloheximide.	Cycloheximide	187-200	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	29-34
8852946-6	1996	The inhibition of PGHS-2 and cPLA2 mRNA expression by IL-4 (10 ng/ml) was present at 1 h, reached a maximum at 4 h, and persisted for 24 h. The effects were maintained in the presence of cycloheximide.	Cycloheximide	187-200	interleukin 4	Mus musculus	54-58
8780259-6	1996	Immunofluorescence revealed that AQP-2 was located on intracellular vesicles in nonstimulated cells but was relocated to the plasma membrane after vasopressin treatment, even in the presence of cycloheximide.	Cycloheximide	194-207	aquaporin 2	Sus scrofa	33-38
8778231-8	1996	Incubation with cycloheximide or 10% fetal calf serum increased c-myc mRNA levels 3- and 4-fold respectively.	Cycloheximide	16-29	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	64-69
8697149-7	1996	Interestingly, in the presence of cycloheximide, the kinetics of cell killing was more rapid for TNF than anti-Fas (50% inhibition occurred at 3 versus 6h).	Cycloheximide	34-47	tumor necrosis factor	Homo sapiens	97-100
8697149-8	1996	Treatment of both cell types with anti-Fas led to time-dependent DNA fragmentation, but TNF-induced DNA fragmentation occurred only in the presence of cycloheximide.	Cycloheximide	151-164	tumor necrosis factor	Homo sapiens	88-91
8603706-3	1996	Even cycloheximide (CHX) added by itself elicited an early, sustained activation of NF-kappa B followed by an intense induction of iNOS gene expression, irrespective of what degree of protein synthesis inhibition was brought about by the several concentrations tested.	Cycloheximide	5-18	nitric oxide synthase 2	Rattus norvegicus	131-135
8852950-7	1996	Cycloheximide (CHX) suppressed IL-1 beta-induced PGE2 production, suggesting that the production of PGE2 induced by IL-1 beta required de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 beta	Mus musculus	31-40
8852950-7	1996	Cycloheximide (CHX) suppressed IL-1 beta-induced PGE2 production, suggesting that the production of PGE2 induced by IL-1 beta required de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 beta	Mus musculus	116-125
8852950-7	1996	Cycloheximide (CHX) suppressed IL-1 beta-induced PGE2 production, suggesting that the production of PGE2 induced by IL-1 beta required de novo protein synthesis.	Cycloheximide	15-18	interleukin 1 beta	Mus musculus	31-40
8852950-7	1996	Cycloheximide (CHX) suppressed IL-1 beta-induced PGE2 production, suggesting that the production of PGE2 induced by IL-1 beta required de novo protein synthesis.	Cycloheximide	15-18	interleukin 1 beta	Mus musculus	116-125
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	interleukin 1 beta	Mus musculus	39-48
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	prostaglandin-endoperoxide synthase 2	Mus musculus	57-63
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	prostaglandin-endoperoxide synthase 2	Mus musculus	174-180
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	prostaglandin-endoperoxide synthase 2	Mus musculus	174-180
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	interleukin 1 beta	Mus musculus	272-281
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	prostaglandin-endoperoxide synthase 2	Mus musculus	174-180
8852950-8	1996	Northern blot analysis determined that IL-1 beta induced PGHS-2 expression by 30 minutes and mRNA levels were maximal by 1-2 h. Cycloheximide potentiated the accumulation of PGHS-2 mRNA linearly up to 8 h. Dexamethasone, an inhibitor of the induction of PGHS-2, inhibited IL-1 beta-induced PGHS-2 mRNA expression and also suppressed IL-1 beta-stimulated formation of TRAP-positive MNC.	Cycloheximide	128-141	interleukin 1 beta	Mus musculus	272-281
8769851-8	1996	Moreover, the age-induced expression of the 38-kDa protein is preceded by a pronounced increase in the GAPDH mRNA level, which is abolished by actinomycin-D, cycloheximide, or the GAPDH antisense, but not sense, oligonucleotide.	Cycloheximide	158-171	glyceraldehyde-3-phosphate dehydrogenase	Homo sapiens	103-108
8774443-6	1996	Cycloheximide treatment of bcl-x-/- telencephalic cell cultures failed to prevent the increased cell death observed in low FCS-containing medium, suggesting a protein synthesis-independent apoptosis.	Cycloheximide	0-13	BCL2-like 1	Mus musculus	27-32
8648910-11	1996	The long term but not the short term effect of PMA to stimulate the Na-HCO3 cotransporter activity was prevented by the protein synthesis inhibitors, actinomycin D or cycloheximide.	Cycloheximide	167-180	electrogenic sodium bicarbonate cotransporter 1	Oryctolagus cuniculus	68-89
8700155-7	1996	The dexamethasone-induced increase in regucalcin mRNA levels was completely blocked by the simultaneous administration of cycloheximide (150 micrograms/100 g), although the drug administration had no effect on the mRNA levels in control rats.	Cycloheximide	122-135	regucalcin	Rattus norvegicus	38-48
8603706-3	1996	Even cycloheximide (CHX) added by itself elicited an early, sustained activation of NF-kappa B followed by an intense induction of iNOS gene expression, irrespective of what degree of protein synthesis inhibition was brought about by the several concentrations tested.	Cycloheximide	20-23	nitric oxide synthase 2	Rattus norvegicus	131-135
8603706-4	1996	When given together, TPA and CHX exerted additive effects on hepatocellular iNOS mRNA levels.	Cycloheximide	29-32	nitric oxide synthase 2	Rattus norvegicus	76-80
8603706-5	1996	These results suggest the likelihood of an ordered sequence of events by which an activated NF-kappa B mediates the induction of iNOS gene expression in TPA- and/or CHX-treated primary hepatocytes.	Cycloheximide	165-168	nitric oxide synthase 2	Rattus norvegicus	129-133
8701776-8	1996	The enhancement of metastases by IFN-gamma was dependent on de novo protein synthesis since the enhancement was abolished by cycloheximide.	Cycloheximide	125-138	interferon gamma	Mus musculus	33-42
8615377-2	1996	In the human U937 monoblast, C5aR is maximally expressed 4 days after treatment with 1,25(OH)2D3 (or cycloheximide) and prostaglandin E2 combined.	Cycloheximide	101-114	complement C5a receptor 1	Homo sapiens	29-33
8576219-5	1996	The S100 beta- stimulated nitrite production was blocked by cycloheximide and by the NOS inhibitor N-nitro-L-arginine methylester, but not by the inactive D-isomer of the inhibitor.	Cycloheximide	60-73	S100 calcium binding protein B	Rattus norvegicus	4-13
8617749-9	1996	However, the protein synthesis inhibitor cycloheximide blocked activation of hsp70 by low concentrations of IDAM.	Cycloheximide	41-54	heat shock protein family A (Hsp70) member 4	Homo sapiens	77-82
8598211-4	1996	Cycloheximide completely blocked the increase in TGase activity induced by HGF, suggesting that HGF stimulated de novo synthesis of TGase within 6 h. Both [35S]methionine incorporation and Northern blotting analyses supported this possibility.	Cycloheximide	0-13	hepatocyte growth factor	Rattus norvegicus	75-78
8598211-4	1996	Cycloheximide completely blocked the increase in TGase activity induced by HGF, suggesting that HGF stimulated de novo synthesis of TGase within 6 h. Both [35S]methionine incorporation and Northern blotting analyses supported this possibility.	Cycloheximide	0-13	hepatocyte growth factor	Rattus norvegicus	96-99
8598228-4	1996	Inhibition of protein synthesis by treatment with cycloheximide increased B-myb messenger RNA levels, suggesting that one or more labile proteins act as repressors of B-myb transcription.	Cycloheximide	50-63	MYB proto-oncogene like 2	Homo sapiens	74-79
8852838-2	1996	A can1 cyh2 cell carrying two negative selection markers, the CAN1 and CYH2 genes, on a YCp plasmid is sensitive to canavanine and cycloheximide, but the cell becomes resistant to both drugs when the plasmid has a deletion over the CAN1 and CYH2 genes.	Cycloheximide	131-144	arginine permease CAN1	Saccharomyces cerevisiae S288C	2-6
8852838-2	1996	A can1 cyh2 cell carrying two negative selection markers, the CAN1 and CYH2 genes, on a YCp plasmid is sensitive to canavanine and cycloheximide, but the cell becomes resistant to both drugs when the plasmid has a deletion over the CAN1 and CYH2 genes.	Cycloheximide	131-144	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	7-11
8852838-2	1996	A can1 cyh2 cell carrying two negative selection markers, the CAN1 and CYH2 genes, on a YCp plasmid is sensitive to canavanine and cycloheximide, but the cell becomes resistant to both drugs when the plasmid has a deletion over the CAN1 and CYH2 genes.	Cycloheximide	131-144	arginine permease CAN1	Saccharomyces cerevisiae S288C	62-66
8852838-2	1996	A can1 cyh2 cell carrying two negative selection markers, the CAN1 and CYH2 genes, on a YCp plasmid is sensitive to canavanine and cycloheximide, but the cell becomes resistant to both drugs when the plasmid has a deletion over the CAN1 and CYH2 genes.	Cycloheximide	131-144	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	71-75
21544372-7	1996	Subsequent addition of serum reactivates FGF-LC expression and further addition of cycloheximide results in superinduction of mRNA suggesting that FGF-4 may be classified as an early response gene.	Cycloheximide	83-96	fibroblast growth factor 4	Homo sapiens	147-152
8592007-7	1996	Degradation of Cx32 mRNA was blocked by the administration of actinomycin D, but not by cycloheximide, prior to injection of LPS.	Cycloheximide	88-101	gap junction protein, beta 1	Rattus norvegicus	15-19
8647902-4	1996	Tyrosine phosphorylation of PDGF beta-receptors induced by plating on collagen type I was inhibited by cytochalasin D and herbimycin A, unaffected by cycloheximide and enhanced by orthovanadate.	Cycloheximide	150-163	platelet derived growth factor subunit B	Homo sapiens	28-32
8822345-4	1996	The autostimulation of TGF-beta 1 mRNA was nullified by cycloheximide treatment of the cells.	Cycloheximide	56-69	transforming growth factor beta 1	Homo sapiens	23-33
8838651-9	1996	When HL60 cells were stimulated by diverse apoptosis inducers such as camptothecin, staurosporine, cycloheximide, and A23187, the extent of NuMA cleavage to produce a 180 kDa product was comparable with the degree of oligonucleosomal laddering.	Cycloheximide	99-112	nuclear mitotic apparatus protein 1	Homo sapiens	140-144
8632345-9	1996	The ability of RU-38486 and cycloheximide to block dexamethasone effects indicates that the steroid interference on mu-mediated withdrawal involves a protein synthesis-dependent mechanism via glucocorticoid receptor.	Cycloheximide	28-41	glucocorticoid receptor	Oryctolagus cuniculus	192-215
8611150-4	1996	Actinomycin D and cycloheximide treatment in vivo and in vitro indicated that laminin gamma 1 overexpression in cultured hepatocytes was under the control of transcriptional mechanisms.	Cycloheximide	18-31	laminin subunit gamma 1	Rattus norvegicus	78-93
8848429-6	1996	In cells pretreated with cycloheximide (CHX), induction of Egr-1 mRNA reached a maximum at 60 min and remained elevated for at least 240 min.	Cycloheximide	25-38	early growth response 1	Mus musculus	59-64
8645630-10	1996	Induction of synthesis of a short half-life peptide(s) with degradative activity was demonstrated by addition of cycloheximide or puromycine (both at 50 microM) which completely blocked ER disappearance.	Cycloheximide	113-126	estrogen receptor 1	Homo sapiens	186-188
8848429-6	1996	In cells pretreated with cycloheximide (CHX), induction of Egr-1 mRNA reached a maximum at 60 min and remained elevated for at least 240 min.	Cycloheximide	40-43	early growth response 1	Mus musculus	59-64
8561783-5	1996	Dexamethasone-induced ABP mRNA level was no change in the cells after addition of cycloheximide but almost reduced by actinomycin-D pretreatment.	Cycloheximide	82-95	sex hormone binding globulin	Rattus norvegicus	22-25
8561789-0	1996	Superinduction of NF-kappa B by actinomycin D and cycloheximide in epithelial cells.	Cycloheximide	50-63	nuclear factor kappa B subunit 1	Homo sapiens	18-28
8561789-5	1996	We also demonstrate that IL-1 beta costimulation with a protein synthesis inhibitor, cycloheximide, or a transcription blocker, actinomycin D, results in superinduction of NF-kappa B but not the transcription factors Oct 1, AP-1, and Sp-1.	Cycloheximide	85-98	interleukin 1 beta	Homo sapiens	25-34
8561789-5	1996	We also demonstrate that IL-1 beta costimulation with a protein synthesis inhibitor, cycloheximide, or a transcription blocker, actinomycin D, results in superinduction of NF-kappa B but not the transcription factors Oct 1, AP-1, and Sp-1.	Cycloheximide	85-98	nuclear factor kappa B subunit 1	Homo sapiens	172-182
8561789-5	1996	We also demonstrate that IL-1 beta costimulation with a protein synthesis inhibitor, cycloheximide, or a transcription blocker, actinomycin D, results in superinduction of NF-kappa B but not the transcription factors Oct 1, AP-1, and Sp-1.	Cycloheximide	85-98	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	224-228
8820971-5	1996	The induction of i-NOS by LPS was abolished by cycloheximide, actinomycin D, or dexamethasone.	Cycloheximide	47-60	nitric oxide synthase 2	Rattus norvegicus	17-22
9244191-7	1996	Unlike vascular smooth muscle cells, induction of HB-EGF gene transcription by TPA was blocked completely by incubation with cycloheximide, suggesting that protein synthesis may be a prerequisite for HB-EGF gene transcription in Mahlavu cells.	Cycloheximide	125-138	heparin binding EGF like growth factor	Homo sapiens	50-56
8726701-5	1996	Furthermore, the stimulatory effects of Ang II on PP2A activity were inhibited by pretreatment of cultures with pertussis toxin (PTX) (200 ng/ml; 24 h) indicating the involvement of an inhibitory G-protein; and by cycloheximide (CHX) (1 microgram/ml; 30 min) indicating a requirement for protein synthesis.	Cycloheximide	214-227	angiotensinogen	Rattus norvegicus	40-46
8726701-5	1996	Furthermore, the stimulatory effects of Ang II on PP2A activity were inhibited by pretreatment of cultures with pertussis toxin (PTX) (200 ng/ml; 24 h) indicating the involvement of an inhibitory G-protein; and by cycloheximide (CHX) (1 microgram/ml; 30 min) indicating a requirement for protein synthesis.	Cycloheximide	229-232	angiotensinogen	Rattus norvegicus	40-46
8615653-5	1996	Cycloheximide superinduced the expression of TNF-alpha mRNA and, accordingly, the release of its protein.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	45-54
8772428-5	1996	In GMC, cycloheximide inhibited MEK-1 mRNA induction but stimulated p42 MAPK mRNA expression in the absence and presence of FBS, ET-1, or PDGF.	Cycloheximide	8-21	mitogen activated protein kinase kinase 1	Rattus norvegicus	32-37
8772428-5	1996	In GMC, cycloheximide inhibited MEK-1 mRNA induction but stimulated p42 MAPK mRNA expression in the absence and presence of FBS, ET-1, or PDGF.	Cycloheximide	8-21	mitogen activated protein kinase 1	Rattus norvegicus	68-76
8562392-4	1996	Cycloheximide abrogated the effects of both GM-CSF and butyrate.	Cycloheximide	0-13	colony stimulating factor 2	Homo sapiens	44-50
8788500-4	1996	The 5-HT-induced increase in Levels on 5-HT2A receptor mRNA did not require de novo protein synthesis since the increase was not affected by prior treatment with the protein synthesis inhibitor cycloheximide.	Cycloheximide	194-207	5-hydroxytryptamine receptor 2A	Homo sapiens	39-54
9075572-4	1996	Human EpoR gene expression was significantly upregulated by IL-1 alpha and the protein inhibitor cycloheximide, but significantly downregulated by the calcium ionophore ionomycin and the phorbol ester PMA.	Cycloheximide	97-110	erythropoietin receptor	Homo sapiens	6-10
8866697-7	1996	A surprising induction of DOR mRNA by the protein synthesis inhibitor cycloheximide (CHX) suggests that either a repressor molecule or degrading enzymes/proteases may regulate basal levels of this mRNA.	Cycloheximide	70-83	opioid receptor, delta 1	Mus musculus	26-29
8866697-7	1996	A surprising induction of DOR mRNA by the protein synthesis inhibitor cycloheximide (CHX) suggests that either a repressor molecule or degrading enzymes/proteases may regulate basal levels of this mRNA.	Cycloheximide	85-88	opioid receptor, delta 1	Mus musculus	26-29
8548766-2	1996	In human K562 erythroleukemic cells, PGA1 induces the synthesis of a M(r) 70,000 hsp (hsp70) by cycloheximide-sensitive activation of heat shock transcription factor (HSF).	Cycloheximide	96-109	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	81-84
8548766-2	1996	In human K562 erythroleukemic cells, PGA1 induces the synthesis of a M(r) 70,000 hsp (hsp70) by cycloheximide-sensitive activation of heat shock transcription factor (HSF).	Cycloheximide	96-109	heat shock protein family A (Hsp70) member 4	Homo sapiens	86-91
8548766-2	1996	In human K562 erythroleukemic cells, PGA1 induces the synthesis of a M(r) 70,000 hsp (hsp70) by cycloheximide-sensitive activation of heat shock transcription factor (HSF).	Cycloheximide	96-109	interleukin 6	Homo sapiens	134-165
8548766-2	1996	In human K562 erythroleukemic cells, PGA1 induces the synthesis of a M(r) 70,000 hsp (hsp70) by cycloheximide-sensitive activation of heat shock transcription factor (HSF).	Cycloheximide	96-109	interleukin 6	Homo sapiens	167-170
8835848-10	1996	The insulin-induced increase in pro-alpha 1 (I) collagen mRNA was blocked by the presence of cycloheximide indicating a requirement for new protein synthesis.	Cycloheximide	93-106	insulin	Homo sapiens	4-11
8546699-4	1996	Cycloheximide completely blocked the increase in TGase activity induced by EGF, suggesting that EGF stimulated de novo synthesis of TGase within 6 h. Furthermore, Northern blotting analysis indicated that EGF increased the expression of TGase mRNA.	Cycloheximide	0-13	epidermal growth factor like 1	Rattus norvegicus	75-78
8536624-6	1996	The induction of the IGFBP-4 transcript persisted up to 48 h. This response was inhibited by cycloheximide as well as actinomycin D.	Cycloheximide	93-106	insulin-like growth factor binding protein 4	Mus musculus	21-28
8546699-4	1996	Cycloheximide completely blocked the increase in TGase activity induced by EGF, suggesting that EGF stimulated de novo synthesis of TGase within 6 h. Furthermore, Northern blotting analysis indicated that EGF increased the expression of TGase mRNA.	Cycloheximide	0-13	epidermal growth factor like 1	Rattus norvegicus	96-99
8546699-4	1996	Cycloheximide completely blocked the increase in TGase activity induced by EGF, suggesting that EGF stimulated de novo synthesis of TGase within 6 h. Furthermore, Northern blotting analysis indicated that EGF increased the expression of TGase mRNA.	Cycloheximide	0-13	epidermal growth factor like 1	Rattus norvegicus	96-99
8622563-14	1996	Nitric oxide synthase (NOS) inhibitors, superoxide dismutase (SOD), catalase, mannitol and cycloheximide, reversed the edema suppressions by TGF-beta1 +/- immunosuppressant at 30 min and 6 hr after Dex.	Cycloheximide	91-104	transforming growth factor, beta 1	Mus musculus	141-150
8680718-9	1995	6 Studies with IL-1 alpha/IFN-gamma combination demonstrated a time dependent expression of iNOS mRNA, first observed at 6 h, peaked at 24 h and was undetectable by 72 h. IL-1 alpha (0.3-10 ng ml-1) and IFN-gamma (10-300 u ml-1) in combination induced a concentration-dependent expression of iNOS mRNA at 24 h. 7 Pretreatment with cycloheximide before IL-1 alpha/IFN-gamma stimulation reduced nitrite levels to basal values.	Cycloheximide	331-344	interleukin 1 alpha	Homo sapiens	15-25
8680718-9	1995	6 Studies with IL-1 alpha/IFN-gamma combination demonstrated a time dependent expression of iNOS mRNA, first observed at 6 h, peaked at 24 h and was undetectable by 72 h. IL-1 alpha (0.3-10 ng ml-1) and IFN-gamma (10-300 u ml-1) in combination induced a concentration-dependent expression of iNOS mRNA at 24 h. 7 Pretreatment with cycloheximide before IL-1 alpha/IFN-gamma stimulation reduced nitrite levels to basal values.	Cycloheximide	331-344	interferon gamma	Homo sapiens	26-35
8680718-9	1995	6 Studies with IL-1 alpha/IFN-gamma combination demonstrated a time dependent expression of iNOS mRNA, first observed at 6 h, peaked at 24 h and was undetectable by 72 h. IL-1 alpha (0.3-10 ng ml-1) and IFN-gamma (10-300 u ml-1) in combination induced a concentration-dependent expression of iNOS mRNA at 24 h. 7 Pretreatment with cycloheximide before IL-1 alpha/IFN-gamma stimulation reduced nitrite levels to basal values.	Cycloheximide	331-344	nitric oxide synthase 2	Homo sapiens	92-96
8719803-13	1995	Cycloheximide (1 microM) abolished induction of L-arginine transport and nitrite accumulation in response to LPS and IFN-gamma.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	117-126
7588308-2	1995	We have now demonstrated that Apo A-I also causes a secondary increase in hPL release, beginning about 6 h after exposure to Apo A-I, that is blocked by cycloheximide and actinomycin D.	Cycloheximide	153-166	apolipoprotein A1	Homo sapiens	30-37
7588308-2	1995	We have now demonstrated that Apo A-I also causes a secondary increase in hPL release, beginning about 6 h after exposure to Apo A-I, that is blocked by cycloheximide and actinomycin D.	Cycloheximide	153-166	galectin 1	Homo sapiens	74-77
7588308-2	1995	We have now demonstrated that Apo A-I also causes a secondary increase in hPL release, beginning about 6 h after exposure to Apo A-I, that is blocked by cycloheximide and actinomycin D.	Cycloheximide	153-166	apolipoprotein A1	Homo sapiens	125-132
9363259-10	1995	Only hCG kinetics were significantly different between tissue incubated with and without cycloheximide or iodoacetic acid.	Cycloheximide	89-102	chorionic gonadotropin subunit beta 5	Homo sapiens	5-8
8565625-6	1996	The results from treatment of BEL hybrids with actinomycin D or cycloheximide suggested that suppression of lck gene expression in the hybrids might not be due to posttranscriptional control.	Cycloheximide	64-77	lymphocyte protein tyrosine kinase	Mus musculus	108-111
8536642-0	1996	Acute nuclear actions of growth hormone (GH): cycloheximide inhibits inducible activator protein-1 activity, but does not block GH-regulated signal transducer and activator of transcription activation or gene expression.	Cycloheximide	46-59	growth hormone 1	Homo sapiens	25-39
8536642-0	1996	Acute nuclear actions of growth hormone (GH): cycloheximide inhibits inducible activator protein-1 activity, but does not block GH-regulated signal transducer and activator of transcription activation or gene expression.	Cycloheximide	46-59	growth hormone 1	Homo sapiens	41-43
8536642-0	1996	Acute nuclear actions of growth hormone (GH): cycloheximide inhibits inducible activator protein-1 activity, but does not block GH-regulated signal transducer and activator of transcription activation or gene expression.	Cycloheximide	46-59	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	79-98
8536642-3	1996	In this study, we have used the protein synthesis inhibitor, cycloheximide (CHX), to investigate which of the acute actions of GH are primary hormonal responses and which require concurrent protein synthesis.	Cycloheximide	61-74	growth hormone 1	Homo sapiens	127-129
8536642-3	1996	In this study, we have used the protein synthesis inhibitor, cycloheximide (CHX), to investigate which of the acute actions of GH are primary hormonal responses and which require concurrent protein synthesis.	Cycloheximide	76-79	growth hormone 1	Homo sapiens	127-129
8536642-6	1996	By contrast, CHX completely inhibits the induction of activator protein-1 DNA-binding activity by GH, indicating that this action is secondary to the stimulation of Fos and/or Jun protein biosynthesis.	Cycloheximide	13-16	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	54-73
8536642-6	1996	By contrast, CHX completely inhibits the induction of activator protein-1 DNA-binding activity by GH, indicating that this action is secondary to the stimulation of Fos and/or Jun protein biosynthesis.	Cycloheximide	13-16	growth hormone 1	Homo sapiens	98-100
8536642-6	1996	By contrast, CHX completely inhibits the induction of activator protein-1 DNA-binding activity by GH, indicating that this action is secondary to the stimulation of Fos and/or Jun protein biosynthesis.	Cycloheximide	13-16	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	165-168
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	99-112	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	4-8
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	99-112	tumor necrosis factor	Mus musculus	4-7
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	99-112	tumor necrosis factor	Mus musculus	57-60
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	114-117	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	4-8
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	114-117	tumor necrosis factor	Mus musculus	4-7
21544346-4	1996	The TNFr 10T1/2 cells, however, exhibited sensitivity to TNF-induced cell death in the presence of cycloheximide (CHX), whereas TNFs 10T-EJ cells did not show any further increase in sensitivity to TNF-induced cell death in the presence of CHX.	Cycloheximide	114-117	tumor necrosis factor	Mus musculus	57-60
8867766-6	1996	The protein synthesis inhibitor cycloheximide abrogated the effects of IL-1 alpha, IL-1 beta and TNF-alpha on KGF gene induction, indicating that new protein synthesis is required in the process.	Cycloheximide	32-45	interleukin 1 alpha	Homo sapiens	71-81
8867766-6	1996	The protein synthesis inhibitor cycloheximide abrogated the effects of IL-1 alpha, IL-1 beta and TNF-alpha on KGF gene induction, indicating that new protein synthesis is required in the process.	Cycloheximide	32-45	interleukin 1 beta	Homo sapiens	83-92
8867766-6	1996	The protein synthesis inhibitor cycloheximide abrogated the effects of IL-1 alpha, IL-1 beta and TNF-alpha on KGF gene induction, indicating that new protein synthesis is required in the process.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	97-106
8867766-6	1996	The protein synthesis inhibitor cycloheximide abrogated the effects of IL-1 alpha, IL-1 beta and TNF-alpha on KGF gene induction, indicating that new protein synthesis is required in the process.	Cycloheximide	32-45	fibroblast growth factor 7	Homo sapiens	110-113
8598463-4	1996	Our experiments revealed a near perfect correlation between the activity of cPLA2 per cell and susceptibility to TNF in the presence of either cycloheximide (CHI) or actinomycin D (r = 0.97).	Cycloheximide	143-156	phospholipase A2 group IVA	Homo sapiens	76-81
8598463-4	1996	Our experiments revealed a near perfect correlation between the activity of cPLA2 per cell and susceptibility to TNF in the presence of either cycloheximide (CHI) or actinomycin D (r = 0.97).	Cycloheximide	143-156	tumor necrosis factor	Homo sapiens	113-116
8788263-8	1996	The LPS- and TNF-induced increase in arginine transport activity was blocked by cycloheximide and actinomycin D, indicating the requirement for RNA and protein synthesis.	Cycloheximide	80-93	tumor necrosis factor	Rattus norvegicus	13-16
8624460-5	1996	In this review, a novel posttranscriptional regulation of ICAM-1 gene expression by two inflammatory mediators, interferon-gamma and phorbol myristate acetate, and the possible role of the serine/threonine phosphorylation pathway in the cycloheximide-induced ICAM-1 message stabilization are discussed in light of our current understanding of ICAM-1 gene regulation during an inflammatory response.	Cycloheximide	237-250	intercellular adhesion molecule 1	Homo sapiens	58-64
8624460-5	1996	In this review, a novel posttranscriptional regulation of ICAM-1 gene expression by two inflammatory mediators, interferon-gamma and phorbol myristate acetate, and the possible role of the serine/threonine phosphorylation pathway in the cycloheximide-induced ICAM-1 message stabilization are discussed in light of our current understanding of ICAM-1 gene regulation during an inflammatory response.	Cycloheximide	237-250	interferon gamma	Homo sapiens	112-128
8978021-1	1996	The immediate early protein (IE180) of pseudorabies virus (PrV) was generated by cycloheximide (CHX) reversal procedures in PrV-infected swine skin cells.	Cycloheximide	81-94	transcriptional regulator ICP4	Suid alphaherpesvirus 1	29-34
8978021-1	1996	The immediate early protein (IE180) of pseudorabies virus (PrV) was generated by cycloheximide (CHX) reversal procedures in PrV-infected swine skin cells.	Cycloheximide	96-99	transcriptional regulator ICP4	Suid alphaherpesvirus 1	29-34
8537383-9	1995	Cycloheximide treatment further augmented expression of VEGF mRNA induced by cobalt chloride, nickel chloride, and hypoxia in HUVECs.	Cycloheximide	0-13	vascular endothelial growth factor A	Homo sapiens	56-60
8530448-3	1995	Adhesion was found to be inhibited by cycloheximide or actinomycin D, implicating protein synthesis and gene expression in u-PA-induced monocyte adhesion.	Cycloheximide	38-51	plasminogen activator, urokinase	Homo sapiens	123-127
8610279-9	1995	Pretreatment with cycloheximide or actinomycin D abated the response of HUVEC to N-acetylsphingosine in the increased levels of both extracellular and intracellular PAI-1.	Cycloheximide	18-31	serpin family E member 1	Homo sapiens	165-170
7493976-7	1995	Furthermore, the transcription inhibitor actinomycin D and translation inhibitor cycloheximide suppressed TfR mRNA degradation but did not interfere with the IRP dissociation step.	Cycloheximide	81-94	transferrin receptor	Homo sapiens	106-109
8570169-7	1995	In addition, cycloheximide and actinomycin D inhibited wt p53-induced apoptosis.	Cycloheximide	13-26	tumor protein p53	Homo sapiens	58-61
8572166-8	1995	In contrast to blocking NCX induction, cycloheximide potentiated c-Myc induction by serum.	Cycloheximide	39-52	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	65-70
8572176-6	1995	When cellular protein synthesis was inhibited by addition of cycloheximide, gastrin superinduced c-myc mRNA levels.	Cycloheximide	61-74	gastrin	Rattus norvegicus	76-83
8572176-6	1995	When cellular protein synthesis was inhibited by addition of cycloheximide, gastrin superinduced c-myc mRNA levels.	Cycloheximide	61-74	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	97-102
8519657-7	1995	The accumulation of TAM-induced TGF-beta 1 mRNA was increased by cycloheximide, but was not affected by 17 beta-oestradiol.	Cycloheximide	65-78	transforming growth factor beta 1	Homo sapiens	32-42
7586222-5	1995	Destabilization of elastin mRNA can be prevented by incubation in the presence of blockers of DNA transcription (5,6-dichlorobenzimidazole riboside and actinomycin D) and mRNA translation (cycloheximide).	Cycloheximide	189-202	elastin	Gallus gallus	19-26
8690026-7	1995	The treatment of EUE cells with cycloheximide led to superinduction of c-fos expression, (with high levels up to 12 h), and to a c-jun expression that was just detectable.	Cycloheximide	32-45	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-76
8690026-7	1995	The treatment of EUE cells with cycloheximide led to superinduction of c-fos expression, (with high levels up to 12 h), and to a c-jun expression that was just detectable.	Cycloheximide	32-45	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	129-134
7498472-3	1995	When exponential (sensitive) cells were subjected to short-term heating with recovery to accumulate inducible form of HSP70, they also became resistant to all of the employed apoptosis-inducing exposures, and an inhibitor of cytosolic protein synthesis, cycloheximide, prevented acquisition of the resistance.	Cycloheximide	254-267	heat shock protein 1B	Mus musculus	118-123
7493649-4	1995	Both cycloheximide and alpha-amanitin inhibited the increase in uPAR mRNA levels, demonstrating the requirement for the de novo synthesis of a short-lived protein for transcriptional activation.	Cycloheximide	5-18	plasminogen activator, urokinase receptor	Homo sapiens	64-68
8522525-3	1995	A gene encoding the ribosomal protein L41 was cloned from C. utilis, which is sensitive to cycloheximide, and used as a marker gene conferring cycloheximide resistance after modification of its amino acid sequence.	Cycloheximide	91-104	ribosomal protein L41	Homo sapiens	38-41
8522525-3	1995	A gene encoding the ribosomal protein L41 was cloned from C. utilis, which is sensitive to cycloheximide, and used as a marker gene conferring cycloheximide resistance after modification of its amino acid sequence.	Cycloheximide	143-156	ribosomal protein L41	Homo sapiens	38-41
8522525-4	1995	The marker gene was constructed by substitution of the proline codon at position 56 with the glutamine codon by in vitro mutagenesis, as it had been reported previously that the 56th amino acid residue of L41 is responsible for the cycloheximide sensitivity of various organisms (S. Kawai, S. Murao, M. Mochizuki, I. Shibuya, K. Yano, and M. Takagi, J. Bacteriol.	Cycloheximide	232-245	ribosomal protein L41	Homo sapiens	205-208
7500055-10	1995	Exposure of OA-affected cartilage to interleukin 1 beta, tumor necrosis factor-alpha, and lipopolysaccharide resulted in approximately 20-50% augmentation of nitrite accumulation, which was also sensitive to cycloheximide and pyrrolidine dithiocarbamate.	Cycloheximide	208-221	interleukin 1 beta	Homo sapiens	37-84
8543924-6	1995	Inclusion of actinomycin D (1.78 mumol/l) or cycloheximide (0.8 mumol/l), inhibitors of RNA and protein synthesis respectively, in the medium effectively abrogated the inhibitory effects of dexamethasone (0.1 mumol/l) on the secretory responses to TRH (10 nmol/l), VIP (10 nmol/l) and forskolin (100 mumol/l).	Cycloheximide	45-58	vasoactive intestinal peptide	Rattus norvegicus	265-268
8675632-7	1995	Treatment with cycloheximide produced a threefold increase in cNOS mRNA at all O2 concentrations, suggesting that cNOS mRNA expression is negatively regulated under basal condition.	Cycloheximide	15-28	nitric oxide synthase 3	Bos taurus	62-66
8675632-7	1995	Treatment with cycloheximide produced a threefold increase in cNOS mRNA at all O2 concentrations, suggesting that cNOS mRNA expression is negatively regulated under basal condition.	Cycloheximide	15-28	nitric oxide synthase 3	Bos taurus	114-118
8524254-1	1995	Semidominant mutations in the PDR1 or PDR3 gene lead to elevated resistance to cycloheximide and oligomycin.	Cycloheximide	79-92	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	30-34
8524254-1	1995	Semidominant mutations in the PDR1 or PDR3 gene lead to elevated resistance to cycloheximide and oligomycin.	Cycloheximide	79-92	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	38-42
8524254-3	1995	Cycloheximide resistance mediated by PDR1 and PDR3 requires the presence of the PDR5 membrane transporter-encoding gene.	Cycloheximide	0-13	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	37-41
8524254-3	1995	Cycloheximide resistance mediated by PDR1 and PDR3 requires the presence of the PDR5 membrane transporter-encoding gene.	Cycloheximide	0-13	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	46-50
8524254-3	1995	Cycloheximide resistance mediated by PDR1 and PDR3 requires the presence of the PDR5 membrane transporter-encoding gene.	Cycloheximide	0-13	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	80-84
8590805-4	1995	A kinetic analysis of integrin internalization in cycloheximide-treated NRK cells showed that each of the fibroblast integrins we examined (in both the beta 1 and beta 3 families) are lost from the cell surface after detachment from substratum.	Cycloheximide	50-63	hemoglobin, beta adult major chain	Mus musculus	152-169
8536719-2	1995	In the present study, we show that DEUP blocks the cAMP-stimulated mitochondrial accumulation of the 30-kDa mitochondrial proteins (recently named steroidogenic acute regulatory StAR proteins) that are believed to be the cycloheximide-sensitive factors induced by trophic hormones and cAMP.	Cycloheximide	221-234	steroidogenic acute regulatory protein	Rattus norvegicus	178-182
8719890-8	1995	The effect of the kinase and phosphatase blockers was inhibitable by agents known to affect protein synthesis (cycloheximide) and exportation (brefeldin A), indicating that the restored cell-cell contacts were mediated chiefly by an intracellular pool of N-cadherin molecules recruited to the membrane.	Cycloheximide	111-124	cadherin 2	Homo sapiens	255-265
7595061-5	1995	Cycloheximide treatment of the cultures containing M-CSF and IFN-gamma inhibited the production of IL-1 beta and TNF-alpha.	Cycloheximide	0-13	colony stimulating factor 1	Homo sapiens	51-56
8547188-9	1995	A recently identified protein termed Steroidogenic Acute Regulatory protein (StAR) has the necessary properties of enhancing steroidogenesis, rapid cAMP inducibility and rapid cycloheximide sensitivity that characterize the long-sought acute regulator of steroidogenesis.	Cycloheximide	176-189	steroidogenic acute regulatory protein	Homo sapiens	37-75
8547188-9	1995	A recently identified protein termed Steroidogenic Acute Regulatory protein (StAR) has the necessary properties of enhancing steroidogenesis, rapid cAMP inducibility and rapid cycloheximide sensitivity that characterize the long-sought acute regulator of steroidogenesis.	Cycloheximide	176-189	steroidogenic acute regulatory protein	Homo sapiens	77-81
7589574-5	1995	MCP-1 mRNA levels were regulated by changes in the stability of the mRNA: inhibition of protein synthesis by cycloheximide by itself induced MCP-1 mRNA expression and led to superinduction in the presence of PDGF.	Cycloheximide	109-122	C-C motif chemokine ligand 2	Rattus norvegicus	0-5
7589574-5	1995	MCP-1 mRNA levels were regulated by changes in the stability of the mRNA: inhibition of protein synthesis by cycloheximide by itself induced MCP-1 mRNA expression and led to superinduction in the presence of PDGF.	Cycloheximide	109-122	C-C motif chemokine ligand 2	Rattus norvegicus	141-146
7579439-9	1995	Brief treatment of IL-1 alpha/TNF alpha-stimulated CDCL cells with cycloheximide before receptor induction reduces the synergistic increase in growth factor mRNA by 40% to 60% compared with cells not treated with CHX.	Cycloheximide	67-80	interleukin 1 alpha	Homo sapiens	19-29
7579439-9	1995	Brief treatment of IL-1 alpha/TNF alpha-stimulated CDCL cells with cycloheximide before receptor induction reduces the synergistic increase in growth factor mRNA by 40% to 60% compared with cells not treated with CHX.	Cycloheximide	67-80	tumor necrosis factor	Homo sapiens	30-39
7579439-9	1995	Brief treatment of IL-1 alpha/TNF alpha-stimulated CDCL cells with cycloheximide before receptor induction reduces the synergistic increase in growth factor mRNA by 40% to 60% compared with cells not treated with CHX.	Cycloheximide	213-216	interleukin 1 alpha	Homo sapiens	19-29
7579439-9	1995	Brief treatment of IL-1 alpha/TNF alpha-stimulated CDCL cells with cycloheximide before receptor induction reduces the synergistic increase in growth factor mRNA by 40% to 60% compared with cells not treated with CHX.	Cycloheximide	213-216	tumor necrosis factor	Homo sapiens	30-39
8581287-9	1995	Relaxation responses to des-ARg9-BK, but not BK, at both 3 h and 6 h were significantly attenuated by the protein synthesis inhibitors, cycloheximide (30 and 100 microM) and actinomycin D (2 microM).	Cycloheximide	136-149	kininogen 1	Bos taurus	33-35
7593204-14	1995	Furthermore, these are the first studies to demonstrate that polysomal destabilization by PURO can block CHX induction of pgp.	Cycloheximide	105-108	phosphoglycolate phosphatase	Homo sapiens	122-125
7593213-9	1995	Inhibition of protein synthesis by cycloheximide resulted in a large increase in RXR alpha and RXR beta mRNA levels.	Cycloheximide	35-48	retinoid X receptor alpha	Mus musculus	81-90
7593213-9	1995	Inhibition of protein synthesis by cycloheximide resulted in a large increase in RXR alpha and RXR beta mRNA levels.	Cycloheximide	35-48	retinoid X receptor beta	Mus musculus	95-103
7593213-10	1995	This effect of cycloheximide was time and concentration dependent with maximal stimulation of RXR alpha and RXR beta mRNAs occurring at 4 h of treatment.	Cycloheximide	15-28	retinoid X receptor alpha	Mus musculus	94-103
7593213-10	1995	This effect of cycloheximide was time and concentration dependent with maximal stimulation of RXR alpha and RXR beta mRNAs occurring at 4 h of treatment.	Cycloheximide	15-28	retinoid X receptor beta	Mus musculus	108-116
7593213-11	1995	Inhibition of transcription with actinomycin D completely abolished the cycloheximide-induced increase of RXR beta.	Cycloheximide	72-85	retinoid X receptor beta	Mus musculus	106-114
7593213-13	1995	Nuclear run-on assays showed that cycloheximide treatment of intact B16 melanoma cells stimulated the transcription rate of RXR beta, but not RXR alpha.	Cycloheximide	34-47	retinoid X receptor beta	Mus musculus	124-132
8656066-9	1995	However, cycloheximide induced a selective degradation of MSR I transcripts, leaving MSR II levels unaltered.	Cycloheximide	9-22	progestin and adipoQ receptor family member 7	Homo sapiens	58-61
8544401-3	1995	The purpose of these studies was (1) to determine whether c-fos is expressed as part of a typical immediate-early (IE) gene response, which would require co-expression of c-jun and sensitivity to cycloheximide, and (2) to determine whether the cells expressing c-Fos are the same as those undergoing DNA synthesis.	Cycloheximide	196-209	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
8544401-5	1995	c-jun and c-fos mRNA were rapidly and briefly expressed following renal ischemia and their expression was superinduced by cycloheximide in a manner typical of an immediate-early gene response.	Cycloheximide	122-135	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
7556928-4	1995	Strong superinduction of Gnot1 transcripts in the presence of cycloheximide also indicates the presence of a potent and labile intracellular inhibitor capable of modulating Gnot1 expression.	Cycloheximide	62-75	notochord homeobox	Gallus gallus	25-30
7556928-4	1995	Strong superinduction of Gnot1 transcripts in the presence of cycloheximide also indicates the presence of a potent and labile intracellular inhibitor capable of modulating Gnot1 expression.	Cycloheximide	62-75	notochord homeobox	Gallus gallus	173-178
8904315-0	1995	Regulation of ICAM-1 mRNA stability by cycloheximide: role of serine/threonine phosphorylation and protein synthesis.	Cycloheximide	39-52	intercellular adhesion molecule 1	Mus musculus	14-20
8904315-3	1995	We examined the effect of cycloheximide on the murine intercellular adhesion molecule-1 (ICAM-1; CD54) gene expression in several cell lines including A20 (B cell lymphoma), T28 (T cell hybridoma), P388D1 (monocytic cell), SVEC4-10 (lymphoid endothelial cell), and ICAM-1-transfected murine fibroblast L cells.	Cycloheximide	26-39	intercellular adhesion molecule 1	Mus musculus	54-87
8904315-3	1995	We examined the effect of cycloheximide on the murine intercellular adhesion molecule-1 (ICAM-1; CD54) gene expression in several cell lines including A20 (B cell lymphoma), T28 (T cell hybridoma), P388D1 (monocytic cell), SVEC4-10 (lymphoid endothelial cell), and ICAM-1-transfected murine fibroblast L cells.	Cycloheximide	26-39	intercellular adhesion molecule 1	Mus musculus	89-95
8904315-3	1995	We examined the effect of cycloheximide on the murine intercellular adhesion molecule-1 (ICAM-1; CD54) gene expression in several cell lines including A20 (B cell lymphoma), T28 (T cell hybridoma), P388D1 (monocytic cell), SVEC4-10 (lymphoid endothelial cell), and ICAM-1-transfected murine fibroblast L cells.	Cycloheximide	26-39	intercellular adhesion molecule 1	Mus musculus	97-101
8904315-4	1995	Cycloheximide was indeed able to dramatically increase the accumulation of ICAM-1 mRNA in all the cell lines examined except T28, and this seemed to be due to the stabilization of the ICAM-1 mRNA as indicated by the half-life analysis.	Cycloheximide	0-13	intercellular adhesion molecule 1	Mus musculus	75-81
8904315-4	1995	Cycloheximide was indeed able to dramatically increase the accumulation of ICAM-1 mRNA in all the cell lines examined except T28, and this seemed to be due to the stabilization of the ICAM-1 mRNA as indicated by the half-life analysis.	Cycloheximide	0-13	intercellular adhesion molecule 1	Mus musculus	184-190
8904315-7	1995	The effect of cycloheximide on ICAM-1 mRNA was markedly suppressed by serine/threonine (ser/thr) kinase inhibitors, H-7 and staurosporine, whereas the ser/thr phosphatase inhibitor, okadaic acid, augmented the cycloheximide effect.	Cycloheximide	14-27	intercellular adhesion molecule 1	Mus musculus	31-37
8904315-7	1995	The effect of cycloheximide on ICAM-1 mRNA was markedly suppressed by serine/threonine (ser/thr) kinase inhibitors, H-7 and staurosporine, whereas the ser/thr phosphatase inhibitor, okadaic acid, augmented the cycloheximide effect.	Cycloheximide	210-223	intercellular adhesion molecule 1	Mus musculus	31-37
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	158-171	intercellular adhesion molecule 1	Mus musculus	40-46
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	158-171	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	158-171	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	158-171	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	348-361	intercellular adhesion molecule 1	Mus musculus	40-46
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	348-361	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	348-361	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-9	1995	Unexpectedly, the level of cell surface ICAM-1 as well as de novo synthesis of ICAM-1 in SVEC4-10 and the ICAM-1-transfected L cells were also upregulated by cycloheximide, whereas the overall protein synthesis in these cells was profoundly inhibited, suggesting that ICAM-1 protein synthesis in these cells escapes the translational inhibition by cycloheximide.	Cycloheximide	348-361	intercellular adhesion molecule 1	Mus musculus	79-85
8904315-10	1995	These results suggest that the stabilization of ICAM-1 mRNA by cycloheximide is independent of its translational inhibition and that ser/thr phosphorylation of unidentified protein(s) seems to play a crucial role in this effect.	Cycloheximide	63-76	intercellular adhesion molecule 1	Mus musculus	48-54
7476894-7	1995	The increased expression was suppressed by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, an RNA synthesis inhibitor, whereas the protein synthesis inhibitor cycloheximide enhanced the expression several-fold, suggesting that induction of mdr1 by these analogues is regulated at both the transcriptional and post-transcriptional levels.	Cycloheximide	161-174	ATP binding cassette subfamily B member 1	Homo sapiens	242-246
7476903-3	1995	This effect was concentration dependent and resulted in a 20-40-fold increase in the release of TNF-alpha that was sensitive to actinomycin D and cycloheximide.	Cycloheximide	146-159	tumor necrosis factor	Homo sapiens	96-105
8559306-2	1995	The antitumor activity of TNF-alpha against C6 cells was partially inhibited by actinomycin D and cycloheximide, suggesting that it is possibly dependent upon new ribonucleic acid and protein synthesis.	Cycloheximide	98-111	tumor necrosis factor	Rattus norvegicus	26-35
8584140-8	1995	Cycloheximide increased CCK mRNA levels when compared to isoproterenol acting alone.	Cycloheximide	0-13	cholecystokinin	Homo sapiens	24-27
8592587-5	1995	The effect of cycloheximide or acinomycin D was also examined on the increase in ET production by rHuEpo.	Cycloheximide	14-27	endothelin 1	Homo sapiens	81-83
8592587-8	1995	The supernatant concentrations of ET cultured with rHuEpo at 5000 mU/ml or more showed significantly greater values than those without rHuEpo and the increase in ET in the supernatants of media containing 5000 mU/ml rHuEpo was inhibited by incubation with 0.2 microgram/ml actinomycin D or 10 micrograms/ml cycloheximide.	Cycloheximide	307-320	endothelin 1	Homo sapiens	34-36
8592587-8	1995	The supernatant concentrations of ET cultured with rHuEpo at 5000 mU/ml or more showed significantly greater values than those without rHuEpo and the increase in ET in the supernatants of media containing 5000 mU/ml rHuEpo was inhibited by incubation with 0.2 microgram/ml actinomycin D or 10 micrograms/ml cycloheximide.	Cycloheximide	307-320	endothelin 1	Homo sapiens	162-164
7558437-7	1995	Pre-treatment of PSN-1 cells by an inhibitor of protein synthesis, cycloheximide, or of protein processing, benzyl-N-acetyl-alpha-D-galactosaminide, reduced endothelial-cell-retraction activity in the CM.	Cycloheximide	67-80	5'-nucleotidase, cytosolic IIIA	Homo sapiens	17-22
7575510-5	1995	Superinduction of CYP1A1 mRNA occurred in cells treated with cycloheximide.	Cycloheximide	61-74	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	18-24
7575539-5	1995	The dexamethasone-stimulated increase of ob mRNA was only partially blocked by protein synthesis inhibitors cycloheximide (20 micrograms/ml) or anisomycin (200 microM).	Cycloheximide	108-121	leptin	Rattus norvegicus	41-43
7575668-6	1995	The glucocorticoid-dependent alteration in LC-1 distribution in C6 glioma cells was attenuated by the protein synthesis inhibitor, cycloheximide, indicating the involvement of de novo LC-1 synthesis.	Cycloheximide	131-144	annexin A1	Homo sapiens	43-47
7575668-6	1995	The glucocorticoid-dependent alteration in LC-1 distribution in C6 glioma cells was attenuated by the protein synthesis inhibitor, cycloheximide, indicating the involvement of de novo LC-1 synthesis.	Cycloheximide	131-144	annexin A1	Homo sapiens	184-188
7548228-3	1995	Northern blot analysis and nuclear run-on assay revealed that uPA gene transcription was repressed by Bt2cAMP and the repression was negated by inhibition of de novo protein synthesis by cycloheximide.	Cycloheximide	187-200	plasminogen activator, urokinase	Homo sapiens	62-65
7662972-2	1995	Treatment of a human myelogenous leukemia cell line, ML-1a, with TNF in the presence of cycloheximide triggers endonucleolytic activity and apoptotic cell death within 90 minutes.	Cycloheximide	88-101	tumor necrosis factor	Homo sapiens	65-68
11854837-2	1995	Cycloheximide superinduced the message for COX II in the presence of IL-1beta.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	69-77
7577656-9	1995	Cycloheximide (CHX) incubation abolished the inhibitory effect of IFN-alpha on GM-CSF expression, suggesting the requirement of a labile protein.	Cycloheximide	0-13	interferon alpha	Mus musculus	66-75
7577656-9	1995	Cycloheximide (CHX) incubation abolished the inhibitory effect of IFN-alpha on GM-CSF expression, suggesting the requirement of a labile protein.	Cycloheximide	0-13	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	79-85
7577656-9	1995	Cycloheximide (CHX) incubation abolished the inhibitory effect of IFN-alpha on GM-CSF expression, suggesting the requirement of a labile protein.	Cycloheximide	15-18	interferon alpha	Mus musculus	66-75
7577656-9	1995	Cycloheximide (CHX) incubation abolished the inhibitory effect of IFN-alpha on GM-CSF expression, suggesting the requirement of a labile protein.	Cycloheximide	15-18	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	79-85
7641323-3	1995	Cycloheximide almost completely inhibited PDGF-B but not ICAM-1 mRNA induction elicited by lyso-PC, suggesting that dependence on de novo protein synthesis for PDGF-B is different from that for ICAM-1.	Cycloheximide	0-13	platelet derived growth factor subunit B	Homo sapiens	42-48
7641323-3	1995	Cycloheximide almost completely inhibited PDGF-B but not ICAM-1 mRNA induction elicited by lyso-PC, suggesting that dependence on de novo protein synthesis for PDGF-B is different from that for ICAM-1.	Cycloheximide	0-13	platelet derived growth factor subunit B	Homo sapiens	160-166
7544275-14	1995	The addition of cycloheximide markedly inhibited IL-1 beta-induced IGFBP-3 mRNA levels.	Cycloheximide	16-29	interleukin 1 beta	Homo sapiens	49-58
7544275-14	1995	The addition of cycloheximide markedly inhibited IL-1 beta-induced IGFBP-3 mRNA levels.	Cycloheximide	16-29	insulin like growth factor binding protein 3	Homo sapiens	67-74
7544275-15	1995	However, IL-1 beta was able to induce IGFBP-3 mRNA levels even in the presence of cycloheximide.	Cycloheximide	82-95	interleukin 1 beta	Homo sapiens	9-18
8523463-9	1995	Addition of dexamethasone, genistein, actinomycin D or cycloheximide significantly suppressed the IL-1 alpha-induced CINC accumulation.	Cycloheximide	55-68	interleukin 1 alpha	Rattus norvegicus	98-108
8520468-5	1995	The nocturnal increase of retinal and pineal AA-NAT activity was prevented by cycloheximide; the drug did not affect A-NAT activity in these tissues.	Cycloheximide	78-91	aralkylamine N-acetyltransferase	Gallus gallus	45-51
7492303-7	1995	The increase of immunoreactive Cox-2 lasted for about 24 h and was also blocked by actinomycin D or cycloheximide, but not by brefeldin A.	Cycloheximide	100-113	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	31-36
8590306-9	1995	The timing, cycloheximide sensitivity, and selectivity of stimulated release of TNF-R75 by monocytes are consistent with previous observations on other cell types of late (8-20 h) increased synthesis and turnover of cell surface TNF-R75, but not TNF-R55, after stimulation with TNF-alpha or IL-1.	Cycloheximide	12-25	TNF receptor superfamily member 1B	Homo sapiens	80-87
8544401-5	1995	c-jun and c-fos mRNA were rapidly and briefly expressed following renal ischemia and their expression was superinduced by cycloheximide in a manner typical of an immediate-early gene response.	Cycloheximide	122-135	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	10-15
8544404-5	1995	Further analysis showed that various cell lines of human proximal tubular epithelial cells (PTEC) produce MCP-1 in culture under serum-free conditions and that the production is inhibited by cycloheximide.	Cycloheximide	191-204	C-C motif chemokine ligand 2	Homo sapiens	106-111
7592777-7	1995	Furthermore, in the presence of cycloheximide, the STE11-induced activation of MPF as well as the induction and accumulation of Mos was blocked, and the activation of MAPK was greatly reduced.	Cycloheximide	32-45	mitogen-activated protein kinase kinase kinase STE11	Saccharomyces cerevisiae S288C	51-56
7592777-7	1995	Furthermore, in the presence of cycloheximide, the STE11-induced activation of MPF as well as the induction and accumulation of Mos was blocked, and the activation of MAPK was greatly reduced.	Cycloheximide	32-45	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	79-82
8674845-8	1995	Removal of extracellular bFGF with heparin resulted in a rapid, cycloheximide-sensitive increase in high-affinity bFGF binding sites.	Cycloheximide	64-77	fibroblast growth factor 2	Homo sapiens	25-29
8674845-8	1995	Removal of extracellular bFGF with heparin resulted in a rapid, cycloheximide-sensitive increase in high-affinity bFGF binding sites.	Cycloheximide	64-77	fibroblast growth factor 2	Homo sapiens	114-118
8674850-4	1995	The GH activities in this cell line were not mediated by IGF-I production: (1) no IGF-I mRNA could be detected in poly-A RNA preparation, and IGF-I level was very low; (2) neither IGF-I mRNA nor the protein, were increased upon GH treatment; (3) DNA synthesis stimulatory activities of GH and IGF-I were additive; (4) the GH-induced IGFBP-3 mRNA increase was not inhibited by cycloheximide treatment.	Cycloheximide	376-389	gonadotropin releasing hormone receptor	Rattus norvegicus	4-6
7478578-6	1995	The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis.	Cycloheximide	80-93	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	18-21
7478578-6	1995	The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis.	Cycloheximide	80-93	ribosomal protein S6 kinase A6 S homeolog	Xenopus laevis	38-50
7478578-6	1995	The activation of MPF, MAP kinase and S6 kinase II by PKC zeta was sensitive to cycloheximide, while induction of GVBD was independent of protein synthesis.	Cycloheximide	80-93	protein kinase C zeta L homeolog	Xenopus laevis	54-62
7559652-11	1995	Cycloheximide was likewise effective in increasing the amount of rhoB mRNA, whereas Bt2cAMP, 12-O-tetradecanoylphorbol-13-acetate, and retinoic acid were without effect.	Cycloheximide	0-13	ras homolog family member B	Mus musculus	65-69
7561073-2	1995	This cytotoxic effect does not involve the Fas death pathway and differs from the TNF-triggered death of tumor cells in several respects: 1) It is a slower process, requiring 2 to 3 days; 2) it is blocked, rather than enhanced, by cycloheximide; and 3) based on the agonistic effect of anti-TNF receptor Abs, it involves a synergistic effect of both the 55-kDa TNFR1 and the 75-kDa TNFR2, as opposed to the dominance of TNFR1 for tumor cytotoxicity.	Cycloheximide	231-244	tumor necrosis factor	Homo sapiens	82-85
7485516-8	1995	Inhibition of LPS-induced MIP-1 alpha mRNA by dexamethasone was attenuated by the protein synthesis inhibitor cycloheximide, indicating the involvement of a protein intermediate.	Cycloheximide	110-123	C-C motif chemokine ligand 3	Homo sapiens	26-37
7546777-5	1995	Cycloheximide almost completely abrogated the IGF-I-stimulated increase in CM IGFBP-3, suggesting that ongoing protein synthesis is necessary for the IGF-I-stimulated increase in IGFBP-3 abundance.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	46-51
7546777-5	1995	Cycloheximide almost completely abrogated the IGF-I-stimulated increase in CM IGFBP-3, suggesting that ongoing protein synthesis is necessary for the IGF-I-stimulated increase in IGFBP-3 abundance.	Cycloheximide	0-13	insulin like growth factor binding protein 3	Homo sapiens	78-85
7546777-5	1995	Cycloheximide almost completely abrogated the IGF-I-stimulated increase in CM IGFBP-3, suggesting that ongoing protein synthesis is necessary for the IGF-I-stimulated increase in IGFBP-3 abundance.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	150-155
7546777-5	1995	Cycloheximide almost completely abrogated the IGF-I-stimulated increase in CM IGFBP-3, suggesting that ongoing protein synthesis is necessary for the IGF-I-stimulated increase in IGFBP-3 abundance.	Cycloheximide	0-13	insulin like growth factor binding protein 3	Homo sapiens	179-186
8595383-3	1995	We show that cycloheximide (CH), an inhibitor of protein synthesis, induces iNOS mRNA in VSM and potentiates the induction of iNOS mRNA caused by LPS.	Cycloheximide	13-26	nitric oxide synthase 2	Homo sapiens	76-80
8595383-3	1995	We show that cycloheximide (CH), an inhibitor of protein synthesis, induces iNOS mRNA in VSM and potentiates the induction of iNOS mRNA caused by LPS.	Cycloheximide	13-26	nitric oxide synthase 2	Homo sapiens	126-130
8595383-3	1995	We show that cycloheximide (CH), an inhibitor of protein synthesis, induces iNOS mRNA in VSM and potentiates the induction of iNOS mRNA caused by LPS.	Cycloheximide	28-30	nitric oxide synthase 2	Homo sapiens	76-80
8595383-3	1995	We show that cycloheximide (CH), an inhibitor of protein synthesis, induces iNOS mRNA in VSM and potentiates the induction of iNOS mRNA caused by LPS.	Cycloheximide	28-30	nitric oxide synthase 2	Homo sapiens	126-130
7588060-9	1995	Fertilization of cycloheximide-treated oocytes revealed that continuous Ca2+ oscillations in response to sperm were observed after nuclear envelope breakdown but not during interphase.	Cycloheximide	17-30	carbonic anhydrase 2	Mus musculus	72-75
23282387-8	1995	The action of GROa was independent of cytochalasin D, staurosporine, and pertussis toxin but was inhibited by sodium azide and cycloheximide.	Cycloheximide	127-140	C-X-C motif chemokine ligand 1	Homo sapiens	14-18
7649093-10	1995	Cycloheximide (23 micrograms/ml) alone increased GHF-1 mRNA levels (6-fold increase after treatment for 12 h, P < 0.01), as well as potentiating GHRH-induced increase in GHF-1 mRNA concentration (9-fold increase after treatment with GHRH plus cycloheximide for 12 h, P < 0.01).	Cycloheximide	0-13	POU class 1 homeobox 1	Rattus norvegicus	49-54
7649093-10	1995	Cycloheximide (23 micrograms/ml) alone increased GHF-1 mRNA levels (6-fold increase after treatment for 12 h, P < 0.01), as well as potentiating GHRH-induced increase in GHF-1 mRNA concentration (9-fold increase after treatment with GHRH plus cycloheximide for 12 h, P < 0.01).	Cycloheximide	0-13	growth hormone releasing hormone	Rattus norvegicus	148-152
7649093-10	1995	Cycloheximide (23 micrograms/ml) alone increased GHF-1 mRNA levels (6-fold increase after treatment for 12 h, P < 0.01), as well as potentiating GHRH-induced increase in GHF-1 mRNA concentration (9-fold increase after treatment with GHRH plus cycloheximide for 12 h, P < 0.01).	Cycloheximide	0-13	POU class 1 homeobox 1	Rattus norvegicus	173-178
7649093-10	1995	Cycloheximide (23 micrograms/ml) alone increased GHF-1 mRNA levels (6-fold increase after treatment for 12 h, P < 0.01), as well as potentiating GHRH-induced increase in GHF-1 mRNA concentration (9-fold increase after treatment with GHRH plus cycloheximide for 12 h, P < 0.01).	Cycloheximide	0-13	growth hormone releasing hormone	Rattus norvegicus	236-240
7649093-10	1995	Cycloheximide (23 micrograms/ml) alone increased GHF-1 mRNA levels (6-fold increase after treatment for 12 h, P < 0.01), as well as potentiating GHRH-induced increase in GHF-1 mRNA concentration (9-fold increase after treatment with GHRH plus cycloheximide for 12 h, P < 0.01).	Cycloheximide	246-259	growth hormone releasing hormone	Rattus norvegicus	148-152
7649107-9	1995	The protein synthesis inhibitor, cycloheximide, prevented AR induction by TPA, suggesting that a component of the TPA induction of AR is indirect and dependent upon protein synthesis.	Cycloheximide	33-46	amphiregulin	Homo sapiens	58-60
7649107-9	1995	The protein synthesis inhibitor, cycloheximide, prevented AR induction by TPA, suggesting that a component of the TPA induction of AR is indirect and dependent upon protein synthesis.	Cycloheximide	33-46	amphiregulin	Homo sapiens	131-133
7664840-5	1995	Moreover, protein synthesis inhibitors such as cycloheximide (CHX) can facilitate apoptotic triggering by TNF, and mitochondrial function was suggested to be essential in the TNF-mediated apoptotic process.	Cycloheximide	47-60	tumor necrosis factor	Homo sapiens	106-109
7664840-5	1995	Moreover, protein synthesis inhibitors such as cycloheximide (CHX) can facilitate apoptotic triggering by TNF, and mitochondrial function was suggested to be essential in the TNF-mediated apoptotic process.	Cycloheximide	47-60	tumor necrosis factor	Homo sapiens	175-178
7664840-5	1995	Moreover, protein synthesis inhibitors such as cycloheximide (CHX) can facilitate apoptotic triggering by TNF, and mitochondrial function was suggested to be essential in the TNF-mediated apoptotic process.	Cycloheximide	62-65	tumor necrosis factor	Homo sapiens	106-109
7664840-5	1995	Moreover, protein synthesis inhibitors such as cycloheximide (CHX) can facilitate apoptotic triggering by TNF, and mitochondrial function was suggested to be essential in the TNF-mediated apoptotic process.	Cycloheximide	62-65	tumor necrosis factor	Homo sapiens	175-178
7584631-14	1995	The half life of ornithine decarboxylase in promastigote forms grown in the presence of cycloheximide was >6 hr.	Cycloheximide	88-101	ornithine decarboxylase 1	Homo sapiens	17-40
7657802-4	1995	During cardiocyte hypertrophy evoked by endothelin-1, Phenylephrine, or PMA, the steady state level of BNP mRNA increased as rapidly as the "immediate-early" induction of the c-fos gene expression, and reached a maximal level within 1 h. Actinomycin D, a transcriptional inhibitor, completely diminished the response, while the translational blocked with cycloheximide did not inhibit it.	Cycloheximide	355-368	natriuretic peptide B	Rattus norvegicus	103-106
7543927-0	1995	Melatonin biosynthesis in cultured chick retinal photoreceptor cells: calcium and cyclic AMP protect serotonin N-acetyltransferase from inactivation in cycloheximide-treated cells.	Cycloheximide	152-165	aralkylamine N-acetyltransferase	Gallus gallus	101-130
7543927-4	1995	After induction, in the presence of cycloheximide, NAT activity declined with a half-life of approximately 30 min.	Cycloheximide	36-49	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	51-54
7643127-8	1995	This posttranscriptional destablization of ligatin mRNA was mimicked by the translation inhibitor, cycloheximide, but not by puromycin.	Cycloheximide	99-112	ligatin	Homo sapiens	43-50
7665981-11	1995	Addition of cycloheximide prevented the cAMP-mediated increase in TM mRNA and curtailed the down-regulation of myogenic mRNA species, alpha-actin, and tropomyosin.	Cycloheximide	12-25	thrombomodulin	Homo sapiens	66-68
7637960-0	1995	Effects of cycloheximide on chromatin-bound and -unbound PCNA in HeLa cells.	Cycloheximide	11-24	proliferating cell nuclear antigen	Homo sapiens	57-61
7595061-5	1995	Cycloheximide treatment of the cultures containing M-CSF and IFN-gamma inhibited the production of IL-1 beta and TNF-alpha.	Cycloheximide	0-13	interferon gamma	Homo sapiens	61-70
7637960-1	1995	We examined the effects of cycloheximide on the amount of chromatin-bound and -unbound PCNA subpopulations in HeLa cells.	Cycloheximide	27-40	proliferating cell nuclear antigen	Homo sapiens	87-91
7637960-2	1995	The chromatin-bound PCNA content decreased rapidly in the presence of cycloheximide, whereas the reduction of the total amount of PCNA was minimal even 24 h after the treatment with cycloheximide.	Cycloheximide	70-83	proliferating cell nuclear antigen	Homo sapiens	20-24
7637960-2	1995	The chromatin-bound PCNA content decreased rapidly in the presence of cycloheximide, whereas the reduction of the total amount of PCNA was minimal even 24 h after the treatment with cycloheximide.	Cycloheximide	182-195	proliferating cell nuclear antigen	Homo sapiens	130-134
7595061-5	1995	Cycloheximide treatment of the cultures containing M-CSF and IFN-gamma inhibited the production of IL-1 beta and TNF-alpha.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	99-108
7595061-5	1995	Cycloheximide treatment of the cultures containing M-CSF and IFN-gamma inhibited the production of IL-1 beta and TNF-alpha.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	113-122
7544578-5	1995	CD95-mediated apoptosis is inhibited by dexamethasone both after cytokine sensitization and upon coexposure to CD95 antibodies and actinomycin D or cycloheximide.	Cycloheximide	148-161	Fas cell surface death receptor	Homo sapiens	0-4
7667287-4	1995	We found that the CrmA-expressing HeLa cells are resistant to TNF-alpha/cycloheximide (CHX)-induced apoptosis.	Cycloheximide	72-85	CrmA or CPXV207 protein	Cowpox virus	18-22
7667287-4	1995	We found that the CrmA-expressing HeLa cells are resistant to TNF-alpha/cycloheximide (CHX)-induced apoptosis.	Cycloheximide	87-90	CrmA or CPXV207 protein	Cowpox virus	18-22
7658471-8	1995	Auxin-induction of two late genes, IAA7 and IAA8, is inhibited by cycloheximide, indicating requirement of protein synthesis for their activation.	Cycloheximide	66-79	indole-3-acetic acid 7	Arabidopsis thaliana	35-39
7658471-8	1995	Auxin-induction of two late genes, IAA7 and IAA8, is inhibited by cycloheximide, indicating requirement of protein synthesis for their activation.	Cycloheximide	66-79	indoleacetic acid-induced protein 8	Arabidopsis thaliana	44-48
7646519-6	1995	In the cycloheximide-treated HL-60 cells, the level of Oct-1 also reduced.	Cycloheximide	7-20	POU class 2 homeobox 1	Homo sapiens	55-60
7642643-6	1995	When translation is blocked (e.g. by cycloheximide), expression of IL-2 mRNA can be superinduced by 2 orders of magnitude.	Cycloheximide	37-50	interleukin 2	Homo sapiens	67-71
7645620-7	1995	Interleukin-1 receptor antagonist, cycloheximide, and actinomycin D blocked the effects of interleukin-1 beta (p < 0.05).	Cycloheximide	35-48	interleukin 1 beta	Homo sapiens	91-109
8588972-4	1995	A brief exposure to cycloheximide profoundly blocked EGF-evoked GP2 secretion.	Cycloheximide	20-33	epidermal growth factor like 1	Rattus norvegicus	53-56
8526991-7	1995	Moreover, the expression of COX-2 mRNA in IL-1 beta-stimulated cells was superinduced by preincubation with cycloheximide, but completely abolished by actinomycin D.	Cycloheximide	108-121	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	28-33
8526991-7	1995	Moreover, the expression of COX-2 mRNA in IL-1 beta-stimulated cells was superinduced by preincubation with cycloheximide, but completely abolished by actinomycin D.	Cycloheximide	108-121	interleukin 1 beta	Homo sapiens	42-51
7628383-8	1995	Kinetic analyses of the turnover of cell surface bFGF receptors in the presence of cycloheximide showed that PMA accelerated loss of receptors from the cell surface, suggesting the enhanced receptor internalization by PMA resulting in the receptor reduction.	Cycloheximide	83-96	fibroblast growth factor 2	Homo sapiens	49-53
7648967-3	1995	EGF stimulated an increase in cyclooxygenase activity, which was reduced by protein synthesis inhibitor, actinomycin D, and cycloheximide.	Cycloheximide	124-137	pro-epidermal growth factor	Cavia porcellus	0-3
7628352-7	1995	IL-1 beta-induced AS and iNOS mRNA expression was prevented by an inhibitor of the activation factor NF-kappa B pyrrolidine diaminoguanidine, an inhibitor of gene transcription (actinomycin D), and a blocker of protein synthesis (cycloheximide), suggesting coregulation of AS and iNOS by cytokines.	Cycloheximide	230-243	interleukin 1 beta	Homo sapiens	0-9
7628352-7	1995	IL-1 beta-induced AS and iNOS mRNA expression was prevented by an inhibitor of the activation factor NF-kappa B pyrrolidine diaminoguanidine, an inhibitor of gene transcription (actinomycin D), and a blocker of protein synthesis (cycloheximide), suggesting coregulation of AS and iNOS by cytokines.	Cycloheximide	230-243	nitric oxide synthase 2	Homo sapiens	25-29
7628352-7	1995	IL-1 beta-induced AS and iNOS mRNA expression was prevented by an inhibitor of the activation factor NF-kappa B pyrrolidine diaminoguanidine, an inhibitor of gene transcription (actinomycin D), and a blocker of protein synthesis (cycloheximide), suggesting coregulation of AS and iNOS by cytokines.	Cycloheximide	230-243	nuclear factor kappa B subunit 1	Homo sapiens	101-111
8588972-4	1995	A brief exposure to cycloheximide profoundly blocked EGF-evoked GP2 secretion.	Cycloheximide	20-33	glycoprotein 2	Rattus norvegicus	64-67
7593271-4	1995	Moreover, the inhibition of protein synthesis by cycloheximide caused a superinduction in the amounts of the U1-snRNP-specific 70K transcripts.	Cycloheximide	49-62	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	Mus musculus	112-117
7593322-10	1995	In cells recovering from AMD treatment in the presence of cycloheximide Rev and B23 showed coincident relocation to nucleoli.	Cycloheximide	58-71	Rev	Human immunodeficiency virus 1	72-75
7499787-8	1995	Previous studies demonstrated that parathyroid hormone-related peptide gene expression in keratinocytes can be modulated by serum, growth factors and cycloheximide although there is a species and cellular specificity.	Cycloheximide	150-163	parathyroid hormone like hormone	Homo sapiens	35-70
21153140-1	1995	To explore the regulation of follistatin gene expression, porcine granulosa cells were incubated with the translational inhibitor, cycloheximide (CHX), for periods from 6-24 h. This resulted in a 3 to 10-fold increase in follistatin mRNA accumulation compared to vehicle treated control cultures.	Cycloheximide	131-144	follistatin	Homo sapiens	29-40
21153140-1	1995	To explore the regulation of follistatin gene expression, porcine granulosa cells were incubated with the translational inhibitor, cycloheximide (CHX), for periods from 6-24 h. This resulted in a 3 to 10-fold increase in follistatin mRNA accumulation compared to vehicle treated control cultures.	Cycloheximide	131-144	follistatin	Homo sapiens	221-232
21153140-1	1995	To explore the regulation of follistatin gene expression, porcine granulosa cells were incubated with the translational inhibitor, cycloheximide (CHX), for periods from 6-24 h. This resulted in a 3 to 10-fold increase in follistatin mRNA accumulation compared to vehicle treated control cultures.	Cycloheximide	146-149	follistatin	Homo sapiens	29-40
21153140-5	1995	Results in the longer term differed, as pretreatment of granulosa cells with CHX for 20 h suppressed the induction of follistatin gene expression by both EGF and phorbol 12-myristate-13-acetate.	Cycloheximide	77-80	follistatin	Homo sapiens	118-129
8546815-4	1995	Incubation with cycloheximide also induced an increase in the basal TRH-R mRNA level and completely reversed the EGF-induced reduction of TRH-R mRNA levels.	Cycloheximide	16-29	thyrotropin releasing hormone receptor	Rattus norvegicus	68-73
8546815-4	1995	Incubation with cycloheximide also induced an increase in the basal TRH-R mRNA level and completely reversed the EGF-induced reduction of TRH-R mRNA levels.	Cycloheximide	16-29	epidermal growth factor like 1	Rattus norvegicus	113-116
8546815-4	1995	Incubation with cycloheximide also induced an increase in the basal TRH-R mRNA level and completely reversed the EGF-induced reduction of TRH-R mRNA levels.	Cycloheximide	16-29	thyrotropin releasing hormone receptor	Rattus norvegicus	138-143
8676218-6	1995	In fact, the addition of cycloheximide to cultured hepatocytes increased the level of c-myc mRNA either in the presence or absence of amino acids, though the levels of other mRNAs were not changed significantly.	Cycloheximide	25-38	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	86-91
7662587-0	1995	Regulation of sex hormone-binding globulin secretion and gene expression by cycloheximide in vitro.	Cycloheximide	76-89	sex hormone binding globulin	Homo sapiens	14-42
7662587-2	1995	Inhibition of protein synthesis by cycloheximide suppressed SHBG levels.	Cycloheximide	35-48	sex hormone binding globulin	Homo sapiens	60-64
7662587-7	1995	In contrast to SHBG protein levels, cycloheximide increased SHBG mRNA levels.	Cycloheximide	36-49	sex hormone binding globulin	Homo sapiens	60-64
7662587-8	1995	When the effect of cycloheximide on the rate of SHBG mRNA decay was tested, the drug was found to extend the half-life of SHBG mRNA.	Cycloheximide	19-32	sex hormone binding globulin	Homo sapiens	48-52
7662587-8	1995	When the effect of cycloheximide on the rate of SHBG mRNA decay was tested, the drug was found to extend the half-life of SHBG mRNA.	Cycloheximide	19-32	sex hormone binding globulin	Homo sapiens	122-126
7662587-10	1995	Treatment with cycloheximide together with any of the hormones resulted in an increase in SHBG mRNA levels.	Cycloheximide	15-28	sex hormone binding globulin	Homo sapiens	90-94
7643615-1	1995	A basic helix-loop-helix phosphoprotein gene, G0S8, was recently isolated by differential screening of cDNA from human blood mononuclear cells stimulated with a T cell mitogen and cycloheximide.	Cycloheximide	180-193	regulator of G protein signaling 2	Homo sapiens	46-50
7623800-7	1995	Finally, we provide evidence in the absence of PDR1 for a PDR3-controlled transcriptional induction of the drug pump by cycloheximide and propose a model for the mechanism governing the transcriptional autoregulation of Pdr3p.	Cycloheximide	120-133	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	58-62
7565811-3	1995	Treatment of U937 with IFN-gamma for 9 hr in the presence of cycloheximide led to super-induction of Fc gamma RI expression.	Cycloheximide	61-74	interferon gamma	Homo sapiens	23-32
7565811-3	1995	Treatment of U937 with IFN-gamma for 9 hr in the presence of cycloheximide led to super-induction of Fc gamma RI expression.	Cycloheximide	61-74	Fc gamma receptor Ia	Homo sapiens	101-112
7623834-6	1995	Moreover, we show that in the liver, c-myc exon 2 sequences are able to down-regulate an otherwise stable H-2K mRNA when embedded within it and to induce its transient accumulation after cycloheximide treatment and soon after liver ablation.	Cycloheximide	187-200	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	37-42
7623800-7	1995	Finally, we provide evidence in the absence of PDR1 for a PDR3-controlled transcriptional induction of the drug pump by cycloheximide and propose a model for the mechanism governing the transcriptional autoregulation of Pdr3p.	Cycloheximide	120-133	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	220-225
7638737-8	1995	The results with actinomycin D and cycloheximide suggested that LPSp effects did not require transcription, but IL-1 enhancement required protein synthesis.	Cycloheximide	35-48	interferon regulatory factor 6	Homo sapiens	64-68
8585010-3	1995	These thrombin effects were inhibited by cycloheximide (CHX), an inhibitor of protein biosynthesis.	Cycloheximide	41-54	coagulation factor II, thrombin	Homo sapiens	6-14
7638749-11	1995	The dexamethasone-induce increase of GS messenger RNA level was completely blocked by the glucocorticoid receptor antagonist RU38486 and by the transcriptional inhibitor actinomycin D but was not inhibited by the translational inhibitor cycloheximide.	Cycloheximide	237-250	glutamate-ammonia ligase	Rattus norvegicus	37-39
8585010-3	1995	These thrombin effects were inhibited by cycloheximide (CHX), an inhibitor of protein biosynthesis.	Cycloheximide	56-59	coagulation factor II, thrombin	Homo sapiens	6-14
7608559-7	1995	In contrast, the later phase of PGD2 production is blocked by dexamethasone, cycloheximide, or NS-398, a PGS-2-specific nonsteroidal anti-inflammatory drug that inhibits PGS-2 enzyme activity but not PGS-1 activity.	Cycloheximide	77-90	prostaglandin D2 synthase (brain)	Mus musculus	32-36
7626041-4	1995	This action of interleukin-1 beta was blocked by co-incubation with cycloheximide, an inhibitor of protein synthesis, which demonstrated that de novo protein synthesis was required.	Cycloheximide	68-81	interleukin 1 beta	Homo sapiens	15-33
7605994-11	1995	Finally, both p40 and p35 were directly induced by LPS in the presence of cycloheximide.	Cycloheximide	74-87	interleukin 9	Homo sapiens	14-17
7605994-11	1995	Finally, both p40 and p35 were directly induced by LPS in the presence of cycloheximide.	Cycloheximide	74-87	interleukin 12A	Homo sapiens	22-25
7628635-3	1995	Western analysis using anti-p53 or anti-WAF1 monoclonal antibodies demonstrated that these two protein levels were increased 3 h after delta 12-PGJ2 treatment, and accumulated for up to 12 h. The induction of p53 protein seemed to be dependent on the increase of p53 mRNA level, which was inhibited by CHX treatment.	Cycloheximide	302-305	tumor protein p53	Homo sapiens	209-212
7628635-3	1995	Western analysis using anti-p53 or anti-WAF1 monoclonal antibodies demonstrated that these two protein levels were increased 3 h after delta 12-PGJ2 treatment, and accumulated for up to 12 h. The induction of p53 protein seemed to be dependent on the increase of p53 mRNA level, which was inhibited by CHX treatment.	Cycloheximide	302-305	tumor protein p53	Homo sapiens	209-212
7622488-3	1995	We constructed a lambda cDNA library from transforming growth factor beta 1-pretreated murine Swiss 3T3 cells stimulated with lipopolysaccharide (LPS) or serum in the presence of cycloheximide, screened 15,000 plaques by differential hybridization, and cloned 12 LPS-induced, dexamethasone-attenuated cDNAs.	Cycloheximide	179-192	hemoglobin, beta adult major chain	Mus musculus	69-75
7608559-7	1995	In contrast, the later phase of PGD2 production is blocked by dexamethasone, cycloheximide, or NS-398, a PGS-2-specific nonsteroidal anti-inflammatory drug that inhibits PGS-2 enzyme activity but not PGS-1 activity.	Cycloheximide	77-90	decorin	Mus musculus	105-110
7608559-7	1995	In contrast, the later phase of PGD2 production is blocked by dexamethasone, cycloheximide, or NS-398, a PGS-2-specific nonsteroidal anti-inflammatory drug that inhibits PGS-2 enzyme activity but not PGS-1 activity.	Cycloheximide	77-90	decorin	Mus musculus	170-175
7608559-7	1995	In contrast, the later phase of PGD2 production is blocked by dexamethasone, cycloheximide, or NS-398, a PGS-2-specific nonsteroidal anti-inflammatory drug that inhibits PGS-2 enzyme activity but not PGS-1 activity.	Cycloheximide	77-90	phosphatidylglycerophosphate synthase 1	Mus musculus	200-205
7619053-9	1995	Although pretreatment with cycloheximide inhibits 125I-IL-6 binding, IFN-alpha does not cause a selective decrease in the levels of gp130 or IL-6 receptor mRNA at times when 125I-IL-6 binding is inhibited.	Cycloheximide	27-40	interleukin 6	Homo sapiens	55-59
7545441-8	1995	Moreover, the use of cycloheximide, a protein synthesis inhibitor, showed that while tPA stimulation did not require intermediary protein synthesis, the decrease in uPA production was dependent upon protein synthesis.	Cycloheximide	21-34	plasminogen activator, urokinase	Rattus norvegicus	165-168
7796421-7	1995	Cycloheximide abolished the induction of TIMPs and MMP2 mRNAs by 8-bromo-cAMP, indicating that the induction depends on a newly synthesized protein(s) whose expression may be regulated by cAMP.	Cycloheximide	0-13	matrix metallopeptidase 2	Homo sapiens	51-55
7669843-4	1995	IL-1 alpha-induced increases in PGE2 accumulation and COX activity were greatly reduced or prevented by cycloheximide (CHX), actinomycin D, and dexamethasone (DEX).	Cycloheximide	104-117	interleukin 1 alpha	Rattus norvegicus	0-10
7669843-4	1995	IL-1 alpha-induced increases in PGE2 accumulation and COX activity were greatly reduced or prevented by cycloheximide (CHX), actinomycin D, and dexamethasone (DEX).	Cycloheximide	119-122	interleukin 1 alpha	Rattus norvegicus	0-10
7547511-6	1995	Furthermore, treatment with cycloheximide or DTT, which inhibit protein synthesis without altering intracellular calcium levels, can substitute for thapsigargin or ionophores in stimulating VL30 gene expression.	Cycloheximide	28-41	RIKEN cDNA A130040M12 gene	Mus musculus	190-194
7628462-4	1995	Cycloheximide alone caused a significant increase in apo AI mRNA.	Cycloheximide	0-13	apolipoprotein A1	Homo sapiens	53-59
7601425-7	1995	Stimulation of Kupffer cells by phorbol ester markedly induced gelatinase B release, which was inhibited by cycloheximide.	Cycloheximide	108-121	matrix metallopeptidase 9	Rattus norvegicus	63-75
7621861-3	1995	Generation of both the anergic state and the increased p59fyn activity was prevented in the presence of calcium-free medium, cycloheximide (CHX), or cyclosporin A (CsA), and could be mimicked by the calcium ionophore ionomycin.	Cycloheximide	125-138	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	55-61
7621861-3	1995	Generation of both the anergic state and the increased p59fyn activity was prevented in the presence of calcium-free medium, cycloheximide (CHX), or cyclosporin A (CsA), and could be mimicked by the calcium ionophore ionomycin.	Cycloheximide	140-143	FYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	55-61
7621867-10	1995	In L3 and L alpha beta cells, transcription of the endogenous IL-2 gene was suppressed by cyclosporin A and enhanced by cycloheximide.	Cycloheximide	120-133	interleukin 2	Mus musculus	62-66
7628539-13	1995	We further demonstrate that cycloheximide also has an effect on the up-regulation, suggesting a role for protein synthesis in the regulation of CRABP-II gene expression.	Cycloheximide	28-41	cellular retinoic acid binding protein 2	Homo sapiens	144-152
8586491-4	1995	Several were inhibitory, and the concentrations which caused a 50% reduction in IL-10 production were 0.38 microM cyclosporin-A, 0.0073 microM dexamethasone, 0.045 microM prednisolone and 0.31 microM cycloheximide.	Cycloheximide	200-213	interleukin 10	Mus musculus	80-85
7593254-9	1995	Treatment of cultures with 36 microM cycloheximide 1 h prior to 1,25(OH)2D3 addition resulted in superinduction of VDR mRNA levels but sharply reduced CaBP steady-state mRNA levels.	Cycloheximide	37-50	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	115-118
7593257-8	1995	This induction was inhibited by actinomycin D and cycloheximide, suggesting transcriptional and translational regulation of MMP and TIMP.	Cycloheximide	50-63	TIMP metallopeptidase inhibitor 1	Homo sapiens	132-136
7790384-12	1995	The rate of mdr1b mRNA decay in primary d-15 UE cells was decreased by treatment with alpha-amanitin or cycloheximide, suggesting that the decay pathway requires both transcription and de novo protein synthesis.	Cycloheximide	104-117	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	12-17
7790389-7	1995	When retinoic acid was added to cycloheximide-treated cultures TIMP-1 mRNA levels were reduced at 5 hr compared with controls.	Cycloheximide	32-45	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	63-69
7637390-3	1995	However, the rate of transient induction kinetics was modulated by cycloheximide (CHX) indicating that secondary response genes are involved in the regulation of IL-8 RNA levels.	Cycloheximide	67-80	C-X-C motif chemokine ligand 8	Homo sapiens	162-166
7637390-3	1995	However, the rate of transient induction kinetics was modulated by cycloheximide (CHX) indicating that secondary response genes are involved in the regulation of IL-8 RNA levels.	Cycloheximide	82-85	C-X-C motif chemokine ligand 8	Homo sapiens	162-166
7667244-7	1995	Substances that block glucose transport (100 microM cytochalasin B) and protein synthesis (1 mM cycloheximide) also markedly reduced insulin biosynthesis.	Cycloheximide	96-109	insulin	Homo sapiens	133-140
7675826-3	1995	Application of 10 ng/ml IL-1 alpha increased the production of PGF2 alpha for 2-24 h. Coincubation of IL-1 alpha with actinomycin D (1 microgram/ml) or cycloheximide (10 micrograms/ml) completely blocked the increase in PGF2 alpha.	Cycloheximide	152-165	interleukin 1 alpha	Homo sapiens	24-34
7623773-14	1995	The increase in AIF4(-)-induced PI hydrolysis after 24-hr TPA treatment was also inhibited by cycloheximide, indicating that new synthesis of BK receptors and G proteins was required after down-regulation of PKC-alpha and PKC-delta.	Cycloheximide	94-107	itchy E3 ubiquitin protein ligase	Homo sapiens	16-20
7623773-14	1995	The increase in AIF4(-)-induced PI hydrolysis after 24-hr TPA treatment was also inhibited by cycloheximide, indicating that new synthesis of BK receptors and G proteins was required after down-regulation of PKC-alpha and PKC-delta.	Cycloheximide	94-107	protein kinase C alpha	Homo sapiens	208-217
7782324-7	1995	In the presence of cycloheximide, the (Sp)-8-Br-cAMPS treatment enhances only the wild-type current amplitudes and induces accumulation of wild-type channels in the plasma membrane of the oocyte.	Cycloheximide	19-32	calmodulin 2, pseudogene 1	Rattus norvegicus	48-53
7797564-4	1995	In addition, nascent SR alpha polypeptides of varying lengths were generated by cycloheximide treatment of translation reactions.	Cycloheximide	80-93	amyloid beta precursor protein binding family B member 3	Homo sapiens	21-29
7794260-4	1995	beta-actin mRNA levels rapidly declined in HL-60 cells following induction of apoptosis by actinomycin D, but were transiently elevated by two other apoptosis-inducing agents, cycloheximide and ionophore A23187.	Cycloheximide	176-189	POTE ankyrin domain family member F	Homo sapiens	0-10
7794283-8	1995	Furthermore, effects of actinomycin D and cycloheximide suggest that biosynthesis of AM is designed for quick response to physiological stimulation.	Cycloheximide	42-55	adrenomedullin	Rattus norvegicus	85-87
7759889-8	1995	The accumulation of IL-8 within these organelles is inhibited by cycloheximide but not actinomycin D, suggesting that IL-8 accumulation is under translational, rather than transcriptional control.	Cycloheximide	65-78	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
7759889-8	1995	The accumulation of IL-8 within these organelles is inhibited by cycloheximide but not actinomycin D, suggesting that IL-8 accumulation is under translational, rather than transcriptional control.	Cycloheximide	65-78	C-X-C motif chemokine ligand 8	Homo sapiens	118-122
7796817-7	1995	IRP induction by H2O2 appears to involve the disassembly of its cubane 4Fe-4S cluster and occurs even in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	153-166	Wnt family member 2	Homo sapiens	0-3
7607538-4	1995	Constitutive expression of xR11 in cultured rat fibroblast (Rat-1) cells conferred a strong protection against cell death induced by the cytotoxic agents staurosporine and cycloheximide, by serum deprivation and specific deregulation of c-myc.	Cycloheximide	172-185	BCL2 like 1 S homeolog	Xenopus laevis	27-31
7780157-7	1995	Moreover, the addition of cycloheximide (CHX) to LPS-stimulated monocytes resulted in a superinduction of COX-2 mRNA, whereas CHX almost abrogated the abilities of IL-10 and IL-4 to inhibit this gene expression.	Cycloheximide	26-39	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	106-111
7780157-7	1995	Moreover, the addition of cycloheximide (CHX) to LPS-stimulated monocytes resulted in a superinduction of COX-2 mRNA, whereas CHX almost abrogated the abilities of IL-10 and IL-4 to inhibit this gene expression.	Cycloheximide	26-39	interleukin 4	Homo sapiens	174-178
7544689-8	1995	Simultaneous incubation of IL-1 beta with NG-monomethyl-L-arginine, genistein, calphostin C, cycloheximide, or actinomycin D completely inhibited the IL-1 beta induced NO production by cardiac myocytes.	Cycloheximide	93-106	interleukin 1 beta	Rattus norvegicus	27-36
7780157-7	1995	Moreover, the addition of cycloheximide (CHX) to LPS-stimulated monocytes resulted in a superinduction of COX-2 mRNA, whereas CHX almost abrogated the abilities of IL-10 and IL-4 to inhibit this gene expression.	Cycloheximide	41-44	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	106-111
7780157-7	1995	Moreover, the addition of cycloheximide (CHX) to LPS-stimulated monocytes resulted in a superinduction of COX-2 mRNA, whereas CHX almost abrogated the abilities of IL-10 and IL-4 to inhibit this gene expression.	Cycloheximide	41-44	interleukin 10	Homo sapiens	164-169
7780157-7	1995	Moreover, the addition of cycloheximide (CHX) to LPS-stimulated monocytes resulted in a superinduction of COX-2 mRNA, whereas CHX almost abrogated the abilities of IL-10 and IL-4 to inhibit this gene expression.	Cycloheximide	41-44	interleukin 4	Homo sapiens	174-178
7540853-6	1995	The simultaneous addition, to deprived cells, of the growth factor, and of cycloheximide (CHX) for 2 h inhibited GM-CSF mRNA expression, suggesting the requirement for newly made proteins for GM-CSF gene transcription.	Cycloheximide	75-88	colony stimulating factor 2	Homo sapiens	113-119
7540853-6	1995	The simultaneous addition, to deprived cells, of the growth factor, and of cycloheximide (CHX) for 2 h inhibited GM-CSF mRNA expression, suggesting the requirement for newly made proteins for GM-CSF gene transcription.	Cycloheximide	75-88	colony stimulating factor 2	Homo sapiens	192-198
7540853-6	1995	The simultaneous addition, to deprived cells, of the growth factor, and of cycloheximide (CHX) for 2 h inhibited GM-CSF mRNA expression, suggesting the requirement for newly made proteins for GM-CSF gene transcription.	Cycloheximide	90-93	colony stimulating factor 2	Homo sapiens	113-119
7540853-6	1995	The simultaneous addition, to deprived cells, of the growth factor, and of cycloheximide (CHX) for 2 h inhibited GM-CSF mRNA expression, suggesting the requirement for newly made proteins for GM-CSF gene transcription.	Cycloheximide	90-93	colony stimulating factor 2	Homo sapiens	192-198
7544689-8	1995	Simultaneous incubation of IL-1 beta with NG-monomethyl-L-arginine, genistein, calphostin C, cycloheximide, or actinomycin D completely inhibited the IL-1 beta induced NO production by cardiac myocytes.	Cycloheximide	93-106	interleukin 1 beta	Rattus norvegicus	150-159
7641849-8	1995	All ocular tissues and cultured cells tested contained mRNA for Tf, however Tf was secreted into the bathing medium from lens epithelial cell cultures, but not from either the pigmented or non-pigmented epithelial cells of the ciliary body cultures, but not from either the pigmented or non-pigmented epithelial cells of the ciliary body Cycloheximide inhibited secretion of Tf from the lens epithelial cells.	Cycloheximide	338-351	inhibitor of carbonic anhydrase	Canis lupus familiaris	76-78
7669718-4	1995	Treatment with IL-6 increased the susceptibility of these cells to induction of apoptosis by Adriamycin or cycloheximide, but treatment with DEX or with IL-6 and DEX did not.	Cycloheximide	107-120	interleukin 6	Homo sapiens	15-19
7669718-6	1995	Another myeloid leukemia that shows barely detectable expression of bcl-2 also showed up-regulated expression of bcl-XL but no change in bax after induction of differentiation with granulocyte-macrophage colony-stimulating factor, and this reduced cell susceptibility to induction of apoptosis by Adriamycin or cycloheximide.	Cycloheximide	311-324	BCL2 apoptosis regulator	Homo sapiens	68-73
7669718-6	1995	Another myeloid leukemia that shows barely detectable expression of bcl-2 also showed up-regulated expression of bcl-XL but no change in bax after induction of differentiation with granulocyte-macrophage colony-stimulating factor, and this reduced cell susceptibility to induction of apoptosis by Adriamycin or cycloheximide.	Cycloheximide	311-324	BCL2 like 1	Homo sapiens	113-119
7538461-9	1995	IGFBP-5 transcripts were barely detectable in the presence of the protein synthesis inhibitor cycloheximide at 3.6 microM, and further suppressive effects of BMP-2 on IGFBP-5 mRNA could not be determined.	Cycloheximide	94-107	insulin-like growth factor binding protein 5	Rattus norvegicus	0-7
7641849-8	1995	All ocular tissues and cultured cells tested contained mRNA for Tf, however Tf was secreted into the bathing medium from lens epithelial cell cultures, but not from either the pigmented or non-pigmented epithelial cells of the ciliary body cultures, but not from either the pigmented or non-pigmented epithelial cells of the ciliary body Cycloheximide inhibited secretion of Tf from the lens epithelial cells.	Cycloheximide	338-351	inhibitor of carbonic anhydrase	Canis lupus familiaris	76-78
7797171-0	1995	Effects of vomitoxin (deoxynivalenol) and cycloheximide on IL-2, 4, 5 and 6 secretion and mRNA levels in murine CD4+ cells.	Cycloheximide	42-55	interleukin 2	Mus musculus	59-63
7590899-3	1995	A 20 min incubation with TGF-beta was sufficient to induce adherence and this could be inhibited by cycloheximide.	Cycloheximide	100-113	transforming growth factor beta 1	Homo sapiens	25-33
8529070-6	1995	The glucocorticoid effect on DA1 of arterial smooth muscle cells became apparent after hours of incubation in the presence of the steroid and was significantly inhibited by cycloheximide (10 micrograms/ml) and by the glucocorticoid receptor antagonist RU-38486, indicating that the effect required protein synthesis through glucocorticoid receptors.	Cycloheximide	173-186	RT1 class II, locus Da	Rattus norvegicus	29-32
7539458-5	1995	Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU.	Cycloheximide	133-146	BCL2 apoptosis regulator	Homo sapiens	21-26
7539458-5	1995	Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU.	Cycloheximide	133-146	tumor necrosis factor	Homo sapiens	43-52
7775599-1	1995	Previously we have shown that IGF-I protected MCF-7 cells against death induced by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	115-128	insulin like growth factor 1	Homo sapiens	30-35
7775599-1	1995	Previously we have shown that IGF-I protected MCF-7 cells against death induced by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	130-133	insulin like growth factor 1	Homo sapiens	30-35
7791344-5	1995	The TNF stimulatory effect was blocked by actinomycin D and cycloheximide.	Cycloheximide	60-73	tumor necrosis factor	Homo sapiens	4-7
7601099-7	1995	Most of the stimulation was blocked by cycloheximide, indicating direct and indirect mechanisms of BSP gene regulation.	Cycloheximide	39-52	integrin-binding sialoprotein	Rattus norvegicus	99-102
7762612-3	1995	Inhibition of protein synthesis by cycloheximide (2 micrograms/ml) obviated thrombin"s chemotactic effect.	Cycloheximide	35-48	coagulation factor II, thrombin	Homo sapiens	76-84
7741713-5	1995	The stimulations by PDGF-BB and TGF-beta 1 were partly dependent on protein synthesis, since parts of the effects were inhibited by cycloheximide; in contrast, the effects mediated by PMA were not.	Cycloheximide	132-145	transforming growth factor beta 1	Homo sapiens	32-42
7750207-3	1995	The effects of amiloride on the modulation of uPA mRNA and protein induced by phorbol ester (PMA) and cycloheximide (CHX) were studied in four colon cancer cell lines, HCT116, KM12SM, LIM1215 and LS123.	Cycloheximide	102-115	plasminogen activator, urokinase	Homo sapiens	46-49
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	transforming growth factor, beta 1	Mus musculus	0-10
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	interleukin 4	Mus musculus	16-20
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	chemokine (C-C motif) ligand 2	Mus musculus	46-51
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	interleukin 1 alpha	Mus musculus	63-73
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	113-126	interferon gamma	Mus musculus	77-86
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	transforming growth factor, beta 1	Mus musculus	0-10
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	interleukin 4	Mus musculus	16-20
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	chemokine (C-C motif) ligand 2	Mus musculus	46-51
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	interleukin 1 alpha	Mus musculus	63-73
7768303-9	1995	TGF-beta 1- and IL-4-mediated augmentation of MCP-1/JE mRNA by IL-1 alpha or IFN-gamma was partially reversed by cycloheximide (CHX), whereas potentiation of IP-10 by either modulator remained unaffected.	Cycloheximide	128-131	interferon gamma	Mus musculus	77-86
7720665-4	1995	The protein synthesis inhibitor cycloheximide, as well as two inhibitors of protein kinase C, staurosporine and sangivamycin, prevented the bFGF induction of collagenase transcripts, whereas indomethacin, an inhibitor of prostaglandin synthesis, decreased the effect of bFGF on collagenase mRNA levels by about 50%.	Cycloheximide	32-45	fibroblast growth factor 2	Rattus norvegicus	140-144
7720665-4	1995	The protein synthesis inhibitor cycloheximide, as well as two inhibitors of protein kinase C, staurosporine and sangivamycin, prevented the bFGF induction of collagenase transcripts, whereas indomethacin, an inhibitor of prostaglandin synthesis, decreased the effect of bFGF on collagenase mRNA levels by about 50%.	Cycloheximide	32-45	fibroblast growth factor 2	Rattus norvegicus	270-274
7750207-3	1995	The effects of amiloride on the modulation of uPA mRNA and protein induced by phorbol ester (PMA) and cycloheximide (CHX) were studied in four colon cancer cell lines, HCT116, KM12SM, LIM1215 and LS123.	Cycloheximide	117-120	plasminogen activator, urokinase	Homo sapiens	46-49
7737651-7	1995	The induction of Stat3 appears to be part of the initial response of the remnant liver to partial hepatectomy, because it occurs in the presence of cycloheximide-mediated protein synthesis blockade.	Cycloheximide	148-161	signal transducer and activator of transcription 3	Rattus norvegicus	17-22
7636805-3	1995	The increase in prostaglandin E2 accumulation induced by epidermal growth factor was inhibited by alpha-amanitin (2 micrograms ml-1), cycloheximide (0.5 micrograms ml-1) and dexamethasone (5 mumol l-1).	Cycloheximide	134-147	epidermal growth factor like 1	Rattus norvegicus	57-80
7636805-4	1995	Epidermal growth factor increased cyclooxygenase activity in the stromal cells in a time-dependent fashion and this increase in activity was also inhibited by alpha-amanitin, cycloheximide and dexamethasone.	Cycloheximide	175-188	epidermal growth factor like 1	Rattus norvegicus	0-23
8531193-6	1995	However, the effect of TNF-alpha on P formation is blocked by cycloheximide (1 microgram/ml).	Cycloheximide	62-75	tumor necrosis factor	Homo sapiens	23-32
7539271-3	1995	The results revealed that when ionizing radiation (either fission-spectrum neutrons or gamma rays) was administered 15 min after cycloheximide treatment of SHE cells, the radiation exposure reduced cycloheximide-mediated gene induction of c-fos, histone H4, and c-jun.	Cycloheximide	198-211	proto-oncogene c-Fos	Mesocricetus auratus	239-244
7539271-3	1995	The results revealed that when ionizing radiation (either fission-spectrum neutrons or gamma rays) was administered 15 min after cycloheximide treatment of SHE cells, the radiation exposure reduced cycloheximide-mediated gene induction of c-fos, histone H4, and c-jun.	Cycloheximide	198-211	histone H4	Mesocricetus auratus	246-256
7546015-7	1995	Cycloheximide at 1.25 microM completely inhibited cytokine-induced PLA2 release.	Cycloheximide	0-13	phospholipase A2 group IB	Rattus norvegicus	67-71
7565801-9	1995	The TSH-induced effect in each case is inhibited by cycloheximide; the TSH-induced decrease in SSBP/DNA complex formation requires the presence of insulin or calf serum, exactly as does TSH-induced down-regulation of TSHR RNA levels.	Cycloheximide	52-65	single stranded DNA binding protein 1	Rattus norvegicus	95-99
12228470-7	1995	Treatment of cells with cycloheximide (5 [mu]g mL-1) during adaptation completely inhibited DIC transport induction, whereas treatment with chloramphenicol (400 [mu]g mL-1) had no effect, indicating the requirement for cytoplasmic protein synthesis in the induction.	Cycloheximide	24-37	L1 cell adhesion molecule	Mus musculus	47-51
7649352-5	1995	FSH-dependent c-myc mRNA levels were superinduced in cells treated for 3 h with cycloheximide but it was reduced by actinomycin-D pretreatment.	Cycloheximide	80-93	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	14-19
7730328-9	1995	Lipopolysaccharide and cycloheximide were also potent inducers of C-193 mRNA.	Cycloheximide	23-36	ankyrin repeat domain 1	Homo sapiens	66-71
7697853-6	1995	These increases in ecto-5"-nucleotidase activity were inhibited by GF109203X, an inhibitor of protein kinase C, and mimicked by phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C. The increase in ecto-5"-nucleotidase was not prevented by cycloheximide.	Cycloheximide	259-272	5' nucleotidase, ecto	Rattus norvegicus	19-39
7774811-7	1995	Expression of p21 message following serum restimulation is superinducible by cycloheximide in wild-type but not in p53-deficient cells.	Cycloheximide	77-90	tumor protein, translationally-controlled 1	Mus musculus	14-17
7726832-2	1995	The inhibitory effect of okadaic acid on elastin mRNA levels was efficiently prevented by retinoic acid and cycloheximide and was further enhanced by phorbol ester treatment.	Cycloheximide	108-121	elastin	Homo sapiens	41-48
7539514-7	1995	Incubation of resistant T-ALL with the protein synthesis inhibitor cycloheximide reversed resistance and induced sensitivity to anti-APO-1 mediated apoptosis in most T-ALL.	Cycloheximide	67-80	Fas cell surface death receptor	Homo sapiens	133-138
7734449-3	1995	We observed that the stimulation of HMGR activity by PG was completely prevented by cycloheximide.	Cycloheximide	84-97	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	36-40
7733301-5	1995	Fluticasone-induced increases in SLPI transcript levels were inhibited by cycloheximide, suggesting protein synthesis may be required for this response.	Cycloheximide	74-87	secretory leukocyte peptidase inhibitor	Homo sapiens	33-37
7537465-6	1995	The maximum effect of the hormone, approximately threefold increase, was observed 1-2 h after addition of the hormone but was still apparent up to 48 h. FAS transcription but not that of actin was inhibited by cycloheximide and puromycin in both control and dexamethasone-treated cultures.	Cycloheximide	210-223	fatty acid synthase	Rattus norvegicus	153-156
7537467-4	1995	Coincubation with the transcription inhibitor actinomycin D or the translation inhibitor cycloheximide prevented the cytokine induction of iNOS mRNA and NO production, indicating that synthesis of intermediary proteins stimulated transcription of the iNOS gene.	Cycloheximide	89-102	nitric oxide synthase 2, inducible	Mus musculus	139-143
7537467-4	1995	Coincubation with the transcription inhibitor actinomycin D or the translation inhibitor cycloheximide prevented the cytokine induction of iNOS mRNA and NO production, indicating that synthesis of intermediary proteins stimulated transcription of the iNOS gene.	Cycloheximide	89-102	nitric oxide synthase 2, inducible	Mus musculus	251-255
7882362-8	1995	Analyses of the vitamin D3 responses in the presence of cycloheximide or actinomycin D indicated that the TGF-beta 1 mRNA induction was dependent on both protein and RNA synthesis.	Cycloheximide	56-69	transforming growth factor beta 1	Homo sapiens	106-116
7534697-7	1995	HOBIT cells, but not the osteosarcoma cell lines, appeared to produce a cycloheximide-sensitive inhibitor of the IGFBP-4 proteolytic reaction.	Cycloheximide	72-85	insulin like growth factor binding protein 4	Homo sapiens	113-120
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	tumor necrosis factor	Homo sapiens	15-18
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	metallothionein 2A	Homo sapiens	137-142
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	tumor necrosis factor	Homo sapiens	163-166
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	interferon beta 1	Homo sapiens	180-188
7640344-3	1995	The effects of TNF and IFN-beta were further distinguished by the action of the protein synthesis inhibitor cycloheximide, which reduced MT-II mRNA stimulation by TNF but enhanced IFN-beta-induced MT-II mRNA.	Cycloheximide	108-121	metallothionein 2A	Homo sapiens	197-202
7895671-12	1995	Inhibition of protein synthesis by cycloheximide potentiated the effect of DEX, and raised the abundance of PGHS-1, PGHS-2, and gamma-actin mRNAs in untreated cells.	Cycloheximide	35-48	prostaglandin-endoperoxide synthase 1	Homo sapiens	108-114
7895671-12	1995	Inhibition of protein synthesis by cycloheximide potentiated the effect of DEX, and raised the abundance of PGHS-1, PGHS-2, and gamma-actin mRNAs in untreated cells.	Cycloheximide	35-48	prostaglandin-endoperoxide synthase 2	Homo sapiens	116-122
7744046-5	1995	Both actinomycin D and cycloheximide blocked the hCG-induced decrease in both receptor number and mRNA levels.	Cycloheximide	23-36	chorionic gonadotropin subunit beta 5	Homo sapiens	49-52
7543894-7	1995	Cycloheximide rapidly diminished cochlear ODC activity and expression of ODC protein.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	42-45
7737276-5	1995	TcR triggering of degranulation also results in new synthesis of the lytic proteins, which can be inhibited by cycloheximide (CHX).	Cycloheximide	111-124	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	0-3
7737276-5	1995	TcR triggering of degranulation also results in new synthesis of the lytic proteins, which can be inhibited by cycloheximide (CHX).	Cycloheximide	126-129	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	0-3
7535734-5	1995	Similarly, TNF cytotoxicity occurred in Hep G2 cells sensitized with cycloheximide (CHX), and cytotoxicity to both inhibitors was dose dependent.	Cycloheximide	69-82	tumor necrosis factor	Homo sapiens	11-14
7535734-5	1995	Similarly, TNF cytotoxicity occurred in Hep G2 cells sensitized with cycloheximide (CHX), and cytotoxicity to both inhibitors was dose dependent.	Cycloheximide	84-87	tumor necrosis factor	Homo sapiens	11-14
7721946-7	1995	By immunofluorescence microscopy, AMF-R tubules are clearly distinguished from the calnexin labeled rough endoplasmic reticulum and AMF-R tubule expression is stable to extended cycloheximide treatment.	Cycloheximide	178-191	autocrine motility factor receptor	Canis lupus familiaris	132-137
7699321-5	1995	This expression of CD40L starts between 1 and 2 h, peaks at 6 h, and remains at a high level for > 20 h. It is totally prevented by adding a concentration of cycloheximide that inhibits CD25 synthesis by these activated cells.	Cycloheximide	161-174	CD40 ligand	Homo sapiens	19-24
7699321-5	1995	This expression of CD40L starts between 1 and 2 h, peaks at 6 h, and remains at a high level for > 20 h. It is totally prevented by adding a concentration of cycloheximide that inhibits CD25 synthesis by these activated cells.	Cycloheximide	161-174	interleukin 2 receptor subunit alpha	Homo sapiens	189-193
7619212-8	1995	Both cycloheximide and actinomycin D inhibited the inductive effect of t-RA on ActR-IIB gene expression, in contrast to ActR-II whose gene expression was not suppressed by cycloheximide but abolished by actinomycin D.	Cycloheximide	5-18	activin receptor IIB	Mus musculus	79-87
7722423-7	1995	Cycloheximide treatment of peritoneal macrophages inhibited the increase in cathepsin H mRNA levels induced by IFN-gamma, suggesting that the increase in cathepsin mRNA levels requires de novo protein synthesis.	Cycloheximide	0-13	cathepsin H	Mus musculus	76-87
7722423-7	1995	Cycloheximide treatment of peritoneal macrophages inhibited the increase in cathepsin H mRNA levels induced by IFN-gamma, suggesting that the increase in cathepsin mRNA levels requires de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Mus musculus	111-120
7791544-7	1995	The proportion of extracellular B-isoforms increased with time, presumably due to instability of A-isoforms at 37 degrees C. Cycloheximide inhibited the release of Hex activity, whereas NH4Cl increased the extracellular fraction of Hex, even at a concentration of 1 mmol/l.	Cycloheximide	125-138	O-GlcNAcase	Homo sapiens	164-167
7716083-11	1995	The stimulatory effect of prolactin on E1 alpha was inhibited by actinomycin and cycloheximide, thereby indicating that prolactin stimulated the biosynthesis of E1 alpha.	Cycloheximide	81-94	branched chain keto acid dehydrogenase E1 subunit alpha	Rattus norvegicus	39-47
7716083-11	1995	The stimulatory effect of prolactin on E1 alpha was inhibited by actinomycin and cycloheximide, thereby indicating that prolactin stimulated the biosynthesis of E1 alpha.	Cycloheximide	81-94	branched chain keto acid dehydrogenase E1 subunit alpha	Rattus norvegicus	161-169
7696302-1	1995	The effects of the protein synthesis inhibitors actinomycin D and cycloheximide on the cellular content of the calcium binding protein synexin, and on the secretory response of cultured bovine adrenal medullary chromaffin cells were determined.	Cycloheximide	66-79	annexin A7	Bos taurus	135-142
7696302-3	1995	The synexin level was reduced by 50% after 133 h of incubation in the presence of 2 micrograms/ml actinomycin D or 5 micrograms/ml cycloheximide.	Cycloheximide	131-144	annexin A7	Bos taurus	4-11
7534132-5	1995	Cycloheximide (CHX), a protein synthesis inhibitor, caused increases in c-kit mRNA levels in K562YO cells.	Cycloheximide	0-13	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	72-77
7534132-5	1995	Cycloheximide (CHX), a protein synthesis inhibitor, caused increases in c-kit mRNA levels in K562YO cells.	Cycloheximide	15-18	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	72-77
7535529-10	1995	The capacity of nicotinamide to increase the abundance of membrane associated Gs alpha was reversed when the cells were cultured in the presence of 20 micrograms/mL cycloheximide.	Cycloheximide	165-178	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	78-86
7543894-7	1995	Cycloheximide rapidly diminished cochlear ODC activity and expression of ODC protein.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	73-76
7887903-9	1995	Pretreatment with cycloheximide (CX) markedly attenuated NaB- and/or CD-stimulated p52(PAI-1) expression.	Cycloheximide	33-35	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	83-86
7900779-7	1995	However, this effect required > 1 h of exposure to CM, was additive with the effects of vasopressin, calcium ionophore, and hypertonicity, and was blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	193-206	arginine vasopressin	Rattus norvegicus	91-102
7900784-4	1995	Furthermore, this ANG II action was inhibited by both cycloheximide (1 microgram/ml) and actinomycin D (10(-6) M), indicating that synthesis of new glucose transporters is involved.	Cycloheximide	54-67	angiotensinogen	Rattus norvegicus	18-24
7887903-9	1995	Pretreatment with cycloheximide (CX) markedly attenuated NaB- and/or CD-stimulated p52(PAI-1) expression.	Cycloheximide	33-35	serpin family E member 1	Rattus norvegicus	87-92
7887903-10	1995	CX alone, however, induced low levels of p52(PAI-1) mRNA; increased p52(PAI-1) protein synthesis was evident after release of KNRK cells from CX blockade.	Cycloheximide	0-2	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	41-44
7887903-10	1995	CX alone, however, induced low levels of p52(PAI-1) mRNA; increased p52(PAI-1) protein synthesis was evident after release of KNRK cells from CX blockade.	Cycloheximide	0-2	serpin family E member 1	Rattus norvegicus	45-50
7720186-5	1995	This initial activation of PLA2 could be inhibited by cycloheximide and actinomycin D, indicating the requirement of gene transcription.	Cycloheximide	54-67	phospholipase A2 group IIA	Homo sapiens	27-31
7866997-4	1995	In the presence of cycloheximide, a protein synthesis inhibitor, phytohemagglutinin-induced HOX-11 up-regulation was suppressed, indicating that HOX-11 acts as a delayed early response gene which requires protein synthesis.	Cycloheximide	19-32	T cell leukemia homeobox 1	Homo sapiens	92-98
7866997-4	1995	In the presence of cycloheximide, a protein synthesis inhibitor, phytohemagglutinin-induced HOX-11 up-regulation was suppressed, indicating that HOX-11 acts as a delayed early response gene which requires protein synthesis.	Cycloheximide	19-32	T cell leukemia homeobox 1	Homo sapiens	145-151
7614555-2	1995	Transformation by CDR1 of a PDR5-disrupted host hypersensitive to cycloheximide and chloramphenicol resulted in resistance to cycloheximide, chloramphenicol and other drugs, such as the antifungal miconazole, with collateral hypersensitivity to oligomycin, nystatin and 2,4 dinitrophenol.	Cycloheximide	66-79	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	28-32
7614555-2	1995	Transformation by CDR1 of a PDR5-disrupted host hypersensitive to cycloheximide and chloramphenicol resulted in resistance to cycloheximide, chloramphenicol and other drugs, such as the antifungal miconazole, with collateral hypersensitivity to oligomycin, nystatin and 2,4 dinitrophenol.	Cycloheximide	126-139	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	28-32
7780739-6	1995	Incubation of NIH 3T3 fibroblasts with cycloheximide prevents both synthesis of CL100 and inactivation of p42mapk after stimulation with serum.	Cycloheximide	39-52	dual specificity phosphatase 1	Rattus norvegicus	80-85
7887903-9	1995	Pretreatment with cycloheximide (CX) markedly attenuated NaB- and/or CD-stimulated p52(PAI-1) expression.	Cycloheximide	18-31	similar to Mitochondrial processing peptidase beta subunit, mitochondrial precursor (Beta-MPP; P-52)	Rattus norvegicus	83-86
7887903-9	1995	Pretreatment with cycloheximide (CX) markedly attenuated NaB- and/or CD-stimulated p52(PAI-1) expression.	Cycloheximide	18-31	serpin family E member 1	Rattus norvegicus	87-92
7867726-6	1995	On the other hand, cycloheximide treatment by itself caused upregulation of RET transcripts.	Cycloheximide	19-32	ret proto-oncogene	Homo sapiens	76-79
7780739-6	1995	Incubation of NIH 3T3 fibroblasts with cycloheximide prevents both synthesis of CL100 and inactivation of p42mapk after stimulation with serum.	Cycloheximide	39-52	mitogen activated protein kinase 1	Rattus norvegicus	106-113
7780739-7	1995	RESULTS: Depleting cells of CL100 and preventing its induction using cycloheximide stopped the inactivation of p42mapk in Swiss 3T3 fibroblasts following stimulation with epidermal growth factor (EGF), but had no effect on the rapid inactivation of p42mapk in response to EGF in adipose (3T3-L1) or chromaffin (PC12) cells or in response to platelet-derived growth factor (PDGF) in endothelial (PAE) cells.	Cycloheximide	69-82	mitogen-activated protein kinase 1	Mus musculus	111-118
7883838-6	1995	The insulin-induced ET-1 secretion was inhibited by genistein, a tyrosine kinase inhibitor, and by cycloheximide, a protein synthesis inhibitor, suggesting that it requires de novo protein synthesis rather than ET-1 release from intracellular stores.	Cycloheximide	99-112	insulin	Homo sapiens	4-11
7883838-6	1995	The insulin-induced ET-1 secretion was inhibited by genistein, a tyrosine kinase inhibitor, and by cycloheximide, a protein synthesis inhibitor, suggesting that it requires de novo protein synthesis rather than ET-1 release from intracellular stores.	Cycloheximide	99-112	endothelin 1	Homo sapiens	20-24
7884000-7	1995	Cycloheximide partially reversed elastin mRNA instability.	Cycloheximide	0-13	elastin	Homo sapiens	33-40
7613249-10	1995	The increase in ET-1 release was actinomycin D-sensitive, and ET-1 mRNA abundance was greatly enhanced by cycloheximide.	Cycloheximide	106-119	endothelin 1	Homo sapiens	16-20
7613249-10	1995	The increase in ET-1 release was actinomycin D-sensitive, and ET-1 mRNA abundance was greatly enhanced by cycloheximide.	Cycloheximide	106-119	endothelin 1	Homo sapiens	62-66
7868906-9	1995	6) TNF-alpha-induced apoptosis of normal or inflammatory PBN and bone marrow neutrophils was enhanced by treatment with low doses of cycloheximide that alone were barely able to induce neutrophil apoptosis; however, apoptosis of PEN was not.	Cycloheximide	133-146	tumor necrosis factor	Homo sapiens	3-12
7884320-4	1995	Induction of Mg21 mRNA by IFN-gamma occurred in the presence of cycloheximide, indicating that expression of Mg21 mRNA does not require protein synthesis.	Cycloheximide	64-77	T cell specific GTPase 1	Mus musculus	13-17
7884320-4	1995	Induction of Mg21 mRNA by IFN-gamma occurred in the presence of cycloheximide, indicating that expression of Mg21 mRNA does not require protein synthesis.	Cycloheximide	64-77	interferon gamma	Mus musculus	26-35
7532282-2	1995	Within 5 min of monocyte adhesion, the level of the I kappa B alpha protein is markedly diminished but is rapidly replaced in a cycloheximide-sensitive manner within 20 min.	Cycloheximide	128-141	NFKB inhibitor alpha	Homo sapiens	52-67
7723769-0	1995	Spontaneous and cycloheximide-induced interleukin-10 mRNA expression in human mononuclear cells.	Cycloheximide	16-29	interleukin 10	Homo sapiens	38-52
7723769-2	1995	In order to define the cell type in which IL-10 gene is spontaneously expressed we used the reverse polymerase chain reaction for IL-10 mRNA expression, which was also used to study the effects of cycloheximide (CHX).	Cycloheximide	197-210	interleukin 10	Homo sapiens	42-47
7723769-2	1995	In order to define the cell type in which IL-10 gene is spontaneously expressed we used the reverse polymerase chain reaction for IL-10 mRNA expression, which was also used to study the effects of cycloheximide (CHX).	Cycloheximide	212-215	interleukin 10	Homo sapiens	42-47
7776981-6	1995	Down-regulation of IGF-I mRNA by IFN gamma is dependent on de novo protein synthesis and is abrogated by coculture with cycloheximide.	Cycloheximide	120-133	insulin-like growth factor 1	Mus musculus	19-24
7776981-6	1995	Down-regulation of IGF-I mRNA by IFN gamma is dependent on de novo protein synthesis and is abrogated by coculture with cycloheximide.	Cycloheximide	120-133	interferon gamma	Mus musculus	33-42
7789612-9	1995	In the presence cycloheximide, IL-1 beta markedly stimulated preproET-1 mRNA expression, whereas EGF was less effective.	Cycloheximide	16-29	interleukin 1 beta	Homo sapiens	31-40
7854771-6	1995	The expression of p53 was reduced to 60% for the first 4 h after the addition of cycloheximide, and showed no significant changes at least for 20 h. Treatment with Triton X-100 increased p53 immunoreactivity throughout the cell cycle.	Cycloheximide	81-94	tumor protein p53	Homo sapiens	18-21
7725341-3	1995	The insulin-dependent increase in cytosolic GST activity was abolished by the pretreatment of the animals with an inhibitor of protein synthesis (cycloheximide).	Cycloheximide	146-159	hematopoietic prostaglandin D synthase	Rattus norvegicus	44-47
7878674-10	1995	Treatment with actinomycin D or cycloheximide prior to the addition of Pb precluded induction of p23.	Cycloheximide	32-45	RAS related	Rattus norvegicus	97-100
7758824-8	1995	The up-regulation of LRPR1 mRNA expression by FSH was also observed in the presence of the protein synthesis inhibitor cycloheximide, indicating that FSH regulates LRPR1 mRNA expression through a direct mechanism which does not require de novo protein synthesis.	Cycloheximide	119-132	centromere protein I	Rattus norvegicus	21-26
7758824-8	1995	The up-regulation of LRPR1 mRNA expression by FSH was also observed in the presence of the protein synthesis inhibitor cycloheximide, indicating that FSH regulates LRPR1 mRNA expression through a direct mechanism which does not require de novo protein synthesis.	Cycloheximide	119-132	centromere protein I	Rattus norvegicus	164-169
7876163-5	1995	Pretreatment for 1 h with cycloheximide suppressed grp78 mRNA induction and eIF-2 alpha phosphorylation in response to either stressor.	Cycloheximide	26-39	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	51-56
7876163-5	1995	Pretreatment for 1 h with cycloheximide suppressed grp78 mRNA induction and eIF-2 alpha phosphorylation in response to either stressor.	Cycloheximide	26-39	eukaryotic translation initiation factor 2A	Rattus norvegicus	76-87
7876163-6	1995	Prolonged (17 h) cycloheximide blockade increased eIF-2 alpha phosphorylation without inducing grp78 mRNA.	Cycloheximide	17-30	eukaryotic translation initiation factor 2A	Rattus norvegicus	50-61
7883167-8	1995	The UPF2 gene is dispensable for vegetative growth, but upf2 delta strains were found to be more sensitive to the translational elongation inhibitor cycloheximide than UPF2+.	Cycloheximide	149-162	Nmd2p	Saccharomyces cerevisiae S288C	4-8
7766844-2	1995	To examine the possibility that de novo synthesis of ITFs was necessary for increased expression of trk mRNA we prevented protein synthesis for 5 h using the protein synthesis inhibitor, cycloheximide (4 x 10 mg kg-1, i.p., 1 h before and 1, 2 and 3 h after injury).	Cycloheximide	187-200	neurotrophic receptor tyrosine kinase 1	Homo sapiens	100-103
7766844-4	1995	Cycloheximide had no effect on trkB mRNA expression but attenuated the injury-induced increase in trkC mRNA expression in dentate gyrus at 4 h by 75%.	Cycloheximide	0-13	neurotrophic receptor tyrosine kinase 3	Homo sapiens	98-102
7857970-6	1995	SP-A and SP-C mRNA production and steady-state levels were reduced after treatment with cycloheximide.	Cycloheximide	88-101	pulmonary surfactant-associated protein A	Oryctolagus cuniculus	0-4
7857970-6	1995	SP-A and SP-C mRNA production and steady-state levels were reduced after treatment with cycloheximide.	Cycloheximide	88-101	pulmonary surfactant-associated protein C	Oryctolagus cuniculus	9-13
7883167-8	1995	The UPF2 gene is dispensable for vegetative growth, but upf2 delta strains were found to be more sensitive to the translational elongation inhibitor cycloheximide than UPF2+.	Cycloheximide	149-162	Nmd2p	Saccharomyces cerevisiae S288C	56-60
7845676-2	1995	Freshly isolated PBMCs, which are in the Go phase of the cell cycle, were shown to express low levels of p53 mRNA that was rapidly degraded with a half life of 1 h. The rapid decay of p53 mRNA in quiescent PBMCs was dependent on global protein synthesis as treatment with cycloheximide resulted in stabilization of the p53 message.	Cycloheximide	272-285	tumor protein p53	Homo sapiens	105-108
7865217-7	1995	Using reverse transcription-polymerase chain reaction and a human pulmonary mucoepidermoid carcinoma cell line (NCI-H292), increases in MUC-2 steady-state mRNA levels were first detectable after 30 min of TNF-alpha stimulation and persisted for 24 h. Cycloheximide did not inhibit TNF-alpha-mediated MUC-2 mRNA expression at 1 h, suggesting that new protein translation was not required.	Cycloheximide	251-264	mucin 2, oligomeric mucus/gel-forming	Homo sapiens	136-141
7755659-7	1995	The effect of l-triiodothyronine on HMG CoA reductase was abolished by cycloheximide, and not by actinomycin D.	Cycloheximide	71-84	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	36-53
7534483-3	1995	Thymosin beta 4 mRNA was induced even in the presence of cycloheximide.	Cycloheximide	57-70	thymosin, beta 4, X chromosome	Mus musculus	0-15
7588378-5	1995	The effect of AII, but not forskolin, was blocked by the presence of cycloheximide.	Cycloheximide	69-82	NLR family pyrin domain containing 3	Homo sapiens	14-17
7780040-6	1995	In contrast, the known translational inhibitor cycloheximide did not demonstrate selectivity for IL-6; this agent decreased the GM-CSF-induced increase in total translational activity in parallel with its effects on IL-6.	Cycloheximide	47-60	colony stimulating factor 2	Homo sapiens	128-134
7780040-6	1995	In contrast, the known translational inhibitor cycloheximide did not demonstrate selectivity for IL-6; this agent decreased the GM-CSF-induced increase in total translational activity in parallel with its effects on IL-6.	Cycloheximide	47-60	interleukin 6	Homo sapiens	216-220
7757262-9	1995	However, chronic addition of cycloheximide prior to deprivation greatly impaired the differentiation of NGF/dbcAMP cells, allowing these cells to withstand trophic support withdrawal.	Cycloheximide	29-42	nerve growth factor	Rattus norvegicus	104-107
7529748-6	1995	Induction of endothelial iNOS mRNA was inhibited by cycloheximide, which indicated a requirement for de novo protein synthesis.	Cycloheximide	52-65	nitric oxide synthase 2, inducible	Mus musculus	25-29
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	toll-like receptor 4	Mus musculus	44-47
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	interferon regulatory factor 2	Mus musculus	59-64
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	interferon regulatory factor 8	Mus musculus	69-74
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	interferon regulatory factor 1	Mus musculus	118-123
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	jun proto-oncogene	Mus musculus	127-142
7822029-9	1995	Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene.	Cycloheximide	0-13	toll-like receptor 4	Mus musculus	144-147
8852339-2	1995	Transformation by CDR 1 of a PDR 5 disrupted host hypersensitive to cycloheximide and chloramphenicol resulted in resistance to these as well as other unrelated drugs.	Cycloheximide	68-81	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	29-34
7745610-3	1995	Here we show that the Oct-2 mRNA is rapidly induced in DRG cells exposed to NGF and that such induction still occurs to a lesser extent in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	187-200	POU class 2 homeobox 2	Rattus norvegicus	22-27
7852844-3	1995	Under all three conditions, both forms of TGF-beta (20 ng/ml) induced a two- to fourfold increase in C3 concentration in monocyte supernatants harvested after 2 or 5 days of cell culture, an effect that was abrogated by cycloheximide.	Cycloheximide	220-233	transforming growth factor beta 1	Homo sapiens	42-50
7536858-9	1995	Both actinomycin D and cycloheximide significantly inhibited NO synthesis and iNOS mRNA expression.	Cycloheximide	23-36	nitric oxide synthase 2	Rattus norvegicus	78-82
7829234-7	1995	The protein synthesis inhibitor cycloheximide super-induced basal and GM-CSF-induced ICAM-I transcripts, thus excluding a role for secondary polypeptide mediators.	Cycloheximide	32-45	colony stimulating factor 2	Homo sapiens	70-76
7836779-4	1995	The assay showed that TNF-dependent DNA fragmentation was potentiated by cycloheximide and occurred within 90 min.	Cycloheximide	73-86	tumor necrosis factor	Homo sapiens	22-25
7537677-5	1995	Endothelial cells and macrophages also contained comparable amounts of cyclooxygenase-2 protein after incubation with endotoxin for 24 h which was prevented by pretreatment with cycloheximide (10 micrograms ml-1; 30 min prior to endotoxin).	Cycloheximide	178-191	prostaglandin-endoperoxide synthase 2	Bos taurus	71-87
7835696-1	1995	The murine macrophage inflammatory protein 1 beta mRNA (MIP-1 beta) is rapidly and transiently induced in macrophages by lipopolysaccharide (LPS), serum or cycloheximide.	Cycloheximide	156-169	chemokine (C-C motif) ligand 4	Mus musculus	11-49
7835696-1	1995	The murine macrophage inflammatory protein 1 beta mRNA (MIP-1 beta) is rapidly and transiently induced in macrophages by lipopolysaccharide (LPS), serum or cycloheximide.	Cycloheximide	156-169	chemokine (C-C motif) ligand 4	Mus musculus	56-66
7841194-3	1995	Transcription was also activated by cycloheximide (CHX) even during serum starvation, indicating that the expression of the PDGF-A chain is inhibited by transcription suppressor factor with a short life during serum starvation.	Cycloheximide	36-49	platelet derived growth factor subunit A	Homo sapiens	124-130
7841194-3	1995	Transcription was also activated by cycloheximide (CHX) even during serum starvation, indicating that the expression of the PDGF-A chain is inhibited by transcription suppressor factor with a short life during serum starvation.	Cycloheximide	51-54	platelet derived growth factor subunit A	Homo sapiens	124-130
7851388-2	1995	A rapid increase in activity (maximal at 10 min) is followed by a lower persistent level of activity which is maximal at 4-6 h. The second peak of MAP kinase activity is markedly attenuated by the protein synthesis inhibitor cycloheximide and, consequently, is paralleled by a marked de-novo synthesis of p42 and p44 MAP kinases, as measured by immunoprecipitation of [35S]methionine-labeled mesangial cells and by a 700% increase in total MAP kinase protein, as detected by Western-blot analysis.	Cycloheximide	225-238	cyclin dependent kinase 20	Homo sapiens	305-308
7851388-2	1995	A rapid increase in activity (maximal at 10 min) is followed by a lower persistent level of activity which is maximal at 4-6 h. The second peak of MAP kinase activity is markedly attenuated by the protein synthesis inhibitor cycloheximide and, consequently, is paralleled by a marked de-novo synthesis of p42 and p44 MAP kinases, as measured by immunoprecipitation of [35S]methionine-labeled mesangial cells and by a 700% increase in total MAP kinase protein, as detected by Western-blot analysis.	Cycloheximide	225-238	interferon induced protein 44	Homo sapiens	313-316
7572337-23	1995	In animals injected with cycloheximide the bone marrow PI and PIP kinase activities exhibited t1/2 = 0.12 hr, the shortest decay rate in comparison with 8 enzymes of purine and pyrimidine biosynthesis with t1/2 = 0.6 to 4.3 hr.	Cycloheximide	25-38	prolactin induced protein	Homo sapiens	62-65
7538424-8	1995	TNF-alpha-induced destabilization of cNOS mRNA could be partially prevented by coincubation with cycloheximide (1 mumol/L) but was not reproduced by addition of sodium nitroprusside.	Cycloheximide	97-110	tumor necrosis factor	Homo sapiens	0-9
7538424-8	1995	TNF-alpha-induced destabilization of cNOS mRNA could be partially prevented by coincubation with cycloheximide (1 mumol/L) but was not reproduced by addition of sodium nitroprusside.	Cycloheximide	97-110	nitric oxide synthase 3	Homo sapiens	37-41
7826318-9	1995	Inhibition of protein synthesis by cycloheximide induced an overexpression of insulin-receptor mRNA levels in the presence of glucose, suggesting that labile repressor protein(s) could be implicated in the effects of glucose.	Cycloheximide	35-48	insulin receptor	Homo sapiens	78-94
7536096-15	1995	Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7.	Cycloheximide	37-50	interleukin 1 beta	Rattus norvegicus	129-138
7536096-15	1995	Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7.	Cycloheximide	37-50	tumor necrosis factor	Rattus norvegicus	144-149
7536096-15	1995	Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7.	Cycloheximide	52-54	interleukin 1 beta	Rattus norvegicus	129-138
7536096-15	1995	Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7.	Cycloheximide	52-54	tumor necrosis factor	Rattus norvegicus	144-149
7712031-19	1995	The up-regulation of the B2 receptor by forskolin was mediated through protein synthesis, since cycloheximide blocked this response.7 It is concluded that the pharmacological characteristics of the bradykinin receptors in canine cultured TSMCs are primarily of the B2 receptor subtype.	Cycloheximide	96-109	kininogen 1	Canis lupus familiaris	198-208
7600455-10	1995	However, in the presence of actinomycin D or cycloheximide, nuclear AHR remained elevated in cells exposed to TCDD, at levels similar to or greater than the maximum previously observed after 1-h incubations.	Cycloheximide	45-58	aryl hydrocarbon receptor	Homo sapiens	68-71
7749068-4	1995	In all these cell lines the level of gamma 2 mRNA increased 2-4 h after induction reaching a stable plateau after 8-12 h. The IFN-gamma induction of gamma 2 mRNA could be blocked by cycloheximide in human amniotic (AMA) cells, epithelial HeLa cells and HT1080 fibroblasts, but not in T98G glioblastoma cells.	Cycloheximide	182-195	tryptophanyl-tRNA synthetase 1	Homo sapiens	37-44
7749068-4	1995	In all these cell lines the level of gamma 2 mRNA increased 2-4 h after induction reaching a stable plateau after 8-12 h. The IFN-gamma induction of gamma 2 mRNA could be blocked by cycloheximide in human amniotic (AMA) cells, epithelial HeLa cells and HT1080 fibroblasts, but not in T98G glioblastoma cells.	Cycloheximide	182-195	interferon gamma	Homo sapiens	126-135
7749068-4	1995	In all these cell lines the level of gamma 2 mRNA increased 2-4 h after induction reaching a stable plateau after 8-12 h. The IFN-gamma induction of gamma 2 mRNA could be blocked by cycloheximide in human amniotic (AMA) cells, epithelial HeLa cells and HT1080 fibroblasts, but not in T98G glioblastoma cells.	Cycloheximide	182-195	tryptophanyl-tRNA synthetase 1	Homo sapiens	149-156
7586758-6	1995	Interestingly, treatment of blastula or gastrula embryos at high temperatures (37 degrees C for 1 h) or with the protein synthesis inhibitor, cycloheximide, followed by heat shock, led to enhanced accumulation of the pre-tailbud (PTB) hsp 30 mRNAs.	Cycloheximide	142-155	heat shock protein 30E L homeolog	Xenopus laevis	235-241
7750518-9	1995	When cells were stimulated with TSH in the presence of cycloheximide, the Golgi cisternae lost their predominant immunoreactivity for beta-APP and were rapidly emptied (within 30 min).	Cycloheximide	55-68	amyloid beta precursor protein	Rattus norvegicus	134-142
7795173-8	1995	The CSF release was dependent on protein synthesis as it was completely inhibited by cycloheximide (50.0 micrograms/ml).	Cycloheximide	85-98	colony stimulating factor 2	Homo sapiens	4-7
7843230-8	1995	Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times.	Cycloheximide	11-24	RELA proto-oncogene, NF-kB subunit	Homo sapiens	39-42
7843230-8	1995	Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times.	Cycloheximide	11-24	REL proto-oncogene, NF-kB subunit	Homo sapiens	47-52
8930020-7	1995	Furthermore, cycloheximide induces stabilization of VEGF mRNA in normal cells but has no effect on VEGF transcript stability in tumor cells that contain stabilized transcripts.	Cycloheximide	13-26	vascular endothelial growth factor A	Homo sapiens	52-56
7721348-8	1995	In fact, cycloheximide induced the expression of IRG1, suggesting that a protein repressor prevents the expression of IRG1 when uninduced.	Cycloheximide	9-22	aconitate decarboxylase 1	Mus musculus	49-53
7814399-3	1995	Northern analysis revealed a dose- and time-dependent suppression of BPAG1 expression by IFN-gamma in cultured human keratinocytes from several different donors, and incubation of the cells with IFN-gamma in the presence of cycloheximide demonstrated that this effect required ongoing protein synthesis.	Cycloheximide	224-237	dystonin	Homo sapiens	69-74
7814399-3	1995	Northern analysis revealed a dose- and time-dependent suppression of BPAG1 expression by IFN-gamma in cultured human keratinocytes from several different donors, and incubation of the cells with IFN-gamma in the presence of cycloheximide demonstrated that this effect required ongoing protein synthesis.	Cycloheximide	224-237	interferon gamma	Homo sapiens	195-204
7721958-9	1995	In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis.	Cycloheximide	19-32	transforming growth factor beta 1	Homo sapiens	34-42
7721958-9	1995	In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis.	Cycloheximide	19-32	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
7721958-9	1995	In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis.	Cycloheximide	19-32	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	111-116
7721958-9	1995	In the presence of cycloheximide, TGF-beta causes super-induction of c-fos mRNA at 30 min, indicating that the c-fos expression by TGF-beta is independent of new protein synthesis.	Cycloheximide	19-32	transforming growth factor beta 1	Homo sapiens	131-139
7768965-6	1995	Interestingly, induction of TIS21 expression was obliterated in the human lung cancer cells; A549 cells completely lost the ability to express TIS21 after a combined treatment of TPA and cycloheximide.	Cycloheximide	187-200	BTG anti-proliferation factor 2	Homo sapiens	28-33
7768965-6	1995	Interestingly, induction of TIS21 expression was obliterated in the human lung cancer cells; A549 cells completely lost the ability to express TIS21 after a combined treatment of TPA and cycloheximide.	Cycloheximide	187-200	BTG anti-proliferation factor 2	Homo sapiens	143-148
7768965-7	1995	We also measured the induction of TIS genes by TPA and/or cycloheximide in Raw264.7 mouse macrophage cells and U937 human histiocytic lymphoma cells.	Cycloheximide	58-71	programmed cell death 4	Mus musculus	34-37
7721348-8	1995	In fact, cycloheximide induced the expression of IRG1, suggesting that a protein repressor prevents the expression of IRG1 when uninduced.	Cycloheximide	9-22	aconitate decarboxylase 1	Mus musculus	118-122
7706411-7	1994	During a 20 degrees C temperature block Sso2p accumulated in the Golgi complex and was chased to the plasma membrane by a subsequent 37 degrees C incubation in the presence of cycloheximide.	Cycloheximide	176-189	syntaxin	Saccharomyces cerevisiae S288C	40-45
8587480-5	1995	Cycloheximide (10 micrograms/ml) inhibited MEK-1 mRNA induction but stimulated p42 MAPK mRNA expression in both the absence and the presence of ET-1 and/or PDGF BB.	Cycloheximide	0-13	mitogen-activated protein kinase kinase 1	Homo sapiens	43-48
8587480-5	1995	Cycloheximide (10 micrograms/ml) inhibited MEK-1 mRNA induction but stimulated p42 MAPK mRNA expression in both the absence and the presence of ET-1 and/or PDGF BB.	Cycloheximide	0-13	mitogen-activated protein kinase 1	Homo sapiens	79-87
8587480-5	1995	Cycloheximide (10 micrograms/ml) inhibited MEK-1 mRNA induction but stimulated p42 MAPK mRNA expression in both the absence and the presence of ET-1 and/or PDGF BB.	Cycloheximide	0-13	endothelin 1	Homo sapiens	144-148
7731170-7	1995	Actinomycin D reduced ET-1-stimulated PGE2 synthesis and COX-2 mRNA expression, while cycloheximide superinduced COX-2 mRNA.	Cycloheximide	86-99	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	113-118
7596215-6	1995	Cycloheximide (1 microM), a protein synthesis inhibitor, perfused together with DEX reverted the inhibitory effects of dexamethasone on the expression of the penicillin-induced CA1 epileptiform bursting.	Cycloheximide	0-13	carbonic anhydrase 1	Rattus norvegicus	177-180
18475618-3	1995	Interleukin-1beta caused a delayed increase in short-circuit current (I(sc)) which was attributed to protein synthesis since the effect was inhibited by cycloheximide.	Cycloheximide	153-166	interleukin-1 beta	Oryctolagus cuniculus	0-17
18475618-5	1995	Prostaglandin E(2) levels increased in tissue treated with interleukin-1beta, but this increase was reversed by cycloheximide.	Cycloheximide	112-125	interleukin-1 beta	Oryctolagus cuniculus	59-76
7760844-7	1995	This was accompanied by an increase in mRNA for C/EBP delta, which was superinduced by cycloheximide and, unlike the increase in C/EBP beta protein, was not observed with insulin.	Cycloheximide	87-100	CCAAT enhancer binding protein delta	Homo sapiens	48-59
7796928-2	1995	Ten-minute pulses of 20 nmol/l GnRH administered 150 min apart resulted in the manifestation of the self-priming effect, an effect which was inhibited by 5 mumol/l cycloheximide.	Cycloheximide	164-177	gonadotropin releasing hormone 1	Rattus norvegicus	31-35
8555651-4	1995	Cycloheximide blocked the effects of IL-10 in a reversible manner.	Cycloheximide	0-13	interleukin 10	Homo sapiens	37-42
8532589-7	1995	The effect of zinc sulfate to enhance the IGF-I-increased alkaline phosphatase activity and protein concentration in the cells was clearly prevented by the presence of cycloheximide (10(-6) M), staurosporin (10(-8) M), or okadaic acid (10(-7) M) with an effective concentration.	Cycloheximide	168-181	insulin-like growth factor 1	Mus musculus	42-47
7803498-6	1994	The elevation of SAT activity was completely prevented when cycloheximide was added to the culture simultaneously.	Cycloheximide	60-73	spermidine/spermine N1-acetyl transferase 1	Mus musculus	17-20
7527398-5	1994	p54 MAP kinase (also called stress-activated protein kinase) is a c-Jun kinase first isolated from livers of cycloheximide-treated rats.	Cycloheximide	109-122	interferon induced protein with tetratricopeptide repeats 2	Homo sapiens	0-3
7527398-5	1994	p54 MAP kinase (also called stress-activated protein kinase) is a c-Jun kinase first isolated from livers of cycloheximide-treated rats.	Cycloheximide	109-122	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-71
7989309-6	1994	In addition, by kinetically down-regulating TNF receptor expression with phorbol esters, cycloheximide, or trypsin, we determined that receptors were necessary for transduction of the TNF signal.	Cycloheximide	89-102	tumor necrosis factor	Homo sapiens	44-47
7989309-6	1994	In addition, by kinetically down-regulating TNF receptor expression with phorbol esters, cycloheximide, or trypsin, we determined that receptors were necessary for transduction of the TNF signal.	Cycloheximide	89-102	tumor necrosis factor	Homo sapiens	184-187
7994042-16	1994	The increase of M-CSF mRNA induction by CHX was 2.5 times higher in cord MNCs compared with that in adult MNCs.	Cycloheximide	40-43	colony stimulating factor 1	Homo sapiens	16-21
7813795-7	1994	Induction of Xlim1, 1A11, and, partially, Xbrachyury transcripts in the marginal zone was blocked by cycloheximide treatment through late blastula stages, whereas Goosecoid and Xwnt8 mRNAs were expressed in the absence of protein synthesis, indicating that these sets of markers are activated in vivo through different pathways.	Cycloheximide	101-114	LIM homeobox 1 L homeolog	Xenopus laevis	13-18
7988435-5	1994	Cycloheximide and actinomycin-D inhibited basal TIMP-1 and TIMP-2 activity and inhibited the ability of FSH, 8-bromo-cAMP, and TPA to stimulate TIMP activity.	Cycloheximide	0-13	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	48-54
7988435-5	1994	Cycloheximide and actinomycin-D inhibited basal TIMP-1 and TIMP-2 activity and inhibited the ability of FSH, 8-bromo-cAMP, and TPA to stimulate TIMP activity.	Cycloheximide	0-13	TIMP metallopeptidase inhibitor 2	Rattus norvegicus	59-65
7958676-7	1994	Treatment with DEX plus cycloheximide or actinomycin showed a requirement for protein synthesis and implicated transcriptional regulation of MnSOD messenger RNA by DEX.	Cycloheximide	24-37	superoxide dismutase 2	Rattus norvegicus	141-146
7982472-10	1994	The effects of actinomycin D and cycloheximide on IGF-I-induced FN mRNA levels were also examined.	Cycloheximide	33-46	insulin-like growth factor 1	Rattus norvegicus	50-55
7982472-11	1994	Inhibition of the IGF-I-induced FN mRNA levels by actinomycin D and an increase of FN mRNA levels by cycloheximide suggest that IGF-I regulates FN mRNA synthesis at the transcriptional level.	Cycloheximide	101-114	fibronectin 1	Rattus norvegicus	83-85
7982472-11	1994	Inhibition of the IGF-I-induced FN mRNA levels by actinomycin D and an increase of FN mRNA levels by cycloheximide suggest that IGF-I regulates FN mRNA synthesis at the transcriptional level.	Cycloheximide	101-114	insulin-like growth factor 1	Rattus norvegicus	128-133
7982472-11	1994	Inhibition of the IGF-I-induced FN mRNA levels by actinomycin D and an increase of FN mRNA levels by cycloheximide suggest that IGF-I regulates FN mRNA synthesis at the transcriptional level.	Cycloheximide	101-114	fibronectin 1	Rattus norvegicus	83-85
7843800-4	1994	Cycloheximide also had no effect on mucin mRNA in RA+ cultures, but, like actinomycin D, it prevented the precipitous drop in mucin mRNA in RA- cultures.	Cycloheximide	0-13	solute carrier family 13 member 2	Rattus norvegicus	126-131
7893997-8	1994	In contrast, the changes in EGF and SGP-2 mRNA levels were blocked by cycloheximide, indicating that these responses required new protein synthesis during the first few hours after folic acid injury.	Cycloheximide	70-83	epidermal growth factor	Mus musculus	28-31
7893997-8	1994	In contrast, the changes in EGF and SGP-2 mRNA levels were blocked by cycloheximide, indicating that these responses required new protein synthesis during the first few hours after folic acid injury.	Cycloheximide	70-83	clusterin	Mus musculus	36-41
7872067-8	1994	The effects of BMP-2 on IGF-I and II transcripts and polypeptide levels were dependent on protein synthesis and decreased in the presence of cycloheximide at 3.6 microM.	Cycloheximide	141-154	bone morphogenetic protein 2	Rattus norvegicus	15-20
7872067-8	1994	The effects of BMP-2 on IGF-I and II transcripts and polypeptide levels were dependent on protein synthesis and decreased in the presence of cycloheximide at 3.6 microM.	Cycloheximide	141-154	insulin-like growth factor 1	Rattus norvegicus	24-29
7989473-11	1994	Cycloheximide had no effect on basal alpha-subunit mRNA levels at 2 or 24 h. However, it inhibited at 24 h the induction of the alpha-subunit by hCG.	Cycloheximide	0-13	chorionic gonadotropin subunit beta 5	Homo sapiens	145-148
7989474-5	1994	A protein synthesis inhibitor (cycloheximide) and RNA synthesis inhibitor (actinomycin D) completely blocked GH secretion from lymphocytes.	Cycloheximide	31-44	growth hormone 1	Homo sapiens	109-111
7700023-7	1994	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in quiescent mesangial cells, and the combination of ET-1 and cycloheximide resulted in a greater induction of cPLA2 gene expression when compared to ET-1 alone.	Cycloheximide	35-48	phospholipase A2 group IVA	Rattus norvegicus	65-70
7700023-7	1994	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in quiescent mesangial cells, and the combination of ET-1 and cycloheximide resulted in a greater induction of cPLA2 gene expression when compared to ET-1 alone.	Cycloheximide	151-164	phospholipase A2 group IVA	Rattus norvegicus	200-205
7700023-7	1994	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in quiescent mesangial cells, and the combination of ET-1 and cycloheximide resulted in a greater induction of cPLA2 gene expression when compared to ET-1 alone.	Cycloheximide	151-164	endothelin 1	Rattus norvegicus	239-243
7966593-8	1994	On the other hand, Tax induces no apparent degradation of MAD3, although experiments using cycloheximide indicate that it decreases the half-life of MAD3.	Cycloheximide	91-104	NFKB inhibitor alpha	Homo sapiens	149-153
7895902-5	1994	The potentiating effect of 1,25(OH)2D3 on TNF action was abolished by cycloheximide indicating that their interaction requires protein synthesis.	Cycloheximide	70-83	tumor necrosis factor	Homo sapiens	42-45
11550711-9	1994	Furthermore, administration of cycloheximide, an inhibitor of protein synthesis, resulted in the superinduction of both IGF-I and c-myc mRNAs.	Cycloheximide	31-44	insulin-like growth factor 1	Rattus norvegicus	120-125
7534852-8	1994	This inhibition was also evident in calcium-free medium and was reversed by L-NAME and by two inhibitors of protein synthesis that are reported to block the inducible-NO synthase, such as dexamethasone (Dex 10(-7) M) and cycloheximide (Chx 10(-6) M).	Cycloheximide	221-234	visual system homeobox 2	Homo sapiens	236-242
11550711-9	1994	Furthermore, administration of cycloheximide, an inhibitor of protein synthesis, resulted in the superinduction of both IGF-I and c-myc mRNAs.	Cycloheximide	31-44	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	130-135
11550711-11	1994	The superinduction of c-myc gene by cycloheximide also indicates that fresh protein synthesis of an intermediate protein was not required for GH-induced c-myc expression.	Cycloheximide	36-49	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	22-27
7988663-7	1994	It is now well established that cyclopentenone prostaglandins, which exert potent antiviral activity in several DNA and RNA virus models, induce hsp70 synthesis through cycloheximide-sensitive activation of heat shock transcription factor.	Cycloheximide	169-182	heat shock protein family A (Hsp70) member 4	Homo sapiens	145-150
7949102-10	1994	Cycloheximide had no effect on PTX3 induction in U937 cells, but was inhibitory on monocytes exposed to LPS or IL-1 beta.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	111-120
7957253-5	1994	After release of cycloheximide inhibition, DNA fragmentation associated with apoptosis occurred in the cycloheximide-treated thymocyte nuclei, in which deoxyribonuclease gamma activity was only observed.	Cycloheximide	17-30	deoxyribonuclease 1-like 3	Rattus norvegicus	152-175
7957253-5	1994	After release of cycloheximide inhibition, DNA fragmentation associated with apoptosis occurred in the cycloheximide-treated thymocyte nuclei, in which deoxyribonuclease gamma activity was only observed.	Cycloheximide	103-116	deoxyribonuclease 1-like 3	Rattus norvegicus	152-175
7980594-1	1994	In cultured rat aortic smooth muscle cells (RASMCs) IL-1 beta induced TGF-beta 1 mRNA expression, which was concentration (10 pM-10 nM)- and time (2-48 h) -dependent, and sensitive to cycloheximide.	Cycloheximide	184-197	interleukin 1 beta	Rattus norvegicus	52-61
7980594-1	1994	In cultured rat aortic smooth muscle cells (RASMCs) IL-1 beta induced TGF-beta 1 mRNA expression, which was concentration (10 pM-10 nM)- and time (2-48 h) -dependent, and sensitive to cycloheximide.	Cycloheximide	184-197	transforming growth factor, beta 1	Rattus norvegicus	70-80
7998962-11	1994	The constitutive NF-kappa B appears to be functionally active, since a low level of tumour necrosis factor (TNF) transcript is detectable in monocytes, and this level can be increased by blocking transcript degradation using cycloheximide.	Cycloheximide	225-238	nuclear factor kappa B subunit 1	Homo sapiens	17-27
7998962-11	1994	The constitutive NF-kappa B appears to be functionally active, since a low level of tumour necrosis factor (TNF) transcript is detectable in monocytes, and this level can be increased by blocking transcript degradation using cycloheximide.	Cycloheximide	225-238	tumor necrosis factor	Homo sapiens	84-106
7998962-11	1994	The constitutive NF-kappa B appears to be functionally active, since a low level of tumour necrosis factor (TNF) transcript is detectable in monocytes, and this level can be increased by blocking transcript degradation using cycloheximide.	Cycloheximide	225-238	tumor necrosis factor	Homo sapiens	108-111
7947935-3	1994	When protein synthesis was inhibited by cycloheximide treatment in UMR 106-01 cells, the action of 1,25(OH)2D3 on PAI-1 mRNA was abolished, as was observed previously with parathyroid hormone (PTH) treatment.	Cycloheximide	40-53	serpin family E member 1	Rattus norvegicus	114-119
7957239-6	1994	The cPLA2 and cyclooxygenase-2 enzymic activities are dependent upon de novo synthesis of mRNA and protein, since they were inhibited by actinomycin D and cycloheximide.	Cycloheximide	155-168	phospholipase A2 group IVA	Homo sapiens	4-9
7957239-6	1994	The cPLA2 and cyclooxygenase-2 enzymic activities are dependent upon de novo synthesis of mRNA and protein, since they were inhibited by actinomycin D and cycloheximide.	Cycloheximide	155-168	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-30
7982208-2	1994	Xenopus c-jun mRNA is induced in quiescent Xenopus A6 kidney cells by 12-O-tetradecanoylphorbol-13-acetate, PDGF and cycloheximide.	Cycloheximide	117-130	jun proto-oncogene L homeolog	Xenopus laevis	8-13
7947935-3	1994	When protein synthesis was inhibited by cycloheximide treatment in UMR 106-01 cells, the action of 1,25(OH)2D3 on PAI-1 mRNA was abolished, as was observed previously with parathyroid hormone (PTH) treatment.	Cycloheximide	40-53	parathyroid hormone	Rattus norvegicus	193-196
7977715-1	1994	The effect of cycloheximide (CHX) on the expression of secretogranin II (SgII), a member of the granin family of secretory proteins, was investigated in rat pituitary GH4C1 (GH) cells.	Cycloheximide	14-27	secretogranin II	Rattus norvegicus	55-71
7977715-1	1994	The effect of cycloheximide (CHX) on the expression of secretogranin II (SgII), a member of the granin family of secretory proteins, was investigated in rat pituitary GH4C1 (GH) cells.	Cycloheximide	14-27	secretogranin II	Rattus norvegicus	73-77
7977715-1	1994	The effect of cycloheximide (CHX) on the expression of secretogranin II (SgII), a member of the granin family of secretory proteins, was investigated in rat pituitary GH4C1 (GH) cells.	Cycloheximide	29-32	secretogranin II	Rattus norvegicus	55-71
7977715-1	1994	The effect of cycloheximide (CHX) on the expression of secretogranin II (SgII), a member of the granin family of secretory proteins, was investigated in rat pituitary GH4C1 (GH) cells.	Cycloheximide	29-32	secretogranin II	Rattus norvegicus	73-77
7947088-1	1994	The proteolytic modification of plasminogen activator inhibitor 2 (PAI-2) was studied during apoptosis in the human promyelocytic leukaemic NB4 cell line during treatment with the phosphatase inhibitors okadaic acid and calyculin A as well as the protein synthesis inhibitor cycloheximide.	Cycloheximide	275-288	serpin family B member 2	Homo sapiens	32-65
7849555-3	1994	This apoTDO increase was blocked by conventional inhibitors of protein synthesis (actinomycin D, cycloheximide), thereby revealing that such CoCL2-mediated apoprotein increase truly reflected TDO induction.	Cycloheximide	97-110	tryptophan 2,3-dioxygenase	Rattus norvegicus	8-11
7894891-5	1994	The stimulated increase in TAT activity elicited by the hormone or cyclic nucleotide was prevented by injection of cycloheximide or cordycepin.	Cycloheximide	115-128	tyrosine aminotransferase	Gallus gallus	27-30
7534490-8	1994	IL-1 beta-induced NO synthesis was significantly inhibited by NG-monomethyl-L-arginine, cycloheximide, actinomycin D, dexamethasone, and TGF-beta.	Cycloheximide	88-101	interleukin 1 beta	Rattus norvegicus	0-9
7525250-10	1994	In the presence of 10 micrograms/ml cycloheximide, IGFBP-1 gene expression was superinduced by bGH, whereas the effect of glucagon was uninfluenced.	Cycloheximide	36-49	insulin-like growth factor binding protein 1	Rattus norvegicus	51-58
7956942-9	1994	When the cells were treated with the protein synthesis inhibitor cycloheximide (20 micrograms/ml) 20 min before stimulation of the cells with hCG, both basal and hCG-stimulated FS mRNA levels increased at 24 h, indicating stabilization of the transcripts.	Cycloheximide	65-78	hypertrichosis 2 (generalised, congenital)	Homo sapiens	142-145
7956942-9	1994	When the cells were treated with the protein synthesis inhibitor cycloheximide (20 micrograms/ml) 20 min before stimulation of the cells with hCG, both basal and hCG-stimulated FS mRNA levels increased at 24 h, indicating stabilization of the transcripts.	Cycloheximide	65-78	hypertrichosis 2 (generalised, congenital)	Homo sapiens	162-165
7957194-4	1994	Simultaneous addition of cycloheximide with bFGF completely abolished induction of pS2 protein, although it did not affect the induction of pS2 mRNA.	Cycloheximide	25-38	taste 2 receptor member 64 pseudogene	Homo sapiens	83-86
7957582-7	1994	Radiation-induced apoptosis in TcR-alpha/beta+ T cells and B cells was efficiently inhibited by cycloheximide, indicating the requirement of de novo protein synthesis, including p53 protein, for radiation-induced apoptosis in both subpopulations.	Cycloheximide	96-109	T cell receptor alpha constant	Homo sapiens	31-40
7957582-7	1994	Radiation-induced apoptosis in TcR-alpha/beta+ T cells and B cells was efficiently inhibited by cycloheximide, indicating the requirement of de novo protein synthesis, including p53 protein, for radiation-induced apoptosis in both subpopulations.	Cycloheximide	96-109	tumor protein p53	Homo sapiens	178-181
7530691-7	1994	was stimulated by the cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), an effect enhanced by endotoxin [lipopolysaccharide (LPS)], reduced by the competitive inhibitor of L-arginine metabolism, NG-monomethyl-L-arginine (L-NMMA) and inhibited by cycloheximide.	Cycloheximide	281-294	interferon gamma	Rattus norvegicus	32-48
7530691-7	1994	was stimulated by the cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), an effect enhanced by endotoxin [lipopolysaccharide (LPS)], reduced by the competitive inhibitor of L-arginine metabolism, NG-monomethyl-L-arginine (L-NMMA) and inhibited by cycloheximide.	Cycloheximide	281-294	interferon gamma	Rattus norvegicus	50-59
7530691-7	1994	was stimulated by the cytokines interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), an effect enhanced by endotoxin [lipopolysaccharide (LPS)], reduced by the competitive inhibitor of L-arginine metabolism, NG-monomethyl-L-arginine (L-NMMA) and inhibited by cycloheximide.	Cycloheximide	281-294	tumor necrosis factor	Rattus norvegicus	95-104
7525612-7	1994	Furthermore, we observed that cycloheximide treatment of malignant but not benign H-ras transformed cells significantly elevated ODC message level.	Cycloheximide	30-43	ornithine decarboxylase, structural 1	Mus musculus	129-132
7525612-8	1994	Treatment of malignant cells with both cycloheximide and forskolin together resulted in a further additive elevation in ODC message, but a similar treatment of benign tumor cells reduced the forskolin-mediated increase in ODC message.	Cycloheximide	39-52	ornithine decarboxylase, structural 1	Mus musculus	120-123
7525612-8	1994	Treatment of malignant cells with both cycloheximide and forskolin together resulted in a further additive elevation in ODC message, but a similar treatment of benign tumor cells reduced the forskolin-mediated increase in ODC message.	Cycloheximide	39-52	ornithine decarboxylase, structural 1	Mus musculus	222-225
7721656-5	1994	Testosterone-induced c-myc mRNA levels were also increased in cells after addition of cycloheximide but reduced by actinomycin-D pretreatment.	Cycloheximide	86-99	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	21-26
7962114-7	1994	Cycloheximide blocked the induction of c-myc mRNA in the absence of an effect on c-fos induction.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Sus scrofa	39-44
7969075-8	1994	Rather, in the presence of cycloheximide, forskolin stimulated SgII mRNA levels 3.6 +/- 0.7-fold above control.	Cycloheximide	27-40	secretogranin II	Rattus norvegicus	63-67
7969075-10	1994	The superinduction of SgII mRNA by cycloheximide and forskolin was related to the extent of protein synthesis inhibition, was observed in cells treated with forskolin and other protein synthesis inhibitors, and was blunted in PKA-deficient PC-12 cells, suggesting that this effect was dependent on inhibition of protein synthesis and activation of PKA.	Cycloheximide	35-48	secretogranin II	Rattus norvegicus	22-26
7969075-12	1994	Transcription of the SgII gene was not significantly affected by treatment with either forskolin or cycloheximide alone but was increased 12.9 +/- 1.0-fold above control in nuclei from cells treated with cycloheximide and forskolin together.	Cycloheximide	100-113	secretogranin II	Rattus norvegicus	21-25
7969075-12	1994	Transcription of the SgII gene was not significantly affected by treatment with either forskolin or cycloheximide alone but was increased 12.9 +/- 1.0-fold above control in nuclei from cells treated with cycloheximide and forskolin together.	Cycloheximide	204-217	secretogranin II	Rattus norvegicus	21-25
7929425-6	1994	The induction of apoD mRNA was independent of the synthesis of proteins de novo, as demonstrated by the fact that the induction was also detected in the presence of cycloheximide.	Cycloheximide	165-178	apolipoprotein D	Homo sapiens	17-21
7980544-4	1994	Experiments using actinomycin D and cycloheximide indicated that VEGF mRNA levels in cardiac cells are regulated both at transcriptional and post transcriptional levels.	Cycloheximide	36-49	vascular endothelial growth factor A	Rattus norvegicus	65-69
7956904-3	1994	The comoplete inhibition of IL-1 alpha- and UEC-induced PGE2 secretion by cycloheximide and actinomycin-D in the presence of a saturating concentration of arachidonic acid indicated that IL-1 alpha and UEC act to a large extent by inducing de novo expression of PG endoperoxide synthase (PGHS).	Cycloheximide	74-87	interleukin 1 alpha	Mus musculus	28-38
7956904-3	1994	The comoplete inhibition of IL-1 alpha- and UEC-induced PGE2 secretion by cycloheximide and actinomycin-D in the presence of a saturating concentration of arachidonic acid indicated that IL-1 alpha and UEC act to a large extent by inducing de novo expression of PG endoperoxide synthase (PGHS).	Cycloheximide	74-87	interleukin 1 alpha	Mus musculus	187-197
7929310-6	1994	Treatment with cycloheximide over 18 h resulted in a time-dependent decrease in cytosolic 85-kDa PLA2 protein and activity (half-life = 4 h), but there was no change in the particulate type II 14-kDa-like PLA2 activity.	Cycloheximide	15-28	phospholipase A2 group IB	Homo sapiens	97-101
7929310-6	1994	Treatment with cycloheximide over 18 h resulted in a time-dependent decrease in cytosolic 85-kDa PLA2 protein and activity (half-life = 4 h), but there was no change in the particulate type II 14-kDa-like PLA2 activity.	Cycloheximide	15-28	phospholipase A2 group IB	Homo sapiens	205-209
7923384-5	1994	However, the nuclear expression of Jun-B is induced within 2 hr following sIg cross-linking and is completely blocked by cycloheximide.	Cycloheximide	121-134	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	35-40
7930567-7	1994	However, the induction of NGFI-B by IL-2 is dependent on the presence of cycloheximide.	Cycloheximide	73-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	26-32
7930567-7	1994	However, the induction of NGFI-B by IL-2 is dependent on the presence of cycloheximide.	Cycloheximide	73-86	interleukin 2	Homo sapiens	36-40
7930569-4	1994	However, comparative studies using extracts of D10.G4.1 cells treated with the cellular activators Con A and PMA and the inhibitors cycloheximide and cyclosporin A indicated that the binding activities to the conserved elements in the IL-5 and GM-CSF genes (designated NF-IL-5A and NF-GM-CSFA, respectively) are regulated by different signaling pathways.	Cycloheximide	132-145	interleukin 5	Mus musculus	235-239
7930569-4	1994	However, comparative studies using extracts of D10.G4.1 cells treated with the cellular activators Con A and PMA and the inhibitors cycloheximide and cyclosporin A indicated that the binding activities to the conserved elements in the IL-5 and GM-CSF genes (designated NF-IL-5A and NF-GM-CSFA, respectively) are regulated by different signaling pathways.	Cycloheximide	132-145	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	244-250
7929292-9	1994	The assembly of labeled apoB-100 VLDL was acutely (within min) and completely blocked by cycloheximide, if the cycloheximide was added after the pulse labeling period.	Cycloheximide	89-102	apolipoprotein B	Rattus norvegicus	24-32
7929292-9	1994	The assembly of labeled apoB-100 VLDL was acutely (within min) and completely blocked by cycloheximide, if the cycloheximide was added after the pulse labeling period.	Cycloheximide	111-124	apolipoprotein B	Rattus norvegicus	24-32
7945366-4	1994	This induction is abolished by preheating the SAP or diminished by treating the cells with cycloheximide.	Cycloheximide	91-104	amyloid P component, serum	Rattus norvegicus	46-49
7926031-4	1994	Protocols for treating cells with actinomycin D and cycloheximide were established that eliminate detection of MKP-1 mRNA and protein in PC 12 cells.	Cycloheximide	52-65	dual specificity phosphatase 1	Rattus norvegicus	111-116
7943343-4	1994	TNF-alpha-induced IL-8 mRNA expression showed a biphasic response in HAEC, with an early increase at 2 h followed by a sustained increase from 8 h, which was abolished by the addition of cycloheximide, suggesting that the synthesis of another protein was involved.	Cycloheximide	187-200	tumor necrosis factor	Homo sapiens	0-9
7869421-2	1994	The stimulatory effect on NGF mRNA expression of astroglial cells in culture by 4-methylcatechol (MC), an alkylcatechol, and/or PMA was blocked by treatment of the cells with cycloheximide, suggesting de novo synthesis of some cellular protein(s) is essential for the observed increase in the NGF mRNA level.	Cycloheximide	175-188	nerve growth factor	Mus musculus	26-29
7869421-2	1994	The stimulatory effect on NGF mRNA expression of astroglial cells in culture by 4-methylcatechol (MC), an alkylcatechol, and/or PMA was blocked by treatment of the cells with cycloheximide, suggesting de novo synthesis of some cellular protein(s) is essential for the observed increase in the NGF mRNA level.	Cycloheximide	175-188	nerve growth factor	Mus musculus	293-296
7943343-4	1994	TNF-alpha-induced IL-8 mRNA expression showed a biphasic response in HAEC, with an early increase at 2 h followed by a sustained increase from 8 h, which was abolished by the addition of cycloheximide, suggesting that the synthesis of another protein was involved.	Cycloheximide	187-200	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
7945240-4	1994	The accumulation of ALP mRNA was inhibited by both actinomycin D and cycloheximide, indicating that its induction is a complex event and may involve other regulatory proteins.	Cycloheximide	69-82	alkaline phosphatase, placental	Homo sapiens	20-23
7850896-3	1994	However, expression of secondarily inducible genes, cyclin D1 and D3 and cdk2, was ts and was cycloheximide sensitive.	Cycloheximide	94-107	cyclin D1	Rattus norvegicus	52-68
7850896-3	1994	However, expression of secondarily inducible genes, cyclin D1 and D3 and cdk2, was ts and was cycloheximide sensitive.	Cycloheximide	94-107	cyclin dependent kinase 2	Rattus norvegicus	73-77
7882421-2	1994	Disruption of YDR1 resulted in hypersensitivity to cycloheximide, cerulenin, compactin, staurosporine and fluphenazine, indicating that YDR1 is an important determinant of cross resistance to apparently-unrelated drugs.	Cycloheximide	51-64	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	14-18
7943374-5	1994	Pretreatment of VSMC with cycloheximide (20 micrograms/ml) or actinomycin D (5 micrograms/ml) completely inhibited angiotensin II-induced alpha 1-mRNA accumulation.	Cycloheximide	26-39	angiotensinogen	Rattus norvegicus	115-129
7958409-4	1994	Similarly, in Experiment 2 the exposure of metaphase II oocytes to cycloheximide initiated a rapid fall in MPF activity, progression to anaphase, the extrusion of the second polar body, and the formation of a pronucleus.	Cycloheximide	67-80	mesothelin	Mus musculus	107-110
7958409-12	1994	The decline in intracellular MPF activity reached basal levels 6 to 10 hr after the addition of cycloheximide and was accompanied by the slow and gradual decondensation of chromatin.	Cycloheximide	96-109	mesothelin	Mus musculus	29-32
7958409-16	1994	Third, we postulate that the slow escape from metaphase arrest in oocytes treated with both etoposide and cycloheximide reflects a gradual decrease of MPF activity due to normal protein turnover without new synthesis.	Cycloheximide	106-119	mesothelin	Mus musculus	151-154
7523094-7	1994	Because cycloheximide (CHX) treatment of cultured rat H4IIE cells has been shown to prolong IGFBP-1 mRNA half-life while decreasing its transcription, Tg mice were treated with CHX to test the possibility that instability of the liver transgene mRNA influenced its abundance.	Cycloheximide	8-21	insulin-like growth factor binding protein 1	Rattus norvegicus	92-99
7523094-7	1994	Because cycloheximide (CHX) treatment of cultured rat H4IIE cells has been shown to prolong IGFBP-1 mRNA half-life while decreasing its transcription, Tg mice were treated with CHX to test the possibility that instability of the liver transgene mRNA influenced its abundance.	Cycloheximide	23-26	insulin-like growth factor binding protein 1	Rattus norvegicus	92-99
7925107-8	1994	The lag period preceding the increase in VIP mRNA led to experiments with the translational inhibitor cycloheximide showing an indirect effect of RA on VIP mRNA expression.	Cycloheximide	102-115	vasoactive intestinal peptide	Homo sapiens	41-44
7925107-8	1994	The lag period preceding the increase in VIP mRNA led to experiments with the translational inhibitor cycloheximide showing an indirect effect of RA on VIP mRNA expression.	Cycloheximide	102-115	vasoactive intestinal peptide	Homo sapiens	152-155
7925652-5	1994	Inhibition of transcription with actinomycin D or translation with cycloheximide also resulted in apoptosis, which reached a maximum value of approximately 35 to 40% of cells after 24 h. TNF alpha induction of apoptosis was either potentiated or abrogated by cycloheximide, depending on the timing of TNF alpha exposure in relation to inhibition of protein synthesis.	Cycloheximide	67-80	tumor necrosis factor	Bos taurus	187-196
7925652-5	1994	Inhibition of transcription with actinomycin D or translation with cycloheximide also resulted in apoptosis, which reached a maximum value of approximately 35 to 40% of cells after 24 h. TNF alpha induction of apoptosis was either potentiated or abrogated by cycloheximide, depending on the timing of TNF alpha exposure in relation to inhibition of protein synthesis.	Cycloheximide	259-272	tumor necrosis factor	Bos taurus	187-196
7882421-5	1994	YDR1 was responsible for cycloheximide, cerulenin and compactin resistance, whereas, SNQ2 was responsible for 4-NQO resistance.	Cycloheximide	25-38	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	0-4
7860090-8	1994	This 2.8-kb transcript was in addition to the expected 1.0-kb, transiently expressed IL-2 message, and it could be superinduced in the presence of cycloheximide.	Cycloheximide	147-160	interleukin 2	Homo sapiens	85-89
7929563-7	1994	The long-term nuclear forskolin-induced accumulation of bFGF was prevented by cycloheximide or by antisense bFGF oligonucleotide and was also accompanied by an increase in bFGF mRNA.	Cycloheximide	78-91	fibroblast growth factor 2	Homo sapiens	56-60
7929837-7	1994	Finally, 10 microM cycloheximide partially prevented the increase in glucokinase Vmax induced by 24 h of high glucose, but had no effect at 6 h, suggesting the early increase in enzymatic activity did not require protein synthesis.	Cycloheximide	19-32	glucokinase	Rattus norvegicus	69-80
7931070-9	1994	Together, these data suggest that CIITA is the IFN-inducible cycloheximide sensitive factor previously shown to be required for the induction of MHC class II gene expression.	Cycloheximide	61-74	class II major histocompatibility complex transactivator	Homo sapiens	34-39
7964554-10	1994	Northern blot analysis of MEPM cells treated with TGF beta 1 revealed that steady-state levels of mRNA encoding for procollagen alpha 1 (I) and alpha 1 (III) were increased and that these effects were ablated by cycloheximide but not actinomycin.	Cycloheximide	212-225	transforming growth factor beta 1	Homo sapiens	50-60
7964554-10	1994	Northern blot analysis of MEPM cells treated with TGF beta 1 revealed that steady-state levels of mRNA encoding for procollagen alpha 1 (I) and alpha 1 (III) were increased and that these effects were ablated by cycloheximide but not actinomycin.	Cycloheximide	212-225	adrenoceptor alpha 1D	Homo sapiens	116-151
8000501-6	1994	Cycloheximide markedly decreased tissue gastrin concentration, but increased gastrin mRNA levels, whereas it had no effects on gastrin release.	Cycloheximide	0-13	gastrin	Homo sapiens	40-47
8000501-6	1994	Cycloheximide markedly decreased tissue gastrin concentration, but increased gastrin mRNA levels, whereas it had no effects on gastrin release.	Cycloheximide	0-13	gastrin	Homo sapiens	77-84
8000501-6	1994	Cycloheximide markedly decreased tissue gastrin concentration, but increased gastrin mRNA levels, whereas it had no effects on gastrin release.	Cycloheximide	0-13	gastrin	Homo sapiens	77-84
7852866-3	1994	Inhibition of protein synthesis with cycloheximide (CHX) or puromycin resulted in superinduction of LDL receptor mRNA levels by mitogenic stimulation.	Cycloheximide	37-50	low density lipoprotein receptor	Homo sapiens	100-112
7852866-3	1994	Inhibition of protein synthesis with cycloheximide (CHX) or puromycin resulted in superinduction of LDL receptor mRNA levels by mitogenic stimulation.	Cycloheximide	52-55	low density lipoprotein receptor	Homo sapiens	100-112
7852866-7	1994	The protein synthesis inhibitors CHX and anisomycin, but not puromycin, also directly stimulated LDL receptor mRNA levels, suggesting that these compounds could provide a signal required for LDL receptor gene transcription.	Cycloheximide	33-36	low density lipoprotein receptor	Homo sapiens	97-109
7852866-7	1994	The protein synthesis inhibitors CHX and anisomycin, but not puromycin, also directly stimulated LDL receptor mRNA levels, suggesting that these compounds could provide a signal required for LDL receptor gene transcription.	Cycloheximide	33-36	low density lipoprotein receptor	Homo sapiens	191-203
7852866-8	1994	Taken together, these data indicate that various non-sterol stimuli, including activation of protein kinase C, increases in intracellular calcium, inhibition of protein synthesis, and signals generated by the protein synthesis inhibitors CHX and anisomycin, induce LDL receptor gene expression.	Cycloheximide	238-241	low density lipoprotein receptor	Homo sapiens	265-277
7532249-9	1994	However, cycloheximide alone resulted in a significant up-regulation of DAF mRNA levels on HMC.	Cycloheximide	9-22	CD55 molecule (Cromer blood group)	Homo sapiens	72-75
7861725-7	1994	Cycloheximide and actinomycin D blocked the production of IL-1 alpha and -beta protein, showing that de novo production of IL-1 or synthesis of mRNA stabilizing proteins are needed after stimulation.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	58-78
7861725-7	1994	Cycloheximide and actinomycin D blocked the production of IL-1 alpha and -beta protein, showing that de novo production of IL-1 or synthesis of mRNA stabilizing proteins are needed after stimulation.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	58-62
7969043-7	1994	This effect can be blocked by prior treatment of VSMC with actinomycin D or cycloheximide, suggesting that the effect of the growth factors on AT1 receptor gene expression is mediated through induction of an unknown gene or genes that function to destabilize AT1 receptor mRNA and that mRNA translation is essential for the destabilizing effect.	Cycloheximide	76-89	angiotensin II receptor, type 1a	Rattus norvegicus	143-146
7969043-7	1994	This effect can be blocked by prior treatment of VSMC with actinomycin D or cycloheximide, suggesting that the effect of the growth factors on AT1 receptor gene expression is mediated through induction of an unknown gene or genes that function to destabilize AT1 receptor mRNA and that mRNA translation is essential for the destabilizing effect.	Cycloheximide	76-89	angiotensin II receptor, type 1a	Rattus norvegicus	259-262
7524486-4	1994	Cycloheximide, an inhibitor of protein synthesis, prevented IL-1 beta-induced expression of iNOS mRNA, but not MnSOD mRNA.	Cycloheximide	0-13	interleukin 1 beta	Rattus norvegicus	60-69
7524486-4	1994	Cycloheximide, an inhibitor of protein synthesis, prevented IL-1 beta-induced expression of iNOS mRNA, but not MnSOD mRNA.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	92-96
8089148-3	1994	We now report that RNAs encoding the glycolytic enzymes aldolase A (ALDA), phosphoglycerate kinase 1 (PGK1), and pyruvate kinase M were induced by exposure of Hep3B or HeLa cells to inducers of HIF-1 (1% O2, cobalt chloride, or desferrioxamine), whereas cycloheximide blocked induction of glycolytic RNAs and HIF-1 activity.	Cycloheximide	254-267	aldolase, fructose-bisphosphate A	Homo sapiens	56-66
8089148-3	1994	We now report that RNAs encoding the glycolytic enzymes aldolase A (ALDA), phosphoglycerate kinase 1 (PGK1), and pyruvate kinase M were induced by exposure of Hep3B or HeLa cells to inducers of HIF-1 (1% O2, cobalt chloride, or desferrioxamine), whereas cycloheximide blocked induction of glycolytic RNAs and HIF-1 activity.	Cycloheximide	254-267	aldolase, fructose-bisphosphate A	Homo sapiens	68-72
8089148-3	1994	We now report that RNAs encoding the glycolytic enzymes aldolase A (ALDA), phosphoglycerate kinase 1 (PGK1), and pyruvate kinase M were induced by exposure of Hep3B or HeLa cells to inducers of HIF-1 (1% O2, cobalt chloride, or desferrioxamine), whereas cycloheximide blocked induction of glycolytic RNAs and HIF-1 activity.	Cycloheximide	254-267	phosphoglycerate kinase 1	Homo sapiens	75-100
8089148-3	1994	We now report that RNAs encoding the glycolytic enzymes aldolase A (ALDA), phosphoglycerate kinase 1 (PGK1), and pyruvate kinase M were induced by exposure of Hep3B or HeLa cells to inducers of HIF-1 (1% O2, cobalt chloride, or desferrioxamine), whereas cycloheximide blocked induction of glycolytic RNAs and HIF-1 activity.	Cycloheximide	254-267	phosphoglycerate kinase 1	Homo sapiens	102-106
8083194-6	1994	Induction of PGHS-2 mRNA was transient with a peak after 2-3 h. Stimulated mRNA levels persisted for more than 6 h when transcription was inhibited by actinomycin D or when translation was inhibited by cycloheximide.	Cycloheximide	202-215	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	13-19
8083217-7	1994	When translation is blocked, e.g. by cycloheximide, expression of IL-1 beta mRNA is superinduced by 2 orders of magnitude.	Cycloheximide	37-50	interleukin 1 beta	Homo sapiens	66-75
8083217-12	1994	This regulation is specific for RA: when induced by phorbol ester, IL-1 beta gene expression is also superinduced by cycloheximide but that response is accompanied by enhanced mRNA stability.	Cycloheximide	117-130	interleukin 1 beta	Homo sapiens	67-76
8086474-7	1994	Cycloheximide itself increases VDUP1 mRNA levels.	Cycloheximide	0-13	thioredoxin interacting protein	Homo sapiens	31-36
8077234-10	1994	Concurrent treatment with HB-EGF and cycloheximide resulted in superinduction of HB-EGF and AR, suggesting that these peptides are immediate early genes in RIE-1 cells.	Cycloheximide	37-50	heparin-binding EGF-like growth factor	Rattus norvegicus	81-87
8092305-5	1994	The glucocorticoid effect on DA1 of arterial smooth muscle cells became apparent after hours of incubation in the presence of the steroid and was significantly inhibited by cycloheximide (10 micrograms/ml) or by the glucocorticoid receptor antagonist RU-38486, indicating that the effect required protein synthesis through glucocorticoid receptors.	Cycloheximide	173-186	RT1 class II, locus Da	Rattus norvegicus	29-32
8069931-10	1994	The effects of fibronectin/RGDS were blocked by actinomycin D and cycloheximide.	Cycloheximide	66-79	fibronectin 1	Homo sapiens	15-26
8086500-5	1994	Furthermore, only the IGF-1 response was inhibited by cycloheximide.	Cycloheximide	54-67	insulin-like growth factor 1	Rattus norvegicus	22-27
7849646-5	1994	The administration of cycloheximide resulted in the decreases of both TS activity and TS mRNA level while actinomycin D had no effect.	Cycloheximide	22-35	thymidylate synthetase	Rattus norvegicus	70-72
7849646-5	1994	The administration of cycloheximide resulted in the decreases of both TS activity and TS mRNA level while actinomycin D had no effect.	Cycloheximide	22-35	thymidylate synthetase	Rattus norvegicus	86-88
8069931-10	1994	The effects of fibronectin/RGDS were blocked by actinomycin D and cycloheximide.	Cycloheximide	66-79	ral guanine nucleotide dissociation stimulator	Homo sapiens	27-31
7532054-5	1994	The stimulation of IGFBP-2 by IGF-I and insulin was reversibly abolished by incubation with protein synthesis inhibitors such as cycloheximide.	Cycloheximide	129-142	insulin like growth factor binding protein 2	Homo sapiens	19-26
7532054-5	1994	The stimulation of IGFBP-2 by IGF-I and insulin was reversibly abolished by incubation with protein synthesis inhibitors such as cycloheximide.	Cycloheximide	129-142	insulin like growth factor 1	Homo sapiens	30-35
7532054-5	1994	The stimulation of IGFBP-2 by IGF-I and insulin was reversibly abolished by incubation with protein synthesis inhibitors such as cycloheximide.	Cycloheximide	129-142	insulin	Homo sapiens	40-47
7836514-8	1994	The release of C3 from both cell types could be inhibited by cycloheximide.	Cycloheximide	61-74	complement C3	Homo sapiens	15-17
7914230-7	1994	Cycloheximide inhibited CD4 reexpression and both anti-CD4 and anti-CD3 antibody-induced migration in cells treated with gp120.	Cycloheximide	0-13	CD4 molecule	Homo sapiens	24-27
7803619-3	1994	Cycloheximide (CHX) and actinomycin D (Act D) did not affect basal, but completely inhibited IL-1 beta-stimulated prostaglandin F2 alpha (PGF2 alpha) production (p < 0.05).	Cycloheximide	0-13	interleukin 1 beta	Bos taurus	93-102
7803619-3	1994	Cycloheximide (CHX) and actinomycin D (Act D) did not affect basal, but completely inhibited IL-1 beta-stimulated prostaglandin F2 alpha (PGF2 alpha) production (p < 0.05).	Cycloheximide	15-18	interleukin 1 beta	Bos taurus	93-102
7852289-4	1994	The endocytic transport of HRP-YA30 mAb continued in the presence of the protein synthesis inhibitor, cycloheximide, indicating that LGP85 is cycled between the cell surface and lysosomes or endosomes, like other lysosomal membrane glycoproteins, lamp-1 and lamp-2, as reported previously [Akasaki et al.	Cycloheximide	102-115	scavenger receptor class B, member 2	Rattus norvegicus	133-138
8083371-7	1994	In 3T3 cells, acid activated IE genes by a different mechanism in that the increase in mRNA did not include c-jun, was more prolonged, and was blocked by cycloheximide.	Cycloheximide	154-167	jun proto-oncogene	Mus musculus	29-31
8051422-11	1994	Furthermore, cycloheximide potentiated the TNF-mediated effect but not that mediated through anti-p60, thus also indicating a difference in the mechanism of action of these two agents.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	43-46
7528818-5	1994	This induction of CKB mRNA i) is due to increased transcription; ii) occurs rapidly (with maximal induction after 6 hr; iii) requires the activity of protein kinase A (PKA), but iv) does not require de novo protein synthesis and, in fact, is superinduced in the presence of cycloheximide.	Cycloheximide	274-287	creatine kinase B	Homo sapiens	18-21
7527352-9	1994	Androgen stimulation of DBI/ACBP mRNA levels was abolished in the presence of the protein synthesis inhibitor cycloheximide, implying a role for labile or androgen-induced proteins in this androgen stimulation.	Cycloheximide	110-123	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	24-27
7527352-9	1994	Androgen stimulation of DBI/ACBP mRNA levels was abolished in the presence of the protein synthesis inhibitor cycloheximide, implying a role for labile or androgen-induced proteins in this androgen stimulation.	Cycloheximide	110-123	diazepam binding inhibitor, acyl-CoA binding protein	Homo sapiens	28-32
7898457-4	1994	An inhibitor of proteins synthesis, cycloheximide, or reduced temperature, both of which reduce translational efficiency, stimulate the ADP-ribosylation of BiP/GRP78.	Cycloheximide	36-49	heat shock protein 5	Mus musculus	156-159
7898457-4	1994	An inhibitor of proteins synthesis, cycloheximide, or reduced temperature, both of which reduce translational efficiency, stimulate the ADP-ribosylation of BiP/GRP78.	Cycloheximide	36-49	heat shock protein 5	Mus musculus	160-165
8065303-4	1994	On the other hand, there was a dramatic increase in c-Myc mRNA expression in TNF-alpha-sensitive D98 cells, but not in TNF-alpha-resistant H21 cells, which was only observed when the cells were treated with cycloheximide.	Cycloheximide	207-220	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	52-57
8065303-4	1994	On the other hand, there was a dramatic increase in c-Myc mRNA expression in TNF-alpha-sensitive D98 cells, but not in TNF-alpha-resistant H21 cells, which was only observed when the cells were treated with cycloheximide.	Cycloheximide	207-220	tumor necrosis factor	Homo sapiens	77-86
8065320-9	1994	Incubation of fertilized eggs with cycloheximide prevented the embryonic inhibition of cdk2 RNA polyadenylation but did not affect the robust polyadenylation of B4 RNA.	Cycloheximide	35-48	cyclin-dependent kinase 2 S homeolog	Xenopus laevis	87-91
8063804-7	1994	The protein synthesis inhibitor cycloheximide inhibited collagenase mRNA induction by TNF or IFN-beta, suggesting that induction by both agents is indirect.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	86-89
8063804-7	1994	The protein synthesis inhibitor cycloheximide inhibited collagenase mRNA induction by TNF or IFN-beta, suggesting that induction by both agents is indirect.	Cycloheximide	32-45	interferon beta 1	Homo sapiens	93-101
8068661-7	1994	When cells were incubated in the presence of the protein synthesis inhibitor cycloheximide, little or no methylation of the STE14-dependent species was detected while the methylation of the STE14-independent substrates was unaffected.	Cycloheximide	77-90	protein-S-isoprenylcysteine carboxyl O-methyltransferase	Saccharomyces cerevisiae S288C	190-195
8080455-5	1994	Enhanced AP1 activity was still observed when OA was added to the cells together with the transcription inhibitor actinomycin D, or with the protein synthesis inhibitor cycloheximide, indicating that it is actually AP1 activation due to posttranslational modifications that triggers transcription of the fos and jun genes.	Cycloheximide	169-182	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	9-12
8046244-6	1994	In vivo treatment of mice with ActD/TNF caused hepatic failure, which was significantly reduced by co-treatment with CHX.	Cycloheximide	117-120	tumor necrosis factor	Mus musculus	36-39
8046245-9	1994	This increase was not detectable in the presence of actinomycin D but was further induced in the presence of cycloheximide, consistent with the major site of XDH/XO up-regulation occurring at the transcriptional level.	Cycloheximide	109-122	xanthine dehydrogenase	Bos taurus	158-161
7914230-7	1994	Cycloheximide inhibited CD4 reexpression and both anti-CD4 and anti-CD3 antibody-induced migration in cells treated with gp120.	Cycloheximide	0-13	CD4 molecule	Homo sapiens	55-58
7914230-7	1994	Cycloheximide inhibited CD4 reexpression and both anti-CD4 and anti-CD3 antibody-induced migration in cells treated with gp120.	Cycloheximide	0-13	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	121-126
8001633-3	1994	Cycloheximide (20 micrograms ml-1) present during the 20-h preincubation completely prevented the interferon-gamma effect.	Cycloheximide	0-13	interferon gamma	Bos taurus	98-114
8061052-8	1994	Cycloheximide also inhibited FN release, but this inhibition was additive to that with monensin.	Cycloheximide	0-13	fibronectin 1	Homo sapiens	29-31
8052613-5	1994	Pretreatment with the protein synthesis inhibitor cycloheximide prevented both kainate-mediated p53 induction and neuronal damage.	Cycloheximide	50-63	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	96-99
8053890-8	1994	Finally, we demonstrated that calcium-mediated down-regulation of MRP8-MRP14 can be antagonized by cycloheximide, suggesting that a calcium-induced repressor protein is responsible for suppression of MRP8-MRP14 at the transcriptional level.	Cycloheximide	99-112	S100 calcium binding protein A8	Homo sapiens	66-70
8053890-8	1994	Finally, we demonstrated that calcium-mediated down-regulation of MRP8-MRP14 can be antagonized by cycloheximide, suggesting that a calcium-induced repressor protein is responsible for suppression of MRP8-MRP14 at the transcriptional level.	Cycloheximide	99-112	S100 calcium binding protein A9	Homo sapiens	71-76
8053890-8	1994	Finally, we demonstrated that calcium-mediated down-regulation of MRP8-MRP14 can be antagonized by cycloheximide, suggesting that a calcium-induced repressor protein is responsible for suppression of MRP8-MRP14 at the transcriptional level.	Cycloheximide	99-112	S100 calcium binding protein A8	Homo sapiens	200-204
8053890-8	1994	Finally, we demonstrated that calcium-mediated down-regulation of MRP8-MRP14 can be antagonized by cycloheximide, suggesting that a calcium-induced repressor protein is responsible for suppression of MRP8-MRP14 at the transcriptional level.	Cycloheximide	99-112	S100 calcium binding protein A9	Homo sapiens	205-210
8039596-5	1994	Endothelial denudation or addition of cycloheximide prevented the growth-factor effects.	Cycloheximide	38-51	myotrophin	Rattus norvegicus	66-79
7827405-7	1994	Consistent with this, rapid degradation of ALG7, ALG1 and ALG2 mRNAs was completely abolished in the presence of cycloheximide.	Cycloheximide	113-126	UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase	Saccharomyces cerevisiae S288C	43-47
7827405-7	1994	Consistent with this, rapid degradation of ALG7, ALG1 and ALG2 mRNAs was completely abolished in the presence of cycloheximide.	Cycloheximide	113-126	chitobiosyldiphosphodolichol beta-1,4 mannosyltransferase	Saccharomyces cerevisiae S288C	49-53
7827405-7	1994	Consistent with this, rapid degradation of ALG7, ALG1 and ALG2 mRNAs was completely abolished in the presence of cycloheximide.	Cycloheximide	113-126	GDP-Man:Man(1)GlcNAc(2)-PP-dolichol alpha-1,3-mannosyltransferase	Saccharomyces cerevisiae S288C	58-62
7853352-11	1994	Pretreatment of hepatocytes with cycloheximide, to inhibit protein synthesis, increased TNF alpha-induced cytotoxicity.	Cycloheximide	33-46	tumor necrosis factor	Mus musculus	88-97
7853352-12	1994	Cycloheximide pretreatment also potentiated PLA2 activation, ATP depletion, and GSSG efflux.	Cycloheximide	0-13	phospholipase A2, group V	Mus musculus	44-48
7853352-13	1994	CPZ and BPB both reduced the extent of PLA2 activation, ATP depletion, GSSG formation, and cytotoxicity in the cycloheximide pretreated cells exposed to TNF alpha.	Cycloheximide	111-124	tumor necrosis factor	Mus musculus	153-162
8068179-8	1994	Comparison of the effects of chromium(VI) with those of cycloheximide suggests that chromium(VI) targets its effects to a labile, constitutively expressed repressor involved in PEPCK gene regulation.	Cycloheximide	56-69	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	177-182
8048072-0	1994	Elevated gene expression and production of interleukins 2, 4, 5, and 6 during exposure to vomitoxin (deoxynivalenol) and cycloheximide in the EL-4 thymoma.	Cycloheximide	121-134	epilepsy 4	Mus musculus	142-146
8048072-4	1994	IL-2, 5, and 6 were also significantly elevated in the presence of 10-100 ng/ml of cycloheximide (CHX), another protein synthesis inhibitor, after 8 days of culture.	Cycloheximide	83-96	interleukin 2	Mus musculus	0-4
8048072-4	1994	IL-2, 5, and 6 were also significantly elevated in the presence of 10-100 ng/ml of cycloheximide (CHX), another protein synthesis inhibitor, after 8 days of culture.	Cycloheximide	98-101	interleukin 2	Mus musculus	0-4
8076631-10	1994	The presence of an accessory factor in the VDR-DNA complexes was indirectly shown by treatment of the cells with 9-cis retinoic acid and by cycloheximide.	Cycloheximide	140-153	vitamin D receptor	Homo sapiens	43-46
8021515-5	1994	The inhibitory activity of IL-10 was abrogated by cycloheximide, suggesting an involvement of newly synthesized proteins in IL-10 action.	Cycloheximide	50-63	interleukin 10	Homo sapiens	27-32
8021515-5	1994	The inhibitory activity of IL-10 was abrogated by cycloheximide, suggesting an involvement of newly synthesized proteins in IL-10 action.	Cycloheximide	50-63	interleukin 10	Homo sapiens	124-129
8048473-6	1994	Levels of HSP-72 mRNA, determined by dot-blot analysis, reached a maximum at 2 h and returned to baseline within 8 h. Both actinomycin D and cycloheximide blocked HSP-72 induction.	Cycloheximide	141-154	heat shock protein family A (Hsp70) member 1A	Homo sapiens	10-16
8048473-6	1994	Levels of HSP-72 mRNA, determined by dot-blot analysis, reached a maximum at 2 h and returned to baseline within 8 h. Both actinomycin D and cycloheximide blocked HSP-72 induction.	Cycloheximide	141-154	heat shock protein family A (Hsp70) member 1A	Homo sapiens	163-169
8048485-3	1994	The increase of M-CSF mRNA expression was observed as early as 2 h after TGF-beta or IL-1 addition and was superinduced by cycloheximide treatment.	Cycloheximide	123-136	colony stimulating factor 1 (macrophage)	Mus musculus	16-21
7948416-2	1994	It has been found that only the sublethal (3 mg/kg) dose of cycloheximide which induces the superexpression of c-fos and c-myc oncogenes can promote sphingosine accumulation in the cell.	Cycloheximide	60-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	111-116
7948416-2	1994	It has been found that only the sublethal (3 mg/kg) dose of cycloheximide which induces the superexpression of c-fos and c-myc oncogenes can promote sphingosine accumulation in the cell.	Cycloheximide	60-73	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	121-126
8037686-6	1994	When the effect of cycloheximide on the decay of Mn-SOD mRNA was examined by inhibiting mRNA synthesis with actinomycin D, cycloheximide had virtually no effect on mRNA stability, suggesting that accumulation of the mRNA was caused by activation by this reagent of transcription of the gene.	Cycloheximide	19-32	superoxide dismutase 2	Homo sapiens	49-55
8037686-7	1994	PMA pretreatment of HeLa cells markedly enhanced cycloheximide-dependent superinduction of Mn-SOD mRNA.	Cycloheximide	49-62	superoxide dismutase 2	Homo sapiens	91-97
7517205-10	1994	The increase in PAI-1 and TF mRNA was also seen when HepG2 were incubated with HGF in the presence of cycloheximide, thereby indicating that de novo protein synthesis is not required to mediate the effect.	Cycloheximide	102-115	serpin family E member 1	Homo sapiens	16-21
7517205-10	1994	The increase in PAI-1 and TF mRNA was also seen when HepG2 were incubated with HGF in the presence of cycloheximide, thereby indicating that de novo protein synthesis is not required to mediate the effect.	Cycloheximide	102-115	coagulation factor III, tissue factor	Homo sapiens	26-28
7517205-10	1994	The increase in PAI-1 and TF mRNA was also seen when HepG2 were incubated with HGF in the presence of cycloheximide, thereby indicating that de novo protein synthesis is not required to mediate the effect.	Cycloheximide	102-115	hepatocyte growth factor	Homo sapiens	79-82
7921603-13	1994	Cycloheximide also abolished the potentiating actions of CTX, forskolin, and dibutyryl cyclic AMP on BK-induced IPs formation and Ca2+ mobilization.	Cycloheximide	0-13	kininogen 1	Canis lupus familiaris	101-103
8012956-5	1994	The kinetics of this transient induction, which is enhanced by cycloheximide, demonstrates that WAF1/CIP1 is an immediate-early gene the transcript of which reaches a peak at approximately 2 h following serum or growth factor stimulation.	Cycloheximide	63-76	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	96-100
8012956-5	1994	The kinetics of this transient induction, which is enhanced by cycloheximide, demonstrates that WAF1/CIP1 is an immediate-early gene the transcript of which reaches a peak at approximately 2 h following serum or growth factor stimulation.	Cycloheximide	63-76	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	101-105
8012956-5	1994	The kinetics of this transient induction, which is enhanced by cycloheximide, demonstrates that WAF1/CIP1 is an immediate-early gene the transcript of which reaches a peak at approximately 2 h following serum or growth factor stimulation.	Cycloheximide	63-76	jun proto-oncogene	Mus musculus	112-127
7517798-11	1994	Cycloheximide and actinomycin D completely inhibited the IL-1 beta-induced NOx production and iNOS mRNA expression.	Cycloheximide	0-13	interleukin 1 beta	Rattus norvegicus	57-66
7517798-11	1994	Cycloheximide and actinomycin D completely inhibited the IL-1 beta-induced NOx production and iNOS mRNA expression.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	94-98
8013080-10	1994	Immunoblot analyses revealed that there was a 2.6-fold greater abundance of cyclooxygenase-1 protein at PO2 of 40 versus 680 mm Hg, and the increase at lower oxygen tension was inhibited by cycloheximide.	Cycloheximide	190-203	prostaglandin G/H synthase 1	Ovis aries	76-92
8013362-6	1994	The effects of bFGF, TGF beta 1, and PDGF-BB on IGF-II mRNA were dependent on protein synthesis and decreased in the presence of cycloheximide at 3.6 microM, but were independent of cell division, because they were observed in the presence and absence of 1 mM hydroxyurea.	Cycloheximide	129-142	fibroblast growth factor 2	Rattus norvegicus	15-19
8013362-6	1994	The effects of bFGF, TGF beta 1, and PDGF-BB on IGF-II mRNA were dependent on protein synthesis and decreased in the presence of cycloheximide at 3.6 microM, but were independent of cell division, because they were observed in the presence and absence of 1 mM hydroxyurea.	Cycloheximide	129-142	transforming growth factor, beta 1	Rattus norvegicus	21-31
8013362-6	1994	The effects of bFGF, TGF beta 1, and PDGF-BB on IGF-II mRNA were dependent on protein synthesis and decreased in the presence of cycloheximide at 3.6 microM, but were independent of cell division, because they were observed in the presence and absence of 1 mM hydroxyurea.	Cycloheximide	129-142	insulin-like growth factor 2	Rattus norvegicus	48-54
7516314-6	1994	Experiments with the protein synthesis inhibitor cycloheximide revealed that G(Anh)MTetra-induced G-CSF mRNA expression was independent of new protein synthesis.	Cycloheximide	49-62	colony stimulating factor 3	Homo sapiens	98-103
8007969-9	1994	A high-copy-number plasmid carrying the PDR3 gene elevated resistance to both oligomycin and cycloheximide.	Cycloheximide	93-106	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	40-44
8007969-11	1994	These data are consistent with the notion that PDR3 acts to increase cycloheximide resistance by elevating the level of PDR5 transcription, while PDR3-mediated oligomycin resistance acts through some other target gene.	Cycloheximide	69-82	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	47-51
8007969-11	1994	These data are consistent with the notion that PDR3 acts to increase cycloheximide resistance by elevating the level of PDR5 transcription, while PDR3-mediated oligomycin resistance acts through some other target gene.	Cycloheximide	69-82	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	120-124
8058063-12	1994	On the other hand, cycloheximide completely blocked the increase in [125I]Tyr3SMS binding induced by EGF and gastrin.	Cycloheximide	19-32	epidermal growth factor	Rattus norvegicus	101-104
8058063-12	1994	On the other hand, cycloheximide completely blocked the increase in [125I]Tyr3SMS binding induced by EGF and gastrin.	Cycloheximide	19-32	gastrin	Rattus norvegicus	109-116
8208549-9	1994	We present evidence that the 8 kb c-MET mRNA undergoes rapid degradation with a half-life of less than 30 min and that this decay can be quickly inhibited by cycloheximide.	Cycloheximide	158-171	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	34-39
7978238-7	1994	Cycloheximide (50 micrograms/ml) and actinomycin D (5 micrograms/ml) sensitized L929 cells to TNF-induced killing.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	94-97
8029644-5	1994	The inhibitory effect of IFN-gamma was neutralized by treatment of the macrophages with cycloheximide.	Cycloheximide	88-101	interferon gamma	Mus musculus	25-34
8012939-2	1994	After 8 h of culture in the presence or absence of vinblastine, cycloheximide was added to the medium, a 4.5-fold increase in the half-life of the ornithine decarboxylase activity was observed in vinblastine-treated cells.	Cycloheximide	64-77	ornithine decarboxylase, structural 1	Mus musculus	147-170
8006027-7	1994	Incorporation of d70 kDa into the extracellular matrix was dependent upon protein synthesis; in cycloheximide-treated cultures that lacked a pre-existing matrix, d70 kDa accumulated in the extracellular matrix only in the presence of intact fibronectin.	Cycloheximide	96-109	fibronectin 1	Homo sapiens	241-252
8204886-10	1994	Cellular treatment with cycloheximide enhanced IL-2 gene transcription once activation was initiated, implicating the involvement of a labile repressor(s).	Cycloheximide	24-37	interleukin 2	Mus musculus	47-51
8204888-4	1994	Gelatinase induction by TNF-alpha and TPA was inhibited by actinomycin D or cycloheximide, indicating that de novo protein synthesis was required.	Cycloheximide	76-89	tumor necrosis factor	Homo sapiens	24-33
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 10	Homo sapiens	13-18
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	tumor necrosis factor	Homo sapiens	127-136
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 1 alpha	Homo sapiens	249-259
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	tumor necrosis factor	Homo sapiens	263-272
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 1 alpha	Homo sapiens	249-259
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	colony stimulating factor 2	Homo sapiens	327-333
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 6	Homo sapiens	335-339
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	C-X-C motif chemokine ligand 8	Homo sapiens	341-345
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 10	Homo sapiens	350-355
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 1 alpha	Homo sapiens	249-259
8004813-4	1994	In contrast, IL-10 was weakly expressed when fibroblasts were stimulated with LPS, IL-1 alpha or tumour necrosis factor-alpha (TNF-alpha), but the expression was enhanced in the presence of cycloheximide combined with optimal concentrations of LPS, IL-1 alpha or TNF-alpha, IL-1 alpha was a more potent stimulator than LPS for GM-CSF, IL-6, IL-8 and IL-10 expression, but not for IL-1 alpha and IL-1 beta.	Cycloheximide	190-203	interleukin 1 beta	Homo sapiens	395-404
8194473-7	1994	The effect of AII, but not forskolin, was reversed by treatment in the presence of cycloheximide.	Cycloheximide	83-96	NLR family pyrin domain containing 3	Homo sapiens	14-17
8194480-7	1994	The effects of PDGF on PDGF-A mRNA and polypeptide levels were prevented by the protein synthesis inhibitor cycloheximide at 3.6 microM.	Cycloheximide	108-121	platelet derived growth factor subunit A	Rattus norvegicus	23-29
8005391-0	1994	Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S49 cells.	Cycloheximide	95-108	B cell leukemia/lymphoma 2	Mus musculus	0-5
8005391-8	1994	Cycloheximide (CX) and A23187 also had antiproliferative and cell killing effects in both cell types, although higher concentrations of each agent were needed to kill S49-Bcl-2 cells.	Cycloheximide	0-13	B cell leukemia/lymphoma 2	Mus musculus	171-176
8200985-6	1994	The increased expression of VEGF mRNA produced by PGE2 was rapid (maximal at 1 h), transient (declined by 3 h), potentiated by cycloheximide, and abolished by actinomycin D.	Cycloheximide	127-140	vascular endothelial growth factor A	Rattus norvegicus	28-32
7514637-2	1994	Zymosan stimulated IL-8 production, which increased with increasing particle numbers and was abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	138-151	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Cycloheximide	98-111	interleukin 6	Mus musculus	48-52
7948430-4	1994	The inhibitory effect of IL-1 was inhibited by cycloheximide suggesting that de novo protein synthesis is required.	Cycloheximide	47-60	interleukin 1 beta	Homo sapiens	25-29
8176224-8	1994	The expression of the C10 message in response to cytokines was completely blocked by cycloheximide, whereas the other three chemokines were all overexpressed in the presence of this inhibitor.	Cycloheximide	85-98	chemokine (C-C motif) ligand 6	Mus musculus	22-25
8176225-9	1994	Moreover, the up-regulation of hPAF-R mRNA by IFN-gamma was independent of de novo protein synthesis since cycloheximide, an inhibitor of protein synthesis, did not affect this up-regulation.	Cycloheximide	107-120	platelet activating factor receptor	Homo sapiens	31-37
8177321-2	1994	The kinase p54 (M(r) 54,000), which was first isolated from cycloheximide-treated rats, is proline-directed like Erks-1/2, and requires both Tyr and Ser/Thr phosphorylation for activity.	Cycloheximide	60-73	ETS proto-oncogene 1, transcription factor	Rattus norvegicus	11-14
8177321-2	1994	The kinase p54 (M(r) 54,000), which was first isolated from cycloheximide-treated rats, is proline-directed like Erks-1/2, and requires both Tyr and Ser/Thr phosphorylation for activity.	Cycloheximide	60-73	mitogen activated protein kinase 3	Rattus norvegicus	113-121
8181074-4	1994	To assess the underlying molecular mechanism of IL-6-regulated apoptosis, two chemical compounds, cycloheximide (CHX) and aurintricarboxylic acid (ATA), were used to treat the cells.	Cycloheximide	113-116	interleukin 6	Mus musculus	48-52
7914436-6	1994	In contrast to IL-3 mRNA, the expression of IL-5 mRNA was dependent on de novo protein synthesis, since cycloheximide (CHX) blocked the Con A plus PMA induced IL-5 mRNA expression.	Cycloheximide	104-117	interleukin 5	Homo sapiens	44-48
7914436-6	1994	In contrast to IL-3 mRNA, the expression of IL-5 mRNA was dependent on de novo protein synthesis, since cycloheximide (CHX) blocked the Con A plus PMA induced IL-5 mRNA expression.	Cycloheximide	104-117	interleukin 5	Homo sapiens	159-163
21567024-6	1994	The apoptosis and increased expression of TGF-beta 1 could be completely blocked;by the addition of cycloheximide given within 12 h of RA treatment.	Cycloheximide	100-113	transforming growth factor beta 1	Homo sapiens	42-52
7514189-4	1994	NG-monomethyl-L-arginine (L-NMMA), which blocks the activity of both constitutive and inducible nitric oxide synthase (cNOS and iNOS), aminoguanidine, a recently described selective iNOS inhibitor, dexamethasone, or cycloheximide abolished the release of NO2- and attenuated the exaggerated BK-induced PGE2 production.	Cycloheximide	216-229	nitric oxide synthase, inducible	Oryctolagus cuniculus	86-117
7523426-8	1994	When fibronectin synthesis, and consequently fibril formation, was inhibited by cycloheximide, large adhesion plaque-like structures were formed at the cell margin.	Cycloheximide	80-93	fibronectin 1	Gallus gallus	5-16
8157957-9	1994	We also noted a dramatic difference in the cycloheximide sensitivity of LT, LT-beta, and TNF-alpha mRNAs.	Cycloheximide	43-56	lymphotoxin B	Mus musculus	76-83
8157957-9	1994	We also noted a dramatic difference in the cycloheximide sensitivity of LT, LT-beta, and TNF-alpha mRNAs.	Cycloheximide	43-56	tumor necrosis factor	Mus musculus	89-98
8163951-4	1994	Treatment of PM with cycloheximide results in a significant accumulation of IFN-gamma mRNA, suggesting that a short-lived IFN-gamma mRNA accumulates when protein synthesis is inhibited.	Cycloheximide	21-34	interferon gamma	Mus musculus	76-85
8049158-9	1994	However, cycloheximide alone is able to increase by 6-fold rasGAP mRNA expression.	Cycloheximide	9-22	RAS p21 protein activator 1	Mus musculus	59-65
8003445-10	1994	Cycloheximide (50 micrograms/ml) inhibited 17 beta-estradiol-induced tyrosinase stimulation (P < 0.001).	Cycloheximide	0-13	tyrosinase	Homo sapiens	69-79
7514713-6	1994	Furthermore, the increase in rG-CSF binding sites due to histamine treatment seemed to take place in association with the externalization of G-CSF receptors, because 1) the binding increase was observed in the presence of cycloheximide, 2) no concomitant increase in [3H]leucine uptake was elicited, and 3) colchicine and cytochalasin D effectively prevented the increase in rG-CSF binding due to histamine.	Cycloheximide	222-235	colony stimulating factor 3	Rattus norvegicus	29-35
7514713-6	1994	Furthermore, the increase in rG-CSF binding sites due to histamine treatment seemed to take place in association with the externalization of G-CSF receptors, because 1) the binding increase was observed in the presence of cycloheximide, 2) no concomitant increase in [3H]leucine uptake was elicited, and 3) colchicine and cytochalasin D effectively prevented the increase in rG-CSF binding due to histamine.	Cycloheximide	222-235	colony stimulating factor 3	Rattus norvegicus	30-35
8163951-4	1994	Treatment of PM with cycloheximide results in a significant accumulation of IFN-gamma mRNA, suggesting that a short-lived IFN-gamma mRNA accumulates when protein synthesis is inhibited.	Cycloheximide	21-34	interferon gamma	Mus musculus	122-131
8167153-3	1994	Inhibition of the response to IL-6 by cycloheximide and alpha-amanitin indicates that increases in PAI-1 are dependent on both protein and RNA synthesis.	Cycloheximide	38-51	interleukin 6	Homo sapiens	30-34
8167153-3	1994	Inhibition of the response to IL-6 by cycloheximide and alpha-amanitin indicates that increases in PAI-1 are dependent on both protein and RNA synthesis.	Cycloheximide	38-51	serpin family E member 1	Homo sapiens	99-104
8170983-3	1994	S-phase arrest also promoted tumor necrosis factor alpha-induced apoptosis, eliminating the normal requirement for simultaneous cycloheximide treatment.	Cycloheximide	128-141	tumor necrosis factor	Homo sapiens	29-56
8175699-8	1994	After HGF stimulation, HGF receptor expression follows c-FOS and c-JUN induction with a peak approximately 4 h. Pretreatment with the protein synthesis inhibitor puromycin strongly reduced the response to HGF, while cycloheximide alone increased the level of the receptor mRNA.	Cycloheximide	216-229	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	23-35
8175699-8	1994	After HGF stimulation, HGF receptor expression follows c-FOS and c-JUN induction with a peak approximately 4 h. Pretreatment with the protein synthesis inhibitor puromycin strongly reduced the response to HGF, while cycloheximide alone increased the level of the receptor mRNA.	Cycloheximide	216-229	hepatocyte growth factor	Homo sapiens	23-26
8175725-4	1994	Cycloheximide induces high levels of SM-20 mRNA and superinduces it in the presence of serum, suggesting that the increase in SM-20 mRNA levels is not dependent on protein synthesis and is part of the primary response to growth agonists.	Cycloheximide	0-13	egl-9 family hypoxia-inducible factor 3	Rattus norvegicus	37-42
8175725-4	1994	Cycloheximide induces high levels of SM-20 mRNA and superinduces it in the presence of serum, suggesting that the increase in SM-20 mRNA levels is not dependent on protein synthesis and is part of the primary response to growth agonists.	Cycloheximide	0-13	egl-9 family hypoxia-inducible factor 3	Rattus norvegicus	126-131
7512951-6	1994	In addition, linkage of the radiolabel to eNOS was insensitive to hydroxylamine treatment, and incorporation of the radiolabel into eNOS was abolished by cyclo-heximide.	Cycloheximide	154-168	nitric oxide synthase 3	Bos taurus	132-136
7513155-2	1994	In murine macrophage cell lines, LPS-induced increases in iNOS mRNA were blocked by either cycloheximide or actinomycin D.	Cycloheximide	91-104	nitric oxide synthase 2, inducible	Mus musculus	58-62
8166711-3	1994	The secondary but not immediate release of ET-1 was prevented by actinomycin D (8 x 10(-7) M) or cycloheximide (3.6 x 10(-6) M).	Cycloheximide	97-110	endothelin 1	Homo sapiens	43-47
8166725-5	1994	We show in this report that deprivation of serum, epidermal growth factor and thyrotropin triggers internucleosomal DNA fragmentation and morphological modifications characteristic of apoptotic cell death in dog thyroid cells in primary culture; cycloheximide treatment has the same effect.	Cycloheximide	246-259	epidermal growth factor	Canis lupus familiaris	50-73
8168150-6	1994	Treatment with cycloheximide indicated that the expression of TNF-alpha mRNA does not require new protein synthesis.	Cycloheximide	15-28	tumor necrosis factor	Mus musculus	62-71
8174132-2	1994	The results demonstrate that okadaic acid treatment is associated with a transient induction of EGR-1 gene expression which was detectable by 30 min to 1 h and peaked at 3-6 h. EGR-1 mRNA was superinduced in cells treated with both okadaic acid and the protein synthesis inhibitor cycloheximide.	Cycloheximide	281-294	early growth response 1	Homo sapiens	96-101
8174132-2	1994	The results demonstrate that okadaic acid treatment is associated with a transient induction of EGR-1 gene expression which was detectable by 30 min to 1 h and peaked at 3-6 h. EGR-1 mRNA was superinduced in cells treated with both okadaic acid and the protein synthesis inhibitor cycloheximide.	Cycloheximide	281-294	early growth response 1	Homo sapiens	177-182
8174132-4	1994	In contrast, treatment with both okadaic acid and cycloheximide prolonged the half-life of EGR-1 transcripts.	Cycloheximide	50-63	early growth response 1	Homo sapiens	91-96
8147926-6	1994	RESULTS: IL-1 induced an increase in COX activity (as assessed by prostaglandin E2 release) that was dose- and time-dependent and was blocked by cycloheximide, actinomycin D, and dexamethasone.	Cycloheximide	145-158	interleukin 1 alpha	Homo sapiens	9-13
7908231-3	1994	Induction by IL-13 was not blocked, but rather superinduced, in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	112-125	interleukin 13	Homo sapiens	13-18
8054453-5	1994	Since cycloheximide alone also caused an increase of TF mRNA levels and gene transcription it is concluded that the transcriptional activation of the TF gene does not require protein synthesis.	Cycloheximide	6-19	coagulation factor III, tissue factor	Homo sapiens	53-55
8054453-5	1994	Since cycloheximide alone also caused an increase of TF mRNA levels and gene transcription it is concluded that the transcriptional activation of the TF gene does not require protein synthesis.	Cycloheximide	6-19	coagulation factor III, tissue factor	Homo sapiens	150-152
8142255-7	1994	When cycloheximide was present during the first 36 h priming period of dexamethasone treatment, there was an immediate loss of c-myc protein and apoptosis at 54 h was completely inhibited.	Cycloheximide	5-18	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	127-132
8143789-7	1994	Addition of cycloheximide (CHX), an inhibitor of protein synthesis, to cultures led to superinduction of activin mRNA transcripts regardless of TPA exposure, but significantly attenuated the cAMP-induced mRNA levels.	Cycloheximide	12-25	inhibin subunit beta E	Homo sapiens	105-112
8143789-7	1994	Addition of cycloheximide (CHX), an inhibitor of protein synthesis, to cultures led to superinduction of activin mRNA transcripts regardless of TPA exposure, but significantly attenuated the cAMP-induced mRNA levels.	Cycloheximide	27-30	inhibin subunit beta E	Homo sapiens	105-112
8163333-16	1994	When protein synthesis was inhibited by cycloheximide, bFGF synthesis was blocked in the presence of CEMF, leading to inhibition of corneal endothelium modulation.	Cycloheximide	40-53	fibroblast growth factor 2	Homo sapiens	55-59
8014194-11	1994	Since inhibition of protein synthesis by cycloheximide also leads to a decrease in TNF receptors, it is possible that the density-dependent reduction in TNF receptor number is due to an overall decrease in protein synthesis.	Cycloheximide	41-54	tumor necrosis factor	Homo sapiens	83-86
8030437-10	1994	Further studies indicated that the effects of phosphoryl compounds on ALP-specific activity could not be correlated with effects on ALP reaction kinetics, cell proliferation, or acid phosphatase activity and that the beta-glycero-P(i)-dependent increase in ALP activity was blocked by cycloheximide but not actinomycin D.	Cycloheximide	285-298	alkaline phosphatase, placental	Homo sapiens	70-73
8144558-5	1994	In contrast, inhibition of translation in trans, by the addition of cycloheximide, stabilized the deadenylated form of MFA2 mRNA.	Cycloheximide	68-81	mating pheromone a	Saccharomyces cerevisiae S288C	119-123
8144558-6	1994	Furthermore, the MFA2 transcripts that were not translated due to a stem-loop in the 5"-UTR were also stabilized in the presence of cycloheximide, suggesting that cycloheximide is likely to affect mRNA stability indirectly.	Cycloheximide	132-145	mating pheromone a	Saccharomyces cerevisiae S288C	17-21
8144558-6	1994	Furthermore, the MFA2 transcripts that were not translated due to a stem-loop in the 5"-UTR were also stabilized in the presence of cycloheximide, suggesting that cycloheximide is likely to affect mRNA stability indirectly.	Cycloheximide	163-176	mating pheromone a	Saccharomyces cerevisiae S288C	17-21
8144559-5	1994	Furthermore, the induction of L17 and S25 mRNA content was blocked by cycloheximide, demonstrating the requirement for a newly synthesized protein in the signaling pathway.	Cycloheximide	70-83	ribosomal protein S25	Homo sapiens	38-41
8163557-8	1994	Cycloheximide treatment amplified Pax-3 induction and prolonged the signal.	Cycloheximide	0-13	paired box 3	Mus musculus	34-39
8163651-7	1994	The competitive inhibitor of NO production, NG-monomethyl-arginine (L-NMMA), and cycloheximide abolished the increase in nitrite production induced by TNF-alpha + IFN-gamma + LPS, while hydrocortisone had no effect, as previously reported for chondrocytes.	Cycloheximide	81-94	tumor necrosis factor	Mus musculus	151-160
8163651-7	1994	The competitive inhibitor of NO production, NG-monomethyl-arginine (L-NMMA), and cycloheximide abolished the increase in nitrite production induced by TNF-alpha + IFN-gamma + LPS, while hydrocortisone had no effect, as previously reported for chondrocytes.	Cycloheximide	81-94	interferon gamma	Mus musculus	163-172
8163651-7	1994	The competitive inhibitor of NO production, NG-monomethyl-arginine (L-NMMA), and cycloheximide abolished the increase in nitrite production induced by TNF-alpha + IFN-gamma + LPS, while hydrocortisone had no effect, as previously reported for chondrocytes.	Cycloheximide	81-94	toll-like receptor 4	Mus musculus	175-178
8014598-6	1994	Both gonadotrophin secretion and [3H]AA release responses to LHRH and to phorbol ester varied in parallel during the oestrous cycle and in ovariectomized/oestradiol-17 beta-replaced animals, as did their sensitivity to quinacrine and the protein synthesis inhibitor cycloheximide.	Cycloheximide	266-279	gonadotropin releasing hormone 1	Rattus norvegicus	61-65
8144935-3	1994	Although inhibition of protein synthesis was found to superinduce the expression of PMN-derived chemokine steady-state mRNA, the inhibitory activity of IL-10 was completely abrogated in the presence of either cycloheximide or puromycin.	Cycloheximide	209-222	interleukin 10	Homo sapiens	152-157
8144938-4	1994	The protein synthesis inhibitor, cycloheximide, had no detectable effect on levels of IL-8 mRNA expression in PMN incubated in medium alone; however, cycloheximide could selectively modulate IL-8 mRNA transcription in PMN, depending on the cytokine used.	Cycloheximide	33-46	C-X-C motif chemokine ligand 8	Homo sapiens	191-195
8144938-4	1994	The protein synthesis inhibitor, cycloheximide, had no detectable effect on levels of IL-8 mRNA expression in PMN incubated in medium alone; however, cycloheximide could selectively modulate IL-8 mRNA transcription in PMN, depending on the cytokine used.	Cycloheximide	150-163	C-X-C motif chemokine ligand 8	Homo sapiens	191-195
8144938-5	1994	Cycloheximide did not affect or alter IL-8 mRNA induction in IL-2-treated PMN but abrogated it in granulocyte macrophage-CSF-treated PMN and super-induced the level of IL-8 mRNA in C. albicans-treated PMN.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	168-172
8145039-6	1994	The stimulatory effect of GM-CSF on FLAP mRNA was inhibited by prior treatment of the cells with the transcription inhibitor, actinomycin D, and pretreatment of the cells with the protein synthesis inhibitor, cycloheximide, failed to prevent the increase in FLAP mRNA induced by GM-CSF.	Cycloheximide	209-222	colony stimulating factor 2	Homo sapiens	26-32
8145039-6	1994	The stimulatory effect of GM-CSF on FLAP mRNA was inhibited by prior treatment of the cells with the transcription inhibitor, actinomycin D, and pretreatment of the cells with the protein synthesis inhibitor, cycloheximide, failed to prevent the increase in FLAP mRNA induced by GM-CSF.	Cycloheximide	209-222	arachidonate 5-lipoxygenase activating protein	Homo sapiens	36-40
7512581-2	1994	We show that the SP-augmented IL-2 mRNA signal is totally abrogated by an early addition of cyclosporin A, actinomycin D or cycloheximide.	Cycloheximide	124-137	interleukin 2	Homo sapiens	30-34
7908680-6	1994	Induction of TGK mRNA by either TPA or Ca++ is blocked in the presence of cycloheximide, suggesting that a PKC-dependent protein factor is required for TGK gene expression in response to both stimuli.	Cycloheximide	74-87	transglutaminase 1, K polypeptide	Mus musculus	13-16
7908680-6	1994	Induction of TGK mRNA by either TPA or Ca++ is blocked in the presence of cycloheximide, suggesting that a PKC-dependent protein factor is required for TGK gene expression in response to both stimuli.	Cycloheximide	74-87	transglutaminase 1, K polypeptide	Mus musculus	152-155
8061119-4	1994	The data show that incubation with IL-4 results in a dose-dependent, 2-3 x increase in M-CSFr with no change in binding affinity and a maximal effect on binding at about 12 h. This increase in M-CSFr is dependent upon new, specific protein synthesis as shown by the inhibitory action of cycloheximide, and gel analysis of radiolabeled, specific protein, immunoprecipitated with anti-M-CSFr antibody.	Cycloheximide	287-300	interleukin 4	Mus musculus	35-39
8131213-1	1994	EL4 mouse thymoma cells sensitive to TNF-mediated lysis only in the presence of cycloheximide (S-EL4) or in the presence or absence of cycloheximide (N-EL4) were used in these experiments.	Cycloheximide	80-93	epilepsy 4	Mus musculus	0-3
8131213-1	1994	EL4 mouse thymoma cells sensitive to TNF-mediated lysis only in the presence of cycloheximide (S-EL4) or in the presence or absence of cycloheximide (N-EL4) were used in these experiments.	Cycloheximide	80-93	tumor necrosis factor	Mus musculus	37-40
8131213-1	1994	EL4 mouse thymoma cells sensitive to TNF-mediated lysis only in the presence of cycloheximide (S-EL4) or in the presence or absence of cycloheximide (N-EL4) were used in these experiments.	Cycloheximide	135-148	epilepsy 4	Mus musculus	0-3
8131213-1	1994	EL4 mouse thymoma cells sensitive to TNF-mediated lysis only in the presence of cycloheximide (S-EL4) or in the presence or absence of cycloheximide (N-EL4) were used in these experiments.	Cycloheximide	135-148	tumor necrosis factor	Mus musculus	37-40
8131213-2	1994	Murine tumor cell line (S-EL4) sensitivity to TNF cytotoxicity is augmented when cycloheximide is added together with TNF or when cycloheximide is added 1 hr before or after TNF.	Cycloheximide	81-94	epilepsy 4	Mus musculus	26-29
8131213-2	1994	Murine tumor cell line (S-EL4) sensitivity to TNF cytotoxicity is augmented when cycloheximide is added together with TNF or when cycloheximide is added 1 hr before or after TNF.	Cycloheximide	81-94	tumor necrosis factor	Mus musculus	46-49
8131213-2	1994	Murine tumor cell line (S-EL4) sensitivity to TNF cytotoxicity is augmented when cycloheximide is added together with TNF or when cycloheximide is added 1 hr before or after TNF.	Cycloheximide	130-143	epilepsy 4	Mus musculus	26-29
8131213-2	1994	Murine tumor cell line (S-EL4) sensitivity to TNF cytotoxicity is augmented when cycloheximide is added together with TNF or when cycloheximide is added 1 hr before or after TNF.	Cycloheximide	130-143	tumor necrosis factor	Mus musculus	46-49
8061119-4	1994	The data show that incubation with IL-4 results in a dose-dependent, 2-3 x increase in M-CSFr with no change in binding affinity and a maximal effect on binding at about 12 h. This increase in M-CSFr is dependent upon new, specific protein synthesis as shown by the inhibitory action of cycloheximide, and gel analysis of radiolabeled, specific protein, immunoprecipitated with anti-M-CSFr antibody.	Cycloheximide	287-300	colony stimulating factor 1 receptor	Mus musculus	87-93
8061119-4	1994	The data show that incubation with IL-4 results in a dose-dependent, 2-3 x increase in M-CSFr with no change in binding affinity and a maximal effect on binding at about 12 h. This increase in M-CSFr is dependent upon new, specific protein synthesis as shown by the inhibitory action of cycloheximide, and gel analysis of radiolabeled, specific protein, immunoprecipitated with anti-M-CSFr antibody.	Cycloheximide	287-300	colony stimulating factor 1 receptor	Mus musculus	193-199
8061119-4	1994	The data show that incubation with IL-4 results in a dose-dependent, 2-3 x increase in M-CSFr with no change in binding affinity and a maximal effect on binding at about 12 h. This increase in M-CSFr is dependent upon new, specific protein synthesis as shown by the inhibitory action of cycloheximide, and gel analysis of radiolabeled, specific protein, immunoprecipitated with anti-M-CSFr antibody.	Cycloheximide	287-300	colony stimulating factor 1 receptor	Mus musculus	193-199
8056147-6	1994	The PTHrP gene contains nucleotide sequence motifs in common with members of the immediate-early response gene family, as well as other hallmark features which include induction by growth factors, serum or cycloheximide and relatively short-lived mRNA.	Cycloheximide	206-219	parathyroid hormone like hormone	Homo sapiens	4-9
12232162-3	1994	Inhibition of protein synthesis with cycloheximide completely blocked arachidonate-induced hypersensitive necrosis and browning, including HMGR gene induction and phytoalexin accumulation.	Cycloheximide	37-50	3-hydroxy-3-methylglutaryl-coenzyme A reductase 1	Solanum tuberosum	139-143
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	12-25	interleukin 2	Homo sapiens	102-106
8032680-10	1994	TRH-induced jun B and c-fos responses were characteristic of immediate early genes as shown by the superinduction observed under cycloheximide treatment and the total inhibition elicited by actinomycin D.	Cycloheximide	129-142	thyrotropin releasing hormone	Rattus norvegicus	0-3
8032680-10	1994	TRH-induced jun B and c-fos responses were characteristic of immediate early genes as shown by the superinduction observed under cycloheximide treatment and the total inhibition elicited by actinomycin D.	Cycloheximide	129-142	JunB proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	12-17
8032680-10	1994	TRH-induced jun B and c-fos responses were characteristic of immediate early genes as shown by the superinduction observed under cycloheximide treatment and the total inhibition elicited by actinomycin D.	Cycloheximide	129-142	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	22-27
7510678-8	1994	Protein synthesis was required for the induction of NOS mRNA because addition of cycloheximide dramatically reduced IFN-gamma plus picolonic acid-induced NOS mRNA expression.	Cycloheximide	81-94	interferon gamma	Mus musculus	116-125
8141779-9	1994	Egr-1 mRNA expression was super-induced by the inhibitor of protein synthesis, cycloheximide.	Cycloheximide	79-92	early growth response 1	Rattus norvegicus	0-5
8144899-10	1994	IL-4 secretion was slower (t1/2 of 1.5 h) than histamine release and was inhibited by cycloheximide.	Cycloheximide	86-99	interleukin 4	Homo sapiens	0-4
7509812-4	1994	In cycloheximide-treated cells, B1 increases the decline of CD23 from the cell surface.	Cycloheximide	3-16	Fc epsilon receptor II	Homo sapiens	60-64
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	12-25	CD4 molecule	Homo sapiens	119-122
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	12-25	CD4 molecule	Homo sapiens	123-126
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	27-30	interleukin 2	Homo sapiens	102-106
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	27-30	CD4 molecule	Homo sapiens	119-122
7518260-6	1994	Addition of cycloheximide (CHx) 4 h after T cell activation resulted in substantial superinduction of IL-2 mRNA in the CD4+CD45RO+ population but had little effect on CD4+CD45RA+ cells.	Cycloheximide	27-30	CD4 molecule	Homo sapiens	123-126
8055872-10	1994	Cycloheximide prevents the effect of A23187 and stabilizes the mts1 RNA, probably by blocking the synthesis of these nucleases.	Cycloheximide	0-13	S100 calcium binding protein A4	Homo sapiens	63-67
8106488-5	1994	Both PLA2-II expression and PGE2 synthesis were completely suppressed by pretreatment of the cells with actinomycin D, cycloheximide, or dexamethasone.	Cycloheximide	119-132	phospholipase A2 group IIA	Homo sapiens	5-9
8018565-9	1994	The protein synthesis inhibitor cycloheximide completely abolished the PMA-induced down-modulation of the p53 mRNA, suggesting that a short-lived protein was involved in the down-modulation.	Cycloheximide	32-45	tumor protein p53	Homo sapiens	106-109
8119183-13	1994	The enhancement of PTH action by CHX is compatible with feedback inhibition of tPA transcription by a hormone-activated repressor (which has been proposed to occur in granulosa cells) but effects of CHX on tPA mRNA stability may also occur.	Cycloheximide	33-36	parathyroid hormone	Rattus norvegicus	19-22
8161377-11	1994	TSC-22 mRNA transiently increased 4-fold in the presence of FSH, reached maximal levels at 3 h, and returned to prestimulation levels by 12 h. The FSH-stimulated increase was independent of protein synthesis because it occurred in the presence of cycloheximide and FSH.	Cycloheximide	247-260	TSC22 domain family, member 1	Rattus norvegicus	0-6
8125162-8	1994	The induction of RAR gamma is attenuated by the protein synthesis inhibitor, cycloheximide, while the induction of RAR beta increases slightly.	Cycloheximide	77-90	retinoic acid receptor gamma	Homo sapiens	17-26
8125162-9	1994	Studies with actinomycin D and cycloheximide show that all three receptors have different half-lives, with RAR gamma having the longest half-life at 8 h. Gel shift analysis of known retinoic acid response elements (RAREs) in the RAR beta and RAR gamma genes demonstrates that the upregulation of these by genes by RA involves increased binding of complexes to the individual RAREs.	Cycloheximide	31-44	retinoic acid receptor beta	Homo sapiens	229-237
8195803-2	1994	Cycloheximide reversibly inhibited the release, and the binding protein was identified as transcobalamin II (TCII) based on molecular size, reaction with anti-human TCII antiserum, precipitation with 2.0 M ammonium sulfate and its ability to bind radioactive cyanocobalamin.	Cycloheximide	0-13	transcobalamin 2	Homo sapiens	109-113
8195803-2	1994	Cycloheximide reversibly inhibited the release, and the binding protein was identified as transcobalamin II (TCII) based on molecular size, reaction with anti-human TCII antiserum, precipitation with 2.0 M ammonium sulfate and its ability to bind radioactive cyanocobalamin.	Cycloheximide	0-13	transcobalamin 2	Homo sapiens	165-169
8107211-10	1994	Rev was found in the same subcellular compartments of cells treated for extended periods with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	94-107	Rev	Human immunodeficiency virus 1	0-3
8114707-0	1994	Reactivation of apolipoprotein II gene transcription by cycloheximide reveals two steps in the deactivation of estrogen receptor-mediated transcription.	Cycloheximide	56-69	apovitellenin 1	Gallus gallus	16-33
8114707-4	1994	Inhibition of protein synthesis with cycloheximide (CHX) or puromycin following estrogen withdrawal superinduces apoII mRNA without affecting apoII mRNA stability.	Cycloheximide	37-50	apovitellenin 1	Gallus gallus	113-118
8114707-4	1994	Inhibition of protein synthesis with cycloheximide (CHX) or puromycin following estrogen withdrawal superinduces apoII mRNA without affecting apoII mRNA stability.	Cycloheximide	52-55	apovitellenin 1	Gallus gallus	113-118
8114707-9	1994	The second event is revealed by the CHX-induced superinduction of apoII mRNA following hormone withdrawal.	Cycloheximide	36-39	apovitellenin 1	Gallus gallus	66-71
8206322-7	1994	This effect was exerted at the mRNA level and the use of cycloheximide, a protein synthesis inhibitor, suggested that GH did not require any other intermediary protein for inducing tPA-mRNA.	Cycloheximide	57-70	gonadotropin releasing hormone receptor	Rattus norvegicus	118-120
8117098-3	1994	PEPCK expression was also transiently but highly inducible on Day 14 by dexamethasone, cAMP, cycloheximide, and pactamycin, but not by retinoic acid.	Cycloheximide	93-106	phosphoenolpyruvate carboxykinase 1	Gallus gallus	0-5
8117098-5	1994	Dexamethasone- and cycloheximide-induced increases in mRNA expression were principally due to increases in the rate of PEPCK gene transcription.	Cycloheximide	19-32	phosphoenolpyruvate carboxykinase 1	Gallus gallus	119-124
8307980-5	1994	However, delta sts1 cells exhibit supersensitivity to sporidesmin and to other structurally unrelated drugs such as cycloheximide.	Cycloheximide	116-129	Sts1p	Saccharomyces cerevisiae S288C	15-19
8307982-8	1994	By using the protein synthesis inhibitor cycloheximide, it was shown that G(Anh)MTetra-induced IL-6 mRNA expression depends on the synthesis of new protein, whereas G(Anh)MTetra-induced IL-1 beta mRNA accumulation does not.	Cycloheximide	41-54	interleukin 6	Homo sapiens	95-99
7508407-4	1994	Results show that both cycloheximide and anisomycin can efficiently induce i-NOS mRNA, even when used at concentrations so low (0.25 microgram/ml) to have only negligible effects on protein synthesis; puromycin, on the other hand, shows only a limited effect on i-NOS mRNA expression, detectable only when cells are treated with higher concentrations of inhibitor (25 micrograms/ml).	Cycloheximide	23-36	nitric oxide synthase 2, inducible	Mus musculus	75-80
8117098-6	1994	Following an initial induction by dexamethasone, PEPCK expression was no longer responsive to a second administration of dexamethasone but was still responsive to cycloheximide and cAMP.	Cycloheximide	163-176	phosphoenolpyruvate carboxykinase 1	Gallus gallus	49-54
8117098-7	1994	PEPCK induction by dexamethasone or cycloheximide progressively diminished between 12 and 15 days of development.	Cycloheximide	36-49	phosphoenolpyruvate carboxykinase 1	Gallus gallus	0-5
8117098-8	1994	By Day 16, PEPCK expression was no longer responsive to dexamethasone, but was still inducible by cAMP and this induction was increased by cycloheximide.	Cycloheximide	139-152	phosphoenolpyruvate carboxykinase 1	Gallus gallus	11-16
7508407-4	1994	Results show that both cycloheximide and anisomycin can efficiently induce i-NOS mRNA, even when used at concentrations so low (0.25 microgram/ml) to have only negligible effects on protein synthesis; puromycin, on the other hand, shows only a limited effect on i-NOS mRNA expression, detectable only when cells are treated with higher concentrations of inhibitor (25 micrograms/ml).	Cycloheximide	23-36	nitric oxide synthase 2, inducible	Mus musculus	262-267
7508407-5	1994	In RAW 264.7 cells, low concentrations of cycloheximide trigger an immediate-early gene response, as indicated by induction of c-fos and JE mRNAs, and can efficiently activate transcription of transiently transfected recombinant reporter genes including either the i-NOS or the c-fos gene promoters.	Cycloheximide	42-55	FBJ osteosarcoma oncogene	Mus musculus	127-132
7508407-5	1994	In RAW 264.7 cells, low concentrations of cycloheximide trigger an immediate-early gene response, as indicated by induction of c-fos and JE mRNAs, and can efficiently activate transcription of transiently transfected recombinant reporter genes including either the i-NOS or the c-fos gene promoters.	Cycloheximide	42-55	nitric oxide synthase 2, inducible	Mus musculus	265-270
7508407-5	1994	In RAW 264.7 cells, low concentrations of cycloheximide trigger an immediate-early gene response, as indicated by induction of c-fos and JE mRNAs, and can efficiently activate transcription of transiently transfected recombinant reporter genes including either the i-NOS or the c-fos gene promoters.	Cycloheximide	42-55	FBJ osteosarcoma oncogene	Mus musculus	278-283
8170347-7	1994	Increases of NGF mRNA by agents acting on the promoter could be observed in normal and transgenic astrocytes only after inhibition of the protein synthesis by cycloheximide, suggesting a similar rapid turnover of normal and transgenic transcripts.	Cycloheximide	159-172	nerve growth factor	Mus musculus	13-16
8170349-8	1994	Furthermore, prevention of c-fos translation by pretreatment with protein synthesis inhibitor cycloheximide attenuated this dehydration induced increase in vasopressin mRNA.	Cycloheximide	94-107	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-32
8170349-8	1994	Furthermore, prevention of c-fos translation by pretreatment with protein synthesis inhibitor cycloheximide attenuated this dehydration induced increase in vasopressin mRNA.	Cycloheximide	94-107	arginine vasopressin	Rattus norvegicus	156-167
7507831-5	1994	Treatment with cycloheximide inhibited CT- plus IBMX-mediated PR mRNA stimulation, but not the induction of E2, indicating that the PR mRNA response to cAMP is not a primary one and probably requires de novo protein synthesis.	Cycloheximide	15-28	progesterone receptor	Homo sapiens	62-64
7507831-5	1994	Treatment with cycloheximide inhibited CT- plus IBMX-mediated PR mRNA stimulation, but not the induction of E2, indicating that the PR mRNA response to cAMP is not a primary one and probably requires de novo protein synthesis.	Cycloheximide	15-28	progesterone receptor	Homo sapiens	132-134
8179820-1	1994	G0S8 is a member of a set of putative G0/G1 switch regulatory genes (G0S genes) selected by screening cDNA libraries prepared from blood mononuclear cells cultured for 2 hr with lectin and cycloheximide.	Cycloheximide	189-202	regulator of G protein signaling 2	Homo sapiens	0-4
7508894-5	1994	The release of immunoreactive and bioactive PTHrP was increased by incubating the cells with forskolin, 3-isobutyl-1-methylxanthine or dibutyryl cAMP even in the presence of the protein-synthesis inhibitor cycloheximide for 6 hr.	Cycloheximide	206-219	parathyroid hormone like hormone	Homo sapiens	44-49
7509342-7	1994	Actinomycin D abolished the cAMP-induced iNOS mRNA, whereas cycloheximide remarkably increased iNOS mRNA levels in the presence and absence of 8-bromo-cAMP (superinduction).	Cycloheximide	60-73	nitric oxide synthase 2	Rattus norvegicus	95-99
7509342-8	1994	Actinomycin D, but not dexamethasone, completely abolished the cycloheximide-induced iNOS mRNA.	Cycloheximide	63-76	nitric oxide synthase 2	Rattus norvegicus	85-89
7507966-7	1994	The histamine-induced DAF expression was inhibited by actinomycin D and cycloheximide and accompanied by an increase in the DAF mRNA level, indicating that both transcription and translation are required.	Cycloheximide	72-85	CD55 molecule (Cromer blood group)	Homo sapiens	22-25
8300851-5	1994	Results indicated that MCP-1 mRNA expression was maximal within 3 h, and was further augmented by the protein synthesis inhibitor cycloheximide (CY).	Cycloheximide	130-143	C-C motif chemokine ligand 2	Homo sapiens	23-28
8300851-5	1994	Results indicated that MCP-1 mRNA expression was maximal within 3 h, and was further augmented by the protein synthesis inhibitor cycloheximide (CY).	Cycloheximide	145-147	C-C motif chemokine ligand 2	Homo sapiens	23-28
8301134-2	1994	Treatment of macrophages from BCG-resistant mice with 1 U of rIFN-gamma induced transient I-A expression that decayed in the presence of cycloheximide.	Cycloheximide	137-150	interferon gamma	Rattus norvegicus	61-71
8301137-5	1994	The enhancement of M-CSF message levels in the presence of IL-1 beta was blocked by cycloheximide, suggesting that de novo protein synthesis was required.	Cycloheximide	84-97	colony stimulating factor 1	Homo sapiens	19-24
8301137-5	1994	The enhancement of M-CSF message levels in the presence of IL-1 beta was blocked by cycloheximide, suggesting that de novo protein synthesis was required.	Cycloheximide	84-97	interleukin 1 beta	Homo sapiens	59-68
8301141-9	1994	While crg-2 mRNA appeared within 2 h and reached a maximum in 6 to 8 h, Ia mRNA was not detected before 8 h. Cycloheximide superinduced crg-2 mRNA induced by IFN-gamma or UV-NDV but it abolished Ia mRNA induction by the same stimuli.	Cycloheximide	109-122	chemokine (C-X-C motif) ligand 10	Mus musculus	6-11
8301141-9	1994	While crg-2 mRNA appeared within 2 h and reached a maximum in 6 to 8 h, Ia mRNA was not detected before 8 h. Cycloheximide superinduced crg-2 mRNA induced by IFN-gamma or UV-NDV but it abolished Ia mRNA induction by the same stimuli.	Cycloheximide	109-122	chemokine (C-X-C motif) ligand 10	Mus musculus	136-141
8301141-9	1994	While crg-2 mRNA appeared within 2 h and reached a maximum in 6 to 8 h, Ia mRNA was not detected before 8 h. Cycloheximide superinduced crg-2 mRNA induced by IFN-gamma or UV-NDV but it abolished Ia mRNA induction by the same stimuli.	Cycloheximide	109-122	interferon gamma	Homo sapiens	158-167
8126384-7	1994	Cycloheximide and actinomycin D completely abolished PMA-stimulated t-PA secretion.	Cycloheximide	0-13	plasminogen activator, tissue type	Homo sapiens	68-72
8190258-4	1994	In the guinea-pig enteric nervous system, c-Myc-like immunoreactivity detected by two different antibodies remained detectable for up to 4 h in the presence of cycloheximide.	Cycloheximide	160-173	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	42-47
8159792-7	1994	Accumulation of SAUR-AC1 mRNA is readily induced by natural and synthetic auxins and by the translational inhibitor cycloheximide.	Cycloheximide	116-129	SAUR-like auxin-responsive protein family	Arabidopsis thaliana	16-24
7508406-4	1994	Cycloheximide potentiated the expression of iNOS mRNA in SMCs in culture stimulated with LPS+IFN gamma but attenuated the response in aortic strips.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	44-48
7508406-4	1994	Cycloheximide potentiated the expression of iNOS mRNA in SMCs in culture stimulated with LPS+IFN gamma but attenuated the response in aortic strips.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	93-102
7507665-1	1994	We have devised procedures for decreasing the amount of IRS-1 in 3T3-L1 adipocytes (viz., chronic treatments with insulin, dexamethasone, 1-methyl-3-isobutylxanthine, cycloheximide or actinomycin D) and have determined the correlation between the amounts of IRS-1, insulin receptor, GluT4 and phosphatidylinositol 3"-kinase regulatory subunit with insulin-responsive dGlc transport.	Cycloheximide	167-180	insulin receptor substrate 1	Homo sapiens	56-61
7507317-3	1994	The synthesis was abolished by the stereoselective inhibitors of NO synthase (NOS), NG-monomethyl-L-arginine, N omega-nitro-L-arginine and N omega-nitro-L-arginine methyl ester and by cycloheximide.	Cycloheximide	184-197	nitric oxide synthase 2	Homo sapiens	65-76
8141314-8	1994	The protein synthesis inhibitor cycloheximide abolished the effect of TGF-beta 1 on both cAMP accumulation and on beta-adrenergic receptor number, indicating that protein synthesis is involved.	Cycloheximide	32-45	transforming growth factor beta 1	Homo sapiens	70-80
8283055-5	1994	Prior treatment of the cells with the protein synthesis inhibitor cycloheximide abolished this effect of GM-CSF.	Cycloheximide	66-79	colony stimulating factor 2	Homo sapiens	105-111
8073837-7	1994	IL-8 and huGRO mRNAs were constitutively produced in KC, as was demonstrated after incubation with cycloheximide.	Cycloheximide	99-112	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
8304461-5	1994	Studies using the protein synthesis inhibitor cycloheximide suggest that c-fos and c-jun are part of the "immediate-early" response of the small intestine.	Cycloheximide	46-59	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	73-78
8085941-4	1994	In the presence of cycloheximide, the effect of TGF-beta 1 on CYPIA1 mRNA disappeared.	Cycloheximide	19-32	transforming growth factor beta 1	Homo sapiens	48-58
8085941-4	1994	In the presence of cycloheximide, the effect of TGF-beta 1 on CYPIA1 mRNA disappeared.	Cycloheximide	19-32	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	62-68
7735115-6	1994	During metaphase I, the reactivation of MPF activity can be disrupted in two different ways: 1) cycloheximide, an inhibitor of protein synthesis, by preventing the synthesis of new cyclins, provokes the disappearance of MPF kinase activity and the reformation of a nucleus; 2) when the cAMP level is increased during the metaphase I period in cdc25-injected oocytes, MPF kinase activity drops following a rephosphorylation of tyrosine 15 of p34cdc2, while the cyclin turn-over remains unaffected.	Cycloheximide	96-109	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	40-43
7735115-6	1994	During metaphase I, the reactivation of MPF activity can be disrupted in two different ways: 1) cycloheximide, an inhibitor of protein synthesis, by preventing the synthesis of new cyclins, provokes the disappearance of MPF kinase activity and the reformation of a nucleus; 2) when the cAMP level is increased during the metaphase I period in cdc25-injected oocytes, MPF kinase activity drops following a rephosphorylation of tyrosine 15 of p34cdc2, while the cyclin turn-over remains unaffected.	Cycloheximide	96-109	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	220-223
7735115-6	1994	During metaphase I, the reactivation of MPF activity can be disrupted in two different ways: 1) cycloheximide, an inhibitor of protein synthesis, by preventing the synthesis of new cyclins, provokes the disappearance of MPF kinase activity and the reformation of a nucleus; 2) when the cAMP level is increased during the metaphase I period in cdc25-injected oocytes, MPF kinase activity drops following a rephosphorylation of tyrosine 15 of p34cdc2, while the cyclin turn-over remains unaffected.	Cycloheximide	96-109	cell division cycle 25C L homeolog	Xenopus laevis	343-348
7735115-6	1994	During metaphase I, the reactivation of MPF activity can be disrupted in two different ways: 1) cycloheximide, an inhibitor of protein synthesis, by preventing the synthesis of new cyclins, provokes the disappearance of MPF kinase activity and the reformation of a nucleus; 2) when the cAMP level is increased during the metaphase I period in cdc25-injected oocytes, MPF kinase activity drops following a rephosphorylation of tyrosine 15 of p34cdc2, while the cyclin turn-over remains unaffected.	Cycloheximide	96-109	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	220-223
7735115-6	1994	During metaphase I, the reactivation of MPF activity can be disrupted in two different ways: 1) cycloheximide, an inhibitor of protein synthesis, by preventing the synthesis of new cyclins, provokes the disappearance of MPF kinase activity and the reformation of a nucleus; 2) when the cAMP level is increased during the metaphase I period in cdc25-injected oocytes, MPF kinase activity drops following a rephosphorylation of tyrosine 15 of p34cdc2, while the cyclin turn-over remains unaffected.	Cycloheximide	96-109	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	441-448
8274731-3	1994	We further show that G-CSFR message is superinduced by cycloheximide and that these patterns of regulation are altered in leukemic cell lines.	Cycloheximide	55-68	colony stimulating factor 3 receptor (granulocyte)	Mus musculus	21-27
8287602-7	1994	Cycloheximide was able to inhibit C3 and factor H production, suggesting de novo synthesis of the proteins.	Cycloheximide	0-13	complement factor H	Homo sapiens	41-49
7765241-6	1994	However, cycloheximide blocked the production of IL-10 from the Ts clone.	Cycloheximide	9-22	interleukin 10	Homo sapiens	49-54
8138050-14	1994	Prior treatment with cycloheximide abolished 60-70% of the increase in GPAT activity caused by cold-exposure.	Cycloheximide	21-34	glycerol-3-phosphate acyltransferase, mitochondrial	Rattus norvegicus	71-75
7664533-8	1994	Furthermore, the islet glucokinase mRNA level increased in response to 1 microM glibenclamide with 5.5 mM glucose and the response was abolished by cycloheximide, which indicates the involvement of protein synthesis in the glibenclamide-induced mRNA change.	Cycloheximide	148-161	glucokinase	Rattus norvegicus	23-34
8269997-7	1994	The protein synthesis inhibitor, cycloheximide, induced the expression of 5.6-kb RXR alpha mRNA and further enhanced the inductive effect of t-RA.	Cycloheximide	33-46	retinoid X receptor alpha	Homo sapiens	81-90
8269997-8	1994	In contrast, cycloheximide prevented the t-RA-regulated expression of both 3.8- and 2.3-kb RXR gamma mRNA, suggesting that ongoing protein synthesis was required for the regulation of RXR gamma gene.	Cycloheximide	13-26	retinoid X receptor alpha	Homo sapiens	91-94
8269997-8	1994	In contrast, cycloheximide prevented the t-RA-regulated expression of both 3.8- and 2.3-kb RXR gamma mRNA, suggesting that ongoing protein synthesis was required for the regulation of RXR gamma gene.	Cycloheximide	13-26	retinoid X receptor alpha	Homo sapiens	184-187
7506700-4	1994	Cycloheximide, which abolished the cytokine-induced increase in nitrite production, had no effect on the interferon-gamma-induced increase in mRNA levels but partially inhibited that induced by interleukin-1 beta and markedly inhibited that induced by tumor necrosis factor-alpha.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	194-212
7506700-4	1994	Cycloheximide, which abolished the cytokine-induced increase in nitrite production, had no effect on the interferon-gamma-induced increase in mRNA levels but partially inhibited that induced by interleukin-1 beta and markedly inhibited that induced by tumor necrosis factor-alpha.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	252-279
7509221-1	1994	Effects of cycloheximide, an inhibitor of protein synthesis, on histamine release from RBL-2H3 cells were examined.	Cycloheximide	11-24	RB transcriptional corepressor like 2	Rattus norvegicus	87-92
8262617-6	1994	The expression of IL-8 mRNA from LTA- but not lipopolysaccharide (LPS)-treated PBM was superinduced by concomitant treatment with cycloheximide, indicating that the expression of IL-8 mRNA from LTA-treated PBM was negatively controlled by repressor proteins.	Cycloheximide	130-143	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
8262617-6	1994	The expression of IL-8 mRNA from LTA- but not lipopolysaccharide (LPS)-treated PBM was superinduced by concomitant treatment with cycloheximide, indicating that the expression of IL-8 mRNA from LTA-treated PBM was negatively controlled by repressor proteins.	Cycloheximide	130-143	C-X-C motif chemokine ligand 8	Homo sapiens	179-183
8254194-10	1994	IL-8 and MCP-1 gene expression by monocytes appeared to require de novo protein synthesis, in that cycloheximide blocked the expression of mRNA for both IL-8 and MCP-1 in PHA-stimulated cells.	Cycloheximide	99-112	chemokine (C-X-C motif) ligand 15	Mus musculus	0-4
8288917-8	1994	Dexamethasone (10 nM), and the protein synthesis inhibitors actinomycin D (1 microM) and cycloheximide (3 micrograms/ml) completely abolished the effect of interleukin-1 on 15-HETE formation.	Cycloheximide	89-102	interleukin 1 alpha	Homo sapiens	156-169
7714548-8	1994	Cycloheximide-inhibitable DNA fragmentation was also found in the KEG-1 implanted in vivo rat model following the administration of ACNU.	Cycloheximide	0-13	glycine-N-acyltransferase-like 2	Rattus norvegicus	66-71
8133303-3	1994	Low doses of cycloheximide beginning 10 min after ischemia (1.0 microgram/g body weight in saline followed by 1.0 microgram/g every 24 h) reduced the number of dying cells in the CA1 area, whereas high doses (2.0 micrograms/g, followed by 1.0 microgram/g every 12 h) increased the number of dying cells.	Cycloheximide	13-26	carbonic anhydrase 1	Homo sapiens	179-182
8136297-6	1994	Treatment of cells with cycloheximide completely abolished the observed androgen effect suggesting that the induction of the MVDP gene by androgens depends on continuous protein synthesis.	Cycloheximide	24-37	aldo-keto reductase family 1, member B7	Mus musculus	125-129
8158578-4	1994	The induction of beta 2AR mRNA temporally preceded the increase in receptor binding activity, reaching a maximum after 4 to 6 h of treatment, and remaining elevated for up to 24 h. Prior exposure of the cells to the protein synthesis inhibitor cycloheximide prevented the butyrate-induced increase in receptor binding but had no effect on the increase in receptor mRNA.	Cycloheximide	244-257	adrenoceptor beta 2	Homo sapiens	17-25
9419743-5	1994	RESULTS: The concentration-related stimulation of decidual PGE2 production by IL-1 beta and TNF alpha was completely abrogated by cycloheximide and actinomycin D treatment.	Cycloheximide	130-143	interleukin 1 beta	Homo sapiens	78-87
9419743-5	1994	RESULTS: The concentration-related stimulation of decidual PGE2 production by IL-1 beta and TNF alpha was completely abrogated by cycloheximide and actinomycin D treatment.	Cycloheximide	130-143	tumor necrosis factor	Homo sapiens	92-101
7934617-6	1994	Actually, addition of cycloheximide caused a severe loss of activity of cathepsin B and of sphingomyelinase.	Cycloheximide	22-35	cathepsin B	Mus musculus	72-83
18472956-7	1994	Pretreatment of SMC with NDGA, cycloheximide, and actinomycin not only inhibited IL-1 and TNT induced HETEs synthesis but also abolished LTB(4) production when co-incubated with macrophages.	Cycloheximide	31-44	chromosome 16 open reading frame 82	Homo sapiens	90-93
8167370-7	1994	Chitinase mRNA abundance increased slightly following cycloheximide application; however, its potent induction by salicylic acid was inhibited by cycloheximide treatment.	Cycloheximide	54-67	acidic endochitinase	Cucumis sativus	0-9
8167370-7	1994	Chitinase mRNA abundance increased slightly following cycloheximide application; however, its potent induction by salicylic acid was inhibited by cycloheximide treatment.	Cycloheximide	146-159	acidic endochitinase	Cucumis sativus	0-9
7970084-7	1994	Cycloheximide inhibited IL-6 production without irreversible cell toxicity, indicating de-novo synthesis.	Cycloheximide	0-13	interleukin 6	Homo sapiens	24-28
8142954-2	1994	We found that protein synthesis inhibition by cycloheximide (CHX) blocked IFN alpha-mRNA expression, except when PBMC were preincubated with a conditioned medium as a potential source of cytokines.	Cycloheximide	46-59	interferon alpha 1	Homo sapiens	74-83
8142954-2	1994	We found that protein synthesis inhibition by cycloheximide (CHX) blocked IFN alpha-mRNA expression, except when PBMC were preincubated with a conditioned medium as a potential source of cytokines.	Cycloheximide	61-64	interferon alpha 1	Homo sapiens	74-83
8262257-4	1993	The results obtained indicate that the exposure of U937 cells to cycloheximide facilitates TNF-mediated PCD via a short term cell death program and modifies the expression of CD4 surface molecules.	Cycloheximide	65-78	tumor necrosis factor	Homo sapiens	91-94
8262257-4	1993	The results obtained indicate that the exposure of U937 cells to cycloheximide facilitates TNF-mediated PCD via a short term cell death program and modifies the expression of CD4 surface molecules.	Cycloheximide	65-78	CD4 molecule	Homo sapiens	175-178
8280160-8	1993	Cycloheximide and Actinomycin D treatment decreased the surface expression of IL-4R by 50% in about 2 h and 7 h, respectively, in both TNF treated and untreated cells indicating the half life for the IL-4R protein expression.	Cycloheximide	0-13	interleukin 4 receptor, alpha	Mus musculus	78-83
8280160-8	1993	Cycloheximide and Actinomycin D treatment decreased the surface expression of IL-4R by 50% in about 2 h and 7 h, respectively, in both TNF treated and untreated cells indicating the half life for the IL-4R protein expression.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	135-138
8280160-8	1993	Cycloheximide and Actinomycin D treatment decreased the surface expression of IL-4R by 50% in about 2 h and 7 h, respectively, in both TNF treated and untreated cells indicating the half life for the IL-4R protein expression.	Cycloheximide	0-13	interleukin 4 receptor, alpha	Mus musculus	200-205
7903099-9	1993	An unstable negative regulatory protein may control TCR-beta expression in this cell clone because fully spliced TCR-beta transcripts are dramatically induced in the cytoplasm after treatment with any of five different protein synthesis inhibitors (cycloheximide, anisomyosin, emetine, puromycin, and pactamycin), all of which act by distinct mechanisms to inhibit protein synthesis.	Cycloheximide	249-262	T cell receptor beta chain	Mus musculus	113-121
8254194-10	1994	IL-8 and MCP-1 gene expression by monocytes appeared to require de novo protein synthesis, in that cycloheximide blocked the expression of mRNA for both IL-8 and MCP-1 in PHA-stimulated cells.	Cycloheximide	99-112	chemokine (C-C motif) ligand 2	Mus musculus	9-14
8254194-10	1994	IL-8 and MCP-1 gene expression by monocytes appeared to require de novo protein synthesis, in that cycloheximide blocked the expression of mRNA for both IL-8 and MCP-1 in PHA-stimulated cells.	Cycloheximide	99-112	chemokine (C-X-C motif) ligand 15	Mus musculus	153-157
8254194-10	1994	IL-8 and MCP-1 gene expression by monocytes appeared to require de novo protein synthesis, in that cycloheximide blocked the expression of mRNA for both IL-8 and MCP-1 in PHA-stimulated cells.	Cycloheximide	99-112	chemokine (C-C motif) ligand 2	Mus musculus	162-167
8254194-11	1994	However, treatment of monocytes with cycloheximide resulted in the superinduction of IL-8 compared with control monocytes.	Cycloheximide	37-50	C-X-C motif chemokine ligand 8	Homo sapiens	85-89
7902828-7	1993	However, treatment with cycloheximide, after stimulation with IFN-gamma, resulted in increased levels of membrane associated ICAM-1.	Cycloheximide	24-37	interferon gamma	Homo sapiens	62-71
7902828-7	1993	However, treatment with cycloheximide, after stimulation with IFN-gamma, resulted in increased levels of membrane associated ICAM-1.	Cycloheximide	24-37	intercellular adhesion molecule 1	Homo sapiens	125-131
7902828-8	1993	Correspondingly, the level of sICAM-1 in the supernatant was low in comparison with controls, suggesting that cycloheximide acted via stabilization of membrane ICAM-1 or via prevention of some enzymatic cleavage event.	Cycloheximide	110-123	intercellular adhesion molecule 1	Homo sapiens	31-37
8245000-2	1993	Serum induction of PGHS-2 mRNA levels was rapid, transient, increased by cycloheximide, and inhibited 72% by cortisol.	Cycloheximide	73-86	prostaglandin-endoperoxide synthase 2	Mus musculus	19-25
7503983-5	1993	The increase in PLP RNA level showed a slow kinetics and was blocked by cycloheximide, suggesting a posttranscriptional regulation by RA.	Cycloheximide	72-85	proteolipid protein 1	Homo sapiens	16-19
8245000-4	1993	Serum stimulation of PGHS-1 mRNA was slower, decreased by cycloheximide, and inhibited 28% by cortisol.	Cycloheximide	58-71	prostaglandin-endoperoxide synthase 1	Mus musculus	21-27
7508326-6	1993	Treatment of cells with cycloheximide (1 microgram ml-1) inhibited the time-dependent (1-8 h) induction of NO synthase and arginine transport mediated by LPS.	Cycloheximide	24-37	toll-like receptor 4	Mus musculus	154-157
7902207-4	1993	The augmented effects of TGF-alpha was abolished by cycloheximide.	Cycloheximide	52-65	transforming growth factor alpha	Homo sapiens	25-34
8131794-1	1993	In an attempt to understand more directly the molecular mechanisms involved in the cellular response of endothelial cells to Interleukin-1 (IL-1), we have made several cDNA libraries from human umbilical vein endothelial cells (HUVEC) stimulated for 1 h with IL-1 in the presence of cycloheximide.	Cycloheximide	283-296	interleukin 1 alpha	Homo sapiens	140-144
8243279-6	1993	The regulation of LPS-stimulated TNF alpha mRNA expression in vitro was also investigated by employing the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	135-148	tumor necrosis factor	Mus musculus	33-42
8243279-6	1993	The regulation of LPS-stimulated TNF alpha mRNA expression in vitro was also investigated by employing the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	150-153	tumor necrosis factor	Mus musculus	33-42
8253274-7	1993	The early, growth factor-dependent expression does occur in the presence of the protein synthesis inhibitor cycloheximide, suggesting that XFKH2 expression during gastrula stage may be an immediate early response to mesoderm induction.	Cycloheximide	108-121	forkhead box A1 L homeolog	Xenopus laevis	139-144
8269960-5	1993	They are hypersensitive to the protein synthesis inhibitors, cycloheximide and G418, implicating PPQ1 in the regulation of translation.	Cycloheximide	61-74	protein-serine/threonine phosphatase	Saccharomyces cerevisiae S288C	97-101
8262139-10	1993	Addition of serum, phorbol ester, or cycloheximide to both C6 cells and fibroblasts induces the level bFGF mRNA transcripts 10-fold after 1-4 h. This rapid induction after cell activation indicates that bFGF is an early response gene.	Cycloheximide	37-50	fibroblast growth factor 2	Rattus norvegicus	102-106
8262139-10	1993	Addition of serum, phorbol ester, or cycloheximide to both C6 cells and fibroblasts induces the level bFGF mRNA transcripts 10-fold after 1-4 h. This rapid induction after cell activation indicates that bFGF is an early response gene.	Cycloheximide	37-50	fibroblast growth factor 2	Rattus norvegicus	203-207
7510923-10	1993	In addition, the finding that the immunofluorescence of vimentin was more homogeneous in quiescent, serum-deprived astrocytes and also in astrocytes exposed to an inhibitor of protein synthesis, cycloheximide, may suggest that phosphorylation of the epitope B3 depends on a protein factor present in fetal calf serum.	Cycloheximide	195-208	vimentin	Rattus norvegicus	56-64
8253877-8	1993	Cycloheximide (3.6 mumol/l) diminished IGF-I-stimulated AIB uptake by 55%.	Cycloheximide	0-13	insulin like growth factor 1	Gallus gallus	39-44
8151134-3	1993	When cycloheximide was added at the viral induction time, the inhibition of TNF-alpha superproduction and DNA synthesis was still observed.	Cycloheximide	5-18	tumor necrosis factor	Homo sapiens	76-85
7511786-8	1993	Similarly, 3-6 h were required for stimulation of IGF-I gene transcription by insulin, but a 40% decrease in IGFBP-1 gene transcription could be detected within 15 min after adding 10(-6) M insulin, and suppression of IGFBP-1 transcription by insulin was unaffected by the presence of cycloheximide.	Cycloheximide	285-298	insulin-like growth factor binding protein 1	Rattus norvegicus	109-116
8264546-0	1993	Cycloheximide induces the alpha 1B adrenergic receptor gene by activation of transcription in DDT1 MF-2 smooth muscle cells.	Cycloheximide	0-13	alpha-1B adrenergic receptor	Mesocricetus auratus	26-54
8241261-6	1993	An inhibitor of protein synthesis, cycloheximide, increased the level of PTP-S transcripts by 6-fold in control lymphocytes but did not increase the level of PTP-1 transcripts.	Cycloheximide	35-48	6-pyruvoyl-tetrahydropterin synthase	Rattus norvegicus	73-78
8241261-7	1993	Treatment with cycloheximide increased the half-life of PTP-S transcripts in resting lymphocytes.	Cycloheximide	15-28	6-pyruvoyl-tetrahydropterin synthase	Rattus norvegicus	56-61
8228214-5	1993	This additional, calcium-dependent effect, on both CD4 and CD8 expression, is abrogated by either cycloheximide or actinomycin D, and so depends on new RNA and protein synthesis.	Cycloheximide	98-111	CD4 antigen	Mus musculus	51-54
8228214-5	1993	This additional, calcium-dependent effect, on both CD4 and CD8 expression, is abrogated by either cycloheximide or actinomycin D, and so depends on new RNA and protein synthesis.	Cycloheximide	98-111	CD8a molecule	Homo sapiens	59-62
8228247-7	1993	Ongoing protein synthesis was not required for IL-1 beta secretion because mature IL-1 beta release occurred in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	160-173	interleukin 1 beta	Homo sapiens	82-91
8250866-4	1993	The DNase I protection pattern by nuclear extract of the cycloheximide-treated regenerating liver showed the same results with normal liver.	Cycloheximide	57-70	deoxyribonuclease 1	Rattus norvegicus	4-11
8226882-1	1993	Incubation with 1 nM triiodothyronine (T3) decreased cycloheximide-induced c-fos mRNA levels and the mRNA response to the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA; 100 nM) or to forskolin (15 microM).	Cycloheximide	53-66	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
8411260-12	1993	MMP-2 activation was inhibited by cycloheximide and was sensitive to a metalloproteinase inhibitor but not to aspartyl, serine, or cysteinyl protease inhibitors.	Cycloheximide	34-47	matrix metallopeptidase 2	Homo sapiens	0-5
7511786-8	1993	Similarly, 3-6 h were required for stimulation of IGF-I gene transcription by insulin, but a 40% decrease in IGFBP-1 gene transcription could be detected within 15 min after adding 10(-6) M insulin, and suppression of IGFBP-1 transcription by insulin was unaffected by the presence of cycloheximide.	Cycloheximide	285-298	insulin-like growth factor binding protein 1	Rattus norvegicus	218-225
7902093-7	1993	The increased expression of ICAM-1 was inhibited by cycloheximide and actinomycin D.	Cycloheximide	52-65	intercellular adhesion molecule 1	Homo sapiens	28-34
8240289-6	1993	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in serum-starved mesangial cells, and the combination of EGF and cycloheximide resulted in super-induction of cPLA2 gene expression compared with EGF alone.	Cycloheximide	35-48	phospholipase A2 group IVA	Rattus norvegicus	65-70
8240289-6	1993	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in serum-starved mesangial cells, and the combination of EGF and cycloheximide resulted in super-induction of cPLA2 gene expression compared with EGF alone.	Cycloheximide	154-167	phospholipase A2 group IVA	Rattus norvegicus	199-204
8240289-6	1993	Inhibition of protein synthesis by cycloheximide increased basal cPLA2 mRNA accumulation in serum-starved mesangial cells, and the combination of EGF and cycloheximide resulted in super-induction of cPLA2 gene expression compared with EGF alone.	Cycloheximide	154-167	epidermal growth factor like 1	Rattus norvegicus	235-238
8186366-10	1993	Finally, the enhancing effect of the protein synthesis inhibitor cycloheximide on the various features of TNF-induced cytotoxicity was determined.	Cycloheximide	65-78	tumor necrosis factor	Mus musculus	106-109
8216855-3	1993	The effect of cAMP on P450scc expression was abolished by cycloheximide in JEG-3 cells, but it was superinduced in mouse adrenal Y1 cells.	Cycloheximide	58-71	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	22-29
8224206-3	1993	This effect of IL-1 beta on the cPLA2 activity is inhibited by actinomycin D and cycloheximide, indicating that both transcription and translation are involved.	Cycloheximide	81-94	interleukin 1 beta	Rattus norvegicus	15-24
8224206-3	1993	This effect of IL-1 beta on the cPLA2 activity is inhibited by actinomycin D and cycloheximide, indicating that both transcription and translation are involved.	Cycloheximide	81-94	phospholipase A2 group IVA	Rattus norvegicus	32-37
8294225-2	1993	The inhibitory effect of DHT or R1881 on Leydig cell 3 beta-HSD enzyme activity, however, was abolished when adult cells were cultured in the presence of the anti-androgen cyproterone acetate (CPA; 10(-6) M) or the protein synthesis inhibitor cycloheximide (CX; 1 microgram/ml).	Cycloheximide	243-256	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	53-63
8294225-2	1993	The inhibitory effect of DHT or R1881 on Leydig cell 3 beta-HSD enzyme activity, however, was abolished when adult cells were cultured in the presence of the anti-androgen cyproterone acetate (CPA; 10(-6) M) or the protein synthesis inhibitor cycloheximide (CX; 1 microgram/ml).	Cycloheximide	258-260	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	53-63
7901332-7	1993	Treatment with NGF and cycloheximide, or actinomycin D, which inhibit protein and RNA synthesis, respectively, blocked the NGF stimulation of GCS and glucose 6-phosphate dehydrogenase.	Cycloheximide	23-36	nerve growth factor	Rattus norvegicus	123-126
7901332-7	1993	Treatment with NGF and cycloheximide, or actinomycin D, which inhibit protein and RNA synthesis, respectively, blocked the NGF stimulation of GCS and glucose 6-phosphate dehydrogenase.	Cycloheximide	23-36	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	142-145
7901332-7	1993	Treatment with NGF and cycloheximide, or actinomycin D, which inhibit protein and RNA synthesis, respectively, blocked the NGF stimulation of GCS and glucose 6-phosphate dehydrogenase.	Cycloheximide	23-36	glucose-6-phosphate dehydrogenase	Rattus norvegicus	150-183
8228330-13	1993	Cycloheximide treatment blocked this IL-8 protein induction.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
8231238-0	1993	p145 expression during the cell cycle in HL-60 cell line and normal human lymphocytes: effects of camptothecin, vinblastine, cycloheximide, actinomycin D, retinoic acid and DMSO.	Cycloheximide	125-138	POM121 transmembrane nucleoporin	Homo sapiens	0-4
8231238-8	1993	Cycloheximide and actinomycin D had similar effects on p145 in HL-60 cells: expression of p145 gradually decreased from 1 to 6 h incubation in all phases of the cell cycle.	Cycloheximide	0-13	POM121 transmembrane nucleoporin	Homo sapiens	55-59
8231238-8	1993	Cycloheximide and actinomycin D had similar effects on p145 in HL-60 cells: expression of p145 gradually decreased from 1 to 6 h incubation in all phases of the cell cycle.	Cycloheximide	0-13	POM121 transmembrane nucleoporin	Homo sapiens	90-94
7692234-6	1993	The macromolecular synthesis inhibitors actinomycin D and cycloheximide triggered rapid cell death of FDC-P1 cells in the presence of interleukin-3, but the cells could be protected by Bcl-2.	Cycloheximide	58-71	interleukin 3	Mus musculus	134-147
7935356-8	1993	Phosphorylation of eIF-2 alpha in response to A23187 or DTT was not prevented by conventional inhibitors of translation including cycloheximide, pactamycin, puromycin, or verrucarin.	Cycloheximide	130-143	eukaryotic translation initiation factor 2A	Rattus norvegicus	19-30
8115044-7	1993	Following superinduction of c-fos gene by osmotic stimulation plus cycloheximide treatment, a conspicuous Fos-like immunoreactivity was detected in dispersed chromatin regions, whereas the heterochromatin masses, nucleoli and coiled bodies showed no immunoreaction.	Cycloheximide	67-80	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
8115044-7	1993	Following superinduction of c-fos gene by osmotic stimulation plus cycloheximide treatment, a conspicuous Fos-like immunoreactivity was detected in dispersed chromatin regions, whereas the heterochromatin masses, nucleoli and coiled bodies showed no immunoreaction.	Cycloheximide	67-80	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-109
8115044-9	1993	Since Fos proteins are known to be short-lived, the expression of these nuclear constituents, under conditions of protein synthesis inhibition induced by the cycloheximide, suggests the stabilization of chromatin-bound Fos complexes or, alternatively, a preferential synthesis of Fos proteins.	Cycloheximide	158-171	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	219-222
8115044-9	1993	Since Fos proteins are known to be short-lived, the expression of these nuclear constituents, under conditions of protein synthesis inhibition induced by the cycloheximide, suggests the stabilization of chromatin-bound Fos complexes or, alternatively, a preferential synthesis of Fos proteins.	Cycloheximide	158-171	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	219-222
8414506-4	1993	DNA damage (initiated by radiation) induced a rapid, cycloheximide-sensitive increase in the levels of nuclear p53-DNA binding activity and an increase in the half-life of the p53 protein.	Cycloheximide	53-66	transformation related protein 53, pseudogene	Mus musculus	111-114
8414506-4	1993	DNA damage (initiated by radiation) induced a rapid, cycloheximide-sensitive increase in the levels of nuclear p53-DNA binding activity and an increase in the half-life of the p53 protein.	Cycloheximide	53-66	transformation related protein 53, pseudogene	Mus musculus	176-179
8153084-3	1993	IL-1 beta stimulation occurred in the presence of added arachidonic acid but was abrogated by treatment with cycloheximide and actinomycin D.	Cycloheximide	109-122	interleukin 1 beta	Homo sapiens	0-9
8408001-3	1993	Induction of HIF-1 is inhibited by cycloheximide, which also inhibits induction of erythropoietin RNA.	Cycloheximide	35-48	hypoxia inducible factor 1 subunit alpha	Homo sapiens	13-18
8408001-3	1993	Induction of HIF-1 is inhibited by cycloheximide, which also inhibits induction of erythropoietin RNA.	Cycloheximide	35-48	erythropoietin	Homo sapiens	83-97
8407955-2	1993	In this study, differential hybridization was used to screen a cDNA library constructed from human mammary carcinoma MDA-468 cells that were stimulated with transforming growth factor beta-1 (TGF-beta 1) in the presence of cycloheximide.	Cycloheximide	223-236	transforming growth factor beta 1	Homo sapiens	157-190
8407955-2	1993	In this study, differential hybridization was used to screen a cDNA library constructed from human mammary carcinoma MDA-468 cells that were stimulated with transforming growth factor beta-1 (TGF-beta 1) in the presence of cycloheximide.	Cycloheximide	223-236	transforming growth factor beta 1	Homo sapiens	192-202
8215400-13	1993	Cycloheximide blocked PGHS-2 mRNA decrease.	Cycloheximide	0-13	prostaglandin-endoperoxide synthase 2	Mus musculus	22-28
8221965-11	1993	On the other hand, pretreatment with cycloheximide in an artificial model of OTC deficiency (Swiss-ICR normal mice on an arginine-deficient diet treated thereafter with norvaline, an inhibitor of OTC), caused a significant decrease in urinary orotate.	Cycloheximide	37-50	ornithine transcarbamylase	Mus musculus	77-80
8375478-8	1993	Coadministration of cycloheximide blocked the TNF-alpha-induced degradation of beta-actin mRNA.	Cycloheximide	20-33	tumor necrosis factor	Homo sapiens	46-55
8375478-8	1993	Coadministration of cycloheximide blocked the TNF-alpha-induced degradation of beta-actin mRNA.	Cycloheximide	20-33	POTE ankyrin domain family member F	Homo sapiens	79-89
8405069-7	1993	This inhibitory effect of IL-10 was already apparent at the TF mRNA level and was prevented by co-incubation with cycloheximide (20 micrograms/ml).	Cycloheximide	114-127	interleukin 10	Homo sapiens	26-31
8405069-7	1993	This inhibitory effect of IL-10 was already apparent at the TF mRNA level and was prevented by co-incubation with cycloheximide (20 micrograms/ml).	Cycloheximide	114-127	coagulation factor III, tissue factor	Homo sapiens	60-62
8262555-9	1993	Cycloheximide (10(-6) M) significantly inhibited GM-CSF-induced CD69 expression, suggesting a requirement for protein synthesis.	Cycloheximide	0-13	colony stimulating factor 2	Homo sapiens	49-55
8218108-3	1993	Increased binding was evident within 10 minutes of treatment of cycloheximide-treated cells with LPA and was due to an increase in the number of fibronectin binding sites.	Cycloheximide	64-77	fibronectin 1	Homo sapiens	145-156
8218112-7	1993	Cycloheximide inhibited the induction of TF protein activity, but it enhanced the accumulation of TF mRNA in MM-LDL- and LPS-induced endothelial cells.	Cycloheximide	0-13	coagulation factor III, tissue factor	Homo sapiens	41-43
8218112-7	1993	Cycloheximide inhibited the induction of TF protein activity, but it enhanced the accumulation of TF mRNA in MM-LDL- and LPS-induced endothelial cells.	Cycloheximide	0-13	coagulation factor III, tissue factor	Homo sapiens	98-100
8406799-6	1993	When protein synthesis of MP-stimulated PBMC was inhibited by cycloheximide, a superinduction of mRNAs for IL-4 and IL-10 and, more markedly, gamma interferon was observed.	Cycloheximide	62-75	interleukin 4	Homo sapiens	107-111
8406799-6	1993	When protein synthesis of MP-stimulated PBMC was inhibited by cycloheximide, a superinduction of mRNAs for IL-4 and IL-10 and, more markedly, gamma interferon was observed.	Cycloheximide	62-75	interleukin 10	Homo sapiens	116-121
8227185-8	1993	Cycloheximide treatment inhibited 1,25 (OH)2 D3-induced IL-4R upregulation, suggesting that protein synthesis was required.	Cycloheximide	0-13	interleukin 4 receptor, alpha	Mus musculus	56-61
8262555-9	1993	Cycloheximide (10(-6) M) significantly inhibited GM-CSF-induced CD69 expression, suggesting a requirement for protein synthesis.	Cycloheximide	0-13	CD69 molecule	Homo sapiens	64-68
8104219-6	1993	The anti-Kp43-mediated effect, which required the preactivation of cells with IL-2, was inhibited by cycloheximide and actinomycin D and was associated with an increase in the levels of TNF-alpha-specific mRNA.	Cycloheximide	101-114	killer cell lectin like receptor D1	Homo sapiens	9-13
8104219-6	1993	The anti-Kp43-mediated effect, which required the preactivation of cells with IL-2, was inhibited by cycloheximide and actinomycin D and was associated with an increase in the levels of TNF-alpha-specific mRNA.	Cycloheximide	101-114	interleukin 2	Homo sapiens	78-82
8292488-0	1993	Cycloheximide prevents kainate-induced neuronal death and c-fos expression in adult rat brain.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	58-63
8292488-5	1993	Pretreatment with cycloheximide did not affect the transient induction of c-fos observed in numerous structures, but significantly reduced the prolonged expression of c-fos mRNA in kainate-vulnerable regions.	Cycloheximide	18-31	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	167-172
8292488-9	1993	These results not only demonstrate that kainate-induced neurotoxicity and the prolonged expression of c-fos are both prevented by cycloheximide, but also strengthen idea that prolonged c-fos expression is a marker of neuronal death.	Cycloheximide	130-143	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	102-107
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	goosecoid homeobox S homeolog	Xenopus laevis	52-61
8408243-6	1993	In fetal hepatocytes, but not postnatal day 2 hepatocytes, cycloheximide appeared to stabilize beta 2-adrenergic receptor gene transcripts in the presence of actinomycin D.	Cycloheximide	59-72	adrenoceptor beta 2	Rattus norvegicus	95-121
8231107-12	1993	In the presence of cycloheximide, TGF-beta 1 induction of alpha 1(IV) mRNA was markedly attenuated in both cell lines, suggesting that this effect of TGF-beta 1 requires protein synthesis.	Cycloheximide	19-32	transforming growth factor, beta 1	Rattus norvegicus	34-44
8231107-12	1993	In the presence of cycloheximide, TGF-beta 1 induction of alpha 1(IV) mRNA was markedly attenuated in both cell lines, suggesting that this effect of TGF-beta 1 requires protein synthesis.	Cycloheximide	19-32	transforming growth factor, beta 1	Rattus norvegicus	150-160
7506818-7	1993	Both the dexamethasone-induced "externalization" of LC1 by the pituitary tissue and the concomitant steroid-induced inhibition of peptide release were blocked by cycloheximide (1.0 microgram/ml) but not by actinomycin D (0.5 microgram/ml).	Cycloheximide	162-175	annexin A1	Rattus norvegicus	52-55
8264660-11	1993	Cycloheximide also potentiated PMA"s effect on BNP mRNA after 1.5, 9.5, and 24 h of treatment.	Cycloheximide	0-13	natriuretic peptide B	Rattus norvegicus	47-50
8276131-3	1993	Time-course studies showed that the decreases in nuclear ER and ER-ERE binding in TCDD-treated cells were observed within 1 to 3 h after treatment, respectively, and persisted for up to 24 h. Cycloheximide (10 microM) did not affect the TCDD-mediated response, whereas 1 microM alpha-naphthoflavone, an aryl hydrocarbon (Ah) receptor antagonist, partially blocked downregulation of nuclear ER binding by TCDD.	Cycloheximide	192-205	estrogen receptor 1	Homo sapiens	57-59
8415680-5	1993	The BMP-2 effect was not blocked by actinomycin D, while it was blocked by cycloheximide, suggesting that BMP-2 regulates Id gene expression at least in part via posttranscriptional events, which require protein synthesis.	Cycloheximide	75-88	bone morphogenetic protein 2	Rattus norvegicus	106-111
8257866-11	1993	The protein synthesis inhibitor, cycloheximide, superinduced prepro-ET-1 mRNA within 4 h, but NaI did not.	Cycloheximide	33-46	endothelin 1	Homo sapiens	68-72
8379943-4	1993	This increase in TfR mRNA was blocked by Tf-Fe and by cycloheximide.	Cycloheximide	54-67	transferrin receptor	Homo sapiens	17-20
8379943-4	1993	This increase in TfR mRNA was blocked by Tf-Fe and by cycloheximide.	Cycloheximide	54-67	transferrin	Homo sapiens	17-19
8134905-5	1993	The t-PA mRNA expression induced by thrombin was completely blocked by pretreatment of the cells with an inhibitor of translation, cycloheximide (CHX).	Cycloheximide	131-144	plasminogen activator, tissue type	Homo sapiens	4-8
8134905-5	1993	The t-PA mRNA expression induced by thrombin was completely blocked by pretreatment of the cells with an inhibitor of translation, cycloheximide (CHX).	Cycloheximide	131-144	coagulation factor II, thrombin	Homo sapiens	36-44
8134905-5	1993	The t-PA mRNA expression induced by thrombin was completely blocked by pretreatment of the cells with an inhibitor of translation, cycloheximide (CHX).	Cycloheximide	146-149	plasminogen activator, tissue type	Homo sapiens	4-8
8134905-5	1993	The t-PA mRNA expression induced by thrombin was completely blocked by pretreatment of the cells with an inhibitor of translation, cycloheximide (CHX).	Cycloheximide	146-149	coagulation factor II, thrombin	Homo sapiens	36-44
8378347-5	1993	Addition of the protein-synthesis-inhibitor cycloheximide superinduced c-fos and c-jun, strongly potentiating the PAF effect, but inhibited the induction of collagenase type I expression, suggesting the existence of a transcriptional factor linking the two events.	Cycloheximide	44-57	transcription factor Jun	Oryctolagus cuniculus	81-86
8360167-9	1993	The induction of the 12-lipoxygenase mRNA by EGF was completely blocked by 35 microM cycloheximide, if present in culture medium during EGF treatment, indicating that a de novo protein biosynthesis was essential for EGF-induced 12-lipoxygenase mRNA expression.	Cycloheximide	85-98	epidermal growth factor	Homo sapiens	45-48
8360167-9	1993	The induction of the 12-lipoxygenase mRNA by EGF was completely blocked by 35 microM cycloheximide, if present in culture medium during EGF treatment, indicating that a de novo protein biosynthesis was essential for EGF-induced 12-lipoxygenase mRNA expression.	Cycloheximide	85-98	epidermal growth factor	Homo sapiens	136-139
8360167-9	1993	The induction of the 12-lipoxygenase mRNA by EGF was completely blocked by 35 microM cycloheximide, if present in culture medium during EGF treatment, indicating that a de novo protein biosynthesis was essential for EGF-induced 12-lipoxygenase mRNA expression.	Cycloheximide	85-98	epidermal growth factor	Homo sapiens	136-139
8360185-7	1993	Treatment of cells with both cycloheximide and IL-1 reduced the levels of PN-1 mRNA.	Cycloheximide	29-42	serpin family E member 2	Homo sapiens	74-78
8360185-12	1993	A sustained decrease in PN-1 mRNA was also seen when cells were treated with cycloheximide and DXM.	Cycloheximide	77-90	serpin family E member 2	Homo sapiens	24-28
7693011-4	1993	Addition of cycloheximide suppressed the stimulation of CCK mRNA expression, whereas expression of c-fos mRNA was super-induced by the simultaneous addition of cycloheximide and forskolin or foetal calf serum.	Cycloheximide	12-25	cholecystokinin	Homo sapiens	56-59
7693011-4	1993	Addition of cycloheximide suppressed the stimulation of CCK mRNA expression, whereas expression of c-fos mRNA was super-induced by the simultaneous addition of cycloheximide and forskolin or foetal calf serum.	Cycloheximide	160-173	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-104
8311923-3	1993	RESULTS: Protein synthesis inhibition with cycloheximide or actinomycin D resulted in complete abrogation of the stimulation of PGE2 production by IL-1 beta, TNF alpha, and EGF.	Cycloheximide	43-56	interleukin 1 beta	Homo sapiens	147-156
8311923-3	1993	RESULTS: Protein synthesis inhibition with cycloheximide or actinomycin D resulted in complete abrogation of the stimulation of PGE2 production by IL-1 beta, TNF alpha, and EGF.	Cycloheximide	43-56	tumor necrosis factor	Homo sapiens	158-167
8311923-3	1993	RESULTS: Protein synthesis inhibition with cycloheximide or actinomycin D resulted in complete abrogation of the stimulation of PGE2 production by IL-1 beta, TNF alpha, and EGF.	Cycloheximide	43-56	epidermal growth factor	Homo sapiens	173-176
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	forkhead box A4 L homeolog	Xenopus laevis	108-112
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	notochord homeobox L homeolog	Xenopus laevis	118-122
8349038-11	1993	RNA and protein synthesis inhibitors actinomycin and cycloheximide abolished the enhancing effects of high glucose on GLUT2 mRNA.	Cycloheximide	53-66	solute carrier family 2 member 2	Rattus norvegicus	118-123
7689953-9	1993	Treatment of cells with actinomycin-D or cycloheximide could prevent a phorbol ester-induced block of IGF-dependent IGFBP-4 proteolysis.	Cycloheximide	41-54	insulin like growth factor binding protein 4	Homo sapiens	116-123
7689954-12	1993	Although the synthesis of IGFBP-2 and IGFBP-4 were both inhibited by cycloheximide, actinomycin D blocked the synthesis of basal and bFGF-induced IGFBP-4 but not IGFBP-2.	Cycloheximide	69-82	insulin-like growth factor binding protein 2	Rattus norvegicus	26-33
7689954-12	1993	Although the synthesis of IGFBP-2 and IGFBP-4 were both inhibited by cycloheximide, actinomycin D blocked the synthesis of basal and bFGF-induced IGFBP-4 but not IGFBP-2.	Cycloheximide	69-82	insulin-like growth factor binding protein 4	Rattus norvegicus	38-45
8359233-8	1993	We observed, however, that the inhibition of protein synthesis by cycloheximide (CH) in this setting of early monocytic differentiation increased both c-fms and CSF-1 steady-state transcript levels.	Cycloheximide	66-79	colony stimulating factor 1 receptor	Homo sapiens	151-156
8359233-8	1993	We observed, however, that the inhibition of protein synthesis by cycloheximide (CH) in this setting of early monocytic differentiation increased both c-fms and CSF-1 steady-state transcript levels.	Cycloheximide	66-79	colony stimulating factor 1	Homo sapiens	161-166
8359233-8	1993	We observed, however, that the inhibition of protein synthesis by cycloheximide (CH) in this setting of early monocytic differentiation increased both c-fms and CSF-1 steady-state transcript levels.	Cycloheximide	81-83	colony stimulating factor 1 receptor	Homo sapiens	151-156
8359233-8	1993	We observed, however, that the inhibition of protein synthesis by cycloheximide (CH) in this setting of early monocytic differentiation increased both c-fms and CSF-1 steady-state transcript levels.	Cycloheximide	81-83	colony stimulating factor 1	Homo sapiens	161-166
8395401-7	1993	The two cell types responded differently also to a protein synthesis inhibitor, cycloheximide, with respect to TM message accumulation.	Cycloheximide	80-93	thrombomodulin	Mus musculus	111-113
8224368-4	1993	Its effect on ODC was completely prevented by cycloheximide, that on SAT only partially.	Cycloheximide	46-59	ornithine decarboxylase 1	Rattus norvegicus	14-17
8395533-0	1993	Interleukin-3 inhibits cycloheximide induction of C-jun mRNA in human monocytes: possible role for a serine/threonine phosphatase.	Cycloheximide	23-36	interleukin 3	Homo sapiens	0-13
8395533-0	1993	Interleukin-3 inhibits cycloheximide induction of C-jun mRNA in human monocytes: possible role for a serine/threonine phosphatase.	Cycloheximide	23-36	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	50-55
8395533-1	1993	Cycloheximide is a strong inducer of the c-jun protooncogene mRNA at concentrations (< or = 50 ng/ml) that do not inhibit protein synthesis in human monocytes.	Cycloheximide	0-13	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	41-46
8395533-3	1993	The pluripotent colony stimulating factor interleukin-3 (IL-3) (10 ng/ml) is also a modest inducer of the c-jun gene in these cells; however, in combination with cycloheximide, IL-3 dramatically reduces the c-jun induction below levels induced by cycloheximide alone.	Cycloheximide	162-175	interleukin 3	Homo sapiens	42-55
8395533-3	1993	The pluripotent colony stimulating factor interleukin-3 (IL-3) (10 ng/ml) is also a modest inducer of the c-jun gene in these cells; however, in combination with cycloheximide, IL-3 dramatically reduces the c-jun induction below levels induced by cycloheximide alone.	Cycloheximide	162-175	interleukin 3	Homo sapiens	57-61
8395533-3	1993	The pluripotent colony stimulating factor interleukin-3 (IL-3) (10 ng/ml) is also a modest inducer of the c-jun gene in these cells; however, in combination with cycloheximide, IL-3 dramatically reduces the c-jun induction below levels induced by cycloheximide alone.	Cycloheximide	247-260	interleukin 3	Homo sapiens	42-55
8395533-3	1993	The pluripotent colony stimulating factor interleukin-3 (IL-3) (10 ng/ml) is also a modest inducer of the c-jun gene in these cells; however, in combination with cycloheximide, IL-3 dramatically reduces the c-jun induction below levels induced by cycloheximide alone.	Cycloheximide	247-260	interleukin 3	Homo sapiens	57-61
8395533-3	1993	The pluripotent colony stimulating factor interleukin-3 (IL-3) (10 ng/ml) is also a modest inducer of the c-jun gene in these cells; however, in combination with cycloheximide, IL-3 dramatically reduces the c-jun induction below levels induced by cycloheximide alone.	Cycloheximide	247-260	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-111
8395533-4	1993	This is a true inhibition and is not due to a change in temporal kinetics of induction because the suppression in the presence of IL-3 is observed at both 30 and 60 min after simultaneous addition of both IL-3 and cycloheximide.	Cycloheximide	214-227	interleukin 3	Homo sapiens	130-134
8395533-5	1993	Preincubation of monocytes with 12.5 nM okadaic acid (a potent inhibitor of protein phosphatases 1 and 2A) and cycloheximide prior to addition of IL-3 restored the level of c-jun induction to that mediated by cycloheximide alone.	Cycloheximide	111-124	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-178
8395533-5	1993	Preincubation of monocytes with 12.5 nM okadaic acid (a potent inhibitor of protein phosphatases 1 and 2A) and cycloheximide prior to addition of IL-3 restored the level of c-jun induction to that mediated by cycloheximide alone.	Cycloheximide	209-222	interleukin 3	Homo sapiens	146-150
8395533-5	1993	Preincubation of monocytes with 12.5 nM okadaic acid (a potent inhibitor of protein phosphatases 1 and 2A) and cycloheximide prior to addition of IL-3 restored the level of c-jun induction to that mediated by cycloheximide alone.	Cycloheximide	209-222	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	173-178
8395533-7	1993	These observations suggest that activation of protein serine/threonine phosphatase(s) underlies the ability of IL-3 to inhibit cycloheximide induction of c-jun in monocytes.	Cycloheximide	127-140	interleukin 3	Homo sapiens	111-115
8395533-7	1993	These observations suggest that activation of protein serine/threonine phosphatase(s) underlies the ability of IL-3 to inhibit cycloheximide induction of c-jun in monocytes.	Cycloheximide	127-140	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-159
8258647-5	1993	Abrogation of the protective effect of DEX by actinomycin D and cycloheximide demonstrated that protection against TNF-alpha requires de novo synthesis of mRNA and proteins.	Cycloheximide	64-77	tumor necrosis factor	Mus musculus	115-124
8243810-5	1993	The protein synthesis inhibitor cycloheximide inhibited the release of both [3H]AA and LH that had been induced by PDBu, whereas LH release induced by the PLA2 activator mellitin was cycloheximide-insensitive.	Cycloheximide	183-196	phospholipase A2 group IB	Rattus norvegicus	155-159
8247016-3	1993	We found that the protein synthesis inhibitors cycloheximide or anisomycin alone enhanced TRHR mRNA accumulation and, in the presence of Dex, caused a 10- to 20-fold superinduction of TRHR mRNA.	Cycloheximide	47-60	thyrotropin releasing hormone receptor	Rattus norvegicus	90-94
8247016-3	1993	We found that the protein synthesis inhibitors cycloheximide or anisomycin alone enhanced TRHR mRNA accumulation and, in the presence of Dex, caused a 10- to 20-fold superinduction of TRHR mRNA.	Cycloheximide	47-60	thyrotropin releasing hormone receptor	Rattus norvegicus	184-188
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	goosecoid homeobox S homeolog	Xenopus laevis	63-66
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	LIM homeobox 1 L homeolog	Xenopus laevis	69-75
7915634-4	1993	By the criterion of cycloheximide (CHX) resistance, goosecoid (gsc), Xlim-1, Xbra, Mix.1, XFKH1/pintallavis/XFD1, and Xnot are immediate early response genes in mesoderm/induction.	Cycloheximide	20-33	T-box transcription factor Tr L homeolog	Xenopus laevis	77-81
7689840-8	1993	Induction of GTPCH mRNA was apparent by 2 h, peaked at 4 h, and was sustained at high levels for at least 24 h. Induction of GTPCH mRNA by LPS/IFN was substantially enhanced by cycloheximide, suggesting that mRNA levels are depressed by a labile protein.	Cycloheximide	177-190	GTP cyclohydrolase 1	Rattus norvegicus	13-18
7689840-8	1993	Induction of GTPCH mRNA was apparent by 2 h, peaked at 4 h, and was sustained at high levels for at least 24 h. Induction of GTPCH mRNA by LPS/IFN was substantially enhanced by cycloheximide, suggesting that mRNA levels are depressed by a labile protein.	Cycloheximide	177-190	GTP cyclohydrolase 1	Rattus norvegicus	125-130
7689840-8	1993	Induction of GTPCH mRNA was apparent by 2 h, peaked at 4 h, and was sustained at high levels for at least 24 h. Induction of GTPCH mRNA by LPS/IFN was substantially enhanced by cycloheximide, suggesting that mRNA levels are depressed by a labile protein.	Cycloheximide	177-190	interferon gamma	Rattus norvegicus	143-146
8353835-4	1993	The down regulation of catalase gene expression seen in transformed lines may occur transcriptionally rather than posttranscriptionally as demonstrated by cycloheximide and/or actinomycin D treatment.	Cycloheximide	155-168	catalase	Mus musculus	23-31
8394586-7	1993	When synthesis of maternal 67Cu-ceruloplasmin (from 67Cu administered on albumin and transcuprein) was inhibited with cycloheximide, uptake by nonhepatic tissues was reduced markedly.	Cycloheximide	118-131	ceruloplasmin	Rattus norvegicus	32-45
8396258-4	1993	Induction of these lines in the presence of estradiol and an inhibitor of protein synthesis, cycloheximide, resulted in the activation of the endogenous myogenin gene but did not activate the muscle-specific creatine kinase or cardiac alpha-actin gene.	Cycloheximide	93-106	myogenin	Mus musculus	153-161
8397429-8	1993	The decay of c-fos mRNA was inhibited by cycloheximide markedly but was not changed significantly by actinomycin D.	Cycloheximide	41-54	FBJ osteosarcoma oncogene	Mus musculus	13-18
8357831-11	1993	Inhibition of protein synthesis with cycloheximide (CHX) increased differentially the half-life of CSF-1 mRNA in L6 alpha 1 myotubes compared to L6 alpha 1 myoblasts.	Cycloheximide	37-50	colony stimulating factor 1	Rattus norvegicus	99-104
8357831-11	1993	Inhibition of protein synthesis with cycloheximide (CHX) increased differentially the half-life of CSF-1 mRNA in L6 alpha 1 myotubes compared to L6 alpha 1 myoblasts.	Cycloheximide	52-55	colony stimulating factor 1	Rattus norvegicus	99-104
8349600-4	1993	Phosphate incorporation in the presence of cycloheximide indicates that phosphorylation occurred on pre-existing MPR46.	Cycloheximide	43-56	mannose-6-phosphate receptor, cation dependent	Homo sapiens	113-118
8349628-11	1993	Pretreatment with cycloheximide prevented induction of LDL receptor mRNA by TNF, but not by IL-1, suggesting stimulation of LDL receptor transcription by TNF requires protein synthesis.	Cycloheximide	18-31	low density lipoprotein receptor	Homo sapiens	55-67
8349628-11	1993	Pretreatment with cycloheximide prevented induction of LDL receptor mRNA by TNF, but not by IL-1, suggesting stimulation of LDL receptor transcription by TNF requires protein synthesis.	Cycloheximide	18-31	tumor necrosis factor	Homo sapiens	76-79
8349628-11	1993	Pretreatment with cycloheximide prevented induction of LDL receptor mRNA by TNF, but not by IL-1, suggesting stimulation of LDL receptor transcription by TNF requires protein synthesis.	Cycloheximide	18-31	low density lipoprotein receptor	Homo sapiens	124-136
8349628-11	1993	Pretreatment with cycloheximide prevented induction of LDL receptor mRNA by TNF, but not by IL-1, suggesting stimulation of LDL receptor transcription by TNF requires protein synthesis.	Cycloheximide	18-31	tumor necrosis factor	Homo sapiens	154-157
8356057-8	1993	In a time-course study, TPA induction of the endogenous PDGF-B mRNA and formation of the TPA-inducible complex occurred over the same time frame, and both events were specifically blocked by the addition of cycloheximide.	Cycloheximide	207-220	platelet derived growth factor subunit B	Homo sapiens	56-62
8264567-1	1993	Acute treatment of rats with recombinant tumour necrosis factor (TNF-alpha) caused an enhanced proteolytic rate--measured as tyrosine released in the presence of cycloheximide-in soleus muscle (34%).	Cycloheximide	162-175	tumor necrosis factor	Rattus norvegicus	65-74
8344913-5	1993	The time course of Rev-Erb induction was similar to that of C/EBP alpha, an important transcriptional regulator in adipocytes, and Rev-Erb mRNA was superinduced by cycloheximide.	Cycloheximide	164-177	nuclear receptor subfamily 1, group D, member 2	Mus musculus	131-138
8344966-5	1993	Protein synthesis inhibition with cycloheximide increased basal IGF I mRNA levels but blocked ang II-induced IGF I expression.	Cycloheximide	34-47	insulin like growth factor 1	Homo sapiens	64-69
8344966-5	1993	Protein synthesis inhibition with cycloheximide increased basal IGF I mRNA levels but blocked ang II-induced IGF I expression.	Cycloheximide	34-47	angiotensinogen	Homo sapiens	94-100
8344966-5	1993	Protein synthesis inhibition with cycloheximide increased basal IGF I mRNA levels but blocked ang II-induced IGF I expression.	Cycloheximide	34-47	insulin like growth factor 1	Homo sapiens	109-114
7688368-0	1993	Cycloheximide stabilizes insulin-like growth factor-binding protein-1 (IGFBP-1) mRNA and inhibits IGFBP-1 transcription in H4-II-E rat hepatoma cells.	Cycloheximide	0-13	insulin-like growth factor binding protein 1	Rattus norvegicus	25-69
7688368-0	1993	Cycloheximide stabilizes insulin-like growth factor-binding protein-1 (IGFBP-1) mRNA and inhibits IGFBP-1 transcription in H4-II-E rat hepatoma cells.	Cycloheximide	0-13	insulin-like growth factor binding protein 1	Rattus norvegicus	71-78
7688368-0	1993	Cycloheximide stabilizes insulin-like growth factor-binding protein-1 (IGFBP-1) mRNA and inhibits IGFBP-1 transcription in H4-II-E rat hepatoma cells.	Cycloheximide	0-13	insulin-like growth factor binding protein 1	Rattus norvegicus	98-105
7688368-5	1993	We now examine the effect of the protein synthesis inhibitor, cycloheximide, on the hormonal regulation of IGFBP-1 gene expression.	Cycloheximide	62-75	insulin-like growth factor binding protein 1	Rattus norvegicus	107-114
7688368-7	1993	By contrast, cycloheximide treatment abolished the decrease in IGFBP-1 mRNA induced by insulin.	Cycloheximide	13-26	insulin-like growth factor binding protein 1	Rattus norvegicus	63-70
7688368-9	1993	Cycloheximide alone also decreased IGFBP-1 transcription.	Cycloheximide	0-13	insulin-like growth factor binding protein 1	Rattus norvegicus	35-42
7688368-12	1993	Stabilization was demonstrated directly in actinomycin D-treated cells, where the t1/2 of IGFBP-1 mRNA increased from approximately 2 to approximately 20 h in the presence of cycloheximide; insulin did not affect IGFBP-1 mRNA turnover.	Cycloheximide	175-188	insulin-like growth factor binding protein 1	Rattus norvegicus	90-97
7688368-13	1993	Thus, cycloheximide-sensitive labile proteins contribute to the maintenance of basal IGFBP-1 promoter activity and the rapid turnover of IGFBP-1 mRNA, which determine the dynamic regulation of IGFBP-1 gene expression.	Cycloheximide	6-19	insulin-like growth factor binding protein 1	Rattus norvegicus	85-92
7688368-13	1993	Thus, cycloheximide-sensitive labile proteins contribute to the maintenance of basal IGFBP-1 promoter activity and the rapid turnover of IGFBP-1 mRNA, which determine the dynamic regulation of IGFBP-1 gene expression.	Cycloheximide	6-19	insulin-like growth factor binding protein 1	Rattus norvegicus	137-144
7688368-13	1993	Thus, cycloheximide-sensitive labile proteins contribute to the maintenance of basal IGFBP-1 promoter activity and the rapid turnover of IGFBP-1 mRNA, which determine the dynamic regulation of IGFBP-1 gene expression.	Cycloheximide	6-19	insulin-like growth factor binding protein 1	Rattus norvegicus	137-144
8347686-6	1993	Actinomycin D and cycloheximide inhibited both the basal and IL-1 alpha-induced production of M-CSF, suggesting a requirement for de novo RNA and protein synthesis.	Cycloheximide	18-31	interleukin 1 alpha	Homo sapiens	61-71
8347686-6	1993	Actinomycin D and cycloheximide inhibited both the basal and IL-1 alpha-induced production of M-CSF, suggesting a requirement for de novo RNA and protein synthesis.	Cycloheximide	18-31	colony stimulating factor 1	Homo sapiens	94-99
8348950-4	1993	Both induction of tolerance to energy deprivation and hsp68/70 synthesis were totally suppressed by cycloheximide, an inhibitor of cytosolic protein synthesis.	Cycloheximide	100-113	heat shock protein 1B	Mus musculus	54-59
8368327-8	1993	The effect of dexamethasone on fatty acid synthase mRNA was rapid, biphasic, and partly inhibited by actinomycin D and cycloheximide.	Cycloheximide	119-132	fatty acid synthase	Rattus norvegicus	31-50
8325888-5	1993	The mechanism appears to be a release of "detainment" of TS translation, since addition of cycloheximide, a translational inhibitor, blocked the TS protein levels from rising.	Cycloheximide	91-104	thymidylate synthetase	Homo sapiens	57-59
8250811-11	1993	Inhibition of protein synthesis by cycloheximide prevented the increase in VT receptors induced by TNF alpha.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	99-108
8354273-4	1993	The increase in the pS2 protein content of the medium by TPA was inhibited by simultaneous addition of cycloheximide, but not by that of actinomycin D.	Cycloheximide	103-116	taste 2 receptor member 64 pseudogene	Homo sapiens	20-23
8104473-7	1993	However, treatment of ACH-2 cells with cycloheximide elicited production of the 3 kb transcript suggesting the possibility for a repressor protein(s) to act at the level of transcription and/or stability of the 3 kb mRNA.	Cycloheximide	39-52	acyl-CoA thioesterase 1	Homo sapiens	22-27
8335353-8	1993	In addition, IFN-alpha 2 mRNA accumulation is superinduced when primed monocytes are treated with LPS plus cycloheximide, while TNF mRNA is relatively unaffected.	Cycloheximide	107-120	interferon alpha 2	Homo sapiens	13-24
8344985-13	1993	In addition, evidence was obtained for a cycloheximide sensitive regulator of ornithine decarboxylase gene expression, since the presence of this protein synthesis inhibitor increased the levels of ornithine decarboxylase message, and this effect was synergistically augmented by exposure of cells to cycloheximide and induction of TGF-beta 1 gene expression together.	Cycloheximide	41-54	ornithine decarboxylase, structural 1	Mus musculus	78-101
8344985-13	1993	In addition, evidence was obtained for a cycloheximide sensitive regulator of ornithine decarboxylase gene expression, since the presence of this protein synthesis inhibitor increased the levels of ornithine decarboxylase message, and this effect was synergistically augmented by exposure of cells to cycloheximide and induction of TGF-beta 1 gene expression together.	Cycloheximide	41-54	ornithine decarboxylase, structural 1	Mus musculus	198-221
8344985-13	1993	In addition, evidence was obtained for a cycloheximide sensitive regulator of ornithine decarboxylase gene expression, since the presence of this protein synthesis inhibitor increased the levels of ornithine decarboxylase message, and this effect was synergistically augmented by exposure of cells to cycloheximide and induction of TGF-beta 1 gene expression together.	Cycloheximide	41-54	transforming growth factor, beta 1	Mus musculus	332-342
8344985-13	1993	In addition, evidence was obtained for a cycloheximide sensitive regulator of ornithine decarboxylase gene expression, since the presence of this protein synthesis inhibitor increased the levels of ornithine decarboxylase message, and this effect was synergistically augmented by exposure of cells to cycloheximide and induction of TGF-beta 1 gene expression together.	Cycloheximide	301-314	ornithine decarboxylase, structural 1	Mus musculus	78-101
8344985-13	1993	In addition, evidence was obtained for a cycloheximide sensitive regulator of ornithine decarboxylase gene expression, since the presence of this protein synthesis inhibitor increased the levels of ornithine decarboxylase message, and this effect was synergistically augmented by exposure of cells to cycloheximide and induction of TGF-beta 1 gene expression together.	Cycloheximide	301-314	ornithine decarboxylase, structural 1	Mus musculus	198-221
7901101-4	1993	F and P each induced a time-dependent increase in NPY-mRNA relative abundance, and this was inhibited by staurosporine, an inhibitor of both protein kinase A and C. Cycloheximide (CHX) inhibited F/P induction of mRNA in a time-dependent manner.	Cycloheximide	165-178	neuropeptide Y	Rattus norvegicus	50-53
8218593-8	1993	Both TNF-R55 and TNF-R75 mRNA showed a prolonged half-life after incubation with the inhibitor of protein synthesis cycloheximide, indicating superinduction of the genes.	Cycloheximide	116-129	TNF receptor superfamily member 1A	Homo sapiens	5-12
8218593-8	1993	Both TNF-R55 and TNF-R75 mRNA showed a prolonged half-life after incubation with the inhibitor of protein synthesis cycloheximide, indicating superinduction of the genes.	Cycloheximide	116-129	TNF receptor superfamily member 1B	Homo sapiens	17-24
8224518-5	1993	In the rat, both liver GH-R and serum GH-BP declined after cycloheximide injection following first-order kinetics.	Cycloheximide	59-72	growth hormone receptor	Rattus norvegicus	23-27
8224518-8	1993	In contrast, the decline in rabbit liver GH-R, following cycloheximide treatment was accompanied by simultaneous time-dependent accumulation of serum GH-BP.	Cycloheximide	57-70	growth hormone receptor	Oryctolagus cuniculus	41-45
8232317-6	1993	When protein synthesis was inhibited using cycloheximide, basal levels of LPL mRNA were increased, and there was no GH stimulation.	Cycloheximide	43-56	lipoprotein lipase	Rattus norvegicus	74-77
8102055-5	1993	By using the protein synthesis inhibitor, cycloheximide, we also show that the 20:4-mediated regulatory effects upon SCD2 or c-fos are completely independent of new protein synthesis.	Cycloheximide	42-55	stearoyl-Coenzyme A desaturase 2	Mus musculus	117-121
8102055-5	1993	By using the protein synthesis inhibitor, cycloheximide, we also show that the 20:4-mediated regulatory effects upon SCD2 or c-fos are completely independent of new protein synthesis.	Cycloheximide	42-55	FBJ osteosarcoma oncogene	Mus musculus	125-130
8325888-5	1993	The mechanism appears to be a release of "detainment" of TS translation, since addition of cycloheximide, a translational inhibitor, blocked the TS protein levels from rising.	Cycloheximide	91-104	thymidylate synthetase	Homo sapiens	145-147
8329706-6	1993	Actinomycin D and cycloheximide blocked CRP-stimulated PCA, suggesting that de novo TF protein synthesis was required.	Cycloheximide	18-31	C-reactive protein	Homo sapiens	40-43
8333833-5	1993	The supplementation of cycloheximide (CHX) together with IL-1 beta resulted in the superinduction of TNF-alpha mRNA, suggesting that de novo protein synthesis is not required in IL-1-induced TNF-alpha mRNA expression.	Cycloheximide	23-36	tumor necrosis factor	Mus musculus	101-110
8333833-5	1993	The supplementation of cycloheximide (CHX) together with IL-1 beta resulted in the superinduction of TNF-alpha mRNA, suggesting that de novo protein synthesis is not required in IL-1-induced TNF-alpha mRNA expression.	Cycloheximide	38-41	tumor necrosis factor	Mus musculus	101-110
8325387-6	1993	Cycloheximide blocks butyrate-dependent reduction of c-myc mRNA levels.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	53-58
7686146-4	1993	In contrast to PMA, actinomycin D and cycloheximide reduced the CFTR protein content by 19 and 9% in HT-29 cells and by 22 and 40% in PLJ-4.7 cells, respectively, while inhibiting total cellular RNA and protein synthesis by over 80%.	Cycloheximide	38-51	CF transmembrane conductance regulator	Homo sapiens	64-68
8391879-7	1993	The treatment of FVA cells with cycloheximide (CHX) 10 micrograms/mL, which in itself activates the expression of VL30 caused a superinduction of the Epo signal.	Cycloheximide	32-45	visual system homeobox 2	Mus musculus	47-54
8325843-5	1993	Fetal calf serum, insulin, IGF-I, 12-O-tetradecanoylphorbol (TPA), and cycloheximide induced a 2.2-kilobase c-fos transcript in neurons.	Cycloheximide	71-84	FBJ osteosarcoma oncogene	Mus musculus	108-113
8373725-6	1993	Bradykinin-stimulated release of arachidonic acid was prevented by down-regulating protein kinase C by pretreatment with phorbol 12-myristate 13-acetate and was unaffected by inhibitors of protein synthesis actinomycin D or cycloheximide.	Cycloheximide	224-237	kininogen 1	Homo sapiens	0-10
8373725-7	1993	On the other hand, interleukin-1 amplification of bradykinin-stimulated release of arachidonic acid was blocked by actinomycin D and cycloheximide.	Cycloheximide	133-146	interleukin 1 alpha	Homo sapiens	19-32
8373725-7	1993	On the other hand, interleukin-1 amplification of bradykinin-stimulated release of arachidonic acid was blocked by actinomycin D and cycloheximide.	Cycloheximide	133-146	kininogen 1	Homo sapiens	50-60
7685252-8	1993	This reduction in cNOS message in response to TNF-alpha depended on protein synthesis as it was blocked by cycloheximide.	Cycloheximide	107-120	nitric oxide synthase 3	Homo sapiens	18-22
7685252-8	1993	This reduction in cNOS message in response to TNF-alpha depended on protein synthesis as it was blocked by cycloheximide.	Cycloheximide	107-120	tumor necrosis factor	Homo sapiens	46-55
8391879-7	1993	The treatment of FVA cells with cycloheximide (CHX) 10 micrograms/mL, which in itself activates the expression of VL30 caused a superinduction of the Epo signal.	Cycloheximide	32-45	RIKEN cDNA A130040M12 gene	Mus musculus	114-118
8391879-7	1993	The treatment of FVA cells with cycloheximide (CHX) 10 micrograms/mL, which in itself activates the expression of VL30 caused a superinduction of the Epo signal.	Cycloheximide	32-45	erythropoietin	Mus musculus	150-153
8081973-6	1993	Concomitant treatment with cycloheximide did not prevent the stimulation by TGF-beta 1 and resulted in exceptional superinduction for the fibronectin gene.	Cycloheximide	27-40	fibronectin 1	Rattus norvegicus	138-149
8355466-6	1993	The synthesis of C4 by PTEC and its regulation by IFN-gamma was fully inhibitable by the addition of cycloheximide, indicating that protein synthesis is required for an increase in C4 secretion.	Cycloheximide	101-114	interferon gamma	Homo sapiens	50-59
12231875-4	1993	Our results indicate that the increase in activities of SOD and ascorbate peroxidase involved de novo protein synthesis that was sensitive to the nuclear-directed protein synthesis inhibitor cycloheximide.	Cycloheximide	191-204	SOD	Triticum aestivum	56-59
8514758-1	1993	The transcriptional induction of the chicken ovalbumin gene by steroid hormones is abolished by inhibitors of protein synthesis such as cycloheximide, suggesting that a labile protein mediates this process.	Cycloheximide	136-149	ovalbumin (SERPINB14)	Gallus gallus	45-54
12231875-4	1993	Our results indicate that the increase in activities of SOD and ascorbate peroxidase involved de novo protein synthesis that was sensitive to the nuclear-directed protein synthesis inhibitor cycloheximide.	Cycloheximide	191-204	peroxidase-like	Triticum aestivum	74-84
8319692-7	1993	Upon cycloheximide treatment, the mutant ODC activity did not decrease appreciably for at least 3 h, whereas wild-type ODC activity decreased with a half-life of 1 h. In-vitro-synthesized mutant ODC with the Cys441-->Trp (or Ala) replacement was also stable in a reticulocyte-lysate ODC-degradation system.	Cycloheximide	5-18	ornithine decarboxylase 1	Homo sapiens	41-44
8509381-2	1993	The addition of IGF-I (50 ng/ml) to quiescent smooth muscle cell cultures resulted in a 5-fold increase in the steady-state levels of tropoelastin mRNA beginning between 2 and 4 h and reaching maximal levels at 8 h. Addition of cycloheximide blocked the effect of IGF-I.	Cycloheximide	228-241	insulin-like growth factor 1	Rattus norvegicus	16-21
8509381-2	1993	The addition of IGF-I (50 ng/ml) to quiescent smooth muscle cell cultures resulted in a 5-fold increase in the steady-state levels of tropoelastin mRNA beginning between 2 and 4 h and reaching maximal levels at 8 h. Addition of cycloheximide blocked the effect of IGF-I.	Cycloheximide	228-241	elastin	Rattus norvegicus	134-146
7685015-8	1993	Cycloheximide blocked FGF-1 expression in primary culture indicating that the increase represents newly synthesized factor rather than release from the extracellular matrix.	Cycloheximide	0-13	fibroblast growth factor 1	Rattus norvegicus	22-27
8499486-5	1993	This induction was initially observed at 6 h post-TPA treatment and continued to increase up to 48 h. Proteinase induction was inhibited by actinomycin D and cycloheximide, indicating that nascent RNA and protein synthesis were required.	Cycloheximide	158-171	plasminogen activator, tissue type	Homo sapiens	50-53
8499486-5	1993	This induction was initially observed at 6 h post-TPA treatment and continued to increase up to 48 h. Proteinase induction was inhibited by actinomycin D and cycloheximide, indicating that nascent RNA and protein synthesis were required.	Cycloheximide	158-171	endogenous retrovirus group K member 10	Homo sapiens	102-112
8505313-7	1993	The increase of PTP1C mRNA induced by TPA treatment was inhibited by cycloheximide, suggesting that new protein synthesis is required for the increase by TPA of PTP1C mRNA expression.	Cycloheximide	69-82	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	16-21
8505313-7	1993	The increase of PTP1C mRNA induced by TPA treatment was inhibited by cycloheximide, suggesting that new protein synthesis is required for the increase by TPA of PTP1C mRNA expression.	Cycloheximide	69-82	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	161-166
8162329-7	1993	The induction of ODC by EGF was inhibited by pretreatment of cultures with either cycloheximide or actinomycin D, suggesting that both protein synthesis and gene transcription are important in the EGF induction of ODC.	Cycloheximide	82-95	ornithine decarboxylase 1	Homo sapiens	17-20
8162329-7	1993	The induction of ODC by EGF was inhibited by pretreatment of cultures with either cycloheximide or actinomycin D, suggesting that both protein synthesis and gene transcription are important in the EGF induction of ODC.	Cycloheximide	82-95	epidermal growth factor	Homo sapiens	24-27
8162329-7	1993	The induction of ODC by EGF was inhibited by pretreatment of cultures with either cycloheximide or actinomycin D, suggesting that both protein synthesis and gene transcription are important in the EGF induction of ODC.	Cycloheximide	82-95	epidermal growth factor	Homo sapiens	197-200
8162329-7	1993	The induction of ODC by EGF was inhibited by pretreatment of cultures with either cycloheximide or actinomycin D, suggesting that both protein synthesis and gene transcription are important in the EGF induction of ODC.	Cycloheximide	82-95	ornithine decarboxylase 1	Homo sapiens	214-217
8339754-5	1993	The induction of CYP2E1 by isoniazid was not accompanied by an increased level of CYP2E1 mRNA, and was completely blocked by pretreatment with cycloheximide or sodium fluoride, inhibitors of mRNA translation.	Cycloheximide	143-156	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	17-23
8500722-11	1993	The IL-1 beta effect was also blocked by cycloheximide and was spontaneously reversible after 60 minutes.	Cycloheximide	41-54	interleukin 1 beta	Rattus norvegicus	4-13
7684042-13	1993	Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	57-62
7684042-13	1993	Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion.	Cycloheximide	0-13	insulin like growth factor binding protein 3	Homo sapiens	147-154
7684042-13	1993	Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion.	Cycloheximide	0-13	insulin like growth factor binding protein 2	Homo sapiens	156-163
7684042-13	1993	Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion.	Cycloheximide	0-13	insulin like growth factor binding protein 5	Homo sapiens	169-176
8354961-11	1993	The partial but significant inhibition of the T3 stimulation of HTGL activity by actinomycin D and cycloheximide suggests that the effects of T3 may be mediated by other cellular processes that are more directly regulated by the hormone.	Cycloheximide	99-112	lipase C, hepatic type	Homo sapiens	64-68
8371077-8	1993	Incubation with cycloheximide suggested that the effect of IGF-I involved increased protein synthesis.	Cycloheximide	16-29	insulin like growth factor 1	Gallus gallus	59-64
7688579-10	1993	Interestingly, the effect of cycloheximide on the induction of the p80 mRNA was found to be additive with that of dibutyryl cAMP but not with phorbol ester.	Cycloheximide	29-42	coilin	Homo sapiens	67-70
8514874-2	1993	TNF-alpha protein was detectable by immunohistochemistry in blood eosinophils of hypereosinophilic subjects, and purified blood eosinophils from three atopic donors exhibited cycloheximide-inhibitable spontaneous release of TNF-alpha in vitro.	Cycloheximide	175-188	tumor necrosis factor	Homo sapiens	0-9
8514874-2	1993	TNF-alpha protein was detectable by immunohistochemistry in blood eosinophils of hypereosinophilic subjects, and purified blood eosinophils from three atopic donors exhibited cycloheximide-inhibitable spontaneous release of TNF-alpha in vitro.	Cycloheximide	175-188	tumor necrosis factor	Homo sapiens	224-233
8496597-0	1993	Differential action of cycloheximide and activation stimuli on transcription of tumor necrosis factor-alpha, IL-1 beta, IL-8, and P53 genes in human monocytes.	Cycloheximide	23-36	tumor necrosis factor	Homo sapiens	80-107
8496597-0	1993	Differential action of cycloheximide and activation stimuli on transcription of tumor necrosis factor-alpha, IL-1 beta, IL-8, and P53 genes in human monocytes.	Cycloheximide	23-36	interleukin 1 beta	Homo sapiens	109-118
8496597-0	1993	Differential action of cycloheximide and activation stimuli on transcription of tumor necrosis factor-alpha, IL-1 beta, IL-8, and P53 genes in human monocytes.	Cycloheximide	23-36	C-X-C motif chemokine ligand 8	Homo sapiens	120-124
8496597-0	1993	Differential action of cycloheximide and activation stimuli on transcription of tumor necrosis factor-alpha, IL-1 beta, IL-8, and P53 genes in human monocytes.	Cycloheximide	23-36	tumor protein p53	Homo sapiens	130-133
8496597-1	1993	In the present study we have analyzed superinduction of TNF-alpha mRNA and enhancement of TNF-alpha gene transcription by cycloheximide (Chx) in human blood monocytes isolated by continuous Percoll gradient and activated in vitro.	Cycloheximide	122-135	tumor necrosis factor	Homo sapiens	90-99
8496597-1	1993	In the present study we have analyzed superinduction of TNF-alpha mRNA and enhancement of TNF-alpha gene transcription by cycloheximide (Chx) in human blood monocytes isolated by continuous Percoll gradient and activated in vitro.	Cycloheximide	137-140	tumor necrosis factor	Homo sapiens	90-99
8098356-9	1993	Incubation of ECL cells with the protein synthesis inhibitor, cycloheximide, for 4 h partially reversed the effect of glucose deprivation on the abundance of the GLUT1 transcript.	Cycloheximide	62-75	solute carrier family 2 member 1	Bos taurus	162-167
8098356-10	1993	On the other hand, incubation with cycloheximide for 24 h completely blocked the effect of glucose deprivation on the GLUT1 transcript.	Cycloheximide	35-48	solute carrier family 2 member 1	Bos taurus	118-123
8492125-3	1993	The rise of AAAD activity induced by the antagonists is prevented by pretreatment with cycloheximide.	Cycloheximide	87-100	dopa decarboxylase	Mus musculus	12-16
8502244-5	1993	The addition of cyclohexamide (CX), a protein synthesis inhibitor, to cultures undergoing stimulation with either PMA or IFN-gamma, increased the levels of CD32C mRNA synthesis suggesting that regulatory degradation proteins may be involved.	Cycloheximide	31-33	interferon gamma	Homo sapiens	121-130
8502244-5	1993	The addition of cyclohexamide (CX), a protein synthesis inhibitor, to cultures undergoing stimulation with either PMA or IFN-gamma, increased the levels of CD32C mRNA synthesis suggesting that regulatory degradation proteins may be involved.	Cycloheximide	31-33	Fc gamma receptor IIc (gene/pseudogene)	Homo sapiens	156-161
19912934-3	1993	Treatment with PSIs, either cycloheximide (CHX) or anisomycin (ANI), increased the levels of TH mRNA in the adrenal.	Cycloheximide	28-41	tyrosine hydroxylase	Rattus norvegicus	93-95
8497062-5	1993	lef-1 was found to be an early gene transcribed as a 1.8-kb RNA in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	115-128	lymphoid enhancer binding factor 1	Homo sapiens	0-5
7684906-2	1993	The synthesis of NO induced by IL-1 beta was concentration- and time- dependent, occurred after a lag period of approximately 6h and was inhibited by NG-monomethyl-L-arginine, cycloheximide, dexamethasone and hydrocortisone, but not by indomethacin.	Cycloheximide	176-189	interleukin 1 beta	Homo sapiens	31-40
8389208-5	1993	Our results furthermore indicated that the myogenic RNA processing could be reversed for both types of Ca2+ pumps since the expression of the PMCA1 and SERCA2 muscle-specific messengers was rapidly down-regulated by cycloheximide treatment.	Cycloheximide	216-229	ATPase, Ca++ transporting, plasma membrane 1	Mus musculus	142-147
8389208-5	1993	Our results furthermore indicated that the myogenic RNA processing could be reversed for both types of Ca2+ pumps since the expression of the PMCA1 and SERCA2 muscle-specific messengers was rapidly down-regulated by cycloheximide treatment.	Cycloheximide	216-229	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	152-158
8485705-4	1993	The protein synthesis inhibitor cycloheximide blocks the increase in p53 following DNA damage.	Cycloheximide	32-45	tumor protein p53	Homo sapiens	69-72
8490029-4	1993	Incorporation of [3H]Ile into PTHRP in cell extracts increased over 20 min during pulse labeling and then remained constant throughout the incubation period up to 6 h. In contrast, the release of [3H]PTHRP into culture medium increased progressively over 6 h. Addition of cycloheximide or unlabeled Ile almost completely blocked incorporation of [3H]Ile into newly synthesised PTHRP.	Cycloheximide	272-285	parathyroid hormone-like hormone	Rattus norvegicus	200-205
8490029-4	1993	Incorporation of [3H]Ile into PTHRP in cell extracts increased over 20 min during pulse labeling and then remained constant throughout the incubation period up to 6 h. In contrast, the release of [3H]PTHRP into culture medium increased progressively over 6 h. Addition of cycloheximide or unlabeled Ile almost completely blocked incorporation of [3H]Ile into newly synthesised PTHRP.	Cycloheximide	272-285	parathyroid hormone-like hormone	Rattus norvegicus	200-205
8486633-4	1993	Both the acceleration of ODC degradation and the induction of antizyme were inhibited by cycloheximide, but not by actinomycin D.	Cycloheximide	89-102	ornithine decarboxylase 1	Homo sapiens	25-28
8486633-9	1993	ODC phosphorylation occurred even when its new synthesis was inhibited by cycloheximide.	Cycloheximide	74-87	ornithine decarboxylase 1	Homo sapiens	0-3
8388650-6	1993	However, when AI and C cells were incubated with 7 x 10(-6) M cycloheximide, the increment in pHi and enhanced proton pump activity was abolished.	Cycloheximide	62-75	glucose-6-phosphate isomerase	Rattus norvegicus	94-97
8504830-6	1993	In contrast, addition of cycloheximide markedly increased the stability of the message (half-life = 18 h), suggesting that a short-lived protein plays a key role in modulating heme oxygenase-1 mRNA levels.	Cycloheximide	25-38	heme oxygenase 1	Gallus gallus	176-192
8482360-10	1993	Cycloheximide enhanced COX-2 transcript levels, but did not modulate IL-1 induction of COX-2.	Cycloheximide	0-13	prostaglandin G/H synthase 2	Oryctolagus cuniculus	23-28
8482361-1	1993	L-Ascorbic acid 2-phosphate (Asc 2-P), a long-acting vitamin C derivative, stimulated transcription of genes for pro alpha 1(I) and pro alpha 2(I) collagen in normal human skin fibroblasts after 8 h of treatment in the absence or in the presence of cycloheximide, indicating Asc 2-P stimulates transcription of type I collagen genes in the absence of protein synthesis.	Cycloheximide	249-262	pyrin domain containing 1	Homo sapiens	29-34
19912934-3	1993	Treatment with PSIs, either cycloheximide (CHX) or anisomycin (ANI), increased the levels of TH mRNA in the adrenal.	Cycloheximide	43-46	tyrosine hydroxylase	Rattus norvegicus	93-95
8478050-2	1993	Endotoxin-induced TNF production by MEF was inhibited by cycloheximide.	Cycloheximide	57-70	tumor necrosis factor	Mus musculus	18-21
8478613-1	1993	The tumor necrosis factor (TNF-alpha or TNF) gene is activated by both lipopolysaccharide (LPS) and cycloheximide in RAW 264.7 macrophages, whereas neither stimulus activates the gene in 3T3 fibroblasts.	Cycloheximide	100-113	tumor necrosis factor	Mus musculus	27-36
8478613-1	1993	The tumor necrosis factor (TNF-alpha or TNF) gene is activated by both lipopolysaccharide (LPS) and cycloheximide in RAW 264.7 macrophages, whereas neither stimulus activates the gene in 3T3 fibroblasts.	Cycloheximide	100-113	tumor necrosis factor	Mus musculus	27-30
8345459-7	1993	Actinomycin D (500 ng ml-1) and cycloheximide (500 ng ml-1) inhibited hydroxyproline secretion induced by combined relaxin and oestrogen treatment.	Cycloheximide	32-45	prorelaxin	Sus scrofa	115-122
8387950-9	1993	Preincubation of the cells with cycloheximide or actinomycin D totally abolished the up-regulatory effect of tumor necrosis factor on low-density lipoprotein receptors.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	109-130
8510379-9	1993	Inhibition of protein synthesis by cycloheximide (10 micrograms/ml) abolished the stimulation of ET-1 release by rHuEPO.	Cycloheximide	35-48	endothelin 1	Homo sapiens	97-101
8387227-4	1993	The effect disappears within 24 h. The effect of IFN-gamma may be a result of augmented receptor synthesis since treatment with cycloheximide reduces the phagocytosis.	Cycloheximide	128-141	interferon gamma	Mus musculus	49-58
8097930-6	1993	In addition, cycloheximide decreased the rate at which induced levels of TAT mRNA were degraded.	Cycloheximide	13-26	tyrosine aminotransferase	Rattus norvegicus	73-76
8473346-10	1993	Cycloheximide induced PHS II mRNA without a corresponding activity increase demonstrating that translation of the 4.3-kb message is required for increased prostacyclin biosynthesis.	Cycloheximide	0-13	prostaglandin-endoperoxide synthase 2	Homo sapiens	22-28
8476858-4	1993	For interstitial collagenase, induction was transcriptionally regulated as demonstrated by nuclear run-on experiments, and required the synthesis of proteins as indicated by cycloheximide treatment.	Cycloheximide	174-187	matrix metallopeptidase 1	Homo sapiens	4-28
8476858-7	1993	However, TPA exposure markedly prolonged the half-life of TIMP mRNA from 4 h to > 20 h. While cycloheximide treatment completely blocked TPA-mediated induction of collagenase mRNA, it only marginally interfered with simultaneously induced TIMP mRNA levels.	Cycloheximide	97-110	TIMP metallopeptidase inhibitor 1	Homo sapiens	58-62
8476858-7	1993	However, TPA exposure markedly prolonged the half-life of TIMP mRNA from 4 h to > 20 h. While cycloheximide treatment completely blocked TPA-mediated induction of collagenase mRNA, it only marginally interfered with simultaneously induced TIMP mRNA levels.	Cycloheximide	97-110	TIMP metallopeptidase inhibitor 1	Homo sapiens	242-246
7682243-5	1993	The addition of cycloheximide completely blocked the VitD3 induction of CD14 mRNA expression, indicating that the induction was dependent on ongoing protein synthesis.	Cycloheximide	16-29	CD14 molecule	Homo sapiens	72-76
8477754-1	1993	Two genes (SCR1 and SCR2) encoding natural cycloheximide resistance in the budding yeast Schwanniomyces occidentalis have been cloned by expression in Saccharomyces cerevisiae.	Cycloheximide	43-56	SCR1	Saccharomyces cerevisiae S288C	11-15
8477754-1	1993	Two genes (SCR1 and SCR2) encoding natural cycloheximide resistance in the budding yeast Schwanniomyces occidentalis have been cloned by expression in Saccharomyces cerevisiae.	Cycloheximide	43-56	bifunctional N-glycosylase/AP lyase NTG2	Saccharomyces cerevisiae S288C	20-24
8477754-2	1993	Both genes determine resistance to the inhibitory action of cycloheximide on the ribosome, SCR1 and SCR2 are present as single copies in Schwanniomyces occidentalis, where they map on chromosomes II and V, respectively.	Cycloheximide	60-73	SCR1	Saccharomyces cerevisiae S288C	91-95
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	51-64	tumor necrosis factor	Homo sapiens	76-79
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	51-64	tumor necrosis factor	Homo sapiens	98-101
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	51-64	tumor necrosis factor	Homo sapiens	98-101
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	66-69	tumor necrosis factor	Homo sapiens	76-79
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	66-69	tumor necrosis factor	Homo sapiens	98-101
8483246-7	1993	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the TNF mRNA level in the TNF resistant lines was increased while the sensitive lines required an additional signal, such as exogenous TNF, to upregulate the mRNA.	Cycloheximide	66-69	tumor necrosis factor	Homo sapiens	98-101
8477754-2	1993	Both genes determine resistance to the inhibitory action of cycloheximide on the ribosome, SCR1 and SCR2 are present as single copies in Schwanniomyces occidentalis, where they map on chromosomes II and V, respectively.	Cycloheximide	60-73	bifunctional N-glycosylase/AP lyase NTG2	Saccharomyces cerevisiae S288C	100-104
8097587-6	1993	Cycloheximide was found to block gro alpha mRNA degradation at the level of poly(A) shortening.	Cycloheximide	0-13	C-X-C motif chemokine ligand 1	Homo sapiens	33-42
8463228-9	1993	Differences between FAS mRNA levels in cells grown in the presence versus the absence of glucose were inhibited by cycloheximide but not puromycin, suggesting that glucose regulation of FAS mRNA stability is not dependent on translation.	Cycloheximide	115-128	fatty acid synthase	Homo sapiens	20-23
8463228-9	1993	Differences between FAS mRNA levels in cells grown in the presence versus the absence of glucose were inhibited by cycloheximide but not puromycin, suggesting that glucose regulation of FAS mRNA stability is not dependent on translation.	Cycloheximide	115-128	fatty acid synthase	Homo sapiens	186-189
8459105-11	1993	Addition of cycloheximide (50 micrograms/ml) inhibited formation of IL-2, IL-4 and IL-6 SFC by approximately 90%.	Cycloheximide	12-25	interleukin 2	Mus musculus	68-72
8459105-11	1993	Addition of cycloheximide (50 micrograms/ml) inhibited formation of IL-2, IL-4 and IL-6 SFC by approximately 90%.	Cycloheximide	12-25	interleukin 4	Mus musculus	74-78
8459105-11	1993	Addition of cycloheximide (50 micrograms/ml) inhibited formation of IL-2, IL-4 and IL-6 SFC by approximately 90%.	Cycloheximide	12-25	interleukin 6	Mus musculus	83-87
8458381-4	1993	Furthermore, eosinophil production of IL-8 in the presence of calcium ionophore could be inhibited with the immunomodulating agent cyclosporin A and the protein synthesis inhibitor cycloheximide.	Cycloheximide	181-194	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
8481893-4	1993	In contrast, receptor increase after 18 h of incubation with insulin and GM-CSF was sensitive to cycloheximide indicating that long term effects of these growth factors are mediated through protein synthesis.	Cycloheximide	97-110	insulin	Homo sapiens	61-68
8481893-4	1993	In contrast, receptor increase after 18 h of incubation with insulin and GM-CSF was sensitive to cycloheximide indicating that long term effects of these growth factors are mediated through protein synthesis.	Cycloheximide	97-110	colony stimulating factor 2	Homo sapiens	73-79
7683563-11	1993	Simultaneous addition of dexamethasone (0.01-1 microM) or cycloheximide (0.03-3 microM) inhibited in a concentration-dependent manner TNF alpha- and IL-1 beta-induced expression of Ca(2+)-independent NO synthase activity.	Cycloheximide	58-71	tumor necrosis factor	Homo sapiens	134-143
7683563-11	1993	Simultaneous addition of dexamethasone (0.01-1 microM) or cycloheximide (0.03-3 microM) inhibited in a concentration-dependent manner TNF alpha- and IL-1 beta-induced expression of Ca(2+)-independent NO synthase activity.	Cycloheximide	58-71	interleukin 1 beta	Homo sapiens	149-158
8097138-4	1993	An 8 h exposure to cycloheximide, which strongly induced MDR mRNAs in rat liver cells, also increased, although to a far lesser extent, MDR mRNA levels in human, mouse and hamster hepatocytes, indicating that P-gp expression in normal liver parenchymal cells could be at least partly negatively regulated by a labile protein factor.	Cycloheximide	19-32	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	209-213
8453631-10	1993	The induction of CEA mRNA was completely inhibited with either cycloheximide (protein synthesis inhibitor) or actinomycin D (RNA synthesis inhibitor), but the induction of BGP mRNA was superinduced by cycloheximide.	Cycloheximide	63-76	CEA cell adhesion molecule 3	Homo sapiens	17-20
8453631-10	1993	The induction of CEA mRNA was completely inhibited with either cycloheximide (protein synthesis inhibitor) or actinomycin D (RNA synthesis inhibitor), but the induction of BGP mRNA was superinduced by cycloheximide.	Cycloheximide	201-214	CEA cell adhesion molecule 1	Homo sapiens	172-175
8453631-11	1993	The difference in the kinetics of induction and effect of cycloheximide on CEA and BGP mRNAs suggest that the two genes are regulated differently in the same cell line.	Cycloheximide	58-71	CEA cell adhesion molecule 3	Homo sapiens	75-78
8453631-11	1993	The difference in the kinetics of induction and effect of cycloheximide on CEA and BGP mRNAs suggest that the two genes are regulated differently in the same cell line.	Cycloheximide	58-71	CEA cell adhesion molecule 1	Homo sapiens	83-86
7681765-3	1993	In primary cultures of rat renal tubular cells, 1,25-(OH)2D3 produced a 26-fold increase in P450cc24 mRNA which was detectable at 4 h, maximal at 24 h, and returned almost to baseline by 48 h. The induction was inhibited by actinomycin D, 5,6-dichloro-1-b-D-ribofuranosyl benzimidazole (DRB), and cycloheximide, and it was specific for vitamin D compounds containing a 1-hydroxyl group.	Cycloheximide	297-310	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	92-100
8482333-8	1993	Two protein synthesis inhibitors, cycloheximide and puromycin, blocked the CD-induced increase in beta-actin mRNA, in contrast to the serum-induced increase which is insensitive to inhibitors of protein synthesis.	Cycloheximide	34-47	actin, beta	Mus musculus	98-108
7682222-5	1993	The cdc2 mRNA accumulation is prevented when protein synthesis is blocked with cycloheximide, also if the drug is added at a time when the synthesis of cdc2 mRNA is already under way.	Cycloheximide	79-92	cyclin-dependent kinase 1	Mus musculus	4-8
7682222-5	1993	The cdc2 mRNA accumulation is prevented when protein synthesis is blocked with cycloheximide, also if the drug is added at a time when the synthesis of cdc2 mRNA is already under way.	Cycloheximide	79-92	cyclin-dependent kinase 1	Mus musculus	152-156
7683060-10	1993	To elucidate the mechanism of reduction in various myelin gene messages upon modulation of PKC, we analyzed mRNA levels in oligodendrocytes, which were pretreated with either the transcriptional inhibitor actinomycin D or the protein synthesis blocker cycloheximide before exposure to 4 beta-PDB.	Cycloheximide	252-265	protein kinase C, alpha	Rattus norvegicus	91-94
8462486-3	1993	In the presence of cycloheximide (CHX), stimulation by PKC activators or by serum leads to a "superinduction" of the c-fos gene.	Cycloheximide	19-32	FBJ osteosarcoma oncogene	Mus musculus	117-122
8462486-3	1993	In the presence of cycloheximide (CHX), stimulation by PKC activators or by serum leads to a "superinduction" of the c-fos gene.	Cycloheximide	34-37	FBJ osteosarcoma oncogene	Mus musculus	117-122
8324080-5	1993	Iron chelators also protected L929 cells from the cytotoxicity of TNF plus cycloheximide, suggesting that iron plays a role in this mode of TNF killing as well.	Cycloheximide	75-88	tumor necrosis factor	Mus musculus	140-143
8391491-5	1993	Whereas induction by epidermal growth factor (EGF) was abolished by cycloheximide and puromycin, increases in PRL mRNA caused by thyrotropin releasing hormone, 12-O-tetradecanoylphorbol 13-acetate, forskolin, or dibutyryl cyclic AMP were unaffected.	Cycloheximide	68-81	epidermal growth factor like 1	Rattus norvegicus	21-44
8391491-5	1993	Whereas induction by epidermal growth factor (EGF) was abolished by cycloheximide and puromycin, increases in PRL mRNA caused by thyrotropin releasing hormone, 12-O-tetradecanoylphorbol 13-acetate, forskolin, or dibutyryl cyclic AMP were unaffected.	Cycloheximide	68-81	epidermal growth factor like 1	Rattus norvegicus	46-49
8479424-5	1993	The induction of RD22 mRNA by ABA was inhibited by cycloheximide.	Cycloheximide	51-64	BURP domain-containing protein	Arabidopsis thaliana	17-21
12231779-2	1993	In roots, NO3- treatment caused a rapid (within 30 min), transient, and cycloheximide-independent accumulation of GS2 and Fd-GOGAT transcripts.	Cycloheximide	72-85	glutamine synthetase, chloroplastic	Zea mays	114-117
8479154-2	1993	EXPERIMENTAL DESIGN: We have studied the time course of the induction and the effects of cycloheximide treatment on the expression of c-fos, c-jun and the heat-shock gene HSP 70 in ischemic-reperfused livers; extracts of these livers have also been examined for the binding to a synthetic oligonucleotide containing the heat-shock consensus sequence (HSE) in order to reveal the possible presence of an active heat-shock factor (HSF) in ischemic-reperfused tissue.	Cycloheximide	89-102	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	134-139
8479154-2	1993	EXPERIMENTAL DESIGN: We have studied the time course of the induction and the effects of cycloheximide treatment on the expression of c-fos, c-jun and the heat-shock gene HSP 70 in ischemic-reperfused livers; extracts of these livers have also been examined for the binding to a synthetic oligonucleotide containing the heat-shock consensus sequence (HSE) in order to reveal the possible presence of an active heat-shock factor (HSF) in ischemic-reperfused tissue.	Cycloheximide	89-102	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	171-177
7681987-3	1993	To increase the frequency of IL-2-induced transcripts represented in the library, the protein synthesis inhibitor cycloheximide was included during the 2-hr IL-2 stimulation to superinduce gene expression, and the uridine analogue 4-thiouridine was utilized to enable selective purification of newly synthesized transcripts.	Cycloheximide	114-127	interleukin 2	Homo sapiens	29-33
7681987-3	1993	To increase the frequency of IL-2-induced transcripts represented in the library, the protein synthesis inhibitor cycloheximide was included during the 2-hr IL-2 stimulation to superinduce gene expression, and the uridine analogue 4-thiouridine was utilized to enable selective purification of newly synthesized transcripts.	Cycloheximide	114-127	interleukin 2	Homo sapiens	157-161
8348080-5	1993	Stimulation in the presence of cycloheximide shows that only c-jun, jun-D, c-fos, and JE gene activations are primary responses to the hormone in rat uterine cells.	Cycloheximide	31-44	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	75-80
7682068-6	1993	Cycloheximide added along with LPS + IFN gamma totally inhibits iNOS activity, while cycloheximide added 6 h after LPS + IFN gamma did not reduce NO2- and NO3- in tissue culture supernatants.	Cycloheximide	0-13	nitric oxide synthase 2	Rattus norvegicus	64-68
8457592-3	1993	Cycloheximide (20 microgram/ml) blocked the appearance of GA3-induced isozymes, suggesting that it is dependent on de novo protein synthesis.	Cycloheximide	0-13	succinyl-CoA:glutarate-CoA transferase	Homo sapiens	58-61
12231779-8	1993	Rapid, transient, and cycloheximide-independent NR mRNA expression was seen in the NO3--treated leaves, demonstrating that NO3- was not limiting.	Cycloheximide	22-35	nitrate reductase [NADH] 1	Zea mays	48-50
12231791-9	1993	Pretreatment of leaf discs with the protein synthesis inhibitor cycloheximide inhibited the induction of [beta]-GTase by SA and prevented the formation of GSA.	Cycloheximide	64-77	GNAS complex locus	Homo sapiens	155-158
7680009-5	1993	Cycloheximide, which abolished both the IFN gamma- and TNF alpha-induced increases in nitrite production, had no effect on the IFN gamma-induced increase in iNOS mRNA but markedly inhibited the TNF alpha-induced one.	Cycloheximide	0-13	interferon gamma	Homo sapiens	40-49
7680009-5	1993	Cycloheximide, which abolished both the IFN gamma- and TNF alpha-induced increases in nitrite production, had no effect on the IFN gamma-induced increase in iNOS mRNA but markedly inhibited the TNF alpha-induced one.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	55-64
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	C-X-C motif chemokine ligand 8	Homo sapiens	74-78
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	98-107
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	interleukin 1 beta	Homo sapiens	112-121
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	C-C motif chemokine ligand 5	Homo sapiens	126-132
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	interleukin 1 beta	Homo sapiens	152-161
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	C-C motif chemokine ligand 5	Homo sapiens	195-201
7680648-5	1993	Preincubation of the cells with cycloheximide "superinduced" the level of IL-8 mRNA stimulated by TNF alpha and IL-1 beta and RANTES mRNA stimulated by IL-1 beta, but decreased the expression of RANTES mRNA in response to TNF alpha.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	222-231
7680009-5	1993	Cycloheximide, which abolished both the IFN gamma- and TNF alpha-induced increases in nitrite production, had no effect on the IFN gamma-induced increase in iNOS mRNA but markedly inhibited the TNF alpha-induced one.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	194-203
8095395-7	1993	In the presence of cycloheximide, a marked superinduction of ICAM-1 was observed, while the repressive effect of dexamethasone remained, supporting the hypothesis that dexamethasone acts directly at the transcriptional level.	Cycloheximide	19-32	intercellular adhesion molecule 1	Homo sapiens	61-67
8460712-7	1993	The immediate inhibitory effect of 100 nM dexamethasone on SP-A mRNA content was completely blocked in the presence of cycloheximide.	Cycloheximide	119-132	surfactant protein A1	Homo sapiens	59-63
8480471-8	1993	By contrast, the addition of cycloheximide (5 x 10(-5) mol/l) dramatically reduced the secretion of immunoreactive EGF.	Cycloheximide	29-42	epidermal growth factor	Homo sapiens	115-118
8460936-9	1993	The increase in LRAT activity by retinoic acid in the vitamin A-deficient rat was blocked completely by both actinomycin D and cycloheximide.	Cycloheximide	127-140	lecithin retinol acyltransferase	Rattus norvegicus	16-20
8460937-4	1993	Carbamyl phosphate synthetase mRNA levels responded synergistically to the combined hormones and peaked 240-fold above controls at 24 h although activity only increased 1.4-fold at 48 h. Argininosuccinate lyase and synthetase mRNAs were induced by an increased transcriptional rate, were not induced by single hormones, responded synergistically to combined hormones, and showed a partial blockage of mRNA induction by cycloheximide.	Cycloheximide	419-432	argininosuccinate lyase	Rattus norvegicus	187-210
8460940-14	1993	The increase in PAF-AH activity was inhibited by actinomycin D and cycloheximide.	Cycloheximide	67-80	phospholipase A2 group VII	Homo sapiens	16-22
8503951-4	1993	Interleukin-1 (IL-1) and, to a lesser extent, tumor necrosis factor alpha (TNF alpha) stimulated GM-CSF formation within 3 h; mRNA levels also increased particularly in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	218-231	interleukin 1 alpha	Homo sapiens	15-19
8503951-4	1993	Interleukin-1 (IL-1) and, to a lesser extent, tumor necrosis factor alpha (TNF alpha) stimulated GM-CSF formation within 3 h; mRNA levels also increased particularly in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	218-231	tumor necrosis factor	Homo sapiens	46-73
8503951-4	1993	Interleukin-1 (IL-1) and, to a lesser extent, tumor necrosis factor alpha (TNF alpha) stimulated GM-CSF formation within 3 h; mRNA levels also increased particularly in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	218-231	tumor necrosis factor	Homo sapiens	75-84
8503951-4	1993	Interleukin-1 (IL-1) and, to a lesser extent, tumor necrosis factor alpha (TNF alpha) stimulated GM-CSF formation within 3 h; mRNA levels also increased particularly in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	218-231	colony stimulating factor 2	Homo sapiens	97-103
8503951-5	1993	IL-1, TNF alpha and, in addition, interferon-gamma (IFN-gamma) raised the M-CSF levels within 6 h; cycloheximide potentiated the effects of IL-1 and TNF alpha on mRNA levels.	Cycloheximide	99-112	interleukin 1 alpha	Homo sapiens	0-4
8503951-5	1993	IL-1, TNF alpha and, in addition, interferon-gamma (IFN-gamma) raised the M-CSF levels within 6 h; cycloheximide potentiated the effects of IL-1 and TNF alpha on mRNA levels.	Cycloheximide	99-112	tumor necrosis factor	Homo sapiens	6-15
8503951-5	1993	IL-1, TNF alpha and, in addition, interferon-gamma (IFN-gamma) raised the M-CSF levels within 6 h; cycloheximide potentiated the effects of IL-1 and TNF alpha on mRNA levels.	Cycloheximide	99-112	interleukin 1 alpha	Homo sapiens	140-144
8503951-5	1993	IL-1, TNF alpha and, in addition, interferon-gamma (IFN-gamma) raised the M-CSF levels within 6 h; cycloheximide potentiated the effects of IL-1 and TNF alpha on mRNA levels.	Cycloheximide	99-112	tumor necrosis factor	Homo sapiens	149-158
8382972-7	1993	Moreover, TPA also inhibited DNA fragmentation induced by vinblastine, cycloheximide, calphostin C, and x-rays.	Cycloheximide	71-84	plasminogen activator, tissue type	Homo sapiens	10-13
8318676-1	1993	We have isolated a cDNA (NC28) transcribed from a mRNA which is transiently induced in U937 promonocytic cells by PMA and super-induced by cycloheximide.	Cycloheximide	139-152	C-C motif chemokine ligand 7	Homo sapiens	25-29
8325238-11	1993	Cingulin assembly at the tight junction is sensitive to cycloheximide and is identifiable approx.	Cycloheximide	56-69	cingulin	Mus musculus	0-8
8444174-7	1993	The biological half life of TxS was 10.5 h, as determined by PGH2 incorporation into TxB2 after cycloheximide treatment.	Cycloheximide	96-109	thromboxane A synthase 1	Homo sapiens	28-31
8392959-10	1993	The addition of cycloheximide or actinomycin D to the media did not affect the basal production of estradiol but completely blocked the bGH and hCG stimulation of the aromatization of exogenous testosterone to estradiol.	Cycloheximide	16-29	hypertrichosis 2 (generalised, congenital)	Homo sapiens	144-147
8461254-6	1993	The presence of the protein synthesis inhibitor cycloheximide completely prevented PMA-induced synthesis of IL-5 mRNA by both NIMP-TH1 and EL-4 cells, indicating that induction of IL-5 mRNA via PMA stimulation requires de novo synthesis of a presumptive trans-acting factor(s).	Cycloheximide	48-61	interleukin 5	Mus musculus	108-112
8440198-8	1993	Both the induction and degradation of CRBP mRNA were inhibited by the protein synthesis inhibitor cycloheximide.	Cycloheximide	98-111	retinol binding protein 1	Rattus norvegicus	38-42
8358016-3	1993	A close correlation was observed between the priming kinetics of GM-CSF on 5-LO activation and on LT synthesis; moreover, the effects of the cytokine on both 5-LO activation and LT synthesis were inhibited when the cells had been exposed to either the protein synthesis inhibitor, cycloheximide (CX), or the transcription inhibitor, actinomycin D (AD), prior to incubation with GM-CSF.	Cycloheximide	281-294	colony stimulating factor 2	Homo sapiens	65-71
8358016-3	1993	A close correlation was observed between the priming kinetics of GM-CSF on 5-LO activation and on LT synthesis; moreover, the effects of the cytokine on both 5-LO activation and LT synthesis were inhibited when the cells had been exposed to either the protein synthesis inhibitor, cycloheximide (CX), or the transcription inhibitor, actinomycin D (AD), prior to incubation with GM-CSF.	Cycloheximide	296-298	colony stimulating factor 2	Homo sapiens	65-71
8436829-7	1993	Of significance was the observation that cycloheximide could selectively modulate TNF-alpha mRNA transcription in neutrophils, depending on the cytokine used.	Cycloheximide	41-54	tumor necrosis factor	Homo sapiens	82-91
8461254-6	1993	The presence of the protein synthesis inhibitor cycloheximide completely prevented PMA-induced synthesis of IL-5 mRNA by both NIMP-TH1 and EL-4 cells, indicating that induction of IL-5 mRNA via PMA stimulation requires de novo synthesis of a presumptive trans-acting factor(s).	Cycloheximide	48-61	interleukin 5	Mus musculus	180-184
8441406-9	1993	A repressional mechanism involving a labile repressor protein may be responsible for the inhibition of RNA splicing since treatment of SL12.4 cells with the protein synthesis inhibitor cycloheximide reversibly induces a rapid and dramatic accumulation of fully spliced TCR-beta transcripts in the cytoplasm, concomitant with a decline in TCR-beta pre-mRNAs in the nucleus.	Cycloheximide	185-198	T cell receptor beta chain	Mus musculus	269-277
8441406-9	1993	A repressional mechanism involving a labile repressor protein may be responsible for the inhibition of RNA splicing since treatment of SL12.4 cells with the protein synthesis inhibitor cycloheximide reversibly induces a rapid and dramatic accumulation of fully spliced TCR-beta transcripts in the cytoplasm, concomitant with a decline in TCR-beta pre-mRNAs in the nucleus.	Cycloheximide	185-198	T cell receptor beta chain	Mus musculus	338-346
8455639-7	1993	Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Homo sapiens	38-47
8455353-9	1993	The production of IL-6 by MC is inhibitable by cycloheximide, thus indicating de novo synthesis.	Cycloheximide	47-60	interleukin 6	Rattus norvegicus	18-22
12231740-2	1993	By using the cytoplasmic protein synthesis inhibitor cycloheximide (CHX), we previously reported that the reversible in vivo light activation of the C4 PEPC protein-serine kinase requires protein synthesis.	Cycloheximide	53-66	MLO-like protein 4	Zea mays	152-156
12231740-2	1993	By using the cytoplasmic protein synthesis inhibitor cycloheximide (CHX), we previously reported that the reversible in vivo light activation of the C4 PEPC protein-serine kinase requires protein synthesis.	Cycloheximide	68-71	MLO-like protein 4	Zea mays	152-156
12231740-3	1993	In the present leaf gas-exchange study, we have examined how and to what extent the CHX-induced inhibition of PEPC protein kinase activity/PEPC phosphorylation in the light influences C4 photosynthesis.	Cycloheximide	84-87	MLO-like protein 4	Zea mays	110-114
12231740-3	1993	In the present leaf gas-exchange study, we have examined how and to what extent the CHX-induced inhibition of PEPC protein kinase activity/PEPC phosphorylation in the light influences C4 photosynthesis.	Cycloheximide	84-87	MLO-like protein 4	Zea mays	139-143
8438587-3	1993	Treatment of Lpsn PM with cycloheximide (CHX) resulted in a marked accumulation of IFN-beta mRNA, which was not associated with an increase in IFN-beta gene transcription.	Cycloheximide	26-39	interferon beta 1, fibroblast	Mus musculus	83-91
8438587-3	1993	Treatment of Lpsn PM with cycloheximide (CHX) resulted in a marked accumulation of IFN-beta mRNA, which was not associated with an increase in IFN-beta gene transcription.	Cycloheximide	41-44	interferon beta 1, fibroblast	Mus musculus	83-91
7916701-1	1993	In the course of studying the ST2 gene, which was initially found to be expressed specifically at the G0/G1 transitional state in BALB/c-3T3 cells and was one of the primary response genes, we found another ST2-related mRNA, designated as ST2L, in serum-stimulated BALB/c-3T3 cells in the presence of cycloheximide.	Cycloheximide	301-314	interleukin 1 receptor-like 1	Mus musculus	30-33
7916701-1	1993	In the course of studying the ST2 gene, which was initially found to be expressed specifically at the G0/G1 transitional state in BALB/c-3T3 cells and was one of the primary response genes, we found another ST2-related mRNA, designated as ST2L, in serum-stimulated BALB/c-3T3 cells in the presence of cycloheximide.	Cycloheximide	301-314	interleukin 1 receptor-like 1	Mus musculus	207-210
7916701-1	1993	In the course of studying the ST2 gene, which was initially found to be expressed specifically at the G0/G1 transitional state in BALB/c-3T3 cells and was one of the primary response genes, we found another ST2-related mRNA, designated as ST2L, in serum-stimulated BALB/c-3T3 cells in the presence of cycloheximide.	Cycloheximide	301-314	interleukin 1 receptor-like 1	Mus musculus	239-243
8439572-6	1993	Cycloheximide reversed the instability induced by 1,25(OH)2D3, prolonging the half-life of c-myc mRNA in both uninduced and 1,25(OH)2D3-induced HL-60 cells to > 60 min, indicating a translational requirement for the destabilization process.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	91-96
8439287-6	1993	However, inhibiting proliferation with cycloheximide resulted in increased sensitivity to TNF, implying that mitogenesis itself was not essential for a cytotoxic response.	Cycloheximide	39-52	tumor necrosis factor	Homo sapiens	90-93
7679081-3	1993	Moreover, the stimulatory effects of recombinant IL-1 beta on NOS mRNA expression are prevented by co-incubation with an inhibitor of gene transcription (actinomycin D) or an inhibitor of protein synthesis (cycloheximide).	Cycloheximide	207-220	interleukin 1 beta	Homo sapiens	49-58
8455639-7	1993	Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis.	Cycloheximide	0-13	polymeric immunoglobulin receptor	Homo sapiens	68-72
8455639-7	1993	Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis.	Cycloheximide	0-13	polymeric immunoglobulin receptor	Homo sapiens	108-112
8455639-7	1993	Cycloheximide treatment abolished the IFN-gamma induced increase in pIgR mRNA, indicating that induction of pIgR mRNA by IFN-gamma requires de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Homo sapiens	121-130
8427712-4	1993	Cycloheximide (2.5 micrograms/ml) did not affect glucocorticoid induction of SP-B mRNA but markedly decreased induction of SP-C mRNA.	Cycloheximide	0-13	surfactant protein C	Homo sapiens	123-127
8447456-8	1993	Cycloheximide (an inhibitor of protein synthesis) attenuated the inhibitory effect of TNF-alpha and LPS on contractions to 5-hydroxytryptamine.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	86-95
24190557-5	1993	This effect of zinc in mitogen activated thymocytes may be due to the stabilization of ODC, which was found to decay with a half life of 65 min after the block of protein synthesis with cycloheximide.	Cycloheximide	186-199	ornithine decarboxylase 1	Rattus norvegicus	87-90
8427857-7	1993	Induction of PDGF-A and TGF-beta 1 was attenuated by cycloheximide, but bFGF induction was unaffected.	Cycloheximide	53-66	platelet derived growth factor subunit A	Homo sapiens	13-19
8427857-7	1993	Induction of PDGF-A and TGF-beta 1 was attenuated by cycloheximide, but bFGF induction was unaffected.	Cycloheximide	53-66	transforming growth factor beta 1	Homo sapiens	24-34
8427857-8	1993	Moreover, cycloheximide superinduced IEGs and revealed PDGF-B transcripts, which were otherwise undetected.	Cycloheximide	10-23	platelet derived growth factor subunit B	Homo sapiens	55-61
8427967-5	1993	Spectrin reorganization induced by IFN-alpha was abrogated by the protein synthesis inhibitor cycloheximide.	Cycloheximide	94-107	interferon alpha 1	Homo sapiens	35-44
8435072-6	1993	Actinomycin D and cycloheximide completely blocked the increase in ODC activity induced by alpha MDG.	Cycloheximide	18-31	ornithine decarboxylase 1	Sus scrofa	67-70
8382112-0	1993	Effects of cycloheximide on the induction of CYP1A1 gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in three human breast cancer cell lines.	Cycloheximide	11-24	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	45-51
8382112-6	1993	These results suggest that aryl hydrocarbon non-responsive MDA-MB-231 and Hs578-T human breast cancer cell lines contain the CYP1A1 gene and treatment with cycloheximide increases both constitutive and TCDD-induced CYP1A1 gene expression.	Cycloheximide	156-169	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	125-131
8382112-6	1993	These results suggest that aryl hydrocarbon non-responsive MDA-MB-231 and Hs578-T human breast cancer cell lines contain the CYP1A1 gene and treatment with cycloheximide increases both constitutive and TCDD-induced CYP1A1 gene expression.	Cycloheximide	156-169	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	215-221
8425178-5	1993	This effect of IL-6 on ir-ET-1 secretion was inhibited by actinomycin D and cycloheximide, indicating that IL-6 stimulates de novo synthesis of ir-ET-1 at a transcriptional level.	Cycloheximide	76-89	interleukin 6	Homo sapiens	15-19
8425178-5	1993	This effect of IL-6 on ir-ET-1 secretion was inhibited by actinomycin D and cycloheximide, indicating that IL-6 stimulates de novo synthesis of ir-ET-1 at a transcriptional level.	Cycloheximide	76-89	interleukin 6	Homo sapiens	107-111
8425199-6	1993	IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-gamma binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide.	Cycloheximide	178-191	interleukin 1 alpha	Homo sapiens	0-4
8425199-6	1993	IL-1 caused a time- and dose-dependent increase in 125I-labeled IFN-gamma binding that was maximal at 6 h, persisted for at least 24 h, and was blocked by both actinomycin D and cycloheximide.	Cycloheximide	178-191	interferon gamma	Homo sapiens	64-73
8425199-8	1993	IL-1 also produced a time- and dose-dependent increase in IFN-gamma receptor mRNA levels that was maximal at 3 h and persisted for at least 24 h. Actinomycin D, but not cycloheximide, completely blocked the IL-1-mediated increase in IFN-gamma receptor mRNA levels.	Cycloheximide	169-182	interleukin 1 alpha	Homo sapiens	0-4
7678205-11	1993	Induction of u-PAR by PMA was inhibited when HUVEC were preincubated with either cycloheximide or H7 but was unaffected by DAM.	Cycloheximide	81-94	plasminogen activator, urokinase receptor	Homo sapiens	13-18
8432403-5	1993	Induction studies in the presence of cycloheximide establish that IMP-E1 is a primary response locus while IMP-L1 transcription is a secondary response.	Cycloheximide	37-50	Ecdysone-inducible gene E1	Drosophila melanogaster	66-72
8436189-8	1993	Inhibition of protein synthesis by cycloheximide superinduced both basal and inducible IL-1ra mRNA.	Cycloheximide	35-48	interleukin 1 receptor antagonist	Homo sapiens	87-93
8473010-7	1993	Further observations revealed that, in human PMN, degradation of IL-8 mRNA is finely regulated, and that cycloheximide (CHX), an inhibitor of protein synthesis, super-induces the mRNA accumulation for IL-8 in a dose- and time-dependent manner.	Cycloheximide	105-118	C-X-C motif chemokine ligand 8	Homo sapiens	201-205
8473010-7	1993	Further observations revealed that, in human PMN, degradation of IL-8 mRNA is finely regulated, and that cycloheximide (CHX), an inhibitor of protein synthesis, super-induces the mRNA accumulation for IL-8 in a dose- and time-dependent manner.	Cycloheximide	120-123	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
8473010-7	1993	Further observations revealed that, in human PMN, degradation of IL-8 mRNA is finely regulated, and that cycloheximide (CHX), an inhibitor of protein synthesis, super-induces the mRNA accumulation for IL-8 in a dose- and time-dependent manner.	Cycloheximide	120-123	C-X-C motif chemokine ligand 8	Homo sapiens	201-205
8389378-6	1993	Cyclin D1 is directly induced by growth factors, i.e. in the presence of cycloheximide, and its expression does not significantly fluctuate during the cell cycle in synchronized cells.	Cycloheximide	73-86	cyclin D1	Homo sapiens	0-9
8428961-5	1993	PLA2-I increased the activity of prostaglandin endoperoxide synthase (PES), and PLA2-I-stimulated PGE2 synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	0-4
8428961-5	1993	PLA2-I increased the activity of prostaglandin endoperoxide synthase (PES), and PLA2-I-stimulated PGE2 synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	phospholipase A2, group IIA (platelets, synovial fluid)	Mus musculus	80-84
8428965-17	1993	Cycloheximide added to the serum-stimulated cultures at an early or mid-G1 phase inhibited the CBP/tk binding activity.	Cycloheximide	0-13	CREB binding protein	Homo sapiens	95-98
8425916-4	1993	The inhibition of EGF receptor autophosphorylation by bFGF was reduced in the presence of cycloheximide.	Cycloheximide	90-103	fibroblast growth factor 2	Rattus norvegicus	54-58
8140823-3	1993	Quantitative modifications of cycloheximide and N,N"-(p-xylylidene)-bis-aminoguanidine-2HCl resistance are observed in diploids containing the pma1 and pdr1 genes in trans configuration.	Cycloheximide	30-43	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	152-156
8432783-6	1993	Cotreatment of chorion cells or decidual cells with IL-1 beta and actinomycin D or cycloheximide abrogated IL-8 production.	Cycloheximide	83-96	C-X-C motif chemokine ligand 8	Homo sapiens	107-111
8473568-2	1993	It is proposed that cycloheximide acts as an inhibitor of the endotoxin-induced activation of phospholipase A2, thereby inhibiting the synthesis of leukotrienes which is now known to be a prerequisite for tumour necrosis factor-alpha (TNF) biosynthesis, the latter cytokine being regarded as the terminal mediator of the fatal D-galactosamine and endotoxin-induced syndrome.	Cycloheximide	20-33	phospholipase A2, group IB, pancreas	Mus musculus	94-110
8473568-2	1993	It is proposed that cycloheximide acts as an inhibitor of the endotoxin-induced activation of phospholipase A2, thereby inhibiting the synthesis of leukotrienes which is now known to be a prerequisite for tumour necrosis factor-alpha (TNF) biosynthesis, the latter cytokine being regarded as the terminal mediator of the fatal D-galactosamine and endotoxin-induced syndrome.	Cycloheximide	20-33	tumor necrosis factor	Mus musculus	235-238
7678621-4	1993	4-1BB was categorized as an early activation gene since the protein synthesis inhibitor, cycloheximide, blocked the induction of 4-1BB mRNA.	Cycloheximide	89-102	TNF receptor superfamily member 9	Rattus norvegicus	0-5
7678621-4	1993	4-1BB was categorized as an early activation gene since the protein synthesis inhibitor, cycloheximide, blocked the induction of 4-1BB mRNA.	Cycloheximide	89-102	TNF receptor superfamily member 9	Rattus norvegicus	129-134
7680863-0	1993	Tri-iodothyronine and cycloheximide enhance insulin-like growth factor-binding protein-1 gene expression in human hepatoma cells.	Cycloheximide	22-35	insulin like growth factor binding protein 1	Homo sapiens	44-88
7680863-5	1993	This was accompanied by an increase (+ 50%) in the amount of IGFBP-1 mRNA, which could be prevented by cycloheximide, a protein synthesis inhibitor.	Cycloheximide	103-116	insulin like growth factor binding protein 1	Homo sapiens	61-68
7680863-6	1993	Cycloheximide transiently enhanced (+ 200%) the accumulation of IGFBP-1 mRNA at 3-12 h of incubation, when no effect of tri-iodothyronine was observed.	Cycloheximide	0-13	insulin like growth factor binding protein 1	Homo sapiens	64-71
7680863-8	1993	The acute stimulation of IGFBP-1 gene transcription by cycloheximide associates this gene with a number of growth-related genes encoding growth- and tumour-associated peptides.	Cycloheximide	55-68	insulin like growth factor binding protein 1	Homo sapiens	25-32
8430098-5	1993	Induction of EGFR mRNA expression by TNF-alpha was abrogated by cycloheximide but occurred independently of TNF-alpha-induced production of TGF-alpha protein.	Cycloheximide	64-77	epidermal growth factor receptor	Homo sapiens	13-17
8430098-5	1993	Induction of EGFR mRNA expression by TNF-alpha was abrogated by cycloheximide but occurred independently of TNF-alpha-induced production of TGF-alpha protein.	Cycloheximide	64-77	tumor necrosis factor	Homo sapiens	37-46
8438058-5	1993	We also demonstrate that inhibition of protein synthesis with cycloheximide abrogates the down-regulation of both histone H1 gene transcription and mRNA levels in irradiated cells.	Cycloheximide	62-75	H1.0 linker histone	Homo sapiens	114-124
8434236-5	1993	Inhibition with 5,6-dichloro-1-beta-ribofuranosyl-benzimidazole (DRB) indicated a half-life for IFN-gamma-induced SC mRNA of approximately 1 h. Cycloheximide (CHX) abolished the IFN-gamma-induced accumulation of SC mRNA in a reversible manner; the time-course suggested that de novo synthesis of protein factor(s) with a turnover time shorter than 6 h was required for accumulation of SC message.	Cycloheximide	144-157	interferon gamma	Homo sapiens	96-105
8434236-5	1993	Inhibition with 5,6-dichloro-1-beta-ribofuranosyl-benzimidazole (DRB) indicated a half-life for IFN-gamma-induced SC mRNA of approximately 1 h. Cycloheximide (CHX) abolished the IFN-gamma-induced accumulation of SC mRNA in a reversible manner; the time-course suggested that de novo synthesis of protein factor(s) with a turnover time shorter than 6 h was required for accumulation of SC message.	Cycloheximide	159-162	interferon gamma	Homo sapiens	96-105
7678412-6	1993	Cycloheximide inhibited the induction of mac-NOS mRNA by IFN-gamma and LPS, indicating that expression of this mRNA required de novo protein synthesis.	Cycloheximide	0-13	nitric oxide synthase 2, inducible	Mus musculus	41-48
7678412-6	1993	Cycloheximide inhibited the induction of mac-NOS mRNA by IFN-gamma and LPS, indicating that expression of this mRNA required de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Mus musculus	57-66
8420973-3	1993	Addition of angiotensin II to serum-deprived SMC resulted in a marked induction of PTHrP mRNA by 2 h, with a peak (6-10-fold) at 4-6 h. Angiotensin II effects on PTHrP gene expression were inhibited by saralasin, an angiotensin II receptor antagonist, and blocked by actinomycin D and cycloheximide, suggesting a requirement for gene transcription and protein synthesis.	Cycloheximide	285-298	angiotensinogen	Rattus norvegicus	12-26
8420973-3	1993	Addition of angiotensin II to serum-deprived SMC resulted in a marked induction of PTHrP mRNA by 2 h, with a peak (6-10-fold) at 4-6 h. Angiotensin II effects on PTHrP gene expression were inhibited by saralasin, an angiotensin II receptor antagonist, and blocked by actinomycin D and cycloheximide, suggesting a requirement for gene transcription and protein synthesis.	Cycloheximide	285-298	angiotensinogen	Rattus norvegicus	136-150
8420973-3	1993	Addition of angiotensin II to serum-deprived SMC resulted in a marked induction of PTHrP mRNA by 2 h, with a peak (6-10-fold) at 4-6 h. Angiotensin II effects on PTHrP gene expression were inhibited by saralasin, an angiotensin II receptor antagonist, and blocked by actinomycin D and cycloheximide, suggesting a requirement for gene transcription and protein synthesis.	Cycloheximide	285-298	parathyroid hormone-like hormone	Rattus norvegicus	162-167
8420984-9	1993	Chimeric tissue factor.beta-globin mRNAs were superinduced by the protein synthesis inhibitor cycloheximide, and this superinduction may be due in part to stabilization of the mRNA.	Cycloheximide	94-107	coagulation factor III, tissue factor	Homo sapiens	9-22
7679994-3	1993	Inhibition of the thrombin-stimulated release of endothelin and vasopressin by cycloheximide (44 and 56%, respectively) and NCDC (59 and 88%, respectively) indicates that the release of these peptides is at least partially dependent on the ability of thrombin to stimulate protein synthesis and activate the phospholipase C pathway.	Cycloheximide	79-92	prothrombin	Oryctolagus cuniculus	18-26
8419467-8	1993	After treatment with cycloheximide, a protein synthesis inhibitor, IFN-gamma and TNF-alpha mRNA could be detected in both sites in otherwise normal mice.	Cycloheximide	21-34	interferon gamma	Mus musculus	67-76
8419467-8	1993	After treatment with cycloheximide, a protein synthesis inhibitor, IFN-gamma and TNF-alpha mRNA could be detected in both sites in otherwise normal mice.	Cycloheximide	21-34	tumor necrosis factor	Mus musculus	81-90
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	93-95
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	185-187
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	185-187
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	93-95
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	185-187
7678000-4	1993	The increase was detectable within 2 h and declined to near basal level by 6 h. Induction of TF mRNA was not blocked by cycloheximide, treatment with cycloheximide alone also increased TF mRNA levels, and thrombin in combination with cycloheximide further enhanced the accumulation of TF mRNA.	Cycloheximide	150-163	coagulation factor III, tissue factor	Homo sapiens	185-187
8416207-3	1993	In Wish and HEL cells, co-treatment with cycloheximide was required for IFN-gamma to increase the level of RB mRNA.	Cycloheximide	41-54	NCK interacting protein with SH3 domain	Homo sapiens	3-7
8416207-3	1993	In Wish and HEL cells, co-treatment with cycloheximide was required for IFN-gamma to increase the level of RB mRNA.	Cycloheximide	41-54	interferon gamma	Homo sapiens	72-81
8416207-3	1993	In Wish and HEL cells, co-treatment with cycloheximide was required for IFN-gamma to increase the level of RB mRNA.	Cycloheximide	41-54	RB transcriptional corepressor 1	Homo sapiens	107-109
8416207-4	1993	Pre-treatment of THP-1 cells with cycloheximide prior to IFN-gamma treatment augmented the effects of IFN-gamma on RB gene expression.	Cycloheximide	34-47	GLI family zinc finger 2	Homo sapiens	17-22
8416207-4	1993	Pre-treatment of THP-1 cells with cycloheximide prior to IFN-gamma treatment augmented the effects of IFN-gamma on RB gene expression.	Cycloheximide	34-47	interferon gamma	Homo sapiens	102-111
8416207-4	1993	Pre-treatment of THP-1 cells with cycloheximide prior to IFN-gamma treatment augmented the effects of IFN-gamma on RB gene expression.	Cycloheximide	34-47	RB transcriptional corepressor 1	Homo sapiens	115-117
8416207-7	1993	This cytokine increases the abundance of RB mRNA in monocytoid cell lines, reinforced by prior treatment with cycloheximide.	Cycloheximide	110-123	RB transcriptional corepressor 1	Homo sapiens	41-43
8140823-3	1993	Quantitative modifications of cycloheximide and N,N"-(p-xylylidene)-bis-aminoguanidine-2HCl resistance are observed in diploids containing the pma1 and pdr1 genes in trans configuration.	Cycloheximide	30-43	H(+)-exporting P2-type ATPase PMA1	Saccharomyces cerevisiae S288C	143-147
8356916-8	1993	(4) Actinomycin or cycloheximide treatment blocked the increase in liver deoxycytidine kinase activity induced by steroid or deoxycytidine treatment.	Cycloheximide	19-32	deoxycytidine kinase	Rattus norvegicus	73-93
8356916-10	1993	(5) Cycloheximide treatment of rats carrying hepatomas yielded a t1/2 = 3.4 hr in the tumor for deoxycytidine kinase activity which was the shortest among the examined enzymes of purine and pyrimidine biosynthesis.	Cycloheximide	4-17	deoxycytidine kinase	Rattus norvegicus	96-116
8430802-4	1993	IL-1 beta also stimulated the cycloheximide-sensitive uptake of [35S] methionine uptake by the tissue.	Cycloheximide	30-43	interleukin 1 beta	Rattus norvegicus	0-9
8100705-4	1993	This prolongation of shortened latency by the thyrotropin-releasing hormone and its analogues in cycloheximide-treated mice was antagonized by scopolamine but not by haloperidol.	Cycloheximide	97-110	thyrotropin releasing hormone	Mus musculus	46-75
8424834-7	1993	Use of cycloheximide and actinomycin D confirmed that TNF alpha was inducing MCP-1 expression at both the transcriptional and translational levels.	Cycloheximide	7-20	tumor necrosis factor	Homo sapiens	54-63
8424834-7	1993	Use of cycloheximide and actinomycin D confirmed that TNF alpha was inducing MCP-1 expression at both the transcriptional and translational levels.	Cycloheximide	7-20	C-C motif chemokine ligand 2	Homo sapiens	77-82
8417800-12	1993	Furthermore, it appeared that the induction of IL-4 mRNA was dependent on protein synthesis because cycloheximide (CHX) blocked the Con A- and Con A+PMA-induced expression of IL-4 mRNA.	Cycloheximide	100-113	interleukin 4	Homo sapiens	47-51
8417800-12	1993	Furthermore, it appeared that the induction of IL-4 mRNA was dependent on protein synthesis because cycloheximide (CHX) blocked the Con A- and Con A+PMA-induced expression of IL-4 mRNA.	Cycloheximide	100-113	interleukin 4	Homo sapiens	175-179
8417800-12	1993	Furthermore, it appeared that the induction of IL-4 mRNA was dependent on protein synthesis because cycloheximide (CHX) blocked the Con A- and Con A+PMA-induced expression of IL-4 mRNA.	Cycloheximide	115-118	interleukin 4	Homo sapiens	47-51
8417800-12	1993	Furthermore, it appeared that the induction of IL-4 mRNA was dependent on protein synthesis because cycloheximide (CHX) blocked the Con A- and Con A+PMA-induced expression of IL-4 mRNA.	Cycloheximide	115-118	interleukin 4	Homo sapiens	175-179
8427785-3	1993	Results from cycloheximide and actinomycin D experiments indicated that the dexamethasone-mediated reduction in uPA RNA required both new protein and RNA synthesis.	Cycloheximide	13-26	plasminogen activator, urokinase	Rattus norvegicus	112-115
7764603-8	1993	Cycloheximide delayed cell death caused by HGF deprivation.	Cycloheximide	0-13	hepatocyte growth factor	Mus musculus	43-46
8395366-6	1993	The protein synthesis inhibitor cycloheximide (CHX) inhibits the activin-dependent induction of Xbra partially, while induction of <protein-id="397759">Mix.	Cycloheximide	32-45	T-box transcription factor Tr L homeolog	Xenopus laevis	96-100
7678728-1	1993	The present study examines the effect of inhibiting protein synthesis with cycloheximide on the induction of the genes for cytochrome P4502H1 (CYP2H1) and 5-aminolevulinate synthase (ALAS) in phenobarbital-treated chick embryo livers.	Cycloheximide	75-88	cytochrome P450 2H1	Gallus gallus	143-149
7678728-3	1993	Cycloheximide treatment alone also induced the levels of mRNA for CYP2H1 and ALAS by 7- and 3-fold, respectively, but in combination, cycloheximide and phenobarbital elicited an additional effect resulting in a 33- and 40-fold increase, respectively.	Cycloheximide	0-13	cytochrome P450 2H1	Gallus gallus	66-72
7678728-3	1993	Cycloheximide treatment alone also induced the levels of mRNA for CYP2H1 and ALAS by 7- and 3-fold, respectively, but in combination, cycloheximide and phenobarbital elicited an additional effect resulting in a 33- and 40-fold increase, respectively.	Cycloheximide	134-147	cytochrome P450 2H1	Gallus gallus	66-72
8287833-7	1993	Cycloheximide decreased the LHRH-stimulated release of LH and FSH but this effect was not altered by EtOH.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	28-32
8419145-2	1993	In Ob1771 cells exposed to GH, under conditions where protein synthesis is inhibited by cycloheximide, the modulation of LPL gene expression is prevented, suggesting that synthesis of trans-acting factor(s) is required to modulate LPL gene expression.	Cycloheximide	88-101	lipoprotein lipase	Mus musculus	121-124
8490101-7	1993	De novo protein synthesis was required for the expression of the IL-1 beta inducing factor, as shown by cycloheximide treatment.	Cycloheximide	104-117	interleukin 1 beta	Homo sapiens	65-74
8395366-6	1993	The protein synthesis inhibitor cycloheximide (CHX) inhibits the activin-dependent induction of Xbra partially, while induction of <protein-id="397759">Mix.	Cycloheximide	47-50	T-box transcription factor Tr L homeolog	Xenopus laevis	96-100
8395366-9	1993	Induction and superinduction by CHX have previously been observed for immediate early genes in a variety of systems, notably for the activation of c-fos expression by serum stimulation, but have not been reported in early amphibian embryos.	Cycloheximide	32-35	FBJ murine osteosarcoma viral oncogene homolog S homeolog	Xenopus laevis	147-152
8405145-12	1993	SIP and LH/hCG actions were also blocked when the cells were incubated in the presence of cycloheximide.	Cycloheximide	90-103	tumor protein p53 inducible nuclear protein 1	Homo sapiens	0-3
7689005-6	1993	It was also found that cycloheximide exerted the inhibitory influence on the spontaneous culture-mediated expression of CD23 on CD5+ but not CD5- B cells of the patients.	Cycloheximide	23-36	Fc epsilon receptor II	Homo sapiens	120-124
7689005-6	1993	It was also found that cycloheximide exerted the inhibitory influence on the spontaneous culture-mediated expression of CD23 on CD5+ but not CD5- B cells of the patients.	Cycloheximide	23-36	CD5 molecule	Homo sapiens	128-131
8443122-3	1993	Induction of the PILOT gene is detectable in human T cells 20 min following activation in the presence of cycloheximide and is fully suppressed by CyA.	Cycloheximide	106-119	early growth response 3	Homo sapiens	17-22
8225910-0	1993	Effect of gamma-interferon or cycloheximide treatment on viral and c-myc transcripts in bovine-papillomavirus-type-1-transformed primary mouse fibroblasts.	Cycloheximide	30-43	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	67-72
8225910-6	1993	Cycloheximide treatment increased both viral and c-myc gene transcripts 3- to 20-fold in all cell lines.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	49-54
8381791-11	1993	Induction of GRP78 synthesis by OA was abolished in cells pretreated with actinomycin D and cycloheximide, indicating that it was regulated at the transcriptional level and its induction required de novo protein synthesis.	Cycloheximide	92-105	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	13-18
8432738-11	1993	The cycloheximide induced activity peaked after 20 h. Interestingly, cycloheximide alone has previously been shown to potentiate TGF alpha release from a cell line producing its precursor constitutively.	Cycloheximide	4-17	transforming growth factor alpha	Homo sapiens	129-138
8432738-11	1993	The cycloheximide induced activity peaked after 20 h. Interestingly, cycloheximide alone has previously been shown to potentiate TGF alpha release from a cell line producing its precursor constitutively.	Cycloheximide	69-82	transforming growth factor alpha	Homo sapiens	129-138
8380855-10	1993	However, cycloheximide did decrease the recovery of NT Bmax after exposure of cells to NT2 for 12 hr.	Cycloheximide	9-22	zinc finger protein 263	Mus musculus	87-90
18475517-3	1993	In addition, a potent inhibitor of protein synthesis, cycloheximide (10 muM), totally inhibited the stimulating effect of hPTH-(1-34) on prostaglandin endoperoxide synthase (PG synthase, EC 1.14.99.1).	Cycloheximide	54-67	latexin	Homo sapiens	72-75
8352892-4	1993	Serum-induced translocation of the p53 protein from the nucleus to the cytoplasm, as well as DNA and protein synthesis, were inhibited by cycloheximide.	Cycloheximide	138-151	tumor protein p53	Homo sapiens	35-38
8380222-4	1993	However, in the presence of cycloheximide, tPA transcription was not turned off but continued at a high rate for several hours.	Cycloheximide	28-41	plasminogen activator, tissue type	Rattus norvegicus	43-46
8380222-5	1993	This phenomenon may at least partly explain the earlier finding that tPA mRNA is superinduced by FSH in the presence of cycloheximide.	Cycloheximide	120-133	plasminogen activator, tissue type	Rattus norvegicus	69-72
8495796-7	1993	The E2 action on gec1 gene required the presence of cycloheximide.	Cycloheximide	52-65	gamma-aminobutyric acid receptor-associated protein-like 1	Cavia porcellus	17-21
8054703-6	1993	The potentiation of IL6 mRNA by TGF-beta 1 required de novo synthesis of an intermediate protein since treatment with cycloheximide abrogated the amount of mRNA enhanced by TGF-beta 1 without affecting IL1 alpha-driven mRNA production.	Cycloheximide	118-131	interleukin 6	Homo sapiens	20-23
8054703-6	1993	The potentiation of IL6 mRNA by TGF-beta 1 required de novo synthesis of an intermediate protein since treatment with cycloheximide abrogated the amount of mRNA enhanced by TGF-beta 1 without affecting IL1 alpha-driven mRNA production.	Cycloheximide	118-131	transforming growth factor beta 1	Homo sapiens	32-42
8054703-6	1993	The potentiation of IL6 mRNA by TGF-beta 1 required de novo synthesis of an intermediate protein since treatment with cycloheximide abrogated the amount of mRNA enhanced by TGF-beta 1 without affecting IL1 alpha-driven mRNA production.	Cycloheximide	118-131	transforming growth factor beta 1	Homo sapiens	173-183
7678355-8	1993	The TNF-alpha-stimulated VCAM-1 expression is also inhibited by the PKC-specific inhibitor calphostin C. Protein synthesis inhibition with cycloheximide (CHX) and blocking of transcription with actinomycin D (ACT D) also inhibits the TNF-alpha and PMA-stimulated upregulation of VCAM-1.	Cycloheximide	139-152	tumor necrosis factor	Homo sapiens	4-13
7678355-8	1993	The TNF-alpha-stimulated VCAM-1 expression is also inhibited by the PKC-specific inhibitor calphostin C. Protein synthesis inhibition with cycloheximide (CHX) and blocking of transcription with actinomycin D (ACT D) also inhibits the TNF-alpha and PMA-stimulated upregulation of VCAM-1.	Cycloheximide	139-152	vascular cell adhesion molecule 1	Homo sapiens	25-31
7678355-8	1993	The TNF-alpha-stimulated VCAM-1 expression is also inhibited by the PKC-specific inhibitor calphostin C. Protein synthesis inhibition with cycloheximide (CHX) and blocking of transcription with actinomycin D (ACT D) also inhibits the TNF-alpha and PMA-stimulated upregulation of VCAM-1.	Cycloheximide	154-157	tumor necrosis factor	Homo sapiens	4-13
7678355-8	1993	The TNF-alpha-stimulated VCAM-1 expression is also inhibited by the PKC-specific inhibitor calphostin C. Protein synthesis inhibition with cycloheximide (CHX) and blocking of transcription with actinomycin D (ACT D) also inhibits the TNF-alpha and PMA-stimulated upregulation of VCAM-1.	Cycloheximide	154-157	vascular cell adhesion molecule 1	Homo sapiens	25-31
8235310-6	1993	Both cycloheximide and actinomycin D inhibited CA 125 synthesis.	Cycloheximide	5-18	mucin 16, cell surface associated	Homo sapiens	47-53
1281991-2	1992	A protein synthesis inhibitor cycloheximide (CHX) caused a 2-3-fold increase in the amount of IGFBP-1 mRNA, which could be accounted for the observed stabilization in decay of IGFBP-1 mRNA after CHX treatment.	Cycloheximide	30-43	insulin like growth factor binding protein 1	Homo sapiens	94-101
1281991-2	1992	A protein synthesis inhibitor cycloheximide (CHX) caused a 2-3-fold increase in the amount of IGFBP-1 mRNA, which could be accounted for the observed stabilization in decay of IGFBP-1 mRNA after CHX treatment.	Cycloheximide	30-43	insulin like growth factor binding protein 1	Homo sapiens	176-183
1281991-2	1992	A protein synthesis inhibitor cycloheximide (CHX) caused a 2-3-fold increase in the amount of IGFBP-1 mRNA, which could be accounted for the observed stabilization in decay of IGFBP-1 mRNA after CHX treatment.	Cycloheximide	45-48	insulin like growth factor binding protein 1	Homo sapiens	94-101
1281991-2	1992	A protein synthesis inhibitor cycloheximide (CHX) caused a 2-3-fold increase in the amount of IGFBP-1 mRNA, which could be accounted for the observed stabilization in decay of IGFBP-1 mRNA after CHX treatment.	Cycloheximide	45-48	insulin like growth factor binding protein 1	Homo sapiens	176-183
1339286-7	1992	Cycloheximide-mediated inhibition of inducible C4BP gene expression demonstrated the requirement for ongoing protein synthesis.	Cycloheximide	0-13	complement component 4 binding protein, alpha	Rattus norvegicus	47-51
1334088-13	1992	Insulin receptor mRNA levels were reduced to 56% of their base line within 6 h when growth-arrested cells were stimulated to proliferate; protein inhibition with cycloheximide completely inhibited the decline in insulin receptor mRNA.	Cycloheximide	162-175	insulin receptor	Homo sapiens	212-228
1460280-5	1992	De novo protein synthesis is not required for TNF-alpha expression because the inclusion of cycloheximide does not prevent expression of the gene and acts to superinduce TNF-alpha mRNA levels.	Cycloheximide	92-105	tumor necrosis factor	Rattus norvegicus	170-179
1460280-7	1992	Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	57-66
1460280-7	1992	Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	89-98
1460280-7	1992	Cycloheximide acts to increase both transcription of the TNF-alpha gene and stability of TNF-alpha mRNA thereby resulting in increased TNF-alpha steady state mRNA levels.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	89-98
1476163-9	1992	Both the increase in cellular cysteine levels and GCS activity were blocked by cycloheximide and actinomycin D.	Cycloheximide	79-92	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	50-53
1280478-6	1992	Enhanced G-CSF mRNA levels were observed when SMC were treated with cycloheximide in the absence or presence of added cytokine.	Cycloheximide	68-81	colony stimulating factor 3	Homo sapiens	9-14
1280481-4	1992	Inhibition of RNA and protein synthesis by actinomycin-D and cycloheximide impeded the protection of apoptosis by GM-CSF.	Cycloheximide	61-74	colony stimulating factor 2	Homo sapiens	114-120
1333300-7	1992	The TNF-alpha-induced increase in VT-1 binding could be inhibited by simultaneous addition of the protein synthesis inhibitor cycloheximide.	Cycloheximide	126-139	tumor necrosis factor	Homo sapiens	4-13
1338570-2	1992	Cycloheximide inhibited the secretion of both apolipoproteins (apo) AI and B, but the reduction in apo AI secretion was evident at earlier times.	Cycloheximide	0-13	apolipoprotein A1	Homo sapiens	46-70
1335375-7	1992	The level of CYP1A1 mRNA after MCA treatment was elevated in the presence of cycloheximide.	Cycloheximide	77-90	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	13-19
1446636-2	1992	In bovine adrenocortical cells, cycloheximide prevents ACTH- or cAMP-induced accumulation of the mRNAs for cytochrome P450scc and adrenodoxin, but in human cells, cycloheximide induces the accumulation of adrenodoxin mRNA.	Cycloheximide	32-45	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	107-125
1457040-6	1992	The protein synthesis inhibitors cycloheximide and puromycin abrogated the induction of PRLR gene transcription at 1 hr and 2 hr, which demonstrated that on-going protein synthesis was required for the ORG 2058 effect and suggested that progestins may exert some transcriptional effects via the induction of an intermediary protein.	Cycloheximide	33-46	prolactin receptor	Homo sapiens	88-92
1334975-7	1992	IL-1 beta also induces the accumulation of cGMP by the insulinoma cell line Rin-m5F, and both NMMA as well as the protein synthesis inhibitor cycloheximide prevent this cGMP accumulation.	Cycloheximide	142-155	interleukin 1 beta	Rattus norvegicus	0-9
1334975-7	1992	IL-1 beta also induces the accumulation of cGMP by the insulinoma cell line Rin-m5F, and both NMMA as well as the protein synthesis inhibitor cycloheximide prevent this cGMP accumulation.	Cycloheximide	142-155	Ras-like without CAAX 2	Rattus norvegicus	76-79
1460416-10	1992	The two tryptase fragmentins were slow acting and were partly suppressed by blocking proteins synthesis with cycloheximide in the YAC-1 target cell.	Cycloheximide	109-122	ADP-ribosyltransferase 1	Mus musculus	130-135
1460427-11	1992	The addition of actinomycin D or cycloheximide to the HIV-infected monocytes before coculture reduced, &gt; 2.5-fold, the levels of TNF-alpha.	Cycloheximide	33-46	tumor necrosis factor	Homo sapiens	132-141
1362041-7	1992	Upregulation of ICAM-1 surface expression became evident some hours after cytokine stimulation and was inhibited by both actinomycin D and cycloheximide, indicating a requirement for de novo RNA and protein synthesis.	Cycloheximide	139-152	intercellular adhesion molecule 1	Homo sapiens	16-22
1334506-6	1992	The induction of glycogen resynthesis triggered by VIP or NA is dependent on protein synthesis, since both cycloheximide and actinomycin D abolish it entirely.	Cycloheximide	107-120	vasoactive intestinal polypeptide	Mus musculus	51-54
1336558-10	1992	Cycloheximide, on the other hand, inhibited only NGF but not BDNF mRNA induction.	Cycloheximide	0-13	nerve growth factor	Mus musculus	49-52
1336558-10	1992	Cycloheximide, on the other hand, inhibited only NGF but not BDNF mRNA induction.	Cycloheximide	0-13	brain derived neurotrophic factor	Mus musculus	61-65
22217834-12	1992	Cycloheximide also repressed cAMP-induced levels of CYP17 to 12% of levels observed in the absence of cycloheximide.	Cycloheximide	0-13	cytochrome P450, family 17, subfamily a, polypeptide 1	Mus musculus	52-57
1331513-8	1992	In the presence of cycloheximide, NS3 and NS3A immunofluorescence staining was pronounced in the Golgi complex, confirming that NS3 and NS3A are competent for transport to the Golgi apparatus after synthesis.	Cycloheximide	19-32	KRAS proto-oncogene, GTPase	Homo sapiens	34-37
1454064-9	1992	After depletion of this labile repressor by cycloheximide treatment, steady-state RAG-1 and RAG-2 RNA levels, and their transcription rates, were elevated four- to six-fold; but were still susceptible to elimination by TPA treatment.	Cycloheximide	44-57	recombination activating 1	Homo sapiens	82-87
1454064-9	1992	After depletion of this labile repressor by cycloheximide treatment, steady-state RAG-1 and RAG-2 RNA levels, and their transcription rates, were elevated four- to six-fold; but were still susceptible to elimination by TPA treatment.	Cycloheximide	44-57	recombination activating 2	Homo sapiens	92-97
1474892-6	1992	The Sal4p:ribosome association was only maintained when ribosomes were prepared in the presence of the translation elongation inhibitor cycloheximide; in uninhibited cells much lower levels of Sal4p were detectable in the "run-off" polysomes.	Cycloheximide	136-149	translation termination factor eRF1	Saccharomyces cerevisiae S288C	4-9
1491688-5	1992	The ability of PModS to elevate transferrin mRNA levels was inhibited by cycloheximide.	Cycloheximide	73-86	transferrin	Homo sapiens	32-43
19912894-1	1992	The level of proenkephalin mRNA in bovine adrenal chromaffin cells was studied in the presence of cycloheximide, an inhibitor of translation, and two modulators of proenkephalin synthesis, nicotine and 12-O-tetradecanoylphorbol-13-acetate (TPA).	Cycloheximide	98-111	proenkephalin	Bos taurus	13-26
19912894-2	1992	Cycloheximide (CHX) abolished the induction of proenkephalin mRNA expression and protein synthesis by these two modulators, indicating that de novo protein synthesis was necessary for proenkephalin gene activation.	Cycloheximide	0-13	proenkephalin	Bos taurus	47-60
19912894-2	1992	Cycloheximide (CHX) abolished the induction of proenkephalin mRNA expression and protein synthesis by these two modulators, indicating that de novo protein synthesis was necessary for proenkephalin gene activation.	Cycloheximide	0-13	proenkephalin	Bos taurus	184-197
19912894-2	1992	Cycloheximide (CHX) abolished the induction of proenkephalin mRNA expression and protein synthesis by these two modulators, indicating that de novo protein synthesis was necessary for proenkephalin gene activation.	Cycloheximide	15-18	proenkephalin	Bos taurus	47-60
19912894-2	1992	Cycloheximide (CHX) abolished the induction of proenkephalin mRNA expression and protein synthesis by these two modulators, indicating that de novo protein synthesis was necessary for proenkephalin gene activation.	Cycloheximide	15-18	proenkephalin	Bos taurus	184-197
1448916-2	1992	In cells treated with poly rl:rC and cycloheximide, appearance of TH3 DNA-binding activity was inversely proportional to the disappearance of a constitutive complex TH1 and coincided temporally with induction of IFN-beta gene transcription.	Cycloheximide	37-50	negative elongation factor complex member C/D	Homo sapiens	165-168
1448916-2	1992	In cells treated with poly rl:rC and cycloheximide, appearance of TH3 DNA-binding activity was inversely proportional to the disappearance of a constitutive complex TH1 and coincided temporally with induction of IFN-beta gene transcription.	Cycloheximide	37-50	interferon beta 1	Homo sapiens	212-220
1445935-6	1992	Cycloheximide (20 micrograms/ml) also significantly lowered the levels of the three isozymes of AdoMet synthetase in Ga3-treated aleurones, thereby suggesting the requirement of de-novo protein synthesis for the complete induction of isozymes.	Cycloheximide	0-13	S-adenosylmethionine synthase	Triticum aestivum	96-113
1279686-5	1992	The ACTH-induced increase in both adrenal steroidogenesis and rate of DBI processing were completely inhibited by cycloheximide; this result suggests the requirement for the de novo synthesis of a protein with a short half-life, probably an endopeptidase.	Cycloheximide	114-127	diazepam binding inhibitor	Rattus norvegicus	70-73
1279690-7	1992	Further, the release of FGF-1 by NIH 3T3 cell transfectants in response to heat shock is reduced significantly by both actinomycin D and cycloheximide.	Cycloheximide	137-150	fibroblast growth factor 1	Mus musculus	24-29
1429677-9	1992	Moreover, cycloheximide antagonized the IL-10-dependent reduction in cytokine mRNA levels.	Cycloheximide	10-23	interleukin 10	Homo sapiens	40-45
1444645-7	1992	Inhibition of protein synthesis by cycloheximide as well as addition of cyclic adenosine monophosphate synergistically enhanced the suppression of mitochondrial respiration by TNF alpha, resulting in complex I activity of 6.9 +/- 1.6% and 24.9 +/- 2.9% of that of untreated cells.	Cycloheximide	35-48	tumor necrosis factor	Rattus norvegicus	176-185
1467312-7	1992	The effect of PMA on calcyclin expression was blocked by the simultaneous addition of the PKC inhibitor staurosporine and by protein synthesis inhibition with cycloheximide.	Cycloheximide	159-172	S100 calcium binding protein A6	Homo sapiens	21-30
1292634-8	1992	In addition, experiments with the protein synthesis inhibitor cycloheximide suggested that the induction of mRNAs for both the heavy and light (beta 2-microglobulin) chains of the HLA class I antigen by TNF did not require de novo protein synthesis.	Cycloheximide	62-75	beta-2-microglobulin	Homo sapiens	144-164
1292634-8	1992	In addition, experiments with the protein synthesis inhibitor cycloheximide suggested that the induction of mRNAs for both the heavy and light (beta 2-microglobulin) chains of the HLA class I antigen by TNF did not require de novo protein synthesis.	Cycloheximide	62-75	tumor necrosis factor	Homo sapiens	203-206
1330491-7	1992	Northern blot analysis of mRNA from UMR 106-01 cells treated for 3 h with 2 microM PGE2, 10 nM PTH, or 10 ng/ml EGF in the presence of cycloheximide demonstrated that all three agents induced the expression of c-fos and c-jun mRNA.	Cycloheximide	135-148	epidermal growth factor like 1	Rattus norvegicus	112-115
1330491-7	1992	Northern blot analysis of mRNA from UMR 106-01 cells treated for 3 h with 2 microM PGE2, 10 nM PTH, or 10 ng/ml EGF in the presence of cycloheximide demonstrated that all three agents induced the expression of c-fos and c-jun mRNA.	Cycloheximide	135-148	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	210-215
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Cycloheximide	170-183	nucleophosmin 1	Homo sapiens	44-47
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Cycloheximide	170-183	nucleophosmin 1	Homo sapiens	77-90
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Cycloheximide	18-31	insulin like growth factor binding protein 5	Homo sapiens	58-65
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Cycloheximide	18-31	insulin like growth factor binding protein 5	Homo sapiens	152-159
1483963-0	1992	Insulinlike growth factor-1 inhibits cell death induced by cycloheximide in MCF-7 cells: a model system for analyzing control of cell death.	Cycloheximide	59-72	insulin like growth factor 1	Homo sapiens	0-27
1483963-2	1992	In the present study we investigated the effect of insulinlike growth factor-1, insulin, and epidermal growth factor on cell death induced by cycloheximide in the confluent MCF-7 cells, and correlated this effect to the inhibition rate of protein synthesis.	Cycloheximide	142-155	insulin like growth factor 1	Homo sapiens	51-78
1483963-2	1992	In the present study we investigated the effect of insulinlike growth factor-1, insulin, and epidermal growth factor on cell death induced by cycloheximide in the confluent MCF-7 cells, and correlated this effect to the inhibition rate of protein synthesis.	Cycloheximide	142-155	insulin	Homo sapiens	51-58
1483963-2	1992	In the present study we investigated the effect of insulinlike growth factor-1, insulin, and epidermal growth factor on cell death induced by cycloheximide in the confluent MCF-7 cells, and correlated this effect to the inhibition rate of protein synthesis.	Cycloheximide	142-155	epidermal growth factor	Homo sapiens	93-116
1429849-7	1992	In addition, treatment of cells with cycloheximide appears to stabilize the GLUT-2 mRNA, preventing the usual down-regulation of this gene in cultured hepatocytes.	Cycloheximide	37-50	solute carrier family 2 member 2	Rattus norvegicus	76-82
1426041-4	1992	Upon removal of camptothecin, which induced B23-translocation in HeLa cells, nucleophosmin/B23 relocalized into nucleoli within 2 h. Relocation occurs in the presence of cycloheximide which inhibits new protein synthesis.	Cycloheximide	170-183	nucleophosmin 1	Homo sapiens	91-94
1401924-6	1992	Maximum accumulation of IL-8 mRNA was observed after 6 h of incubation with LR, and the elevation persisted over 24 h. Inhibition of protein synthesis by cycloheximide resulted in superinduction of IL-8 mRNAs by LR.	Cycloheximide	154-167	C-X-C motif chemokine ligand 8	Homo sapiens	24-28
1401924-6	1992	Maximum accumulation of IL-8 mRNA was observed after 6 h of incubation with LR, and the elevation persisted over 24 h. Inhibition of protein synthesis by cycloheximide resulted in superinduction of IL-8 mRNAs by LR.	Cycloheximide	154-167	C-X-C motif chemokine ligand 8	Homo sapiens	198-202
1432687-9	1992	The treatment of BAMC cells with 20 microM cycloheximide (a protein synthesis inhibitor) inhibited both the increased secretion of ME and proENK mRNA level induced by AA and PGE2 in a time-dependent manner, indicating that the delayed secretion of ME and the increase in proENK mRNA level induced by AA and PGE2 require protein synthesis.	Cycloheximide	43-56	proenkephalin	Bos taurus	138-144
1432687-9	1992	The treatment of BAMC cells with 20 microM cycloheximide (a protein synthesis inhibitor) inhibited both the increased secretion of ME and proENK mRNA level induced by AA and PGE2 in a time-dependent manner, indicating that the delayed secretion of ME and the increase in proENK mRNA level induced by AA and PGE2 require protein synthesis.	Cycloheximide	43-56	proenkephalin	Bos taurus	271-277
1331416-9	1992	The addition of cycloheximide to the slice-perfusing medium containing dexamethasone prevented the inhibitory effects of the drug toward the morphine and DAMGO-induced CA1 epileptiform bursting.	Cycloheximide	16-29	carbonic anhydrase 1	Rattus norvegicus	168-171
1290964-4	1992	Furthermore, the TPA-induced down-regulation of GM-CSFR beta-subunit mRNA expression and its recovery were blocked by cycloheximide (CHX), a protein synthesis inhibitor, suggesting that these modulations required de novo protein synthesis.	Cycloheximide	118-131	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	48-55
1290964-4	1992	Furthermore, the TPA-induced down-regulation of GM-CSFR beta-subunit mRNA expression and its recovery were blocked by cycloheximide (CHX), a protein synthesis inhibitor, suggesting that these modulations required de novo protein synthesis.	Cycloheximide	133-136	colony stimulating factor 2 receptor subunit alpha	Homo sapiens	48-55
1282669-7	1992	Cycloheximide pretreatment blocked the TGF beta 1-induced decrease in albumin and AFP mRNA levels.	Cycloheximide	0-13	transforming growth factor, beta 1	Mus musculus	39-49
1282669-7	1992	Cycloheximide pretreatment blocked the TGF beta 1-induced decrease in albumin and AFP mRNA levels.	Cycloheximide	0-13	alpha fetoprotein	Mus musculus	82-85
1480173-6	1992	PTH also stimulated an increase in c-jun mRNA, but in a biphasic manner, with maximal levels at 30 min and 2 h. These responses were dose dependent, not altered by cotreatment with the protein synthesis inhibitor cycloheximide, and preceded PTH-induced expression of matrix metallo-proteinase-1 mRNA.	Cycloheximide	213-226	parathyroid hormone	Rattus norvegicus	0-3
1282723-4	1992	The TNF-alpha- and IL-1-stimulated ICAM-1 expression is also inhibited with the transcriptional inhibitor actinomycin D and with the protein synthesis inhibitor cycloheximide.	Cycloheximide	161-174	tumor necrosis factor	Mus musculus	4-13
1282723-4	1992	The TNF-alpha- and IL-1-stimulated ICAM-1 expression is also inhibited with the transcriptional inhibitor actinomycin D and with the protein synthesis inhibitor cycloheximide.	Cycloheximide	161-174	interleukin 1 complex	Mus musculus	19-23
1282723-4	1992	The TNF-alpha- and IL-1-stimulated ICAM-1 expression is also inhibited with the transcriptional inhibitor actinomycin D and with the protein synthesis inhibitor cycloheximide.	Cycloheximide	161-174	intercellular adhesion molecule 1	Mus musculus	35-41
1340123-12	1992	The effects observed with antisense oligomers to p34cdc2 kinase are strikingly similar to what is observed when low concentrations of the drug cycloheximide are added to these cells at different times after serum stimulation; entry into S-phase is significantly inhibited when cycloheximide is added up to 12 hours postimulation.	Cycloheximide	143-156	cyclin dependent kinase 1	Homo sapiens	49-56
1340123-12	1992	The effects observed with antisense oligomers to p34cdc2 kinase are strikingly similar to what is observed when low concentrations of the drug cycloheximide are added to these cells at different times after serum stimulation; entry into S-phase is significantly inhibited when cycloheximide is added up to 12 hours postimulation.	Cycloheximide	277-290	cyclin dependent kinase 1	Homo sapiens	49-56
1445297-3	1992	In this paper we report that acute cytotoxicity elicited by TNF, in the presence of cycloheximide (CHX), also utilizes this pathway since inhibitors of lipoxygenase action fully prevent TNF/CHX killing of several cell lines.	Cycloheximide	84-97	tumor necrosis factor	Homo sapiens	60-63
1445297-3	1992	In this paper we report that acute cytotoxicity elicited by TNF, in the presence of cycloheximide (CHX), also utilizes this pathway since inhibitors of lipoxygenase action fully prevent TNF/CHX killing of several cell lines.	Cycloheximide	84-97	tumor necrosis factor	Homo sapiens	186-189
1445297-3	1992	In this paper we report that acute cytotoxicity elicited by TNF, in the presence of cycloheximide (CHX), also utilizes this pathway since inhibitors of lipoxygenase action fully prevent TNF/CHX killing of several cell lines.	Cycloheximide	99-102	tumor necrosis factor	Homo sapiens	60-63
1445297-3	1992	In this paper we report that acute cytotoxicity elicited by TNF, in the presence of cycloheximide (CHX), also utilizes this pathway since inhibitors of lipoxygenase action fully prevent TNF/CHX killing of several cell lines.	Cycloheximide	99-102	tumor necrosis factor	Homo sapiens	186-189
1445297-5	1992	Radical scavengers such as NAC and PDTC prevent TNF/CHX-induced cell killing and reduce MnSOD induction by TNF.	Cycloheximide	52-55	synuclein alpha	Homo sapiens	27-30
1445297-5	1992	Radical scavengers such as NAC and PDTC prevent TNF/CHX-induced cell killing and reduce MnSOD induction by TNF.	Cycloheximide	52-55	tumor necrosis factor	Homo sapiens	48-51
1394518-0	1992	High-level resistance to cycloheximide resulting from an interaction of the mutated pdr3 and cyh genes in yeast.	Cycloheximide	25-38	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	84-88
1430209-5	1992	Treatment with retinoic acid results in a rapid induction (within 4 h) of thrombospondin (TSP) message which is independent of intervening protein synthesis and superinducible in the presence of cycloheximide.	Cycloheximide	195-208	thrombospondin 1	Homo sapiens	74-88
1430209-5	1992	Treatment with retinoic acid results in a rapid induction (within 4 h) of thrombospondin (TSP) message which is independent of intervening protein synthesis and superinducible in the presence of cycloheximide.	Cycloheximide	195-208	thrombospondin 1	Homo sapiens	90-93
1400506-6	1992	In pulse-chase experiments, the LDL effect on apoE accumulation in the media was observed when it was added only during the chase even in the presence of cycloheximide, indicating that LDL is functioning at a post-translational level.	Cycloheximide	154-167	apolipoprotein E	Homo sapiens	46-50
1327512-7	1992	The emergence of an active form of TGF-beta was also observed in cultures of Type A tumor cells, the protein synthesis of which was almost completely inhibited by pretreatment with cycloheximide.	Cycloheximide	181-194	transforming growth factor beta 1	Homo sapiens	35-43
1417842-1	1992	In this report we show that the adenovirus E3 region 14.7 kDa protein, heat and sodium arsenite, which have been defined previously as inhibitors of cytolysis, inhibit the tumor necrosis factor-alpha (TNF)-induced release of 3H-arachidonic acid from cycloheximide-sensitized C3HA fibroblasts.	Cycloheximide	250-263	tumor necrosis factor	Homo sapiens	172-199
1417842-1	1992	In this report we show that the adenovirus E3 region 14.7 kDa protein, heat and sodium arsenite, which have been defined previously as inhibitors of cytolysis, inhibit the tumor necrosis factor-alpha (TNF)-induced release of 3H-arachidonic acid from cycloheximide-sensitized C3HA fibroblasts.	Cycloheximide	250-263	tumor necrosis factor	Homo sapiens	201-204
1384061-5	1992	Using extracts prepared from cycloheximide-arrested interphase cells, we show that although p42MAPK activation can occur in response to cyclin-activated cdc2, the Ras-induced activation of p42MAPK occurs without intervening cdc2 activation.	Cycloheximide	29-42	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	92-99
1384061-5	1992	Using extracts prepared from cycloheximide-arrested interphase cells, we show that although p42MAPK activation can occur in response to cyclin-activated cdc2, the Ras-induced activation of p42MAPK occurs without intervening cdc2 activation.	Cycloheximide	29-42	proliferating cell nuclear antigen S homeolog	Xenopus laevis	136-142
1384061-5	1992	Using extracts prepared from cycloheximide-arrested interphase cells, we show that although p42MAPK activation can occur in response to cyclin-activated cdc2, the Ras-induced activation of p42MAPK occurs without intervening cdc2 activation.	Cycloheximide	29-42	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	153-157
1384061-5	1992	Using extracts prepared from cycloheximide-arrested interphase cells, we show that although p42MAPK activation can occur in response to cyclin-activated cdc2, the Ras-induced activation of p42MAPK occurs without intervening cdc2 activation.	Cycloheximide	29-42	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	189-196
1409718-7	1992	Cycloheximide partially blocks the induction of CCND1 and CCND3 gene expression by serum, suggesting that both de novo protein synthesis-dependent and -independent pathways contribute to induction.	Cycloheximide	0-13	cyclin D1	Homo sapiens	48-53
1409718-7	1992	Cycloheximide partially blocks the induction of CCND1 and CCND3 gene expression by serum, suggesting that both de novo protein synthesis-dependent and -independent pathways contribute to induction.	Cycloheximide	0-13	cyclin D3	Homo sapiens	58-63
1384500-4	1992	Protein synthesis inhibitors, actinomycin D and cycloheximide, were potent in inhibiting the SP-induced cortisol secretion.	Cycloheximide	48-61	tachykinin precursor 1	Bos taurus	93-95
1524447-6	1992	Cycloheximide increased the transcription rate of the CYP2H1/2 genes to a similar extent as did PIA, and had little or no effect on CYP2H1 mRNA half-life.	Cycloheximide	0-13	cytochrome P450 2H1	Gallus gallus	54-62
1524447-6	1992	Cycloheximide increased the transcription rate of the CYP2H1/2 genes to a similar extent as did PIA, and had little or no effect on CYP2H1 mRNA half-life.	Cycloheximide	0-13	cytochrome P450 2H1	Gallus gallus	54-60
1524447-10	1992	Cycloheximide acetate required deesterification to cycloheximide for both inhibition of protein synthesis and induction of CYP2H1 mRNA.	Cycloheximide	51-64	cytochrome P450 2H1	Gallus gallus	123-129
1384465-5	1992	cGMP formation and nitrite production induced by IL-1 beta pretreatment of islets are also blocked by the protein synthesis inhibitor, cycloheximide.	Cycloheximide	135-148	interleukin 1 beta	Homo sapiens	49-58
1384465-6	1992	The formation of cGMP does not appear to mediate the inhibitory effects of IL-1 beta on insulin secretion since a concentration of cycloheximide (1 microM) that blocks IL-1 beta-induced inhibition of glucose-stimulated insulin secretion and nitric oxide formation does not prevent cGMP accumulation, thus dissociating the two events.	Cycloheximide	131-144	interleukin 1 beta	Homo sapiens	168-177
1384465-6	1992	The formation of cGMP does not appear to mediate the inhibitory effects of IL-1 beta on insulin secretion since a concentration of cycloheximide (1 microM) that blocks IL-1 beta-induced inhibition of glucose-stimulated insulin secretion and nitric oxide formation does not prevent cGMP accumulation, thus dissociating the two events.	Cycloheximide	131-144	insulin	Homo sapiens	219-226
1384465-8	1992	spectroscopy, IL-1 beta is shown to induce the formation of a g = 2.04 iron-nitrosyl feature in islets which is prevented by cycloheximide, demonstrating the requirement of protein synthesis for IL-1 beta-induced nitric oxide formation.	Cycloheximide	125-138	interleukin 1 beta	Homo sapiens	14-23
1384465-8	1992	spectroscopy, IL-1 beta is shown to induce the formation of a g = 2.04 iron-nitrosyl feature in islets which is prevented by cycloheximide, demonstrating the requirement of protein synthesis for IL-1 beta-induced nitric oxide formation.	Cycloheximide	125-138	interleukin 1 beta	Homo sapiens	195-204
1384465-12	1992	Inhibition of islet glucose oxidation appears to be mediated by nitric oxide since both NMMA and cycloheximide prevent IL-1 beta-induced inhibition of glucose oxidation.	Cycloheximide	97-110	interleukin 1 beta	Homo sapiens	119-128
1394518-2	1992	The cycloheximide resistance level due to either the pdr3-1 or the cyh mutation alone was low and was not altered by the ogd1 mutation which increased the physiological acidification of the culture.	Cycloheximide	4-17	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	53-57
1394518-3	1992	When pdr3-1 and cyh mutations occurred simultaneously in the haploid yeast strain their interaction was synergistic and resulted in high-level resistance to cycloheximide.	Cycloheximide	157-170	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	5-9
1448115-5	1992	Although the c-jun mRNA level was increased by cycloheximide alone, a further 2.4-fold increase was seen when the cells were treated with MPA in the presence of cycloheximide.	Cycloheximide	47-60	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
1382861-8	1992	This enhancement is abrogated by pretreatment of effector cells with cycloheximide, suggesting that protein synthesis is required for IL-6 to enhance LAK cell activity.	Cycloheximide	69-82	interleukin 6	Homo sapiens	134-138
1427396-7	1992	Interestingly, the effect of the protein synthesis inhibitors, emetine and cycloheximide, was similar to that of CsA, suggesting that CsA decreased selected resistance to CDDP and decreased basal resistance to ADR by affecting a protein synthesis-dependent resistance mechanism(s).	Cycloheximide	75-88	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	134-137
1325978-8	1992	Inhibition of PTH response by monokines was blocked by cycloheximide.	Cycloheximide	55-68	parathyroid hormone-like hormone	Rattus norvegicus	14-17
1400875-6	1992	Additionally, treatment of chorion cells with IL-1 beta in combination with actinomycin-D or cycloheximide attenuated the stimulatory action of IL-1 beta on IL-6 production.	Cycloheximide	93-106	interleukin 1 beta	Homo sapiens	144-153
1400875-6	1992	Additionally, treatment of chorion cells with IL-1 beta in combination with actinomycin-D or cycloheximide attenuated the stimulatory action of IL-1 beta on IL-6 production.	Cycloheximide	93-106	interleukin 6	Homo sapiens	157-161
1456083-4	1992	The addition of serum together with cycloheximide, an inhibitor of protein synthesis, resulted in the superinduction of both c-fos and c-jun mRNAs.	Cycloheximide	36-49	FBJ osteosarcoma oncogene	Mus musculus	125-130
1456083-4	1992	The addition of serum together with cycloheximide, an inhibitor of protein synthesis, resulted in the superinduction of both c-fos and c-jun mRNAs.	Cycloheximide	36-49	jun proto-oncogene	Mus musculus	135-140
1522134-6	1992	Treatment of amnion cells stimulated by IL-1 beta with cycloheximide resulted in increased IL-8 production, while incubation of IL-1 beta treated amnion cells with actinomycin D resulted in a concentration-dependent decrease in detectable amounts of IL-8.	Cycloheximide	55-68	interleukin 1 beta	Homo sapiens	40-49
1522134-6	1992	Treatment of amnion cells stimulated by IL-1 beta with cycloheximide resulted in increased IL-8 production, while incubation of IL-1 beta treated amnion cells with actinomycin D resulted in a concentration-dependent decrease in detectable amounts of IL-8.	Cycloheximide	55-68	C-X-C motif chemokine ligand 8	Homo sapiens	91-95
1522134-6	1992	Treatment of amnion cells stimulated by IL-1 beta with cycloheximide resulted in increased IL-8 production, while incubation of IL-1 beta treated amnion cells with actinomycin D resulted in a concentration-dependent decrease in detectable amounts of IL-8.	Cycloheximide	55-68	C-X-C motif chemokine ligand 8	Homo sapiens	250-254
1421567-1	1992	Treatment of AKR-2B mouse fibroblasts with serum growth factors or inhibitors of protein synthesis, such as cycloheximide, results in a stimulation of cytoskeletal beta-actin transcription but has no effect on transcription of muscle-specific isotypes, such as the vascular smooth muscle (VSM) alpha-actin gene.	Cycloheximide	108-121	actin, beta	Mus musculus	164-174
1448115-5	1992	Although the c-jun mRNA level was increased by cycloheximide alone, a further 2.4-fold increase was seen when the cells were treated with MPA in the presence of cycloheximide.	Cycloheximide	161-174	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
1382069-4	1992	Treatment of resting endothelial cells with three different protein synthesis inhibitors, cycloheximide (CHX), anisomycin, and emetine, caused an increase in the steady-state level of ELAM-1 mRNA above that observed with IL (interleukin)-1 alone.	Cycloheximide	90-103	selectin E	Homo sapiens	184-190
1382069-4	1992	Treatment of resting endothelial cells with three different protein synthesis inhibitors, cycloheximide (CHX), anisomycin, and emetine, caused an increase in the steady-state level of ELAM-1 mRNA above that observed with IL (interleukin)-1 alone.	Cycloheximide	105-108	selectin E	Homo sapiens	184-190
1355503-3	1992	Culture of eosinophils in the presence of cytokines and cycloheximide prevented expression of ICAM-1 and HLA-DR, showing that de novo eosinophil protein synthesis is occurring.	Cycloheximide	56-69	intercellular adhesion molecule 1	Homo sapiens	94-100
1517573-8	1992	Cycloheximide treatment enhanced the expression of IL-2, IL-2R alpha, c-myc, and c-fos mRNA in spleen cells from both normal and infected mice.	Cycloheximide	0-13	interleukin 2	Mus musculus	51-55
1517573-8	1992	Cycloheximide treatment enhanced the expression of IL-2, IL-2R alpha, c-myc, and c-fos mRNA in spleen cells from both normal and infected mice.	Cycloheximide	0-13	interleukin 2 receptor, alpha chain	Mus musculus	57-68
1517573-8	1992	Cycloheximide treatment enhanced the expression of IL-2, IL-2R alpha, c-myc, and c-fos mRNA in spleen cells from both normal and infected mice.	Cycloheximide	0-13	FBJ osteosarcoma oncogene	Mus musculus	81-86
1530617-4	1992	A protein synthesis inhibitor cycloheximide abolished the IL-6 release, suggesting a de novo synthesis.	Cycloheximide	30-43	interleukin 6	Homo sapiens	58-62
1528857-7	1992	This effect of RU 28362 was blocked by coincubation with cycloheximide, indicating that the GC receptor-Ca2+ channel interaction depends on de novo protein synthesis.	Cycloheximide	57-70	carbonic anhydrase 2	Homo sapiens	104-107
1520705-9	1992	PMA and the calcium-mobilizing hormones increased c-fos expression above the level observed with cycloheximide alone.	Cycloheximide	97-110	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	50-55
1282820-5	1992	Similarly, treatment of cells with low doses of cycloheximide also generated a partial shift of repressed PABP mRNA into the actively translated fraction.	Cycloheximide	48-61	poly(A) binding protein cytoplasmic 1	Homo sapiens	106-110
1382409-1	1992	In A-431 cells, platelet-activating factor (PAF) induces the expression of c-fos and TIS-1 genes in both the absence and the presence of cycloheximide in a structurally specific and receptor-coupled manner.	Cycloheximide	137-150	PCNA clamp associated factor	Homo sapiens	16-42
1382409-1	1992	In A-431 cells, platelet-activating factor (PAF) induces the expression of c-fos and TIS-1 genes in both the absence and the presence of cycloheximide in a structurally specific and receptor-coupled manner.	Cycloheximide	137-150	PCNA clamp associated factor	Homo sapiens	44-47
1324147-5	1992	Since cycloheximide, a protein synthesis inhibitor, inhibited the increase in bFGF binding induced by FSH, it is suggested that protein synthesis might be involved in the FSH stimulation of bFGF receptor induction.	Cycloheximide	6-19	fibroblast growth factor 2	Rattus norvegicus	78-82
1324147-5	1992	Since cycloheximide, a protein synthesis inhibitor, inhibited the increase in bFGF binding induced by FSH, it is suggested that protein synthesis might be involved in the FSH stimulation of bFGF receptor induction.	Cycloheximide	6-19	fibroblast growth factor 2	Rattus norvegicus	190-194
1499941-4	1992	Cotreatment of cells exposed to LPS or TNF-alpha with actinomycin D or cycloheximide showed that de novo transcription but not protein synthesis is required for the LPS- and TNF-alpha-dependent induction in MnSOD mRNA.	Cycloheximide	71-84	tumor necrosis factor	Rattus norvegicus	39-48
1499941-4	1992	Cotreatment of cells exposed to LPS or TNF-alpha with actinomycin D or cycloheximide showed that de novo transcription but not protein synthesis is required for the LPS- and TNF-alpha-dependent induction in MnSOD mRNA.	Cycloheximide	71-84	tumor necrosis factor	Rattus norvegicus	174-183
1499941-4	1992	Cotreatment of cells exposed to LPS or TNF-alpha with actinomycin D or cycloheximide showed that de novo transcription but not protein synthesis is required for the LPS- and TNF-alpha-dependent induction in MnSOD mRNA.	Cycloheximide	71-84	superoxide dismutase 2	Rattus norvegicus	207-212
1426528-6	1992	The ODC response to DiCl-RB was prevented by cycloheximide and was not due to stabilization of the enzyme.	Cycloheximide	45-58	Ornithine decarboxylase 1	Drosophila melanogaster	4-7
1506413-0	1992	Brefeldin A, thapsigargin, and AIF4- stimulate the accumulation of GRP78 mRNA in a cycloheximide dependent manner, whilst induction by hypoxia is independent of protein synthesis.	Cycloheximide	83-96	itchy E3 ubiquitin protein ligase	Homo sapiens	31-35
1506413-0	1992	Brefeldin A, thapsigargin, and AIF4- stimulate the accumulation of GRP78 mRNA in a cycloheximide dependent manner, whilst induction by hypoxia is independent of protein synthesis.	Cycloheximide	83-96	heat shock protein family A (Hsp70) member 5	Homo sapiens	67-72
1506413-6	1992	The increased accumulation of GRP78 mRNA after exposure of cells to either thapsigargin, brefeldin A, AIF4-, A23187, or tunicamycin can be blocked by pre-incubation in cycloheximide.	Cycloheximide	168-181	heat shock protein family A (Hsp70) member 5	Homo sapiens	30-35
1506413-6	1992	The increased accumulation of GRP78 mRNA after exposure of cells to either thapsigargin, brefeldin A, AIF4-, A23187, or tunicamycin can be blocked by pre-incubation in cycloheximide.	Cycloheximide	168-181	itchy E3 ubiquitin protein ligase	Homo sapiens	102-106
1402550-8	1992	Cycloheximide prevented the self-priming action of GnRH by inhibiting GnRH-induced protein synthesis.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	51-55
1402550-8	1992	Cycloheximide prevented the self-priming action of GnRH by inhibiting GnRH-induced protein synthesis.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	70-74
1402550-9	1992	The initial protein synthesis-independent GnRH-stimulated LH release, which was already suppressed by FSH treatment, remained suppressed in the presence of cycloheximide.	Cycloheximide	156-169	gonadotropin releasing hormone 1	Rattus norvegicus	42-46
1522240-11	1992	Cycloheximide was a potent LIF mRNA inducer and dexamethasone inhibited LIF induced by PMA or IL-1 beta.	Cycloheximide	0-13	LIF interleukin 6 family cytokine	Homo sapiens	27-30
1522240-11	1992	Cycloheximide was a potent LIF mRNA inducer and dexamethasone inhibited LIF induced by PMA or IL-1 beta.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	94-103
1331775-3	1992	The decay rate of PEPCK mRNA was also slowed in cells incubated with cycloheximide, but not in cells incubated with other translation inhibitors, such as puromycin or pactamycin, even though protein synthesis was inhibited 85-95% by these agents.	Cycloheximide	69-82	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	18-23
1324935-10	1992	ANP or cycloheximide comparably inhibited ET-1 translation while increasing ET-1 mRNA levels, suggesting that the two events are related.	Cycloheximide	7-20	endothelin 1	Bos taurus	42-46
1324935-10	1992	ANP or cycloheximide comparably inhibited ET-1 translation while increasing ET-1 mRNA levels, suggesting that the two events are related.	Cycloheximide	7-20	endothelin 1	Bos taurus	76-80
1499731-0	1992	Nerve growth factor rapidly regulates VGF gene transcription through cycloheximide sensitive and insensitive pathways.	Cycloheximide	69-82	VGF nerve growth factor inducible	Rattus norvegicus	38-41
1499731-5	1992	VGF mRNA half-life was found to substantially decrease in PC12 cells treated with NGF for 9-25 h. Partial inhibition of VGF gene transcription and superinduction of cytoplasmic VGF mRNA levels in the presence of both NGF and cycloheximide suggests that the VGF gene may be regulated through multiple pathways, some of which can be activated in the presence of protein synthesis inhibitors as are the immediate early genes, while others require newly synthesized proteins.	Cycloheximide	225-238	VGF nerve growth factor inducible	Rattus norvegicus	0-3
1324671-3	1992	ET-1 induced-increase in binding capacity was abolished by cycloheximide.	Cycloheximide	59-72	endothelin 1	Homo sapiens	0-4
1324671-5	1992	Cycloheximide (1 microgram/ml) alone induced an increase in u-PAR mRNA level and this effect was enhanced when cycloheximide was combined with ET-1.	Cycloheximide	0-13	plasminogen activator, urokinase receptor	Homo sapiens	60-65
1324671-5	1992	Cycloheximide (1 microgram/ml) alone induced an increase in u-PAR mRNA level and this effect was enhanced when cycloheximide was combined with ET-1.	Cycloheximide	0-13	endothelin 1	Homo sapiens	143-147
1324671-5	1992	Cycloheximide (1 microgram/ml) alone induced an increase in u-PAR mRNA level and this effect was enhanced when cycloheximide was combined with ET-1.	Cycloheximide	111-124	plasminogen activator, urokinase receptor	Homo sapiens	60-65
1639811-3	1992	The glucagon effect on CYP2E1 degradation was abolished by either cycloheximide treatment of cells, indicating the involvement of protein components with rapid turnover, or by lowering of the culture temperature to 23 degrees C. The rapid phase of CYP2E1 degradation was not influenced by inhibitors of the autophagosomal/lysosomal pathway.	Cycloheximide	66-79	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	23-29
1381147-6	1992	Treatment with cycloheximide increased albumin mRNA to the basal level, which was effectively suppressed by dextran, and resulted in superinduction of apo B mRNA.	Cycloheximide	15-28	albumin	Rattus norvegicus	39-46
1497091-6	1992	In addition, when neutrophils were treated with cycloheximide, there was evidence for "superinduction" of steady-state levels of IL-8 mRNA and inhibition of antigenic IL-8 production.	Cycloheximide	48-61	C-X-C motif chemokine ligand 8	Homo sapiens	129-133
1497091-6	1992	In addition, when neutrophils were treated with cycloheximide, there was evidence for "superinduction" of steady-state levels of IL-8 mRNA and inhibition of antigenic IL-8 production.	Cycloheximide	48-61	C-X-C motif chemokine ligand 8	Homo sapiens	167-171
1497606-1	1992	Incubation of cycloheximide-treated cardiac myocytes results in a time-dependent increase in cellular and heparin-releasable lipoprotein lipase (LPL) activities.	Cycloheximide	14-27	lipoprotein lipase	Homo sapiens	125-143
1497606-1	1992	Incubation of cycloheximide-treated cardiac myocytes results in a time-dependent increase in cellular and heparin-releasable lipoprotein lipase (LPL) activities.	Cycloheximide	14-27	lipoprotein lipase	Homo sapiens	145-148
1426065-3	1992	The combination of cycloheximide and recombinant interleukin-1 caused a 14-fold enhancement of interleukin-1 alpha and interleukin-1 beta mRNA expression above that observed after cells were stimulated with interleukin-1 alone.	Cycloheximide	19-32	interleukin 1 alpha	Homo sapiens	95-108
1426065-3	1992	The combination of cycloheximide and recombinant interleukin-1 caused a 14-fold enhancement of interleukin-1 alpha and interleukin-1 beta mRNA expression above that observed after cells were stimulated with interleukin-1 alone.	Cycloheximide	19-32	interleukin 1 beta	Homo sapiens	119-137
1426065-3	1992	The combination of cycloheximide and recombinant interleukin-1 caused a 14-fold enhancement of interleukin-1 alpha and interleukin-1 beta mRNA expression above that observed after cells were stimulated with interleukin-1 alone.	Cycloheximide	19-32	interleukin 1 alpha	Homo sapiens	95-108
1639472-4	1992	IL-8 is detected by enzyme-linked immunosorbent assay within 2 h of stimulation, with steady a increase in its level through 72 h. Further studies demonstrated that LPS could serve as a primary stimulus for the expression of IL-8, since LPS challenge in the presence of cycloheximide resulted in superinduction of bone marrow mononuclear cell-derived IL-8 mRNA.	Cycloheximide	270-283	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
1639472-4	1992	IL-8 is detected by enzyme-linked immunosorbent assay within 2 h of stimulation, with steady a increase in its level through 72 h. Further studies demonstrated that LPS could serve as a primary stimulus for the expression of IL-8, since LPS challenge in the presence of cycloheximide resulted in superinduction of bone marrow mononuclear cell-derived IL-8 mRNA.	Cycloheximide	270-283	C-X-C motif chemokine ligand 8	Homo sapiens	225-229
1639472-4	1992	IL-8 is detected by enzyme-linked immunosorbent assay within 2 h of stimulation, with steady a increase in its level through 72 h. Further studies demonstrated that LPS could serve as a primary stimulus for the expression of IL-8, since LPS challenge in the presence of cycloheximide resulted in superinduction of bone marrow mononuclear cell-derived IL-8 mRNA.	Cycloheximide	270-283	C-X-C motif chemokine ligand 8	Homo sapiens	225-229
1322417-5	1992	However, when protein synthesis was inhibited with 100 microM cycloheximide, the increase of tPA and uPA mRNA by hPTH(1-34) was enhanced in UMR 106-01 cells and became evident in calvarial osteoblasts.	Cycloheximide	62-75	plasminogen activator, tissue type	Rattus norvegicus	93-96
1322417-5	1992	However, when protein synthesis was inhibited with 100 microM cycloheximide, the increase of tPA and uPA mRNA by hPTH(1-34) was enhanced in UMR 106-01 cells and became evident in calvarial osteoblasts.	Cycloheximide	62-75	plasminogen activator, urokinase	Rattus norvegicus	101-104
1353499-8	1992	Cycloheximide was used to reduced the ER concentration of Tg relative to chaperones, with subsequent removal of the drug in order to rapidly restore Tg synthesis.	Cycloheximide	0-13	thyroglobulin	Homo sapiens	58-60
1353499-8	1992	Cycloheximide was used to reduced the ER concentration of Tg relative to chaperones, with subsequent removal of the drug in order to rapidly restore Tg synthesis.	Cycloheximide	0-13	thyroglobulin	Homo sapiens	149-151
1353765-13	1992	Both the hormone-mediated increase in cell GSH and GCS activity were blocked with either cycloheximide or actinomycin D.	Cycloheximide	89-102	glutamate-cysteine ligase, catalytic subunit	Rattus norvegicus	51-54
1639869-7	1992	Cycloheximide (7.5 micrograms.ml-1) completely inhibited pro alpha 1(I) collagen gene expression induced by IGF-I.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	108-113
1500822-6	1992	The protein synthesis inhibitor, cycloheximide, which itself markedly stimulates the accumulation of PAI-1, appears to prevent the induction by thrombin, suggesting that thrombin may act by inducing another effector such as interleukin-1.	Cycloheximide	33-46	serpin family E member 1	Homo sapiens	101-106
1500822-6	1992	The protein synthesis inhibitor, cycloheximide, which itself markedly stimulates the accumulation of PAI-1, appears to prevent the induction by thrombin, suggesting that thrombin may act by inducing another effector such as interleukin-1.	Cycloheximide	33-46	coagulation factor II, thrombin	Homo sapiens	144-152
1500822-6	1992	The protein synthesis inhibitor, cycloheximide, which itself markedly stimulates the accumulation of PAI-1, appears to prevent the induction by thrombin, suggesting that thrombin may act by inducing another effector such as interleukin-1.	Cycloheximide	33-46	coagulation factor II, thrombin	Homo sapiens	170-178
1282159-12	1992	Cycloheximide and nitro-L-arginine inhibited the relaxations and the production of nitrite evoked by interleukin-1 beta-treated cells.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	101-119
1405321-10	1992	Inhibition studies with cycloheximide indicated de novo synthesis of TNF alpha.	Cycloheximide	24-37	tumor necrosis factor	Homo sapiens	69-78
1406697-5	1992	We also provide data which suggest that T3 nuclear receptor(s) have a direct role on MyoD1 gene transcription: 1) C2 cells express the alpha 1 form of T3 nuclear receptors; 2) T3 up-regulates MyoD1 gene transcription and does not affect MyoD1 mRNA stability, as demonstrated by run-on and actinomycin D chase experiments, respectively; and 3) this transcriptional activation does not need the synthesis of intermediate protein(s) since it is not abolished by simultaneous treatment with cycloheximide.	Cycloheximide	487-500	myogenic differentiation 1	Homo sapiens	85-90
1641474-0	1992	Reduction of levels of nuclear-associated protein in heated cells by cycloheximide, D2O, and thermotolerance.	Cycloheximide	69-82	catenin beta like 1	Homo sapiens	23-49
1322599-2	1992	Oligonucleotides encoding some of these sites bind specifically to purified NF-kappa B protein and an NF-kappa B-like protein in nuclear extracts of phorbol ester- or cycloheximide-induced human embryonic lung (HEL) cells.	Cycloheximide	167-180	nuclear factor kappa B subunit 1	Homo sapiens	76-86
1322599-2	1992	Oligonucleotides encoding some of these sites bind specifically to purified NF-kappa B protein and an NF-kappa B-like protein in nuclear extracts of phorbol ester- or cycloheximide-induced human embryonic lung (HEL) cells.	Cycloheximide	167-180	nuclear factor kappa B subunit 1	Homo sapiens	102-112
1321828-0	1992	Superinduction of CYP1A1 transcription by cycloheximide.	Cycloheximide	42-55	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	18-24
1321828-2	1992	Nuclear run-off experiments reveal that four distinct DNA domains, each of which contains a binding site for the liganded Ah receptor, can mediate the superinduction of transcription by 2,3,7,8-tetrachlorodibenzo-p-dioxin plus cycloheximide.	Cycloheximide	227-240	aryl hydrocarbon receptor	Homo sapiens	122-133
1321736-8	1992	The reappearance of IL6-binding sites at the cell surface required greater than 8 h and was sensitive to cycloheximide, suggesting that gp80 is not recycled after internalization.	Cycloheximide	105-118	interleukin 6	Homo sapiens	20-23
1321736-8	1992	The reappearance of IL6-binding sites at the cell surface required greater than 8 h and was sensitive to cycloheximide, suggesting that gp80 is not recycled after internalization.	Cycloheximide	105-118	interleukin 6 receptor	Homo sapiens	136-140
1379472-5	1992	For cultures of EL4 cells grown in the presence of 5 microM 7-ketocholestanol, for example, the addition of appropriate concentrations of cycloheximide, puromycin, emetine, and actinomycin increased the percentage of viable cells from a control value of less than 6% to 66%, 28%, 76% and 42%, respectively.	Cycloheximide	138-151	epilepsy 4	Mus musculus	16-19
1618817-8	1992	TNF-alpha-induced enhancement of LDL receptor gene expression was not observed when cycloheximide was present.	Cycloheximide	84-97	tumor necrosis factor	Homo sapiens	0-9
1618817-8	1992	TNF-alpha-induced enhancement of LDL receptor gene expression was not observed when cycloheximide was present.	Cycloheximide	84-97	low density lipoprotein receptor	Homo sapiens	33-45
1618850-5	1992	In both transfectants, the maximal insulin-induced increase (approximately 3.5-fold) in uptake was cycloheximide-sensitive and was paralleled by equivalent increases in the levels of GLUT-1 immunoreactive protein and mRNA.	Cycloheximide	99-112	insulin	Homo sapiens	35-42
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	CCAAT enhancer binding protein alpha	Homo sapiens	51-62
1617671-2	1992	All three inducers elicit a characteristic immediate early response of c-fos which is inhibited by the protein kinase inhibitor H7 but enhanced by the protein synthesis inhibitor cycloheximide.	Cycloheximide	179-192	FBJ osteosarcoma oncogene	Mus musculus	71-76
1632457-3	1992	By immunogold silver staining, epipolarization microscopy and dispersive X-ray spectrometry, we have shown that matrix-associated PAI-1 is synthesized by spreading human mesangial cells, as indicated by the time-dependent accumulation of PAI-1 and the inhibitory effect of cycloheximide.	Cycloheximide	273-286	serpin family E member 1	Homo sapiens	130-135
1636747-8	1992	By utilizing stable isotope methods, we could demonstrate that IL-1 increased free arachidonate levels, implying new PLA2 synthesis over a time course that was maximal at 6 h and was cycloheximide and actinomycin D sensitive.	Cycloheximide	183-196	interleukin 1 alpha	Homo sapiens	63-67
1636747-8	1992	By utilizing stable isotope methods, we could demonstrate that IL-1 increased free arachidonate levels, implying new PLA2 synthesis over a time course that was maximal at 6 h and was cycloheximide and actinomycin D sensitive.	Cycloheximide	183-196	phospholipase A2 group IB	Homo sapiens	117-121
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	solute carrier family 2 member 4	Homo sapiens	64-69
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	transcription factor AP-2 alpha	Homo sapiens	79-82
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	tumor necrosis factor	Homo sapiens	141-144
1618860-10	1992	The rapid coordinate transcriptional regulation of C/EBP-alpha, GLUT4, and 422/aP2 by TNF in the presence of cycloheximide suggests that the TNF-induced loss of GLUT4 protein may be mediated by a post-translational modification of an existing transcription factor.	Cycloheximide	109-122	solute carrier family 2 member 4	Homo sapiens	161-166
1419903-5	1992	c-jun mRNA levels were superinduced in cells treated with both okadaic acid and cycloheximide, whereas inhibition of protein synthesis had little, if any, effect on okadaic acid-induced c-jun transcription.	Cycloheximide	80-93	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
1419903-7	1992	In contrast, treatment with both okadaic acid and cycloheximide was associated with stabilization (t 1/2 = 90 min) of c-jun transcripts.	Cycloheximide	50-63	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	118-123
1617647-8	1992	Cycloheximide inhibited the expression of IL-4 receptors by 50% in about 2 h in both cell types indicating both the half-life of IL-4 receptors and the requirement for protein synthesis for the tat III up-regulation of IL-4 receptors.	Cycloheximide	0-13	interleukin 4	Homo sapiens	42-46
1617647-8	1992	Cycloheximide inhibited the expression of IL-4 receptors by 50% in about 2 h in both cell types indicating both the half-life of IL-4 receptors and the requirement for protein synthesis for the tat III up-regulation of IL-4 receptors.	Cycloheximide	0-13	interleukin 4	Homo sapiens	129-133
1617647-8	1992	Cycloheximide inhibited the expression of IL-4 receptors by 50% in about 2 h in both cell types indicating both the half-life of IL-4 receptors and the requirement for protein synthesis for the tat III up-regulation of IL-4 receptors.	Cycloheximide	0-13	interleukin 4	Homo sapiens	129-133
1628615-5	1992	Thirdly, the recently described capacity to act positively as nuclear signalling agonists to stimulate pp33/pp15 phosphorylation is restricted to compounds such as anisomycin and cycloheximide; these, but not emetine or puromycin, will induce c-fos/c-jun on their own.	Cycloheximide	179-192	nuclear transport factor 2	Homo sapiens	108-112
1628615-5	1992	Thirdly, the recently described capacity to act positively as nuclear signalling agonists to stimulate pp33/pp15 phosphorylation is restricted to compounds such as anisomycin and cycloheximide; these, but not emetine or puromycin, will induce c-fos/c-jun on their own.	Cycloheximide	179-192	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	243-248
1628615-5	1992	Thirdly, the recently described capacity to act positively as nuclear signalling agonists to stimulate pp33/pp15 phosphorylation is restricted to compounds such as anisomycin and cycloheximide; these, but not emetine or puromycin, will induce c-fos/c-jun on their own.	Cycloheximide	179-192	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	249-254
1618554-5	1992	Increases in angiotensin II receptors were dependent on protein synthesis as evidenced by the time dependency of upregulation and inhibition by cycloheximide.	Cycloheximide	144-157	angiotensinogen	Rattus norvegicus	13-27
1535090-10	1992	The protein synthesis inhibitor cycloheximide abrogated GM-CSF receptor up-regulation induced by both rMuIL-3 and rMuGM-CSF, whereas actinomycin D inhibited only the second (8-24 h) phase of GM-CSF receptor up-regulation induced by exposure to high concentrations rMuGM-CSF (10 ng/ml).	Cycloheximide	32-45	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	56-62
1535090-10	1992	The protein synthesis inhibitor cycloheximide abrogated GM-CSF receptor up-regulation induced by both rMuIL-3 and rMuGM-CSF, whereas actinomycin D inhibited only the second (8-24 h) phase of GM-CSF receptor up-regulation induced by exposure to high concentrations rMuGM-CSF (10 ng/ml).	Cycloheximide	32-45	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	117-123
1279189-3	1992	p75NGFR mRNA levels are increased by either cycloheximide or nerve growth factor (NGF) treatment of C6 cells as measured using RT-PCR.	Cycloheximide	44-57	nerve growth factor	Rattus norvegicus	3-6
1279189-5	1992	TrkB mRNA levels were increased by cycloheximide treatment of type I astrocyte cultures but not by NGF treatment.	Cycloheximide	35-48	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	0-4
1356258-6	1992	Furthermore, the protective effects of EGF on glutamate neurotoxicity disappeared in the presence of cycloheximide (0.1 microM), a protein synthesis inhibitor.	Cycloheximide	101-114	epidermal growth factor like 1	Rattus norvegicus	39-42
1377399-5	1992	The time-dependent increase in the amount of S-protein was significantly reduced by the presence of cycloheximide (10 micrograms/ml) in the cell cultures.	Cycloheximide	100-113	vitronectin	Homo sapiens	45-54
1610348-5	1992	When IL-1 alpha-induced fibroblasts were exposed to cycloheximide there was enhancement of the net de novo synthesis and secretion of IL-6 as followed by [35S]-methionine labeling ("superinduction") but the secreted cytokine was no longer phosphorylated as monitored by [32P] labeling.	Cycloheximide	52-65	interleukin 1 alpha	Homo sapiens	5-15
1610348-5	1992	When IL-1 alpha-induced fibroblasts were exposed to cycloheximide there was enhancement of the net de novo synthesis and secretion of IL-6 as followed by [35S]-methionine labeling ("superinduction") but the secreted cytokine was no longer phosphorylated as monitored by [32P] labeling.	Cycloheximide	52-65	interleukin 6	Homo sapiens	134-138
1610348-7	1992	Furthermore, IL-6 phosphorylation is inhibited by cycloheximide through a mechanism different from the drug"s effects on polypeptide synthesis per se.	Cycloheximide	50-63	interleukin 6	Homo sapiens	13-17
1596884-7	1992	The thrombin effect on tumor cells was optimum at 1 h of incubation with thrombin, did not require active thrombin on the tumor cell surface, and did not require protein synthesis (not inhibited by cycloheximide).	Cycloheximide	198-211	coagulation factor II	Mus musculus	4-12
1597444-3	1992	Contrary to the commonly observed short half-life of mouse ODC in mammalian cells, however, the mouse ODC activity expressed in T. brucei remained stable for at least 6 h when protein synthesis was inhibited by cycloheximide.	Cycloheximide	211-224	ornithine decarboxylase, structural 1	Mus musculus	102-105
1597486-4	1992	Exposure to cycloheximide had little effect on tropoelastin mRNA levels in control cells but partially restored tropoelastin mRNA levels in cells pretreated with 1,25(OH)2D3 and prevented repression when added together with 1,25(OH)2D3.	Cycloheximide	12-25	elastin	Bos taurus	112-124
1319698-2	1992	Angiotensin converting enzyme was released spontaneously and the angiotensin converting enzyme derived from rheumatoid nodule cells was suppressed in a dose and time dependent manner by the protein synthesis inhibitor cycloheximide.	Cycloheximide	218-231	angiotensin I converting enzyme	Homo sapiens	0-29
1319698-2	1992	Angiotensin converting enzyme was released spontaneously and the angiotensin converting enzyme derived from rheumatoid nodule cells was suppressed in a dose and time dependent manner by the protein synthesis inhibitor cycloheximide.	Cycloheximide	218-231	angiotensin I converting enzyme	Homo sapiens	65-94
1599423-5	1992	In cell cultures stimulated for only 24 h, the induced thermogenin was subsequently specifically and rapidly degraded, with a half-life of 20 h. As the half-life was prolonged by cycloheximide treatment, the degradation was apparently due to the induction of specific proteins after cessation of adrenergic stimulation.	Cycloheximide	179-192	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	55-66
1599423-6	1992	In cell cultures continuously stimulated with noradrenaline for 5 days, the induced thermogenin was degraded much more slowly after noradrenaline removal, with a half-life of 70 h. This half-life was unchanged by cycloheximide treatment, and the degradation after cycloheximide was in parallel with the degradation of protein in general, and was therefore non-specific.	Cycloheximide	213-226	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	84-95
1599423-6	1992	In cell cultures continuously stimulated with noradrenaline for 5 days, the induced thermogenin was degraded much more slowly after noradrenaline removal, with a half-life of 70 h. This half-life was unchanged by cycloheximide treatment, and the degradation after cycloheximide was in parallel with the degradation of protein in general, and was therefore non-specific.	Cycloheximide	264-277	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	84-95
1591723-0	1992	Parathyroid hormone-like peptide shares features with members of the early response gene family: rapid induction by serum, growth factors, and cycloheximide.	Cycloheximide	143-156	parathyroid hormone-like hormone	Rattus norvegicus	0-32
1591723-2	1992	Previous studies have demonstrated that PLP gene expression is regulated by serum and cycloheximide, features common to the regulation of a number of different early response genes.	Cycloheximide	86-99	parathyroid hormone-like hormone	Rattus norvegicus	40-43
1591723-6	1992	Cycloheximide alone induced PLP gene expression; however, PLP mRNA transcripts were not superinduced in the presence of both serum and cycloheximide.	Cycloheximide	0-13	parathyroid hormone-like hormone	Rattus norvegicus	28-31
1317778-11	1992	Furthermore, pretreatment with cycloheximide (5 micrograms/ml) increased both basal and ACTH-increased c-fos mRNA.	Cycloheximide	31-44	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	103-108
1597153-5	1992	Results from experiments with the protein synthesis inhibitor cycloheximide and the mRNA synthesis inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzidimidazole suggest 1) that during induction of POMC gene expression no de novo protein synthesis is required and, 2) that deinduction of POMC gene expression requires transcriptional activation of an mRNA-degradation system.	Cycloheximide	62-75	proopiomelanocortin L homeolog	Xenopus laevis	196-200
1634442-0	1992	Serum and insulin inhibit cell death induced by cycloheximide in the human breast cancer cell line MCF-7.	Cycloheximide	48-61	insulin	Homo sapiens	10-17
1284250-11	1992	Cycloheximide inhibited DNA breakdown in a dose dependent manner in cultures lacking EPO, but two other protein synthesis inhibitors, pactamycin and puromycin, did not prevent DNA breakdown.	Cycloheximide	0-13	erythropoietin	Mus musculus	85-88
1375619-5	1992	The quantity of HSP72 produced was markedly decreased by co-treatment with 1 microgram/ml of cycloheximide in delta 12-PGJ2-treated cells, and similarly reduced in HSC-I cells following heat treatment.	Cycloheximide	93-106	heat shock protein family A (Hsp70) member 1A	Homo sapiens	16-21
1316484-5	1992	In contrast, cycloheximide treatment increased stable mRNA levels and transcription initiation rates from both the IE94-IFN and IE94-CAT hybrid genes.	Cycloheximide	13-26	interferon alpha 1	Homo sapiens	120-123
1319454-8	1992	The effect of IL-1 took 2 h to develop and was blocked by cycloheximide (100 mumol/l).	Cycloheximide	58-71	interleukin 1 alpha	Homo sapiens	14-18
1354270-12	1992	cAMP-stimulated APA activity was suppressed by cycloheximide.	Cycloheximide	47-60	glutamyl aminopeptidase	Homo sapiens	16-19
1599449-6	1992	These results suggest that there are at least two pathways to down-regulate AT1 mRNA; one way is an angiotensin II-induced, protein kinase C-independent, and cycloheximide-sensitive pathway and the other is an angiotensin II-independent, cAMP-induced, and cycloheximide-insensitive pathway.	Cycloheximide	158-171	angiotensin II receptor, type 1a	Rattus norvegicus	76-79
1599449-6	1992	These results suggest that there are at least two pathways to down-regulate AT1 mRNA; one way is an angiotensin II-induced, protein kinase C-independent, and cycloheximide-sensitive pathway and the other is an angiotensin II-independent, cAMP-induced, and cycloheximide-insensitive pathway.	Cycloheximide	256-269	angiotensin II receptor, type 1a	Rattus norvegicus	76-79
1374453-3	1992	One of these cDNA, designated B94, detects a rapidly and transiently induced 4-kb transcript in TNF-treated HUVE cells, and this transcript is superinduced in the concomitant presence of cycloheximide.	Cycloheximide	187-200	tumor necrosis factor, alpha-induced protein 2	Mus musculus	30-33
1374453-3	1992	One of these cDNA, designated B94, detects a rapidly and transiently induced 4-kb transcript in TNF-treated HUVE cells, and this transcript is superinduced in the concomitant presence of cycloheximide.	Cycloheximide	187-200	tumor necrosis factor	Mus musculus	96-99
1533652-3	1992	The finding reported here that IL-9 expression is blocked by cycloheximide strongly supports this hypothesis.	Cycloheximide	61-74	interleukin 9	Homo sapiens	31-35
1578146-6	1992	IL-8 release was dependent on FMLP-induced de novo protein synthesis because it was inhibited by cycloheximide, was paralleled by enhanced expression of IL-8 mRNA and was potentiated from two- to sixfold after preincubation of PMN with cytochalasin B.	Cycloheximide	97-110	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
1578146-6	1992	IL-8 release was dependent on FMLP-induced de novo protein synthesis because it was inhibited by cycloheximide, was paralleled by enhanced expression of IL-8 mRNA and was potentiated from two- to sixfold after preincubation of PMN with cytochalasin B.	Cycloheximide	97-110	formyl peptide receptor 1	Homo sapiens	30-34
1584804-8	1992	IL-1 mRNA accumulates in young fibroblasts treated with cycloheximide, suggesting that it is transcribed but unstable in these cells; accumulation of IL-1 mRNA in old fibroblasts may be due at least in part to increased stability.	Cycloheximide	56-69	interleukin 1 alpha	Homo sapiens	0-4
1587353-1	1992	The murine ST2 gene, which encodes a protein remarkably similar to the extracellular portion of murine interleukin 1 receptor types 1 and 2, is expressed in growth-stimulated BALB/c-3T3 cells in the presence of 50 micrograms/ml of cycloheximide.	Cycloheximide	231-244	interleukin 1 receptor-like 1	Mus musculus	11-14
1315773-3	1992	ApoB 100 nascent polypeptides were shown to be secreted from pulse-labeled Hep G2 cells after treatment with puromycin and chase for 1 or 2 h in the presence of puromycin and cycloheximide.	Cycloheximide	175-188	apolipoprotein B	Homo sapiens	0-8
1632803-3	1992	The suppressive effect of RA on pS2 mRNA was inhibited by cycloheximide.	Cycloheximide	58-71	taste 2 receptor member 64 pseudogene	Homo sapiens	32-35
1587353-4	1992	Furthermore, a longer ST2-related mRNA was found in BALB/c-3T3 cells that were stimulated to proliferate in the presence of cycloheximide.	Cycloheximide	124-137	interleukin 1 receptor-like 1	Mus musculus	22-25
1633112-6	1992	Run-on analysis showed that transcription of the GM-CSF gene was low to undetectable in unstimulated cells; stimulation led to transcriptional activation, which was weak at 6 h but had increased 16-fold at 24 h. In addition, the mRNA half-life decreased during activation, from 2.5 h at 6 h down to 45 min at 24 h. Cycloheximide treatment increased GM-CSF mRNA half-life (3- and 4-fold, respectively).	Cycloheximide	315-328	colony stimulating factor 2	Homo sapiens	49-55
1319843-2	1992	We demonstrate that disruption of PDR5 causes marked hypersensitivity not only to cycloheximide but also to sulphometuron methyl and the mitochondrial inhibitors chloramphenicol, lincomycin, erythromycin and antimycin.	Cycloheximide	82-95	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	34-38
1319843-3	1992	Genetic analysis of double mutants containing an insertion in PDR5 (pdr5:Tn5), which renders cells hypersensitive to cycloheximide, and a pdr1 mutation, which confers resistance to this inhibitor, indicates that the expression of resistance requires a functional PDR5 gene.	Cycloheximide	117-130	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	62-66
1319843-3	1992	Genetic analysis of double mutants containing an insertion in PDR5 (pdr5:Tn5), which renders cells hypersensitive to cycloheximide, and a pdr1 mutation, which confers resistance to this inhibitor, indicates that the expression of resistance requires a functional PDR5 gene.	Cycloheximide	117-130	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	68-72
1533599-1	1992	Microinjection of a bacterially expressed stable delta 90 sea urchin cyclin B into Xenopus prophase oocytes, in absence or presence of cycloheximide, provokes the activation of histone H1 kinase and the tyrosine dephosphorylation of p34cdc2.	Cycloheximide	135-148	proliferating cell nuclear antigen S homeolog	Xenopus laevis	69-75
1533599-4	1992	When delta 90 cyclin is microinjected into oocytes depleted of endogenous cyclins (cycloheximide-treated metaphase I) and in the presence of a high intracellular concentration of cAMP, p34cdc2 kinase is tyrosine rephosphorylated.	Cycloheximide	83-96	proliferating cell nuclear antigen S homeolog	Xenopus laevis	14-20
1533599-4	1992	When delta 90 cyclin is microinjected into oocytes depleted of endogenous cyclins (cycloheximide-treated metaphase I) and in the presence of a high intracellular concentration of cAMP, p34cdc2 kinase is tyrosine rephosphorylated.	Cycloheximide	83-96	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	185-192
1572288-7	1992	Cycloheximide prevented the inhibitory effect of these agents on IGF-I mRNA levels, suggesting that their effect is at least partly dependent upon protein synthesis.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	65-70
1572291-6	1992	The requirement of de novo protein synthesis for thyroid hormone-mediated induction of FN mRNA was examined by the addition of cycloheximide 15 min before T3 addition.	Cycloheximide	127-140	fibronectin 1	Rattus norvegicus	87-89
1319667-6	1992	Both effects were dose dependent, with 1-4 ng/ml of TGF-beta producing maximal effects, and both effects were blocked by the protein synthesis inhibitor cycloheximide (2-5 microM).	Cycloheximide	153-166	transforming growth factor, beta 1	Rattus norvegicus	52-60
1381781-8	1992	The inhibitory effect of IL-1 beta was endothelium and prostaglandin independent, but was prevented by a treatment with NG-nitro-L-arginine (a nitric oxide synthesis inhibitor), cycloheximide, dexamethasone, or IRA.	Cycloheximide	178-191	interleukin-1 beta	Oryctolagus cuniculus	25-34
1601743-7	1992	Cycloheximide, but no actinomycin D, inhibited the effect of insulin on androgen receptor binding.	Cycloheximide	0-13	insulin	Homo sapiens	61-68
1613426-7	1992	Pretreatment of rats with the antiandrogen cyproterone acetate (5 mg/rat) or the protein synthesis inhibitor cycloheximide (10 mg/rat) did not affect the enzyme activity of testes injected with DMSO, but counteracted the inhibitory effect of DHT on 3 beta-HSD activity in the contralateral testis.	Cycloheximide	109-122	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	249-259
1315361-9	1992	The TGF-beta-mediated inhibition of P815 basal binding to endothelium is dependent on protein synthesis because cycloheximide reverses the TGF-beta effect.	Cycloheximide	112-125	transforming growth factor, beta 1	Mus musculus	4-12
1315361-9	1992	The TGF-beta-mediated inhibition of P815 basal binding to endothelium is dependent on protein synthesis because cycloheximide reverses the TGF-beta effect.	Cycloheximide	112-125	transforming growth factor, beta 1	Mus musculus	139-147
1380583-7	1992	Tyrosine amino-transferase (TAT) activity in the rat liver increased significantly by GC administration, and the increased TAT activity was completely abrogated by simultaneous administration of 5 mg/kg of cycloheximide (CH).	Cycloheximide	206-219	tyrosine aminotransferase	Rattus norvegicus	0-26
1380583-7	1992	Tyrosine amino-transferase (TAT) activity in the rat liver increased significantly by GC administration, and the increased TAT activity was completely abrogated by simultaneous administration of 5 mg/kg of cycloheximide (CH).	Cycloheximide	206-219	tyrosine aminotransferase	Rattus norvegicus	28-31
1380583-7	1992	Tyrosine amino-transferase (TAT) activity in the rat liver increased significantly by GC administration, and the increased TAT activity was completely abrogated by simultaneous administration of 5 mg/kg of cycloheximide (CH).	Cycloheximide	206-219	tyrosine aminotransferase	Rattus norvegicus	123-126
1593910-11	1992	In contrast, c-myc was expressed at high levels in UCSD/AML1 cells and showed evidence for specific regulation in response to cycloheximide, phorbol ester, and GM-CSF withdrawal and restimulation.	Cycloheximide	126-139	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	13-18
1376410-7	1992	Treatment of cells with cycloheximide demonstrates that, while PSA/hGK-1 basal transcription strictly depends on continuous protein synthesis, transcriptional induction by androgen does not.	Cycloheximide	24-37	kallikrein related peptidase 3	Homo sapiens	63-66
1376410-7	1992	Treatment of cells with cycloheximide demonstrates that, while PSA/hGK-1 basal transcription strictly depends on continuous protein synthesis, transcriptional induction by androgen does not.	Cycloheximide	24-37	kallikrein related peptidase 2	Homo sapiens	67-72
1603084-7	1992	Inhibition of protein synthesis with cycloheximide abrogated the effect of PMA on bFGF mRNA levels, but only partially inhibited the effect of PMA on IGF-I mRNA levels.	Cycloheximide	37-50	fibroblast growth factor 2	Rattus norvegicus	82-86
1373875-6	1992	We have previously demonstrated that c-fgr is transcriptionally activated in U937 cells treated with either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or cycloheximide (CHX).	Cycloheximide	155-168	FGR proto-oncogene, Src family tyrosine kinase	Homo sapiens	37-42
1569109-11	1992	PT-alpha mRNA induction seems to require the synthesis of proteic factor(s) since PT-alpha mRNA response to serum restoration was abolished in the presence of cycloheximide.	Cycloheximide	159-172	pre T cell antigen receptor alpha	Mus musculus	0-8
1569109-11	1992	PT-alpha mRNA induction seems to require the synthesis of proteic factor(s) since PT-alpha mRNA response to serum restoration was abolished in the presence of cycloheximide.	Cycloheximide	159-172	pre T cell antigen receptor alpha	Mus musculus	82-90
1608534-1	1992	C-fos mRNA expression by stimulation with subcutaneous (s.c.) administration of saline or cycloheximide (CHX) was examined in the rat striatum with or without pretreatment with ceruletide, an analogue of cholecystokinin.	Cycloheximide	90-103	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
1608534-1	1992	C-fos mRNA expression by stimulation with subcutaneous (s.c.) administration of saline or cycloheximide (CHX) was examined in the rat striatum with or without pretreatment with ceruletide, an analogue of cholecystokinin.	Cycloheximide	105-108	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
1373875-6	1992	We have previously demonstrated that c-fgr is transcriptionally activated in U937 cells treated with either 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or cycloheximide (CHX).	Cycloheximide	170-173	FGR proto-oncogene, Src family tyrosine kinase	Homo sapiens	37-42
1373875-8	1992	These results suggest that TPA and CHX induce c-fgr mRNA accumulation by different mechanisms.	Cycloheximide	35-38	FGR proto-oncogene, Src family tyrosine kinase	Homo sapiens	46-51
1608534-2	1992	The c-fos mRNA induction 1 h after CHX stimulation (25 mg/kg, s.c.) was significantly suppressed by ceruletide pretreatment (80 micrograms/kg, s.c.) 2 h before CHX stimulation in the striatum, and tended to be suppressed by ceruletide pretreatment 4 h before saline or CHX stimulation.	Cycloheximide	35-38	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1608534-2	1992	The c-fos mRNA induction 1 h after CHX stimulation (25 mg/kg, s.c.) was significantly suppressed by ceruletide pretreatment (80 micrograms/kg, s.c.) 2 h before CHX stimulation in the striatum, and tended to be suppressed by ceruletide pretreatment 4 h before saline or CHX stimulation.	Cycloheximide	160-163	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1608534-2	1992	The c-fos mRNA induction 1 h after CHX stimulation (25 mg/kg, s.c.) was significantly suppressed by ceruletide pretreatment (80 micrograms/kg, s.c.) 2 h before CHX stimulation in the striatum, and tended to be suppressed by ceruletide pretreatment 4 h before saline or CHX stimulation.	Cycloheximide	160-163	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	4-9
1315521-5	1992	Cycloheximide and actinomycin D blocked the action of RA, suggesting that RA may regulate transferrin and albumin gene expression indirectly in human liver cells.	Cycloheximide	0-13	transferrin	Homo sapiens	90-101
1315521-5	1992	Cycloheximide and actinomycin D blocked the action of RA, suggesting that RA may regulate transferrin and albumin gene expression indirectly in human liver cells.	Cycloheximide	0-13	albumin	Homo sapiens	106-113
1373503-10	1992	TGF-beta 2 induction was only weakly enhanced by cycloheximide and was completely inhibited by actinomycin D.	Cycloheximide	49-62	transforming growth factor beta 2	Homo sapiens	0-10
1567912-8	1992	And (iv), increased secretion of lipoprotein lipase activity was only observed after 3 h of incubation with adrenaline and was blocked by cycloheximide.	Cycloheximide	138-151	lipoprotein lipase	Rattus norvegicus	33-51
1551894-4	1992	Induction of LAP mRNA is a secondary response to IFN-gamma, blocked by inhibition of protein synthesis with cycloheximide.	Cycloheximide	108-121	LAP	Homo sapiens	13-16
1551894-4	1992	Induction of LAP mRNA is a secondary response to IFN-gamma, blocked by inhibition of protein synthesis with cycloheximide.	Cycloheximide	108-121	interferon gamma	Homo sapiens	49-58
1551904-9	1992	The presence of asparagine increased the half-life of ODC protein by 3-5-fold when measured in the presence of cycloheximide.	Cycloheximide	111-124	ornithine decarboxylase, structural 1	Mus musculus	54-57
1551915-6	1992	PAI-2 mRNA accumulation was inducible by cycloheximide but prevented by actinomycin D.	Cycloheximide	41-54	serpin family B member 2	Homo sapiens	0-5
1566827-7	1992	The action of PRL on AIB uptake requires both ongoing RNA and protein synthesis, since puromycin (50 micrograms/ml), cycloheximide (5 micrograms/ml), and actinomycin D (1 microgram/ml) abolished the PRL response.	Cycloheximide	117-130	prolactin	Mus musculus	14-17
1550338-4	1992	The effect of RA on PKC alpha mRNA induction was not direct since the induction was abolished when cycloheximide was included in the incubation medium.	Cycloheximide	99-112	protein kinase C, alpha	Mus musculus	20-29
1567364-4	1992	In contrast, the stimulatory effect of transforming growth factor-beta 1 reached a maximum after 24 h. The stimulatory effect of PDGF-BB was inhibited by cycloheximide.	Cycloheximide	154-167	transforming growth factor beta 1	Homo sapiens	39-72
1372530-10	1992	Finally, the addition of cycloheximide, an inhibitor of protein synthesis, prior to but not after irradiation, abolished the increase in MGMT activity.	Cycloheximide	25-38	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	137-141
1551129-9	1992	Cycloheximide treatment of the Y8 and ED2 cells resulted in a marked increase in the steady-state p53 mRNA level, indicating that a protein which was rapidly turned over was responsible for the extremely short half-life of p53 mRNA in these two cell lines.	Cycloheximide	0-13	transformation related protein 53, pseudogene	Mus musculus	98-101
1551129-9	1992	Cycloheximide treatment of the Y8 and ED2 cells resulted in a marked increase in the steady-state p53 mRNA level, indicating that a protein which was rapidly turned over was responsible for the extremely short half-life of p53 mRNA in these two cell lines.	Cycloheximide	0-13	transformation related protein 53, pseudogene	Mus musculus	223-226
1339344-5	1992	In addition, binding of NF-jun to its recognition site is enhanced by treatment of cells with 12-O-tetradecanoylphorbol-13-acetate, tumor necrosis factor alpha or the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	210-213	tumor necrosis factor	Homo sapiens	132-159
1555580-6	1992	Inhibition of de novo protein synthesis by cycloheximide increases PAI-2 mRNA levels in both resting (sevenfold) and PMA-treated cells (fivefold) after 4 h, but has no detectable effect on the rate of PAI-2 gene transcription.	Cycloheximide	43-56	serpin family B member 2	Homo sapiens	67-72
1555580-8	1992	Furthermore, the PAI-2 mRNA transcript is stabilized in the presence of cycloheximide, with a fourfold increase in the observed half-life.	Cycloheximide	72-85	serpin family B member 2	Homo sapiens	17-22
1313770-3	1992	Here, we show that cells released from cdc28ts arrest in the presence of cycloheximide show wild-type levels of induction for HO, CLN1, and CDC9 (DNA ligase).	Cycloheximide	73-86	cyclin CLN1	Saccharomyces cerevisiae S288C	130-134
1313770-3	1992	Here, we show that cells released from cdc28ts arrest in the presence of cycloheximide show wild-type levels of induction for HO, CLN1, and CDC9 (DNA ligase).	Cycloheximide	73-86	DNA ligase (ATP) CDC9	Saccharomyces cerevisiae S288C	140-144
1313770-5	1992	This lag may be due, at least in part, to association of the Cdc28 peptide with G1 cyclins to form an active kinase complex because overexpression of CLN2 prior to release in cycloheximide increases the rate of induction for CDC9 and HO.	Cycloheximide	175-188	cyclin-dependent serine/threonine-protein kinase CDC28	Saccharomyces cerevisiae S288C	61-66
1313770-5	1992	This lag may be due, at least in part, to association of the Cdc28 peptide with G1 cyclins to form an active kinase complex because overexpression of CLN2 prior to release in cycloheximide increases the rate of induction for CDC9 and HO.	Cycloheximide	175-188	cyclin CLN2	Saccharomyces cerevisiae S288C	150-154
1313770-6	1992	Consistent with this, release from pheromone arrest (where CLN1 and CLN2 are not expressed) in cycloheximide shows no induction at all.	Cycloheximide	95-108	cyclin CLN1	Saccharomyces cerevisiae S288C	59-63
1313770-6	1992	Consistent with this, release from pheromone arrest (where CLN1 and CLN2 are not expressed) in cycloheximide shows no induction at all.	Cycloheximide	95-108	cyclin CLN2	Saccharomyces cerevisiae S288C	68-72
1313770-9	1992	Insertion of a 20-bp fragment from the CDC9 promoter (containing a MluI element) upstream of LacZ confers both periodic expression and transcriptional induction in cycloheximide following release from cdc28ts arrest.	Cycloheximide	164-177	DNA ligase (ATP) CDC9	Saccharomyces cerevisiae S288C	39-43
1317349-6	1992	Up-regulation of TNF receptors by IL-6 is dependent on de novo protein synthesis since receptor induction is abolished in the presence of cycloheximide.	Cycloheximide	138-151	interleukin 6	Homo sapiens	34-38
1555891-4	1992	Further investigation showed that treatment of BC1 cells with either of the protein synthesis inhibitors, cycloheximide or anisomycin, increased the level of both nuclear and cytoplasmic uPA RNA 6- to 18-fold in 4 hr, whilst inducing a maximum 2.6-fold increase in the rate of uPA gene transcription.	Cycloheximide	106-119	plasminogen activator, urokinase	Homo sapiens	187-190
1555891-4	1992	Further investigation showed that treatment of BC1 cells with either of the protein synthesis inhibitors, cycloheximide or anisomycin, increased the level of both nuclear and cytoplasmic uPA RNA 6- to 18-fold in 4 hr, whilst inducing a maximum 2.6-fold increase in the rate of uPA gene transcription.	Cycloheximide	106-119	plasminogen activator, urokinase	Homo sapiens	277-280
1548355-5	1992	Treatment of decidual cells with actinomycin D or cycloheximide abrogated the increase in IL-6 production induced by IL-1 beta.	Cycloheximide	50-63	interleukin 6	Homo sapiens	90-94
1548355-5	1992	Treatment of decidual cells with actinomycin D or cycloheximide abrogated the increase in IL-6 production induced by IL-1 beta.	Cycloheximide	50-63	interleukin 1 beta	Homo sapiens	117-126
1577874-7	1992	The percentage of cells undergoing apoptosis depended on the concentration of TNF and was augmented by the addition of cycloheximide.	Cycloheximide	119-132	tumor necrosis factor	Homo sapiens	78-81
1577874-8	1992	A TNF-resistant variant derived from U937 did not undergo apoptosis in response to TNF, even in the presence of cycloheximide.	Cycloheximide	112-125	tumor necrosis factor	Homo sapiens	2-5
1545132-7	1992	Most of the AP-1 activity could be eliminated when the anti-AIM mAb was added to the culture medium in the presence of cycloheximide, suggesting that de novo protein synthesis is crucial for the induction of AP-1-binding activity.	Cycloheximide	119-132	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-16
1545132-7	1992	Most of the AP-1 activity could be eliminated when the anti-AIM mAb was added to the culture medium in the presence of cycloheximide, suggesting that de novo protein synthesis is crucial for the induction of AP-1-binding activity.	Cycloheximide	119-132	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	208-212
1374482-5	1992	The stimulatory effect was vitiated by cycloheximide indicating the involvement of intermediate genes in the PLP gene activation.	Cycloheximide	39-52	proteolipid protein 1	Rattus norvegicus	109-112
1381180-12	1992	When the granulosa cells were pulse-treated for 2 h with cycloheximide (10 micrograms/ml), they exhibited a transient rise in LH receptor RNA content which was followed by a delayed receptor increase especially at 72 h of stimulation.	Cycloheximide	57-70	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	126-137
1316854-8	1992	The protein synthesis inhibitor cycloheximide diminished basal, CT-, TPA-, and EGF-stimulated P-450scc mRNA accumulation whereas the opposite was observed for the adrenodoxin mRNA.	Cycloheximide	32-45	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	94-102
1350056-3	1992	The glucocorticoid-mediated TAT expression was inhibited by cycloheximide, a protein synthesis inhibitor, and by RU486, a glucocorticoid antagonist, suggesting that glucocorticoid induction requires protein synthesis and may be mediated through hormone receptors.	Cycloheximide	60-73	tyrosine aminotransferase	Rattus norvegicus	28-31
1533011-5	1992	TcR-alpha mRNA levels can be dramatically augmented in RS4.2 cells by three distinct mechanisms: in response to treatment with either phorbol myristate acetate (PMA), calcium ionophore (A23187), or cycloheximide (CHX).	Cycloheximide	198-211	T cell receptor alpha constant	Homo sapiens	0-9
1533011-5	1992	TcR-alpha mRNA levels can be dramatically augmented in RS4.2 cells by three distinct mechanisms: in response to treatment with either phorbol myristate acetate (PMA), calcium ionophore (A23187), or cycloheximide (CHX).	Cycloheximide	213-216	T cell receptor alpha constant	Homo sapiens	0-9
1549109-8	1992	Cycloheximide pretreatment, which inhibits the antiproliferative effects of PGA2, prevents activation of the heat shock factor and induction of HSP70 mRNA by PGA2.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 4	Homo sapiens	144-149
1313426-8	1992	Resensitization of the cell to thrombin following a brief exposure to thrombin required up to 24 h and could be inhibited with cycloheximide.	Cycloheximide	127-140	coagulation factor II, thrombin	Homo sapiens	31-39
1313426-8	1992	Resensitization of the cell to thrombin following a brief exposure to thrombin required up to 24 h and could be inhibited with cycloheximide.	Cycloheximide	127-140	coagulation factor II, thrombin	Homo sapiens	70-78
1313426-9	1992	Resensitization to TRP42/55 after exposure to thrombin, or to thrombin after exposure to TRP42/55, on the other hand, was detectable within 30 min and could be inhibited by serine/threonine phosphatase inhibitors, but not by cycloheximide.	Cycloheximide	225-238	coagulation factor II, thrombin	Homo sapiens	62-70
1314092-7	1992	Pretreatment with cycloheximide blocked the increase in the 4.1 kb calmodulin mRNA induced by dibutyryl cyclic AMP, but only partially blocked the increase in the 1.4 kb and 1.7 kb transcripts.	Cycloheximide	18-31	calmodulin 1	Rattus norvegicus	67-77
1550560-2	1992	Cells exposed to cycloheximide and IGF I together showed super-induction of c-jun transcripts.	Cycloheximide	17-30	jun proto-oncogene	Mus musculus	76-81
1531844-7	1992	Treatment of IFN-gamma/IL-2-stimulated macrophages with cycloheximide blocks the suppressive effect of IL-4, suggesting that de novo synthesis of an intermediate protein is part of the suppressive mechanism.	Cycloheximide	56-69	interferon gamma	Mus musculus	13-22
1531844-7	1992	Treatment of IFN-gamma/IL-2-stimulated macrophages with cycloheximide blocks the suppressive effect of IL-4, suggesting that de novo synthesis of an intermediate protein is part of the suppressive mechanism.	Cycloheximide	56-69	interleukin 2	Mus musculus	23-27
1531844-7	1992	Treatment of IFN-gamma/IL-2-stimulated macrophages with cycloheximide blocks the suppressive effect of IL-4, suggesting that de novo synthesis of an intermediate protein is part of the suppressive mechanism.	Cycloheximide	56-69	interleukin 4	Mus musculus	103-107
1531846-11	1992	In unstimulated T cells the t1/2 of high Mr CD45 mRNA was estimated at 2.8 h. CD45 mRNA is super-induced in the presence of the protein synthesis inhibitor, cycloheximide, indicating that the degradation and/or splicing of CD45 mRNA is controlled by a labile pathway, and suggesting that mechanisms may exist in vivo to prolong synthesis of CD45RA.	Cycloheximide	157-170	protein tyrosine phosphatase receptor type C	Homo sapiens	44-48
1531846-11	1992	In unstimulated T cells the t1/2 of high Mr CD45 mRNA was estimated at 2.8 h. CD45 mRNA is super-induced in the presence of the protein synthesis inhibitor, cycloheximide, indicating that the degradation and/or splicing of CD45 mRNA is controlled by a labile pathway, and suggesting that mechanisms may exist in vivo to prolong synthesis of CD45RA.	Cycloheximide	157-170	protein tyrosine phosphatase receptor type C	Homo sapiens	78-82
1531846-11	1992	In unstimulated T cells the t1/2 of high Mr CD45 mRNA was estimated at 2.8 h. CD45 mRNA is super-induced in the presence of the protein synthesis inhibitor, cycloheximide, indicating that the degradation and/or splicing of CD45 mRNA is controlled by a labile pathway, and suggesting that mechanisms may exist in vivo to prolong synthesis of CD45RA.	Cycloheximide	157-170	protein tyrosine phosphatase receptor type C	Homo sapiens	78-82
1558167-11	1992	The levels of GDH mRNA are also increased by treating cells with adenosine 3",5"-cyclic monophosphate, epinephrine, triiodothyronine, or retinoic acid, whereas treatment with angiotensin II, vasopressin, phorbol 12-myristate 13-acetate, or cycloheximide did not produce an increase.	Cycloheximide	240-253	angiotensinogen	Rattus norvegicus	175-189
1378338-11	1992	Myocytes possessed Ca(2+)-dependent NO synthase activity and expressed, after treatment with tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), a Ca(2+)-independent NO synthase, the induction of which was prevented by dexamethasone and cycloheximide.	Cycloheximide	262-275	interleukin 1 beta	Rattus norvegicus	138-156
1378338-11	1992	Myocytes possessed Ca(2+)-dependent NO synthase activity and expressed, after treatment with tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), a Ca(2+)-independent NO synthase, the induction of which was prevented by dexamethasone and cycloheximide.	Cycloheximide	262-275	interleukin 1 beta	Rattus norvegicus	158-167
1315920-6	1992	Treating JS1 cells with cycloheximide (CHX), an inhibitor of protein synthesis that commonly potentiates induction of early response genes by presumably inhibiting synthesis of transcriptional repressors, markedly induces the transcription of NGFI-A and c-fos as well as p75NGFR genes.	Cycloheximide	24-37	early growth response 1	Rattus norvegicus	243-249
1315920-6	1992	Treating JS1 cells with cycloheximide (CHX), an inhibitor of protein synthesis that commonly potentiates induction of early response genes by presumably inhibiting synthesis of transcriptional repressors, markedly induces the transcription of NGFI-A and c-fos as well as p75NGFR genes.	Cycloheximide	24-37	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	254-259
1618137-11	1992	Finally, injection of partially purified MPF into cycloheximide-arrested eggs induced cortical microtubule breakdown.	Cycloheximide	50-63	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	41-44
1735464-4	1992	PGA2 induction of gadd153 mRNA was completely prevented by the presence of actinomycin D at a concentration sufficient to block transcription and was partially inhibited (50%) by the protein synthesis inhibitor cycloheximide.	Cycloheximide	211-224	DNA damage inducible transcript 3	Homo sapiens	18-25
1533388-5	1992	This down-regulation of IL-1RtI by IL-1 is blocked by cycloheximide, suggesting de novo protein synthesis is necessary for decreased RNA stability.	Cycloheximide	54-67	interleukin 1 receptor type 1	Homo sapiens	24-31
1533388-5	1992	This down-regulation of IL-1RtI by IL-1 is blocked by cycloheximide, suggesting de novo protein synthesis is necessary for decreased RNA stability.	Cycloheximide	54-67	interleukin 1 beta	Homo sapiens	24-28
1740498-2	1992	Several studies indicate that cytochrome P-450AROM activity is induced by glucocorticoids such as dexamethasone (DEX) and superinduced by DEX plus cycloheximide (CHX).	Cycloheximide	147-160	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	30-50
1740498-2	1992	Several studies indicate that cytochrome P-450AROM activity is induced by glucocorticoids such as dexamethasone (DEX) and superinduced by DEX plus cycloheximide (CHX).	Cycloheximide	162-165	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	30-50
1740498-5	1992	Incubation of cells with DEX plus CHX resulted in a further increase in levels of cytochrome P-450AROM messenger RNA (mRNA) when compared to cells treated with DEX alone, suggesting that inhibition of protein synthesis superinduces transcription of the cytochrome P-450AROM gene.	Cycloheximide	34-37	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	93-102
1740498-5	1992	Incubation of cells with DEX plus CHX resulted in a further increase in levels of cytochrome P-450AROM messenger RNA (mRNA) when compared to cells treated with DEX alone, suggesting that inhibition of protein synthesis superinduces transcription of the cytochrome P-450AROM gene.	Cycloheximide	34-37	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	82-102
1379308-7	1992	Cycloheximide blocked the stimulatory effect of isoproterenol on both the PLP and MAG genes, indicating that the effect of cAMP on the myelin genes is mediated by protein product(s) of other cAMP-response gene(s).	Cycloheximide	0-13	proteolipid protein 1	Rattus norvegicus	74-77
1562528-4	1992	In both these cell types, bFGF (1-200 ng/ml) and IGF-I (25-200 ng/ml) significantly stimulated oestrone sulphatase activity in a dose-dependent manner (by 8-60%) after 48 h. Additionally, cycloheximide significantly inhibited (by 90-120%) this stimulation of oestrone sulphatase activity by the two growth factors in both MCF-7 and MDA-MB-231 cells.	Cycloheximide	188-201	fibroblast growth factor 2	Homo sapiens	26-30
1562528-4	1992	In both these cell types, bFGF (1-200 ng/ml) and IGF-I (25-200 ng/ml) significantly stimulated oestrone sulphatase activity in a dose-dependent manner (by 8-60%) after 48 h. Additionally, cycloheximide significantly inhibited (by 90-120%) this stimulation of oestrone sulphatase activity by the two growth factors in both MCF-7 and MDA-MB-231 cells.	Cycloheximide	188-201	insulin like growth factor 1	Homo sapiens	49-54
1738191-4	1992	Tax1 induction of NF-kappa B occurred in the presence of cycloheximide, and Tax1 stimulation did not result in increased levels of NF-kappa B or c-rel RNA.	Cycloheximide	57-70	contactin 2	Homo sapiens	0-4
1738191-4	1992	Tax1 induction of NF-kappa B occurred in the presence of cycloheximide, and Tax1 stimulation did not result in increased levels of NF-kappa B or c-rel RNA.	Cycloheximide	57-70	nuclear factor kappa B subunit 1	Homo sapiens	18-28
1379199-9	1992	We found that the protein synthesis inhibitor cycloheximide completely abolished the recruitment of PRL-releasing cells by NIL/E2 treatment, whereas the RNA synthesis inhibitor actinomycin D had no effect on this response.	Cycloheximide	46-59	prolactin	Rattus norvegicus	100-103
1639218-3	1992	Like insulin, cycloheximide and anisomycin, two protein synthesis inhibitors, induced p33 transcription and reduced PEPCK transcription.	Cycloheximide	14-27	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	116-121
1347304-13	1992	The protein- and RNA-synthesis inhibitors cycloheximide and actinomycin D prevented expression of ICAM-1 in a dose-dependent fashion.	Cycloheximide	42-55	intercellular adhesion molecule 1	Homo sapiens	98-104
1740146-5	1992	The loss of cytochrome b6/f complexes during gametogenesis is prevented by the addition of cycloheximide, but is chloramphenicol insensitive.	Cycloheximide	91-104	cytochrome b6	Chlamydomonas reinhardtii	12-27
1310679-6	1992	Treatment of the cells with TSH or forskolin transiently increased the TSHr mRNA level after 20 h, an effect inhibited by cycloheximide.	Cycloheximide	122-135	thyroid stimulating hormone receptor	Canis lupus familiaris	71-75
1346397-4	1992	The increases in HMG-CoA synthase and HMG-CoA reductase mRNAs were maximal after treatment of THP-1 cells with 10 micrograms/ml A23187 for 3 h. The stimulation was blocked by actinomycin D but not by cycloheximide treatment.	Cycloheximide	200-213	GLI family zinc finger 2	Homo sapiens	94-99
1371688-5	1992	The bleomycin-induced increase of TGF-beta mRNA was decreased by cells cultured in the presence of either cycloheximide, an inhibitor of protein synthesis, or 2-mercapto-1-(beta-4-pyridethyl) benzimidazole, an inhibitor of RNA synthesis.	Cycloheximide	106-119	transforming growth factor, beta 1	Rattus norvegicus	34-42
1739130-9	1992	Because heat-inactivated TNF-alpha failed to induce synthesis of IL-8 mRNA, and cycloheximide augmented TNF-alpha-induced synthesis, IL-8 expression appears to be a stimulus-specific primary induction phenomenon.	Cycloheximide	80-93	tumor necrosis factor	Homo sapiens	104-113
1370798-6	1992	When cycloheximide (75 microM) was included along with forskolin, PMA, or forskolin plus PMA for a period of 10 h, the increase in NPY medium content was abolished.	Cycloheximide	5-18	neuropeptide Y	Rattus norvegicus	131-134
1371965-10	1992	Cycloheximide completely inhibited the IL-3-induced expression of CD25, indicating the necessity for protein synthesis, and although most of the CD25+ cells were in G0/G1 phase, 25% of the cells were in S or G2M phase, indicating that receptor expression was not cell-cycle dependent.	Cycloheximide	0-13	interleukin 3	Homo sapiens	39-43
1371965-10	1992	Cycloheximide completely inhibited the IL-3-induced expression of CD25, indicating the necessity for protein synthesis, and although most of the CD25+ cells were in G0/G1 phase, 25% of the cells were in S or G2M phase, indicating that receptor expression was not cell-cycle dependent.	Cycloheximide	0-13	interleukin 2 receptor subunit alpha	Homo sapiens	66-70
1733726-5	1992	The increase in PAI-1 protein and the decrease in PA activity were obtained over the same concentration range, with a half-maximally effective concentration of dexamethasone of about 10(-9) M. The increase in PAI-1 mRNA caused by dexamethasone was retained with cycloheximide treatment, but abolished with actinomycin-D.	Cycloheximide	262-275	serpin family E member 1	Rattus norvegicus	16-21
1733726-5	1992	The increase in PAI-1 protein and the decrease in PA activity were obtained over the same concentration range, with a half-maximally effective concentration of dexamethasone of about 10(-9) M. The increase in PAI-1 mRNA caused by dexamethasone was retained with cycloheximide treatment, but abolished with actinomycin-D.	Cycloheximide	262-275	serpin family E member 1	Rattus norvegicus	209-214
1740241-7	1992	The expression of c-fos was inhibited by superoxide dismutase but not by catalase and was super-induced by cycloheximide.	Cycloheximide	107-120	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	18-23
1581584-6	1992	Moreover, in the presence of cycloheximide, phorbol esters down-regulated p75 expression but did not up-regulate p55 expression.	Cycloheximide	29-42	interleukin 2 receptor subunit beta	Homo sapiens	74-77
1370842-3	1992	Inhibition of overall protein and heat shock protein (HSP) synthesis (greater than 95%) by cycloheximide (25 micrograms/ml) during tolerance development nearly completely abolished thermotolerance induced by arsenite, while significant levels of heat-induced thermotolerance were still apparent.	Cycloheximide	91-104	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	54-57
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	32-45	interleukin 1 alpha	Homo sapiens	59-63
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	66-69
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	32-45	CD46 molecule	Homo sapiens	87-90
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	47-49	interleukin 1 alpha	Homo sapiens	59-63
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	47-49	tumor necrosis factor	Homo sapiens	66-69
1370516-9	1992	The protein synthesis inhibitor cycloheximide (Cy) blocked IL-1-, TNF-, or LPS-induced MCP gene expression in monocytes.	Cycloheximide	47-49	CD46 molecule	Homo sapiens	87-90
1370516-11	1992	Moreover, Cy superinduced MCP gene expression in cells other than monocytes, including endothelial cells, smooth muscle cell and fibrosarcoma cells, indicating different mechanisms of regulation in mononuclear phagocytes vs cells of other lineages.	Cycloheximide	10-12	CD46 molecule	Homo sapiens	26-29
1730867-8	1992	Inhibition of protein synthesis with cycloheximide also results in enhanced expression of CD11a mRNA in HL-60 cells without increasing CD11a transcription.	Cycloheximide	37-50	integrin subunit alpha L	Homo sapiens	90-95
1730873-8	1992	IFN-gamma-induction of ICSBP mRNA is resistant to cycloheximide but sensitive to protein kinase inhibitors (H7, H8, HA-1004, staurosporine) at doses that suggest that protein kinase C is a likely target.	Cycloheximide	50-63	interferon gamma	Mus musculus	0-9
1730873-8	1992	IFN-gamma-induction of ICSBP mRNA is resistant to cycloheximide but sensitive to protein kinase inhibitors (H7, H8, HA-1004, staurosporine) at doses that suggest that protein kinase C is a likely target.	Cycloheximide	50-63	interferon regulatory factor 8	Mus musculus	23-28
1732416-9	1992	Fragmentin activity was not dependent on protein synthesis, as cycloheximide treatment of YAC-1 cells did not prevent DNA damage.	Cycloheximide	63-76	ADP-ribosyltransferase 1	Mus musculus	90-95
1729407-7	1992	The AADC activity in the striatum showed a time-dependent response after the administration of SCH 23390 and pimozide: the activity was increased within 30 min and the increases lasted 2-4 h. Inhibition of protein synthesis by cycloheximide (10 mg/kg, 0.5 h) had no effect on the striatal AADC activity or on the increases in striatal AADC activity produced by pimozide or SCH 23390.	Cycloheximide	227-240	dopa decarboxylase	Rattus norvegicus	4-8
1729407-7	1992	The AADC activity in the striatum showed a time-dependent response after the administration of SCH 23390 and pimozide: the activity was increased within 30 min and the increases lasted 2-4 h. Inhibition of protein synthesis by cycloheximide (10 mg/kg, 0.5 h) had no effect on the striatal AADC activity or on the increases in striatal AADC activity produced by pimozide or SCH 23390.	Cycloheximide	227-240	dopa decarboxylase	Rattus norvegicus	289-293
1729407-7	1992	The AADC activity in the striatum showed a time-dependent response after the administration of SCH 23390 and pimozide: the activity was increased within 30 min and the increases lasted 2-4 h. Inhibition of protein synthesis by cycloheximide (10 mg/kg, 0.5 h) had no effect on the striatal AADC activity or on the increases in striatal AADC activity produced by pimozide or SCH 23390.	Cycloheximide	227-240	dopa decarboxylase	Rattus norvegicus	289-293
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	tumor necrosis factor	Homo sapiens	38-47
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	interleukin 1 beta	Homo sapiens	88-97
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	tumor necrosis factor	Homo sapiens	108-117
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	tumor necrosis factor	Homo sapiens	108-117
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	interleukin 1 beta	Homo sapiens	253-262
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	146-159	tumor necrosis factor	Homo sapiens	108-117
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	161-164	tumor necrosis factor	Homo sapiens	108-117
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	161-164	tumor necrosis factor	Homo sapiens	108-117
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	161-164	interleukin 1 beta	Homo sapiens	253-262
1732280-6	1992	Kinetic analysis demonstrated optimum TNF-alpha mRNA expression after a 4 h exposure to IL-1 beta, and peak TNF-alpha protein production at 18 h. Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased expression of TNF-alpha mRNA in IL-1 beta stimulated CH235-MG cells, indicating that de novo protein synthesis is not required for astroglioma TNF-alpha gene expression.	Cycloheximide	161-164	tumor necrosis factor	Homo sapiens	108-117
1576243-8	1992	Finally, a protein synthesis inhibitor, cycloheximide, partially counteracted the negative effects of TPA on IL-2 mRNA accumulation and on proliferation.	Cycloheximide	40-53	interleukin 2	Bos taurus	109-113
1310814-3	1992	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the frequency of IFN-alpha mRNA-containing cells, measured after 6h, was decreased by 85-90%.	Cycloheximide	51-64	interferon alpha 1	Homo sapiens	89-98
1310814-3	1992	In the presence of the protein synthesis inhibitor cycloheximide (CHX), the frequency of IFN-alpha mRNA-containing cells, measured after 6h, was decreased by 85-90%.	Cycloheximide	66-69	interferon alpha 1	Homo sapiens	89-98
1310816-5	1992	The cyclic AMP-induced IL-1 production differed in some aspects from the bacterial lipopolysaccharide-induced IL-1 production: (1) the kinetics of both IL-1 gene expression and protein production was much slower; (2) the IL-1 beta gene expression was superinducible by inhibiting the protein synthesis with cycloheximide.	Cycloheximide	307-320	interleukin 1 beta	Homo sapiens	23-27
1310816-5	1992	The cyclic AMP-induced IL-1 production differed in some aspects from the bacterial lipopolysaccharide-induced IL-1 production: (1) the kinetics of both IL-1 gene expression and protein production was much slower; (2) the IL-1 beta gene expression was superinducible by inhibiting the protein synthesis with cycloheximide.	Cycloheximide	307-320	interleukin 1 beta	Homo sapiens	221-230
1730086-13	1992	In contrast, cycloheximide decreased the prothrombinase activity expressed by the monocyte membrane surface, as well as the activity associated with vesicles released from both stimulated and unstimulated cells.	Cycloheximide	13-26	coagulation factor X	Homo sapiens	41-55
1310050-6	1992	The enhancement of HDC activity by dexamethasone was completely suppressed by cycloheximide or actinomycin D.	Cycloheximide	78-91	histidine decarboxylase	Mus musculus	19-22
1310051-12	1992	The increase in HDC activity was due to the de novo synthesis of the enzyme, since it was suppressed by the addition of cycloheximide or actinomycin D, and was well correlated with the marked accumulation of a 2.7 kilobase HDC mRNA.	Cycloheximide	120-133	histidine decarboxylase	Mus musculus	16-19
1310051-12	1992	The increase in HDC activity was due to the de novo synthesis of the enzyme, since it was suppressed by the addition of cycloheximide or actinomycin D, and was well correlated with the marked accumulation of a 2.7 kilobase HDC mRNA.	Cycloheximide	120-133	histidine decarboxylase	Mus musculus	223-226
1370465-2	1992	Differential screening of a TNF-stimulated, cycloheximide-treated human umbilical vein endothelial cell library has resulted in the cloning of several novel cDNAs whose protein products are involved in the primary response of the endothelium to TNF.	Cycloheximide	44-57	tumor necrosis factor	Homo sapiens	28-31
1370465-2	1992	Differential screening of a TNF-stimulated, cycloheximide-treated human umbilical vein endothelial cell library has resulted in the cloning of several novel cDNAs whose protein products are involved in the primary response of the endothelium to TNF.	Cycloheximide	44-57	tumor necrosis factor	Homo sapiens	245-248
1730665-3	1992	The TH-induced up-regulation in cultured cells is inhibited by cycloheximide when measured either by a transcription initiation assay that measures transcripts of the 5" most exon or by synthesis of full-length TR beta mRNA.	Cycloheximide	63-76	thyroid hormone receptor, beta S homeolog	Xenopus laevis	211-218
1730604-3	1992	We find, however, that in the presence of either actinomycin D (Act D) or cycloheximide (CHI), TNF is indeed able to induce phospholipase activity and that the TNF-induced activation of PLA2 occurs 2-4 h before the onset of 51Cr release.	Cycloheximide	74-87	tumor necrosis factor	Homo sapiens	95-98
1730604-3	1992	We find, however, that in the presence of either actinomycin D (Act D) or cycloheximide (CHI), TNF is indeed able to induce phospholipase activity and that the TNF-induced activation of PLA2 occurs 2-4 h before the onset of 51Cr release.	Cycloheximide	74-87	tumor necrosis factor	Homo sapiens	160-163
1730604-3	1992	We find, however, that in the presence of either actinomycin D (Act D) or cycloheximide (CHI), TNF is indeed able to induce phospholipase activity and that the TNF-induced activation of PLA2 occurs 2-4 h before the onset of 51Cr release.	Cycloheximide	74-87	phospholipase A2 group IB	Homo sapiens	186-190
1294020-7	1992	IL-6 transcripts were strongly superinduced after cycloheximide treatment, suggesting that a labile protein regulates IL-6 mRNA levels in these cells.	Cycloheximide	50-63	interleukin 6	Homo sapiens	0-4
1294020-7	1992	IL-6 transcripts were strongly superinduced after cycloheximide treatment, suggesting that a labile protein regulates IL-6 mRNA levels in these cells.	Cycloheximide	50-63	interleukin 6	Homo sapiens	118-122
1535517-4	1992	Furthermore, cycloheximide, an inhibitor of protein synthesis, could also prevent the early IL-1 beta-induced stimulation of insulin release.	Cycloheximide	13-26	interleukin 1 beta	Mus musculus	92-101
1356505-1	1992	We have obtained the alphoid DNA clones, pK1 and pK2, from the extrachromosomal DNA of Hela cells treated by cycloheximide (30 micrograms/ml).	Cycloheximide	109-122	prokineticin 2	Homo sapiens	49-52
1730100-2	1992	Initial experiments designed to validate the assay revealed that the number of IL-1 beta spot forming cells was increased by exposing normal blood monocytes to LPS and that spot formation was prevented by incubating the cells with cycloheximide.	Cycloheximide	231-244	interleukin 1 beta	Homo sapiens	79-88
1733566-3	1992	Cycloheximide, an inhibitor of protein synthesis, inhibited the mancozeb-caused ODC induction, indicating the effect on enzyme protein synthesis.	Cycloheximide	0-13	ornithine decarboxylase, structural 1	Mus musculus	80-83
1427413-2	1992	In both amnion and placental tissues, cycloheximide inhibited the fibronectin output indicating that it was being synthesized.	Cycloheximide	38-51	fibronectin 1	Homo sapiens	66-77
1563013-2	1992	Since enhancement of EGF-R expression by rTNF-alpha was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNF alpha may be protein-synthesis-dependent.	Cycloheximide	127-140	epidermal growth factor receptor	Homo sapiens	21-26
1563013-2	1992	Since enhancement of EGF-R expression by rTNF-alpha was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNF alpha may be protein-synthesis-dependent.	Cycloheximide	127-140	tumor necrosis factor	Rattus norvegicus	41-51
1563013-2	1992	Since enhancement of EGF-R expression by rTNF-alpha was inhibited when cells were treated with the protein synthesis inhibitor cycloheximide, the effects of rTNF alpha may be protein-synthesis-dependent.	Cycloheximide	127-140	tumor necrosis factor	Rattus norvegicus	157-167
1309347-10	1992	Thus, cycloheximide inhibits the transcriptional action of both TSH/cAMP and insulin/IGF-I/serum within 4 h, i.e. a rapidly synthesized protein is an intermediate in both cases.	Cycloheximide	6-19	insulin-like growth factor 1	Rattus norvegicus	85-90
1309352-10	1992	Inhibition of protein synthesis by cycloheximide decreased basal, CT and TPA stimulated P-450AROM mRNA levels but increased the expression of 17 beta-HSD mRNA.	Cycloheximide	35-48	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	88-97
1309352-10	1992	Inhibition of protein synthesis by cycloheximide decreased basal, CT and TPA stimulated P-450AROM mRNA levels but increased the expression of 17 beta-HSD mRNA.	Cycloheximide	35-48	hydroxysteroid 17-beta dehydrogenase 1	Homo sapiens	142-153
1309352-12	1992	The present results suggest that: 1) induction of P-450AROM mRNA may at least partly be responsible for our previously reported increases in the rate of conversion of androgens to estrogens by CT and TPA in JEG-3 cells; 2) 17 beta-HSD mRNA expression is mainly controlled through a cAMP-dependent mechanism in contrast to the multifactorial control of P-450AROM mRNA; and 3) protein synthesis inhibition by cycloheximide has opposite effects on the mRNA levels of these two key enzymes in placental estrogen metabolism.	Cycloheximide	407-420	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	50-59
1309352-12	1992	The present results suggest that: 1) induction of P-450AROM mRNA may at least partly be responsible for our previously reported increases in the rate of conversion of androgens to estrogens by CT and TPA in JEG-3 cells; 2) 17 beta-HSD mRNA expression is mainly controlled through a cAMP-dependent mechanism in contrast to the multifactorial control of P-450AROM mRNA; and 3) protein synthesis inhibition by cycloheximide has opposite effects on the mRNA levels of these two key enzymes in placental estrogen metabolism.	Cycloheximide	407-420	hydroxysteroid 17-beta dehydrogenase 1	Homo sapiens	223-234
12106320-2	1992	CHX administered 1 h before transient (30 min) forebrain ischaemia increased the survival of animals, decreased body weight loss and reduced the occurrence of delayed degeneration in the CA1 pyramidal region.	Cycloheximide	0-3	carbonic anhydrase 1	Rattus norvegicus	187-190
1727804-6	1992	Treatment of partially hepatectomized mice with cycloheximide increased hepatic epidermal growth factor receptor messenger RNA levels about fivefold by prolonging the half-life of the messenger RNA to 11.2 hr, although this treatment inhibited the increase in transcription induced by partial hepatectomy.	Cycloheximide	48-61	epidermal growth factor receptor	Mus musculus	80-112
1727804-7	1992	Cycloheximide also increased epidermal growth factor receptor messenger RNA levels in the liver or kidney of sham-operated mice about threefold, primarily through stabilizing epidermal growth factor receptor messenger RNA.	Cycloheximide	0-13	epidermal growth factor receptor	Mus musculus	29-61
1727804-7	1992	Cycloheximide also increased epidermal growth factor receptor messenger RNA levels in the liver or kidney of sham-operated mice about threefold, primarily through stabilizing epidermal growth factor receptor messenger RNA.	Cycloheximide	0-13	epidermal growth factor receptor	Mus musculus	175-207
1756856-8	1991	Actinomycin D and cycloheximide prevented and RU 38486, a glucocorticoid receptor antagonist, suppressed the DEX-induced increase in APA activity.	Cycloheximide	18-31	glutamyl aminopeptidase	Homo sapiens	133-136
1313774-3	1992	The purpose of this study was to establish whether MnSOD was increased in cells selected for resistance to cytolysis by TNF in combination with cycloheximide.	Cycloheximide	144-157	superoxide dismutase 2	Homo sapiens	51-56
1345790-8	1992	Indeed, this direct cytotoxicity was completely abrogated by anti-TNF-alpha antibody and was sensitive to the metabolic inhibitors (cyclosporin A, CT, cycloheximide, and actinomycin D), all of which blocked CD4+/CD8+ T cell TNF-alpha production.	Cycloheximide	151-164	tumor necrosis factor	Homo sapiens	66-75
1345790-8	1992	Indeed, this direct cytotoxicity was completely abrogated by anti-TNF-alpha antibody and was sensitive to the metabolic inhibitors (cyclosporin A, CT, cycloheximide, and actinomycin D), all of which blocked CD4+/CD8+ T cell TNF-alpha production.	Cycloheximide	151-164	tumor necrosis factor	Homo sapiens	224-233
1734947-11	1992	Moreover, cycloheximide treatment abolished the protective effect against NK-CMC induced by IFN-alpha or by IL-2.	Cycloheximide	10-23	interferon alpha 1	Homo sapiens	92-101
1734947-11	1992	Moreover, cycloheximide treatment abolished the protective effect against NK-CMC induced by IFN-alpha or by IL-2.	Cycloheximide	10-23	interleukin 2	Homo sapiens	108-112
1732723-7	1992	However, the finding that ara-C-induced binding of NF-kappa B to DNA occurs in the presence of cycloheximide indicates that this agent activates preexisting NF-kappa B protein.	Cycloheximide	95-108	nuclear factor kappa B subunit 1	Homo sapiens	51-61
1738371-9	1992	Dexamethasone and cA-induced tPA mRNA has a half-life of 2.75 h; tPA mRNA degradation is significantly inhibited by either cycloheximide or actinomycin-D.	Cycloheximide	123-136	plasminogen activator, tissue type	Rattus norvegicus	65-68
1280364-7	1992	Furthermore, bFGF was also able to stimulate ODC mRNA synthesis in the presence of cycloheximide.	Cycloheximide	83-96	fibroblast growth factor 2	Rattus norvegicus	13-17
1280364-7	1992	Furthermore, bFGF was also able to stimulate ODC mRNA synthesis in the presence of cycloheximide.	Cycloheximide	83-96	ornithine decarboxylase 1	Rattus norvegicus	45-48
1571090-4	1992	The suppressive effects of IL-4 appear to be dependent upon de novo protein synthesis, as cycloheximide abrogated the IL-4-induced reduction in TNF-alpha mRNA levels from PBM.	Cycloheximide	90-103	interleukin 4	Homo sapiens	27-31
1571090-4	1992	The suppressive effects of IL-4 appear to be dependent upon de novo protein synthesis, as cycloheximide abrogated the IL-4-induced reduction in TNF-alpha mRNA levels from PBM.	Cycloheximide	90-103	interleukin 4	Homo sapiens	118-122
1571090-4	1992	The suppressive effects of IL-4 appear to be dependent upon de novo protein synthesis, as cycloheximide abrogated the IL-4-induced reduction in TNF-alpha mRNA levels from PBM.	Cycloheximide	90-103	tumor necrosis factor	Homo sapiens	144-153
1472283-3	1992	LPS-induced IL6 mRNA was inhibited by treatment with cycloheximide (5 micrograms/ml), implicating the participation of a secondary protein mediator in the induction process, or the dependence upon protein synthesis for receptor ligand interactions.	Cycloheximide	53-66	interleukin 6	Mus musculus	12-15
1731978-3	1992	When cytoplasmic protein synthesis was inhibited by cycloheximide, nitrate reductase mRNA was induced by nitrate in all tissues to levels equal to or greater than those found with nitrate treatment alone.	Cycloheximide	52-65	nitrate reductase [NADH] 1	Zea mays	67-84
1731978-4	1992	Treatment of maize tissues with cycloheximide in the absence of nitrate had only a small effect on the accumulation of the nitrate reductase mRNA.	Cycloheximide	32-45	nitrate reductase [NADH] 1	Zea mays	123-140
21043896-9	1992	PAF acetylhydrolase activity in the culture medium increased time-dependently for at least 48 h. Treatment of calvaria for 12 h with cycloheximide (1 mug/ml), an inhibitor of protein synthesis, almost completely prevented the appearance of acetylhydrolase activity in the culture medium.	Cycloheximide	133-146	phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)	Mus musculus	0-19
1565846-4	1992	Simultaneous treatment of BMDM with cycloheximide inhibited the suppressive effect of rIFN-alpha 4, indicating that IFN induced the expression of one or several new proteins encoded by gene(s) within the If-1l locus which are responsible for the NDV-specific downregulation of IFN-alpha/beta production.	Cycloheximide	36-49	interferon alpha	Mus musculus	87-96
1761541-10	1991	Induction of MnSOD gene expression was prevented by addition of actinomycin D and cycloheximide.	Cycloheximide	82-95	superoxide dismutase 2	Homo sapiens	13-18
1744113-5	1991	When protein synthesis was inhibited by cycloheximide during TPA pretreatment, TNF no more enhanced the Mn-SOD mRNA accumulation.	Cycloheximide	40-53	tumor necrosis factor	Homo sapiens	79-82
1761057-4	1991	ODC activity was stable in cycloheximide-treated embryos, indicating that before the MBT this enzyme was not degraded.	Cycloheximide	27-40	ornithine decarboxylase 1 L homeolog	Xenopus laevis	0-3
1761057-8	1991	Treatment of post-MBT embryos with cycloheximide lead to an accentuation of the normally observed decrease in ODC activity.	Cycloheximide	35-48	ornithine decarboxylase 1 L homeolog	Xenopus laevis	110-113
1661096-9	1991	The addition of cycloheximide to smooth muscle cells during their incubation with IL-1 beta completely inhibited smooth muscle cell nitrite production, the effects of the smooth muscle cells on platelet cGMP levels, and platelet responses to thrombin.	Cycloheximide	16-29	interleukin 1 beta	Rattus norvegicus	82-91
1661096-9	1991	The addition of cycloheximide to smooth muscle cells during their incubation with IL-1 beta completely inhibited smooth muscle cell nitrite production, the effects of the smooth muscle cells on platelet cGMP levels, and platelet responses to thrombin.	Cycloheximide	16-29	coagulation factor II	Rattus norvegicus	242-250
1952937-5	1991	This ODC mRNA was sequestered from translational machinery since it was not shifted to the polysome fraction when peptide elongation was specifically inhibited by a low concentration of cycloheximide.	Cycloheximide	186-199	ornithine decarboxylase 1	Homo sapiens	5-8
1748685-9	1991	The increase of PKC activity induced by anti-HLA class II antibodies was completely abolished by the treatment with actinomycin D, a transcriptional inhibitor, or cycloheximide, a translational inhibitor.	Cycloheximide	163-176	protein kinase C alpha	Homo sapiens	16-19
1667088-6	1991	The rapid turnover of LMP in transformed BALB/c 3T3 cells is blocked by cycloheximide, which indicates that turnover requires ongoing protein synthesis.	Cycloheximide	72-85	PDZ and LIM domain 7	Mus musculus	22-25
1667088-7	1991	Greater than 90% of newly synthesized LMP is present at the cell surface within 20 min of synthesis, and the detectable protein remains at this location for up to 6 h. If cells are grown in the presence of cycloheximide such that turnover of LMP is inhibited, an internalized pool of LMP can be detected; this observation indicates that turnover of LMP is likely to be preceded by internalization and that, once internalized, LMP is rapidly degraded.	Cycloheximide	206-219	PDZ and LIM domain 7	Homo sapiens	38-41
1667088-7	1991	Greater than 90% of newly synthesized LMP is present at the cell surface within 20 min of synthesis, and the detectable protein remains at this location for up to 6 h. If cells are grown in the presence of cycloheximide such that turnover of LMP is inhibited, an internalized pool of LMP can be detected; this observation indicates that turnover of LMP is likely to be preceded by internalization and that, once internalized, LMP is rapidly degraded.	Cycloheximide	206-219	PDZ and LIM domain 7	Homo sapiens	242-245
1667088-7	1991	Greater than 90% of newly synthesized LMP is present at the cell surface within 20 min of synthesis, and the detectable protein remains at this location for up to 6 h. If cells are grown in the presence of cycloheximide such that turnover of LMP is inhibited, an internalized pool of LMP can be detected; this observation indicates that turnover of LMP is likely to be preceded by internalization and that, once internalized, LMP is rapidly degraded.	Cycloheximide	206-219	PDZ and LIM domain 7	Homo sapiens	242-245
1667088-7	1991	Greater than 90% of newly synthesized LMP is present at the cell surface within 20 min of synthesis, and the detectable protein remains at this location for up to 6 h. If cells are grown in the presence of cycloheximide such that turnover of LMP is inhibited, an internalized pool of LMP can be detected; this observation indicates that turnover of LMP is likely to be preceded by internalization and that, once internalized, LMP is rapidly degraded.	Cycloheximide	206-219	PDZ and LIM domain 7	Homo sapiens	242-245
1667088-7	1991	Greater than 90% of newly synthesized LMP is present at the cell surface within 20 min of synthesis, and the detectable protein remains at this location for up to 6 h. If cells are grown in the presence of cycloheximide such that turnover of LMP is inhibited, an internalized pool of LMP can be detected; this observation indicates that turnover of LMP is likely to be preceded by internalization and that, once internalized, LMP is rapidly degraded.	Cycloheximide	206-219	PDZ and LIM domain 7	Homo sapiens	242-245
1952937-9	1991	Paradoxically more than 70% of ODC mRNA was shifted into polysomes by putrescine in the presence of low concentrations of cycloheximide.	Cycloheximide	122-135	ornithine decarboxylase 1	Homo sapiens	31-34
1933897-1	1991	Studies of parathyroid hormone-like peptide (PLP) have demonstrated that PLP gene expression is inducible by serum, growth factors, and cycloheximide.	Cycloheximide	136-149	parathyroid hormone-like hormone	Rattus norvegicus	11-43
1933897-1	1991	Studies of parathyroid hormone-like peptide (PLP) have demonstrated that PLP gene expression is inducible by serum, growth factors, and cycloheximide.	Cycloheximide	136-149	parathyroid hormone-like hormone	Rattus norvegicus	45-48
1933897-1	1991	Studies of parathyroid hormone-like peptide (PLP) have demonstrated that PLP gene expression is inducible by serum, growth factors, and cycloheximide.	Cycloheximide	136-149	parathyroid hormone-like hormone	Rattus norvegicus	73-76
1724447-10	1991	Cycloheximide alone reduced CD14, but when added in combination with rIFNg the effect on CD14 downregulation was more pronounced.	Cycloheximide	0-13	CD14 molecule	Homo sapiens	28-32
1724447-10	1991	Cycloheximide alone reduced CD14, but when added in combination with rIFNg the effect on CD14 downregulation was more pronounced.	Cycloheximide	0-13	CD14 molecule	Homo sapiens	89-93
1752945-5	1991	The serum induction of PTHrP mRNA was blocked by actinomycin D and by cycloheximide indicating the need for protein synthesis to evoke the serum effect on PTHrP gene transcription.	Cycloheximide	70-83	parathyroid hormone-like hormone	Rattus norvegicus	23-28
1752945-5	1991	The serum induction of PTHrP mRNA was blocked by actinomycin D and by cycloheximide indicating the need for protein synthesis to evoke the serum effect on PTHrP gene transcription.	Cycloheximide	70-83	parathyroid hormone-like hormone	Rattus norvegicus	155-160
1682389-6	1991	In contrast to the Ag-dependent, MHC-restricted cytotoxicity, the heat-shock-induced sensitivity to Th1 clones was a) Ag independent and MHC unrestricted, b) insensitive to CD4-mAb, c) resistant to actinomycin D and cycloheximide, and d) greatly enhanced by cholera toxin, PGE1, PGE2, and dibutyryl cAMP.	Cycloheximide	216-229	negative elongation factor complex member C/D	Homo sapiens	100-103
1940379-8	1991	HILDA/LIF mRNA expression was largely inhibited when monocytes were stimulated in the presence of cycloheximide (CHX) added either at the onset or 4 h after the beginning of the stimulation period.	Cycloheximide	98-111	LIF interleukin 6 family cytokine	Homo sapiens	0-5
1940379-8	1991	HILDA/LIF mRNA expression was largely inhibited when monocytes were stimulated in the presence of cycloheximide (CHX) added either at the onset or 4 h after the beginning of the stimulation period.	Cycloheximide	98-111	LIF interleukin 6 family cytokine	Homo sapiens	6-9
1940379-8	1991	HILDA/LIF mRNA expression was largely inhibited when monocytes were stimulated in the presence of cycloheximide (CHX) added either at the onset or 4 h after the beginning of the stimulation period.	Cycloheximide	113-116	LIF interleukin 6 family cytokine	Homo sapiens	0-5
1940379-8	1991	HILDA/LIF mRNA expression was largely inhibited when monocytes were stimulated in the presence of cycloheximide (CHX) added either at the onset or 4 h after the beginning of the stimulation period.	Cycloheximide	113-116	LIF interleukin 6 family cytokine	Homo sapiens	6-9
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	32-45	interferon alpha 1	Homo sapiens	93-102
1719094-8	1991	Thus, both cycloheximide and actinomycin D blocked the increase on MC DAF observed after incubation with IC and serum.	Cycloheximide	11-24	CD55 molecule (Cromer blood group)	Homo sapiens	70-73
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	32-45	interferon beta 1	Homo sapiens	107-115
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	32-45	interferon alpha 1	Homo sapiens	93-96
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	47-50	interferon alpha 1	Homo sapiens	93-102
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	47-50	interferon beta 1	Homo sapiens	107-115
1666118-2	1991	The protein synthesis inhibitor cycloheximide (CHX) totally prevented the appearance of both IFN-alpha and IFN-beta mRNA, also in cultures supplemented with a conditioned medium (CM) assumed to contain soluble factors necessary for the IFN induction.	Cycloheximide	47-50	interferon alpha 1	Homo sapiens	93-96
1944291-4	1991	rpd3 mutations confer pleiotropic phenotypes, including (i) mating defects, (ii) hypersensitivity to cycloheximide, (iii) inability to sporulate as homozygous diploids, and (iv) constitutive derepression of acid phosphatase.	Cycloheximide	101-114	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	0-4
1766879-3	1991	Deoxycholate released functional NF-kappa B from cytoplasmic extracts and functional NF-kappa B was present in J558L following cycloheximide but not phorbol ester treatment.	Cycloheximide	127-140	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	85-95
1658006-6	1991	However, in marked contrast to that observed with PMA, fucoidan-induced expression of RAW264.7 uPA activity was partially insensitive to cycloheximide and actinomycin D.	Cycloheximide	137-150	plasminogen activator, urokinase	Mus musculus	95-98
1659897-7	1991	The 8-Br-cAMP stimulation of SCP2 mRNA accumulation was completely inhibited by actinomycin D and cycloheximide.	Cycloheximide	98-111	sterol carrier protein 2	Rattus norvegicus	29-33
1834666-5	1991	Moreover, Northern blot analysis revealed that cycloheximide superinduces p47-phox mRNA expression by increasing its half-life and without affecting p47-phox gene transcription.	Cycloheximide	47-60	pleckstrin	Homo sapiens	74-77
1834666-5	1991	Moreover, Northern blot analysis revealed that cycloheximide superinduces p47-phox mRNA expression by increasing its half-life and without affecting p47-phox gene transcription.	Cycloheximide	47-60	neutrophil cytosolic factor 1	Homo sapiens	74-82
1726704-8	1991	Because cycloheximide or actinomycin D impeded the protection of apoptosis by hIL-5, some new RNA and protein synthesis appeared to be required in this phenomena.	Cycloheximide	8-21	interleukin 5	Homo sapiens	78-83
1741740-4	1991	The simultaneous addition of cycloheximide (2.5 micrograms/ml) abrogated the effects of dexamethasone on synthesis of C2, B and C1-inh, but the effect of indomethacin on the synthesis of these components was unchanged.	Cycloheximide	29-42	serpin family G member 1	Homo sapiens	128-134
1719559-6	1991	A 10- to 20-fold increase in IGF binding protein I mRNA was seen 16-48 hr after exposure of the HepG2 cells to insulin and IGF-I, an increase abolished by cycloheximide.	Cycloheximide	155-168	insulin	Homo sapiens	111-118
1719559-6	1991	A 10- to 20-fold increase in IGF binding protein I mRNA was seen 16-48 hr after exposure of the HepG2 cells to insulin and IGF-I, an increase abolished by cycloheximide.	Cycloheximide	155-168	insulin like growth factor 1	Homo sapiens	123-128
1946467-6	1991	The p53-mediated repression of c-fos gene expression occurred even in the presence of cycloheximide.	Cycloheximide	86-99	tumor protein p53	Homo sapiens	4-7
1946467-6	1991	The p53-mediated repression of c-fos gene expression occurred even in the presence of cycloheximide.	Cycloheximide	86-99	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-36
1657152-11	1991	Glucose addition to the pfk26 mutant strain in the absence of cycloheximide, on the other hand, caused a ca.	Cycloheximide	62-75	6-phosphofructo-2-kinase	Saccharomyces cerevisiae S288C	24-29
1939146-1	1991	Pretreatment of HT-1080 fibrosarcoma cells with tumor necrosis factor (TNF) induced resistance to the cytolytic activity of this cytokine in combination with cycloheximide.	Cycloheximide	158-171	tumor necrosis factor	Homo sapiens	48-69
1939161-4	1991	uPA mRNA became highly stable by pretreatment with either cycloheximide or pactamycin, and the stabilizing effect of cycloheximide treatment was time dependent with the full effect exerted by 60 min.	Cycloheximide	58-71	plasminogen activator, urokinase	Sus scrofa	0-3
1939161-4	1991	uPA mRNA became highly stable by pretreatment with either cycloheximide or pactamycin, and the stabilizing effect of cycloheximide treatment was time dependent with the full effect exerted by 60 min.	Cycloheximide	117-130	plasminogen activator, urokinase	Sus scrofa	0-3
1939161-7	1991	In this system, uPA mRNA was completely stable when fractions were obtained from cells pretreated with cycloheximide, but very unstable in control fractions, paralleling uPA mRNA stability in intact cells.	Cycloheximide	103-116	plasminogen activator, urokinase	Sus scrofa	16-19
1939161-10	1991	When PMS from cycloheximide/calcitonin-treated cells was mixed with PMS from untreated cells, uPA mRNA was not destabilized.	Cycloheximide	14-27	plasminogen activator, urokinase	Sus scrofa	94-97
1723921-4	1991	The inhibitory effect of cycloheximide could be overcome by simultaneous perfusion with insulin-like growth factor I (IGF-1).	Cycloheximide	25-38	insulin-like growth factor 1	Rattus norvegicus	88-116
1723921-4	1991	The inhibitory effect of cycloheximide could be overcome by simultaneous perfusion with insulin-like growth factor I (IGF-1).	Cycloheximide	25-38	insulin-like growth factor 1	Rattus norvegicus	118-123
1939146-1	1991	Pretreatment of HT-1080 fibrosarcoma cells with tumor necrosis factor (TNF) induced resistance to the cytolytic activity of this cytokine in combination with cycloheximide.	Cycloheximide	158-171	tumor necrosis factor	Homo sapiens	71-74
1726053-7	1991	Serum-inducible HBGF-1 and HBGF-2 mRNA expression does not occur when RNA synthesis is repressed by actinomycin D but can occur in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	147-160	fibroblast growth factor 1	Homo sapiens	16-22
1939146-6	1991	Cells expressing constitutively PAI-2 were treated with TNF and cycloheximide to select cells with increased resistance to cytolysis and enhanced PAI-2 expression.	Cycloheximide	64-77	serpin family B member 2	Homo sapiens	32-37
1726053-7	1991	Serum-inducible HBGF-1 and HBGF-2 mRNA expression does not occur when RNA synthesis is repressed by actinomycin D but can occur in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	147-160	fibroblast growth factor 2	Homo sapiens	27-33
1939146-6	1991	Cells expressing constitutively PAI-2 were treated with TNF and cycloheximide to select cells with increased resistance to cytolysis and enhanced PAI-2 expression.	Cycloheximide	64-77	serpin family B member 2	Homo sapiens	146-151
1939146-7	1991	PAI-2 gradually disappeared during a treatment with TNF and cycloheximide.	Cycloheximide	60-73	serpin family B member 2	Homo sapiens	0-5
1934297-4	1991	After temporary treatment of hepatocytes for 10 h with cycloheximide, an inhibitor of protein synthesis, AHH activity measured 14 h later was at a normal low level, although medium-change-associated CYP1A1 mRNA were increased by cycloheximide treatment.	Cycloheximide	55-68	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	105-108
1934297-4	1991	After temporary treatment of hepatocytes for 10 h with cycloheximide, an inhibitor of protein synthesis, AHH activity measured 14 h later was at a normal low level, although medium-change-associated CYP1A1 mRNA were increased by cycloheximide treatment.	Cycloheximide	55-68	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	199-205
1934297-4	1991	After temporary treatment of hepatocytes for 10 h with cycloheximide, an inhibitor of protein synthesis, AHH activity measured 14 h later was at a normal low level, although medium-change-associated CYP1A1 mRNA were increased by cycloheximide treatment.	Cycloheximide	229-242	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	199-205
1934297-5	1991	However, if cells were treated with either actinomycin D, alpha-amanitin or cordycepin, which are inhibitors of RNA synthesis, after exposure to cycloheximide, prominent induction of AHH activity was observed, the levels being almost equal to those for hepatocytes treated with benz[a]anthracene, a potent AHH inducer.	Cycloheximide	145-158	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	183-186
1934297-5	1991	However, if cells were treated with either actinomycin D, alpha-amanitin or cordycepin, which are inhibitors of RNA synthesis, after exposure to cycloheximide, prominent induction of AHH activity was observed, the levels being almost equal to those for hepatocytes treated with benz[a]anthracene, a potent AHH inducer.	Cycloheximide	145-158	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	306-309
1655420-6	1991	The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen.	Cycloheximide	32-45	plasminogen activator, urokinase	Homo sapiens	74-79
1655420-6	1991	The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen.	Cycloheximide	32-45	transforming growth factor beta 1	Homo sapiens	145-155
1655420-6	1991	The protein synthesis inhibitor cycloheximide also increased the level of u-PAR mRNA in a time-dependent fashion and when both cycloheximide and TGF-beta 1 were used, an additive effect was seen.	Cycloheximide	127-140	plasminogen activator, urokinase	Homo sapiens	74-79
1657577-9	1991	Similar treatment with cycloheximide (an inhibitor of protein synthesis) revealed distinct differences between the RI alpha and C alpha subunits vs. the RII subunits; cycloheximide reduced the decay of both RII beta and RII alpha mRNAs, whereas steady state levels of mRNAs for RI alpha and C alpha actually increased after cycloheximide treatment of previously (Bu)2cAMP-stimulated cultures.	Cycloheximide	23-36	protein kinase cAMP-dependent type I regulatory subunit alpha	Rattus norvegicus	220-229
1657577-9	1991	Similar treatment with cycloheximide (an inhibitor of protein synthesis) revealed distinct differences between the RI alpha and C alpha subunits vs. the RII subunits; cycloheximide reduced the decay of both RII beta and RII alpha mRNAs, whereas steady state levels of mRNAs for RI alpha and C alpha actually increased after cycloheximide treatment of previously (Bu)2cAMP-stimulated cultures.	Cycloheximide	167-180	protein kinase cAMP-dependent type I regulatory subunit alpha	Rattus norvegicus	220-229
1657577-9	1991	Similar treatment with cycloheximide (an inhibitor of protein synthesis) revealed distinct differences between the RI alpha and C alpha subunits vs. the RII subunits; cycloheximide reduced the decay of both RII beta and RII alpha mRNAs, whereas steady state levels of mRNAs for RI alpha and C alpha actually increased after cycloheximide treatment of previously (Bu)2cAMP-stimulated cultures.	Cycloheximide	167-180	protein kinase cAMP-dependent type I regulatory subunit alpha	Rattus norvegicus	220-229
1935779-5	1991	The IGF-II concentrations in calvarial culture medium were in the 1- to 3-nM range, and these levels were suppressed by cycloheximide (3.6 microM) by almost 80%.	Cycloheximide	120-133	insulin-like growth factor 2	Rattus norvegicus	4-10
1834697-8	1991	Increased expression of IL-1R on normal PMN was induced in vitro by incubating cells with recombinant human granulocyte-macrophage/colony-stimulating factor for 18 h and this response was inhibited by cycloheximide, suggesting the possibility that de novo synthesis of IL-1R might occur in PMN during the sepsis syndrome.	Cycloheximide	201-214	interleukin 1 receptor type 1	Homo sapiens	24-29
1834697-8	1991	Increased expression of IL-1R on normal PMN was induced in vitro by incubating cells with recombinant human granulocyte-macrophage/colony-stimulating factor for 18 h and this response was inhibited by cycloheximide, suggesting the possibility that de novo synthesis of IL-1R might occur in PMN during the sepsis syndrome.	Cycloheximide	201-214	interleukin 1 receptor type 1	Homo sapiens	269-274
1939646-8	1991	The increase in TGF-beta 1 mRNA levels by dexamethasone was further potentiated two to threefold by cycloheximide, suggesting that the steroid effect may be due to inhibition of the synthesis of proteins that decrease TGF-beta 1 gene transcription or the stability of its transcripts.	Cycloheximide	100-113	transforming growth factor beta 1	Homo sapiens	16-26
1939646-8	1991	The increase in TGF-beta 1 mRNA levels by dexamethasone was further potentiated two to threefold by cycloheximide, suggesting that the steroid effect may be due to inhibition of the synthesis of proteins that decrease TGF-beta 1 gene transcription or the stability of its transcripts.	Cycloheximide	100-113	transforming growth factor beta 1	Homo sapiens	218-228
1655898-6	1991	The treatment of B cells with cycloheximide results in the appearance of CK II activity within 15 min, and this induction is partially explainable by a cycloheximide-elicited increase in cellular levels of polyamines.	Cycloheximide	30-43	casein kinase 2 alpha 1	Homo sapiens	73-78
1655898-6	1991	The treatment of B cells with cycloheximide results in the appearance of CK II activity within 15 min, and this induction is partially explainable by a cycloheximide-elicited increase in cellular levels of polyamines.	Cycloheximide	152-165	casein kinase 2 alpha 1	Homo sapiens	73-78
1717608-9	1991	Cycloheximide partially reduces the increased conversion but completely blocks interleukin-1-induced release of prostaglandin E2 from intact cells.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	79-92
1813662-6	1991	Both cycloheximide and actinomycin D inhibited the increase in cyclooxygenase activity caused by EGF plus anthralin.	Cycloheximide	5-18	epidermal growth factor	Mus musculus	97-100
1946363-2	1991	Mutations in the yeast ribosomal protein L29 gene (CYH2) are known that confer cycloheximide resistance.	Cycloheximide	79-92	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	51-55
1803619-0	1991	Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide.	Cycloheximide	124-137	coagulation factor III, tissue factor	Homo sapiens	25-38
1803619-8	1991	These studies indicate that TF cofactor activity on LPS/CHX-treated monocytes was approximately 7 times greater than that present on LPS-treated cells.	Cycloheximide	56-59	coagulation factor III, tissue factor	Homo sapiens	28-30
1803619-9	1991	Increased TF functional activity may be due to CHX-induced alterations in the type and content of phospholipids (PL) in the cell membrane.	Cycloheximide	47-50	coagulation factor III, tissue factor	Homo sapiens	10-12
1953764-2	1991	Treatment with cycloheximide did not affect the basal expression but markedly enhanced the TCDD-inducible expression of ALDH-3 mRNA.	Cycloheximide	15-28	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	120-126
1953764-3	1991	The co-treatment of cycloheximide and TCDD for 24 h caused a 10-fold greater accumulation of ALDH-3 mRNA than did TCDD alone.	Cycloheximide	20-33	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	93-99
1953764-5	1991	The superinduction of ALDH-3 mRNA was observed only when cycloheximide was added prior to or simultaneously with the addition of TCDD.	Cycloheximide	57-70	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	22-28
1913677-4	1991	In contrast, cycloheximide prevented the early, minor enzymatic induction peak of t-PA.	Cycloheximide	13-26	plasminogen activator, tissue type	Homo sapiens	82-86
1913677-7	1991	Cycloheximide or actinomycin D treatments blocked the later t-PA response.	Cycloheximide	0-13	plasminogen activator, tissue type	Homo sapiens	60-64
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	140-153	interleukin 1 beta	Homo sapiens	213-217
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	interleukin 1 beta	Homo sapiens	64-73
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	interleukin 1 beta	Homo sapiens	64-68
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	interleukin 1 beta	Homo sapiens	226-235
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	interleukin 1 beta	Homo sapiens	226-235
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	tumor necrosis factor	Homo sapiens	295-298
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	tumor necrosis factor	Homo sapiens	303-306
1918980-8	1991	To determine if protein synthesis was required for induction of Il-1 beta gene expression, we treated PMN simultaneously with cytokines and cycloheximide, and found that cycloheximide enhanced the accumulation of Il-1-induced Il-1 beta mRNA, but abrogated the accumulation of Il-1 beta mRNA, by TNF- or TNF plus Il-1-treated PMN.	Cycloheximide	170-183	interleukin 1 beta	Homo sapiens	213-217
1932110-14	1991	Inhibition of elongation by cycloheximide treatment resulted in a shift of the ODC mRNA from the region of the gradient containing ribosomal subunits to that containing mono- and polysomes, indicating that most of the ODC mRNA was accessible to translation.	Cycloheximide	28-41	ornithine decarboxylase 1	Homo sapiens	79-82
1932110-14	1991	Inhibition of elongation by cycloheximide treatment resulted in a shift of the ODC mRNA from the region of the gradient containing ribosomal subunits to that containing mono- and polysomes, indicating that most of the ODC mRNA was accessible to translation.	Cycloheximide	28-41	ornithine decarboxylase 1	Homo sapiens	218-221
1932114-1	1991	Northern blot analysis revealed that metallothionein (MT) mRNAs accumulate after inhibition of protein synthesis with cycloheximide (CHX) in primary cultures of chick embryo hepatocytes and fibroblasts, as well as in an established mouse hepatoma cell line.	Cycloheximide	118-131	metallothionein 4	Gallus gallus	37-52
1932114-1	1991	Northern blot analysis revealed that metallothionein (MT) mRNAs accumulate after inhibition of protein synthesis with cycloheximide (CHX) in primary cultures of chick embryo hepatocytes and fibroblasts, as well as in an established mouse hepatoma cell line.	Cycloheximide	118-131	metallothionein 4	Gallus gallus	54-56
1932114-1	1991	Northern blot analysis revealed that metallothionein (MT) mRNAs accumulate after inhibition of protein synthesis with cycloheximide (CHX) in primary cultures of chick embryo hepatocytes and fibroblasts, as well as in an established mouse hepatoma cell line.	Cycloheximide	133-136	metallothionein 4	Gallus gallus	37-52
1932114-1	1991	Northern blot analysis revealed that metallothionein (MT) mRNAs accumulate after inhibition of protein synthesis with cycloheximide (CHX) in primary cultures of chick embryo hepatocytes and fibroblasts, as well as in an established mouse hepatoma cell line.	Cycloheximide	133-136	metallothionein 4	Gallus gallus	54-56
1654863-5	1991	Cycloheximide, a blocker of protein synthesis, suppressed the cAMP-dependent increase of 5"-nucleotidase activity.	Cycloheximide	0-13	5' nucleotidase, ecto	Rattus norvegicus	89-104
1832087-3	1991	In the presence of cycloheximide the TNF-resistant S-EL4 cells were lysed by both TNFs.	Cycloheximide	19-32	tumor necrosis factor	Mus musculus	37-40
1832087-7	1991	When macrophages were activated with LPS +/- IFN-gamma in the presence of cycloheximide or activated just with IFN-gamma their activity after fixation with paraformaldehyde was no longer detected.	Cycloheximide	74-87	interferon gamma	Mus musculus	45-54
1909216-0	1991	The defective in vitro expression of interferon-gamma messenger RNA in rheumatoid arthritis is recovered by cycloheximide.	Cycloheximide	108-121	interferon gamma	Homo sapiens	37-53
1909216-2	1991	In this study, we have examined the superinduction effect of cycloheximide (CHX) on the IFN-gamma mRNA expression in PHA-stimulated T lymphocytes from nine patients with active RA compared to three healthy individuals.	Cycloheximide	61-74	interferon gamma	Homo sapiens	88-97
1909216-2	1991	In this study, we have examined the superinduction effect of cycloheximide (CHX) on the IFN-gamma mRNA expression in PHA-stimulated T lymphocytes from nine patients with active RA compared to three healthy individuals.	Cycloheximide	76-79	interferon gamma	Homo sapiens	88-97
1654270-4	1991	Both expressions are superinduced in the presence of cycloheximide as in mitogenically stimulated fibroblasts but, in the presence of cycloheximide alone, the expressions of c-jun and jun D are clearly unstable with time.	Cycloheximide	53-66	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	174-179
1654270-4	1991	Both expressions are superinduced in the presence of cycloheximide as in mitogenically stimulated fibroblasts but, in the presence of cycloheximide alone, the expressions of c-jun and jun D are clearly unstable with time.	Cycloheximide	134-147	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	174-179
1655396-10	1991	Cycloheximide, an inhibitor of protein synthesis, prevents the effect of CT and 12-O-tetradecanoyl phorbol-13-acetate on TGF-beta 1 mRNA expression in JEG-3 cells, suggesting that a protein mediator may be involved in the transduction of their effects.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	121-131
1716585-4	1991	Addition of cycloheximide in MPF-injected stage IV oocytes induces neither the inhibition of histone H1 kinase activity nor the cyclin B2 degradation.	Cycloheximide	12-25	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	29-32
1889704-6	1991	When protein synthesis was blocked by addition of cycloheximide, ornithine decarboxylase mRNA levels remained unchanged in response to glucocorticoids, indicating a primary effect of dexamethasone.	Cycloheximide	50-63	ornithine decarboxylase 1	Rattus norvegicus	65-88
1721042-10	1991	Cycloheximide treatment, however, inhibited the recovery of perforin and serine protease RNAs.	Cycloheximide	0-13	coagulation factor II, thrombin	Homo sapiens	73-88
1656025-9	1991	Heavy membrane Bmax values were also augmented in the presence of cycloheximide and naltrexone for 48 h. Activities of beta-glucuronidase and beta-hexoseaminidase were diminished in total homogenates and subcellular fractions from naltrexone-treated cells, suggesting an opioid-induced alteration in lysosomal enzyme trafficking.	Cycloheximide	66-79	glucuronidase, beta	Mus musculus	119-137
1655729-9	1991	When added 1 h prior to PMA, however, cycloheximide prevented the induction of PAI-1 mRNA, which suggests that PMA exerts its stimulating transcriptional activity through a newly synthesized regulatory protein.	Cycloheximide	38-51	serpin family E member 1	Homo sapiens	79-84
1655729-10	1991	When cycloheximide was added 2 h after PMA, when the PAI-1 gene transcription rate was maximally increased, the two PAI-1 mRNAs reached even higher levels than with PMA alone and maximal mRNA levels were maintained for a much longer period (up to 8 h).	Cycloheximide	5-18	serpin family E member 1	Homo sapiens	53-58
1655729-10	1991	When cycloheximide was added 2 h after PMA, when the PAI-1 gene transcription rate was maximally increased, the two PAI-1 mRNAs reached even higher levels than with PMA alone and maximal mRNA levels were maintained for a much longer period (up to 8 h).	Cycloheximide	5-18	serpin family E member 1	Homo sapiens	116-121
1655740-4	1991	In a similar fashion, oncostatin M also increased the number of cell surface LDL receptors by a mechanism that was inhibited by cycloheximide or the protein kinase C inhibitor H-7.	Cycloheximide	128-141	oncostatin M	Homo sapiens	22-34
1917937-10	1991	Similar to the initial inhibitory effect of insulin, the protein synthesis inhibitors cycloheximide or anisomycin decreased c-myc transcription.	Cycloheximide	86-99	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	124-129
1832493-4	1991	To study the involvement of transcriptional and post-transcriptional factors in this regulations, we have analysed the effect of cycloheximide, a protein synthesis inhibitor, on the steady-state of the lck mRNA.	Cycloheximide	129-142	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	202-205
1832493-5	1991	Cycloheximide superinduced lck mRNA by increasing its stability, although cycloheximide concomitantly decreased lck transcription.	Cycloheximide	0-13	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	27-30
1832493-5	1991	Cycloheximide superinduced lck mRNA by increasing its stability, although cycloheximide concomitantly decreased lck transcription.	Cycloheximide	74-87	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	112-115
1832493-7	1991	Second, lck mRNA down-modulation observed after full activation was inhibited by cycloheximide.	Cycloheximide	81-94	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	8-11
1653227-6	1991	CSF-1-dependent elevation of CT mRNA content was neither attenuated nor superinduced by the inhibition of protein synthesis with cycloheximide.	Cycloheximide	129-142	colony stimulating factor 1 (macrophage)	Mus musculus	0-5
1909330-7	1991	The TA1-R6 cells, however, are capable of incorporating exogenous 20:4 into PC and PE, and when loaded in such manner they become significantly more sensitive to the cytotoxic effects of TNF in the presence of cycloheximide.	Cycloheximide	210-223	tumor necrosis factor	Homo sapiens	187-190
1660971-3	1991	In this study we show that the MR- and GR-mediated changes of the membrane properties are prevented in the presence of the protein synthesis inhibitor cycloheximide, thus suggesting a genomic action of the steroids.	Cycloheximide	151-164	nuclear receptor subfamily 3 group C member 1	Homo sapiens	39-41
1832263-5	1991	Incubation of U-87 MG cells with cortisol or dexamethasone for as little as 6 h resulted in an upregulation of IL-1R expression, which could be blocked by coincubation with cycloheximide or actinomycin D.	Cycloheximide	173-186	interleukin 1 receptor type 1	Homo sapiens	111-116
1804558-3	1991	Under the marked inhibition of protein synthesis by cycloheximide, H-7 still showed a full effect on the increase in LPL activity.	Cycloheximide	52-65	lipoprotein lipase	Rattus norvegicus	117-120
1651851-7	1991	Whereas cycloheximide prevented the LH/cAMP-mediated decrease in P450arom mRNA in the differentiated cells, enzyme activity remained unaltered during the same 6-h period.	Cycloheximide	8-21	cytochrome P450, family 19, subfamily a, polypeptide 1	Rattus norvegicus	65-73
1714838-6	1991	Basal and LH-induced PR mRNA levels were not affected by progesterone (100 ng/ml), estrogen (100 ng/ml), and RU 486 (10 ng/ml) at 3 h. The mechanism of the increased PR mRNA levels was studied in the presence of actinomycin-D and cycloheximide.	Cycloheximide	230-243	progesterone receptor	Homo sapiens	21-23
1714838-7	1991	While inhibition of RNA synthesis with actinomycin-D blocked LH-induced PR mRNA expression, inhibition of protein synthesis with cycloheximide increased basal and LH-induced PR mRNA levels.	Cycloheximide	129-142	progesterone receptor	Homo sapiens	174-176
1714838-9	1991	There may be a cycloheximide-sensitive mechanism that modulates PR mRNA stability.	Cycloheximide	15-28	progesterone receptor	Homo sapiens	64-66
1874173-8	1991	Furthermore, cycloheximide (1 microgram/ml) markedly blocked hCG-induced P450scc mRNA expression.	Cycloheximide	13-26	chorionic gonadotropin subunit beta 5	Homo sapiens	61-64
1874173-8	1991	Furthermore, cycloheximide (1 microgram/ml) markedly blocked hCG-induced P450scc mRNA expression.	Cycloheximide	13-26	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	73-80
1874181-9	1991	The addition of cycloheximide (10 micrograms/ml) to cAMP-treated cultures for 24 h completely suppressed both constitutive and cAMP-induced 3 beta HSD mRNA levels.	Cycloheximide	16-29	histidine ammonia lyase	Mus musculus	147-150
1874181-10	1991	Cycloheximide also repressed cAMP-induced levels of P450(17 alpha) to 12% of levels observed in the absence of cycloheximide.	Cycloheximide	0-13	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	52-56
1724449-5	1991	Attachment by this vitronectin-independent reaction was inhibited by the protein synthesis inhibitor cycloheximide and also by the microtubule-disrupting drugs demicolcemid and nocodazole.	Cycloheximide	101-114	vitronectin	Mus musculus	19-30
1856599-6	1991	Antigenic and bioactive IL-8 were significantly apparent by 4-8 h, respectively, and increased significantly to maximal levels by 24 h. Furthermore, adherent PBMC IL-8 gene expression was suppressed by either concomitant treatment with actinomycin-D or cycloheximide, yet specific neutralizing antibodies directed against either IL-1 beta or tumor necrosis factor (TNF)-alpha failed to alter adherence-induced steady-state IL-8 mRNA levels.	Cycloheximide	253-266	C-X-C motif chemokine ligand 8	Homo sapiens	24-28
1856599-6	1991	Antigenic and bioactive IL-8 were significantly apparent by 4-8 h, respectively, and increased significantly to maximal levels by 24 h. Furthermore, adherent PBMC IL-8 gene expression was suppressed by either concomitant treatment with actinomycin-D or cycloheximide, yet specific neutralizing antibodies directed against either IL-1 beta or tumor necrosis factor (TNF)-alpha failed to alter adherence-induced steady-state IL-8 mRNA levels.	Cycloheximide	253-266	C-X-C motif chemokine ligand 8	Homo sapiens	163-167
1856599-6	1991	Antigenic and bioactive IL-8 were significantly apparent by 4-8 h, respectively, and increased significantly to maximal levels by 24 h. Furthermore, adherent PBMC IL-8 gene expression was suppressed by either concomitant treatment with actinomycin-D or cycloheximide, yet specific neutralizing antibodies directed against either IL-1 beta or tumor necrosis factor (TNF)-alpha failed to alter adherence-induced steady-state IL-8 mRNA levels.	Cycloheximide	253-266	interleukin 1 beta	Homo sapiens	329-338
1856599-6	1991	Antigenic and bioactive IL-8 were significantly apparent by 4-8 h, respectively, and increased significantly to maximal levels by 24 h. Furthermore, adherent PBMC IL-8 gene expression was suppressed by either concomitant treatment with actinomycin-D or cycloheximide, yet specific neutralizing antibodies directed against either IL-1 beta or tumor necrosis factor (TNF)-alpha failed to alter adherence-induced steady-state IL-8 mRNA levels.	Cycloheximide	253-266	tumor necrosis factor	Homo sapiens	342-375
1856599-6	1991	Antigenic and bioactive IL-8 were significantly apparent by 4-8 h, respectively, and increased significantly to maximal levels by 24 h. Furthermore, adherent PBMC IL-8 gene expression was suppressed by either concomitant treatment with actinomycin-D or cycloheximide, yet specific neutralizing antibodies directed against either IL-1 beta or tumor necrosis factor (TNF)-alpha failed to alter adherence-induced steady-state IL-8 mRNA levels.	Cycloheximide	253-266	C-X-C motif chemokine ligand 8	Homo sapiens	163-167
1798856-5	1991	Cycloheximide and dopamine decreased the prolactin synthesis, but ethanol reduced the effect of dopamine.	Cycloheximide	0-13	prolactin	Rattus norvegicus	41-50
1909029-3	1991	When cells expressing this unstable mRNA are treated with inhibitors of protein synthesis (cycloheximide or puromycin), the steady-state level of the encoded human TfR mRNA is increased due to a stabilization of the transcript.	Cycloheximide	91-104	transferrin receptor	Homo sapiens	164-167
1715603-4	1991	Furthermore CD4+ T cells from the NA fraction but not from the NP fraction are activated cells: their inhibitory activity is abrogated after preincubation with cycloheximide.	Cycloheximide	160-173	CD4 antigen	Mus musculus	12-15
1874723-4	1991	The insulin-induced loss of the intact beta subunit from the cellular membranes is inhibited by cycloheximide.	Cycloheximide	96-109	insulin	Homo sapiens	4-11
1886766-5	1991	In fact, efficient activation of the IRF-E apparently requires an event in addition to de novo IRF-1 induction, which can be elicited by NDV even in the presence of protein synthesis inhibitor, cycloheximide.	Cycloheximide	194-207	tripartite motif containing 63	Homo sapiens	37-40
1886766-5	1991	In fact, efficient activation of the IRF-E apparently requires an event in addition to de novo IRF-1 induction, which can be elicited by NDV even in the presence of protein synthesis inhibitor, cycloheximide.	Cycloheximide	194-207	tripartite motif containing 63	Homo sapiens	95-98
1714478-4	1991	Increased levels of the CSF Ag were detected after 2 to 8 h stimulation with IL-1, and the optimum dose of IL-1 was 10 to 100 U/ml (0.06 to 0.6 nM IL-1 alpha; 0.02 to 0.2 nM IL-1 beta); neither CSF was detectable in nonstimulated cultures nor in IL-1-stimulated cultures treated with actinomycin D or cycloheximide, indicating the requirement for de novo RNA and protein synthesis.	Cycloheximide	301-314	colony stimulating factor 2	Homo sapiens	24-27
1714478-4	1991	Increased levels of the CSF Ag were detected after 2 to 8 h stimulation with IL-1, and the optimum dose of IL-1 was 10 to 100 U/ml (0.06 to 0.6 nM IL-1 alpha; 0.02 to 0.2 nM IL-1 beta); neither CSF was detectable in nonstimulated cultures nor in IL-1-stimulated cultures treated with actinomycin D or cycloheximide, indicating the requirement for de novo RNA and protein synthesis.	Cycloheximide	301-314	interleukin 1 beta	Homo sapiens	107-111
1714478-4	1991	Increased levels of the CSF Ag were detected after 2 to 8 h stimulation with IL-1, and the optimum dose of IL-1 was 10 to 100 U/ml (0.06 to 0.6 nM IL-1 alpha; 0.02 to 0.2 nM IL-1 beta); neither CSF was detectable in nonstimulated cultures nor in IL-1-stimulated cultures treated with actinomycin D or cycloheximide, indicating the requirement for de novo RNA and protein synthesis.	Cycloheximide	301-314	interleukin 1 beta	Homo sapiens	107-111
1677644-11	1991	The use of cycloheximide indicated that the effect of insulin on alpha 2-adrenergic receptor mRNA does not require protein synthesis.	Cycloheximide	11-24	insulin	Homo sapiens	54-61
1650153-6	1991	Inhibition of protein synthesis by cycloheximide blocked the PAF-enhanced NK cell activity after preincubation for 18 h. Extracellular Ca2+ was also needed for the action of PAF as suggested by the effects of Ca2+ chelation with ethyleneglycol-bis-(beta-aminoethyl ether)-N,N"-tetraacetic acid (EGTA) and inhibition of Ca2+ entry into the cells with verapamil and diltiazem, all of which abrogated the action of PAF.	Cycloheximide	35-48	PCNA clamp associated factor	Rattus norvegicus	61-64
1934297-7	1991	After washing out cycloheximide and/or benz[a]anthracene, the decrease in the mRNA amounts was delayed in the presence of actinomycin D and half amounts were found even 12 h later; while without actinomycin D they reduced with a half-life of 3-4 h. The observations indicate that CYP1A1 gene expression might be regulated at the post-transcriptional level with compensatory mRNA stabilization under conditions of blocked further production, resulting in elevation of AHH activity.	Cycloheximide	18-31	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	280-286
1934297-7	1991	After washing out cycloheximide and/or benz[a]anthracene, the decrease in the mRNA amounts was delayed in the presence of actinomycin D and half amounts were found even 12 h later; while without actinomycin D they reduced with a half-life of 3-4 h. The observations indicate that CYP1A1 gene expression might be regulated at the post-transcriptional level with compensatory mRNA stabilization under conditions of blocked further production, resulting in elevation of AHH activity.	Cycloheximide	18-31	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	467-470
1713511-8	1991	After blocking protein synthesis with cycloheximide, IL-1- or FBS-induced M-CSF expression and IL-1 plus FBS-induced GM-CSF expression still occurred and was increased.	Cycloheximide	38-51	interleukin 1 complex	Mus musculus	53-57
1713511-8	1991	After blocking protein synthesis with cycloheximide, IL-1- or FBS-induced M-CSF expression and IL-1 plus FBS-induced GM-CSF expression still occurred and was increased.	Cycloheximide	38-51	colony stimulating factor 1 (macrophage)	Mus musculus	74-79
1713511-9	1991	IL-1-induced G-CSF expression was completely prevented in these cells by pretreatment with cycloheximide, illustrating that, for this effect, intermediate protein synthesis was required.	Cycloheximide	91-104	interleukin 1 complex	Mus musculus	0-4
1713511-9	1991	IL-1-induced G-CSF expression was completely prevented in these cells by pretreatment with cycloheximide, illustrating that, for this effect, intermediate protein synthesis was required.	Cycloheximide	91-104	colony stimulating factor 3 (granulocyte)	Mus musculus	13-18
1713511-12	1991	After blocking protein synthesis with cycloheximide, IL-1-or FBS-induced increase in M-CSF transcription rate was also observed.	Cycloheximide	38-51	interleukin 1 complex	Mus musculus	53-57
1713511-12	1991	After blocking protein synthesis with cycloheximide, IL-1-or FBS-induced increase in M-CSF transcription rate was also observed.	Cycloheximide	38-51	colony stimulating factor 1 (macrophage)	Mus musculus	85-90
1649745-13	1991	Stimulation by OCT of VDR levels, ALP activity, and osteocalcin secretion were inhibited by the addition of 5 microM cycloheximide, indicating that these actions of OCT require new protein synthesis.	Cycloheximide	117-130	vitamin D receptor	Rattus norvegicus	22-25
1830498-5	1991	Cycloheximide inhibited CSF-1-induced IL-1 alpha mRNA synthesis, but augmented IL-1 beta mRNA production and did not affect induction of IL-1Ra mRNA.	Cycloheximide	0-13	colony stimulating factor 1 (macrophage)	Mus musculus	24-29
1830498-5	1991	Cycloheximide inhibited CSF-1-induced IL-1 alpha mRNA synthesis, but augmented IL-1 beta mRNA production and did not affect induction of IL-1Ra mRNA.	Cycloheximide	0-13	interleukin 1 alpha	Mus musculus	38-48
1649745-13	1991	Stimulation by OCT of VDR levels, ALP activity, and osteocalcin secretion were inhibited by the addition of 5 microM cycloheximide, indicating that these actions of OCT require new protein synthesis.	Cycloheximide	117-130	bone gamma-carboxyglutamate protein	Rattus norvegicus	52-63
1855463-0	1991	Regulation of proenkephalin A messenger ribonucleic acid levels in normal B lymphocytes: specific inhibition by glucocorticoid hormones and superinduction by cycloheximide.	Cycloheximide	158-171	proenkephalin	Rattus norvegicus	14-29
2065663-5	1991	NAC and other thiol compounds also blocked the activation of NF-kappa B by cycloheximide, double-stranded RNA, calcium ionophore, TNF-alpha, active phorbol ester, interleukin-1, lipopolysaccharide and lectin.	Cycloheximide	75-88	X-linked Kx blood group	Homo sapiens	0-3
2065663-5	1991	NAC and other thiol compounds also blocked the activation of NF-kappa B by cycloheximide, double-stranded RNA, calcium ionophore, TNF-alpha, active phorbol ester, interleukin-1, lipopolysaccharide and lectin.	Cycloheximide	75-88	nuclear factor kappa B subunit 1	Homo sapiens	61-71
1855463-5	1991	In the presence of cycloheximide, a protein synthesis inhibitor, PEA mRNA was superinduced by a factor of 15-fold.	Cycloheximide	19-32	proenkephalin	Rattus norvegicus	65-68
1855463-6	1991	Sorting by flow cytometry of cycloheximide-treated cells followed by in situ hybridization analysis revealed that the expression of PEA mRNA was exclusively confined to a small fraction of B cells.	Cycloheximide	29-42	proenkephalin	Rattus norvegicus	132-135
1713920-3	1991	Secretion of IGF-I immunoreactivity by cells from TC-1 murine bone marrow stromal cells was time-dependent and inhibited by cycloheximide.	Cycloheximide	124-137	insulin-like growth factor 1	Mus musculus	13-18
1714462-8	1991	Both the severing of cytokeratin filaments and cytokeratin hyperphosphorylation are reversed by treatment with cycloheximide.	Cycloheximide	111-124	Keratin 12, gene 4 L homeolog	Xenopus laevis	21-32
1714462-8	1991	Both the severing of cytokeratin filaments and cytokeratin hyperphosphorylation are reversed by treatment with cycloheximide.	Cycloheximide	111-124	Keratin 12, gene 4 L homeolog	Xenopus laevis	47-58
1942774-3	1991	The latter was achieved by analyzing the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation, respectively.	Cycloheximide	111-124	interleukin 2	Homo sapiens	59-63
1916897-2	1991	In the present study, cycloheximide-treated lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages had a five- to six-fold increase in tumour necrosis factor (TNF) mRNA when compared to parallel LPS-stimulated controls.	Cycloheximide	22-35	toll-like receptor 4	Mus musculus	64-67
1916897-2	1991	In the present study, cycloheximide-treated lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages had a five- to six-fold increase in tumour necrosis factor (TNF) mRNA when compared to parallel LPS-stimulated controls.	Cycloheximide	22-35	tumor necrosis factor	Mus musculus	146-168
1916897-2	1991	In the present study, cycloheximide-treated lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages had a five- to six-fold increase in tumour necrosis factor (TNF) mRNA when compared to parallel LPS-stimulated controls.	Cycloheximide	22-35	tumor necrosis factor	Mus musculus	170-173
1916897-2	1991	In the present study, cycloheximide-treated lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages had a five- to six-fold increase in tumour necrosis factor (TNF) mRNA when compared to parallel LPS-stimulated controls.	Cycloheximide	22-35	toll-like receptor 4	Mus musculus	206-209
1916897-4	1991	The down-regulation of IL-1 beta by cycloheximide was not apparent for IL-1 alpha mRNA, which had a two- to three-fold increase in the LPS-stimulated cycloheximide-treated macrophages.	Cycloheximide	36-49	interleukin 1 beta	Mus musculus	23-32
1916897-4	1991	The down-regulation of IL-1 beta by cycloheximide was not apparent for IL-1 alpha mRNA, which had a two- to three-fold increase in the LPS-stimulated cycloheximide-treated macrophages.	Cycloheximide	36-49	toll-like receptor 4	Mus musculus	135-138
1916897-4	1991	The down-regulation of IL-1 beta by cycloheximide was not apparent for IL-1 alpha mRNA, which had a two- to three-fold increase in the LPS-stimulated cycloheximide-treated macrophages.	Cycloheximide	150-163	interleukin 1 beta	Mus musculus	23-32
1916897-4	1991	The down-regulation of IL-1 beta by cycloheximide was not apparent for IL-1 alpha mRNA, which had a two- to three-fold increase in the LPS-stimulated cycloheximide-treated macrophages.	Cycloheximide	150-163	toll-like receptor 4	Mus musculus	135-138
1916897-5	1991	A similar profile was observed in vivo in which up-regulation of TNF, but not IL-1 beta mRNA, was apparent in mice administered cycloheximide plus LPS relative to LPS alone.	Cycloheximide	128-141	tumor necrosis factor	Mus musculus	65-68
1916897-6	1991	Cycloheximide-treated LPS-stimulated macrophages demonstrated a significant increase in transcriptional activity for TNF, but not IL-1 beta, by nuclear run-on transcription assays and an increase in the amount of the nuclear binding factor NFKB when compared to LPS controls.	Cycloheximide	0-13	toll-like receptor 4	Mus musculus	22-25
1916897-6	1991	Cycloheximide-treated LPS-stimulated macrophages demonstrated a significant increase in transcriptional activity for TNF, but not IL-1 beta, by nuclear run-on transcription assays and an increase in the amount of the nuclear binding factor NFKB when compared to LPS controls.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	117-120
1916897-6	1991	Cycloheximide-treated LPS-stimulated macrophages demonstrated a significant increase in transcriptional activity for TNF, but not IL-1 beta, by nuclear run-on transcription assays and an increase in the amount of the nuclear binding factor NFKB when compared to LPS controls.	Cycloheximide	0-13	interleukin 1 beta	Mus musculus	130-139
1916897-6	1991	Cycloheximide-treated LPS-stimulated macrophages demonstrated a significant increase in transcriptional activity for TNF, but not IL-1 beta, by nuclear run-on transcription assays and an increase in the amount of the nuclear binding factor NFKB when compared to LPS controls.	Cycloheximide	0-13	toll-like receptor 4	Mus musculus	262-265
1916897-7	1991	The cycloheximide-mediated increase in TNF mRNA was also related to an increased stability of the TNF message, while no significant increase in stability was apparent in IL-1 beta mRNA.	Cycloheximide	4-17	tumor necrosis factor	Mus musculus	39-42
1916897-7	1991	The cycloheximide-mediated increase in TNF mRNA was also related to an increased stability of the TNF message, while no significant increase in stability was apparent in IL-1 beta mRNA.	Cycloheximide	4-17	tumor necrosis factor	Mus musculus	98-101
1916897-8	1991	Therefore, the differential expression of TNF and IL-1 beta mRNA in cycloheximide-treated macrophages involves both transcriptional and post-transcriptional regulatory mechanisms.	Cycloheximide	68-81	tumor necrosis factor	Mus musculus	42-45
1916897-8	1991	Therefore, the differential expression of TNF and IL-1 beta mRNA in cycloheximide-treated macrophages involves both transcriptional and post-transcriptional regulatory mechanisms.	Cycloheximide	68-81	interleukin 1 beta	Mus musculus	50-59
1942774-3	1991	The latter was achieved by analyzing the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation, respectively.	Cycloheximide	111-124	interferon gamma	Homo sapiens	68-77
1942777-5	1991	Increased beta 2m mRNA was seen after a minimum of one hour contact time with Cuprophan both in the presence and absence of cycloheximide.	Cycloheximide	124-137	beta-2-microglobulin	Homo sapiens	10-17
1944304-4	1991	The E2 effect on collagen mRNA lags behind that produced by recombinant IGF-I by about 12 h and was also abolished in the presence of cycloheximide or by the addition of antibodies against IGF-I.	Cycloheximide	134-147	insulin-like growth factor 1	Rattus norvegicus	72-77
19912810-10	1991	Cycloheximide (CHX), a protein synthesis inhibitor, potentiated and prolonged the effect of FGF on fos expression.	Cycloheximide	0-13	FBJ osteosarcoma oncogene	Mus musculus	99-102
19912810-10	1991	Cycloheximide (CHX), a protein synthesis inhibitor, potentiated and prolonged the effect of FGF on fos expression.	Cycloheximide	15-18	FBJ osteosarcoma oncogene	Mus musculus	99-102
1650483-8	1991	Chemoattraction by both fMet-Leu-Phe and TGF-beta 1 was inhibited by cycloheximide and actinomycin D.	Cycloheximide	69-82	transforming growth factor beta 1	Homo sapiens	41-51
1858872-6	1991	Cycloheximide pretreatment blocked the appearance of selenoprotein P in response to selenium injection.	Cycloheximide	0-13	selenoprotein P	Rattus norvegicus	53-68
1875907-11	1991	Treatment of astrocytes with cycloheximide increased (about 6-fold) NGF mRNA content, and this content failed to increase further with IL-1 or bFGF treatment.	Cycloheximide	29-42	nerve growth factor	Rattus norvegicus	68-71
1649834-6	1991	The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels.	Cycloheximide	110-123	matrix metallopeptidase 2	Homo sapiens	19-24
1649834-6	1991	The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels.	Cycloheximide	110-123	TIMP metallopeptidase inhibitor 1	Homo sapiens	43-47
1649834-6	1991	The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels.	Cycloheximide	110-123	transforming growth factor beta 1	Homo sapiens	83-93
1649834-6	1991	The changes in the MMP-2, collagenase, and TIMP mRNA concentrations in response to TGF-beta 1 were blocked by cycloheximide indicating that protein synthesis was required to mediate the effects of TGF-beta 1 on these mRNA levels.	Cycloheximide	110-123	transforming growth factor beta 1	Homo sapiens	197-207
2071571-5	1991	Inclusion of 10 microM cycloheximide in these cultures for 48 h caused a greater increase in Egr-1 mRNA, whereas the expression of alpha-MHC transcripts was ablated.	Cycloheximide	23-36	early growth response 1	Rattus norvegicus	93-98
1910304-3	1991	The time course of glycogen synthase activation measured by the activity ratio (low G-6-P/high G-6-P) in response to insulin was biphasic with the first peak at 15 min and the second peak at 4 to 6 h. When cells were incubated with insulin and cycloheximide, the first peak persisted while the second peak was abolished.	Cycloheximide	244-257	insulin	Homo sapiens	117-124
1907289-7	1991	TIS gene induction by metal is a primary response; TIS8, which encodes a zinc-finger transcription factor, and TIS28 (c-fos) can be induced in the presence of cadmium and cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	171-184	early growth response 1	Mus musculus	51-55
1651781-4	1991	In contrast, enhancement of IL-6 production by dibutyryl cyclic AMP or cycloheximide was not affected by LiCl.	Cycloheximide	71-84	interleukin 6	Mus musculus	28-32
1907289-7	1991	TIS gene induction by metal is a primary response; TIS8, which encodes a zinc-finger transcription factor, and TIS28 (c-fos) can be induced in the presence of cadmium and cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	171-184	FBJ osteosarcoma oncogene	Mus musculus	118-123
1905804-3	1991	A DNA element, similar to the binding site for the transcription factor NFkB, is located around--1865 with respect to the start site of transcription in the uPA promoter and confers superinducibility by these agents in the presence of cycloheximide (CHX).	Cycloheximide	235-248	plasminogen activator, urokinase	Homo sapiens	157-160
2056124-5	1991	Coincubation of either cremophor alone or cycloheximide with CSA resulted in minimal ET present in the EC supernatants (P less than 0.01 each).	Cycloheximide	42-55	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	Homo sapiens	61-64
1905804-3	1991	A DNA element, similar to the binding site for the transcription factor NFkB, is located around--1865 with respect to the start site of transcription in the uPA promoter and confers superinducibility by these agents in the presence of cycloheximide (CHX).	Cycloheximide	250-253	plasminogen activator, urokinase	Homo sapiens	157-160
1710984-17	1991	This restitution by dexamethasone of the PCK mRNA inducibility by glucagon was inhibited by cycloheximide.	Cycloheximide	92-105	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	41-44
1645554-7	1991	In addition, actinomycin D and cycloheximide both inhibited the TCDD-mediated decrease of nuclear estrogen receptor levels in the Hepa 1c1c7 wild-type cells, and these results suggest that TCDD may induce specific gene products which are involved in this process.	Cycloheximide	31-44	estrogen receptor 1 (alpha)	Mus musculus	98-115
1828893-6	1991	Cycloheximide and the injection of antisense oligonucleotides specific to the c-mos transcript blocked alpha o-induced maturation.	Cycloheximide	0-13	MOS proto-oncogene, serine/threonine kinase L homeolog	Xenopus laevis	78-83
2037570-3	1991	Exposure of these cells to 300 microM anisomycin or 500 microM cycloheximide caused a maximal, 7-fold increase in 2-deoxyglucose transport rate after 4-8 h. The effects due to either insulin (0.5 h) or anisomycin (5 h) on the kinetics of zero-trans 3-O-methyl[14C]glucose transport were similar, resulting in 2.5-3-fold increases in apparent Vmax values (control Vmax = 1.6 +/- 0.3 x 10(-7) mmol/s/10(6) cells) coupled with approximately 2-fold decreases in apparent Km values (control Km = 23 +/- 3.3 mM).	Cycloheximide	63-76	insulin	Homo sapiens	183-190
1712527-6	1991	Cycloheximide suppressed almost completely both the basal and the stimulated production of IGFBP-3.	Cycloheximide	0-13	insulin like growth factor binding protein 3	Homo sapiens	91-98
1878996-1	1991	A multi-copy plasmid containing the SNQ3 gene confers hyper-resistance to 4-nitroquinoline-N-oxide (4NQO), Trenimon, MNNG, cycloheximide, and to sulfometuron methyl in yeast transformants.	Cycloheximide	123-136	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	36-40
2058689-4	1991	The induction of Mn SOD by LPS was blocked by both a RNA synthesis inhibitor, actinomycin D, and a protein synthesis inhibitor, cycloheximide.	Cycloheximide	128-141	superoxide dismutase 2	Homo sapiens	17-23
1717064-8	1991	Cycloheximide added to incubation medium with steroid inhibited the stimulating effect on PAL only.	Cycloheximide	0-13	leucine-rich repeat, Ig-like and transmembrane domains 1	Rattus norvegicus	90-93
2053915-5	1991	Cycloheximide and actinomycin D caused a concentration-dependent suppression of the PDGF-BB-mediated potentiation of radiolabeled IL-1 alpha binding to RAC and cell responsiveness to IL-1 alpha.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	130-140
2053915-5	1991	Cycloheximide and actinomycin D caused a concentration-dependent suppression of the PDGF-BB-mediated potentiation of radiolabeled IL-1 alpha binding to RAC and cell responsiveness to IL-1 alpha.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	183-193
1709096-10	1991	These results fully confirm recent data obtained in vitro with exogenous cyclin added to cycloheximide-treated Xenopus egg extracts.	Cycloheximide	89-102	proliferating cell nuclear antigen S homeolog	Xenopus laevis	73-79
1863358-4	1991	We have previously shown that P450scc mRNA is regulated by tropic hormones and cAMP by a cycloheximide-independent mechanism in mouse Leydig tumor MA-10 cells.	Cycloheximide	89-102	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	30-37
1885215-10	1991	Cytokine-induced synthesis of PLA2 was inhibited 80% by 10 microM cycloheximide but not by dexamethasone over the range of 10(-6) to 10(-8) M. FRCC-derived PLA2 was neutral-active with a pH optimum of 6-7.5 and was calcium-dependent with optimal activity in the presence of 2-7 mM calcium.	Cycloheximide	66-79	phospholipase A2 group IB	Homo sapiens	30-34
2064996-7	1991	Inhibition of protein synthesis with cycloheximide also had no detectable effect on EGR-1 gene transcription but was associated with superinduction of EGR-1 mRNA levels in GM-CSF-treated cells.	Cycloheximide	37-50	early growth response 1	Homo sapiens	151-156
2064996-7	1991	Inhibition of protein synthesis with cycloheximide also had no detectable effect on EGR-1 gene transcription but was associated with superinduction of EGR-1 mRNA levels in GM-CSF-treated cells.	Cycloheximide	37-50	colony stimulating factor 2	Homo sapiens	172-178
1903413-5	1991	Treatment of monocytes with cycloheximide in the presence of GM-CSF blocked TOMS-1Ag induction completely, indicating that de novo protein synthesis was required for its expression.	Cycloheximide	28-41	colony stimulating factor 2	Homo sapiens	61-67
1919073-4	1991	In addition to the fact that this induction occurs in the presence of cycloheximide and/or anti-IFN-alpha/beta antibodies in fibroblasts, we observed that, in IFN-resistant Daudi cells, ISG15 and IP-10 genes which are not induced by IFN-beta, are still inducible by dsRNA.	Cycloheximide	70-83	C-X-C motif chemokine ligand 10	Homo sapiens	196-201
1885215-10	1991	Cytokine-induced synthesis of PLA2 was inhibited 80% by 10 microM cycloheximide but not by dexamethasone over the range of 10(-6) to 10(-8) M. FRCC-derived PLA2 was neutral-active with a pH optimum of 6-7.5 and was calcium-dependent with optimal activity in the presence of 2-7 mM calcium.	Cycloheximide	66-79	phospholipase A2 group IB	Homo sapiens	156-160
1652971-4	1991	Cycloheximide also induced increased levels of rat adrenal mRNAs for LDL receptor and HMG-CoA reductase, but this effect was not additive with that of ACTH.	Cycloheximide	0-13	low density lipoprotein receptor	Rattus norvegicus	69-81
2033250-9	1991	The protein synthesis inhibitors puromycin, emetine, and cycloheximide also blocked the decline in pP29 during IL-1 treatment.	Cycloheximide	57-70	interleukin 1 alpha	Homo sapiens	111-115
2033254-0	1991	Superinduction of IL-2 gene transcription in the presence of cycloheximide.	Cycloheximide	61-74	interleukin 2	Homo sapiens	18-22
2033254-2	1991	To date, it has been shown that the protein synthesis inhibitor cycloheximide (CHX) up-regulates IL-2 expression in T cells by stabilizing its mRNA.	Cycloheximide	64-77	interleukin 2	Homo sapiens	97-101
2033254-2	1991	To date, it has been shown that the protein synthesis inhibitor cycloheximide (CHX) up-regulates IL-2 expression in T cells by stabilizing its mRNA.	Cycloheximide	79-82	interleukin 2	Homo sapiens	97-101
1653047-5	1991	Inhibition of protein synthesis by cycloheximide prevented the primary effect of TNF.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	81-84
2046020-8	1991	Treatment of donors, but not recipients, with either BN 25021, dexamethasone, actinomycin D or cycloheximide inhibited the late eosinophil accumulation triggered by transferred PAF pleural washing, indicating that the generation of this eosinophilotactic activity, but not its effects, is suppressed by those agents.	Cycloheximide	95-108	PCNA clamp associated factor	Rattus norvegicus	177-180
2038320-2	1991	This instability, like that of the maternal Eg2 transcript, was abolished by treatment of the embryos with cycloheximide.	Cycloheximide	107-120	aurora kinase A L homeolog	Xenopus laevis	44-47
2046332-6	1991	Cycloheximide experiments provided evidence that the TGF-beta 1-elicited upregulation of the expression of the fibronectin gene is, but that of type IV collagen is not, entirely dependent on protein synthesis, suggesting two different mechanisms for enhancement of gene expression.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	53-63
2046332-6	1991	Cycloheximide experiments provided evidence that the TGF-beta 1-elicited upregulation of the expression of the fibronectin gene is, but that of type IV collagen is not, entirely dependent on protein synthesis, suggesting two different mechanisms for enhancement of gene expression.	Cycloheximide	0-13	fibronectin 1	Homo sapiens	111-122
19912801-13	1991	Effects of s(1)-AII on induction of pEK mRNA by angiotensin and by nicotine were prevented by the translational inhibitor cycloheximide.	Cycloheximide	122-135	proenkephalin	Bos taurus	36-39
2038320-3	1991	Analysis of the polysome distribution of the maternal Eg2 mRNA in cycloheximide-treated and untreated embryos showed that Eg2 mRNA was released from polysomes after fertilization and that the stabilization caused by cycloheximide treatment was not due to a reloading of ribosomes onto the mRNA.	Cycloheximide	66-79	aurora kinase A L homeolog	Xenopus laevis	54-57
2038320-3	1991	Analysis of the polysome distribution of the maternal Eg2 mRNA in cycloheximide-treated and untreated embryos showed that Eg2 mRNA was released from polysomes after fertilization and that the stabilization caused by cycloheximide treatment was not due to a reloading of ribosomes onto the mRNA.	Cycloheximide	66-79	aurora kinase A L homeolog	Xenopus laevis	122-125
2038320-3	1991	Analysis of the polysome distribution of the maternal Eg2 mRNA in cycloheximide-treated and untreated embryos showed that Eg2 mRNA was released from polysomes after fertilization and that the stabilization caused by cycloheximide treatment was not due to a reloading of ribosomes onto the mRNA.	Cycloheximide	216-229	aurora kinase A L homeolog	Xenopus laevis	122-125
2048154-3	1991	This is shown here by intracerebral injections of mixtures of T-2 toxin and cycloheximide, leading to potentiation of their toxic effects.	Cycloheximide	76-89	solute carrier family 25 member 5	Homo sapiens	62-65
1896966-3	1991	The thrombin-induced decrease in the accumulation of 35S-GAG in the cell layer occurred even in the presence of actinomycin D or cycloheximide.	Cycloheximide	129-142	coagulation factor II, thrombin	Bos taurus	4-12
2048200-5	1991	Inhibition of protein synthesis with cycloheximide during IFN-alpha or CsA treatment blocked their ability to reduce the expression of c-myc.	Cycloheximide	37-50	interferon alpha 1	Homo sapiens	58-67
2048200-5	1991	Inhibition of protein synthesis with cycloheximide during IFN-alpha or CsA treatment blocked their ability to reduce the expression of c-myc.	Cycloheximide	37-50	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	135-140
2040014-3	1991	We show here that the tumor promoter okadaic acid, which inhibits protein phosphatases 1 and 2A, and the protein synthesis inhibitors anisomycin and cycloheximide also stimulate pp33 and pp15 phosphorylation.	Cycloheximide	149-162	nuclear transport factor 2	Homo sapiens	187-191
2072891-0	1991	Effect of dexamethasone and cycloheximide on the expression of amplified EGF-receptor gene in human A431 carcinoma cell line.	Cycloheximide	28-41	epidermal growth factor receptor	Homo sapiens	73-85
1676388-0	1991	Differential modulation of yeast actin, tubulin, and YPT1 mRNA levels by cycloheximide.	Cycloheximide	73-86	actin	Saccharomyces cerevisiae S288C	33-38
1676388-0	1991	Differential modulation of yeast actin, tubulin, and YPT1 mRNA levels by cycloheximide.	Cycloheximide	73-86	Rab family GTPase YPT1	Saccharomyces cerevisiae S288C	53-57
1676388-1	1991	We have examined the effects of cycloheximide (Chx) on transcription of genes encoding the yeast beta-actin (ACT), beta-tubulin (TUB) and yeast protein 1 (YPT1).	Cycloheximide	32-45	actin	Saccharomyces cerevisiae S288C	102-107
1676388-1	1991	We have examined the effects of cycloheximide (Chx) on transcription of genes encoding the yeast beta-actin (ACT), beta-tubulin (TUB) and yeast protein 1 (YPT1).	Cycloheximide	32-45	Rab family GTPase YPT1	Saccharomyces cerevisiae S288C	155-159
1676388-1	1991	We have examined the effects of cycloheximide (Chx) on transcription of genes encoding the yeast beta-actin (ACT), beta-tubulin (TUB) and yeast protein 1 (YPT1).	Cycloheximide	47-50	actin	Saccharomyces cerevisiae S288C	102-107
1676388-1	1991	We have examined the effects of cycloheximide (Chx) on transcription of genes encoding the yeast beta-actin (ACT), beta-tubulin (TUB) and yeast protein 1 (YPT1).	Cycloheximide	47-50	TUB bipartite transcription factor	Homo sapiens	129-132
1676388-1	1991	We have examined the effects of cycloheximide (Chx) on transcription of genes encoding the yeast beta-actin (ACT), beta-tubulin (TUB) and yeast protein 1 (YPT1).	Cycloheximide	47-50	Rab family GTPase YPT1	Saccharomyces cerevisiae S288C	155-159
2026872-5	1991	The initial 2 to 3 h lag period may be necessary for production of a protein(s) that mediates this inhibitory effect because treatment with the protein synthesis inhibitor, cycloheximide, blocked the marked reduction of IL-1 message levels induced by IL-4.	Cycloheximide	173-186	interleukin 1 beta	Homo sapiens	220-224
2026872-5	1991	The initial 2 to 3 h lag period may be necessary for production of a protein(s) that mediates this inhibitory effect because treatment with the protein synthesis inhibitor, cycloheximide, blocked the marked reduction of IL-1 message levels induced by IL-4.	Cycloheximide	173-186	interleukin 4	Homo sapiens	251-255
2026872-9	1991	In addition, the kinetics of inhibition and the fact that cycloheximide blocks this process suggest that IL-4 induces or enhances synthesis of a protein(s) that mediates these effects.	Cycloheximide	58-71	interleukin 4	Homo sapiens	105-109
2072891-2	1991	We have studied the effect of steroid hormone dexamethasone (DEX) and protein synthesis inhibitor cycloheximide (CHX) on the expression of EGF-R gene in this cell line.	Cycloheximide	98-111	epidermal growth factor receptor	Homo sapiens	139-144
2072891-2	1991	We have studied the effect of steroid hormone dexamethasone (DEX) and protein synthesis inhibitor cycloheximide (CHX) on the expression of EGF-R gene in this cell line.	Cycloheximide	113-116	epidermal growth factor receptor	Homo sapiens	139-144
2072891-3	1991	DEX treatment and protein synthesis inhibition by CHX treatment cause a rapid 3 to 4 fold increase in the level of EGF-R mRNA and combined treatment of the above two agents have less than additive effect.	Cycloheximide	50-53	epidermal growth factor receptor	Homo sapiens	115-120
2025652-5	1991	When inhibitors of transcription (actinomycin-D) or translation (cycloheximide) were added following a maximal induction of fibrinogen mRNA expression by IL-6, the decay of mRNA was significantly diminished.	Cycloheximide	65-78	interleukin 6	Rattus norvegicus	154-158
2025652-6	1991	Furthermore, the addition of cycloheximide (CHX) to hepatocytes increased fibrinogen mRNA levels, but only if the cells had been stimulated with IL-6.	Cycloheximide	29-42	interleukin 6	Rattus norvegicus	145-149
2025652-6	1991	Furthermore, the addition of cycloheximide (CHX) to hepatocytes increased fibrinogen mRNA levels, but only if the cells had been stimulated with IL-6.	Cycloheximide	44-47	interleukin 6	Rattus norvegicus	145-149
1878745-10	1991	Interleukin-1 beta (IL-1 beta), applied at low concentrations (100-250 pg ml-1) on aortic strips between 3 h and 6.5 h of incubation time, mimicked the selective stimulatory effect of the cycloheximide pulse on responses to des-Arg9-BK.	Cycloheximide	188-201	interleukin-1 beta	Oryctolagus cuniculus	0-18
2035580-4	1991	Release of CA 125 decreased in the presence of dexamethasone (10(-6) mol/L) or cycloheximide (0.1 micrograms/ml) and increased when colchicine (0.01 micrograms/ml) was added to the culture medium.	Cycloheximide	79-92	mucin 16, cell surface associated	Homo sapiens	11-17
1878745-10	1991	Interleukin-1 beta (IL-1 beta), applied at low concentrations (100-250 pg ml-1) on aortic strips between 3 h and 6.5 h of incubation time, mimicked the selective stimulatory effect of the cycloheximide pulse on responses to des-Arg9-BK.	Cycloheximide	188-201	interleukin-1 beta	Oryctolagus cuniculus	20-29
1902124-8	1991	Cycloheximide alone is also capable of inducing a rapid increase in class I transcription in both cell types, suggesting that constitutive attenuation of class I transcription may be a common phenomenon, and that IFN-gamma may act, in part, by interfering with such attenuation.	Cycloheximide	0-13	interferon gamma	Homo sapiens	213-222
1850696-6	1991	Thus, RARs can participate directly in transcriptional induction of the LB1 gene, even though this induction is cycloheximide sensitive and RARs are present in F9 cells prior to RA addition.	Cycloheximide	112-125	laminin B1	Mus musculus	72-75
2021975-8	1991	Cycloheximide was found to induce the secretion of superoxide anions by monocytes, but a role for reactive oxygen species in cycloheximide-induced augmentation of ADCC could not be established by experiments involving the use of catalase or superoxide dismutase.	Cycloheximide	125-138	catalase	Homo sapiens	229-237
1913874-1	1991	In CYH2/cyh2 heterozygous diploids of the yeast Saccharomyces cerevisiae resistance is dominant over sensitivity at low (0.5-5 micrograms/ml) cycloheximide (cyh) concentrations.	Cycloheximide	142-155	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	3-7
1913874-1	1991	In CYH2/cyh2 heterozygous diploids of the yeast Saccharomyces cerevisiae resistance is dominant over sensitivity at low (0.5-5 micrograms/ml) cycloheximide (cyh) concentrations.	Cycloheximide	142-155	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	8-12
1913874-1	1991	In CYH2/cyh2 heterozygous diploids of the yeast Saccharomyces cerevisiae resistance is dominant over sensitivity at low (0.5-5 micrograms/ml) cycloheximide (cyh) concentrations.	Cycloheximide	8-11	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	3-7
1913874-5	1991	From a genomic library of this strain, constructed in vector YCp50, two plasmids (pRC1 and pRC13) have been isolated which, respectively, confer high- and low-resistance phenotypes to cyh-sensitive S. cerevisiae strains.	Cycloheximide	184-187	carboxypeptidase C PRC1	Saccharomyces cerevisiae S288C	82-86
1874802-6	1991	Based upon studies with cycloheximide, de novo protein biosynthesis was required for TNF-mediated ODC induction in ME-180 cells.	Cycloheximide	24-37	tumor necrosis factor	Homo sapiens	85-88
2019789-7	1991	Cycloheximide, an inhibitor of protein synthesis, blocked the hepatic release of immunoreactive factor XII in both hormone-treated and untreated rats, suggesting that factor XII translation was directly affected.	Cycloheximide	0-13	coagulation factor XII	Rattus norvegicus	96-106
2016538-7	1991	Addition of the protein synthesis inhibitor cycloheximide blocked the induced increases in IL-4R expression, indicating the requirement for de novo protein synthesis.	Cycloheximide	44-57	interleukin 4 receptor, alpha	Mus musculus	91-96
2019789-7	1991	Cycloheximide, an inhibitor of protein synthesis, blocked the hepatic release of immunoreactive factor XII in both hormone-treated and untreated rats, suggesting that factor XII translation was directly affected.	Cycloheximide	0-13	coagulation factor XII	Rattus norvegicus	167-177
2072929-4	1991	PLP gene expression was rapidly and transiently induced by serum and cycloheximide, but the butyrate induction of PLP mRNA transcripts was not dependent on serum or new protein synthesis.	Cycloheximide	69-82	parathyroid hormone-like hormone	Rattus norvegicus	0-3
2072929-6	1991	The rapid induction of PLP gene expression after the exposure of islet cells to sodium butyrate, serum, and cycloheximide suggests that PLP may be a member of a class of early response genes involved in the regulation of cellular growth or differentiation.	Cycloheximide	108-121	parathyroid hormone-like hormone	Rattus norvegicus	23-26
2072929-6	1991	The rapid induction of PLP gene expression after the exposure of islet cells to sodium butyrate, serum, and cycloheximide suggests that PLP may be a member of a class of early response genes involved in the regulation of cellular growth or differentiation.	Cycloheximide	108-121	parathyroid hormone-like hormone	Rattus norvegicus	136-139
2018782-3	1991	The putrescine-induced ODC decay was faster than the ODC decay in the presence of cycloheximide.	Cycloheximide	82-95	ornithine decarboxylase 1 L homeolog	Xenopus laevis	53-56
1712407-6	1991	Hox 2.3 was also super-induced by serum, in the presence of cycloheximide, in cells rested previously in serum-free media, suggesting that new protein synthesis was not required for expressive augmentation.	Cycloheximide	60-73	homeobox B7	Mus musculus	0-7
2018782-4	1991	Simultaneous addition of cycloheximide blocked the putrescine-induced acceleration of ODC decay, indicating an involvement of protein synthesis.	Cycloheximide	25-38	ornithine decarboxylase 1 L homeolog	Xenopus laevis	86-89
1826697-5	1991	The reduction was transient, and receptor binding was recovered by incubation at 37 degrees C for 8 h. The recovery of G-CSF binding was inhibited in the presence of cycloheximide.	Cycloheximide	166-179	colony stimulating factor 3 (granulocyte)	Mus musculus	119-124
2029548-11	1991	Actinomycin D and cycloheximide inhibited the potentiation of the prostaglandin E2 formation induced by TNF or TNF + FK, indicating that both RNA and protein synthesis are required for the potentiation.	Cycloheximide	18-31	tumor necrosis factor-like	Rattus norvegicus	104-107
1707871-4	1991	However, apparently full-length species of IFN-beta mRNA accumulated after prolonged incubation with cycloheximide.	Cycloheximide	101-114	interferon beta 1, fibroblast	Mus musculus	43-51
1707871-6	1991	These findings suggest that at least two nuclease activities are involved in degrading IFN-beta mRNA; one deadenylates this mRNA and decays in cycloheximide-treated cells, while the other apparently breaks down deadenylated mRNA.	Cycloheximide	143-156	interferon beta 1, fibroblast	Mus musculus	87-95
1651101-5	1991	ST-59 receptor induction by serum was greatly amplified by cycloheximide and could be detected in actively growing LS-180 cells.	Cycloheximide	59-72	nuclear receptor subfamily 4 group A member 1	Homo sapiens	0-5
2029548-11	1991	Actinomycin D and cycloheximide inhibited the potentiation of the prostaglandin E2 formation induced by TNF or TNF + FK, indicating that both RNA and protein synthesis are required for the potentiation.	Cycloheximide	18-31	tumor necrosis factor-like	Rattus norvegicus	111-114
1868030-3	1991	Its kinetics of growth regulation (time of increase in mRNA levels, sensitivity to cycloheximide, behavior in G1-specific temperature-sensitive mutants) classify the SC1 gene as a late growth-regulated gene, like the histone genes and the genes coding for the proteins of the DNA synthesis apparatus.	Cycloheximide	83-96	transcription factor 19	Homo sapiens	166-169
2060898-4	1991	Cycloheximide (5 micrograms/ml) almost completely inhibited the accumulation of IGF-I and albumin in the medium.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	80-85
1849469-4	1991	Limited treatment with cycloheximide (CHI) for the initial 8 h affected AHH activity measured after 24 h; BA-induced AHH activity was decreased if the treatment started day 1 after seeding of the cells from either strain, whereas if started at day 3 the enzyme activities in hepatocytes from C57BL/6 strain were approximately doubled and those from DBA/2 increased to 130%.	Cycloheximide	23-36	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	72-75
1849469-4	1991	Limited treatment with cycloheximide (CHI) for the initial 8 h affected AHH activity measured after 24 h; BA-induced AHH activity was decreased if the treatment started day 1 after seeding of the cells from either strain, whereas if started at day 3 the enzyme activities in hepatocytes from C57BL/6 strain were approximately doubled and those from DBA/2 increased to 130%.	Cycloheximide	23-36	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	117-120
1709940-6	1991	PDGF A-chain mRNA levels increase when quiescent HUVE cells are treated with the protein synthesis inhibitor cycloheximide; therefore, the effect of cycloheximide on PDGF A-chain mRNA decay was also investigated.	Cycloheximide	109-122	platelet derived growth factor subunit A	Homo sapiens	0-6
1770016-7	1991	Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene.	Cycloheximide	129-142	transforming growth factor beta 1	Homo sapiens	0-31
1770016-7	1991	Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene.	Cycloheximide	129-142	transforming growth factor beta 1	Homo sapiens	33-41
1770016-7	1991	Transforming growth factor beta (TGF-beta) also induced mRNA of TS at 8 hours after stimulation and the induction was blocked by cycloheximide, suggesting that TGF-beta requires the mediation of new protein synthesis to induce a TS gene.	Cycloheximide	129-142	transforming growth factor beta 1	Homo sapiens	160-168
2010034-6	1991	Last, addition of cycloheximide to one-cell embryos late in G2 inhibits neither cleavage to the two-cell stage nor the increase in the relative amount of hsp70 mRNA.	Cycloheximide	18-31	heat shock protein 1B	Mus musculus	154-159
1681426-9	1991	Cycloheximide treatment caused a dramatic increase in AR mRNA in kidneys of Tfm mice, but not wild-type mice, suggesting that the Tfm mutation results in an unstable AR mRNA.	Cycloheximide	0-13	androgen receptor	Mus musculus	54-56
1651364-6	1991	The time course of priming by 100 U/ml IFN-gamma showed that at least a 1-h exposure was required, and a maximal effect was seen at 24 h. Priming after a 4-h exposure to 100 U/ml IFN-gamma was completely inhibited by 1 micrograms/ml cycloheximide.	Cycloheximide	233-246	interferon gamma	Homo sapiens	179-188
2005892-4	1991	p42 also becomes tyrosine phosphorylated after microinjection of oocytes with partially purified M-phase-promoting factor, even in the presence of cycloheximide.	Cycloheximide	147-160	cyclin-dependent kinase 20 S homeolog	Xenopus laevis	0-3
1681426-9	1991	Cycloheximide treatment caused a dramatic increase in AR mRNA in kidneys of Tfm mice, but not wild-type mice, suggesting that the Tfm mutation results in an unstable AR mRNA.	Cycloheximide	0-13	androgen receptor	Mus musculus	76-79
1681426-9	1991	Cycloheximide treatment caused a dramatic increase in AR mRNA in kidneys of Tfm mice, but not wild-type mice, suggesting that the Tfm mutation results in an unstable AR mRNA.	Cycloheximide	0-13	androgen receptor	Mus musculus	130-133
1681426-9	1991	Cycloheximide treatment caused a dramatic increase in AR mRNA in kidneys of Tfm mice, but not wild-type mice, suggesting that the Tfm mutation results in an unstable AR mRNA.	Cycloheximide	0-13	androgen receptor	Mus musculus	166-168
2030912-5	1991	Phorbol ester-accelerated processing of the cell surface CSF-1 precursor was abrogated by long-term exposure to phorbol, but was not inhibited by pretreatment with cycloheximide or incubation in serum-free medium.	Cycloheximide	164-177	colony stimulating factor 1	Homo sapiens	57-62
11607171-3	1991	In this report, we provide evidence that cycloheximide, an inhibitor of cytoplasmic protein synthesis, when fed to detached leaves of C4 monocots (maize, sorghum) and dicots (Portulaca oleracea) in the dark or light, completely prevents the in vivo light activation of PEPC-PK activity regardless of whether the protein kinase activity is assessed in vivo or in vitro.	Cycloheximide	41-54	MLO-like protein 4	Zea mays	269-273
2005103-11	1991	The appearance of microsomal phospholipase A2 activity did not require ischemia-induced transcription or translation since identical increases in enzymic activity were obtained in hearts previously treated with actinomycin D and cycloheximide.	Cycloheximide	229-242	phospholipase A2	Oryctolagus cuniculus	29-45
1848242-5	1991	The protein synthesis inhibitor cycloheximide (10 micrograms/ml) also increases the level of u-PAR mRNA.	Cycloheximide	32-45	plasminogen activator, urokinase	Homo sapiens	93-98
1672341-5	1991	In addition, although coincubation of HER2/neu-expressing targets with cycloheximide resulted in significant TNF-induced lysis, when compared to HER2/neu-nonexpressing targets similarly treated with cycloheximide, a significant relative resistance was still present.	Cycloheximide	71-84	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
1672341-5	1991	In addition, although coincubation of HER2/neu-expressing targets with cycloheximide resulted in significant TNF-induced lysis, when compared to HER2/neu-nonexpressing targets similarly treated with cycloheximide, a significant relative resistance was still present.	Cycloheximide	71-84	tumor necrosis factor	Homo sapiens	109-112
1672341-5	1991	In addition, although coincubation of HER2/neu-expressing targets with cycloheximide resulted in significant TNF-induced lysis, when compared to HER2/neu-nonexpressing targets similarly treated with cycloheximide, a significant relative resistance was still present.	Cycloheximide	199-212	erb-b2 receptor tyrosine kinase 2	Homo sapiens	38-42
1900938-5	1991	Preincubation with cycloheximide was associated with superinduction of JUN and EGR1 in x-irradiated cells.	Cycloheximide	19-32	early growth response 1	Homo sapiens	79-83
1872882-3	1991	Surprisingly, the overall structure of the PRS2 gene was found to be identical to that of the suppressor scl1+ gene restoring the SCL1-1 mutation that suppresses crl3 cycloheximide-resistant, temperature-sensitive lethality.	Cycloheximide	167-180	ribose phosphate diphosphokinase subunit PRS2	Saccharomyces cerevisiae S288C	43-47
1872882-3	1991	Surprisingly, the overall structure of the PRS2 gene was found to be identical to that of the suppressor scl1+ gene restoring the SCL1-1 mutation that suppresses crl3 cycloheximide-resistant, temperature-sensitive lethality.	Cycloheximide	167-180	proteasome core particle subunit alpha 1	Saccharomyces cerevisiae S288C	105-109
1872882-3	1991	Surprisingly, the overall structure of the PRS2 gene was found to be identical to that of the suppressor scl1+ gene restoring the SCL1-1 mutation that suppresses crl3 cycloheximide-resistant, temperature-sensitive lethality.	Cycloheximide	167-180	proteasome core particle subunit alpha 1	Saccharomyces cerevisiae S288C	130-136
1872882-3	1991	Surprisingly, the overall structure of the PRS2 gene was found to be identical to that of the suppressor scl1+ gene restoring the SCL1-1 mutation that suppresses crl3 cycloheximide-resistant, temperature-sensitive lethality.	Cycloheximide	167-180	proteasome regulatory particle base subunit RPT6	Saccharomyces cerevisiae S288C	162-166
1999176-8	1991	The insulin-induced stimulation of hCG synthesis was inhibited by cycloheximide.	Cycloheximide	66-79	insulin	Homo sapiens	4-11
1825296-7	1991	In contrast, when CTB or a monoclonal anti-GM1 antibody was also added to the medium, cycloheximide-induced neuritogenesis was amplified further on pFN and sensitivity to peptide A inhibition was abolished.	Cycloheximide	86-99	phosphate cytidylyltransferase 1B, choline	Homo sapiens	18-21
1847861-0	1991	Cycloheximide inhibits interferon-gamma-induced class II major histocompatibility complex antigen expression in cultured rat thyroid cells.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	23-39
1847861-7	1991	However, 0.01-10 micrograms/ml cycloheximide inhibited IFN gamma-induced RT1.B antigen expression in a dose-dependent manner.	Cycloheximide	31-44	interferon gamma	Homo sapiens	55-64
1847861-7	1991	However, 0.01-10 micrograms/ml cycloheximide inhibited IFN gamma-induced RT1.B antigen expression in a dose-dependent manner.	Cycloheximide	31-44	RT1 class II, locus B	Rattus norvegicus	73-78
1825296-9	1991	These results also indicate that (a) cycloheximide treatment leads to loss of substratum selectivity in neuritogenesis, (b) this negative regulation of neurite outgrowth is affected by integrin receptor association with labile regulatory proteins (disintegrins) as well as with GM1, and (c) complexing of GM1 by multivalent GM1-binding proteins shifts neuritogenesis from an RGDS-dependent integrin mechanism to an RGDS-independent receptor mechanism.	Cycloheximide	37-50	ral guanine nucleotide dissociation stimulator	Homo sapiens	375-379
1825296-9	1991	These results also indicate that (a) cycloheximide treatment leads to loss of substratum selectivity in neuritogenesis, (b) this negative regulation of neurite outgrowth is affected by integrin receptor association with labile regulatory proteins (disintegrins) as well as with GM1, and (c) complexing of GM1 by multivalent GM1-binding proteins shifts neuritogenesis from an RGDS-dependent integrin mechanism to an RGDS-independent receptor mechanism.	Cycloheximide	37-50	ral guanine nucleotide dissociation stimulator	Homo sapiens	415-419
1847167-10	1991	However, priming PMN by both GH and IGF-I required de novo protein synthesis, because cycloheximide completely abrogated enhanced O2- secretion that was caused by these growth factors.	Cycloheximide	86-99	growth hormone 1	Homo sapiens	29-31
1995305-10	1991	The inclusion of cycloheximide in the protocol indicated that TGF beta induction of collagen alpha 1 (IV) mRNA was signaled by proteins already present in the cells but that TGF beta required the synthesis of a protein(s) to fully induce expression of fibronectin and laminin B1 mRNA.	Cycloheximide	17-30	transforming growth factor beta 1	Homo sapiens	62-70
1847717-8	1991	Macrophages were primed with low doses of rIFN-gamma in order to induce transient, cycloheximide-sensitive Ia expression.	Cycloheximide	83-96	interferon gamma	Rattus norvegicus	42-52
1847717-9	1991	The cells were then treated with high doses of rIFN-gamma in order to induce persistent, cycloheximide-resistant Ia expression.	Cycloheximide	89-102	interferon gamma	Rattus norvegicus	47-57
1847167-10	1991	However, priming PMN by both GH and IGF-I required de novo protein synthesis, because cycloheximide completely abrogated enhanced O2- secretion that was caused by these growth factors.	Cycloheximide	86-99	insulin like growth factor 1	Homo sapiens	36-41
1651033-2	1991	This protection is abrogated by pretreatment of infected cells with cycloheximide, suggesting that it is due to a protein induced early after Ad5 infection.	Cycloheximide	68-81	Alzheimer disease, familial, type 5	Homo sapiens	142-145
1648584-7	1991	The induction by rIL-1 beta was blocked by cycloheximide and dexamethasone.	Cycloheximide	43-56	interleukin 1 beta	Rattus norvegicus	17-27
1995646-4	1991	Treatment of adult aortic SMC with cycloheximide dramatically elevated CypIa1 mRNA levels and had little effect on the amount of this mRNA in pup SMC.	Cycloheximide	35-48	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	71-77
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	9-22	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	84-90
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	9-22	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	279-285
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	172-185	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	84-90
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	172-185	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	279-285
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	172-185	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	84-90
1995646-5	1991	That the cycloheximide effect in adult SMC was due to enhanced transcription of the CypIa1 gene was demonstrated by 1) the ability of actinomycin D to completely block the cycloheximide-induced increase in steady-state mRNA levels, and 2) the increased transcription rate of the CypIa1 gene in cycloheximide-treated adult nuclei determined via nuclear transcription assays.	Cycloheximide	172-185	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	279-285
1671400-4	1991	The CD3-mediated CD2 up-regulation was suppressed by cycloheximide and actinomycin D, indicating that it requires de novo protein and RNA synthesis.	Cycloheximide	53-66	CD2 molecule	Homo sapiens	17-20
1989989-4	1991	Pretreatment of cells with cycloheximide completely inhibited insulin-stimulated ODC expression; actinomycin D partially inhibited this effect.	Cycloheximide	27-40	insulin	Homo sapiens	62-69
1993692-8	1991	Inhibiting protein synthesis with cycloheximide blocked the effect of rIL-1 beta on elastin mRNA levels.	Cycloheximide	34-47	interleukin 1 beta	Rattus norvegicus	70-80
1993692-8	1991	Inhibiting protein synthesis with cycloheximide blocked the effect of rIL-1 beta on elastin mRNA levels.	Cycloheximide	34-47	elastin	Rattus norvegicus	84-91
1989989-4	1991	Pretreatment of cells with cycloheximide completely inhibited insulin-stimulated ODC expression; actinomycin D partially inhibited this effect.	Cycloheximide	27-40	ornithine decarboxylase 1	Homo sapiens	81-84
1996661-2	1991	Northern blot analysis demonstrated a marked increase in SP-B mRNA expression after treatment with dexamethasone for 48 h. Actinomycin D, puromycin, or cycloheximide blocked the induction of SP-B mRNA by glucocorticoid.	Cycloheximide	152-165	surfactant protein B	Homo sapiens	57-61
1996661-2	1991	Northern blot analysis demonstrated a marked increase in SP-B mRNA expression after treatment with dexamethasone for 48 h. Actinomycin D, puromycin, or cycloheximide blocked the induction of SP-B mRNA by glucocorticoid.	Cycloheximide	152-165	surfactant protein B	Homo sapiens	191-195
1824688-3	1991	The latter was achieved by analyzing, respectively, the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation.	Cycloheximide	126-139	interleukin 2	Homo sapiens	74-78
1824688-3	1991	The latter was achieved by analyzing, respectively, the superinduction of IL-2 and IFN-gamma mRNA occurring upon culture with cycloheximide or after low-dose gamma-irradiation.	Cycloheximide	126-139	interferon gamma	Homo sapiens	83-92
1824688-7	1991	In cells from trisomic subjects, superinduction of IFN-gamma mRNA by cycloheximide was at least as extensive as for normal donors, while in the case of IL-2 mRNA, it was weaker.	Cycloheximide	69-82	interferon gamma	Homo sapiens	51-60
1993549-6	1991	GM-CSF mRNA was, however, detected in the tumor cells in the presence of an mRNA-stabilizing agent, cycloheximide, suggesting the possibility that the tumor cells of this type were transcribing GM-CSF gene, and secreting it in undetectable levels; (3) in culture of the 4 remaining poorly or non-metastatic tumors, neither CSF activity nor GM-CSF mRNA could be detected even in the presence of cycloheximide.	Cycloheximide	100-113	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6
1996953-8	1991	Since the stability of the mRNA was unchanged by TGF-beta and the increased expression of SPPI mRNA could be blocked by cycloheximide, TGF-beta appears to increase transcription of the SppI gene indirectly by stimulating the synthesis of a protein that promotes transcription.	Cycloheximide	120-133	transforming growth factor, beta 1	Rattus norvegicus	135-143
1995415-6	1991	We find that induction by cycloheximide is due to stabilization of c-myc transcripts.	Cycloheximide	26-39	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	67-72
1995415-7	1991	The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene.	Cycloheximide	59-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	45-50
1995415-7	1991	The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene.	Cycloheximide	59-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	115-120
1995415-7	1991	The requirements for increased expression of c-myc mRNA by cycloheximide are the presence of the sequence encoding c-myc amino acids 335-439 on a mRNA that can be translated; all other portions of the c-myc gene are dispensable, and this sequence can confer induction of mRNA expression by protein synthesis inhibitors on a heterologous gene.	Cycloheximide	59-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	115-120
1993549-6	1991	GM-CSF mRNA was, however, detected in the tumor cells in the presence of an mRNA-stabilizing agent, cycloheximide, suggesting the possibility that the tumor cells of this type were transcribing GM-CSF gene, and secreting it in undetectable levels; (3) in culture of the 4 remaining poorly or non-metastatic tumors, neither CSF activity nor GM-CSF mRNA could be detected even in the presence of cycloheximide.	Cycloheximide	394-407	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-6
1671051-5	1991	The RNA synthesis inhibitor, actinomycin D, and the protein synthesis inhibitor, cycloheximide, strongly inhibited the ability of CD4 cells, but not CD8 cells, to induce target DNA fragmentation.	Cycloheximide	81-94	CD4 antigen	Mus musculus	130-133
1899904-7	1991	The addition of actinomycin D and cycloheximide reduced the TPA enhancement of PHS mRNA, indicating that the increase in PHS activity required de novo RNA and protein synthesis.	Cycloheximide	34-47	pterin-4 alpha-carbinolamine dehydratase 1	Rattus norvegicus	79-82
1846878-9	1991	The presence of 5 ng/ml PAF, enhanced the secretion of [35S]methionine-labeled PAF acetylhydrolase and cycloheximide inhibited both the basal and PAF-stimulated secretion of the labeled enzyme.	Cycloheximide	103-116	PCNA clamp associated factor	Homo sapiens	24-27
1846880-3	1991	The more pronounced effects of TNF were accompanied by an augmented surface membrane depolarization rate and were insensitive to both pertussis toxin and calcium ion chelation, but were negated by concomitant incubation with puromycin or cycloheximide during priming.	Cycloheximide	238-251	tumor necrosis factor	Homo sapiens	31-34
1899904-7	1991	The addition of actinomycin D and cycloheximide reduced the TPA enhancement of PHS mRNA, indicating that the increase in PHS activity required de novo RNA and protein synthesis.	Cycloheximide	34-47	pterin-4 alpha-carbinolamine dehydratase 1	Rattus norvegicus	121-124
1993075-4	1991	The initiation inhibitor 2-(4-methyl-2,6-dinitroanilino)-N-methylpropionamide causes accumulation of albumin mRNA in 20-80S mRNP particles whereas the elongation inhibitor cycloheximide causes albumin mRNA to accumulate in polysomes.	Cycloheximide	172-185	Albumin A	Xenopus laevis	193-200
2020980-4	1991	Cycloheximide, but not actinomycin D, inhibits microsomal androgen receptor replenishment, indicating that testosterone may control microsomal receptor levels acutely by posttranscriptional mechanisms.	Cycloheximide	0-13	androgen receptor	Rattus norvegicus	58-75
1846535-2	1991	Northern blot analyses revealed that stimulation with bFGF resulted in a 5-fold increase in FGF receptor mRNA levels at 6-8 h followed by a decline to the unstimulated levels at 24 h. Simultaneous addition of cycloheximide blocked bFGF-induced accumulation of FGF receptor mRNA, although exposure of SC-3 cells to cycloheximide alone caused marginal increase in its basal level.	Cycloheximide	209-222	fibroblast growth factor 2	Mus musculus	54-58
1703446-5	1991	Both RNA and enzyme activity remained at these levels in cells that were incubated in the presence of cycloheximide (CHX, 20 micrograms/ml) for up to 48 h, which suggests that hprt gene expression in resting lymphocytes depends mainly on a stable protein with a half-life of more than 48 h. In phytohemagglutinin (PHA) stimulated lymphocytes, the hprt-RNA levels increased 10-20-fold, while the enzyme activity increased 5-fold.	Cycloheximide	102-115	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	176-180
1703446-5	1991	Both RNA and enzyme activity remained at these levels in cells that were incubated in the presence of cycloheximide (CHX, 20 micrograms/ml) for up to 48 h, which suggests that hprt gene expression in resting lymphocytes depends mainly on a stable protein with a half-life of more than 48 h. In phytohemagglutinin (PHA) stimulated lymphocytes, the hprt-RNA levels increased 10-20-fold, while the enzyme activity increased 5-fold.	Cycloheximide	102-115	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	347-351
1703446-5	1991	Both RNA and enzyme activity remained at these levels in cells that were incubated in the presence of cycloheximide (CHX, 20 micrograms/ml) for up to 48 h, which suggests that hprt gene expression in resting lymphocytes depends mainly on a stable protein with a half-life of more than 48 h. In phytohemagglutinin (PHA) stimulated lymphocytes, the hprt-RNA levels increased 10-20-fold, while the enzyme activity increased 5-fold.	Cycloheximide	117-120	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	176-180
1846535-2	1991	Northern blot analyses revealed that stimulation with bFGF resulted in a 5-fold increase in FGF receptor mRNA levels at 6-8 h followed by a decline to the unstimulated levels at 24 h. Simultaneous addition of cycloheximide blocked bFGF-induced accumulation of FGF receptor mRNA, although exposure of SC-3 cells to cycloheximide alone caused marginal increase in its basal level.	Cycloheximide	209-222	fibroblast growth factor 2	Homo sapiens	231-235
1846535-2	1991	Northern blot analyses revealed that stimulation with bFGF resulted in a 5-fold increase in FGF receptor mRNA levels at 6-8 h followed by a decline to the unstimulated levels at 24 h. Simultaneous addition of cycloheximide blocked bFGF-induced accumulation of FGF receptor mRNA, although exposure of SC-3 cells to cycloheximide alone caused marginal increase in its basal level.	Cycloheximide	314-327	fibroblast growth factor 2	Mus musculus	54-58
1708303-8	1991	NGF synthesized by astrocytes is rapidly secreted into the culture medium and aFGF enhances NGF secretion from the transcription level, because cycloheximide and actinomycin-D completely inhibited NGF secretion by astrocytes in the presence or absence of aFGF.	Cycloheximide	144-157	nerve growth factor	Rattus norvegicus	0-3
1985693-4	1991	In the presence of either actinomycin D (Act D) or cycloheximide, the stability of biologically functional Epo mRNA was much greater than that observed in the absence of these agents and much greater than that which has been reported in vivo.	Cycloheximide	51-64	erythropoietin	Homo sapiens	107-110
1985911-1	1991	We have cloned a serum- and cycloheximide-inducible mRNA from AKR-2B murine fibroblasts which encodes a protein with significant sequence similarity to human tissue factor, a cellular initiator of the blood coagulation cascade.	Cycloheximide	28-41	coagulation factor III, tissue factor	Homo sapiens	158-171
1782324-6	1991	When islets were exposed for 12 h to 50 U/ml rIL-1 beta in the presence of either an inhibitor of gene transcription (actinomycin D) or an inhibitor of mRNA translation (cycloheximide) there was a complete protection against the suppressive effects of rIL-1 beta on insulin release, (pro)insulin biosynthesis and insulin mRNA contents.	Cycloheximide	170-183	interleukin 1 beta	Rattus norvegicus	45-55
1986775-6	1991	The secretion of ERP by THP-1 is suppressed by the protein synthesis inhibitors actinomycin D and cycloheximide.	Cycloheximide	98-111	GLI family zinc finger 2	Homo sapiens	24-29
1712552-5	1991	Posttranscriptional control of HILDLA/LIF mRNA levels by an increase in mRNA half-life was demonstrated in the synergy between phorbol ester and 1,25-dihydroxyvitamin D3 and in the superinduction of HILDA/LIF transcript accumulation when CHX was added to stimulated cells shortly before cell harvesting.	Cycloheximide	238-241	LIF interleukin 6 family cytokine	Homo sapiens	38-41
1712552-5	1991	Posttranscriptional control of HILDLA/LIF mRNA levels by an increase in mRNA half-life was demonstrated in the synergy between phorbol ester and 1,25-dihydroxyvitamin D3 and in the superinduction of HILDA/LIF transcript accumulation when CHX was added to stimulated cells shortly before cell harvesting.	Cycloheximide	238-241	LIF interleukin 6 family cytokine	Homo sapiens	199-204
1712552-5	1991	Posttranscriptional control of HILDLA/LIF mRNA levels by an increase in mRNA half-life was demonstrated in the synergy between phorbol ester and 1,25-dihydroxyvitamin D3 and in the superinduction of HILDA/LIF transcript accumulation when CHX was added to stimulated cells shortly before cell harvesting.	Cycloheximide	238-241	LIF interleukin 6 family cytokine	Homo sapiens	205-208
1846528-5	1991	Furthermore, actinomycin D or cycloheximide completely suppressed cAMP-stimulated secretion of phospholipase A2.	Cycloheximide	30-43	phospholipase A2 group IB	Rattus norvegicus	95-111
1782324-6	1991	When islets were exposed for 12 h to 50 U/ml rIL-1 beta in the presence of either an inhibitor of gene transcription (actinomycin D) or an inhibitor of mRNA translation (cycloheximide) there was a complete protection against the suppressive effects of rIL-1 beta on insulin release, (pro)insulin biosynthesis and insulin mRNA contents.	Cycloheximide	170-183	interleukin 1 beta	Rattus norvegicus	252-262
1989579-8	1991	Estimates of the half-life of MT mRNA by using actinomycin D suggested for cycloheximide, but not puromycin, decreased the decay rate of MT mRNA.	Cycloheximide	75-88	metallothionein 4	Gallus gallus	30-32
1989579-8	1991	Estimates of the half-life of MT mRNA by using actinomycin D suggested for cycloheximide, but not puromycin, decreased the decay rate of MT mRNA.	Cycloheximide	75-88	metallothionein 4	Gallus gallus	137-139
1782401-6	1991	The C5a or FMLP effects were more tachyphylactic in tissues continuously exposed to cycloheximide; this phenomenon was particularly pronounced for FMLP.	Cycloheximide	84-97	complement C5a receptor 1	Homo sapiens	4-7
1801706-7	1991	The induction of uPA by TNF was inhibited by actinomycin D and cycloheximide implying the necessity of RNA and protein synthesis, respectively.	Cycloheximide	63-76	plasminogen activator, urokinase	Homo sapiens	17-20
1801706-7	1991	The induction of uPA by TNF was inhibited by actinomycin D and cycloheximide implying the necessity of RNA and protein synthesis, respectively.	Cycloheximide	63-76	tumor necrosis factor	Homo sapiens	24-27
1782401-6	1991	The C5a or FMLP effects were more tachyphylactic in tissues continuously exposed to cycloheximide; this phenomenon was particularly pronounced for FMLP.	Cycloheximide	84-97	formyl peptide receptor 1	Homo sapiens	11-15
1782401-6	1991	The C5a or FMLP effects were more tachyphylactic in tissues continuously exposed to cycloheximide; this phenomenon was particularly pronounced for FMLP.	Cycloheximide	84-97	formyl peptide receptor 1	Homo sapiens	147-151
1892733-9	1991	Cycloheximide and actinomycin D inhibited the stimulation of arachidonic acid release by IL-1, PMA or DiC8.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	89-93
1892733-10	1991	The addition of cycloheximide or actinomycin D 15-45 min after IL-1 also inhibited IL-1 stimulated arachidonic acid release, indicating that continued protein synthesis was required for IL-1 action.	Cycloheximide	16-29	interleukin 1 alpha	Homo sapiens	63-67
1892733-10	1991	The addition of cycloheximide or actinomycin D 15-45 min after IL-1 also inhibited IL-1 stimulated arachidonic acid release, indicating that continued protein synthesis was required for IL-1 action.	Cycloheximide	16-29	interleukin 1 alpha	Homo sapiens	83-87
1892733-10	1991	The addition of cycloheximide or actinomycin D 15-45 min after IL-1 also inhibited IL-1 stimulated arachidonic acid release, indicating that continued protein synthesis was required for IL-1 action.	Cycloheximide	16-29	interleukin 1 alpha	Homo sapiens	83-87
1900228-8	1991	The usefulness of the technique was further examined following treatment of exponentially growing HL-60 cells with 2.5 micrograms/ml cycloheximide for 0 to 12 h. Cycloheximide treatment was found to cause a significant decrease in c-myc oncoprotein content within 2 h (P less than 0.05), a relative increase in the proportion of G0/G1 cells and a modest decrease in total cellular protein.	Cycloheximide	133-146	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	231-236
1959325-2	1991	In the liver of the frog, Rana negromaculata, the activity of ornithine decarboxylase (ODC) was induced by dietary stimuli and was rapidly lost upon intraperitoneal injection of cycloheximide or putrescine.	Cycloheximide	178-191	ornithine decarboxylase, structural 1	Mus musculus	62-85
1959325-2	1991	In the liver of the frog, Rana negromaculata, the activity of ornithine decarboxylase (ODC) was induced by dietary stimuli and was rapidly lost upon intraperitoneal injection of cycloheximide or putrescine.	Cycloheximide	178-191	ornithine decarboxylase, structural 1	Mus musculus	87-90
1900228-8	1991	The usefulness of the technique was further examined following treatment of exponentially growing HL-60 cells with 2.5 micrograms/ml cycloheximide for 0 to 12 h. Cycloheximide treatment was found to cause a significant decrease in c-myc oncoprotein content within 2 h (P less than 0.05), a relative increase in the proportion of G0/G1 cells and a modest decrease in total cellular protein.	Cycloheximide	162-175	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	231-236
1702702-5	1991	Cycloheximide (1 microM) abolished the effect of RA on hCG and hCG-alpha secretion in the BeWo cell line.	Cycloheximide	0-13	glycoprotein hormones, alpha polypeptide	Homo sapiens	55-58
1702702-5	1991	Cycloheximide (1 microM) abolished the effect of RA on hCG and hCG-alpha secretion in the BeWo cell line.	Cycloheximide	0-13	chromogranin A	Homo sapiens	63-72
1764267-7	1991	The insulin induced increase of hsp90 alpha-mRNA was suppressed by cycloheximide (10 micrograms/ml) but not by an inhibitor of DNA synthesis, demonstrating that this induction requires protein neosynthesis.	Cycloheximide	67-80	insulin	Gallus gallus	4-11
1671048-9	1991	NGF treatment for 6 h increased NGF receptor mRNA fourfold; this increase was inhibited by cycloheximide.	Cycloheximide	91-104	nerve growth factor	Rattus norvegicus	0-3
2049179-5	1991	The protein synthesis inhibitor, cycloheximide, enhances survival on IL3 removal, suggesting that death is an active process.	Cycloheximide	33-46	interleukin 3	Homo sapiens	69-72
1671048-9	1991	NGF treatment for 6 h increased NGF receptor mRNA fourfold; this increase was inhibited by cycloheximide.	Cycloheximide	91-104	nerve growth factor receptor	Rattus norvegicus	32-44
2059565-6	1991	Blockade of protein synthesis with cycloheximide abrogated the stimulatory action of retinoic acid upon thymosin beta-10 mRNA accumulation; this observation suggests that activation of the thymosin beta-10 gene in this cell line by retinoic acid is dependent upon the de novo synthesis of a labile protein.	Cycloheximide	35-48	thymosin, beta 10	Rattus norvegicus	104-120
2059565-6	1991	Blockade of protein synthesis with cycloheximide abrogated the stimulatory action of retinoic acid upon thymosin beta-10 mRNA accumulation; this observation suggests that activation of the thymosin beta-10 gene in this cell line by retinoic acid is dependent upon the de novo synthesis of a labile protein.	Cycloheximide	35-48	thymosin, beta 10	Rattus norvegicus	189-205
1705635-7	1991	Co-culture with cycloheximide mostly abrogated the induction of CD13, suggesting that CD13 expression was mainly dependent on de novo protein synthesis.	Cycloheximide	16-29	alanyl aminopeptidase, membrane	Homo sapiens	64-68
1705635-7	1991	Co-culture with cycloheximide mostly abrogated the induction of CD13, suggesting that CD13 expression was mainly dependent on de novo protein synthesis.	Cycloheximide	16-29	alanyl aminopeptidase, membrane	Homo sapiens	86-90
1708099-6	1991	Cycloheximide treatment resulted in a superinduction of both c-fos and c-myc and prevented any further stimulation by IGF-I.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Canis lupus familiaris	71-76
1943477-3	1991	As low as 10(-10) M PAF caused detectable expression of these genes with a maximum observed at 10(-7) M. In the presence of cycloheximide, increases in the gene expression were noticeable at 20 min and peaked between 30-60 min.	Cycloheximide	124-137	PCNA clamp associated factor	Homo sapiens	20-23
1672730-3	1991	The protein synthesis inhibitors cycloheximide (CHX) and pactamycin rapidly and reversibly increased CD4 and CD8 mRNA in the cloned cell lines, suggesting that a labile inhibitor protein(s) may regulate the expression of these transcripts.	Cycloheximide	33-46	CD4 antigen	Mus musculus	101-104
1672730-3	1991	The protein synthesis inhibitors cycloheximide (CHX) and pactamycin rapidly and reversibly increased CD4 and CD8 mRNA in the cloned cell lines, suggesting that a labile inhibitor protein(s) may regulate the expression of these transcripts.	Cycloheximide	48-51	CD4 antigen	Mus musculus	101-104
1708099-6	1991	Cycloheximide treatment resulted in a superinduction of both c-fos and c-myc and prevented any further stimulation by IGF-I.	Cycloheximide	0-13	insulin like growth factor 1	Canis lupus familiaris	118-123
1905388-5	1991	Maximal TNF release occurred at 8 h of LPS stimulation, and required both protein and RNA synthesis as evidenced by the ability of both actinomycin D and cycloheximide to inhibit its release.	Cycloheximide	154-167	tumor necrosis factor	Homo sapiens	8-11
1850108-9	1991	When Sertoli cells were incubated with 8-(4-chlorophenylthio) cAMP and cycloheximide, a potent inhibitor of protein synthesis, we observed a super-induction of the mRNAs for c-fos (10-fold) and RI alpha (2-fold).	Cycloheximide	71-84	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	174-179
1986224-4	1991	NF-kappa B activation by TNF alpha was initially cycloheximide insensitive, but maintenance of NF-kappa B activity required ongoing protein synthesis and continuous stimulation by TNF alpha.	Cycloheximide	49-62	nuclear factor kappa B subunit 1	Homo sapiens	0-10
1986224-4	1991	NF-kappa B activation by TNF alpha was initially cycloheximide insensitive, but maintenance of NF-kappa B activity required ongoing protein synthesis and continuous stimulation by TNF alpha.	Cycloheximide	49-62	tumor necrosis factor	Homo sapiens	25-34
1704120-3	1991	C-fos in SMS-SB cells can still be induced by serum, TPA and the calcium ionophore, A23187, and superinduced by the combination of serum and cycloheximide.	Cycloheximide	141-154	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
1702421-4	1990	The mechanisms of reduction of SPR mRNA levels were studied by treatment of AR42J cells with actinomycin D or cycloheximide.	Cycloheximide	110-123	tachykinin receptor 1	Rattus norvegicus	31-34
1986403-8	1991	Also, cycloheximide and puromycin appeared to lower the temperature threshold about 1 degree C with respect to the translocation of hsp-70.	Cycloheximide	6-19	heat shock protein family A (Hsp70) member 4	Homo sapiens	132-138
1710190-9	1990	The proteinacious nature of the acid-stable IGF binding activity under study was indicated by its sensitivity to relatively low concentrations of cycloheximide, its apparent deactivation following repeated cycles of freezing and thawing, and its virtual elimination when subjected to boiling or trypsin treatment.	Cycloheximide	146-159	insulin-like growth factor 1	Rattus norvegicus	44-47
1710190-10	1990	Cycloheximide-induced blockade of protein biosynthesis also revealed that the IGF binding activity is subject to measurable turnover thereby suggesting that its accumulation represents the balance struck between synthetic and degradative processes.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	78-81
2148087-5	1990	Cycloheximide and actinomycin D enhanced bradykinin-induced prostacyclin synthesis and apparently blocked the effect of IAP.	Cycloheximide	0-13	kininogen 1	Homo sapiens	41-51
1826973-6	1991	The suppression of bradykinin-induced prostacyclin synthesis by DMS 21-A was completely blocked by cycloheximide.	Cycloheximide	99-112	kininogen 1	Homo sapiens	19-29
2148087-5	1990	Cycloheximide and actinomycin D enhanced bradykinin-induced prostacyclin synthesis and apparently blocked the effect of IAP.	Cycloheximide	0-13	islet amyloid polypeptide	Homo sapiens	120-123
1701436-7	1990	This increase in PAI-1 mRNA levels was mediated by an increase in PAI-1 gene transcription and was abated in the presence of cycloheximide.	Cycloheximide	125-138	serpin family E member 1	Homo sapiens	17-22
2176478-6	1990	The increase of CK activity in ROS 17/2.8 cells caused by bPTH-(1-84) or hPTH-(28-48) was completely inhibited by either cycloheximide or actinomycin D, as was shown previously for rat calvaria cell cultures.	Cycloheximide	121-134	parathyroid hormone	Homo sapiens	73-77
2260995-9	1990	The prior administration of cycloheximide to Wistar rats ablated the clofibrate-dependent induction of both cytochrome P450IVA1 and peroxisomal-dependent lipid metabolism and also blocked the corresponding synthesis of enzyme proteins.	Cycloheximide	28-41	cytochrome P450, family 4, subfamily a, polypeptide 1	Rattus norvegicus	108-127
1701176-6	1990	In the presence of cycloheximide, a protein synthesis inhibitor, uPA mRNA was stabilized, but the effect of ionomycin on Br-cAMP-induced mRNA accumulation was still maintained.	Cycloheximide	19-32	plasminogen activator, urokinase	Sus scrofa	65-68
2124239-9	1990	In separate studies on the effect of IL-1 on AA mobilization, we found that IL-1 induced an increase in phospholipase A2 (PLA2) activity and that cycloheximide blocked the increase, suggesting the requirement for new protein synthesis.	Cycloheximide	146-159	interleukin 1 alpha	Homo sapiens	37-41
2128194-2	1990	Pretreatment of bovine aortic endothelial cells with cycloheximide enhanced their capacity to release prostacyclin in response to adenosine 5"-triphosphate (ATP) and bradykinin.	Cycloheximide	53-66	kininogen 1	Bos taurus	166-176
2174430-5	1990	In the presence of saturating concentrations of 125I-ANF1-28 when cells are warmed from 4 to 37 degrees C, there is first a decrease and then an almost complete replenishment of surface C-ANF receptors, a phenomenon that is not altered by protein synthesis inhibition with cycloheximide.	Cycloheximide	273-286	natriuretic peptide A	Bos taurus	53-56
2174435-9	1990	The changes in MMP and TIMP mRNA levels induced by ConA were blocked by the protein synthesis inhibitor cycloheximide, and the half-lives of collagenase and MMP-2 mRNAs (53 and 46 h, respectively) were unaffected, indicating that ConA exerts its effects transcriptionally, through pathways requiring de novo protein synthesis.	Cycloheximide	104-117	TIMP metallopeptidase inhibitor 1	Homo sapiens	23-27
2126188-4	1990	By contrast, prolonged (17-h) exposure of IFLE to cycloheximide or puromycin resulted in their reaction with antibodies of all major isotypes (IgM, IgG1, IgG2a, IgG2b, IgG3, IgA) containing kappa-light chains.	Cycloheximide	50-63	immunoglobulin heavy constant gamma 3 (G3m marker)	Homo sapiens	168-172
1979590-4	1990	TNF-alpha-induced increases in mesangial cGMP content were evident at 8 h and maximal at 18-24 h. The TNF-alpha-induced stimulation of mesangial cell cGMP production was abrogated by actinomycin D or cycloheximide suggesting dependence on new RNA or protein synthesis.	Cycloheximide	200-213	tumor necrosis factor	Bos taurus	0-9
1979590-4	1990	TNF-alpha-induced increases in mesangial cGMP content were evident at 8 h and maximal at 18-24 h. The TNF-alpha-induced stimulation of mesangial cell cGMP production was abrogated by actinomycin D or cycloheximide suggesting dependence on new RNA or protein synthesis.	Cycloheximide	200-213	tumor necrosis factor	Bos taurus	102-111
2121799-8	1990	Furthermore, astrocyte class II mRNA expression was inhibited when cycloheximide (CHX) was added together with IFN-gamma or IFN-gamma/TNF-alpha, and when CHX was added up to 4 h after treatment with IFN-gamma or IFN-gamma/TNF-alpha.	Cycloheximide	67-80	tumor necrosis factor	Homo sapiens	222-231
2121799-8	1990	Furthermore, astrocyte class II mRNA expression was inhibited when cycloheximide (CHX) was added together with IFN-gamma or IFN-gamma/TNF-alpha, and when CHX was added up to 4 h after treatment with IFN-gamma or IFN-gamma/TNF-alpha.	Cycloheximide	82-85	tumor necrosis factor	Homo sapiens	222-231
2121800-9	1990	Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased levels of IL-6 mRNA in both unstimulated and stimulated astrocytes, indicating that ongoing protein synthesis is not required for astrocyte IL-6 gene expression.	Cycloheximide	0-13	interleukin 6	Rattus norvegicus	85-89
2121800-9	1990	Cycloheximide (CHX), an inhibitor of protein synthesis, markedly increased levels of IL-6 mRNA in both unstimulated and stimulated astrocytes, indicating that ongoing protein synthesis is not required for astrocyte IL-6 gene expression.	Cycloheximide	15-18	interleukin 6	Rattus norvegicus	85-89
2123942-3	1990	The protein synthesis inhibitor, cycloheximide, blunted TNF-induced 2-deoxyglucose uptake, suggesting that new synthesis was in part responsible for the observed increase.	Cycloheximide	33-46	tumor necrosis factor	Mus musculus	56-59
2082182-4	1990	Addition of 25 micrograms/ml cycloheximide (CHX) to the testosterone-pretreated cells resulted in a loss of the testosterone-mediated decrease in ODC mRNA levels by 4 h. Surprisingly, a further 1.8-fold increase in ODC mRNA was observed at 8 h compared to that in untreated cells.	Cycloheximide	29-42	ornithine decarboxylase 1	Rattus norvegicus	146-149
2082182-4	1990	Addition of 25 micrograms/ml cycloheximide (CHX) to the testosterone-pretreated cells resulted in a loss of the testosterone-mediated decrease in ODC mRNA levels by 4 h. Surprisingly, a further 1.8-fold increase in ODC mRNA was observed at 8 h compared to that in untreated cells.	Cycloheximide	29-42	ornithine decarboxylase 1	Rattus norvegicus	215-218
2082182-4	1990	Addition of 25 micrograms/ml cycloheximide (CHX) to the testosterone-pretreated cells resulted in a loss of the testosterone-mediated decrease in ODC mRNA levels by 4 h. Surprisingly, a further 1.8-fold increase in ODC mRNA was observed at 8 h compared to that in untreated cells.	Cycloheximide	44-47	ornithine decarboxylase 1	Rattus norvegicus	146-149
2082182-4	1990	Addition of 25 micrograms/ml cycloheximide (CHX) to the testosterone-pretreated cells resulted in a loss of the testosterone-mediated decrease in ODC mRNA levels by 4 h. Surprisingly, a further 1.8-fold increase in ODC mRNA was observed at 8 h compared to that in untreated cells.	Cycloheximide	44-47	ornithine decarboxylase 1	Rattus norvegicus	215-218
2082182-7	1990	These results demonstrate that the mechanism by which testosterone decreases ODC mRNA levels requires continual protein synthesis, since the effect can be abolished by treating the cells with CHX or puromycin.	Cycloheximide	192-195	ornithine decarboxylase 1	Rattus norvegicus	77-80
2127956-4	1990	An LH/CG surge in vivo or LH treatment of PO follicles in vitro caused a rapid decline of all LH/CG receptor mRNAs in PO follicles, which was prevented by cycloheximide.	Cycloheximide	155-168	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	94-108
2243505-3	1990	Both actinomycin-D and cycloheximide could abrogate PMA-induced p55 membrane expression, suggesting the need for de novo mRNA and protein synthesis.	Cycloheximide	23-36	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	64-67
2247073-4	1990	We found that both induction of RAD9-dependent arrest in G2 and recovery from arrest could occur in the presence of the protein synthesis inhibitor cycloheximide, showing that the mechanism of RAD9-dependent control involves a posttranslational mechanism(s).	Cycloheximide	148-161	chromatin-binding protein RAD9	Saccharomyces cerevisiae S288C	32-36
2247073-4	1990	We found that both induction of RAD9-dependent arrest in G2 and recovery from arrest could occur in the presence of the protein synthesis inhibitor cycloheximide, showing that the mechanism of RAD9-dependent control involves a posttranslational mechanism(s).	Cycloheximide	148-161	chromatin-binding protein RAD9	Saccharomyces cerevisiae S288C	193-197
1702214-4	1990	The expression of the inducible NO synthase was inhibited by the protein synthesis inhibitor cycloheximide, a compound that had no direct effect on the activity of either of the two enzymes.	Cycloheximide	93-106	nitric oxide synthase 2	Homo sapiens	22-43
2073592-2	1990	Neuronal damage in the hippocampal CA1 subfield 72 h after ischemic insult was dramatically decreased by the lasting inhibition of protein synthesis through consecutive administration of cycloheximide.	Cycloheximide	187-200	carbonic anhydrase 1	Rattus norvegicus	35-38
2128972-3	1990	Heparin-induced tPA production was dose- and time-dependent and was inhibited by cycloheximide.	Cycloheximide	81-94	chromosome 20 open reading frame 181	Homo sapiens	16-19
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Cycloheximide	77-90	colony stimulating factor 2	Homo sapiens	118-124
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Cycloheximide	77-90	colony stimulating factor 3	Homo sapiens	129-134
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Cycloheximide	77-90	interleukin 1 alpha	Homo sapiens	157-161
1700731-7	1990	The transcription inhibitor, actinomycin D, and protein synthesis inhibitor, cycloheximide, inhibited the increase in GM-CSF and G-CSF production induced by IL-1 and TNF.	Cycloheximide	77-90	tumor necrosis factor	Homo sapiens	166-169
1700978-8	1990	Cycloheximide completely blocked the increase in alpha 2M receptor expression when added simultaneously with the CSF-1; greater than 50% inhibition was observed when the cycloheximide was added up to 8 h later.	Cycloheximide	0-13	PZP, alpha-2-macroglobulin like	Mus musculus	49-57
1700978-8	1990	Cycloheximide completely blocked the increase in alpha 2M receptor expression when added simultaneously with the CSF-1; greater than 50% inhibition was observed when the cycloheximide was added up to 8 h later.	Cycloheximide	0-13	colony stimulating factor 1 (macrophage)	Mus musculus	113-118
1700978-8	1990	Cycloheximide completely blocked the increase in alpha 2M receptor expression when added simultaneously with the CSF-1; greater than 50% inhibition was observed when the cycloheximide was added up to 8 h later.	Cycloheximide	170-183	PZP, alpha-2-macroglobulin like	Mus musculus	49-57
2173488-6	1990	Cycloheximide and actinomycin D were also inhibitory to enzyme induction, indicating that enhancement of enzyme activity by EGF and cAMP was not due to post-translational modification.	Cycloheximide	0-13	epidermal growth factor	Homo sapiens	124-127
2173915-3	1990	We show here that the 5" flanking region of Cyp1a-2 from - 1843 to +52 (base pairs relative to the Transcription initiation site) linked to the chloramphenicol acetyltransferase (CAT) reporter gene in stable Hepa-1 transformants produces no basal or TCDD- or cycloheximide-inducible CAT activity.	Cycloheximide	259-272	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	44-51
2173915-4	1990	On the other hand, the Cyp1a-2 promoter from -63 to +52 driving the CAT gene is inducible by cycloheximide.	Cycloheximide	93-106	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	23-30
2253786-1	1990	The effect of cycloheximide (CHX) on denervation-induced acetylcholine receptor (AChR) expression was investigated in chickens one day after nerve section, using probe excess solution hybridization to quantitate AChR alpha-subunit gene transcript levels and run-on analysis to measure subunit gene activity.	Cycloheximide	14-27	cholinergic receptor nicotinic delta subunit	Gallus gallus	57-79
2253786-1	1990	The effect of cycloheximide (CHX) on denervation-induced acetylcholine receptor (AChR) expression was investigated in chickens one day after nerve section, using probe excess solution hybridization to quantitate AChR alpha-subunit gene transcript levels and run-on analysis to measure subunit gene activity.	Cycloheximide	14-27	cholinergic receptor nicotinic delta subunit	Gallus gallus	81-85
2253786-1	1990	The effect of cycloheximide (CHX) on denervation-induced acetylcholine receptor (AChR) expression was investigated in chickens one day after nerve section, using probe excess solution hybridization to quantitate AChR alpha-subunit gene transcript levels and run-on analysis to measure subunit gene activity.	Cycloheximide	29-32	cholinergic receptor nicotinic delta subunit	Gallus gallus	57-79
2253786-1	1990	The effect of cycloheximide (CHX) on denervation-induced acetylcholine receptor (AChR) expression was investigated in chickens one day after nerve section, using probe excess solution hybridization to quantitate AChR alpha-subunit gene transcript levels and run-on analysis to measure subunit gene activity.	Cycloheximide	29-32	cholinergic receptor nicotinic delta subunit	Gallus gallus	81-85
2229049-2	1990	Moreover, it appears that glucose modulates insulin receptor affinity through de novo protein synthesis rather than through covalent modification of receptors, since cycloheximide selectively inhibited the glucose-induced increase in insulin binding capacity (ED50 of 360 ng/ml) and restored receptor affinity to control values.	Cycloheximide	166-179	insulin receptor	Homo sapiens	44-60
2229049-2	1990	Moreover, it appears that glucose modulates insulin receptor affinity through de novo protein synthesis rather than through covalent modification of receptors, since cycloheximide selectively inhibited the glucose-induced increase in insulin binding capacity (ED50 of 360 ng/ml) and restored receptor affinity to control values.	Cycloheximide	166-179	insulin	Homo sapiens	44-51
2229066-3	1990	Similarly, incubation of chromaffin cells with cycloheximide (10(-6) M), given at 0-6 h, blocks the increase in Penk mRNA after stimulation with histamine and nicotine indicating that ongoing protein synthesis is necessary for the delayed rise of Penk mRNA.	Cycloheximide	47-60	proenkephalin	Bos taurus	112-116
2229066-3	1990	Similarly, incubation of chromaffin cells with cycloheximide (10(-6) M), given at 0-6 h, blocks the increase in Penk mRNA after stimulation with histamine and nicotine indicating that ongoing protein synthesis is necessary for the delayed rise of Penk mRNA.	Cycloheximide	47-60	proenkephalin	Bos taurus	247-251
2229079-6	1990	The effect of the hormone on LDL receptor activity can be mimicked by 8-Br-cAMP and is completely abolished by the protein synthesis inhibitor cycloheximide but not by actinomycin D.	Cycloheximide	143-156	low density lipoprotein receptor	Rattus norvegicus	29-41
2088477-8	1990	The induction of OTS-5 and OTS-8 was decreased in the presence of cycloheximide.	Cycloheximide	66-79	podoplanin	Mus musculus	27-32
2104238-4	1990	It was found that early pretreatment with cycloheximide interferes with TNF-alpha mRNA induction by Staphylococcus aureus.	Cycloheximide	42-55	tumor necrosis factor	Homo sapiens	72-81
2226308-6	1990	Induction of renin and prorenin production by LH in cultured theca cells was dependent upon de novo protein synthesis, since the action of LH could be completely blocked by the protein synthesis inhibitor, cycloheximide.	Cycloheximide	206-219	renin	Bos taurus	13-18
2227101-8	1990	AChR aggregation induced by any treatment was not inhibited by cycloheximide, Ca2+ channel blockers, or protease inhibitors but was blocked by Co2+ and sodium azide.	Cycloheximide	63-76	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	0-4
1699745-9	1990	The production of IGFBPs was inhibited by cycloheximide.	Cycloheximide	42-55	insulin like growth factor binding protein 1	Homo sapiens	18-24
1699746-3	1990	Secretion of IGF-I immunoreactivity was blocked in the presence of cycloheximide, suggesting de novo synthesis.	Cycloheximide	67-80	insulin-like growth factor 1	Rattus norvegicus	13-18
2226300-10	1990	IGF-II-stimulated 3 beta HSD activity was completely inhibited by concurrent treatment with either actinomycin D or cycloheximide, suggesting that new mRNA and protein synthesis are required for IGF-II to exert its stimulatory effect.	Cycloheximide	116-129	insulin like growth factor 2	Homo sapiens	0-6
2226300-10	1990	IGF-II-stimulated 3 beta HSD activity was completely inhibited by concurrent treatment with either actinomycin D or cycloheximide, suggesting that new mRNA and protein synthesis are required for IGF-II to exert its stimulatory effect.	Cycloheximide	116-129	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	18-28
2226300-10	1990	IGF-II-stimulated 3 beta HSD activity was completely inhibited by concurrent treatment with either actinomycin D or cycloheximide, suggesting that new mRNA and protein synthesis are required for IGF-II to exert its stimulatory effect.	Cycloheximide	116-129	insulin like growth factor 2	Homo sapiens	195-201
2276626-5	1990	These effects appear to result from stabilization of the ftz protein, since ftz stripes decay much more slowly in mutant embryos than in wild type after injection of the protein synthesis inhibitor cycloheximide.	Cycloheximide	198-211	fushi tarazu	Drosophila melanogaster	57-60
2276626-5	1990	These effects appear to result from stabilization of the ftz protein, since ftz stripes decay much more slowly in mutant embryos than in wild type after injection of the protein synthesis inhibitor cycloheximide.	Cycloheximide	198-211	fushi tarazu	Drosophila melanogaster	76-79
2145367-5	1990	As described for other cell types, pretreatment of C3HA cells with TNF prevented cytolysis by TNF plus cycloheximide or TNF plus cytochalasin E, indicating that TNF induces a response that protects against these treatments.	Cycloheximide	103-116	tumor necrosis factor	Mus musculus	67-70
2212668-2	1990	Using a quantitative dot-blot immunoassay for the IL-2R alpha subunit, a rapid disappearance of this polypeptide from cells is demonstrated in the presence of the translation inhibitor, cycloheximide.	Cycloheximide	186-199	interleukin 2 receptor subunit alpha	Homo sapiens	50-61
2212676-5	1990	Northern blot analyses with actinomycin D or cycloheximide revealed that these second messengers induce the transcription of DRA and B and DPA and B genes without de novo protein synthesis.	Cycloheximide	45-58	solute carrier family 26 member 3	Homo sapiens	125-128
2122233-7	1990	The junB and c-fos mRNAs, instead, were increased to the same extent or less by amino acid starvation than by cycloheximide treatment.	Cycloheximide	110-123	transcription factor jun-B	Cricetulus griseus	4-8
1965839-3	1990	The expression of NGF-R mRNA in C6 cells can be up-regulated by cycloheximide and its own ligand, NGF; and it can be rapidly down-regulated by epidermal growth factor (EGF).	Cycloheximide	64-77	nerve growth factor receptor	Rattus norvegicus	18-23
1965839-3	1990	The expression of NGF-R mRNA in C6 cells can be up-regulated by cycloheximide and its own ligand, NGF; and it can be rapidly down-regulated by epidermal growth factor (EGF).	Cycloheximide	64-77	nerve growth factor	Rattus norvegicus	18-21
1698783-4	1990	The stimulatory effects of TGF-beta were prevented by the inhibitors of protein synthesis and DNA transcription, cycloheximide, or actinomycin D, respectively.	Cycloheximide	113-126	transforming growth factor beta 1	Homo sapiens	27-35
2233719-1	1990	We have previously described the cloning of a group of novel cellular immediate-early response genes whose expression in human umbilical vein endothelial cells is induced by tumor necrosis factor alpha in the presence of cycloheximide.	Cycloheximide	221-234	tumor necrosis factor	Homo sapiens	174-201
2120207-10	1990	In addition, treatment with IGF-I for 3 h or more resulted in sustained increase in 1,2-DAG mass, which was attenuated by cycloheximide.	Cycloheximide	122-135	insulin-like growth factor 1	Mus musculus	28-33
2170366-6	1990	Further, treatment of NG108-15 cells with cycloheximide, throughout the time period required to produce maximal prostaglandin E1-dependent down-regulation of Gs alpha, demonstrated that complete suppression of de novo protein synthesis could not mimic the effect of prostaglandin E1 and hence even complete inhibition of transcription of the Gs alpha gene and/or translation of pre-existing mRNA could not account for these results.	Cycloheximide	42-55	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	158-166
2170366-6	1990	Further, treatment of NG108-15 cells with cycloheximide, throughout the time period required to produce maximal prostaglandin E1-dependent down-regulation of Gs alpha, demonstrated that complete suppression of de novo protein synthesis could not mimic the effect of prostaglandin E1 and hence even complete inhibition of transcription of the Gs alpha gene and/or translation of pre-existing mRNA could not account for these results.	Cycloheximide	42-55	GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus	Mus musculus	342-350
2170374-2	1990	An hepatic protein kinase that phosphorylates microtubule-associated protein 2 (MAP-2) on Ser/Thr residues is markedly activated after intraperitoneal injection of cycloheximide in the rat.	Cycloheximide	164-177	microtubule-associated protein 2	Rattus norvegicus	46-78
2170518-8	1990	This enhanced CRP response was sensitive to cycloheximide.	Cycloheximide	44-57	C-reactive protein	Homo sapiens	14-17
2121048-4	1990	Actinomycin D and cycloheximide blocked the PMA-stimulated COX activity but not AA release.	Cycloheximide	18-31	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	59-62
2170374-2	1990	An hepatic protein kinase that phosphorylates microtubule-associated protein 2 (MAP-2) on Ser/Thr residues is markedly activated after intraperitoneal injection of cycloheximide in the rat.	Cycloheximide	164-177	microtubule-associated protein 2	Rattus norvegicus	80-85
2170374-6	1990	The activity of the cycloheximide-stimulated MAP-2 kinase (pp54 MAP-2 kinase) toward potential polypeptide substrates was compared to that of an insulin-stimulated MAP-2 kinase (pp42 MAP-2 kinase).	Cycloheximide	20-33	microtubule-associated protein 2	Rattus norvegicus	45-50
2170374-6	1990	The activity of the cycloheximide-stimulated MAP-2 kinase (pp54 MAP-2 kinase) toward potential polypeptide substrates was compared to that of an insulin-stimulated MAP-2 kinase (pp42 MAP-2 kinase).	Cycloheximide	20-33	microtubule-associated protein 2	Rattus norvegicus	64-69
2170374-6	1990	The activity of the cycloheximide-stimulated MAP-2 kinase (pp54 MAP-2 kinase) toward potential polypeptide substrates was compared to that of an insulin-stimulated MAP-2 kinase (pp42 MAP-2 kinase).	Cycloheximide	20-33	microtubule-associated protein 2	Rattus norvegicus	64-69
2170374-10	1990	Cycloheximide-activated pp54 MAP-2 protein kinase appears to be a previously uncharacterized protein kinase that is itself regulated through Ser/Thr phosphorylation and, perhaps, polypeptide regulators with basic domains.	Cycloheximide	0-13	microtubule-associated protein 2	Rattus norvegicus	29-34
1702972-11	1990	Previous studies of c-fos RNA from HeLa cells indicate that this is due to cycloheximide-dependent stabilization of poly(A) tails.	Cycloheximide	75-88	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-25
2144551-10	1990	The protein synthesis inhibitor cycloheximide did not block the induction of any of these genes, and in fact, super-induced the expression of c-jun and hck.	Cycloheximide	32-45	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	142-147
2211838-4	1990	However, at later times (4-8 h) the combination of cycloheximide and bFGF superinduced TS mRNA levels, suggesting the existence of a labile inhibitor of transcription or a short-lived RNase that might be produced in response to prolonged treatment with bFGF.	Cycloheximide	51-64	fibroblast growth factor 2	Mus musculus	253-257
2144551-10	1990	The protein synthesis inhibitor cycloheximide did not block the induction of any of these genes, and in fact, super-induced the expression of c-jun and hck.	Cycloheximide	32-45	HCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	152-155
2118988-8	1990	Upon mixing in vitro the cytoplasmic fraction of gamma interferon-treated HeLaM cells with that of cells treated with alpha interferon and cycloheximide, active ISGF3 was reconstituted, presumably through complementation of two components, ISGF3 gamma and ISGF3 alpha, present in the two respective fractions.	Cycloheximide	139-152	interferon regulatory factor 9	Homo sapiens	161-166
2215247-5	1990	Thrombin-induced ir-endothelin-1 release also was inhibited completely by 10 micrograms/mL cycloheximide.	Cycloheximide	91-104	coagulation factor II, thrombin	Homo sapiens	0-8
2215247-5	1990	Thrombin-induced ir-endothelin-1 release also was inhibited completely by 10 micrograms/mL cycloheximide.	Cycloheximide	91-104	endothelin 1	Homo sapiens	20-32
2398896-10	1990	Nuclear run-on transcription assays show that the gene for p47 is induced at the transcriptional level in a cycloheximide-insensitive manner.	Cycloheximide	108-121	pleckstrin	Homo sapiens	59-62
2098699-6	1990	The LPS of A. actinomycetemcomitans stimulated increased levels of IL-1 beta mRNA in the presence of cycloheximide, showing that stimulation by this LPS did not require new synthesis of protein.	Cycloheximide	101-114	interleukin 1 beta	Homo sapiens	67-76
2254900-2	1990	Pretreatment of chondrocytes with actinomycin D or cycloheximide significantly inhibited IL-1 induced PLA2 activation and secretion, suggesting that the enzyme induction process is RNA and protein synthesis dependent.	Cycloheximide	51-64	interleukin 1 alpha	Homo sapiens	89-93
2254900-2	1990	Pretreatment of chondrocytes with actinomycin D or cycloheximide significantly inhibited IL-1 induced PLA2 activation and secretion, suggesting that the enzyme induction process is RNA and protein synthesis dependent.	Cycloheximide	51-64	phospholipase A2	Oryctolagus cuniculus	102-106
2123531-6	1990	When protein synthesis is inhibited by injection of cycloheximide, the expression of c-myc, c-fos, jun B, c-jun and jun D mRNA is also transiently increased.	Cycloheximide	52-65	FBJ osteosarcoma oncogene	Mus musculus	92-97
2123531-6	1990	When protein synthesis is inhibited by injection of cycloheximide, the expression of c-myc, c-fos, jun B, c-jun and jun D mRNA is also transiently increased.	Cycloheximide	52-65	jun B proto-oncogene	Mus musculus	99-104
2123531-6	1990	When protein synthesis is inhibited by injection of cycloheximide, the expression of c-myc, c-fos, jun B, c-jun and jun D mRNA is also transiently increased.	Cycloheximide	52-65	jun proto-oncogene	Mus musculus	106-111
2123531-6	1990	When protein synthesis is inhibited by injection of cycloheximide, the expression of c-myc, c-fos, jun B, c-jun and jun D mRNA is also transiently increased.	Cycloheximide	52-65	jun D proto-oncogene	Mus musculus	116-121
2127639-5	1990	Tyrosinase activation by the psoralens, like that of alpha-melanotropin, was blocked by actinomycin-D or cycloheximide demonstrating that the actions of the drugs may have involved both transcriptional and translational events in the stimulation of melanogenesis.	Cycloheximide	105-118	tyrosinase	Mus musculus	0-10
2122450-2	1990	The dominant S6 kinase purified from livers of cycloheximide-treated rats is also a 70-kDa polypeptide.	Cycloheximide	47-60	ribosomal protein S6 kinase B1	Rattus norvegicus	13-22
2391415-7	1990	A20-HL cells took up specific Ag for stimulation of 42-6A cells in the presence of cycloheximide, a reversible protein synthesis inhibitor.	Cycloheximide	83-96	immunoglobulin kappa variable 1-27	Homo sapiens	0-3
2172977-2	1990	The cells were appropriately treated with cycloheximide before fusion, which emptied them of their respective secretory proteins, serum albumin for the Hep G2 cells and procollagen I for the WI-38 cells.	Cycloheximide	42-55	albumin	Homo sapiens	130-143
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	137-150	interleukin 6	Homo sapiens	15-19
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	137-150	interleukin 6	Homo sapiens	182-186
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	137-150	tumor necrosis factor	Homo sapiens	222-231
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	152-155	interleukin 6	Homo sapiens	15-19
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	152-155	interleukin 6	Homo sapiens	182-186
2226778-7	1990	Stimulation of IL-6 transcripts in fibroblasts did also not require new protein synthesis as exposure to the protein synthesis inhibitor cycloheximide (CHX) enhanced accumulation of IL-6 mRNA in the presence or absence of TNF-alpha or LT.	Cycloheximide	152-155	tumor necrosis factor	Homo sapiens	222-231
2169239-2	1990	When LPL activity in cardiac myocytes was depleted by treatment of rats with cycloheximide (2 mg/kg; 2.5 h) and inclusion of the protein-synthesis inhibitor in the isolation solutions, incubation with CPT-cAMP or forskolin did not influence the rate of repletion of LPL activity in cells or the recovery of heparin-releasable LPL activity.	Cycloheximide	77-90	lipoprotein lipase	Rattus norvegicus	5-8
2203768-4	1990	Neurons preincubated with cycloheximide (10 micrograms/ml) 30 min prior to insulin treatment showed the same degree of stimulation of PKC activity by insulin.	Cycloheximide	26-39	insulin	Gallus gallus	150-157
2171924-8	1990	Their culture supernatants showed 1.86 +/- 0.38 units/ml of angiotensin-converting enzyme (ACE) activity, which was inhibited by cycloheximide.	Cycloheximide	129-142	angiotensin-converting enzyme	Oryctolagus cuniculus	91-94
2393297-5	1990	Heme depletion did not appear to explain these observations because the inhibitory effects of cycloheximide on the induction of P450b/e mRNA were not overcome by supplementation of the medium with exogenous heme or with delta-aminolevulinic acid.	Cycloheximide	94-107	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	128-133
2393297-10	1990	Such analyses confirmed that cycloheximide treatment selectively increased P450PCN1(IIIA1) mRNA in female rat liver, whereas the amount of mRNA for P450PCN2(IIIA2), a closely related male-specific family member, was unaffected.	Cycloheximide	29-42	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	75-83
2200823-7	1990	The IL-4-induced inhibition of IL-8 mRNA expression was dependent on protein synthesis, as the suppressive effects of IL-4 were significantly negated by the addition of cycloheximide.	Cycloheximide	169-182	interleukin 4	Homo sapiens	4-8
2391378-8	1990	TGF beta enhancement of PTH and isoproterenol responses was blocked by prior treatment of cells with cycloheximide but not indomethacin.	Cycloheximide	101-114	transforming growth factor, beta 1	Rattus norvegicus	0-8
2200823-7	1990	The IL-4-induced inhibition of IL-8 mRNA expression was dependent on protein synthesis, as the suppressive effects of IL-4 were significantly negated by the addition of cycloheximide.	Cycloheximide	169-182	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
2200823-7	1990	The IL-4-induced inhibition of IL-8 mRNA expression was dependent on protein synthesis, as the suppressive effects of IL-4 were significantly negated by the addition of cycloheximide.	Cycloheximide	169-182	interleukin 4	Homo sapiens	118-122
2177654-4	1990	The induction of NF-kappa B by okadaic acid was enhanced by cycloheximide or phytohemagglutinin (PHA).	Cycloheximide	60-73	nuclear factor kappa B subunit 1	Homo sapiens	17-27
1981248-0	1990	[Activation of transcription of the tyrosine aminotransferase gene in the rat McA-RN 7777 hepatoma cell line by cycloheximide].	Cycloheximide	112-125	tyrosine aminotransferase	Rattus norvegicus	36-61
1696944-6	1990	In the presence of cycloheximide, c-jun and c-myc genes were superinduced by the addition of cadmium.	Cycloheximide	19-32	jun proto-oncogene	Mus musculus	34-39
1981248-1	1990	The expression of the tyrosine aminotransferase (TAT) mRNA after cycloheximide treatment was analysed by Northern blotting method in Morris rat hepatoma cell lines.	Cycloheximide	65-78	tyrosine aminotransferase	Rattus norvegicus	22-47
1981248-1	1990	The expression of the tyrosine aminotransferase (TAT) mRNA after cycloheximide treatment was analysed by Northern blotting method in Morris rat hepatoma cell lines.	Cycloheximide	65-78	tyrosine aminotransferase	Rattus norvegicus	49-52
1981248-2	1990	The level of TAT mRNA increased after 6-8 h of cycloheximide treatment only in the McA-RH 7777 cell line.	Cycloheximide	47-60	tyrosine aminotransferase	Rattus norvegicus	13-16
1981248-3	1990	McA-RH 7777 nuclear run-off assay showed that TAT transcription was induced by cycloheximide treatment.	Cycloheximide	79-92	tyrosine aminotransferase	Rattus norvegicus	46-49
1981248-4	1990	Both glucocorticoid and cycloheximide modulated TAT gene transcription in a synergistic way.	Cycloheximide	24-37	tyrosine aminotransferase	Rattus norvegicus	48-51
2146820-3	1990	Bolus injection of ANF (0.07 micrograms/kg, diluted in 1 ml 0.9% NaCl, n = 7) increased diameter of proximal segments of LAD (11 +/- 4%) and Cx (10 +/- 4%) (p less than 0.02 each vs control) without altering heart rate and mean arterial pressure (MAP).	Cycloheximide	141-143	natriuretic peptide A	Homo sapiens	19-22
2168170-6	1990	Cycloheximide partially blocked the induction of GLUT1 mRNA by insulin but not by glucose deprivation.	Cycloheximide	0-13	solute carrier family 2 member 1	Homo sapiens	49-54
2168170-6	1990	Cycloheximide partially blocked the induction of GLUT1 mRNA by insulin but not by glucose deprivation.	Cycloheximide	0-13	insulin	Homo sapiens	63-70
1696944-6	1990	In the presence of cycloheximide, c-jun and c-myc genes were superinduced by the addition of cadmium.	Cycloheximide	19-32	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	44-49
1696944-8	1990	Induction of c-myc and c-jun by cadmium and c-fos by a combination of cadmium and cycloheximide could be abolished by blocking transcription with actinomycin D.	Cycloheximide	82-95	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	13-18
1696944-8	1990	Induction of c-myc and c-jun by cadmium and c-fos by a combination of cadmium and cycloheximide could be abolished by blocking transcription with actinomycin D.	Cycloheximide	82-95	jun proto-oncogene	Mus musculus	23-28
1696944-8	1990	Induction of c-myc and c-jun by cadmium and c-fos by a combination of cadmium and cycloheximide could be abolished by blocking transcription with actinomycin D.	Cycloheximide	82-95	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	44-49
2169419-6	1990	In contrast to these results, cycloheximide did not induce collagenase mRNA but, rather, prevented its induction by interleukin-1 beta.	Cycloheximide	30-43	interleukin 1 beta	Homo sapiens	116-134
2166111-12	1990	IL-1 enhancement of PGE2-stimulated adenylate cyclase was detected between 1 to 2 h, was maximal at 4 to 5 h, was not prevented by cycloheximide treatment, and was seen in membranes from IL-1 pretreated cells.	Cycloheximide	131-144	interleukin 1 beta	Homo sapiens	0-4
1695903-8	1990	Moreover, in a series of HeLa cell clones, the levels of p50 are directly proportional to the magnitude of induction produced by CHX.	Cycloheximide	129-132	nuclear factor kappa B subunit 1	Homo sapiens	57-60
2396988-2	1990	Actinomycin D, cycloheximide and diclofenac attenuate the TGF beta 2-induced PGE2 formation.	Cycloheximide	15-28	transforming growth factor, beta 2	Rattus norvegicus	58-68
1695907-9	1990	Inhibition of protein synthesis by cycloheximide prior to the exposure of LLC-PK1 cells to colchicine, nocodazole, or cytochalasin B, largely prevented the induction of uPA mRNA.	Cycloheximide	35-48	plasminogen activator, urokinase	Sus scrofa	169-172
1979013-4	1990	When neutrophils were incubated in the presence of cycloheximide, they progressively lost their ability to generate reactive oxidants in response to fMet-Leu-Phe so that by 5 h incubation with this inhibitor they could only generate about 25% of the oxidative response stimulated in untreated cells, and the expression of CD16 and CD18 was grossly impaired.	Cycloheximide	51-64	Fc gamma receptor IIIa	Homo sapiens	322-326
2165488-11	1990	Cycloheximide treatment also increased alpha 1 and decreased alpha 2 mRNA levels, with the alpha 1/alpha 2 ratio increasing approximately 10-fold.	Cycloheximide	0-13	adrenoceptor alpha 1D	Homo sapiens	39-68
2382730-0	1990	Enhancement of tumor necrosis factor-induced endothelial cell injury by cycloheximide.	Cycloheximide	72-85	tumor necrosis factor	Homo sapiens	15-36
2382730-3	1990	We now report that cycloheximide (CHX), an inhibitor of protein synthesis, renders endothelial cells highly susceptible to TNF-induced lysis.	Cycloheximide	19-32	tumor necrosis factor	Homo sapiens	123-126
2382730-3	1990	We now report that cycloheximide (CHX), an inhibitor of protein synthesis, renders endothelial cells highly susceptible to TNF-induced lysis.	Cycloheximide	34-37	tumor necrosis factor	Homo sapiens	123-126
1979013-4	1990	When neutrophils were incubated in the presence of cycloheximide, they progressively lost their ability to generate reactive oxidants in response to fMet-Leu-Phe so that by 5 h incubation with this inhibitor they could only generate about 25% of the oxidative response stimulated in untreated cells, and the expression of CD16 and CD18 was grossly impaired.	Cycloheximide	51-64	integrin subunit beta 2	Homo sapiens	331-335
2078571-7	1990	Inducible prepro ET-1mRNA expression was accompanied by a cycloheximide-inhibitable release of ET-1 peptide into the medium of rVSMC.	Cycloheximide	58-71	endothelin 1	Rattus norvegicus	17-21
2278886-3	1990	In quiescent fibroblasts, c-rel expression is maximally induced by serum or 12-O-tetradecanoylphorbol-13-acetate within 60 min and is superinduced in serum-stimulated fibroblasts by cycloheximide.	Cycloheximide	182-195	reticuloendotheliosis oncogene	Mus musculus	26-31
2127699-2	1990	In cells stimulated with serum and cycloheximide, vinculin expression was superinduced and vinculin mRNA levels persisted longer than in cells stimulated with serum alone.	Cycloheximide	35-48	vinculin	Homo sapiens	50-58
2127699-2	1990	In cells stimulated with serum and cycloheximide, vinculin expression was superinduced and vinculin mRNA levels persisted longer than in cells stimulated with serum alone.	Cycloheximide	35-48	vinculin	Homo sapiens	91-99
2127700-8	1990	In both naive and TPA-desensitized human fibroblasts or WISH cells, prolonged IFN treatment induced a desensitized state that was reversible by cycloheximide.	Cycloheximide	144-157	interferon alpha 1	Homo sapiens	78-81
1695566-9	1990	By day 5, exposure to (Bu)2cAMP induced a 5- to 6-fold increase in IGFBP-1 release that was completely inhibited by exposure to cycloheximide.	Cycloheximide	128-141	insulin like growth factor binding protein 1	Homo sapiens	67-74
2203676-5	1990	The maximum induction of IL-4 receptor expression was achieved by 4 hr of incubation with rIL-2 and was completely blocked by cycloheximide.	Cycloheximide	126-139	interleukin 4	Rattus norvegicus	25-29
2115429-11	1990	The decrease in hybridization signal for BGP mRNA was detectable by 1 h after IFN exposure and continued to decline at 6 and 24 h. Treatment with cycloheximide (5 micrograms/ml) blocked the inhibitory effect of IFN on steady state levels of BGP mRNA.	Cycloheximide	146-159	bone gamma-carboxyglutamate protein	Rattus norvegicus	41-44
2115429-11	1990	The decrease in hybridization signal for BGP mRNA was detectable by 1 h after IFN exposure and continued to decline at 6 and 24 h. Treatment with cycloheximide (5 micrograms/ml) blocked the inhibitory effect of IFN on steady state levels of BGP mRNA.	Cycloheximide	146-159	interferon gamma	Rattus norvegicus	78-81
2115429-11	1990	The decrease in hybridization signal for BGP mRNA was detectable by 1 h after IFN exposure and continued to decline at 6 and 24 h. Treatment with cycloheximide (5 micrograms/ml) blocked the inhibitory effect of IFN on steady state levels of BGP mRNA.	Cycloheximide	146-159	interferon gamma	Rattus norvegicus	211-214
2115429-11	1990	The decrease in hybridization signal for BGP mRNA was detectable by 1 h after IFN exposure and continued to decline at 6 and 24 h. Treatment with cycloheximide (5 micrograms/ml) blocked the inhibitory effect of IFN on steady state levels of BGP mRNA.	Cycloheximide	146-159	bone gamma-carboxyglutamate protein	Rattus norvegicus	241-244
1704377-9	1990	Scattering was blocked by inhibitors of protein and RNA but not DNA synthesis; SF- and agent-stimulated migration were ablated by cycloheximide.	Cycloheximide	130-143	hepatocyte growth factor	Canis lupus familiaris	79-81
2384603-9	1990	Translational inhibition with cycloheximide inhibited both the IGF-I-mediated increase in LH binding and stimulation of androgen synthesis.	Cycloheximide	30-43	insulin-like growth factor 1	Rattus norvegicus	63-68
1695244-6	1990	The stimulation of NAT activity in E6 cultures was inhibited by actinomycin D and cycloheximide, suggesting the involvement of RNA and protein synthesis.	Cycloheximide	82-95	arylamine N-acetyltransferase, liver isozyme	Gallus gallus	19-22
2115543-7	1990	Addition of protein or RNA synthesis inhibitors (cycloheximide, emetine, actinomycin D) during exposure to rIL-2 and rIFN-gamma totally abrogated the ability of macrophages to express this effector reaction; inhibitors of protein kinase C, PG, or calcium redistribution had no effect.	Cycloheximide	49-62	interleukin 2	Rattus norvegicus	107-112
2115543-7	1990	Addition of protein or RNA synthesis inhibitors (cycloheximide, emetine, actinomycin D) during exposure to rIL-2 and rIFN-gamma totally abrogated the ability of macrophages to express this effector reaction; inhibitors of protein kinase C, PG, or calcium redistribution had no effect.	Cycloheximide	49-62	interferon gamma	Rattus norvegicus	117-127
2370555-6	1990	The induction of NGF mRNA is inhibited by cycloheximide, NGF mRNA levels decrease to similar values after 4 h of incubation with actinomycin D alone or in combination with TPA.	Cycloheximide	42-55	nerve growth factor	Mus musculus	17-20
2142689-6	1990	These clones are used to study the time course of expression and the sensitivity to cycloheximide inhibition of IL2-induced mRNAs.	Cycloheximide	84-97	interleukin 2	Mus musculus	112-115
2166057-9	1990	When cultures are exposed to cycloheximide before the binding assay, both the amount of IGFBPs that are released into the assay buffer and the amount of [125I]-IGF-I that is repartitioned are decreased.	Cycloheximide	29-42	insulin like growth factor 1	Homo sapiens	160-165
1707095-0	1990	Effect of cycloheximide and actinomycin D on thymidylate synthase and thymidine kinase in regenerating rat liver after partial hepatectomy.	Cycloheximide	10-23	thymidylate synthetase	Rattus norvegicus	45-65
1707095-2	1990	The increases in the activities of hepatic thymidylate synthase and thymidine kinase were significantly suppressed at 24 h after 70% partial hepatectomy in rats that had been administered cycloheximide.	Cycloheximide	188-201	thymidylate synthetase	Rattus norvegicus	43-63
2171043-11	1990	Rather, IL-1 beta appeared to increase the synthesis of PKC in both membrane and cytosol preparations, an effect which could be prevented by coincubation with cycloheximide.	Cycloheximide	159-172	interleukin 1 beta	Homo sapiens	8-17
2164018-8	1990	However, acylation of CNP was inhibited 24-32% by cycloheximide.	Cycloheximide	50-63	2',3'-cyclic nucleotide 3' phosphodiesterase	Rattus norvegicus	22-25
2114401-10	1990	Protein synthesis inhibitors (cycloheximide, anisomycin) also induced the transcription of the c-fos gene.	Cycloheximide	30-43	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	95-100
2162843-4	1990	Even though cAMP-enhanced accumulation of P-450C21 mRNA in primary cultures of bovine adrenocortical cells is inhibited by the protein synthesis inhibitor, cycloheximide, reporter gene transcription enhanced by the cAMP-responsive -129/-96-base pair fragment of the human CYP21B gene is not.	Cycloheximide	156-169	steroid 21-hydroxylase	Bos taurus	42-50
1694171-3	1990	Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis.	Cycloheximide	234-247	interleukin 1 alpha	Homo sapiens	92-102
1694171-3	1990	Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis.	Cycloheximide	234-247	interleukin 1 alpha	Homo sapiens	191-201
1694171-3	1990	Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis.	Cycloheximide	234-247	interleukin 1 alpha	Homo sapiens	191-201
1694171-3	1990	Our data demonstrate that 1) the Cox mRNA is expressed at low levels in untreated cells; 2) IL-1 alpha induces the Cox mRNA within 2 h, and this induction is sustained for more than 24 h; 3) IL-1 alpha induction is dose-dependent; 4) cycloheximide potentiates the induction of the Cox mRNA by IL-1 alpha while actinomycin D prevents the induction, and 5) IL-1 alpha also stimulates Cox production in a time-dependent fashion which correlates with the increase in prostacyclin synthesis.	Cycloheximide	234-247	interleukin 1 alpha	Homo sapiens	191-201
2162843-4	1990	Even though cAMP-enhanced accumulation of P-450C21 mRNA in primary cultures of bovine adrenocortical cells is inhibited by the protein synthesis inhibitor, cycloheximide, reporter gene transcription enhanced by the cAMP-responsive -129/-96-base pair fragment of the human CYP21B gene is not.	Cycloheximide	156-169	cytochrome P450 family 21 subfamily A member 2	Homo sapiens	272-278
2165999-6	1990	Cycloheximide, a blocker of protein synthesis, suppressed the cytokine-dependent increase of 5"-nucleotidase activity.	Cycloheximide	0-13	5' nucleotidase, ecto	Rattus norvegicus	93-108
1972706-10	1990	Maximal induction of transglutaminase Type II mRNA occurred between 18 and 24 h. The increase in Type II transglutaminase mRNA levels was blocked by the presence of cycloheximide, suggesting that this increase in mRNA by TGF-beta 1 is dependent on protein synthesis.	Cycloheximide	165-178	transforming growth factor beta 1	Homo sapiens	221-231
2151766-10	1990	Enhancement of 2",5"-AS gene expression by IL 6 was observed even when protein synthesis was inhibited by cycloheximide.	Cycloheximide	106-119	interleukin 6	Mus musculus	43-47
2365817-7	1990	Its expression is inhibited by cycloheximide or acyclovir, indicating this LAT is synthesized late in the viral replicative cycle.	Cycloheximide	31-44	linker for activation of T cells	Homo sapiens	75-78
1972722-9	1990	Both IFN-gamma and IL-5 were produced de novo, because treatment of T cells with cycloheximide inhibited both IFN-gamma and IL-5 SFC.	Cycloheximide	81-94	interferon gamma	Mus musculus	5-14
1972722-9	1990	Both IFN-gamma and IL-5 were produced de novo, because treatment of T cells with cycloheximide inhibited both IFN-gamma and IL-5 SFC.	Cycloheximide	81-94	interleukin 5	Mus musculus	19-23
1972722-9	1990	Both IFN-gamma and IL-5 were produced de novo, because treatment of T cells with cycloheximide inhibited both IFN-gamma and IL-5 SFC.	Cycloheximide	81-94	interferon gamma	Mus musculus	110-119
1972722-9	1990	Both IFN-gamma and IL-5 were produced de novo, because treatment of T cells with cycloheximide inhibited both IFN-gamma and IL-5 SFC.	Cycloheximide	81-94	interleukin 5	Rattus norvegicus	124-128
2141616-9	1990	The inhibitory effect of Dex on the steady state level of Fc gamma RI mRNA in U-937 cells was blocked by an inhibitor of protein synthesis, cycloheximide, suggesting that Dex-induced proteins were involved in the regulation of Fc gamma RI expression.	Cycloheximide	140-153	Fc gamma receptor Ia	Homo sapiens	58-69
2141616-9	1990	The inhibitory effect of Dex on the steady state level of Fc gamma RI mRNA in U-937 cells was blocked by an inhibitor of protein synthesis, cycloheximide, suggesting that Dex-induced proteins were involved in the regulation of Fc gamma RI expression.	Cycloheximide	140-153	Fc gamma receptor Ia	Homo sapiens	227-238
2162889-5	1990	The IL-1-induced increase in beta AR density was half-maximal after 6 h, was reversible at a similar rate, and was blocked by 1 microM of cycloheximide.	Cycloheximide	138-151	interleukin 1 beta	Homo sapiens	4-8
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cycloheximide	63-76	interleukin 4	Mus musculus	95-99
2114411-5	1990	In cultures incubated in the presence of cycloheximide, plasma fibronectin was bound to the cell surface and was assembled into extracellular fibrils.	Cycloheximide	41-54	fibronectin 1	Homo sapiens	63-74
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cycloheximide	63-76	interleukin 5	Mus musculus	104-108
2142529-9	1990	Effects of cyclosporine A and the protein synthesis inhibitors cycloheximide and anisomycin on IL-4 and IL-5 gene expression suggest that these genes are activated by different pathways after anti-CD3 stimulation.	Cycloheximide	63-76	CD3 antigen, epsilon polypeptide	Mus musculus	197-200
2354999-7	1990	There was also no evidence of superinduction of mRNA in peripheral blood mononuclear cells stimulated with LPS, whereas, tumor necrosis factor alpha mRNA was elevated in the presence of cycloheximide.	Cycloheximide	186-199	tumor necrosis factor	Homo sapiens	121-148
2114514-1	1990	In an attempt to elucidate possible mechanism(s) for stimulated arachidonic acid metabolism by phorbol 12-myristate 13-acetate (PMA) and epidermal growth factor (EGF) in porcine thyroid cells, we examined the effects of protein kinase inhibitors, isoquinolinesulfonamide derivatives (H-7 and HA-1004), and cycloheximide.	Cycloheximide	306-319	epidermal growth factor	Homo sapiens	162-165
2114514-2	1990	The production of PGE2 stimulated by either PMA or EGF was strongly inhibited by H-7, with an ID50 value of approximately 20 to 25 mumol/L in each case, as well as by cycloheximide, with an ID50 value of less than 0.5 micrograms/mL in each case.	Cycloheximide	167-180	epidermal growth factor	Homo sapiens	51-54
2114514-5	1990	The EGF- and PMA-stimulated release of 3H-arachidonic acid from the cells was also strongly inhibited by H-7 and cycloheximide.	Cycloheximide	113-126	epidermal growth factor	Homo sapiens	4-7
1693528-6	1990	Furthermore, mRNA for IL-6 and IL-1 beta was dramatically superinduced by the combination of cycloheximide and TNF alpha.	Cycloheximide	93-106	interleukin 6	Homo sapiens	22-26
2194573-9	1990	Both fatty acids were also incorporated into CD9 in hydroxylamine-sensitive bonds in the presence of cycloheximide, reaching 30-40% of the levels in untreated controls.	Cycloheximide	101-114	CD9 molecule	Homo sapiens	45-48
2194573-12	1990	Limited proteolysis analysis with Staphylococcus aureus V8 proteinase of CD9, labeled in the absence or presence of cycloheximide, showed that [3H]myristic acid and [3H]palmitic acid labeled identical peptides, and to the same extent, suggesting that myristate is an alternative substrate for the transacylase(s) involved.	Cycloheximide	116-129	CD9 molecule	Homo sapiens	73-76
1693528-6	1990	Furthermore, mRNA for IL-6 and IL-1 beta was dramatically superinduced by the combination of cycloheximide and TNF alpha.	Cycloheximide	93-106	interleukin 1 beta	Homo sapiens	31-40
1693617-7	1990	Cycloheximide (10 micrograms/ml) alone caused induction of TF mRNA.	Cycloheximide	0-13	coagulation factor III, tissue factor	Homo sapiens	59-61
2112424-5	1990	ODC induction was inhibited by cycloheximide and also, up to some extent, by actinomycin D.	Cycloheximide	31-44	ornithine decarboxylase, structural 1	Mus musculus	0-3
1693636-8	1990	The anti-LFA-3-mediated augmentation of IL-1 release required both new protein and RNA synthesis as shown by the ability of cycloheximide and actinomycin-D to inhibit augmentation of IL-1 production by TE cells, and by direct quantitation of IL-1 alpha and IL-1 beta mRNA by Northern blot analysis.	Cycloheximide	124-137	CD58 molecule	Homo sapiens	9-14
1693636-8	1990	The anti-LFA-3-mediated augmentation of IL-1 release required both new protein and RNA synthesis as shown by the ability of cycloheximide and actinomycin-D to inhibit augmentation of IL-1 production by TE cells, and by direct quantitation of IL-1 alpha and IL-1 beta mRNA by Northern blot analysis.	Cycloheximide	124-137	interleukin 1 beta	Homo sapiens	40-44
1693636-8	1990	The anti-LFA-3-mediated augmentation of IL-1 release required both new protein and RNA synthesis as shown by the ability of cycloheximide and actinomycin-D to inhibit augmentation of IL-1 production by TE cells, and by direct quantitation of IL-1 alpha and IL-1 beta mRNA by Northern blot analysis.	Cycloheximide	124-137	interleukin 1 beta	Homo sapiens	183-187
1693636-8	1990	The anti-LFA-3-mediated augmentation of IL-1 release required both new protein and RNA synthesis as shown by the ability of cycloheximide and actinomycin-D to inhibit augmentation of IL-1 production by TE cells, and by direct quantitation of IL-1 alpha and IL-1 beta mRNA by Northern blot analysis.	Cycloheximide	124-137	interleukin 1 alpha	Homo sapiens	242-252
1696777-2	1990	On the other hand, cycloheximide significantly inhibited the increase of alpha 2 macroglobulin concentration in adjuvant inflammation, however, it had no antiinflammatory effect.	Cycloheximide	19-32	alpha-2-macroglobulin	Rattus norvegicus	73-94
1693636-8	1990	The anti-LFA-3-mediated augmentation of IL-1 release required both new protein and RNA synthesis as shown by the ability of cycloheximide and actinomycin-D to inhibit augmentation of IL-1 production by TE cells, and by direct quantitation of IL-1 alpha and IL-1 beta mRNA by Northern blot analysis.	Cycloheximide	124-137	interleukin 1 beta	Homo sapiens	257-266
2160972-3	1990	The 3-kilobase edg-1 transcript is rapidly induced when endothelial cells are treated with PMA and superinduced in the presence of cycloheximide.	Cycloheximide	131-144	sphingosine-1-phosphate receptor 1	Homo sapiens	15-20
2140531-5	1990	The Ia-inductive effects of both IL-4 and IgE-antigen complexes were inhibited by cycloheximide and actinomycin-D.	Cycloheximide	82-95	interleukin 4	Mus musculus	33-37
2163613-8	1990	The most striking effects of PMA and insulin on Fru-2,6-P2 production are observed after long-term treatment (24 h) and are abolished by actinomycin, cycloheximide and puromycin, suggesting that protein synthesis is involved.	Cycloheximide	150-163	insulin	Homo sapiens	37-44
2163613-8	1990	The most striking effects of PMA and insulin on Fru-2,6-P2 production are observed after long-term treatment (24 h) and are abolished by actinomycin, cycloheximide and puromycin, suggesting that protein synthesis is involved.	Cycloheximide	150-163	zinc finger and BTB domain containing 22	Homo sapiens	48-51
2140531-6	1990	However, whereas actinomycin-D and cycloheximide blocked IL-4 induction of Fc epsilon RII expression, inhibition of transcription or protein synthesis did not abrogate the increased expression of Fc epsilon R associated with IgE-antigen complexes.	Cycloheximide	35-48	interleukin 4	Mus musculus	57-61
2140531-6	1990	However, whereas actinomycin-D and cycloheximide blocked IL-4 induction of Fc epsilon RII expression, inhibition of transcription or protein synthesis did not abrogate the increased expression of Fc epsilon R associated with IgE-antigen complexes.	Cycloheximide	35-48	Fc receptor, IgE, low affinity II, alpha polypeptide	Mus musculus	75-89
2189889-4	1990	The stimulation of renin release was paralleled by a stimulation of cellular renin content and was completely inhibited by cycloheximide, indicating that relaxin also stimulated renin synthesis.	Cycloheximide	123-136	renin	Homo sapiens	19-24
2334910-4	1990	With either TNF or IL-1 beta as the stimulus, TNF mRNA is induced first, peaks within 1-3 h, and declines to nearly undetectable levels by 9 h. TNF mRNA accumulation is enhanced in the presence of cycloheximide indicating that de novo protein synthesis is not required for maximal TNF mRNA induction.	Cycloheximide	197-210	tumor necrosis factor	Homo sapiens	12-15
2334910-4	1990	With either TNF or IL-1 beta as the stimulus, TNF mRNA is induced first, peaks within 1-3 h, and declines to nearly undetectable levels by 9 h. TNF mRNA accumulation is enhanced in the presence of cycloheximide indicating that de novo protein synthesis is not required for maximal TNF mRNA induction.	Cycloheximide	197-210	interleukin 1 beta	Homo sapiens	19-28
2334910-4	1990	With either TNF or IL-1 beta as the stimulus, TNF mRNA is induced first, peaks within 1-3 h, and declines to nearly undetectable levels by 9 h. TNF mRNA accumulation is enhanced in the presence of cycloheximide indicating that de novo protein synthesis is not required for maximal TNF mRNA induction.	Cycloheximide	197-210	tumor necrosis factor	Homo sapiens	46-49
2334910-4	1990	With either TNF or IL-1 beta as the stimulus, TNF mRNA is induced first, peaks within 1-3 h, and declines to nearly undetectable levels by 9 h. TNF mRNA accumulation is enhanced in the presence of cycloheximide indicating that de novo protein synthesis is not required for maximal TNF mRNA induction.	Cycloheximide	197-210	tumor necrosis factor	Homo sapiens	46-49
2334910-4	1990	With either TNF or IL-1 beta as the stimulus, TNF mRNA is induced first, peaks within 1-3 h, and declines to nearly undetectable levels by 9 h. TNF mRNA accumulation is enhanced in the presence of cycloheximide indicating that de novo protein synthesis is not required for maximal TNF mRNA induction.	Cycloheximide	197-210	tumor necrosis factor	Homo sapiens	46-49
2334910-5	1990	In contrast, IL-1 beta mRNA is induced later, peaks at 3-9 h, and remains considerably elevated at 18 h. IL-1 beta mRNA accumulation is partially suppressed in the presence of cycloheximide.	Cycloheximide	176-189	interleukin 1 beta	Homo sapiens	13-22
2334910-5	1990	In contrast, IL-1 beta mRNA is induced later, peaks at 3-9 h, and remains considerably elevated at 18 h. IL-1 beta mRNA accumulation is partially suppressed in the presence of cycloheximide.	Cycloheximide	176-189	interleukin 1 beta	Homo sapiens	105-114
1693565-4	1990	The release of IGF-II and IGF binding proteins into serum-free conditioned medium (1.7 pmol/10(6) cells.24 h and 0.8 pmol binding sites/10(6) cells.24 h for 3 days, respectively) is inhibited 80% by cycloheximide (10 micrograms/ml).	Cycloheximide	199-212	insulin like growth factor 2	Homo sapiens	15-21
2114348-8	1990	C-jun induction occurred with cycloheximide alone, but partial hepatectomy further increased c-jun expression, indicating that new protein synthesis was not required for this effect.	Cycloheximide	30-43	jun proto-oncogene	Mus musculus	0-5
2113968-5	1990	All thrombin effects, however, were suppressed by the simultaneous addition of cycloheximide, indicating that the enhancing effects of thrombin were due to an increase in the production of PAs and PAI-1, via protein synthesis.	Cycloheximide	79-92	coagulation factor II, thrombin	Homo sapiens	4-12
2113968-5	1990	All thrombin effects, however, were suppressed by the simultaneous addition of cycloheximide, indicating that the enhancing effects of thrombin were due to an increase in the production of PAs and PAI-1, via protein synthesis.	Cycloheximide	79-92	coagulation factor II, thrombin	Homo sapiens	135-143
2113968-5	1990	All thrombin effects, however, were suppressed by the simultaneous addition of cycloheximide, indicating that the enhancing effects of thrombin were due to an increase in the production of PAs and PAI-1, via protein synthesis.	Cycloheximide	79-92	serpin family E member 1	Homo sapiens	197-202
2111449-6	1990	However, the mRNA from both genes increased markedly after cycloheximide injection, suggesting that the regulation of c-myc mRNA abundance in the regenerating liver differs from that occurring after protein synthesis inhibition.	Cycloheximide	59-72	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-123
2342469-2	1990	To analyze the early genetic response to the mitogenic signals of Prl, a cDNA library was constructed from Nb2 T cells stimulated for 4 h with Prl and the protein synthesis inhibitor cycloheximide.	Cycloheximide	183-196	prolactin	Mus musculus	66-69
2150351-7	1990	Cycloheximide not only synergized with LPS but also induced TNF-alpha mRNA expression by itself.	Cycloheximide	0-13	toll-like receptor 4	Mus musculus	39-42
2150351-7	1990	Cycloheximide not only synergized with LPS but also induced TNF-alpha mRNA expression by itself.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	60-69
2159816-7	1990	EPA/TIMP induction required continuous protein synthesis, being completely inhibited by addition of the protein synthesis inhibitor cycloheximide simultaneously with TPA, but only partially inhibited in a time-dependent manner if cycloheximide was added after TPA.	Cycloheximide	132-145	TIMP metallopeptidase inhibitor 1	Homo sapiens	4-8
2159816-7	1990	EPA/TIMP induction required continuous protein synthesis, being completely inhibited by addition of the protein synthesis inhibitor cycloheximide simultaneously with TPA, but only partially inhibited in a time-dependent manner if cycloheximide was added after TPA.	Cycloheximide	230-243	TIMP metallopeptidase inhibitor 1	Homo sapiens	4-8
2205247-6	1990	For lamin C this process is dependent upon protein synthesis and can be inhibited with cycloheximide.	Cycloheximide	87-100	lamin A/C	Homo sapiens	4-9
2328771-5	1990	Experiments in the presence of cycloheximide suggested that vimentin induction is probably a direct response to the action of butyrate, not mediated by the prior induction of other gene products.	Cycloheximide	31-44	vimentin	Homo sapiens	60-68
2199320-8	1990	Progression from the alpha-factor-induced G1 block to induction of RNR1 mRNA is blocked by cycloheximide, further defining the requirement for protein synthesis in the G1- to S-phase transition.	Cycloheximide	91-104	mitochondrially encoded 12S RNA	Homo sapiens	67-71
2108965-10	1990	Expression of both monokine genes in response to IFN gamma/IL-2 treatment was independent of protein synthesis as cycloheximide did not inhibit the accumulation of specific mRNA.	Cycloheximide	114-127	interferon gamma	Mus musculus	49-58
2108965-10	1990	Expression of both monokine genes in response to IFN gamma/IL-2 treatment was independent of protein synthesis as cycloheximide did not inhibit the accumulation of specific mRNA.	Cycloheximide	114-127	interleukin 2	Mus musculus	59-63
2180586-5	1990	Treatment of these cells with rIFN-gamma resulted in a cycloheximide resistant Ia expression of both parental haplotypes.	Cycloheximide	55-68	interferon gamma	Rattus norvegicus	30-40
2318820-0	1990	Regulation of parathyroid hormone-related peptide gene expression by cycloheximide.	Cycloheximide	69-82	parathyroid hormone like hormone	Homo sapiens	14-49
2156894-5	1990	Simultaneous addition of 2 microM cycloheximide prevented the insulin-induced decline in resistance; in fact, this combination caused a significant increase in electrical resistance.	Cycloheximide	34-47	insulin	Homo sapiens	62-69
2318909-5	1990	Loss of Ca2(+)-dependent adhesion following treatment of cells with heparin-binding growth factors (HBGFs) is prevented by pre-treatment of cell layers with cycloheximide.	Cycloheximide	157-170	carbonic anhydrase 2	Homo sapiens	8-11
2156928-7	1990	Although the expression of NCF/IL-8 mRNA (1.8 kb) was first detectable between 1 and 2 h poststimulation, significant chemotactic bioactivity was not observed until about 4 h. Heat-inactivated (100 degrees C, 30 min) cytokine failed to induced NCF/IL-8 mRNA synthesis, and cotreatment of cells with cytokine and cycloheximide super-induced NCF/IL-8 mRNA while inhibiting production of bioactivity.	Cycloheximide	312-325	neutrophil cytosolic factor 4	Homo sapiens	27-30
2324612-9	1990	Cycloheximide inhibited the accumulation of both immunoreactive and coagulant factor XII.	Cycloheximide	0-13	coagulation factor XII	Rattus norvegicus	78-88
2200903-5	1990	Treatment with cycloheximide (10 micrograms/ml) and H7, a protein kinase C inhibitor (20 microM), inhibited this induction, suggesting that c-myc induction by these agents requires protein synthesis and protein kinase C activation.	Cycloheximide	15-28	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	140-145
2157136-4	1990	This transcriptional repression can be blocked with cycloheximide, suggesting that the synthesis of a virus-inducible repressor is necessary for the postinduction turnoff of the IFN-beta gene.	Cycloheximide	52-65	interferon beta 1	Homo sapiens	178-186
2326077-5	1990	To test the role of prior protein synthesis in these phenomena, we examined the effect of cycloheximide, and found that this reagent, either alone or in combination with EGF, leads to an increase in the level of EGF-receptor mRNA.	Cycloheximide	90-103	epidermal growth factor receptor	Homo sapiens	212-224
2139082-11	1990	Further, use of nonrelevant antibodies did not result in spot formation, and treatment of mitogen-activated T cells with cycloheximide inhibited both IFN-gamma- and IL-5-specific SFC.	Cycloheximide	121-134	interferon gamma	Mus musculus	150-159
2139082-11	1990	Further, use of nonrelevant antibodies did not result in spot formation, and treatment of mitogen-activated T cells with cycloheximide inhibited both IFN-gamma- and IL-5-specific SFC.	Cycloheximide	121-134	interleukin 5	Mus musculus	165-169
1968462-8	1990	Treatment of cells with phorbol esters and cycloheximide resulted in superinduction of all three mRNAs; HMG-CoA synthase mRNA levels increased 35-fold, farnesyl pyrophosphate synthetase 17-fold, and HMG-CoA reductase 16-fold 5 h after treatment.	Cycloheximide	43-56	farnesyl diphosphate synthase	Rattus norvegicus	152-185
1968462-8	1990	Treatment of cells with phorbol esters and cycloheximide resulted in superinduction of all three mRNAs; HMG-CoA synthase mRNA levels increased 35-fold, farnesyl pyrophosphate synthetase 17-fold, and HMG-CoA reductase 16-fold 5 h after treatment.	Cycloheximide	43-56	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	199-216
2318311-4	1990	The effects of PMA or serum also require a synthesis of protein since the level of NGF transcripts remained stable in the presence of cycloheximide.	Cycloheximide	134-147	nerve growth factor	Mus musculus	83-86
2320412-6	1990	Furthermore, cycloheximide was able to overcome completely the dexamethasone-induced down-regulation of the c-myc gene expression.	Cycloheximide	13-26	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	108-113
1970506-8	1990	Inductions of pEK but not TH or PNMT mRNAs were inhibited by cycloheximide.	Cycloheximide	61-74	proenkephalin	Bos taurus	14-17
2105950-5	1990	In the presence of cycloheximide, a greater increase in c-fos mRNA was seen by stretching.	Cycloheximide	19-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	56-61
2105957-6	1990	Moreover, hypoosmotic stress extended the half-life of ODC activity from 35 +/- 10 to 212 +/- 67 min and blocked any degradation of the radiolabeled immunoreactive protein, which had a half-life of 28 +/- 6 min under isotonic conditions, for at least 120 min after addition of cycloheximide.	Cycloheximide	277-290	ornithine decarboxylase, structural 1	Mus musculus	55-58
1692695-8	1990	Cycloheximide suppressed the induction of PAL but not of gamma-GT activity.	Cycloheximide	0-13	leucine-rich repeat, Ig-like and transmembrane domains 1	Rattus norvegicus	42-45
2107976-0	1990	Cathepsin B secretion by rabbit articular chondrocytes: modulation by cycloheximide and glycosaminoglycans.	Cycloheximide	70-83	cathepsin B	Oryctolagus cuniculus	0-11
2107976-3	1990	Addition to chondrocyte cultures of the protein biosynthesis inhibitor, cycloheximide, resulted in a concentration-dependent reduction of cathepsin B secretion, which was fully restored after removal of cycloheximide.	Cycloheximide	72-85	cathepsin B	Oryctolagus cuniculus	138-149
2107976-3	1990	Addition to chondrocyte cultures of the protein biosynthesis inhibitor, cycloheximide, resulted in a concentration-dependent reduction of cathepsin B secretion, which was fully restored after removal of cycloheximide.	Cycloheximide	203-216	cathepsin B	Oryctolagus cuniculus	138-149
2155279-7	1990	These findings suggested that MT disassembly was responsible for the observed downregulation of TNF-alpha R. The protein synthesis inhibitor cycloheximide inhibited binding of TNF-alpha to a similar extent and with a similar time course as colchicine in the absence of added ligand.	Cycloheximide	141-154	tumor necrosis factor	Homo sapiens	96-105
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	37-50	insulin-like growth factor 1	Mus musculus	162-167
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	37-50	epidermal growth factor	Mus musculus	170-173
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	37-50	epidermal growth factor	Mus musculus	184-187
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	52-55	insulin-like growth factor 1	Mus musculus	162-167
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	52-55	epidermal growth factor	Mus musculus	170-173
2193035-9	1990	Inhibition of protein synthesis with cycloheximide (CHX, 1 or 5 micrograms/ml) over a 20-hour period was associated with decreased survival of cells protected by IGF-1 + EGF or PDGF + EGF + IGF, but also with decreased survival of cells incubated in the absence of growth factors or serum.	Cycloheximide	52-55	epidermal growth factor	Mus musculus	184-187
2155279-7	1990	These findings suggested that MT disassembly was responsible for the observed downregulation of TNF-alpha R. The protein synthesis inhibitor cycloheximide inhibited binding of TNF-alpha to a similar extent and with a similar time course as colchicine in the absence of added ligand.	Cycloheximide	141-154	tumor necrosis factor	Homo sapiens	176-185
2160601-4	1990	The response to NGF was blocked by cycloheximide, indicating a requirement for ongoing protein synthesis.	Cycloheximide	35-48	nerve growth factor	Rattus norvegicus	16-19
2308934-5	1990	chx1 mRNA concentration is increased by cycloheximide treatment of activated B cells, as well as T cells, and it is rapidly and transiently induced, in a cycloheximide-enhanced manner, upon serum stimulation of resting 3T3 fibroblastoid cells.	Cycloheximide	40-53	immediate early response 2	Mus musculus	0-4
2200794-10	1990	Cycloheximide treatment prevents the rise in soluble actin and myosin as well as causing a reduction in SF number by 1/2 on the DOC-derived substratum and 2/3 on CT-DOC-derived substratum.	Cycloheximide	0-13	myosin heavy chain 14	Homo sapiens	63-69
2308934-5	1990	chx1 mRNA concentration is increased by cycloheximide treatment of activated B cells, as well as T cells, and it is rapidly and transiently induced, in a cycloheximide-enhanced manner, upon serum stimulation of resting 3T3 fibroblastoid cells.	Cycloheximide	154-167	immediate early response 2	Mus musculus	0-4
1689299-5	1990	HBGF-1 induction of PDGF A-chain mRNA expression occurs in the presence of the protein synthesis inhibitor cycloheximide and thus does not require de novo protein synthesis.	Cycloheximide	107-120	fibroblast growth factor 1	Homo sapiens	0-6
1689299-5	1990	HBGF-1 induction of PDGF A-chain mRNA expression occurs in the presence of the protein synthesis inhibitor cycloheximide and thus does not require de novo protein synthesis.	Cycloheximide	107-120	platelet derived growth factor subunit A	Homo sapiens	20-26
2107102-5	1990	Addition of inhibitor of protein synthesis, cycloheximide (CHX), at an early stage of induction periods (0-4 h) inhibits the IFN gamma induction by poly I:poly C.	Cycloheximide	44-57	interferon gamma	Homo sapiens	125-134
2105946-7	1990	TPA treatment of HL-60 cells in the presence of cycloheximide was associated with superinduction of c-jun transcripts.	Cycloheximide	48-61	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-105
2105946-11	1990	In contrast, the half-life of c-jun RNA in TPA-treated HL-60 cells exposed to cycloheximide and actinomycin D was greater than 2 h. These findings suggested that the increase in c-jun RNA observed during TPA-induced monocytic differentiation is mediated by both transcriptional and post-transcriptional mechanisms.	Cycloheximide	78-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
2105946-11	1990	In contrast, the half-life of c-jun RNA in TPA-treated HL-60 cells exposed to cycloheximide and actinomycin D was greater than 2 h. These findings suggested that the increase in c-jun RNA observed during TPA-induced monocytic differentiation is mediated by both transcriptional and post-transcriptional mechanisms.	Cycloheximide	78-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	178-183
1968059-11	1990	Incubation in the presence of cycloheximide resulted in a 52.3 +/- 8.4% (p less than 0.01) increase in gastrin mRNA levels under basal conditions, but had no effect following antral somatostatin immunoneutralization.	Cycloheximide	30-43	gastrin	Canis lupus familiaris	103-110
1968059-11	1990	Incubation in the presence of cycloheximide resulted in a 52.3 +/- 8.4% (p less than 0.01) increase in gastrin mRNA levels under basal conditions, but had no effect following antral somatostatin immunoneutralization.	Cycloheximide	30-43	somatostatin	Canis lupus familiaris	182-194
2406243-9	1990	On exposure of endothelial cells to TNF there is a rapid and substantial increase in levels of mRNA encoding the six genes, which are further superinduced by cycloheximide.	Cycloheximide	158-171	tumor necrosis factor	Homo sapiens	36-39
2107102-5	1990	Addition of inhibitor of protein synthesis, cycloheximide (CHX), at an early stage of induction periods (0-4 h) inhibits the IFN gamma induction by poly I:poly C.	Cycloheximide	59-62	interferon gamma	Homo sapiens	125-134
2107102-6	1990	Cell free translation assay using RNAs isolated from NNA cells which are induced by poly I:poly C in the presence of CHX reveals that in these RNAs, IFN gamma mRNA does not exist.	Cycloheximide	117-120	interferon gamma	Homo sapiens	149-158
2106270-5	1990	With the use of scraped intestinal mucosa from cycloheximide-treated rats, the time course of the decline in ODC activity yielded a half-life of approximately 22 min.	Cycloheximide	47-60	ornithine decarboxylase 1	Rattus norvegicus	109-112
2102780-1	1990	The effect of actinomycin D and cycloheximide on basal tryptophan-2,3-dioxygenase (EC 1.13.11.11) activity in Wistar rat liver and on the enzyme activity induced by pretreatment with haemin was studied.	Cycloheximide	32-45	tryptophan 2,3-dioxygenase	Rattus norvegicus	55-81
2306223-1	1990	Products of the mitochondrial genome were identified in the bovine kidney cell line NBL-1 by labelling with [35S]methionine in the presence of cycloheximide.	Cycloheximide	143-156	NBL1, DAN family BMP antagonist	Bos taurus	84-89
1688884-4	1990	Nuclear run-off assays demonstrated that surface activation of U937 cells increased the transcription rate of the IGF-I gene four- to fivefold, a process that was inhibited by cycloheximide, suggesting that active protein synthesis was involved in the activation pathway.	Cycloheximide	176-189	insulin like growth factor 1	Homo sapiens	114-119
2154372-6	1990	On the contrary, both quantitative and qualitative changes in the alpha binding can be detected with extracts from uninduced cells or from cells treated with IL-6 or IL-6 + cycloheximide.	Cycloheximide	173-186	interleukin 6	Homo sapiens	166-170
2105339-4	1990	The combination of a protein synthesis inhibitor, cycloheximide, and TNF increased levels of CSF-1 mRNA compared with treatment by TNF alone.	Cycloheximide	50-63	colony stimulating factor 1	Homo sapiens	93-98
2105339-4	1990	The combination of a protein synthesis inhibitor, cycloheximide, and TNF increased levels of CSF-1 mRNA compared with treatment by TNF alone.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	131-134
2105965-6	1990	The increase in GalNAcT activity after heating was similar in exponentially growing and plateau-phase cultures and was inhibited neither by cycloheximide nor actinomycin D.	Cycloheximide	140-153	beta-1,4-N-acetyl-galactosaminyltransferase 1	Homo sapiens	16-23
2153682-10	1990	PDGF-induced secretion of MEP was inhibited 84% by cycloheximide, suggesting that protein synthesis is required to elicit this effect.	Cycloheximide	51-64	cathepsin L	Mus musculus	26-29
2153712-5	1990	The basal and thrombin-stimulated production of endothelin were prevented by the protein synthetase inhibitor cycloheximide (10(-6) M).	Cycloheximide	110-123	coagulation factor II, thrombin	Sus scrofa	14-22
1688884-6	1990	Like the increased transcription of the IGF-I gene, modulation of IGF-I mRNA transcript levels required active protein synthesis; in the presence of cycloheximide constitutive IGF-I mRNA levels increased and surface activation no longer caused a decrease in transcript number.	Cycloheximide	149-162	insulin like growth factor 1	Homo sapiens	40-45
2329999-6	1990	The half-life of bFGF mRNA, determined after transcriptional arrest with actinomycin-D, was approximately 10 min in T98-G cells, but was extended to 120 min in the presence of cycloheximide.	Cycloheximide	176-189	fibroblast growth factor 2	Homo sapiens	17-21
2304905-4	1990	In contrast, cycloheximide potentiated the limited increase of alpha-subunit mRNA levels evoked by the neuropeptide calcitonin gene-related peptide.	Cycloheximide	13-26	ovomucin, alpha subunit	Gallus gallus	63-76
2304905-6	1990	Moreover, cycloheximide decreased the high level of alpha-subunit mRNA present at early stages of in vitro maturation of muscle primary cultures without blocking the further increase of the muscle-specific creatine phosphokinase mRNA.	Cycloheximide	10-23	ovomucin, alpha subunit	Gallus gallus	52-65
2153415-7	1990	The elevation of ACE seemed to require new protein synthesis, since 0.1 micrograms/ml cycloheximide inhibited the elevation produced by monensin and A23187.	Cycloheximide	86-99	angiotensin I converting enzyme	Bos taurus	17-20
1968222-2	1990	Pretreatment with cycloheximide blocked the induction of PRL gene transcription by pimozide but had no effect on the inhibition of transcription by ergocryptine.	Cycloheximide	18-31	prolactin	Rattus norvegicus	57-60
2295643-9	1990	Cycloheximide treatment of U937 cells resulted in a partial block of TPA-mediated cathepsin G down-regulation, indicating that continuous protein synthesis is required for down-regulation to occur.	Cycloheximide	0-13	cathepsin G	Homo sapiens	82-93
2129102-2	1990	Addition of fetal calf serum (FCS) to serum-starved cells in the presence of cycloheximid induced a modest increase in c-fos and c-jun mRNA levels, whereas growth hormone (GH) in the presence of cycloheximid had little or no effect, when added to RIN 5AH cells maintained in 0.5% FCS for 2 days prior to stimulation.	Cycloheximide	77-89	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	119-124
1688581-12	1990	The increased expression of DAF only was evident 8 h after PMA addition and was blocked by the RNA and protein synthesis inhibitors, actinomycin D and cycloheximide, indicating that both transcription and translation are required for DAF synthesis induced by phorbol esters.	Cycloheximide	151-164	CD55 molecule (Cromer blood group)	Homo sapiens	28-31
1688581-12	1990	The increased expression of DAF only was evident 8 h after PMA addition and was blocked by the RNA and protein synthesis inhibitors, actinomycin D and cycloheximide, indicating that both transcription and translation are required for DAF synthesis induced by phorbol esters.	Cycloheximide	151-164	CD55 molecule (Cromer blood group)	Homo sapiens	234-237
2406172-7	1990	Using the amnion cells in primary monolayer culture to investigate the regulation of preproendothelin mRNA expression, we found that epidermal growth factor (EGF) and interleukin-1 (IL-1) act to stimulate preproendothelin mRNA levels; in addition, the induction of preproendothelin mRNA by either of these agents is enhanced upon simultaneous treatment with cycloheximide.	Cycloheximide	358-371	interleukin 1 alpha	Homo sapiens	133-186
2104763-6	1990	In contrast, endothelial cells did not contain or elaborate R binder, the other major circulating binding protein for cobalamin, Cycloheximide inhibited the elaboration of TC II, suggesting that the endothelial cells synthesize the protein.	Cycloheximide	129-142	transcobalamin 2	Homo sapiens	172-177
2104763-8	1990	However, thrombin did appear to partially protect TC II release from inhibition by cycloheximide.	Cycloheximide	83-96	coagulation factor II, thrombin	Homo sapiens	9-17
1982985-4	1990	Hydrocortisone acetate alone and cycloheximide alone or after hydrocortisone acetate treatment stimulated the rate of TAT gene transcription.	Cycloheximide	33-46	tyrosine aminotransferase	Rattus norvegicus	118-121
2104763-8	1990	However, thrombin did appear to partially protect TC II release from inhibition by cycloheximide.	Cycloheximide	83-96	transcobalamin 2	Homo sapiens	50-55
2322985-0	1990	Cycloheximide-induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian tumor cells.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	36-39
2173639-5	1990	Superoxide dismutase restores acetylcholine responses to myocardial ischemia followed by reperfusion, whereas cycloheximide restores acetylcholine responses to TNF.	Cycloheximide	110-123	tumor necrosis factor-like	Rattus norvegicus	160-163
2169831-9	1990	The increase in cell surface uPA produced by exposure to EGF required protein synthesis and could be blocked by cycloheximide.	Cycloheximide	112-125	plasminogen activator, urokinase	Homo sapiens	29-32
2169831-9	1990	The increase in cell surface uPA produced by exposure to EGF required protein synthesis and could be blocked by cycloheximide.	Cycloheximide	112-125	epidermal growth factor	Homo sapiens	57-60
2322985-10	1990	Pretreatment of cells for 24 h with TNF and 24 h with CHX resulted in augmentation of the cytotoxicity of PA-1 and SKOV-3, whereas pretreatment for 24 h with CHX followed by 24 h with TNF resulted in no cytotoxicity.	Cycloheximide	54-57	PAXIP1 associated glutamate rich protein 1	Homo sapiens	106-121
2322985-11	1990	Cells pretreated with CHX for 24 h showed poor binding of [125]I-TNF and poor internalization, whereas cells pretreated for 24 h with TNF showed marked enhancement of internalization.	Cycloheximide	22-25	tumor necrosis factor	Homo sapiens	65-68
2322985-12	1990	The sensitivity of freshly derived ovarian carcinoma lines to TNF and CHX demonstrated that TNF-resistant cells became more sensitive if treated with CHX.	Cycloheximide	70-73	tumor necrosis factor	Homo sapiens	92-95
2127691-6	1990	In a Xenopus kidney cell line, the fos gene can be transcriptionally activated by serum growth factors and 12-O-tetradecanoylphorbol-13-acetate, and the fos mRNA can be superinduced by cycloheximide.	Cycloheximide	185-198	FBJ murine osteosarcoma viral oncogene homolog S homeolog	Xenopus laevis	35-38
2110509-7	1990	This effect of CQ on t-PA generation in endothelial cells was susceptible to cycloheximide inhibition.	Cycloheximide	77-90	plasminogen activator, tissue type	Homo sapiens	21-25
2127691-6	1990	In a Xenopus kidney cell line, the fos gene can be transcriptionally activated by serum growth factors and 12-O-tetradecanoylphorbol-13-acetate, and the fos mRNA can be superinduced by cycloheximide.	Cycloheximide	185-198	FBJ murine osteosarcoma viral oncogene homolog S homeolog	Xenopus laevis	153-156
1979777-5	1990	After prolonged (16 h) exposure to 30 nM VIP that resulted in marked (75%) downregulation, 60% of the adenylate cyclase responsiveness could recover within 30-120 min even in the presence of cycloheximide, but further resensitization was cycloheximide-sensitive.	Cycloheximide	191-204	vasoactive intestinal peptide	Homo sapiens	41-44
2185927-10	1990	Further experiments using cycloheximide point to a direct effect of insulin on oligodendrocyte CST induction.	Cycloheximide	26-39	galactose-3-O-sulfotransferase 1	Mus musculus	95-98
1979777-5	1990	After prolonged (16 h) exposure to 30 nM VIP that resulted in marked (75%) downregulation, 60% of the adenylate cyclase responsiveness could recover within 30-120 min even in the presence of cycloheximide, but further resensitization was cycloheximide-sensitive.	Cycloheximide	238-251	vasoactive intestinal peptide	Homo sapiens	41-44
1979777-8	1990	In intact cells exposed to VIP-like peptides, the receptors were rapidly desensitized, then down-regulated, the resensitization mechanism being not immediately inhibited by cycloheximide.	Cycloheximide	173-186	vasoactive intestinal peptide	Homo sapiens	27-30
1968392-2	1990	The cytolytic activity of CD4 clones, but not CD8 clones, was sensitive to the RNA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide.	Cycloheximide	153-166	CD4 molecule	Homo sapiens	26-29
2294017-5	1990	The enhanced PGE2 synthesis was inhibited by indomethacin as well as actinomycin D, while cycloheximide surprisingly potentiated PGE2 synthesis in response to both IL-1 beta and TNF alpha.	Cycloheximide	90-103	interleukin 1 beta	Canis lupus familiaris	164-173
2294017-5	1990	The enhanced PGE2 synthesis was inhibited by indomethacin as well as actinomycin D, while cycloheximide surprisingly potentiated PGE2 synthesis in response to both IL-1 beta and TNF alpha.	Cycloheximide	90-103	tumor necrosis factor	Canis lupus familiaris	178-187
2166546-7	1990	Addition of the protein synthesis inhibitor cycloheximide to unperturbed cultures of BHK or NIH 3T3 cells resulted in a time-dependent loss of cell-surface bFGF receptors, demonstrating that the receptors turn over constantly in the absence of ligand.	Cycloheximide	44-57	fibroblast growth factor 2	Mus musculus	156-160
2293997-4	1990	The increase in beta-casein transcripts was detected as early as 30 min of induction with insulin, hydrocortisone, and PRL, and its level increased more than 100-fold over the initial level at 24 h. The increase in beta-casein transcripts was blocked by concomitant addition of the protein synthesis inhibitors cycloheximide or puromycin with the three hormones.	Cycloheximide	311-324	casein beta	Mus musculus	16-27
2293997-4	1990	The increase in beta-casein transcripts was detected as early as 30 min of induction with insulin, hydrocortisone, and PRL, and its level increased more than 100-fold over the initial level at 24 h. The increase in beta-casein transcripts was blocked by concomitant addition of the protein synthesis inhibitors cycloheximide or puromycin with the three hormones.	Cycloheximide	311-324	casein beta	Mus musculus	215-226
2293997-5	1990	Cycloheximide inhibited the increase in beta-casein gene transcription that was elicited by insulin, hydrocortisone, and PRL, but did not alter the stability of beta-casein transcripts.	Cycloheximide	0-13	casein beta	Mus musculus	40-51
2407710-3	1990	The total content of fibronectin in endothelial cells exposed to flow was found to be lower than that in static controls after periods of 12 to 48 h. In the presence of cycloheximide there was no difference in the fibronectin content of sheared and unsheared cells.	Cycloheximide	169-182	fibronectin 1	Homo sapiens	21-32
2151634-5	1990	Cycloheximide strongly suppresses the expression of Fc epsilon RII, both in TPA-stimulated and unstimulated cells; this effect can be partly reversed by culturing the cells in the presence of IgE.	Cycloheximide	0-13	Fc epsilon receptor II	Homo sapiens	52-66
2190998-4	1990	However, upon cycloheximide block of protein synthesis mitotin labeled during S phase is rapidly degraded, while the degradation of mitotin labeled during late G2 phase is abolished, resulting in its net and marked increase.	Cycloheximide	14-27	minichromosome maintenance complex component 2	Homo sapiens	55-62
2126556-6	1990	Cycloheximide, actinomycin-D, and mytomycin-C completely inhibited the rIL-4-induced IgG4 and IgE secretion, indicating that de novo protein, RNA, and DNA synthesis was required.	Cycloheximide	0-13	interleukin 4	Rattus norvegicus	71-76
1688564-7	1990	Cycloheximide (CHX), inhibitor of protein synthesis, also markedly increased levels of IL-6 mRNA.	Cycloheximide	0-13	interleukin 6	Homo sapiens	87-91
1688564-7	1990	Cycloheximide (CHX), inhibitor of protein synthesis, also markedly increased levels of IL-6 mRNA.	Cycloheximide	15-18	interleukin 6	Homo sapiens	87-91
2295836-4	1990	Increased PGE2 synthesis in response to IL-1 was inhibited by cycloheximide, suggesting a requirement for new protein synthesis.	Cycloheximide	62-75	interleukin 1 alpha	Homo sapiens	40-44
2104663-5	1990	Moreover, cycloheximide induced limited activation of NF-kappa B comparable to that in wild-type 70Z/3 pre-B cells in two of the three variant lines.	Cycloheximide	10-23	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	54-64
2196901-4	1990	Actinomycin D and cycloheximide inhibited the insulin-stimulated expression of chromatin receptors.	Cycloheximide	18-31	insulin	Homo sapiens	46-53
2157975-8	1990	Inhibition of protein synthesis by cycloheximide totally blocks the 8-bromo-cAMP-induced decrease in PAI-1 mRNA.	Cycloheximide	35-48	serpin family E member 2	Rattus norvegicus	101-106
2157975-9	1990	Cycloheximide alone causes a 5- to 10-fold increase in tPA mRNA, and no further hormonal effect is observed.	Cycloheximide	0-13	plasminogen activator, tissue type	Rattus norvegicus	55-58
33806920-4	2021	Metabolic labeling experiments using 35S or cycloheximide suggested that the formation of hypoglycosylated COX-2 was dependent on de novo synthesis of the protein rather than the deglycosylation of the native protein.	Cycloheximide	44-57	prostaglandin-endoperoxide synthase 2	Homo sapiens	107-112
2250947-4	1990	The addition of cycloheximide (0.5 micrograms/ml) to cultures simultaneously with retinoids suppressed the retinoid effect on EGF-binding.	Cycloheximide	16-29	LOC521832	Bos taurus	126-129
33973684-5	2021	Cycloheximide chase assays together with treatment by protein degradation and mannose trimming inhibitors demonstrated that the defect in NKCC2 maturation arise from ER retention and associated degradation (ERAD).	Cycloheximide	0-13	solute carrier family 12 member 1	Homo sapiens	138-143
33972750-10	2021	AT1R protein was less degraded when SNX1 was downregulated, as reflected by a cycloheximide chase assay.	Cycloheximide	78-91	angiotensin II, type I receptor-associated protein	Mus musculus	0-4
33972750-10	2021	AT1R protein was less degraded when SNX1 was downregulated, as reflected by a cycloheximide chase assay.	Cycloheximide	78-91	sorting nexin 1	Mus musculus	36-40
33803345-5	2021	Treatment with cycloheximide and MG132 revealed that both endogenous CREB3 and CREB3L2 are proteasome substrates.	Cycloheximide	15-28	cAMP responsive element binding protein 3	Homo sapiens	69-74
33803345-5	2021	Treatment with cycloheximide and MG132 revealed that both endogenous CREB3 and CREB3L2 are proteasome substrates.	Cycloheximide	15-28	cAMP responsive element binding protein 3 like 2	Homo sapiens	79-86
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	SEL1L adaptor subunit of ERAD E3 ubiquitin ligase	Homo sapiens	46-51
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	cAMP responsive element binding protein 3	Homo sapiens	163-168
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	cAMP responsive element binding protein 3 like 2	Homo sapiens	173-180
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	cAMP responsive element binding protein 3 like 2	Homo sapiens	241-248
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	SEL1L adaptor subunit of ERAD E3 ubiquitin ligase	Homo sapiens	284-289
33803345-7	2021	Consistent with these findings, cells lacking SEL1L, a crucial ER-associated protein degradation (ERAD) component, showed increased expression of both full-length CREB3 and CREB3L2; however, cycloheximide treatment downregulated full-length CREB3L2 protein expression more rapidly in SEL1L-deficient cells than the full-length CREB3 protein.	Cycloheximide	191-204	cAMP responsive element binding protein 3	Homo sapiens	173-178
19369700-6	2009	Augmented FUT5 transcription takes place in cycloheximide-treated HSV-1-infected cells, suggesting a more direct role for IE viral RNA during activation of cellular FUT5.	Cycloheximide	44-57	fucosyltransferase 5	Homo sapiens	10-14
21055460-7	2011	In addition to these effects, NAC treatment elicited a dose- and time-dependent increase in the Cyr61 expression that was accompanied by an increase in its mRNA and blocked by cycloheximide pretreatment.	Cycloheximide	176-189	cellular communication network factor 1	Homo sapiens	96-101
16879986-5	2006	On exposure to cycloheximide, increased Tyr degradation was seen in amelanotic cells, as indicated by increased co-localization of p27 and Tyr.	Cycloheximide	15-28	tyrosinase	Mus musculus	40-43
16879986-5	2006	On exposure to cycloheximide, increased Tyr degradation was seen in amelanotic cells, as indicated by increased co-localization of p27 and Tyr.	Cycloheximide	15-28	cyclin-dependent kinase inhibitor 1B	Mus musculus	131-134
16879986-5	2006	On exposure to cycloheximide, increased Tyr degradation was seen in amelanotic cells, as indicated by increased co-localization of p27 and Tyr.	Cycloheximide	15-28	tyrosinase	Mus musculus	139-142
10854241-2	2000	The immediate early gene pip92 has been identified in serum-stimulated BALB/c 3T3 fibroblasts, activated T lymphocytes treated with cycloheximide, and fibroblast growth factor-stimulated hippocampal cells during neuronal differentiation.	Cycloheximide	132-145	immediate early response 2	Mus musculus	25-30
7669726-3	1995	TPA treatment induces ctsl mRNA in a manner that is dose-dependent, occurs at the level of transcription, and is ablated by cotreatment with cycloheximide but is unaffected by dexamethasone.	Cycloheximide	141-154	cathepsin L	Homo sapiens	22-26
9742210-6	1998	Treatment with cycloheximide inhibited both the accumulation of GIF0010 and the induction of the BiP mRNA, suggesting that the ER localization of the PG and subsequent gene expression require the nascent protein synthesis.	Cycloheximide	15-28	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	97-100
9063496-7	1997	Addition of the protein synthesis inhibitor cycloheximide to cultured human umbilical vein cells resulted in a strong reduction (about 70%) of anti-clusterin binding to co-cultured beads, which strongly supports de novo synthesis of clusterin in EC.	Cycloheximide	44-57	clusterin	Homo sapiens	148-157
9063496-7	1997	Addition of the protein synthesis inhibitor cycloheximide to cultured human umbilical vein cells resulted in a strong reduction (about 70%) of anti-clusterin binding to co-cultured beads, which strongly supports de novo synthesis of clusterin in EC.	Cycloheximide	44-57	clusterin	Homo sapiens	233-242
7669726-5	1995	Similar to TPA, staurosporine alone increases ctsl transcription, an effect that is inhibited by cycloheximide.	Cycloheximide	97-110	cathepsin L	Homo sapiens	46-50
34968781-3	2022	BRCA2 degradation reportedly requires ubiquitination of the C-terminal region; thus, fragments of amino acid (aa) residues 2241-2940 were produced and assayed for their degradation following cycloheximide (CHX) treatment.	Cycloheximide	191-204	BRCA2 DNA repair associated	Homo sapiens	0-5
7925361-5	1994	Inhibition of protein synthesis by cycloheximide increased the thyroid-hormone-induced stimulation of apoE mRNA.	Cycloheximide	35-48	apolipoprotein E	Homo sapiens	102-106
7925361-8	1994	Cycloheximide blocked the action of thyroid hormone, suggesting that thyroid hormone regulates the turnover of apoE mRNA via the synthesis of de novo protein.	Cycloheximide	0-13	apolipoprotein E	Homo sapiens	111-115
34563636-9	2022	The stability of RNF126 and 14-3-3sigma was determined by cycloheximide (CHX) based stability assay and ubiquitination detection by co-IP.	Cycloheximide	58-71	ring finger protein 126	Homo sapiens	17-23
34563636-9	2022	The stability of RNF126 and 14-3-3sigma was determined by cycloheximide (CHX) based stability assay and ubiquitination detection by co-IP.	Cycloheximide	58-71	stratifin	Homo sapiens	28-39
34968781-3	2022	BRCA2 degradation reportedly requires ubiquitination of the C-terminal region; thus, fragments of amino acid (aa) residues 2241-2940 were produced and assayed for their degradation following cycloheximide (CHX) treatment.	Cycloheximide	206-209	BRCA2 DNA repair associated	Homo sapiens	0-5
34487557-7	2022	We next assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with JG-98 in the presence of cycloheximide and found BAG3, HSPB5, and HSPB8 half-lives were reduced, indicating that complex formation with HSP70 is important for their stability.	Cycloheximide	119-132	BAG cochaperone 3	Rattus norvegicus	58-62
34487557-7	2022	We next assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with JG-98 in the presence of cycloheximide and found BAG3, HSPB5, and HSPB8 half-lives were reduced, indicating that complex formation with HSP70 is important for their stability.	Cycloheximide	119-132	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	63-68
34487557-7	2022	We next assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with JG-98 in the presence of cycloheximide and found BAG3, HSPB5, and HSPB8 half-lives were reduced, indicating that complex formation with HSP70 is important for their stability.	Cycloheximide	119-132	BAG cochaperone 3	Rattus norvegicus	143-147
34487557-7	2022	We next assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with JG-98 in the presence of cycloheximide and found BAG3, HSPB5, and HSPB8 half-lives were reduced, indicating that complex formation with HSP70 is important for their stability.	Cycloheximide	119-132	heat shock protein family B (small) member 8	Rattus norvegicus	160-165
34487557-7	2022	We next assessed protein half-life with disruption of the BAG3-HSP70 complex by treating with JG-98 in the presence of cycloheximide and found BAG3, HSPB5, and HSPB8 half-lives were reduced, indicating that complex formation with HSP70 is important for their stability.	Cycloheximide	119-132	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	230-235
34960758-3	2021	RESULTS: While IFNs alone were insufficient to completely abolish replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), IFNalpha, in combination with remdesivir, EIDD-2801, camostat, cycloheximide, or convalescent serum, proved to be more effective.	Cycloheximide	206-219	interferon alpha 1	Homo sapiens	143-151
34855201-4	2022	EXPERIMENTAL APPROACH: The inhibitory action of trimethoprim on Snail protein and the related molecular mechanisms were revealed by molecular docking, biolayer interferometry, immunoblotting, immunoprecipitation, qRT-PCR, pull-down, and cycloheximide pulse-chase assays.	Cycloheximide	237-250	snail family transcriptional repressor 1	Homo sapiens	64-69
34520103-9	2021	Using a protein synthesis inhibitor, cycloheximide, we also observed that fenofibrate inhibited HIF-1alpha protein synthesis.	Cycloheximide	37-50	hypoxia inducible factor 1 subunit alpha	Homo sapiens	96-106
7628359-7	1995	When ROB were treated with cycloheximide for the same period, only a small decrease in PTHrP binding (20%) was observed, suggesting that PTH/PTHrP receptors do not have a rapid turnover.	Cycloheximide	27-40	parathyroid hormone-like hormone	Rattus norvegicus	87-92
7628359-7	1995	When ROB were treated with cycloheximide for the same period, only a small decrease in PTHrP binding (20%) was observed, suggesting that PTH/PTHrP receptors do not have a rapid turnover.	Cycloheximide	27-40	parathyroid hormone-like hormone	Rattus norvegicus	141-146
7628359-8	1995	Cycloheximide also reduced PTH-stimulated cAMP production; after coincubation of cycloheximide with TGF beta 2, this inhibition was smaller than that in ROB cultures treated with TGF beta 2 exclusively.	Cycloheximide	0-13	transforming growth factor, beta 2	Rattus norvegicus	100-110
7628359-8	1995	Cycloheximide also reduced PTH-stimulated cAMP production; after coincubation of cycloheximide with TGF beta 2, this inhibition was smaller than that in ROB cultures treated with TGF beta 2 exclusively.	Cycloheximide	0-13	transforming growth factor, beta 2	Rattus norvegicus	179-189
7628359-8	1995	Cycloheximide also reduced PTH-stimulated cAMP production; after coincubation of cycloheximide with TGF beta 2, this inhibition was smaller than that in ROB cultures treated with TGF beta 2 exclusively.	Cycloheximide	81-94	transforming growth factor, beta 2	Rattus norvegicus	100-110
34900980-5	2021	Besides, the HUWE1 mechanism in reducing the number and function of Treg cells in ITP was investigated by immunoprecipitation, cycloheximide-chase assay, ubiquitin experiment and immunofluorescence assay.	Cycloheximide	127-140	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Homo sapiens	13-18
34753419-3	2021	Although a histone deacetylase, Rpd3, is also required for cycloheximide resistance in rho0/- cells, it is currently unknown whether Rpd3 and its DNA binding partners, Ume6 and Ash1, are involved in the activation of PDR5 transcription and PDR in rho0/- cells.	Cycloheximide	59-72	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	32-36
34780278-6	2022	We found that SP-A post-transcriptionally restricts LPS-induced TLR4 protein expression in primary AMs from healthy humans, rats, wild-type and SP-A-/- mice by further decreasing cycloheximide-reduced TLR4 protein translation and enhances the co-localization of TLR4 with the late endosome/lysosome.	Cycloheximide	179-192	surfactant protein A1	Homo sapiens	14-18
34780278-6	2022	We found that SP-A post-transcriptionally restricts LPS-induced TLR4 protein expression in primary AMs from healthy humans, rats, wild-type and SP-A-/- mice by further decreasing cycloheximide-reduced TLR4 protein translation and enhances the co-localization of TLR4 with the late endosome/lysosome.	Cycloheximide	179-192	toll like receptor 4	Homo sapiens	64-68
34780278-6	2022	We found that SP-A post-transcriptionally restricts LPS-induced TLR4 protein expression in primary AMs from healthy humans, rats, wild-type and SP-A-/- mice by further decreasing cycloheximide-reduced TLR4 protein translation and enhances the co-localization of TLR4 with the late endosome/lysosome.	Cycloheximide	179-192	toll-like receptor 4	Mus musculus	201-205
34753419-5	2021	RESULTS: rho0 cells in the rpd3  and ume6  strains, with the exception of the ash1  strain, were sensitive to fluconazole and cycloheximide.	Cycloheximide	126-139	DNA-binding transcriptional regulator UME6	Saccharomyces cerevisiae S288C	37-41
34802056-4	2021	Additionally, the stability of EZH2 induced by FBW7 was analyzed by cycloheximide chase assay.	Cycloheximide	68-81	F-box and WD-40 domain protein 7	Mus musculus	47-51
34791500-8	2022	Furthermore, LCIB relocated toward the pyrenoid at 2.6-3.4 microM CO2, even in cells in the dark or treated with DCMU and cycloheximide in light.	Cycloheximide	122-135	uncharacterized protein	Chlamydomonas reinhardtii	13-17
34753419-5	2021	RESULTS: rho0 cells in the rpd3  and ume6  strains, with the exception of the ash1  strain, were sensitive to fluconazole and cycloheximide.	Cycloheximide	126-139	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	27-31
34753419-5	2021	RESULTS: rho0 cells in the rpd3  and ume6  strains, with the exception of the ash1  strain, were sensitive to fluconazole and cycloheximide.	Cycloheximide	126-139	DNA-binding transcription repressor ASH1	Saccharomyces cerevisiae S288C	78-82
34753419-7	2021	Transcriptional expression of PDR5 was reduced in cycloheximide-exposed and unexposed rho0 cells of the ume6  strain; the transcriptional positive response of PDR5 to cycloheximide exposure was also impaired in this strain.	Cycloheximide	50-63	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	30-34
34753419-7	2021	Transcriptional expression of PDR5 was reduced in cycloheximide-exposed and unexposed rho0 cells of the ume6  strain; the transcriptional positive response of PDR5 to cycloheximide exposure was also impaired in this strain.	Cycloheximide	50-63	DNA-binding transcriptional regulator UME6	Saccharomyces cerevisiae S288C	104-108
34753419-7	2021	Transcriptional expression of PDR5 was reduced in cycloheximide-exposed and unexposed rho0 cells of the ume6  strain; the transcriptional positive response of PDR5 to cycloheximide exposure was also impaired in this strain.	Cycloheximide	50-63	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	159-163
34753419-7	2021	Transcriptional expression of PDR5 was reduced in cycloheximide-exposed and unexposed rho0 cells of the ume6  strain; the transcriptional positive response of PDR5 to cycloheximide exposure was also impaired in this strain.	Cycloheximide	167-180	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	30-34
34753419-7	2021	Transcriptional expression of PDR5 was reduced in cycloheximide-exposed and unexposed rho0 cells of the ume6  strain; the transcriptional positive response of PDR5 to cycloheximide exposure was also impaired in this strain.	Cycloheximide	167-180	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	159-163
34684632-5	2021	The ABCA-1 degradation rate was determined after cell incubation with cycloheximide, and ABCA1 protein level by immunoblot.	Cycloheximide	70-83	ATP binding cassette subfamily A member 1	Homo sapiens	4-10
34769510-3	2021	Here we report that three translation inhibitors (cycloheximide, lactimidomycin, and rocaglamide A) can facilitate the nuclear translocation of TFEB/TFE3 via dephosphorylation and 14-3-3 dissociation.	Cycloheximide	50-63	transcription factor EB	Homo sapiens	144-148
34769510-3	2021	Here we report that three translation inhibitors (cycloheximide, lactimidomycin, and rocaglamide A) can facilitate the nuclear translocation of TFEB/TFE3 via dephosphorylation and 14-3-3 dissociation.	Cycloheximide	50-63	transcription factor binding to IGHM enhancer 3	Homo sapiens	149-153
34769510-3	2021	Here we report that three translation inhibitors (cycloheximide, lactimidomycin, and rocaglamide A) can facilitate the nuclear translocation of TFEB/TFE3 via dephosphorylation and 14-3-3 dissociation.	Cycloheximide	50-63	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta	Homo sapiens	180-186
34719205-13	2021	Besides, overexpression of MAP17 accelerated cycloheximide (CHX, a protein synthesis inhibitor)-induced p53 degradation, while low expression of MAP17 slowed down CHX-induced p53 degradation, suggesting that MAP17 can regulate p53 stability.	Cycloheximide	45-58	PDZK1 interacting protein 1	Homo sapiens	27-32
34719205-13	2021	Besides, overexpression of MAP17 accelerated cycloheximide (CHX, a protein synthesis inhibitor)-induced p53 degradation, while low expression of MAP17 slowed down CHX-induced p53 degradation, suggesting that MAP17 can regulate p53 stability.	Cycloheximide	45-58	tumor protein p53	Homo sapiens	104-107
34646892-8	2021	Stability of the c-Myc protein was measured using cycloheximide.	Cycloheximide	50-63	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	17-22
34425283-4	2021	Reduction of Vif by CHIP expression is due to its increased rate of degradation as shown by cycloheximide (CHX) chase assay.	Cycloheximide	92-105	Vif	Human immunodeficiency virus 1	13-16
34425283-4	2021	Reduction of Vif by CHIP expression is due to its increased rate of degradation as shown by cycloheximide (CHX) chase assay.	Cycloheximide	107-110	Vif	Human immunodeficiency virus 1	13-16
34303041-6	2021	Additionally, BAY11-7082, actinomycin D, and cycloheximide have inhibitory effects on As2O3-induced expression of BCL-2 mRNA and protein, and restore the cell viability of BEAS-2B cells.	Cycloheximide	45-58	BCL2 apoptosis regulator	Homo sapiens	114-119
34690553-7	2021	According to the gene expression pattern of DEGs, we speculated five candidate drugs with potential therapeutic value for APA, one of which is cycloheximide, an inhibitor for phospholipid biosynthesis.	Cycloheximide	143-156	delta 4-desaturase, sphingolipid 1	Homo sapiens	44-48
34560123-6	2021	Cycloheximide, a protein synthesis inhibitor, completely inhibited As2O3-induced GRP78 protein expression.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 5	Homo sapiens	81-86
34417577-6	2022	Additionally, inhibition of TFEB activation by ROS scavenger N-acetyl cysteine or inhibition of protein synthesis by cycloheximide effectively compromises ATF4 upregulation and apoptosis in response to 15d-PGJ2.	Cycloheximide	117-130	activating transcription factor 4	Homo sapiens	155-159
34297722-2	2021	In this study, we performed a cycloheximide (CHX) chase assay to measure the half-lives of approximately 30 human lysosomal membrane proteins (LMPs) and identified RNF152 and LAPTM4A as short-lived membrane proteins.	Cycloheximide	30-43	ring finger protein 152	Homo sapiens	164-170
34638549-0	2021	The Bul1/2 Alpha-Arrestins Promote Ubiquitylation and Endocytosis of the Can1 Permease upon Cycloheximide-Induced TORC1-Hyperactivation.	Cycloheximide	92-105	ubiquitin-ubiquitin ligase BUL1	Saccharomyces cerevisiae S288C	4-16
34638549-0	2021	The Bul1/2 Alpha-Arrestins Promote Ubiquitylation and Endocytosis of the Can1 Permease upon Cycloheximide-Induced TORC1-Hyperactivation.	Cycloheximide	92-105	arginine permease CAN1	Saccharomyces cerevisiae S288C	73-77
34638549-4	2021	In this work, we dissect the molecular mechanisms eliciting the endocytosis of Can1, the arginine permease, in response to cycloheximide-induced TORC1 hyperactivation.	Cycloheximide	123-136	arginine permease CAN1	Saccharomyces cerevisiae S288C	79-83
34638549-5	2021	We show that cycloheximide promotes Rsp5-dependent Can1 ubiquitylation and endocytosis in a manner dependent on the Bul1/2 alpha-arrestins.	Cycloheximide	13-26	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	36-40
34638549-5	2021	We show that cycloheximide promotes Rsp5-dependent Can1 ubiquitylation and endocytosis in a manner dependent on the Bul1/2 alpha-arrestins.	Cycloheximide	13-26	arginine permease CAN1	Saccharomyces cerevisiae S288C	51-55
34638549-5	2021	We show that cycloheximide promotes Rsp5-dependent Can1 ubiquitylation and endocytosis in a manner dependent on the Bul1/2 alpha-arrestins.	Cycloheximide	13-26	ubiquitin-ubiquitin ligase BUL1	Saccharomyces cerevisiae S288C	116-128
34638549-7	2021	The previously reported inhibition by cycloheximide of transporter recycling, from the trans-Golgi network to the plasma membrane, seems to additionally contribute to efficient Can1 downregulation.	Cycloheximide	38-51	arginine permease CAN1	Saccharomyces cerevisiae S288C	177-181
34372882-5	2021	The stability of KSR1 protein was detected by cycloheximide (CHX) treatment.	Cycloheximide	46-59	kinase suppressor of ras 1	Homo sapiens	17-21
34372882-5	2021	The stability of KSR1 protein was detected by cycloheximide (CHX) treatment.	Cycloheximide	61-64	kinase suppressor of ras 1	Homo sapiens	17-21
34376133-7	2022	METHODS: MDA-MB-231 cells were treated with 17beta-estradiol (E2) and EGFR expression was studied by western blotting at different intervals by using Cycloheximide chase.	Cycloheximide	150-163	epidermal growth factor receptor	Homo sapiens	70-74
34376133-9	2022	RESULTS: EGFR expression was reduced with beta-estradiol treatment in MDA-MB-231 cell line with Cycloheximide chase.	Cycloheximide	96-109	epidermal growth factor receptor	Homo sapiens	9-13
34114669-7	2022	Furthermore, we showed that CCL5 could be secreted from monocytes treated with the protein synthesis inhibitor (cycloheximide) and Golgi blocker (brefeldin A).	Cycloheximide	112-125	C-C motif chemokine ligand 5	Homo sapiens	28-32
34281099-5	2021	The viability of HGF cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT), neutral red uptake, and trypan blue assay after treatment with different concentrations of CHX and ME (0.3125 to 10 microg/mL).	Cycloheximide	209-212	hepatocyte growth factor	Homo sapiens	17-20
34281099-10	2021	The viability of CHX- and ME-treated HGF cells estimated at higher concentrations (10 microg/mL) using trypan blue assay was found to be 2.18% and 47.36%, respectively.	Cycloheximide	17-20	hepatocyte growth factor	Homo sapiens	37-40
34106567-6	2021	Protein expression of Forkhead Box C1 (FOXC1) was increased by USP28 over-expression, whereas knockdown of USP28 aggravated cycloheximide (CHX; protein synthesis inhibitor) stimulated decrease of FOXC1.	Cycloheximide	124-137	ubiquitin specific peptidase 28	Homo sapiens	107-112
34106567-6	2021	Protein expression of Forkhead Box C1 (FOXC1) was increased by USP28 over-expression, whereas knockdown of USP28 aggravated cycloheximide (CHX; protein synthesis inhibitor) stimulated decrease of FOXC1.	Cycloheximide	124-137	forkhead box C1	Homo sapiens	196-201
34350116-7	2021	The connection between UBD and p53 was analyzed using Western blotting, immunoprecipitation, proteasome inhibition assay and Cycloheximide (CHX) chase assay.	Cycloheximide	125-138	tumor protein p53	Homo sapiens	31-34
34350116-7	2021	The connection between UBD and p53 was analyzed using Western blotting, immunoprecipitation, proteasome inhibition assay and Cycloheximide (CHX) chase assay.	Cycloheximide	140-143	tumor protein p53	Homo sapiens	31-34
34222769-9	2021	As previously seen for ABI5, ABF1, and ABF3, epitope-tagged constitutively expressed ABF2 degrades in seedlings treated with cycloheximide and is stabilized following treatment with the proteasome inhibitor MG132.	Cycloheximide	125-138	Basic-leucine zipper (bZIP) transcription factor family protein	Arabidopsis thaliana	23-27
34222769-9	2021	As previously seen for ABI5, ABF1, and ABF3, epitope-tagged constitutively expressed ABF2 degrades in seedlings treated with cycloheximide and is stabilized following treatment with the proteasome inhibitor MG132.	Cycloheximide	125-138	abscisic acid responsive element-binding factor 1	Arabidopsis thaliana	29-33
34222769-9	2021	As previously seen for ABI5, ABF1, and ABF3, epitope-tagged constitutively expressed ABF2 degrades in seedlings treated with cycloheximide and is stabilized following treatment with the proteasome inhibitor MG132.	Cycloheximide	125-138	abscisic acid responsive elements-binding factor 3	Arabidopsis thaliana	39-43
34631502-6	2021	However, in the presence of cycloheximide, a translation inhibitor, methylmercury delayed the degradation of TCF3 protein.	Cycloheximide	28-41	transcription factor 3	Mus musculus	109-113
34073955-6	2021	Similarly, protease incubation led to acute upregulation of anti-BSP immunofluorescence signals, which was blocked by cycloheximide, suggesting de novo formation of BSP.	Cycloheximide	118-131	integrin binding sialoprotein	Homo sapiens	65-68
34073955-6	2021	Similarly, protease incubation led to acute upregulation of anti-BSP immunofluorescence signals, which was blocked by cycloheximide, suggesting de novo formation of BSP.	Cycloheximide	118-131	integrin binding sialoprotein	Homo sapiens	165-168
34088288-8	2021	Cycloheximide chase analysis was used to determine the c-Myc protein half-lives before and after matrine treatment.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	55-60
35513753-6	2022	Elevated O-GlcNAcylation level promoted NLRX1 ubiquitination and decreased NLRX1 stability proved by ubiquitination and cycloheximide (CHX) chase experiments, and enhanced the interaction between NLRX1 and inhibitor of nuclear factor kappaB kinase-alpha (IKK-alpha), thus reducing the expression of inflammatory cytokine IL-1beta in M1 macrophages.	Cycloheximide	120-133	NLR family member X1	Homo sapiens	75-80
34522714-6	2021	Finally, the effect of sulfuretin on BACE1 and im-APP was selectively attenuated by the translation inhibitor cycloheximide and by lysosomal inhibitor chloroquine, respectively.	Cycloheximide	110-123	beta-secretase 1	Homo sapiens	37-42
34522714-6	2021	Finally, the effect of sulfuretin on BACE1 and im-APP was selectively attenuated by the translation inhibitor cycloheximide and by lysosomal inhibitor chloroquine, respectively.	Cycloheximide	110-123	amyloid beta precursor protein	Homo sapiens	47-53
35274760-8	2022	Cycloheximide (CHX) chase and co-IP assay of ubiquitination showed that MCTS1 could increase LARP7 protein half-life and reduce its poly-ubiquitination.	Cycloheximide	0-13	MCTS1 re-initiation and release factor	Homo sapiens	72-77
35298837-8	2022	The soluble recombinant protein Trx-TNFSF10 could induce cytotoxicity and apoptosis in HeLa cells with cycloheximide as a promoter.	Cycloheximide	103-116	thioredoxin	Homo sapiens	32-35
35298837-8	2022	The soluble recombinant protein Trx-TNFSF10 could induce cytotoxicity and apoptosis in HeLa cells with cycloheximide as a promoter.	Cycloheximide	103-116	TNF superfamily member 10	Homo sapiens	36-43
35523398-3	2022	In this study, the cellular effects of a glycine powder and an erythritol/chlorhexidine (CHX) powder on human gingival fibroblasts (HGF) were investigated.	Cycloheximide	89-92	hepatocyte growth factor	Homo sapiens	132-135
35411556-10	2022	Moreover, we found that calcitriol could increase myosin heavy chain (MHC) protein translation and overall nascent protein synthesis in a cycloheximide-sensitive manner, indicating that calcitriol can directly bind and enhance ribosomal activity to boost muscle growth.	Cycloheximide	138-151	major histocompatibility complex, class I, C	Homo sapiens	50-68
35411556-10	2022	Moreover, we found that calcitriol could increase myosin heavy chain (MHC) protein translation and overall nascent protein synthesis in a cycloheximide-sensitive manner, indicating that calcitriol can directly bind and enhance ribosomal activity to boost muscle growth.	Cycloheximide	138-151	major histocompatibility complex, class I, C	Homo sapiens	70-73
35248528-8	2022	After cycloheximide treatment, the FL-SMN1 levels in both the 683T > A and 844C > T were increased significantly compared with that of untreated cells.	Cycloheximide	6-19	survival of motor neuron 1, telomeric	Homo sapiens	38-42
34999138-6	2022	Here we demonstrate the increased abundance and half-life of TPK1 mRNA and the assembly of this mRNA in cytoplasmic foci during heat shock at 37  C. The resistance of the foci to cycloheximide-induced disassembly along with the polysome profiling analysis suggest that TPK1 mRNA is impaired for entry into translation.	Cycloheximide	179-192	cAMP-dependent protein kinase catalytic subunit TPK1	Saccharomyces cerevisiae S288C	61-65
35397606-7	2022	The regulation of MMP2 by p-ATF1-T184 was investigated by a series of experiments including quantitative RT-PCR, western blot, gelatin zymography assay, Chromatin immunoprecipitation (ChIP), luciferase reporter assay and cycloheximide experiment.	Cycloheximide	221-234	matrix metallopeptidase 2	Homo sapiens	18-22
35397606-7	2022	The regulation of MMP2 by p-ATF1-T184 was investigated by a series of experiments including quantitative RT-PCR, western blot, gelatin zymography assay, Chromatin immunoprecipitation (ChIP), luciferase reporter assay and cycloheximide experiment.	Cycloheximide	221-234	activating transcription factor 1	Homo sapiens	28-32
35266648-8	2022	Moreover, cycloheximide chase assay showed that degradation of TYR was decreased in IFNG-treated cells.	Cycloheximide	10-23	tyrosinase	Homo sapiens	63-66
35266648-8	2022	Moreover, cycloheximide chase assay showed that degradation of TYR was decreased in IFNG-treated cells.	Cycloheximide	10-23	interferon gamma	Homo sapiens	84-88
35462504-8	2022	Cycloheximide (CHX) was added to 293T cells transfected with wild-type or mutant NLRC4 plasmid to detect the degradation of NLRC4 protein.	Cycloheximide	0-13	NLR family CARD domain containing 4	Homo sapiens	124-129
35462504-8	2022	Cycloheximide (CHX) was added to 293T cells transfected with wild-type or mutant NLRC4 plasmid to detect the degradation of NLRC4 protein.	Cycloheximide	15-18	NLR family CARD domain containing 4	Homo sapiens	124-129
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	106-119	tumor protein p53	Homo sapiens	23-26
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	106-119	MDM2 proto-oncogene	Homo sapiens	28-32
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	106-119	ribosomal protein L5	Homo sapiens	37-41
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	106-119	ribosomal protein L15	Homo sapiens	57-62
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	121-124	tumor protein p53	Homo sapiens	23-26
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	121-124	MDM2 proto-oncogene	Homo sapiens	28-32
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	121-124	ribosomal protein L5	Homo sapiens	37-41
35410346-8	2022	The connection between p53, MDM2 and RPL5/11 affected by RPL15 was analyzed using immunoprecipitation and Cycloheximide (CHX) chase assay.	Cycloheximide	121-124	ribosomal protein L15	Homo sapiens	57-62
35391558-4	2022	The stability of AUF1 and its degradation by ubiquitin-proteasome pathway were examined by cycloheximide chase analysis and co-immunoprecipitation assay.	Cycloheximide	91-104	heterogeneous nuclear ribonucleoprotein D	Homo sapiens	17-21
35313791-6	2022	Cycloheximide chase assay was applied to explore the influence of UBE2B and RAD18 on ZMYM2 degradation.	Cycloheximide	0-13	ubiquitin conjugating enzyme E2 B	Homo sapiens	66-71
35313791-6	2022	Cycloheximide chase assay was applied to explore the influence of UBE2B and RAD18 on ZMYM2 degradation.	Cycloheximide	0-13	RAD18 E3 ubiquitin protein ligase	Homo sapiens	76-81
35313791-6	2022	Cycloheximide chase assay was applied to explore the influence of UBE2B and RAD18 on ZMYM2 degradation.	Cycloheximide	0-13	zinc finger MYM-type containing 2	Homo sapiens	85-90
34999138-6	2022	Here we demonstrate the increased abundance and half-life of TPK1 mRNA and the assembly of this mRNA in cytoplasmic foci during heat shock at 37  C. The resistance of the foci to cycloheximide-induced disassembly along with the polysome profiling analysis suggest that TPK1 mRNA is impaired for entry into translation.	Cycloheximide	179-192	cAMP-dependent protein kinase catalytic subunit TPK1	Saccharomyces cerevisiae S288C	269-273
35350760-6	2022	The mechanisms of which HNK functions as a direct inhibitor of HIF-1alpha were verified through the ubiquitination assay, the Co-IP assay, and the cycloheximide (CHX) pulse-chase assay.	Cycloheximide	147-160	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-73
35336175-8	2022	UME6 is also required for the cycloheximide-induced transcription of PDR5 in nonfermentable media but not in fermentable media.	Cycloheximide	30-43	DNA-binding transcriptional regulator UME6	Saccharomyces cerevisiae S288C	0-4
35336175-8	2022	UME6 is also required for the cycloheximide-induced transcription of PDR5 in nonfermentable media but not in fermentable media.	Cycloheximide	30-43	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	69-73
35279675-6	2022	In vitro, treatment with tumour necrosis factor-alpha (TNF-alpha) plus cycloheximide (CHX) or SLE sera induced HK2 cells to undergo pyroptosis in a caspase-3- and GSDME-dependent manner.	Cycloheximide	71-84	caspase 3	Mus musculus	148-157
35350760-6	2022	The mechanisms of which HNK functions as a direct inhibitor of HIF-1alpha were verified through the ubiquitination assay, the Co-IP assay, and the cycloheximide (CHX) pulse-chase assay.	Cycloheximide	162-165	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-73
35098684-7	2022	Cycloheximide (CHX) was introduced to measure half-lives of KLF4 and deubiquitination assay was used to detect deubiquitination ability of OTUD1.	Cycloheximide	0-13	Kruppel like factor 4	Homo sapiens	60-64
35149839-5	2022	CBLC depletion markedly decreased the half-life of AURKA in cycloheximide-treated LAD cells.	Cycloheximide	60-73	Cbl proto-oncogene C	Homo sapiens	0-4
35149839-5	2022	CBLC depletion markedly decreased the half-life of AURKA in cycloheximide-treated LAD cells.	Cycloheximide	60-73	aurora kinase A	Homo sapiens	51-56
35118791-7	2022	Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs.	Cycloheximide	0-13	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	48-54
35118791-7	2022	Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs.	Cycloheximide	0-13	annexin A3	Rattus norvegicus	65-68
35118791-7	2022	Cycloheximide, but not actinomycin D, abolished LC3 II and total LC3 increase elicited by Ang II in RASMCs.	Cycloheximide	0-13	angiotensinogen	Rattus norvegicus	90-96
35118791-8	2022	In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II.	Cycloheximide	15-28	angiotensinogen	Rattus norvegicus	43-49
35118791-8	2022	In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II.	Cycloheximide	15-28	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	71-76
35118791-8	2022	In A7r5 cells, cycloheximide prevented the Ang II-mediated increase of LC3 I and total LC3, but not LC3 II.	Cycloheximide	15-28	annexin A3	Rattus norvegicus	87-90
35611163-6	2022	Mechanistically, it was found that OTUB2 promoted the stabilization of PJA1 by deubiquitylation, based on immunoprecipitation (IP) and cycloheximide (CHX) assays.	Cycloheximide	135-148	OTU deubiquitinase, ubiquitin aldehyde binding 2	Homo sapiens	35-40
35203628-9	2022	Moreover, by inhibiting TLR4 activation and de novo protein synthesis by LPS-binding protein (LBP) manipulation and cycloheximide, our data showed that the TLR4 signal and de novo protein synthesis are necessary for microglia to develop PGE2 tolerance in NG cells under the ET challenge.	Cycloheximide	116-129	toll like receptor 4	Homo sapiens	24-28
35203628-9	2022	Moreover, by inhibiting TLR4 activation and de novo protein synthesis by LPS-binding protein (LBP) manipulation and cycloheximide, our data showed that the TLR4 signal and de novo protein synthesis are necessary for microglia to develop PGE2 tolerance in NG cells under the ET challenge.	Cycloheximide	116-129	toll like receptor 4	Homo sapiens	156-160
35159343-9	2022	VPA had no effect on CCN1 mRNA expression, but inhibition of protein synthesis by cycloheximide showed that VPA slowed down the CCN1 protein degradation.	Cycloheximide	82-95	protein phosphatase 3 catalytic subunit alpha	Homo sapiens	128-132
35197064-13	2022	Although FcepsilonRIalpha mRNA expression was not increased by IgE in dissociated trigeminal ganglion neurons, FcepsilonRIalpha protein level was enhanced by IgE in a cycloheximide-resistance manner, with concordant enhancement of neuronal responses to IgE-IC.	Cycloheximide	167-180	Fc receptor, IgE, high affinity I, alpha polypeptide	Mus musculus	111-127
35611163-6	2022	Mechanistically, it was found that OTUB2 promoted the stabilization of PJA1 by deubiquitylation, based on immunoprecipitation (IP) and cycloheximide (CHX) assays.	Cycloheximide	135-148	praja ring finger ubiquitin ligase 1	Homo sapiens	71-75
2556264-7	1989	However, in contrast to the TC-II enhanson, the H-2Kb enhanson exhibits a very low activity in HeLa cells, but can be strongly induced by TPA and/or cycloheximide treatments which suggests that its cognate factor is inactivated (repressed) by an inhibitor protein.	Cycloheximide	149-162	transcobalamin 2	Homo sapiens	28-33
35144669-8	2022	SMAD4 half-life was assessed by cycloheximide treatment in HNC cell lines, together with betaTRCP1-dependent SMAD4 ubiquitination.	Cycloheximide	32-45	SMAD family member 4	Homo sapiens	0-5
35001891-7	2022	The degradation of the extracellular domain of NOTCH3 (NOTCH3ECD) was analyzed by Cycloheximide Pulse-Chase Experiment.	Cycloheximide	82-95	notch receptor 3	Homo sapiens	47-53
35001891-7	2022	The degradation of the extracellular domain of NOTCH3 (NOTCH3ECD) was analyzed by Cycloheximide Pulse-Chase Experiment.	Cycloheximide	82-95	notch receptor 3	Homo sapiens	55-64
2556264-8	1989	Interestingly, cycloheximide, but not TPA treatment, could induce the activity of both the TC-II and H-2Kb enhansons in F9 embryonal carcinoma cells, suggesting that these cells lack some component(s) of the protein kinase C signal transduction pathway.	Cycloheximide	15-28	transcobalamin 2	Homo sapiens	91-96
2597146-2	1989	The presence of cycloheximide (CHX) leads to up to 7.5-fold superinduction of LDL receptor mRNA within 4 hr and, upon removal of this inhibitor, to superinduction of LDL receptor protein as well.	Cycloheximide	16-29	low density lipoprotein receptor	Homo sapiens	78-90
2512344-6	1989	Induction of Leu 13 Ag expression by IFN-gamma was suppressed by cycloheximide.	Cycloheximide	65-78	interferon induced transmembrane protein 1	Homo sapiens	13-19
2597146-2	1989	The presence of cycloheximide (CHX) leads to up to 7.5-fold superinduction of LDL receptor mRNA within 4 hr and, upon removal of this inhibitor, to superinduction of LDL receptor protein as well.	Cycloheximide	16-29	low density lipoprotein receptor	Homo sapiens	166-178
2597146-2	1989	The presence of cycloheximide (CHX) leads to up to 7.5-fold superinduction of LDL receptor mRNA within 4 hr and, upon removal of this inhibitor, to superinduction of LDL receptor protein as well.	Cycloheximide	31-34	low density lipoprotein receptor	Homo sapiens	78-90
2597146-2	1989	The presence of cycloheximide (CHX) leads to up to 7.5-fold superinduction of LDL receptor mRNA within 4 hr and, upon removal of this inhibitor, to superinduction of LDL receptor protein as well.	Cycloheximide	31-34	low density lipoprotein receptor	Homo sapiens	166-178
2686982-4	1989	The most potent activator of the S6 kinase in liver extracts was cycloheximide.	Cycloheximide	65-78	ribosomal protein S6 kinase B1	Rattus norvegicus	33-42
2512344-6	1989	Induction of Leu 13 Ag expression by IFN-gamma was suppressed by cycloheximide.	Cycloheximide	65-78	interferon gamma	Homo sapiens	37-46
2555368-7	1989	Treatment of cells with cycloheximide stabilized tissue factor and PAI-2 mRNAs and increased their induction by PMA or TNF.	Cycloheximide	24-37	tumor necrosis factor	Homo sapiens	119-122
2604000-3	1989	Inhibition (86%) of hepatic fibronectin synthesis by pretreatment with cycloheximide limited the recovery of fibronectin levels by only 60%, suggesting a source(s) other than hepatic synthesis may contribute to the restoration of plasma fibronectin.	Cycloheximide	71-84	fibronectin 1	Rattus norvegicus	28-39
2604000-3	1989	Inhibition (86%) of hepatic fibronectin synthesis by pretreatment with cycloheximide limited the recovery of fibronectin levels by only 60%, suggesting a source(s) other than hepatic synthesis may contribute to the restoration of plasma fibronectin.	Cycloheximide	71-84	fibronectin 1	Rattus norvegicus	109-120
2604000-3	1989	Inhibition (86%) of hepatic fibronectin synthesis by pretreatment with cycloheximide limited the recovery of fibronectin levels by only 60%, suggesting a source(s) other than hepatic synthesis may contribute to the restoration of plasma fibronectin.	Cycloheximide	71-84	fibronectin 1	Rattus norvegicus	109-120
2557044-8	1989	However, we found that cycloheximide, when added to synovial fibroblast cultures up to 6 hours after treatment with IL-1, inhibited the expression of collagenase mRNA.	Cycloheximide	23-36	interleukin 1 alpha	Homo sapiens	116-120
2532602-7	1989	The protein synthesis inhibitor cycloheximide (CHX) increases the expression of all three cytoplasmic CD3 delta transcripts, indicating that their level of expression may be regulated by a labile inhibitor protein(s).	Cycloheximide	32-45	CD3 antigen, epsilon polypeptide	Mus musculus	102-105
2532602-7	1989	The protein synthesis inhibitor cycloheximide (CHX) increases the expression of all three cytoplasmic CD3 delta transcripts, indicating that their level of expression may be regulated by a labile inhibitor protein(s).	Cycloheximide	47-50	CD3 antigen, epsilon polypeptide	Mus musculus	102-105
2557227-9	1989	Protein synthesis inhibitors cycloheximide and anisomycin also increased markedly the concentration of c-fos mRNA, and in the presence of anisomycin c-fos mRNA was superinduced by the alpha-adrenergic agonist norepinephrine.	Cycloheximide	29-42	FBJ osteosarcoma oncogene	Mus musculus	103-108
2557227-9	1989	Protein synthesis inhibitors cycloheximide and anisomycin also increased markedly the concentration of c-fos mRNA, and in the presence of anisomycin c-fos mRNA was superinduced by the alpha-adrenergic agonist norepinephrine.	Cycloheximide	29-42	FBJ osteosarcoma oncogene	Mus musculus	149-154
2511244-7	1989	Cycloheximide (CHX) was able to induce IL-1 mRNA but did not induce transcription of either IL-1 gene.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	39-43
2511244-7	1989	Cycloheximide (CHX) was able to induce IL-1 mRNA but did not induce transcription of either IL-1 gene.	Cycloheximide	15-18	interleukin 1 beta	Homo sapiens	39-43
2555698-3	1989	Activation by IFN-alpha was rapid, transient, and cycloheximide resistant.	Cycloheximide	50-63	interferon alpha 1	Homo sapiens	14-23
2555698-4	1989	Activation by IFN-gamma was slower, sustained, and delayed by cycloheximide.	Cycloheximide	62-75	interferon gamma	Homo sapiens	14-23
2560810-7	1989	The forskolin-induced increase of TG transcription requires ongoing protein synthesis, as it is blocked by cycloheximide.	Cycloheximide	107-120	thyroglobulin	Canis lupus familiaris	34-36
2628732-2	1989	When COMMA D cells were pretreated with insulin and PRL for 24 h, the addition of glucocorticoids induced a greater than 20-fold increase in beta-casein mRNA accumulation with an apparent lag of greater than 8 h. Addition of cycloheximide and anisomycin not only prevented this increase, but unexpectedly, resulted in the rapid disappearance of preexisting beta-casein mRNA with a half-life of approximately 2 h. Under the same conditions, the levels of beta-actin and histone H4 mRNAs were increased markedly.	Cycloheximide	225-238	casein beta	Mus musculus	141-152
2628732-2	1989	When COMMA D cells were pretreated with insulin and PRL for 24 h, the addition of glucocorticoids induced a greater than 20-fold increase in beta-casein mRNA accumulation with an apparent lag of greater than 8 h. Addition of cycloheximide and anisomycin not only prevented this increase, but unexpectedly, resulted in the rapid disappearance of preexisting beta-casein mRNA with a half-life of approximately 2 h. Under the same conditions, the levels of beta-actin and histone H4 mRNAs were increased markedly.	Cycloheximide	225-238	casein beta	Mus musculus	357-368
2695743-11	1989	Increased steady-state levels of RAD2 mRNA are induced by cycloheximide in asynchronously dividing populations of cells, but not in non-replicating cells arrested in G1 phase of the cell cycle.	Cycloheximide	58-71	ssDNA endodeoxyribonuclease RAD2	Saccharomyces cerevisiae S288C	33-37
2531899-1	1989	In this report we present evidence that Con A-activated T helper 2 cells transcribe the interleukin 2 (IL-2) gene when cycloheximide is added 3 hr after stimulation.	Cycloheximide	119-132	interleukin 2	Homo sapiens	88-101
2531899-1	1989	In this report we present evidence that Con A-activated T helper 2 cells transcribe the interleukin 2 (IL-2) gene when cycloheximide is added 3 hr after stimulation.	Cycloheximide	119-132	interleukin 2	Homo sapiens	103-107
2531899-5	1989	Nuclear run-on experiments indicate that IL-2 transcription in T helper 2 cells depends on the presence of cycloheximide.	Cycloheximide	107-120	interleukin 2	Homo sapiens	41-45
2594781-5	1989	After 20 hr of culture, IL-2R mRNA was markedly decreased in both IL-2-toxin- and cycloheximide-treated phytohemagglutinin-activated T cells.	Cycloheximide	82-95	interleukin 2 receptor subunit beta	Homo sapiens	24-29
2555368-6	1989	Nuclear runoff assays showed that PMA, TNF, or cycloheximide induced transcription of the tissue factor gene, whereas the genes for thrombomodulin, PAI-1, and PAI-2 apparently were transcribed at the same relative rate in the presence or absence of these agents.	Cycloheximide	47-60	coagulation factor III, tissue factor	Homo sapiens	90-103
2555368-7	1989	Treatment of cells with cycloheximide stabilized tissue factor and PAI-2 mRNAs and increased their induction by PMA or TNF.	Cycloheximide	24-37	coagulation factor III, tissue factor	Homo sapiens	49-62
2555368-7	1989	Treatment of cells with cycloheximide stabilized tissue factor and PAI-2 mRNAs and increased their induction by PMA or TNF.	Cycloheximide	24-37	serpin family B member 2	Homo sapiens	67-72
2684789-1	1989	In Saccharomyces cerevisiae, the SCL-1 mutation is a dominant suppressor of the cycloheximide-resistant, temperature-sensitive (ts) lethal mutation, crl3 [McCusker and Haber, Genetics 119 (1988a) 303-315].	Cycloheximide	80-93	proteasome core particle subunit alpha 1	Saccharomyces cerevisiae S288C	33-38
2684789-1	1989	In Saccharomyces cerevisiae, the SCL-1 mutation is a dominant suppressor of the cycloheximide-resistant, temperature-sensitive (ts) lethal mutation, crl3 [McCusker and Haber, Genetics 119 (1988a) 303-315].	Cycloheximide	80-93	proteasome regulatory particle base subunit RPT6	Saccharomyces cerevisiae S288C	149-153
2556329-7	1989	ODC serum induction in the transfectants was sensitive to cycloheximide and polyamine additions, and the half-life of the enzyme was very short, like that in normal CHO cells.	Cycloheximide	58-71	ornithine decarboxylase 1	Homo sapiens	0-3
2679879-8	1989	Further, the insulin-dependent increase of glucose-6-phosphate dehydrogenase mRNA was blocked by cycloheximide, suggesting that synthesis of a peptide is required.	Cycloheximide	97-110	glucose-6-phosphate dehydrogenase	Rattus norvegicus	43-76
2484059-1	1989	Conditioned medium obtained from bovine pulmonary artery smooth muscle cells (SMC) in culture was found to elevate angiotensin-I-converting enzyme (ACE) of bovine pulmonary artery endothelial cells (EC) by 2- to 3-fold upon incubation for 24 to 48 h. The elevation in ACE was time dependent and inhibited by 10(-6) M cycloheximide, making it likely that the elevation was related to new protein synthesis by EC.	Cycloheximide	317-330	angiotensin I converting enzyme	Bos taurus	148-151
2597166-6	1989	The increase of ODC activity was almost completely blocked by the addition of cycloheximide or actinomycin D.	Cycloheximide	78-91	ornithine decarboxylase 1	Homo sapiens	16-19
2513867-3	1989	Secretion of VIII:C by cultured LEC was inhibited by cycloheximide and by monensin.	Cycloheximide	53-66	cytochrome c oxidase subunit 8A	Homo sapiens	13-17
2554812-7	1989	Complete removal of SCP2 from cytosol by treatment with anti-SCP2 IgG decreased cytosolic stimulatory activity by an increment that was independent of ACTH or CX treatment.	Cycloheximide	159-161	sterol carrier protein 2	Rattus norvegicus	20-24
2594781-5	1989	After 20 hr of culture, IL-2R mRNA was markedly decreased in both IL-2-toxin- and cycloheximide-treated phytohemagglutinin-activated T cells.	Cycloheximide	82-95	interleukin 2	Homo sapiens	24-28
2594781-6	1989	Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.	Cycloheximide	357-370	interleukin 2	Homo sapiens	24-28
2594781-6	1989	Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.	Cycloheximide	357-370	interleukin 2 receptor subunit beta	Homo sapiens	40-45
2594781-6	1989	Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.	Cycloheximide	357-370	interleukin 2	Homo sapiens	40-44
2477228-11	1989	In AtT-20 cells, time-course studies and studies with cycloheximide indicate that dexamethasone exerts its effects on PAM mRNA levels by an indirect mechanism involving protein synthesis.	Cycloheximide	54-67	peptidylglycine alpha-amidating monooxygenase	Mus musculus	118-121
2594781-6	1989	Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.	Cycloheximide	357-370	interleukin 2	Homo sapiens	40-44
2481662-8	1989	Moreover, both morphological differentiation and the suppressive effect on N-myc gene expression by rHuIFN-gamma were inhibited in the presence of cycloheximide.	Cycloheximide	147-160	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	75-80
2477232-13	1989	Similar to that in cells treated with FSH, inhibition of protein synthesis by cycloheximide resulted in the superinduction of tPA mRNA in isoproterenol-treated cells.	Cycloheximide	78-91	plasminogen activator, tissue type	Rattus norvegicus	126-129
2509363-3	1989	TNF-induced resistance to chlamydiae could be blocked with cycloheximide, suggesting that it involves the function of some induced proteins.	Cycloheximide	59-72	tumor necrosis factor	Homo sapiens	0-3
2601720-2	1989	Addition of cycloheximide increased the steady-state levels of c-rel mRNA.	Cycloheximide	12-25	reticuloendotheliosis oncogene	Mus musculus	63-68
2477086-9	1989	The c-jun transcripts in myelomonocytic cells have a half-life of approximately 20 minutes and are superinduced by cycloheximide, which affects both the degradation rate of mRNA and the transcriptional activity of the c-jun gene.	Cycloheximide	115-128	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
2691880-11	1989	Cycloheximide inhibits TSH-increased thyroglobulin but not peroxidase mRNA levels.	Cycloheximide	0-13	thyroglobulin	Rattus norvegicus	37-50
2559490-6	1989	Cycloheximide inhibited the induction of PCA by THP-1 cells, which shows that the protein synthesis is essential to mediate the effect of TNF-alpha.	Cycloheximide	0-13	GLI family zinc finger 2	Homo sapiens	48-53
2559490-6	1989	Cycloheximide inhibited the induction of PCA by THP-1 cells, which shows that the protein synthesis is essential to mediate the effect of TNF-alpha.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	138-147
2530096-4	1989	The anti-amnesic effect of minaprine on the cycloheximide-induced memory impairment was also antagonized by a serotonin (5-HT) releaser, p-chloroamphetamine, and by a 5-HT precursor, 5-hydroxytryptophan, whereas a 5-HT1A-selective agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, was inactive.	Cycloheximide	44-57	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	214-220
2506186-4	1989	We investigated the molecular basis for these diverse actions of TNF by differential screening of a cDNA library prepared from TNF and cycloheximide-treated human umbilical vein endothelial (HUVE) cells.	Cycloheximide	135-148	tumor necrosis factor	Homo sapiens	65-68
2583082-5	1989	Escape-time analyses with green wheat seedlings show that the cycloheximide block for Cab gene expression is after the primary signal transduction step linked to phytochrome photoconversion.	Cycloheximide	62-75	neural proliferation, differentiation and control 1	Homo sapiens	86-89
2507660-10	1989	Furthermore, if cycloheximide was added 24 h after IFN-gamma, it actually caused a superinduction of HLA-B transcripts.	Cycloheximide	16-29	interferon gamma	Homo sapiens	51-60
2507660-10	1989	Furthermore, if cycloheximide was added 24 h after IFN-gamma, it actually caused a superinduction of HLA-B transcripts.	Cycloheximide	16-29	major histocompatibility complex, class I, B	Homo sapiens	101-106
2615771-4	1989	Partial suppression of protein synthesis with moderate concentration of cycloheximide at a late stage of infection resulted in a differential inhibition of vRNA segments synthesis and stimulation of mRNA synthesis, leading to restoration of an "early" pattern in both cases.	Cycloheximide	72-85	vault RNA 1-1	Homo sapiens	156-160
2783134-1	1989	Ornithine decarboxylase activity in Friend erythroleukemia cells decayed with a half-life of 50 minutes after addition of cycloheximide and at a faster rate after addition of spermidine.	Cycloheximide	122-135	ornithine decarboxylase 1	Homo sapiens	0-23
2549056-6	1989	Treatment of ACTH-stimulated cells with cycloheximide reverses the rise in SAP (t1/2 congruent to 5-7 min).	Cycloheximide	40-53	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	75-78
2549056-10	1989	Considered together with the biological activity previously demonstrated for SAP in vitro, these data are consistent with its role as a cAMP-dependent, cycloheximide-sensitive modulator of steroid biosynthesis.	Cycloheximide	152-165	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	77-80
2476237-1	1989	Tumor necrosis factor (TNF) induces the synthesis of protein(s) that can protect cells against subsequent killing by TNF in the presence of cycloheximide.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	0-21
2476237-1	1989	Tumor necrosis factor (TNF) induces the synthesis of protein(s) that can protect cells against subsequent killing by TNF in the presence of cycloheximide.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	23-26
2476237-1	1989	Tumor necrosis factor (TNF) induces the synthesis of protein(s) that can protect cells against subsequent killing by TNF in the presence of cycloheximide.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	117-120
2476237-3	1989	Overexpression of MnSOD confers increased resistance to TNF plus cycloheximide on the 293 human embryonic kidney cell line.	Cycloheximide	65-78	superoxide dismutase 2	Homo sapiens	18-23
2476237-4	1989	Conversely, expression of antisense MnSOD RNA renders these cells sensitive to TNF even in the absence of cycloheximide.	Cycloheximide	106-119	superoxide dismutase 2	Homo sapiens	36-41
2670930-8	1989	Analysis of mRNA life span by using actinomycin D demonstrates that PPET-1 mRNA has a short intracellular half-life of about 15 min and is superinduced by cycloheximide.	Cycloheximide	155-168	endothelin 1	Homo sapiens	68-74
2674950-3	1989	GM-CSF-stimulated adherence must require new RNA and protein synthesis because actinomycin D and cycloheximide abolished existing adherence and prevented further monocyte attachment.	Cycloheximide	97-110	colony stimulating factor 2	Homo sapiens	0-6
2510361-3	1989	This t-PA effect was reduced by cycloheximide, suggesting that the involvement of specific protein synthesis, and by inhibitors of t-PA"s enzymatic activity, suggesting a requirement for a free catalytic site.	Cycloheximide	32-45	plasminogen activator, tissue type	Homo sapiens	5-9
2760046-0	1989	Purification of a hepatic S6 kinase from cycloheximide-treated Rats.	Cycloheximide	41-54	ribosomal protein S6 kinase B1	Rattus norvegicus	26-35
2760046-1	1989	Cycloheximide injection of rats results in the activation of a protein kinase that phosphorylates 40 S ribosomal protein S6.	Cycloheximide	0-13	ribosomal protein S6	Rattus norvegicus	103-123
2760046-7	1989	This S6 kinase probably underlies the increased hepatic S6 phosphorylation observed after cycloheximide treatment, which in turn corresponds to the mitogen-activated S6 kinase.	Cycloheximide	90-103	ribosomal protein S6 kinase B1	Rattus norvegicus	5-14
2760046-7	1989	This S6 kinase probably underlies the increased hepatic S6 phosphorylation observed after cycloheximide treatment, which in turn corresponds to the mitogen-activated S6 kinase.	Cycloheximide	90-103	ribosomal protein S6 kinase B1	Rattus norvegicus	166-175
2753911-7	1989	This was shown in cells treated with heparin and cycloheximide to be equal to 1 for LPL antigen but significantly greater than 1 for LPL activity assayed under standard conditions.	Cycloheximide	49-62	lipoprotein lipase	Mus musculus	84-87
2753911-7	1989	This was shown in cells treated with heparin and cycloheximide to be equal to 1 for LPL antigen but significantly greater than 1 for LPL activity assayed under standard conditions.	Cycloheximide	49-62	lipoprotein lipase	Mus musculus	133-136
2676720-7	1989	Cycloheximide experiments provide evidence that the galactose- and glucose-triggered GAL4 protein mobility shifts are due to post-translational modification.	Cycloheximide	0-13	galactose-responsive transcription factor GAL4	Saccharomyces cerevisiae S288C	85-89
2551629-6	1989	Pretreatment of cells with cycloheximide, under conditions which inhibited protein synthesis by greater than 90%, reduced the cAMP response to hPTH but did not block the further inhibitory actions of E2, T, or 5 alpha-DHT.	Cycloheximide	27-40	parathyroid hormone	Homo sapiens	143-147
2551637-6	1989	Insulin- and IGF-I-stimulated 3 beta HSD activities were completely inhibited by concurrent treatment with either actinomycin-D or cycloheximide, suggesting that new mRNA and protein synthesis are required for these peptides to exert their effects.	Cycloheximide	131-144	insulin	Homo sapiens	0-7
2551637-6	1989	Insulin- and IGF-I-stimulated 3 beta HSD activities were completely inhibited by concurrent treatment with either actinomycin-D or cycloheximide, suggesting that new mRNA and protein synthesis are required for these peptides to exert their effects.	Cycloheximide	131-144	insulin like growth factor 1	Homo sapiens	13-18
2551637-6	1989	Insulin- and IGF-I-stimulated 3 beta HSD activities were completely inhibited by concurrent treatment with either actinomycin-D or cycloheximide, suggesting that new mRNA and protein synthesis are required for these peptides to exert their effects.	Cycloheximide	131-144	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Homo sapiens	30-40
2516865-3	1989	Using a combined treatment with cycloheximide and actinomycin D we observed that in HeLa cells IFN-alpha did not need ongoing protein synthesis to induce the enzyme, whereas the addition of cycloheximide prevented the induction by IFN-gamma.	Cycloheximide	32-45	interferon alpha 1	Homo sapiens	95-104
2516865-3	1989	Using a combined treatment with cycloheximide and actinomycin D we observed that in HeLa cells IFN-alpha did not need ongoing protein synthesis to induce the enzyme, whereas the addition of cycloheximide prevented the induction by IFN-gamma.	Cycloheximide	32-45	interferon gamma	Homo sapiens	231-240
2516865-3	1989	Using a combined treatment with cycloheximide and actinomycin D we observed that in HeLa cells IFN-alpha did not need ongoing protein synthesis to induce the enzyme, whereas the addition of cycloheximide prevented the induction by IFN-gamma.	Cycloheximide	190-203	interferon gamma	Homo sapiens	231-240
2789262-7	1989	Furthermore, the TdT mRNA decline is blocked in the presence of cycloheximide, showing that new protein synthesis is required for inactivation of the gene.	Cycloheximide	64-77	DNA nucleotidylexotransferase	Homo sapiens	17-20
2480463-2	1989	Treatment with cycloheximide increased the sensitivity and responsiveness of isolated rat pancreatic acini to CCK-octapeptide (CCK-8) and thus plasma levels of CCK-8 as low was 0.17 pM were detectable.	Cycloheximide	15-28	cholecystokinin	Rattus norvegicus	110-113
2480463-2	1989	Treatment with cycloheximide increased the sensitivity and responsiveness of isolated rat pancreatic acini to CCK-octapeptide (CCK-8) and thus plasma levels of CCK-8 as low was 0.17 pM were detectable.	Cycloheximide	15-28	cholecystokinin	Homo sapiens	127-130
2480463-2	1989	Treatment with cycloheximide increased the sensitivity and responsiveness of isolated rat pancreatic acini to CCK-octapeptide (CCK-8) and thus plasma levels of CCK-8 as low was 0.17 pM were detectable.	Cycloheximide	15-28	cholecystokinin	Homo sapiens	127-130
2554289-5	1989	cAMP-stimulated accumulation of P450scc mRNA continued in the presence of cycloheximide.	Cycloheximide	74-87	cytochrome P450, family 11, subfamily a, polypeptide 1	Mus musculus	32-39
2551690-14	1989	Activation of the MAP2 kinase occurred shortly after the addition of EGF or phorbol ester even in the presence of protein synthesis inhibitors (cycloheximide, puromycin and emetin).	Cycloheximide	144-157	microtubule associated protein 2	Homo sapiens	18-22
2768276-2	1989	Incubations in cycloheximide led to a marked increase in LDL receptor mRNA abundance as detected by Northern or slot-blot hybridization analyses.	Cycloheximide	15-28	low density lipoprotein receptor	Homo sapiens	57-69
2768276-4	1989	After the addition of cycloheximide, induction of LDL receptor mRNA levels was rapid (peaking between 2 and 3 h) and transient (falling to control levels by 24 h).	Cycloheximide	22-35	low density lipoprotein receptor	Homo sapiens	50-62
2768276-5	1989	This incubation could not be accounted for by the modest stabilization of mature LDL receptor mRNA species produced by cycloheximide and was completely abolished by concurrent addition of actinomycin D.	Cycloheximide	119-132	low density lipoprotein receptor	Homo sapiens	81-93
2768276-6	1989	Nuclear run-off transcription assays demonstrated increased LDL receptor gene transcription after 20-min incubations in cycloheximide.	Cycloheximide	120-133	low density lipoprotein receptor	Homo sapiens	60-72
2768276-7	1989	Induction of LDL receptor mRNA by cycloheximide was partially resistant to sterol suppression and was at least additive with induction produced by growth activation of cells using platelet-derived growth factors.	Cycloheximide	34-47	low density lipoprotein receptor	Homo sapiens	13-25
2788520-9	1989	However, we could only detect IL6 message in cells incubated with LPS under "superinduction" conditions with cycloheximide, consistent with lower levels of IL6 biological activity in response to LPS compared to IL1 stimulation.	Cycloheximide	109-122	interleukin 6	Homo sapiens	30-33
2583364-0	1989	Dexamethasone control of growth hormone mRNA levels in GH3 pituitary cells is cycloheximide-sensitive and primarily posttranscriptional.	Cycloheximide	78-91	gonadotropin releasing hormone receptor	Rattus norvegicus	25-39
2583364-3	1989	In GH3 cells pretreated for 2 h with cycloheximide, the rise in nuclear and cytoplasmic GH mRNA levels mediated by dexamethasone was blocked completely.	Cycloheximide	37-50	gonadotropin releasing hormone receptor	Rattus norvegicus	3-5
2583364-5	1989	These data suggest that the stimulation of GH mRNA levels by glucocorticoids is initiated within the nucleus and that cycloheximide-sensitive events are essential for this stimulation to occur.	Cycloheximide	118-131	gonadotropin releasing hormone receptor	Rattus norvegicus	43-45
2550931-0	1989	Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.	Cycloheximide	79-92	thrombomodulin	Mus musculus	17-31
2550931-2	1989	Cycloheximide, an inhibitor of protein synthesis, increased levels of thrombomodulin mRNA, as measured in an S1 nuclease protection assay, to 2.5-4.0 times control levels.	Cycloheximide	0-13	thrombomodulin	Mus musculus	70-84
2550931-3	1989	Thrombomodulin transcription in response to cycloheximide treatment, as determined by nuclear run-on analysis, was 3.9 +/- 1.3 (mean +/- SD) times that found in untreated cells.	Cycloheximide	44-57	thrombomodulin	Mus musculus	0-14
2550931-8	1989	We conclude that thrombomodulin expression is determined in part by the rate of transcription and that thrombomodulin mRNA levels in hemangioma cells are increased by treatment with cycloheximide or thrombin.	Cycloheximide	182-195	thrombomodulin	Mus musculus	17-31
2550931-8	1989	We conclude that thrombomodulin expression is determined in part by the rate of transcription and that thrombomodulin mRNA levels in hemangioma cells are increased by treatment with cycloheximide or thrombin.	Cycloheximide	182-195	thrombomodulin	Mus musculus	103-117
2550931-9	1989	The increased transcription in response to cycloheximide suggests the existence of a labile protein repressor of thrombomodulin transcription.	Cycloheximide	43-56	thrombomodulin	Mus musculus	113-127
2547768-8	1989	Treatment with 50 microM cycloheximide abolished the ACTH-induced increases in inositol polyphosphate responses during AII stimulation, but had no effect on the responses of untreated cells to AII.	Cycloheximide	25-38	proopiomelanocortin	Homo sapiens	53-57
2547768-8	1989	Treatment with 50 microM cycloheximide abolished the ACTH-induced increases in inositol polyphosphate responses during AII stimulation, but had no effect on the responses of untreated cells to AII.	Cycloheximide	25-38	angiotensinogen	Homo sapiens	119-122
2546742-6	1989	TSH, acting within 5 min, induced a modest increase in transferrin binding, due to a cycloheximide-resistant increase in binding sites.	Cycloheximide	85-98	transferrin	Rattus norvegicus	55-66
2788596-2	1989	Nuclease which degrades chromatin produces in vivo fragments of nucleosomal size; the double-strand breaks appear as the result of the accumulation of single-strand breaks with 3"-OH ends; the nuclease is inhibited by Zn2+ and DTNB and its activity is depressed by cycloheximide pretreatment.	Cycloheximide	265-278	dystrobrevin beta	Homo sapiens	227-231
2554685-4	1989	Induction of ODC activity by PTH was partly inhibited by actinomycin D and cycloheximide, with 40 and 55% inhibition, respectively.	Cycloheximide	75-88	ornithine decarboxylase 1	Rattus norvegicus	13-16
2501387-6	1989	Cycloheximide (CHX) treatment altered the rate of PAI-1 and t-PA mRNA accumulation, but both were able to increase in the absence of protein synthesis.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	50-55
2501387-6	1989	Cycloheximide (CHX) treatment altered the rate of PAI-1 and t-PA mRNA accumulation, but both were able to increase in the absence of protein synthesis.	Cycloheximide	0-13	plasminogen activator, tissue type	Homo sapiens	60-64
2501387-6	1989	Cycloheximide (CHX) treatment altered the rate of PAI-1 and t-PA mRNA accumulation, but both were able to increase in the absence of protein synthesis.	Cycloheximide	15-18	serpin family E member 1	Homo sapiens	50-55
2501387-6	1989	Cycloheximide (CHX) treatment altered the rate of PAI-1 and t-PA mRNA accumulation, but both were able to increase in the absence of protein synthesis.	Cycloheximide	15-18	plasminogen activator, tissue type	Homo sapiens	60-64
2501387-8	1989	The increase in u-PA message level was augmented in a synergistic fashion by CHX.	Cycloheximide	77-80	plasminogen activator, urokinase	Homo sapiens	16-20
2473991-2	1989	BP-28 was produced by fetal liver explants at approximately 200 ng/mg total tissue protein.day between days 3 and 6 in culture and was inhibited 60% after 3-day exposure to cycloheximide (10 micrograms/mL).	Cycloheximide	173-186	BP28	Homo sapiens	0-5
2477086-9	1989	The c-jun transcripts in myelomonocytic cells have a half-life of approximately 20 minutes and are superinduced by cycloheximide, which affects both the degradation rate of mRNA and the transcriptional activity of the c-jun gene.	Cycloheximide	115-128	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	218-223
2677674-12	1989	However, erg6 delta cells exhibit pleiotropic phenotypes that include defective conjugation, hypersensitivity to cycloheximide, resistance to nystatin, a severely diminished capacity for genetic transformation, and defective tryptophan uptake.	Cycloheximide	113-126	sterol 24-C-methyltransferase	Saccharomyces cerevisiae S288C	9-13
2787453-10	1989	In contrast, no IL-1 beta message was detectable, not even after treatment of the cells with phorbol ester or cycloheximide, which resulted in approximately 5-fold enhancement of IL-1 alpha mRNA expression.	Cycloheximide	110-123	interleukin 1 alpha	Homo sapiens	179-189
2739725-4	1989	We now report that a synthetic copy of the c-fos SRE is sufficient to confer cycloheximide-dependent inducibility upon a heterologous promoter.	Cycloheximide	77-90	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-48
2476035-5	1989	Local intradermal injections of actinomycin D, cycloheximide or puromycin could inhibit in a dose- and time-dependent manner neutrophil emigration induced by interleukin-1, tumor necrosis factor alpha or endotoxin, but not by the leukocyte chemoattractants C5a des arg (zymosan-activated plasma), n-formyl-methionyl-leucyl-phenylalanine or leukotriene B4.	Cycloheximide	47-60	tumor necrosis factor	Oryctolagus cuniculus	158-200
2568860-11	1989	G/M-CSF mRNA levels were "superinduced" by the combination of LPS and cycloheximide, a protein synthesis inhibitor.	Cycloheximide	70-83	colony stimulating factor 1 (macrophage)	Mus musculus	2-7
2731170-3	1989	Stimulative effects of estrogen on both cell growth and synthesis/secretion of pS2 protein were inhibited completely by actinomycin D, cycloheximide, and antiestrogen.	Cycloheximide	135-148	taste 2 receptor member 64 pseudogene	Homo sapiens	79-82
2736628-4	1989	Both TGF-beta 1-induced and basal levels of fibronectin were completely abolished by cycloheximide, suggesting that protein synthesis was required.	Cycloheximide	85-98	transforming growth factor, beta 1	Mus musculus	5-15
2736628-4	1989	Both TGF-beta 1-induced and basal levels of fibronectin were completely abolished by cycloheximide, suggesting that protein synthesis was required.	Cycloheximide	85-98	fibronectin 1	Mus musculus	44-55
2791215-4	1989	The half-life of ODC activity, measured after cycloheximide treatment, increased almost six-fold after addition of sodium arsenite.	Cycloheximide	46-59	ornithine decarboxylase 1	Homo sapiens	17-20
2544397-9	1989	Suppression of protein synthesis by cycloheximide inhibited the induction of tPA mRNA by EGF, whereas similar treatment resulted in the superinduction of tPA mRNA in FSH-treated cells, suggesting that EGF and FSH do not share the same pathway.	Cycloheximide	36-49	plasminogen activator, tissue type	Rattus norvegicus	77-80
2544397-9	1989	Suppression of protein synthesis by cycloheximide inhibited the induction of tPA mRNA by EGF, whereas similar treatment resulted in the superinduction of tPA mRNA in FSH-treated cells, suggesting that EGF and FSH do not share the same pathway.	Cycloheximide	36-49	epidermal growth factor like 1	Rattus norvegicus	89-92
2544400-3	1989	The administration of cycloheximide with ACTH resulted in a 73% decrease in reductase activity compared to control values, but did not prevent the enhancing effect of ACTH on the reductase mRNA level.	Cycloheximide	22-35	proopiomelanocortin	Homo sapiens	41-45
2544400-8	1989	Thus, we have shown that both cycloheximide and aminoglutethimide can prevent the enhancing effect of ACTH on HMG-CoA reductase activity, but their modes of action differ.	Cycloheximide	30-43	proopiomelanocortin	Homo sapiens	102-106
2544400-11	1989	As for the ACTH-cycloheximide-treated groups, the adrenal free cholesterol content was also increased, but the effect of ACTH on the reductase mRNA level was not prevented, presumably because this drug blocked the synthesis of a putative sterol regulatory protein that is required to repress HMG-CoA reductase gene transcription.	Cycloheximide	16-29	proopiomelanocortin	Homo sapiens	11-15
2551669-8	1989	Expression of the translocated c-myc alleles was also affected by TPA; however, only if cycloheximide was simultaneously present.	Cycloheximide	88-101	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	31-36
2551669-9	1989	TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations.	Cycloheximide	9-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
2551669-9	1989	TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations.	Cycloheximide	118-131	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	158-163
2551669-9	1989	TPA plus cycloheximide induced a rapid decrease of c-myc RNA derived from the translocated allele within 6 h, whereas cycloheximide alone led to abolition of c-myc RNA after 16-24 h. This rapid decline of c-myc RNA was observed in Raji and BL41 cells, but not in three cell lines with variant t(2;8) and t(8;22) translocations.	Cycloheximide	118-131	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	158-163
2501229-8	1989	The addition of cycloheximide or actinomycin D to the thrombin-treated cultures resulted in a reduction of t-PA levels in the media.	Cycloheximide	16-29	coagulation factor II, thrombin	Bos taurus	54-62
2501229-8	1989	The addition of cycloheximide or actinomycin D to the thrombin-treated cultures resulted in a reduction of t-PA levels in the media.	Cycloheximide	16-29	plasminogen activator, tissue type	Bos taurus	107-111
2550486-4	1989	Two separable processes control the desensitization of the EGF receptor by pp60v-src, both of which are independent of protein kinase C. The first is rapid and transient, while the second is sensitive to cycloheximide and persists long after inactivation of pp60v-src.	Cycloheximide	204-217	epidermal growth factor	Mus musculus	59-62
2526195-3	1989	These receptors are synthesized de novo by the LC since cycloheximide completely inhibits the appearance of Fc epsilon R2/CD23.	Cycloheximide	56-69	Fc epsilon receptor II	Homo sapiens	122-126
2471731-2	1989	Preincubation of monocytes in 100 U/ml IFN-gamma or in 0.25 microgram/ml cycloheximide (Cx) leads to a partial maintenance of the ability to produce IL-1 in response to subsequent stimulation with LPS, whereas preincubation in both reagents leads to a near complete maintenance of this response.	Cycloheximide	73-86	interleukin 1 beta	Homo sapiens	149-153
2471731-2	1989	Preincubation of monocytes in 100 U/ml IFN-gamma or in 0.25 microgram/ml cycloheximide (Cx) leads to a partial maintenance of the ability to produce IL-1 in response to subsequent stimulation with LPS, whereas preincubation in both reagents leads to a near complete maintenance of this response.	Cycloheximide	88-90	interleukin 1 beta	Homo sapiens	149-153
2471731-9	1989	Cx preincubation led to increases in both the peak and duration of transcription as well as to enhanced secretion of IL-1 beta protein.	Cycloheximide	0-2	interleukin 1 beta	Homo sapiens	117-126
2477692-0	1989	The transcriptional response of the human chorionic gonadotropin beta-subunit gene to cAMP is cycloheximide sensitive and is mediated by cis-acting sequences different from that found in the alpha-subunit gene.	Cycloheximide	94-107	chorionic gonadotropin subunit beta 3	Homo sapiens	42-77
2476654-7	1989	The accumulation of the arylsulfatase transcript is also suppressed by the addition of cycloheximide.	Cycloheximide	87-100	uncharacterized protein	Chlamydomonas reinhardtii	24-37
2552298-3	1989	After treatment of JEG-3 choriocarcinoma cells with cycloheximide, basal levels of alpha and CG beta mRNAs decreased over 12 h to 27% and 13% of control values, respectively.	Cycloheximide	52-65	chorionic gonadotropin subunit beta 3	Homo sapiens	93-100
16666905-6	1989	NR was synthesized de novo, since cycloheximide completely blocked its induction.	Cycloheximide	34-47	nitrate reductase [NADH] 1	Zea mays	0-2
2501786-7	1989	Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells.	Cycloheximide	44-57	plasminogen activator, urokinase	Homo sapiens	25-29
2501786-7	1989	Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells.	Cycloheximide	194-207	plasminogen activator, urokinase	Homo sapiens	25-29
2501786-7	1989	Inhibition of endogenous u-PA production by cycloheximide reduced [3H]thymidine incorporation significantly; after addition of exogenous u-PA, [3H]thymidine incorporation increased again in the cycloheximide-treated cells.	Cycloheximide	194-207	plasminogen activator, urokinase	Homo sapiens	137-141
2499579-11	1989	In fact, treatment with cycloheximide (2 micrograms/ml) alone also increased PAI-1 mRNA levels.	Cycloheximide	24-37	serpin family E member 1	Bos taurus	77-82
2499579-12	1989	Treatment with cycloheximide in combination with TGF-beta, LPS, or TNF-alpha further enhanced the accumulation of PAI-1 mRNA.	Cycloheximide	15-28	serpin family E member 1	Bos taurus	114-119
2760930-3	1989	alpha-Tubulin poly(A) tail lengths were measured during normal accumulation and degradation, and in cycloheximide-treated cells.	Cycloheximide	100-113	tubulin alpha 1b	Homo sapiens	0-13
2760930-8	1989	A large fraction of alpha-tubulin mRNA accumulates as mRNA with very short poly(A) tails (less than 10 residues) in the presence of cycloheximide, indicating that deadenylated alpha-tubulin mRNAs can be stable in vivo, at least in the absence of protein synthesis.	Cycloheximide	132-145	tubulin alpha 1b	Homo sapiens	20-33
2500119-8	1989	Cycloheximide superinduced the expression of c-fos, egr-1 and c-myc after PMA treatment; INDO inhibited this superinduction.	Cycloheximide	0-13	FBJ osteosarcoma oncogene	Mus musculus	45-50
2500119-8	1989	Cycloheximide superinduced the expression of c-fos, egr-1 and c-myc after PMA treatment; INDO inhibited this superinduction.	Cycloheximide	0-13	early growth response 1	Mus musculus	52-57
2527495-7	1989	The turnover of the Raji IL-1 receptor, measured by inhibiting protein synthesis with cycloheximide, was much faster than that of the EL4 IL-1 receptor, with a half-time of 2 h as against 5 h. Treatment of 125I-IL-1-labelled IL-1 receptors in Raji and EL4 cells with neuraminidase decreased their molecular mass by approx.	Cycloheximide	86-99	interleukin 1 alpha	Homo sapiens	25-29
2542313-9	1989	The addition of actinomycin D or cycloheximide reversed the heparin-induced increase in H-TGL activity and mRNA.	Cycloheximide	33-46	lipase C, hepatic type	Homo sapiens	88-93
2552772-0	1989	Cycloheximide inhibits the induction of collagenase mRNA in chondrocytes exposed to synovial factors or recombinant interleukin-1.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	116-129
2475226-9	1989	Following exposure to cycloheximide, AFP and albumin levels in HuH-6 were inhibited.	Cycloheximide	22-35	alpha fetoprotein	Homo sapiens	37-40
2477692-0	1989	The transcriptional response of the human chorionic gonadotropin beta-subunit gene to cAMP is cycloheximide sensitive and is mediated by cis-acting sequences different from that found in the alpha-subunit gene.	Cycloheximide	94-107	cathelicidin antimicrobial peptide	Homo sapiens	86-90
2766930-1	1989	Simultaneous treatment of the rat hepatocyte-derived cell line LCS7 with cycloheximide and polycyclic aromatic compounds increased CYP1A1 (cytochrome P450c) gene transcription rate four- to sixfold and mRNA levels 20-fold relative to the levels in cells treated with inducers alone.	Cycloheximide	73-86	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	131-137
2766930-1	1989	Simultaneous treatment of the rat hepatocyte-derived cell line LCS7 with cycloheximide and polycyclic aromatic compounds increased CYP1A1 (cytochrome P450c) gene transcription rate four- to sixfold and mRNA levels 20-fold relative to the levels in cells treated with inducers alone.	Cycloheximide	73-86	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	139-155
2766930-4	1989	Thus, treatment with cycloheximide revealed two phases to the response of the CYP1A1 gene to inducer.	Cycloheximide	21-34	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	78-84
2766930-9	1989	All of these exhibited elevated levels of CYP1A1 mRNA following simultaneous treatment with inducer and cycloheximide; transcription rate was superinduced three- to fourfold in primary hepatocytes, and CYP1A1 mRNA levels were superinduced 20- to 25-fold in both kidney and lung explants.	Cycloheximide	104-117	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	42-48
2502420-7	1989	Second, the expression of I-A beta was inhibited when cells were treated with both IFN-gamma and cycloheximide, while the expression of TNF and C3 was not.	Cycloheximide	97-110	histocompatibility 2, class II antigen A, beta 1	Mus musculus	26-34
2502420-8	1989	Interestingly, the sensitivity to cycloheximide only lasted 30 min following the addition of IFN-gamma, after which cycloheximide had no effect on the expression of I-A beta.	Cycloheximide	34-47	interferon gamma	Mus musculus	93-102
2553500-4	1989	Pretreatment of atrial cells with cycloheximide does not change the effect of insulin on the fast calcium current but dramatically facilitates the insulin-induced activation of the slower calcium current.	Cycloheximide	34-47	insulin	Canis lupus familiaris	147-154
2545528-5	1989	In a single-cell culture, GBF activity is inducible by cAMP, and its appearance is inhibited by cycloheximide, which suggests that the factor, or a protein component required for binding of the factor, is directly induced by cAMP and may be the rate-limiting factor required for cAMP induction of pst-cathepsin expression.	Cycloheximide	96-109	Kruppel like factor 6	Homo sapiens	26-29
2545586-6	1989	The up-regulation of IGF-I binding was unaffected by treatment with 0.1 mM cycloheximide, but was blunted by 5 microM colchicine.	Cycloheximide	75-88	insulin like growth factor 1	Homo sapiens	21-26
2542003-5	1989	This effect of TSH on TPO mRNA accumulation in FRTL5 cells was time related (it was already present after 4 h and was maximal after 24 h of cell exposure to TSH), dose related (0.01 and 1 mU/ml were, respectively, the lowest and the maximally effective doses), and independent of new protein synthesis, in that it was not prevented by cycloheximide (100 microM).	Cycloheximide	335-348	thyroid peroxidase	Rattus norvegicus	22-25
2500449-8	1989	Stability of IL-1 beta mRNA in fibroblasts exposed to TPA was more than fourfold greater than after fibroblasts were exposed to either TNF alpha or cycloheximide.	Cycloheximide	148-161	interleukin 1 beta	Homo sapiens	13-22
2786549-9	1989	The acquisition of cell resistance to perforin by these IL-2-independent cell lines after activation with stimulatory reagents was independent of protein and RNA neosynthesis: emetine, cycloheximide, and actinomycin D, while effectively blocking the incorporation of [35S]methionine into cell proteins, did not affect the induced increase in perforin resistance.	Cycloheximide	185-198	interleukin 2	Homo sapiens	56-60
2786047-5	1989	Fn release by exudate cells during adherence purification was less affected by cycloheximide treatment than was subsequent Fn secretion by purified macrophages.	Cycloheximide	79-92	fibronectin 1	Rattus norvegicus	0-2
2498530-6	1989	The accumulation of this mRNA is markedly increased in PM treated with LPS or IFN-gamma, and it is further enhanced in the presence of the inhibitor of protein synthesis, cycloheximide.	Cycloheximide	171-184	toll-like receptor 4	Mus musculus	71-74
2498530-6	1989	The accumulation of this mRNA is markedly increased in PM treated with LPS or IFN-gamma, and it is further enhanced in the presence of the inhibitor of protein synthesis, cycloheximide.	Cycloheximide	171-184	interferon gamma	Mus musculus	78-87
2474468-0	1989	Effects of cycloheximide on hepatic and uterine insulin-like growth factor-I mRNA.	Cycloheximide	11-24	insulin-like growth factor 1	Rattus norvegicus	48-76
2474468-3	1989	Administration of cycloheximide 30 min prior to GH injection completely abolished this response.	Cycloheximide	18-31	gonadotropin releasing hormone receptor	Rattus norvegicus	48-50
2474468-4	1989	In contrast, in pituitary intact rats killed 6 h after administration of cycloheximide, hepatic IGF-I mRNA abundance was not significantly different from untreated control rats although the serum IGF-I concentration was significantly reduced; 119.9 +/- 11.8 vs. 270.2 +/- 48.7 ng/ml, P less than 0.005.	Cycloheximide	73-86	insulin-like growth factor 1	Rattus norvegicus	96-101
2474468-4	1989	In contrast, in pituitary intact rats killed 6 h after administration of cycloheximide, hepatic IGF-I mRNA abundance was not significantly different from untreated control rats although the serum IGF-I concentration was significantly reduced; 119.9 +/- 11.8 vs. 270.2 +/- 48.7 ng/ml, P less than 0.005.	Cycloheximide	73-86	insulin-like growth factor 1	Rattus norvegicus	196-201
2474468-6	1989	Cycloheximide did not block the E2-induced increase in IGF-I mRNA but rather significantly enhanced the IGF-I response.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	104-109
2765502-6	1989	Addition of cycloheximide (CHX) to undifferentiated THP-1 cells resulted in a transient increase in steady-state mRNA levels (3-fold).	Cycloheximide	12-25	GLI family zinc finger 2	Homo sapiens	52-57
2765502-6	1989	Addition of cycloheximide (CHX) to undifferentiated THP-1 cells resulted in a transient increase in steady-state mRNA levels (3-fold).	Cycloheximide	27-30	GLI family zinc finger 2	Homo sapiens	52-57
2542296-2	1989	The c-jun transcripts increase within 15 min after NGF addition, peak at 1 h, and decline to basal level by 4 h. Actinomycin D inhibits the increase, and cycloheximide prevents the decrease of c-jun mRNA.	Cycloheximide	154-167	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
2542296-2	1989	The c-jun transcripts increase within 15 min after NGF addition, peak at 1 h, and decline to basal level by 4 h. Actinomycin D inhibits the increase, and cycloheximide prevents the decrease of c-jun mRNA.	Cycloheximide	154-167	nerve growth factor	Rattus norvegicus	51-54
2542296-2	1989	The c-jun transcripts increase within 15 min after NGF addition, peak at 1 h, and decline to basal level by 4 h. Actinomycin D inhibits the increase, and cycloheximide prevents the decrease of c-jun mRNA.	Cycloheximide	154-167	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	193-198
2540196-2	1989	In contrast to the c-fos gene, induction of the thyroglobulin gene by TSH or cAMP is slow (10 h) and sensitive to cycloheximide treatment.	Cycloheximide	114-127	thyroglobulin	Rattus norvegicus	48-61
2785770-5	1989	Moreover, perfusion with 20-100 micrograms/ml cycloheximide, an inhibitor of protein synthesis, blocked the TNF-induced impairment of the relaxation to ACh.	Cycloheximide	46-59	tumor necrosis factor	Homo sapiens	108-111
2541929-7	1989	This is in contrast to the protein synthesis inhibitor, cycloheximide, which leads to a stabilization of TNF-alpha mRNA.	Cycloheximide	56-69	tumor necrosis factor	Mus musculus	105-114
2498115-9	1989	The half-life of ODC in procyclic forms grown in the presence of cycloheximide was greater than 6 hr, while that of bloodstream trypomastigotes in mice treated with cycloheximide was 5 hr.	Cycloheximide	65-78	ornithine decarboxylase, structural 1	Mus musculus	17-20
2498115-9	1989	The half-life of ODC in procyclic forms grown in the presence of cycloheximide was greater than 6 hr, while that of bloodstream trypomastigotes in mice treated with cycloheximide was 5 hr.	Cycloheximide	165-178	ornithine decarboxylase, structural 1	Mus musculus	17-20
2541139-5	1989	In both fibroblasts strains, stimulation of EGR1 expression by all these agents exhibited rapid, transient kinetics and could be superinduced if protein synthesis was inhibited through the addition of cycloheximide.	Cycloheximide	201-214	early growth response 1	Homo sapiens	44-48
2715194-4	1989	The parallel rise in antigenically positive protein and procoagulant activity was first observed about 2 h after serum stimulation with a peak at 12 h followed by a slow decline during the next 36 h. The serum-induced synthesis of the tissue factor mRNA was independent of de novo protein synthesis as demonstrated by the increased tissue factor mRNA levels generated in the presence of cycloheximide.	Cycloheximide	387-400	coagulation factor III, tissue factor	Homo sapiens	235-248
2542953-4	1989	The increase in the two mRNAs appears interrelated because cycloheximide inhibits the accumulation of c-Fos protein and NGF mRNA elicited by isoproterenol.	Cycloheximide	59-72	FBJ osteosarcoma oncogene	Mus musculus	102-107
2542953-4	1989	The increase in the two mRNAs appears interrelated because cycloheximide inhibits the accumulation of c-Fos protein and NGF mRNA elicited by isoproterenol.	Cycloheximide	59-72	nerve growth factor	Mus musculus	120-123
2540967-9	1989	Pretreatment of SMC with actinomycin D or cycloheximide completely suppresses basal and cAMP-stimulated secretion of phospholipase A2 activity, thus demonstrating that transcription and protein synthesis are necessary for enzyme release.	Cycloheximide	42-55	phospholipase A2 group IB	Rattus norvegicus	117-133
2651161-2	1989	Infusions of gonadotropin-releasing hormone (GnRH) or PMA in a perifusion system stimulated a partial secretion of LH from diestrous II and ovariectomized + estradiol-treated female pituitaries (responses inhibited by cycloheximide).	Cycloheximide	218-231	gonadotropin releasing hormone 1	Homo sapiens	13-43
2649169-4	1989	However, unlike its ligand, cycloheximide studies indicated that internalized mIL-3 receptors are recycled to the cell surface.	Cycloheximide	28-41	interleukin 3	Mus musculus	78-83
2661062-7	1989	Readdition of TSH (0.1-100 mU/ml) to cells lacking M/TPO-Ag elicited its reappearance within 48-72 h. This effect of TSH was prevented by 10 microM cycloheximide but not by methimazole (0.1-2 mM).	Cycloheximide	148-161	thyroid peroxidase	Homo sapiens	53-56
2497277-7	1989	The cytotoxicity of IFN-gamma, in contrast to that of TNF is inhibited by actinomycin or cycloheximide.	Cycloheximide	89-102	interferon gamma	Mus musculus	20-29
2497277-7	1989	The cytotoxicity of IFN-gamma, in contrast to that of TNF is inhibited by actinomycin or cycloheximide.	Cycloheximide	89-102	tumor necrosis factor	Mus musculus	54-57
2494994-0	1989	Transient increase in the c-fos mRNA level after change of culture condition from serum absence to serum presence and after cycloheximide addition in rat 3Y1 fibroblasts.	Cycloheximide	124-137	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	26-31
2494994-2	1989	Subsequent serum deprivation followed by serum re-addition or subsequent cycloheximide addition caused a transient re-increase in the c-fos mRNA level.	Cycloheximide	73-86	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	134-139
2784674-5	1989	Pretreatment of cells with actinomycin D or cycloheximide inhibits basal and cytokine-stimulated PGE2 and PLA2 release.	Cycloheximide	44-57	phospholipase A2 group IB	Homo sapiens	106-110
2925656-2	1989	TNF is not toxic to either adipocytes or preadipocytes when used alone but is highly toxic to these cells when used in conjunction with cycloheximide, yielding virtually 100% killing within 4-6 h of treatment.	Cycloheximide	136-149	tumor necrosis factor	Homo sapiens	0-3
2925656-6	1989	The adipocyte differentiation-inducing agents, dexamethasone and indomethacin, block the cytotoxicity induced by TNF alone in the TA1 R-6 line but do not block the rapid cytotoxicity of TNF and cycloheximide in the parental line.	Cycloheximide	194-207	tumor necrosis factor	Homo sapiens	113-116
2569873-5	1989	The increase of asparagine synthetase activity was inhibited by cycloheximide and somewhat by actinomycin D, suggesting de novo enzyme synthesis during the stimulation.	Cycloheximide	64-77	asparagine synthetase	Mus musculus	16-37
2500672-0	1989	Effects of 5-HT2 receptor antagonist on cycloheximide-induced amnesia in mice.	Cycloheximide	40-53	hypothermia due to alcohol sensitivity 2	Mus musculus	13-16
2550695-7	1989	Stimulation of ecto-5"-nucleotidase activity by MCM was inhibited by cycloheximide, which suggests that protein synthesis was required.	Cycloheximide	69-82	5' nucleotidase, ecto	Rattus norvegicus	15-35
2546063-8	1989	3) Induction of CRABP mRNA by RA was blocked by the protein synthesis inhibitor cycloheximide, whereas induction of CRBP mRNA was not.	Cycloheximide	80-93	cellular retinoic acid binding protein 1	Homo sapiens	16-21
2537976-6	1989	However, in a third cell line (JY), cycloheximide blocked viral induction of the interferon beta gene but not the TNF-alpha gene.	Cycloheximide	36-49	interferon beta 1	Homo sapiens	81-96
2538821-6	1989	We also identified another early gene, F9, whose expression is stimulated upon starvation, is not responsive to cAMP, and is hyperstimulated by cycloheximide, in a manner similar to the cycloheximide stimulation of c-fos and other serum-induced genes in mammalian cells.	Cycloheximide	186-199	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	215-220
2464596-4	1989	The actions of phorbol esters are only seen in those types of cultured cells where cycloheximide in the presence of IFN prevents long term IFN treatment of cells from inducing a "desensitized state."	Cycloheximide	83-96	interferon alpha 1	Homo sapiens	139-142
2914963-4	1989	The induction of ornithine decarboxylase by both NGF and PMA is inhibited by cycloheximide and actinomycin D suggesting that both agents increase enzyme activity by increasing gene transcription.	Cycloheximide	77-90	ornithine decarboxylase 1	Rattus norvegicus	17-40
2914963-4	1989	The induction of ornithine decarboxylase by both NGF and PMA is inhibited by cycloheximide and actinomycin D suggesting that both agents increase enzyme activity by increasing gene transcription.	Cycloheximide	77-90	nerve growth factor	Rattus norvegicus	49-52
2463877-7	1989	Cycloheximide blocked this enhanced turnover of p60src, but did not block the herbimycin-induced inactivation of p60src kinase.	Cycloheximide	0-13	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	48-54
2493244-3	1989	Cycloheximide and other metabolic inhibitors did not alter the modulation but inhibited significantly the re-expression of CD4.	Cycloheximide	0-13	CD4 molecule	Homo sapiens	123-126
2464942-10	1989	MDGF secretion by bleomycin-stimulated alveolar macrophages was inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguairetic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity(ABSTRACT TRUNCATED AT 250 WORDS)	Cycloheximide	77-90	pro-platelet basic protein	Mus musculus	0-4
2469744-4	1989	Cycloheximide combined with chloramphenicol further inhibited the antiviral effect of IFN than that observed by either drug alone.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	86-89
2469009-10	1989	In contrast, cycloheximide alone causes an increase in tPA mRNA, and in combination with dexamethasone, no further increase is observed.	Cycloheximide	13-26	plasminogen activator, tissue type	Rattus norvegicus	55-58
2523515-6	1989	The half-life of c-fms transcripts in TPA-induced HL-60 cells was found to be at least 6 h, while inhibition of protein synthesis with cycloheximide (CHX) decreased this half-life to 4 h. Moreover, inhibition of protein synthesis was associated with decreases in c-fms mRNA levels and a block in the induction of c-fms transcripts by TPA.	Cycloheximide	150-153	colony stimulating factor 1 receptor	Homo sapiens	263-268
2523515-6	1989	The half-life of c-fms transcripts in TPA-induced HL-60 cells was found to be at least 6 h, while inhibition of protein synthesis with cycloheximide (CHX) decreased this half-life to 4 h. Moreover, inhibition of protein synthesis was associated with decreases in c-fms mRNA levels and a block in the induction of c-fms transcripts by TPA.	Cycloheximide	150-153	colony stimulating factor 1 receptor	Homo sapiens	263-268
2537240-7	1989	An accumulation of receptors at the cell surface was observed in the absence of de novo protein synthesis, since cycloheximide caused a significant increase in insulin binding to the cells.	Cycloheximide	113-126	insulin	Homo sapiens	160-167
2723482-6	1989	Cycloheximide significantly decreased the concentrations of CA125 in the medium and in tissues of the eutopic and heterotopic endometrium.	Cycloheximide	0-13	mucin 16, cell surface associated	Homo sapiens	60-65
2919164-4	1989	Transcriptional induction of both LDL-R and HMG-CoA reductase genes (5.6- and 2-fold, respectively) was also observed when undifferentiated cells were treated with cycloheximide (CHX), resulting in a transient increase in steady-state mRNA (7- and 3-fold, respectively).	Cycloheximide	164-177	low density lipoprotein receptor	Homo sapiens	34-39
2919164-4	1989	Transcriptional induction of both LDL-R and HMG-CoA reductase genes (5.6- and 2-fold, respectively) was also observed when undifferentiated cells were treated with cycloheximide (CHX), resulting in a transient increase in steady-state mRNA (7- and 3-fold, respectively).	Cycloheximide	179-182	low density lipoprotein receptor	Homo sapiens	34-39
2718149-4	1989	Cycloheximide by itself induced the accumulation of high levels of tissue factor mRNA in these cells.	Cycloheximide	0-13	coagulation factor III, tissue factor	Homo sapiens	67-80
2492191-4	1989	Cycloheximide potentiated the c-fos induction by both EGF and antibody.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
2492191-4	1989	Cycloheximide potentiated the c-fos induction by both EGF and antibody.	Cycloheximide	0-13	epidermal growth factor	Homo sapiens	54-57
2535781-2	1989	Cycloheximide (0.1 micrograms/ml) blocked the elevation in ACE produced by A23187.	Cycloheximide	0-13	angiotensin I converting enzyme	Bos taurus	59-62
2912446-5	1989	This suppression was abolished when L-929 cells were treated with actinomycin D or cycloheximide, suggesting that TGF-beta might inhibit the action of TNF via de novo protein synthesis.	Cycloheximide	83-96	transforming growth factor, beta 1	Mus musculus	114-122
2912446-5	1989	This suppression was abolished when L-929 cells were treated with actinomycin D or cycloheximide, suggesting that TGF-beta might inhibit the action of TNF via de novo protein synthesis.	Cycloheximide	83-96	tumor necrosis factor	Mus musculus	151-154
2492047-9	1989	Cycloheximide inhibited IFN-gamma production, but did not inhibit exocytosis of BLTE activity or cytolysis.	Cycloheximide	0-13	interferon gamma	Mus musculus	24-33
2785495-8	1989	Cycloheximide (Cy) inhibited the production of TNF-alpha.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	47-56
2785495-8	1989	Cycloheximide (Cy) inhibited the production of TNF-alpha.	Cycloheximide	0-2	tumor necrosis factor	Homo sapiens	47-56
2910855-10	1989	Inhibition of protein synthesis with cycloheximide completely prevented the sustained increase in LDL receptor mRNA levels measured after 24 h. Low concentrations of LDL (5 micrograms of cholesterol/ml) and oxygenated sterols also suppressed the level of LDL receptor mRNA measured after a 24-h incubation.	Cycloheximide	37-50	low density lipoprotein receptor	Homo sapiens	98-110
2910855-10	1989	Inhibition of protein synthesis with cycloheximide completely prevented the sustained increase in LDL receptor mRNA levels measured after 24 h. Low concentrations of LDL (5 micrograms of cholesterol/ml) and oxygenated sterols also suppressed the level of LDL receptor mRNA measured after a 24-h incubation.	Cycloheximide	37-50	low density lipoprotein receptor	Homo sapiens	255-267
2535847-5	1989	Furthermore, the effect of insulin on the FAS mRNA level was abolished by cycloheximide administration.	Cycloheximide	74-87	fatty acid synthase	Mus musculus	42-45
2785335-2	1989	IL 1 induced PMN leukocyte accumulation that was slow in onset, reaching a peak rate at 3-4 h and that was inhibitable by Actinomycin D and Cycloheximide.	Cycloheximide	140-153	interleukin 1 alpha	Homo sapiens	0-4
2912130-8	1989	The increase in [125I]ANG II-specific binding elicited by DOCA was abolished by cotreatment with the mineralocorticoid receptor blockers mespirenone or ZK97894 and by cotreatment with cycloheximide.	Cycloheximide	184-197	angiotensinogen	Rattus norvegicus	22-28
2492187-6	1989	In contrast, stimulation of t-PA synthesis was completely inhibited by actinomycin D and cycloheximide; partially inhibited by cytochalasin D, vinblastine, and trifluoperazine; and not affected by indomethacin.	Cycloheximide	89-102	plasminogen activator, tissue type	Homo sapiens	28-32
2605669-5	1989	The two independently collected fractions of ODC peaks exhibited different affinity for pyridoxal 5"-phosphate in vitro and sensitivity to cycloheximide in vivo.	Cycloheximide	139-152	ornithine decarboxylase 1	Rattus norvegicus	45-48
2540955-5	1989	This effect is correlated with the ability of phorbol ester and diacylglycerol analogues to activate protein kinase C. The TPA-induced phosphorylation of the L-myc protein occurs in a protein synthesis-independent manner as it is not inhibited by cycloheximide or anisomycin.	Cycloheximide	247-260	MYCL proto-oncogene, bHLH transcription factor	Homo sapiens	158-163
2909392-2	1989	N51 mRNA is rapidly induced by serum, including in the presence of cycloheximide, demonstrating that its induction does not require de novo protein synthesis.	Cycloheximide	67-80	chemokine (C-X-C motif) ligand 1	Mus musculus	0-3
2465936-5	1989	However, cycloheximide abolished the synergy between TRH and hpGRF.	Cycloheximide	9-22	thyrotropin releasing hormone	Gallus gallus	53-56
2732096-5	1989	Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA.	Cycloheximide	29-42	interferon beta 1	Homo sapiens	120-128
2732096-5	1989	Induction in the presence of cycloheximide and actinomycin D (superinduction conditions) exhibited an enhanced level of IFN-beta mRNA with a maximum at 4-8 h. The kinetics of the IFN-beta mRNA expression in the cytoplasm as revealed by in situ hybridization proved to be compatible with the results of Northern blotting experiments of total cellular RNA.	Cycloheximide	29-42	interferon beta 1	Homo sapiens	179-187
2473287-4	1989	The rapid induction of ppET-1 mRNA by TPA or ionomycin occurred even in the presence of cycloheximide, indicating that the mRNA induction does not require de novo protein synthesis.	Cycloheximide	88-101	endothelin 1	Homo sapiens	23-29
2561422-2	1989	DAF1-1 cells transferred into low cycloheximide express an increased G1 phase in their cycle, suggesting that G1 regulation is present but cryptic in the DAF1-1 cycle in rich medium.	Cycloheximide	34-47	cyclin CLN3	Saccharomyces cerevisiae S288C	0-4
2484967-2	1989	Cycloheximide decreased GTP cyclohydrolase I activity at 48 and 96 h, but had little effect on dihydropteridine reductase activity.	Cycloheximide	0-13	GTP cyclohydrolase 1	Rattus norvegicus	24-44
2491756-6	1989	Cycloheximide and actinomycin D were without effect on the early increase in ODC activity but inhibited the delayed increase in ODC activity, an observation suggesting that the initial increase in activity reflects an activation of a cryptic ODC via a posttranslational process, whereas the delayed increase in activity results from ODC synthesis mainly under transcriptional control.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	128-131
2491756-6	1989	Cycloheximide and actinomycin D were without effect on the early increase in ODC activity but inhibited the delayed increase in ODC activity, an observation suggesting that the initial increase in activity reflects an activation of a cryptic ODC via a posttranslational process, whereas the delayed increase in activity results from ODC synthesis mainly under transcriptional control.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	128-131
2491756-6	1989	Cycloheximide and actinomycin D were without effect on the early increase in ODC activity but inhibited the delayed increase in ODC activity, an observation suggesting that the initial increase in activity reflects an activation of a cryptic ODC via a posttranslational process, whereas the delayed increase in activity results from ODC synthesis mainly under transcriptional control.	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	128-131
2527510-4	1989	The steady-state level of IL-1 alpha mRNA in these cells could be drastically increased by a short culture of the cells with the protein synthesis inhibitor cycloheximide or with PMA.	Cycloheximide	157-170	interleukin 1 alpha	Homo sapiens	26-36
2561794-3	1989	Homologous down regulations of beta-adrenoceptors and VIP/helodermin receptors were less rapidly reversible and depended on protein synthesis as they were inhibited by cycloheximide: beta-adrenoceptors recovered faster than VIP/helodermin receptors.	Cycloheximide	168-181	vasoactive intestinal polypeptide	Mus musculus	54-57
2796592-6	1989	Pretreatment of rats with actinomycin D and cycloheximide almost completely blocked the BSP-mediated increase of ODC and SAMDC activities.	Cycloheximide	44-57	integrin-binding sialoprotein	Rattus norvegicus	88-91
2796592-6	1989	Pretreatment of rats with actinomycin D and cycloheximide almost completely blocked the BSP-mediated increase of ODC and SAMDC activities.	Cycloheximide	44-57	ornithine decarboxylase 1	Rattus norvegicus	113-116
2796592-6	1989	Pretreatment of rats with actinomycin D and cycloheximide almost completely blocked the BSP-mediated increase of ODC and SAMDC activities.	Cycloheximide	44-57	adenosylmethionine decarboxylase 1	Rattus norvegicus	121-126
2501120-3	1989	Cycloheximide caused an increase of PAI-1 mRNA in T-CAR1 cells, but not in HT-1080 cells; during this increase the relative abundance of the two PAI-1 mRNA species, of 2.3 kb and 3.4 kb, respectively, changed strongly in favor of the longer transcript.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	36-41
2501120-3	1989	Cycloheximide caused an increase of PAI-1 mRNA in T-CAR1 cells, but not in HT-1080 cells; during this increase the relative abundance of the two PAI-1 mRNA species, of 2.3 kb and 3.4 kb, respectively, changed strongly in favor of the longer transcript.	Cycloheximide	0-13	nuclear receptor subfamily 1 group I member 3	Homo sapiens	52-56
2501120-3	1989	Cycloheximide caused an increase of PAI-1 mRNA in T-CAR1 cells, but not in HT-1080 cells; during this increase the relative abundance of the two PAI-1 mRNA species, of 2.3 kb and 3.4 kb, respectively, changed strongly in favor of the longer transcript.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	145-150
2536889-7	1989	The protein synthesis inhibitor cycloheximide does not prevent either the dexamethasone-induced decrease or the CPT-cAMP-induced increase in tPA message and, in fact, augments the cAMP-induced increase in tPA mRNA.	Cycloheximide	32-45	plasminogen activator, tissue type	Rattus norvegicus	205-208
2536889-9	1989	Cycloheximide alone causes a marked increase in PAI-1 mRNA, but does not block the induction by either CPT-cAMP or dexamethasone.	Cycloheximide	0-13	serpin family E member 1	Rattus norvegicus	48-53
2538725-7	1989	Cycloheximide also caused accumulation of c-fgr transcripts in U937 cells; no superinduction was observed when TPA and cycloheximide were added at the same time.	Cycloheximide	0-13	FGR proto-oncogene, Src family tyrosine kinase	Homo sapiens	42-47
2674860-5	1989	Furthermore, both P1/P2 and P3 mRNA levels are similarly regulated by cycloheximide and by dimethylsulfoxide (DMSO) in murine erythroleukemia Friend cells.	Cycloheximide	70-83	zinc finger protein 185	Mus musculus	18-30
2771409-5	1989	However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression.	Cycloheximide	28-41	BCL2 apoptosis regulator	Homo sapiens	105-110
2771409-5	1989	However, in the presence of cycloheximide (inhibitor of protein synthesis), the half-life of some of the bcl-2/Ig mRNAs produced by these cells was prolonged, indicating that in some circumstances mRNA stability may contribute to deregulated bcl-2 expression.	Cycloheximide	28-41	BCL2 apoptosis regulator	Homo sapiens	242-247
2771409-6	1989	Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription.	Cycloheximide	85-98	BCL2 apoptosis regulator	Homo sapiens	25-30
2771409-6	1989	Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription.	Cycloheximide	85-98	BCL2 apoptosis regulator	Homo sapiens	144-149
2771409-6	1989	Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated bcl-2 mRNAs through inhibition of bcl-2 gene transcription.	Cycloheximide	85-98	BCL2 apoptosis regulator	Homo sapiens	144-149
2474813-5	1989	Then isolated acini were treated with 300 microM cycloheximide for 2 h. This treatment prevented the decreases in the sensitivity and responsiveness of amylase release to CCK-8 stimulation and made these alterations in one series of experiments negligible.	Cycloheximide	49-62	cholecystokinin	Homo sapiens	171-174
2643096-2	1989	The resistance of normal cells can often be overcome by treatment with inhibitors of transcription or translation such as actinomycin D or cycloheximide (CHI), suggesting that normal cells produce a protein(s) that protects them from TNF-induced cytolysis.	Cycloheximide	139-152	tumor necrosis factor	Mus musculus	234-237
2848814-9	1988	Cycloheximide caused an inhibition of both basal as well as Bt2cAMP-stimulated rates of transcription of SP-A mRNA in the rabbit fetal lung tissue in vitro.	Cycloheximide	0-13	pulmonary surfactant-associated protein A	Oryctolagus cuniculus	105-109
2787228-8	1989	Actinomycin D and cycloheximide inhibited IL-1 dependent cartilage destruction whereas indomethacin did not.	Cycloheximide	18-31	interleukin 1 beta	Homo sapiens	42-46
3224360-3	1988	The injection of cycloheximide, a potent inhibitor of protein synthesis, although it did curtail the rise in NAT activity for at least 2 hr, did not elicit decreases in the activities of either 5"-D or NAT enzymes.	Cycloheximide	17-30	N-acetyltransferase 1	Rattus norvegicus	109-112
3148377-10	1988	Furthermore, the partial maintenance of LPS-induced IL-1 production seen after cells were pre-incubated in gamma-IFN was markedly increased by the inclusion of 0.25 microgram/ml cycloheximide during the 24 h pre-incubation.	Cycloheximide	178-191	interleukin 1 alpha	Homo sapiens	52-56
3148377-12	1988	Pre-incubation in gamma-IFN and cycloheximide leads to separate but synergistic effects on the maintenance of LPS-induced IL-1 production in cultured monocytes.	Cycloheximide	32-45	interleukin 1 alpha	Homo sapiens	122-126
2973977-5	1988	IGF-I-mediated effects were inhibited by cycloheximide (3.6 microM), suggesting that the increase in PRL was the result of newly synthesized hormone.	Cycloheximide	41-54	insulin like growth factor 1	Homo sapiens	0-5
3203692-6	1988	Inhibition of TNF-mediated cytotoxicity was evident in both the presence and absence of actinomycin D or cycloheximide.	Cycloheximide	105-118	tumor necrosis factor	Mus musculus	14-17
3203696-4	1988	However, subsequent to treatment with the weaker viral inducer Newcastle disease virus (NDV) both IFN-beta and the 12S RNA transcripts are induced to a higher level in the presence of cycloheximide.	Cycloheximide	184-197	interferon beta 1	Homo sapiens	98-106
2855194-5	1988	The increase in PTH binding was attributed to an increase in the availability of receptor binding sites, not to altered receptor binding affinity, and was blocked by cycloheximide.	Cycloheximide	166-179	parathyroid hormone	Rattus norvegicus	16-19
2973977-5	1988	IGF-I-mediated effects were inhibited by cycloheximide (3.6 microM), suggesting that the increase in PRL was the result of newly synthesized hormone.	Cycloheximide	41-54	prolactin	Homo sapiens	101-104
3141509-6	1988	Cycloheximide inhibited the late peak of PAF synthesis indicating that protein synthesis is required for synthesis of the phospholipid PAF.	Cycloheximide	0-13	PCNA clamp associated factor	Homo sapiens	41-44
3141509-6	1988	Cycloheximide inhibited the late peak of PAF synthesis indicating that protein synthesis is required for synthesis of the phospholipid PAF.	Cycloheximide	0-13	PCNA clamp associated factor	Homo sapiens	135-138
2577870-5	1988	Inhibition of protein synthesis by cycloheximide for 4 h induced a 70% increase in Lmyc and 30% increase in Bmyc transcript levels, indicating that the expression of these genes is negatively regulated by a short-lived protein.	Cycloheximide	35-48	v-myc avian myelocytomatosis viral oncogene lung carcinoma derived	Mus musculus	83-87
2577870-5	1988	Inhibition of protein synthesis by cycloheximide for 4 h induced a 70% increase in Lmyc and 30% increase in Bmyc transcript levels, indicating that the expression of these genes is negatively regulated by a short-lived protein.	Cycloheximide	35-48	brain expressed myelocytomatosis oncogene	Mus musculus	108-112
3263703-6	1988	These effects of TNF-alpha and IL-1 on target cells may contribute to their reported protective activity against radiation as well as their ability to induce resistance to cell killing induced by the combination of TNF-alpha and cycloheximide.	Cycloheximide	229-242	tumor necrosis factor	Mus musculus	17-26
3263703-6	1988	These effects of TNF-alpha and IL-1 on target cells may contribute to their reported protective activity against radiation as well as their ability to induce resistance to cell killing induced by the combination of TNF-alpha and cycloheximide.	Cycloheximide	229-242	interleukin 1 complex	Mus musculus	31-35
2463066-6	1988	The blockade of c-fos gene expression seen in antisense-cells could be caused by rapid degradation of the c-fos message, since c-fos mRNA expression was rescued in these cells when treated with protein synthesis inhibitor, cycloheximide.	Cycloheximide	223-236	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
2463066-6	1988	The blockade of c-fos gene expression seen in antisense-cells could be caused by rapid degradation of the c-fos message, since c-fos mRNA expression was rescued in these cells when treated with protein synthesis inhibitor, cycloheximide.	Cycloheximide	223-236	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-111
2463066-6	1988	The blockade of c-fos gene expression seen in antisense-cells could be caused by rapid degradation of the c-fos message, since c-fos mRNA expression was rescued in these cells when treated with protein synthesis inhibitor, cycloheximide.	Cycloheximide	223-236	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	106-111
2500672-3	1989	Nonselective serotonin (5-HT) antagonist methysergide and selective 5-HT2 antagonist ritanserin significantly attenuated impairment of memory caused by CXM.	Cycloheximide	152-155	hypothermia due to alcohol sensitivity 2	Mus musculus	70-73
3049125-7	1988	Brief exposure to cycloheximide after 30 min or more of insulin stimulation increased the magnitude of insulin-stimulated activity without changing the overall pattern of activity increase.	Cycloheximide	18-31	insulin S homeolog	Xenopus laevis	56-63
3049125-7	1988	Brief exposure to cycloheximide after 30 min or more of insulin stimulation increased the magnitude of insulin-stimulated activity without changing the overall pattern of activity increase.	Cycloheximide	18-31	insulin S homeolog	Xenopus laevis	103-110
3145931-0	1988	Transferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures.	Cycloheximide	76-89	transferrin	Rattus norvegicus	0-11
3145931-1	1988	The influence of different modes of FSH stimulation and cycloheximide on transferrin secretion by rat Sertoli cells was investigated using a superfusion culture system.	Cycloheximide	56-69	transferrin	Rattus norvegicus	73-84
3145931-8	1988	Addition of cycloheximide decreased both basal and FSH-stimulated transferrin secretion.	Cycloheximide	12-25	transferrin	Rattus norvegicus	66-77
3241124-1	1988	Treatment of cultured human skin fibroblasts with cycloheximide retarded the down-regulation of low density lipoprotein (LDL) receptor activity caused by 25-hydroxycholesterol.	Cycloheximide	50-63	low density lipoprotein receptor	Homo sapiens	96-134
3241124-2	1988	The rate of LDL receptor degradation, measured directly by means of [35S]methionine pulse-chase experiments, was also markedly inhibited by cycloheximide (or puromycin), suggesting that continuous synthesis of a short-lived mediator protein(s) was necessary for normal LDL receptor turnover.	Cycloheximide	140-153	low density lipoprotein receptor	Homo sapiens	12-24
3241124-2	1988	The rate of LDL receptor degradation, measured directly by means of [35S]methionine pulse-chase experiments, was also markedly inhibited by cycloheximide (or puromycin), suggesting that continuous synthesis of a short-lived mediator protein(s) was necessary for normal LDL receptor turnover.	Cycloheximide	140-153	low density lipoprotein receptor	Homo sapiens	269-281
3241124-3	1988	In the absence of cycloheximide, both the up- and down-regulation of LDL receptor activity took place with a half-time of approximately 12 hr.	Cycloheximide	18-31	low density lipoprotein receptor	Homo sapiens	69-81
3062367-5	1988	The protein synthesis inhibitor cycloheximide enhanced the effect of TPA on the ets-2 protein and could itself slow turnover of the protein.	Cycloheximide	32-45	ETS proto-oncogene 2, transcription factor	Homo sapiens	80-85
3142469-4	1988	Cycloheximide abrogated increase in poly(ADP-ribose) polymerase gene expression suggesting that a newly synthesized protein(s) was involved in poly(ADP-ribose) polymerase gene induction in lectin-stimulated T lymphocytes.	Cycloheximide	0-13	poly(ADP-ribose) polymerase 1	Homo sapiens	36-63
3142469-4	1988	Cycloheximide abrogated increase in poly(ADP-ribose) polymerase gene expression suggesting that a newly synthesized protein(s) was involved in poly(ADP-ribose) polymerase gene induction in lectin-stimulated T lymphocytes.	Cycloheximide	0-13	poly(ADP-ribose) polymerase 1	Homo sapiens	143-170
3262618-7	1988	The protein synthesis inhibitor cycloheximide (10 micrograms/ml) also increased the level of PAI-1 mRNA, and when both cycloheximide and PMA were used, an additive effect was observed.	Cycloheximide	32-45	serpin family E member 1	Homo sapiens	93-98
3262618-7	1988	The protein synthesis inhibitor cycloheximide (10 micrograms/ml) also increased the level of PAI-1 mRNA, and when both cycloheximide and PMA were used, an additive effect was observed.	Cycloheximide	119-132	serpin family E member 1	Homo sapiens	93-98
3262618-8	1988	Cycloheximide changed the ratio between the two PAI-1 mRNAs in favor of the 3.4-kilobase species.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	48-53
3049587-7	1988	Cycloheximide prevented the induction of SDH mRNA by dexamethasone and glucagon, suggesting that ongoing protein synthesis is required for the induction by glucocorticoids and glucagon.	Cycloheximide	0-13	serine dehydratase	Rattus norvegicus	41-44
3170563-5	1988	Inhibition of protein synthesis by cycloheximide abolished the increase in TfR expression mediated by either agent.	Cycloheximide	35-48	transferrin receptor	Rattus norvegicus	75-78
2458855-2	1988	AHH activity was induced by treatment with benz[a]anthracene and combined treatment with cycloheximide for an initial short period during the induction enhanced benz[a]anthracene-inducible AHH activity.	Cycloheximide	89-102	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	0-3
2458855-2	1988	AHH activity was induced by treatment with benz[a]anthracene and combined treatment with cycloheximide for an initial short period during the induction enhanced benz[a]anthracene-inducible AHH activity.	Cycloheximide	89-102	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	189-192
2458855-5	1988	In addition, 3-methoxybenzamide was found to further increase the enhancing effects of cycloheximide on benz[a]anthracene induction of AHH.	Cycloheximide	87-100	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	135-138
2844850-3	1988	The levels of both PDGF-1 and PDGF-2 transcripts were superinduced when these cells were treated with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	102-115	platelet derived growth factor subunit A	Homo sapiens	19-25
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	384-397	indoleamine 2,3-dioxygenase 2	Homo sapiens	95-101
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	384-397	indoleamine 2,3-dioxygenase 1	Homo sapiens	95-98
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	384-397	indoleamine 2,3-dioxygenase 1	Homo sapiens	225-228
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	467-480	indoleamine 2,3-dioxygenase 2	Homo sapiens	95-101
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	467-480	indoleamine 2,3-dioxygenase 1	Homo sapiens	95-98
2466915-5	1988	These are as follows: 1) antibody to the 42,000 dalton protein neutralizes the activity of the IDO; 2) examination of a variety of cell lines reveals a correlation between the presence of this protein and the presence of the IDO; and 3) the induction of both the IDO and the 42,000 dalton protein is blocked under conditions in which the IFN treatment is performed in the presence of cycloheximide, and actinomycin D is added to the cells prior to the removal of the cycloheximide.	Cycloheximide	467-480	indoleamine 2,3-dioxygenase 1	Homo sapiens	225-228
3196319-7	1988	This suppression of ALA synthase mRNA by haem was blocked by cycloheximide treatment which did not block the induction of ALA synthase mRNA by drugs.	Cycloheximide	61-74	5'-aminolevulinate synthase 1	Gallus gallus	20-32
3196319-8	1988	In fact, cycloheximide synergistically increased the drug induction of ALA synthase mRNA, suggesting the presence of a labile protein factor which may interact with a haem-responsive element of the ALA synthase gene.	Cycloheximide	9-22	5'-aminolevulinate synthase 1	Gallus gallus	71-83
3196319-8	1988	In fact, cycloheximide synergistically increased the drug induction of ALA synthase mRNA, suggesting the presence of a labile protein factor which may interact with a haem-responsive element of the ALA synthase gene.	Cycloheximide	9-22	5'-aminolevulinate synthase 1	Gallus gallus	198-210
2459140-4	1988	The elevation of ACE seemed to require de novo protein synthesis since it was reduced by 0.1 microgram/ml cycloheximide.	Cycloheximide	106-119	angiotensin I converting enzyme	Bos taurus	17-20
3054513-8	1988	The second phase of the biphasic effect and the increase in soluble cellular fibronectin were blocked by cycloheximide.	Cycloheximide	105-118	fibronectin 1	Homo sapiens	77-88
2844850-3	1988	The levels of both PDGF-1 and PDGF-2 transcripts were superinduced when these cells were treated with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	102-115	platelet derived growth factor subunit B	Homo sapiens	30-36
3194703-10	1988	The release was inhibited by cycloheximide but not by actinomycin D, indicating that the TNF detected did not represent TNF present in vivo.	Cycloheximide	29-42	tumor necrosis factor	Homo sapiens	89-92
3416990-1	1988	Dopamine beta-hydroxylase (DBH) enzyme activity was associated in rat superior cervical ganglion with tetrameric DBH-A (294,000 D) and dimeric DBH-B (147,000 D) and in rat adrenal gland with DBH-A and a novel molecular form of DBH, defined as DBH-C, with a molecular weight of 125,000 D. Pretreatment of the rats with cycloheximide markedly reduced DBH activity without altering the molecular heterogeneity.	Cycloheximide	318-331	dopamine beta-hydroxylase	Rattus norvegicus	0-25
3152599-3	1988	Induction of c-myc expression by IL-2, but not lectin or ionomycin plus phorbol ester, was inhibited in the presence of cycloheximide.	Cycloheximide	120-133	interleukin 2	Mus musculus	33-37
3234481-3	1988	NIK-247 administered pre- and post-training or pre-retention test (24 h after training) prevented the disruption of memory induced by cycloheximide administered immediately after training.	Cycloheximide	134-147	mitogen-activated protein kinase kinase kinase 14	Mus musculus	0-3
3139753-7	1988	Cycloheximide treatment caused the TPA/A23187-stimulated lpr cells to express large amounts of c-myc mRNA, but not IL-2R mRNA.	Cycloheximide	0-13	Fas (TNF receptor superfamily member 6)	Mus musculus	57-60
3139753-8	1988	The deficient expression of c-myc and its correction by cycloheximide treatment were also observed in Con A-stimulated lpr Lyt-2- L3T4- T cells.	Cycloheximide	56-69	Fas (TNF receptor superfamily member 6)	Mus musculus	119-122
3139753-8	1988	The deficient expression of c-myc and its correction by cycloheximide treatment were also observed in Con A-stimulated lpr Lyt-2- L3T4- T cells.	Cycloheximide	56-69	CD8 antigen, alpha chain	Mus musculus	123-128
3139753-10	1988	These findings suggest that two separate mechanisms differentiated by their sensitivity to cycloheximide can inhibit the accumulation of mRNA for early competence genes in lpr Lyt-2- L3T4- T cells.	Cycloheximide	91-104	Fas (TNF receptor superfamily member 6)	Mus musculus	172-175
3139753-10	1988	These findings suggest that two separate mechanisms differentiated by their sensitivity to cycloheximide can inhibit the accumulation of mRNA for early competence genes in lpr Lyt-2- L3T4- T cells.	Cycloheximide	91-104	CD8 antigen, alpha chain	Mus musculus	176-181
3416990-1	1988	Dopamine beta-hydroxylase (DBH) enzyme activity was associated in rat superior cervical ganglion with tetrameric DBH-A (294,000 D) and dimeric DBH-B (147,000 D) and in rat adrenal gland with DBH-A and a novel molecular form of DBH, defined as DBH-C, with a molecular weight of 125,000 D. Pretreatment of the rats with cycloheximide markedly reduced DBH activity without altering the molecular heterogeneity.	Cycloheximide	318-331	dopamine beta-hydroxylase	Rattus norvegicus	27-30
3403539-0	1988	Identification of the 40 S ribosomal protein S6 phosphorylation sites induced by cycloheximide.	Cycloheximide	81-94	ribosomal protein S6	Rattus norvegicus	22-47
3224822-0	1988	Activation of the adenovirus-2 E2a late promoter during inhibition of protein synthesis by cycloheximide.	Cycloheximide	91-104	transcription factor 3	Homo sapiens	31-34
3178765-4	1988	On the contrary, the proportion of ODC present as a complex with antizyme was 24-fold higher in females than in males, and the decay of renal ODC activity after cycloheximide treatment was about 5-fold more rapid in females than in males.	Cycloheximide	161-174	ornithine decarboxylase, structural 1	Mus musculus	35-38
3178765-4	1988	On the contrary, the proportion of ODC present as a complex with antizyme was 24-fold higher in females than in males, and the decay of renal ODC activity after cycloheximide treatment was about 5-fold more rapid in females than in males.	Cycloheximide	161-174	ornithine decarboxylase, structural 1	Mus musculus	142-145
3178765-6	1988	These results are consistent with the previous observation in HTC cells that the decay rate of ODC activity in the presence of cycloheximide correlated well with the proportion of ODC present as a complex with antizyme, suggesting the ubiquitous role of antizyme in ODC degradation.	Cycloheximide	127-140	ornithine decarboxylase 1	Rattus norvegicus	95-98
3178765-6	1988	These results are consistent with the previous observation in HTC cells that the decay rate of ODC activity in the presence of cycloheximide correlated well with the proportion of ODC present as a complex with antizyme, suggesting the ubiquitous role of antizyme in ODC degradation.	Cycloheximide	127-140	ornithine decarboxylase antizyme 1	Mus musculus	210-218
3178765-6	1988	These results are consistent with the previous observation in HTC cells that the decay rate of ODC activity in the presence of cycloheximide correlated well with the proportion of ODC present as a complex with antizyme, suggesting the ubiquitous role of antizyme in ODC degradation.	Cycloheximide	127-140	ornithine decarboxylase antizyme 1	Mus musculus	254-262
2461329-1	1988	Novel patterns of engrailed RNA were observed in early Drosophila embryos injected with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	88-101	engrailed	Drosophila melanogaster	18-27
2842289-2	1988	It is based on the introduction into a cyh2 host (resistant to the drug cycloheximide) of a tandemly duplicated CYH2 gene (a dominant allele, conferring sensitivity to cycloheximide), and subsequent selection for Cyhr derivatives.	Cycloheximide	72-85	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	39-43
2842289-2	1988	It is based on the introduction into a cyh2 host (resistant to the drug cycloheximide) of a tandemly duplicated CYH2 gene (a dominant allele, conferring sensitivity to cycloheximide), and subsequent selection for Cyhr derivatives.	Cycloheximide	72-85	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	112-116
2842289-2	1988	It is based on the introduction into a cyh2 host (resistant to the drug cycloheximide) of a tandemly duplicated CYH2 gene (a dominant allele, conferring sensitivity to cycloheximide), and subsequent selection for Cyhr derivatives.	Cycloheximide	168-181	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	39-43
2842289-2	1988	It is based on the introduction into a cyh2 host (resistant to the drug cycloheximide) of a tandemly duplicated CYH2 gene (a dominant allele, conferring sensitivity to cycloheximide), and subsequent selection for Cyhr derivatives.	Cycloheximide	168-181	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	112-116
2457619-8	1988	Procoagulant expression may, as for other cytokines involved in inflammatory responses, be regulated by short lived repressor proteins as low dose cycloheximide superinduced procoagulant responses to both LPS and IFN-gamma and caused the extracellular expression of procoagulant in response to IFN-gamma.	Cycloheximide	147-160	toll-like receptor 4	Mus musculus	205-208
2457619-8	1988	Procoagulant expression may, as for other cytokines involved in inflammatory responses, be regulated by short lived repressor proteins as low dose cycloheximide superinduced procoagulant responses to both LPS and IFN-gamma and caused the extracellular expression of procoagulant in response to IFN-gamma.	Cycloheximide	147-160	interferon gamma	Mus musculus	213-222
2457619-8	1988	Procoagulant expression may, as for other cytokines involved in inflammatory responses, be regulated by short lived repressor proteins as low dose cycloheximide superinduced procoagulant responses to both LPS and IFN-gamma and caused the extracellular expression of procoagulant in response to IFN-gamma.	Cycloheximide	147-160	interferon gamma	Mus musculus	294-303
2970508-4	1988	Factor H synthesis was inhibited by cycloheximide but returned to the levels seen in untreated cultures after removal of the inhibitor.	Cycloheximide	36-49	complement factor H	Homo sapiens	0-8
3261760-9	1988	PMA induction of TCR-alpha and -beta mRNA was shown to occur in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	112-125	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	17-20
3261760-10	1988	The 1.6-kb TCR-alpha and the 1.0-kb D beta J beta C beta TCR-beta gene transcripts were fully induced in the presence of cycloheximide, whereas the 1.3-kb V beta D beta J beta C beta transcript was only partly induced in the presence of cycloheximide.	Cycloheximide	121-134	T cell receptor alpha constant	Homo sapiens	11-20
3261760-10	1988	The 1.6-kb TCR-alpha and the 1.0-kb D beta J beta C beta TCR-beta gene transcripts were fully induced in the presence of cycloheximide, whereas the 1.3-kb V beta D beta J beta C beta transcript was only partly induced in the presence of cycloheximide.	Cycloheximide	121-134	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	11-14
3139993-9	1988	In the presence of the protein synthesis inhibitor, cycloheximide, FSH-stimulated tPA message levels were enhanced by 30-fold, revealing superinduction of tPA mRNA levels by this pathway.	Cycloheximide	52-65	plasminogen activator, tissue type	Rattus norvegicus	82-85
3139993-9	1988	In the presence of the protein synthesis inhibitor, cycloheximide, FSH-stimulated tPA message levels were enhanced by 30-fold, revealing superinduction of tPA mRNA levels by this pathway.	Cycloheximide	52-65	plasminogen activator, tissue type	Rattus norvegicus	155-158
3139993-10	1988	In contrast the induction of tPA mRNA by GnRH was inhibited by cycloheximide indicating that the synthesis of an intermediate protein is required for the GnRH effect.	Cycloheximide	63-76	plasminogen activator, tissue type	Rattus norvegicus	29-32
3139993-10	1988	In contrast the induction of tPA mRNA by GnRH was inhibited by cycloheximide indicating that the synthesis of an intermediate protein is required for the GnRH effect.	Cycloheximide	63-76	gonadotropin releasing hormone 1	Rattus norvegicus	41-45
3139993-10	1988	In contrast the induction of tPA mRNA by GnRH was inhibited by cycloheximide indicating that the synthesis of an intermediate protein is required for the GnRH effect.	Cycloheximide	63-76	gonadotropin releasing hormone 1	Rattus norvegicus	154-158
3265471-9	1988	Finally, by increasing the half-life of 4F2HC mRNA, cycloheximide treatment of resting T cells induced an approximately five fold increase in the levels of 4F2HC gene expression, although the physiologic significance of this mechanism remains unclear.	Cycloheximide	52-65	solute carrier family 3 member 2	Homo sapiens	40-45
3265471-9	1988	Finally, by increasing the half-life of 4F2HC mRNA, cycloheximide treatment of resting T cells induced an approximately five fold increase in the levels of 4F2HC gene expression, although the physiologic significance of this mechanism remains unclear.	Cycloheximide	52-65	solute carrier family 3 member 2	Homo sapiens	156-161
3265472-5	1988	TPA-treated monocytes exposed to actinomycin D further demonstrated that the half-life of the CSF-1 mRNA is 0.9 h. The results also demonstrated that the protein synthesis inhibitor, cycloheximide (CHX), increases CSF-1 mRNA levels in both resting and TPA-treated monocytes.	Cycloheximide	183-196	colony stimulating factor 1	Homo sapiens	94-99
3265472-5	1988	TPA-treated monocytes exposed to actinomycin D further demonstrated that the half-life of the CSF-1 mRNA is 0.9 h. The results also demonstrated that the protein synthesis inhibitor, cycloheximide (CHX), increases CSF-1 mRNA levels in both resting and TPA-treated monocytes.	Cycloheximide	183-196	colony stimulating factor 1	Homo sapiens	214-219
3265472-5	1988	TPA-treated monocytes exposed to actinomycin D further demonstrated that the half-life of the CSF-1 mRNA is 0.9 h. The results also demonstrated that the protein synthesis inhibitor, cycloheximide (CHX), increases CSF-1 mRNA levels in both resting and TPA-treated monocytes.	Cycloheximide	198-201	colony stimulating factor 1	Homo sapiens	94-99
3265472-7	1988	Moreover, treatment of monocytes with CHX and actinomycin D demonstrated that inhibition of protein synthesis is associated with stabilization of the CSF-1 transcript.	Cycloheximide	38-41	colony stimulating factor 1	Homo sapiens	150-155
2460966-6	1988	Stimulation of endothelial cells in the presence of cycloheximide (CHX) results in superinduction of mainly the 3.0 kb PAI-1 mRNA.	Cycloheximide	52-65	serpin family E member 1	Homo sapiens	119-124
2460966-6	1988	Stimulation of endothelial cells in the presence of cycloheximide (CHX) results in superinduction of mainly the 3.0 kb PAI-1 mRNA.	Cycloheximide	67-70	serpin family E member 1	Homo sapiens	119-124
3403539-1	1988	Injection of cycloheximide into rats induced the incorporation of up to 5 mol of phosphate/mol of liver 40 S ribosomal protein S6.	Cycloheximide	13-26	ribosomal protein S6	Rattus norvegicus	104-129
2898361-6	1988	On the other hand, cycloheximide (20 microM) completely inhibited the secondary increase in PRL release in response to PRL-RF but had no effect on the acute release.	Cycloheximide	19-32	prolactin	Homo sapiens	92-95
3403063-4	1988	The increase of 90K expression was due to de novo protein synthesis since cycloheximide, added within 3 hr of the beginning of rIFN-alpha 2b stimulation treatment, completely abolished the effect of rIFN-alpha 2b.	Cycloheximide	74-87	galectin 3 binding protein	Homo sapiens	16-19
2456200-7	1988	Readdition of TSH (250 microU/ml) to the culture medium of cells lacking the M/TPO antigen elicited its reappearance within 24-48 h. This effect of TSH was prevented by 10 microM cycloheximide or 0.5-5 micrograms/ml actinomycin D.	Cycloheximide	179-192	thyroid peroxidase	Rattus norvegicus	79-82
2842348-9	1988	Both cycloheximide and puromycin inhibited the RA induction of the collagen IV (alpha 1), laminin B1, and J6 mRNAs.	Cycloheximide	5-18	laminin B1	Mus musculus	90-100
3410884-6	1988	Treatment of fibroblasts with cycloheximide before and during serum treatment blocked the ability of serum to induce the expression of the HBGF-2/bFGF gene.	Cycloheximide	30-43	fibroblast growth factor 2	Homo sapiens	139-145
3410884-6	1988	Treatment of fibroblasts with cycloheximide before and during serum treatment blocked the ability of serum to induce the expression of the HBGF-2/bFGF gene.	Cycloheximide	30-43	fibroblast growth factor 2	Homo sapiens	146-150
3139787-5	1988	Stimulation of IFN-gamma mRNA by both PMA and IL2 could occur in the presence of cycloheximide, indicating that protein synthesis was not required for the initial stimulation to occur.	Cycloheximide	81-94	interferon gamma	Homo sapiens	15-24
3139787-5	1988	Stimulation of IFN-gamma mRNA by both PMA and IL2 could occur in the presence of cycloheximide, indicating that protein synthesis was not required for the initial stimulation to occur.	Cycloheximide	81-94	interleukin 2	Homo sapiens	46-49
3262700-7	1988	The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells.	Cycloheximide	108-121	interleukin 1 alpha	Homo sapiens	25-28
3262700-7	1988	The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells.	Cycloheximide	108-121	interferon beta 1	Homo sapiens	56-64
3262700-7	1988	The inhibitory action of IL1 on poly(I).poly(C)-induced IFN-beta synthesis was abolished in the presence of cycloheximide, suggesting that it is mediated indirectly by an IL1-induced product in the FS-4 cells.	Cycloheximide	108-121	interleukin 1 alpha	Homo sapiens	171-174
2463477-5	1988	Both G- and GM-CSF mRNA concentrations coordinately increased after exposure of the cells to TNF alpha (greater than or equal to 5 ng/ml), 12-O-tetradecanoylphorbol 13-acetate (TPA) (greater than or equal to 5 x 10(-10) M), or cycloheximide (20 micrograms/ml).	Cycloheximide	227-240	colony stimulating factor 2	Homo sapiens	12-18
2839482-2	1988	With receptor synthesis inhibited by cycloheximide, the half-life of the surface TNF receptor was 2 h in the absence of TNF and 30 min in its presence, suggesting that the TNF receptor is non-recycling and that its internalization is accelerated by TNF.	Cycloheximide	37-50	tumor necrosis factor	Homo sapiens	81-84
2839482-3	1988	During cell incubation with TNF receptor degradation suppressed by chloroquine, the number of surface TNF receptors remained approximately constant, but the total number of surface and internal TNF receptors increased gradually, at 3 h reaching 1.5 times the initial number, thus suggesting continuous synthesis, externalization, internalization, and degradation of the TNF receptor in the absence of cycloheximide.	Cycloheximide	401-414	tumor necrosis factor	Homo sapiens	28-31
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	56-69	tumor necrosis factor	Homo sapiens	88-91
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	56-69	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	56-69	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	56-69	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	56-69	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	268-281	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	268-281	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	268-281	tumor necrosis factor	Homo sapiens	123-126
2839482-5	1988	During incubations with protein synthesis suppressed by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in number to a peak at 60 min and gradually decreasing, and cells previously exposed to cycloheximide with or without TNF showed no recurrence of surface TNF receptors, suggesting that the TNF receptor is non-recycling.	Cycloheximide	268-281	tumor necrosis factor	Homo sapiens	123-126
2899075-6	1988	Both PCNA/cyclin and thymidine kinase genes share two fundamental characteristics, i.e. they are not inducible in a G1-specific ts mutant of the cell cycle at the restrictive temperature and their expression is inhibited by cycloheximide, indicating that unlike early growth-regulated genes, they require the previous expression of other growth-regulated genes.	Cycloheximide	224-237	proliferating cell nuclear antigen	Homo sapiens	5-16
3260778-5	1988	Chondrocytes incubated with cycloheximide showed a first-order decrease in rate of uptake of radiolabelled sulphate (t1/2 = 25 mins) but interleukin 1 induced inhibition showed a delay of at least 1 hr, consistent with a requirement to deplete intracellular pools of protein before effects on post-translational events could be observed.	Cycloheximide	28-41	interleukin 1 alpha	Homo sapiens	137-150
3292293-2	1988	Cycloheximide and puromycin, well-known inhibitors of protein synthesis, block the maturation process induced by progesterone and insulin but do not affect the maturation caused by H-raslys12 protein microinjection.	Cycloheximide	0-13	insulin S homeolog	Xenopus laevis	130-137
3290209-5	1988	MCF-7 nuclear runon assays show that c-myc transcription rates remain unchanged from base line for 24 h after E2 administration; as well, cycloheximide inhibition of protein synthesis superinduces c-myc expression and prevents E2 modulation of transcript levels.	Cycloheximide	138-151	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	197-202
3261295-6	1988	This activity of TNF is inhibited by treating endothelial cells with the inhibitors of protein or RNA synthesis cycloheximide or actinomycin D.	Cycloheximide	112-125	tumor necrosis factor	Homo sapiens	17-20
2898361-6	1988	On the other hand, cycloheximide (20 microM) completely inhibited the secondary increase in PRL release in response to PRL-RF but had no effect on the acute release.	Cycloheximide	19-32	prolactin	Homo sapiens	119-122
3416834-6	1988	To identify low-abundance proteins induced directly after prolactin stimulation, mRNA was accumulated during 5 h of stimulation of HC11 cells with prolactin in the presence of cycloheximide.	Cycloheximide	176-189	heterochromatin, Chr 11	Mus musculus	131-135
3049288-0	1988	Influence of cycloheximide on acute diabetogenic effects of S-carboxymethylated human growth hormone in obese (ob/ob) mice.	Cycloheximide	13-26	growth hormone 1	Homo sapiens	86-100
3372995-3	1988	Optimal effect of the hormone on DR alpha mRNA was reached by 72 h. DU-Mel 17 cells were responsive to 1,25(OH)2D3 in a dose-dependent manner, and a reduction in DR alpha mRNA was seen at concentrations as low as 5 x 10(-13) M. The action of 1,25(OH)2D3 on DR alpha mRNA levels was dependent on protein synthesis as evidenced by inhibition of its effect upon addition of cycloheximide.	Cycloheximide	371-384	solute carrier family 26 member 3	Homo sapiens	162-170
2968288-6	1988	Induction of cyclooxygenase by EGF and TGF-beta also was prevented by cycloheximide but not by actinomycin D.	Cycloheximide	70-83	epidermal growth factor	Homo sapiens	31-34
2968288-6	1988	Induction of cyclooxygenase by EGF and TGF-beta also was prevented by cycloheximide but not by actinomycin D.	Cycloheximide	70-83	transforming growth factor beta 1	Homo sapiens	39-47
3133656-3	1988	Treatment with the protein synthesis inhibitor, cycloheximide, abolishes the IFN-gamma-induced accumulation of HLA-DR alpha mRNA, indicating that de novo synthesis of a trans-acting protein factor is required for induction of this major histocompatibility complex class II gene.	Cycloheximide	48-61	interferon gamma	Homo sapiens	77-86
3133656-3	1988	Treatment with the protein synthesis inhibitor, cycloheximide, abolishes the IFN-gamma-induced accumulation of HLA-DR alpha mRNA, indicating that de novo synthesis of a trans-acting protein factor is required for induction of this major histocompatibility complex class II gene.	Cycloheximide	48-61	major histocompatibility complex, class II, DR alpha	Homo sapiens	111-123
3133656-6	1988	IFN-gamma-induced transcription of HLA-DR alpha and of the invariant chain gene was blocked by treatment with cycloheximide, but IFN-gamma-induced transcription of HLA-A2 was unaffected.	Cycloheximide	110-123	interferon gamma	Homo sapiens	0-9
3133656-6	1988	IFN-gamma-induced transcription of HLA-DR alpha and of the invariant chain gene was blocked by treatment with cycloheximide, but IFN-gamma-induced transcription of HLA-A2 was unaffected.	Cycloheximide	110-123	major histocompatibility complex, class II, DR alpha	Homo sapiens	35-47
2455523-3	1988	Induction of DT-diaphorase activity was dependent upon new RNA and protein synthesis, as shown by experiments employing actinomycin D and cycloheximide respectively.	Cycloheximide	138-151	NAD(P)H dehydrogenase, quinone 1	Mus musculus	13-26
3139271-7	1988	Cycloheximide added before, at the same time as, or up to 30-60 min after epidermal growth factor completely abolished the stimulation.	Cycloheximide	0-13	epidermal growth factor	Homo sapiens	74-97
3169039-9	1988	Treatment of F11 cells with cycloheximide failed to inhibit neurite extension on pFN but did partially inhibit extension on CTB; this contrasts with the very high sensitivity of neurite formation by neuroblastoma cells on CTB substrata reported previously.	Cycloheximide	28-41	phosphate cytidylyltransferase 1B, choline	Homo sapiens	124-127
3372995-3	1988	Optimal effect of the hormone on DR alpha mRNA was reached by 72 h. DU-Mel 17 cells were responsive to 1,25(OH)2D3 in a dose-dependent manner, and a reduction in DR alpha mRNA was seen at concentrations as low as 5 x 10(-13) M. The action of 1,25(OH)2D3 on DR alpha mRNA levels was dependent on protein synthesis as evidenced by inhibition of its effect upon addition of cycloheximide.	Cycloheximide	371-384	solute carrier family 26 member 3	Homo sapiens	162-170
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	70-83	interferon alpha 1	Homo sapiens	28-37
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	70-83	interferon gamma	Homo sapiens	41-50
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	70-83	interferon alpha 1	Homo sapiens	28-31
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	70-83	interferon alpha 1	Homo sapiens	262-271
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	70-83	interferon gamma	Homo sapiens	276-285
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	140-153	interferon alpha 1	Homo sapiens	28-37
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	140-153	interferon gamma	Homo sapiens	41-50
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	140-153	interferon alpha 1	Homo sapiens	28-31
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	140-153	interferon alpha 1	Homo sapiens	262-271
2452894-8	1988	When cells are treated with IFN-alpha or IFN-gamma in the presence of cycloheximide, and actinomycin D is added prior to the removal of the cycloheximide, the cells produce the IFN-induced 56,000-dalton protein and develop an antiviral state in response to both IFN-alpha and IFN-gamma.	Cycloheximide	140-153	interferon gamma	Homo sapiens	276-285
3405206-11	1988	Gamma-actin gene was superinduced in serum-stimulated cells by cycloheximide, an inhibitor of translation.	Cycloheximide	63-76	actin, gamma, cytoplasmic 1	Mus musculus	0-11
3259230-8	1988	When protein synthesis was blocked by either cycloheximide, puromycin, or emetine, the induction of alpha 1-acid glycoprotein mRNA by recombinant human interleukin-1 beta was impaired suggesting the involvement of a short-lived protein in the induction of alpha 1-acid glycoprotein mRNA.	Cycloheximide	45-58	interleukin 1 beta	Homo sapiens	152-170
2842166-5	1988	Since both inhibition of the de novo synthesis of acetylcholinesterase by cycloheximide and the re-inhibition of acetylcholinesterase in vitro by soman did not affect the improvement of neuromuscular transmission, it was concluded that this recovery of neuromuscular transmission can not be attributed to synthesis of new acetylcholinesterase.	Cycloheximide	74-87	acetylcholinesterase	Rattus norvegicus	50-70
3395549-3	1988	The enhancement of VP-16-induced DNA cleavage seen with oestrogen exposure is antagonised both by antioestrogen treatment and by cycloheximide, an inhibitor of protein synthesis, but not by the DNA synthesis inhibitor aphidicolin.	Cycloheximide	129-142	host cell factor C1	Homo sapiens	19-24
3416229-3	1988	Actinomycin D (4 microM) and cycloheximide (10 microM) each abolished 25-hydroxyvitamin D3 24-hydroxylase synthesis when added at the start of perfusion but not when added 4 h later; they did not affect 25-hydroxyvitamin D3 1-hydroxylase activity.	Cycloheximide	29-42	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	70-105
2454869-7	1988	Cycloheximide treatment led to induction of a large amount of c-fos mRNA in clones expressing c-fos antisense RNA as well as in control F9 clones.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	62-67
2454869-7	1988	Cycloheximide treatment led to induction of a large amount of c-fos mRNA in clones expressing c-fos antisense RNA as well as in control F9 clones.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	94-99
2454869-8	1988	The amount of c-fos antisense RNA was also increased by cycloheximide treatment.	Cycloheximide	56-69	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-19
2454869-9	1988	We postulate that c-fos antisense RNA blocks expression of the endogenous c-fos gene by accelerating the degradation of c-fos mRNA and that cycloheximide treatment interferes with this degradation.	Cycloheximide	140-153	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
2454869-9	1988	We postulate that c-fos antisense RNA blocks expression of the endogenous c-fos gene by accelerating the degradation of c-fos mRNA and that cycloheximide treatment interferes with this degradation.	Cycloheximide	140-153	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
2896216-9	1988	The protein synthesis inhibitor, cycloheximide, increased its half-time by fourfold to 3.5 h. The data imply the existence of a labile factor, dependent on protein synthesis that is important in the regulation of CD2 mRNA.	Cycloheximide	33-46	CD2 molecule	Homo sapiens	213-216
3290254-4	1988	Studies using cycloheximide as a protein synthesis inhibitor showed that the inhibitory action of 1,25(OH)2D3 on GM-CSF expression was dependent on new protein synthesis.	Cycloheximide	14-27	colony stimulating factor 2	Homo sapiens	113-119
2833510-0	1988	Tumor necrosis factor receptors and cytocidal activity are down-regulated by activators of protein kinase C. Human HeLa cells and murine L(S) cells are highly sensitive to the cytocidal activity of tumor necrosis factor (TNF) when simultaneously treated with the inhibitor of protein synthesis cycloheximide.	Cycloheximide	294-307	tumor necrosis factor	Mus musculus	0-21
2833510-0	1988	Tumor necrosis factor receptors and cytocidal activity are down-regulated by activators of protein kinase C. Human HeLa cells and murine L(S) cells are highly sensitive to the cytocidal activity of tumor necrosis factor (TNF) when simultaneously treated with the inhibitor of protein synthesis cycloheximide.	Cycloheximide	294-307	tumor necrosis factor	Mus musculus	198-219
2833510-0	1988	Tumor necrosis factor receptors and cytocidal activity are down-regulated by activators of protein kinase C. Human HeLa cells and murine L(S) cells are highly sensitive to the cytocidal activity of tumor necrosis factor (TNF) when simultaneously treated with the inhibitor of protein synthesis cycloheximide.	Cycloheximide	294-307	tumor necrosis factor	Mus musculus	221-224
3134064-5	1988	Cycloheximide inhibited the expression of PCA by U937 cells, showing that protein synthesis was necessary to mediate the effects of rTNF.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	132-136
3259999-2	1988	Pretreatment with cycloheximide (Cyclo) or aminoglutethimide (Ag) prevented these effects of hCG, while Actinomycin D (Act-D) or Azastene, an inhibitor of 3-hydroxysteroid dehydrogenase, were ineffective.	Cycloheximide	18-31	chorionic gonadotropin subunit beta 5	Homo sapiens	93-96
3259999-2	1988	Pretreatment with cycloheximide (Cyclo) or aminoglutethimide (Ag) prevented these effects of hCG, while Actinomycin D (Act-D) or Azastene, an inhibitor of 3-hydroxysteroid dehydrogenase, were ineffective.	Cycloheximide	33-38	chorionic gonadotropin subunit beta 5	Homo sapiens	93-96
3360150-2	1988	Here we demonstrate that this calmodulin increase is reduced by injection of cycloheximide (translation inhibitor) and actinomycin D (transcription inhibitor).	Cycloheximide	77-90	calmodulin 1	Rattus norvegicus	30-40
2965726-11	1988	The induction of CD23 and class II MHC Ag by IL-4 required intact protein synthesis as shown by its inhibition by cycloheximide.	Cycloheximide	114-127	Fc epsilon receptor II	Homo sapiens	17-21
2965726-11	1988	The induction of CD23 and class II MHC Ag by IL-4 required intact protein synthesis as shown by its inhibition by cycloheximide.	Cycloheximide	114-127	interleukin 4	Homo sapiens	45-49
3291183-3	1988	The stimulation appeared at 3-6 h of incubation and lasted at least 24 h. It was suppressed by EGF antibodies and blocked by protein synthesis inhibitor cycloheximide.	Cycloheximide	153-166	epidermal growth factor	Homo sapiens	95-98
3350209-5	1988	Thereafter, however, in the presence of cycloheximide the meiotic spindle was not formed and MPF disappeared, although the chromosomes remained condensed.	Cycloheximide	40-53	mesothelin	Mus musculus	93-96
3350209-6	1988	After removing cycloheximide, MPF reappeared and was followed by the first metaphase and subsequently by polar body emission.	Cycloheximide	15-28	mesothelin	Mus musculus	30-33
3350209-10	1988	Addition of cycloheximide to such cytochalasin-treated oocytes, in which the meiotic cycle was arrested at the first metaphase, caused the MPF levels to decrease and was followed by movement of chromosomes to both poles where they decondensed and two nucleus-like structures were formed.	Cycloheximide	12-25	mesothelin	Mus musculus	139-142
3360058-9	1988	AChE activities were 30% higher in tissues incubated with cycloheximide 10(-3) M (P less than 0.02).	Cycloheximide	58-71	acetylcholinesterase	Rattus norvegicus	0-4
3396760-2	1988	Pretreatment of adipocytes with 20 micrograms/ml cycloheximide resulted in a rapid decline (t1/2 approximately 45 min) of the 125I-human growth hormone (hGH) binding capacity of the cells.	Cycloheximide	49-62	growth hormone 1	Homo sapiens	137-151
2965145-4	1988	During treatment, basal levels (activities expressed in the absence of exogenous proteolytic activation) of Chs1 and Chs2 increased nine- and fourfold, respectively, through a mechanism dependent on protein synthesis, since the effect was abolished by cycloheximide.	Cycloheximide	252-265	chitin synthase CHS1	Saccharomyces cerevisiae S288C	108-112
2965145-4	1988	During treatment, basal levels (activities expressed in the absence of exogenous proteolytic activation) of Chs1 and Chs2 increased nine- and fourfold, respectively, through a mechanism dependent on protein synthesis, since the effect was abolished by cycloheximide.	Cycloheximide	252-265	chitin synthase CHS2	Saccharomyces cerevisiae S288C	117-121
3258332-4	1988	The degradation of IL-2 mRNA is selectively sensitive to cycloheximide and actinomycin D, inhibitors of protein and RNA synthesis, respectively.	Cycloheximide	57-70	interleukin 2	Homo sapiens	19-23
3258601-11	1988	Cycloheximide (0.1 mM), an inhibitor of protein synthesis, blocked the inhibitory effect of both TNF alpha and interleukin-1 on procollagen alpha 1(I) mRNA.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	97-106
3343244-9	1988	Addition of cycloheximide or puromycin to such cultures substantially reduced basal levels and markedly attenuated the cAMP-induced accumulation of cytochrome P450scc mRNA, but augmented the accumulation of adrenodoxin and fos mRNAs in additive and multiplicative fashions, respectively.	Cycloheximide	12-25	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	148-166
3125175-9	1988	In fact, the effects of TGF beta and cycloheximide on PAI-1 mRNA were additive.	Cycloheximide	37-50	serpin family E member 1	Homo sapiens	54-59
3125175-10	1988	In contrast, the induction of fibronectin, beta-actin, and type I procollagen (synthesized only in WI-38 cells) was abrogated by cycloheximide.	Cycloheximide	129-142	fibronectin 1	Homo sapiens	30-41
2838341-0	1988	[Modification by cycloheximide of the effects of insulin on the transport of calcium by sarcolemma of the myocardium].	Cycloheximide	17-30	insulin	Homo sapiens	49-56
2838341-3	1988	Pretreatment of myocardial preparation with cycloheximide in low concentrations completely blocks the inhibitory insulin effect on Ca2+-current due, probably, to a decrease in peptide formation.	Cycloheximide	44-57	insulin	Homo sapiens	113-120
2838341-5	1988	Possible mechanisms of modifying effect of cycloheximide on the function of insulin-dependent regulatory system in the myocardium, are discussed.	Cycloheximide	43-56	insulin	Homo sapiens	76-83
3316977-7	1987	Cycloheximide was also shown to significantly increase the c-fos mRNA level in HeLa cells.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	59-64
3390142-13	1988	Upon cycloheximide treatment, both free ODC activity and ODC-antizyme complex rapidly disappeared, although free antizyme and the inactive ODC protein were both quite stable.	Cycloheximide	5-18	ornithine decarboxylase, structural 1	Mus musculus	40-43
3390142-13	1988	Upon cycloheximide treatment, both free ODC activity and ODC-antizyme complex rapidly disappeared, although free antizyme and the inactive ODC protein were both quite stable.	Cycloheximide	5-18	ornithine decarboxylase, structural 1	Mus musculus	57-60
3390142-13	1988	Upon cycloheximide treatment, both free ODC activity and ODC-antizyme complex rapidly disappeared, although free antizyme and the inactive ODC protein were both quite stable.	Cycloheximide	5-18	ornithine decarboxylase, structural 1	Mus musculus	57-60
3371541-6	1988	Levels of SCP2 in the membrane-free supernatant are increased 2-fold already after 2 min incubation with LH and remain elevated for 24 h. The same response occurs with cells preincubated in the presence of cycloheximide for 4 h. SCP2 levels are also 2-fold increased after incubation with dibutyryl cAMP or 4 beta-phorbol 12-myristate 13-acetate (PMA) whereas these compounds stimulate steroid production 5.5- and 2-fold respectively.	Cycloheximide	206-219	sterol carrier protein 2	Rattus norvegicus	10-14
3371541-6	1988	Levels of SCP2 in the membrane-free supernatant are increased 2-fold already after 2 min incubation with LH and remain elevated for 24 h. The same response occurs with cells preincubated in the presence of cycloheximide for 4 h. SCP2 levels are also 2-fold increased after incubation with dibutyryl cAMP or 4 beta-phorbol 12-myristate 13-acetate (PMA) whereas these compounds stimulate steroid production 5.5- and 2-fold respectively.	Cycloheximide	206-219	sterol carrier protein 2	Rattus norvegicus	229-233
3281094-7	1988	However, a novel 3.0 kilobase transcript with homology to c-myb was detected in cycloheximide-treated NIH3T3 cells.	Cycloheximide	80-93	myeloblastosis oncogene	Mus musculus	58-63
3342259-3	1988	Administration of cycloheximide, phenoxybenzamine, phorbol 12-myristate 13-acetate, nifedipine, dexamethasone or indomethacin to partially hepatectomized rats prevented the synthesis of thymidylate synthetase in regenerating liver.	Cycloheximide	18-31	thymidylate synthetase	Rattus norvegicus	186-208
3123483-4	1988	However, the addition of increasing concentrations of tissue-type plasminogen activator (t-PA) or urokinase to confluent endothelial cells produced a saturable (3.0 pmol/5 x 10(5) cells), dose-dependent increase of the activator-PAI-1 complex in the conditioned medium even in the presence of actinomycin D or cycloheximide.	Cycloheximide	310-323	plasminogen activator, tissue type	Homo sapiens	54-87
3123483-4	1988	However, the addition of increasing concentrations of tissue-type plasminogen activator (t-PA) or urokinase to confluent endothelial cells produced a saturable (3.0 pmol/5 x 10(5) cells), dose-dependent increase of the activator-PAI-1 complex in the conditioned medium even in the presence of actinomycin D or cycloheximide.	Cycloheximide	310-323	plasminogen activator, tissue type	Homo sapiens	89-93
2829746-2	1988	With receptor synthesis inhibited by cycloheximide, the half-life of the surface TNF receptor was 2h in the absence of TNF and 30min in its presence, suggesting that the TNF receptor was non-recycling and that its internalization was accelerated by TNF.	Cycloheximide	37-50	tumor necrosis factor	Homo sapiens	81-84
2829746-3	1988	During cell incubation with suppression of TNF receptor degradation by chloroquine, the number of surface TNF receptors remained approximately constants, but the total number of surface and internal TNF receptors increased gradually, at 3h reaching 1.5 times of the initial number, thus suggesting continuous synthesis, externalization, internalization, and degradation of the TNF receptor in the absence of cycloheximide.	Cycloheximide	408-421	tumor necrosis factor	Homo sapiens	43-46
2829746-6	1988	In incubation with suppression of protein synthesis by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in the number to a peak level at 60 min and gradually decreasing.	Cycloheximide	55-68	tumor necrosis factor	Homo sapiens	87-90
2829746-6	1988	In incubation with suppression of protein synthesis by cycloheximide following surface TNF receptor digestion by trypsin, TNF receptors reappeared on the cell surface, increasing in the number to a peak level at 60 min and gradually decreasing.	Cycloheximide	55-68	tumor necrosis factor	Homo sapiens	122-125
3123388-7	1988	CSF production by peritoneal adherent cells was completely inhibited by cycloheximide (50 micrograms/ml), and neither the elimination of T cells from the peritoneal adherent cells by treating them with anti-Thy-1.2 antibody plus complement nor the addition of T cells affected CSF production.	Cycloheximide	72-85	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	0-3
2828427-7	1988	Furthermore, both sensitive and resistant epithelial tumor cells had the capacity to express TNF transcripts in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	161-174	tumor necrosis factor	Homo sapiens	93-96
2452846-3	1988	The protein synthesis inhibitor cycloheximide (CHX) also stimulates rapid but more stable expression of c-fos mRNA in these cells.	Cycloheximide	32-45	FBJ osteosarcoma oncogene	Mus musculus	104-109
2452846-3	1988	The protein synthesis inhibitor cycloheximide (CHX) also stimulates rapid but more stable expression of c-fos mRNA in these cells.	Cycloheximide	47-50	FBJ osteosarcoma oncogene	Mus musculus	104-109
3276786-4	1988	We observed that the IFN-beta 2 gene is transcribed at a low level in uninduced FS-4 cells and that this transcriptional activity is increased 2- to 3-fold in cycloheximide-treated cells, 20- to 35-fold in IL-1 alpha-treated cells, and 5- to 15-fold in TNF-treated cells.	Cycloheximide	159-172	interleukin 6	Homo sapiens	21-31
3276786-4	1988	We observed that the IFN-beta 2 gene is transcribed at a low level in uninduced FS-4 cells and that this transcriptional activity is increased 2- to 3-fold in cycloheximide-treated cells, 20- to 35-fold in IL-1 alpha-treated cells, and 5- to 15-fold in TNF-treated cells.	Cycloheximide	159-172	tumor necrosis factor	Homo sapiens	253-256
3276786-6	1988	The enhancing effect of IL-1 alpha on IFN-beta 2 gene transcription, but not that of TNF, PDGF, or IFN-beta 1, is inhibited by cycloheximide, suggesting that newly-synthesized protein is involved in the increase in IFN-beta 2 transcription in response to IL-1 alpha but not in the response to the other stimuli.	Cycloheximide	127-140	interleukin 1 alpha	Homo sapiens	24-34
3276786-6	1988	The enhancing effect of IL-1 alpha on IFN-beta 2 gene transcription, but not that of TNF, PDGF, or IFN-beta 1, is inhibited by cycloheximide, suggesting that newly-synthesized protein is involved in the increase in IFN-beta 2 transcription in response to IL-1 alpha but not in the response to the other stimuli.	Cycloheximide	127-140	interleukin 6	Homo sapiens	38-48
3276786-6	1988	The enhancing effect of IL-1 alpha on IFN-beta 2 gene transcription, but not that of TNF, PDGF, or IFN-beta 1, is inhibited by cycloheximide, suggesting that newly-synthesized protein is involved in the increase in IFN-beta 2 transcription in response to IL-1 alpha but not in the response to the other stimuli.	Cycloheximide	127-140	interleukin 6	Homo sapiens	215-225
3276786-6	1988	The enhancing effect of IL-1 alpha on IFN-beta 2 gene transcription, but not that of TNF, PDGF, or IFN-beta 1, is inhibited by cycloheximide, suggesting that newly-synthesized protein is involved in the increase in IFN-beta 2 transcription in response to IL-1 alpha but not in the response to the other stimuli.	Cycloheximide	127-140	interleukin 1 alpha	Homo sapiens	255-265
3285298-2	1988	Treatment with cycloheximide also causes a transient increase in the c-H-ras, c-myc and RaLV RNAs, with a time course similar to that obtained with UV irradiation.	Cycloheximide	15-28	HRas proto-oncogene, GTPase	Homo sapiens	69-76
3285298-2	1988	Treatment with cycloheximide also causes a transient increase in the c-H-ras, c-myc and RaLV RNAs, with a time course similar to that obtained with UV irradiation.	Cycloheximide	15-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	78-83
3127037-1	1988	The half-lives of tyrosinase isozymes, a key enzyme in melanogenesis, have been determined using two different approaches: (a) cycloheximide treatment of mice bearing growing tumors and measurement of the residual enzymatic activity.	Cycloheximide	127-140	tyrosinase	Mus musculus	18-28
3129288-6	1988	The protein synthesis inhibitor cycloheximide (CHX) induces a 20-fold increase in mature TCR-alpha transcript accumulation without a concomitant increase in TCR-alpha gene transcription suggesting that CHX reverses the nuclear post-transcriptional events which prevent mature TCR-alpha mRNA accumulation.	Cycloheximide	32-45	T cell receptor alpha chain	Mus musculus	89-98
3129288-6	1988	The protein synthesis inhibitor cycloheximide (CHX) induces a 20-fold increase in mature TCR-alpha transcript accumulation without a concomitant increase in TCR-alpha gene transcription suggesting that CHX reverses the nuclear post-transcriptional events which prevent mature TCR-alpha mRNA accumulation.	Cycloheximide	47-50	T cell receptor alpha chain	Mus musculus	89-98
3129288-7	1988	CHX also induces full length TCR-beta transcripts greater than 90-fold while TCR-beta gene transcription increases only 2- to 4-fold.	Cycloheximide	0-3	T cell receptor alpha variable 6-3	Mus musculus	29-32
3129288-7	1988	CHX also induces full length TCR-beta transcripts greater than 90-fold while TCR-beta gene transcription increases only 2- to 4-fold.	Cycloheximide	0-3	T cell receptor beta chain	Mus musculus	29-37
3335205-5	1988	The concentration of IGF-I in the calvarial culture medium was 1 nM and was suppressed by cycloheximide.	Cycloheximide	90-103	insulin-like growth factor 1	Rattus norvegicus	21-26
3391424-5	1988	The mean production of HCG, HPL, SP1, and PAPP-A was decreased when either cycloheximide, puromycin, iodoacetic acid, or 2,4-dinitrophenol had been added to the perfusing medium.	Cycloheximide	75-88	pappalysin 1	Homo sapiens	42-48
3138175-3	1988	Treatment with cycloheximide, an inhibitor of protein synthesis, prevented the IFN-gamma-mediated accumulation of E alpha mRNA in the mouse macrophage cell line P388 D.1, indicating that induction of E alpha mRNA in P388 D.1 cells requires de novo synthesis of a protein intermediate.	Cycloheximide	15-28	interferon gamma	Mus musculus	79-88
3246539-3	1988	Artificial inhibition of either RNA or protein synthesis by L-M cells, by addition of actinomycin D or cycloheximide, increased the cytotoxic effect of TNF and thus suggested that the elevated RNA and protein synthesis is related not to the cytotoxic reaction itself but rather to a defense mechanism.	Cycloheximide	103-116	tumor necrosis factor	Homo sapiens	152-155
3121740-7	1988	The early accumulation of TFR mRNA in PDB/ionomycin-stimulated T cells seemed, in part, independent of the interaction of IL-2 with its own receptor, because TFR mRNA was detectable as early as 1 hr after stimulation and addition of cycloheximide before addition of PDB/ionomycin did not abolish the PDB/ionomycin-induced accumulation of TFR mRNA.	Cycloheximide	233-246	transferrin receptor	Homo sapiens	26-29
3278078-9	1988	Cycloheximide at 5-10 micrograms/ml completely blocked IL-1-induced breakdown.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	55-59
3210813-5	1988	Expression of TNF protein was assayed for by cytotoxic activity for cycloheximide-treated SV80 fibroblasts.	Cycloheximide	68-81	tumor necrosis factor	Cricetulus griseus	14-17
3135483-7	1988	(Bu)2cAMP treatment led to a sustained induction of c-fos mRNA, with increased mRNA levels being maintained after 12 h. The FSH-dependent induction of c-fos mRNA was still present in cells treated for 3 h with cycloheximide, but it was greatly reduced by actinomycin D pretreatment.	Cycloheximide	210-223	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-57
3135483-7	1988	(Bu)2cAMP treatment led to a sustained induction of c-fos mRNA, with increased mRNA levels being maintained after 12 h. The FSH-dependent induction of c-fos mRNA was still present in cells treated for 3 h with cycloheximide, but it was greatly reduced by actinomycin D pretreatment.	Cycloheximide	210-223	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	151-156
3279036-9	1988	Transformation led also to about 3-fold stabilization of ODC as determined by an exposure of the cells to cycloheximide.	Cycloheximide	106-119	ornithine decarboxylase, structural 1	Mus musculus	57-60
2832315-4	1988	The enhancing effect of rIFN-gamma on the respiratory response of PMN was not blocked by polymixin B sulphate, but an anti-rIFN-gamma monoclonal antibody and cycloheximide and actinomycin D were effective inhibitors.	Cycloheximide	158-171	interferon gamma	Rattus norvegicus	24-34
2832424-9	1988	The induction of ODC mRNA by either LPS or TPA was blocked by the addition of cycloheximide (25 micrograms/ml) or anisomycin (0.1 mM) to the cellular incubation mixture.	Cycloheximide	78-91	ornithine decarboxylase, structural 1	Mus musculus	17-20
2832424-11	1988	Experiments in which cycloheximide addition was delayed after LPS treatment indicated that some of the required protein synthesis occurred within the first 30 minutes and that complete expression of ODC mRNA was possible if protein synthesis continued for at least 2 hours before cycloheximide was added.	Cycloheximide	21-34	ornithine decarboxylase, structural 1	Mus musculus	199-202
2832424-11	1988	Experiments in which cycloheximide addition was delayed after LPS treatment indicated that some of the required protein synthesis occurred within the first 30 minutes and that complete expression of ODC mRNA was possible if protein synthesis continued for at least 2 hours before cycloheximide was added.	Cycloheximide	280-293	ornithine decarboxylase, structural 1	Mus musculus	199-202
3126194-7	1988	Cycloheximide, an inhibitor of protein biosynthesis induced a rapid transient increase of t-PA, u-PA and PAI-1 mRNA and a sustained increase of PAI-2 mRNA, but blocked the more long term effects of Dex, suggesting that both constitutive and hormonally regulated maintenance of mRNA steady state levels required protein biosynthesis.	Cycloheximide	0-13	plasminogen activator, tissue type	Homo sapiens	90-94
3126194-7	1988	Cycloheximide, an inhibitor of protein biosynthesis induced a rapid transient increase of t-PA, u-PA and PAI-1 mRNA and a sustained increase of PAI-2 mRNA, but blocked the more long term effects of Dex, suggesting that both constitutive and hormonally regulated maintenance of mRNA steady state levels required protein biosynthesis.	Cycloheximide	0-13	plasminogen activator, urokinase	Homo sapiens	96-100
3126194-7	1988	Cycloheximide, an inhibitor of protein biosynthesis induced a rapid transient increase of t-PA, u-PA and PAI-1 mRNA and a sustained increase of PAI-2 mRNA, but blocked the more long term effects of Dex, suggesting that both constitutive and hormonally regulated maintenance of mRNA steady state levels required protein biosynthesis.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	105-110
3126194-7	1988	Cycloheximide, an inhibitor of protein biosynthesis induced a rapid transient increase of t-PA, u-PA and PAI-1 mRNA and a sustained increase of PAI-2 mRNA, but blocked the more long term effects of Dex, suggesting that both constitutive and hormonally regulated maintenance of mRNA steady state levels required protein biosynthesis.	Cycloheximide	0-13	serpin family B member 2	Homo sapiens	144-149
2965211-8	1988	Since cycloheximide and actinomycin D inhibited the induction of IL-1-R by GC, synthesis of both new RNA and protein seems to be required for IL-1-R induction.	Cycloheximide	6-19	interleukin 1 receptor type 1	Homo sapiens	65-71
2892891-3	1988	Cycloheximide and actinomycin D inhibited the induction of glutamine synthetase in astrocytes by neurons, whereas cytosine arabinoside had no apparent effect.	Cycloheximide	0-13	glutamate-ammonia ligase	Rattus norvegicus	59-79
3278316-8	1988	PDGF B-chain transcripts in newborn rat aortic SMC are short-lived and increased 5-fold by 3 hr after treatment with cycloheximide.	Cycloheximide	117-130	platelet derived growth factor subunit B	Rattus norvegicus	0-6
3283822-4	1988	It is suggested that X-radiation induction of pRL gene expression is related to the increased transcription of the corresponding mRNA since their level does not change in conditions of cycloheximide blockade of the protein synthesis.	Cycloheximide	185-198	prolactin	Rattus norvegicus	46-49
3422640-2	1988	TGF-beta regulates the level and molecular size of these proteoglycans by acting simultaneously at two levels: it elevates the biosynthetic rate of the 45-kDa proteoglycan core protein in a cycloheximide- and actinomycin D-sensitive manner, and it induces an increase in the molecular mass of the glycosaminoglycan chains.	Cycloheximide	190-203	transforming growth factor beta 1	Homo sapiens	0-8
3422482-5	1988	Concomitant treatment with cycloheximide prevented the stimulation observed with TGF-beta.	Cycloheximide	27-40	transforming growth factor, beta 1	Mus musculus	81-89
3341033-5	1988	The increases in ODC and heme oxygenase activities evoked by DEM were almost completely blocked by pretreatment of rats with either actinomycin D or cycloheximide.	Cycloheximide	149-162	ornithine decarboxylase 1	Rattus norvegicus	17-20
3121611-5	1988	(iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction.	Cycloheximide	6-19	interferon gamma	Homo sapiens	103-112
3121611-5	1988	(iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction.	Cycloheximide	6-19	interferon gamma	Homo sapiens	203-212
3121611-5	1988	(iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction.	Cycloheximide	6-19	interferon gamma	Homo sapiens	203-212
3121611-5	1988	(iii) Cycloheximide (50 micrograms/ml) and anisomycin (10 micron or higher) inhibited the induction by IFN-gamma but not by IFN-alpha 2, suggesting the requirement for some newly synthesized, presumably IFN-gamma-induced, protein factor(s) in IFN-gamma-mediated but not in IFN-alpha 2-mediated induction.	Cycloheximide	6-19	interferon alpha 2	Homo sapiens	273-284
3121611-6	1988	Interestingly, this inhibition by cycloheximide of the IFN-gamma-mediated induction was overcome by 24 h, whereas a sustained inhibition was obtained with anisomycin.	Cycloheximide	34-47	interferon gamma	Homo sapiens	55-64
3121611-8	1988	As analyzed by nuclear runoff transcription, IFN-gamma induced the transcription of C5-4-specific RNA within 2 h and it was inhibited by cycloheximide, indicating that the newly synthesized protein mediator(s) required plays a role in the transcriptional activation of the C5-4 gene by IFN-gamma.	Cycloheximide	137-150	interferon gamma	Homo sapiens	45-54
3121611-8	1988	As analyzed by nuclear runoff transcription, IFN-gamma induced the transcription of C5-4-specific RNA within 2 h and it was inhibited by cycloheximide, indicating that the newly synthesized protein mediator(s) required plays a role in the transcriptional activation of the C5-4 gene by IFN-gamma.	Cycloheximide	137-150	interferon gamma	Homo sapiens	286-295
2447802-8	1988	Despite the inhibition of flow in vasopressin-treated tissues, the cAMP-dependent protein kinase ratio (-cAMP/+cAMP), an index of in vivo cAMP effect, was elevated in cycloheximide-treated tissues, suggesting modulation at a distal site in the stimulatory cascade.	Cycloheximide	167-180	arginine vasopressin	Homo sapiens	34-45
2447802-9	1988	Cycloheximide inhibited flow when 10 microM forskolin or 0.2 mM 8-BrcAMP was substituted for vasopressin in the fourth period; however, MIX (4 mM)-stimulated flow was enhanced by 1 microgram/ml cycloheximide but inhibited by 200 micrograms/ml cycloheximide.	Cycloheximide	0-13	arginine vasopressin	Homo sapiens	93-104
2470302-0	1988	Interleukin-1 alpha mRNA induced by cycloheximide PMA, and retinoic acid is reduced by dexamethasone in PAM-212 keratinocytes.	Cycloheximide	36-49	interleukin 1 alpha	Homo sapiens	0-19
2470302-0	1988	Interleukin-1 alpha mRNA induced by cycloheximide PMA, and retinoic acid is reduced by dexamethasone in PAM-212 keratinocytes.	Cycloheximide	36-49	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	104-107
2470302-1	1988	Keratinocytes in culture produce detectable amounts of IL-1 alpha mRNA constitutively and can be stimulated to express increased amounts of IL-1 alpha mRNA by cycloheximide, PMA, and retinoic acid.	Cycloheximide	159-172	interleukin 1 alpha	Homo sapiens	55-65
2470302-1	1988	Keratinocytes in culture produce detectable amounts of IL-1 alpha mRNA constitutively and can be stimulated to express increased amounts of IL-1 alpha mRNA by cycloheximide, PMA, and retinoic acid.	Cycloheximide	159-172	interleukin 1 alpha	Homo sapiens	140-150
2829853-9	1988	These studies show that hCG and db cyclic AMP stimulation of MA-10 cells results in the rapid induction of cycloheximide-sensitive proteins located in the mitochondria which may be instrumental in the acute regulation of steroidogenesis.	Cycloheximide	107-120	hypertrichosis 2 (generalised, congenital)	Homo sapiens	24-27
3144696-2	1988	This increase of c-fos and c-myc transcripts could result from both an increased gene transcription and a stabilization of the corresponding mRNAs, as suggested by the effects of cycloheximide and actinomycin D.	Cycloheximide	179-192	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	17-22
3144696-2	1988	This increase of c-fos and c-myc transcripts could result from both an increased gene transcription and a stabilization of the corresponding mRNAs, as suggested by the effects of cycloheximide and actinomycin D.	Cycloheximide	179-192	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	27-32
3691536-4	1987	The untranslated ODC mRNA in resting cells could be completely shifted into polysomes by a 15-min treatment of the cells with appropriate concentrations of cycloheximide.	Cycloheximide	156-169	ornithine decarboxylase	Bos taurus	17-20
2827645-3	1987	After thymidine block, growth-arrested Ob17PY cells become able to bind ApoAI, ApoAII and HDL3; this recovery is prevented in actinomycin D- or cycloheximide-treated cells.	Cycloheximide	144-157	apolipoprotein A-II	Mus musculus	79-85
2827645-3	1987	After thymidine block, growth-arrested Ob17PY cells become able to bind ApoAI, ApoAII and HDL3; this recovery is prevented in actinomycin D- or cycloheximide-treated cells.	Cycloheximide	144-157	high density lipoprotein (HDL) level 3	Mus musculus	90-94
3503705-6	1987	The products of the tra-2 gene are also required for continuous transcription of the yolk-protein genes, suggesting that the pathway inhibited by the cycloheximide is that of the sex-determination hierarchy.	Cycloheximide	150-163	transformer 2	Drosophila melanogaster	20-25
3503705-6	1987	The products of the tra-2 gene are also required for continuous transcription of the yolk-protein genes, suggesting that the pathway inhibited by the cycloheximide is that of the sex-determination hierarchy.	Cycloheximide	150-163	Yolk protein 1	Drosophila melanogaster	85-97
3121313-6	1987	Cycloheximide even superinduces this gene when added together with poly(rI).poly(rC) and interleukin-1 (but not when added with interferon).	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	89-102
2834347-5	1987	Following removal of TNF from growth medium, binding activity was restored within 3 h. Cycloheximide prevented the restoration of TNF receptors, suggesting that de novo synthesis of receptors was required to restore the binding activity.	Cycloheximide	87-100	tumor necrosis factor	Homo sapiens	130-133
3480288-5	1987	The rise in AP activity started 6 h after TGF beta 1 addition and was blocked by cycloheximide and actinomycin D.	Cycloheximide	81-94	transforming growth factor, beta 1	Rattus norvegicus	42-52
3680518-3	1987	The proteinase could not be detected in the media of cultures that had been treated with 0.5 micrograms/ml of cycloheximide.	Cycloheximide	110-123	endogenous retrovirus group K member 25	Homo sapiens	4-14
2824613-14	1987	However, both mediators act by inducing the transcription of the HDC gene and de novo synthesis of this enzyme since actinomycin D or cycloheximide abolish GM-CSF-or IL-3-induced histamine-producing cell-stimulating activity.	Cycloheximide	134-147	histidine decarboxylase	Mus musculus	65-68
2824613-14	1987	However, both mediators act by inducing the transcription of the HDC gene and de novo synthesis of this enzyme since actinomycin D or cycloheximide abolish GM-CSF-or IL-3-induced histamine-producing cell-stimulating activity.	Cycloheximide	134-147	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	156-162
2824613-14	1987	However, both mediators act by inducing the transcription of the HDC gene and de novo synthesis of this enzyme since actinomycin D or cycloheximide abolish GM-CSF-or IL-3-induced histamine-producing cell-stimulating activity.	Cycloheximide	134-147	interleukin 3	Mus musculus	166-170
2484717-6	1987	Androgen treatment of 4-day castrate rats caused c-myc mRNA levels to decrease within 4 h. Cycloheximide increased c-myc mRNA severalfold within 2 h. The net increase in c-myc mRNA after cycloheximide treatment was greater in the castrate than in the noncastrate or in androgen-treated castrate rats.	Cycloheximide	91-104	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	115-120
2484717-6	1987	Androgen treatment of 4-day castrate rats caused c-myc mRNA levels to decrease within 4 h. Cycloheximide increased c-myc mRNA severalfold within 2 h. The net increase in c-myc mRNA after cycloheximide treatment was greater in the castrate than in the noncastrate or in androgen-treated castrate rats.	Cycloheximide	91-104	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	115-120
2890635-8	1987	The induction of SAA is pretranslational and is likely to be mediated by protein factor(s) since incubation with cycloheximide diminished IL-1-dependent increase in SAA mRNA.	Cycloheximide	113-126	serum amyloid A1 cluster	Homo sapiens	17-20
2890635-8	1987	The induction of SAA is pretranslational and is likely to be mediated by protein factor(s) since incubation with cycloheximide diminished IL-1-dependent increase in SAA mRNA.	Cycloheximide	113-126	interleukin 1 alpha	Homo sapiens	138-142
2890635-8	1987	The induction of SAA is pretranslational and is likely to be mediated by protein factor(s) since incubation with cycloheximide diminished IL-1-dependent increase in SAA mRNA.	Cycloheximide	113-126	serum amyloid A1 cluster	Homo sapiens	165-168
2960953-1	1987	We have isolated and characterized a Neurospora crassa gene homologous to the yeast CYH2 gene encoding L29, a cycloheximide sensitivity-conferring protein of the cytoplasmic ribosome.	Cycloheximide	110-123	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	84-88
3689389-0	1987	Differential effects of cycloheximide on rat liver cytochrome P-450 gene transcription in the whole animal and hepatoma cell culture.	Cycloheximide	24-37	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	51-67
3689389-2	1987	Administration of cycloheximide blocks the induction of cytochrome P-450 (c+d) messenger RNAs by 3-methylcholanthrene as well as cytochrome P-450 (b+e) messenger RNAs by Phenobarbitone.	Cycloheximide	18-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	56-72
3689389-2	1987	Administration of cycloheximide blocks the induction of cytochrome P-450 (c+d) messenger RNAs by 3-methylcholanthrene as well as cytochrome P-450 (b+e) messenger RNAs by Phenobarbitone.	Cycloheximide	18-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	129-145
3689395-1	1987	As in many other cell types, autoregulation of tubulin synthesis is evident in the intestinal epithelium of normal (vitamin D-replete) chicks: Suppression of protein (tubulin) synthesis by cycloheximide administration in vivo resulted within 30 min in a two-fold increase in RNA hybridizing with an alpha-tubulin probe.	Cycloheximide	189-202	tubulin alpha-5 chain	Gallus gallus	299-312
2444591-6	1987	However, treatment of chondroblasts with low concentrations of cycloheximide, an elongation inhibitor, suggests movement of the ribosomes on the alpha 2(I) collagen RNA may be partially blocked, resulting in a severe reduction in the translation elongation rate.	Cycloheximide	63-76	collagen type I alpha 2 chain	Gallus gallus	145-164
22358442-4	1987	The expression of c-fos by PMN was superinduced by cycloheximide.	Cycloheximide	51-64	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
3308495-10	1987	In addition, the N-myc and c-myc genes differed in F9 cells with respect to (i) the kinetics of expression following induction of differentiation, c-myc undergoing quicker changes than N-myc; (ii) the response to cycloheximide inhibition of protein synthesis, indicating that c-myc but not N-myc is down-regulated by a short-lived protein; and (iii) the half-lives of the transcripts, estimated to be approximately 40 min for c-myc and 130 min for N-myc.	Cycloheximide	213-226	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	17-22
2478164-4	1987	However, when cycloheximide, an inhibitor of protein synthesis is added at the time of virus infection, extensive cleavage or rRNA is observed in IFN-treated, infected cells.	Cycloheximide	14-27	interferon alpha 1	Homo sapiens	146-149
3316977-8	1987	There results are consistent with the observation that these inducers of the heat shock response, as well as cycloheximide, repress protein synthesis and suggest that the increase in the level of c-fos mRNA is caused by an inhibition of protein synthesis.	Cycloheximide	109-122	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	196-201
3497983-5	1987	rIL-1 induced IL-1-alpha mRNA only in EC treated concomitantly with cycloheximide (2 micrograms/ml).	Cycloheximide	68-81	interleukin 1 alpha	Homo sapiens	14-24
3497983-8	1987	rIL-1 also induced the release of biologically active IL-1 from EC, which was inhibited by cycloheximide (1 microgram/ml).	Cycloheximide	91-104	interleukin 1 beta	Homo sapiens	1-5
3632701-6	1987	Inhibition of protein synthesis by cycloheximide (10 micrograms/ml) led to a superinduction of ODC mRNA in the presence of TPA, which suggested that a short-lived protein may be responsible for negative control of ODC expression.	Cycloheximide	35-48	ornithine decarboxylase 1	Rattus norvegicus	95-98
3632701-6	1987	Inhibition of protein synthesis by cycloheximide (10 micrograms/ml) led to a superinduction of ODC mRNA in the presence of TPA, which suggested that a short-lived protein may be responsible for negative control of ODC expression.	Cycloheximide	35-48	ornithine decarboxylase 1	Rattus norvegicus	214-217
3497923-4	1987	A similar rapid increase in c-fos and c-myc mRNA was seen in quiescent FS-4 cells exposed to cycloheximide.	Cycloheximide	93-106	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
3497923-4	1987	A similar rapid increase in c-fos and c-myc mRNA was seen in quiescent FS-4 cells exposed to cycloheximide.	Cycloheximide	93-106	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	38-43
3620483-3	1987	After addition of cycloheximide, cell-associated lipoprotein lipase activity decreased rapidly.	Cycloheximide	18-31	lipoprotein lipase	Homo sapiens	49-67
3624250-3	1987	We now report that when protein synthesis is inhibited in mouse peritoneal macrophages by treatment with cycloheximide, puromycin, or actinomycin D, native LDL-induced whole-cell ACAT activity and CE accumulation is 10-fold higher than that seen in LDL-treated control cells.	Cycloheximide	105-118	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	179-183
3624250-4	1987	The enhancement of ACAT activity was seen 4 h after the addition of cycloheximide, and ACAT activity returned to control values 4 h after the withdrawal of cycloheximide.	Cycloheximide	68-81	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	19-23
3624250-4	1987	The enhancement of ACAT activity was seen 4 h after the addition of cycloheximide, and ACAT activity returned to control values 4 h after the withdrawal of cycloheximide.	Cycloheximide	156-169	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	87-91
3624250-5	1987	Postnuclear supernatants and microsomes from cycloheximide-treated mouse peritoneal macrophages also had higher ACAT activity than microsomes from control cells, but the relative enhancement (maximum 3.3-fold) was less than that seen when ACAT was assayed in the intact cell.	Cycloheximide	45-58	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	112-116
3624250-5	1987	Postnuclear supernatants and microsomes from cycloheximide-treated mouse peritoneal macrophages also had higher ACAT activity than microsomes from control cells, but the relative enhancement (maximum 3.3-fold) was less than that seen when ACAT was assayed in the intact cell.	Cycloheximide	45-58	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	239-243
3624250-6	1987	In contrast to the situation with mouse peritoneal macrophages, cycloheximide treatment of J774 macrophages, which under normal conditions display high ACAT activity and CE accumulation in the presence of native LDL, did not result in further enhancement of either ACAT activity or LDL-induced CE accumulation.	Cycloheximide	64-77	acetyl-Coenzyme A acetyltransferase 1	Mus musculus	152-156
2820238-4	1987	Cycloheximide, 5 microM, completely inhibited the GnRH-stimulated LH and FSH secretion.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Homo sapiens	50-54
3040409-0	1987	Cycloheximide induces accumulation of vasoactive intestinal peptide (VIP) binding sites at the cell surface of a human colonic adenocarcinoma cell line (HT29-D4).	Cycloheximide	0-13	vasoactive intestinal peptide	Homo sapiens	69-72
3040409-2	1987	Incubation of monolayers of HT29-D4 cells (a clone of the human colonic adenocarcinoma cell line HT29) in the presence of 17.5 microM cycloheximide resulted in an increase in the number of vasoactive intestinal peptide (VIP) binding sites at the cell surface without any change in the affinity of receptor for its ligand.	Cycloheximide	134-147	vasoactive intestinal peptide	Homo sapiens	220-223
3040409-3	1987	The increase in 125I-VIP-binding capacity was dose-dependent between 0.35 microM and 17.5 microM cycloheximide and was correlated with the inhibition of protein biosynthesis.	Cycloheximide	97-110	vasoactive intestinal peptide	Homo sapiens	21-24
3040409-5	1987	We found that VIP receptors of HT29-D4 cells with such an enhanced binding capacity behaved like those of control cells with respect to receptor internalization and recycling (i.e. the cycle of occupied receptors was insensitive to cycloheximide).	Cycloheximide	232-245	vasoactive intestinal peptide	Homo sapiens	14-17
3115790-2	1987	Upon treatment with cycloheximide or other kinds of protein synthesis inhibitors, the transcription of HIG1 gene was induced in L cell transformants as well as in T cell transformants.	Cycloheximide	20-33	HIG1 domain family, member 1A	Mus musculus	103-107
3115790-3	1987	Transcription rate of bacterial gpt gene, which was derived from the plasmid vector used for transfection of HIG1 gene and located just upstream of HIG1 in the transformants, was also greatly enhanced after cycloheximide treatment.	Cycloheximide	207-220	HIG1 domain family, member 1A	Mus musculus	109-113
3115790-3	1987	Transcription rate of bacterial gpt gene, which was derived from the plasmid vector used for transfection of HIG1 gene and located just upstream of HIG1 in the transformants, was also greatly enhanced after cycloheximide treatment.	Cycloheximide	207-220	HIG1 domain family, member 1A	Mus musculus	148-152
3115790-5	1987	Nuclear transcription assay indicated that the appearance of HIG1 gene transcripts after treatment with cycloheximide was mainly due to the induction of the transcription.	Cycloheximide	104-117	HIG1 domain family, member 1A	Mus musculus	61-65
3115790-6	1987	Deletion of an enhancer element from HIG1 gene lowered the inducing activity of cycloheximide in the L cell transformants, but a low level of HIG1 gene expression was still observed.	Cycloheximide	80-93	HIG1 domain family, member 1A	Mus musculus	37-41
3374475-2	1988	The secretion of LPL occurred in two phases: a rapid release (5-10 min of incubation with heparin) that was independent of protein synthesis followed by a slower rate of release that was inhibited by cycloheximide.	Cycloheximide	200-213	lipoprotein lipase	Rattus norvegicus	17-20
3308493-5	1987	This response of cessation of cell division is different from the response of cells to an equivalent limitation of protein synthesis using cycloheximide or verrucarin A, which implies that the PRT1 gene product could separately influence both cellular growth via protein synthesis and events in the regulation of cell proliferation.	Cycloheximide	139-152	translation initiation factor eIF3 core subunit b	Saccharomyces cerevisiae S288C	193-197
2821226-9	1987	Cycloheximide (3.5 microM) blocked both the recovery of alpha-1 receptors and the recovery of alpha-1-stimulated inositide hydrolysis after 24 hr of NE pretreatment.	Cycloheximide	0-13	adrenoceptor alpha 1D	Homo sapiens	56-63
2821226-9	1987	Cycloheximide (3.5 microM) blocked both the recovery of alpha-1 receptors and the recovery of alpha-1-stimulated inositide hydrolysis after 24 hr of NE pretreatment.	Cycloheximide	0-13	adrenoceptor alpha 1D	Homo sapiens	94-101
2959858-2	1987	In the presence of the protein synthesis inhibitors pactamycin or cycloheximide, E1A was correctly posttranslationally modified (phosphorylated) and transported to the nucleus; but it failed to stimulate the transcription of an injected gene containing the human heat shock protein 70 promoter.	Cycloheximide	66-79	macrophage stimulating 1 S homeolog	Xenopus laevis	81-84
2959858-4	1987	If oocytes were cultured in the presence of cycloheximide after E1A stimulated transcription, however, the high level of transcription was maintained for several hours without new protein synthesis.	Cycloheximide	44-57	macrophage stimulating 1 S homeolog	Xenopus laevis	64-67
3109985-7	1987	ODC activity was maximal by 4 to 8 hr and could be completely inhibited by preincubation of the cells with actinomycin D or cycloheximide, indicating that de novo synthesis of RNA and protein is necessary for enzyme induction.	Cycloheximide	124-137	ornithine decarboxylase, structural 1	Mus musculus	0-3
3624492-0	1987	Human chorionic gonadotropin and 8-bromo cyclic adenosine monophosphate promote an acute increase in cytochrome P450scc and adrenodoxin messenger RNAs in cultured human granulosa cells by a cycloheximide-insensitive mechanism.	Cycloheximide	190-203	cytochrome P450 family 11 subfamily A member 1	Homo sapiens	101-119
2888113-5	1987	Phorbol ester, dexamethasone, and cycloheximide distinguished between bradykinin-stimulated PGE2 synthesis and InsP formation.	Cycloheximide	34-47	kininogen 1	Homo sapiens	70-80
2888113-8	1987	Cycloheximide inhibited bradykinin-stimulated PGE2 synthesis but was without effect on bradykinin-stimulated InsP formation.	Cycloheximide	0-13	kininogen 1	Homo sapiens	24-34
3632665-4	1987	Additionally, we were able to detect stable ODC mRNAs in cycloheximide pretreated fibroblasts.	Cycloheximide	57-70	ornithine decarboxylase, structural 1	Mus musculus	44-47
3496959-8	1987	In the presence of cycloheximide, the EGF receptor mRNA was super-induced in response to EGF.	Cycloheximide	19-32	epidermal growth factor receptor	Homo sapiens	38-50
3496959-9	1987	Treatment of the cells with TGF beta enhances the EGF-dependent superinduction of EGF receptor mRNA produced by cycloheximide, suggesting that the stimulatory action of TGF beta does not depend on continuous protein synthesis.	Cycloheximide	112-125	transforming growth factor beta 1	Homo sapiens	28-36
3496959-9	1987	Treatment of the cells with TGF beta enhances the EGF-dependent superinduction of EGF receptor mRNA produced by cycloheximide, suggesting that the stimulatory action of TGF beta does not depend on continuous protein synthesis.	Cycloheximide	112-125	epidermal growth factor receptor	Homo sapiens	82-94
3496959-9	1987	Treatment of the cells with TGF beta enhances the EGF-dependent superinduction of EGF receptor mRNA produced by cycloheximide, suggesting that the stimulatory action of TGF beta does not depend on continuous protein synthesis.	Cycloheximide	112-125	transforming growth factor beta 1	Homo sapiens	169-177
2442724-4	1987	Treatment of undifferentiated PCC4 cells by cycloheximide led to transcriptional induction of the endo A gene, and the same effect was observed after this treatment in PCC4-31 cells.	Cycloheximide	44-57	keratin 8	Mus musculus	98-104
3611087-13	1987	When protein synthesis was blocked by cycloheximide, the level of lipoprotein lipase activity in adipocytes decreased more rapidly than the amount of lipase protein in the cells.	Cycloheximide	38-51	lipoprotein lipase	Bos taurus	66-84
3312425-5	1987	The IFN effect was not expressed at 4 degrees C, and the ribosomal 60S subunit inactivators, cycloheximide, abrin, and shigella toxin, completely blocked the expression of the IFN-induced anti-invasive state of the cell.	Cycloheximide	93-106	interferon alpha 1	Homo sapiens	176-179
3037540-11	1987	Most importantly, whereas MSH-induced arborization occurred in the presence of cycloheximide, actinomycin D, or in enucleated cells, the reversal of arborization did not.	Cycloheximide	79-92	proopiomelanocortin	Homo sapiens	26-29
3474651-6	1987	The superinduction of c-fos and c-myc expression by an inhibitor of protein synthesis (cycloheximide) was reflected in the persistence of the unfolded, transcriptionally active state of their component nucleosomes.	Cycloheximide	87-100	FBJ osteosarcoma oncogene	Mus musculus	22-27
3629591-8	1987	It is concluded that the cycloheximide pretreatment potentiates DFP toxicity by a mechanism that is related to inhibition of the synthesis of proteins such as AChE, BuChE, and CarbE.	Cycloheximide	25-38	acetylcholinesterase	Rattus norvegicus	159-163
3629591-8	1987	It is concluded that the cycloheximide pretreatment potentiates DFP toxicity by a mechanism that is related to inhibition of the synthesis of proteins such as AChE, BuChE, and CarbE.	Cycloheximide	25-38	butyrylcholinesterase	Rattus norvegicus	165-170
3034414-8	1987	However, cycloheximide treatment does exert a posttranscriptional effect involving the specific stabilization of the c-myc message.	Cycloheximide	9-22	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	117-122
3594575-1	1987	Tumor necrosis factor (TNF) is cytocidal for human and murine cells when protein synthesis is inhibited by cycloheximide, but some protease inhibitors completely protect these cells from TNF cytotoxicity.	Cycloheximide	107-120	tumor necrosis factor	Homo sapiens	0-21
3621358-0	1987	Studies on ornithine decarboxylase from liver, kidney and tumoral tissues during activity decay following cycloheximide administration.	Cycloheximide	106-119	ornithine decarboxylase 1	Rattus norvegicus	11-34
3474142-7	1987	The increase in AP activity mediated by TGF beta could be completely inhibited with actinomycin D and cycloheximide.	Cycloheximide	102-115	transforming growth factor, beta 1	Rattus norvegicus	40-48
3497813-7	1987	Both c-fos and c-myc mRNA expression were super-induced by the addition of cycloheximide.	Cycloheximide	75-88	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	5-10
3497813-7	1987	Both c-fos and c-myc mRNA expression were super-induced by the addition of cycloheximide.	Cycloheximide	75-88	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	15-20
3594575-1	1987	Tumor necrosis factor (TNF) is cytocidal for human and murine cells when protein synthesis is inhibited by cycloheximide, but some protease inhibitors completely protect these cells from TNF cytotoxicity.	Cycloheximide	107-120	tumor necrosis factor	Homo sapiens	23-26
3040496-4	1987	The induction of class I proteins by interferon-gamma was nearly completely abolished by cycloheximide.	Cycloheximide	89-102	interferon gamma	Rattus norvegicus	37-53
3153473-0	1987	Cycloheximide inhibits S-14 gene transcription and abolishes DNase I hypersensitive S-14 sites in the livers of euthyroid but not hypothyroid rats.	Cycloheximide	0-13	thyroid hormone responsive	Rattus norvegicus	23-27
3496595-1	1987	A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor.	Cycloheximide	176-189	interferon beta 1	Homo sapiens	77-92
3496595-1	1987	A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor.	Cycloheximide	176-189	interferon beta 1	Homo sapiens	94-102
3496595-1	1987	A 26-kDa protein, originally described in human fibroblasts superinduced for interferon beta (IFN-beta) production, and termed IFN-beta 2 by other investigators, is induced by cycloheximide and by a 22-kDa, interleukin 1 (IL-1)-related factor.	Cycloheximide	176-189	interleukin 6	Homo sapiens	127-137
3496595-4	1987	Addition of cycloheximide to recombinant (r)IL-1 beta and rTNF further enhances the level of 26-kDa-protein mRNA.	Cycloheximide	12-25	interleukin 1 beta	Homo sapiens	44-53
3496595-4	1987	Addition of cycloheximide to recombinant (r)IL-1 beta and rTNF further enhances the level of 26-kDa-protein mRNA.	Cycloheximide	12-25	tumor necrosis factor	Rattus norvegicus	58-62
3593748-5	1987	Cycloheximide (0.5 mM) inhibited uptake of cholesterol by enterocytes and blocked its effect on 125I-labeled HDL3 binding.	Cycloheximide	0-13	HDL3	Homo sapiens	109-113
2438034-6	1987	Actinomycin D, cycloheximide, and the tyrosinase inhibitor phenylthiocarbamide blocked tyrosinase activation but did not alter the inhibitory effect of PGE1 on proliferation.	Cycloheximide	15-28	tyrosinase	Mus musculus	87-97
3153473-0	1987	Cycloheximide inhibits S-14 gene transcription and abolishes DNase I hypersensitive S-14 sites in the livers of euthyroid but not hypothyroid rats.	Cycloheximide	0-13	deoxyribonuclease 1	Rattus norvegicus	61-68
3153473-0	1987	Cycloheximide inhibits S-14 gene transcription and abolishes DNase I hypersensitive S-14 sites in the livers of euthyroid but not hypothyroid rats.	Cycloheximide	0-13	thyroid hormone responsive	Rattus norvegicus	84-88
3495577-5	1987	Cycloheximide inhibition of new protein synthesis causes a superinduction of IL 1 message, but does not alter the initial kinetics of message production.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	77-81
3041200-3	1987	Cycloheximide blocked the action of insulin on glycogen synthase, glycogen synthase phosphatase and phosphorylase phosphatase.	Cycloheximide	0-13	insulin	Homo sapiens	36-43
2959271-10	1987	However, exposure of minced pieces of hearts of hypothyroid rats to tri-iodothyronine for 5 h resulted in a clear increase in phosphofructokinase-1 activity, which was partially prevented by the simultaneous addition of cycloheximide.	Cycloheximide	220-233	phosphofructokinase, liver type	Rattus norvegicus	126-147
3106075-4	1987	The rise in enzyme activity was blocked by actinomycin D and cycloheximide, suggesting control at the transcriptional and translational levels, alpha-Difluoromethylornithine (DFMO), a catalytic and irreversible inhibitor of ODC, prevented the appearance of enzyme activity.	Cycloheximide	61-74	ornithine decarboxylase 1	Homo sapiens	224-227
3111844-2	1987	TGF-beta causes an early increase in the PAI-1 mRNA level which reaches a maximal 50-fold enhancement after 8 h. Blocking of protein synthesis with cycloheximide causes an equally strong increase in the level of PAI-1 mRNA.	Cycloheximide	148-161	serpin family E member 1	Homo sapiens	41-46
3111844-2	1987	TGF-beta causes an early increase in the PAI-1 mRNA level which reaches a maximal 50-fold enhancement after 8 h. Blocking of protein synthesis with cycloheximide causes an equally strong increase in the level of PAI-1 mRNA.	Cycloheximide	148-161	serpin family E member 1	Homo sapiens	212-217
3570161-7	1987	The maximal drug-induced increases in carnitine acetyltransferase activity were not additive, and the induction of carnitine acetyltransferase by ciprofibrate was blocked by addition (1 micrograms per ml) of cycloheximide or actinomycin D.	Cycloheximide	208-221	carnitine O-acetyltransferase	Rattus norvegicus	38-65
3570161-7	1987	The maximal drug-induced increases in carnitine acetyltransferase activity were not additive, and the induction of carnitine acetyltransferase by ciprofibrate was blocked by addition (1 micrograms per ml) of cycloheximide or actinomycin D.	Cycloheximide	208-221	carnitine O-acetyltransferase	Rattus norvegicus	115-142
3114133-4	1987	The half-life of IL 2 mRNA is only 30 min, but can be prolonged significantly by cycloheximide.	Cycloheximide	81-94	interleukin 2	Mus musculus	17-21
3114133-5	1987	At later post stimulation times IL 2 gene transcription is reduced, as indicated by the reduced effect of cycloheximide.	Cycloheximide	106-119	interleukin 2	Mus musculus	32-36
3494807-6	1987	IL-1 alpha mRNA was detected in SMC treated with cycloheximide (1 microgram/ml) and rIL-1 beta, or cycloheximide alone.	Cycloheximide	49-62	interleukin 1 alpha	Homo sapiens	0-10
3494807-6	1987	IL-1 alpha mRNA was detected in SMC treated with cycloheximide (1 microgram/ml) and rIL-1 beta, or cycloheximide alone.	Cycloheximide	99-112	interleukin 1 alpha	Homo sapiens	0-10
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	186-199	insulin like growth factor 1	Homo sapiens	54-59
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	186-199	insulin like growth factor 1	Homo sapiens	108-113
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	186-199	insulin like growth factor 1	Homo sapiens	108-113
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	186-199	insulin like growth factor 1	Homo sapiens	108-113
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	245-258	insulin like growth factor 1	Homo sapiens	54-59
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	245-258	insulin like growth factor 1	Homo sapiens	108-113
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	245-258	insulin like growth factor 1	Homo sapiens	108-113
3270536-0	1987	Differential DNase I sensitivity of the two complementary nucleosomal DNA strands in cycloheximide-treated Ehrlich ascites tumor cells.	Cycloheximide	85-98	deoxyribonuclease I	Mus musculus	13-20
3673025-3	1987	Treatment of the cells with cycloheximide and hypertonic NaCl solution, virtually depressing the radioactive label incorporation into PEK cell proteins, also inhibits the synthesis of virus-specific proteins p69, p21, p15, and p12.	Cycloheximide	28-41	islet cell autoantigen 1	Homo sapiens	208-211
3673025-3	1987	Treatment of the cells with cycloheximide and hypertonic NaCl solution, virtually depressing the radioactive label incorporation into PEK cell proteins, also inhibits the synthesis of virus-specific proteins p69, p21, p15, and p12.	Cycloheximide	28-41	H3 histone pseudogene 16	Homo sapiens	213-216
3673025-3	1987	Treatment of the cells with cycloheximide and hypertonic NaCl solution, virtually depressing the radioactive label incorporation into PEK cell proteins, also inhibits the synthesis of virus-specific proteins p69, p21, p15, and p12.	Cycloheximide	28-41	cyclin dependent kinase inhibitor 2B	Homo sapiens	218-221
3673025-3	1987	Treatment of the cells with cycloheximide and hypertonic NaCl solution, virtually depressing the radioactive label incorporation into PEK cell proteins, also inhibits the synthesis of virus-specific proteins p69, p21, p15, and p12.	Cycloheximide	28-41	DNA polymerase epsilon 4, accessory subunit	Homo sapiens	227-230
3105595-4	1987	The dexamethasone-induced increases in histamine content and histidine decarboxylase activity were completely suppressed by the addition of cycloheximide and actinomycin D.	Cycloheximide	140-153	histidine decarboxylase	Mus musculus	61-84
2435724-5	1987	The consequences of incubation with actinomycin D, cycloheximide, dibutyryl cyclic AMP, and 6-azauridine on the flux across CTP synthetase and on NTP pools differed considerably between wild type and mutant cells.	Cycloheximide	51-64	solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1	Mus musculus	124-127
3031163-3	1987	However, when protein synthesis was inhibited by cycloheximide, rTNF was cytotoxic for these cells but not for BT-20 cells.	Cycloheximide	49-62	tumor necrosis factor	Rattus norvegicus	64-68
3579307-7	1987	Cycloheximide, a cytosolic protein synthesis inhibitor, abolished both peaks of MnSOD activity, while chloramphenicol, a mitochondrial protein synthesis inhibitor, has no effect on either peak.	Cycloheximide	0-13	superoxide dismutase 2, mitochondrial	Mus musculus	80-85
2886202-0	1987	Cycloheximide blocks insulin-like growth factor I but not somatostatin inhibition of growth hormone secretion.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	21-49
2886202-4	1987	The major finding is that cycloheximide, a protein synthesis inhibitor, blocks inhibition of GRF-stimulated growth hormone release caused by IGF-I, without changing the inhibition caused by somatostatin.	Cycloheximide	26-39	growth hormone releasing hormone	Rattus norvegicus	93-96
2886202-4	1987	The major finding is that cycloheximide, a protein synthesis inhibitor, blocks inhibition of GRF-stimulated growth hormone release caused by IGF-I, without changing the inhibition caused by somatostatin.	Cycloheximide	26-39	gonadotropin releasing hormone receptor	Rattus norvegicus	108-122
2886202-4	1987	The major finding is that cycloheximide, a protein synthesis inhibitor, blocks inhibition of GRF-stimulated growth hormone release caused by IGF-I, without changing the inhibition caused by somatostatin.	Cycloheximide	26-39	insulin-like growth factor 1	Rattus norvegicus	141-146
2886202-7	1987	Cycloheximide (15 micrograms/mL) totally blocked the effect of IGF-I but not somatostatin.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	63-68
3107751-3	1987	This specific increase of c-fos steady-state levels is dependent on the incubation time with a maximal level of induction (over 40-fold) after approximately 1 h. The accumulation of c-fos transcripts is suppressed by alpha-amanitin while cycloheximide intensifies induction only moderately.	Cycloheximide	238-251	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-31
3030707-8	1987	Cycloheximide prevented Bu2cAMP augmentation of LHRH-stimulated FSH secretion.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	48-52
3104072-6	1987	Treatment of cells during the GM1 supplementation period with cycloheximide completely abolished the ability of cells to generate neurites on CTB and decreased the adhesive capacity of cells as well; a similar treatment of cells had no adverse effect on adherence or neurite extension on pFN.	Cycloheximide	62-75	chitobiase	Homo sapiens	142-145
3549566-7	1987	Treatment of Gin-1 cell cultures with cycloheximide, an inhibitor of protein synthesis, markedly inhibited FTAF production.	Cycloheximide	38-51	gypsy retrotransposon integrase 1	Homo sapiens	13-18
3029159-8	1987	The E2-related increase was abolished by cycloheximide, indicating that the changes were due to alterations in the synthesis of SHBG rather than to alterations in the release of previously synthesized protein.	Cycloheximide	41-54	sex hormone binding globulin	Homo sapiens	128-132
3104528-5	1987	Expression of c-fos in PMN was superinduced by exposure to cycloheximide.	Cycloheximide	59-72	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-19
2856304-5	1987	The relative affinity of the type I receptor for Sm-C/IGF-I was apparently increased because unlabeled Sm-C/IGF-I (12 ng/ml) competitively displaced 63% of radiolabeled Sm-C/IGF-I after cycloheximide exposure, whereas in cultures not exposed to cycloheximide [125I]Sm-C/IGF-I binding was increased by 11%.	Cycloheximide	245-258	insulin like growth factor 1	Homo sapiens	108-113
2856304-6	1987	Coincubation of fibroblast conditioned media containing the 35 K protein with cycloheximide-treated fibroblast monolayers resulted in restoration of the paradoxical increase in Sm-C/IGF-I binding and loss of sensitivity to competition by unlabeled Sm-C/IGF-I.	Cycloheximide	78-91	insulin like growth factor 1	Homo sapiens	182-187
2856304-6	1987	Coincubation of fibroblast conditioned media containing the 35 K protein with cycloheximide-treated fibroblast monolayers resulted in restoration of the paradoxical increase in Sm-C/IGF-I binding and loss of sensitivity to competition by unlabeled Sm-C/IGF-I.	Cycloheximide	78-91	insulin like growth factor 1	Homo sapiens	253-258
3648478-5	1987	Emetine, an inhibitor of protein synthesis which acts by a different mechanism than cycloheximide, also blocked the induction of the spot 14 nuclear precursor RNA.	Cycloheximide	84-97	thyroid hormone responsive	Rattus norvegicus	133-140
3586660-5	1987	Estradiol also significantly stimulated the transcription of the prolactin gene in cultures in which protein synthesis was grossly inhibited by cycloheximide.	Cycloheximide	144-157	prolactin	Rattus norvegicus	65-74
3032180-9	1987	Moreover, in serum starved cells simultaneously stimulated by serum and infected, only the 2.2 kb fos transcript can be superinduced by the protein synthesis inhibitor cycloheximide, while the appearance of the 4.5 kb fos mRNA is completely blocked by this treatment.	Cycloheximide	168-181	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-101
3470198-7	1987	Addition of cycloheximide to HEL cells treated for a short period with phorbol ester superinduced the expression of the c-sis gene.	Cycloheximide	12-25	platelet derived growth factor subunit B	Homo sapiens	120-125
3815331-3	1987	Both ODC activity and protein levels peak at 4.5 h after TPA treatment and rapidly fall to basal levels by 24 h. Cycloheximide treatment of mice in which ODC had been previously induced by TPA indicated a similar rapid turnover of both ODC catalytic activity and protein levels.	Cycloheximide	113-126	ornithine decarboxylase, structural 1	Mus musculus	154-157
3815331-3	1987	Both ODC activity and protein levels peak at 4.5 h after TPA treatment and rapidly fall to basal levels by 24 h. Cycloheximide treatment of mice in which ODC had been previously induced by TPA indicated a similar rapid turnover of both ODC catalytic activity and protein levels.	Cycloheximide	113-126	ornithine decarboxylase, structural 1	Mus musculus	154-157
3026790-6	1987	Cycloheximide (2 microM) inhibited 1,25-(OH)2D3 induction of CaBP, indicating that the mechanism requires new protein synthesis.	Cycloheximide	0-13	calcium-binding protein	Gallus gallus	61-65
3107949-4	1987	The increased expression of CD2 and the initial expression of Tac were totally inhibited by cycloheximide, but were not affected by sufficient actinomycin-D to block the T cell proliferative response.	Cycloheximide	92-105	CD2 molecule	Homo sapiens	28-31
3107985-3	1987	gamma-Irradiated cells produce, after exposure to cycloheximide, up to 12-fold greater amounts of IFN-gamma activity.	Cycloheximide	50-63	interferon gamma	Homo sapiens	98-107
3107985-8	1987	The superinductive effects of cycloheximide and gamma-irradiation on levels of IFN-gamma are additive, suggesting that they affect different aspects of IFN-gamma gene expression.	Cycloheximide	30-43	interferon gamma	Homo sapiens	79-88
3107985-8	1987	The superinductive effects of cycloheximide and gamma-irradiation on levels of IFN-gamma are additive, suggesting that they affect different aspects of IFN-gamma gene expression.	Cycloheximide	30-43	interferon gamma	Homo sapiens	152-161
3595728-5	1987	Emetine, cycloheximide and puromycin inhibited both basal and hCG stimulated protein synthesis as well as progesterone production in the cells.	Cycloheximide	9-22	hypertrichosis 2 (generalised, congenital)	Homo sapiens	62-65
2950120-5	1987	Dexamethasone-induced fibronectin binding to HT-1080 cells was time dependent, dose dependent, and inhibited by cycloheximide.	Cycloheximide	112-125	fibronectin 1	Homo sapiens	22-33
2433469-7	1987	Cycloheximide treatment (without virus infection) also gave a rapid 30-fold increase in steady-state levels of correctly initiated mRNA from both types of IE94-IFN hybrid genes, but had no effect on cells containing the IE175-IFN construct.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	160-163
2433469-7	1987	Cycloheximide treatment (without virus infection) also gave a rapid 30-fold increase in steady-state levels of correctly initiated mRNA from both types of IE94-IFN hybrid genes, but had no effect on cells containing the IE175-IFN construct.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	226-229
3569711-7	1987	Pretreatment of mice with the protein synthesis inhibitor cycloheximide abolished both epidermal and hepatic ODC induction.	Cycloheximide	58-71	ornithine decarboxylase, structural 1	Mus musculus	109-112
2840565-5	1987	While inhibition of RNA synthesis with actinomycin D blocked the hCG or cAMP-induced rise in LDL receptor mRNA content, inhibition of protein synthesis with cycloheximide augmented basal or hCG- or cAMP-stimulated LDL receptor mRNA levels.	Cycloheximide	157-170	low density lipoprotein receptor	Homo sapiens	214-226
3648478-6	1987	The increased rate of spot 14 gene transcription observed after T3 treatment, as measured by nuclear run-on assay, was similarly completely abolished in the presence of cycloheximide.	Cycloheximide	169-182	thyroid hormone responsive	Rattus norvegicus	22-29
3102610-9	1987	In contrast, cycloheximide, an inhibitor of protein synthesis, completely abrogated IL-2R expression and proliferation of stimulated lymphocytes.	Cycloheximide	13-26	interleukin 2 receptor, alpha chain	Mus musculus	84-89
3103102-6	1987	Treatment of cells with cycloheximide stabilizes c-fos mRNA.	Cycloheximide	24-37	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	49-54
3028794-12	1987	Since cycloheximide blocked the effects of PMA on hCG down-regulation, it is likely that the phorbol esters and 1-oleoyl-2-acetyl-sn-glycerol induce the synthesis of some proteins which blocked the recycling of internalized receptors.	Cycloheximide	6-19	hypertrichosis 2 (generalised, congenital)	Homo sapiens	50-53
3455047-6	1987	However, actinomycin D and cycloheximide prevented the effect of hCG.	Cycloheximide	27-40	hypertrichosis 2 (generalised, congenital)	Homo sapiens	65-68
3102470-7	1987	In the presence of cycloheximide, the induction of tPA mRNA by FSH or LH is not greatly affected, indicating that this phase of the response to gonadotropins does not require the synthesis of new protein.	Cycloheximide	19-32	plasminogen activator, tissue type	Rattus norvegicus	51-54
3102470-8	1987	However, the decrease in tPA mRNA levels observed 24 h after FSH treatment is affected by cycloheximide, in that the drug delays the reduction in mRNA levels seen with hormone alone.	Cycloheximide	90-103	plasminogen activator, tissue type	Rattus norvegicus	25-28
3100024-9	1987	Inhibition of protein synthesis by the administration of cycloheximide to adult mice caused a marked increase in the amount of Moloney murine leukemia virus-, intracisternal A particle-, and VL30-related RNAs in the livers of the treated mice, suggesting the existence of labile proteins that normally regulate the abundance of these transcripts.	Cycloheximide	57-70	RIKEN cDNA A130040M12 gene	Mus musculus	191-195
3295065-4	1987	The c-myc RNA reduction was also detected in cells whose protein synthesis was inhibited by more than 95% with cycloheximide or emetine.	Cycloheximide	111-124	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	4-9
3582728-3	1987	The relative response to prolactin over basal activities was relatively unaffected by indomethacin but decreased with cycloheximide, suggesting that prostaglandins do not mediate the effects of the hormone, but that a high rate of protein synthesis is a prerequisite for its expression.	Cycloheximide	118-131	prolactin	Rattus norvegicus	25-34
3027106-14	1987	In contrast, spermidine-mediated ODC degradation was substantially decreased by inhibitors of protein synthesis (cycloheximide, emetine, and puromycin).	Cycloheximide	113-126	ornithine decarboxylase, structural 1	Mus musculus	33-36
3803453-5	1987	Inhibition of protein synthesis by cycloheximide after the mild heat shock increased the maximal accumulation of hsp 70 encoding mRNA but did not prevent the subsequent decrease in this mRNA species.	Cycloheximide	35-48	heat shock protein family A (Hsp70) member 4	Homo sapiens	113-119
3804995-5	1987	Analysis of the effects of varying durations of cycloheximide treatment indicates that both the endogenous AGP gene and the transfected AGP-beta-globin chimeric gene are induced normally by dexamethasone during the first 1-2h of concurrent treatment.	Cycloheximide	48-61	orosomucoid 1	Rattus norvegicus	107-110
3804995-5	1987	Analysis of the effects of varying durations of cycloheximide treatment indicates that both the endogenous AGP gene and the transfected AGP-beta-globin chimeric gene are induced normally by dexamethasone during the first 1-2h of concurrent treatment.	Cycloheximide	48-61	orosomucoid 1	Rattus norvegicus	136-139
3804995-6	1987	In addition, pretreatment with cycloheximide yields a decrease in the subsequent induction of both beta-globin and AGP RNAs.	Cycloheximide	31-44	orosomucoid 1	Rattus norvegicus	115-118
3539932-1	1987	Cycloheximide, a potent inhibitor of protein synthesis, has been used to examine the relationship between recruitment of hexose carriers and the activation of glucose transport by insulin in rat adipocytes.	Cycloheximide	0-13	insulin	Homo sapiens	180-187
3539932-8	1987	When isolated membranes were analyzed with an antiserum prepared against human erythrocyte glucose transporter, decreased cross-reactivity was observed in plasma membranes prepared from cycloheximide/insulin-treated cells compared to those from insulin cells.	Cycloheximide	186-199	insulin	Homo sapiens	200-207
3539932-9	1987	The present findings indicate that incubation of adipocytes with cycloheximide greatly reduces the number of hexose carriers in the plasma membrane of insulin-stimulated cells.	Cycloheximide	65-78	insulin	Homo sapiens	151-158
3026286-2	1987	Ten proteins were classified as IE by their time of synthesis and by their synthesis in the presence of actinomycin D following reversal of a cycloheximide mediated protein synthesis block.	Cycloheximide	142-155	jun proto-oncogene	Mus musculus	32-34
3131075-12	1987	Synthesis of TNF is inhibited by actinomycin D or cycloheximide, indicating that it is an inducible protein.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	13-16
3330013-3	1987	When protein synthesis was inhibited by cycloheximide, however, TNF was cytotoxic for all cells except BT-20 cells.	Cycloheximide	40-53	tumor necrosis factor	Homo sapiens	64-67
2892751-9	1987	It was observed that treatment of undifferentiated EC cells with the inhibitor of protein synthesis cycloheximide resulted in slight accumulation of Hox2.3 mRNA, suggesting the involvement of a short-lived protein in keeping the level of homeobox-gene transcription low in EC cells.	Cycloheximide	100-113	homeobox B7	Mus musculus	149-155
2895720-2	1987	The regulation of Hox 1.1 expression was probed by using cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	57-70	homeobox A7	Mus musculus	18-25
3582274-3	1987	Newly synthesized rat TPO was observed in the presence of TSH (10 mU/ml), an effect which was completely blocked by co-incubation with cycloheximide.	Cycloheximide	135-148	thyroid peroxidase	Rattus norvegicus	22-25
2430786-6	1987	Cycloheximide virtually eliminated measurable iIGF-I in culture, suggesting that the peptide measured was newly synthesized, and degradation of IGF-I by cultured granulosa cells was negligible.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	47-52
3545852-3	1987	Combined treatment with cycloheximide and actinomycin D also stimulates production and enhances production induced by IL 1 or poly(rI).poly(rC).	Cycloheximide	24-37	interleukin 1 alpha	Homo sapiens	118-122
3609441-4	1987	ODC induction in C3H/10T1/2 CL8 cells was completely inhibited by cycloheximide and actinomycin D.	Cycloheximide	66-79	ornithine decarboxylase, structural 1	Mus musculus	0-3
3102944-4	1987	First, elevation of uPA mRNA after irradiation was severely blocked by cycloheximide.	Cycloheximide	71-84	plasminogen activator, urokinase	Homo sapiens	20-23
3098881-6	1987	This effect was dependent on a free active site in thrombin and specific protein synthesis (inhibited by cycloheximide and dactinomycin) but unrelated to prostacyclin synthesis (no effect of aspirin or indomethacin).	Cycloheximide	105-118	coagulation factor II, thrombin	Homo sapiens	51-59
2826904-8	1987	Cycloheximide (0.2 mM) rapidly blocked (less than 10 min) cellular steroidogenesis, cholesterol SCC activity, and access of cholesterol to cytochrome P-450scc without affecting mitochondrial-free cholesterol.	Cycloheximide	0-13	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	139-158
3320557-6	1987	Treatment of cells with cycloheximide increases LDL receptor mRNA levels, and the stimulatory response to hCG and 8-bromo-cAMP is enhanced in the presence of cycloheximide.	Cycloheximide	24-37	low density lipoprotein receptor	Homo sapiens	48-60
2895487-0	1987	Influence of gamma-radiation and cycloheximide on by hydrocortisone induced tyrosine aminotransferase and tryptophan-2,3-dioxygenase activity in the rat liver.	Cycloheximide	33-46	tryptophan 2,3-dioxygenase	Rattus norvegicus	106-132
2880581-2	1986	This increase in ATPase activity takes place during the three hours lag period that precede the cell division after diluting stationary cells into fresh medium and is prevented by cycloheximide.	Cycloheximide	180-193	dynein axonemal heavy chain 8	Homo sapiens	17-23
3539592-4	1986	This elevation in PGK mRNA still occurred in the presence of the protein-synthesis inhibitor cycloheximide, but was not observed in cells bearing the rna1.1 mutation.	Cycloheximide	93-106	phosphoglycerate kinase	Saccharomyces cerevisiae S288C	18-21
3792312-4	1986	Cycloheximide treatment and incubation at reduced temperatures also reduced the rate of protein synthesis and stimulated the ADP-ribosylation of P80.	Cycloheximide	0-13	coilin	Mus musculus	145-148
3096577-4	1986	Injections of cycloheximide added to the normal domains of ftz expression, creating novel expression patterns that were dependent on the time of injection.	Cycloheximide	14-27	fushi tarazu	Drosophila melanogaster	59-62
3780535-7	1986	The protein synthesis inhibitor cycloheximide (25 micrograms/100 g BW) did not cause any change in the 1,25(OH)2D3-induced CaBP mRNA but blocked the CaBP increase after hormone injection.	Cycloheximide	32-45	S100 calcium binding protein G	Rattus norvegicus	149-153
3096698-4	1986	Up to 85% of the cells became immunofluorescently labeled in the presence of FSH, and its induced P-450scc synthesis was inhibited by cycloheximide and alpha-amanitin.	Cycloheximide	134-147	cytochrome P450, family 11, subfamily a, polypeptide 1	Rattus norvegicus	98-106
3491091-7	1986	Interleukin-1 alpha mRNA was detected when SMC were incubated with endotoxin under "superinduction" conditions with cycloheximide.	Cycloheximide	116-129	interleukin 1 alpha	Homo sapiens	0-19
2946796-23	1986	EA 1 expression was due to de novo synthesis, as the induction of EA 1 was blocked by cycloheximide and actinomycin D.	Cycloheximide	86-99	CD69 molecule	Homo sapiens	0-4
2946796-23	1986	EA 1 expression was due to de novo synthesis, as the induction of EA 1 was blocked by cycloheximide and actinomycin D.	Cycloheximide	86-99	CD69 molecule	Homo sapiens	66-70
3097128-10	1986	This could be partially reversed by restimulation with lectin in the presence of cycloheximide, suggesting a role for a labile protein repressor in the down-regulation of IL 2 mRNA expression.	Cycloheximide	81-94	interleukin 2	Mus musculus	171-175
3540941-4	1986	Cycloheximide treatment in combination with insulin or phorbol 12-myristate 13-acetate resulted in superinduction of c-fos mRNA.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-122
3096988-5	1986	The half-life for surface high affinity IL2 receptors, as measured in the presence of cycloheximide, is about 1 h and does not depend upon the presence of IL2.	Cycloheximide	86-99	interleukin 2	Homo sapiens	40-43
3778524-4	1986	The increases of both ODC and SAT activities produced by MGBG were blocked by treatment with cycloheximide, suggesting that the increase of enzyme activity resulted from the synthesis of new enzyme proteins.	Cycloheximide	93-106	ornithine decarboxylase 1	Homo sapiens	22-25
3535799-7	1986	Cycloheximide which blocked the glucose refeeding effect on hexose transport, decreased the ability of insulin to stimulate hexose transport.	Cycloheximide	0-13	insulin	Homo sapiens	103-110
3535799-8	1986	Specific 125I-insulin binding was increased by glucose refeeding of glucose-starved cells and this change in binding was inhibited by tunicamycin and cycloheximide.	Cycloheximide	150-163	insulin	Homo sapiens	14-21
2946302-6	1986	Treatment of mononuclear cells by cycloheximide resulted in complete inhibition of anti-U1 RNP secretion, which indicates that antibody in the culture supernatants reflects the active biologic phenomenon in vitro.	Cycloheximide	34-47	small nuclear ribonucleoprotein U1 subunit 70	Homo sapiens	88-94
3533520-8	1986	Interestingly, incubation of uterine cells with 10(-5) M cycloheximide (which inhibits 98% of protein synthesis) completely arrests ER turnover, suggesting that ER turnover, which is rapid, is probably dependent upon the synthesis of other rapidly turning over proteins.	Cycloheximide	57-70	estrogen receptor 1	Rattus norvegicus	132-134
3533520-8	1986	Interestingly, incubation of uterine cells with 10(-5) M cycloheximide (which inhibits 98% of protein synthesis) completely arrests ER turnover, suggesting that ER turnover, which is rapid, is probably dependent upon the synthesis of other rapidly turning over proteins.	Cycloheximide	57-70	estrogen receptor 1	Rattus norvegicus	161-163
2437144-3	1986	First-trimester decidual explants produced CA125 in vitro and cycloheximide significantly reduced the concentration of CA125 both in the medium and in the tissue.	Cycloheximide	62-75	mucin 16, cell surface associated	Homo sapiens	119-124
3020171-6	1986	The increase in uninduced and dexamethasone-induced GPDH activity was blocked by cycloheximide and actinomycin D, indicating that de novo protein and RNA synthesis are required.	Cycloheximide	81-94	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	52-56
2944738-9	1986	Insulin and IGF-I stimulated testosterone formation as early as 3 h after administration, and their effects were completely blocked by the addition of a protein synthesis inhibitor, cycloheximide (1 microgram/ml).	Cycloheximide	182-195	insulin-like growth factor 1	Rattus norvegicus	12-17
3539629-4	1986	The effects of insulin were prevented by 15 min pretreatment with 2 micrograms ml-1 cycloheximide or by 2 micrograms ml-1 actinomycin D, suggesting a role for new protein synthesis in the actions of insulin on glucose transport in this cell type.	Cycloheximide	84-97	insulin	Bos taurus	15-22
3539629-4	1986	The effects of insulin were prevented by 15 min pretreatment with 2 micrograms ml-1 cycloheximide or by 2 micrograms ml-1 actinomycin D, suggesting a role for new protein synthesis in the actions of insulin on glucose transport in this cell type.	Cycloheximide	84-97	insulin	Bos taurus	199-206
3027204-5	1986	However, the presence of cycloheximide during incubation with IFN had no effect on the synthesis of CKp76 after removal of both agents.	Cycloheximide	25-38	interferon alpha 1	Homo sapiens	62-65
3099164-2	1986	We found that several different inhibitors of DNA synthesis, which were each able to block cells at the G1-S-phase boundary, induced an enhanced cycloheximide-sensitive synthesis of an early S-phase cell cycle-regulated enzyme, dihydrofolate reductase, and of other proteins as well.	Cycloheximide	145-158	dihydrofolate reductase	Homo sapiens	228-251
3758081-1	1986	When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. &amp; Fiers, W. (1982) Proc.	Cycloheximide	86-99	interferon beta 1	Homo sapiens	122-137
3758081-1	1986	When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. &amp; Fiers, W. (1982) Proc.	Cycloheximide	86-99	interferon beta 1	Homo sapiens	139-147
3758081-1	1986	When human fibroblast cells were stimulated with poly(I) X poly(C) in the presence of cycloheximide for the production of interferon-beta (IFN-beta), a 26-kDa protein could be immunoprecipitated by antiserum raised against partially purified human IFN-beta [Content, J., De Wit, L., Pierard, D., Derynck, R., De Clercq, E. &amp; Fiers, W. (1982) Proc.	Cycloheximide	86-99	interferon beta 1	Homo sapiens	248-256
3732165-7	1986	Cycloheximide at a dose (50 micrograms/ml) that inhibited the synthesis of trichloroacetic acid-precipitable [35S]methionyl placental proteins by more than 80% completely blocked the stimulatory effects of diC8 and PMA on hPL synthesis and release.	Cycloheximide	0-13	galectin 1	Homo sapiens	222-225
3023310-13	1986	The turnover of TNF receptors on HeLA S3 cells seemed to be rapid, since the level of specific binding quickly decreased after treatment with 100 micrograms/ml of cycloheximide at 37 degrees C with a half-life of about 1.5 h. The crosslinking of the cell-bound 125I-TNF with the use of disuccinimidyl suberate yielded a complex of 105 kDa for HeLa S3 and THP-1 cells, and a complex of 100 kDa for U937 cells.	Cycloheximide	163-176	tumor necrosis factor	Homo sapiens	16-19
3023310-13	1986	The turnover of TNF receptors on HeLA S3 cells seemed to be rapid, since the level of specific binding quickly decreased after treatment with 100 micrograms/ml of cycloheximide at 37 degrees C with a half-life of about 1.5 h. The crosslinking of the cell-bound 125I-TNF with the use of disuccinimidyl suberate yielded a complex of 105 kDa for HeLa S3 and THP-1 cells, and a complex of 100 kDa for U937 cells.	Cycloheximide	163-176	tumor necrosis factor	Homo sapiens	266-269
3023310-13	1986	The turnover of TNF receptors on HeLA S3 cells seemed to be rapid, since the level of specific binding quickly decreased after treatment with 100 micrograms/ml of cycloheximide at 37 degrees C with a half-life of about 1.5 h. The crosslinking of the cell-bound 125I-TNF with the use of disuccinimidyl suberate yielded a complex of 105 kDa for HeLa S3 and THP-1 cells, and a complex of 100 kDa for U937 cells.	Cycloheximide	163-176	GLI family zinc finger 2	Homo sapiens	355-360
3734037-9	1986	Between 7 and 27 h, the amount of PP12 released by cycloheximide-treated tissues was 20.0 +/- 7% of that released by control tissues (P less than 0.01).	Cycloheximide	51-64	insulin like growth factor binding protein 1	Homo sapiens	34-38
3580037-0	1986	Effect of cycloheximide on the development of thermotolerance and the synthesis of 68-kilodalton heat shock protein in Chinese hamster V79 and mouse L cells in vitro.	Cycloheximide	10-23	10 kDa heat shock protein, mitochondrial	Cricetulus griseus	97-115
2879848-6	1987	Cycloheximide completely inhibited the increase in the quantity of TGase antigen in the insoluble fraction, 8 h post-stimulation, while actinomycin D caused a partial inhibition.	Cycloheximide	0-13	transglutaminase 1	Homo sapiens	67-72
3092223-5	1986	Since the protein synthesis inhibitor cycloheximide partially reverses TCR-beta repression in the hybrid cells, we postulate that a labile repressor protein is involved.	Cycloheximide	38-51	T cell receptor beta chain	Mus musculus	71-79
3541907-9	1986	Glucagon, adrenaline and theophylline all produced a significant decline in the cell-surface immunodetectable lipoprotein lipase, which in the case examined (adrenaline) was partially additive with regard to the independent effect of cycloheximide.	Cycloheximide	234-247	lipoprotein lipase	Homo sapiens	110-128
3022071-4	1986	The metabolic inhibitor of protein synthesis, cycloheximide, was employed to obtain additional information concerning the fate of 1,25-dihydroxyvitamin D3 receptor complexes.	Cycloheximide	46-59	vitamin D (1,25- dihydroxyvitamin D3) receptor	Gallus gallus	130-163
3526909-4	1986	IL-1 alpha mRNA was also detected when endothelial cells were exposed to endotoxin under "superinduction" conditions in the presence of cycloheximide.	Cycloheximide	136-149	interleukin 1 alpha	Homo sapiens	0-10
2424928-9	1986	IR-IGF-I secretion was reversibly inhibited by 5.3 microM cycloheximide, suggesting that the IR-IGF-I was the result of de novo protein synthesis.	Cycloheximide	58-71	insulin like growth factor 1	Homo sapiens	3-8
2424928-9	1986	IR-IGF-I secretion was reversibly inhibited by 5.3 microM cycloheximide, suggesting that the IR-IGF-I was the result of de novo protein synthesis.	Cycloheximide	58-71	insulin like growth factor 1	Homo sapiens	96-101
2426286-4	1986	The expression of T antigen and fibronectin was sensitive to actinomycin D and cycloheximide.	Cycloheximide	79-92	fibronectin 1	Mus musculus	32-43
3785214-5	1986	ODCase mRNA was rapidly reinduced by exposure of quiescent, differentiated cells to medium with 20% serum or by inhibition of protein synthesis with cycloheximide.	Cycloheximide	149-162	ornithine decarboxylase, structural 1	Mus musculus	0-6
3785214-7	1986	The mechanisms whereby mitogens and protein synthesis inhibitors induced ODCase transcription appeared to be different since cycloheximide potentiated the effects of mitogens, resulting in superinduction of ODCase transcription to a level significantly greater than in the presence of mitogens alone.	Cycloheximide	125-138	ornithine decarboxylase, structural 1	Mus musculus	73-79
3785214-7	1986	The mechanisms whereby mitogens and protein synthesis inhibitors induced ODCase transcription appeared to be different since cycloheximide potentiated the effects of mitogens, resulting in superinduction of ODCase transcription to a level significantly greater than in the presence of mitogens alone.	Cycloheximide	125-138	ornithine decarboxylase, structural 1	Mus musculus	207-213
3733741-2	1986	In the rabbit reticulocyte lysate, human preplacental lactogen biosynthesis is arrested by addition of cycloheximide prior to supplementation with dog pancreatic microsomal membranes, which have previously been shown to translocate and process nascent secretory proteins in a cotranslational manner.	Cycloheximide	103-116	chorionic somatomammotropin hormone 2	Homo sapiens	54-62
3016728-4	1986	The down-regulation of GR mRNA levels appears to be independent of protein synthesis, since it also was observed in the presence of cycloheximide.	Cycloheximide	132-145	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	23-25
3016728-5	1986	However, cycloheximide caused a 4-fold increase in intracellular levels of GR mRNA.	Cycloheximide	9-22	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	75-77
3720666-5	1986	The increase in ASTP activity after adrenalectomy was inhibited by actinomycin D or cycloheximide.	Cycloheximide	84-97	glycerol kinase	Rattus norvegicus	16-20
3018372-0	1986	Involvement of cycloheximide-sensitive mediators in the steroidogenic action of adrenocorticotropin and angiotensin II.	Cycloheximide	15-28	angiotensinogen	Homo sapiens	104-118
3018372-7	1986	In addition, the stimulatory effect of cAMP and PGE1, which are considered to be the second messengers of ACTH and angiotensin II in amphibian interrenal gland, was blocked by cycloheximide.	Cycloheximide	176-189	proopiomelanocortin	Homo sapiens	106-129
3721058-7	1986	RCP induction was completely inhibited by both alpha-amanitin and cycloheximide for prolonged periods while E-stimulated RBP production was affected only partially by alpha-amanitin.	Cycloheximide	66-79	CGRP receptor component	Homo sapiens	0-3
3721058-8	1986	Likewise, cycloheximide inhibition of RBP accumulation followed a pattern similar to that of hepatic general protein synthesis.	Cycloheximide	10-23	retinol binding protein 4	Homo sapiens	38-41
3014510-5	1986	In the presence of cycloheximide, the c-fos gene is superinduced and the increased level of c-fos mRNA persists for at least 24 hr.	Cycloheximide	19-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	38-43
3014510-5	1986	In the presence of cycloheximide, the c-fos gene is superinduced and the increased level of c-fos mRNA persists for at least 24 hr.	Cycloheximide	19-32	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	92-97
3092394-7	1986	Both the decrease in PGI2 production after thrombin/ionophore and the increase after re-stimulation with AA were blunted in the presence of the protein synthesis inhibitor cycloheximide (0.1-0.2 micrograms/ml).	Cycloheximide	172-185	coagulation factor II, thrombin	Homo sapiens	43-51
3487543-4	1986	Treatment of cells with cycloheximide prior to, and after, the pulse extended the half-life of p110 further than post-treatment alone, and addition of both actinomycin D and cycloheximide to cells pretreated with cycloheximide extended the half-life even further.	Cycloheximide	24-37	spliceosome associated factor 3, U4/U6 recycling protein	Homo sapiens	95-99
2423265-5	1986	This specific ODC staining in cells surrounding hair follicles was inhibited by pretreatment of mice with either retinoic acid or cycloheximide 1 h before TPA treatment.	Cycloheximide	130-143	ornithine decarboxylase, structural 1	Mus musculus	14-17
2422018-6	1986	Avidin production was dependent on protein and RNA synthesis, since induction was inhibited by cycloheximide and actinomycin D.	Cycloheximide	95-108	avidin	Gallus gallus	0-6
3087999-10	1986	Furthermore, reversible inhibition (i.e., treatment with cycloheximide) of protein synthesis during LPS treatment abrogated the acquisition of tumoricidal function.	Cycloheximide	57-70	toll-like receptor 4	Mus musculus	100-103
2423537-1	1986	Using primary culture methods, we show that purified astrocytes from embryonic mouse or rat central nervous system (CNS) can be induced to produce interferon (IFN) activity when pretreated with a standard IFN-superinducing regimen of polyribonucleotide, cycloheximide, and actinomycin D, whereas IFN activity was not inducible in neuronal cultures derived from mouse CNS.	Cycloheximide	254-267	interferon gamma	Mus musculus	159-162
3539950-7	1986	However, when HUVEC were exposed to 2.5 or 25 micrograms ml-1 of cycloheximide for 4 h before and during the adherence assays, the adherence to fibronectin was 50-200% greater than to types I and III collagen.	Cycloheximide	65-78	fibronectin 1	Homo sapiens	144-155
3539950-11	1986	In the presence of cycloheximide anti-fibronectin antibodies totally blocked HUVEC adherence.	Cycloheximide	19-32	fibronectin 1	Homo sapiens	38-49
3754873-6	1986	When induction of differentiation in responsive cells was delayed by cycloheximide, a temporal correlation could be made between changes in the expression of the c-myc gene and differentiation.	Cycloheximide	69-82	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	162-167
2427623-5	1986	The induction of indoleamine 2,3-dioxygenase by IFN-gamma was inhibited by treatment of the cultures with either actinomycin D or cycloheximide, and thus was dependent on both RNA and protein synthesis.	Cycloheximide	130-143	interferon gamma	Homo sapiens	48-57
3097508-6	1986	Thus, although little mRNA 561 was synthesized in cells treated either with IFN-gamma alone or with IFN-alpha A and cycloheximide, a large quantity of this mRNA was induced in cells which had been pretreated with IFN-gamma and then treated with IFN-alpha A and cycloheximide.	Cycloheximide	261-274	interferon gamma	Homo sapiens	213-222
3097508-8	1986	This rapid turnover could be blocked by actinomycin D or cycloheximide indicating that another IFN-inducible protein may mediate this process.	Cycloheximide	57-70	interferon alpha 1	Homo sapiens	95-98
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	MYB proto-oncogene, transcription factor	Homo sapiens	151-156
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	NRAS proto-oncogene, GTPase	Homo sapiens	158-163
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	transferrin receptor	Homo sapiens	169-172
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	202-207
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	interleukin 2	Homo sapiens	209-212
3012540-8	1986	Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and IL2R.	Cycloheximide	44-57	interleukin 2 receptor subunit alpha	Homo sapiens	218-222
3487091-4	1986	Induction of PCA by rTNF was concentration dependent (maximum, 500 units/ml), time dependent, reversible, and blocked by cycloheximide and actinomycin D, and it occurred without detectable endothelial cell damage.	Cycloheximide	121-134	tumor necrosis factor	Rattus norvegicus	20-24
3085953-4	1986	Superinduction of c-fos in the presence of cycloheximide occurs primarily because of stabilization of c-fos mRNA.	Cycloheximide	43-56	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
3085953-4	1986	Superinduction of c-fos in the presence of cycloheximide occurs primarily because of stabilization of c-fos mRNA.	Cycloheximide	43-56	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	102-107
3720728-2	1986	The induction of some of these polypeptides p27 (27 kd), p35 (35 kd), p38 (38 kd) and p69 (69 kd) can be "superinduced" in the presence of cycloheximide and completely blocked by actinomycin D.	Cycloheximide	139-152	dynactin 6	Mus musculus	44-47
3720728-2	1986	The induction of some of these polypeptides p27 (27 kd), p35 (35 kd), p38 (38 kd) and p69 (69 kd) can be "superinduced" in the presence of cycloheximide and completely blocked by actinomycin D.	Cycloheximide	139-152	interleukin 12a	Mus musculus	57-60
3720728-2	1986	The induction of some of these polypeptides p27 (27 kd), p35 (35 kd), p38 (38 kd) and p69 (69 kd) can be "superinduced" in the presence of cycloheximide and completely blocked by actinomycin D.	Cycloheximide	139-152	mitogen-activated protein kinase 14	Mus musculus	70-73
3720728-2	1986	The induction of some of these polypeptides p27 (27 kd), p35 (35 kd), p38 (38 kd) and p69 (69 kd) can be "superinduced" in the presence of cycloheximide and completely blocked by actinomycin D.	Cycloheximide	139-152	islet cell autoantigen 1	Mus musculus	86-89
2431284-2	1986	The induction by EGF can be blocked by cycloheximide.	Cycloheximide	39-52	epidermal growth factor like 1	Rattus norvegicus	17-20
3955064-8	1986	After cycloheximide, lipoprotein lipase activity decreased with a half-life of 22 min.	Cycloheximide	6-19	lipoprotein lipase	Cavia porcellus	21-39
3023888-6	1986	In contrast to serum, p21 did not stimulate total RNA or protein synthesis, but some RNA and protein synthesis must have been needed for the p21-driven G1 transit because it could be stopped by actinomycin D or cycloheximide.	Cycloheximide	211-224	KRAS proto-oncogene, GTPase	Rattus norvegicus	141-144
2420790-5	1986	Cycloheximide blocked the effect of DEX on AFP mRNA levels in both the McA-RH8994 and 7777 cell lines, showing that ongoing protein synthesis is required for glucocorticoids either to enhance or to suppress AFP gene expression in these cell lines.	Cycloheximide	0-13	alpha-fetoprotein	Rattus norvegicus	43-46
2420790-5	1986	Cycloheximide blocked the effect of DEX on AFP mRNA levels in both the McA-RH8994 and 7777 cell lines, showing that ongoing protein synthesis is required for glucocorticoids either to enhance or to suppress AFP gene expression in these cell lines.	Cycloheximide	0-13	alpha-fetoprotein	Rattus norvegicus	207-210
3707902-4	1986	Removal of LDL from the medium causes rapid inactivation of ACAT activity; the t1/2 for the initial inactivation rate is 0.8 h. Preincubation with protein synthesis inhibitors (cycloheximide or emetine) for 2 h or longer lengthens the t1/2 for the initial inactivation rate to approximately 2.1 h. When LDL is removed for more than 10 h, the cells contain only 3% of the original ACAT activity.	Cycloheximide	177-190	sterol O-acyltransferase 1	Cricetulus griseus	60-64
3707902-4	1986	Removal of LDL from the medium causes rapid inactivation of ACAT activity; the t1/2 for the initial inactivation rate is 0.8 h. Preincubation with protein synthesis inhibitors (cycloheximide or emetine) for 2 h or longer lengthens the t1/2 for the initial inactivation rate to approximately 2.1 h. When LDL is removed for more than 10 h, the cells contain only 3% of the original ACAT activity.	Cycloheximide	177-190	sterol O-acyltransferase 1	Cricetulus griseus	380-384
3707902-5	1986	Cycloheximide under this condition causes an 8-fold increase in ACAT activity; the increase approaches a maximum in 6-8 h. The extent of ACAT activation by cycloheximide inversely depends on exogenous sterol present in the medium; LDL diminishes the activation, while cationized LDL or 25-hydroxycholesterol completely abolishes the activation.	Cycloheximide	0-13	sterol O-acyltransferase 1	Cricetulus griseus	64-68
3707902-5	1986	Cycloheximide under this condition causes an 8-fold increase in ACAT activity; the increase approaches a maximum in 6-8 h. The extent of ACAT activation by cycloheximide inversely depends on exogenous sterol present in the medium; LDL diminishes the activation, while cationized LDL or 25-hydroxycholesterol completely abolishes the activation.	Cycloheximide	0-13	sterol O-acyltransferase 1	Cricetulus griseus	137-141
3707902-5	1986	Cycloheximide under this condition causes an 8-fold increase in ACAT activity; the increase approaches a maximum in 6-8 h. The extent of ACAT activation by cycloheximide inversely depends on exogenous sterol present in the medium; LDL diminishes the activation, while cationized LDL or 25-hydroxycholesterol completely abolishes the activation.	Cycloheximide	156-169	sterol O-acyltransferase 1	Cricetulus griseus	64-68
3707902-5	1986	Cycloheximide under this condition causes an 8-fold increase in ACAT activity; the increase approaches a maximum in 6-8 h. The extent of ACAT activation by cycloheximide inversely depends on exogenous sterol present in the medium; LDL diminishes the activation, while cationized LDL or 25-hydroxycholesterol completely abolishes the activation.	Cycloheximide	156-169	sterol O-acyltransferase 1	Cricetulus griseus	137-141
3707902-6	1986	Adding LDL back to the sterol-free medium causes a 40-70-fold increase in ACAT activity; however, the activation of LDL is not further augmented if the cells are pretreated with cycloheximide.	Cycloheximide	178-191	sterol O-acyltransferase 1	Cricetulus griseus	74-78
3707903-4	1986	(1986) Biochemistry (preceding paper in this issue)] that in Chinese hamster ovary (CHO) cells activation of acyl coenzyme A:cholesterol acyltransferase (ACAT) activity by treating cells with cycloheximide was abolished by providing exogenous sterol in the medium.	Cycloheximide	192-205	sterol O-acyltransferase 1	Cricetulus griseus	154-158
3707903-8	1986	In sterol-free medium, if sterol synthesis is blocked by specific enzyme inhibitors or through mutation, the ACAT activation by cycloheximide is again abolished.	Cycloheximide	128-141	sterol O-acyltransferase 1	Cricetulus griseus	109-113
3955081-2	1986	The hepatocyte preparation released angiotensinogen at a basal rate of 50-120 pmol/g wet weight per h. Release was linear with time for at least 4 h. Angiotensinogen secretion was reduced in the presence of actinomycin D, and inhibited by cycloheximide, puromycin, colchicine and vinblastine.	Cycloheximide	239-252	angiotensinogen	Rattus norvegicus	150-165
3770792-0	1986	Cycloheximide-induced inhibition of cathepsin B activity in rat skeletal muscle.	Cycloheximide	0-13	cathepsin B	Rattus norvegicus	36-47
2419474-11	1986	The subsequent downregulation of lymphokine and c-myc mRNAs was retarded by cycloheximide.	Cycloheximide	76-89	interleukin 2	Homo sapiens	33-43
2419474-11	1986	The subsequent downregulation of lymphokine and c-myc mRNAs was retarded by cycloheximide.	Cycloheximide	76-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	48-53
3007667-3	1986	Experiments using cycloheximide or actinomycin D and kinetic studies showed that this IFN originated mainly in IFN which resided within the cell as a result of the first induction and was released after the second stimulation.	Cycloheximide	18-31	interferon alpha 1	Homo sapiens	86-89
3007667-3	1986	Experiments using cycloheximide or actinomycin D and kinetic studies showed that this IFN originated mainly in IFN which resided within the cell as a result of the first induction and was released after the second stimulation.	Cycloheximide	18-31	interferon alpha 1	Homo sapiens	111-114
3088147-6	1986	In contrast to IFN-beta 2 mRNA, cycloheximide treatment of lymphocytes produced a slight accumulation of IFN-gamma mRNA.	Cycloheximide	32-45	interferon gamma	Homo sapiens	105-114
3004901-5	1986	Studies on the effect of actinomycin D or cycloheximide treatment indicated that the vitamin may enhance de novo synthesis of ALP.	Cycloheximide	42-55	alopecia, recessive	Mus musculus	126-129
3007125-11	1986	Cycloheximide and actinomycin D inhibit hCG-mediated and 8-BrcAMP-mediated down-regulation.	Cycloheximide	0-13	hypertrichosis 2 (generalised, congenital)	Homo sapiens	40-43
3013245-4	1986	Transient expression assays showed that cells treated with cycloheximide post-transfection contained as much as three times the amount of viral RNA transcribed from regions E1A and E1B.	Cycloheximide	59-72	small nucleolar RNA, H/ACA box 73a	Mus musculus	181-184
3013245-6	1986	Cycloheximide treatment also increased the number of transformants induced by a transformation defective E1B mutant of Ad12 (cyt mutant).	Cycloheximide	0-13	small nucleolar RNA, H/ACA box 73a	Mus musculus	105-108
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	TNF receptor superfamily member 1A	Homo sapiens	0-5
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	interferon gamma	Homo sapiens	70-79
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	interferon gamma	Homo sapiens	151-160
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	interferon gamma	Homo sapiens	151-160
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	TNF receptor superfamily member 1A	Homo sapiens	370-375
3007500-3	1986	TNF-R expression was significantly increased after 6 h of exposure to IFN-gamma (100 units/ml), and it remained elevated in the continuous presence of IFN-gamma for at least 20 h. Incubation of cells with IFN-gamma in the presence of cycloheximide, followed by treatment with actinomycin D and reversal of the inhibition of protein synthesis, also resulted in increased TNF-R expression as compared to cultures subjected to the same treatments in the absence of IFN-gamma.	Cycloheximide	234-247	interferon gamma	Homo sapiens	151-160
3785158-2	1986	Treatment of rat embryonic fibroblasts with cycloheximide for 6 h after a 20-min interval at 45 degrees C inhibits protein synthesis, including heat shock protein (hsp) synthesis, and results in an accumulation of hsp 70 mRNA, but has no effect on subsequent survival responses to 45 degrees C hyperthermia.	Cycloheximide	44-57	selenoprotein K	Rattus norvegicus	144-162
3785158-2	1986	Treatment of rat embryonic fibroblasts with cycloheximide for 6 h after a 20-min interval at 45 degrees C inhibits protein synthesis, including heat shock protein (hsp) synthesis, and results in an accumulation of hsp 70 mRNA, but has no effect on subsequent survival responses to 45 degrees C hyperthermia.	Cycloheximide	44-57	selenoprotein K	Rattus norvegicus	164-167
3785158-2	1986	Treatment of rat embryonic fibroblasts with cycloheximide for 6 h after a 20-min interval at 45 degrees C inhibits protein synthesis, including heat shock protein (hsp) synthesis, and results in an accumulation of hsp 70 mRNA, but has no effect on subsequent survival responses to 45 degrees C hyperthermia.	Cycloheximide	44-57	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	214-220
3785158-3	1986	hsp 70 mRNA levels decreased within 1 h after removal of cycloheximide but then appeared to stabilize during the next 2 h (3 h after drug removal and 9 h after heat shock).	Cycloheximide	57-70	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-6
3785158-4	1986	hsp 70 mRNA accumulation could be further increased by a second heat shock at 45 degrees C for 20 min 6 h after the first hyperthermic exposure in cycloheximide-treated cells.	Cycloheximide	147-160	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	0-6
3512250-9	1986	Cycloheximide totally inhibited the PP12 release induced by P from proliferative endometrium, and in secretory endometrium, it either totally blocked PP12 release or inhibited the stimulation due to P. [35S]Methionine was incorporated into immunoprecipitable PP12 in cultures of secretory and P-treated proliferative phase endometria.	Cycloheximide	0-13	insulin like growth factor binding protein 1	Homo sapiens	36-40
3485132-9	1986	The decline of H4/18 binding from peak levels is prevented by cycloheximide, a protein synthesis inhibitor.	Cycloheximide	62-75	H1.8 linker histone	Homo sapiens	15-20
3512250-9	1986	Cycloheximide totally inhibited the PP12 release induced by P from proliferative endometrium, and in secretory endometrium, it either totally blocked PP12 release or inhibited the stimulation due to P. [35S]Methionine was incorporated into immunoprecipitable PP12 in cultures of secretory and P-treated proliferative phase endometria.	Cycloheximide	0-13	insulin like growth factor binding protein 1	Homo sapiens	150-154
3512250-9	1986	Cycloheximide totally inhibited the PP12 release induced by P from proliferative endometrium, and in secretory endometrium, it either totally blocked PP12 release or inhibited the stimulation due to P. [35S]Methionine was incorporated into immunoprecipitable PP12 in cultures of secretory and P-treated proliferative phase endometria.	Cycloheximide	0-13	insulin like growth factor binding protein 1	Homo sapiens	150-154
3773893-6	1986	If IFN priming is carried out in the presence of cycloheximide, a approximately 200-fold increase in induction is observed.	Cycloheximide	49-62	interferon alpha 1	Homo sapiens	3-6
3085656-3	1986	The increase in diamine oxidase activity by exogenous putrescine was prevented by the administration of actinomycin D and cycloheximide, suggesting that syntheses of mRNA and protein are involved.	Cycloheximide	122-135	amine oxidase, copper containing 1	Rattus norvegicus	16-31
3955844-1	1986	Repeated doses of the protein synthesis inhibitor cycloheximide prevented the increases in rat liver mitochondrial and cytosolic aspartate aminotransferase, in alanine aminotransferase and in protein content observed 24 h after a single carbon tetrachloride injection.	Cycloheximide	50-63	glutamic-oxaloacetic transaminase 1	Rattus norvegicus	101-155
3002188-5	1986	Cycloheximide prevented (Bu)2cAMP augmentation of LHRH-induced secretion.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	50-54
3509992-8	1986	Pretreatment of rats with the translational inhibitor cycloheximide completely suppressed the O6-AT stimulation.	Cycloheximide	54-67	O-6-methylguanine-DNA methyltransferase	Rattus norvegicus	94-99
3329042-2	1986	In the yeast Saccharomyces cerevisiae, two nuclear pleiotropic drug resistance mutations pdr3-1 (former designation mucPR) and pdr3-2 (former designation DRI9/T7) have been selected as resistant to mucidin and as resistant to chloramphenicol plus cycloheximide, respectively.	Cycloheximide	247-260	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	89-93
3329042-2	1986	In the yeast Saccharomyces cerevisiae, two nuclear pleiotropic drug resistance mutations pdr3-1 (former designation mucPR) and pdr3-2 (former designation DRI9/T7) have been selected as resistant to mucidin and as resistant to chloramphenicol plus cycloheximide, respectively.	Cycloheximide	247-260	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	127-131
3077972-11	1986	Ornithine decarboxylase, another enzyme that is rapidly induced by tumor promoters, is inhibited by both cycloheximide and actinomycin D in the presence of TPA (O"Brien, 1976).	Cycloheximide	105-118	ornithine decarboxylase 1	Homo sapiens	0-23
2431930-5	1986	Calcium antagonists (cobalt and verapamil), monensin and cycloheximide inhibited both the release of hepatic lipase and VLDL.	Cycloheximide	57-70	lipase C, hepatic type	Rattus norvegicus	101-115
3081641-6	1986	Cycloheximide inhibits the induction of the invariant chain mRNA by interferon-gamma, suggesting that protein synthesis is required.	Cycloheximide	0-13	interferon gamma	Homo sapiens	68-84
3484763-7	1986	IL 2 mRNA could be superinduced several folds by addition of cycloheximide 3 hr after induction of J32 with mitogens.	Cycloheximide	61-74	interleukin 2	Homo sapiens	0-4
3948865-5	1986	Addition of 10 mM putrescine caused a rapid decay of ODC activity, which was faster than ODC decay in the presence of cycloheximide.	Cycloheximide	118-131	ornithine decarboxylase 1	Rattus norvegicus	89-92
3079667-3	1986	Induction involved a sequence of transcription, translation, and secretion, all necessary for HMT synthesis and release into the supernatant as determined by blocking of these functions with the drugs actinomycin D, cycloheximide, and monensin, respectively; HMT levels reached a peak within 4-6 h and thereafter declined.	Cycloheximide	216-229	histamine N-methyltransferase	Homo sapiens	94-97
3486324-3	1986	hCG produced an increase in 17-hydroxyprogesterone, and androstenedione, but a drastic decrease in enzyme activity within 6 h; this could be largely prevented by pretreatment of the rats with cycloheximide or aminoglutethimide but actinomycin D was ineffective.	Cycloheximide	192-205	glycoprotein hormones, alpha polypeptide	Homo sapiens	0-3
3955844-4	1986	This effect of cycloheximide lends support to the hypothesis that the liver enzyme increases after CCl4 are probably due to increased synthesis, in addition to the classically held mechanisms of leakage from necrotic or damaged hepatocytes.	Cycloheximide	15-28	C-C motif chemokine ligand 4	Rattus norvegicus	99-103
3515129-3	1986	Recent studies regarding the influence of cycloheximide on the temperature-dependent increase in survival and mutation frequencies of a thermoconditional rev2 mutant lead to the suggestion that the REV2-coded mutagenic repair function is UV-inducible.	Cycloheximide	42-55	DNA helicase RAD5	Saccharomyces cerevisiae S288C	154-158
3754136-7	1986	The pretreatment of animals with either actinomycin D or cycloheximide almost completely blocked the Co2+-mediated increase of ODC activity.	Cycloheximide	57-70	ornithine decarboxylase 1	Rattus norvegicus	127-130
3515129-3	1986	Recent studies regarding the influence of cycloheximide on the temperature-dependent increase in survival and mutation frequencies of a thermoconditional rev2 mutant lead to the suggestion that the REV2-coded mutagenic repair function is UV-inducible.	Cycloheximide	42-55	DNA helicase RAD5	Saccharomyces cerevisiae S288C	198-202
3079910-7	1986	Nuclear transcription assays revealed that cycloheximide, like LPS, activated kappa-gene transcription.	Cycloheximide	43-56	toll-like receptor 4	Mus musculus	63-66
3081967-7	1986	The effect of BK was inhibited by cycloheximide but not by actinomycin-D.	Cycloheximide	34-47	kininogen 1	Bos taurus	14-16
2999973-5	1985	Further, the results demonstrate that the increase in intracellular concentration of c-myc RNA induced by cycloheximide treatment of normal cells is the result of stabilization of this message.	Cycloheximide	106-119	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90
3878084-6	1985	Cycloheximide and actinomycin D block these IL-1 actions on endothelium, which suggests the requirement for de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	44-48
2999163-10	1985	Cycloheximide did not prevent the increased basal glucose incorporation in glucose-starved cells, but markedly inhibited the insulin response, while in glucose-fed cells, cycloheximide stimulated basal glucose incorporation.	Cycloheximide	0-13	insulin	Homo sapiens	125-132
3851809-4	1985	Suppression of protein synthesis with cycloheximide blocked the induction of ACE activity but only partially inhibited neurite outgrowth in the mevinolin-treated cultures.	Cycloheximide	38-51	acetylcholinesterase	Mus musculus	77-80
2415552-3	1985	The antigen could be removed from cultured neurons by trypsinization and its resynthesis was blocked by cycloheximide, suggesting that the carbohydrate epitope detected by HNK-1 was attached to a de novo synthesized protein.	Cycloheximide	104-117	beta-1,3-glucuronyltransferase 1	Rattus norvegicus	172-177
2416819-8	1986	A protein synthesis inhibitor (cycloheximide) and an RNA synthesis inhibitor (actinomycin D) prevented the acquisition of adhesiveness stimulated by IL 1 and endotoxin but not by TPA.	Cycloheximide	31-44	interleukin 1 alpha	Homo sapiens	149-153
3939323-2	1985	This acceleration was abolished by incubating the oocytes with cycloheximide or puromycin during a 2-h interval between pp60v-src microinjection and progesterone addition.	Cycloheximide	63-76	SRC proto-oncogene, non-receptor tyrosine kinase L homeolog	Xenopus laevis	120-129
3001700-6	1985	Addition of cycloheximide together with EGF further enhances EGF receptor RNA accumulation.	Cycloheximide	12-25	epidermal growth factor receptor	Homo sapiens	61-73
4089833-3	1985	The generation of tissue factor activity was evident after 6 hours of incubation and was dependent on RNA and protein synthesis, as indicated by the inhibitory effects of actinomycin D and cycloheximide.	Cycloheximide	189-202	LOC101909187	Bos taurus	18-31
3935113-3	1985	We show here that in mitogen induced peripheral blood lymphocytes, inhibition of protein synthesis using three different inhibitors (cycloheximide, puromycin, pactamycin) resulted in an increase in the steady-state levels of IFN-gamma mRNA.	Cycloheximide	133-146	interferon gamma	Homo sapiens	225-234
3902825-0	1985	The effects of cycloheximide and chloroquine on insulin receptor metabolism.	Cycloheximide	15-28	insulin receptor	Homo sapiens	48-64
2412804-11	1985	Indirectly, the role of new protein and RNA synthesis was examined during hormonal regulation of renin induction using protein and RNA synthesis inhibitors such as cycloheximide, puromycin, actinomycin D, or rifampicin.	Cycloheximide	164-177	renin	Bos taurus	97-102
3877078-7	1985	IL-1 induction of endothelial adhesivity was concentration dependent (maximum, 10 U/ml), time dependent (peak, 4-6 h), and reversible, was blocked by cycloheximide (10 micrograms/ml) or actinomycin D (5 micrograms/ml) but not by acetylsalicylic acid (100 microM), and occurred without detectable endothelial cell damage.	Cycloheximide	150-163	interleukin 1 alpha	Homo sapiens	0-4
3935643-3	1985	Endometrial adenocarcinoma cells (HEC-1, HEC-50), both in monolayers and suspension, also responded to medium renewal by increasing ODC activity about 10-fold after 4 h, with subsequent reduction to control levels after 7 h. These effects were blocked by actinomycin D and cycloheximide.	Cycloheximide	273-286	NDC80 kinetochore complex component	Homo sapiens	34-39
3935643-3	1985	Endometrial adenocarcinoma cells (HEC-1, HEC-50), both in monolayers and suspension, also responded to medium renewal by increasing ODC activity about 10-fold after 4 h, with subsequent reduction to control levels after 7 h. These effects were blocked by actinomycin D and cycloheximide.	Cycloheximide	273-286	ornithine decarboxylase 1	Homo sapiens	132-135
3930598-5	1985	The generation of cellular and supernatant IL 2R was: dependent on cellular activation, rapid, radioresistant (3000 rad), and inhibited by cycloheximide treatment.	Cycloheximide	139-152	interleukin 2 receptor subunit alpha	Homo sapiens	43-48
2934802-3	1985	The enhancement of nascent C3b (C3bx) binding to C3bA on these cells could be reversed by inhibiting the process at different stages, using either cycloheximide, phenyl-methyl-sulphonyl-fluoride, salycil hydroxamic acid, or methylamine.	Cycloheximide	147-160	complement C3	Homo sapiens	27-30
2414665-11	1985	In agreement with this interpretation, we detected myc RNA as stable transcripts in differentiated F9 cells after treatment of the cells with cycloheximide.	Cycloheximide	142-155	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-54
4062932-4	1985	Previous results in the literature have shown that 2 other oncogenes, c-myc and c-fos, can be induced by growth factors in the presence of cycloheximide.	Cycloheximide	139-152	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	70-75
4062932-4	1985	Previous results in the literature have shown that 2 other oncogenes, c-myc and c-fos, can be induced by growth factors in the presence of cycloheximide.	Cycloheximide	139-152	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	80-85
4043313-1	1985	The fatal syndrome produced by cycloheximide given 6 h after a hepatonecrogenic dose of CCl4 is due neither to direct toxic synergism between CCl4 and cycloheximide nor to transient sinusoidal thrombosis.	Cycloheximide	31-44	chemokine (C-C motif) ligand 4	Mus musculus	88-92
4043313-1	1985	The fatal syndrome produced by cycloheximide given 6 h after a hepatonecrogenic dose of CCl4 is due neither to direct toxic synergism between CCl4 and cycloheximide nor to transient sinusoidal thrombosis.	Cycloheximide	31-44	chemokine (C-C motif) ligand 4	Mus musculus	142-146
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	130-134
3876934-5	1985	Addition of cycloheximide to the 22-kDa factor resulted in further significant increases in mRNA levels for both the 26-kDa-protein and IFN-beta.	Cycloheximide	12-25	interferon beta 1	Homo sapiens	136-144
4043251-5	1985	In HEp-2 cells treated with cycloheximide during exposure to CD for 20 h, the relative rate of actin synthesis measured after removal of cycloheximide was twofold higher than with CD alone and such cells exhibited a twofold slower decline in the rate of actin synthesis during recovery from CD in the continued presence of cycloheximide.	Cycloheximide	28-41	DNL-type zinc finger	Homo sapiens	3-6
4043251-5	1985	In HEp-2 cells treated with cycloheximide during exposure to CD for 20 h, the relative rate of actin synthesis measured after removal of cycloheximide was twofold higher than with CD alone and such cells exhibited a twofold slower decline in the rate of actin synthesis during recovery from CD in the continued presence of cycloheximide.	Cycloheximide	137-150	DNL-type zinc finger	Homo sapiens	3-6
4043251-5	1985	In HEp-2 cells treated with cycloheximide during exposure to CD for 20 h, the relative rate of actin synthesis measured after removal of cycloheximide was twofold higher than with CD alone and such cells exhibited a twofold slower decline in the rate of actin synthesis during recovery from CD in the continued presence of cycloheximide.	Cycloheximide	137-150	DNL-type zinc finger	Homo sapiens	3-6
4043251-6	1985	These effects of cycloheximide, which resemble observations on "super-induction", suggest that actin synthesis in CD-treated and recovering HEp-2 cells may be regulated by a repressor protein.	Cycloheximide	17-30	DNL-type zinc finger	Homo sapiens	140-143
3902825-3	1985	Through the use of the heavy-isotope density shift technique, cycloheximide was found to inhibit both the synthesis of new insulin receptor and the inactivation of old cellular insulin receptor.	Cycloheximide	62-75	insulin receptor	Homo sapiens	123-139
3902825-3	1985	Through the use of the heavy-isotope density shift technique, cycloheximide was found to inhibit both the synthesis of new insulin receptor and the inactivation of old cellular insulin receptor.	Cycloheximide	62-75	insulin receptor	Homo sapiens	177-193
3902825-5	1985	Cycloheximide did, however, rapidly and completely inhibit the inactivation of the insulin receptor.	Cycloheximide	0-13	insulin receptor	Homo sapiens	83-99
3902825-6	1985	In the presence of extracellular insulin, this effect of cycloheximide resulted in the long-term (6 h) accumulation of receptor in a trypsin-resistant intracellular compartment.	Cycloheximide	57-70	insulin	Homo sapiens	33-40
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	41-45
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	130-134
3876401-7	1985	Addition of cycloheximide blocked generation of IL-1 activity.	Cycloheximide	12-25	interleukin 1 alpha	Homo sapiens	48-52
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	130-134
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	130-134
2993420-6	1985	The enhanced binding and cytotoxicity of IL 1-treated target cells was only observed when the latter cells were preincubated with IL 1 at 37 degrees C, and was not evident at 4 degrees C. Furthermore, the IL 1-mediated effect could be abolished by treating the target cells with cycloheximide before the IL 1 pulse, or by adding rabbit anti-human IL 1 together with the IL 1.	Cycloheximide	279-292	interleukin 1 alpha	Homo sapiens	130-134
16593618-3	1985	The incorporation of [(35)S]methionine into p230 was completely inhibited by cycloheximide, whereas chloramphenicol had no effect.	Cycloheximide	77-90	golgin A4	Homo sapiens	44-48
3915532-5	1985	The PDGF-modulated increase in MEP RNA is unlike PDGF-modulated c-myc and c-fos RNA accumulation because it is blocked by cycloheximide, suggesting a requirement for de novo protein synthesis.	Cycloheximide	122-135	neurolysin (metallopeptidase M3 family)	Mus musculus	31-34
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	9-16
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	43-50
2413053-3	1985	The first peak of TGase activity was affected neither by cycloheximide nor by actinomycin D, which inhibited protein synthesis.	Cycloheximide	57-70	transglutaminase 1	Homo sapiens	18-23
2417348-4	1985	The thrombin-induced thromboplastin activity was inhibited by incubation of the cells with cycloheximide (2 micrograms/ml) or actinomycin D (2 micrograms/ml) showing that the response depended on de novo protein and RNA synthesis.	Cycloheximide	91-104	coagulation factor II, thrombin	Homo sapiens	4-12
2991264-5	1985	E2-stimulated increases in EGF receptor levels are also blocked by cycloheximide and actinomycin D, suggesting that the observed effect represents de novo synthesis of the EGF receptor and may be mediated by a transcriptional mechanism.	Cycloheximide	67-80	epidermal growth factor	Rattus norvegicus	27-30
2991264-5	1985	E2-stimulated increases in EGF receptor levels are also blocked by cycloheximide and actinomycin D, suggesting that the observed effect represents de novo synthesis of the EGF receptor and may be mediated by a transcriptional mechanism.	Cycloheximide	67-80	epidermal growth factor	Rattus norvegicus	172-175
4019471-6	1985	Experiments using actinomycin D and cycloheximide suggest that transcription is required for the erythropoietin-induced porphobilinogen deaminase activity, indicating that induction is probably at the level of de novo synthesis of enzyme.	Cycloheximide	36-49	erythropoietin	Homo sapiens	97-111
4019471-6	1985	Experiments using actinomycin D and cycloheximide suggest that transcription is required for the erythropoietin-induced porphobilinogen deaminase activity, indicating that induction is probably at the level of de novo synthesis of enzyme.	Cycloheximide	36-49	hydroxymethylbilane synthase	Homo sapiens	120-145
3935304-5	1985	A modified medium (mPA-D; addition of cetrimide, omission of sulphapyridine and actidione) was more selective and sufficiently recovered noninjured cells.	Cycloheximide	80-89	paddle	Mus musculus	19-24
3930253-5	1985	Phenylthiourea, cycloheximide or actinomycin D inhibit dopaoxidase activity, but also cell proliferation in alpha-MSH pre-stimulated cells.	Cycloheximide	16-29	pro-opiomelanocortin-alpha	Mus musculus	108-117
3894347-7	1985	Cycloheximide markedly decreased osteocalcin concentrations in control and 1,25-(OH)2D3-treated calvariae.	Cycloheximide	0-13	bone gamma-carboxyglutamate protein	Rattus norvegicus	33-44
3839137-7	1985	Pharmacologic (1.2 nmol/100 g per 3 h) 1,25(OH)2D3 treatment resulted in a change in the Arrhenius plot of phosphate transport to a biphasic one with a transition temperature of 30 degrees C. This effect was not blocked by cycloheximide.	Cycloheximide	223-236	period circadian regulator 3	Homo sapiens	30-35
3933177-2	1985	Cycloheximide prevented the induction of these mRNAs when rIFN-gamma, but not rIFN-alpha 2, was the inducer.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	58-68
4005299-4	1985	The reversible inhibition of transcobalamin II secretion by cycloheximide demonstrated that human fibroblasts are capable of de novo transcobalamin II synthesis.	Cycloheximide	60-73	transcobalamin 2	Homo sapiens	29-46
4005299-4	1985	The reversible inhibition of transcobalamin II secretion by cycloheximide demonstrated that human fibroblasts are capable of de novo transcobalamin II synthesis.	Cycloheximide	60-73	transcobalamin 2	Homo sapiens	133-150
3871948-3	1985	The stimulation by TGF-beta was abolished when cycloheximide was present during the incubation, suggesting that protein synthesis is required for the effect.	Cycloheximide	47-60	transforming growth factor, beta 1	Rattus norvegicus	19-27
4001331-4	1985	The administration of cycloheximide 48 h after irradiation removes completely the increase in the level of blood serum fibronectin.	Cycloheximide	22-35	fibronectin 1	Rattus norvegicus	119-130
3994735-0	1985	Changes in rat liver immunoreactive cathepsin D after cycloheximide.	Cycloheximide	54-67	cathepsin D	Rattus norvegicus	36-47
3994735-2	1985	By this method, the drop in activity of rat liver cathepsin D effected by repeated doses of cycloheximide, a protein synthesis inhibitor, reflects a parallel change in total enzyme protein content, the specific activity being stable in the course of the treatment.	Cycloheximide	92-105	cathepsin D	Rattus norvegicus	50-61
2981664-7	1985	Both PTH and forskolin decreased the further metabolism of [3H]1,25-(OH)2D3, probably by inhibiting its 24-hydroxylation, but there are also cycloheximide-sensitive steps in the metabolism of 1,25-(OH)2D3 that are not affected by PTH and forskolin.	Cycloheximide	141-154	parathyroid hormone	Gallus gallus	5-8
3882760-4	1985	The insulin resistance activity was decreased by coincubation with the protein synthesis inhibitor, cycloheximide.	Cycloheximide	100-113	insulin	Homo sapiens	4-11
4038724-2	1985	In this present study, we investigated the correlation between the preovulatory increase in progesterone and the periovulatory increase in plasminogen activator (PA) activities was completely suppressed with simultaneous injection with hCG of a minimum effective dose of cycloheximide to block ovulation completely.	Cycloheximide	271-284	hypertrichosis 2 (generalised, congenital)	Homo sapiens	236-239
2983318-3	1985	In the presence of cycloheximide, IL-2 binding sites declined with a half-time (t1/2) of 2.6 hr, whereas the decay of anti-Tac binding sites was much slower (t 1/2 = 6.4 hr).	Cycloheximide	19-32	interleukin 2	Homo sapiens	34-38
3155725-10	1985	The turnover of the rIFN-gamma receptor was measured by inhibiting protein synthesis with cycloheximide and the half-life of this receptor was found to be 2 h. The unglycosylated rIFN-gamma was bound to cellular receptors with an affinity similar to that previously reported for natural IFN-gamma.	Cycloheximide	90-103	interferon gamma	Rattus norvegicus	20-30
3155725-10	1985	The turnover of the rIFN-gamma receptor was measured by inhibiting protein synthesis with cycloheximide and the half-life of this receptor was found to be 2 h. The unglycosylated rIFN-gamma was bound to cellular receptors with an affinity similar to that previously reported for natural IFN-gamma.	Cycloheximide	90-103	interferon gamma	Homo sapiens	21-30
2987201-2	1985	The enzyme activity increased in a dose-dependent manner after addition of PTH to the culture, reaching a maximum at 8 h. The increase in the enzyme activity was abolished by cycloheximide or actinomycin D.	Cycloheximide	175-188	parathyroid hormone	Oryctolagus cuniculus	75-78
3888973-2	1985	Pulse-labeling by intravenous injection of [3H]leucine and pulse-chasing after 10 min by cycloheximide injection resulted in the maximal labeling of the receptor in the rough microsomes at 15 min, in the smooth microsomes and the heavy Golgi subfraction (GF3) at 25 min and in the intermediate plus light Golgi subfraction (GF1+2) at 30 min.	Cycloheximide	89-102	GATA binding protein 1	Rattus norvegicus	324-327
3934183-6	1985	Antigen (GT) was released from the membrane surface by trypsin digestion, and its reappearance required protein synthesis, since cycloheximide effectively prevented repopulation of the cell surface.	Cycloheximide	129-142	N-acetyllactosaminide alpha-1,3-galactosyltransferase	Bos taurus	9-11
3883395-2	1985	Blocking protein synthesis with cycloheximide in replicating cells caused partial inhibition of the RAD54 dependent function but some repair activity remained detectable.	Cycloheximide	32-45	DNA-dependent ATPase RAD54	Saccharomyces cerevisiae S288C	100-105
3983531-5	1985	At a concentration known to block protein synthesis in most cells (10(-5) M), cycloheximide markedly suppressed the NAG releasing response to MCCM.	Cycloheximide	78-91	O-GlcNAcase	Homo sapiens	116-119
6517942-5	1984	The increase of ornithine decarboxylase seen on the administration of cadmium was cancelled by pretreatment of rats with cycloheximide.	Cycloheximide	121-134	ornithine decarboxylase 1	Rattus norvegicus	16-39
6096161-2	1984	A nonhistone protein, which migrates between oxidized histone H3 and histone H1 has been found to be increased in amount following cycloheximide treatment.	Cycloheximide	131-144	histone cluster 1, H3b	Rattus norvegicus	54-64
6096161-2	1984	A nonhistone protein, which migrates between oxidized histone H3 and histone H1 has been found to be increased in amount following cycloheximide treatment.	Cycloheximide	131-144	H1.0 linker histone	Rattus norvegicus	69-79
6512493-3	1984	However, a remarkable production of human gamma 1 chain was induced in mouse L cells containing HIG1 gene when the cells were treated with cycloheximide for a short period.	Cycloheximide	139-152	HIG1 domain family, member 1A	Mus musculus	96-100
6502226-4	1984	Incubation for 30 min in the presence of emetine, cycloheximide, or puromycin decreased the frequency of occurrence of LTP in field CA1 elicited by repetitive stimulation of the Schaffer collaterals.	Cycloheximide	50-63	carbonic anhydrase 1	Rattus norvegicus	132-135
6510549-7	1984	Addition of cycloheximide to cell cultures during primary estrogen treatment abolishes both receptor up-regulation and increased rate of vitellogenin gene transcription on secondary stimulation.	Cycloheximide	12-25	a1-a	Xenopus laevis	137-149
6440835-6	1984	The enhanced LDH activity in the M phi cultured with NSP for 96 hr was completely inhibited by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	95-108	reticulon 1	Mus musculus	53-56
6334309-5	1984	An inhibitor of protein synthesis, cycloheximide, was also found to induce beta- and gamma-actin mRNA accumulation.	Cycloheximide	35-48	actin, beta	Mus musculus	75-96
6093261-5	1984	Expression of the authentic c-fos gene is induced by PDGF and superinduced by the combination of PDGF and cycloheximide.	Cycloheximide	106-119	FBJ osteosarcoma oncogene	Mus musculus	28-33
6438086-11	1984	Furthermore, both 125I-HDL3 and 125I-T-HDL3 association with fibroblasts preincubated with varying concentrations of cholesterol increased in parallel with the free cholesterol content of the cells; although cycloheximide blocked this increase in HDL3-cell association, cycloheximide also prevented the increase in cholesterol content of cholesterol-treated cells.	Cycloheximide	270-283	HDL3	Homo sapiens	39-43
6438086-11	1984	Furthermore, both 125I-HDL3 and 125I-T-HDL3 association with fibroblasts preincubated with varying concentrations of cholesterol increased in parallel with the free cholesterol content of the cells; although cycloheximide blocked this increase in HDL3-cell association, cycloheximide also prevented the increase in cholesterol content of cholesterol-treated cells.	Cycloheximide	270-283	HDL3	Homo sapiens	39-43
6092356-9	1984	This produced a parallel increase in surface and intracellular transferrin receptors, reaching 2-fold at 24 h and 3-fold at 48 h. This increase in receptor number required ongoing protein synthesis and could be blocked by cycloheximide.	Cycloheximide	222-235	transferrin	Homo sapiens	63-74
6493000-3	1984	The enhancement of 3H labelled-prolactin synthesis induced by ethanol was suppressed by cycloheximide.	Cycloheximide	88-101	prolactin	Homo sapiens	31-40
6488182-14	1984	The induction of ALDH is blocked by actinomycin D, alpha-amanitin, and cycloheximide.	Cycloheximide	71-84	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	17-21
6436496-7	1984	Induction of STE3 RNA occurs even if protein synthesis is blocked by cycloheximide.	Cycloheximide	69-82	Ste3p	Saccharomyces cerevisiae S288C	13-17
6090108-10	1984	The half-time of GH receptor loss after inhibition of protein synthesis with cycloheximide (0.1 mM) was 1.25 +/- 0.14 h, n = 3).	Cycloheximide	77-90	growth hormone receptor	Mus musculus	17-28
6512024-1	1984	When a hepatotoxic dose of CCl4 is followed in 6 h (but not in 18 h) by 30 micrograms per g body weight of cycloheximide, a lethal, shock-like state develops.	Cycloheximide	107-120	chemokine (C-C motif) ligand 4	Mus musculus	27-31
6433991-3	1984	Pyrazole (an inhibitor of alcohol dehydrogenase), cycloheximide or actinomycin D (inhibitors of macromolecular syntheses), as well as prior adrenalectomy, prevented the ethanol-induced stimulation of diamine oxidase in the liver, but not in the kidney.	Cycloheximide	50-63	amine oxidase, copper containing 1	Rattus norvegicus	200-215
6091048-3	1984	The IFN-beta 1 RNA synthesized by nuclei of uninduced SR117-21E cells is similar to that made by nuclei of poly(rI):(rC)-induced cells, but does not accumulate and hence no IFN is produced unless the cells have been treated either by ds RNA or by cycloheximide.	Cycloheximide	247-260	interferon alpha 1	Homo sapiens	4-7
6333239-2	1984	We have previously demonstrated a dramatic superinduction of the formation of IL-2 and of biologically active IL-2 mRNA in the presence of cycloheximide, an inhibitor of translation.	Cycloheximide	139-152	interleukin 2	Homo sapiens	78-82
6333239-2	1984	We have previously demonstrated a dramatic superinduction of the formation of IL-2 and of biologically active IL-2 mRNA in the presence of cycloheximide, an inhibitor of translation.	Cycloheximide	139-152	interleukin 2	Homo sapiens	110-114
6209265-8	1984	Actinomycin D and cycloheximide reduced the enzyme activities stimulated by Bt2-cAMP.	Cycloheximide	18-31	belted 2	Mus musculus	76-79
6470042-6	1984	The NGF production was blocked by inhibitors of messenger RNA synthesis (actinomycin D) and of polyadenylation (9-beta-D-arabinofuranosyladenine) as well as by inhibitors of translation (cycloheximide).	Cycloheximide	187-200	nerve growth factor	Rattus norvegicus	4-7
6611372-9	1984	This UV-induced activity was cycloheximide-sensitive, suggesting that de novo protein synthesis rather than release from cells was responsible for the increased IL 1 activity.	Cycloheximide	29-42	interleukin 1 complex	Mus musculus	161-165
6092170-6	1984	Homologous ligand GnRH-R induction in hpg mouse pituitaries in vivo is prevented by prior treatment with cycloheximide, a non-specific protein synthesis inhibitor.	Cycloheximide	105-118	gonadotropin releasing hormone receptor	Mus musculus	18-24
6092170-6	1984	Homologous ligand GnRH-R induction in hpg mouse pituitaries in vivo is prevented by prior treatment with cycloheximide, a non-specific protein synthesis inhibitor.	Cycloheximide	105-118	gonadotropin releasing hormone 1	Mus musculus	38-41
6493583-3	1984	The recovery of AChE molecular form activities subsequent to identical DFP-inactivation was blocked to a large extent (65-85%) by in vivo treatment with cycloheximide, a protein synthesis inhibitor.	Cycloheximide	153-166	acetylcholinesterase	Rattus norvegicus	16-20
6736651-15	1984	LPS-induced changes were dependent on de novo protein synthesis; cycloheximide prevented enhancement of phagocytosis, Fc receptor capacity, and colony formation.	Cycloheximide	65-78	Fc receptor	Mus musculus	118-129
6743356-6	1984	ODC induction by LPS was suppressed by dexamethasone and cycloheximide.	Cycloheximide	57-70	ornithine decarboxylase, structural 1	Mus musculus	0-3
6375731-7	1984	Cycloheximide perfusion induced a dramatic decrease of lipoprotein lipase and neutral lipase activity, indicating a half-life of less than 90 min for both enzymes.	Cycloheximide	0-13	lipoprotein lipase	Rattus norvegicus	55-73
6375731-7	1984	Cycloheximide perfusion induced a dramatic decrease of lipoprotein lipase and neutral lipase activity, indicating a half-life of less than 90 min for both enzymes.	Cycloheximide	0-13	lipase G, endothelial type	Rattus norvegicus	67-73
6744241-7	1984	Pretreatment of the animals either with actinomycin D or with cycloheximide completely blocked anthralin mediated ODC induction suggesting that de novo ODC-mRNA synthesis and subsequent translation is involved in this process.	Cycloheximide	62-75	ornithine decarboxylase 1	Rattus norvegicus	114-117
6744241-7	1984	Pretreatment of the animals either with actinomycin D or with cycloheximide completely blocked anthralin mediated ODC induction suggesting that de novo ODC-mRNA synthesis and subsequent translation is involved in this process.	Cycloheximide	62-75	ornithine decarboxylase 1	Rattus norvegicus	152-155
6738811-8	1984	administration of prolactin to these animals increases the rate of DA synthesis in the median eminence within 4 h (rapid "tonic" component) and then causes a further increase after 12 h (delayed "induction" component); only the latter component is blocked by treatment with cycloheximide, indicating the involvement in protein synthesis.	Cycloheximide	274-287	prolactin	Homo sapiens	18-27
6373760-12	1984	From these observations, we conclude that 1) internalization is not rate-limiting in insulin receptor degradation, 2) chloroquine has no effect on the internalization of insulin receptors but inhibits the intracellular degradation of receptors, 3) cycloheximide interferes with both the internalization and degradation of insulin receptors, and 4) the plateau in the loss of labeled receptors from the cell surface after 60 min at 37 degrees C could be due to a new steady state balance between internalization and recycling of photoaffinity-labeled receptors.	Cycloheximide	248-261	insulin receptor	Rattus norvegicus	322-346
6626167-5	1983	Haemin was as effective as cycloheximide in causing depletion of ALA synthase in hepatocytes.	Cycloheximide	27-40	5'-aminolevulinate synthase 1	Gallus gallus	65-77
24173416-1	1983	Mutations in sup1 and sup2 genes may cause cycloheximide-dependent growth in yeast Saccharomyces cerevisiae.	Cycloheximide	43-56	translation termination factor eRF1	Saccharomyces cerevisiae S288C	13-17
24173416-1	1983	Mutations in sup1 and sup2 genes may cause cycloheximide-dependent growth in yeast Saccharomyces cerevisiae.	Cycloheximide	43-56	SUP2	Saccharomyces cerevisiae S288C	22-26
24173416-5	1983	The number of binding sites per ribosome or per 60S subunit in the cycloheximide dependent mutant remains unchanged.Circular dichroism spectra of a mutant ribosomes in the presence as well as in the absence of antibiotic revealed that sup1 and sup2 mutations alter conformation of the yeast cytoplasmic ribosomes.	Cycloheximide	67-80	translation termination factor eRF1	Saccharomyces cerevisiae S288C	235-239
6193139-7	1983	Inhibitors of protein and RNA synthesis (cycloheximide, actinomycin D, and alpha-amanatin) inhibited insulin action.	Cycloheximide	41-54	insulin	Sus scrofa	101-108
6311299-6	1983	In all treatment groups, addition of 5 microM cycloheximide to the perifusion media significantly inhibited GnRH-stimulated LH release during the late phase without significantly altering the initial LH response except in the OVX + E2P group in which it was partially inhibited.	Cycloheximide	46-59	gonadotropin releasing hormone 1	Rattus norvegicus	108-112
6306017-9	1983	The process of recovering CSF-1-binding activity is completely blocked by the addition of cycloheximide.	Cycloheximide	90-103	colony stimulating factor 1 (macrophage)	Mus musculus	26-31
6345556-0	1983	Maturation-promoting factor induces nuclear envelope breakdown in cycloheximide-arrested embryos of Xenopus laevis.	Cycloheximide	66-79	cyclin-dependent kinase 1 L homeolog	Xenopus laevis	0-27
6602193-9	1983	Only 8% secretion was noted at 4 degrees C; however, this increased to 70% to 80% at 37 degrees C. Development of binding sites in vitro appeared to require new protein synthesis, since addition of 1 microgram/ml cycloheximide during the preincubation prevented the subsequent CSF binding.	Cycloheximide	213-226	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	277-280
6306284-0	1983	Cycloheximide induces expression of the human interferon beta 1 gene in mouse cells transformed by bovine papillomavirus-interferon beta 1 recombinants.	Cycloheximide	0-13	interferon beta 1	Homo sapiens	46-63
6306284-0	1983	Cycloheximide induces expression of the human interferon beta 1 gene in mouse cells transformed by bovine papillomavirus-interferon beta 1 recombinants.	Cycloheximide	0-13	interferon beta 1	Homo sapiens	121-138
6306284-4	1983	In contrast, cycloheximide without double-stranded RNA could induce significant levels of human IFN in the bovine papillomavirus IFN-beta 1 mouse transformants.	Cycloheximide	13-26	interferon alpha 1	Homo sapiens	96-99
6306284-4	1983	In contrast, cycloheximide without double-stranded RNA could induce significant levels of human IFN in the bovine papillomavirus IFN-beta 1 mouse transformants.	Cycloheximide	13-26	interferon alpha 1	Homo sapiens	129-132
6306284-5	1983	After cycloheximide treatment, these cells contained IFN-beta 1 mRNA whose 5" ends originated in the authentic start site of the human IFN-beta 1 gene, as shown by S1 nuclease mapping.	Cycloheximide	6-19	interferon alpha 1	Homo sapiens	53-56
6306284-5	1983	After cycloheximide treatment, these cells contained IFN-beta 1 mRNA whose 5" ends originated in the authentic start site of the human IFN-beta 1 gene, as shown by S1 nuclease mapping.	Cycloheximide	6-19	interferon alpha 1	Homo sapiens	135-138
6306284-7	1983	The results also confirmed that the inhibitor of protein synthesis, cycloheximide, can induce expression of a human IFN gene.	Cycloheximide	68-81	interferon alpha 1	Homo sapiens	116-119
6349621-3	1983	Cycloheximide (2.8 micrograms/ml) increased insulin binding by 30% within 6 h, an effect that persisted for up to 25 h. This drug had a specific inhibitory effect on the degradation of proteins prelabelled for 10 h with [14C]glucosamine, without affecting the degradation of total proteins.	Cycloheximide	0-13	insulin	Homo sapiens	44-51
6349621-7	1983	First, the rate of release of degraded insulin into the medium was 600 molecules/min per hepatocyte with 1 nM labelled hormone, and increased (preincubation with cycloheximide) or decreased (tunicamycin) as a function of the amount of cell-bound insulin.	Cycloheximide	162-175	insulin	Homo sapiens	39-46
6133857-13	1983	However, when cycloheximide was administered 1 h after leupeptin, the formation of autophagosomes and the sequestration of cytoplasmic enzymes were inhibited but the vacuolar uptake of acid phosphatase and cathepsin D continued to increase for several hours.	Cycloheximide	14-27	cathepsin D	Rattus norvegicus	206-217
6304624-1	1983	Mutations in the yeast gene CYH2 can lead to resistance to cycloheximide, an inhibitor of eukaryotic protein synthesis.	Cycloheximide	59-72	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	28-32
6132864-8	1983	It did not alter gamma-glutamyltransferase subcellular distribution; (ii) ethanol had no immediate effect when added directly to the assay mixture; (iii) the lag period and the time course of the increase in gamma-glutamyltransferase activity were those expected for an induction process; (iv) the increase in gamma-glutamyltransferase activity was prevented by cycloheximide and actinomycin D suggesting that ethanol acted at the transcriptional level.	Cycloheximide	362-375	gamma-glutamyltransferase 1	Rattus norvegicus	208-233
6132864-8	1983	It did not alter gamma-glutamyltransferase subcellular distribution; (ii) ethanol had no immediate effect when added directly to the assay mixture; (iii) the lag period and the time course of the increase in gamma-glutamyltransferase activity were those expected for an induction process; (iv) the increase in gamma-glutamyltransferase activity was prevented by cycloheximide and actinomycin D suggesting that ethanol acted at the transcriptional level.	Cycloheximide	362-375	gamma-glutamyltransferase 1	Rattus norvegicus	208-233
6405745-2	1983	Although luteinizing hormone enhanced both ornithine decarboxylase activity and testosterone production at a similar physiological dose range, we found dissociation in the two responses in terms of their temporal aspect and the way they were affected by an irreversible inhibitor of ornithine decarboxylase, alpha-difluoromethylornithine, and protein synthesis inhibitor cycloheximide.	Cycloheximide	371-384	ornithine decarboxylase 1	Rattus norvegicus	283-306
6133634-6	1983	The increases in gamma-glutamyl transpeptidase and glutathione S-transferase activities by laccaic acid and monascus pigments could be inhibited by the simultaneous addition of either actinomycin D or cycloheximide.	Cycloheximide	201-214	gamma-glutamyltransferase 1	Rattus norvegicus	17-46
6133634-6	1983	The increases in gamma-glutamyl transpeptidase and glutathione S-transferase activities by laccaic acid and monascus pigments could be inhibited by the simultaneous addition of either actinomycin D or cycloheximide.	Cycloheximide	201-214	hematopoietic prostaglandin D synthase	Rattus norvegicus	51-76
6301908-6	1983	This paradoxical up-regulation of GnRH receptor number occurred over a period of 6 h and was completely abolished in the presence of cycloheximide.	Cycloheximide	133-146	gonadotropin releasing hormone receptor	Rattus norvegicus	34-47
6300905-9	1983	Fourth, blocking PA synthesis or activity with cycloheximide or dexamethasone prevents down-regulation of the EGF receptor.	Cycloheximide	47-60	epidermal growth factor receptor	Homo sapiens	110-122
6295747-8	1983	Treatment with CHX increased the amounts of membrane-bound and internalized [125I]iodo-hCG and decreased the amounts of [125I]iodo-hCG that were degraded.	Cycloheximide	15-18	hypertrichosis 2 (generalised, congenital)	Homo sapiens	87-90
6295747-8	1983	Treatment with CHX increased the amounts of membrane-bound and internalized [125I]iodo-hCG and decreased the amounts of [125I]iodo-hCG that were degraded.	Cycloheximide	15-18	hypertrichosis 2 (generalised, congenital)	Homo sapiens	131-134
6404539-4	1983	Actinomycin D (2 X 10(-5) M) and cycloheximide (10(-4) M) had an inhibitory effect on the action of TRH on LH release.	Cycloheximide	33-46	thyrotropin releasing hormone	Rattus norvegicus	100-103
6405987-3	1983	We show that cycloheximide seems to interact at the level of the natural GnRH penetration mechanism in the cytoplasm.	Cycloheximide	13-26	gonadotropin releasing hormone 1	Homo sapiens	73-77
6323593-9	1983	The half-life of the IFN receptor in the presence of cycloheximide was about 3 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Cycloheximide	53-66	interferon alpha-H	Bos taurus	21-24
6348479-5	1983	Furthermore, the REV2 dependent recovery of survival could be blocked or nearly blocked by cycloheximide added at any time during repair.	Cycloheximide	91-104	DNA helicase RAD5	Saccharomyces cerevisiae S288C	17-21
6348480-2	1983	Influence of cycloheximide on UV-irradiated exponentially growing rev2ts cells.	Cycloheximide	13-26	DNA helicase RAD5	Saccharomyces cerevisiae S288C	66-70
7162991-3	1982	The relative transcription rate of the vitellogenin genes in estrogen stimulated liver is similar in control and cycloheximide treated animals (800-1000 ppm).	Cycloheximide	113-126	a1-a	Xenopus laevis	39-51
7162991-6	1982	Since the overall rate of vitellogenin mRNA synthesis is a function of both the selective estrogen activation of vitellogenin gene transcription which is not blocked by cycloheximide and the increased rate of total nuclear RNA synthesis which is blocked by cycloheximide, the total rate of vitellogenin mRNA synthesis is markedly reduced following cycloheximide administration.	Cycloheximide	257-270	a1-a	Xenopus laevis	26-38
6295498-6	1982	Cycloheximide abolished the effect of angiotensin II on aldosterone production, but not on phosphatidylinositol synthesis.	Cycloheximide	0-13	angiotensinogen	Rattus norvegicus	38-52
6216918-4	1982	75Se was incorporated into selenoprotein P by liver slices in a process that was sensitive to the protein synthesis inhibitor cycloheximide.	Cycloheximide	126-139	selenoprotein P	Rattus norvegicus	27-42
6749858-0	1982	The phosphorylation of ribosomal protein S6 in rat tissues following cycloheximide injection, in diabetes, and after denervation of diaphragm.	Cycloheximide	69-82	ribosomal protein S6	Rattus norvegicus	23-43
7118891-5	1982	In the presence of cycloheximide such that VLDL apoprotein synthesis is inhibited 98%, the secretion of lipids labeled from a [3H]palmitate pulse by hepatocyte monolayers was halted only after completed apoprotein chains had cleared the cell.	Cycloheximide	19-32	very low density lipoprotein receptor	Gallus gallus	43-47
6288144-8	1982	These results, together with the reversible inhibition of Epo and CSA production by cycloheximide, demonstrate that these molecules are synthesized by the macrophage.	Cycloheximide	84-97	erythropoietin	Mus musculus	58-61
7153708-9	1982	The stimulatory effect of PMA on monocyte C3b and C3b" receptor function occurs within minutes, is stable for hours, is cycloheximide insensitive, and can be inhibited with colchicine.	Cycloheximide	120-133	endogenous retrovirus group K member 3	Homo sapiens	42-45
7153708-9	1982	The stimulatory effect of PMA on monocyte C3b and C3b" receptor function occurs within minutes, is stable for hours, is cycloheximide insensitive, and can be inhibited with colchicine.	Cycloheximide	120-133	endogenous retrovirus group K member 3	Homo sapiens	50-53
6286730-4	1982	The effect of DM on ACE production was completely inhibited by actinomycin D or cycloheximide.	Cycloheximide	80-93	angiotensin I converting enzyme	Rattus norvegicus	20-23
7096338-5	1982	Proalbumin in rough microsomes contained an average of two cysteines; the additional cysteine thiol was largely situated in the COOH-terminal region and disappeared rapidly after blocking albumin synthesis with cycloheximide.	Cycloheximide	211-224	albumin	Rattus norvegicus	3-10
7115771-12	1982	With the use of these analogs and of analogs of other amino acids it is shown that the rapid fall in ornithine decarboxylase activity that is noted following cycloheximide treatment may not be a consequence of the inhibition of protein synthesis.	Cycloheximide	158-171	ornithine decarboxylase 1	Homo sapiens	101-124
6750608-12	1982	Mutations in cyh2 or cry1, producing resistance to cycloheximide and crytopleurine due to mutant ribosomal proteins, do not produce a mak- phenotype.	Cycloheximide	51-64	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	13-17
6750608-12	1982	Mutations in cyh2 or cry1, producing resistance to cycloheximide and crytopleurine due to mutant ribosomal proteins, do not produce a mak- phenotype.	Cycloheximide	51-64	ribosomal 40S subunit protein S14A	Saccharomyces cerevisiae S288C	21-25
6810932-2	1982	The administration to animals of cycloheximide or actinomycin D prevented the increase in diamine oxidase activity normally observed during the first hours after hepatectomy.	Cycloheximide	33-46	amine oxidase, copper containing 1	Rattus norvegicus	90-105
6810932-3	1982	The study of the turnover rate of diamine oxidase with cycloheximide demonstrated that the half-life of this enzyme was about 15 h in normal and regenerating liver.	Cycloheximide	55-68	amine oxidase, copper containing 1	Rattus norvegicus	34-49
7107714-3	1982	If cycloheximide (1.25 muM) was present together with thymidine, no net protein accumulation took place during the treatment, and the subsequent duration of S, G2, and M was similar to that of untreated cells.	Cycloheximide	3-16	latexin	Homo sapiens	23-26
7109579-0	1982	The effect of ether stress and cycloheximide treatment on cholesterol binding and enzyme turnover of adrenal cortical cytochrome P450scc.	Cycloheximide	31-44	cytochrome P450, family 11, subfamily a, polypeptide 1	Rattus norvegicus	118-136
7048676-2	1982	Extracts from the embryos preliminary affected by insulin possessed a lower stabilizing ability, the hormonal effect being removed to a considerable extent by actinomycin D and cycloheximide.	Cycloheximide	177-190	insulin	Homo sapiens	50-57
6283287-4	1982	One hour pretreatment of the cells with cycloheximide, a inhibitor of protein synthesis, significantly decreased the cellular ACTH secretory response to Ang II.	Cycloheximide	40-53	angiotensinogen	Rattus norvegicus	153-159
7082380-3	1982	The activity of ferrochelatase was required for formation of cobalt protoporphyrin since inhibition of ferrochelatase with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (in the presence of cycloheximide) inhibited formation of cobalt protoporphyrin and resulted in accumulation of protoporphyrin.	Cycloheximide	185-198	ferrochelatase	Gallus gallus	16-30
6278953-7	1982	Cycloheximide was used to study the role of protein synthesis in the upregulation of gastrin receptors in vagotomized and refed rats, and it prevented the rise of gastrin binding capacity to either normal or above-normal values.	Cycloheximide	0-13	gastrin	Rattus norvegicus	85-92
6278953-7	1982	Cycloheximide was used to study the role of protein synthesis in the upregulation of gastrin receptors in vagotomized and refed rats, and it prevented the rise of gastrin binding capacity to either normal or above-normal values.	Cycloheximide	0-13	gastrin	Rattus norvegicus	163-170
6278953-10	1982	These results coupled with the maximal reduction of gastrin receptor 3 h after cycloheximide injection indicate that the gastrin receptor has a short half-life.	Cycloheximide	79-92	gastrin	Rattus norvegicus	121-128
7037172-3	1982	The accumulation of thiol proteinase in the culture medium was inhibited by cycloheximide, hydrocortisone, and aldosterone, but not by estradiol or the peptide hormones insulin or prolactin.	Cycloheximide	76-89	endogenous retrovirus group K member 18	Homo sapiens	26-36
6282890-11	1982	This recovery of surface ASGP binding activity occurred in the absence of significant protein synthesis (i.e., basal medium or 1 mM cycloheximide).	Cycloheximide	132-145	mucin 4, cell surface associated	Rattus norvegicus	25-29
6800407-3	1982	During the period of fumarase accumulation, cycloheximide prevented further fumarase synthesis and enzyme levels decreased at a rate comparable to the rate of decline normally observed 8-12 h after the start of induction.	Cycloheximide	44-57	fumarate hydratase	Homo sapiens	21-29
6800407-3	1982	During the period of fumarase accumulation, cycloheximide prevented further fumarase synthesis and enzyme levels decreased at a rate comparable to the rate of decline normally observed 8-12 h after the start of induction.	Cycloheximide	44-57	fumarate hydratase	Homo sapiens	76-84
6799006-5	1982	The administration of cycloheximide or actinomycin D to nephrectomized rates prevented the increase in diamine oxidase activity.	Cycloheximide	22-35	amine oxidase, copper containing 1	Rattus norvegicus	103-118
6799006-6	1982	The study of the turnover rate of diamine oxidase with cycloheximide demonstrated that the half-life of this enzyme was about 14 h in normal and hypertrophic kidney.	Cycloheximide	55-68	amine oxidase, copper containing 1	Rattus norvegicus	34-49
6276146-2	1982	T3 acting alone induced a 29-fold increase of spot 14 within 4 h, an increase which was completely inhibited by the concomitant administration of cycloheximide.	Cycloheximide	146-159	thyroid hormone responsive	Rattus norvegicus	46-53
6460623-10	1982	Consequently it was shown that the OLI2 gene product, a 20-kDa peptide with high cycloheximide-resistant label, which was generally taken to be "subunit 6" of the ATPase, is not in fact identical to this peptide.	Cycloheximide	81-94	F1F0 ATP synthase subunit a	Saccharomyces cerevisiae S288C	35-39
7037542-0	1982	[Effect of cycloheximide on the expression of mutation in the sup2 gene of Saccharomyces cerevisiae yeasts].	Cycloheximide	11-24	SUP2	Saccharomyces cerevisiae S288C	62-66
7108559-1	1982	The turnover of acetylcholinesterase (AChE) and its molecular forms was measured by following the loss of enzyme activity in the right hemidiaphragms of Sprague-Dawley rats treated with cycloheximide, 20 mg/kg, every 4 h. This treatment inhibited 96% of the incorporation of [3H]leucine into muscle protein.	Cycloheximide	186-199	acetylcholinesterase	Rattus norvegicus	16-36
7108559-1	1982	The turnover of acetylcholinesterase (AChE) and its molecular forms was measured by following the loss of enzyme activity in the right hemidiaphragms of Sprague-Dawley rats treated with cycloheximide, 20 mg/kg, every 4 h. This treatment inhibited 96% of the incorporation of [3H]leucine into muscle protein.	Cycloheximide	186-199	acetylcholinesterase	Rattus norvegicus	38-42
7108559-5	1982	Sucrose density gradient experiments showed that the cycloheximide-induced low of AChE activity was restricted to the 4S enzyme, which had an apparent half-life of 6.2 h.	Cycloheximide	53-66	acetylcholinesterase	Rattus norvegicus	82-86
7149923-1	1982	The effect of cycloheximide, chloramphenicol, ethidium bromide (EB), aurin tricarboxylic acid (ATA), and actinomycin D on the production of interferon (IFN) in human embryo fibroblasts (HAT) and L929 cells, stimulated with RNA from Piptoporus betulinus (Pb-RNA) was studied.	Cycloheximide	14-27	interferon alpha 1	Homo sapiens	140-156
7149923-2	1982	Treatment of HAT cells with cycloheximide superinduced the production of IFN.	Cycloheximide	28-41	interferon alpha 1	Homo sapiens	73-76
7083470-8	1982	In contrast, the ODC activity of the mouse skin papillomas declined at a rate similar to that in TPA-treated epidermis for only the first 15-20 min after cycloheximide injection.	Cycloheximide	154-167	ornithine decarboxylase, structural 1	Mus musculus	17-20
7067943-4	1982	The data presented indicate that inhibition of protein synthesis by the use of cycloheximide prevents the appearance of TPA induced inhibition of the expression of differentiative products, such as creatine phosphokinase (CPK) activity and acetylcholine receptors (AChR).	Cycloheximide	79-92	cholinergic receptor nicotinic delta subunit	Gallus gallus	240-263
7067943-4	1982	The data presented indicate that inhibition of protein synthesis by the use of cycloheximide prevents the appearance of TPA induced inhibition of the expression of differentiative products, such as creatine phosphokinase (CPK) activity and acetylcholine receptors (AChR).	Cycloheximide	79-92	cholinergic receptor nicotinic delta subunit	Gallus gallus	265-269
6749717-2	1982	The amount of 125I-insulin bound to the cell surface was found to remain relatively constant during times of active insulin degradation over a wide range of insulin concentrations, even in the presence of cycloheximide.	Cycloheximide	205-218	insulin	Homo sapiens	19-26
6813159-8	1982	Actinomycin D and cycloheximide administration reduced the oestradiol-induced and control cholesterol 7 alpha-hydroxylase activity to the same level, 6 hr after the injections.	Cycloheximide	18-31	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	90-121
7045584-7	1982	The observed post UV-increase in proteinase B activity was inhibited by cycloheximide and was dose dependent.	Cycloheximide	72-85	proteinase B	Saccharomyces cerevisiae S288C	33-45
7045585-6	1982	Cycloheximide, an inhibitor of protein synthesis, blocks the post-UV enhancement in proteinase B activity observed in rad1-3 indicating that, as in the wild-type cells, an inducible process is involved.	Cycloheximide	0-13	proteinase B	Saccharomyces cerevisiae S288C	84-96
6185934-9	1982	Both actinomycin D and cycloheximide blocked the testosterone stimulation of AAT activity.	Cycloheximide	23-36	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	77-80
6273120-4	1981	Similar to previously reported effects on phosphatidic acid and inositide phospholipids, cycloheximide blocked the effects of ACTH and cAMP on phosphatidylcholine and phosphatidylethanolamine.	Cycloheximide	89-102	proopiomelanocortin	Homo sapiens	126-130
6273120-6	1981	Our findings strongly suggest that ACTH, via cAMP, stimulates de novo phosphatidate synthesis by a cycloheximide-sensitive, Ca++-dependent process, and this stimulation causes a rapid generalized increase in adrenal phospholipids.	Cycloheximide	99-112	proopiomelanocortin	Homo sapiens	35-39
7339299-7	1981	Both ornithine decarboxylase and spermidine N1-acetyltransferase turn over rapidly as indicated by the loss of activity in response to cycloheximide.	Cycloheximide	135-148	ornithine decarboxylase 1	Rattus norvegicus	5-28
6278481-6	1981	Cycloheximide (1 mM) counteracts the inhibitory effect of dexamethasone on VIP-induced cAMP production, which suggests the involvement of a rapid protein synthesis mechanism.	Cycloheximide	0-13	vasoactive intestinal peptide	Rattus norvegicus	75-78
6174973-6	1981	The degradation of interferon beta mRNA in the induced cells requires ongoing protein synthesis; accumulation of interferon beta mRNA was observed in the continuous presence of cycloheximide.	Cycloheximide	177-190	interferon beta 1	Homo sapiens	113-128
6174090-4	1981	The maximum of ATP : citrate lyase is likewise suppressed at the levels of both translation and transcription, as shown by administration of cycloheximide and 5-azacytidine, respectively.	Cycloheximide	141-154	ATP citrate lyase	Rattus norvegicus	15-34
6795031-4	1981	ODC activity and progesterone production also correlated closely after administration of various inhibitors of protein or RNA synthesis [cycloheximide (10 microgram/ml), actinomycin D (1 microgram/ml), or alpha-amanitin (1 microgram/ml)].	Cycloheximide	137-150	ornithine decarboxylase 1	Homo sapiens	0-3
7031662-9	1981	The acceleration of receptor degradation induced by insulin was partially blocked by 100 microM cycloheximide.	Cycloheximide	96-109	insulin	Homo sapiens	52-59
7285867-3	1981	During cycloheximide-maintained inhibition of protein synthesis, the rate of inactivation of ventral prostate L-ornithine decarboxylase (ODC) or S-adenosyl-L-methionine decarboxylase (AMDC) activity and dorsolateral prostate AMDC activity was comparable in the prostates of young and aged AXC rats.	Cycloheximide	7-20	ornithine decarboxylase 1	Rattus norvegicus	110-135
7336169-3	1981	Cultured melanoma cells treated for 16 h with puromycin or cycloheximide (final concentration, 1.0 micrograms/ml) displayed increased susceptibility to ADCC even though the cell surface expression of MAA was not changed.	Cycloheximide	59-72	MAA	Homo sapiens	200-203
6792927-5	1981	Serine-induced increases in insulin binding were detectable after 15 min of incubation and were abolished by the addition of cycloheximide (1 micrograms/ml) but not by actinomycin D (1 microgram/ml).	Cycloheximide	125-138	insulin	Homo sapiens	28-35
6456021-2	1981	Repression by 95% of protein synthesis in rat liver cells after a single injection of a sublethal dose of cycloheximide (0.3 mg per 100 g of body weight) accelerates the transport of loosely bound to chromatin NHB (sNHB), in particular, that of proteins HMG 1 and HMG 2 from the cytoplasm into the nuclei.	Cycloheximide	106-119	high mobility group box 1	Rattus norvegicus	254-259
6456021-2	1981	Repression by 95% of protein synthesis in rat liver cells after a single injection of a sublethal dose of cycloheximide (0.3 mg per 100 g of body weight) accelerates the transport of loosely bound to chromatin NHB (sNHB), in particular, that of proteins HMG 1 and HMG 2 from the cytoplasm into the nuclei.	Cycloheximide	106-119	high mobility group box 2-like 1	Rattus norvegicus	264-269
7272363-5	1981	An injection of cycloheximide to the animals results in an increase in the size of the transferrin polyribosomes up to 16 monoribosomes per 1 mRNA molecule.	Cycloheximide	16-29	transferrin	Rattus norvegicus	87-98
7251587-2	1981	Cycloheximide treatment of macrophage cultures blocked the spontaneous secretion of lipoprotein lipase.	Cycloheximide	0-13	lipoprotein lipase	Homo sapiens	84-102
6455440-7	1981	The insulin-stimulated increase was insensitive to cycloheximide and cyanide during the first 30 minutes, and this early, rapid stimulation was also produced by brain FGF (fibroblast growth factor), pituitary FGF, epidermal growth factor, calf serum, and some but not all samples of follicular fluid.	Cycloheximide	51-64	insulin	Bos taurus	4-11
6973358-0	1981	Density labelling characterisation of the effects of cordycepin and cycloheximide on the turnover of phenylalanine ammonia-lyase.	Cycloheximide	68-81	phenylalanine ammonia-lyase	Solanum tuberosum	101-128
6973358-4	1981	The effect of delayed treatment with cycloheximide or cordycepin on the turnover of phenylalanine ammonia-lyase has been analysed by density labelling with 2H from 2H2O.	Cycloheximide	37-50	phenylalanine ammonia-lyase	Solanum tuberosum	84-111
6973358-5	1981	Delayed introduction of cycloheximide or cordycepin reduces the rate of labelling of phenylalanine ammonia-lyase whilst preventing the decay in enzyme activity observed in controls not treated with inhibitor, and this labelling pattern cannot be accounted for by effects of cycloheximide or cordecypin on the labelling of amino acid pools.	Cycloheximide	24-37	phenylalanine ammonia-lyase	Solanum tuberosum	85-112
6973358-6	1981	It is concluded that delayed treatment with cycloheximide or cordycepin leads to the maintenance of high levels of phenylalanine ammonia-lyase by inhibition of the removal of active enzyme rather than by maintenance of high rates of enzyme synthesis.	Cycloheximide	44-57	phenylalanine ammonia-lyase	Solanum tuberosum	115-142
6262047-0	1981	Parathyroid hormone and adenosine-3",5"-monophosphate acutely increase phospholipids of the phosphatidate-polyphosphoinositide pathway in rabbit kidney cortex tubules in vitro by a cycloheximide-sensitive process.	Cycloheximide	181-194	parathyroid hormone	Oryctolagus cuniculus	0-19
6262047-3	1981	Pretreating the tubules with cycloheximide inhibited these phospholipid effects of PTH and cAMP.	Cycloheximide	29-42	parathyroid hormone	Oryctolagus cuniculus	83-86
6785072-6	1981	Perifusion with 3.5 x 10(-5) M cycloheximide or 10(-6) M actinomycin D 1 h before and during T3 administration led to greater TSH release with TRH than in the presence of T3 alone.	Cycloheximide	31-44	thyrotropin releasing hormone	Rattus norvegicus	143-146
6942410-3	1981	Inhibitors of protein synthesis--i.e., cycloheximide and puromycin--markedly decreased the rate of degradation of the insulin receptor, the half-life for receptor decay increasing from 7.5 hr without to 25 hr with inhibitor.	Cycloheximide	39-52	insulin receptor	Mus musculus	118-134
6787849-8	1981	The putrescine-catabolizing ability returns with a half-time of recovery of 15-18 h, corresponding to the estimates of SHAFF and BEAVEN [36] for recovery of intestinal DAO activity following administration of heparin or cycloheximide.	Cycloheximide	220-233	amine oxidase, copper containing 1	Rattus norvegicus	168-171
7024288-6	1981	Protein synthesis furthermore does not seem to be required, since a significant insulin effect can be seen in the presence of the protein synthesis inhibitor, cycloheximide.	Cycloheximide	159-172	insulin	Homo sapiens	80-87
6257679-9	1981	Both phases of the increase in glucokinase activity were inhibited by cycloheximide, whereas the addition to the culture medium of cordycepin or actinomycin D prevented only the initial increase in activity and not the second increase, which arose from the addition of 8-bromo-cGMP to the cultures.	Cycloheximide	70-83	glucokinase	Homo sapiens	31-42
7004856-8	1981	Cycloheximide inhibited the progesterone augmentation and the LHRH self-priming without affecting the LH secretory response to the initial LHRH pulse in the absence of steroid.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	62-66
6260821-7	1981	Studies with actinomycin-D and cycloheximide support the hypothesis that cAMP can also mediate posttranslational activation of tyrosinase.	Cycloheximide	31-44	tyrosinase	Homo sapiens	127-137
6291319-4	1981	Cycloheximide (10(-5)M) given simultaneously with the LH--RH totally blocked the observed effect of LH--RH.	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	100-106
7326828-7	1981	The in vivo induction of rat liver ODC activity by TPA appeared to be under transcriptional control since administration of 2 mg actinomycin D/kg body weight or 50 mg cycloheximide/kg body weight 1 h prior to application of the tumor promotor prevented the increase of ODC activity.	Cycloheximide	167-180	ornithine decarboxylase 1	Rattus norvegicus	35-38
7326828-7	1981	The in vivo induction of rat liver ODC activity by TPA appeared to be under transcriptional control since administration of 2 mg actinomycin D/kg body weight or 50 mg cycloheximide/kg body weight 1 h prior to application of the tumor promotor prevented the increase of ODC activity.	Cycloheximide	167-180	ornithine decarboxylase 1	Rattus norvegicus	269-272
6283502-5	1981	Time dependent uptake of 35S-methionine into CCK-LI was observed in cultured frog retinas and this uptake was blocked with 0.2 mM cycloheximide.	Cycloheximide	130-143	cholecystokinin	Homo sapiens	45-48
6171829-18	1981	Inhibition of protein synthesis with cycloheximide causes a lengthening of the t1/2 for insulin receptor degradation to 26 hours.	Cycloheximide	37-50	insulin receptor	Mus musculus	88-104
7460011-3	1980	Preincubation of the PAM 212 cells with cycloheximide prevented attachment.	Cycloheximide	40-53	peptidylglycine alpha-amidating monooxygenase	Mus musculus	21-24
7460011-5	1980	Extracts of the EHS tumor, which produces an extracellular matrix containing basement membrane components, were tested for their ability to promote attachment to cycloheximide-treated PAM 212 cells.	Cycloheximide	162-175	peptidylglycine alpha-amidating monooxygenase	Mus musculus	184-187
7460011-6	1980	Saline extracts of the tumor stimulated the attachment of the PAM 212 cells to type IV collagen in the presence of cycloheximide.	Cycloheximide	115-128	peptidylglycine alpha-amidating monooxygenase	Mus musculus	62-65
7191796-7	1980	Progesterone receptor synthesis was inhibited by cycloheximide.	Cycloheximide	49-62	progesterone receptor	Rattus norvegicus	0-21
7441519-4	1980	TCDD-induction of AHH and cytochrome P-450 contents can be completely inhibited by a single pretreatment with either actinomycin D or cycloheximide, suggesting TCDD induces de novo synthesis of specific proteins.	Cycloheximide	134-147	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	18-21
7441519-4	1980	TCDD-induction of AHH and cytochrome P-450 contents can be completely inhibited by a single pretreatment with either actinomycin D or cycloheximide, suggesting TCDD induces de novo synthesis of specific proteins.	Cycloheximide	134-147	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	26-42
6164058-5	1980	Both are induced by poly(rI.rC), but IFN-beta 2 mRNA is induced to about 10% in cells by cycloheximide treatment alone whereas under these conditions IFN-beta 1 is not induced.	Cycloheximide	89-102	interleukin 6	Homo sapiens	37-47
7000764-8	1980	Likewise, cycloheximide prevented the insulin-induced loss of receptors.	Cycloheximide	10-23	insulin	Meleagris gallopavo	38-45
7000764-12	1980	Following removal of insulin from the growth medium, about one-half of the receptors were restored within 10 h and the full complement of insulin receptors was restored within 24 h. Cycloheximide prevented restoration of the insulin receptor.	Cycloheximide	182-195	insulin	Meleagris gallopavo	21-28
7000764-12	1980	Following removal of insulin from the growth medium, about one-half of the receptors were restored within 10 h and the full complement of insulin receptors was restored within 24 h. Cycloheximide prevented restoration of the insulin receptor.	Cycloheximide	182-195	insulin	Meleagris gallopavo	138-145
7000764-12	1980	Following removal of insulin from the growth medium, about one-half of the receptors were restored within 10 h and the full complement of insulin receptors was restored within 24 h. Cycloheximide prevented restoration of the insulin receptor.	Cycloheximide	182-195	insulin receptor	Meleagris gallopavo	138-154
7417523-5	1980	The stimulation by 1 alpha-hydroxy-vitamin D-3 on the release of Ca2+, Pi and beta-glucuronidase was suppressed by a protein synthesis inhibitor, cycloheximide.	Cycloheximide	146-159	glucuronidase, beta	Mus musculus	78-96
24310191-7	1980	Additions of cycloheximide inhibit the development of NR, AS and GDH activities and also the incorporation of acetate-(14)C and leucine into protein.	Cycloheximide	13-26	nitrate reductase [NADH] 1	Zea mays	54-56
24310191-7	1980	Additions of cycloheximide inhibit the development of NR, AS and GDH activities and also the incorporation of acetate-(14)C and leucine into protein.	Cycloheximide	13-26	glutamic dehydrogenase1	Zea mays	65-68
6252041-0	1980	5"-Nucleotidase activity in liver homogenates of rats treated with CCl4, colchicine, cycloheximide, emetine, ethanol, ethionine and 5-fluorotryptophan.	Cycloheximide	85-98	5' nucleotidase, ecto	Rattus norvegicus	0-15
6777146-6	1980	This effect of progestagens was found to be time-dependent and maximal inhibition was found after 12-20 h. However, more effective inhibition of LH-RH stimulated rLH release was caused by preincubation with cycloheximide suggesting the importance of protein synthesis in the course of LH-RH augmented gonadotropin release.	Cycloheximide	207-220	gonadotropin releasing hormone 1	Rattus norvegicus	145-150
6777146-6	1980	This effect of progestagens was found to be time-dependent and maximal inhibition was found after 12-20 h. However, more effective inhibition of LH-RH stimulated rLH release was caused by preincubation with cycloheximide suggesting the importance of protein synthesis in the course of LH-RH augmented gonadotropin release.	Cycloheximide	207-220	gonadotropin releasing hormone 1	Rattus norvegicus	285-290
6997370-6	1980	Treatment of cells with the protein synthesis inhibitors cycloheximide and pactamycin reduced fibronectin localization in the endoplasmic reticulum to 50% of normal levels.	Cycloheximide	57-70	fibronectin 1	Gallus gallus	94-105
6161227-13	1980	Evidence for the participation of the transport process in the renewal of AChE in the distal portions of the axon was obtained in experiments using diisopropylphosphorofluoridate and cycloheximide.	Cycloheximide	183-196	acetylcholinesterase	Rattus norvegicus	74-78
7455665-5	1980	(iii) Cycloheximide, the protein-synthesis inhibitor, reduces the enkephalin-increasing effect of acupuncture, indicating that one of the mechanisms by which acupuncture elevates the enkephalin levels is the acceleration of biosynthesis.	Cycloheximide	6-19	proenkephalin	Rattus norvegicus	66-76
7455665-5	1980	(iii) Cycloheximide, the protein-synthesis inhibitor, reduces the enkephalin-increasing effect of acupuncture, indicating that one of the mechanisms by which acupuncture elevates the enkephalin levels is the acceleration of biosynthesis.	Cycloheximide	6-19	proenkephalin	Rattus norvegicus	183-193
7407213-4	1980	The induction, which exhibited saturation kinetics with maximum stimulation at 150 microgram HDL phospholipid/ml medium, occurred only in the late-log and stationary phases of cell growth and was abolished by 0.1 mM actinomycin D or cycloheximide.l Apoliproprotein HDL3 did not stimulate enzyme activity, whereas the total lipid extract of HDL3 was about 1.7 times more potent than were the native HDL3 in stimulating enzyme activity.	Cycloheximide	233-246	HDL3	Homo sapiens	265-269
7407213-4	1980	The induction, which exhibited saturation kinetics with maximum stimulation at 150 microgram HDL phospholipid/ml medium, occurred only in the late-log and stationary phases of cell growth and was abolished by 0.1 mM actinomycin D or cycloheximide.l Apoliproprotein HDL3 did not stimulate enzyme activity, whereas the total lipid extract of HDL3 was about 1.7 times more potent than were the native HDL3 in stimulating enzyme activity.	Cycloheximide	233-246	HDL3	Homo sapiens	340-344
7407213-4	1980	The induction, which exhibited saturation kinetics with maximum stimulation at 150 microgram HDL phospholipid/ml medium, occurred only in the late-log and stationary phases of cell growth and was abolished by 0.1 mM actinomycin D or cycloheximide.l Apoliproprotein HDL3 did not stimulate enzyme activity, whereas the total lipid extract of HDL3 was about 1.7 times more potent than were the native HDL3 in stimulating enzyme activity.	Cycloheximide	233-246	HDL3	Homo sapiens	340-344
7002940-16	1980	Cycloheximide reversibly inhibited the spreading of hypoblast and endoblast, and this effect could be eliminated, at least for hypoblast, by the addition of plasma fibronectin.	Cycloheximide	0-13	fibronectin 1	Gallus gallus	164-175
6254035-5	1980	Two of these ACTH-responsive proteins are among the nine major adrenal polypeptides that fulfill the criteria of mitochondrial translation products: (i) their synthesis in intact cells is specifically resistant to inhibition by cycloheximide yet uniquely sensitive to chloramphenicol and (ii) they are synthesized in vitro by isolated mitochondria.	Cycloheximide	228-241	pro-opiomelanocortin-alpha	Mus musculus	13-17
6245854-3	1980	This late eluting steroidogenic activity is enhanced by ACTH treatment and diminished by cycloheximide treatment, which also inhibits adrenal protein synthesis and ACTH-induced steroidogenesis.	Cycloheximide	89-102	proopiomelanocortin	Homo sapiens	164-168
6245854-6	1980	It seems likely that the ACTH effect on cytosolic steroidogenic activity is due to changes in polyphosphoinositides, since these phospholipids are specifically stimulated by ACTH, cycloheximide blocks the ACTH-induced increase in polyphosphoinositides, and these phospholipids comigrate with steroidogenic activity during gel filtration of adrenal cytosol.	Cycloheximide	180-193	proopiomelanocortin	Homo sapiens	25-29
6245854-6	1980	It seems likely that the ACTH effect on cytosolic steroidogenic activity is due to changes in polyphosphoinositides, since these phospholipids are specifically stimulated by ACTH, cycloheximide blocks the ACTH-induced increase in polyphosphoinositides, and these phospholipids comigrate with steroidogenic activity during gel filtration of adrenal cytosol.	Cycloheximide	180-193	proopiomelanocortin	Homo sapiens	174-178
6245854-6	1980	It seems likely that the ACTH effect on cytosolic steroidogenic activity is due to changes in polyphosphoinositides, since these phospholipids are specifically stimulated by ACTH, cycloheximide blocks the ACTH-induced increase in polyphosphoinositides, and these phospholipids comigrate with steroidogenic activity during gel filtration of adrenal cytosol.	Cycloheximide	180-193	proopiomelanocortin	Homo sapiens	174-178
6245854-7	1980	These findings along with other findings from our laboratory suggest that polyphosphoinositides may function as a cycloheximide-sensitive mediator in the steroidogenic action of ACTH.	Cycloheximide	114-127	proopiomelanocortin	Homo sapiens	178-182
6968261-3	1980	Following neuraminidase treatment, IgM Fc receptors could be regenerated by reincubation of T cells at 37 degrees C. The regeneration of IgM Fc receptors could be blocked by treatment with cycloheximide.	Cycloheximide	189-202	neuraminidase 1	Homo sapiens	10-23
7418971-2	1980	Reduction in tumour load 4 hr after the administration of cycloheximide and CCl4 is life-saving: treatment with a hepatotoxic dose of CCl4 30 hr before challenge with cycloheximide and CCl4 also nullifies that otherwise life-threatening treatment.	Cycloheximide	58-71	chemokine (C-C motif) ligand 4	Mus musculus	134-138
7418971-2	1980	Reduction in tumour load 4 hr after the administration of cycloheximide and CCl4 is life-saving: treatment with a hepatotoxic dose of CCl4 30 hr before challenge with cycloheximide and CCl4 also nullifies that otherwise life-threatening treatment.	Cycloheximide	58-71	chemokine (C-C motif) ligand 4	Mus musculus	134-138
7418971-2	1980	Reduction in tumour load 4 hr after the administration of cycloheximide and CCl4 is life-saving: treatment with a hepatotoxic dose of CCl4 30 hr before challenge with cycloheximide and CCl4 also nullifies that otherwise life-threatening treatment.	Cycloheximide	167-180	chemokine (C-C motif) ligand 4	Mus musculus	134-138
7418971-2	1980	Reduction in tumour load 4 hr after the administration of cycloheximide and CCl4 is life-saving: treatment with a hepatotoxic dose of CCl4 30 hr before challenge with cycloheximide and CCl4 also nullifies that otherwise life-threatening treatment.	Cycloheximide	167-180	chemokine (C-C motif) ligand 4	Mus musculus	134-138
6251113-0	1980	Parathyroid hormone acutely increases polyphosphoinositides of the rabbit kidney cortex by a cycloheximide-sensitive process.	Cycloheximide	93-106	parathyroid hormone	Oryctolagus cuniculus	0-19
6251113-2	1980	Cycloheximide pretreatment abolishes these effects of PTH.	Cycloheximide	0-13	parathyroid hormone	Oryctolagus cuniculus	54-57
6251113-4	1980	Cycloheximide-sensitive effects of PTH, e.g., phosphaturia, may require polyphosphoinositides and/or other phospholipids.	Cycloheximide	0-13	parathyroid hormone	Oryctolagus cuniculus	35-38
6901733-3	1980	Studies on the role of protein synthesis in this response to TRH led to the finding that an inhibitor of ribosomal translation, cycloheximide, also stimulated uridine uptake acutely.	Cycloheximide	128-141	thyrotropin releasing hormone	Homo sapiens	61-64
2418133-19	1985	However, both the plaquing efficiency and plaque size of Sindbis virus (an excellent IFN inducer) were enhanced markedly on cells treated with indomethacin or low concentrations of cycloheximide during the aging process.	Cycloheximide	181-194	interferon	Gallus gallus	85-88
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	43-50
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	43-50
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	43-50
3928421-4	1985	However, insulin-induced downregulation of insulin receptors was: (1) demonstrable in receptor-positive cells, (2) dependent on insulin concentration, (3) temporally unrelated to insulin internalization, and (4) prevented by culture at 4 degrees C but not by cycloheximide at 37 degrees C. Recovery of insulin receptors required further culture of cells in media depleted of insulin for 24 h. Scatchard analysis revealed loss of receptor number without changes in receptor affinity.	Cycloheximide	259-272	insulin	Homo sapiens	43-50
2410037-7	1985	Cycloheximide, at a dose of 0.1 mg/rat, was given at 12 h before hCG, immediately after hCG, and at 9 h after hCG.	Cycloheximide	0-13	hypertrichosis 2 (generalised, congenital)	Homo sapiens	65-68
2410037-7	1985	Cycloheximide, at a dose of 0.1 mg/rat, was given at 12 h before hCG, immediately after hCG, and at 9 h after hCG.	Cycloheximide	0-13	hypertrichosis 2 (generalised, congenital)	Homo sapiens	88-91
2410037-7	1985	Cycloheximide, at a dose of 0.1 mg/rat, was given at 12 h before hCG, immediately after hCG, and at 9 h after hCG.	Cycloheximide	0-13	hypertrichosis 2 (generalised, congenital)	Homo sapiens	88-91
4039222-1	1985	The organization and synthesis of the vimentin-containing cytoskeletal network as well as the metastatic capability of B16-F1 melanoma cells were investigated in cells treated with cycloheximide (CH).	Cycloheximide	181-194	vimentin	Mus musculus	38-46
3996322-6	1985	The induction of the initial phase of increased PRL gene transcription by 16 alpha-estradiol was observed in animals in which cycloheximide or puromycin had greatly inhibited pituitary protein synthesis.	Cycloheximide	126-139	prolactin	Rattus norvegicus	48-51
3889916-6	1985	Purified CTX was cytotoxic in the presence of cycloheximide but in its absence induced resistance to cytotoxicity; this resistance was manifested by decreased vulnerability to CTX in a subsequent incubation in the presence of cycloheximide.	Cycloheximide	46-59	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	9-12
3889916-6	1985	Purified CTX was cytotoxic in the presence of cycloheximide but in its absence induced resistance to cytotoxicity; this resistance was manifested by decreased vulnerability to CTX in a subsequent incubation in the presence of cycloheximide.	Cycloheximide	226-239	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	9-12
4039726-3	1985	The effect of PMA on t-PA mRNA levels is completely blocked by pretreatment of the cells with the inhibitor of translation, cycloheximide, indicating that it requires the biosynthesis of at least one protein intermediate.	Cycloheximide	124-137	plasminogen activator, tissue type	Homo sapiens	21-25
4039726-4	1985	In contrast, mRNA of the oncogene product c-myc can be induced for a brief period immediately following serum starvation in the presence and absence of PMA, and in the presence of cycloheximide.	Cycloheximide	180-193	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	42-47
2579961-10	1985	Because FGF, EGF, and serum cause the SIPs to be produced at concentrations of cycloheximide that inhibit 85% of bulk protein and DNA synthesis, it follows that the SIPs are produced directly from the action of the growth factor and not as a consequence of increased growth.	Cycloheximide	79-92	epidermal growth factor	Mus musculus	13-16
2859345-8	1985	Cycloheximide significantly (P less than 0.01) enhanced GRF-stimulated release of GH during a 60-min incubation, but inhibited both basal and GRF-stimulated release over 4 and 8 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Cycloheximide	0-13	growth hormone releasing hormone	Homo sapiens	56-59
2859345-8	1985	Cycloheximide significantly (P less than 0.01) enhanced GRF-stimulated release of GH during a 60-min incubation, but inhibited both basal and GRF-stimulated release over 4 and 8 h.(ABSTRACT TRUNCATED AT 250 WORDS)	Cycloheximide	0-13	growth hormone releasing hormone	Homo sapiens	142-145
3886824-2	1985	Cycloheximide (7.1 mumol/l) blocked the priming effect of LHRH (elicited by 8.5 nmol LHRH/l) and protein synthesis (assessed by gel electrophoresis of 35S-labelled pituitary proteins).	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	58-62
3886824-2	1985	Cycloheximide (7.1 mumol/l) blocked the priming effect of LHRH (elicited by 8.5 nmol LHRH/l) and protein synthesis (assessed by gel electrophoresis of 35S-labelled pituitary proteins).	Cycloheximide	0-13	gonadotropin releasing hormone 1	Rattus norvegicus	85-89
3161018-5	1985	Chorionic villi supported the cycloheximide-sensitive incorporation of [3H]leucine into immunoreactive beta-hexosaminidase thereby providing direct evidence for enzyme biosynthesis.	Cycloheximide	30-43	O-GlcNAcase	Homo sapiens	103-122
2996254-5	1985	These results suggest that TRH and DN-1417, known to reverse the amnesia produced by the protein synthesis inhibitor cycloheximide, have ameliorating effects on the retrieval process of memory.	Cycloheximide	117-130	thyrotropin releasing hormone	Mus musculus	27-30
3882403-8	1985	The stimulatory effects of somatomedin C/IGF I were inhibited by cycloheximide and actinomycin D, indicating that protein and RNA synthesis are required for the full expression of somatomedin C"s differentiative effects.	Cycloheximide	65-78	insulin like growth factor 1	Sus scrofa	27-40
3882403-8	1985	The stimulatory effects of somatomedin C/IGF I were inhibited by cycloheximide and actinomycin D, indicating that protein and RNA synthesis are required for the full expression of somatomedin C"s differentiative effects.	Cycloheximide	65-78	insulin like growth factor 1	Sus scrofa	41-46
3882403-8	1985	The stimulatory effects of somatomedin C/IGF I were inhibited by cycloheximide and actinomycin D, indicating that protein and RNA synthesis are required for the full expression of somatomedin C"s differentiative effects.	Cycloheximide	65-78	insulin like growth factor 1	Sus scrofa	180-193
3882405-5	1985	Cycloheximide (50 micrograms/ml) induced a slight diminution of control PRL receptor levels and partially reversed the effect of 50 nM PRL.	Cycloheximide	0-13	prolactin	Rattus norvegicus	72-75
3882405-5	1985	Cycloheximide (50 micrograms/ml) induced a slight diminution of control PRL receptor levels and partially reversed the effect of 50 nM PRL.	Cycloheximide	0-13	prolactin	Rattus norvegicus	135-138
3882405-6	1985	Approximately 60% of the PRL receptors were resistant to the effect of cycloheximide.	Cycloheximide	71-84	prolactin	Rattus norvegicus	25-28
3971916-3	1985	Cycloheximide was used to study the effect of a protein synthesis inhibitor on the secretion of PP12 by decidua.	Cycloheximide	0-13	insulin like growth factor binding protein 1	Homo sapiens	96-100
3971916-7	1985	The addition of cycloheximide into cultures decreased the total amount of PP12 in the decidua and in its culture medium by more than 50%, indicating that one part of PP12 in decidua was performed and another part was newly synthesized.	Cycloheximide	16-29	insulin like growth factor binding protein 1	Homo sapiens	74-78
3971916-7	1985	The addition of cycloheximide into cultures decreased the total amount of PP12 in the decidua and in its culture medium by more than 50%, indicating that one part of PP12 in decidua was performed and another part was newly synthesized.	Cycloheximide	16-29	insulin like growth factor binding protein 1	Homo sapiens	166-170
3999742-5	1985	An administration of 150 micrograms cycloheximide, that effectively blocked protein synthesis in the uterus of the E2-implanted rats, completely inhibited the replenishment of soluble ER induced by 5 micrograms E2.	Cycloheximide	36-49	estrogen receptor 1	Rattus norvegicus	184-186
3999742-6	1985	These findings, combined with our previous findings that replenishment of ER following a single E2 administration in the pituitary of chronically estrogenized rats was inhibited by cycloheximide, suggest that replenishment of ER is entirely dependent on protein synthesis in chronically estrogenized rats.	Cycloheximide	181-194	estrogen receptor 1	Rattus norvegicus	74-76
3999742-6	1985	These findings, combined with our previous findings that replenishment of ER following a single E2 administration in the pituitary of chronically estrogenized rats was inhibited by cycloheximide, suggest that replenishment of ER is entirely dependent on protein synthesis in chronically estrogenized rats.	Cycloheximide	181-194	estrogen receptor 1	Rattus norvegicus	226-228
3999813-7	1985	Cycloheximide totally inhibited glycolytic enzyme induction as well as cell transformation.	Cycloheximide	0-13	hexokinase 1	Homo sapiens	32-49
2984678-3	1985	The development of 125I-Pin binding to Sertoli cell lysates is blocked by cycloheximide.	Cycloheximide	74-87	dynein light chain LC8-type 1	Rattus norvegicus	24-27
4005226-5	1985	Cycloheximide clearly prevented the 17-h effects of CTAP III on 2dG uptake.	Cycloheximide	0-13	pro-platelet basic protein	Homo sapiens	52-60
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	75-98
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	100-103
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	174-177
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	174-177
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	174-177
4039135-1	1985	A good correlation was observed between the reciprocal of the half-life of ornithine decarboxylase (ODC) activity in the presence of cycloheximide and the relative amount of ODC-antizyme complex to total ODC (free ODC plus complexed ODC) activity in HTC cells examined at various times after cell dilution or change of medium.	Cycloheximide	133-146	ornithine decarboxylase 1	Rattus norvegicus	174-177
3871636-4	1985	The ornithine decarboxylase induction by the factor was suppressed by cycloheximide, but actinomycin D did not suppress the induction, or rather enhanced it.	Cycloheximide	70-83	ornithine decarboxylase, structural 1	Mus musculus	4-27
4015847-8	1985	The increased TO activities found after ethanol or corticosterone treatment were influenced in the same manner and to the same extent by cycloheximide.	Cycloheximide	137-150	tryptophan 2,3-dioxygenase	Rattus norvegicus	14-16
2578798-4	1985	The requirement of de novo protein synthesis for the increase in albumin and decrease of AFP by butyrate was demonstrated by inhibition studies with cycloheximide.	Cycloheximide	149-162	alpha fetoprotein	Homo sapiens	89-92
2982573-3	1985	Cycloheximide (15 micrograms/ml) inhibited both IGF I and BP production by more than 90%, while actinomycin D (0.1 microgram/ml) caused less marked, but still significant, inhibition.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	48-53
4072800-13	1985	Decay of total ODC activity (free plus complexed ODC) was more rapid with putrescine than with cycloheximide.	Cycloheximide	95-108	ornithine decarboxylase 1	Rattus norvegicus	15-18
4072800-13	1985	Decay of total ODC activity (free plus complexed ODC) was more rapid with putrescine than with cycloheximide.	Cycloheximide	95-108	ornithine decarboxylase 1	Rattus norvegicus	49-52
4026200-8	1985	Finally, injection of tryptophan and cycloheximide blocked the tryptophan-2,3-dioxygenase response while the tryptophan hydroxylase response was unaltered in both control and TD diet mice.	Cycloheximide	37-50	tryptophan 2,3-dioxygenase	Mus musculus	63-89
2983665-9	1985	The recovery of receptors after the removal of EGF was retarded in the absence of serum and prevented by the presence of cycloheximide or actinomycin D.	Cycloheximide	121-134	epidermal growth factor like 1	Rattus norvegicus	47-50
3965045-2	1985	Tissue factor activity was inducible by endotoxin, and its induction was inhibited by 1 microgram/mL of actinomycin D, 10 micrograms/mL of cycloheximide, and 0.2 micrograms/mL of tunicamycin.	Cycloheximide	139-152	coagulation factor III	Mus musculus	0-13
3881183-7	1985	Presence of cycloheximide leads to superinduction of c-fos mRNA transcripts.	Cycloheximide	12-25	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-58
4038400-6	1985	The labeling of P16 with [35S]methionine in primary rat hepatocyte cultures was inhibited by more than 90% by the cytoplasmic translation inhibitor cycloheximide, but unaffected by the mitochondrial-specific agent chloramphenicol.	Cycloheximide	148-161	cyclin-dependent kinase inhibitor 2A	Rattus norvegicus	16-19
6479164-1	1984	Cycloheximide reversal experiments in chick embryo fibroblasts and mouse L-929 cells indicate that the poxvirus-induced enzymes DNA polymerase and "alkaline" DNase are immediate early gene products of the virus.	Cycloheximide	0-13	jun proto-oncogene	Mus musculus	168-183
6432060-4	1984	EGTA appeared to inhibit the synthesis of ornithine decarboxylase, because the half-life values of ornithine decarboxylase activity were similar (37-47 min) in the presence of EGTA or protein synthesis inhibitors such as cycloheximide or emetine.	Cycloheximide	221-234	ornithine decarboxylase 1	Rattus norvegicus	42-65
6432060-5	1984	Also, calcium readdition rapidly reversed EGTA inhibition of ornithine decarboxylase activity by a mechanism which could be blocked by cycloheximide.	Cycloheximide	135-148	ornithine decarboxylase 1	Rattus norvegicus	61-84
6432061-4	1984	EGTA appeared to block antizyme synthesis, because the half-life values of antizyme activity in the presence of EGTA or cycloheximide were similar (121-143 min).	Cycloheximide	120-133	ornithine decarboxylase antizyme 1	Mus musculus	75-83
6432061-5	1984	Also, calcium readdition rapidly reversed EGTA inhibition of antizyme activity by a mechanism which could be blocked by cycloheximide.	Cycloheximide	120-133	ornithine decarboxylase antizyme 1	Mus musculus	61-69
6480400-0	1984	The inhibitory effect of actinomycin D and cycloheximide on the increase in activity of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase in experimentally induced diseased skeletal muscles.	Cycloheximide	43-56	glucose-6-phosphate dehydrogenase	Rattus norvegicus	88-121
6432701-3	1984	Cycloheximide suppressed the inhibitory effects of recombinant interferon-gamma and crude lymphokines.	Cycloheximide	0-13	interferon gamma	Mus musculus	63-79
6504240-6	1984	Pulse-chase experiments using a similar system and adding cycloheximide at different incubation times showed that the appearance of label into mature PLP was immediately blocked by the inhibitor of protein synthesis.	Cycloheximide	58-71	proteolipid protein 1	Rattus norvegicus	150-153
6382407-4	1984	At the temperature where survival is high, 23 degrees C, rad54-3 strains are able to repair X-ray-induced double-strand breaks, while at the temperature where survival is low, 36 degrees C, these strains are unable to repair rad54-3 strains provide a system to study the effects of drugs that block protein synthesis such as cycloheximide on repair of X-ray damage.	Cycloheximide	325-338	DNA-dependent ATPase RAD54	Saccharomyces cerevisiae S288C	57-62
6088483-6	1984	Cycloheximide (0.2 mM) rapidly blocked (less than 10 min) cellular steroidogenesis, cholesterol SCC activity, and access of cholesterol to cytochrome P-450scc without affecting mitochondrial free cholesterol.	Cycloheximide	0-13	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	139-158
6472449-0	1984	C-myc transcript is induced in rat liver at a very early stage of regeneration or by cycloheximide treatment.	Cycloheximide	85-98	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	0-5
6472449-4	1984	A still larger increase in c-myc transcription (approximately 600-fold) is observed in the liver when protein synthesis is inhibited by an injection of cycloheximide.	Cycloheximide	152-165	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	27-32
6466702-0	1984	Effect of propranolol and cycloheximide on the ethanol-induced increase in liver tryptophan oxygenase activity in starved rats.	Cycloheximide	26-39	tryptophan 2,3-dioxygenase	Rattus norvegicus	81-101
6466702-4	1984	In another experiment, where cycloheximide was used to block protein synthesis, it was found that increased protein synthesis rather than decreased protein degradation is probably responsible for the accumulation of liver tryptophan oxygenase after ethanol ingestion.	Cycloheximide	29-42	tryptophan 2,3-dioxygenase	Rattus norvegicus	222-242
6094601-9	1984	The restoration of CSF-1-binding activity after CSF-1 induced down-regulation was inhibited by cycloheximide, a potent protein synthesis inhibitor.	Cycloheximide	95-108	colony stimulating factor 1 (macrophage)	Mus musculus	19-24
6094601-9	1984	The restoration of CSF-1-binding activity after CSF-1 induced down-regulation was inhibited by cycloheximide, a potent protein synthesis inhibitor.	Cycloheximide	95-108	colony stimulating factor 1 (macrophage)	Mus musculus	48-53
6146632-5	1984	In each case the increase in glutamine synthetase activity required several hours to reach a maximum and was prevented by cycloheximide, suggesting that the change occurred through increased enzyme biosynthesis.	Cycloheximide	122-135	glutamate-ammonia ligase	Rattus norvegicus	29-49
6477895-7	1984	Both forms of the enzyme were rapidly labeled in vivo, and the immunoprecipitable ornithine decarboxylase protein was almost completely lost after 4-h exposure to cycloheximide, confirming directly the very rapid turnover of this enzyme.	Cycloheximide	163-176	ornithine decarboxylase, structural 1	Mus musculus	82-105
6540247-5	1984	The increases in cathepsin B and plasminogen activator activities were apparent after a 24 h treatment with DMSO and were suppressed by simultaneous treatment with cycloheximide, which suggested that they were due to syntheses of new proteins.	Cycloheximide	164-177	cathepsin B	Mus musculus	17-28
6734740-4	1984	Actinomycin D and cycloheximide inhibited alkaline phosphatase activity induced by Tf, suggesting that Tf may enhance de novo synthesis of the enzyme.	Cycloheximide	18-31	transferrin	Mus musculus	83-85
6734740-4	1984	Actinomycin D and cycloheximide inhibited alkaline phosphatase activity induced by Tf, suggesting that Tf may enhance de novo synthesis of the enzyme.	Cycloheximide	18-31	transferrin	Mus musculus	103-105
6748659-4	1984	However, cytosol ER was rapidly replenished, which was accompanied by nuclear ER reduction, and both values returned to the pre-injection levels at 4 h. An administration of 150 micrograms cycloheximide, that effectively blocked protein synthesis in the E2-implanted and 5 micrograms E2 injected rats, completely inhibited the replenishment of ER.	Cycloheximide	189-202	estrogen receptor 1	Rattus norvegicus	17-19
6748659-4	1984	However, cytosol ER was rapidly replenished, which was accompanied by nuclear ER reduction, and both values returned to the pre-injection levels at 4 h. An administration of 150 micrograms cycloheximide, that effectively blocked protein synthesis in the E2-implanted and 5 micrograms E2 injected rats, completely inhibited the replenishment of ER.	Cycloheximide	189-202	estrogen receptor 1	Rattus norvegicus	78-80
6748659-4	1984	However, cytosol ER was rapidly replenished, which was accompanied by nuclear ER reduction, and both values returned to the pre-injection levels at 4 h. An administration of 150 micrograms cycloheximide, that effectively blocked protein synthesis in the E2-implanted and 5 micrograms E2 injected rats, completely inhibited the replenishment of ER.	Cycloheximide	189-202	estrogen receptor 1	Rattus norvegicus	78-80
6373768-6	1984	Cycloheximide (and puromycin) pretreatment prevented insulin-induced increases in phospholipids and rapidly reversed ongoing insulin effects on phospholipids and pyruvate dehydrogenase activity.	Cycloheximide	0-13	insulin	Homo sapiens	53-60
6373768-6	1984	Cycloheximide (and puromycin) pretreatment prevented insulin-induced increases in phospholipids and rapidly reversed ongoing insulin effects on phospholipids and pyruvate dehydrogenase activity.	Cycloheximide	0-13	insulin	Homo sapiens	125-132
6202495-8	1984	Simultaneous treatment of cultured pituitary cells with either GnRH, KCl, or (Bu)2cAMP and cycloheximide completely prevented GnRH-R increases, while not affecting either basal or GnRH and KCl-stimulated LH secretion.	Cycloheximide	91-104	gonadotropin releasing hormone receptor	Rattus norvegicus	126-132
6725951-3	1984	In contrast, IFN-gamma was fully capable of inducing cytotoxic pM phi in the presence of Cy.	Cycloheximide	89-91	interferon gamma	Mus musculus	13-22
6725951-4	1984	Moreover, pM phi treated with mixtures of IFN in the presence of Cy were activated for cytotoxicity only by IFN-gamma together with IFN-alpha or IFN-beta, but not by IFN-alpha plus IFN-beta.	Cycloheximide	65-67	interferon gamma	Mus musculus	108-117
6725951-4	1984	Moreover, pM phi treated with mixtures of IFN in the presence of Cy were activated for cytotoxicity only by IFN-gamma together with IFN-alpha or IFN-beta, but not by IFN-alpha plus IFN-beta.	Cycloheximide	65-67	interferon alpha	Mus musculus	132-141
6725951-4	1984	Moreover, pM phi treated with mixtures of IFN in the presence of Cy were activated for cytotoxicity only by IFN-gamma together with IFN-alpha or IFN-beta, but not by IFN-alpha plus IFN-beta.	Cycloheximide	65-67	interferon beta 1, fibroblast	Mus musculus	145-153
6204893-3	1984	At least 2 h preincubation was required and this effect of the LHRH agonist was negated by the protein synthesis inhibitor cycloheximide and by the phosphodiesterase inhibitor methylisobutylxanthine (MIX).	Cycloheximide	123-136	gonadotropin releasing hormone 1	Rattus norvegicus	63-67
6609159-4	1984	In contrast, the protein synthesis inhibitor cycloheximide blocked BGP synthesis in both untreated and 1,25-(OH)2D3-treated cells.	Cycloheximide	45-58	bone gamma-carboxyglutamate protein	Homo sapiens	67-70
6376245-5	1984	Cycloheximide (20 micrograms/ml), a translational inhibitor of protein synthesis, prevented the insulin-mediated increase in the enzyme activity and the incorporation of 14C-acetate into sterols.	Cycloheximide	0-13	insulin	Homo sapiens	96-103
6232126-5	1984	This increase in E2DH activity was dose dependent from 10(-10) to 10(-7) M medroxyprogesterone acetate and inhibited by both actinomycin D and cycloheximide.	Cycloheximide	143-156	hydroxysteroid 17-beta dehydrogenase 1	Homo sapiens	17-21
6142927-8	1984	The possibility that the compactin-induced increase in glutamine synthetase activity is caused by an increase in synthesis of the enzyme was suggested by prevention of the increase by cycloheximide.	Cycloheximide	184-197	glutamate-ammonia ligase	Homo sapiens	55-75
6609365-6	1984	The presence of cycloheximide leads to extensive superinduction of IL-2, concomitant with an increase in active IL-2 mRNA formation up to 30-fold over normal levels.	Cycloheximide	16-29	interleukin 2	Homo sapiens	67-71
6609365-6	1984	The presence of cycloheximide leads to extensive superinduction of IL-2, concomitant with an increase in active IL-2 mRNA formation up to 30-fold over normal levels.	Cycloheximide	16-29	interleukin 2	Homo sapiens	112-116
6609365-7	1984	The repressor appears to be short-lived, as the addition of cycloheximide after shutoff leads to an immediate resumption of active IL-2 mRNA formation.	Cycloheximide	60-73	interleukin 2	Homo sapiens	131-135
6324870-1	1984	Inhibitors of protein synthesis, cycloheximide and puromycin, blocked ACTH (adrenocorticotropin)-induced increases in phospholipid mass, including phosphatidylinositol, but paradoxically increase 32P-labelling (but not [3H]glycerol-labelling) therein.	Cycloheximide	33-46	proopiomelanocortin	Homo sapiens	70-74
6324870-3	1984	These effects of cycloheximide and puromycin occurred in ACTH-treated (but not in control) cells.	Cycloheximide	17-30	proopiomelanocortin	Homo sapiens	57-61
6372790-4	1984	(d) Sublethal doses of cycloheximide inhibited by 60 and 90% the stimulatory action of insulin and glucagon on plasma glycine disappearance, respectively.	Cycloheximide	23-36	insulin	Oryctolagus cuniculus	87-94
6327320-5	1984	Protein synthesis inhibitors such as cycloheximide (1 microgram/ml, 48 h) and actinomycin D (50 micrograms/ml, 48 h), that abolished the TfR expression at the K562 cell surface, had no effect on NK sensitivity.	Cycloheximide	37-50	transferrin receptor	Homo sapiens	137-140
6425302-14	1984	However, MPF appearance is blocked by cycloheximide applied before mitosis; and MPF disappearance is blocked by cytostatic factor.	Cycloheximide	38-51	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	9-12
6323296-3	1984	alpha 1-AT export to medium was delayed by tunicamycin, inhibited by cycloheximide but unaffected by colchicine.	Cycloheximide	69-82	serpin family A member 1	Homo sapiens	0-10
6319493-10	1984	Cycloheximide, puromycin, emetine, and actinomycin D blocked NK activation by IFN and poly I:C as well as the acquisition of resistance to PGE2-mediated suppression.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	78-81
6142935-6	1984	Cycloheximide treatment blocked the enhanced cyclic AMP response induced by SRIF pretreatment, suggesting a requirement for protein synthesis.	Cycloheximide	0-13	somatostatin	Mus musculus	76-80
6201197-1	1984	A sharp and strong suppression of protein synthesis by cycloheximide in liver cells of starving rats is paralleled with activation of RNA synthesis and glucose-6-phosphate dehydrogenase production.	Cycloheximide	55-68	glucose-6-phosphate dehydrogenase	Rattus norvegicus	152-185
6319448-13	1984	Down-regulation of EGF receptors was reversible, with 50% recovery by 16 h. However, cycloheximide (10 micrograms/ml) blocked EGF-induced down-regulation and receptor recovery.	Cycloheximide	85-98	epidermal growth factor	Homo sapiens	19-22
6319448-13	1984	Down-regulation of EGF receptors was reversible, with 50% recovery by 16 h. However, cycloheximide (10 micrograms/ml) blocked EGF-induced down-regulation and receptor recovery.	Cycloheximide	85-98	epidermal growth factor	Homo sapiens	126-129
6693384-2	1984	The synthesis of NGF by heart cells was greatly reduced by addition of actinomycin D or cycloheximide but not by cytosine arabinoside, suggesting that the synthesis of NGF by heart cells required DNA transcription but not DNA replication.	Cycloheximide	88-101	nerve growth factor	Mus musculus	17-20
6197883-11	1984	Cycloheximide added to pregnancy-associated serum significantly inhibited the release of PAPP-A from trophoblast and decidua.	Cycloheximide	0-13	pappalysin 1	Homo sapiens	89-95
6197883-14	1984	The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.	Cycloheximide	245-258	pappalysin 1	Homo sapiens	15-21
6197883-14	1984	The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.	Cycloheximide	245-258	prolactin	Homo sapiens	32-35
6197883-14	1984	The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.	Cycloheximide	245-258	pappalysin 1	Homo sapiens	297-303
6197883-14	1984	The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.	Cycloheximide	245-258	prolactin	Homo sapiens	305-308
6197883-14	1984	The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues.	Cycloheximide	245-258	galectin 1	Homo sapiens	314-317
6696388-0	1984	Effect of cycloheximide on increased aspartate aminotransferase in carbon tetrachloride hepatotoxicity.	Cycloheximide	10-23	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	37-63
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	269-282	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	53-79
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	269-282	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	81-85
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	269-282	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	284-286	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	53-79
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	284-286	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	81-85
6696388-1	1984	The previously reported increases in liver and serum aspartate aminotransferase (ASAT) activities and liver protein content 24 hours after the administration of carbon tetrachloride (CCl4) were reduced by administering multiple doses of the protein synthesis inhibitor cycloheximide (CH).	Cycloheximide	284-286	C-C motif chemokine ligand 4	Rattus norvegicus	183-187
6365134-2	1984	Inhibition of protein synthesis with cycloheximide during incubation at permissive conditions blocks this REV 2 dependent recovery process in stationary phase rev 2ts cells, whereas it can be reduced but not totally abolished in exponentially growing cells.	Cycloheximide	37-50	DNA helicase RAD5	Saccharomyces cerevisiae S288C	106-111
6319010-5	1984	TGF-beta has little effect on the rate of overall protein synthesis, but the increase it induces in EGF binding can be completely inhibited by cycloheximide and tunicamycin.	Cycloheximide	143-156	epidermal growth factor like 1	Rattus norvegicus	100-103
6423285-5	1984	The labeled ornithine decarboxylase was lost rapidly from both nucleus and cytoplasm of all the cell types examined, and labeling by radioactive alpha-difluoro-methylornithine was greatly reduced if the mice were pretreated for 5 h with cycloheximide to block protein synthesis.	Cycloheximide	237-250	ornithine decarboxylase, structural 1	Mus musculus	12-35
6198116-8	1984	Cycloheximide has been shown to inhibit the stimulatory effect of IFN on human and murine NK cells whilst not influencing endogenous cytotoxicity.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	66-69
6198116-9	1984	In contrast, we found that both the stimulatory effect of IFN on rat NK cells and endogenous activity were equally inhibited by cycloheximide.	Cycloheximide	128-141	interferon alpha 1	Homo sapiens	58-61
6146468-5	1984	Pretreatment with cycloheximide or actinomycin D abolished the ecdysterone action on brain AChE.	Cycloheximide	18-31	acetylcholinesterase	Rattus norvegicus	91-95
6723612-4	1984	During the culture period, CX (0.5 microgram/ml) totally abolished the production of both DX-stimulated enzymes (sucrase, maltase, lactase) and DX-insensitive enzymes (aminopeptidase, alkaline phosphatase).	Cycloheximide	27-29	lactase	Rattus norvegicus	131-138
6526264-2	1984	Cycloheximide and actinomycin D also inhibit the tolerance to morphine and ethanol in smooth muscle of rat vas deferens.	Cycloheximide	0-13	arginine vasopressin	Rattus norvegicus	107-110
6690450-10	1984	ODC activity was totally abolished if either cycloheximide (10 micrograms/ml) or putrescine (10 mM) was added to cultures immediately prior to Ca2+ addition.	Cycloheximide	45-58	ornithine decarboxylase 1	Homo sapiens	0-3
6197492-8	1984	When cycloheximide was added 1 h before EGF, ornithine decarboxylase activity was obliterated.	Cycloheximide	5-18	epidermal growth factor	Homo sapiens	40-43
6197492-8	1984	When cycloheximide was added 1 h before EGF, ornithine decarboxylase activity was obliterated.	Cycloheximide	5-18	ornithine decarboxylase 1	Homo sapiens	45-68
6538894-1	1984	Does the human "beta 2 interferon" (HuIFN-beta 2) mRNA of length 1.3 kb obtained from poly(I) X poly(C) and cycloheximide-induced human diploid fibroblasts (FS-4) code for an interferon per se, or for a protein which, in turn, induces IFN-beta in the cell culture assay that is usually used to detect the antiviral activity of the translation product (obtained from Xenopus laevis oocytes) of this mRNA?	Cycloheximide	108-121	interferon beta 1	Homo sapiens	38-46
6099864-4	1984	IFN was inhibited by treatment of cells with either actinomycin D or cycloheximide, indicating the requirement of IFN-mRNA and protein for de novo synthesis.	Cycloheximide	69-82	interferon alpha 1	Homo sapiens	0-3
6439980-4	1984	Further examination revealed that for macrophages to participate in enhanced IFN gamma production, first contact between cycloheximide-treated macrophages and T cells was required.	Cycloheximide	121-134	interferon gamma	Mus musculus	77-86
6324149-5	1984	Ang II stimulated beta END-LI release was blocked by cycloheximide and decreased by corticosterone (5 nmol/l).	Cycloheximide	53-66	angiotensinogen	Rattus norvegicus	0-6
6643499-5	1983	In the presence of cycloheximide or puromycin, such that apopeptide synthesis was halted from the start of the chase, the secretion of VLDL 3H-glycerolipid was depressed after 30 min of chase, without having influenced the temporal pattern of the newly synthesized VLDL 3H-apolipoprotein and 3H-glycerolipid secretion.	Cycloheximide	19-32	very low density lipoprotein receptor	Gallus gallus	135-139
6643499-5	1983	In the presence of cycloheximide or puromycin, such that apopeptide synthesis was halted from the start of the chase, the secretion of VLDL 3H-glycerolipid was depressed after 30 min of chase, without having influenced the temporal pattern of the newly synthesized VLDL 3H-apolipoprotein and 3H-glycerolipid secretion.	Cycloheximide	19-32	very low density lipoprotein receptor	Gallus gallus	265-269
6606489-4	1983	This induction of c-myc mRNA occurs in the presence of cycloheximide and, therefore, does not require the synthesis of new protein species.	Cycloheximide	55-68	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	18-23
6606489-6	1983	In addition, c-myc mRNA is "superinduced" by the combination of cycloheximide and mitogen, a finding consistent with a model that a labile protein may regulate c-myc levels in these cells.	Cycloheximide	64-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	13-18
6606489-6	1983	In addition, c-myc mRNA is "superinduced" by the combination of cycloheximide and mitogen, a finding consistent with a model that a labile protein may regulate c-myc levels in these cells.	Cycloheximide	64-77	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	160-165
6196179-3	1983	However, treatment with cycloheximide or puromycin before the hCG injection prevented the decrease in the activity of these enzymes by hCG.	Cycloheximide	24-37	hypertrichosis 2 (generalised, congenital)	Homo sapiens	62-65
6196179-3	1983	However, treatment with cycloheximide or puromycin before the hCG injection prevented the decrease in the activity of these enzymes by hCG.	Cycloheximide	24-37	hypertrichosis 2 (generalised, congenital)	Homo sapiens	135-138
6196179-5	1983	In correlation with the changes in these enzyme activities induced by hCG, the concentration of ovarian microsomal cytochrome P-450 decreased to barely detectable level after hCG treatment; this decrease was also prevented by pretreatment with cycloheximide.	Cycloheximide	244-257	hypertrichosis 2 (generalised, congenital)	Homo sapiens	70-73
6196179-5	1983	In correlation with the changes in these enzyme activities induced by hCG, the concentration of ovarian microsomal cytochrome P-450 decreased to barely detectable level after hCG treatment; this decrease was also prevented by pretreatment with cycloheximide.	Cycloheximide	244-257	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	115-131
6196179-5	1983	In correlation with the changes in these enzyme activities induced by hCG, the concentration of ovarian microsomal cytochrome P-450 decreased to barely detectable level after hCG treatment; this decrease was also prevented by pretreatment with cycloheximide.	Cycloheximide	244-257	hypertrichosis 2 (generalised, congenital)	Homo sapiens	175-178
6198267-5	1983	Addition of cycloheximide or Actinomycin D inhibited protein synthesis and RNA synthesis, respectively, and prevented the stimulation of hCG by sodium butyrate.	Cycloheximide	12-25	hypertrichosis 2 (generalised, congenital)	Homo sapiens	137-140
6323262-3	1983	Second, by using standard yeast transformation methods, the wild-type HIS3 locus of a cycloheximide resistant strain (cyh2r) was replaced by this his3-CYH2 substitution.	Cycloheximide	86-99	imidazoleglycerol-phosphate dehydratase HIS3	Saccharomyces cerevisiae S288C	70-74
6323262-4	1983	The resulting strain is sensitive to cycloheximide because CYH2 is dominant to cyh2r.	Cycloheximide	37-50	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	59-63
6323262-6	1983	Selection for cycloheximide-resistant colonies resulted in the replacement of the his3-CYH2 allele by newly introduced his3 alleles.	Cycloheximide	14-27	imidazoleglycerol-phosphate dehydratase HIS3	Saccharomyces cerevisiae S288C	82-86
6323262-6	1983	Selection for cycloheximide-resistant colonies resulted in the replacement of the his3-CYH2 allele by newly introduced his3 alleles.	Cycloheximide	14-27	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	87-91
6323262-6	1983	Selection for cycloheximide-resistant colonies resulted in the replacement of the his3-CYH2 allele by newly introduced his3 alleles.	Cycloheximide	14-27	imidazoleglycerol-phosphate dehydratase HIS3	Saccharomyces cerevisiae S288C	119-123
6363204-1	1983	Selection of sup1 and sup2 mutants in the yeast Saccharomyces cerevisiae on cycloheximide containing media revealed classes of mutants that either are completely unable to grow on YAPD without cycloheximide or need this drug under high temperature incubation (30 or 36 degrees C).	Cycloheximide	76-89	translation termination factor eRF1	Saccharomyces cerevisiae S288C	13-17
6363204-1	1983	Selection of sup1 and sup2 mutants in the yeast Saccharomyces cerevisiae on cycloheximide containing media revealed classes of mutants that either are completely unable to grow on YAPD without cycloheximide or need this drug under high temperature incubation (30 or 36 degrees C).	Cycloheximide	76-89	SUP2	Saccharomyces cerevisiae S288C	22-26
6363204-1	1983	Selection of sup1 and sup2 mutants in the yeast Saccharomyces cerevisiae on cycloheximide containing media revealed classes of mutants that either are completely unable to grow on YAPD without cycloheximide or need this drug under high temperature incubation (30 or 36 degrees C).	Cycloheximide	193-206	translation termination factor eRF1	Saccharomyces cerevisiae S288C	13-17
6653870-3	1983	Cycloheximide interfered with neither the secretory process nor the secretory response to different stimuli, but decreased the amount of PTH and SP-I secreted.	Cycloheximide	0-13	parathyroid hormone	Bos taurus	137-140
6653870-3	1983	Cycloheximide interfered with neither the secretory process nor the secretory response to different stimuli, but decreased the amount of PTH and SP-I secreted.	Cycloheximide	0-13	chromogranin A	Bos taurus	145-149
6431710-0	1983	[Interaction with cholinergic drugs in reversal of cycloheximide-induced amnesia by thyrotropin-releasing hormone and its analog DN-1417 in mice].	Cycloheximide	51-64	thyrotropin releasing hormone	Mus musculus	84-113
6638109-3	1983	The de novo synthesis of myometrical prolactin is supported by no detectable prolactin in initial tissue homogenate, nondetectable prolactin production during the first 24 hours of culture, cycloheximide inhibition of prolactin production with recovery of production in control medium, and tritiated leucine incorporation into prolactin.	Cycloheximide	190-203	prolactin	Homo sapiens	37-46
6355103-8	1983	These results suggest that the accumulation of insulin receptors at the cell surface following treatment with cycloheximide results from inhibition of synthesis of proteins involved in insulin receptor turnover.	Cycloheximide	110-123	insulin receptor	Mus musculus	47-63
6197965-1	1983	Subcutaneous post-trial administration of the neuropeptide substance P was found to reverse the amnestic effects of both electroconvulsive shock and cycloheximide.	Cycloheximide	149-162	tachykinin 1	Mus musculus	59-70
6197965-2	1983	Substance P was observed to reverse the amnestic effects of cycloheximide in both C57B1/6J and heterogeneous strain (HS) mice.	Cycloheximide	60-73	tachykinin 1	Mus musculus	0-11
6414723-0	1983	Activation of xanthine dehydrogenase during the prenatal period through L-thyroxine, thiourea and cycloheximide.	Cycloheximide	98-111	xanthine dehydrogenase	Homo sapiens	14-36
6414723-1	1983	Xanthine dehydrogenase activity in the liver of embryonic chicks has been shown to be inducible by L-thyroxine, thiourea, and cycloheximide.	Cycloheximide	126-139	xanthine dehydrogenase	Homo sapiens	0-22
6411770-6	1983	De novo synthesis of HF was confirmed by demonstrating incorporation of [14C]lysine into specific immunoprecipitates of HF, and by the observations that both specific incorporation of labeled amino acid and net release of immunoassayable HF were inhibited by the administration of cycloheximide.	Cycloheximide	281-294	coagulation factor XII	Rattus norvegicus	21-23
6410926-6	1983	Coincident with this effect, insulin increased the lipoprotein lipase activity fraction inhibitable by cycloheximide (0.01 mg/ml), and the immunotitratable enzyme activity.	Cycloheximide	103-116	insulin	Homo sapiens	29-36
6410926-6	1983	Coincident with this effect, insulin increased the lipoprotein lipase activity fraction inhibitable by cycloheximide (0.01 mg/ml), and the immunotitratable enzyme activity.	Cycloheximide	103-116	lipoprotein lipase	Homo sapiens	51-69
6140085-0	1983	Effects of actinomycin D and cycloheximide on the activities of catalase and D-amino acid oxidase in the rat kidney cortex during sodium restriction.	Cycloheximide	29-42	catalase	Rattus norvegicus	64-72
6140085-0	1983	Effects of actinomycin D and cycloheximide on the activities of catalase and D-amino acid oxidase in the rat kidney cortex during sodium restriction.	Cycloheximide	29-42	D-amino-acid oxidase	Rattus norvegicus	77-97
6307657-2	1983	LH receptor induction by FSH was fully inhibited by the addition of cycloheximide to the incubation media, but resumed after cycloheximide was removed.	Cycloheximide	68-81	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	0-11
6307657-2	1983	LH receptor induction by FSH was fully inhibited by the addition of cycloheximide to the incubation media, but resumed after cycloheximide was removed.	Cycloheximide	125-138	luteinizing hormone/choriogonadotropin receptor	Homo sapiens	0-11
6872942-7	1983	Moreover, at concentrations not causing irreversible cell damage, inhibitors of protein synthesis, cycloheximide and actinomycin D, produced 87% and 76% reductions, respectively, in rIGF-II release in 24 h, and inhibitors of oxidative phosphorylation, dinitrophenol and sodium azide, reduced rIGF-II release by 72% and 78%, respectively.	Cycloheximide	99-112	insulin-like growth factor 2	Rattus norvegicus	182-189
6872942-7	1983	Moreover, at concentrations not causing irreversible cell damage, inhibitors of protein synthesis, cycloheximide and actinomycin D, produced 87% and 76% reductions, respectively, in rIGF-II release in 24 h, and inhibitors of oxidative phosphorylation, dinitrophenol and sodium azide, reduced rIGF-II release by 72% and 78%, respectively.	Cycloheximide	99-112	insulin-like growth factor 2	Rattus norvegicus	292-299
6192085-1	1983	Macromolecular synthesis of immune interferon (IFN-gamma) by the L12-R4 T cell lymphoma, stimulated by phorbol myristic acetate, was studied by using reversible inhibitors of protein synthesis, puromycin and cycloheximide, and an irreversible inhibitor of RNA synthesis, actinomycin D.	Cycloheximide	208-221	interferon gamma	Mus musculus	47-56
6231380-1	1983	The specific activity of cardiac cathepsin B is significantly decreased by starvation and corticosteroid treatment in vivo, and by exposure of the heart in vitro to insulin, hydrocortisone and cycloheximide.	Cycloheximide	193-206	cathepsin B	Homo sapiens	33-44
6135463-1	1983	Administration of cycloheximide (0.1-0.4 mg/kg bw) to rats caused a progressive drop of cathepsin A, B, C and D activity in the liver and kidneys.	Cycloheximide	18-31	cathepsin A	Rattus norvegicus	88-111
6135463-3	1983	On the contrary, the activity of other lysosomal hydroxylases (beta-galactosidase and arylsulfatases A and B) dropped by not more than 10-25% in all the organs under study, regardless of the fact that the dose of cycloheximide was maximal.	Cycloheximide	213-226	galactosidase, beta 1	Rattus norvegicus	63-81
6135463-3	1983	On the contrary, the activity of other lysosomal hydroxylases (beta-galactosidase and arylsulfatases A and B) dropped by not more than 10-25% in all the organs under study, regardless of the fact that the dose of cycloheximide was maximal.	Cycloheximide	213-226	arylsulfatase A	Rattus norvegicus	86-108
6189519-10	1983	In the presence of cycloheximide, the dibutyryl cAMP-induced heparin-releasable and residual lipoprotein lipase activity declined at the same rate as the basal activity.	Cycloheximide	19-32	lipoprotein lipase	Rattus norvegicus	93-111
6853503-11	1983	The half-life of immunoreactive ornithine decarboxylase in mouse kidney, as measured after inhibition of protein synthesis in vivo by cycloheximide administration, was 16 min in nontreated and 140 min in androgen-treated male animals, while the corresponding values for the catalytically active enzyme were 9 and 90 min.	Cycloheximide	134-147	ornithine decarboxylase, structural 1	Mus musculus	32-55
6852208-6	1983	The tryptophan-induced stimulation of hepatic ODC activity was not affected by prior adrenalectomy but was abolished by pretreatment with cycloheximide.	Cycloheximide	138-151	ornithine decarboxylase 1	Rattus norvegicus	46-49
6857995-4	1983	Addition of cycloheximide throughout the growth cycle resulted in an immediate cessation of coat protein production and an enhanced degradation of viral RNA.	Cycloheximide	12-25	golgi phosphoprotein 3	Homo sapiens	92-104
6305669-3	1983	This maintenance reflects a dynamic phenomenon involving receptor synthesis, since addition of cycloheximide (1 microgram/ml) in the culture medium results within 12 hr in a marked decline of PRL receptor levels.	Cycloheximide	95-108	prolactin	Rattus norvegicus	192-195
6832058-7	1983	Cycloheximide (28 micrograms/ml) inhibited the production of UG by the cells in culture whereas actinomycin-D (5 micrograms/ml) and cordycipin (50 micrograms/ml) increased its production.	Cycloheximide	0-13	uteroglobin	Oryctolagus cuniculus	61-63
6220058-4	1983	The decrease in IgE measured was due to inhibition of newly formed IgE by U266, as shown by control experiments with cycloheximide.	Cycloheximide	117-130	immunoglobulin heavy constant epsilon	Homo sapiens	16-19
6301476-2	1983	The administration of either cycloheximide or actinomycin D completely blocked the CCl4-mediated induction of choline kinase activity, indicating that the elevated activity could be due to the change in the enzyme level.	Cycloheximide	29-42	C-C motif chemokine ligand 4	Rattus norvegicus	83-87
6218830-4	1983	The administration of cycloheximide or actinomycin D prevented the increase in diamine oxidase activity during the first 24 h after isoproterenol administration, demonstrating that the rise in diamine oxidase activity was due to synthesis of new enzyme.	Cycloheximide	22-35	amine oxidase, copper containing 1	Rattus norvegicus	79-94
6218830-4	1983	The administration of cycloheximide or actinomycin D prevented the increase in diamine oxidase activity during the first 24 h after isoproterenol administration, demonstrating that the rise in diamine oxidase activity was due to synthesis of new enzyme.	Cycloheximide	22-35	amine oxidase, copper containing 1	Rattus norvegicus	193-208
6600465-5	1983	This enhancement was the result of de novo immunoglobulin synthesis, since the amount of IgE and IgG spontaneously released from lysed and lysed-and-cultured mononuclear cells was significantly less than that detected in the cell cultures, and the augmentation was completely ablated by the treatment of the cells with cycloheximide or mitomycin C.	Cycloheximide	319-332	immunoglobulin heavy constant epsilon	Homo sapiens	89-92
6292303-8	1983	Release of the IgE isotype-specific helper factor was inhibited by cycloheximide and tunicamycin, and its activity was destroyed by treatment with trypsin and neuraminidase.	Cycloheximide	67-80	immunoglobulin heavy constant epsilon	Homo sapiens	15-18
6303811-4	1983	The increase in the number of melanocytes after treatment with alpha-MSH or DBc-AMP was also completely suppressed when mice were injected with actinomycin D or cycloheximide.	Cycloheximide	161-174	pro-opiomelanocortin-alpha	Mus musculus	63-72
6348480-5	1983	However, a REV2 dependent repair activity independent of de novo synthesis is detectable, even in the presence of up to 200 micrograms/ml cycloheximide, a response not found in stationary phase cells.	Cycloheximide	138-151	DNA helicase RAD5	Saccharomyces cerevisiae S288C	11-15
6845354-5	1983	The stimulation of CAT activity and palmitoyl-CoA oxidation produced by clofibrate and MEHP was inhibited by cycloheximide.	Cycloheximide	109-122	carnitine O-acetyltransferase	Rattus norvegicus	19-22
6130784-2	1982	Tyrosine aminotransferase messenger ribonucleic acid (mRNA) activity in rat liver was rapidly increased 3-6-fold following in vivo administration of hydrocortisone acetate, dibutyryladenosine cyclic 3",5"-phosphate, or the protein synthesis inhibitor cycloheximide.	Cycloheximide	251-264	tyrosine aminotransferase	Rattus norvegicus	0-25
6130784-3	1982	Treatment with the steroid hormone or cyclic nucleotide in combination with cycloheximide resulted in levels of tyrosine aminotransferase mRNA 10-20-fold greater than control values.	Cycloheximide	76-89	tyrosine aminotransferase	Rattus norvegicus	112-137
6130784-5	1982	The rapid decline in tyrosine aminotransferase mRNA activity following cordycepin inhibition of de novo RNA synthesis was prevented by cycloheximide treatment.	Cycloheximide	135-148	tyrosine aminotransferase	Rattus norvegicus	21-46
6130784-7	1982	Based upon the effects of cycloheximide and pactamycin on rat liver polysome structure, it is concluded that the cycloheximide-mediated increase in tyrosine aminotransferase mRNA activity is the result of stabilization of the mRNA molecule which renders the message less susceptible to inactivation and degradation in the cytoplasm.	Cycloheximide	26-39	tyrosine aminotransferase	Rattus norvegicus	148-173
6130784-7	1982	Based upon the effects of cycloheximide and pactamycin on rat liver polysome structure, it is concluded that the cycloheximide-mediated increase in tyrosine aminotransferase mRNA activity is the result of stabilization of the mRNA molecule which renders the message less susceptible to inactivation and degradation in the cytoplasm.	Cycloheximide	113-126	tyrosine aminotransferase	Rattus norvegicus	148-173
6130784-8	1982	The action of cycloheximide is very specific for tyrosine aminotransferase, phosphoenolpyruvate carboxykinase, and probably several other mRNAs that code for minor liver proteins that turn over rapidly in response to hormonal or metabolic stimuli.	Cycloheximide	14-27	tyrosine aminotransferase	Rattus norvegicus	49-74
7162991-6	1982	Since the overall rate of vitellogenin mRNA synthesis is a function of both the selective estrogen activation of vitellogenin gene transcription which is not blocked by cycloheximide and the increased rate of total nuclear RNA synthesis which is blocked by cycloheximide, the total rate of vitellogenin mRNA synthesis is markedly reduced following cycloheximide administration.	Cycloheximide	257-270	a1-a	Xenopus laevis	26-38
6817811-7	1982	Measurement of turnover times by incubating the cells with cycloheximide revealed a short turnover time for the enzymic activity tested with exogenous [1-14C]arachidonate (2.3 h) and a relatively long turnover time for the cyclooxygenase activity tested with endogenous substrate released after thrombin treatment of the cells (54 h).	Cycloheximide	59-72	coagulation factor II, thrombin	Homo sapiens	295-303
6186342-4	1982	Cycloheximide could inhibit this incorporation of [14C]leucine into immunoprecipitable AFP and albumin.	Cycloheximide	0-13	alpha-fetoprotein	Rattus norvegicus	87-90
6818330-6	1982	Hydrocortisone also blocked the induction of IFN by double-stranded RNA (dsRNA), cycloheximide and actinomycin D in FS11 cells.	Cycloheximide	81-94	interferon alpha 1	Homo sapiens	45-48
6181147-6	1982	Inhibition of protein synthesis by cycloheximide or monocyte depletion abolished de novo alpha 1-PI synthesis, but only monocyte depletion inhibited alpha 1-PI expression.	Cycloheximide	35-48	serpin family A member 1	Homo sapiens	89-99
6127595-8	1982	The presence of 10(-4)m cycloheximide in NaCl(+) medium enhanced the c-AMP response to physiological concentrations of TSH.	Cycloheximide	24-37	cathelicidin antimicrobial peptide	Homo sapiens	69-74
7126620-1	1982	The activity of the rate-limiting enzyme of the cholesterol biosynthetic pathway, 3-hydroxy-3-methylglutaryl coenzyme A reductase in Chinese hamster ovary (CHO) cells decreased more rapidly in cells treated with 25-hydroxycholesterol alone (t 1/2 = 1.5 h) than in those incubated with cycloheximide alone (t 1/2 = 5 h).	Cycloheximide	285-298	3-hydroxy-3-methylglutaryl-coenzyme A reductase	Cricetulus griseus	82-129
6123556-12	1982	Cycloheximide (10 micrograms/ml) inhibited the dbcAMP effect on glutamine synthetase activity and also decreased the control enzyme activity by 60%.	Cycloheximide	0-13	glutamate-ammonia ligase	Homo sapiens	64-84
6289827-0	1982	Inhibition of membrane-bound adrenodoxin-adrenodoxin reductase activity by puromycin and cycloheximide, which antagonize the adrenal steroidogenic action of ACTH.	Cycloheximide	89-102	proopiomelanocortin	Homo sapiens	157-161
6806278-3	1982	Part of the increase in the activity of ornithine decarboxylase was due to a decreased rate of degradation of the enzyme since activity declined more slowly (t1/2 80 min) in androgen-treated BALB/c mice than in controls (t1/2 20 min) when protein synthesis was inhibited by cycloheximide.	Cycloheximide	274-287	ornithine decarboxylase, structural 1	Mus musculus	40-63
6806278-4	1982	When ornithine decarboxylase protein was labeled in vivo by injection of [5-14C]difluoromethylornithine, the rate of disappearance of the labeled protein was exactly the same as the rate of loss of ornithine decarboxylase activity when protein synthesis was inhibited by cycloheximide, confirming that ornithine decarboxylase protein does turn over rapidly in vivo.	Cycloheximide	271-284	ornithine decarboxylase, structural 1	Mus musculus	5-28
24186233-0	1982	Multiple allelic states of the cyh2 gene cause low- and high-level cycloheximide resistance in Saccharomyces cerevisiae.	Cycloheximide	67-80	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	31-35
24186233-1	1982	At least four different mutations at the cyh2 locus (rp1X; gene product: YL24) of Saccharomyces cerevisiae confer cycloheximide resistance.	Cycloheximide	114-127	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	41-45
6123553-4	1982	Cycloheximide or actinomycin D blocked the increase in glutamine synthetase activity observed in the absence of glutamine.	Cycloheximide	0-13	glutamate-ammonia ligase	Homo sapiens	55-75
7109827-6	1982	Pretreatment of the animals with either cycloheximide or actinomycin D delayed the onset of ODC induction.	Cycloheximide	40-53	ornithine decarboxylase 1	Rattus norvegicus	92-95
6285288-1	1982	A cosmid clone bank of yeast DNA has been used to isolate the cycloheximide resistance gene cyh2 of Saccharomyces cerevisiae.	Cycloheximide	62-75	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	92-96
6178110-1	1982	Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1.	Cycloheximide	94-107	interferon beta 1	Homo sapiens	149-164
6178110-1	1982	Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1.	Cycloheximide	94-107	interferon beta 1	Homo sapiens	166-174
6178110-1	1982	Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1.	Cycloheximide	94-107	interferon beta 1	Homo sapiens	342-350
6178110-1	1982	Human fibroblast cells treated with a combination of inhibitors of protein and RNA synthesis [cycloheximide and actinomycin D as used to superinduce interferon beta (IFN-beta)] secrete two proteins with molecular masses of 22000 and 27000 kilodaltons (called 22-kDal and 27-kDal) that are precipitable with an antiserum raised against impure IFN-beta but are antigenically distinct from IFN-beta 1.	Cycloheximide	94-107	interferon beta 1	Homo sapiens	342-350
16661304-5	1980	The increase in NADP-GPDH was inhibited by cycloheximide but not by chloramphenicol.	Cycloheximide	43-56	NADP-dependent glyceraldehyde-3-phosphate dehydrogenase	Zea mays	21-25
6996676-1	1980	Glucose, and certain sugars that can readily be converted to glucose 6-phosphate, bring about an activation of adipose-tissue lipoprotein lipase when epididymal fat-bodies from starved rats are incubated in the presence of cycloheximide.	Cycloheximide	223-236	lipoprotein lipase	Rattus norvegicus	126-144
6996676-4	1980	On the other hand, the addition of glucose still brings about an increase in lipoprotein lipase activity after preincubation in the absence of cycloheximide for as long as 4h.	Cycloheximide	143-156	lipoprotein lipase	Rattus norvegicus	77-95
16593618-5	1985	Eighthour periods of exposure to cycloheximide produced a shift in the phase of the oscillation of p230 synthesis.	Cycloheximide	33-46	golgin A4	Homo sapiens	99-103
6159362-3	1980	Hypophysectomy does not prevent the post-ischemic increases of ornithine decarboxylase and RNA synthesis; but pre-treatment of the animals with cycloheximide--which has a dual effect on the activity of ornithine decarboxylase--abolishes the post-ischemic enhancement of RNA synthesis.	Cycloheximide	144-157	ornithine decarboxylase 1	Homo sapiens	63-86
7408936-2	1980	(a) Active synthesis, susceptible to inhibition by puromycin or cycloheximide was shown to peak 4 to 6 h after removal of EAG complexes; it required addition of at least 2% fetal calf serum.	Cycloheximide	64-77	potassium voltage-gated channel subfamily H member 1	Homo sapiens	122-125
6104755-4	1980	The half-life of ODC was determined after cycloheximide administration.	Cycloheximide	42-55	ornithine decarboxylase, structural 1	Mus musculus	17-20
7394309-5	1980	The induction of ornithine decarboxylase activity by nafenopin, as well as the potentiating effect of phentolamine was inhibited by 1,3-diaminopropane and cycloheximide, implying a requirement for synthesis of new enzyme protein for both effects.	Cycloheximide	155-168	ornithine decarboxylase 1	Rattus norvegicus	17-40
6159362-3	1980	Hypophysectomy does not prevent the post-ischemic increases of ornithine decarboxylase and RNA synthesis; but pre-treatment of the animals with cycloheximide--which has a dual effect on the activity of ornithine decarboxylase--abolishes the post-ischemic enhancement of RNA synthesis.	Cycloheximide	144-157	ornithine decarboxylase 1	Homo sapiens	202-225
6258784-3	1980	The ODC increase was inhibited by actinomycin D and cycloheximide and was dependent on the addition of serum growth factors.	Cycloheximide	52-65	ornithine decarboxylase 1	Homo sapiens	4-7
6102386-8	1980	Cycloheximide inhibited protein synthesis &gt;95% within 30 min, and caused an immediate decline of stimulated ODCase activity with a half-time of 20-30 min.	Cycloheximide	0-13	ornithine decarboxylase, structural 1	Mus musculus	111-117
7356627-2	1980	When cells grown on medium containing 10% human whole serum were exposed to medium containing 10% human lipoprotein-deficient serum, LDL receptor activity increased within 4 h and then decreased between 12 and 24 h. This early, transient increase in binding was inhibited by cycloheximide, suggesting that new protein synthesis was involved.	Cycloheximide	275-288	low density lipoprotein receptor	Homo sapiens	133-145
6262574-5	1980	Analysis of the immunoprecipitates by polyacrylamide gel electrophoresis revealed that a 30,000-dalton protein, cytochrome b, as well as 16,000-dalton protein were labeled in the presence of cycloheximide, indicating that they are products of mitochondrial protein synthesis.	Cycloheximide	191-204	cytochrome b	Saccharomyces cerevisiae S288C	112-124
6113605-6	1980	When the half-lives of ODC and TAT were measured 24 hr after partial hepatectomy by using cycloheximide, it appeared that ethanol caused a significant stabilization of both enzymes.	Cycloheximide	90-103	ornithine decarboxylase 1	Rattus norvegicus	23-26
6113605-6	1980	When the half-lives of ODC and TAT were measured 24 hr after partial hepatectomy by using cycloheximide, it appeared that ethanol caused a significant stabilization of both enzymes.	Cycloheximide	90-103	tyrosine aminotransferase	Rattus norvegicus	31-34
394553-2	1979	First, during incubation of pituitary glands of intact dioestrous female rats with a maximally active concentration of LH-RH, the inhibitor of protein synthesis cycloheximide was added at various times after the beginning of the incubation.	Cycloheximide	161-174	gonadotropin releasing hormone 1	Rattus norvegicus	119-124
394553-4	1979	Secondly, LH-RH was injected iv after which the protein factor was assayed by incubating the pituitary glands with a maximally active concentration of LH-RH in the presence of cycloheximide and measuring LH release in vitro.	Cycloheximide	176-189	gonadotropin releasing hormone 1	Rattus norvegicus	10-15
394553-6	1979	This response could be suppressed by injecting cycloheximide prior to LH-RH.	Cycloheximide	47-60	gonadotropin releasing hormone 1	Rattus norvegicus	70-75
231039-7	1979	Inhibition of protein synthesis by cycloheximide prevented the induction of CNP in serum-free cultures.	Cycloheximide	35-48	2',3'-cyclic nucleotide 3' phosphodiesterase	Homo sapiens	76-79
393708-1	1979	Temporal inhibition of protein synthesis with cycloheximide prevents subsequent insulin, but not serum-stimulated DNA synthesis in G1-arrested chick embryo fibroblasts (CEF).	Cycloheximide	46-59	insulin	Gallus gallus	80-87
229262-7	1979	Treatment of uninfected BGM cells with cycloheximide resulted in alterations in the GSL pattern which were similar to those observed in herpes simplex virus type 1-infected cells.	Cycloheximide	39-52	cathepsin A	Homo sapiens	84-87
495675-6	1979	The addition of 100 micrograms/ml of cycloheximide to the medium prevented the net increase in PRL content during incubation.	Cycloheximide	37-50	prolactin	Homo sapiens	95-98
515010-0	1979	Prolactin receptors in organ culture of rabbit mammary gland: effect of cycloheximide and prolactin.	Cycloheximide	72-85	prolactin	Oryctolagus cuniculus	0-9
489015-2	1979	Cycloheximide(CHM)-resistant mutant Chinese hamster ovary (CHO) and human cells were induced with N-nitrosomethylurea (NMU) and ethyl methanesulfonate (EMS); the mutants were viable and showed unlimited growth in the presence of CHM (7 X 10(-7) M), whereas this concentration inhibits protein synthesis in vivo as well as in vitro.	Cycloheximide	0-13	rab proteins geranylgeranyltransferase component A 1	Cricetulus griseus	14-17
489015-2	1979	Cycloheximide(CHM)-resistant mutant Chinese hamster ovary (CHO) and human cells were induced with N-nitrosomethylurea (NMU) and ethyl methanesulfonate (EMS); the mutants were viable and showed unlimited growth in the presence of CHM (7 X 10(-7) M), whereas this concentration inhibits protein synthesis in vivo as well as in vitro.	Cycloheximide	0-13	CHM Rab escort protein	Homo sapiens	229-232
486136-0	1979	Inhibition by cycloheximide of degradation of cytochrome P-450 in primary cultures of adult rat liver parenchymal cells and in vivo.	Cycloheximide	14-27	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	46-62
486136-5	1979	The decline in cytochrome P-450 and the subsequent increase in haem oxygenase activity was prevented by incubation of hepatocytes in medium containing an inhibitor of protein synthesis such as cycloheximide, puromycin, actinomycin D, or azaserine.	Cycloheximide	193-206	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	15-31
486136-8	1979	These results suggest that the conditions of cell culture stimulate selective degradation of cytochrome P-450 by a process that is inhibited by cycloheximide and hence may require protein synthesis.	Cycloheximide	144-157	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	93-109
486136-11	1979	Administration of cycloheximide to either bromobenzene-treated rats or to untreated rats decreased the degradation of the haem moiety of cytochrome P-450.	Cycloheximide	18-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	137-153
486136-13	1979	These findings confirm that the catabolism of hepatic cytochrome P-450 haem is controlled by similar cycloheximide-sensitive processes in the basal steady state in vivo, as stimulated by bromobenzene in vivo, or in hepatocytes under the conditions of cell culture.	Cycloheximide	101-114	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	54-70
486492-5	1979	Lysine and ornithine decarboxylase activities were lost to similar extents on inhibition of protein synthesis by cycloheximide and on exposure to alpha-difluoromethylornithine.	Cycloheximide	113-126	ornithine decarboxylase 1	Rattus norvegicus	11-34
225188-7	1979	Cycloheximide, an inhibitor of protein synthesis, completely inhibited CSA release.	Cycloheximide	0-13	excision repaiross-complementing rodent repair deficiency, complementation group 8	Mus musculus	71-74
225163-6	1979	4) The stimulatory effect of Ca2+ on corticoidogenesis was completely blocked by cycloheximide.	Cycloheximide	81-94	carbonic anhydrase 2	Rattus norvegicus	29-32
446480-16	1979	Cycloheximide addition to the incubation medium accelerated the decrease in cholesterol 7 alpha-hydroxylase activity.	Cycloheximide	0-13	cytochrome P450 family 7 subfamily A member 1	Rattus norvegicus	76-107
457783-2	1979	Disappearance of insulin receptors occurred more rapidly in the presence of tunicamycin than when protein synthesis was inhibited by cycloheximide and was accompanied by a diminution in sensitivity of the adipocytes to the acute effects of insulin and anti-insulin receptor antibody on hexose uptake and metabolism.	Cycloheximide	133-146	insulin	Homo sapiens	17-24
420716-8	1979	Cycloheximide and actinomycin D blocked the biologic actions of CTAP-III.	Cycloheximide	0-13	pro-platelet basic protein	Homo sapiens	64-72
114468-6	1979	TRH, nevertheless, significantly increased PRL release in the presence of cycloheximide.	Cycloheximide	74-87	thyrotropin releasing hormone	Homo sapiens	0-3
155942-6	1979	Tyrosinase activity of control cells was significantly reduced following a 24 h exposure to actinomycin D or cycloheximide.	Cycloheximide	109-122	tyrosinase	Mus musculus	0-10
7378429-5	1980	Treatment of cultures with cycloheximide or 2-deoxyglucose eliminated the second phase of release as well as cell-associated lipoprotein lipase activity.	Cycloheximide	27-40	lipoprotein lipase	Rattus norvegicus	125-143
523954-7	1979	Pre-treatment of fasted adult rats with cycloheximide (1.5 mg/kg) was found to abolish the 30 min tryptophan-mediated stimulation of both polymerase I and II activities.	Cycloheximide	40-53	RNA polymerase II, I and III subunit F	Rattus norvegicus	138-157
523954-8	1979	In cycloheximide pretreated rats the activity of polymerase II, but not polymerase I returned to its original level 5 h after tryptophan force-feeding.	Cycloheximide	3-16	RNA polymerase II, I and III subunit F	Rattus norvegicus	49-62
426782-11	1979	A single injection of diaminopropane produced an extremely rapid decay of liver ornithine decarboxylase activity (half-life about 12min), which was comparable with, or swifter than, that induced by cycloheximide.	Cycloheximide	198-211	ornithine decarboxylase 1	Rattus norvegicus	80-103
426782-12	1979	However, although after cycloheximide treatment the amount of immunotitrable ornithine decarboxylase decreased only slightly more slowly than the enzyme activity, diaminopropane injection did not decrease the amount of the immunoreactive protein, but, on the contrary, invariably caused a marked increase in the apparent amount of antigen, after some lag period.	Cycloheximide	24-37	ornithine decarboxylase 1	Rattus norvegicus	77-100
514097-9	1979	Production of factor B was completely inhibited by 1 microgram of cycloheximide per ml and was restored by its removal.	Cycloheximide	66-79	complement factor B	Mus musculus	14-22
215475-7	1978	The concentration of cycloheximide required to cause 50% inhibition of the responses to ACTH and dibutyryl cyclic AMP was approximately the same for steroidogenesis by whole cells, for production of pregnenolone by isolated mitochondria, for incorporation of [3H]tyrosine into Y-1 cell protein and for the increase in synthesis of protein associated with mitochondria produced by ACTH (0.08--0.2 microgram/ml).	Cycloheximide	21-34	proopiomelanocortin	Homo sapiens	88-92
215475-7	1978	The concentration of cycloheximide required to cause 50% inhibition of the responses to ACTH and dibutyryl cyclic AMP was approximately the same for steroidogenesis by whole cells, for production of pregnenolone by isolated mitochondria, for incorporation of [3H]tyrosine into Y-1 cell protein and for the increase in synthesis of protein associated with mitochondria produced by ACTH (0.08--0.2 microgram/ml).	Cycloheximide	21-34	proopiomelanocortin	Homo sapiens	380-384
738395-1	1978	The production of tissue plasminogen activator (TPA) in rat tongue organ cultures is strongly inhibitied by low concentrations of the protein synthesis inhibitor cycloheximide.	Cycloheximide	162-175	plasminogen activator, tissue type	Rattus norvegicus	18-46
701808-4	1978	De novo synthesis was confirmed by reversible inhibition of C1 and C1q production by cycloheximide (0.5 microgram/ml) and puromycin (1 microgram/ml), by incorporation of radiolabeled amino acids into the C1s subcomponent, and by uptake of incorporated radioactivity by EA, which was sensitive to EDTA.	Cycloheximide	85-98	complement C1q A chain	Homo sapiens	67-70
277113-5	1978	Cycloheximide administered prior to bromobenzene inhibited significantly the effect of bromobenzene on the total N-acetyl-beta-glucosaminidase activity.	Cycloheximide	0-13	O-GlcNAcase	Rattus norvegicus	113-142
369847-7	1978	In other experiments, cycloheximide blocked synthesis of [14C]A-LH and greatly reduced the GnRH-induced synthesis and release of [3H]GA-LH, but reduced release of IR-LH by only 25%.	Cycloheximide	22-35	gonadotropin releasing hormone 1	Rattus norvegicus	91-95
727996-0	1978	The effect of cycloheximide on cholecystokinin-evoked pancreatic juice of the anaesthetized rat.	Cycloheximide	14-27	cholecystokinin	Rattus norvegicus	31-46
100227-2	1978	The activities of 2 enzymes (LDH and sMDH) were enhanced after puff induction, an effect that was abolished in the presence of cycloheximide.	Cycloheximide	127-140	Lactate dehydrogenase	Drosophila melanogaster	29-32
100227-2	1978	The activities of 2 enzymes (LDH and sMDH) were enhanced after puff induction, an effect that was abolished in the presence of cycloheximide.	Cycloheximide	127-140	Malate dehydrogenase 1	Drosophila melanogaster	37-41
357438-7	1978	In pulse-chase experiments using cycloheximide, fibronectin was sequentially transferred from the intracellular to the fibrillar extracellular forms.	Cycloheximide	33-46	fibronectin 1	Gallus gallus	48-59
208644-6	1978	However, preincubation with cycloheximide or diphtheria toxin led to superinduction of ACTH-induced cyclic AMP formation.	Cycloheximide	28-41	proopiomelanocortin	Homo sapiens	87-91
213036-0	1978	Effect of thyroid hormone, actinomycin D, cycloheximide and puromycin on TRH-induced secretion of TSH, as studied by pituitary concentration of cyclic AMP and intrathyroidal colloid droplet formation.	Cycloheximide	42-55	thyrotropin releasing hormone	Homo sapiens	73-76
27525-3	1978	The increase in tyrosine hydroxylase specific activity is likely to be due to the increased synthesis of new enzyme protein rather than an activation of existing protein molecules, inasmuch as this increase is completely blocked by cycloheximide.	Cycloheximide	232-245	tyrosine hydroxylase	Rattus norvegicus	16-36
678446-4	1978	Cycloheximide alone can also induce significant concentration of SAA, but a longer time is required than for LPS.	Cycloheximide	0-13	serum amyloid A1 cluster	Homo sapiens	65-68
352690-7	1978	The incorporation of radioactive leucine into the apoprotein of cytochrome b isolated by immunoprecipitation followed by gel electrophoresis was insensitive to cycloheximide (an inhibitor of cytoplasmic protein synthesis) and sensitive to acriflavin, erythromycin, and chloramphenicol (inhibitors of mitochondrial protein synthesis).	Cycloheximide	160-173	cytochrome b	Saccharomyces cerevisiae S288C	64-76
26567-0	1978	Cycloheximide causes increased accumulation of translatable mRNA for tyrosine aminotransferase and tryptophan oxygenase in livers of cortisol-treated rats.	Cycloheximide	0-13	tyrosine aminotransferase	Rattus norvegicus	69-94
26567-3	1978	Cortisol leads to an increase of the translatable mRNAs for tyrosine aminotransferase and tryptophan oxygenase with a maximum at approximately 6 h. Cycloheximide was administered 4 h after treatment with cortisol; 2 h later, the activities of tyrosine aminotransferase and tryptophan oxygenase mRNA had increased five-fold and two-fold, respectively, compared to the activities reached with cortisol alone.	Cycloheximide	148-161	tyrosine aminotransferase	Rattus norvegicus	60-85
26567-3	1978	Cortisol leads to an increase of the translatable mRNAs for tyrosine aminotransferase and tryptophan oxygenase with a maximum at approximately 6 h. Cycloheximide was administered 4 h after treatment with cortisol; 2 h later, the activities of tyrosine aminotransferase and tryptophan oxygenase mRNA had increased five-fold and two-fold, respectively, compared to the activities reached with cortisol alone.	Cycloheximide	148-161	tyrosine aminotransferase	Rattus norvegicus	243-268
26567-6	1978	The increase in tyrosine aminotransferase and tryptophan oxygenase activity by cortisol was immediately blocked by cycloheximide.	Cycloheximide	115-128	tyrosine aminotransferase	Rattus norvegicus	16-41
666903-0	1978	Effect of cycloheximide on the induction of tryptophan oxygenase mRNA by hydrocortisone in vivo.	Cycloheximide	10-23	tryptophan 2,3-dioxygenase	Homo sapiens	44-64
206656-5	1978	Induction of db-cyclic GMP-treated cells by NDV in the presence of cycloheximide and actinomycin D suggests that db-cyclic GMP enhances transcription of the interferon gene, and thereby augments interferon production.	Cycloheximide	67-80	5'-nucleotidase, cytosolic II	Homo sapiens	23-26
206656-5	1978	Induction of db-cyclic GMP-treated cells by NDV in the presence of cycloheximide and actinomycin D suggests that db-cyclic GMP enhances transcription of the interferon gene, and thereby augments interferon production.	Cycloheximide	67-80	5'-nucleotidase, cytosolic II	Homo sapiens	123-126
16660336-4	1978	The race T-infected susceptible inbred showed no increase or a decrease in the enzyme activity, whereas in most cases both inbreds infected with race O exhibited a further peroxidase enhancement.Pretreatment of healthy leaves or leaf discs with cycloheximide at concentrations which did not cause a loss of turgor had no effect on peroxidase enhancement.	Cycloheximide	245-258	peroxidase 1	Zea mays	172-182
16660336-4	1978	The race T-infected susceptible inbred showed no increase or a decrease in the enzyme activity, whereas in most cases both inbreds infected with race O exhibited a further peroxidase enhancement.Pretreatment of healthy leaves or leaf discs with cycloheximide at concentrations which did not cause a loss of turgor had no effect on peroxidase enhancement.	Cycloheximide	245-258	peroxidase 1	Zea mays	331-341
16660336-5	1978	However, in tissues inoculated with either the race T or O, cycloheximide, at concentrations which did not affect the mechanical injury-induced increase in peroxidase activity, did inhibit the enzyme enhancement and did cause a loss of turgor.The observed changes in isoperoxidase activities (a) confirm the assumption that the infection-induced enhancement of this enzyme results from a nonspecific response to injury; (b) support the postulation that the often observed small or no increases in peroxidase activity to compatible hosts are a consequence of metabolic disorders rather than the cause of a lower resistance; and (c) indicate that cycloheximide as a protein synthesis inhibitor may increase the compatibility between the host and pathogen, enhance metabolic disorders in inoculated tissues, and in consequence interfere with the nonspecific cell response to injury.Actinomycin D did not affect the mechanical injury- or infection-induced peroxidase enhancement.	Cycloheximide	60-73	peroxidase 1	Zea mays	270-280
16660336-5	1978	However, in tissues inoculated with either the race T or O, cycloheximide, at concentrations which did not affect the mechanical injury-induced increase in peroxidase activity, did inhibit the enzyme enhancement and did cause a loss of turgor.The observed changes in isoperoxidase activities (a) confirm the assumption that the infection-induced enhancement of this enzyme results from a nonspecific response to injury; (b) support the postulation that the often observed small or no increases in peroxidase activity to compatible hosts are a consequence of metabolic disorders rather than the cause of a lower resistance; and (c) indicate that cycloheximide as a protein synthesis inhibitor may increase the compatibility between the host and pathogen, enhance metabolic disorders in inoculated tissues, and in consequence interfere with the nonspecific cell response to injury.Actinomycin D did not affect the mechanical injury- or infection-induced peroxidase enhancement.	Cycloheximide	60-73	peroxidase 1	Zea mays	270-280
638167-11	1978	The half-time of lipoprotein lipase in the F1 cultures was 35 min and full restoration of enzyme activity was found 60 min after complete removal of cycloheximide from the system.	Cycloheximide	149-162	lipoprotein lipase	Rattus norvegicus	17-35
743991-4	1978	Cycloheximide, at a level of 2.5 X 10(-5) M, suppressed [3H]leucine incorporation by 93% and inhibited the stimulation of 14CO2 formation by insulin.	Cycloheximide	0-13	insulin	Bos taurus	141-148
618881-5	1978	Cycloheximide injected in similar fashion, inhibited the 1,25(OH)2D3-mediated increase in intestinal protein synthesis, serum calcium, CaBP, and alkaline phosphatase activity.	Cycloheximide	0-13	centrin 1	Homo sapiens	135-139
30718-4	1978	The increase in ODC activity was suppressed by treatment with cycloheximide (50 mg/kg) and dactinomycin, 500 microgram/rat, confirming that the enzyme response reflects protein synthesis.	Cycloheximide	62-75	ornithine decarboxylase 1	Rattus norvegicus	16-19
746337-5	1978	Cycloheximide, colchicine, 4-amino-pyrazolopyrimidine, and D-galactosamine depress the secretion of both TG and LCAT.	Cycloheximide	0-13	lecithin cholesterol acyltransferase	Rattus norvegicus	112-116
16660163-4	1977	The increase in the root tip is sensitive to cordycepin, 6-methylpurine, and cycloheximide, which indicates that both RNA and protein synthesis are involved in the formation of asparagine synthetase in the root tip sections.	Cycloheximide	77-90	LOC100856906	Zea mays	177-198
924016-3	1977	ABP synthesis is inhibited at 0 degrees C or in the presence of cycloheximide, puromycin or sodium fluoride.	Cycloheximide	64-77	sex hormone binding globulin	Rattus norvegicus	0-3
200929-3	1977	The nerve growth factor-mediated increase in ornithine decarboxylase activity in vitro can be prevented by the addition of cycloheximide, actinomycin D, or antibody to nerve growth factor.	Cycloheximide	123-136	ornithine decarboxylase 1	Rattus norvegicus	45-68
20194-3	1977	The augmented enzyme activity results from enhanced enzyme synthesis since it can be abolished by cycloheximide and NGF has been shown to enhance the incorporation of [3H]leucine into DBH molecules.	Cycloheximide	98-111	dopamine beta-hydroxylase	Rattus norvegicus	184-187
198803-5	1977	In the salts/glucose medium, the rate of loss of ODC activity following the inhibition of protein synthesis by cycloheximide or puromycin depends upon the presence or absence of asparagine; loss is rapid only in the absence of asparagine and does not appear to be related to the inhibition of protein synthesis.	Cycloheximide	111-124	ornithine decarboxylase, structural 1	Mus musculus	49-52
16659969-8	1977	Both the increase in total invertase activity and the apparent loss of inhibitor after slicing were partially blocked by actinomycin D and completely blocked by cycloheximide.The presence of the inhibitor can lead to serious errors in the usual whole disk method of assay for invertase in slices.	Cycloheximide	161-174	beta-fructofuranosidase, insoluble isoenzyme 1-like	Solanum tuberosum	276-285
561829-6	1977	Acetylcholinesterase release was significantly reduced when protein synthesis and microtubules were disrupted by cycloheximide and colchicine, respectively.	Cycloheximide	113-126	acetylcholinesterase (Cartwright blood group)	Gallus gallus	0-20
884108-1	1977	Blockage of protein synthesis in HeLa cells by cycloheximide leads to selective effects on the levels of DNA polymerases alpha, beta, and gamma in the cell.	Cycloheximide	47-60	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	105-126
884108-2	1977	The total activity of DNA polymerase alpha remains unchanged after 7 h exposure of cells to cycloheximide but drops to 50% of its original level after 24 h. The level of the beta-polymerase falls rapidly in the cell and is reduced to less than 30% of its initial value by 7 h after treatment of the cells with cycloheximide.	Cycloheximide	92-105	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	22-42
884108-2	1977	The total activity of DNA polymerase alpha remains unchanged after 7 h exposure of cells to cycloheximide but drops to 50% of its original level after 24 h. The level of the beta-polymerase falls rapidly in the cell and is reduced to less than 30% of its initial value by 7 h after treatment of the cells with cycloheximide.	Cycloheximide	310-323	DNA polymerase alpha 1, catalytic subunit	Homo sapiens	22-42
884108-4	1977	The cycloheximide-treated cells also show the presence of a new form of the alpha-polymerase, designated alpha1, which can be clearly detected as a separate entity in column chromatography.	Cycloheximide	4-17	adrenoceptor alpha 1D	Homo sapiens	105-111
884108-5	1977	The level of alpha1 in the nucleus increases during the period that the cells are treated and cycloheximide so that after 24 h it represents almost 50% of the nuclear DNA polymerase activity.	Cycloheximide	94-107	adrenoceptor alpha 1D	Homo sapiens	13-19
884108-6	1977	The presence of alpha1 in the cytoplasmic fraction can also be demonstrated in both cycloheximide-treated and normal, growing cells.	Cycloheximide	84-97	adrenoceptor alpha 1D	Homo sapiens	16-22
194994-2	1977	Actinomycin D, or cycloheximide, completely prevented an increase in ODC when given with PMSG, but only cycloheximide lowered the enzyme activity when given 18 h later.	Cycloheximide	18-31	ornithine decarboxylase 1	Rattus norvegicus	69-72
849733-6	1977	They are, however, blocked by the addition of inhibitors of RNA (actinomycin D) or protein (cycloheximide or puromycin) synthesis, suggesting that the thyroid hormone increases the synthesis of the alpha-lactalbumin molecule itself.	Cycloheximide	92-105	lactalbumin, alpha	Mus musculus	198-215
45486-6	1977	Studies with cycloheximide indicated that the inducible GDH and another GDH isozyme were stable in fully induced cells in the absence of protein synthesis.	Cycloheximide	13-26	glutamate dehydrogenase 1	Homo sapiens	56-59
45486-6	1977	Studies with cycloheximide indicated that the inducible GDH and another GDH isozyme were stable in fully induced cells in the absence of protein synthesis.	Cycloheximide	13-26	glutamate dehydrogenase 1	Homo sapiens	72-75
45486-8	1977	Addition of cycloheximide, at the time of inducer removal, prevented this loss in activity of the inducible GDH.	Cycloheximide	12-25	glutamate dehydrogenase 1	Homo sapiens	108-111
301142-9	1977	Cycloheximide, actinomycin D and cordycepin block both non-insulin and insulin-induced derepression.	Cycloheximide	0-13	insulin	Gallus gallus	59-66
301142-9	1977	Cycloheximide, actinomycin D and cordycepin block both non-insulin and insulin-induced derepression.	Cycloheximide	0-13	insulin	Gallus gallus	71-78
194922-11	1977	Results of these experiments provide direct demonstration of gastrin synthesis by rat antral mucosal explants in organ culture, indicate that both gastrin and total antral protein synthesis are inhibited by cycloheximide, and demonstrate DBCAMP-induced stimulation of both gastrin synthesis and secretion, suggesting the potentially important role of cyclic AMP in gastrin cell function.	Cycloheximide	207-220	gastrin	Rattus norvegicus	147-154
194922-11	1977	Results of these experiments provide direct demonstration of gastrin synthesis by rat antral mucosal explants in organ culture, indicate that both gastrin and total antral protein synthesis are inhibited by cycloheximide, and demonstrate DBCAMP-induced stimulation of both gastrin synthesis and secretion, suggesting the potentially important role of cyclic AMP in gastrin cell function.	Cycloheximide	207-220	gastrin	Rattus norvegicus	147-154
194922-11	1977	Results of these experiments provide direct demonstration of gastrin synthesis by rat antral mucosal explants in organ culture, indicate that both gastrin and total antral protein synthesis are inhibited by cycloheximide, and demonstrate DBCAMP-induced stimulation of both gastrin synthesis and secretion, suggesting the potentially important role of cyclic AMP in gastrin cell function.	Cycloheximide	207-220	gastrin	Rattus norvegicus	147-154
884101-2	1977	In cycloheximide-treated fibroblasts, the rate of cell proteolysis and the specific activity of cathepsin D show a rapid, concurrent, and proportional decrease over a 48 h period.	Cycloheximide	3-16	cathepsin D	Homo sapiens	96-107
196374-1	1977	It is established that in embryos incubated until the early blastula stage in the solution of insulin with addition of cycloheximide or puromycin, there is neither a decrease in the hexokinase and glucose-61 phosphate dehydrogenase activities nor an increase in the phosphofructokinase activity, as it is shown under the influence of insulin only.	Cycloheximide	119-132	insulin	Homo sapiens	94-101
196374-4	1977	Actinomycin D alone inhibits the hexokinase and activates the phosphofructokinase activities in the embryos and eggs, puromycin decreases their hexokinase activity and cycloheximide has the same effect on the glucose-6-phosphatase activity in the embryos only.	Cycloheximide	168-181	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	209-230
24420020-2	1977	The increases in PAL and CA4H activity can be inhibited by actinomycin-D, cordycepin and cycloheximide.	Cycloheximide	89-102	phenylalanine ammonia-lyase	Solanum tuberosum	17-20
68070-3	1977	The acetylcholinesterase activity (AChE) of cultured chick embryo muscle fibers that remains after the cells have been treated with the protein synthesis inhibitor cycloheximide was examined with cytochemical stains and the electron microscope.	Cycloheximide	164-177	acetylcholinesterase (Cartwright blood group)	Gallus gallus	4-33
214005-8	1977	After this injection, GVBD occurs earlier than during incubation with progesterone and is accompanied by the formation of the same proteins and of MPF, both suppressed by cycloheximide.	Cycloheximide	171-184	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	147-150
192141-1	1977	Combined use of interferon inductor poly-IC and antibiotics (cycloheximide and actinomycin D) provided a significant increase (up to 1000 times) in interferon production by chick, mouse, monkey and human cells.	Cycloheximide	61-74	interferon	Gallus gallus	16-26
192141-1	1977	Combined use of interferon inductor poly-IC and antibiotics (cycloheximide and actinomycin D) provided a significant increase (up to 1000 times) in interferon production by chick, mouse, monkey and human cells.	Cycloheximide	61-74	interferon	Gallus gallus	148-158
557039-2	1977	Stimulation of prostaglandin synthesis in transformed mouse fibroblasts by serum, thrombin, and bradykinin was blocked by actinomycin D and cycloheximide.	Cycloheximide	140-153	coagulation factor II	Mus musculus	82-90
15559-5	1977	Ornithine decarboxylase activity in chick-embryo pelvic leaflets was maintained at the value in vivo for up to 22h when the isolated tissue was incubated in a modified Waymouth"s medium (MB 752/1) at 37 degrees C. After addition of cycloheximide to the incubation medium, ornithine decarboxylase activity declined, with a half-life of 40 min.	Cycloheximide	232-245	ornithine decarboxylase	Gallus gallus	0-23
842265-5	1977	Cycloheximide caused a rapid decay of the activity of liver ornithine decarboxylase (half-life 15 min) and also a decay of the activity of adenosylmethionine decarboxylase (half-life 36 min).	Cycloheximide	0-13	ornithine decarboxylase 1	Rattus norvegicus	60-83
24420020-2	1977	The increases in PAL and CA4H activity can be inhibited by actinomycin-D, cordycepin and cycloheximide.	Cycloheximide	89-102	trans-cinnamate 4-monooxygenase	Solanum tuberosum	25-29
24420020-6	1977	This superinduction is related to the inhibition by cycloheximide of the subsequent decline in PAL activity and is interpreted in terms of the transcription and translation of the mRNA coding for an inactivator-protein of PAL.	Cycloheximide	52-65	phenylalanine ammonia-lyase	Solanum tuberosum	95-98
24420020-6	1977	This superinduction is related to the inhibition by cycloheximide of the subsequent decline in PAL activity and is interpreted in terms of the transcription and translation of the mRNA coding for an inactivator-protein of PAL.	Cycloheximide	52-65	phenylalanine ammonia-lyase	Solanum tuberosum	222-225
11370244-3	1976	In the experiments presented here, actinomycin D and cycloheximide were used to study the relationships between the synthesis of ribonucleic acid and of protein, the recovery of acetylcholinesterase levels after diisopropylphosphorofluoridate treatment and the increase of acetylcholinesterase levels evoked by choline and its esters.	Cycloheximide	53-66	acetylcholinesterase (Cartwright blood group)	Gallus gallus	178-198
11370244-3	1976	In the experiments presented here, actinomycin D and cycloheximide were used to study the relationships between the synthesis of ribonucleic acid and of protein, the recovery of acetylcholinesterase levels after diisopropylphosphorofluoridate treatment and the increase of acetylcholinesterase levels evoked by choline and its esters.	Cycloheximide	53-66	acetylcholinesterase (Cartwright blood group)	Gallus gallus	273-293
826178-3	1976	The rise in ornithine decarboxylase is reduced by actinomycin D or cycloheximide.	Cycloheximide	67-80	ornithine decarboxylase 1	Rattus norvegicus	12-35
1086769-5	1976	The in vitro increase in G6PD activity is inhibited by the addition of either actinomycin D (5 mug/ml), cycloheximide (5 mug/ml), or cordycepin (150 mug/ml), or by the intrauterine injection of actinomycin D (10 mug/rat).	Cycloheximide	104-117	glucose-6-phosphate dehydrogenase	Rattus norvegicus	25-29
1086769-7	1976	The removal of cycloheximide, which was added at the beginning of incubation after the 12th h, restores the ability of the tissues to increase the G3PD activity, and this restoration is not blocked by the addition of actinomycin D, suggesting that the mRNA activity for uterine G6PD accumulated during in vitro inhibition of protein synthesis by cycloheximide.	Cycloheximide	15-28	glucose-6-phosphate dehydrogenase	Rattus norvegicus	278-282
991924-0	1976	Suppression of renin secretion in the isolated rat kidney by cycloheximide.	Cycloheximide	61-74	renin	Rattus norvegicus	15-20
991924-1	1976	The effect of cycloheximide, an inhibitor of protein synthesis, on basal and stimulated renin secretion was examined in the isolated perfused rat kidney.	Cycloheximide	14-27	renin	Rattus norvegicus	88-93
991924-3	1976	Both basal renin secretion and the response to intrarenal infusion of isoprenaline (0.06 nmol/min/g) or glucagon (0.1 nmol/min/g) were consistently reduced in the cycloheximide-treated group, suggesting dependence of these processes on protein synthesis.	Cycloheximide	163-176	renin	Rattus norvegicus	11-16
62822-4	1976	The majority of p30 antigens detected on the RAG cell surface were removed by trypsin and their reappearance was prevented by cycloheximide, even in the presence of "conditioned medium" containing MuLV.	Cycloheximide	126-139	high mobility group box 1	Mus musculus	16-19
186774-8	1976	Cycloheximide effectively obliterates the ODC and SAMD activities during the entire infectious cycle.	Cycloheximide	0-13	ornithine decarboxylase, structural 1	Mus musculus	42-45
186774-10	1976	The experiments with AMD and cycloheximide suggest that the formation of ODC is subject to post-transcriptional control, whereas that of SAMD is regulated primarily at the transcriptional level.	Cycloheximide	29-42	ornithine decarboxylase, structural 1	Mus musculus	73-76
10011-10	1976	Colchicine or cycloheximide in the incubation medium inhibits secretion of lecithin:cholesterol acyltransferase.	Cycloheximide	14-27	lecithin cholesterol acyltransferase	Rattus norvegicus	75-111
178053-2	1976	These effects of choleragen were not blocked by the beta-adrenoceptor antagonist propranolol, but the increases in cyclic adenosine monophosphate phosphodiesterase and serotonin N-acetyltransferase activities could be prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	263-276	aralkylamine N-acetyltransferase	Rattus norvegicus	168-197
15942-3	1977	Time course studies indicated that the increase in glutamine synthetase activity observed after 24 hr in culture resulted from a two-phase rise in activity and that cycloheximide was effective in suppressing the second-phase rise.	Cycloheximide	165-178	glutamate-ammonia ligase	Gallus gallus	51-71
185609-5	1976	Studies on the effect of actinomycin D, 3"-deoxyadenosine, and cycloheximide support the thesis that L-triiodothyronine induces the accumulation of an RNA species which is rate limiting for growth hormone synthesis and lends further support for a primary action of thyroid hormone at the nuclear level.	Cycloheximide	63-76	gonadotropin releasing hormone receptor	Rattus norvegicus	190-204
185201-7	1976	Actinomycin D with or without these inducers stimulated induction of ODC in L cells, whereas cycloheximide inhibited it, suggesting that these hormones affect the translational level of ODC synthesis.	Cycloheximide	93-106	ornithine decarboxylase, structural 1	Mus musculus	186-189
182385-9	1976	With cycloheximide, however, ovalbumin mRNA accumulation can be prevented.	Cycloheximide	5-18	ovalbumin (SERPINB14)	Gallus gallus	29-38
180007-10	1976	Exposure of the cells to cycloheximide (0.1 mM) produced a progressive but smaller loss of growth hormone receptors, and the effect of cycloheximide was additive to the receptor loss induced by growth hormone, suggesting that cycloheximide inhibited synthesis of receptors while growth hormone accelerated loss of receptors.	Cycloheximide	25-38	growth hormone 1	Homo sapiens	91-105
180007-10	1976	Exposure of the cells to cycloheximide (0.1 mM) produced a progressive but smaller loss of growth hormone receptors, and the effect of cycloheximide was additive to the receptor loss induced by growth hormone, suggesting that cycloheximide inhibited synthesis of receptors while growth hormone accelerated loss of receptors.	Cycloheximide	25-38	growth hormone 1	Homo sapiens	194-208
180007-10	1976	Exposure of the cells to cycloheximide (0.1 mM) produced a progressive but smaller loss of growth hormone receptors, and the effect of cycloheximide was additive to the receptor loss induced by growth hormone, suggesting that cycloheximide inhibited synthesis of receptors while growth hormone accelerated loss of receptors.	Cycloheximide	25-38	growth hormone 1	Homo sapiens	194-208
180007-12	1976	If the growth hormone was removed and replaced with cycloheximide, the return of the receptors was delayed until the cycloheximide was removed.	Cycloheximide	117-130	growth hormone 1	Homo sapiens	7-21
988022-16	1976	The presence of camptothecin, or cordycepin, or cycloheximide in the incubation medium completely blocks the increase in number of 125I-insulin-binding sites resulting from serum starvation.	Cycloheximide	48-61	insulin	Gallus gallus	136-143
789157-4	1976	Both effects of oestradiol could be blocked by cycloheximide, which agent, however, also partly inhibited the response to LH-RH.	Cycloheximide	47-60	gonadotropin releasing hormone 1	Rattus norvegicus	122-127
1270405-6	1976	The effects of actinomycin D, 6-methylpurine, cycloheximide, chloramphenicol, and mitomycin C on the induction of phenylalanine ammonia-lyase were investigated during incubation of the disks.	Cycloheximide	46-59	phenylalanine ammonia-lyase	Solanum tuberosum	114-141
5458-10	1976	Results obtained using cycloheximide suggest that ODC is translated only in the second half of the "activation period."	Cycloheximide	23-36	ornithine decarboxylase	Gallus gallus	50-53
1269089-9	1976	The effects of insulin on protein degradation, amion acid release, and cathepsin D activity persist even when protein synthesis has been inhibited by cycloheximide.	Cycloheximide	150-163	cathepsin D	Mus musculus	71-82
16659529-9	1976	In the presence of cycloheximide, both NADH-nitrate reductase and NO(3) (-)-induced NADH-cytochrome c reductase activities were lost at similar rates in root tips.	Cycloheximide	19-32	nitrate reductase [NADH] 1	Zea mays	44-61
131362-4	1976	Aminotriazole or cycloheximide pretreatment but not pyrazole administration decrease the intensity of polysome rupture caused by CCl4.	Cycloheximide	17-30	C-C motif chemokine ligand 4	Rattus norvegicus	129-133
773743-5	1976	Kex2 is located on chromosome XIV, but it does not show meiotic linkage to any gene previously located on this chromosome.--When the killer plasmid of kex1 or kex2 strains is eliminated by curing with heat or cycloheximide, the strains become sensitive to killing.	Cycloheximide	209-222	kexin KEX2	Saccharomyces cerevisiae S288C	0-4
773743-5	1976	Kex2 is located on chromosome XIV, but it does not show meiotic linkage to any gene previously located on this chromosome.--When the killer plasmid of kex1 or kex2 strains is eliminated by curing with heat or cycloheximide, the strains become sensitive to killing.	Cycloheximide	209-222	serine-type carboxypeptidase	Saccharomyces cerevisiae S288C	151-155
773743-5	1976	Kex2 is located on chromosome XIV, but it does not show meiotic linkage to any gene previously located on this chromosome.--When the killer plasmid of kex1 or kex2 strains is eliminated by curing with heat or cycloheximide, the strains become sensitive to killing.	Cycloheximide	209-222	kexin KEX2	Saccharomyces cerevisiae S288C	159-163
193291-3	1976	Content of urocaninic acid in skin and the histidase activity were altered under effect of administration of cylic-3",5"-AMP, dibutyryl cyclic-3",5"-AMP, glucagon, sodium fluoride, theophylline, actinomycin D and cycloheximide.	Cycloheximide	213-226	histidine ammonia lyase	Rattus norvegicus	43-52
1252468-0	1976	The effect of cycloheximide on galactosyltransferase of rat liver Golgi membranes.	Cycloheximide	14-27	glycoprotein alpha-galactosyltransferase 1	Rattus norvegicus	31-52
1252468-1	1976	An inhibitory effect of cycloheximide on the initial rate of galactosyltransferase of rat liver Golgi membranes has been demonstrated.	Cycloheximide	24-37	glycoprotein alpha-galactosyltransferase 1	Rattus norvegicus	61-82
1252468-7	1976	These results, together with the observation that serum galactosyltransferase was not inhibited by cycloheximide supported the view that the cycloheximide effect may be primarily on the membrane system.	Cycloheximide	141-154	glycoprotein alpha-galactosyltransferase 1	Rattus norvegicus	56-77
1252491-7	1976	All the observed effects of insulin on lipoprotein lipase activity were abolished by cycloheximide treatment in vivo.	Cycloheximide	85-98	lipoprotein lipase	Rattus norvegicus	39-57
1270405-7	1976	Actinomycin D, 6-methylpurine, and cycloheximide all inhibited the formation of phenylalanine ammonia-lyase, though cycloheximide was the most effective at low concentrations.	Cycloheximide	35-48	phenylalanine ammonia-lyase	Solanum tuberosum	80-107
1270405-7	1976	Actinomycin D, 6-methylpurine, and cycloheximide all inhibited the formation of phenylalanine ammonia-lyase, though cycloheximide was the most effective at low concentrations.	Cycloheximide	116-129	phenylalanine ammonia-lyase	Solanum tuberosum	80-107
944453-2	1976	A 24 hr water-saccharin preference test showed that conditioned rats exhibited a very low preference for saccharin whereas rats injected intraventricularly with cycloheximide (CXM, 400 mug) 5, 7, or 9 hr before training exhibited a greatly increased saccharin preference which differed significantly from NaC1 injected controls.	Cycloheximide	161-174	nucleus accumbens associated 1	Rattus norvegicus	305-309
824120-0	1976	TRH induced thyroxine release from thyroid: its prevention by thyroxine influenced by actinomycin D and cycloheximide.	Cycloheximide	104-117	thyrotropin releasing hormone	Rattus norvegicus	0-3
954974-1	1976	Cycloheximide, even in a dose of 0.25 mg/kg administered s.c. to rats stimulated by pancreozymin and secretin, inhibited lipase activity in pancreatic juice.	Cycloheximide	0-13	lipase G, endothelial type	Rattus norvegicus	121-127
954974-2	1976	Lipase activity in serum of control animals was inhibited by cycloheximide.	Cycloheximide	61-74	lipase G, endothelial type	Rattus norvegicus	0-6
179611-7	1976	Cycloheximide inhibits the increase of GAMT activity, induced by glucagon or a combination of glucagon and insulin.	Cycloheximide	0-13	guanidinoacetate N-methyltransferase	Rattus norvegicus	39-43
1174522-0	1975	Effects of colchicine and cycloheximide on the functional and non-functional lipoprotein lipase fractions of rat heart.	Cycloheximide	26-39	lipoprotein lipase	Rattus norvegicus	77-95
1174522-5	1975	Cycloheximide administration to rats starved for 24 h caused a decline in activity in both the functional (half-life of about 2 h) and the non-functional (half-life of about 4 h) lipoprotein lipase fractions.	Cycloheximide	0-13	lipoprotein lipase	Rattus norvegicus	179-197
1033069-3	1976	Using a monospecific antiserum, factor B in concentrated culture supernatants was shown by immunodiffusion and immunoelectrophoresis to be identical to factor B in mouse plasma and to form a characteristic complex with cobra venom factor in the presence of D. A steady rate of factor B secretion was observed for 4 days providing the medium was changed every 24 h. Cycloheximide (0.5 mug/ml), an inhibitor of protein synthesis, caused inhibition (90%) of factor B production.	Cycloheximide	365-378	complement factor B	Mus musculus	32-40
56423-0	1976	Cycloheximide alters axonal transport and subcellular distribution of dopamine-beta-hydroxylase activity.	Cycloheximide	0-13	dopamine beta-hydroxylase	Homo sapiens	70-95
212203-5	1975	From measurements of the rate of decline in 125I-LDL binding activity after administration of cycloheximide, the LDL receptor was calculated to have a half-life of about 25 hr.	Cycloheximide	94-107	low density lipoprotein receptor	Homo sapiens	113-125
171142-8	1975	Stimulation of ODC activity was 90% inhibited by the intraperitoneal administration of actinomycin D (80 mug/100 g body wt) or cycloheximide (400 mug/100 g body wt) given simultaneously with TSH.	Cycloheximide	127-140	ornithine decarboxylase 1	Rattus norvegicus	15-18
766087-12	1975	Similar tissue also exposed to cycloheximide was still responsive to LRH during the latter 1 hour incubation period.	Cycloheximide	31-44	gonadotropin releasing hormone 1	Rattus norvegicus	69-72
172314-3	1975	When cycloheximide was administered in conjunction with testosterone, the increase in 3-phosphoglycerate dehydrogenase and serine hydroxy-methyltransferase activity was significantly reduced compared to injection of testosterone alone.	Cycloheximide	5-18	phosphoglycerate dehydrogenase	Rattus norvegicus	86-118
1239649-4	1975	Low concentrations of cycloheximide completely blocked the synthesis of B protein but did not inhibit the synthesis of viral structural proteins.	Cycloheximide	22-35	tyrosinase related protein 1	Homo sapiens	72-81
169886-13	1975	In cultures incubated for 40 hr with cycloheximide, protein synthesis was inhibited by 85%, but the number of TRH receptors was 76% of control suggesting that the receptor has a long half-life.	Cycloheximide	37-50	thyrotropin releasing hormone	Rattus norvegicus	110-113
169886-14	1975	When GH3 cells were incubated with cycloheximide plus TRH, the number of TRH receptors decreased by only 23% as compared to a decrease of 73% in cells incubated with TRH alone, suggesting that receptor loss is partially dependent on active protein synthesis.	Cycloheximide	35-48	thyrotropin releasing hormone	Rattus norvegicus	73-76
169886-14	1975	When GH3 cells were incubated with cycloheximide plus TRH, the number of TRH receptors decreased by only 23% as compared to a decrease of 73% in cells incubated with TRH alone, suggesting that receptor loss is partially dependent on active protein synthesis.	Cycloheximide	35-48	thyrotropin releasing hormone	Rattus norvegicus	73-76
809057-4	1975	In addition, the rapid decay in ornithine decarboxylase activity in regenerating rat liver after cycloheximide injection is accompanied by a decrease in the immunoreactive protein.	Cycloheximide	97-110	ornithine decarboxylase 1	Rattus norvegicus	32-55
169122-5	1975	In cultures treated with cycloheximide (10 mug/ml) or proline (6.3 mM) the initial binding of [2,3-3H-Pro]TRH to receptors, measured after 1 h, was 97% or 102% of control.	Cycloheximide	25-38	thyrotropin releasing hormone	Rattus norvegicus	106-109
169122-6	1975	However, the incorporation of label from [2,3-3H-Pro]TRH into an acid-precipitable product after 22 h was inhibited by 81 and 74% by cycloheximide (1 mug/ml) and proline (2.5 mM).	Cycloheximide	133-146	thyrotropin releasing hormone	Rattus norvegicus	53-56
1142015-7	1975	Cycloheximide also completely blocked the effect of physiological doses (10 mug) of phylloquinone upon prothrombin synthesis, but only partially blocked the effect of pharmacological doses (2.5 mg) of phylloquinone, suggesting an antagonism between cycloheximide and vitamin K at the ribosomal level.	Cycloheximide	0-13	coagulation factor II, thrombin	Gallus gallus	103-114
167001-7	1975	However, a residual proportion of cholesterol-cytochrome P-450scc complexes remained, even after 10 min of exposure to malate, and was of similar magnitude in mitochondria from both cycloheximide-treated and stressed rats.	Cycloheximide	182-195	cytochrome P450, family 11, subfamily a, polypeptide 1	Rattus norvegicus	57-65
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Cycloheximide	173-186	ornithine decarboxylase 1	Rattus norvegicus	48-51
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Cycloheximide	173-186	ornithine decarboxylase 1	Rattus norvegicus	112-115
165059-7	1975	Little TSH effect was noted before 3 h. Maximal ODC activity occurred between 4 and 5 h. The TSH stimulation of ODC could be inhibited by pretreatment with actinomycin D or cycloheximide, suggesting that the increase in ODC activity requires new RNA and protein synthesis.	Cycloheximide	173-186	ornithine decarboxylase 1	Rattus norvegicus	112-115
807558-5	1975	The inactivation of beta-1,3-glucanse was prevented by cycloheximide.	Cycloheximide	55-68	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	20-28
182566-8	1975	Cycloheximide abolished a stimulatory effect of ACTH and cyclic AMP on steroidogenesis in a responsive adenoma without affecting its basal secretion of cortisol.	Cycloheximide	0-13	proopiomelanocortin	Homo sapiens	48-52
1095654-9	1975	Interaction of MSF with macrophages is sensitive to cycloheximide.	Cycloheximide	52-65	proteoglycan 4	Homo sapiens	15-18
1170287-2	1975	The effects of actinomycin D and cycloheximide on the 12-hour increases in G6PD and 6GPD were determined.	Cycloheximide	33-46	glucose-6-phosphate dehydrogenase	Rattus norvegicus	75-79
1170287-3	1975	Cycloheximide completely blocked the increase in G6PD if administered 2 or 4 hours after start of the meal, while actinomycin D completely blocked the increase in G6PD if administered at 2 hours and almost completely at 4 hours after start of the meal.	Cycloheximide	0-13	glucose-6-phosphate dehydrogenase	Rattus norvegicus	49-53
806079-0	1975	Nature of the increase in renal ornithine decarboxylase activity after cycloheximide administration in the rat.	Cycloheximide	71-84	ornithine decarboxylase 1	Rattus norvegicus	32-55
806079-1	1975	The present study was designed to determine whether the increase in rat renal ornithine decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17) activity after cycloheximide administration was a primary effect on the kidney or was a secondary effect of adrenal or pituitary hormones released in response to the drug.	Cycloheximide	158-171	ornithine decarboxylase 1	Rattus norvegicus	78-101
16659187-4	1975	Actinomycin-D (20 mug/ml) and cycloheximide (5 mug/ml), when present in the incubation medium at early periods of incubation, were capable of inhibiting the development of amylase activity and of preventing the appearance of the starch-degrading bands.The results indicate that the development of alpha-amylase activity in de-embryonated maize kernels is independent of an embryo or an exogenous source of gibberellic acid and suggest that this process involved protein synthesis.	Cycloheximide	30-43	alpha-amylase	Zea mays	297-310
806079-2	1975	Renal ornithine decarboxylase activity was reduced approximately 70% 1 hr after intraperitoneal administration of doses of cycloheximide that also inhibited renal protein synthesis by 68-95% within 1 hr.	Cycloheximide	123-136	ornithine decarboxylase 1	Rattus norvegicus	6-29
806079-4	1975	Peak ornithine decarboxylase activity was directly proportional to cycloheximide doses up to 250 mug; larger doses, which almost abolished protein synthesis for 8 hr, where inhibitory.	Cycloheximide	67-80	ornithine decarboxylase 1	Rattus norvegicus	5-28
1122557-0	1975	Effects of cycloheximide on the "autocatalytic" nature of the maturation promoting factor (MPF) in oocytes of Xenopus laevis.	Cycloheximide	11-24	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	62-89
1122557-0	1975	Effects of cycloheximide on the "autocatalytic" nature of the maturation promoting factor (MPF) in oocytes of Xenopus laevis.	Cycloheximide	11-24	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	91-94
1122557-3	1975	Experiments using cycloheximide suggest that MPF does not need protein synthesis for germinal vesicle breakdown (GVBD), but does require a translational step when serially transferred in order to sustain its renewal ("autocatalytic") capacity.	Cycloheximide	18-31	cyclin-dependent kinase 1 S homeolog	Xenopus laevis	45-48
185104-5	1975	Only cycloheximide was found to significantly reduce the synthesis and subsequent release of insulin-like peptides by the tumoral tissue.	Cycloheximide	5-18	insulin	Homo sapiens	93-100
171178-1	1975	Treatment of the RSV-transformed "poorly" virogenic rat clones LW13-RsK4 and LW13-RsK4 R1 with cycloheximide or puromycin before fusion with chick embryo fibroblasts did not lead to RSV rescue.	Cycloheximide	95-108	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	82-86
814520-3	1975	The relations between the determination of the gene Est-6 expression and its transcription and translation were assessed by studying the effect of the inhibitors of RNA (actinomycin D) and protein synthesis (cycloheximide).	Cycloheximide	208-221	Esterase 6	Drosophila melanogaster	52-57
16659023-3	1975	Specific inhibitors of protein synthesis showed that the formation of ribulose 1,5-diphosphate carboxylase in both division-synchronized and regreening cultures was prevented by both cycloheximide and d-threo-chloramphenicol, whereas phosphoglycolate phosphatase formation was only inhibited by d-threo-chloramphenicol but not by l-threo-chloramphenicol or cycloheximide.	Cycloheximide	183-196	phosphoglycolate phosphatase	Homo sapiens	234-262
4155342-0	1974	Tyrosine hydroxylase inhibition by cycloheximide and anisomycin is not responsible for their amnesic effect.	Cycloheximide	35-48	tyrosine hydroxylase	Homo sapiens	0-20
4377655-10	1974	Cycloheximide or actinomycin D inhibited the prenatal induction of both enzymes and actinomycin D blocked the natural increase of l-serine dehydratase immediately after birth.	Cycloheximide	0-13	serine racemase	Rattus norvegicus	130-150
236036-6	1975	Addition of cycloheximide to fully derepressed cultures results in the decay of System ii with a t1/2 of 14 min, very similar to the turnoacteriol.	Cycloheximide	12-25	interleukin 1 receptor like 1	Homo sapiens	97-107
4372392-3	1974	Treatment of mouse L cells with interferon plus cycloheximide also gives levels of vesicular stomatitis viral complementary RNA synthesis comparable to that observed with the cycloheximide treatment alone.	Cycloheximide	175-188	interferon	Gallus gallus	32-42
4156801-0	1974	Glutamine synthetase in the embryonic chick neural retina: the effects of cycloheximide on the conservation of labile templates for enzyme synthesis.	Cycloheximide	74-87	glutamate-ammonia ligase	Gallus gallus	0-20
4424298-0	1974	The stimulation of the phosphorylation of ribosomal protein S6 by cycloheximide and puromycin.	Cycloheximide	66-79	ribosomal protein S6	Homo sapiens	42-62
4528709-3	1974	Newly synthesized acetylcholinesterase did not stain cytochemically, was rapidly and extensively degraded or released in the presence of 10 muM cycloheximide, and consisted mainly of low-molecular-weight forms.	Cycloheximide	144-157	acetylcholinesterase (Cartwright blood group)	Gallus gallus	18-38
4526203-6	1974	The effects of insulin were prevented by cycloheximide and are probably due to an increased synthesis of 3-hydroxy-3-methylglutaryl CoA reductase or of a protein that regulates its activity.	Cycloheximide	41-54	insulin	Homo sapiens	15-22
4526203-6	1974	The effects of insulin were prevented by cycloheximide and are probably due to an increased synthesis of 3-hydroxy-3-methylglutaryl CoA reductase or of a protein that regulates its activity.	Cycloheximide	41-54	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	105-145
4825244-13	1974	Lysozyme production can be rapidly inhibited by treatment with cycloheximide (0.4 microg/ml) whereas inhibition of its production by colchicine (10(-6) M) occurs only after a lag period of more than 8 h, and is probably due to a secondary effect.	Cycloheximide	63-76	lysozyme	Homo sapiens	0-8
16658744-10	1974	Cycloheximide prevented the increase in peroxidase activity in tobacco pith and potato root, but not in the carrot root.	Cycloheximide	0-13	peroxidase N1	Nicotiana tabacum	40-50
16658745-3	1974	The increase in enzyme activity in early dark phase probably represented de novo enzyme synthesis because it was prevented by the addition of cycloheximide at a concentration known to inhibit protein synthesis on Euglena cytoplasmic ribosomes.When division-synchronized cultures were darkened in early light phase, a doubling of both fumarase and succinate dehydrogenase activity resulted, showing that light was repressing enzyme synthesis.	Cycloheximide	142-155	fumarate hydratase	Homo sapiens	334-342
16658723-4	1974	Cycloheximide, added at the beginning of the incubation period, prevents the development of alpha-amylase and protease activities and the disappearance of starch and protein reserves.	Cycloheximide	0-13	alpha-amylase	Zea mays	92-105
4822728-3	1974	In incubations of liver slices, 1.4mm-compound AHR-1911 decreased by 96% the incorporation of [(14)C]leucine into microsomal proteins, and mitochondrial protein synthesis measured in the presence of cycloheximide was decreased by 44%.	Cycloheximide	199-212	aryl hydrocarbon receptor	Rattus norvegicus	47-50
4428983-0	1974	[Effect of calcium and sodium in the production of renin in vitro: action of cycloheximide].	Cycloheximide	77-90	renin	Homo sapiens	51-56
4352803-0	1973	Reversible inhibition of ACTH-induced corticosteroid release by cycloheximide: evidence for an unidentified cellular messenger.	Cycloheximide	64-77	proopiomelanocortin	Homo sapiens	25-29
4352578-10	1973	In addition, actinomycin D or cycloheximide in doses sufficient to block adrenal RNA and protein synthesis, respectively inhibited the stimulation of ornithine decarboxylase activity by ACTH in vivo.	Cycloheximide	30-43	ornithine decarboxylase 1	Rattus norvegicus	150-173
16658521-1	1973	Cycloheximide inhibited ethylene production in excised pea root tips treated with high levels of indoleacetic acid (100 mum and 10 mum).	Cycloheximide	0-13	latexin	Homo sapiens	120-123
16658521-1	1973	Cycloheximide inhibited ethylene production in excised pea root tips treated with high levels of indoleacetic acid (100 mum and 10 mum).	Cycloheximide	0-13	latexin	Homo sapiens	131-134
16742796-3	1973	Although incorporation of (14)C-labelled amino acid into microsomal cytochrome b(5) is also rapidly inhibited, cycloheximide incompletely inhibits haem labelling of cytochrome b(5) and cytochrome a+a(3), and inhibition occurs only after repeated antibiotic injections.	Cycloheximide	111-124	cytochrome b5 type A	Rattus norvegicus	165-179
4353083-15	1973	Cycloheximide also prevented the loss or induction of pyruvate carboxylase and phosphoenolpyruvate carboxylase activities with high substrate concentrations.	Cycloheximide	0-13	pyruvate carboxylase	Rattus norvegicus	54-74
4353083-15	1973	Cycloheximide also prevented the loss or induction of pyruvate carboxylase and phosphoenolpyruvate carboxylase activities with high substrate concentrations.	Cycloheximide	0-13	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	79-110
16658419-12	1973	Recovery of enzyme activity was prevented by cycloheximide.Based on these results, it appears that nitrate reductase activity was affected primarily by a decrease in the rate of enzyme synthesis at low leaf water potentials.	Cycloheximide	45-58	nitrate reductase [NADH] 1	Zea mays	99-116
4724585-6	1973	The incorporation into secreted vitellogenin, however, continued for 2h after the addition of cycloheximide.	Cycloheximide	94-107	a1-a	Xenopus laevis	32-44
4405624-0	1973	Cycloheximide and acetoxycycloheximide: inhibition of tyrosine hydroxylase activity and amnestic effects.	Cycloheximide	0-13	tyrosine hydroxylase	Rattus norvegicus	54-74
4144063-9	1972	Cycloheximide, which probably lowers gastric histidine decarboxylase activity by inhibiting enzyme synthesis, was maximally effective at a dose level as low as 1 mg/kg.	Cycloheximide	0-13	histidine decarboxylase	Rattus norvegicus	45-68
4144063-12	1972	Combined treatment of vagally denervated rats with brocresine and cycloheximide resulted in a rapid and persistent reduction of the histidine decarboxylase activity.	Cycloheximide	66-79	histidine decarboxylase	Rattus norvegicus	132-155
4650149-0	1972	Effect of cycloheximide on biosynthesis of rat liver catalase.	Cycloheximide	10-23	catalase	Rattus norvegicus	53-61
5389137-8	1969	Cycloheximide (3.6 x 10(-5)M) and puromycin (3.7 x 10(-4)M) suppressed incorporation of labeled amino acids into protein by 93 and 98%, respectively, and suppressed growth hormone production by stimulated and control cells by at least 94%.	Cycloheximide	0-13	gonadotropin releasing hormone receptor	Rattus norvegicus	165-179
4548065-3	1974	Return of enzymatic activity after irreversible inhibition of AChE in "differentiated" cells was blocked by cycloheximide, but not by cordycepin or actinomycin D, suggesting that protein but not mRNA synthesis was required for replacement.	Cycloheximide	108-121	acetylcholinesterase (Cartwright blood group)	Homo sapiens	62-66
4343540-3	1972	The loss of H-2 antigenic activity is not due to the viral inhibition of host cell protein synthesis since cells cultured for 18 hr in the presence of cycloheximide have the same amount of H-2 activity as untreated controls.	Cycloheximide	151-164	relaxin 2	Homo sapiens	12-15
4343540-3	1972	The loss of H-2 antigenic activity is not due to the viral inhibition of host cell protein synthesis since cells cultured for 18 hr in the presence of cycloheximide have the same amount of H-2 activity as untreated controls.	Cycloheximide	151-164	relaxin 2	Homo sapiens	189-192
16658200-0	1972	l-Phenylalanine Ammonia-lyase (Maize): Partial Purification and Response to Gibberellic Acid and Cycloheximide of l-Phenylalanine and l-Tyrosine Ammonia-lyase Activities.	Cycloheximide	97-110	phenylalanine ammonia-lyase	Zea mays	2-29
4672392-7	1972	Inhibition of cellular ribonucleic acid (RNA) and protein synthesis by actinomycin D during SFV infection did not decrease the counts of CPV-1; however, biogenesis of CPV-1 was decreased when viral replication was limited by inhibitors of viral RNA synthesis (guanidine) or of viral protein synthesis (cycloheximide).	Cycloheximide	302-315	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	167-172
4506772-3	1972	Treatment with reserpine, a compound that depletes norepinephrine from nerves, 1-propranolol, a beta-adrenergic blocking agent, or cycloheximide, an inhibitor of protein synthesis, abolishes the nocturnal increase in serotonin N-acetyltransferase activity, indicating that the enzyme activity is modulated by neural release of norepinephrine from sympathetic nerves via beta-adrenergic receptors, and that the increase in enzyme activity is due to synthesis of new enzyme molecules.	Cycloheximide	131-144	aralkylamine N-acetyltransferase	Rattus norvegicus	217-246
5054470-1	1972	We have studied the transport of alpha-aminoisobutyric acid (AIB)-3-(14)C and its response to cortisol and cycloheximide in vitro in blood lymphocytes from untreated patients with chronic lymphocytic leukemia.	Cycloheximide	107-120	ANIB1	Homo sapiens	61-64
5054470-4	1972	Virtually total inhibition of protein synthesis with cycloheximide was found to decrease the accumulation of AIB in cells from four patients which had high rates of AIB transport, but had no effect on transport in cells from four patients which accumulated AIB more slowly.	Cycloheximide	53-66	ANIB1	Homo sapiens	109-112
5054470-4	1972	Virtually total inhibition of protein synthesis with cycloheximide was found to decrease the accumulation of AIB in cells from four patients which had high rates of AIB transport, but had no effect on transport in cells from four patients which accumulated AIB more slowly.	Cycloheximide	53-66	ANIB1	Homo sapiens	165-168
5054470-4	1972	Virtually total inhibition of protein synthesis with cycloheximide was found to decrease the accumulation of AIB in cells from four patients which had high rates of AIB transport, but had no effect on transport in cells from four patients which accumulated AIB more slowly.	Cycloheximide	53-66	ANIB1	Homo sapiens	165-168
5054470-10	1972	Inhibition was noncompetitive in type, suggesting that cortisol decreases the total capacity of the active transport mechanism.Cortisol inhibited AIB transport indirectly by a process which involved de novo protein synthesis, since inhibition (a) appeared only after 60 min of treatment, (b) was present in treated cells which were subsequently incubated for 60 min in cortisol-free medium, and (c) failed to develop during simultaneous blockade of protein synthesis with cycloheximide, even when cycloheximide itself did not decrease AIB transport.	Cycloheximide	472-485	ANIB1	Homo sapiens	146-149
5054470-10	1972	Inhibition was noncompetitive in type, suggesting that cortisol decreases the total capacity of the active transport mechanism.Cortisol inhibited AIB transport indirectly by a process which involved de novo protein synthesis, since inhibition (a) appeared only after 60 min of treatment, (b) was present in treated cells which were subsequently incubated for 60 min in cortisol-free medium, and (c) failed to develop during simultaneous blockade of protein synthesis with cycloheximide, even when cycloheximide itself did not decrease AIB transport.	Cycloheximide	497-510	ANIB1	Homo sapiens	146-149
4117697-0	1972	Stimulatory effect of cycloheximide and related glutarimide antibiotics on liver uridine kinase.	Cycloheximide	22-35	uridine-cytidine kinase 2	Homo sapiens	81-95
16658047-6	1972	The increase in PAL activity induced by irradiated psoralens was prevented when 6-methylpurine (0.5 milligram per milliliter) or cycloheximide (10 micrograms per milliliter) was applied immediately following the irradiation period.	Cycloheximide	129-142	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	16-19
4401379-9	1971	The increase in glucose 6-phosphate dehydrogenase was eliminated by the injection of actinomycin D or cycloheximide.	Cycloheximide	102-115	glucose-6-phosphate dehydrogenase	Rattus norvegicus	16-49
5131730-8	1971	The biosynthesis in vitro of vitellogenin was inhibited by cycloheximide and carbonyl cyanide m-chlorophenylhydrazone, stimulated by increased Ca(2+) concentrations and decreased by raising the incubation temperature from 22 to 37 degrees C. 5.	Cycloheximide	59-72	a1-a	Xenopus laevis	29-41
5283959-1	1971	Previous studies have shown that the vitamin K-induced synthesis of prothrombin in a vitamin K-deficient rat is only slightly inhibited by cycloheximide treatment.	Cycloheximide	139-152	coagulation factor II	Rattus norvegicus	68-79
5283959-3	1971	When cycloheximide (5 mg/kg) was given to vitamin K-deficient rats 30 min before vitamin K, about 70% of the amount of prothrombin seen in rats not treated with cycloheximide was produced (two-stage assay), and the prothrombin band could be seen on the electrophoretic gels.	Cycloheximide	5-18	coagulation factor II	Rattus norvegicus	119-130
5283959-3	1971	When cycloheximide (5 mg/kg) was given to vitamin K-deficient rats 30 min before vitamin K, about 70% of the amount of prothrombin seen in rats not treated with cycloheximide was produced (two-stage assay), and the prothrombin band could be seen on the electrophoretic gels.	Cycloheximide	5-18	coagulation factor II	Rattus norvegicus	215-226
5283959-4	1971	However, if radioactive amino acids are administered to the rats after cycloheximide treatment, the newly formed prothrombin contains no radioactivity.	Cycloheximide	71-84	coagulation factor II	Rattus norvegicus	113-124
5283959-5	1971	The isolated prothrombin does contain radioactivity if the vitamin K-deficient rats are treated with vitamin K but no cycloheximide.	Cycloheximide	118-131	coagulation factor II	Rattus norvegicus	13-24
5093122-0	1971	The effect of cycloheximide and 2-deoxyglucose on the diphasic pattern of insulin secretion.	Cycloheximide	14-27	insulin	Homo sapiens	74-81
4990844-0	1970	Effect of cycloheximide on production of diamine oxidase by the human placenta.	Cycloheximide	10-23	amine oxidase copper containing 1	Homo sapiens	41-56
5493500-18	1970	It was concluded that, in the presence of an abundant amino acid supply, growth hormone can stimulate the synthesis of protein in rat liver slices by a mechanism that is more sensitive to cycloheximide than is the basal protein synthesis.	Cycloheximide	188-201	gonadotropin releasing hormone receptor	Rattus norvegicus	73-87
5513559-8	1970	Both cycloheximide and puromycin suppressed prolactin production by at least 94%.	Cycloheximide	5-18	prolactin	Rattus norvegicus	44-53
5459848-0	1970	Microassay for cathepsin D shows an unexpected effedt of cycloheximide on limb-bone rudiments in organ culture.	Cycloheximide	57-70	cathepsin D	Homo sapiens	15-26
4987311-0	1970	Derepression of tyrosinase synthesis in Neurospora by cycloheximide, actinomycin D, and puromycin.	Cycloheximide	54-67	tyrosinase	Homo sapiens	16-26
5437347-0	1970	Reversal by vitamin K of cycloheximide inhibited biosynthesis of prothrombin in the isolated perfused rat liver.	Cycloheximide	25-38	coagulation factor II	Rattus norvegicus	65-76
4329341-0	1970	Inhibition by cycloheximide and dactinomycin of the activation of lipolysis due to growth hormone in white fat cells.	Cycloheximide	14-27	growth hormone 1	Homo sapiens	83-97
5745898-0	1968	Differential effects of cycloheximide and Trenimon on alkaline ribonuclease and on ribonuclease inhibitor in human amnion cells.	Cycloheximide	24-37	ribonuclease/angiogenin inhibitor 1	Homo sapiens	83-105
5653209-9	1968	Rats given cycloheximide at a dose level that markedly reduced hepatic protein and cytochrome P-450 synthesis but allowed heme synthesis to continue at 60% of its pretreatment level synthesized normal or increased amounts of early bilirubin from delta ALA-4-(14)C. Allylisopropylacetamide intoxication caused little change in early bilirubin formation, whereas aminotriazole given at a time after maximal hepatic heme labeling produced a small but significant increase in the appearance of labeled bilirubin.	Cycloheximide	11-24	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	83-99
16656772-1	1968	The light induced synthesis of phenylalanine ammonia-lyase in disks cut from potato tubers is very sensitive to cycloheximide.	Cycloheximide	112-125	phenylalanine ammonia-lyase	Solanum tuberosum	31-58
17737482-1	1968	The development of L-tyrosine : 2-oxoglutarate aminotransferase in newborn rats is suppressed by actidione (cycloheximide), an inhibitor of protein biosynthesis, administered immediately after birth.	Cycloheximide	97-106	tyrosine aminotransferase	Rattus norvegicus	19-63
17737482-1	1968	The development of L-tyrosine : 2-oxoglutarate aminotransferase in newborn rats is suppressed by actidione (cycloheximide), an inhibitor of protein biosynthesis, administered immediately after birth.	Cycloheximide	108-121	tyrosine aminotransferase	Rattus norvegicus	19-63
4291105-3	1967	The transfer of about 70 percent of the radioactivity of the larger protein to insulin was demonstrated in the absence of new peptide bond synthesis (cycloheximide), or during incubation with unlabeled amino acid (chase).	Cycloheximide	150-163	insulin	Homo sapiens	79-86
5704808-0	1968	The effect of actinomycin D and cycloheximide on the activition by prolactin of lipoprotein lipase in the mammary gland.	Cycloheximide	32-45	lipoprotein lipase	Homo sapiens	80-98
16742412-13	1966	The induction of both nitrate reductase and nitrite reductase is prevented by the inhibitors actinomycin D, puromycin and cycloheximide, indicating a requirement for the synthesis of RNA and protein.	Cycloheximide	122-135	ferredoxin--nitrite reductase, chloroplastic	Raphanus sativus	44-61
33901925-5	2021	Here, we found that blockade of serine/threonine phosphatases 1 (PP1) and 2A (PP2A) with the specific blockers, calyculin A (CalyA) or okadaic acid (OA), and simultaneous blockade of the protein translation by anisomycin or cycloheximide leads to a switch from PSB-impaired LTP to LTD. PP1/PP2A-dependent LTD was extremely sensitive to the intensity of the test stimuli, whose increase restored the field excitatory postsynaptic potentials (fEPSP) to the values corresponding to control LTP in the non-treated slices.	Cycloheximide	224-237	protein phosphatase 2 phosphatase activator	Homo sapiens	78-82
33609540-6	2021	EZH2 stability was checked by treatment with cycloheximide.	Cycloheximide	45-58	enhancer of zeste 2 polycomb repressive complex 2 subunit	Mus musculus	0-4
33880590-6	2021	Via cycloheximide chase experiments, it was identified that GTSE1 overexpression increased the protein turnover of SNAIL1, while knockdown of GTSE1 reduced its degradation rate.	Cycloheximide	4-17	G2 and S-phase expressed 1	Homo sapiens	60-65
34031187-9	2021	These results suggest that TGF-beta1 activates Rho/pMLC2 through an indirect mechanism which was confirmed by sensitivity to cycloheximide treatment.	Cycloheximide	125-138	transforming growth factor beta 1	Homo sapiens	27-36
33784509-8	2021	Furthermore, rapid reduction of cyclin D1 upon DNA damage was attributed to proteasomal degradation, as evidenced by data showing that proteasomal inhibition by MG132 blocked cyclin D1 reduction while cycloheximide facilitated it.	Cycloheximide	201-214	cyclin D1	Homo sapiens	32-41
33880590-6	2021	Via cycloheximide chase experiments, it was identified that GTSE1 overexpression increased the protein turnover of SNAIL1, while knockdown of GTSE1 reduced its degradation rate.	Cycloheximide	4-17	snail family transcriptional repressor 1	Homo sapiens	115-121
33977871-7	2021	Our study reveals the underlying mechanism of BECN1 ubiquitination and degradation that affects autophagic activity and subsequently leads to tumor progression, providing a novel therapeutic strategy that regulates autophagy to combat cancer.Abbreviations: ATG: autophagy-related BECN1: beclin 1 CHX: cycloheximide CoIP: co-immunoprecipitation CUL3: cullin 3 IP: immunoprecipitation MS: mass spectrometry PtdIns3K: phosphatidylinositol 3-kinase UPS: ubiquitin-proteasome system.	Cycloheximide	301-314	beclin 1	Homo sapiens	46-51
33989402-4	2021	The involvement of plastid-encoded FtsH, a key plastid maintenance protease, in recovery from photoinhibition in V. litorea was estimated in cycloheximide-treated cells.	Cycloheximide	141-154	ftsH	Vaucheria litorea	35-39
33989402-7	2021	Higher level of FtsH was also evident in cycloheximide-treated cells during recovery from photoinhibition.	Cycloheximide	41-54	ftsH	Vaucheria litorea	16-20
33676386-5	2021	Results of cycloheximide-chase assay showed that the protein level of mTOR was decreased with the treatment time after the knockdown of lncRNA-AIRN.	Cycloheximide	11-24	mechanistic target of rapamycin kinase	Mus musculus	70-74
33968934-7	2021	The presence of free TBCA is not observed in cells treated with other anti-mitotic agents such as nocodazole or cold shock, neither after translation inhibition by cycloheximide.	Cycloheximide	164-177	tubulin folding cofactor A	Homo sapiens	21-25
33672238-7	2021	Cycloheximide chase assay showed that in cells over-expressing STCH, NKCC2 stability and maturation are heavily impaired.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 13	Homo sapiens	63-67
33759138-5	2021	In the cycloheximide-chase assay, the knockdown of LncRNA AIRN enhanced the stability of STAT1 protein.	Cycloheximide	7-20	signal transducer and activator of transcription 1	Homo sapiens	89-94
33725110-9	2021	Furthermore, treatment with cycloheximide inhibited DAO protein degradation.	Cycloheximide	28-41	D-amino acid oxidase	Sus scrofa	52-55
33723221-9	2021	Further, coimmunoprecipitation (Co-IP) and cycloheximide (CHX) chase experiment demonstrated that PER1 can bind with RACK1 and PI3K to form the PER1/RACK1/PI3K complex in OSCC cells.	Cycloheximide	43-56	receptor for activated C kinase 1	Homo sapiens	117-122
33723221-9	2021	Further, coimmunoprecipitation (Co-IP) and cycloheximide (CHX) chase experiment demonstrated that PER1 can bind with RACK1 and PI3K to form the PER1/RACK1/PI3K complex in OSCC cells.	Cycloheximide	43-56	receptor for activated C kinase 1	Homo sapiens	149-154
33751071-4	2021	Treatment of HEK293T cells transfected with the K700E-mutated SF3B1 with cycloheximide leads to increased accumulation of the aberrant spliced transcript of MAP3K7, demonstrating that the aberrantly spliced transcript of MAP3K7 is targeted by nonsense-mediated decay.	Cycloheximide	73-86	splicing factor 3b subunit 1	Homo sapiens	62-67
33751071-4	2021	Treatment of HEK293T cells transfected with the K700E-mutated SF3B1 with cycloheximide leads to increased accumulation of the aberrant spliced transcript of MAP3K7, demonstrating that the aberrantly spliced transcript of MAP3K7 is targeted by nonsense-mediated decay.	Cycloheximide	73-86	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	157-163
33751071-4	2021	Treatment of HEK293T cells transfected with the K700E-mutated SF3B1 with cycloheximide leads to increased accumulation of the aberrant spliced transcript of MAP3K7, demonstrating that the aberrantly spliced transcript of MAP3K7 is targeted by nonsense-mediated decay.	Cycloheximide	73-86	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	221-227
33439776-8	2021	Blocking protein synthesis using Cycloheximide prevented Cldn-3 upregulation by TNFalpha, verifying the contribution of de novo Cldn-3 synthesis.	Cycloheximide	33-46	claudin 3	Homo sapiens	57-63
33439776-8	2021	Blocking protein synthesis using Cycloheximide prevented Cldn-3 upregulation by TNFalpha, verifying the contribution of de novo Cldn-3 synthesis.	Cycloheximide	33-46	tumor necrosis factor	Homo sapiens	80-88
33759138-5	2021	In the cycloheximide-chase assay, the knockdown of LncRNA AIRN enhanced the stability of STAT1 protein.	Cycloheximide	7-20	antisense of IGF2R non-protein coding RNA	Homo sapiens	58-62
33402011-7	2021	Remarkably, endogenous beta2-adrenergic receptor/ADRB2 dynamic mass redistribution functional responses to norepinephrine were significantly decreased following CHX treatment, with a time course equivalent to that observed with the SNAP-ADRB2 degradation assay.	Cycloheximide	161-164	adrenoceptor beta 2	Homo sapiens	23-48
33402011-7	2021	Remarkably, endogenous beta2-adrenergic receptor/ADRB2 dynamic mass redistribution functional responses to norepinephrine were significantly decreased following CHX treatment, with a time course equivalent to that observed with the SNAP-ADRB2 degradation assay.	Cycloheximide	161-164	adrenoceptor beta 2	Homo sapiens	49-54
33402011-7	2021	Remarkably, endogenous beta2-adrenergic receptor/ADRB2 dynamic mass redistribution functional responses to norepinephrine were significantly decreased following CHX treatment, with a time course equivalent to that observed with the SNAP-ADRB2 degradation assay.	Cycloheximide	161-164	adrenoceptor beta 2	Homo sapiens	237-242
33748123-7	2021	ARL3 protein stability and its interaction with RP2 protein were assessed by cycloheximide chase assay and co-immunoprecipitation (Co-IP) assay.	Cycloheximide	77-90	ADP ribosylation factor like GTPase 3	Homo sapiens	0-4
33672238-7	2021	Cycloheximide chase assay showed that in cells over-expressing STCH, NKCC2 stability and maturation are heavily impaired.	Cycloheximide	0-13	solute carrier family 12 member 1	Homo sapiens	69-74
32602030-8	2021	Furthermore, the effect of LncRNA HOTAIR on MYD88 stability was assessed by cycloheximide (CHX)-chase and by immunoprecipitation and ubiquitination assays that analyzed MYD88 ubiquitination.	Cycloheximide	76-89	myeloid differentiation primary response gene 88	Mus musculus	44-49
33372032-7	2021	For instance, we observed that the inhibition of Trk receptors (K252a), PKC (Go6976), protein translation (cycloheximide) or caspases (zVAD-fmk) provides protection from NGF deprivation-induced death but not from degeneration evoked by BDNF-withdrawal.	Cycloheximide	107-120	neurotrophic receptor tyrosine kinase 1	Homo sapiens	49-52
33461590-6	2021	The turnover of c-Myc variants was determined by degradation in presence of cycloheximide and by optical pulse-chase experiments.. Immunofluorescence of mouse prostate tissue and bioinformatics of human datasets were applied to correlate IKKalpha- and c-Myc levels.	Cycloheximide	76-89	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	16-21
33451909-6	2021	Moreover, the stability of RAC1 protein was detected by cycloheximide-chase and ubiquitination.	Cycloheximide	56-69	Rac family small GTPase 1	Homo sapiens	27-31
33447049-10	2020	Cycloheximide chase assay demonstrates that LA greatly decreases the stability of Survivin, XIAP and RIP1.	Cycloheximide	0-13	X-linked inhibitor of apoptosis	Homo sapiens	92-96
33447049-10	2020	Cycloheximide chase assay demonstrates that LA greatly decreases the stability of Survivin, XIAP and RIP1.	Cycloheximide	0-13	receptor interacting serine/threonine kinase 1	Homo sapiens	101-105
32602030-12	2021	Besides, by cycloheximide (CHX)-chase and immunoprecipitation and ubiquitination assays, the overexpression of the LncRNA HOTAIR enhanced the stability of MYD88 protein and inhibited Nrdp1-mediated ubiquitination of MYD88 protein.	Cycloheximide	12-25	HOX transcript antisense RNA (non-protein coding)	Mus musculus	122-128
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Cycloheximide	46-59	catenin beta 1	Homo sapiens	84-96
32602030-12	2021	Besides, by cycloheximide (CHX)-chase and immunoprecipitation and ubiquitination assays, the overexpression of the LncRNA HOTAIR enhanced the stability of MYD88 protein and inhibited Nrdp1-mediated ubiquitination of MYD88 protein.	Cycloheximide	12-25	myeloid differentiation primary response gene 88	Mus musculus	155-160
33130557-5	2021	Pretreatment with protein synthesis inhibitor Cycloheximide antagonized BBR-induced beta-catenin reduction, suggesting that BBR affects beta-catenin translation.	Cycloheximide	46-59	catenin beta 1	Homo sapiens	136-148
33383653-8	2020	Furthermore, cycloheximide treatment increased HO-1 abundance in p53 KO cells suggesting that p53 modulates HO-1 protein stability.	Cycloheximide	13-26	heme oxygenase 1	Homo sapiens	47-51
33383653-8	2020	Furthermore, cycloheximide treatment increased HO-1 abundance in p53 KO cells suggesting that p53 modulates HO-1 protein stability.	Cycloheximide	13-26	tumor protein p53	Homo sapiens	65-68
33383653-8	2020	Furthermore, cycloheximide treatment increased HO-1 abundance in p53 KO cells suggesting that p53 modulates HO-1 protein stability.	Cycloheximide	13-26	tumor protein p53	Homo sapiens	94-97
33383653-8	2020	Furthermore, cycloheximide treatment increased HO-1 abundance in p53 KO cells suggesting that p53 modulates HO-1 protein stability.	Cycloheximide	13-26	heme oxygenase 1	Homo sapiens	108-112
33249529-6	2020	The stability of the PARP-1 protein and the acetylation level of high mobility group box-1 (HMGB1) were determined by cycloheximide-chase and immunoprecipitation, respectively.	Cycloheximide	118-131	high mobility group box 1	Mus musculus	92-97
33277362-9	2021	Cycloheximide chase studies using induced human neurons and HEK293 cells suggested that PEG10 and TRIM32 are direct clients.	Cycloheximide	0-13	paternally expressed 10	Homo sapiens	88-93
33277362-9	2021	Cycloheximide chase studies using induced human neurons and HEK293 cells suggested that PEG10 and TRIM32 are direct clients.	Cycloheximide	0-13	tripartite motif containing 32	Homo sapiens	98-104
33012513-10	2020	The cycloheximide chase experiment revealed the stabilization of HIF-2alpha by PIN1.	Cycloheximide	4-17	endothelial PAS domain protein 1	Homo sapiens	65-75
33012513-10	2020	The cycloheximide chase experiment revealed the stabilization of HIF-2alpha by PIN1.	Cycloheximide	4-17	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	79-83
32814116-7	2020	Like CaVbeta, Srobeta prevents fast degradation of total CaV2.3 proteins in cycloheximide assays.	Cycloheximide	76-89	carbonic anhydrase 5A	Homo sapiens	5-12
32008086-5	2020	We elucidated the underlying function of EGFL6 in SBVM in vitro and by generating a zebrafish model that overexpresses EGFL6, The cycloheximide (CHX)-chase experiment and CoIP assays were conducted to demonstrate that thalidomide can promote the degradation of EGFL6 by targeting CRBN.	Cycloheximide	145-148	EGF-like-domain, multiple 6	Danio rerio	41-46
32008086-5	2020	We elucidated the underlying function of EGFL6 in SBVM in vitro and by generating a zebrafish model that overexpresses EGFL6, The cycloheximide (CHX)-chase experiment and CoIP assays were conducted to demonstrate that thalidomide can promote the degradation of EGFL6 by targeting CRBN.	Cycloheximide	145-148	EGF-like-domain, multiple 6	Danio rerio	119-124
32008086-5	2020	We elucidated the underlying function of EGFL6 in SBVM in vitro and by generating a zebrafish model that overexpresses EGFL6, The cycloheximide (CHX)-chase experiment and CoIP assays were conducted to demonstrate that thalidomide can promote the degradation of EGFL6 by targeting CRBN.	Cycloheximide	145-148	EGF-like-domain, multiple 6	Danio rerio	119-124
33078455-8	2020	Cycloheximide chase assay showed that the increased level of KLF5 by CLU overexpression was due to decreased degradation of KLF5 protein.	Cycloheximide	0-13	clusterin	Mus musculus	69-72
33078455-8	2020	Cycloheximide chase assay showed that the increased level of KLF5 by CLU overexpression was due to decreased degradation of KLF5 protein.	Cycloheximide	0-13	Kruppel-like factor 5	Mus musculus	124-128
32176291-10	2020	Furthermore, TINCR was demonstrated to inhibit the degradation and ubiquitination of FGF1 in cardiomyocytes using the cycloheximide experiment and the ubiquitination assay.	Cycloheximide	118-131	TINCR ubiquitin domain containing	Rattus norvegicus	13-18
32176291-10	2020	Furthermore, TINCR was demonstrated to inhibit the degradation and ubiquitination of FGF1 in cardiomyocytes using the cycloheximide experiment and the ubiquitination assay.	Cycloheximide	118-131	fibroblast growth factor 1	Rattus norvegicus	85-89
32976921-5	2020	We found that Syt11 is a short-lived protein with a half-life of 1.49 h in the presence of a protein synthesis inhibitor cycloheximide and is mainly degraded by UPP in neurons.	Cycloheximide	121-134	synaptotagmin 11	Homo sapiens	14-19
33240312-5	2020	The expression of miR-296-5p and B-cell leukemia-XL (BCL-XL) was determined using RT-qPCR and Western blot assay in peripheral blood mononuclear cells (PBMCs) of patients with T1DM, tumor necrosis factor-alpha (TNF-alpha)- and cycloheximide (CHX)-induced cell model, and streptozotocin (STZ)-induced rat model.	Cycloheximide	227-240	microRNA 296	Homo sapiens	18-25
33240312-5	2020	The expression of miR-296-5p and B-cell leukemia-XL (BCL-XL) was determined using RT-qPCR and Western blot assay in peripheral blood mononuclear cells (PBMCs) of patients with T1DM, tumor necrosis factor-alpha (TNF-alpha)- and cycloheximide (CHX)-induced cell model, and streptozotocin (STZ)-induced rat model.	Cycloheximide	227-240	BCL2 like 1	Homo sapiens	53-59
33078455-8	2020	Cycloheximide chase assay showed that the increased level of KLF5 by CLU overexpression was due to decreased degradation of KLF5 protein.	Cycloheximide	0-13	Kruppel-like factor 5	Mus musculus	61-65
33204153-9	2020	Cycloheximide chase assay was used to measure the half-life of RUNX2 protein.	Cycloheximide	0-13	RUNX family transcription factor 2	Homo sapiens	63-68
33240312-5	2020	The expression of miR-296-5p and B-cell leukemia-XL (BCL-XL) was determined using RT-qPCR and Western blot assay in peripheral blood mononuclear cells (PBMCs) of patients with T1DM, tumor necrosis factor-alpha (TNF-alpha)- and cycloheximide (CHX)-induced cell model, and streptozotocin (STZ)-induced rat model.	Cycloheximide	242-245	microRNA 296	Homo sapiens	18-25
33240312-5	2020	The expression of miR-296-5p and B-cell leukemia-XL (BCL-XL) was determined using RT-qPCR and Western blot assay in peripheral blood mononuclear cells (PBMCs) of patients with T1DM, tumor necrosis factor-alpha (TNF-alpha)- and cycloheximide (CHX)-induced cell model, and streptozotocin (STZ)-induced rat model.	Cycloheximide	242-245	BCL2 like 1	Homo sapiens	53-59
32814116-7	2020	Like CaVbeta, Srobeta prevents fast degradation of total CaV2.3 proteins in cycloheximide assays.	Cycloheximide	76-89	calcium voltage-gated channel subunit alpha1 E	Homo sapiens	57-63
31905032-7	2020	Thus, the results indicate that CCHFV multiplication imposes an overtly elevated level of LC3 mobilization that involves a possibly novel type of non-canonical lipidation.Abbreviations: BECN1: Beclin 1; CCHF: Crimean-Congo hemorrhagic fever; CCHFV: Crimean-Congo hemorrhagic fever virus; CHX: cycloheximide; ER: endoplasmic reticulum; GFP: green fluorescent protein; GP: glycoproteins; MAP1LC3: microtubule associated protein 1 light chain 3; MOI: multiplicity of infection; n.i.	Cycloheximide	293-306	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	90-93
33036290-4	2020	Klf4 mRNA and protein were rapidly and transiently induced by LH treatment, reaching peak levels after 45 min and declining to basal levels by 3 h. Pretreatment with the protein synthesis inhibitor cycloheximide had no effect on LH-stimulated Klf4 expression, indicating that Klf4 is an immediate early gene in response to LH.	Cycloheximide	198-211	Kruppel like factor 4	Rattus norvegicus	0-4
33162791-5	2020	Quantitative RT-PCR and the cycloheximide (CHX) chase assay resulted in HDAC6 expression is correlated with Pin1 level in H1299 cells.	Cycloheximide	28-41	histone deacetylase 6	Homo sapiens	72-77
32735081-12	2020	A translation inhibitor cycloheximide and small interfering RNA of UPF1 (siRNA-UPF1) increased mRNA or protein expression of TSC1 significantly in cells transfected with the mutant plasmids.	Cycloheximide	24-37	UPF1 RNA helicase and ATPase	Homo sapiens	73-83
32735081-12	2020	A translation inhibitor cycloheximide and small interfering RNA of UPF1 (siRNA-UPF1) increased mRNA or protein expression of TSC1 significantly in cells transfected with the mutant plasmids.	Cycloheximide	24-37	TSC complex subunit 1	Homo sapiens	125-129
32887693-5	2020	In cycloheximide-based protein stability assays, higher protein level of alpha-synuclein was identified in Ubc9-EGFP than in EGFP cells.	Cycloheximide	3-16	synuclein, alpha	Mus musculus	73-88
32887693-5	2020	In cycloheximide-based protein stability assays, higher protein level of alpha-synuclein was identified in Ubc9-EGFP than in EGFP cells.	Cycloheximide	3-16	ubiquitin-conjugating enzyme E2I	Mus musculus	107-111
33162791-5	2020	Quantitative RT-PCR and the cycloheximide (CHX) chase assay resulted in HDAC6 expression is correlated with Pin1 level in H1299 cells.	Cycloheximide	28-41	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	108-112
32757462-5	2020	In the presence of cycloheximide, E2 and G1 treatment counteracted PFKFB3 degradation over time, whereas E2-induced PFKFB3 stabilization was abolished by the GPER antagonist G15.	Cycloheximide	19-32	cystatin 12, pseudogene	Homo sapiens	34-43
32982313-14	2020	Cycloheximide treatment showed that Rab14 downregulated the level of YAP degradation.	Cycloheximide	0-13	RAB14, member RAS oncogene family	Homo sapiens	36-41
32982313-14	2020	Cycloheximide treatment showed that Rab14 downregulated the level of YAP degradation.	Cycloheximide	0-13	Yes1 associated transcriptional regulator	Homo sapiens	69-72
32912211-8	2020	Cycloheximide chase experiments revealed that co-expression of IKK2-EE prolongs the half-life of M22, and constant repression of NF-kappaB signaling by IkappaBalpha-DN strongly reduces protein stability of Tax wildtype suggesting that NF-kappaB activity is required for Tax protein stability.	Cycloheximide	0-13	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	63-67
32912211-8	2020	Cycloheximide chase experiments revealed that co-expression of IKK2-EE prolongs the half-life of M22, and constant repression of NF-kappaB signaling by IkappaBalpha-DN strongly reduces protein stability of Tax wildtype suggesting that NF-kappaB activity is required for Tax protein stability.	Cycloheximide	0-13	nuclear factor kappa B subunit 1	Homo sapiens	129-138
32863938-16	2020	The protein half-life of YAP was analyzed by Cycloheximide assay, and the TEAD activity was detected by Luciferase reporter assays.	Cycloheximide	45-58	yes-associated protein 1	Mus musculus	25-28
32535966-8	2020	The OCT group had a higher percentage of viable cells than the NaOCl and CHX groups (P < 0.05), and induced apoptosis at higher doses.	Cycloheximide	73-76	plexin A2	Homo sapiens	4-7
31659629-8	2020	IL-1-dependent increases in alpha-ENaC protein were mitigated by IL-1ra and cycloheximide.	Cycloheximide	76-89	interleukin 1 complex	Mus musculus	0-4
31659629-8	2020	IL-1-dependent increases in alpha-ENaC protein were mitigated by IL-1ra and cycloheximide.	Cycloheximide	76-89	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	28-38
32573125-3	2020	To validate the predicted splicing impact of a detected STK11 variant, we performed RNA-Seq on mRNA extracted from patient-derived Epstein-Barr virus-transformed lymphocytes treated with cycloheximide to inhibit nonsense-mediated decay ex vivo.	Cycloheximide	187-200	serine/threonine kinase 11	Homo sapiens	56-61
32867821-7	2020	The function of EIF3H on Snail ubiquitination and stability was demonstrated by the cycloheximide (CHX) pulse-chase assay and ubiquitination assay.	Cycloheximide	84-97	eukaryotic translation initiation factor 3 subunit H	Homo sapiens	16-21
32867821-7	2020	The function of EIF3H on Snail ubiquitination and stability was demonstrated by the cycloheximide (CHX) pulse-chase assay and ubiquitination assay.	Cycloheximide	84-97	snail family transcriptional repressor 1	Homo sapiens	25-30
32449268-6	2020	Further research using cycloheximide found that DAPK attenuates the proteasomal degradation of DDX20 protein, which is dependent on the kinase activity of DAPK.	Cycloheximide	23-36	death associated protein kinase 1	Homo sapiens	48-52
32449268-6	2020	Further research using cycloheximide found that DAPK attenuates the proteasomal degradation of DDX20 protein, which is dependent on the kinase activity of DAPK.	Cycloheximide	23-36	DEAD-box helicase 20	Homo sapiens	95-100
32449268-6	2020	Further research using cycloheximide found that DAPK attenuates the proteasomal degradation of DDX20 protein, which is dependent on the kinase activity of DAPK.	Cycloheximide	23-36	death associated protein kinase 1	Homo sapiens	155-159
32360667-5	2020	Here we show that nitric oxide produced by inhibiting protein synthesis (using cycloheximide or anisomycin) is readily coupled to AKT activation in a soluble guanylyl cyclase and cGKII-dependent manner.	Cycloheximide	79-92	thymoma viral proto-oncogene 1	Mus musculus	130-133
32360667-5	2020	Here we show that nitric oxide produced by inhibiting protein synthesis (using cycloheximide or anisomycin) is readily coupled to AKT activation in a soluble guanylyl cyclase and cGKII-dependent manner.	Cycloheximide	79-92	protein kinase, cGMP-dependent, type II	Mus musculus	179-184
32360667-6	2020	Knockdown of cGKII prevents cycloheximide or anisomycin-induced AKT activation and its nuclear accumulation.	Cycloheximide	28-41	protein kinase, cGMP-dependent, type II	Mus musculus	13-18
32360667-8	2020	Indeed, cycloheximide also produces an increase of ERK phosphorylation which is abrogated by a nitric oxide synthase inhibitor.	Cycloheximide	8-21	mitogen-activated protein kinase 1	Mus musculus	51-54
32447485-11	2020	The results of cycloheximide (CHX) and MG-132 assays indicated that SHCBP1 knockdown could attenuate the degradation of TP53 by the proteasome, prolong the half-life of TP53, and enhance the stabilization of TP53.	Cycloheximide	15-28	SHC binding and spindle associated 1	Homo sapiens	68-74
32447485-11	2020	The results of cycloheximide (CHX) and MG-132 assays indicated that SHCBP1 knockdown could attenuate the degradation of TP53 by the proteasome, prolong the half-life of TP53, and enhance the stabilization of TP53.	Cycloheximide	30-33	SHC binding and spindle associated 1	Homo sapiens	68-74
32487733-6	2020	Cycloheximide chase assay revealed that EMD significantly shortened c-Myc half-life by approximately two-fold.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	68-73
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	175-188	WEE1 G2 checkpoint kinase	Homo sapiens	31-35
32668239-2	2020	However, cycloheximide is also known to activate p38 mitogen-activated protein kinase (MAPK), which can delay mitotic entry through a G2/M checkpoint.	Cycloheximide	9-22	mitogen-activated protein kinase 14	Homo sapiens	49-85
32668239-4	2020	We find that p38 inhibitors prevent cycloheximide-treated cells from arresting in G2 phase and that G2 duration is normal in approximately half of these cells.	Cycloheximide	36-49	mitogen-activated protein kinase 14	Homo sapiens	13-16
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	175-188	myelin transcription factor 1	Homo sapiens	36-40
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	74-87	WEE1 G2 checkpoint kinase	Homo sapiens	4-8
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	74-87	WEE1 G2 checkpoint kinase	Homo sapiens	31-35
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	74-87	myelin transcription factor 1	Homo sapiens	36-40
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	74-87	WEE1 G2 checkpoint kinase	Homo sapiens	31-35
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	175-188	WEE1 G2 checkpoint kinase	Homo sapiens	31-35
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	74-87	myelin transcription factor 1	Homo sapiens	158-162
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	175-188	WEE1 G2 checkpoint kinase	Homo sapiens	4-8
32668239-5	2020	The Wee1 inhibitor MK-1775 and Wee1/Myt1 inhibitor PD0166285 also prevent cycloheximide from blocking mitotic entry, raising the possibility that Wee1 and/or Myt1 mediate the cycloheximide-induced G2 arrest.	Cycloheximide	175-188	myelin transcription factor 1	Homo sapiens	158-162
32375946-8	2020	Finally, we observe that ip2-derived IE transcription is cycloheximide-sensitive in reactivating DCs, behaviour consistent with an early gene designation.	Cycloheximide	57-70	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	25-28
32350062-6	2020	Experiments with the protein synthesis inhibitor cycloheximide showed that CYP2A6 protein down-regulation occurs post-translationally.	Cycloheximide	49-62	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	75-81
31945194-5	2020	Treatment with cycloheximide reduced the levels of Zwint-1 while treatment with MG132 to inhibit endogenous ubiquitin-proteasome elevated the levels of Zwint-1 in HEK293T cells or Hela cells.	Cycloheximide	15-28	ZW10 interacting kinetochore protein	Homo sapiens	51-58
31390480-5	2020	Furthermore, the increase in acetylation by LBH589 could inhibit the degradation and improve the accumulation of BmApoLp-III in BmN cells treated with cycloheximide and MG132 respectively.	Cycloheximide	151-164	apolipophorins	Bombyx mori	113-124
32536874-8	2020	Cycloheximide reduced glutamate activated upregulation of NR1 content confirming synthesis of new protein in response to the inflammatory insult.	Cycloheximide	0-13	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	58-61
32134157-12	2020	When the cells were treated with EGF and cycloheximide (CHX), a protein synthesis inhibitor, EGF-reduced CHX-induced CSN6 and PD-L1 turnover in GBM cells.	Cycloheximide	41-54	COP9 signalosome subunit 6	Homo sapiens	117-121
32134157-12	2020	When the cells were treated with EGF and cycloheximide (CHX), a protein synthesis inhibitor, EGF-reduced CHX-induced CSN6 and PD-L1 turnover in GBM cells.	Cycloheximide	41-54	CD274 molecule	Homo sapiens	126-131
32134157-12	2020	When the cells were treated with EGF and cycloheximide (CHX), a protein synthesis inhibitor, EGF-reduced CHX-induced CSN6 and PD-L1 turnover in GBM cells.	Cycloheximide	56-59	COP9 signalosome subunit 6	Homo sapiens	117-121
32134157-12	2020	When the cells were treated with EGF and cycloheximide (CHX), a protein synthesis inhibitor, EGF-reduced CHX-induced CSN6 and PD-L1 turnover in GBM cells.	Cycloheximide	56-59	CD274 molecule	Homo sapiens	126-131
32191993-6	2020	Following treatment with cycloheximide, the IDE protein degradation rate was found to be increased in both FADD-D primary hepatocytes and FADD-knockdown HepG2 cells.	Cycloheximide	25-38	insulin degrading enzyme	Homo sapiens	44-47
32191993-6	2020	Following treatment with cycloheximide, the IDE protein degradation rate was found to be increased in both FADD-D primary hepatocytes and FADD-knockdown HepG2 cells.	Cycloheximide	25-38	Fas associated via death domain	Homo sapiens	107-111
32191993-6	2020	Following treatment with cycloheximide, the IDE protein degradation rate was found to be increased in both FADD-D primary hepatocytes and FADD-knockdown HepG2 cells.	Cycloheximide	25-38	Fas associated via death domain	Homo sapiens	138-142
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	ubiquitin specific peptidase 20	Homo sapiens	26-31
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	protein kinase C zeta	Homo sapiens	67-74
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	receptor interacting serine/threonine kinase 1	Homo sapiens	75-80
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	sequestosome 1	Homo sapiens	81-84
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	tumor necrosis factor	Homo sapiens	106-114
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	nuclear factor kappa B subunit 1	Homo sapiens	124-133
32354117-7	2020	Furthermore, depletion of USP20 disrupts formation of the atypical PKCzeta-RIPK1-p62 complex required for TNFalpha-mediated NF-kappaB activation and significantly increases the apoptosis induced by TNFalpha plus cycloheximide or TNFalpha plus TAK1 inhibitor.	Cycloheximide	212-225	tumor necrosis factor	Homo sapiens	198-206
32440780-9	2020	Furthermore, the interaction between USP7 and Tip60 was identified by IP, Western blot analysis, and cycloheximide (CHX) treatment.	Cycloheximide	101-114	ubiquitin specific peptidase 7	Mus musculus	37-41
32440780-9	2020	Furthermore, the interaction between USP7 and Tip60 was identified by IP, Western blot analysis, and cycloheximide (CHX) treatment.	Cycloheximide	101-114	K(lysine) acetyltransferase 5	Mus musculus	46-51
32440780-9	2020	Furthermore, the interaction between USP7 and Tip60 was identified by IP, Western blot analysis, and cycloheximide (CHX) treatment.	Cycloheximide	116-119	ubiquitin specific peptidase 7	Mus musculus	37-41
32440780-9	2020	Furthermore, the interaction between USP7 and Tip60 was identified by IP, Western blot analysis, and cycloheximide (CHX) treatment.	Cycloheximide	116-119	K(lysine) acetyltransferase 5	Mus musculus	46-51
32126844-5	2020	Interestingly, as we expected, a significant reduction in RHPC absorption (67%) (**p< .01) in presence of cycloheximide (CXI) inhibitor was observed, thus confirming the RHPC could be absorbed by lymphatic transport in vivo.	Cycloheximide	106-119	Rh blood group, D antigen	Rattus norvegicus	58-62
32126844-5	2020	Interestingly, as we expected, a significant reduction in RHPC absorption (67%) (**p< .01) in presence of cycloheximide (CXI) inhibitor was observed, thus confirming the RHPC could be absorbed by lymphatic transport in vivo.	Cycloheximide	106-119	Rh blood group, D antigen	Rattus norvegicus	170-174
32126844-5	2020	Interestingly, as we expected, a significant reduction in RHPC absorption (67%) (**p< .01) in presence of cycloheximide (CXI) inhibitor was observed, thus confirming the RHPC could be absorbed by lymphatic transport in vivo.	Cycloheximide	121-124	Rh blood group, D antigen	Rattus norvegicus	58-62
32126844-5	2020	Interestingly, as we expected, a significant reduction in RHPC absorption (67%) (**p< .01) in presence of cycloheximide (CXI) inhibitor was observed, thus confirming the RHPC could be absorbed by lymphatic transport in vivo.	Cycloheximide	121-124	Rh blood group, D antigen	Rattus norvegicus	170-174
31899052-10	2020	Our results also show that pre-treatment with cycloheximide, an inhibitor of mRNA translation, partially, but not completely, inhibited the expression of TSHR on the cell surfaces of orbital fibroblasts from TAO patients.	Cycloheximide	46-59	thyroid stimulating hormone receptor	Homo sapiens	154-158
32052476-6	2020	Replenishment at the cell surface was slow and sensitive to cycloheximide, suggestive of de novo synthesis of CCR4.	Cycloheximide	60-73	C-C motif chemokine receptor 4	Homo sapiens	110-114
31757931-3	2020	Cycloheximide chase experiments ruled out the possibility that the increased steady-state level of Pdr5 was caused by increased protein stability.	Cycloheximide	0-13	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	99-103
31979093-12	2020	Moreover, PEITC regulated MTDH expression at the post-transcriptional level, which was confirmed using cycloheximide, a protein synthesis inhibitor.	Cycloheximide	103-116	metadherin	Homo sapiens	26-30
31871206-6	2020	A VIG1-deleted mutant shows hypersensitivity to the translation elongation inhibitor cycloheximide, suggesting that VIG1 may have a nonessential role in ribosome function/structure.	Cycloheximide	85-98	uncharacterized protein	Chlamydomonas reinhardtii	2-6
31871206-6	2020	A VIG1-deleted mutant shows hypersensitivity to the translation elongation inhibitor cycloheximide, suggesting that VIG1 may have a nonessential role in ribosome function/structure.	Cycloheximide	85-98	uncharacterized protein	Chlamydomonas reinhardtii	116-120
31668369-4	2020	Western blot analyses of cells treated with cycloheximide (CHX), a protein synthesis inhibitor, showed that SRF was degraded in a time-dependent manner.	Cycloheximide	44-57	serum response factor b	Danio rerio	108-111
31668369-4	2020	Western blot analyses of cells treated with cycloheximide (CHX), a protein synthesis inhibitor, showed that SRF was degraded in a time-dependent manner.	Cycloheximide	59-62	serum response factor b	Danio rerio	108-111
31746366-3	2020	The results demonstrated that NR4A1 was significantly upregulated in TNF-alpha and CHX exposed chondrocytes.	Cycloheximide	83-86	nuclear receptor subfamily 4 group A member 1	Homo sapiens	30-35
32102576-5	2020	NEU3 translation and degradation were assessed by polysome profiling (polysomes efficiently translate mRNAs; monosomes poorly translate mRNAs) and cycloheximide chase after treating cells with or without TGF-beta1 for 48 h.Results: TGF-beta1 increased NEU3 expression and secretion in A549 cells and HSAEpC but did not change total (nuclear + cytosolic) NEU3 mRNA levels.	Cycloheximide	147-160	neuraminidase 3	Homo sapiens	0-4
33268710-8	2020	Co-treatment with nAg10 and cycloheximide, which inhibits translation by inhibiting the translocation step of protein synthesis, decreased the level of Dnmt1 in comparison with nAg10-treated A549 cells, indicating a post-translational effect of nAg10.	Cycloheximide	28-41	DNA methyltransferase 1	Homo sapiens	152-157
31746366-2	2020	The present study aimed to investigate the role of NR4A1 in regulating chondrocyte death in response to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide (CHX) treatment, with a focus on mitochondrial fission and the AMP-activated protein kinase (AMPK) signaling pathway.	Cycloheximide	148-161	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
31746366-2	2020	The present study aimed to investigate the role of NR4A1 in regulating chondrocyte death in response to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide (CHX) treatment, with a focus on mitochondrial fission and the AMP-activated protein kinase (AMPK) signaling pathway.	Cycloheximide	163-166	nuclear receptor subfamily 4 group A member 1	Homo sapiens	51-56
31746366-6	2020	Inhibiting NR4A1 attenuated TNF-alpha and CHX-induced mitochondrial fission and, thus, reduced mitochondrial dysfunction in chondrocytes, mPTP opening-related cell death and migration injury.	Cycloheximide	42-45	nuclear receptor subfamily 4 group A member 1	Homo sapiens	11-16
31847118-9	2019	Exposure of hCECs to cycloheximide revealed an increased stability of NFIB that likely resulted from post-translational glycosylation of this protein when these cells were co-cultured with i3T3.	Cycloheximide	21-34	nuclear factor I B	Homo sapiens	70-74
31736940-5	2019	Pre-incubation of neutrophils with translational inhibitors (cycloheximide or puromycin) markedly decreased NET formation induced by PMA or MIP-2.	Cycloheximide	61-74	C-X-C motif chemokine ligand 2	Homo sapiens	140-145
30929966-18	2019	In the presence of cycloheximide, MARCKS knockdown in VSMCs decreased KIS protein stability but had no effect in ECs.	Cycloheximide	19-32	myristoylated alanine rich protein kinase C substrate	Homo sapiens	34-40
31849607-9	2019	Lastly, we used cycloheximide treatment in the brain to demonstrate that rapid protein translation within 30 min of opioid treatment is required for Hsp90 regulation of opioid response.	Cycloheximide	16-29	heat shock protein, 3	Mus musculus	149-154
31601649-7	2019	Utilizing cycloheximide treatment, we showed that TIP60 catalytic activity is required for stabilization of DeltaNp63alpha protein levels.	Cycloheximide	10-23	lysine acetyltransferase 5	Homo sapiens	50-55
31694585-14	2019	In addition, a cycloheximide chase experiment showed that PRMT5 post-translationally regulated MYC stability.	Cycloheximide	15-28	protein arginine methyltransferase 5	Homo sapiens	58-63
31694585-14	2019	In addition, a cycloheximide chase experiment showed that PRMT5 post-translationally regulated MYC stability.	Cycloheximide	15-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	95-98
31704709-8	2019	Simultaneously, TRAIL-induced de novo translation in resistant cells, when blocked by cycloheximide, abrogated all TRAIL resistance.	Cycloheximide	86-99	TNF superfamily member 10	Homo sapiens	16-21
31704709-8	2019	Simultaneously, TRAIL-induced de novo translation in resistant cells, when blocked by cycloheximide, abrogated all TRAIL resistance.	Cycloheximide	86-99	TNF superfamily member 10	Homo sapiens	115-120
31291699-4	2019	Treatment with cycloheximide and MG132 indicated that endogenous CREB3 is a proteasome substrate.	Cycloheximide	15-28	cAMP responsive element binding protein 3	Homo sapiens	65-70
31491427-7	2019	Cycloheximide chase experiments revealed that mature SLC4A11 showed high degradation stability; however, degradation of immature SLC4A11-B was significantly faster than that of immature SLC4A11-C.	Cycloheximide	0-13	solute carrier family 4 member 11	Homo sapiens	53-60
31591384-4	2019	ICF-induced osterix (OSX) expression was inhibited by cycloheximide and monensin.	Cycloheximide	54-67	Sp7 transcription factor	Homo sapiens	12-19
31176714-7	2019	Therefore, to address this problem, we have used cycloheximide, an inhibitor of translation, and our results clearly indicate that an additional, newly synthesized protein is involved in AhR-dependent induction of SERPINB2 expression by BNF.	Cycloheximide	49-62	aryl hydrocarbon receptor	Homo sapiens	187-190
31325559-5	2019	However, when melatonin was administered along with protein synthesis inhibitor cycloheximide, protein level of Nedd4-1 was further reduced, indicating that melatonin possibly downregulates Nedd4-1 after its synthesis.	Cycloheximide	80-93	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	112-119
31325559-5	2019	However, when melatonin was administered along with protein synthesis inhibitor cycloheximide, protein level of Nedd4-1 was further reduced, indicating that melatonin possibly downregulates Nedd4-1 after its synthesis.	Cycloheximide	80-93	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	190-197
31656861-4	2019	We also compared the stability of wild-type and mutant PAWS1 in cycloheximide-treated cells.	Cycloheximide	64-77	family with sequence similarity 83 member G	Homo sapiens	55-60
31176714-7	2019	Therefore, to address this problem, we have used cycloheximide, an inhibitor of translation, and our results clearly indicate that an additional, newly synthesized protein is involved in AhR-dependent induction of SERPINB2 expression by BNF.	Cycloheximide	49-62	serpin family B member 2	Homo sapiens	214-222
31354696-7	2019	STAT1 protein degradation was studied using cycloheximide.	Cycloheximide	44-57	signal transducer and activator of transcription 1	Homo sapiens	0-5
31383001-12	2019	The stability of Twist1 was determined after blocking protein synthesis with cycloheximide.	Cycloheximide	77-90	twist basic helix-loop-helix transcription factor 1	Mus musculus	17-23
30597534-5	2019	METHODS: The half-life of wild-type (WT) MVK protein and mutants was assessed using cycloheximide treatment of cells.	Cycloheximide	84-97	mevalonate kinase	Homo sapiens	41-44
31050353-6	2019	We found that UBP12/UBP13 can deubiquitinate polyubiquitinated ORE1 in vitro and increase the stability of ORE1 in vivo in MG132/cycloheximide-chase experiments.	Cycloheximide	129-142	ubiquitin-specific protease 12	Arabidopsis thaliana	14-19
31050353-6	2019	We found that UBP12/UBP13 can deubiquitinate polyubiquitinated ORE1 in vitro and increase the stability of ORE1 in vivo in MG132/cycloheximide-chase experiments.	Cycloheximide	129-142	ubiquitin-specific protease 13	Arabidopsis thaliana	20-25
31050353-6	2019	We found that UBP12/UBP13 can deubiquitinate polyubiquitinated ORE1 in vitro and increase the stability of ORE1 in vivo in MG132/cycloheximide-chase experiments.	Cycloheximide	129-142	NAC domain containing protein 6	Arabidopsis thaliana	107-111
31142735-5	2019	By co-treating cells with cycloheximide and MG-132, we proved that CANA promoted proteasomal degradation of beta-catenin protein by increasing phosphorylation of beta-catenin, and CANA-induced inactivation of protein phosphatase 2A was identified being responsible for this effect.	Cycloheximide	26-39	catenin beta 1	Homo sapiens	108-120
31308754-9	2019	Next, PCR, lectin precipitation and cycloheximide (CHX) were used to demonstrate the mechanism of ST6GAL1 on ICAM-1.	Cycloheximide	36-49	beta galactoside alpha 2,6 sialyltransferase 1	Mus musculus	98-105
31308754-9	2019	Next, PCR, lectin precipitation and cycloheximide (CHX) were used to demonstrate the mechanism of ST6GAL1 on ICAM-1.	Cycloheximide	51-54	beta galactoside alpha 2,6 sialyltransferase 1	Mus musculus	98-105
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	162-175	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	123-127
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	162-175	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	129-135
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	162-175	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	136-139
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	177-180	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	123-127
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	177-180	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	129-135
31171704-4	2019	These analyses surprisingly revealed that translation of multiple non-AUG-encoded reporters and the endogenous GUG-encoded DAP5 (eIF4G2/p97) mRNA is resistant to cycloheximide (CHX), a translation inhibitor that severely slows but does not completely abrogate elongation.	Cycloheximide	177-180	eukaryotic translation initiation factor 4 gamma 2	Homo sapiens	136-139
30870658-8	2019	Further, translational inhibitor cycloheximide prevents LPS-induced NF-kappaB activation indicating functional importance of de novo synthesis of SOCS3, at least in part, in toll-like receptor 4 (TLR4)-mediated inflammatory response.	Cycloheximide	33-46	suppressor of cytokine signaling 3	Rattus norvegicus	146-151
30870658-8	2019	Further, translational inhibitor cycloheximide prevents LPS-induced NF-kappaB activation indicating functional importance of de novo synthesis of SOCS3, at least in part, in toll-like receptor 4 (TLR4)-mediated inflammatory response.	Cycloheximide	33-46	toll-like receptor 4	Rattus norvegicus	174-194
30870658-8	2019	Further, translational inhibitor cycloheximide prevents LPS-induced NF-kappaB activation indicating functional importance of de novo synthesis of SOCS3, at least in part, in toll-like receptor 4 (TLR4)-mediated inflammatory response.	Cycloheximide	33-46	toll-like receptor 4	Rattus norvegicus	196-200
30745574-6	2019	Moreover, cycloheximide treatment of MSS31 cells revealed that the rate of S100A4 degradation was accelerated by MTA1 knockdown.	Cycloheximide	10-23	S100 calcium binding protein A4	Mus musculus	75-81
31230721-8	2019	We established a fibroblast line of one mutation carrier, and we demonstrated that reduced mRNA levels of TAOK1 could be increased upon cycloheximide treatment.	Cycloheximide	136-149	TAO kinase 1	Homo sapiens	106-111
30606669-7	2019	Furthermore, co-treatment with CX and NF-kappaB siRNA accelerated the death of apoptotic cells through the decrease of P-gp protein levels.	Cycloheximide	31-33	phosphoglycolate phosphatase	Homo sapiens	119-123
30745574-6	2019	Moreover, cycloheximide treatment of MSS31 cells revealed that the rate of S100A4 degradation was accelerated by MTA1 knockdown.	Cycloheximide	10-23	metastasis associated 1	Mus musculus	113-117
31142735-5	2019	By co-treating cells with cycloheximide and MG-132, we proved that CANA promoted proteasomal degradation of beta-catenin protein by increasing phosphorylation of beta-catenin, and CANA-induced inactivation of protein phosphatase 2A was identified being responsible for this effect.	Cycloheximide	26-39	catenin beta 1	Homo sapiens	162-174
30885946-5	2019	Additionally, the rate of Tat protein degradation as measured by cycloheximide (CHX) chase assay was increased in the presence of CHIP.	Cycloheximide	65-78	tyrosine aminotransferase	Homo sapiens	26-29
31073117-5	2019	Ucn treatment led to rapid phosphorylation of JAK2, which was blocked by the protein synthesis inhibitor cycloheximide or the JAK inhibitor AG490.	Cycloheximide	105-118	urocortin	Mus musculus	0-3
31073117-5	2019	Ucn treatment led to rapid phosphorylation of JAK2, which was blocked by the protein synthesis inhibitor cycloheximide or the JAK inhibitor AG490.	Cycloheximide	105-118	Janus kinase 2	Mus musculus	46-50
31120998-6	2019	Activation of exogenous HoxA9-ER in 32Dcl3 cells reduces Cebpa mRNA even in the presence of cycloheximide, suggesting direct repression.	Cycloheximide	92-105	homeobox A9	Mus musculus	24-29
31117253-10	2019	We further performed the cycloheximide experiment and found that the half-life of Mcl-1 was significantly shortened by RT treatment.	Cycloheximide	25-38	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	82-87
30885946-5	2019	Additionally, the rate of Tat protein degradation as measured by cycloheximide (CHX) chase assay was increased in the presence of CHIP.	Cycloheximide	80-83	tyrosine aminotransferase	Homo sapiens	26-29
31015482-7	2019	Moreover, by using real time qRT-PCR, Cycloheximide chase, luciferase reporter, cell viability and soft agar assays, we have shown that Pin1 increases the tumorigenic and drug-resistant activity of YAP/TAZ through stabilization of YAP/TAZ at protein levels.	Cycloheximide	38-51	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	136-140
30226276-9	2019	The cycloheximide chase assay revealed that RASSF1A expression leads to p53 stabilization and MDM2 homolog degradation.	Cycloheximide	4-17	Ras association domain family member 1	Homo sapiens	44-51
30826064-6	2019	Meanwhile, a cycloheximide chase assay determined that the degradation rates of Magoh L136R and Y14 L118R were faster than their wild-types.	Cycloheximide	13-26	mago homolog, exon junction complex subunit	Homo sapiens	80-85
30902881-6	2019	Importantly, the loss of cIAP1 enhanced TNF-alpha/cycloheximide-induced apoptosis in higher activation statuses of Caspase-8, Caspase-3 without the induction of Complex II.	Cycloheximide	50-63	baculoviral IAP repeat containing 2	Homo sapiens	25-30
30902881-6	2019	Importantly, the loss of cIAP1 enhanced TNF-alpha/cycloheximide-induced apoptosis in higher activation statuses of Caspase-8, Caspase-3 without the induction of Complex II.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	40-49
30902881-6	2019	Importantly, the loss of cIAP1 enhanced TNF-alpha/cycloheximide-induced apoptosis in higher activation statuses of Caspase-8, Caspase-3 without the induction of Complex II.	Cycloheximide	50-63	caspase 8	Homo sapiens	115-124
30902881-6	2019	Importantly, the loss of cIAP1 enhanced TNF-alpha/cycloheximide-induced apoptosis in higher activation statuses of Caspase-8, Caspase-3 without the induction of Complex II.	Cycloheximide	50-63	caspase 3	Homo sapiens	126-135
30908907-5	2019	Finally, we perform a comprehensive mutational analysis of the essential gene RPL28 in budding yeast, mapping sequence constraints on its wild-type function and delineating the binding site of the drug cycloheximide through resistance mutations.	Cycloheximide	202-215	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	78-83
30826064-6	2019	Meanwhile, a cycloheximide chase assay determined that the degradation rates of Magoh L136R and Y14 L118R were faster than their wild-types.	Cycloheximide	13-26	RNA binding motif protein 8A	Homo sapiens	96-99
30781396-7	2019	When protein synthesis was inhibited with cycloheximide (CHX), fisetin prolonged the half-life of Nrf2 from 15 min to 45 min.	Cycloheximide	57-60	NFE2 like bZIP transcription factor 2	Homo sapiens	98-102
30972179-7	2019	Cycloheximide chase analysis, target gene promoter reporter assay and fluorescent staining indicated that NEDD4 plays a critical role in promoting the stability and transcriptional activity of KLF8 in the nucleus.	Cycloheximide	0-13	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	106-111
30972179-7	2019	Cycloheximide chase analysis, target gene promoter reporter assay and fluorescent staining indicated that NEDD4 plays a critical role in promoting the stability and transcriptional activity of KLF8 in the nucleus.	Cycloheximide	0-13	Kruppel like factor 8	Homo sapiens	193-197
30348988-7	2019	Cycloheximide chase and proteasome inhibition experiments revealed that SPP-mediated proteolysis facilitated FKBP8 protein degradation in cytosol.	Cycloheximide	0-13	histocompatibility minor 13	Homo sapiens	72-75
30348988-7	2019	Cycloheximide chase and proteasome inhibition experiments revealed that SPP-mediated proteolysis facilitated FKBP8 protein degradation in cytosol.	Cycloheximide	0-13	FKBP prolyl isomerase 8	Homo sapiens	109-114
30414623-9	2019	In rat granulosa cell cultures, upregulation of Hmga1 was dependent on new protein synthesis because Hmga1 was inhibited by cycloheximide.	Cycloheximide	124-137	high mobility group AT-hook 1	Rattus norvegicus	48-53
30414623-9	2019	In rat granulosa cell cultures, upregulation of Hmga1 was dependent on new protein synthesis because Hmga1 was inhibited by cycloheximide.	Cycloheximide	124-137	high mobility group AT-hook 1	Rattus norvegicus	101-106
30540927-3	2019	The present study demonstrates that cycloheximide or anisomycin applications reduce amplitudes of the field excitatory postsynaptic potentials as well as the presynaptically mediated form of plasticity, the paired-pulse facilitation after LTP induction in neurons of the CA1 area of hippocampus.	Cycloheximide	36-49	carbonic anhydrase 1	Homo sapiens	271-274
30911584-4	2019	The level of CPT1C mutant transcript significantly decreased compared to that of wild-type transcript, and can be recovered after cycloheximide administration, which indicated that nonsense-mediated mRNA decay was a mechanism that might be responsible for the phenotype.	Cycloheximide	130-143	carnitine palmitoyltransferase 1C	Homo sapiens	13-18
30620162-9	2019	Also, addition of CHX to mTAP and Ca(OH)2 increased their cytotoxicity.	Cycloheximide	18-21	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	25-29
30675298-8	2019	The half-life of OVCA1, measured by inhibiting protein synthesis with cycloheximide, was &lt;2 h. The present study demonstrated that OVCA1 may be degraded by the ubiquitin-mediated proteasome pathway and may be considered a short half-life protein.	Cycloheximide	70-83	diphthamide biosynthesis 1	Homo sapiens	17-22
30675298-8	2019	The half-life of OVCA1, measured by inhibiting protein synthesis with cycloheximide, was &lt;2 h. The present study demonstrated that OVCA1 may be degraded by the ubiquitin-mediated proteasome pathway and may be considered a short half-life protein.	Cycloheximide	70-83	diphthamide biosynthesis 1	Homo sapiens	134-139
30566394-5	2019	Apoptosis was induced by addition of tumor necrosis factor-alpha to cycloheximide-sensitized endothelial cells.	Cycloheximide	68-81	tumor necrosis factor	Homo sapiens	37-64
30566394-7	2019	Our results reveal that proteins of healthy basement membrane alleviate cytokine-induced apoptosis whereas precoating with collagen type I had no significant effect on apoptosis by addition of tumor necrosis factor-alpha to cycloheximide-sensitized endothelial cells compared with cells cultured on uncoated plates.	Cycloheximide	224-237	tumor necrosis factor	Homo sapiens	193-220
30641474-6	2019	The upregulation of pRb was blocked by pre-treatment with cycloheximide, a protein synthesis inhibitor, suggesting a requirement of protein synthesis.	Cycloheximide	58-71	RB transcriptional corepressor 1	Homo sapiens	20-23
30626422-14	2019	We further demonstrated, using cycloheximide chase assay, that IGFBP2 promotes EGFR protein stability in response to ABS exposure.	Cycloheximide	31-44	insulin like growth factor binding protein 2	Homo sapiens	63-69
30560896-6	2018	Moreover, heat stress or cycloheximide trigger degradation of Hxt3-GFP and other surface transporter proteins (Itr1, Aqr1) by this ESCRT-independent process.	Cycloheximide	25-38	hexose transporter HXT3	Saccharomyces cerevisiae S288C	62-66
30974966-11	2019	Concomitant treatment with the translation inhibitor cycloheximide (CHX) exerted additional effects on Cx43 degradation.	Cycloheximide	53-66	gap junction protein alpha 1	Homo sapiens	103-107
30974966-11	2019	Concomitant treatment with the translation inhibitor cycloheximide (CHX) exerted additional effects on Cx43 degradation.	Cycloheximide	68-71	gap junction protein alpha 1	Homo sapiens	103-107
31608791-6	2019	Rescue of cycloheximide-mediated inhibition showed that ANP32A is species-specific for modulation of vRNA but not mRNA and cRNA, demonstrating chANP32A-X1 compensated for defective cRNPs produced by PB2 627E virus in mammalian cells.	Cycloheximide	10-23	acidic nuclear phosphoprotein 32 family member A	Homo sapiens	56-62
30922135-10	2019	RESULTS: The activity of heat-inactivated DNA-PK recovered to about 50% of control during an additional incubation at 37  C after heat treatment at 44  C for 15 min in the presence of cycloheximide (which inhibits de novo protein synthesis).	Cycloheximide	184-197	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	42-48
30403549-5	2019	In cycloheximide chase assays, PIAS4 slowed immature F508del degradation threefold and stabilized mature WT CFTR at the plasma membrance.	Cycloheximide	3-16	protein inhibitor of activated STAT 4	Homo sapiens	31-36
30809294-3	2019	Cycloheximide chase assays and deubiquitination assays confirmed that the effect of USP5 on the deubiquitin of SLUG.	Cycloheximide	0-13	ubiquitin specific peptidase 5 (isopeptidase T)	Mus musculus	84-88
30809294-3	2019	Cycloheximide chase assays and deubiquitination assays confirmed that the effect of USP5 on the deubiquitin of SLUG.	Cycloheximide	0-13	snail family zinc finger 2	Mus musculus	111-115
30560896-6	2018	Moreover, heat stress or cycloheximide trigger degradation of Hxt3-GFP and other surface transporter proteins (Itr1, Aqr1) by this ESCRT-independent process.	Cycloheximide	25-38	myo-inositol transporter ITR1	Saccharomyces cerevisiae S288C	111-115
30560896-6	2018	Moreover, heat stress or cycloheximide trigger degradation of Hxt3-GFP and other surface transporter proteins (Itr1, Aqr1) by this ESCRT-independent process.	Cycloheximide	25-38	Aqr1p	Saccharomyces cerevisiae S288C	117-121
31044179-5	2019	Pretreatment with dexamethasone reduced the susceptibility of osteocytes to oxidative stress-induced cell death and conferred protection against TNFalpha/cycloheximide-induced cell death.	Cycloheximide	154-167	tumor necrosis factor	Mus musculus	145-153
30359318-9	2018	Following pretreatment with protein synthesis inhibitor cycloheximide, we found that IL-1beta induced CXCR3 on the surface of MSCs via protein synthesis pathway.	Cycloheximide	56-69	interleukin 1 beta	Homo sapiens	85-93
30226440-5	2018	METHODS: The phenotypic effects of MLN8237 in thyroid cancer cells were evaluated through a series of in vitro and in vivo experiments, and the mechanism of c-Myc affecting MLN8237 response were explored using Western blot, ubiquitination, and cycloheximide chase assays.	Cycloheximide	244-257	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	157-162
30388770-6	2018	We also monitored the degradation kinetics of alpha-syn by using cycloheximide to block protein synthesis.	Cycloheximide	65-78	synuclein alpha	Rattus norvegicus	46-55
30448058-8	2018	Cycloheximide chase analysis revealed that KATNAL1 is more stable in cells.	Cycloheximide	0-13	katanin p60 subunit A-like 1	Mus musculus	43-50
30442142-5	2018	We later clarified the effect of metformin on p53 protein stability using transient transfection and cycloheximide chase analyses.	Cycloheximide	101-114	tumor protein p53	Homo sapiens	46-49
30359318-9	2018	Following pretreatment with protein synthesis inhibitor cycloheximide, we found that IL-1beta induced CXCR3 on the surface of MSCs via protein synthesis pathway.	Cycloheximide	56-69	C-X-C motif chemokine receptor 3	Homo sapiens	102-107
29665004-5	2018	Combined treatment of thiostrepton and cycloheximide/chloroquine prevented the degradation of mutant p53 protein, reinforcing autophagy as the means of mutant p53 destabilization.	Cycloheximide	39-52	tumor protein p53	Homo sapiens	101-104
29665004-5	2018	Combined treatment of thiostrepton and cycloheximide/chloroquine prevented the degradation of mutant p53 protein, reinforcing autophagy as the means of mutant p53 destabilization.	Cycloheximide	39-52	tumor protein p53	Homo sapiens	159-162
30180865-7	2018	Half-life of NOXA protein was determined by cycloheximide treatment and subsequent Western blot analysis.	Cycloheximide	44-57	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	13-17
29471895-9	2018	By using cycloheximide to block new protein translation, we found that 17-AAG accelerated the decay of ETV6/FLT3.	Cycloheximide	9-22	FMS-like tyrosine kinase 3	Mus musculus	108-112
30460108-9	2018	To validate the induction of NCL and Hsp70 expression in response to rotenone, cycloheximide (CHX), a protein synthesis blocker, was administered with rotenone.	Cycloheximide	79-92	nucleolin	Mus musculus	29-32
30460108-9	2018	To validate the induction of NCL and Hsp70 expression in response to rotenone, cycloheximide (CHX), a protein synthesis blocker, was administered with rotenone.	Cycloheximide	79-92	heat shock protein 1B	Mus musculus	37-42
30460108-9	2018	To validate the induction of NCL and Hsp70 expression in response to rotenone, cycloheximide (CHX), a protein synthesis blocker, was administered with rotenone.	Cycloheximide	94-97	nucleolin	Mus musculus	29-32
30460108-9	2018	To validate the induction of NCL and Hsp70 expression in response to rotenone, cycloheximide (CHX), a protein synthesis blocker, was administered with rotenone.	Cycloheximide	94-97	heat shock protein 1B	Mus musculus	37-42
29702146-8	2018	Both TTP and HuR transcripts were sensitive to modulation by anisomycin and cycloheximide.	Cycloheximide	76-89	ZFP36 ring finger protein	Homo sapiens	5-8
29702146-8	2018	Both TTP and HuR transcripts were sensitive to modulation by anisomycin and cycloheximide.	Cycloheximide	76-89	ELAV like RNA binding protein 1	Homo sapiens	13-16
30030326-9	2018	At the same time, sumoylation protected MYB30 from degradation under cycloheximide and ABA treatment.	Cycloheximide	69-82	myb domain protein 30	Arabidopsis thaliana	40-45
30344270-4	2018	Materials and Methods: By blocking protein synthesis with cycloheximide (CHX), the effect of triptolide on AR protein stability was investigated with western blot assay.	Cycloheximide	73-76	androgen receptor	Homo sapiens	107-109
30068990-10	2018	Pri-miR-21 expression was also inhibited by the protein synthesis inhibitor cycloheximide, suggesting that a protein ligand or signaling cofactor synthesized during maturation is necessary for transcription.	Cycloheximide	76-89	microRNA 21	Bos taurus	4-10
29674275-9	2018	Cycloheximide-treated CDK16-silenced NSCLC cells displayed a much milder reduction in p27 protein expression over time relative to untreated CDK16-silenced NSCLC cells.	Cycloheximide	0-13	cyclin dependent kinase 16	Homo sapiens	22-27
29674275-9	2018	Cycloheximide-treated CDK16-silenced NSCLC cells displayed a much milder reduction in p27 protein expression over time relative to untreated CDK16-silenced NSCLC cells.	Cycloheximide	0-13	zinc ribbon domain containing 2	Homo sapiens	86-89
30130531-5	2018	Oppositely, mec1-4 confers resistance to cycloheximide, a translation inhibitor.	Cycloheximide	41-54	protein kinase MEC1	Saccharomyces cerevisiae S288C	12-16
29684855-6	2018	In HCC cells treated by cycloheximide (CHX, the translation inhibitor), radiation significantly increased the half-life of Snail protein, which suggested that radiation increased the expression of Snail via up regulation of its protein stability.	Cycloheximide	24-37	snail family transcriptional repressor 1	Homo sapiens	123-128
29684855-6	2018	In HCC cells treated by cycloheximide (CHX, the translation inhibitor), radiation significantly increased the half-life of Snail protein, which suggested that radiation increased the expression of Snail via up regulation of its protein stability.	Cycloheximide	24-37	snail family transcriptional repressor 1	Homo sapiens	197-202
29684855-6	2018	In HCC cells treated by cycloheximide (CHX, the translation inhibitor), radiation significantly increased the half-life of Snail protein, which suggested that radiation increased the expression of Snail via up regulation of its protein stability.	Cycloheximide	39-42	snail family transcriptional repressor 1	Homo sapiens	123-128
29684855-6	2018	In HCC cells treated by cycloheximide (CHX, the translation inhibitor), radiation significantly increased the half-life of Snail protein, which suggested that radiation increased the expression of Snail via up regulation of its protein stability.	Cycloheximide	39-42	snail family transcriptional repressor 1	Homo sapiens	197-202
30109997-3	2018	The recombinant plasmids were then transfected into HEK293 cells respectively followed by cycloheximide (CHX) treatment for 0, 2, 4 and 8 h. The protein expressions of ANXA11 wild type, ANXA11 G38R and ANXA11 D40G mutations were determined by Western blot.	Cycloheximide	105-108	annexin A11	Homo sapiens	168-174
29671171-3	2018	Cycloheximide (CHX)-chase half-life assays have been used to show that O-GlcNAcylation increases the stability and response of both wild type and Crohn"s variant Nod2, R702W.	Cycloheximide	0-13	nucleotide binding oligomerization domain containing 2	Homo sapiens	162-166
29671171-3	2018	Cycloheximide (CHX)-chase half-life assays have been used to show that O-GlcNAcylation increases the stability and response of both wild type and Crohn"s variant Nod2, R702W.	Cycloheximide	15-18	nucleotide binding oligomerization domain containing 2	Homo sapiens	162-166
29522752-8	2018	Through the use of a dual luciferase reporter assay system and incubation with cycloheximide (CHX) MG132 and actidione (ActD), we found that DDX5 promoted MSR1 protein expression by stabilizing MSR1 mRNA.	Cycloheximide	79-92	DEAD-box helicase 5	Homo sapiens	141-145
29522752-8	2018	Through the use of a dual luciferase reporter assay system and incubation with cycloheximide (CHX) MG132 and actidione (ActD), we found that DDX5 promoted MSR1 protein expression by stabilizing MSR1 mRNA.	Cycloheximide	94-97	DEAD-box helicase 5	Homo sapiens	141-145
28770700-4	2018	In the mouse hepatocyte cell line, TIB-73 cells, TNF-alpha/cycloheximide (T/C) induced RIP1/3 binding only when caspase activity was suppressed by the caspase-specific inhibitor z-VAD-fmk (zVAD).	Cycloheximide	59-72	tumor necrosis factor	Mus musculus	49-58
29522752-8	2018	Through the use of a dual luciferase reporter assay system and incubation with cycloheximide (CHX) MG132 and actidione (ActD), we found that DDX5 promoted MSR1 protein expression by stabilizing MSR1 mRNA.	Cycloheximide	109-118	DEAD-box helicase 5	Homo sapiens	141-145
29514933-12	2018	Moreover, Bul1 is in charge of Jen1 endocytosis after cycloheximide treatment, suggesting that the functional redundancy of ARTs may be explained by their ability to interact with multiple cargoes in various conditions.	Cycloheximide	54-67	ubiquitin-ubiquitin ligase BUL1	Saccharomyces cerevisiae S288C	10-14
29514933-12	2018	Moreover, Bul1 is in charge of Jen1 endocytosis after cycloheximide treatment, suggesting that the functional redundancy of ARTs may be explained by their ability to interact with multiple cargoes in various conditions.	Cycloheximide	54-67	Jen1p	Saccharomyces cerevisiae S288C	31-35
28770700-4	2018	In the mouse hepatocyte cell line, TIB-73 cells, TNF-alpha/cycloheximide (T/C) induced RIP1/3 binding only when caspase activity was suppressed by the caspase-specific inhibitor z-VAD-fmk (zVAD).	Cycloheximide	59-72	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	87-91
29331413-6	2018	Moreover, the radiation sensitivity conferred by miR-449 b could be blunted by cycloheximide, an inhibitor of protein synthesis, or by direct delivery of ATP liposome, supporting eEF-2 kinase as a mediator of the radio-sensitizing effects of miR-449 b.	Cycloheximide	79-92	microRNA 449b	Homo sapiens	49-58
29131527-0	2018	3D matrix-embedding inhibits cycloheximide-mediated sensitization to TNF-alpha-induced apoptosis of human endothelial cells.	Cycloheximide	29-42	tumor necrosis factor	Homo sapiens	69-78
29558889-7	2018	Functional characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).	Cycloheximide	46-59	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	31-36
29558889-7	2018	Functional characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).	Cycloheximide	46-59	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	92-97
29558889-7	2018	Functional characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).	Cycloheximide	46-59	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	92-97
29558889-7	2018	Functional characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).	Cycloheximide	46-59	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	92-97
29558889-7	2018	Functional characterization of NAA10-V111G by cycloheximide chase experiments suggests that NAA10-V111G has a reduced stability compared to NAA10-WT, and in vitro acetylation assays revealed a reduced enzymatic activity of monomeric NAA10-V111G but not for NAA10-V111G in complex with NAA15 (NatA enzymatic activity).	Cycloheximide	46-59	N-alpha-acetyltransferase 10, NatA catalytic subunit	Homo sapiens	92-97
29254988-8	2018	Cycloheximide (protein synthesis inhibitor) blocked E2-induced TGFB1 synthesis providing evidence for de novo synthesis.	Cycloheximide	0-13	transforming growth factor beta 1	Bos taurus	63-68
29534438-7	2018	Moreover, the inhibition of de novo protein synthesis by cycloheximide reduced TXNIP half-life in 24 h, but not in 96 h-1,25(OH)2D3-treated HL-60 cells, demonstrating a possible influence of 1,25(OH)2D3 on TXNIP stability in long-term treatment.	Cycloheximide	57-70	thioredoxin interacting protein	Homo sapiens	79-84
29534438-7	2018	Moreover, the inhibition of de novo protein synthesis by cycloheximide reduced TXNIP half-life in 24 h, but not in 96 h-1,25(OH)2D3-treated HL-60 cells, demonstrating a possible influence of 1,25(OH)2D3 on TXNIP stability in long-term treatment.	Cycloheximide	57-70	thioredoxin interacting protein	Homo sapiens	206-211
29568272-8	2018	In consequence, protein turnover of WT-TRPM4 and TRPM4 variants overexpressed in HEK293 cells was analyzed using cycloheximide, an inhibitor of protein biosynthesis.	Cycloheximide	113-126	transient receptor potential cation channel subfamily M member 4	Homo sapiens	49-54
29568272-9	2018	Upon addition of cycloheximide, WT-TRPM4 decayed with a half-life of ~20 h, while loss-of-expression variants showed a ~30% increase in degradation rate, with a half-life close to 12 h. Together, the gain-of-expression variant showed a higher stability and a doubled half-life compared to WT-TRPM4.	Cycloheximide	17-30	transient receptor potential cation channel subfamily M member 4	Homo sapiens	35-40
29568272-9	2018	Upon addition of cycloheximide, WT-TRPM4 decayed with a half-life of ~20 h, while loss-of-expression variants showed a ~30% increase in degradation rate, with a half-life close to 12 h. Together, the gain-of-expression variant showed a higher stability and a doubled half-life compared to WT-TRPM4.	Cycloheximide	17-30	transient receptor potential cation channel subfamily M member 4	Homo sapiens	292-297
29590644-5	2018	The transcriptional activity of GATA4 was measured in the presence or absence of cycloheximide.	Cycloheximide	81-94	GATA binding protein 4	Homo sapiens	32-37
29164633-11	2018	Immunoblotting assays indicated that Cap promoted a degradation of AR proteins dose-dependently in either cycloheximide pretreated-LNCaP cells or AR-ectopic expressed PC-3 cells.	Cycloheximide	106-119	androgen receptor	Homo sapiens	67-69
29467593-8	2018	Caspase activation was assessed by MTT and PI after treatments with Z-VAD [OME]-FMK, mitomycin c and cycloheximide.	Cycloheximide	101-114	caspase 8	Homo sapiens	0-7
29467593-14	2018	Subsequent activation of caspase-8 after co-incubation of mitomycin c and cycloheximide separately, restored the cell viability in cholesterol depleted MDA-MB 231 cells.	Cycloheximide	74-87	caspase 8	Homo sapiens	25-34
29196261-5	2018	Experiments using cycloheximide, MG132 and bafilomycin A1 have revealed that Sox9 is degraded through the ubiquitin-proteasome pathway and that A-674563 inhibits this degradation, resulting in larger amount of Sox9 protein.	Cycloheximide	18-31	SRY (sex determining region Y)-box 9	Mus musculus	77-81
29607936-8	2018	Cycloheximide (CHX)-based assay in HEK293 cells revealed that intracellular G101S TTR expression level was lower, but extracellular expression was higher than WT TTR, implying enhanced secretion efficiency of G101S TTR protein compared with WT TTR.	Cycloheximide	0-13	transthyretin	Homo sapiens	82-85
29607936-8	2018	Cycloheximide (CHX)-based assay in HEK293 cells revealed that intracellular G101S TTR expression level was lower, but extracellular expression was higher than WT TTR, implying enhanced secretion efficiency of G101S TTR protein compared with WT TTR.	Cycloheximide	15-18	transthyretin	Homo sapiens	82-85
30257240-5	2018	The effect of CYP4B1-PS1-001 in the regulation of NCL was detected by cycloheximide (CHX) and ubiquitination assays.	Cycloheximide	70-83	cytochrome P450, family 4, subfamily b, polypeptide 1, pseudogene 1	Mus musculus	14-24
30257240-5	2018	The effect of CYP4B1-PS1-001 in the regulation of NCL was detected by cycloheximide (CHX) and ubiquitination assays.	Cycloheximide	70-83	nucleolin	Mus musculus	50-53
29597191-6	2018	The half-life of Nrf2 was detected in whole cell lysates and promyelocytic leukemia-nuclear body enriched fractions by cycloheximide-chase.	Cycloheximide	119-132	NFE2 like bZIP transcription factor 2	Homo sapiens	17-21
29080838-14	2018	For the 3 cell lines, the fold increase of the SMN1 transcript levels of cycloheximide ranged from 2.5+-0.4 to 8.3+-0.1, 1.9+-0.2 to 5.0+-0.7 and 2.2+-0.1 to 4.9+-0.2 for two lymphoblastoid cell lines and one fibroblasts cell line, respectively.	Cycloheximide	73-86	survival of motor neuron 1, telomeric	Homo sapiens	47-51
29796387-6	2018	Low concentrations of cycloheximide in the picomolar range were beneficial to TAZ-deficient HeLa cells, as evidenced by the recovery of a good proliferative capacity.	Cycloheximide	22-35	tafazzin, phospholipid-lysophospholipid transacylase	Homo sapiens	78-81
28777484-0	2018	5-Azacytidine specifically inhibits the NIH-3T3 PCD process induced by TNF-alpha and cycloheximide via affecting BCL-XL.	Cycloheximide	85-98	BCL2-like 1	Mus musculus	113-119
29097054-3	2018	METHODS: The ABCA1 decay rate was evaluated in macrophages after treatment with LXR agonist and by incubation with control (C) or AGE-albumin concomitant or not with cycloheximide, MG-132, ammonium chloride and calpain inhibitors were utilized to inhibit, respectively, proteasome, lysosome and ABCA1 proteolysis at cell surface.	Cycloheximide	166-179	ATP binding cassette subfamily A member 1	Homo sapiens	13-18
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	91-104	interleukin 1 alpha	Homo sapiens	40-59
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	91-104	interleukin 1 alpha	Homo sapiens	61-70
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	91-104	tumor necrosis factor	Homo sapiens	142-169
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	91-104	tumor necrosis factor	Homo sapiens	171-180
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	106-109	interleukin 1 alpha	Homo sapiens	40-59
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	106-109	interleukin 1 alpha	Homo sapiens	61-70
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	106-109	tumor necrosis factor	Homo sapiens	142-169
29398714-1	2018	Abstract: The exposure of HeLa cells to interleukin-1 alpha (IL-1alpha) in the presence of cycloheximide (CHX) leads to the release of active tumor necrosis factor alpha (TNF-alpha), eliciting cytocidal effect on these cells.	Cycloheximide	106-109	tumor necrosis factor	Homo sapiens	171-180
29018875-9	2018	Addition of cycloheximide, a protein synthesis inhibitor, drastically reversed the antiapoptotic effect of rPCN.	Cycloheximide	12-25	plectin	Rattus norvegicus	107-111
29122887-11	2017	Through analyses of short-lived Mdh2 as a target of short-lived Gid4, we illustrate the advantages of PRT over degradation assays that lack a reference and/or involve cycloheximide.	Cycloheximide	167-180	glucose-induced degradation complex subunit VID24	Saccharomyces cerevisiae S288C	64-68
29255796-7	2017	Downregulation of hnRNP K impaired the BDNF-induced enhancement of NMDA receptor (NMDAR)-mediated mEPSC, and similar results were obtained upon inhibition of protein synthesis with cycloheximide.	Cycloheximide	181-194	brain-derived neurotrophic factor	Rattus norvegicus	39-43
28543404-3	2017	In this study, we investigated the role of cathepsin D (catD) in TNFalpha/cycloheximide-induced apoptosis in U937 human monocytic cells.	Cycloheximide	74-87	cathepsin D	Homo sapiens	43-54
28543404-3	2017	In this study, we investigated the role of cathepsin D (catD) in TNFalpha/cycloheximide-induced apoptosis in U937 human monocytic cells.	Cycloheximide	74-87	cathepsin D	Homo sapiens	56-60
28965784-3	2017	Here, we discover a novel pathway of Jen1p endocytosis mediated by the alpha-arrestin Bul1p in response to the presence of cycloheximide or rapamycin, or prolonged growth in lactate.	Cycloheximide	123-136	Jen1p	Saccharomyces cerevisiae S288C	37-42
28950212-5	2017	Treatment with two translation inhibitors (puromycin and Cycloheximide (CHX)) markedly increased the levels of FL-SMN1 transcripts with premature translation termination codons (PTCs) (p<0.01) and showed time-dependent (10h>5.5h) but not dose-dependent effects.	Cycloheximide	57-70	survival of motor neuron 1, telomeric	Homo sapiens	114-118
28965784-3	2017	Here, we discover a novel pathway of Jen1p endocytosis mediated by the alpha-arrestin Bul1p in response to the presence of cycloheximide or rapamycin, or prolonged growth in lactate.	Cycloheximide	123-136	ubiquitin-ubiquitin ligase BUL1	Saccharomyces cerevisiae S288C	86-91
29336356-4	2017	Furthermore, cycloheximide treatmentshowed a direct effect on Klf4 transcriptionfacilitated by Tcf7l1.	Cycloheximide	13-26	Kruppel-like factor 4 (gut) L homeolog	Xenopus laevis	62-66
29160790-0	2017	Communication or Toxicity: What Is the Effect of Cycloheximide on Leaf-Cutting Ant Workers?	Cycloheximide	49-62	solute carrier family 25 member 6	Homo sapiens	79-82
29162874-6	2017	Simultaneous exposure to TNF or LPS and a translation inhibitor, cycloheximide, leads to prolonged NF-kappaB activation and a marked increase of transcript levels of NF-kappaB inhibitors, IkappaBalpha and A20.	Cycloheximide	65-78	tumor necrosis factor	Homo sapiens	25-28
28808055-8	2017	The activity and lysosomal recruitment of mTORC1 were rescued by increasing intracellular amino acids via cycloheximide exposure or by Rag overexpression, indicating that amino acid deprivation is the main cause of mTORC1 inactivation via the dynamin inhibition.	Cycloheximide	106-119	CREB regulated transcription coactivator 1	Mus musculus	42-48
27936516-8	2017	Furthermore, pretreatment with cycloheximide, a protein synthesis inhibitor, resulted in a significant decrease in the degradation rate of Hsp27 protein in postconditioned rats, suggesting that the increase in the expression of Hsp27 after HPC might result from its decreased degradation.	Cycloheximide	31-44	heat shock protein family B (small) member 1	Rattus norvegicus	139-144
27936516-8	2017	Furthermore, pretreatment with cycloheximide, a protein synthesis inhibitor, resulted in a significant decrease in the degradation rate of Hsp27 protein in postconditioned rats, suggesting that the increase in the expression of Hsp27 after HPC might result from its decreased degradation.	Cycloheximide	31-44	heat shock protein family B (small) member 1	Rattus norvegicus	228-233
29162874-6	2017	Simultaneous exposure to TNF or LPS and a translation inhibitor, cycloheximide, leads to prolonged NF-kappaB activation and a marked increase of transcript levels of NF-kappaB inhibitors, IkappaBalpha and A20.	Cycloheximide	65-78	NFKB inhibitor alpha	Homo sapiens	188-200
29162874-6	2017	Simultaneous exposure to TNF or LPS and a translation inhibitor, cycloheximide, leads to prolonged NF-kappaB activation and a marked increase of transcript levels of NF-kappaB inhibitors, IkappaBalpha and A20.	Cycloheximide	65-78	immunoglobulin kappa variable 1-27	Homo sapiens	205-208
28882596-7	2017	Cycloheximide, an inhibitor of protein synthesis, and brefeldin A, an inhibitor of protein transport from endoplasmic reticulum, suppressed the long-term insulin effect.	Cycloheximide	0-13	insulin S homeolog	Xenopus laevis	154-161
29336356-4	2017	Furthermore, cycloheximide treatmentshowed a direct effect on Klf4 transcriptionfacilitated by Tcf7l1.	Cycloheximide	13-26	transcription factor 7 like 1 S homeolog	Xenopus laevis	95-101
28730333-8	2017	In addition, we showed that DNMT3B9 protein lacks PWWP domain is less stable compared to other DNMT3B variants which contain PWWP domain through computational predictions and by cycloheximide half-life experiment.	Cycloheximide	178-191	DNA methyltransferase 3 beta	Homo sapiens	28-34
28622550-12	2017	When EGCG and CHX-treated AEPs were challenged with citric acid, there was increase in cystatins and Profilin-1.	Cycloheximide	14-17	profilin 1	Homo sapiens	101-111
28743509-9	2017	We further evaluated p53 levels in the presence of cycloheximide (CHX) and the results showed that the p53 stabilization was regulated at post-translational level through blockage of its degradation.	Cycloheximide	51-64	tumor protein p53	Homo sapiens	21-24
28743509-9	2017	We further evaluated p53 levels in the presence of cycloheximide (CHX) and the results showed that the p53 stabilization was regulated at post-translational level through blockage of its degradation.	Cycloheximide	51-64	tumor protein p53	Homo sapiens	103-106
28743509-9	2017	We further evaluated p53 levels in the presence of cycloheximide (CHX) and the results showed that the p53 stabilization was regulated at post-translational level through blockage of its degradation.	Cycloheximide	66-69	tumor protein p53	Homo sapiens	21-24
28743509-9	2017	We further evaluated p53 levels in the presence of cycloheximide (CHX) and the results showed that the p53 stabilization was regulated at post-translational level through blockage of its degradation.	Cycloheximide	66-69	tumor protein p53	Homo sapiens	103-106
28369600-5	2017	X-ray irradiation increased the mRNA expressions of TLR2 and TLR4, and treatment with a protein synthesis inhibitor cycloheximide abolished the radiation-induced upregulation of their cell surface expressions.	Cycloheximide	116-129	toll like receptor 2	Homo sapiens	52-56
28369600-5	2017	X-ray irradiation increased the mRNA expressions of TLR2 and TLR4, and treatment with a protein synthesis inhibitor cycloheximide abolished the radiation-induced upregulation of their cell surface expressions.	Cycloheximide	116-129	toll like receptor 4	Homo sapiens	61-65
28842570-4	2017	Using phospho-Ser321 as a marker, we show that the transient phosphorylation of RIPK1 intermediate domain induced by TNFalpha leads to RIPK1-independent apoptosis when NF-kappaB activation is inhibited by cycloheximide.	Cycloheximide	205-218	receptor interacting serine/threonine kinase 1	Homo sapiens	80-85
28842570-4	2017	Using phospho-Ser321 as a marker, we show that the transient phosphorylation of RIPK1 intermediate domain induced by TNFalpha leads to RIPK1-independent apoptosis when NF-kappaB activation is inhibited by cycloheximide.	Cycloheximide	205-218	tumor necrosis factor	Homo sapiens	117-125
28842570-4	2017	Using phospho-Ser321 as a marker, we show that the transient phosphorylation of RIPK1 intermediate domain induced by TNFalpha leads to RIPK1-independent apoptosis when NF-kappaB activation is inhibited by cycloheximide.	Cycloheximide	205-218	receptor interacting serine/threonine kinase 1	Homo sapiens	135-140
27996167-10	2017	On the other hand, the IL-1beta secretion is still modulated by Cl- in the presence of IL-1RN, IL-1beta blocking antibody, or cycloheximide, suggesting that Cl- is affecting the IL-1beta maturation/secretion, which in turn starts an autocrine positive feedback loop.	Cycloheximide	126-139	interleukin 1 beta	Homo sapiens	23-31
28901517-4	2017	In the present study, we investigated the role of Cx32 in extrinsic apoptosis induced by treatment with TNFalpha + cycloheximide (CHX) or afatinib in human cervical cancer (CaCx) cells.	Cycloheximide	115-128	gap junction protein beta 1	Homo sapiens	50-54
28901517-4	2017	In the present study, we investigated the role of Cx32 in extrinsic apoptosis induced by treatment with TNFalpha + cycloheximide (CHX) or afatinib in human cervical cancer (CaCx) cells.	Cycloheximide	130-133	gap junction protein beta 1	Homo sapiens	50-54
29051512-6	2017	Whereas R33Q mutation had no effect in the formation of CD300f complexes, the inhibition of protein synthesis with cycloheximide indicated that CD300f R33Q is less stable than native CD300f.	Cycloheximide	115-128	CD300 molecule like family member f	Homo sapiens	144-150
29051512-6	2017	Whereas R33Q mutation had no effect in the formation of CD300f complexes, the inhibition of protein synthesis with cycloheximide indicated that CD300f R33Q is less stable than native CD300f.	Cycloheximide	115-128	CD300 molecule like family member f	Homo sapiens	144-150
28919859-6	2017	Furthermore, falcarindiol significantly inhibited ABCA1 protein degradation in the presence of cycloheximide.	Cycloheximide	95-108	ATP binding cassette subfamily A member 1	Homo sapiens	50-55
28391045-8	2017	Furthermore, luciferase reporter assay and examination of the half-life of CREB1 following inhibition of new protein synthesis by cycloheximide (CHX) revealed that luteolin inhibits the expression of CREB1 at the transcriptional level.	Cycloheximide	145-148	cAMP responsive element binding protein 1	Homo sapiens	200-205
28242811-6	2017	Using the protein synthesis inhibitor cycloheximide, USP18 knockdown significantly reduced the half-life of KRAS, but gain of USP18 expression significantly increased its stability.	Cycloheximide	38-51	ubiquitin specific peptidase 18	Mus musculus	53-58
28661467-8	2017	A fraction of K-Ras protein accumulated in the presence of ROS and cycloheximide, while a substantial proportion was continuously synthesized.	Cycloheximide	67-80	KRAS proto-oncogene, GTPase	Homo sapiens	14-19
28371814-4	2017	UL13 RNA was found to be transcribed starting at 2 h post infection, and the synthesis of the UL13 mRNA was found to be sensitive to the protein synthesis inhibitor cycloheximide (CHX) and tolerant of the DNA polymerase inhibitor ganciclovir (GCV).	Cycloheximide	165-178	UL13	Anatid alphaherpesvirus 1	0-4
28371814-4	2017	UL13 RNA was found to be transcribed starting at 2 h post infection, and the synthesis of the UL13 mRNA was found to be sensitive to the protein synthesis inhibitor cycloheximide (CHX) and tolerant of the DNA polymerase inhibitor ganciclovir (GCV).	Cycloheximide	165-178	UL13	Anatid alphaherpesvirus 1	94-98
28371814-4	2017	UL13 RNA was found to be transcribed starting at 2 h post infection, and the synthesis of the UL13 mRNA was found to be sensitive to the protein synthesis inhibitor cycloheximide (CHX) and tolerant of the DNA polymerase inhibitor ganciclovir (GCV).	Cycloheximide	180-183	UL13	Anatid alphaherpesvirus 1	94-98
28751541-5	2017	In cultured vascular smooth muscle cells (VSMCs), Cavin-1 was downregulated after inhibition of protein synthesis by cycloheximide, which was distinctly prevented by pretreatment with proteasome inhibitor MG132 but not by lysosomal inhibitor chloroquine, suggesting that proteasomal degradation resulted in Cavin-1 downregulation.	Cycloheximide	117-130	caveolae associated protein 1	Homo sapiens	50-57
27883224-10	2017	Cycloheximide pretreatment also inhibited the bFGF-induced REX1 expression, implying the involvement of intermediate molecule(s).	Cycloheximide	0-13	fibroblast growth factor 2	Homo sapiens	46-50
27883224-10	2017	Cycloheximide pretreatment also inhibited the bFGF-induced REX1 expression, implying the involvement of intermediate molecule(s).	Cycloheximide	0-13	RNA exonuclease 1 homolog	Homo sapiens	59-63
28391045-17	2017	We then found that luteolin inhibits CREB1 expression at the transcriptional level by real-time PCR and luciferase reporter assay which confirmed by examination of the half-life of CREB1 following inhibition of new protein synthesis by cycloheximide (CHX).	Cycloheximide	236-249	cAMP responsive element binding protein 1	Homo sapiens	37-42
28391045-17	2017	We then found that luteolin inhibits CREB1 expression at the transcriptional level by real-time PCR and luciferase reporter assay which confirmed by examination of the half-life of CREB1 following inhibition of new protein synthesis by cycloheximide (CHX).	Cycloheximide	251-254	cAMP responsive element binding protein 1	Homo sapiens	37-42
28655995-4	2017	The higher IL-6 expression was not related to transcriptional but posttranscriptional regulation as the IL-6 expression was affected by the addition of cycloheximide but not actinomycin.	Cycloheximide	152-165	interleukin 6	Homo sapiens	11-15
28536481-3	2017	By screening the serine/arginine-rich splicing factors (SRSFs), we report that the transcript and protein levels of SRSF5 were increased in mammalian cells cultured at 32  C. Expression of SRSF5 as well as CIRP and RBM3 were also induced by DNA damage, hypoxia, cycloheximide and hypotonicity.	Cycloheximide	262-275	serine and arginine rich splicing factor 5	Homo sapiens	116-121
28655995-4	2017	The higher IL-6 expression was not related to transcriptional but posttranscriptional regulation as the IL-6 expression was affected by the addition of cycloheximide but not actinomycin.	Cycloheximide	152-165	interleukin 6	Homo sapiens	104-108
28082199-4	2017	The presence of endogenous and exogenous Ric-8A increases Galphai stability as shown in cells treated with the protein synthesis inhibitor cycloheximide; however, Ric-8A fails to efficiently stabilize ADP-ribosylated Galphai.	Cycloheximide	139-152	RIC8 guanine nucleotide exchange factor A	Homo sapiens	41-47
27372520-12	2017	The inhibition of USP7 by P5091 accelerated the degradation of CCDC6 versus control in cycloheximide treated L-NET cells in vitro and sensitized the cells to PARP-inhibitors alone and in combination with cisplatinum.	Cycloheximide	87-100	ubiquitin specific peptidase 7	Homo sapiens	18-22
27372520-12	2017	The inhibition of USP7 by P5091 accelerated the degradation of CCDC6 versus control in cycloheximide treated L-NET cells in vitro and sensitized the cells to PARP-inhibitors alone and in combination with cisplatinum.	Cycloheximide	87-100	coiled-coil domain containing 6	Homo sapiens	63-68
28323848-4	2017	7alphaOHChol-induced IL-8 gene transcription was inhibited by cycloheximide and Akt1 downregulation, but not by OxPAPC.	Cycloheximide	62-75	C-X-C motif chemokine ligand 8	Homo sapiens	21-25
28050781-9	2017	Epoxomicin suppressed TNF-alpha plus CHX-induced degradation of survivin, cIAP1, and XIAP, in addition to apoptosis.	Cycloheximide	37-40	baculoviral IAP repeat containing 2	Homo sapiens	74-79
28050781-9	2017	Epoxomicin suppressed TNF-alpha plus CHX-induced degradation of survivin, cIAP1, and XIAP, in addition to apoptosis.	Cycloheximide	37-40	X-linked inhibitor of apoptosis	Homo sapiens	85-89
28126724-6	2017	In addition, cycloheximide treatment of human lung cancer cells revealed that RBFOX3 increases the stability of Claudin-1 through attenuation of its ubiquitination.	Cycloheximide	13-26	RNA binding fox-1 homolog 3	Homo sapiens	78-84
28126724-6	2017	In addition, cycloheximide treatment of human lung cancer cells revealed that RBFOX3 increases the stability of Claudin-1 through attenuation of its ubiquitination.	Cycloheximide	13-26	claudin 1	Homo sapiens	112-121
28203230-10	2017	Results of infection kinetics and cycloheximide-actinomycin D-chase experiments, strongly suggested that an HCMV immediate early gene product is responsible for the induction of CD83 down-modulation.	Cycloheximide	34-47	CD83 molecule	Homo sapiens	178-182
28228725-2	2017	The water-soluble CORM-A1 reduced apoptosis and NADPH oxidase (NOX)-derived reactive oxygen species (ROS) induced by tumor necrosis factor (TNF)-alpha/cycloheximide (CHX) in mouse MODE-K intestinal epithelial cells (IECs), without influencing TNF-alpha/CHX-induced mitochondrial superoxide anion ([Formula: see text]).	Cycloheximide	253-256	tumor necrosis factor	Mus musculus	117-138
28075616-9	2017	Cycloheximide chase assays indicated that turnover of CXCR4 was accelerated in response to lactoferrin.	Cycloheximide	0-13	C-X-C motif chemokine receptor 4	Homo sapiens	54-59
28075616-9	2017	Cycloheximide chase assays indicated that turnover of CXCR4 was accelerated in response to lactoferrin.	Cycloheximide	0-13	lactotransferrin	Bos taurus	91-102
27987332-10	2017	In addition, cycloheximide chase assay revealed that the half-life of VE-cadherin protein was dramatically reduced by Cullin 3 depletion.	Cycloheximide	13-26	cadherin 5	Homo sapiens	70-81
27987332-10	2017	In addition, cycloheximide chase assay revealed that the half-life of VE-cadherin protein was dramatically reduced by Cullin 3 depletion.	Cycloheximide	13-26	cullin 3	Homo sapiens	118-126
28662510-7	2017	The effect of USP14 in the regulation of Aurora B was detected by cycloheximide (CHX) and deubiquitination assays.	Cycloheximide	66-79	ubiquitin specific peptidase 14	Homo sapiens	14-19
27980214-6	2017	Using the protein synthesis inhibitor cycloheximide (CHX), USP18 knockdown was shown to destabilize PTEN whereas USP18 overexpression stabilized PTEN protein.	Cycloheximide	38-51	ubiquitin specific peptidase 18	Homo sapiens	59-64
27980214-6	2017	Using the protein synthesis inhibitor cycloheximide (CHX), USP18 knockdown was shown to destabilize PTEN whereas USP18 overexpression stabilized PTEN protein.	Cycloheximide	53-56	ubiquitin specific peptidase 18	Homo sapiens	59-64
26393327-6	2017	When the new protein synthesis was blocked by cycloheximide treatment, the degradation rate of Akt2 and p-Akt in oral cancer cells was significantly lower than that in HOKs (P &lt; 0.05).	Cycloheximide	46-59	AKT serine/threonine kinase 2	Homo sapiens	95-99
27909743-11	2017	Both IL-1beta-induced NO production and L-arginine uptake were abolished in the presence of cycloheximide (1 muM).	Cycloheximide	92-105	interleukin 1 beta	Rattus norvegicus	5-13
28278502-13	2017	Interestingly, we observed that Kae induced a premature degradation of DNMT3B by inhibiting protein synthesis with cycloheximide (CHX).	Cycloheximide	115-128	DNA methyltransferase 3B	Mus musculus	71-77
28278502-13	2017	Interestingly, we observed that Kae induced a premature degradation of DNMT3B by inhibiting protein synthesis with cycloheximide (CHX).	Cycloheximide	130-133	DNA methyltransferase 3B	Mus musculus	71-77
28662510-7	2017	The effect of USP14 in the regulation of Aurora B was detected by cycloheximide (CHX) and deubiquitination assays.	Cycloheximide	66-79	aurora kinase B	Homo sapiens	41-49
28662510-7	2017	The effect of USP14 in the regulation of Aurora B was detected by cycloheximide (CHX) and deubiquitination assays.	Cycloheximide	81-84	ubiquitin specific peptidase 14	Homo sapiens	14-19
28662510-7	2017	The effect of USP14 in the regulation of Aurora B was detected by cycloheximide (CHX) and deubiquitination assays.	Cycloheximide	81-84	aurora kinase B	Homo sapiens	41-49
28032861-6	2016	Cycloheximide (CHX) treatment indicated Pin1 stabilized the expression of ATF1 at post-transcription level.	Cycloheximide	0-13	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	40-44
27035356-5	2017	MCPIP1 expression induced by MG132 was inhibited by alpha-amanitin inhibition of gene transcription or cycloheximide inhibition of protein synthesis.	Cycloheximide	103-116	zinc finger CCCH-type containing 12A	Homo sapiens	0-6
28032861-6	2016	Cycloheximide (CHX) treatment indicated Pin1 stabilized the expression of ATF1 at post-transcription level.	Cycloheximide	0-13	activating transcription factor 1	Homo sapiens	74-78
28032861-6	2016	Cycloheximide (CHX) treatment indicated Pin1 stabilized the expression of ATF1 at post-transcription level.	Cycloheximide	15-18	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	40-44
28032861-6	2016	Cycloheximide (CHX) treatment indicated Pin1 stabilized the expression of ATF1 at post-transcription level.	Cycloheximide	15-18	activating transcription factor 1	Homo sapiens	74-78
28035994-8	2016	Cycloheximide chase analyses further revealed an evident reduction in the half-life of cyclin D1 protein by obatoclax, confirming that obatoclax downregulates cyclin D1 through induction of cyclin D1 proteasomal degradation.	Cycloheximide	0-13	cyclin D1	Homo sapiens	87-96
28036027-5	2016	For the analysis of the stability of PDX-1 we performed a cycloheximide chase.	Cycloheximide	58-71	pancreatic and duodenal homeobox 1	Homo sapiens	37-42
28035994-8	2016	Cycloheximide chase analyses further revealed an evident reduction in the half-life of cyclin D1 protein by obatoclax, confirming that obatoclax downregulates cyclin D1 through induction of cyclin D1 proteasomal degradation.	Cycloheximide	0-13	cyclin D1	Homo sapiens	159-168
28035994-8	2016	Cycloheximide chase analyses further revealed an evident reduction in the half-life of cyclin D1 protein by obatoclax, confirming that obatoclax downregulates cyclin D1 through induction of cyclin D1 proteasomal degradation.	Cycloheximide	0-13	cyclin D1	Homo sapiens	159-168
26751719-12	2016	A gamma-secretase inhibitor and cycloheximide treatment rescued Jagged1-attenuated OPG expression.	Cycloheximide	32-45	jagged canonical Notch ligand 1	Homo sapiens	64-71
27836976-9	2016	Finally, pharmacological protection of CA1 ischemic neurons with cycloheximide decreased the formation of SGs and restored eIF4E and eIF4B levels in CA1.	Cycloheximide	65-78	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
27836976-9	2016	Finally, pharmacological protection of CA1 ischemic neurons with cycloheximide decreased the formation of SGs and restored eIF4E and eIF4B levels in CA1.	Cycloheximide	65-78	eukaryotic translation initiation factor 4B	Homo sapiens	133-138
27611480-12	2016	Cycloheximide time course studies indicated that the cyclin E2 protein half-life was more than 12 hours in these cells.	Cycloheximide	0-13	cyclin E2	Homo sapiens	53-62
26751719-12	2016	A gamma-secretase inhibitor and cycloheximide treatment rescued Jagged1-attenuated OPG expression.	Cycloheximide	32-45	TNF receptor superfamily member 11b	Homo sapiens	83-86
26808296-6	2016	Cycloheximide pulse-chase experiments coupled with immunocytochemical analysis revealed that the induction of Snail by H. pylori was regulated at multiple levels, including increased transcription of Snail mRNA, inhibition of protein degradation, and enhancement of nuclear translocation of Snail.	Cycloheximide	0-13	snail family transcriptional repressor 1	Homo sapiens	110-115
27211273-6	2016	Treatment of cultured SF3B1-mutant MDS erythroblasts and a CRISPR/Cas9-generated SF3B1-mutant cell line with the nonsense-mediated decay (NMD) inhibitor cycloheximide showed that the aberrantly spliced ABCB7 transcript is targeted by NMD.	Cycloheximide	153-166	splicing factor 3b subunit 1	Homo sapiens	22-27
27211273-6	2016	Treatment of cultured SF3B1-mutant MDS erythroblasts and a CRISPR/Cas9-generated SF3B1-mutant cell line with the nonsense-mediated decay (NMD) inhibitor cycloheximide showed that the aberrantly spliced ABCB7 transcript is targeted by NMD.	Cycloheximide	153-166	splicing factor 3b subunit 1	Homo sapiens	81-86
27211273-6	2016	Treatment of cultured SF3B1-mutant MDS erythroblasts and a CRISPR/Cas9-generated SF3B1-mutant cell line with the nonsense-mediated decay (NMD) inhibitor cycloheximide showed that the aberrantly spliced ABCB7 transcript is targeted by NMD.	Cycloheximide	153-166	ATP binding cassette subfamily B member 7	Homo sapiens	202-207
27451051-10	2016	Inhibition of ANX1 and ANX2 biosynthesis using cycloheximide (40 mg/kg BW in 5 mL DW/kg BW, IP) abolished this heteroprotection.	Cycloheximide	47-60	annexin A1	Mus musculus	14-18
27806040-0	2016	Cycloheximide Can Induce Bax/Bak Dependent Myeloid Cell Death Independently of Multiple BH3-Only Proteins.	Cycloheximide	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	25-28
27806040-0	2016	Cycloheximide Can Induce Bax/Bak Dependent Myeloid Cell Death Independently of Multiple BH3-Only Proteins.	Cycloheximide	0-13	BCL2 antagonist/killer 1	Homo sapiens	29-32
27806040-4	2016	In factor dependent myeloid (FDM) cell lines, cycloheximide induced apoptosis by a Bax/Bak dependent mechanism, because Bax-/-Bak-/- lines were profoundly resistant, whereas FDM lines lacking one or more genes for BH3-only proteins remained highly sensitive.	Cycloheximide	46-59	BCL2 associated X, apoptosis regulator	Homo sapiens	83-86
27806040-4	2016	In factor dependent myeloid (FDM) cell lines, cycloheximide induced apoptosis by a Bax/Bak dependent mechanism, because Bax-/-Bak-/- lines were profoundly resistant, whereas FDM lines lacking one or more genes for BH3-only proteins remained highly sensitive.	Cycloheximide	46-59	BCL2 antagonist/killer 1	Homo sapiens	87-90
27806040-4	2016	In factor dependent myeloid (FDM) cell lines, cycloheximide induced apoptosis by a Bax/Bak dependent mechanism, because Bax-/-Bak-/- lines were profoundly resistant, whereas FDM lines lacking one or more genes for BH3-only proteins remained highly sensitive.	Cycloheximide	46-59	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
27806040-4	2016	In factor dependent myeloid (FDM) cell lines, cycloheximide induced apoptosis by a Bax/Bak dependent mechanism, because Bax-/-Bak-/- lines were profoundly resistant, whereas FDM lines lacking one or more genes for BH3-only proteins remained highly sensitive.	Cycloheximide	46-59	BCL2 antagonist/killer 1	Homo sapiens	126-129
27806040-5	2016	Addition of cycloheximide led to the rapid loss of Mcl-1 but did not affect the expression of other Bcl-2 family proteins.	Cycloheximide	12-25	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	51-56
27629431-5	2016	We demonstrate that under starvation, protein translation is rapidly diminished and, similar to treatments with the proteosynthesis inhibitors cycloheximide or anisomycin, is associated with a significant reduction of ULK1.	Cycloheximide	143-156	unc-51 like autophagy activating kinase 1	Homo sapiens	218-222
27565733-8	2016	Experiments with cycloheximide supported the role of KDM7A in ICAM1 protein stabilization.	Cycloheximide	17-30	lysine demethylase 7A	Homo sapiens	53-58
27602497-6	2016	At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide.	Cycloheximide	139-152	TNF superfamily member 10	Homo sapiens	40-45
27602497-6	2016	At a later time, however, TZD alone and TRAIL-TZD combination produced a dramatic reduction of GSK3beta expression, which was abolished by cycloheximide.	Cycloheximide	139-152	glycogen synthase kinase 3 beta	Homo sapiens	95-103
27499349-10	2016	This rapid and potent AR suppression by SFN occurred by both AR protein degradation, as suggested by cycloheximide (CHX) co-exposure studies, and by suppression of AR gene expression, as evident from quantitative RT-PCR experiments.	Cycloheximide	101-114	androgen receptor	Homo sapiens	22-24
27499349-10	2016	This rapid and potent AR suppression by SFN occurred by both AR protein degradation, as suggested by cycloheximide (CHX) co-exposure studies, and by suppression of AR gene expression, as evident from quantitative RT-PCR experiments.	Cycloheximide	116-119	androgen receptor	Homo sapiens	22-24
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	tumor necrosis factor	Mus musculus	79-82
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	caspase 3	Mus musculus	212-221
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	caspase 3	Mus musculus	258-280
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	poly (ADP-ribose) polymerase family, member 1	Mus musculus	298-325
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	poly (ADP-ribose) polymerase family, member 1	Mus musculus	327-331
27739412-4	2016	Co-treatment with cycloheximide expedited apoptosis induction in necrostatin-1/TNF-treated L929 cells: typical apoptotic morphological changes, including membrane blebbing and nuclear fragmentation, induction of caspase-3 activity, proteolytic activation of caspases-3, -8, and -9, and cleavage of poly(ADP-ribose) polymerase (PARP) (a well-known substrate of caspase-3) were observed.	Cycloheximide	18-31	caspase 3	Mus musculus	360-369
27581648-4	2016	First, inhibition of translation with cycloheximide had a more potent effect on protein synthesis than rapamycin indicating that mTOR function during hypertrophy is not on general, but rather on specific protein synthesis.	Cycloheximide	38-51	mechanistic target of rapamycin kinase	Homo sapiens	129-133
27565733-8	2016	Experiments with cycloheximide supported the role of KDM7A in ICAM1 protein stabilization.	Cycloheximide	17-30	intercellular adhesion molecule 1	Homo sapiens	62-67
25996834-7	2016	In-vivo pharmacokinetic studies on rats demonstrated increase in the AUC of SLN (26) as compared to that of marketed tablet (13.22), while the presence of lymphatic uptake inhibitor cycloheximide lowered the AUC of SLN to 17.19 which further led credence to the involvement of lymphatic uptake behind improved bioavailability.	Cycloheximide	182-195	sarcolipin	Rattus norvegicus	76-79
27632174-8	2016	Pretreatment with NF-kappaB complex inhibitors, namely Bay11-7085 and IKK inhibitor VII or with a transcription inhibitor (actinomycin D) and protein synthesis inhibitor (cycloheximide), did also abrogate Ang1-mediated increase of MIP-1beta intracellular and extracellular protein levels.	Cycloheximide	171-184	angiopoietin 1	Homo sapiens	205-209
25996834-7	2016	In-vivo pharmacokinetic studies on rats demonstrated increase in the AUC of SLN (26) as compared to that of marketed tablet (13.22), while the presence of lymphatic uptake inhibitor cycloheximide lowered the AUC of SLN to 17.19 which further led credence to the involvement of lymphatic uptake behind improved bioavailability.	Cycloheximide	182-195	sarcolipin	Rattus norvegicus	215-218
26729559-3	2016	Here, we report that continuous cycloheximide [40 mug/mL] treatment of parthenogenotes, androgenotes, and ICSI embryos reveals ORC2 pronuclear instability in the maternal (MPN) but not the paternal pronucleus (PPN).	Cycloheximide	32-45	origin recognition complex subunit 2	Homo sapiens	127-131
27526106-6	2016	Consistently, RNF168 overexpression resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	141-154	ring finger protein 168	Homo sapiens	14-20
27526106-6	2016	Consistently, RNF168 overexpression resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	141-154	forkhead box M1	Homo sapiens	75-80
26891693-5	2016	The activation of caspase-8 during extrinsic apoptosis induced by TNFalpha/cycloheximide (TNFalpha/CHX) was dependent on adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and completely independent of caspase-1 or caspase-11.	Cycloheximide	75-88	caspase 8	Mus musculus	18-27
26891693-5	2016	The activation of caspase-8 during extrinsic apoptosis induced by TNFalpha/cycloheximide (TNFalpha/CHX) was dependent on adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and completely independent of caspase-1 or caspase-11.	Cycloheximide	75-88	tumor necrosis factor	Mus musculus	66-74
26891693-5	2016	The activation of caspase-8 during extrinsic apoptosis induced by TNFalpha/cycloheximide (TNFalpha/CHX) was dependent on adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and completely independent of caspase-1 or caspase-11.	Cycloheximide	75-88	tumor necrosis factor	Mus musculus	90-98
26891693-5	2016	The activation of caspase-8 during extrinsic apoptosis induced by TNFalpha/cycloheximide (TNFalpha/CHX) was dependent on adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and completely independent of caspase-1 or caspase-11.	Cycloheximide	75-88	PYD and CARD domain containing	Mus musculus	196-199
26891693-5	2016	The activation of caspase-8 during extrinsic apoptosis induced by TNFalpha/cycloheximide (TNFalpha/CHX) was dependent on adaptor protein apoptosis-associated speck-like protein containing a CARD (ASC) and completely independent of caspase-1 or caspase-11.	Cycloheximide	75-88	caspase 1	Mus musculus	231-240
26729559-5	2016	Taken together, these data suggest cycloheximide treatment promotes an environment that asymmetrically affects the stability of ORC2 on the MPN, and the ability of the MPN to develop.	Cycloheximide	35-48	origin recognition complex subunit 2	Homo sapiens	128-132
26748560-5	2016	BMP4-induced Smad8/9 expression was cycloheximide-insensitive and LDN-193189-sensitive, suggesting a direct event mediated through BMP type I receptors.	Cycloheximide	36-49	bone morphogenetic protein 4	Homo sapiens	0-4
26748560-5	2016	BMP4-induced Smad8/9 expression was cycloheximide-insensitive and LDN-193189-sensitive, suggesting a direct event mediated through BMP type I receptors.	Cycloheximide	36-49	SMAD family member 9	Homo sapiens	13-18
26748560-5	2016	BMP4-induced Smad8/9 expression was cycloheximide-insensitive and LDN-193189-sensitive, suggesting a direct event mediated through BMP type I receptors.	Cycloheximide	36-49	bone morphogenetic protein 1	Homo sapiens	0-3
27270670-4	2016	This activity-dependent increase of BDNF was abolished by cycloheximide, suggesting local translation, and required activation of glutamate and Trk receptors.	Cycloheximide	58-71	brain derived neurotrophic factor	Homo sapiens	36-40
27392906-10	2016	The expression levels of NanoLuc-tagged ATF6alpha and GRP78 were significantly down-regulated by 2-Cl-Phen in the presence or absence of the translation inhibitor cycloheximide.	Cycloheximide	163-176	activating transcription factor 6	Homo sapiens	40-49
27392906-10	2016	The expression levels of NanoLuc-tagged ATF6alpha and GRP78 were significantly down-regulated by 2-Cl-Phen in the presence or absence of the translation inhibitor cycloheximide.	Cycloheximide	163-176	heat shock protein family A (Hsp70) member 5	Homo sapiens	54-59
27486435-10	2016	Nonetheless, when protein synthesis was blocked with cycloheximide, MRAP was rapidly degraded even when MG132 was included and all lysines were replaced by arginines, implicating non-proteasomal degradation pathways.	Cycloheximide	53-66	melanocortin-2 receptor accessory protein	Cricetulus griseus	68-72
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	118-131	microRNA 122	Homo sapiens	15-22
29435108-6	2018	The effects of DUOX2 mutations were characterized by H2O2 production assays and cycloheximide (CHX) chase experiments.	Cycloheximide	80-93	dual oxidase 2	Homo sapiens	15-20
29435108-6	2018	The effects of DUOX2 mutations were characterized by H2O2 production assays and cycloheximide (CHX) chase experiments.	Cycloheximide	95-98	dual oxidase 2	Homo sapiens	15-20
27107935-9	2016	Cycloheximide blocked the DPN-induced upregulation of non-phosphorylated beta-catenin, suggesting de novo synthesis of this protein.	Cycloheximide	0-13	catenin beta 1	Homo sapiens	73-85
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	118-131	tumor necrosis factor	Homo sapiens	109-117
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	118-131	BCL2 like 2	Homo sapiens	204-209
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	133-136	microRNA 122	Homo sapiens	15-22
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	133-136	tumor necrosis factor	Homo sapiens	109-117
27415790-9	2016	Suppression of miR-122 could reduce apoptosis and caspase activity in pterygium epithelial cell treated with TNFalpha/cycloheximide (CHX), and this effect was abolished by inhibition of the expression of Bcl-w with specific siRNA.	Cycloheximide	133-136	BCL2 like 2	Homo sapiens	204-209
27109480-7	2016	Both CQ and AQ elevated the transcription level of p21 though the activation of p53, but also blocked p21 protein degradation in the presence of cycloheximide, causing p21 protein accumulation mainly in the nucleus.	Cycloheximide	145-158	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-105
27283735-8	2016	Curcumin increased the rate of Tat protein degradation as shown by cycloheximide (CHX) chase assay.	Cycloheximide	67-80	tyrosine aminotransferase	Homo sapiens	31-34
27283735-8	2016	Curcumin increased the rate of Tat protein degradation as shown by cycloheximide (CHX) chase assay.	Cycloheximide	82-85	tyrosine aminotransferase	Homo sapiens	31-34
27296782-3	2016	The carbonaceous reforming reactions include conversion of CHx (x = 0, 1, 2 and 3) species by hydrogen molecules (H2) to form CHx+2 species or oxidation of C atoms by oxygen molecules to form CO2.	Cycloheximide	59-62	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	64-81
27109480-7	2016	Both CQ and AQ elevated the transcription level of p21 though the activation of p53, but also blocked p21 protein degradation in the presence of cycloheximide, causing p21 protein accumulation mainly in the nucleus.	Cycloheximide	145-158	cyclin dependent kinase inhibitor 1A	Homo sapiens	102-105
26825690-5	2016	Incubation of transfected cells in a lipid-rich medium in the presence of cycloheximide showed rapid turnover of cell-associated mutant apoB-48 as compared to that of wild-type apoB-48.	Cycloheximide	74-87	apolipoprotein B	Homo sapiens	136-143
27077371-5	2016	Using cycloheximide, a general inhibitor of mRNA translation, we determined that Foxp3, but not CD25, has a high turnover in IL-2 stimulated Treg.	Cycloheximide	6-19	forkhead box P3	Homo sapiens	81-86
27077371-5	2016	Using cycloheximide, a general inhibitor of mRNA translation, we determined that Foxp3, but not CD25, has a high turnover in IL-2 stimulated Treg.	Cycloheximide	6-19	interleukin 2	Homo sapiens	125-129
26985709-6	2016	In the current study, BMSCs were treated with TNF-alpha/cycloheximide (CHX), and cell death was examined by the Cell Counting Kit-8, Hoechst 33342 staining, and flow cytometric analysis as well as by the level of caspase-3 and caspase-8.	Cycloheximide	71-74	tumor necrosis factor	Homo sapiens	46-55
26825690-5	2016	Incubation of transfected cells in a lipid-rich medium in the presence of cycloheximide showed rapid turnover of cell-associated mutant apoB-48 as compared to that of wild-type apoB-48.	Cycloheximide	74-87	apolipoprotein B	Homo sapiens	177-184
26721884-9	2016	Pulse-chase and cycloheximide-chase assays demonstrated that the marked reduction in the co-transporter protein levels was essentially due to increased protein degradation of the immature form of NKCC2.	Cycloheximide	16-29	solute carrier family 12 member 1	Homo sapiens	196-201
26935021-10	2016	The protein stability of NRF2 was analyzed using cycloheximide and its acetylation in the cells was also determined.	Cycloheximide	49-62	nuclear factor, erythroid derived 2, like 2	Mus musculus	25-29
26148240-8	2016	Importantly, knockdown of OTUB1 by siRNA resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overexpression of WT OTUB1, but not the OTUB1(C91S) mutant, significantly enhances the half-life of FOXM1.	Cycloheximide	146-159	OTU deubiquitinase, ubiquitin aldehyde binding 1	Homo sapiens	26-31
26148240-8	2016	Importantly, knockdown of OTUB1 by siRNA resulted in an increase in turnover of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overexpression of WT OTUB1, but not the OTUB1(C91S) mutant, significantly enhances the half-life of FOXM1.	Cycloheximide	146-159	forkhead box M1	Homo sapiens	80-85
26993100-4	2016	Here we investigated the CA IX ECD shedding in tumor cells undergoing apoptosis in response to cytotoxic drugs, including cycloheximide and doxorubicin.	Cycloheximide	122-135	carbonic anhydrase 9	Homo sapiens	25-30
26606373-7	2016	Instead, TNF-alpha-induced COX-2 upregulation is subject to regulation by the proteasome, and IL-17A acts to increase TNF-alpha-induced COX-2 protein stability as confirmed by cycloheximide chase experiments.	Cycloheximide	176-189	interleukin 17A	Homo sapiens	94-100
26606373-7	2016	Instead, TNF-alpha-induced COX-2 upregulation is subject to regulation by the proteasome, and IL-17A acts to increase TNF-alpha-induced COX-2 protein stability as confirmed by cycloheximide chase experiments.	Cycloheximide	176-189	tumor necrosis factor	Homo sapiens	118-127
26606373-7	2016	Instead, TNF-alpha-induced COX-2 upregulation is subject to regulation by the proteasome, and IL-17A acts to increase TNF-alpha-induced COX-2 protein stability as confirmed by cycloheximide chase experiments.	Cycloheximide	176-189	prostaglandin-endoperoxide synthase 2	Homo sapiens	136-141
26634371-5	2016	As revealed by chase experiments in the presence of cycloheximide, overexpression of UBXN2A seems to interfere with the mortalin-CHIP E3 ubiquitin ligase and consequently suppresses the C-terminus of the HSC70-interacting protein (CHIP)-mediated destabilization of p53, resulting in its stabilization in the cytoplasm and upregulation in the nucleus.	Cycloheximide	52-65	UBX domain protein 2A	Homo sapiens	85-91
26775629-4	2016	METHODS: The expression, phosphorylation and subcellular localization of p53 were detected by real-time PCR, luciferase reporter assay, cycloheximide chase analysis, immunoblotting and immunocytochemistry.	Cycloheximide	136-149	tumor protein p53	Homo sapiens	73-76
27104035-5	2016	Furthermore, cycloheximide (CHX) had completely abolished the glucose uptake activity of MLGS when co-incubated, which further confirmed that glucose uptake activity of MLGS was linked to enhanced expression of GLUT-4 and PPAR-gamma.	Cycloheximide	13-26	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	211-217
27104035-5	2016	Furthermore, cycloheximide (CHX) had completely abolished the glucose uptake activity of MLGS when co-incubated, which further confirmed that glucose uptake activity of MLGS was linked to enhanced expression of GLUT-4 and PPAR-gamma.	Cycloheximide	13-26	peroxisome proliferator activated receptor gamma	Mus musculus	222-232
27104035-5	2016	Furthermore, cycloheximide (CHX) had completely abolished the glucose uptake activity of MLGS when co-incubated, which further confirmed that glucose uptake activity of MLGS was linked to enhanced expression of GLUT-4 and PPAR-gamma.	Cycloheximide	28-31	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	211-217
27104035-5	2016	Furthermore, cycloheximide (CHX) had completely abolished the glucose uptake activity of MLGS when co-incubated, which further confirmed that glucose uptake activity of MLGS was linked to enhanced expression of GLUT-4 and PPAR-gamma.	Cycloheximide	28-31	peroxisome proliferator activated receptor gamma	Mus musculus	222-232
26212375-10	2016	Treatment with cycloheximide, an inhibitor of new protein synthesis, confirmed that mTOR is constitutively expressed and degraded.	Cycloheximide	15-28	mechanistic target of rapamycin kinase	Homo sapiens	84-88
26616053-6	2016	Interestingly, co-immunoiprecipitation of IC-2 and CCT is abolished by prior cycloheximide treatment of cells, suggesting that CCT participates in folding of nascent IC-2.	Cycloheximide	77-90	dynein cytoplasmic 1 intermediate chain 2	Homo sapiens	42-46
26620226-7	2016	This EGF-mediated increase in HIF-1alpha protein was blocked through inhibition of translation by cycloheximide.	Cycloheximide	98-111	epidermal growth factor	Homo sapiens	5-8
26620226-7	2016	This EGF-mediated increase in HIF-1alpha protein was blocked through inhibition of translation by cycloheximide.	Cycloheximide	98-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	30-40
26237084-4	2016	Conversely, whereas the autophagic-lysosomal flux of LC3 halted within ~100 min of cycloheximide treatment, the bulk cargo flux continued at a high rate.	Cycloheximide	83-96	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	53-56
26410677-5	2016	The analysis on Tctex-1 protein was performed in the absence and presence of the ligands JWH 133, 2-AG, and AM 630, the protein biosynthesis inhibitor cycloheximide or the protein degradation blockers MG132, NH4Cl/leupeptin or bafilomycin.	Cycloheximide	151-164	dynein light chain Tctex-type 1	Homo sapiens	16-23
26598521-5	2016	Mutation of the five modified Runx1 tyrosines to aspartate markedly reduced co-immunoprecipitation with HDAC1 and HDAC3, markedly increased stability in cycloheximide or in the presence of co-expressed Cdh1, an E3 ubiquitin ligase coactivator, with reduced ubiquitination, and allowed DNA-binding in gel shift assay similar to wild-type Runx1.	Cycloheximide	153-166	runt related transcription factor 1	Mus musculus	30-35
26482137-9	2016	This study suggests that SC10H2 promastigote infection is able to promote and delay the transduction of early apoptotic signals induced by cycloheximide in THP-1 and RAW264.7 macrophages, revealing that the regulation of intrinsic apoptosis in host cells by SC10H2 in vitro occurs in a host cell-dependent manner.	Cycloheximide	139-152	GLI family zinc finger 2	Homo sapiens	156-161
26508734-4	2016	We also identified mitochondrial isoforms of Pim-1 kinase that were targeted for degradation by AZ58 in combination with TNF-alpha or AZ58 in combination with Fas ligand (FasL) plus cycloheximide (CHX) through caspase-3 to block transformation.	Cycloheximide	182-195	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	45-50
26508734-4	2016	We also identified mitochondrial isoforms of Pim-1 kinase that were targeted for degradation by AZ58 in combination with TNF-alpha or AZ58 in combination with Fas ligand (FasL) plus cycloheximide (CHX) through caspase-3 to block transformation.	Cycloheximide	182-195	caspase 3	Homo sapiens	210-219
26508734-4	2016	We also identified mitochondrial isoforms of Pim-1 kinase that were targeted for degradation by AZ58 in combination with TNF-alpha or AZ58 in combination with Fas ligand (FasL) plus cycloheximide (CHX) through caspase-3 to block transformation.	Cycloheximide	197-200	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	45-50
26616053-6	2016	Interestingly, co-immunoiprecipitation of IC-2 and CCT is abolished by prior cycloheximide treatment of cells, suggesting that CCT participates in folding of nascent IC-2.	Cycloheximide	77-90	dynein cytoplasmic 1 intermediate chain 2	Homo sapiens	166-170
26981393-0	2016	Transcriptomic analysis of mouse EL4 T cells upon T cell activation and in response to protein synthesis inhibition via cycloheximide treatment.	Cycloheximide	120-133	epilepsy 4	Mus musculus	33-36
26796799-3	2016	We also analyzed the half-life of ID1 protein and stability of ID1 mRNA respectively by cycloheximide inhibition test and RT-PCR.	Cycloheximide	88-101	inhibitor of DNA binding 1, HLH protein	Homo sapiens	34-37
26599052-0	2016	Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.	Cycloheximide	0-13	tau	Drosophila melanogaster	85-88
26599052-6	2016	In this study, we found that cycloheximide treatment induced mild activation of a ZVAD-sensitive protease in Drosophila Kc cells, resulting in cleavage of tau at its C-terminus; this cleavage could generate misleading tau protein degradation pattern results depending on the antibodies used in the assay.	Cycloheximide	29-42	tau	Drosophila melanogaster	155-158
26599052-6	2016	In this study, we found that cycloheximide treatment induced mild activation of a ZVAD-sensitive protease in Drosophila Kc cells, resulting in cleavage of tau at its C-terminus; this cleavage could generate misleading tau protein degradation pattern results depending on the antibodies used in the assay.	Cycloheximide	29-42	tau	Drosophila melanogaster	218-221
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	106-119	solute carrier family 12 member 3	Homo sapiens	0-3
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	106-119	solute carrier family 12 member 3	Homo sapiens	133-136
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	106-119	solute carrier family 12 member 3	Homo sapiens	133-136
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	121-124	solute carrier family 12 member 3	Homo sapiens	0-3
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	121-124	solute carrier family 12 member 3	Homo sapiens	133-136
27467688-6	2016	NCC protein expression in Cos-7 cells was markedly decreased after 2 h treatment with protease inhibitor, cycloheximide (CHX) in the NCC alone group, but was significantly decreased after 8 h treatment of CHX in the WNK3 + NCC group.	Cycloheximide	121-124	solute carrier family 12 member 3	Homo sapiens	133-136
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	25-38	growth arrest and DNA-damage-inducible, beta	Rattus norvegicus	80-87
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	25-38	growth arrest and DNA-damage-inducible, beta	Rattus norvegicus	116-123
26388164-5	2015	FSH-stimulated IRS-2 expression was inhibited by actinomycin D or cycloheximide.	Cycloheximide	66-79	insulin receptor substrate 2	Homo sapiens	15-20
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	25-38	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Rattus norvegicus	163-168
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	40-43	growth arrest and DNA-damage-inducible, beta	Rattus norvegicus	80-87
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	40-43	growth arrest and DNA-damage-inducible, beta	Rattus norvegicus	116-123
26698301-7	2015	Moreover, treatment with Cycloheximide (CHX) inhibited endogenous expression of Gadd45b, and promoted expression of Gadd45b after co-treated with lentivirus shRNA-Huwe1.	Cycloheximide	40-43	HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1	Rattus norvegicus	163-168
26568031-6	2015	Using commonly employed cycloheximide as a representative compound, we show that protein synthesis inhibition increased nanoclustering and effector recruitment specifically of active H-ras but not of K-ras.	Cycloheximide	24-37	HRas proto-oncogene, GTPase	Rattus norvegicus	183-188
26568031-7	2015	Consistent with these data, cycloheximide treatment activated both Erk and Akt kinases and specifically promoted H-rasG12V-induced, but not K-rasG12V-induced, PC12 cell differentiation.	Cycloheximide	28-41	Eph receptor B1	Rattus norvegicus	67-70
26568031-7	2015	Consistent with these data, cycloheximide treatment activated both Erk and Akt kinases and specifically promoted H-rasG12V-induced, but not K-rasG12V-induced, PC12 cell differentiation.	Cycloheximide	28-41	AKT serine/threonine kinase 1	Rattus norvegicus	75-78
26639638-4	2015	The results indicated that histone methyltransferase G9a, but not GLP, was involved in the regulation of asymmetric H3K9me2, and G9a was the methyltransferase that induced the appearance of H3K9me2 in the male pronucleus of the zygote treated with cycloheximide.	Cycloheximide	248-261	euchromatic histone lysine N-methyltransferase 2	Mus musculus	53-56
26639638-4	2015	The results indicated that histone methyltransferase G9a, but not GLP, was involved in the regulation of asymmetric H3K9me2, and G9a was the methyltransferase that induced the appearance of H3K9me2 in the male pronucleus of the zygote treated with cycloheximide.	Cycloheximide	248-261	euchromatic histone lysine N-methyltransferase 2	Mus musculus	129-132
26781795-4	2015	Treatment of HL-1 cells with either cycloheximide or MG132 caused an appreciable increase in the amount of AMPKalpha2 protein in ARID5B knockdown cells, which suggests that knockdown of ARID5B mRNA extends the half-life of AMPKalpha2 protein in HL-1 cells via yet unidentified mechanisms.	Cycloheximide	36-49	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	107-117
26781795-4	2015	Treatment of HL-1 cells with either cycloheximide or MG132 caused an appreciable increase in the amount of AMPKalpha2 protein in ARID5B knockdown cells, which suggests that knockdown of ARID5B mRNA extends the half-life of AMPKalpha2 protein in HL-1 cells via yet unidentified mechanisms.	Cycloheximide	36-49	AT rich interactive domain 5B (MRF1-like)	Mus musculus	129-135
26781795-4	2015	Treatment of HL-1 cells with either cycloheximide or MG132 caused an appreciable increase in the amount of AMPKalpha2 protein in ARID5B knockdown cells, which suggests that knockdown of ARID5B mRNA extends the half-life of AMPKalpha2 protein in HL-1 cells via yet unidentified mechanisms.	Cycloheximide	36-49	AT rich interactive domain 5B (MRF1-like)	Mus musculus	186-192
26781795-4	2015	Treatment of HL-1 cells with either cycloheximide or MG132 caused an appreciable increase in the amount of AMPKalpha2 protein in ARID5B knockdown cells, which suggests that knockdown of ARID5B mRNA extends the half-life of AMPKalpha2 protein in HL-1 cells via yet unidentified mechanisms.	Cycloheximide	36-49	protein kinase, AMP-activated, alpha 2 catalytic subunit	Mus musculus	223-233
26535693-3	2015	In addition, the kinetics and localization of the US2 gene and protein were determined by quantitative real-time fluorescent PCR, ganciclovir (GCV), and cycloheximide (CHX) treatment, western-blot, and indirect immunofluorescence assay.	Cycloheximide	153-166	usherin	Homo sapiens	50-53
26606920-8	2015	The UL54 transcript was detected as early as 0.5 h, and peak expression was observed at 24 h. The UL54 gene was insensitive to the DNA polymerase inhibitor Ganciclovir (GCV) and the protein synthesis inhibitor Cycloheximide (CHX), both of which confirmed that UL54 was an immediate early gene.	Cycloheximide	225-228	UL54	Anatid alphaherpesvirus 1	98-102
26606920-8	2015	The UL54 transcript was detected as early as 0.5 h, and peak expression was observed at 24 h. The UL54 gene was insensitive to the DNA polymerase inhibitor Ganciclovir (GCV) and the protein synthesis inhibitor Cycloheximide (CHX), both of which confirmed that UL54 was an immediate early gene.	Cycloheximide	225-228	UL54	Anatid alphaherpesvirus 1	98-102
26327163-5	2015	Nicotine-induced GLAST mRNA expression was significantly inhibited by cycloheximide pretreatment, indicating that a protein intermediary, such as a growth factor, is required for GLAST expression.	Cycloheximide	70-83	solute carrier family 1 member 3	Rattus norvegicus	17-22
26327163-5	2015	Nicotine-induced GLAST mRNA expression was significantly inhibited by cycloheximide pretreatment, indicating that a protein intermediary, such as a growth factor, is required for GLAST expression.	Cycloheximide	70-83	solute carrier family 1 member 3	Rattus norvegicus	179-184
26603452-6	2015	On the other hand, CHX treatment enhanced cell proliferation by 27% (P &lt; 0.01), increased the expression of p120-catenin by 24% (P &lt; 0.04), and of Rho, a GTPase involved in cytoskeleton remodeling, by 18% (P &lt; 0.03).	Cycloheximide	19-22	catenin delta 1	Homo sapiens	111-123
25828538-7	2015	TGF-beta suppression of Ift88 is still observed when the cells are cultured in the presence of a transcriptional inhibitor while the TGF-beta suppression is weakened in the presence of a protein synthesis inhibitor, cycloheximide.	Cycloheximide	216-229	transforming growth factor, beta 1	Mus musculus	133-141
26535693-3	2015	In addition, the kinetics and localization of the US2 gene and protein were determined by quantitative real-time fluorescent PCR, ganciclovir (GCV), and cycloheximide (CHX) treatment, western-blot, and indirect immunofluorescence assay.	Cycloheximide	168-171	usherin	Homo sapiens	50-53
26112988-3	2015	The oncogenic ANP32C protein appears to be highly unstable with a rapid degradation (t1/2&gt;30 min) occurring upon treatment of cells with cycloheximide.	Cycloheximide	140-153	acidic nuclear phosphoprotein 32 family member C	Homo sapiens	14-20
25950825-8	2015	Inhibition of eIF2-P and translational control reduced viability following UVB that was alleviated by cycloheximide (CHX), indicating that translation repression through eIF2-P is central to keratinocyte survival.	Cycloheximide	102-115	eukaryotic translation initiation factor 2 subunit beta	Homo sapiens	14-18
26198031-2	2015	Incubation of human dermal fibroblasts with TAPF (TNF Apoptosis Protection Fraction) protects them from apoptosis induced by the subsequent addition of TNF and cycloheximide (CHX).	Cycloheximide	160-173	tumor necrosis factor	Homo sapiens	50-53
26198031-2	2015	Incubation of human dermal fibroblasts with TAPF (TNF Apoptosis Protection Fraction) protects them from apoptosis induced by the subsequent addition of TNF and cycloheximide (CHX).	Cycloheximide	175-178	tumor necrosis factor	Homo sapiens	50-53
25950825-8	2015	Inhibition of eIF2-P and translational control reduced viability following UVB that was alleviated by cycloheximide (CHX), indicating that translation repression through eIF2-P is central to keratinocyte survival.	Cycloheximide	117-120	eukaryotic translation initiation factor 2 subunit beta	Homo sapiens	14-18
25950825-8	2015	Inhibition of eIF2-P and translational control reduced viability following UVB that was alleviated by cycloheximide (CHX), indicating that translation repression through eIF2-P is central to keratinocyte survival.	Cycloheximide	117-120	eukaryotic translation initiation factor 2 subunit beta	Homo sapiens	170-174
26340004-6	2015	To characterize the mechanism of activation of Hog1 during carbon stress, we examined the turnover of Ssk1 protein levels upon glucose starvation in the presence of cycloheximide and monitored protein levels by western blotting.	Cycloheximide	165-178	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	47-51
26362312-7	2015	Cycloheximide chase experiments were performed to detect the half-life of SNAIL1.	Cycloheximide	0-13	snail family transcriptional repressor 1	Homo sapiens	74-80
26212436-6	2015	Cycloheximide chase analysis revealed that TNF-alpha (10 ng/ml) alone or in combination with IFN-gamma (5 ng/ml) accelerated the degradation of Cx43 protein in cultured spinal astrocytes.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	43-52
26212436-6	2015	Cycloheximide chase analysis revealed that TNF-alpha (10 ng/ml) alone or in combination with IFN-gamma (5 ng/ml) accelerated the degradation of Cx43 protein in cultured spinal astrocytes.	Cycloheximide	0-13	interferon gamma	Rattus norvegicus	93-102
26212436-6	2015	Cycloheximide chase analysis revealed that TNF-alpha (10 ng/ml) alone or in combination with IFN-gamma (5 ng/ml) accelerated the degradation of Cx43 protein in cultured spinal astrocytes.	Cycloheximide	0-13	gap junction protein, alpha 1	Rattus norvegicus	144-148
26313006-8	2015	Inhibition of CyclinB1 induction by Cycloheximide or CDK1 activity by Roscovitine significantly prevented FQI-induced mitotic arrest.	Cycloheximide	36-49	cyclin B1	Mus musculus	14-22
26225746-6	2015	Treatment of PC12D cells with cycloheximide showed that total-TH protein level was reduced by the DA- or BH4-depletion.	Cycloheximide	30-43	tyrosine hydroxylase	Rattus norvegicus	62-64
26340004-6	2015	To characterize the mechanism of activation of Hog1 during carbon stress, we examined the turnover of Ssk1 protein levels upon glucose starvation in the presence of cycloheximide and monitored protein levels by western blotting.	Cycloheximide	165-178	mitogen-activated protein kinase kinase kinase SSK1	Saccharomyces cerevisiae S288C	102-106
25936522-5	2015	In HUVEC depleted of coronin 1A by siRNA transfection, tumor necrosis factor alpha (TNFalpha)+cyclohexamide (CHX) treatment resulted in a decrease in the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive apoptotic cells.	Cycloheximide	109-112	coronin 1A	Homo sapiens	21-31
26338325-8	2015	Cycloheximide chase assays revealed a shortening of APP half-life with exogenous TFEB expression, which was prevented by concomitant inhibition of lysosomal acidification.	Cycloheximide	0-13	transcription factor EB	Mus musculus	81-85
25936522-5	2015	In HUVEC depleted of coronin 1A by siRNA transfection, tumor necrosis factor alpha (TNFalpha)+cyclohexamide (CHX) treatment resulted in a decrease in the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive apoptotic cells.	Cycloheximide	109-112	tumor necrosis factor	Homo sapiens	55-82
25913151-9	2015	Protein synthesis is also required for type I NRG1 mRNA transcription as cycloheximide produced a super-induction of type I, but not type III NRG1 mRNA, possibly through a mechanism involving sustained activation of MAPK and PI3K.	Cycloheximide	73-86	neuregulin 1	Rattus norvegicus	46-50
25913151-9	2015	Protein synthesis is also required for type I NRG1 mRNA transcription as cycloheximide produced a super-induction of type I, but not type III NRG1 mRNA, possibly through a mechanism involving sustained activation of MAPK and PI3K.	Cycloheximide	73-86	neuregulin 1	Rattus norvegicus	142-146
24436242-8	2015	Furthermore, cycloheximide chase showed that PC7/furin siRNA regulation occurred at the level of HIF-1alpha translation.	Cycloheximide	13-26	proprotein convertase subtilisin/kexin type 7	Homo sapiens	45-48
26096700-6	2015	Furthermore, oroxylin A and tectorigenin potently inhibited LPS/CHX-induced phosphorylation of phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase lipoamide kinase isozyme 1, Akt, and glycogen synthase kinase-3beta in the Tat-transduced cells, D3-transfected CHME5 cells, and D3-infected human primary macrophages.	Cycloheximide	64-67	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	95-120
24436242-8	2015	Furthermore, cycloheximide chase showed that PC7/furin siRNA regulation occurred at the level of HIF-1alpha translation.	Cycloheximide	13-26	furin, paired basic amino acid cleaving enzyme	Homo sapiens	49-54
24436242-8	2015	Furthermore, cycloheximide chase showed that PC7/furin siRNA regulation occurred at the level of HIF-1alpha translation.	Cycloheximide	13-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	97-107
26124282-9	2015	Third, protein stabilization also occurred, as indicated by PLD resistance to cycloheximide-induced EGFR protein degradation.	Cycloheximide	78-91	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	60-63
26124282-9	2015	Third, protein stabilization also occurred, as indicated by PLD resistance to cycloheximide-induced EGFR protein degradation.	Cycloheximide	78-91	epidermal growth factor receptor	Homo sapiens	100-104
26096700-6	2015	Furthermore, oroxylin A and tectorigenin potently inhibited LPS/CHX-induced phosphorylation of phosphoinositide 3-kinase (PI3K), pyruvate dehydrogenase lipoamide kinase isozyme 1, Akt, and glycogen synthase kinase-3beta in the Tat-transduced cells, D3-transfected CHME5 cells, and D3-infected human primary macrophages.	Cycloheximide	64-67	AKT serine/threonine kinase 1	Homo sapiens	129-219
26086093-4	2015	27OHChol-induced transcription of the IL-8 gene was blocked by cycloheximide, but not by polymyxin B.	Cycloheximide	63-76	C-X-C motif chemokine ligand 8	Homo sapiens	38-42
26369285-9	2015	Cycloheximide inhibition experiments indicated that the TRAIP protein has a half-life of around four hours.	Cycloheximide	0-13	TRAF interacting protein	Homo sapiens	56-61
26152716-7	2015	The increased recovery rate is not due to enhanced protein synthesis, as hERG mRNA expression was not altered by low K(+) exposure, and the increased recovery was observed in the presence of the protein biosynthesis inhibitor cycloheximide.	Cycloheximide	226-239	ETS transcription factor ERG	Homo sapiens	73-77
26269414-6	2015	The VDR coimmunoprecipitated with all three subunits, and 1,25D treatment accelerated subunit turnover in cycloheximide-treated cells.	Cycloheximide	106-119	vitamin D receptor	Homo sapiens	4-7
26071181-3	2015	Stable overexpression of wild-type CD97 reduced serum starvation- and staurosporine-induced intrinsic and tumor necrosis factor (TNF)/cycloheximide-induced extrinsic apoptosis, indicated by an increase in cell viability, a lower percentage of cells within the subG0/G1 phase, expressing annexin V, or having condensed nuclei, and a reduction of DNA laddering.	Cycloheximide	134-147	adhesion G protein-coupled receptor E5	Homo sapiens	35-39
25972450-8	2015	This in vivo finding is corroborated by the in vitro study showing that cultured cardiac fibroblasts treated with recombinant sFRP2 protein exhibited progressive increase in the expression and activity of TNAP, which was completely abrogated by cycloheximide or tunicamycin.	Cycloheximide	245-258	secreted frizzled-related protein 2	Mus musculus	126-131
26622397-10	2015	In addition, examination of cytoplasmic vacuolization using microscopy indicated that there were a small number of paraptosis cells present at 24 h. The expression levels of Bcl-2 was significantly decreased, while Bax was significantly increased at 48 h. Furthermore, cycloheximide treatment was demonstrated to significantly increase Bcl-2 expression, while decreasing Bax expression (P&gt;0.05).	Cycloheximide	269-282	BCL2 apoptosis regulator	Homo sapiens	174-179
26622397-10	2015	In addition, examination of cytoplasmic vacuolization using microscopy indicated that there were a small number of paraptosis cells present at 24 h. The expression levels of Bcl-2 was significantly decreased, while Bax was significantly increased at 48 h. Furthermore, cycloheximide treatment was demonstrated to significantly increase Bcl-2 expression, while decreasing Bax expression (P&gt;0.05).	Cycloheximide	269-282	BCL2 associated X, apoptosis regulator	Homo sapiens	215-218
26071181-3	2015	Stable overexpression of wild-type CD97 reduced serum starvation- and staurosporine-induced intrinsic and tumor necrosis factor (TNF)/cycloheximide-induced extrinsic apoptosis, indicated by an increase in cell viability, a lower percentage of cells within the subG0/G1 phase, expressing annexin V, or having condensed nuclei, and a reduction of DNA laddering.	Cycloheximide	134-147	annexin A5	Homo sapiens	287-296
25862406-13	2015	ASCT2 stability was determined using cycloheximide.	Cycloheximide	37-50	solute carrier family 1 member 5	Homo sapiens	0-5
25736839-3	2015	In this study, we show that the Arabidopsis sulphotransferase AtSOT12 could sulphonate the bacterial-produced toxin cycloheximide.	Cycloheximide	116-129	sulfotransferase 12	Arabidopsis thaliana	62-69
25736839-4	2015	Loss-of-function mutant sot12 exhibited hypersensitive phenotype to cycloheximide, and expression of AtSOT12 protein in yeast cells conferred resistance to this toxic compound.	Cycloheximide	68-81	sulfotransferase 12	Arabidopsis thaliana	24-29
25981695-7	2015	In addition, cycloheximide lowered DFO-induced Egr1 mRNA levels.	Cycloheximide	13-26	early growth response 1	Homo sapiens	47-51
25162503-7	2015	The inhibitory effect of p-NP (10(-6) M) on spontaneous contractions was blocked by actinomycin D (p&lt;0.001), cycloheximide (p&lt;0.001), fulvestrant (p&lt;0.001) and compound 1b (p&lt;0.001).	Cycloheximide	112-125	purine nucleoside phosphorylase	Rattus norvegicus	25-29
25869056-8	2015	Results in experiments treated with MG-132 or cycloheximide (CHX) showed that andrographolide lowered the content of beta-catenin in cell nucleus resulting from accelerating the degradation of beta-catenin.	Cycloheximide	46-59	catenin (cadherin associated protein), beta 1	Mus musculus	117-129
25870205-5	2015	Addition of cycloheximide, a transforming growth factor (TGF)-beta inhibitor (SB431542), or a neutralizing antibody against TGF-beta1 attenuated the force-induced expression of SOST and POSTN as well as sclerostin and periostin, indicating a role of TGF-beta1 in the pressure-induced expression of these proteins.	Cycloheximide	12-25	sclerostin	Homo sapiens	177-181
25869056-8	2015	Results in experiments treated with MG-132 or cycloheximide (CHX) showed that andrographolide lowered the content of beta-catenin in cell nucleus resulting from accelerating the degradation of beta-catenin.	Cycloheximide	61-64	catenin (cadherin associated protein), beta 1	Mus musculus	117-129
25870205-5	2015	Addition of cycloheximide, a transforming growth factor (TGF)-beta inhibitor (SB431542), or a neutralizing antibody against TGF-beta1 attenuated the force-induced expression of SOST and POSTN as well as sclerostin and periostin, indicating a role of TGF-beta1 in the pressure-induced expression of these proteins.	Cycloheximide	12-25	periostin	Homo sapiens	186-191
25869056-8	2015	Results in experiments treated with MG-132 or cycloheximide (CHX) showed that andrographolide lowered the content of beta-catenin in cell nucleus resulting from accelerating the degradation of beta-catenin.	Cycloheximide	61-64	catenin (cadherin associated protein), beta 1	Mus musculus	193-205
25870205-5	2015	Addition of cycloheximide, a transforming growth factor (TGF)-beta inhibitor (SB431542), or a neutralizing antibody against TGF-beta1 attenuated the force-induced expression of SOST and POSTN as well as sclerostin and periostin, indicating a role of TGF-beta1 in the pressure-induced expression of these proteins.	Cycloheximide	12-25	periostin	Homo sapiens	218-227
25499076-7	2015	To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification.	Cycloheximide	137-150	prolactin	Homo sapiens	24-28
25870205-5	2015	Addition of cycloheximide, a transforming growth factor (TGF)-beta inhibitor (SB431542), or a neutralizing antibody against TGF-beta1 attenuated the force-induced expression of SOST and POSTN as well as sclerostin and periostin, indicating a role of TGF-beta1 in the pressure-induced expression of these proteins.	Cycloheximide	12-25	transforming growth factor beta 1	Homo sapiens	250-259
25907793-12	2015	Secondly, the inhibition of ERRalpha by treatment of MC4-L2 human breast cancer cells with XCT790 (inverse agonist ligand of ERRalpha) before injection into the animals not only increased LDH-B expression in the tumour, but also decreased MCT1 expression in the CX group in comparison to the C group.	Cycloheximide	262-264	estrogen related receptor, alpha	Mus musculus	28-36
25907793-12	2015	Secondly, the inhibition of ERRalpha by treatment of MC4-L2 human breast cancer cells with XCT790 (inverse agonist ligand of ERRalpha) before injection into the animals not only increased LDH-B expression in the tumour, but also decreased MCT1 expression in the CX group in comparison to the C group.	Cycloheximide	262-264	estrogen related receptor alpha	Homo sapiens	125-133
25725292-0	2015	Mitochondria and NADPH oxidases are the major sources of TNF-alpha/cycloheximide-induced oxidative stress in murine intestinal epithelial MODE-K cells.	Cycloheximide	67-80	tumor necrosis factor	Mus musculus	57-66
25725292-1	2015	TNF-alpha/cycloheximide (CHX)-induced apoptosis of the mouse intestinal epithelial cell line MODE-K corresponds with the production of reactive oxygen species (ROS).	Cycloheximide	10-23	tumor necrosis factor	Mus musculus	0-9
25725292-1	2015	TNF-alpha/cycloheximide (CHX)-induced apoptosis of the mouse intestinal epithelial cell line MODE-K corresponds with the production of reactive oxygen species (ROS).	Cycloheximide	25-28	tumor necrosis factor	Mus musculus	0-9
26502574-4	2015	The IL-1 beta-mediated effects were also blocked by cycloheximide, an inhibitor of protein synthesis, as well as AMT and 1400W, which are iNOS inhibitors, and PTIO, an NO scavenger.	Cycloheximide	52-65	interleukin 1 beta	Rattus norvegicus	4-13
26101218-4	2015	In this paper, we show that, in response to alpha pheromone, MFA2 mRNA is assembled with two types of granules; both contain some canonical PB proteins, yet they differ in size, localization, motility, and sensitivity to cycloheximide.	Cycloheximide	221-234	mating pheromone a	Saccharomyces cerevisiae S288C	61-65
25499076-7	2015	To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification.	Cycloheximide	137-150	prolactin	Homo sapiens	244-248
25468426-5	2015	We identified three lncRNAs (GAS5, IDI2-AS1, and SNHG15) that responded to cycloheximide in HEK293 cells.	Cycloheximide	75-88	growth arrest specific 5	Homo sapiens	29-33
25878246-7	2015	The p53R2 protein was cleaved in a caspase-dependent manner in K-562 cells treated with inhibitors of the Bcr-Abl oncogenic kinase and in HeLa 229 cells incubated with TNF-alpha and cycloheximide.	Cycloheximide	182-195	ribonucleotide reductase regulatory TP53 inducible subunit M2B	Homo sapiens	4-9
25468426-5	2015	We identified three lncRNAs (GAS5, IDI2-AS1, and SNHG15) that responded to cycloheximide in HEK293 cells.	Cycloheximide	75-88	isopentenyl-diphosphate delta isomerase 2	Homo sapiens	35-39
25468426-5	2015	We identified three lncRNAs (GAS5, IDI2-AS1, and SNHG15) that responded to cycloheximide in HEK293 cells.	Cycloheximide	75-88	prostaglandin D2 receptor	Homo sapiens	40-43
25468426-5	2015	We identified three lncRNAs (GAS5, IDI2-AS1, and SNHG15) that responded to cycloheximide in HEK293 cells.	Cycloheximide	75-88	small nucleolar RNA host gene 15	Homo sapiens	49-55
25925126-6	2015	Since in most cancer cells survival pathways counteract the effects of TRAIL-induced RCD, sensitizers such as cycloheximide (CHX) are frequently added in cell culture to overcome this problem.	Cycloheximide	110-123	TNF superfamily member 10	Homo sapiens	71-76
24924397-4	2015	Treatment of cells with cycloheximide in the presence of proteasome inhibitor MG132 suggested that Mcl-1 protein levels were regulated at the post-translational step.	Cycloheximide	24-37	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	99-104
25843580-4	2015	CPG13 expression was induced by the addition of 20E, which was inhibited by cycloheximide in the wing disc.	Cycloheximide	76-89	cuticular protein glycine-rich 13	Bombyx mori	0-5
25648792-9	2015	A translation inhibitor cycloheximide and UPF1 small interfering RNA (UPF1 siRNA) significantly increased mRNA or protein expression of EGFP-PC in cells transfected with the mutant plasmids.	Cycloheximide	24-37	UPF1 RNA helicase and ATPase	Homo sapiens	70-74
25594392-7	2015	Pretreatment with cycloheximide, an ER stress inhibitor rescued PA-induced cell death, which was accompanied by the suppression of ER-stress-related HSPA5 and CHOP proteins.	Cycloheximide	18-31	heat shock protein family A (Hsp70) member 5	Homo sapiens	149-154
25594392-7	2015	Pretreatment with cycloheximide, an ER stress inhibitor rescued PA-induced cell death, which was accompanied by the suppression of ER-stress-related HSPA5 and CHOP proteins.	Cycloheximide	18-31	DNA damage inducible transcript 3	Homo sapiens	159-163
24728914-6	2015	Similarly, LDBK produced a significant increase in protein levels of LFA-1 and Mac-1 integrins in human neutrophils, an effect that was reversed by pretreatment of cells with 10 microg/ml cycloheximide or a B1R antagonist.	Cycloheximide	188-201	integrin subunit alpha L	Homo sapiens	69-74
24728914-6	2015	Similarly, LDBK produced a significant increase in protein levels of LFA-1 and Mac-1 integrins in human neutrophils, an effect that was reversed by pretreatment of cells with 10 microg/ml cycloheximide or a B1R antagonist.	Cycloheximide	188-201	integrin subunit alpha M	Homo sapiens	79-84
24728914-6	2015	Similarly, LDBK produced a significant increase in protein levels of LFA-1 and Mac-1 integrins in human neutrophils, an effect that was reversed by pretreatment of cells with 10 microg/ml cycloheximide or a B1R antagonist.	Cycloheximide	188-201	bradykinin receptor B1	Homo sapiens	207-210
25870856-10	2015	Accordingly, by applying a combinatorial approach, we were able to generate novel, hybrid inhibitors consisting of cycloheximide and adamantane, two known FKBP inhibitors that interact with different parts of the PPIase domain, respectively.	Cycloheximide	115-128	FKBP prolyl isomerase 7	Homo sapiens	213-219
25870856-12	2015	Hence, we also propose that cycloheximide derivatives with adamantyl moieties are potent PPIase inhibitors with multiple targets in L. pneumophila.	Cycloheximide	28-41	FKBP prolyl isomerase 7	Homo sapiens	89-95
25907486-3	2015	ABCA1 mRNA and protein expression in mature 3T3-L1 adipocytes post stimulation with various concentrations of insulin was detected by real-time fluorescence-based quantitative techniques and Western blot, respectively, in the absence and presence of CHX (cycloheximide, CHX), calpeptin (calpain pathway inhibitor) or MG-132 (proteasome pathway inhibitor).	Cycloheximide	250-253	ATP binding cassette subfamily A member 1	Homo sapiens	0-5
25475372-6	2015	Quantitative gene expression analysis and cycloheximide chase experiments suggest that PRMT5 regulates MYCN at a post-transcriptional level.	Cycloheximide	42-55	protein arginine methyltransferase 5	Homo sapiens	87-92
25475372-6	2015	Quantitative gene expression analysis and cycloheximide chase experiments suggest that PRMT5 regulates MYCN at a post-transcriptional level.	Cycloheximide	42-55	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	103-107
25337692-8	2015	In addition, omeprazole reduced tyrosinase protein abundance in the presence of cycloheximide, suggestive of increased degradation.	Cycloheximide	80-93	tyrosinase	Homo sapiens	32-42
25425624-4	2015	This loss of Synpo, which occurred in 30-80 minutes, was also seen after treatment with the translational inhibitor cycloheximide.	Cycloheximide	116-129	synaptopodin	Mus musculus	13-18
25907486-3	2015	ABCA1 mRNA and protein expression in mature 3T3-L1 adipocytes post stimulation with various concentrations of insulin was detected by real-time fluorescence-based quantitative techniques and Western blot, respectively, in the absence and presence of CHX (cycloheximide, CHX), calpeptin (calpain pathway inhibitor) or MG-132 (proteasome pathway inhibitor).	Cycloheximide	255-268	ATP binding cassette subfamily A member 1	Homo sapiens	0-5
25907486-3	2015	ABCA1 mRNA and protein expression in mature 3T3-L1 adipocytes post stimulation with various concentrations of insulin was detected by real-time fluorescence-based quantitative techniques and Western blot, respectively, in the absence and presence of CHX (cycloheximide, CHX), calpeptin (calpain pathway inhibitor) or MG-132 (proteasome pathway inhibitor).	Cycloheximide	270-273	ATP binding cassette subfamily A member 1	Homo sapiens	0-5
26044139-6	2015	Notably, Clr-b loss could be partially blocked by titrated cycloheximide treatment, suggesting that early viral or nascent host proteins are required for Clr-b downregulation.	Cycloheximide	59-72	C-type lectin domain family 2, member d	Mus musculus	9-14
25513960-2	2015	TNF-alpha induced up-regulation of cIAP2, whereas cycloheximide (CHX) induced down-regulation of XIAP and survivin.	Cycloheximide	50-63	X-linked inhibitor of apoptosis	Homo sapiens	97-101
25513960-2	2015	TNF-alpha induced up-regulation of cIAP2, whereas cycloheximide (CHX) induced down-regulation of XIAP and survivin.	Cycloheximide	65-68	X-linked inhibitor of apoptosis	Homo sapiens	97-101
25513960-4	2015	Treatment of MKN28 cells with TNF-alpha plus CHX induced degradation of survivin and activation of caspase-8 and -3, followed by degradation of cIAP1 and XIAP and apoptosis.	Cycloheximide	45-48	caspase 8	Homo sapiens	99-115
25513960-4	2015	Treatment of MKN28 cells with TNF-alpha plus CHX induced degradation of survivin and activation of caspase-8 and -3, followed by degradation of cIAP1 and XIAP and apoptosis.	Cycloheximide	45-48	baculoviral IAP repeat containing 2	Homo sapiens	144-149
25513960-4	2015	Treatment of MKN28 cells with TNF-alpha plus CHX induced degradation of survivin and activation of caspase-8 and -3, followed by degradation of cIAP1 and XIAP and apoptosis.	Cycloheximide	45-48	X-linked inhibitor of apoptosis	Homo sapiens	154-158
25792980-5	2015	To determine whether insulin affects SESN2 degradation, we assessed SESN2 turnover by applying the protein synthesis inhibitor, cycloheximide (CHX), and found that following insulin treatment SESN2 protein levels were reduced significantly slower than non-insulin-treated cells.	Cycloheximide	128-141	insulin	Homo sapiens	174-181
25792980-5	2015	To determine whether insulin affects SESN2 degradation, we assessed SESN2 turnover by applying the protein synthesis inhibitor, cycloheximide (CHX), and found that following insulin treatment SESN2 protein levels were reduced significantly slower than non-insulin-treated cells.	Cycloheximide	128-141	insulin	Homo sapiens	174-181
25557483-6	2015	After cycloheximide treatment, cyclin D1 in the persistently infected cells lasted several hours longer than those in acutely infected cells.	Cycloheximide	6-19	cyclin D1	Homo sapiens	31-40
25513960-5	2015	Proteasome inhibitors (MG132 and epoxomicin) suppressed TNF-alpha plus CHX-induced degradation of survivin, cIAP1, and XIAP as well as apoptosis.	Cycloheximide	71-74	baculoviral IAP repeat containing 2	Homo sapiens	108-113
25513960-5	2015	Proteasome inhibitors (MG132 and epoxomicin) suppressed TNF-alpha plus CHX-induced degradation of survivin, cIAP1, and XIAP as well as apoptosis.	Cycloheximide	71-74	X-linked inhibitor of apoptosis	Homo sapiens	119-123
25513960-9	2015	These findings suggest that TNF-alpha plus CHX-induced apoptosis of gastric cancer MKN28 cells may be caused by accelerated degradation of the IAP family members (survivin, cIAP1, and XIAP), in addition to inhibition of NF-kappaB-dependent synthesis of anti-apoptotic molecules.	Cycloheximide	43-46	baculoviral IAP repeat containing 2	Homo sapiens	173-178
25513960-9	2015	These findings suggest that TNF-alpha plus CHX-induced apoptosis of gastric cancer MKN28 cells may be caused by accelerated degradation of the IAP family members (survivin, cIAP1, and XIAP), in addition to inhibition of NF-kappaB-dependent synthesis of anti-apoptotic molecules.	Cycloheximide	43-46	X-linked inhibitor of apoptosis	Homo sapiens	184-188
25513960-9	2015	These findings suggest that TNF-alpha plus CHX-induced apoptosis of gastric cancer MKN28 cells may be caused by accelerated degradation of the IAP family members (survivin, cIAP1, and XIAP), in addition to inhibition of NF-kappaB-dependent synthesis of anti-apoptotic molecules.	Cycloheximide	43-46	nuclear factor kappa B subunit 1	Homo sapiens	220-229
29082276-3	2015	Here we present a full cycloheximide chase assay in our laboratory using a lung adenocarcinoma cell line, CL1-5, as a model.	Cycloheximide	23-36	adhesion G protein-coupled receptor L1	Homo sapiens	106-111
25445539-6	2015	The enhancing effect of zinc ion on the level of TPPP/p25 was independent of the expression level of the protein produced by doxycycline induction at different levels or inhibition of the protein synthesis by cycloheximide.	Cycloheximide	209-222	tubulin polymerization promoting protein	Rattus norvegicus	49-57
26626244-4	2015	RESULTS: The results showed that the numbers of microparticles were increased by tumour necrosis factor (TNF) or the combination of TNF and cycloheximide (CHX).	Cycloheximide	155-158	tumor necrosis factor	Homo sapiens	132-135
26044139-6	2015	Notably, Clr-b loss could be partially blocked by titrated cycloheximide treatment, suggesting that early viral or nascent host proteins are required for Clr-b downregulation.	Cycloheximide	59-72	C-type lectin domain family 2, member d	Mus musculus	154-159
25771978-6	2015	Exposure to cycloheximide revealed that CtIP turns over at DSB sites downstream of resection.	Cycloheximide	12-25	RB binding protein 8, endonuclease	Homo sapiens	40-44
25187356-8	2015	In addition, induction of ATHB12 in the presence of cycloheximide increased the expression of several genes related to cell expansion, such as EXPANSIN A10 (EXPA10) and DWARF4 (DWF4).	Cycloheximide	52-65	homeobox 12	Arabidopsis thaliana	26-32
25187356-8	2015	In addition, induction of ATHB12 in the presence of cycloheximide increased the expression of several genes related to cell expansion, such as EXPANSIN A10 (EXPA10) and DWARF4 (DWF4).	Cycloheximide	52-65	expansin A10	Arabidopsis thaliana	143-155
25187356-8	2015	In addition, induction of ATHB12 in the presence of cycloheximide increased the expression of several genes related to cell expansion, such as EXPANSIN A10 (EXPA10) and DWARF4 (DWF4).	Cycloheximide	52-65	expansin A10	Arabidopsis thaliana	157-163
25187356-8	2015	In addition, induction of ATHB12 in the presence of cycloheximide increased the expression of several genes related to cell expansion, such as EXPANSIN A10 (EXPA10) and DWARF4 (DWF4).	Cycloheximide	52-65	Cytochrome P450 superfamily protein	Arabidopsis thaliana	169-175
25187356-8	2015	In addition, induction of ATHB12 in the presence of cycloheximide increased the expression of several genes related to cell expansion, such as EXPANSIN A10 (EXPA10) and DWARF4 (DWF4).	Cycloheximide	52-65	Cytochrome P450 superfamily protein	Arabidopsis thaliana	177-181
25239507-4	2015	Tracking of a hybrid fluorescent protein containing a UCN I signal peptide expressed in A172 human glioblastoma cells revealed that fluorescence in secretory granules could be decreased by cycloheximide (100mug/ml), indicating that the forward transport of secretory granules containing fluorescent protein was not altered by the inhibition of protein synthesis by cycloheximide.	Cycloheximide	189-202	urocortin	Homo sapiens	54-57
25773964-5	2015	Actinomycin D and cycloheximide were used to block newly synthesized hNIS proteins.	Cycloheximide	18-31	solute carrier family 5 member 5	Homo sapiens	69-73
25239507-4	2015	Tracking of a hybrid fluorescent protein containing a UCN I signal peptide expressed in A172 human glioblastoma cells revealed that fluorescence in secretory granules could be decreased by cycloheximide (100mug/ml), indicating that the forward transport of secretory granules containing fluorescent protein was not altered by the inhibition of protein synthesis by cycloheximide.	Cycloheximide	365-378	urocortin	Homo sapiens	54-57
25401697-6	2014	This was reversed rapidly upon the restoration of glucose, and cyclohexamide (CHX) treatment demonstrated that this deglycosylated VEGFR2 was not a product of de-novo protein synthesis.	Cycloheximide	78-81	kinase insert domain receptor	Homo sapiens	131-137
25315694-9	2014	Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR.	Cycloheximide	151-164	heat shock protein family A (Hsp70) member 8	Homo sapiens	26-31
25315694-9	2014	Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR.	Cycloheximide	151-164	cell death inducing DFFA like effector c	Homo sapiens	93-98
25315694-9	2014	Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR.	Cycloheximide	166-169	heat shock protein family A (Hsp70) member 8	Homo sapiens	26-31
25315694-9	2014	Importantly, knockdown of HSC70 by small interference RNA resulted in increased half-life of FSP27 in cells treated with a protein synthesis inhibitor cycloheximide (CHX) or AICAR.	Cycloheximide	166-169	cell death inducing DFFA like effector c	Homo sapiens	93-98
25242357-5	2014	Moreover, in the presence of cycloheximide, KLF9 significantly increased p53 stability in HCC cells.	Cycloheximide	29-42	Kruppel like factor 9	Homo sapiens	44-48
25242357-5	2014	Moreover, in the presence of cycloheximide, KLF9 significantly increased p53 stability in HCC cells.	Cycloheximide	29-42	tumor protein p53	Homo sapiens	73-76
24477737-6	2014	Cycloheximide chase experiments revealed more rapid turnover of TDP-43 mutant proteins than their wild-type counterpart.	Cycloheximide	0-13	TAR DNA binding protein	Homo sapiens	64-70
24477737-7	2014	The decrease in the TDP-43 level after cycloheximide treatment was partially recovered upon co-treatment with the proteasome inhibitor, epoxomicin, but not the lysosomotropic agent, chloroquine, suggesting involvement of the proteasomal pathway in TDP-43 degradation.	Cycloheximide	39-52	TAR DNA binding protein	Homo sapiens	20-26
24477737-7	2014	The decrease in the TDP-43 level after cycloheximide treatment was partially recovered upon co-treatment with the proteasome inhibitor, epoxomicin, but not the lysosomotropic agent, chloroquine, suggesting involvement of the proteasomal pathway in TDP-43 degradation.	Cycloheximide	39-52	TAR DNA binding protein	Homo sapiens	248-254
25426548-4	2014	FoxM1 downregulation was partially blocked by cycloheximide or actinomycin D, and pulse-chase studies indicate Nutlin-3 enhances FoxM1 mRNA decay.	Cycloheximide	46-59	forkhead box M1	Homo sapiens	0-5
25541949-6	2014	In cycloheximide (CHX)-treated endothelial cells, NONOate, an NO donor, and A23187, an eNOS activator, significantly stabilized SIRT1 protein.	Cycloheximide	3-16	sirtuin 1	Homo sapiens	128-133
25541949-6	2014	In cycloheximide (CHX)-treated endothelial cells, NONOate, an NO donor, and A23187, an eNOS activator, significantly stabilized SIRT1 protein.	Cycloheximide	18-21	sirtuin 1	Homo sapiens	128-133
25530840-5	2014	Turnover of WT and T17M rhodopsin was measured by cycloheximide chase analysis.	Cycloheximide	50-63	rhodopsin	Homo sapiens	24-33
25148872-1	2014	The present study is aimed to determine the protective effect of a novel nanoparticle with antioxidant properties, nanoceria, on reactive oxygen species (ROS) production, and calcium signaling evoked by the tumor necrosis factor-alpha (TNFalpha) in combination with cycloheximide (CHX) on apoptosis in the human histiocytic lymphoma cell line U937.	Cycloheximide	266-279	tumor necrosis factor	Homo sapiens	207-234
25148872-1	2014	The present study is aimed to determine the protective effect of a novel nanoparticle with antioxidant properties, nanoceria, on reactive oxygen species (ROS) production, and calcium signaling evoked by the tumor necrosis factor-alpha (TNFalpha) in combination with cycloheximide (CHX) on apoptosis in the human histiocytic lymphoma cell line U937.	Cycloheximide	266-279	tumor necrosis factor	Homo sapiens	236-244
25148872-1	2014	The present study is aimed to determine the protective effect of a novel nanoparticle with antioxidant properties, nanoceria, on reactive oxygen species (ROS) production, and calcium signaling evoked by the tumor necrosis factor-alpha (TNFalpha) in combination with cycloheximide (CHX) on apoptosis in the human histiocytic lymphoma cell line U937.	Cycloheximide	281-284	tumor necrosis factor	Homo sapiens	207-234
25148872-1	2014	The present study is aimed to determine the protective effect of a novel nanoparticle with antioxidant properties, nanoceria, on reactive oxygen species (ROS) production, and calcium signaling evoked by the tumor necrosis factor-alpha (TNFalpha) in combination with cycloheximide (CHX) on apoptosis in the human histiocytic lymphoma cell line U937.	Cycloheximide	281-284	tumor necrosis factor	Homo sapiens	236-244
25401697-7	2014	VEGFR2 co-receptor Neuropilin-1 was up-regulated four-fold in all MDA-MB-231 cells (parental and two variants) compared to VEGFR2 expression, and was also susceptible to glycemic changes but resistant to CHX treatment for up to 72 hrs.	Cycloheximide	204-207	kinase insert domain receptor	Homo sapiens	0-6
25163517-5	2014	E-cadherin mRNA transcripts were unchanged with starvation, while protein translation inhibition with cycloheximide attenuated E-cadherin protein induction by starvation, suggesting that E-cadherin is regulated at the translational level by serum starvation.	Cycloheximide	102-115	cadherin 1	Homo sapiens	127-137
25163517-5	2014	E-cadherin mRNA transcripts were unchanged with starvation, while protein translation inhibition with cycloheximide attenuated E-cadherin protein induction by starvation, suggesting that E-cadherin is regulated at the translational level by serum starvation.	Cycloheximide	102-115	cadherin 1	Homo sapiens	127-137
25172766-5	2014	We observed that Ptr2 underwent rapid degradation after cycloheximide treatment (half-life, approximately 1 h), and this degradation depended on Rsp5 ubiquitin ligase.	Cycloheximide	56-69	Ptr2p	Saccharomyces cerevisiae S288C	17-21
25465606-8	2014	To examine whether TRalpha is directly induced by T3, we used the translation inhibitor cycloheximide (CHX).	Cycloheximide	88-101	guanine nucleotide binding protein, alpha transducing 1	Mus musculus	19-26
25169430-5	2014	Sesamin delayed the reversal, by the protein synthesis inhibitor cycloheximide (1muM), of the LPS-induced increase of HO-1 protein level.	Cycloheximide	65-78	heme oxygenase 1	Homo sapiens	118-122
25128739-11	2014	Increased HO-1 by HIS was detected at both protein and mRNA levels along with an increase in intracellular peroxide, and this was inhibited by the translational inhibitor, cycloheximide (CHX), the transcriptional inhibitor, actinomycin D (Act D), and the reactive oxygen species scavenger, N-acetylcysteine (NAC).	Cycloheximide	172-185	heme oxygenase 1	Mus musculus	10-14
25128739-11	2014	Increased HO-1 by HIS was detected at both protein and mRNA levels along with an increase in intracellular peroxide, and this was inhibited by the translational inhibitor, cycloheximide (CHX), the transcriptional inhibitor, actinomycin D (Act D), and the reactive oxygen species scavenger, N-acetylcysteine (NAC).	Cycloheximide	187-190	heme oxygenase 1	Mus musculus	10-14
25169430-7	2014	LPS-induced increase of iNOS protein expression was also reversed by cycloheximide, which was not affected by sesamin, unlike HO-1.	Cycloheximide	69-82	nitric oxide synthase 2	Homo sapiens	24-28
25309795-5	2014	METHODS: To confirm the roles of HO-1, carbon monoxide, and cyclic guanosine monophosphate further in the antioxidant effect of HO-1 and bilirubin, cells were treated with cycloheximide, desferoxamine, and zinc deuteroporphyrin IX 2,4 bis glycol, respectively.	Cycloheximide	172-185	heme oxygenase 1	Rattus norvegicus	128-132
25058750-7	2014	Stretch-induced increases in alpha-ENaC expression were suppressed in the presence of either actinomycin D or cycloheximide.	Cycloheximide	110-123	sodium channel, nonvoltage-gated 1 alpha	Mus musculus	29-39
25091623-5	2014	However, 3-DSC-mediated HO-1 induction was completely blocked by treatment with cycloheximide, a translational inhibitor, or rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR).	Cycloheximide	80-93	heme oxygenase 1	Homo sapiens	24-28
25360642-9	2014	Cycloheximide abolished the serum starvation-induced up-regulation of TXNDC5 protein.	Cycloheximide	0-13	thioredoxin domain containing 5	Homo sapiens	70-76
24153105-4	2014	We investigated if Ezh2 controls the fate of embryos at an earlier stage by treating with cycloheximide (CHX) or microinjecting short interfering RNA (siRNA) to restrict embryonic Ezh2 expression during preimplantation.	Cycloheximide	90-103	enhancer of zeste 2 polycomb repressive complex 2 subunit	Mus musculus	19-23
24153105-4	2014	We investigated if Ezh2 controls the fate of embryos at an earlier stage by treating with cycloheximide (CHX) or microinjecting short interfering RNA (siRNA) to restrict embryonic Ezh2 expression during preimplantation.	Cycloheximide	105-108	enhancer of zeste 2 polycomb repressive complex 2 subunit	Mus musculus	19-23
25128767-4	2014	Treatment with actinomycin D or cycloheximide suppressed SGK1 protein levels in cells exposed to CdCl2.	Cycloheximide	32-45	serum/glucocorticoid regulated kinase 1	Homo sapiens	57-61
24806616-9	2014	In contrast to cyclooxygenase 2, the cycloheximide-sensitive PPARbeta/delta expression was not responsive to nuclear factor kappa-light-chain-enhancer of activated B cells inhibition.	Cycloheximide	37-50	peroxisome proliferator-activated receptor delta	Rattus norvegicus	61-69
25119989-8	2014	Treatment of cells with cycloheximide that were harvested at various time points for Western blot analyses was carried out to evaluate p65/RelA protein stability.	Cycloheximide	24-37	RELA proto-oncogene, NF-kB subunit	Homo sapiens	135-138
25119989-8	2014	Treatment of cells with cycloheximide that were harvested at various time points for Western blot analyses was carried out to evaluate p65/RelA protein stability.	Cycloheximide	24-37	RELA proto-oncogene, NF-kB subunit	Homo sapiens	139-143
24601788-7	2014	The translation inhibitor cycloheximide reduced TLR4 protein levels with similar kinetics as PGE2, and its effects were not additive with those of the prostanoid, suggesting that PGE2 inhibits TLR at the translational level.	Cycloheximide	26-39	toll-like receptor 4	Rattus norvegicus	48-52
24983400-5	2014	Ginsenoside Rb1 inhibited lipopolysaccharide/cycloheximide-induced AKT and glycogen synthase kinase-3beta phosphorylation in the D3-transduced macrophages, but not the phosphorylation of PDK-1 and phosphoinositide-3-kinase (PI3K).	Cycloheximide	45-58	RB transcriptional corepressor 1	Homo sapiens	12-15
24872593-5	2014	Viral JNK activation may be blocked by addition of cycloheximide and heat shock protein inhibitors during infection, suggesting that the expression of an IAV-encoded protein is responsible for JNK activation.	Cycloheximide	51-64	mitogen-activated protein kinase 8	Homo sapiens	6-9
24983400-5	2014	Ginsenoside Rb1 inhibited lipopolysaccharide/cycloheximide-induced AKT and glycogen synthase kinase-3beta phosphorylation in the D3-transduced macrophages, but not the phosphorylation of PDK-1 and phosphoinositide-3-kinase (PI3K).	Cycloheximide	45-58	AKT serine/threonine kinase 1	Homo sapiens	67-70
24983400-5	2014	Ginsenoside Rb1 inhibited lipopolysaccharide/cycloheximide-induced AKT and glycogen synthase kinase-3beta phosphorylation in the D3-transduced macrophages, but not the phosphorylation of PDK-1 and phosphoinositide-3-kinase (PI3K).	Cycloheximide	45-58	glycogen synthase kinase 3 beta	Homo sapiens	75-105
24983400-5	2014	Ginsenoside Rb1 inhibited lipopolysaccharide/cycloheximide-induced AKT and glycogen synthase kinase-3beta phosphorylation in the D3-transduced macrophages, but not the phosphorylation of PDK-1 and phosphoinositide-3-kinase (PI3K).	Cycloheximide	45-58	pyruvate dehydrogenase kinase 1	Homo sapiens	187-192
24872593-5	2014	Viral JNK activation may be blocked by addition of cycloheximide and heat shock protein inhibitors during infection, suggesting that the expression of an IAV-encoded protein is responsible for JNK activation.	Cycloheximide	51-64	mitogen-activated protein kinase 8	Homo sapiens	193-196
24939622-6	2014	In contrast, decrease in GCPII protein level by cycloheximide treatment was blocked by VPA, indicating that VPA increases GCPII protein stability.	Cycloheximide	48-61	folate hydrolase 1	Homo sapiens	25-30
24865971-9	2014	Cells lacking Hpm1p are resistant to cycloheximide and verrucarin A and have decreased translational fidelity.	Cycloheximide	37-50	protein-histidine N-methyltransferase	Saccharomyces cerevisiae S288C	14-19
25078078-6	2014	In both species, (a) whereas active CDC2A showed a dynamics similar to cyclin B, inactive CDC2A decreased continuously; (b) when oocytes were blocked in blocking medium containing cycloheximide, PBMP was decelerated significantly while cyclin B and active CDC2A decreasing to the lowest level; (c) whereas sodium vanadate in blocking medium reduced PBMP, epidermal growth factor (EGF) in blocking medium accelerated PBMP significantly with no effect on cyclin B levels.	Cycloheximide	180-193	cyclin-dependent kinase 1	Mus musculus	90-95
25078078-6	2014	In both species, (a) whereas active CDC2A showed a dynamics similar to cyclin B, inactive CDC2A decreased continuously; (b) when oocytes were blocked in blocking medium containing cycloheximide, PBMP was decelerated significantly while cyclin B and active CDC2A decreasing to the lowest level; (c) whereas sodium vanadate in blocking medium reduced PBMP, epidermal growth factor (EGF) in blocking medium accelerated PBMP significantly with no effect on cyclin B levels.	Cycloheximide	180-193	cyclin B1	Sus scrofa	236-244
25078078-6	2014	In both species, (a) whereas active CDC2A showed a dynamics similar to cyclin B, inactive CDC2A decreased continuously; (b) when oocytes were blocked in blocking medium containing cycloheximide, PBMP was decelerated significantly while cyclin B and active CDC2A decreasing to the lowest level; (c) whereas sodium vanadate in blocking medium reduced PBMP, epidermal growth factor (EGF) in blocking medium accelerated PBMP significantly with no effect on cyclin B levels.	Cycloheximide	180-193	cyclin-dependent kinase 1	Mus musculus	90-95
25078078-6	2014	In both species, (a) whereas active CDC2A showed a dynamics similar to cyclin B, inactive CDC2A decreased continuously; (b) when oocytes were blocked in blocking medium containing cycloheximide, PBMP was decelerated significantly while cyclin B and active CDC2A decreasing to the lowest level; (c) whereas sodium vanadate in blocking medium reduced PBMP, epidermal growth factor (EGF) in blocking medium accelerated PBMP significantly with no effect on cyclin B levels.	Cycloheximide	180-193	cyclin B1	Sus scrofa	236-244
25078495-8	2014	Deletion of UBX4 in yeast causes cycloheximide sensitivity, while ubx4 cdc48-3 double mutations cause proteasome mislocalization.	Cycloheximide	33-46	Ubx4p	Saccharomyces cerevisiae S288C	12-16
24939622-6	2014	In contrast, decrease in GCPII protein level by cycloheximide treatment was blocked by VPA, indicating that VPA increases GCPII protein stability.	Cycloheximide	48-61	folate hydrolase 1	Homo sapiens	122-127
24484548-9	2014	Characterization in fibroblasts showed that potentiation of the EGF pathway was significant after 60 minutes of DHT exposure and persisted in the presence of the translational inhibitor cycloheximide.	Cycloheximide	186-199	epidermal growth factor	Homo sapiens	64-67
25000203-8	2014	We noted that neither fasting nor TGFbeta1 changed p27 expression, but after cycloheximide administration, we observed that protein synthesis was influenced by TGFbeta1.	Cycloheximide	77-90	transforming growth factor, beta 1	Rattus norvegicus	160-168
24773508-8	2014	Inhibitors of transcription and translation, actinomycin D and cycloheximide, partially cancelled this process, suggesting that MMP-9 is also de novo synthesized in response to stimuli.	Cycloheximide	63-76	matrix metallopeptidase 9	Homo sapiens	128-133
24446161-9	2014	Furthermore, actinomycin D and cycloheximide completely blocked the induction of SHARP-1 mRNA by insulin.	Cycloheximide	31-44	basic helix-loop-helix family, member e41	Rattus norvegicus	81-88
24855105-9	2014	In addition, activation of mTORC1 by cycloheximide did not inhibit fertilization-induced autophagy in fertilized embryos.	Cycloheximide	37-50	CREB regulated transcription coactivator 1	Mus musculus	27-33
24705868-8	2014	Moreover, in presence of cycloheximide, beta2-adrenoceptor agonist-induced reduction in beta2-adrenoceptor mRNA was converted into stimulation, resulting in a more than 10-fold increase.	Cycloheximide	25-38	adrenoceptor beta 2	Homo sapiens	40-58
24705868-8	2014	Moreover, in presence of cycloheximide, beta2-adrenoceptor agonist-induced reduction in beta2-adrenoceptor mRNA was converted into stimulation, resulting in a more than 10-fold increase.	Cycloheximide	25-38	adrenoceptor beta 2	Homo sapiens	88-106
24785473-11	2014	Transient knockdown of ERalpha abolished the oestrogenic effect on TFPI and co-treatment of MCF7 cells with the protein synthesis inhibitor cycloheximide and 17-beta-oestradiol also led to reduction of TFPI mRNA.	Cycloheximide	140-153	estrogen receptor 1	Homo sapiens	23-30
24785473-11	2014	Transient knockdown of ERalpha abolished the oestrogenic effect on TFPI and co-treatment of MCF7 cells with the protein synthesis inhibitor cycloheximide and 17-beta-oestradiol also led to reduction of TFPI mRNA.	Cycloheximide	140-153	tissue factor pathway inhibitor	Homo sapiens	67-71
24785473-11	2014	Transient knockdown of ERalpha abolished the oestrogenic effect on TFPI and co-treatment of MCF7 cells with the protein synthesis inhibitor cycloheximide and 17-beta-oestradiol also led to reduction of TFPI mRNA.	Cycloheximide	140-153	tissue factor pathway inhibitor	Homo sapiens	202-206
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	tumor necrosis factor	Bos taurus	12-21
24395041-5	2014	shRNA-mediated exhaustive depletion of BRE sensitized D122 cells to apoptosis induced not only by etopoxide, but also by TNF-alpha even in the absence of cycloheximide, which blocks the synthesis of antiapoptotic proteins by TNF-alpha-activated NF-kappaB pathway.	Cycloheximide	154-167	BRISC and BRCA1 A complex member 2	Mus musculus	39-42
24378615-7	2014	Lymphatic transport inhibitor, cycloheximide significantly reduced oral bioavailability of SLN.	Cycloheximide	31-44	sarcolipin	Homo sapiens	91-94
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	tight junction protein 1	Bos taurus	55-59
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	matrix metallopeptidase 2	Bos taurus	236-240
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	matrix metallopeptidase 2	Bos taurus	256-261
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	matrix metallopeptidase 9	Bos taurus	266-271
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	matrix metallopeptidase 9	Bos taurus	288-293
24667088-8	2014	Exposure to TNF-alpha led to significant disruption of ZO-1 and also caused a continuous decline in TER for more than 20 h. These effects were opposed by cycloheximide (protein synthesis inhibitor), GM-6001 (broad spectrum inhibitor of MMPs), minocycline (MMP-2 and MMP-9 inhibitor), and MMP-9 inhibitor I (selective MMP-9 inhibitor).	Cycloheximide	154-167	matrix metallopeptidase 9	Bos taurus	288-293
24667088-11	2014	The functional activity and increase in mRNA levels of MMP-9 were blocked by SB-203580 (selective p38 MAP kinase inhibitor) and cycloheximide.	Cycloheximide	128-141	matrix metallopeptidase 9	Bos taurus	55-60
24523664-5	2014	Shortening the first cycle, by treating embryos with the Wee1A/Myt1 inhibitor PD0166285, resulted in a dramatic reduction in embryo viability, and restoring the length of the first cycle in inhibitor-treated embryos with low doses of cycloheximide partially rescued viability.	Cycloheximide	234-247	WEE2 oocyte meiosis inhibiting kinase L homeolog	Xenopus laevis	57-62
24584189-7	2014	Overexpression of PIAS3 in the A549 wt p53-expressing cell line was found to significantly increase the half-life of p53 in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	140-153	protein inhibitor of activated STAT 3	Homo sapiens	18-23
24584189-7	2014	Overexpression of PIAS3 in the A549 wt p53-expressing cell line was found to significantly increase the half-life of p53 in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	140-153	tumor protein p53	Homo sapiens	39-42
24584189-7	2014	Overexpression of PIAS3 in the A549 wt p53-expressing cell line was found to significantly increase the half-life of p53 in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	140-153	tumor protein p53	Homo sapiens	117-120
24759061-5	2014	However, the expression of viperin mRNA was also increased after stimulation with AP-PG even when new protein synthesis was completely blocked by treatment with cycloheximide.	Cycloheximide	161-174	radical S-adenosyl methionine domain containing 2	Mus musculus	27-34
24447586-6	2014	As a final example we show that our simple model can mimic the different transcriptional outputs observed when cells are treated with two different drugs leading to nuclear localization of NF-kappaB: Leptomycin B and Cycloheximide.	Cycloheximide	217-230	nuclear factor kappa B subunit 1	Homo sapiens	189-198
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	insulin	Homo sapiens	154-161
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	leptin	Homo sapiens	173-179
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	insulin	Homo sapiens	208-215
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	leptin	Homo sapiens	227-233
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	leptin	Homo sapiens	227-233
24405299-5	2014	Interestingly, treatment with the protein synthesis inhibitor cycloheximide and the ER-Golgi trafficking blocker Brefeldin A inhibit both basal and ISLS (insulin-stimulated leptin secretion), suggesting that insulin stimulates leptin secretion by up-regulating leptin synthesis and that leptin-containing vesicles go through the ER-Golgi route.	Cycloheximide	62-75	leptin	Homo sapiens	227-233
24626801-8	2014	The results of cycloheximide (CHX)-chase analysis demonstrated that the Nrf2 protein half-life was prolonged to 58 min when the HL60 cells were pre-incubated with 50 microM MA for 4 h, whereas its half-life was only 20 min in the non-MA treated control cells.	Cycloheximide	15-28	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
24626801-8	2014	The results of cycloheximide (CHX)-chase analysis demonstrated that the Nrf2 protein half-life was prolonged to 58 min when the HL60 cells were pre-incubated with 50 microM MA for 4 h, whereas its half-life was only 20 min in the non-MA treated control cells.	Cycloheximide	30-33	NFE2 like bZIP transcription factor 2	Homo sapiens	72-76
24569876-6	2014	These Dcp2-positive foci contained mRNA, because their formation was inhibited by the presence of cycloheximide.	Cycloheximide	98-111	decapping enzyme complex catalytic subunit	Saccharomyces cerevisiae S288C	6-10
24554781-7	2014	Pretreatment with cycloheximide, PI3K/mTOR inhibitor, or an inhibitor of eIF4E (a translation initiation factor and downstream effector of mTOR) all reduced ganetespib-mediated nuclear HSF1 accumulation, indicating that mTOR blockade confers a negative regulatory effect on HSF1 activity.	Cycloheximide	18-31	heat shock transcription factor 1	Homo sapiens	185-189
24554781-7	2014	Pretreatment with cycloheximide, PI3K/mTOR inhibitor, or an inhibitor of eIF4E (a translation initiation factor and downstream effector of mTOR) all reduced ganetespib-mediated nuclear HSF1 accumulation, indicating that mTOR blockade confers a negative regulatory effect on HSF1 activity.	Cycloheximide	18-31	heat shock transcription factor 1	Homo sapiens	274-278
24303962-9	2014	Finally, Cycloheximide chase experiment exhibited that RNF13-IRE1alpha interaction increased the stability of IRE1alpha.	Cycloheximide	9-22	ring finger protein 13	Homo sapiens	55-60
24303962-9	2014	Finally, Cycloheximide chase experiment exhibited that RNF13-IRE1alpha interaction increased the stability of IRE1alpha.	Cycloheximide	9-22	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	61-70
24303962-9	2014	Finally, Cycloheximide chase experiment exhibited that RNF13-IRE1alpha interaction increased the stability of IRE1alpha.	Cycloheximide	9-22	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	110-119
24525133-0	2014	Cycloheximide inhibits starvation-induced autophagy through mTORC1 activation.	Cycloheximide	0-13	CREB regulated transcription coactivator 1	Mus musculus	60-66
24525133-9	2014	Finally, the inhibitory effect of CHX on starvation-induced autophagy was cancelled by the mTOR inhibitor Torin1.	Cycloheximide	34-37	mechanistic target of rapamycin kinase	Homo sapiens	91-95
24231468-6	2014	Pretreatment of cells with cycloheximide, a translational inhibitor, produced a rapid decline in HSP70 but not HSP30.	Cycloheximide	27-40	heat shock 70kDa protein L homeolog	Xenopus laevis	97-102
24057571-6	2014	Suppression of CdCl2-induced ATF4 expression by LY294002 treatment was markedly blocked by cycloheximide, a translation inhibitor, but not by MG-132, a proteasome inhibitor, or actinomycin D, a transcription inhibitor.	Cycloheximide	91-104	activating transcription factor 4	Homo sapiens	29-33
24231468-6	2014	Pretreatment of cells with cycloheximide, a translational inhibitor, produced a rapid decline in HSP70 but not HSP30.	Cycloheximide	27-40	heat shock protein 30E L homeolog	Xenopus laevis	111-116
24231468-7	2014	The cycloheximide-associated decline of HSP70 was blocked by the proteasomal inhibitor, MG132, but had little effect on the relative level of HSP30.	Cycloheximide	4-17	heat shock 70kDa protein L homeolog	Xenopus laevis	40-45
24231468-8	2014	Also, treatment of cells with the phosphorylation inhibitor, SB203580, in addition to cycloheximide treatment enhanced the stability of HSP30 compared to cycloheximide alone.	Cycloheximide	86-99	heat shock protein 30E L homeolog	Xenopus laevis	136-141
25036962-2	2014	Here, we measured transcriptional responses of the OPDA-responsive genes HsfA2 and DREB2A to the protein synthesis inhibitor cycloheximide and to the HSP90 inhibitor geldanamycin.	Cycloheximide	125-138	heat shock transcription factor A2	Arabidopsis thaliana	73-78
24176035-9	2014	Exposure of TtT/GF cells to cycloheximide with PACAP or glyburide inhibited the increased secretion of VEGF, consistent with control of secretion at the transcription level.	Cycloheximide	28-41	adenylate cyclase activating polypeptide 1	Mus musculus	47-52
24176035-9	2014	Exposure of TtT/GF cells to cycloheximide with PACAP or glyburide inhibited the increased secretion of VEGF, consistent with control of secretion at the transcription level.	Cycloheximide	28-41	vascular endothelial growth factor A	Mus musculus	103-107
24466329-4	2014	Pretreatment with the protein synthesis inhibitor cycloheximide or the protein kinase C inhibitor calphostin C prior to the addition of TNF completely abrogated the TNF-induced increment in peak bradykinin response.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	165-168
24466329-4	2014	Pretreatment with the protein synthesis inhibitor cycloheximide or the protein kinase C inhibitor calphostin C prior to the addition of TNF completely abrogated the TNF-induced increment in peak bradykinin response.	Cycloheximide	50-63	kininogen 1	Homo sapiens	195-205
24575118-9	2014	We also demonstrate that IFN-gamma, but not the other stimuli, reduces the proliferation of cycloheximide-primed HK2 cells without affecting their viability.	Cycloheximide	92-105	interferon gamma	Homo sapiens	25-34
24512659-7	2014	Treatment with cycloheximide at 39 C inhibited the induction of Hsp104 synthesis and suppressed the development of induced thermotolerance to severe shock (50 C), but it had no effect on induced thermotolerance to moderate (45 C) heat shock.	Cycloheximide	15-28	chaperone ATPase HSP104	Saccharomyces cerevisiae S288C	64-70
25036962-2	2014	Here, we measured transcriptional responses of the OPDA-responsive genes HsfA2 and DREB2A to the protein synthesis inhibitor cycloheximide and to the HSP90 inhibitor geldanamycin.	Cycloheximide	125-138	DRE-binding protein 2A	Arabidopsis thaliana	83-89
24789928-2	2014	The phosphoinositide 3-kinase (PI3K)/Akt inhibitor(s) was isolated from PT by using the cytoprotective phenotype of human immunodeficiency virus type 1 (HIV-1) Tat-transduced CHME5 cells against lipopolysaccharide/cycloheximide.	Cycloheximide	214-227	AKT serine/threonine kinase 1	Homo sapiens	37-40
24100123-6	2014	AICD-level is reduced in Grb2 excess condition in Cycloheximide Chase setup.	Cycloheximide	50-63	growth factor receptor bound protein 2	Homo sapiens	25-29
24169559-8	2014	The PPARalpha effect remained, but the PPARgamma effect was lost in the presence of the translational inhibitor cycloheximide.	Cycloheximide	112-125	peroxisome proliferator activated receptor gamma	Homo sapiens	39-48
24144795-6	2014	The NO donor (Z)-1-[N-(3-aminopropyl)-N-(3-ammoniopropyl)amino]diazen-1-ium-1,2-diolate reduced the half-life of CYP2C22 from 8.7 to 3.4 hours in the presence of cycloheximide, demonstrating that NO-dependent downregulation is due to stimulated proteolysis.	Cycloheximide	162-175	cytochrome P450, family 2, subfamily c, polypeptide 22	Rattus norvegicus	113-120
24731625-5	2014	In addition, the protein synthesis inhibitor cycloheximide (0.5mg/mL) counteracted the insulin-elevated glucose uptake, thereby suggesting that newly synthesized transporter protein might take part in the insulin-induced glucose uptake.	Cycloheximide	45-58	insulin	Bos taurus	87-94
23994618-8	2013	Therefore, KLF10 shows shorter protein stability compared with mutant KLF10 that lacks PIN1 binding ability after cycloheximide treatments.	Cycloheximide	114-127	Kruppel like factor 10	Homo sapiens	11-16
24111984-5	2014	The protein-synthesis inhibitor cycloheximide also enhanced Scg2 activation, and the proteasome inhibitor ZLLLH diminished the KT5720-mediated augmentation of Scg2 activation.	Cycloheximide	32-45	secretogranin II	Mus musculus	60-64
24359955-3	2014	Exposure of cultured cells to two drugs, the protein synthesis inhibitor cycloheximide and the V-ATPase inhibitor bafilomycin A1, recently showed that TfR is not only recycled back to the plasma membrane after endocytosis but is constitutively transported to lysosomes for degradation.	Cycloheximide	73-86	transferrin receptor	Mus musculus	151-154
25171190-7	2014	The effect of dexamethasone on Nox1 expression was likely to be indirect as it could be largely blocked by cycloheximide, an inhibitor of protein biosynthesis.	Cycloheximide	107-120	NADPH oxidase 1	Rattus norvegicus	31-35
23994618-8	2013	Therefore, KLF10 shows shorter protein stability compared with mutant KLF10 that lacks PIN1 binding ability after cycloheximide treatments.	Cycloheximide	114-127	Kruppel like factor 10	Homo sapiens	70-75
23994618-8	2013	Therefore, KLF10 shows shorter protein stability compared with mutant KLF10 that lacks PIN1 binding ability after cycloheximide treatments.	Cycloheximide	114-127	peptidylprolyl cis/trans isomerase, NIMA-interacting 1	Homo sapiens	87-91
24221993-13	2013	HIF-1alpha protein was markedly reduced by resveratrol, and inhibiting HIF-1alpha expression with cycloheximide or specific small interfering RNAs suppressed (18)F-FDG uptake.	Cycloheximide	98-111	hypoxia inducible factor 1 subunit alpha	Homo sapiens	71-81
24012499-8	2013	Treatment with cycloheximide indicated that increased m-SR was due to de novo protein synthesis associated with phospho-active forms of ERK1/2, MARCKS, Akt and rapamycin-sensitive mTOR.	Cycloheximide	15-28	mitogen-activated protein kinase 3	Homo sapiens	136-142
24012499-8	2013	Treatment with cycloheximide indicated that increased m-SR was due to de novo protein synthesis associated with phospho-active forms of ERK1/2, MARCKS, Akt and rapamycin-sensitive mTOR.	Cycloheximide	15-28	myristoylated alanine rich protein kinase C substrate	Homo sapiens	144-150
24012499-8	2013	Treatment with cycloheximide indicated that increased m-SR was due to de novo protein synthesis associated with phospho-active forms of ERK1/2, MARCKS, Akt and rapamycin-sensitive mTOR.	Cycloheximide	15-28	mechanistic target of rapamycin kinase	Homo sapiens	180-184
24036213-11	2013	We discovered that actinomycin D-mediated blocking of gene transcription and inhibition of protein synthesis with cycloheximide result in impairment of BST-2 mRNA expression.	Cycloheximide	114-127	bone marrow stromal cell antigen 2	Homo sapiens	152-157
24065356-8	2013	Stability of CDKN1C was studied by western immunoblotting after inhibition of translation with cycloheximide.	Cycloheximide	95-108	cyclin dependent kinase inhibitor 1C	Homo sapiens	13-19
24021805-6	2013	Increasing concentrations of the GR agonist dexamethasone (Dex) resulted in enhanced, dose-dependent 5-HTT cell surface localization in the presence of the protein synthesis inhibitor cycloheximide already 1h after incubation.	Cycloheximide	184-197	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	101-106
24236122-5	2013	Following blockade of de novo protein synthesis by cycloheximide, LPS accelerated Cx43 degradation.	Cycloheximide	51-64	gap junction protein, alpha 1	Rattus norvegicus	82-86
24095829-9	2013	Cycloheximide treatment revealed reduced degradation of Cdkn1b protein by KRGE.	Cycloheximide	0-13	cyclin dependent kinase inhibitor 1B	Homo sapiens	56-62
24098568-8	2013	However, in the presence of cycloheximide or SMAC mimetics, programmed necrosis was only moderately reduced in CYLD(-/-) cells.	Cycloheximide	28-41	CYLD lysine 63 deubiquitinase	Homo sapiens	111-115
24036268-4	2013	We identified six novel short-lived long ncRNAs (MIR22HG, GABPB-AS1, LINC00152, IDI2-AS1, SNHG15, and FLJ33630) that responded to chemical stressors (cisplatin, cycloheximide, and mercury (II) oxide) in HeLa Tet-off cells.	Cycloheximide	161-174	MIR22 host gene	Homo sapiens	49-56
23912906-5	2013	Furthermore, we reported that DcR3 induces very late antigen-4 (VLA--4) expression in THP-1 macrophages, inhibiting cycloheximide-induced apoptosis and that DcR3 binds to membrane-bound TL1A expressed on RA-FLS, resulting in the negative regulation of cell proliferation induced by inflammatory cytokines.	Cycloheximide	116-129	TNF receptor superfamily member 6b	Homo sapiens	30-34
23932921-9	2013	In these cells, cycloheximide treatment led to a loss of P-bodies and to an increase in NCR143/145 RNA stability, thus resulting in up-regulation of miR-143/145 expression.	Cycloheximide	16-29	microRNA 143	Homo sapiens	149-156
23975864-11	2013	The IFN-gamma-mediated induction of Trim21 was completely abolished by inhibiting protein synthesis with cycloheximide, and Trim21 expression could not be induced by IFN-gamma in Irf1(-/-) cells, demonstrating that IFN-gamma induces Trim21 indirectly via IRF1 and not directly via STAT1 activation.	Cycloheximide	105-118	interferon gamma	Homo sapiens	4-13
23975864-11	2013	The IFN-gamma-mediated induction of Trim21 was completely abolished by inhibiting protein synthesis with cycloheximide, and Trim21 expression could not be induced by IFN-gamma in Irf1(-/-) cells, demonstrating that IFN-gamma induces Trim21 indirectly via IRF1 and not directly via STAT1 activation.	Cycloheximide	105-118	tripartite motif containing 21	Homo sapiens	36-42
23942851-10	2013	Higher expression of IGFBP1 protein by PL was suppressed by cycloheximide.	Cycloheximide	60-73	insulin like growth factor binding protein 1	Homo sapiens	21-27
24058635-9	2013	To examine whether leptin is directly induced by T3, we used the translation inhibitor cycloheximide (CHX).	Cycloheximide	87-100	leptin	Mus musculus	19-25
24098681-6	2013	Intriguingly, the IMAGe-associated mutant CDKN1C proteins were fairly stable even in the presence of cycloheximide, whereas the wild-type protein was almost completely degraded via the proteasome pathway, as shown by the lack of degradation with addition of a proteasome inhibitor, MG132.	Cycloheximide	101-114	cyclin dependent kinase inhibitor 1C	Homo sapiens	42-48
24086685-9	2013	Cellular treatment with protein synthesis inhibitor cycloheximide demonstrated a time-dependent intracellular degradation of both S100A16 and S100A14 proteins.	Cycloheximide	52-65	S100 calcium binding protein A16	Homo sapiens	130-137
24086685-9	2013	Cellular treatment with protein synthesis inhibitor cycloheximide demonstrated a time-dependent intracellular degradation of both S100A16 and S100A14 proteins.	Cycloheximide	52-65	S100 calcium binding protein A14	Homo sapiens	142-149
23787120-8	2013	EGF also decreased the expression of Npr2 mRNA in cumulus cells, which may not be involved in meiotic resumption, because the block of NPR2 protein de novo synthesis by cycloheximide had no effect on NPPC and EGF-mediated oocyte maturation.	Cycloheximide	169-182	natriuretic peptide receptor 2	Mus musculus	135-139
24040284-3	2013	Yet, when ZSTK474 is combined with the translation inhibitor cycloheximide, C42Luc cells undergo apoptosis within 6 hours.	Cycloheximide	61-74	CDK5 regulatory subunit associated protein 1	Homo sapiens	76-79
24027419-9	2013	However, cycloheximide treatment alone induced Hsp60 translocation, while rotenone combination delayed this translocation.	Cycloheximide	9-22	heat shock protein family D (Hsp60) member 1	Homo sapiens	47-52
23832230-6	2013	IFNgamma-induced repression of genes associated with regulation of gene expression, cellular development, apoptosis and cell growth resulted from cycloheximide-resistant primary IFNgamma signalling.	Cycloheximide	146-159	interferon gamma	Mus musculus	0-8
23742080-10	2013	Cycloheximide treatment experiments revealed that S185 degrades faster than T185 TMEM106B, potentially due to differences in N-glycosylation at residue N183.	Cycloheximide	0-13	transmembrane protein 106B	Homo sapiens	81-89
23751896-3	2013	AIMS: This study analyses the molecular mechanisms by which TNF, in combination with cycloheximide (CHX), induces apoptosis in human hepatoma-derived Huh7 cells, focusing on the role played by JNK.	Cycloheximide	85-98	MIR7-3 host gene	Homo sapiens	150-154
23751896-3	2013	AIMS: This study analyses the molecular mechanisms by which TNF, in combination with cycloheximide (CHX), induces apoptosis in human hepatoma-derived Huh7 cells, focusing on the role played by JNK.	Cycloheximide	100-103	MIR7-3 host gene	Homo sapiens	150-154
23751896-6	2013	RESULTS: TNF + CHX-induced death of Huh7 cells involved JNK activation since it was partially prevented by suppressing JNK activity or expression.	Cycloheximide	15-18	tumor necrosis factor	Homo sapiens	9-12
23751896-6	2013	RESULTS: TNF + CHX-induced death of Huh7 cells involved JNK activation since it was partially prevented by suppressing JNK activity or expression.	Cycloheximide	15-18	MIR7-3 host gene	Homo sapiens	36-40
23751896-6	2013	RESULTS: TNF + CHX-induced death of Huh7 cells involved JNK activation since it was partially prevented by suppressing JNK activity or expression.	Cycloheximide	15-18	mitogen-activated protein kinase 8	Homo sapiens	56-59
23751896-6	2013	RESULTS: TNF + CHX-induced death of Huh7 cells involved JNK activation since it was partially prevented by suppressing JNK activity or expression.	Cycloheximide	15-18	mitogen-activated protein kinase 8	Homo sapiens	119-122
23788428-4	2013	Here, we present the novel finding that LMP induced by the addition of TNFalpha plus cycloheximide (CHX), the release of lysosomal cathepsins and ROS formation do not occur upstream but downstream of MOMP and require the caspase-3-mediated cleavage of the p75 NDUFS1 subunit of respiratory complex I.	Cycloheximide	85-98	caspase 3	Homo sapiens	221-230
23788428-4	2013	Here, we present the novel finding that LMP induced by the addition of TNFalpha plus cycloheximide (CHX), the release of lysosomal cathepsins and ROS formation do not occur upstream but downstream of MOMP and require the caspase-3-mediated cleavage of the p75 NDUFS1 subunit of respiratory complex I.	Cycloheximide	85-98	TNF receptor superfamily member 1B	Homo sapiens	256-259
23788428-4	2013	Here, we present the novel finding that LMP induced by the addition of TNFalpha plus cycloheximide (CHX), the release of lysosomal cathepsins and ROS formation do not occur upstream but downstream of MOMP and require the caspase-3-mediated cleavage of the p75 NDUFS1 subunit of respiratory complex I.	Cycloheximide	85-98	NADH:ubiquinone oxidoreductase core subunit S1	Homo sapiens	260-266
23832230-6	2013	IFNgamma-induced repression of genes associated with regulation of gene expression, cellular development, apoptosis and cell growth resulted from cycloheximide-resistant primary IFNgamma signalling.	Cycloheximide	146-159	interferon gamma	Mus musculus	178-186
23824493-9	2013	Half-life measurements with cycloheximide indicated that S1P treatment stabilized the HIF-1alpha protein.	Cycloheximide	28-41	hypoxia inducible factor 1 subunit alpha	Homo sapiens	86-96
23977195-8	2013	With both cycloheximide and brefeldin A inhibition assays, it was shown that UBIAD1 may be transported from the endoplasmic reticulum (ER) to the Golgi by a COPII-mediated mechanism.	Cycloheximide	10-23	UbiA prenyltransferase domain containing 1	Homo sapiens	77-83
23769872-6	2013	Cycloheximide chase experiments further showed that MID1 deletion significantly decreased the stability of Ecm7.	Cycloheximide	0-13	Mid1p	Saccharomyces cerevisiae S288C	52-56
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	0-13	midkine	Mus musculus	46-49
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	0-13	mitogen-activated protein kinase 3	Mus musculus	50-56
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	0-13	adiponectin, C1Q and collagen domain containing	Mus musculus	80-91
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	15-18	midkine	Mus musculus	46-49
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	15-18	mitogen-activated protein kinase 3	Mus musculus	50-56
23490586-8	2013	Cycloheximide (CHX)-chase assay revealed that MEK/ERK1/2 inhibition accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	15-18	adiponectin, C1Q and collagen domain containing	Mus musculus	80-91
23538947-8	2013	IL-6 secretion was completely inhibited via inhibitor of transcription (Actinomycin D) or protein synthesis (Cycloheximide) confirming that IL-6 releases constitutively from BeWo cells.	Cycloheximide	109-122	interleukin 6	Homo sapiens	0-4
23538947-8	2013	IL-6 secretion was completely inhibited via inhibitor of transcription (Actinomycin D) or protein synthesis (Cycloheximide) confirming that IL-6 releases constitutively from BeWo cells.	Cycloheximide	109-122	interleukin 6	Homo sapiens	140-144
23805861-7	2013	Inhibition of protein synthesis by cycloheximide was used to distinguish between primary and secondary gastrin regulated genes.	Cycloheximide	35-48	gastrin	Homo sapiens	103-110
23748432-4	2013	Focus formation by Eno2p was inhibited temperature independently by the addition of cycloheximide or rapamycin or by the single substitution of alanine for the Val22 residue.	Cycloheximide	84-97	phosphopyruvate hydratase ENO2	Saccharomyces cerevisiae S288C	19-24
23708668-6	2013	The stability of BLH at normal culture conditions was analyzed with the protein synthesis inhibitor cycloheximide and the proteasome inhibitor MG132.	Cycloheximide	100-113	bleomycin hydrolase	Homo sapiens	17-20
23720739-5	2013	After inhibition of new protein synthesis with cycloheximide, CX50fs disappeared much more rapidly than CX50, suggesting increased degradation of the mutant.	Cycloheximide	47-60	gap junction protein alpha 8	Homo sapiens	62-66
23666621-4	2013	Tat1 was resistant to a 3-h cycloheximide treatment, suggesting that it is highly stable under normal growth conditions.	Cycloheximide	28-41	amino acid transporter TAT1	Saccharomyces cerevisiae S288C	0-4
23499904-0	2013	Cycloheximide inhibits follicle-stimulating hormone beta subunit transcription by blocking de novo synthesis of the labile activin type II receptor in gonadotrope cells.	Cycloheximide	0-13	follicle stimulating hormone beta	Mus musculus	23-56
23762390-6	2013	In some experiments, cycloheximide (0.5 microg/ml) was used to assess the regulation of FBLN-1 production.	Cycloheximide	21-34	fibulin 1	Homo sapiens	88-94
23762390-11	2013	Cycloheximide treatment, which inhibits protein synthesis, decreased both the constitutive release of soluble FBLN-1, and TGF-beta1 induced ECM FBLN-1 deposition.	Cycloheximide	0-13	fibulin 1	Homo sapiens	110-116
23762390-11	2013	Cycloheximide treatment, which inhibits protein synthesis, decreased both the constitutive release of soluble FBLN-1, and TGF-beta1 induced ECM FBLN-1 deposition.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	122-131
23762390-11	2013	Cycloheximide treatment, which inhibits protein synthesis, decreased both the constitutive release of soluble FBLN-1, and TGF-beta1 induced ECM FBLN-1 deposition.	Cycloheximide	0-13	fibulin 1	Homo sapiens	144-150
23762390-12	2013	Furthermore, in cycloheximide treated cells addition of soluble FBLN-1 resulted in incorporation of FBLN-1 into the ECM.	Cycloheximide	16-29	fibulin 1	Homo sapiens	64-70
23762390-12	2013	Furthermore, in cycloheximide treated cells addition of soluble FBLN-1 resulted in incorporation of FBLN-1 into the ECM.	Cycloheximide	16-29	fibulin 1	Homo sapiens	100-106
23686416-8	2013	Cycloheximide abolished the ability of fulv to activate EGFR suggesting the autocrine production of EGFR ligands might be responsible for fulvestrant induced EGFR signaling.	Cycloheximide	0-13	epidermal growth factor receptor	Homo sapiens	56-60
23686416-8	2013	Cycloheximide abolished the ability of fulv to activate EGFR suggesting the autocrine production of EGFR ligands might be responsible for fulvestrant induced EGFR signaling.	Cycloheximide	0-13	epidermal growth factor receptor	Homo sapiens	100-104
23686416-8	2013	Cycloheximide abolished the ability of fulv to activate EGFR suggesting the autocrine production of EGFR ligands might be responsible for fulvestrant induced EGFR signaling.	Cycloheximide	0-13	epidermal growth factor receptor	Homo sapiens	100-104
23499904-4	2013	Using the murine gonadotrope-like cell line, LbetaT2, as a model, we tested the hypothesis that a component of the activin pathway is highly labile in gonadotrope cells and that its rapid loss following CHX treatment impairs activin-stimulated Fshb transcription.	Cycloheximide	203-206	follicle stimulating hormone beta	Mus musculus	244-248
23499904-5	2013	Treatment of cells with CHX for 6h, but not 1h, blocked activin A-stimulated Fshb transcription.	Cycloheximide	24-27	follicle stimulating hormone beta	Mus musculus	77-81
23499904-6	2013	Pre-treatment of LbetaT2 cells with CHX for as few as 2-3h inhibited activin A-stimulated SMAD2/3 phosphorylation without altering total SMAD2/3 protein levels.	Cycloheximide	36-39	SMAD family member 2	Mus musculus	90-97
23499904-6	2013	Pre-treatment of LbetaT2 cells with CHX for as few as 2-3h inhibited activin A-stimulated SMAD2/3 phosphorylation without altering total SMAD2/3 protein levels.	Cycloheximide	36-39	SMAD family member 2	Mus musculus	137-144
23499904-11	2013	Collectively, these data indicate that CHX produces inhibin-like effects in gonadotropes by preventing de novo synthesis of the highly labile ACVR2, thereby blocking activin signaling to the Fshb promoter.	Cycloheximide	39-42	activin receptor IIA	Mus musculus	142-147
23499904-11	2013	Collectively, these data indicate that CHX produces inhibin-like effects in gonadotropes by preventing de novo synthesis of the highly labile ACVR2, thereby blocking activin signaling to the Fshb promoter.	Cycloheximide	39-42	follicle stimulating hormone beta	Mus musculus	191-195
23432726-8	2013	Finally, a cycloheximide chase assay indicated that coexpression of Chk11-365 decelerated the degradation of ectopically expressed RALT, but not that of the S250A mutant.	Cycloheximide	11-24	ERBB receptor feedback inhibitor 1	Rattus norvegicus	131-135
23645752-6	2013	RESULTS: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1.	Cycloheximide	25-38	gremlin 1, DAN family BMP antagonist	Homo sapiens	64-69
23645752-6	2013	RESULTS: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1.	Cycloheximide	25-38	death associated protein kinase 1	Homo sapiens	71-76
23645752-6	2013	RESULTS: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1.	Cycloheximide	25-38	myogenic differentiation 1	Homo sapiens	82-87
23645752-6	2013	RESULTS: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1.	Cycloheximide	25-38	paired box 3	Homo sapiens	114-118
23645752-6	2013	RESULTS: Pulse-chase and cycloheximide experiments suggest that GREM1, DAPK1, and MYOD1 are directly regulated by PAX3-FOXO1.	Cycloheximide	25-38	forkhead box O1	Homo sapiens	119-124
23499907-6	2013	In addition, protein complex immunoprecipitation assays and protein stability assays using cycloheximide revealed that activated Akt (P-Akt1 S473) could bind to hPMS2 directly and induce hPMS2 degradation.	Cycloheximide	91-104	AKT serine/threonine kinase 1	Homo sapiens	129-132
23499907-6	2013	In addition, protein complex immunoprecipitation assays and protein stability assays using cycloheximide revealed that activated Akt (P-Akt1 S473) could bind to hPMS2 directly and induce hPMS2 degradation.	Cycloheximide	91-104	AKT serine/threonine kinase 1	Homo sapiens	134-145
23499907-6	2013	In addition, protein complex immunoprecipitation assays and protein stability assays using cycloheximide revealed that activated Akt (P-Akt1 S473) could bind to hPMS2 directly and induce hPMS2 degradation.	Cycloheximide	91-104	PMS1 homolog 2, mismatch repair system component	Homo sapiens	161-166
23454593-3	2013	Prolonged induction of iNOS expression by LPS was inhibited by cycloheximide, suggesting that de novo protein synthesis was required.	Cycloheximide	63-76	nitric oxide synthase 2, inducible	Mus musculus	23-27
23432726-8	2013	Finally, a cycloheximide chase assay indicated that coexpression of Chk11-365 decelerated the degradation of ectopically expressed RALT, but not that of the S250A mutant.	Cycloheximide	11-24	checkpoint kinase 1	Rattus norvegicus	68-77
23344572-9	2013	Both actinomycin D and cycloheximide treatment prevented the PTH-mediated decrease in Npt2a mRNA, suggesting that the PTH response requires transcription and translation.	Cycloheximide	23-36	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	86-91
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	62-75	caspase 8	Homo sapiens	98-107
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	62-75	caspase 8	Homo sapiens	149-158
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	62-75	CASP8 and FADD like apoptosis regulator	Homo sapiens	170-176
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	77-80	tumor necrosis factor	Homo sapiens	24-33
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	77-80	caspase 8	Homo sapiens	98-107
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	77-80	caspase 8	Homo sapiens	149-158
23397952-6	2013	Cells were treated with TNF-alpha alone or in the presence of cycloheximide (CHX), which promotes caspase-8 activation by eliminating the endogenous caspase-8 inhibitor, c-FLIP.	Cycloheximide	77-80	CASP8 and FADD like apoptosis regulator	Homo sapiens	170-176
23500605-6	2013	Treatment of astrocytes with cycloheximide resulted in time-dependent degradation of by co-treatment with HYS-32 by increasing the half-life of Cx43.	Cycloheximide	29-42	gap junction protein, alpha 1	Rattus norvegicus	144-148
23482872-3	2013	Administration of the cytoplasmic translational inhibitor cycloheximide prevents S deprivation-triggered accumulation of transcripts encoding arylsulfatases (ARS), an extracellular polypeptide that may be important for cell wall biosynthesis (ECP76), a light-harvesting protein (LHCBM9), the selenium-binding protein, and the haloperoxidase (HAP2).	Cycloheximide	58-71	uncharacterized protein	Chlamydomonas reinhardtii	279-285
23627909-14	2013	The decrease in CX3CL1 expression by ET-1 was inhibited by cycloheximide, Ca(2+) chelation and staurosporine.	Cycloheximide	59-72	C-X3-C motif chemokine ligand 1	Rattus norvegicus	16-22
23627909-14	2013	The decrease in CX3CL1 expression by ET-1 was inhibited by cycloheximide, Ca(2+) chelation and staurosporine.	Cycloheximide	59-72	endothelin 1	Rattus norvegicus	37-41
23637932-9	2013	Actinomycin D and cycloheximide could only partially block androgen-induced Cdc25C protein level.	Cycloheximide	18-31	cell division cycle 25C	Homo sapiens	76-82
23002058-4	2013	The mutant MYO1A(7A)  protein was shown to lose its membrane localization in gastric cancer cells and a cycloheximide-chase assay demonstrated that the mutant MYO1A(7A)  protein has reduced stability compared to the wild type MYO1A.	Cycloheximide	104-117	myosin IA	Homo sapiens	11-16
23262029-7	2013	Further, protein stability assays revealed that FoxO3 was degraded more rapidly in MVNP-expressing cells than in control cells following the addition of cycloheximide.	Cycloheximide	153-166	forkhead box O3	Homo sapiens	48-53
23470529-8	2013	Such upregulation of c-FLIPS was rapidly reduced and TRAIL sensitivity was restored by treatment with cycloheximide.	Cycloheximide	102-115	CASP8 and FADD like apoptosis regulator	Homo sapiens	21-28
23470529-8	2013	Such upregulation of c-FLIPS was rapidly reduced and TRAIL sensitivity was restored by treatment with cycloheximide.	Cycloheximide	102-115	TNF superfamily member 10	Homo sapiens	53-58
23348423-4	2013	We show here that siRNA knockdown of the insulin receptor enhanced the cytotoxic action of native Pseudomonas exotoxin and enhanced SS1P toxicity on several human cell lines, but did not affect the response to other cytotoxic agents such as TRAIL, etoposide, and cycloheximide.	Cycloheximide	263-276	insulin receptor	Homo sapiens	41-57
23321477-2	2013	This increase in GLUT3 expression is partially reliant on a transcriptional increase noted in actinomycin D and cycloheximide pretreatment experiments.	Cycloheximide	112-125	solute carrier family 2 (facilitated glucose transporter), member 3	Mus musculus	17-22
23288781-6	2013	KRAS expression was also evaluated in cells transfected with pRC-U and treated with MG-132 or cycloheximide.	Cycloheximide	94-107	KRAS proto-oncogene, GTPase	Homo sapiens	0-4
23144050-5	2013	Increased levels of FUT3, FUT6 and FUT7 RNA were detected already at 3 h post infection, and treatment with cycloheximide, a translation inhibitor, blocked a HSV1-induced increase in the expression of FUT3, FUT6 and FUT7 RNA, suggesting involvement of viral or cellular proteins.	Cycloheximide	108-121	fucosyltransferase 3 (Lewis blood group)	Homo sapiens	20-24
23144050-5	2013	Increased levels of FUT3, FUT6 and FUT7 RNA were detected already at 3 h post infection, and treatment with cycloheximide, a translation inhibitor, blocked a HSV1-induced increase in the expression of FUT3, FUT6 and FUT7 RNA, suggesting involvement of viral or cellular proteins.	Cycloheximide	108-121	fucosyltransferase 6	Homo sapiens	26-30
23144050-5	2013	Increased levels of FUT3, FUT6 and FUT7 RNA were detected already at 3 h post infection, and treatment with cycloheximide, a translation inhibitor, blocked a HSV1-induced increase in the expression of FUT3, FUT6 and FUT7 RNA, suggesting involvement of viral or cellular proteins.	Cycloheximide	108-121	fucosyltransferase 3 (Lewis blood group)	Homo sapiens	201-205
23144050-5	2013	Increased levels of FUT3, FUT6 and FUT7 RNA were detected already at 3 h post infection, and treatment with cycloheximide, a translation inhibitor, blocked a HSV1-induced increase in the expression of FUT3, FUT6 and FUT7 RNA, suggesting involvement of viral or cellular proteins.	Cycloheximide	108-121	fucosyltransferase 6	Homo sapiens	207-211
23144050-5	2013	Increased levels of FUT3, FUT6 and FUT7 RNA were detected already at 3 h post infection, and treatment with cycloheximide, a translation inhibitor, blocked a HSV1-induced increase in the expression of FUT3, FUT6 and FUT7 RNA, suggesting involvement of viral or cellular proteins.	Cycloheximide	108-121	fucosyltransferase 7	Homo sapiens	216-220
23352615-4	2013	In addition, CXCR7 is a primary ERalpha-target gene because the effect of E2 does not require the synthesis of an intermediary protein as revealed by the translational inhibitor cycloheximide treatment.	Cycloheximide	178-191	atypical chemokine receptor 3	Homo sapiens	13-18
23237828-3	2013	However, the action of cycloheximide on expression of adipocyte SOCS-3 gene is unknown.	Cycloheximide	23-36	suppressor of cytokine signaling 3	Homo sapiens	64-70
23237828-4	2013	Using 3T3-L1 adipocytes, we found that cycloheximide up-regulated SOCS-3 mRNA expression in dose- and time-dependent manners.	Cycloheximide	39-52	suppressor of cytokine signaling 3	Homo sapiens	66-72
23237828-5	2013	Treatment with actinomycin D prevented cycloheximide-stimulated SOCS-3 mRNA expression, suggesting that the effect of cycloheximide requires new mRNA synthesis.	Cycloheximide	39-52	suppressor of cytokine signaling 3	Homo sapiens	64-70
23237828-8	2013	Moreover, cycloheximide was observed to up-regulate expression of other SOCS family members, such as SOCS-1, -2, -4, -5, -6, -7, and cytokine-inducible SH2-containing protein (CIS)-1 mRNAs.	Cycloheximide	10-23	suppressor of cytokine signaling 1	Homo sapiens	133-182
23237828-10	2013	These results imply the functional MEK1/ERK-mediated pathway is necessary for the cycloheximide stimulation of SOCS-3 gene expression.	Cycloheximide	82-95	mitogen-activated protein kinase kinase 1	Homo sapiens	35-39
23237828-10	2013	These results imply the functional MEK1/ERK-mediated pathway is necessary for the cycloheximide stimulation of SOCS-3 gene expression.	Cycloheximide	82-95	mitogen-activated protein kinase 1	Homo sapiens	40-43
23237828-10	2013	These results imply the functional MEK1/ERK-mediated pathway is necessary for the cycloheximide stimulation of SOCS-3 gene expression.	Cycloheximide	82-95	suppressor of cytokine signaling 3	Homo sapiens	111-117
23237828-5	2013	Treatment with actinomycin D prevented cycloheximide-stimulated SOCS-3 mRNA expression, suggesting that the effect of cycloheximide requires new mRNA synthesis.	Cycloheximide	118-131	suppressor of cytokine signaling 3	Homo sapiens	64-70
23352615-4	2013	In addition, CXCR7 is a primary ERalpha-target gene because the effect of E2 does not require the synthesis of an intermediary protein as revealed by the translational inhibitor cycloheximide treatment.	Cycloheximide	178-191	estrogen receptor 1	Homo sapiens	32-39
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	Cycloheximide	6-19	mitogen-activated protein kinase kinase 1	Homo sapiens	56-60
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	Cycloheximide	6-19	mitogen-activated protein kinase 8	Homo sapiens	65-68
23280045-3	2013	By administration of cycloheximide or siRNA against mitogen-activated protein kinase phosphatase 7 (MKP-7) in a rat model of ischemia/reperfusion, an obvious enhancement of JNK activity was observed in 4 h of reperfusion following ischemia, suggesting MKP-7 was involved in JNK inactivation after ischemia.	Cycloheximide	21-34	dual specificity phosphatase 16	Rattus norvegicus	100-105
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	Cycloheximide	6-19	mitogen-activated protein kinase kinase 1	Homo sapiens	141-145
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	Cycloheximide	6-19	mitogen-activated protein kinase 8	Homo sapiens	188-191
23237828-7	2013	U0126 and PD98059, respectively, reduced cycloheximide-stimulated SOCS-3 mRNA expression, but SP600125 did not antagonize cycloheximide effect.	Cycloheximide	41-54	suppressor of cytokine signaling 3	Homo sapiens	66-72
23237828-8	2013	Moreover, cycloheximide was observed to up-regulate expression of other SOCS family members, such as SOCS-1, -2, -4, -5, -6, -7, and cytokine-inducible SH2-containing protein (CIS)-1 mRNAs.	Cycloheximide	10-23	suppressor of cytokine signaling 1	Homo sapiens	101-107
23254431-3	2013	To better understand the evolution of these proteins under selective pressure, we exposed a Saccharomyces cerevisiae yeast strain already overexpressing Pdr5 to a lethal concentration of cycloheximide.	Cycloheximide	187-200	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	153-157
23241409-9	2013	Studies performed with cycloheximide showed that agLDL prolongs the LRP1 protein half life.	Cycloheximide	23-36	LDL receptor related protein 1	Homo sapiens	68-72
23136001-4	2013	Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling analysis and caspase cleavage assays demonstrated that 1-desamino-8-d-arginine vasopressin (dDAVP) inhibited apoptosis induced by various agents (staurosporine, actinomycin D, and cycloheximide) in cultured mouse cortical collecting duct cells (mpkCCD).	Cycloheximide	257-270	arginine vasopressin	Homo sapiens	156-167
23280045-3	2013	By administration of cycloheximide or siRNA against mitogen-activated protein kinase phosphatase 7 (MKP-7) in a rat model of ischemia/reperfusion, an obvious enhancement of JNK activity was observed in 4 h of reperfusion following ischemia, suggesting MKP-7 was involved in JNK inactivation after ischemia.	Cycloheximide	21-34	mitogen-activated protein kinase 8	Rattus norvegicus	173-176
23280045-3	2013	By administration of cycloheximide or siRNA against mitogen-activated protein kinase phosphatase 7 (MKP-7) in a rat model of ischemia/reperfusion, an obvious enhancement of JNK activity was observed in 4 h of reperfusion following ischemia, suggesting MKP-7 was involved in JNK inactivation after ischemia.	Cycloheximide	21-34	dual specificity phosphatase 16	Rattus norvegicus	252-257
23280045-3	2013	By administration of cycloheximide or siRNA against mitogen-activated protein kinase phosphatase 7 (MKP-7) in a rat model of ischemia/reperfusion, an obvious enhancement of JNK activity was observed in 4 h of reperfusion following ischemia, suggesting MKP-7 was involved in JNK inactivation after ischemia.	Cycloheximide	21-34	mitogen-activated protein kinase 8	Rattus norvegicus	274-277
23811558-6	2013	Ginsenoside Rh1 significantly inhibited LPS/CHX-induced Akt phosphorylation, as well as mammalian target of rapamycin and Bcl-2-associated death promoter activation in both cell types.	Cycloheximide	44-47	AKT serine/threonine kinase 1	Homo sapiens	56-59
23201403-6	2013	On the other hand, application of a protein synthesis inhibitor, cycloheximide, caused a decrease in the MAPO1 content, implying that proteasome-mediated degradation is involved.	Cycloheximide	65-78	folliculin interacting protein 2	Homo sapiens	105-110
24018687-2	2013	Cycloheximide time-course experiments revealed that the high-molecular-mass forms of DDR1 and DDR2 were significantly less stable than control receptor tyrosine kinases.	Cycloheximide	0-13	discoidin domain receptor tyrosine kinase 1	Homo sapiens	85-89
24018687-2	2013	Cycloheximide time-course experiments revealed that the high-molecular-mass forms of DDR1 and DDR2 were significantly less stable than control receptor tyrosine kinases.	Cycloheximide	0-13	discoidin domain receptor tyrosine kinase 2	Homo sapiens	94-98
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	pellino 3	Mus musculus	13-21
23685731-8	2013	On inhibition of de novo synthesis with cycloheximide, however, p-Smad1/5/8 expression was suppressed only under normoxia.	Cycloheximide	40-53	SMAD family member 1	Homo sapiens	66-73
23712000-9	2013	PD98059 (ERK1/2 inhibitor), wedelolactone (NF-kappaB inhibitor), actinomycin D or cycloheximide significantly inhibited the DSP-enhanced contraction and expression of mRNA and protein of the ETB receptor.	Cycloheximide	82-95	endothelin receptor type B	Rattus norvegicus	191-194
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	30-34
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	tumor necrosis factor	Mus musculus	41-44
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	tumor necrosis factor	Mus musculus	74-77
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	caspase 8	Mus musculus	111-120
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	142-146
24113711-4	2013	We show that Pellino3 targets RIP1, in a TNF-dependent manner, to inhibit TNF-induced complex II formation and caspase 8-mediated cleavage of RIP1 in response to TNF/cycloheximide co-stimulation.	Cycloheximide	166-179	tumor necrosis factor	Mus musculus	74-77
23349769-6	2013	However, cycloheximide reduced the IL-1beta-dependent expression of 13 mRNAs, which, along with the 5 not showing repression by dexamethasone, were not analysed further.	Cycloheximide	9-22	interleukin 1 beta	Homo sapiens	35-43
23457570-5	2013	We found that the stability of endogenous and exogenous Osx reduced after cycloheximide treatment.	Cycloheximide	74-87	Sp7 transcription factor 7	Mus musculus	56-59
23052036-8	2013	Induction of miR-21 was inhibited by the estrogen receptor antagonist fulvestrant, by androgen receptor antagonist bicalutamide, by actinomycin D and cycloheximide, and by inhibitors of the mitogen-activated protein kinases and phosphoinositide 3-kinase pathways.	Cycloheximide	150-163	microRNA 21	Homo sapiens	13-19
23042187-5	2012	Heme oxygenase 1 protein induced by J2, Delta, and 15d was inhibited by the transcriptional inhibitor, actinomycin (Act) D; the translational inhibitor, cycloheximide; and the antioxidant, N-acetyl cysteine (NAC).	Cycloheximide	153-166	heme oxygenase 1	Mus musculus	0-16
22977259-2	2012	FAM129B protein, which is a member of a small family of proteins, was also found to suppress TNFalpha/cycloheximide-induced apoptosis in HeLa cells.	Cycloheximide	102-115	niban apoptosis regulator 2	Homo sapiens	0-7
22977259-2	2012	FAM129B protein, which is a member of a small family of proteins, was also found to suppress TNFalpha/cycloheximide-induced apoptosis in HeLa cells.	Cycloheximide	102-115	tumor necrosis factor	Homo sapiens	93-101
22971756-0	2012	Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling.	Cycloheximide	10-23	epidermal growth factor receptor	Homo sapiens	27-59
23088607-5	2012	Estrogen modulation of HIF-1 and subsequent effects on endothelial cells is dependent on the Akt/PI3K pathway and protein synthesis as validated by the use of the inhibitors wortmannin and cycloheximide which abrogated estrogen"s effects respectively.	Cycloheximide	189-202	AKT serine/threonine kinase 1	Homo sapiens	93-96
23088607-5	2012	Estrogen modulation of HIF-1 and subsequent effects on endothelial cells is dependent on the Akt/PI3K pathway and protein synthesis as validated by the use of the inhibitors wortmannin and cycloheximide which abrogated estrogen"s effects respectively.	Cycloheximide	189-202	hypoxia inducible factor 1 subunit alpha	Homo sapiens	23-28
22948139-8	2012	Additionally, inhibition of translation by cycloheximide treatment rescued IFN-beta induction following PKR knockdown but not IPS-1 knockdown.	Cycloheximide	43-56	interferon beta 1	Homo sapiens	75-83
22948139-8	2012	Additionally, inhibition of translation by cycloheximide treatment rescued IFN-beta induction following PKR knockdown but not IPS-1 knockdown.	Cycloheximide	43-56	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	104-107
22971756-2	2012	Here we demonstrate that cycloheximide induces internalization and redistribution of EGF receptor to early endosomes in HeLa cells independent of receptor tyrosine phosphorylation, but dependent on p38 MAPK activity.	Cycloheximide	25-38	mitogen-activated protein kinase 1	Homo sapiens	198-201
22971756-2	2012	Here we demonstrate that cycloheximide induces internalization and redistribution of EGF receptor to early endosomes in HeLa cells independent of receptor tyrosine phosphorylation, but dependent on p38 MAPK activity.	Cycloheximide	25-38	mitogen-activated protein kinase 3	Homo sapiens	202-206
22971756-4	2012	EGF-induced activation of ERK1/2 was inhibited upon pre-treatment with cycloheximide, but did not activate JNK.	Cycloheximide	71-84	mitogen-activated protein kinase 3	Homo sapiens	26-32
22610671-5	2012	Cycloheximide treatment reversed the effect of 4-HIL on GLUT4 translocation to the basal level suggesting the requirement of new protein synthesis.	Cycloheximide	0-13	solute carrier family 2 member 4	Rattus norvegicus	56-61
22483689-6	2012	ET-1-induced up-regulation of beta(2)-adrenoceptor mRNA was also seen in the presence of cycloheximide excluding indirect effects via up-regulation of other regulatory proteins.	Cycloheximide	89-102	adrenoceptor beta 2	Homo sapiens	30-50
22483689-6	2012	ET-1-induced up-regulation of beta(2)-adrenoceptor mRNA was also seen in the presence of cycloheximide excluding indirect effects via up-regulation of other regulatory proteins.	Cycloheximide	89-102	endothelin 1	Homo sapiens	0-4
22809957-5	2012	Insensitivity to cycloheximide indicated that IL-33 was a direct target of Notch signaling, well in line with the identification of several conserved RBP-Jkappa binding sites in the IL33 gene.	Cycloheximide	17-30	interleukin 33	Homo sapiens	46-51
22986590-9	2012	Strikingly, grouper TCTP, when overexpressed in fathead minnow (FHM) cells, protected them from cell death induced by cycloheximide (CHX).	Cycloheximide	118-131	tumor protein, translationally-controlled 1	Homo sapiens	20-24
22986590-9	2012	Strikingly, grouper TCTP, when overexpressed in fathead minnow (FHM) cells, protected them from cell death induced by cycloheximide (CHX).	Cycloheximide	133-136	tumor protein, translationally-controlled 1	Homo sapiens	20-24
22936788-6	2012	Copper-mediated Jagged1 proteolysis was also observed following the pretreatment of cells with cycloheximide and in a cell-free membrane system, indicating a posttranslational mechanism of sheddase activation.	Cycloheximide	95-108	jagged canonical Notch ligand 1	Homo sapiens	16-23
22521266-2	2012	In this study, the mechanism underlying insulin promoted decrease of MKP-3 protein was investigated by studying MKP-3 protein stability via immunoblot analysis in the presence of cycloheximide using cultured liver cells.	Cycloheximide	179-192	dual specificity phosphatase 6	Rattus norvegicus	69-74
22767315-6	2012	Of note, when translation was blocked in the presence of cycloheximide (CHX), levels of both N-glycosylated and unglycosylated COX-2 proteins induced by cadmium rapidly declined but the decline was prevented by MG132, a 26S proteasomal inhibitor.	Cycloheximide	57-70	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	127-132
22767315-6	2012	Of note, when translation was blocked in the presence of cycloheximide (CHX), levels of both N-glycosylated and unglycosylated COX-2 proteins induced by cadmium rapidly declined but the decline was prevented by MG132, a 26S proteasomal inhibitor.	Cycloheximide	72-75	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	127-132
22902539-9	2012	Furthermore, OXT-dependent transcription was dependent on protein neosynthesis; cycloheximide abolished RGS2 transcription but augmented RCAN1 and COX2 transcriptional readouts.	Cycloheximide	80-93	oxytocin/neurophysin I prepropeptide	Homo sapiens	13-16
22902539-9	2012	Furthermore, OXT-dependent transcription was dependent on protein neosynthesis; cycloheximide abolished RGS2 transcription but augmented RCAN1 and COX2 transcriptional readouts.	Cycloheximide	80-93	regulator of G protein signaling 2	Homo sapiens	104-108
22902539-9	2012	Furthermore, OXT-dependent transcription was dependent on protein neosynthesis; cycloheximide abolished RGS2 transcription but augmented RCAN1 and COX2 transcriptional readouts.	Cycloheximide	80-93	regulator of calcineurin 1	Homo sapiens	137-142
22902539-9	2012	Furthermore, OXT-dependent transcription was dependent on protein neosynthesis; cycloheximide abolished RGS2 transcription but augmented RCAN1 and COX2 transcriptional readouts.	Cycloheximide	80-93	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	147-151
22809957-5	2012	Insensitivity to cycloheximide indicated that IL-33 was a direct target of Notch signaling, well in line with the identification of several conserved RBP-Jkappa binding sites in the IL33 gene.	Cycloheximide	17-30	notch receptor 1	Homo sapiens	75-80
22660975-0	2012	Protective effect of Homer 1a on tumor necrosis factor-alpha with cycloheximide-induced apoptosis is mediated by mitogen-activated protein kinase pathways.	Cycloheximide	66-79	homer scaffold protein 1	Homo sapiens	21-29
22660975-0	2012	Protective effect of Homer 1a on tumor necrosis factor-alpha with cycloheximide-induced apoptosis is mediated by mitogen-activated protein kinase pathways.	Cycloheximide	66-79	tumor necrosis factor	Homo sapiens	33-60
22809957-5	2012	Insensitivity to cycloheximide indicated that IL-33 was a direct target of Notch signaling, well in line with the identification of several conserved RBP-Jkappa binding sites in the IL33 gene.	Cycloheximide	17-30	interleukin 33	Homo sapiens	182-186
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	69-82	tumor necrosis factor	Homo sapiens	29-56
22689575-8	2012	Cycloheximide, a translation elongation inhibitor known to augment intracellular amino acid levels, prevented the effect of bafilomycin on amino acids levels and completely reversed its inhibition of EGF-induced mTORC1 activation.	Cycloheximide	0-13	epidermal growth factor	Homo sapiens	200-203
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	69-82	homer scaffold protein 1	Homo sapiens	121-129
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	69-82	homer scaffold protein 1	Homo sapiens	121-128
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	69-82	homer scaffold protein 1	Homo sapiens	152-159
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	84-87	tumor necrosis factor	Homo sapiens	29-56
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	84-87	homer scaffold protein 1	Homo sapiens	121-129
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	84-87	homer scaffold protein 1	Homo sapiens	121-128
22660975-2	2012	In this study, we found that tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX) treatment transiently increased Homer 1a (the short variant of Homer 1), but did not affect Homer 1b/c (the long variant of Homer 1).	Cycloheximide	84-87	homer scaffold protein 1	Homo sapiens	152-159
22745369-9	2012	The cycloheximide-based protein degradation analysis indicated that t-DARPP extended the half-life of ERBB2, explaining the increase in the basal levels of ERBB2, p-ERBB2(Y1248), and p-AKT(S473).	Cycloheximide	4-17	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107
22511233-5	2012	Mal-C-mediated HO-1 induction was inhibited by treatment with actinomycin D or by cycloheximide.	Cycloheximide	82-95	heme oxygenase 1	Rattus norvegicus	15-19
22760527-9	2012	Mechanistically, RT-PCR assay and cycloheximide chase experiments have indicated that increases in Rac1 protein upon TDP-43 depletion is regulated at the translational level.	Cycloheximide	34-47	Rac family small GTPase 1	Homo sapiens	99-103
22760527-9	2012	Mechanistically, RT-PCR assay and cycloheximide chase experiments have indicated that increases in Rac1 protein upon TDP-43 depletion is regulated at the translational level.	Cycloheximide	34-47	TAR DNA binding protein	Homo sapiens	117-123
22692005-8	2012	The dE7 transcript levels increased when cells were treated with the protein synthesis inhibitor cycloheximide (CHX) or a kinase inhibitor wortmannin (WORT), whilst the FL transcript levels were unchanged, suggesting that the dE7 transcript is a target of nonsense-mediated decay (NMD).	Cycloheximide	97-110	Glutathione S transferase E7	Drosophila melanogaster	4-7
22692005-8	2012	The dE7 transcript levels increased when cells were treated with the protein synthesis inhibitor cycloheximide (CHX) or a kinase inhibitor wortmannin (WORT), whilst the FL transcript levels were unchanged, suggesting that the dE7 transcript is a target of nonsense-mediated decay (NMD).	Cycloheximide	97-110	Glutathione S transferase E7	Drosophila melanogaster	226-229
22692005-8	2012	The dE7 transcript levels increased when cells were treated with the protein synthesis inhibitor cycloheximide (CHX) or a kinase inhibitor wortmannin (WORT), whilst the FL transcript levels were unchanged, suggesting that the dE7 transcript is a target of nonsense-mediated decay (NMD).	Cycloheximide	112-115	Glutathione S transferase E7	Drosophila melanogaster	4-7
22712502-6	2012	Under cycloheximide treatment, the stability of NPM1 protein was enhanced by EDAG overexpression, whereas knockdown of EDAG by lentivirus-mediated small interfering RNA resulted in an increased degradation rate of NPM1 in K562 cells.	Cycloheximide	6-19	nucleophosmin 1	Homo sapiens	48-52
22712502-6	2012	Under cycloheximide treatment, the stability of NPM1 protein was enhanced by EDAG overexpression, whereas knockdown of EDAG by lentivirus-mediated small interfering RNA resulted in an increased degradation rate of NPM1 in K562 cells.	Cycloheximide	6-19	hemogen	Homo sapiens	77-81
22689575-8	2012	Cycloheximide, a translation elongation inhibitor known to augment intracellular amino acid levels, prevented the effect of bafilomycin on amino acids levels and completely reversed its inhibition of EGF-induced mTORC1 activation.	Cycloheximide	0-13	CREB regulated transcription coactivator 1	Mus musculus	212-218
22825471-9	2012	Pretreatment with the protein synthesis inhibitor, cycloheximide, decreased levels of ubiquitinated proteins, ATF3, CHOP, and the overall total cell death, suggesting that inhibition of protein synthesis increases cell survival by relieving proteotoxic stress.	Cycloheximide	51-64	activating transcription factor 3	Homo sapiens	110-114
22825471-9	2012	Pretreatment with the protein synthesis inhibitor, cycloheximide, decreased levels of ubiquitinated proteins, ATF3, CHOP, and the overall total cell death, suggesting that inhibition of protein synthesis increases cell survival by relieving proteotoxic stress.	Cycloheximide	51-64	DNA damage inducible transcript 3	Homo sapiens	116-120
22555848-6	2012	Polyamine-deficient cells also exhibited an increase in resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis, which was prevented by inhibiting SG formation with silencing SG resident proteins Sort1 and TIA-1.	Cycloheximide	98-111	tumor necrosis factor	Homo sapiens	70-97
22555848-6	2012	Polyamine-deficient cells also exhibited an increase in resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis, which was prevented by inhibiting SG formation with silencing SG resident proteins Sort1 and TIA-1.	Cycloheximide	98-111	sortilin 1	Homo sapiens	214-219
22555848-6	2012	Polyamine-deficient cells also exhibited an increase in resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis, which was prevented by inhibiting SG formation with silencing SG resident proteins Sort1 and TIA-1.	Cycloheximide	98-111	TIA1 cytotoxic granule associated RNA binding protein	Homo sapiens	224-229
22465937-14	2012	Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased half-life of the CYP2A6 compared to cells treated only with CHX.	Cycloheximide	18-31	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	109-115
22532685-7	2012	As reported earlier, a combinational treatment of cells with cycloheximide and actinomycin D allowed expression of IE180 without detectable expression of the US3 early protein in PRV-infected cells.	Cycloheximide	61-74	transcriptional regulator ICP4	Suid alphaherpesvirus 1	115-120
22532685-7	2012	As reported earlier, a combinational treatment of cells with cycloheximide and actinomycin D allowed expression of IE180 without detectable expression of the US3 early protein in PRV-infected cells.	Cycloheximide	61-74	serine/threonine protein kinase US3	Suid alphaherpesvirus 1	158-161
22235919-4	2012	In primary rat hepatocytes, the expression level of rCES2 mRNA was increased by treatment with 100 nM dexamethasone, and the increase was completely blocked in the presence of 10 microM mifepristone (RU-486), a potent inhibitor of glucocorticoid receptor (GR), or 10 microg/mL cycloheximide, a translation inhibitor.	Cycloheximide	277-290	carboxylesterase 2	Rattus norvegicus	52-57
22566500-9	2012	Flutamide, actinomycin D, and cycloheximide (protein synthesis inhibitor) diminished testosterone effects on p47phox.	Cycloheximide	30-43	neutrophil cytosolic factor 1	Rattus norvegicus	109-116
22514278-6	2012	Cortactin is polyubiquitinated and degraded within the proteasome, whereas a cortactin(K79R) mutant exhibited proteolytic stability during cyclohexamide (CHX) or LPS treatment.	Cycloheximide	154-157	cortactin	Mus musculus	77-81
22302392-6	2012	In cells treated with CHX, nfkb1 showed an up-regulation by palmitate, suggesting that NF-kappaB could be an IEG.	Cycloheximide	22-25	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-32
22302392-6	2012	In cells treated with CHX, nfkb1 showed an up-regulation by palmitate, suggesting that NF-kappaB could be an IEG.	Cycloheximide	22-25	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	87-96
22314197-6	2012	The presence of 2% PRP significantly inhibited serum starvation- or TNF-alpha/cycloheximide-induced apoptosis in comparison to 2% FBS or 2% PPP.	Cycloheximide	78-91	tumor necrosis factor	Homo sapiens	68-77
22484732-5	2012	Cycloheximide chase analysis             revealed that vorinostat increased the half-life of p27 and p21 proteins.	Cycloheximide	0-13	dynactin subunit 6	Homo sapiens	93-96
22521877-5	2012	However, pretreating cells with cycloheximide (50mug/ml) inhibited LA-induced Nrf2 nuclear accumulation by 94%.	Cycloheximide	32-45	NFE2 like bZIP transcription factor 2	Homo sapiens	78-82
22444557-7	2012	When oocytes precultured with eCG + CHX were further cultured without eCG and CHX, cyclin B1 first decreased but then, because of the ongoing effects of CHX, increased to a level sufficient to induce GVBD.	Cycloheximide	36-39	cyclin B1	Mus musculus	83-92
22493454-6	2012	We used the translational inhibitor cycloheximide to analyze turnover and observed that the stability of the PAA2 protein was decreased in plants grown with elevated Cu.	Cycloheximide	36-49	20S proteasome subunit PAA2	Arabidopsis thaliana	109-113
21986941-5	2012	Sox4 half-life was found to be less than 1 h as evident by inhibition of protein synthesis using cycloheximide.	Cycloheximide	97-110	SRY-box transcription factor 4	Homo sapiens	0-4
22465937-14	2012	Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased half-life of the CYP2A6 compared to cells treated only with CHX.	Cycloheximide	33-36	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	109-115
22442340-6	2012	The protein expression of cPLA(2) was decreased by PG201 in the presence of cycloheximide, an inhibitor of translation, suggesting that PG201 may facilitate the degradation of cPLA(2).	Cycloheximide	76-89	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	26-33
22366249-4	2012	BmorCPG11 expression was also induced by the addition of 20E, which was inhibited by cycloheximide.	Cycloheximide	85-98	cuticular protein glycine-rich 11	Bombyx mori	0-9
22366249-5	2012	Both BmorCPG11 and BR-Z2 were induced by the 20E pulse treatment, but they were inhibited by the addition of cycloheximide.	Cycloheximide	109-122	cuticular protein glycine-rich 11	Bombyx mori	5-14
22442340-6	2012	The protein expression of cPLA(2) was decreased by PG201 in the presence of cycloheximide, an inhibitor of translation, suggesting that PG201 may facilitate the degradation of cPLA(2).	Cycloheximide	76-89	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	176-183
22634761-4	2012	Results from cycloheximide and endosomal Cys protease inhibitor E-64d treatments further suggest that PHO1 degradation is PHO2 dependent and involves multivesicular body-mediated vacuolar proteolysis.	Cycloheximide	13-26	phosphate 1	Arabidopsis thaliana	102-106
22401855-7	2012	Moreover, inhibition of tyrosinase mRNA expression in Nox4 siRNA-treated cells by blocking de novo mRNA and protein synthesis with actinomycin D and cycloheximide respectively indicates that Nox4 repression induces melanogenesis by increasing tyrosinase gene expression.	Cycloheximide	149-162	tyrosinase	Mus musculus	24-34
22401855-7	2012	Moreover, inhibition of tyrosinase mRNA expression in Nox4 siRNA-treated cells by blocking de novo mRNA and protein synthesis with actinomycin D and cycloheximide respectively indicates that Nox4 repression induces melanogenesis by increasing tyrosinase gene expression.	Cycloheximide	149-162	NADPH oxidase 4	Mus musculus	54-58
22401855-7	2012	Moreover, inhibition of tyrosinase mRNA expression in Nox4 siRNA-treated cells by blocking de novo mRNA and protein synthesis with actinomycin D and cycloheximide respectively indicates that Nox4 repression induces melanogenesis by increasing tyrosinase gene expression.	Cycloheximide	149-162	NADPH oxidase 4	Mus musculus	191-195
21954831-5	2012	Further experiments revealed that the agonist-induced STAT3 phosphorylation at Tyr(705) was significantly suppressed by pretreatment with cycloheximide (a ribosome inhibitor), suggesting that de novo protein synthesis might play a critical role for this response.	Cycloheximide	138-151	signal transducer and activator of transcription 3	Homo sapiens	54-59
22534375-11	2012	Tumour necrosis factor-alpha (TNF-alpha) significantly increased GLS expression in RA FLSs; this effect was reduced by pre-treatment with cycloheximide and mithramycin.	Cycloheximide	138-151	tumor necrosis factor	Homo sapiens	30-39
22301110-4	2012	Here, we show that long-term exposure of 18Co cells, a model of human colonic myofibroblasts, with TNF-alpha led to a striking increase in cell surface EGFR expression, an effect that was completely inhibited by cycloheximide.	Cycloheximide	212-225	tumor necrosis factor	Homo sapiens	99-108
22301110-4	2012	Here, we show that long-term exposure of 18Co cells, a model of human colonic myofibroblasts, with TNF-alpha led to a striking increase in cell surface EGFR expression, an effect that was completely inhibited by cycloheximide.	Cycloheximide	212-225	epidermal growth factor receptor	Homo sapiens	152-156
22496554-5	2012	This reduction is due to production of aberrantly spliced transcripts lacking either exon 6 or exons 6 and 7 and their subsequent degradation via non-sense-mediated decay (NMD); inhibition of NMD by cycloheximide treatment stabilized these transcripts and restored the level of Psen1 mRNA in KI/KI brains.	Cycloheximide	199-212	presenilin 1	Mus musculus	278-283
21618512-5	2012	Cisplatin-mediated increase in Bcl-2 expression was blocked by combination with either actinomycin D or cycloheximide.	Cycloheximide	104-117	BCL2 apoptosis regulator	Homo sapiens	31-36
22422887-4	2012	We found that macrophage activation with C1q resulted in cycloheximide-sensitive enhanced engulfment, indicating a requirement for de novo protein synthesis.	Cycloheximide	57-70	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	41-44
22422887-5	2012	To investigate the cycloheximide-sensitive pathway, C1q-elicited macrophage transcripts were identified by microarray.	Cycloheximide	19-32	complement component 1, q subcomponent, alpha polypeptide	Mus musculus	52-55
22306003-4	2012	Our data show that the inhibition of translation by puromycin or cycloheximide blocks both the heat shock and MG132 induced accumulation of SUMO-2/3 conjugates in HEK 293T and U2OS cells.	Cycloheximide	65-78	small ubiquitin like modifier 3	Homo sapiens	140-148
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	89-102	tumor necrosis factor	Homo sapiens	79-88
22261922-7	2012	Messenger RNA for the umami taste receptors (TasR), Tas1R1 and 3, and for the bitter receptors, Tas2R105 and Tas2R108, involved in perception of cycloheximide and denatonium were detected in the auditory tube.	Cycloheximide	145-158	taste receptor, type 2, member 105	Mus musculus	96-104
22261922-7	2012	Messenger RNA for the umami taste receptors (TasR), Tas1R1 and 3, and for the bitter receptors, Tas2R105 and Tas2R108, involved in perception of cycloheximide and denatonium were detected in the auditory tube.	Cycloheximide	145-158	taste receptor, type 2, member 108	Mus musculus	109-117
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	89-102	mitogen-activated protein kinase 14	Homo sapiens	153-156
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	89-102	mitogen-activated protein kinase 8	Homo sapiens	161-182
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	89-102	mitogen-activated protein kinase 8	Homo sapiens	184-187
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	104-107	tumor necrosis factor	Homo sapiens	79-88
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	104-107	mitogen-activated protein kinase 14	Homo sapiens	153-156
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	104-107	mitogen-activated protein kinase 8	Homo sapiens	161-182
22198289-2	2012	Stimulation of human umbilical vein endothelial cells (HUVEC) with IL-1beta or TNF-alpha/cycloheximide (CHX) was found to enhance the phosphorylation of p38 and Jun-N-terminal kinase (JNK) in a time-dependent fashion, but did not affect the time-dependent phosphorylation of extracellular signal-regulated kinase.	Cycloheximide	104-107	mitogen-activated protein kinase 8	Homo sapiens	184-187
22305615-5	2012	The mechanisms of imiquimod-induced decrease in Mcl-1 protein were evaluated by addition of cycloheximide, MG132 proteasome inhibitor or pan-caspase inhibitor.	Cycloheximide	92-105	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-53
21941369-7	2012	Furthermore, transformed AMPK-/- and TSC1-/- MEFs both have higher total protein synthesis rates than wild-type controls, and translation inhibition using cycloheximide partially restores their anoikis resistance, indicating a mechanism whereby mTORC1 inhibition suppresses anoikis.	Cycloheximide	155-168	TSC complex subunit 1	Mus musculus	37-41
21941369-7	2012	Furthermore, transformed AMPK-/- and TSC1-/- MEFs both have higher total protein synthesis rates than wild-type controls, and translation inhibition using cycloheximide partially restores their anoikis resistance, indicating a mechanism whereby mTORC1 inhibition suppresses anoikis.	Cycloheximide	155-168	CREB regulated transcription coactivator 1	Mus musculus	245-251
22253441-5	2012	The neuronal death produced by prolonged CaMKII inhibition is associated with an increase in TUNEL staining and caspase-3 cleavage and is blocked with the translation inhibitor cycloheximide.	Cycloheximide	177-190	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	41-47
22253441-5	2012	The neuronal death produced by prolonged CaMKII inhibition is associated with an increase in TUNEL staining and caspase-3 cleavage and is blocked with the translation inhibitor cycloheximide.	Cycloheximide	177-190	caspase 3	Homo sapiens	112-121
22085560-9	2012	Cycloheximide (CHX)-chase assay revealed that 4-HNE exposure accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	0-13	adiponectin, C1Q and collagen domain containing	Homo sapiens	73-84
22306778-10	2012	Further evidence for persistence of TDP-43 aggregates was obtained by treating cultures with cycloheximide after paraquat treatment.	Cycloheximide	93-106	TAR DNA binding protein	Homo sapiens	36-42
22306778-11	2012	Cycloheximide abolished nearly all cytosolic HuR aggregation (SGs) but large TDP-43-positive aggregates remained.	Cycloheximide	0-13	ELAV like RNA binding protein 1	Homo sapiens	45-48
22245129-8	2012	Under CHX treatment, the stability of Nrf2 protein was enhanced by PMID with decreased turnover rate.	Cycloheximide	6-9	nuclear factor, erythroid derived 2, like 2	Mus musculus	38-42
22085560-9	2012	Cycloheximide (CHX)-chase assay revealed that 4-HNE exposure accelerated adiponectin protein degradation, which was prevented by MG132, a potent proteasome inhibitor.	Cycloheximide	15-18	adiponectin, C1Q and collagen domain containing	Homo sapiens	73-84
21967732-7	2012	The increase was blocked by the system xc- inhibitor (s)-4-carboxyphenylglycine, required at least 12 h FGF-2 treatment, and was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	174-187	fibroblast growth factor 2	Homo sapiens	104-109
22019695-6	2012	Nrf2 protein levels in both nuclear and whole cell lysates were increased after sulforaphane treatment and were decreased by pretreatment with NAC, actinomycin D and cycloheximide.	Cycloheximide	166-179	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
22183712-9	2012	The protein synthesis inhibitor cycloheximide abolished LPS-induced IL-10 mRNA expression and increased LTA- and LPS-induced mRNA for MIP-2 in J774 cells.	Cycloheximide	32-45	interleukin 10	Mus musculus	68-73
22183712-9	2012	The protein synthesis inhibitor cycloheximide abolished LPS-induced IL-10 mRNA expression and increased LTA- and LPS-induced mRNA for MIP-2 in J774 cells.	Cycloheximide	32-45	chemokine (C-X-C motif) ligand 2	Mus musculus	134-139
22233804-4	2012	We found that the levels of BCLb protein diminish quickly after inhibition of protein synthesis with cycloheximide, so we searched for interacting proteins that might affect posttranslational stability of BCLb.	Cycloheximide	101-114	BCL2 like 10	Homo sapiens	28-32
22353876-3	2012	Inhibition of protein synthesis by rapamycin or cycloheximide resulted in the phosphorylation of BiP on threonine residues while ER stress induced by tunicamycin or heat shock caused the fast dephosphorylation of the protein.	Cycloheximide	48-61	heat shock protein family A (Hsp70) member 5	Homo sapiens	97-100
22209981-3	2012	Cycloheximide and Brefeldin A treatment revealed both the expression of S100A8 and S100A9 as secondary response genes and the involvement of polyI:C-induced cytokines herein.	Cycloheximide	0-13	S100 calcium binding protein A8	Homo sapiens	72-78
22209981-3	2012	Cycloheximide and Brefeldin A treatment revealed both the expression of S100A8 and S100A9 as secondary response genes and the involvement of polyI:C-induced cytokines herein.	Cycloheximide	0-13	S100 calcium binding protein A9	Homo sapiens	83-89
23006579-2	2012	RT-PCR and cycloheximide inhibition experiments indicated that PMS-induced HIF-1alpha decrease is involved in post-translational degradation during hypoxia.	Cycloheximide	11-24	hypoxia inducible factor 1 subunit alpha	Homo sapiens	75-85
22863942-2	2012	For the assay of PI3K/Akt pathway, cytoprotective Tat-transduced CHME5 cells, which are the cytoprotective phenotype against lypopolysaccharide (LPS)/cycloheximide (CHX), were used.	Cycloheximide	150-163	AKT serine/threonine kinase 1	Homo sapiens	22-25
22206671-5	2012	When de novo protein synthesis was inhibited by the protein synthesis inhibitor cycloheximide, the intracellular resistin protein levels were drastically reduced by the PFE, suggesting that the PFE promoted the degradation of resistin at the protein level.	Cycloheximide	80-93	resistin	Mus musculus	113-121
22206671-5	2012	When de novo protein synthesis was inhibited by the protein synthesis inhibitor cycloheximide, the intracellular resistin protein levels were drastically reduced by the PFE, suggesting that the PFE promoted the degradation of resistin at the protein level.	Cycloheximide	80-93	resistin	Mus musculus	226-234
22094385-0	2012	Dizocilpine and cycloheximide prevent inhibition of c-Fos gene expression by delta sleep-inducing peptide in the paraventricular nucleus of the hypothalamus in rats with different resistance to emotional stress.	Cycloheximide	16-29	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	52-57
22094385-1	2012	The effects of the non-competitive NMDA-receptor blocker MK-801 (dizocilpine) and the protein synthesis inhibitor cycloheximide on the delta sleep-inducing peptide (DSIP) inhibition of c-Fos immediate early gene expression were studied in the parvocellular subdivision of the hypothalamic paraventricular nucleus (pPVN) of male Wistar rats with either high or low resistance to emotional stress, predicted from differences in their open-field behaviour.	Cycloheximide	114-127	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	185-190
21995960-2	2012	Clusterin mRNA was still upregulated in the presence of the protein synthesis inhibitor cycloheximide, although at a lower level.	Cycloheximide	88-101	clusterin	Rattus norvegicus	0-9
22055894-10	2012	TWEAK induced RelB activation and suppressed IL-6 mRNA expression in TNFalpha-activated FLS and both of these phenomenon were abolished by inhibition of new protein synthesis with cycloheximide.	Cycloheximide	180-193	TNF superfamily member 12	Homo sapiens	0-5
22055894-10	2012	TWEAK induced RelB activation and suppressed IL-6 mRNA expression in TNFalpha-activated FLS and both of these phenomenon were abolished by inhibition of new protein synthesis with cycloheximide.	Cycloheximide	180-193	tumor necrosis factor	Homo sapiens	69-77
22236088-4	2012	Bmal1-LUC and PER2::LUC bioluminescence decreased to basal levels after CHX application.	Cycloheximide	72-75	aryl hydrocarbon receptor nuclear translocator-like	Mus musculus	0-5
22721505-0	2012	TNF-alpha/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial MODE-K cells.	Cycloheximide	10-23	tumor necrosis factor	Mus musculus	0-9
22721505-2	2012	To address these findings in vitro, we assessed TNF-alpha/cycloheximide (CHX)-induced oxidative stress and apoptosis in a mouse intestinal epithelial cell line, MODE-K.	Cycloheximide	73-76	tumor necrosis factor	Mus musculus	48-57
22721505-9	2012	MODE-K cells are sensitive to TNF-alpha-induced apoptosis in the presence of CHX, which is associated with increased intracellular ROS production and caspase-3/7 activation.	Cycloheximide	77-80	tumor necrosis factor	Mus musculus	30-39
22721505-9	2012	MODE-K cells are sensitive to TNF-alpha-induced apoptosis in the presence of CHX, which is associated with increased intracellular ROS production and caspase-3/7 activation.	Cycloheximide	77-80	caspase 3	Mus musculus	150-159
22236088-4	2012	Bmal1-LUC and PER2::LUC bioluminescence decreased to basal levels after CHX application.	Cycloheximide	72-75	period circadian clock 2	Mus musculus	14-18
21938403-8	2012	In addition, cycloheximide, a protein synthesis inhibitor, blocked GC-induced mimecan expression in AtT-20 cells.	Cycloheximide	13-26	osteoglycin	Mus musculus	78-85
21928335-7	2012	Moreover, dexamethasone-induced Ndrg2 mRNA expression was reduced by pretreatment with the protein synthesis inhibitor cycloheximide.	Cycloheximide	119-132	NDRG family member 2	Rattus norvegicus	32-37
22072789-5	2012	Cbc1 associates with polysomes, while the deletion of the CBC1 gene causes hypersensitivity to the translation inhibitor cycloheximide and yields synthetic "sickness" in cells with limiting amounts of translation initiator factor eIF4E.	Cycloheximide	121-134	Sto1p	Saccharomyces cerevisiae S288C	58-62
23056220-7	2012	Increased Abeta generation appears to result from increased turnover of APP as revealed by cycloheximide-chase experiments.	Cycloheximide	91-104	amyloid beta (A4) precursor protein	Mus musculus	10-15
23213349-3	2012	The increase in both Ha-Ras and Ki-Ras was insensitive to the protein synthesis inhibitor, cycloheximide, and was occluded by the proteasomal inhibitor, MG-132.	Cycloheximide	91-104	KRAS proto-oncogene, GTPase	Homo sapiens	32-38
23300602-6	2012	Harmine also prevented p53 degradation in the presence of cycloheximide and activated nuclear accumulation of p53 followed by increasing its transcriptional activity in endothelial cells.	Cycloheximide	58-71	transformation related protein 53, pseudogene	Mus musculus	23-26
23227251-10	2012	Furthermore, the amitriptyline-induced FGF-2 mRNA expression was completely blocked by cycloheximide (an inhibitor of protein synthesis), while the NA-induced FGF-2 mRNA was not.	Cycloheximide	87-100	fibroblast growth factor 2	Rattus norvegicus	39-44
22970294-8	2012	Depletion of total synaptophysin was determined after treatment with cycloheximide.	Cycloheximide	69-82	synaptophysin	Rattus norvegicus	19-32
23071605-4	2012	Transduction of NPCCs with adenovirus containing hHO-1 gene significantly reduced apoptosis compared with the GFP-expressing adenovirus control after treatment with either hydrogen peroxide or hTNF-alpha and cycloheximide.	Cycloheximide	208-221	heme oxygenase 1	Homo sapiens	49-54
23071605-9	2012	As expected, fibroblasts derived from the hHO-1 transgenic pigs were significantly resistant to both hydrogen peroxide damage and hTNF-alpha and cycloheximide-mediated apoptosis when compared with wild-type fibroblasts.	Cycloheximide	145-158	heme oxygenase 1	Homo sapiens	42-47
22530027-8	2012	Here, we demonstrate that in UPF1-depleted or in cycloheximide-treated HeLa and HepG2 cells the HFE transcripts are clearly upregulated, meaning that the physiological HFE mRNA is in fact an NMD-target.	Cycloheximide	49-62	homeostatic iron regulator	Homo sapiens	96-99
22911741-14	2012	Moreover, the HR elicited by PA5 and PA5DeltafliC was enhanced by the addition of cycloheximide, suggesting that the flagellin is one of the PAMPs (pathogen-associated molecular patterns) contributed to induce the PAMP-triggered immunity (PTI).	Cycloheximide	82-95	AWN88_RS22085	Agrobacterium tumefaciens	117-126
22530027-8	2012	Here, we demonstrate that in UPF1-depleted or in cycloheximide-treated HeLa and HepG2 cells the HFE transcripts are clearly upregulated, meaning that the physiological HFE mRNA is in fact an NMD-target.	Cycloheximide	49-62	homeostatic iron regulator	Homo sapiens	168-171
22359684-8	2012	The transcription inhibitor actinomycin D could not block adiponectin-induced UCP2 expression, whereas the protein synthesis inhibitor cycloheximide inhibited the elevation of UCP2 protein but not its mRNA levels.	Cycloheximide	135-148	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	176-180
22238618-5	2012	Functions of PDR5 chimeras were evaluated by fluconazole and cycloheximide resistance assays.	Cycloheximide	61-74	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	13-17
22363611-1	2012	Although TNFalpha is a strong inducer of apoptosis, its cytotoxicity in most normal cells in vitro requires blockade of NFkappaB signaling or inhibition of de novo protein synthesis, typically by the addition of cycloheximide.	Cycloheximide	212-225	tumor necrosis factor	Homo sapiens	9-17
22319556-5	2012	Inhibition of protein synthesis by cycloheximide revealed that poly I:C- or LPS-induced secreted TNF-alpha is synthesized de novo, not released from cellular stores.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	97-106
21970855-11	2011	Cycloheximide-mediated blockade of protein translation reveals that C75- or FASN siRNA-induced shutdown of FASN accelerates decomposition of signaling proteins.	Cycloheximide	0-13	fatty acid synthase	Homo sapiens	76-80
22136156-2	2012	T(3) was also shown to rapidly increase glucose uptake in myocytes exposed to cycloheximide, indicating that it might act nongenomically to regulate GLUT4 availability.	Cycloheximide	78-91	solute carrier family 2 member 4	Rattus norvegicus	149-154
21890490-4	2011	JMJD3 upregulation was strictly dependent on vitamin D receptor (VDR) expression and was abolished by cycloheximide.	Cycloheximide	102-115	lysine demethylase 6B	Homo sapiens	0-5
21749909-4	2011	Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes.	Cycloheximide	45-58	secreted and transmembrane 1	Homo sapiens	86-92
21749909-4	2011	Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes.	Cycloheximide	45-58	interferon gamma	Homo sapiens	214-223
21749909-4	2011	Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes.	Cycloheximide	45-58	secreted and transmembrane 1	Homo sapiens	247-253
21749909-4	2011	Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes.	Cycloheximide	115-128	interferon gamma	Homo sapiens	31-40
21749909-4	2011	Co-treatment of MM6 cells with IFN-gamma and cycloheximide caused a superinduction of SECTM1 mRNA expression while cycloheximide alone had no effect, illustrating that de novo protein synthesis is not required for IFN-gamma enhanced expression of SECTM1 mRNA, a characteristic of IFN early response genes.	Cycloheximide	115-128	interferon alpha 1	Homo sapiens	31-34
21970855-11	2011	Cycloheximide-mediated blockade of protein translation reveals that C75- or FASN siRNA-induced shutdown of FASN accelerates decomposition of signaling proteins.	Cycloheximide	0-13	fatty acid synthase	Homo sapiens	107-111
21836059-9	2011	This finding was also confirmed at the functional level when a significantly higher thiamine uptake was observed in cycloheximide-treated (6 h) cells expressing hTHTR-1 together with hTspan-1 compared with those expressing hTHTR-1 alone.	Cycloheximide	116-129	solute carrier family 19 member 2	Homo sapiens	161-168
21816165-10	2011	Treatment with IGF-1, LiCl or SB216763 increased protein level of Na(+) channel alpha-subunit; it was prevented by cycloheximide.	Cycloheximide	115-128	insulin like growth factor 1	Bos taurus	15-20
21836059-9	2011	This finding was also confirmed at the functional level when a significantly higher thiamine uptake was observed in cycloheximide-treated (6 h) cells expressing hTHTR-1 together with hTspan-1 compared with those expressing hTHTR-1 alone.	Cycloheximide	116-129	tetraspanin 1	Homo sapiens	183-191
21972265-7	2011	Upon cycloheximide treatment, FIT activity was hardly compromised, since Fe deficiency genes like IRON-REGULATED TRANSPORTER1 and FERRIC REDUCTASE OXIDASE2 were still inducible by Fe deficiency.	Cycloheximide	5-18	iron-regulated transporter 1	Arabidopsis thaliana	98-125
21953463-5	2011	SMURF2 alone reduced the protein stability of KLF5 as shown by cycloheximide chase assay, indicating that SMURF2 specifically destabilizes KLF5.	Cycloheximide	63-76	SMAD specific E3 ubiquitin protein ligase 2	Homo sapiens	0-6
21953463-5	2011	SMURF2 alone reduced the protein stability of KLF5 as shown by cycloheximide chase assay, indicating that SMURF2 specifically destabilizes KLF5.	Cycloheximide	63-76	Kruppel like factor 5	Homo sapiens	46-50
21953463-5	2011	SMURF2 alone reduced the protein stability of KLF5 as shown by cycloheximide chase assay, indicating that SMURF2 specifically destabilizes KLF5.	Cycloheximide	63-76	SMAD specific E3 ubiquitin protein ligase 2	Homo sapiens	106-112
21871474-10	2011	Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased half-life of the CYP2A5 compared to cells treated only with CHX.	Cycloheximide	18-31	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	109-115
21871474-10	2011	Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased half-life of the CYP2A5 compared to cells treated only with CHX.	Cycloheximide	33-36	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	109-115
21836059-9	2011	This finding was also confirmed at the functional level when a significantly higher thiamine uptake was observed in cycloheximide-treated (6 h) cells expressing hTHTR-1 together with hTspan-1 compared with those expressing hTHTR-1 alone.	Cycloheximide	116-129	solute carrier family 19 member 2	Homo sapiens	223-230
21868703-9	2011	However, an inducible protein transactivator is also probably necessary, as heme-induced HO-1 mRNA expression was fully inhibited by the protein synthesis inhibitor cycloheximide.	Cycloheximide	165-178	heme oxygenase 1	Homo sapiens	89-93
21592617-7	2011	Feeding plants with sugars clearly decreased the transcript and protein levels, and incubation with cycloheximide revealed a rapid turnover for AtJ8 in darkness.	Cycloheximide	100-113	Chaperone DnaJ-domain superfamily protein	Arabidopsis thaliana	144-148
21900244-8	2011	As measured by pulse-chase and cycloheximide chase assays, a major binding site Nedd4-2 mutant had a shorter cellular half-life than WT Nedd4-2, but this property was not dependent on binding to 14-3-3.	Cycloheximide	31-44	NEDD4 like E3 ubiquitin protein ligase	Homo sapiens	80-87
21903942-1	2011	OBJECTIVE: Tumor necrosis factor-alpha (TNFalpha) may change from a stimulator of reversible activation of endothelial cells (ECs) to a killer when combined with cycloheximide (CHX).	Cycloheximide	162-175	tumor necrosis factor	Homo sapiens	11-38
21903942-1	2011	OBJECTIVE: Tumor necrosis factor-alpha (TNFalpha) may change from a stimulator of reversible activation of endothelial cells (ECs) to a killer when combined with cycloheximide (CHX).	Cycloheximide	162-175	tumor necrosis factor	Homo sapiens	40-48
21903942-1	2011	OBJECTIVE: Tumor necrosis factor-alpha (TNFalpha) may change from a stimulator of reversible activation of endothelial cells (ECs) to a killer when combined with cycloheximide (CHX).	Cycloheximide	177-180	tumor necrosis factor	Homo sapiens	11-38
21903942-1	2011	OBJECTIVE: Tumor necrosis factor-alpha (TNFalpha) may change from a stimulator of reversible activation of endothelial cells (ECs) to a killer when combined with cycloheximide (CHX).	Cycloheximide	177-180	tumor necrosis factor	Homo sapiens	40-48
21978374-9	2011	Co-treatment with protein synthesis inhibitor cycloheximide or proteasome inhibitor MG132 revealed that depletion of ERalpha by WA is post-translational, due to proteasome-dependent ERalpha degradation.	Cycloheximide	46-59	estrogen receptor 1	Homo sapiens	117-124
21415860-5	2011	Surprisingly, Prdx6(KD) cells are markedly resistant to apoptosis induced by TNF-alpha in the presence of cycloheximide, but are highly sensitive to hydrogen peroxide-induced apoptosis.	Cycloheximide	106-119	peroxiredoxin 6	Homo sapiens	14-19
21569845-10	2011	Finally, direct alterations of the functional properties of the glucocorticoid receptor might be responsible for cell death prevention by actinomycin D, DRB, cycloheximide and puromycin.	Cycloheximide	158-171	nuclear receptor subfamily 3, group C, member 1	Mus musculus	64-87
21537832-3	2011	We previously reported that TNFalpha-induced DcR3 overexpression in rheumatoid synovial fibroblasts (RA-FLS) protects the cells from Fas-induced apoptosis and that DcR3 induces VLA-4 expression in THP-1 macrophages to inhibit cycloheximide-induced apoptosis.	Cycloheximide	226-239	tumor necrosis factor	Homo sapiens	28-36
21537832-3	2011	We previously reported that TNFalpha-induced DcR3 overexpression in rheumatoid synovial fibroblasts (RA-FLS) protects the cells from Fas-induced apoptosis and that DcR3 induces VLA-4 expression in THP-1 macrophages to inhibit cycloheximide-induced apoptosis.	Cycloheximide	226-239	TNF receptor superfamily member 6b	Homo sapiens	45-49
21537832-3	2011	We previously reported that TNFalpha-induced DcR3 overexpression in rheumatoid synovial fibroblasts (RA-FLS) protects the cells from Fas-induced apoptosis and that DcR3 induces VLA-4 expression in THP-1 macrophages to inhibit cycloheximide-induced apoptosis.	Cycloheximide	226-239	TNF receptor superfamily member 6b	Homo sapiens	164-168
21660968-6	2011	EGF accelerated the decrease in CLDN2 in the presence of cycloheximide, a translation inhibitor, indicating that EGF reduces the stability of the protein.	Cycloheximide	57-70	epidermal growth factor	Canis lupus familiaris	0-3
21660968-6	2011	EGF accelerated the decrease in CLDN2 in the presence of cycloheximide, a translation inhibitor, indicating that EGF reduces the stability of the protein.	Cycloheximide	57-70	claudin 2	Canis lupus familiaris	32-37
21660968-6	2011	EGF accelerated the decrease in CLDN2 in the presence of cycloheximide, a translation inhibitor, indicating that EGF reduces the stability of the protein.	Cycloheximide	57-70	epidermal growth factor	Canis lupus familiaris	113-116
21756905-0	2011	Downregulation of FLIP by cycloheximide sensitizes human fat cells to CD95-induced apoptosis.	Cycloheximide	26-39	Fas cell surface death receptor	Homo sapiens	70-74
21756905-5	2011	The protein synthesis blocker cycloheximide (CHX) sensitized human fat cells for CD95-induced apoptosis in a caspase-dependent manner.	Cycloheximide	30-43	Fas cell surface death receptor	Homo sapiens	81-85
21756905-5	2011	The protein synthesis blocker cycloheximide (CHX) sensitized human fat cells for CD95-induced apoptosis in a caspase-dependent manner.	Cycloheximide	45-48	Fas cell surface death receptor	Homo sapiens	81-85
21867498-11	2011	DEP-mediated Cyp1b1 induction was inhibited by actinomycin D, cycloheximide, or by an AhR antagonist.	Cycloheximide	62-75	cytochrome P450, family 1, subfamily b, polypeptide 1	Rattus norvegicus	13-19
21697465-9	2011	HSV-2 R1 inhibited the interaction between the Toll/interleukin-1 receptor domain-containing adaptor-inducing beta interferon (IFN-beta) (TRIF) and RIP1, an interaction that is essential for apoptosis triggered by extracellular poly(I   C) plus cycloheximide or TRIF overexpression.	Cycloheximide	245-258	TIR domain containing adaptor molecule 1	Homo sapiens	138-142
21697465-9	2011	HSV-2 R1 inhibited the interaction between the Toll/interleukin-1 receptor domain-containing adaptor-inducing beta interferon (IFN-beta) (TRIF) and RIP1, an interaction that is essential for apoptosis triggered by extracellular poly(I   C) plus cycloheximide or TRIF overexpression.	Cycloheximide	245-258	receptor interacting serine/threonine kinase 1	Homo sapiens	148-152
21621531-8	2011	Transcription of vox is strongly activated by Pou5f1-VP16 even when translation of zygotically expressed transcripts is experimentally inhibited by cycloheximide.	Cycloheximide	148-161	POU domain, class 5, transcription factor 1	Mus musculus	46-52
21585341-3	2011	The secretion of AKR1B10 was not affected by the protein-synthesis inhibitor cycloheximide and the classical protein-secretion pathway inhibitor brefeldin A, but was stimulated by temperature, ATP, Ca(2+) and the Ca(2+) carrier ionomycin, lysosomotropic NH(4)Cl, the G-protein activator GTPgammaS and the G-protein coupling receptor N-formylmethionyl-leucyl-phenylalanine.	Cycloheximide	77-90	aldo-keto reductase family 1 member B10	Homo sapiens	17-24
21562857-6	2011	Accordingly, inhibition of cFLIP-L expression with cycloheximide or through cFLIP short harpin RNA interference restored sensitivity to Fas and/or IFN-alpha.	Cycloheximide	51-64	CASP8 and FADD like apoptosis regulator	Homo sapiens	27-34
21562857-6	2011	Accordingly, inhibition of cFLIP-L expression with cycloheximide or through cFLIP short harpin RNA interference restored sensitivity to Fas and/or IFN-alpha.	Cycloheximide	51-64	CASP8 and FADD like apoptosis regulator	Homo sapiens	27-32
21393419-7	2011	Cycloheximide and rottlerin suppressed the delayed-phase induction of CD38 expression by ATRA but did not affect the early-phase induction.	Cycloheximide	0-13	CD38 molecule	Homo sapiens	70-74
21721951-6	2011	This mechanism can be inhibited by either actinomycin D or cycloheximide, indicating that ADRP-LDs induce newly synthesized SP-B.	Cycloheximide	59-72	perilipin 2	Rattus norvegicus	90-94
21721951-6	2011	This mechanism can be inhibited by either actinomycin D or cycloheximide, indicating that ADRP-LDs induce newly synthesized SP-B.	Cycloheximide	59-72	surfactant protein B	Rattus norvegicus	124-128
21542062-5	2011	In addition, ATP13A2 mRNA with c.3253delC was degraded by nonsense-mediated mRNA decay (NMD), which was protected by cycloheximide treatment.	Cycloheximide	117-130	ATPase cation transporting 13A2	Homo sapiens	13-20
20821348-3	2011	Time course and cycloheximide experiments show that repression of cyclin D1 is a late effect and requires new protein synthesis.	Cycloheximide	16-29	cyclin D1	Homo sapiens	66-75
21463260-9	2011	Lastly, the proteasome inhibitor (MG132) rescues JDP2 degradation following cycloheximide treatment and increases the expression of the JDP2 phospho-mimetic T148E mutant.	Cycloheximide	76-89	Jun dimerization protein 2	Homo sapiens	49-53
21554242-6	2011	Immunofluorescence, cycloheximide-chase and cell-surface-protein biotinylation experiments demonstrate that oligomerization of Cx43-Ub into hemichannels containing wild-type Cx43 or mutant Cx43Y286A is sufficient to drive the internalization of the protein.	Cycloheximide	20-33	gap junction protein alpha 1	Homo sapiens	127-131
26069588-6	2011	RESULTS: Knockdown of EMP1 inhibited cell proliferation, caused cells to shrink, and accelerated the apoptosis induced by serum deprivation or addition of cycloheximide but did not evoke apoptosis in normal culture conditions.	Cycloheximide	155-168	epithelial membrane protein 1	Homo sapiens	22-26
21440540-2	2011	In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF.	Cycloheximide	137-150	interleukin 6	Homo sapiens	227-230
21440540-2	2011	In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF.	Cycloheximide	152-155	TNF superfamily member 10	Homo sapiens	27-32
21440540-2	2011	In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF.	Cycloheximide	152-155	TNF superfamily member 10	Homo sapiens	33-38
21440540-2	2011	In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF.	Cycloheximide	152-155	TNF superfamily member 10	Homo sapiens	33-38
21440540-2	2011	In contrast, the extrinsic TRAIL/TRAIL-Receptor mediated death pathway remained highly active, and exogenous TRAIL in a combination with cycloheximide (CHX) induced higher levels of apoptosis in rho(0) cells compared to rho(+) HSF.	Cycloheximide	152-155	interleukin 6	Homo sapiens	227-230
21463260-3	2011	In the present paper we show that the JDP2 protein level is dramatically reduced in response to serum stimulation, anisomycin treatment, ultraviolet light irradiation and cycloheximide treatment, all of which activate the JNK pathway.	Cycloheximide	171-184	Jun dimerization protein 2	Homo sapiens	38-42
21463260-3	2011	In the present paper we show that the JDP2 protein level is dramatically reduced in response to serum stimulation, anisomycin treatment, ultraviolet light irradiation and cycloheximide treatment, all of which activate the JNK pathway.	Cycloheximide	171-184	mitogen-activated protein kinase 8	Homo sapiens	222-225
21463260-7	2011	In the presence of cycloheximide, JDP2 is rapidly phosphorylated and degraded due to the combined effects of protein synthesis inhibition and activation of JNK.	Cycloheximide	19-32	Jun dimerization protein 2	Homo sapiens	34-38
21463260-7	2011	In the presence of cycloheximide, JDP2 is rapidly phosphorylated and degraded due to the combined effects of protein synthesis inhibition and activation of JNK.	Cycloheximide	19-32	mitogen-activated protein kinase 8	Homo sapiens	156-159
21377978-5	2011	Instead, it was determined to be a cleaved fragment of the full-length 68 kDa AChE protein that could not be inhibited by cycloheximide (CHX) but could be suppressed by caspase inhibitors in apoptotic PC-12 cells.	Cycloheximide	122-135	acetylcholinesterase	Rattus norvegicus	78-82
21377978-5	2011	Instead, it was determined to be a cleaved fragment of the full-length 68 kDa AChE protein that could not be inhibited by cycloheximide (CHX) but could be suppressed by caspase inhibitors in apoptotic PC-12 cells.	Cycloheximide	137-140	acetylcholinesterase	Rattus norvegicus	78-82
21508882-5	2011	Chase experiments with actinomycin D (ActD) demonstrated a 3-fold stabilization of the CTNS mRNA when cells were cultured in low CySS medium for 48 h. Treatment of control cells with cyclohexamide (CHX) increased CTNS mRNA levels, suggesting that CHX blocked the synthesis of proteins involved in mRNA degradation or in repression of the CTNS gene.	Cycloheximide	198-201	cystinosin, lysosomal cystine transporter	Homo sapiens	213-217
21508882-5	2011	Chase experiments with actinomycin D (ActD) demonstrated a 3-fold stabilization of the CTNS mRNA when cells were cultured in low CySS medium for 48 h. Treatment of control cells with cyclohexamide (CHX) increased CTNS mRNA levels, suggesting that CHX blocked the synthesis of proteins involved in mRNA degradation or in repression of the CTNS gene.	Cycloheximide	198-201	cystinosin, lysosomal cystine transporter	Homo sapiens	213-217
21506109-5	2011	However it decreased cell death in C-28/I2 chondrocytes exposed to stimuli previously reported to promptly trigger apoptosis, that is, the cytokine tumor necrosis factor-alpha (TNF) plus cycloheximide (CHX) or the polyamine analogue N(1),N(11)-diethylnorspermine (DENSPM) plus CHX.	Cycloheximide	202-205	tumor necrosis factor	Homo sapiens	177-180
21506109-5	2011	However it decreased cell death in C-28/I2 chondrocytes exposed to stimuli previously reported to promptly trigger apoptosis, that is, the cytokine tumor necrosis factor-alpha (TNF) plus cycloheximide (CHX) or the polyamine analogue N(1),N(11)-diethylnorspermine (DENSPM) plus CHX.	Cycloheximide	277-280	tumor necrosis factor	Homo sapiens	177-180
21670298-5	2011	hSlo1 expressed in HEK293T cells incorporated [(3)H]myristic acid via a posttranslational mechanism, which is insensitive to cycloheximide, an inhibitor of protein biosynthesis.	Cycloheximide	125-138	potassium calcium-activated channel subfamily M alpha 1	Homo sapiens	0-5
21389275-6	2011	The transcriptional (actinomycin D) and translational (cycloheximide) inhibitors, as well as the AMPK inhibitor compound C prevented AICAR-induced reduction of NIS protein content in PCCL3 cells.	Cycloheximide	55-68	solute carrier family 5 member 5	Rattus norvegicus	160-163
21606356-5	2011	Similarly, cycloheximide, a Tas2R108 agonist, evoked a drop in respiratory rate, being sensitive to nicotinic receptor blockade and epithelium removal.	Cycloheximide	11-24	taste receptor, type 2, member 108	Mus musculus	28-36
21346151-4	2011	Cultured human microvascular endothelial cells (HMECs) exposed to LPS activated STAT1 in a delayed manner that was inhibited by cycloheximide treatment.	Cycloheximide	128-141	signal transducer and activator of transcription 1	Homo sapiens	80-85
21463260-8	2011	Pre-treatment of cells with SP600125 prior to cycloheximide treatment significantly prolongs the half-life of JDP2 that is found mainly in the unphosphorylated form.	Cycloheximide	46-59	Jun dimerization protein 2	Homo sapiens	110-114
21518760-9	2011	Cycloheximide chase assay showed a decrease in the half-life of KLF8 protein when PARP-1 expression was suppressed or KLF8-PARP-1 interaction was disrupted.	Cycloheximide	0-13	Kruppel like factor 8	Homo sapiens	64-68
21518760-9	2011	Cycloheximide chase assay showed a decrease in the half-life of KLF8 protein when PARP-1 expression was suppressed or KLF8-PARP-1 interaction was disrupted.	Cycloheximide	0-13	poly(ADP-ribose) polymerase 1	Homo sapiens	82-88
21518760-9	2011	Cycloheximide chase assay showed a decrease in the half-life of KLF8 protein when PARP-1 expression was suppressed or KLF8-PARP-1 interaction was disrupted.	Cycloheximide	0-13	Kruppel like factor 8	Homo sapiens	118-122
21518760-9	2011	Cycloheximide chase assay showed a decrease in the half-life of KLF8 protein when PARP-1 expression was suppressed or KLF8-PARP-1 interaction was disrupted.	Cycloheximide	0-13	poly(ADP-ribose) polymerase 1	Homo sapiens	123-129
21703114-5	2011	Cycloheximide was used to treat SIRT1 RNAi and Control RNAi cells for protein stability assay.	Cycloheximide	0-13	sirtuin 1	Homo sapiens	32-37
21428909-5	2011	However, cycloheximide treatment only partially blocked poly (I:C)-induced MMP-9 gene expression.	Cycloheximide	9-22	matrix metallopeptidase 9	Homo sapiens	75-80
21513489-6	2011	The insulin-induced resistance to cycloheximide and 5-fluorouracil can be used in drug screening to overcome the inefficacy of chemotherapy in obesity-associated colon cancer.	Cycloheximide	34-47	insulin	Homo sapiens	4-11
21458410-5	2011	for 15 h. Cycloheximide blocked NCX activity enhancement produced by 1,25(OH)(2)D(3).	Cycloheximide	10-23	T cell leukemia homeobox 2	Homo sapiens	32-35
21518804-8	2011	We also suggest that m3C has a role in translation, since trm140-Delta trm1-Delta strains (also lacking m2,2G26) are sensitive to low concentrations of cycloheximide.	Cycloheximide	152-165	tRNA(Thr) (cytosine(32)-N(3))-methyltransferase	Saccharomyces cerevisiae S288C	58-64
21518804-8	2011	We also suggest that m3C has a role in translation, since trm140-Delta trm1-Delta strains (also lacking m2,2G26) are sensitive to low concentrations of cycloheximide.	Cycloheximide	152-165	tRNA (guanine26-N2)-dimethyltransferase	Saccharomyces cerevisiae S288C	58-62
21624135-7	2011	Mechanism studies revealed no apparent effect of calpain, proteasome, protease or caspase inhibitors, but HDAC3 was rescued by cycloheximide or actinomycin D treatment.	Cycloheximide	127-140	histone deacetylase 3	Homo sapiens	106-111
21593322-6	2011	In field recordings from CA1, both the translation inhibitor cycloheximide and KN62 significantly reduced DHPG-induced LTD.	Cycloheximide	61-74	carbonic anhydrase 1	Rattus norvegicus	25-28
21334360-2	2011	Here, we confirmed that MYOC is a delayed secondary glucocorticoid-responsive gene by demonstrating that its transcription was not initiated immediately by the addition of dexamethasone (DEX) and was completely inhibited by treatment with cycloheximide.	Cycloheximide	239-252	myocilin	Homo sapiens	24-28
21303922-9	2011	Consistent with a requirement for de novo induction of JunB protein, cycloheximide pretreatment inhibited TGF-beta1 induction of Itgbeta6 mRNA.	Cycloheximide	69-82	transforming growth factor beta 1	Homo sapiens	106-115
21270293-9	2011	While GLUT1 mRNA levels were not affected by overexpression or gene silencing of 4F2hc, GLUT1 degradation after the addition of cycloheximide was significantly suppressed by 4F2hc overexpression and increased by 4F2hc siRNA treatment.	Cycloheximide	128-141	solute carrier family 2 member 1	Homo sapiens	88-93
21270293-9	2011	While GLUT1 mRNA levels were not affected by overexpression or gene silencing of 4F2hc, GLUT1 degradation after the addition of cycloheximide was significantly suppressed by 4F2hc overexpression and increased by 4F2hc siRNA treatment.	Cycloheximide	128-141	solute carrier family 3 member 2	Homo sapiens	174-179
21270293-9	2011	While GLUT1 mRNA levels were not affected by overexpression or gene silencing of 4F2hc, GLUT1 degradation after the addition of cycloheximide was significantly suppressed by 4F2hc overexpression and increased by 4F2hc siRNA treatment.	Cycloheximide	128-141	solute carrier family 3 member 2	Homo sapiens	174-179
21518403-0	2011	Major role of apolipoprotein B in cycloheximide-induced acute hepatic steatosis in mice.	Cycloheximide	34-47	apolipoprotein B	Mus musculus	14-30
21518403-11	2011	CONCLUSION:   We demonstrated that decreased hepatic lipid secretion due to acute apoB reduction is involved in the pathogenesis of CHX-induced liver steatosis.	Cycloheximide	132-135	apolipoprotein B	Mus musculus	82-86
21350193-2	2011	TNF-alpha requires inhibition of antiapoptotic protein synthesis by cycloheximide (CHX).	Cycloheximide	68-81	tumor necrosis factor	Homo sapiens	0-9
21520181-6	2011	The changes in transcript levels for half of these genes were a direct effect of hepcidin, as shown by cycloheximide insensitivity, and dependent on the presence of Stat3.	Cycloheximide	103-116	hepcidin antimicrobial peptide	Mus musculus	81-89
21339290-3	2011	Although overexpression of RIPK1 can cause caspase-8-dependent cell death, when RIPK1(-/-) cells are exposed to TNF and low doses of cycloheximide, they die more readily than wild-type cells, indicating RIPK1 has pro-survival as well as pro-apoptotic activities.	Cycloheximide	133-146	receptor interacting serine/threonine kinase 1	Homo sapiens	80-85
21339290-3	2011	Although overexpression of RIPK1 can cause caspase-8-dependent cell death, when RIPK1(-/-) cells are exposed to TNF and low doses of cycloheximide, they die more readily than wild-type cells, indicating RIPK1 has pro-survival as well as pro-apoptotic activities.	Cycloheximide	133-146	receptor interacting serine/threonine kinase 1	Homo sapiens	80-85
21346255-4	2011	We now report that C/EBPalpha or C/EBPalpha leucine zipper AML mutants bind in vivo to the nfkb1 (p50) promoter and induce its expression even in the presence of cycloheximide.	Cycloheximide	162-175	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	19-29
21346255-4	2011	We now report that C/EBPalpha or C/EBPalpha leucine zipper AML mutants bind in vivo to the nfkb1 (p50) promoter and induce its expression even in the presence of cycloheximide.	Cycloheximide	162-175	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	33-43
21346255-4	2011	We now report that C/EBPalpha or C/EBPalpha leucine zipper AML mutants bind in vivo to the nfkb1 (p50) promoter and induce its expression even in the presence of cycloheximide.	Cycloheximide	162-175	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	91-96
21346255-4	2011	We now report that C/EBPalpha or C/EBPalpha leucine zipper AML mutants bind in vivo to the nfkb1 (p50) promoter and induce its expression even in the presence of cycloheximide.	Cycloheximide	162-175	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	98-101
21466705-6	2011	We also demonstrated that UL15 gene belonged to the late kinetic class as its expression was sensitive to cycloheximide and phosphonoacetic acid.	Cycloheximide	106-119	UL15	Anatid alphaherpesvirus 1	26-30
21533193-8	2011	Using a rabbit model of VEGF-A-driven angiogenesis in skeletal muscle, we demonstrate that CX treatment promotes abnormal blood vessel growth characterized by vessel occlusion, disrupted blood flow, and increased vascular leakage.	Cycloheximide	91-93	vascular endothelial growth factor A	Oryctolagus cuniculus	24-30
21167122-8	2011	To further decipher the mechanism of p53 stabilization, we investigated half-life of p53 in cells treated with cycloheximide to block de novo protein synthesis.	Cycloheximide	111-124	tumor protein p53	Homo sapiens	85-88
21316405-5	2011	Inhibition of de novo protein synthesis with cycloheximide resulted in higher levels of IFN-beta1 and IFN-beta2 RNA levels after BHV-1 infection.	Cycloheximide	45-58	interleukin 6	Homo sapiens	102-111
21711826-5	2011	In vitro treatment with TIMP-1 inhibited cycloheximide-induced cell death of primary mouse hepatocytes.	Cycloheximide	41-54	tissue inhibitor of metalloproteinase 1	Mus musculus	24-30
21316454-9	2011	Although changes in alphaCaMKII or NR2B protein levels are not responsible for this enhanced glutamate vulnerability, this process is blocked by the protein translation inhibitor cycloheximide.	Cycloheximide	179-192	glutamate ionotropic receptor NMDA type subunit 2B	Homo sapiens	35-39
21276770-6	2011	When treated with PGE2, the EP4 agonist ONO-AE1-329 or the cell permeable cAMP analogue, 8-Br-cAMP, P-815 cells showed markedly increased cell surface expression of integrin alphaIIb, alphav and beta3 subunits, and these expressions were significantly reduced by addition of the protein synthesis inhibitor cycloheximide.	Cycloheximide	307-320	prostaglandin E receptor 4 (subtype EP4)	Mus musculus	28-31
21276770-6	2011	When treated with PGE2, the EP4 agonist ONO-AE1-329 or the cell permeable cAMP analogue, 8-Br-cAMP, P-815 cells showed markedly increased cell surface expression of integrin alphaIIb, alphav and beta3 subunits, and these expressions were significantly reduced by addition of the protein synthesis inhibitor cycloheximide.	Cycloheximide	307-320	integrin alpha 2b	Mus musculus	165-200
20857415-6	2011	In support of this speculation, OFSS inhibition of TNF-alpha-induced apoptosis was unaffected by inhibitors of several pro-survival signaling pathways including pI3-kinase (LY294002), MAPK/ERK kinase (PD98059 or U0126), intracellular Ca2+ release (U73122), NO production (L-NAME), or protein synthesis (cycloheximide) that were applied to cells during exposure to OFSS and during TNF-alpha treatment.	Cycloheximide	303-316	tumor necrosis factor	Mus musculus	51-60
21148485-7	2011	However, when apoptosis was induced by exposure to TNFalpha/cycloheximide or other apoptotic signaling molecules, the onset of apoptosis was accelerated 3-4-fold when FAM129B was depleted.	Cycloheximide	60-73	tumor necrosis factor	Homo sapiens	51-59
21148485-7	2011	However, when apoptosis was induced by exposure to TNFalpha/cycloheximide or other apoptotic signaling molecules, the onset of apoptosis was accelerated 3-4-fold when FAM129B was depleted.	Cycloheximide	60-73	niban apoptosis regulator 2	Homo sapiens	167-174
21198637-0	2011	p38 mitogen-activated protein kinase and PI3-kinase are involved in up-regulation of mu opioid receptor transcription induced by cycloheximide.	Cycloheximide	129-142	mitogen-activated protein kinase 14	Mus musculus	0-3
21252230-5	2011	Cycloheximide chase experiments showed that Ecm7 was stabilized by Mid1, and Mid1 was stabilized by Cch1 in non-signaling conditions, suggesting they all interact.	Cycloheximide	0-13	Ecm7p	Saccharomyces cerevisiae S288C	44-48
21252230-5	2011	Cycloheximide chase experiments showed that Ecm7 was stabilized by Mid1, and Mid1 was stabilized by Cch1 in non-signaling conditions, suggesting they all interact.	Cycloheximide	0-13	Mid1p	Saccharomyces cerevisiae S288C	77-81
21205822-8	2011	Furthermore, the AtNug2 knockdown mutant constructed by the RNAi method showed defective growth on the medium containing cycloheximide.	Cycloheximide	121-134	GTP-binding family protein	Arabidopsis thaliana	17-23
21084715-11	2011	The actions of Igf3 could be blocked by cycloheximide, but not by actinomycin D.	Cycloheximide	40-53	insulin-like growth factor 3	Danio rerio	15-19
21198637-0	2011	p38 mitogen-activated protein kinase and PI3-kinase are involved in up-regulation of mu opioid receptor transcription induced by cycloheximide.	Cycloheximide	129-142	serine (or cysteine) peptidase inhibitor, clade A, member 1C	Mus musculus	41-44
21198637-0	2011	p38 mitogen-activated protein kinase and PI3-kinase are involved in up-regulation of mu opioid receptor transcription induced by cycloheximide.	Cycloheximide	129-142	opioid receptor, mu 1	Mus musculus	85-103
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	129-142	opioid receptor, mu 1	Mus musculus	108-111
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	129-142	opioid receptor, mu 1	Mus musculus	220-223
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	129-142	opioid receptor, mu 1	Mus musculus	220-223
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	144-147	opioid receptor, mu 1	Mus musculus	108-111
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	144-147	opioid receptor, mu 1	Mus musculus	220-223
21198637-4	2011	Surprisingly, in the course of our investigation to understand the mechanisms involved in the regulation of MOR gene expression, cycloheximide (CHX), a known protein synthesis inhibitor, markedly induced accumulation of MOR mRNAs in both MOR-negative and -positive cells.	Cycloheximide	144-147	opioid receptor, mu 1	Mus musculus	220-223
21204635-5	2011	Exposure of astrocytes to FPI resulted in a significant upregulation of AQP4 protein in the plasma membrane due to neosynthesis, as cycloheximide blocked the trauma-induced AQP4 upregulation.	Cycloheximide	132-145	aquaporin 4	Homo sapiens	72-76
21204635-5	2011	Exposure of astrocytes to FPI resulted in a significant upregulation of AQP4 protein in the plasma membrane due to neosynthesis, as cycloheximide blocked the trauma-induced AQP4 upregulation.	Cycloheximide	132-145	aquaporin 4	Homo sapiens	173-177
21347335-5	2011	Additionally, when ROS production was blocked by N-acetyl-L-cysteine (NAC), HCC cells were protected against Lexa and CHX combination treatment-induced apoptosis.	Cycloheximide	118-121	X-linked Kx blood group	Homo sapiens	70-73
20724126-5	2011	The stimulatory effect of garlic lectin on IFN-gamma production was completely inhibited by both actinomycin D and cycloheximide, an inhibitor of ribosomal protein synthesis and DNA-dependent RNA polymerase, respectively, and was associated with an increase in IFN-gamma mRNA level.	Cycloheximide	115-128	interferon gamma	Mus musculus	43-52
20724126-5	2011	The stimulatory effect of garlic lectin on IFN-gamma production was completely inhibited by both actinomycin D and cycloheximide, an inhibitor of ribosomal protein synthesis and DNA-dependent RNA polymerase, respectively, and was associated with an increase in IFN-gamma mRNA level.	Cycloheximide	115-128	interferon gamma	Mus musculus	261-270
21143562-7	2011	In addition, a de novo protein synthesis inhibition experiment using cycloheximide showed that the SIRT5(iso1) -specific C-terminus is necessary for maintaining the stability of SIRT5(iso1) .	Cycloheximide	69-82	sirtuin 5	Homo sapiens	99-104
21268072-5	2011	Co-treatment with GA and cycloheximide, a protein synthesis inhibitor, induced a decrease of half-life of mutant p53 protein.	Cycloheximide	25-38	tumor protein p53	Homo sapiens	113-116
21143562-7	2011	In addition, a de novo protein synthesis inhibition experiment using cycloheximide showed that the SIRT5(iso1) -specific C-terminus is necessary for maintaining the stability of SIRT5(iso1) .	Cycloheximide	69-82	eukaryotic translation initiation factor 1	Homo sapiens	105-109
21255728-3	2011	A variety of inhibitors of the PI activity of FKBP12, including FK506, rapamycin, and cycloheximide, increase steady-state palmitoylation.	Cycloheximide	86-99	FKBP prolyl isomerase 1A	Rattus norvegicus	46-52
21283672-12	2011	VDR protein stability was greater in MCF-7-VDRFF cells in the presence of cycloheximide.	Cycloheximide	74-87	vitamin D receptor	Homo sapiens	0-3
21228181-8	2011	When slices were pretreated with translation inhibitor (anisomycin or cycloheximide), group I mGluRs elicited a sustained decrease in FMRP.	Cycloheximide	70-83	fragile X messenger ribonucleoprotein 1	Mus musculus	134-138
21325828-5	2011	Chemical anoxia and overnight recovery induced Hsp70 expression (analyzed by Western blotting) and this was inhibited by actinomycin D as well as by cycloheximide showing that induction of both translation and transcription was involved.	Cycloheximide	149-162	heat shock protein 1B	Mus musculus	47-52
21148191-6	2011	NH4Cl (a lysomotoropic agent) and cycloheximide (a ribosome inhibitor) strongly inhibited modeccin-induced TNF-alpha secretion, but no significant inhibitory effects of these reagents on the PHA-induced TNF-alpha secretion were observed.	Cycloheximide	34-47	tumor necrosis factor	Mus musculus	107-116
20688159-5	2011	Cycloheximide decay assays showed that Akt2 increased the stability and nuclear localization of p27, thus inhibiting the cyclin E/CDK2 complex.	Cycloheximide	0-13	AKT serine/threonine kinase 2	Homo sapiens	39-43
20688159-5	2011	Cycloheximide decay assays showed that Akt2 increased the stability and nuclear localization of p27, thus inhibiting the cyclin E/CDK2 complex.	Cycloheximide	0-13	interferon alpha inducible protein 27	Homo sapiens	96-99
20688159-5	2011	Cycloheximide decay assays showed that Akt2 increased the stability and nuclear localization of p27, thus inhibiting the cyclin E/CDK2 complex.	Cycloheximide	0-13	cyclin dependent kinase 2	Homo sapiens	130-134
20886262-8	2011	Cycloheximide (CHX) chase and proteasome inhibition experiments showed that the ubiquitin-proteasome pathway is involved in Hrd1-mediated ATZ degradation.	Cycloheximide	0-13	synoviolin 1	Homo sapiens	124-128
21467739-0	2011	Cycloheximide suppresses radiation-induced apoptosis in MOLT-4 cells with Arg72 variant of p53 through translational inhibition of p53 accumulation.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	91-94
21467739-0	2011	Cycloheximide suppresses radiation-induced apoptosis in MOLT-4 cells with Arg72 variant of p53 through translational inhibition of p53 accumulation.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	131-134
20886262-8	2011	Cycloheximide (CHX) chase and proteasome inhibition experiments showed that the ubiquitin-proteasome pathway is involved in Hrd1-mediated ATZ degradation.	Cycloheximide	15-18	synoviolin 1	Homo sapiens	124-128
22102901-8	2011	Re-expression of Gal-3 reversed the phenotype of the Gal-3-/- MEFs and dramatically reduced the disappearance of K-Ras in the presence of cycloheximide to the levels seen in wild-type MEFs.	Cycloheximide	138-151	galectin 3	Homo sapiens	17-22
22102901-8	2011	Re-expression of Gal-3 reversed the phenotype of the Gal-3-/- MEFs and dramatically reduced the disappearance of K-Ras in the presence of cycloheximide to the levels seen in wild-type MEFs.	Cycloheximide	138-151	KRAS proto-oncogene, GTPase	Homo sapiens	113-118
21918689-6	2011	The nocodazole-induced prometaphase arrest was also abrogated by pre-treatment of cells with roscovitine, an inhibitor of cyclin-dependent kinases, or with cycloheximide, a protein synthesis inhibitor that was found to suppress cyclin B1 and Cdc2 up-regulation.	Cycloheximide	156-169	cyclin B1	Homo sapiens	228-237
21887213-4	2011	PRINCIPAL FINDINGS: Recombinant studies in COS-7 cells that were transfected with normal and mutant recombinant GNB3 constructs and subjected to cycloheximide chase showed that the mutant GNB3d protein had a much shorter half life compared to normal GNB3.	Cycloheximide	145-158	G protein subunit beta 3	Gallus gallus	188-192
21918689-6	2011	The nocodazole-induced prometaphase arrest was also abrogated by pre-treatment of cells with roscovitine, an inhibitor of cyclin-dependent kinases, or with cycloheximide, a protein synthesis inhibitor that was found to suppress cyclin B1 and Cdc2 up-regulation.	Cycloheximide	156-169	cyclin dependent kinase 1	Homo sapiens	242-246
21159181-10	2010	Western blotting and immunostaining analyses further indicated that changes in expression of several cell cycle regulators and the differentiation marker GFAP were accompanied with cycloheximide-induced cell cycle arrest and cell differentiation.	Cycloheximide	181-194	glial fibrillary acidic protein	Homo sapiens	154-158
21677781-7	2011	Remarkably, ongoing protein synthesis and viral replication are required to maintain repression of the IFNbeta gene in persistently infected cells, as the gene can be activated by the protein synthesis inhibitor cycloheximide, or by the antiviral drug ribavirin.	Cycloheximide	212-225	interferon beta 1	Homo sapiens	103-110
20149622-9	2010	The enhancement of mMDH activity by calcitriol was completely abolished by simultaneous cycloheximide injection to -D. mMDH mRNA levels, detected by RT-PCR, indicate that calcitriol did not affect gene expression.	Cycloheximide	88-101	malate dehydrogenase 2, NAD (mitochondrial)	Mus musculus	19-23
20868760-7	2010	Leptin-mediated increases in the expression of FZD1 were blocked by pre-treatment with the protein synthesis inhibitor cycloheximide or the JAK2 inhibitor AG490.	Cycloheximide	119-132	frizzled class receptor 1	Homo sapiens	47-51
20858750-9	2010	Inhibition of transduction with cycloheximide and inhibition of phosphatases with orthovanadate efficiently blocked DEX-induced downregulation of phospho-ERK1/2.	Cycloheximide	32-45	mitogen activated protein kinase 3	Rattus norvegicus	154-160
20713124-3	2010	Treatment with the 26S proteasome inhibitor MG132 failed to abrogate the suppression of HIF-1alpha accumulation induced by IDPm knockdown, whereas HIF-1alpha levels were reduced by cycloheximide treatment in both control and IDPm siRNA-transfected cells.	Cycloheximide	181-194	hypoxia inducible factor 1 subunit alpha	Homo sapiens	147-157
20713124-3	2010	Treatment with the 26S proteasome inhibitor MG132 failed to abrogate the suppression of HIF-1alpha accumulation induced by IDPm knockdown, whereas HIF-1alpha levels were reduced by cycloheximide treatment in both control and IDPm siRNA-transfected cells.	Cycloheximide	181-194	isocitrate dehydrogenase (NADP(+)) 2	Homo sapiens	225-229
20713176-6	2010	Although cycloheximide (CHX) treatment partially inhibited the Golgi localization of GFP-nSMase2, recovery of GFP-nSMase2 to an intracellular compartment was still observed after photobleaching.	Cycloheximide	9-22	sphingomyelin phosphodiesterase 3	Homo sapiens	89-96
20713176-6	2010	Although cycloheximide (CHX) treatment partially inhibited the Golgi localization of GFP-nSMase2, recovery of GFP-nSMase2 to an intracellular compartment was still observed after photobleaching.	Cycloheximide	24-27	sphingomyelin phosphodiesterase 3	Homo sapiens	89-96
20870767-11	2010	Heterologous expression of CBU1206 rescued S. cerevisiae erg4 sensitivity to growth in the presence of brefeldin A and cycloheximide and resulted in new synthesis of ergosterol.	Cycloheximide	119-132	delta(24(24(1)))-sterol reductase	Saccharomyces cerevisiae S288C	57-61
21080973-6	2010	The strain-induced increases in MMP-13 and TIMP-1 mRNA expression were inhibited by PD098059 and cycloheximide, respectively.	Cycloheximide	97-110	matrix metallopeptidase 13	Mus musculus	32-38
21080973-6	2010	The strain-induced increases in MMP-13 and TIMP-1 mRNA expression were inhibited by PD098059 and cycloheximide, respectively.	Cycloheximide	97-110	tissue inhibitor of metalloproteinase 1	Mus musculus	43-49
20576581-5	2010	After inhibiting protein synthesis using cycloheximide (CHX), we found that levels of both megalin and ClC5 were lower in Cd-challenged cells than in cells treated with Cd or CHX only, which is consistent with reduced translation and/or posttranslational down-regulation.	Cycloheximide	175-178	chloride voltage-gated channel 5	Sus scrofa	103-107
20716444-10	2010	The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors.	Cycloheximide	118-131	endothelin receptor type B	Rattus norvegicus	42-47
20716444-10	2010	The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors.	Cycloheximide	118-131	mitogen-activated protein kinase 8	Rattus norvegicus	240-243
20716444-10	2010	The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors.	Cycloheximide	118-131	endothelin receptor type B	Rattus norvegicus	307-312
20833895-6	2010	Furthermore, secretion is dependent on Sec18p, indicating that it requires ER-to-Golgi trafficking, and accordingly, Crh2-HA accumulates in the ER in ire1Delta and bst1Delta mutants by cycloheximide chase experiments.	Cycloheximide	185-198	Utr2p	Saccharomyces cerevisiae S288C	117-121
20645408-5	2010	The increase in cystine uptake that follows IL-1beta is lacking in astrocytes derived from mice harboring a mutation in Slc7a11 (sut gene), which encodes for xCT, and in wild-type astrocytes treated with the protein synthesis inhibitor cycloheximide.	Cycloheximide	236-249	interleukin 1 beta	Mus musculus	44-52
20851109-4	2010	HeLa cells expressing DN-PP6 showed increased resistance to apoptosis induced by TNF and cycloheximide.	Cycloheximide	89-102	protein phosphatase 6 catalytic subunit	Homo sapiens	25-28
20702393-5	2010	On the other hand, we investigated the degradation of Nucling in connection with proteasome and caspase by using cycloheximide chase.	Cycloheximide	113-126	uveal autoantigen with coiled-coil domains and ankyrin repeats	Mus musculus	54-61
20444542-8	2010	The increased PTEN instability was confirmed by the treatment of HCC827-CR with a protein synthesis inhibitor, cycloheximide.	Cycloheximide	111-124	phosphatase and tensin homolog	Homo sapiens	14-18
20444542-9	2010	In the presence of cycloheximide, overexpressed PTEN was degraded more rapidly ( approximately 12h) in HCC827-CR cells.	Cycloheximide	19-32	phosphatase and tensin homolog	Homo sapiens	48-52
20624918-7	2010	Interestingly, in pX-expressing cells, Mre11 co-immunoprecipitated with transfected Plk1 Polo-box domain, and inhibition of Plk1 increased Mre11 stability in cycloheximide-treated cells.	Cycloheximide	158-171	MRE11 homolog, double strand break repair nuclease	Homo sapiens	39-44
20547174-5	2010	In addition, cells treated with the protein synthesis inhibitor cycloheximide expressed message for longer CD45 isoforms, and treatment with lactacystin, which blocks protein degradation, rescued smaller isoform message expression.	Cycloheximide	64-77	LOC100304617	Ictalurus punctatus	107-111
20946641-6	2010	Strikingly, however, the majority of transcripts up-regulated by UPF1 knockdown were either insensitive to, or even down-regulated by, cycloheximide treatment.	Cycloheximide	135-148	UPF1 RNA helicase and ATPase	Homo sapiens	65-69
20798956-5	2010	Our data showed that resistance to apoptosis was accompanied by high levels of TIMP-1 expression in part mediated by NF-kappaB activation, whereas under apoptotic conditions, in the presence of cycloheximide (CHX), TIMP-1 and alphavbeta3 integrin protein levels were significantly reduced.	Cycloheximide	209-212	TIMP metallopeptidase inhibitor 1	Homo sapiens	215-237
20811726-9	2010	Treatment with the protein synthesis inhibitor cycloheximide sensitized SW948-TR to rhTRAIL-induced apoptosis, indicating that the functionality of the TRAIL receptors was maintained.	Cycloheximide	47-60	TNF superfamily member 10	Homo sapiens	86-91
20624918-7	2010	Interestingly, in pX-expressing cells, Mre11 co-immunoprecipitated with transfected Plk1 Polo-box domain, and inhibition of Plk1 increased Mre11 stability in cycloheximide-treated cells.	Cycloheximide	158-171	polo like kinase 1	Homo sapiens	124-128
20624918-7	2010	Interestingly, in pX-expressing cells, Mre11 co-immunoprecipitated with transfected Plk1 Polo-box domain, and inhibition of Plk1 increased Mre11 stability in cycloheximide-treated cells.	Cycloheximide	158-171	MRE11 homolog, double strand break repair nuclease	Homo sapiens	139-144
19855086-3	2010	TGF-beta, phorbol myristate acetate, and the translation inhibitor cycloheximide induced PAI-1 mRNA and slowed its degradation, suggesting that PAI-1 mRNA could be regulated by interaction of a PAI-1 binding protein (PAI-1 mRNABp) with PAI-1 mRNA.	Cycloheximide	67-80	serpin family E member 1	Homo sapiens	89-94
20886049-7	2010	BAMBI mRNA had a half-life of only 60 minutes and was stabilized by cycloheximide, indicating post-transcriptional regulation due to AU-rich elements, which we identified in the 3" untranslated sequence of both the human and murine BAMBI gene.	Cycloheximide	68-81	BMP and activin membrane bound inhibitor	Homo sapiens	0-5
20700104-5	2010	Conversely, upregulation of NADPH prevented Dronc-mediated apoptosis upon DIAP1 RNAi or cycloheximide treatment.	Cycloheximide	88-101	Death regulator Nedd2-like caspase	Drosophila melanogaster	44-49
20838596-5	2010	In agreement with this, transcriptomic analysis of a transgenic plant expressing PHR1 fused to the hormone ligand domain of the glucocorticoid receptor showed that PHR1 direct targets (i.e., displaying altered expression after GR:PHR1 activation by dexamethasone in the presence of cycloheximide) corresponded largely to Pi starvation-induced genes that are highly enriched in P1BS.	Cycloheximide	282-295	photolyase 1	Arabidopsis thaliana	164-168
20838596-5	2010	In agreement with this, transcriptomic analysis of a transgenic plant expressing PHR1 fused to the hormone ligand domain of the glucocorticoid receptor showed that PHR1 direct targets (i.e., displaying altered expression after GR:PHR1 activation by dexamethasone in the presence of cycloheximide) corresponded largely to Pi starvation-induced genes that are highly enriched in P1BS.	Cycloheximide	282-295	photolyase 1	Arabidopsis thaliana	164-168
19855086-3	2010	TGF-beta, phorbol myristate acetate, and the translation inhibitor cycloheximide induced PAI-1 mRNA and slowed its degradation, suggesting that PAI-1 mRNA could be regulated by interaction of a PAI-1 binding protein (PAI-1 mRNABp) with PAI-1 mRNA.	Cycloheximide	67-80	serpin family E member 1	Homo sapiens	144-149
19855086-3	2010	TGF-beta, phorbol myristate acetate, and the translation inhibitor cycloheximide induced PAI-1 mRNA and slowed its degradation, suggesting that PAI-1 mRNA could be regulated by interaction of a PAI-1 binding protein (PAI-1 mRNABp) with PAI-1 mRNA.	Cycloheximide	67-80	serpin family E member 1	Homo sapiens	144-149
19855086-3	2010	TGF-beta, phorbol myristate acetate, and the translation inhibitor cycloheximide induced PAI-1 mRNA and slowed its degradation, suggesting that PAI-1 mRNA could be regulated by interaction of a PAI-1 binding protein (PAI-1 mRNABp) with PAI-1 mRNA.	Cycloheximide	67-80	serpin family E member 1	Homo sapiens	144-149
19855086-3	2010	TGF-beta, phorbol myristate acetate, and the translation inhibitor cycloheximide induced PAI-1 mRNA and slowed its degradation, suggesting that PAI-1 mRNA could be regulated by interaction of a PAI-1 binding protein (PAI-1 mRNABp) with PAI-1 mRNA.	Cycloheximide	67-80	serpin family E member 1	Homo sapiens	144-149
20630498-9	2010	Cycloheximide pretreatment suppressed the expression of IL-17-induced inflammatory cytokines.	Cycloheximide	0-13	interleukin 17A	Mus musculus	56-61
20832564-8	2010	The Ad5F35-SOCS1-infected islets with higher SOCS1 expression showed decreased levels of active caspase 3 and intranuclear AIF after treatment with tumor necrosis factor-alpha and cycloheximide in vitro.	Cycloheximide	180-193	suppressor of cytokine signaling 1	Rattus norvegicus	11-16
20547156-7	2010	The induction of TGFbeta1 was independent of a change in transcription, but it depended on cycloheximide-inhibited translation.	Cycloheximide	91-104	transforming growth factor beta 1	Homo sapiens	17-25
20608983-3	2010	Here, we report that loss of the type 2A-related serine/threonine protein phosphatase Sit4p renders yeast cells sensitive to cycloheximide, azoles, daunorubicin and rhodamine 6G.	Cycloheximide	125-138	type 2A-related serine/threonine-protein phosphatase SIT4	Saccharomyces cerevisiae S288C	86-91
20832564-8	2010	The Ad5F35-SOCS1-infected islets with higher SOCS1 expression showed decreased levels of active caspase 3 and intranuclear AIF after treatment with tumor necrosis factor-alpha and cycloheximide in vitro.	Cycloheximide	180-193	suppressor of cytokine signaling 1	Rattus norvegicus	45-50
20570689-8	2010	The protein synthesis inhibitor, cycloheximide (which causes "superinduction" of CYP1A1 mRNA in TCDD-treated cells), by itself caused dramatic upregulation (&gt;300-fold) of FMO3 mRNA in Hepa-1 suggesting that cycloheximide prevents synthesis of a labile protein that suppresses FMO3 expression.	Cycloheximide	33-46	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	174-178
20630877-5	2010	Inhibition of protein synthesis in COS cells by cycloheximide reveals remarkably rapid turnover of expressed Sac3(WT) (t((1/2)) = 18.8 min), resulting from a proteasome-dependent clearance as evidenced by the extended Sac3(WT) half-life upon inhibiting proteasome activity.	Cycloheximide	48-61	FIG4 phosphoinositide 5-phosphatase	Homo sapiens	109-113
20570689-8	2010	The protein synthesis inhibitor, cycloheximide (which causes "superinduction" of CYP1A1 mRNA in TCDD-treated cells), by itself caused dramatic upregulation (&gt;300-fold) of FMO3 mRNA in Hepa-1 suggesting that cycloheximide prevents synthesis of a labile protein that suppresses FMO3 expression.	Cycloheximide	33-46	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	81-87
20570689-8	2010	The protein synthesis inhibitor, cycloheximide (which causes "superinduction" of CYP1A1 mRNA in TCDD-treated cells), by itself caused dramatic upregulation (&gt;300-fold) of FMO3 mRNA in Hepa-1 suggesting that cycloheximide prevents synthesis of a labile protein that suppresses FMO3 expression.	Cycloheximide	33-46	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	279-283
20570689-8	2010	The protein synthesis inhibitor, cycloheximide (which causes "superinduction" of CYP1A1 mRNA in TCDD-treated cells), by itself caused dramatic upregulation (&gt;300-fold) of FMO3 mRNA in Hepa-1 suggesting that cycloheximide prevents synthesis of a labile protein that suppresses FMO3 expression.	Cycloheximide	210-223	flavin containing dimethylaniline monoxygenase 3	Homo sapiens	174-178
20623542-10	2010	Consistent with the hypothesis that delta-catenin promotes the interaction of the destruction complex molecules, cycloheximide treatment of cells overexpressing delta-catenin showed enhanced beta-catenin turnover.	Cycloheximide	113-126	catenin beta 1	Rattus norvegicus	191-203
20444961-6	2010	Cycloheximide or Chk2 inhibitor pretreatment abrogated not only activation of Chk2 but also G(2)/M arrest and apoptosis mediated by DIM.	Cycloheximide	0-13	checkpoint kinase 2	Homo sapiens	78-82
20432452-3	2010	Here, we demonstrated that IL-1beta induces ICAM-1 gene expression via the de novo protein synthesis through transcription and translation, which is attenuated by pretreatment with actinomycin D and cycloheximide, respectively.	Cycloheximide	199-212	interleukin 1 beta	Homo sapiens	27-35
20432452-3	2010	Here, we demonstrated that IL-1beta induces ICAM-1 gene expression via the de novo protein synthesis through transcription and translation, which is attenuated by pretreatment with actinomycin D and cycloheximide, respectively.	Cycloheximide	199-212	intercellular adhesion molecule 1	Homo sapiens	44-50
20460432-5	2010	Pim-1 knockdown and inhibition effects on Pgp expression were studied by immunoblotting and flow cytometry and on Pgp stability by immunoblotting after cycloheximide treatment.	Cycloheximide	152-165	Pim-1 proto-oncogene, serine/threonine kinase	Homo sapiens	0-5
19878520-6	2010	Thrombin (2.5 U/mL) induced an increase in immunoreactive ET-1 expression, which was inhibited by cycloheximide (10 microg/mL), and an increase in preproET-1 mRNA expression, as assessed by reverse transcription polymerase chain reaction.	Cycloheximide	98-111	coagulation factor II	Rattus norvegicus	0-8
19878520-6	2010	Thrombin (2.5 U/mL) induced an increase in immunoreactive ET-1 expression, which was inhibited by cycloheximide (10 microg/mL), and an increase in preproET-1 mRNA expression, as assessed by reverse transcription polymerase chain reaction.	Cycloheximide	98-111	endothelin 1	Rattus norvegicus	58-62
20418385-6	2010	The decrease in MYPT1 protein caused by 48-h DETA NO incubation was prevented by ODQ, an inhibitor of guanylyl cyclase, and by inhibitors of proteasomes (MG-132 and lactacystin) but was not affected by the inhibitor of protein synthesis, cycloheximide.	Cycloheximide	238-251	protein phosphatase 1 regulatory subunit 12A	Homo sapiens	16-21
20444237-4	2010	Cycloheximide treatment led to decreased pIgA-R and MAL2 intracellular staining, first in the Golgi then the SAC, suggesting they were apically delivered and that MAL2 was mediating the process.	Cycloheximide	0-13	mal, T cell differentiation protein 2	Homo sapiens	52-56
20444237-4	2010	Cycloheximide treatment led to decreased pIgA-R and MAL2 intracellular staining, first in the Golgi then the SAC, suggesting they were apically delivered and that MAL2 was mediating the process.	Cycloheximide	0-13	mal, T cell differentiation protein 2	Homo sapiens	163-167
20599703-0	2010	NKX3.1 potentiates TNF-alpha/CHX-induced apoptosis of prostate cancer cells through increasing caspase-3 expression and its activity.	Cycloheximide	29-32	NK3 homeobox 1	Homo sapiens	0-6
20599703-0	2010	NKX3.1 potentiates TNF-alpha/CHX-induced apoptosis of prostate cancer cells through increasing caspase-3 expression and its activity.	Cycloheximide	29-32	caspase 3	Homo sapiens	95-104
20385226-8	2010	Activation of NF-kappaB by TNFalpha or cycloheximide increased, whereas its inhibition by 4-hydroxy-2-nonenal or transfection of pIkappaBalphaM suppressed, UCP4 promoter activity.	Cycloheximide	39-52	nuclear factor kappa B subunit 1	Homo sapiens	14-23
20385226-8	2010	Activation of NF-kappaB by TNFalpha or cycloheximide increased, whereas its inhibition by 4-hydroxy-2-nonenal or transfection of pIkappaBalphaM suppressed, UCP4 promoter activity.	Cycloheximide	39-52	solute carrier family 25 member 27	Homo sapiens	156-160
20463057-6	2010	Experiments in adrenocortical H295R and ovarian SKOV-3 cells using cycloheximide and siRNA-mediated gene silencing revealed that glucocorticoid-mediated inhibition of SR-BI gene transcription requires de novo protein synthesis and the glucocorticoid receptor (GR).	Cycloheximide	67-80	scavenger receptor class B member 1	Homo sapiens	167-172
21364655-4	2010	Immunoprecipitation confirmed that C-XIAP-C retained the ability to interact with Smac and impaired extrinsically and intrinsically activated apoptosis in response to tumour necrosis factor-related apoptosis-inducing ligand/cycloheximide and staurosporine.	Cycloheximide	224-237	X-linked inhibitor of apoptosis	Homo sapiens	37-41
20605533-8	2010	Western Blot analysis confirmed that CHX potently inhibited PTZ-induced protein synthesis (c-Fos) in the rat brain, examined 60min after CHX and PTZ administration.	Cycloheximide	37-40	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	91-96
20339915-4	2010	Calcium-mediated up-regulation of c-gelsolin was inhibited by cycloheximide (a general inhibitor of protein synthesis).	Cycloheximide	62-75	gelsolin	Homo sapiens	36-44
20530874-6	2010	The changes in transcript levels for half of these genes were a direct effect of hepcidin, as shown by cycloheximide insensitivity, and dependent on the presence of Stat3.	Cycloheximide	103-116	hepcidin antimicrobial peptide	Mus musculus	81-89
20155807-7	2010	In addition, a cycloheximide chase assay demonstrated that the degradation of Flag-HO-1 protein was slowed by MG-132.	Cycloheximide	15-28	heme oxygenase 1	Homo sapiens	83-87
19538480-5	2010	Furthermore, the use of cycloheximide revealed a two-step regulation of t-PA gene.	Cycloheximide	24-37	plasminogen activator, tissue type	Homo sapiens	72-76
20363880-6	2010	This effect was blocked by the protein synthesis inhibitor cycloheximide and protein secretion inhibitor brefeldin A, indicating that TNFalpha may enhance prochemerin synthesis and secretion from adipocytes.	Cycloheximide	59-72	tumor necrosis factor	Mus musculus	134-142
20399856-3	2010	Induction of the BMWCP10 transcript by ecdysone was partly inhibited in the presence of cycloheximide, which implies that the BMWCP10 promoter is directly and indirectly activated by ecdysone.	Cycloheximide	88-101	cuticular protein RR-1 motif 21	Bombyx mori	17-24
20399856-3	2010	Induction of the BMWCP10 transcript by ecdysone was partly inhibited in the presence of cycloheximide, which implies that the BMWCP10 promoter is directly and indirectly activated by ecdysone.	Cycloheximide	88-101	cuticular protein RR-1 motif 21	Bombyx mori	126-133
20352620-7	2010	Furthermore, the stimulatory effect of EPA on basal apelin release was also observed in the presence of Actinomycin D and Cycloheximide, suggesting that EPA might also regulate apelin secretion by via post-transcriptional mechanisms.	Cycloheximide	122-135	apelin	Mus musculus	52-58
21099311-11	2010	FABP3 and 5 gene transcription required de novo protein synthesis, since inhibition by cycloheximide significantly decreased both FABP mRNAs.	Cycloheximide	87-100	fatty acid binding protein 3	Rattus norvegicus	0-11
20515946-9	2010	Cycloheximide treatment of MKK6-transfected cells does not inhibit OCIAD1 expression, suggesting that MKK6 upregulation is not translationally controlled.	Cycloheximide	0-13	mitogen-activated protein kinase kinase 6	Homo sapiens	27-31
20199105-6	2010	Calnexin binding persists for several hours after translation is stopped with cycloheximide, suggesting that the beta(2) subunit undergoes repeated post-translational calnexin-assisted folding attempts.	Cycloheximide	78-91	calnexin	Canis lupus familiaris	0-8
20351270-7	2010	Time-course experiments and incubation with cycloheximide demonstrated that E6 alternative splicing is a direct and reversible effect of EGF signal transduction, not depending on de novo protein synthesis.	Cycloheximide	44-57	epidermal growth factor	Homo sapiens	137-140
20371726-4	2010	Vinblastine induced the rapid induction of Mcl-1 that was inhibited by PD98059 and cycloheximide.	Cycloheximide	83-96	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	43-48
20123965-4	2010	However, we also noted that cycloheximide partially inhibits R5020 induction of E2F1 expression, indicating that the ligand-dependent actions of PR on this gene may involve additional indirect regulatory pathways.	Cycloheximide	28-41	E2F transcription factor 1	Homo sapiens	80-84
19844261-4	2010	In vitro analysis using minigenes and cycloheximide showed that some selected frameshift mutant alleles are substrates of nonsense-mediated mRNA decay (NMD), confirming that the functional haploinsufficiency of the ELN gene is the main pathomechanism underlying SVAS.	Cycloheximide	38-51	elastin	Homo sapiens	215-218
20054003-10	2010	Both HERP siRNA knockdown and HERP overexpression coupled to cycloheximide chase assays revealed that HERP is necessary for degradation of intracellularly retained p80 by TFM-C.	Cycloheximide	61-74	coilin	Homo sapiens	164-167
20139709-6	2010	Incubation of KCNQ1-expressing oocytes with cycloheximide did not prevent I(Ks) expression following prKCNE1 injection.	Cycloheximide	44-57	potassium voltage-gated channel subfamily Q member 1	Homo sapiens	14-19
19906679-6	2010	This was confirmed using actinomycin D and cycloheximide, which abrogated the induction and nuclear localization of beta-catenin protein.	Cycloheximide	43-56	catenin beta 1	Homo sapiens	116-128
20091742-10	2010	In addition, through the use of cycloheximide and the proteasome inhibitor MG132, we showed that hyperosmolarity significantly increased the half-life and inhibited the protein level of TGF-beta RI by polyubiquitination and proteasomal degradation.	Cycloheximide	32-45	transforming growth factor beta 1	Homo sapiens	186-194
20087596-4	2010	We show that the rpt2a-3, rpn10-1 and rpn12a-1 mutants are hypersensitive to the antibiotic hygromycin B, and tolerant to the translation inhibitor cycloheximide (CHX) and herbicide L-phosphinothricin (PPT).	Cycloheximide	148-161	Phototropic-responsive NPH3 family protein	Arabidopsis thaliana	17-24
19954423-5	2010	UCP3 half-life was examined in the mouse C2C12 myoblast cell line by inhibiting protein synthesis with cycloheximide and monitoring UCP3 protein levels by immunoblot analysis.	Cycloheximide	103-116	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	0-4
20067810-0	2010	Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells.	Cycloheximide	110-123	prolactin	Homo sapiens	79-88
20067810-0	2010	Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells.	Cycloheximide	110-123	prolactin	Homo sapiens	92-96
20067810-5	2010	Addition of cycloheximide increased the absolute concentration of G-hPRL approximately 4-fold and the glycosylated versus non-glycosylated hPRL concentration ratio by approximately 7-fold.	Cycloheximide	12-25	prolactin	Homo sapiens	68-72
19709659-4	2010	To explore the role of apoptosis in the leaky junction pathway, TNFalpha and cycloheximide (TNFalpha/CHX) were used to induce an elevated rate of apoptosis in cultured bovine aortic endothelial cell (BAEC) monolayers and the convective fluxes of LDL and water were measured.	Cycloheximide	77-90	tumor necrosis factor	Bos taurus	92-100
20038583-4	2010	PPARgamma degradation rates are remarkably rapid as measured in the presence of cycloheximide (t(1/2) = 2 h), but silencing Map4k4 had no effect on PPARgamma degradation.	Cycloheximide	80-93	peroxisome proliferator activated receptor gamma	Homo sapiens	0-9
19733178-4	2009	Yeast harboring the npl3-95 mutant allele have an impaired ability to translate lacZ, enhanced sensitivity to cycloheximide and paromomycin, and increased ability to read through translation termination codons.	Cycloheximide	110-123	mRNA-binding protein NPL3	Saccharomyces cerevisiae S288C	20-24
20502009-5	2010	By using cycloheximide to block the de novo protein synthesis, the protein expression of SK-1 under untreated conditions was stable over 24h.	Cycloheximide	9-22	sphingosine kinase 1	Homo sapiens	89-93
20979027-5	2010	Using induction in the presence of the translation blocking drug cycloheximide and chromatin immunoprecipitation assays, we confirm that HoxD1 and Irx3 are both direct Wnt target genes.	Cycloheximide	65-78	homeobox D1 S homeolog	Xenopus laevis	137-142
20979027-5	2010	Using induction in the presence of the translation blocking drug cycloheximide and chromatin immunoprecipitation assays, we confirm that HoxD1 and Irx3 are both direct Wnt target genes.	Cycloheximide	65-78	iroquois homeobox 3 L homeolog	Xenopus laevis	147-151
19878653-9	2009	Furthermore, LXRBSV functions in the presence of cycloheximide.	Cycloheximide	49-62	nuclear receptor subfamily 1, group H, member 2	Mus musculus	13-19
20563322-0	2010	Evidence for differential effects of glucose and cycloheximide on mRNA levels of peroxisome proliferator-activated receptor- (PPAR-) machinery members: Superinduction of PPAR-gamma1 and -gamma2 mRNAs.	Cycloheximide	49-62	peroxisome proliferator activated receptor alpha	Homo sapiens	126-130
20563322-0	2010	Evidence for differential effects of glucose and cycloheximide on mRNA levels of peroxisome proliferator-activated receptor- (PPAR-) machinery members: Superinduction of PPAR-gamma1 and -gamma2 mRNAs.	Cycloheximide	49-62	peroxisome proliferator activated receptor alpha	Homo sapiens	170-174
20563322-5	2010	Furthermore, PPAR-gamma1 and -gamma2 mRNAs were differentially superinduced 1.2-2.5 fold in cells upon the administration of the translational inhibitor cycloheximide.	Cycloheximide	153-166	peroxisome proliferator activated receptor alpha	Homo sapiens	13-17
20563322-8	2010	Second, we demonstrated cycloheximide-induced, transcription-dependent upregulation of mature PPAR-gamma1 and -gamma2 mRNAs in HepG2 cells associated with preferential expression of the PPAR-gamma2 mRNA variant.	Cycloheximide	24-37	peroxisome proliferator activated receptor alpha	Homo sapiens	94-98
20563322-8	2010	Second, we demonstrated cycloheximide-induced, transcription-dependent upregulation of mature PPAR-gamma1 and -gamma2 mRNAs in HepG2 cells associated with preferential expression of the PPAR-gamma2 mRNA variant.	Cycloheximide	24-37	peroxisome proliferator activated receptor alpha	Homo sapiens	186-190
19843871-8	2010	Pretreatment of MIN6 cells with Ca(2+) chelator (EGTA, BAPTA-AM) PKC inhibitor Go-6976 or protein synthesis inhibitor cycloheximide significantly inhibited FA-induced amylin mRNA expression.	Cycloheximide	118-131	islet amyloid polypeptide	Mus musculus	167-173
20208394-5	2010	Pretreatment of cells with cycloheximide, an inhibitor of protein synthesis, completely suppressed increase in CYP2B1/2 mRNA in response to ciprofibrate, suggesting that protein synthesis is required in this process.	Cycloheximide	27-40	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	111-117
19165786-8	2010	Levels of both HYAL1 and HYAL2 mRNA were up-regulated significantly (p &lt; 0.01) by the cyclic tensile load with or without cycloheximide.	Cycloheximide	125-138	hyaluronidase-1	Oryctolagus cuniculus	15-20
19165786-8	2010	Levels of both HYAL1 and HYAL2 mRNA were up-regulated significantly (p &lt; 0.01) by the cyclic tensile load with or without cycloheximide.	Cycloheximide	125-138	LOW QUALITY PROTEIN: hyaluronidase-2	Oryctolagus cuniculus	25-30
20369072-4	2010	This response was strongly aggravated by the addition of cycloheximide and could partially be inhibited by the NF-kappaB inhibitor CAPE, but most effectively by the pan-caspase-inhibitor zVAD-fmk and not by the JNK inhibitor SP600125.	Cycloheximide	57-70	structural maintenance of chromosomes 2	Homo sapiens	131-135
20369072-4	2010	This response was strongly aggravated by the addition of cycloheximide and could partially be inhibited by the NF-kappaB inhibitor CAPE, but most effectively by the pan-caspase-inhibitor zVAD-fmk and not by the JNK inhibitor SP600125.	Cycloheximide	57-70	mitogen-activated protein kinase 8	Homo sapiens	211-214
19754518-5	2009	The suggestion that this uORF exposes transcripts containing it to NMD is supported by (i) the increase in transcript levels upon eliminating the uORF from constructs containing it, (ii) experiments with a modified uORF-peptide, which excluded peptide-specific degradation mechanisms, (iii) the increase in levels of the native AtMHX transcript upon treatment with cycloheximide, which inhibits translation and blocks NMD, and (iv) the sensitivity of transcripts containing the uORF of AtMHX to the presence of introns.	Cycloheximide	365-378	magnesium/proton exchanger	Arabidopsis thaliana	328-333
19800419-4	2009	TSL-mediated HO-1 protein induction was not inhibited by treatment with actinomycin D, a transcriptional inhibitor, but by cycloheximide, a translational inhibitor.	Cycloheximide	123-136	heme oxygenase 1	Mus musculus	13-17
19779967-8	2009	Cycloheximide treatment resulted in increased accumulation of intravenous-injected (99m)Tc-HYNIC-cys-AnxA5 in liver and spleen over controls, which correlated well with TUNEL staining for cell death in corresponding tissue sections.	Cycloheximide	0-13	annexin A5	Rattus norvegicus	101-106
20037637-7	2009	Further experiments with cycloheximide treatment suggested that the up-regulation of calponin 3 by cyclic strain was at post-transcriptional level.	Cycloheximide	25-38	calponin 3	Homo sapiens	85-95
19754518-5	2009	The suggestion that this uORF exposes transcripts containing it to NMD is supported by (i) the increase in transcript levels upon eliminating the uORF from constructs containing it, (ii) experiments with a modified uORF-peptide, which excluded peptide-specific degradation mechanisms, (iii) the increase in levels of the native AtMHX transcript upon treatment with cycloheximide, which inhibits translation and blocks NMD, and (iv) the sensitivity of transcripts containing the uORF of AtMHX to the presence of introns.	Cycloheximide	365-378	magnesium/proton exchanger	Arabidopsis thaliana	486-491
19748482-6	2009	CHX-induced apoptosis in THP-1 was inhibited by DcR3-Fc, of which inhibition against CHX-induced apoptosis and aggregate formation were ameliorated by anti-VLA4 antibody.	Cycloheximide	0-3	GLI family zinc finger 2	Homo sapiens	25-30
20078948-2	2009	METHOD: The degradation pathway of SNF5 was identified with protein synthesis inhibitor cycloheximide (CHX) and a potent proteasome inhibitor MG132, and then the PIH1D1 eukaryotic expression plasmid was transfected to explore its effect on the stability of SNF5.	Cycloheximide	88-101	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	Homo sapiens	35-39
20078948-2	2009	METHOD: The degradation pathway of SNF5 was identified with protein synthesis inhibitor cycloheximide (CHX) and a potent proteasome inhibitor MG132, and then the PIH1D1 eukaryotic expression plasmid was transfected to explore its effect on the stability of SNF5.	Cycloheximide	103-106	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	Homo sapiens	35-39
19748482-6	2009	CHX-induced apoptosis in THP-1 was inhibited by DcR3-Fc, of which inhibition against CHX-induced apoptosis and aggregate formation were ameliorated by anti-VLA4 antibody.	Cycloheximide	0-3	TNF receptor superfamily member 6b	Homo sapiens	48-52
19748482-6	2009	CHX-induced apoptosis in THP-1 was inhibited by DcR3-Fc, of which inhibition against CHX-induced apoptosis and aggregate formation were ameliorated by anti-VLA4 antibody.	Cycloheximide	85-88	GLI family zinc finger 2	Homo sapiens	25-30
19748482-6	2009	CHX-induced apoptosis in THP-1 was inhibited by DcR3-Fc, of which inhibition against CHX-induced apoptosis and aggregate formation were ameliorated by anti-VLA4 antibody.	Cycloheximide	85-88	TNF receptor superfamily member 6b	Homo sapiens	48-52
19751723-7	2009	This, in conjunction with treatment by the protein synthesis inhibitor, cycloheximide, could sensitise a subset of B-NHLr to CD95 apoptosis.	Cycloheximide	72-85	Fas cell surface death receptor	Homo sapiens	125-129
19684181-4	2009	The protective effect of ANG II infusion to restore vascular relaxation was eliminated by coinfusion of either the EGF receptor kinase inhibitor AG-1478 (20 microg/h), the ERK1/2 inhibitor PD-98059 (10 microg/h), or the protein synthesis inhibitor cycloheximide (5 microg/h).	Cycloheximide	248-261	angiotensinogen	Rattus norvegicus	25-31
20032379-7	2009	CHX completely inhibited the caspase activation and the associated apoptosis.	Cycloheximide	0-3	caspase 2	Homo sapiens	29-36
19829698-4	2009	Expression of mRNA from dr6 was inhibited by cycloheximide and partly by phosphonoacetic acid, a known characteristic of herpesvirus early/late genes.	Cycloheximide	45-58	TNF receptor superfamily member 21	Homo sapiens	24-27
19718660-5	2009	Spreading of cancer cells on fibronectin does not require de novo transcription but is sensitive to cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	100-113	fibronectin 1	Homo sapiens	29-40
19741096-6	2009	Cycloheximide-chase assay in the Neuro2a cells indicated that MITOL overexpression promoted mSOD1 degradation and suppressed both the mitochondrial accumulation of mSOD1 and mSOD1-induced reactive oxygen species (ROS) generation.	Cycloheximide	0-13	membrane associated ring-CH-type finger 5	Mus musculus	62-67
19741096-6	2009	Cycloheximide-chase assay in the Neuro2a cells indicated that MITOL overexpression promoted mSOD1 degradation and suppressed both the mitochondrial accumulation of mSOD1 and mSOD1-induced reactive oxygen species (ROS) generation.	Cycloheximide	0-13	superoxide dismutase 1, soluble	Mus musculus	164-169
19741096-6	2009	Cycloheximide-chase assay in the Neuro2a cells indicated that MITOL overexpression promoted mSOD1 degradation and suppressed both the mitochondrial accumulation of mSOD1 and mSOD1-induced reactive oxygen species (ROS) generation.	Cycloheximide	0-13	superoxide dismutase 1, soluble	Mus musculus	164-169
19657054-2	2009	We previously showed that activation of p38 MAPK by cycloheximide in human chondrocytes leads to stabilization of SOX9 mRNA (Tew SR and Hardingham TE.	Cycloheximide	52-65	mitogen-activated protein kinase 14	Homo sapiens	40-43
19657054-2	2009	We previously showed that activation of p38 MAPK by cycloheximide in human chondrocytes leads to stabilization of SOX9 mRNA (Tew SR and Hardingham TE.	Cycloheximide	52-65	SRY-box transcription factor 9	Homo sapiens	114-118
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	caspase 3	Homo sapiens	69-78
19388821-7	2009	Inhibition of Nox4 translation by cycloheximide blocked serum-induced mRNA degradation and Nox4 protein synthesis, and actinomycin-D also delayed Nox4 mRNA decay.	Cycloheximide	34-47	NADPH oxidase 4	Homo sapiens	14-18
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	lipopolysaccharide binding protein	Homo sapiens	192-211
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	caspase 3	Homo sapiens	69-78
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	lipopolysaccharide binding protein	Homo sapiens	192-211
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	lipopolysaccharide binding protein	Homo sapiens	213-216
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	CD14 molecule	Homo sapiens	227-231
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	CD14 molecule	Homo sapiens	391-395
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	lipopolysaccharide binding protein	Homo sapiens	213-216
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	CD14 molecule	Homo sapiens	227-231
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	CD14 molecule	Homo sapiens	391-395
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	34-37	lipopolysaccharide binding protein	Homo sapiens	396-399
19559790-4	2009	In the presence of cycloheximide (CHX), an increase in intracellular caspase-3/7 activity in response to LPS was not detected in HUVEC up to 24 h following stimulation even in the presence of LPS-binding protein (LBP), soluble CD14 and soluble MD-2, whereas the decrease in cell viability and increase in release of the cellular enzyme lactate dehydrogenase (LDH) were observed in a soluble CD14/LBP-dependent manner.	Cycloheximide	19-32	lipopolysaccharide binding protein	Homo sapiens	396-399
19545598-0	2009	Cycloheximide-induced inhibition of protein synthesis in hippocampal pyramidal neurons is time-dependent: differences between CA1 and CA3 areas.	Cycloheximide	0-13	carbonic anhydrase 1	Rattus norvegicus	126-129
19563893-5	2009	Cycloheximide inhibits stimulation at the mRNA level, suggesting that progestin induction of MnSOD mRNA depends on synthesis of protein.	Cycloheximide	0-13	superoxide dismutase 2	Homo sapiens	93-98
19699525-11	2009	Interestingly, IL-8 mRNA was induced by cycloheximide treatment and RANTES showed reduced mRNA but increased protein expression by antibody stimulation.	Cycloheximide	40-53	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
19545598-0	2009	Cycloheximide-induced inhibition of protein synthesis in hippocampal pyramidal neurons is time-dependent: differences between CA1 and CA3 areas.	Cycloheximide	0-13	carbonic anhydrase 3	Rattus norvegicus	134-137
19753315-8	2009	Cycloheximide treatment was used to assess the stability of CLRN1 protein.	Cycloheximide	0-13	clarin 1	Homo sapiens	60-65
19753315-12	2009	Inhibition of protein expression with cycloheximide indicated that WT CLRN1-HA remained stable.	Cycloheximide	38-51	clarin 1	Homo sapiens	70-75
19653226-5	2009	Actinomycin D (an RNA synthesis inhibitor) and cycloheximide (a protein synthesis inhibitor) inhibited sulforaphane-responsive HO-1 mRNA expression, indicating that sulforaphane is a requirement for transcription and de novo protein synthesis.	Cycloheximide	47-60	heme oxygenase 1	Homo sapiens	127-131
19706404-8	2009	Moreover, when de novo protein synthesis was blocked by cycloheximide in OLA1-knockdown cells, they continued to demonstrate increased resistance to both tBH and diamide.	Cycloheximide	56-69	Obg like ATPase 1	Homo sapiens	73-77
19661440-3	2009	Knockdown of Fas-associated death domain protein (FADD) by either siRNA or overexpression of a truncated version of FADD that lacks the N-terminal death effector domain (FADD(DN)) increases the sensitivity of HUVECs to LPS plus cycloheximide-mediated death.	Cycloheximide	228-241	Fas associated via death domain	Homo sapiens	13-48
19661440-3	2009	Knockdown of Fas-associated death domain protein (FADD) by either siRNA or overexpression of a truncated version of FADD that lacks the N-terminal death effector domain (FADD(DN)) increases the sensitivity of HUVECs to LPS plus cycloheximide-mediated death.	Cycloheximide	228-241	Fas associated via death domain	Homo sapiens	50-54
19661440-3	2009	Knockdown of Fas-associated death domain protein (FADD) by either siRNA or overexpression of a truncated version of FADD that lacks the N-terminal death effector domain (FADD(DN)) increases the sensitivity of HUVECs to LPS plus cycloheximide-mediated death.	Cycloheximide	228-241	Fas associated via death domain	Homo sapiens	116-120
19661440-3	2009	Knockdown of Fas-associated death domain protein (FADD) by either siRNA or overexpression of a truncated version of FADD that lacks the N-terminal death effector domain (FADD(DN)) increases the sensitivity of HUVECs to LPS plus cycloheximide-mediated death.	Cycloheximide	228-241	Fas associated via death domain	Homo sapiens	116-120
19740337-4	2009	Induction of iNOS was inhibited by both cycloheximide and actinomycin D, indicating that the induction of iNOS expression by BMP-6 requires new protein synthesis.	Cycloheximide	40-53	nitric oxide synthase 2, inducible	Mus musculus	13-17
19740337-4	2009	Induction of iNOS was inhibited by both cycloheximide and actinomycin D, indicating that the induction of iNOS expression by BMP-6 requires new protein synthesis.	Cycloheximide	40-53	nitric oxide synthase 2, inducible	Mus musculus	106-110
19740337-4	2009	Induction of iNOS was inhibited by both cycloheximide and actinomycin D, indicating that the induction of iNOS expression by BMP-6 requires new protein synthesis.	Cycloheximide	40-53	bone morphogenetic protein 6	Mus musculus	125-130
19505847-7	2009	Cycloheximide inhibited both the induction and basal expression of HERV-K18 env, indicating that de novo synthesis of proteins was necessary.	Cycloheximide	0-13	endogenous retrovirus group K member 18	Homo sapiens	76-79
19376214-4	2009	NaF-induced accumulation of COX-2 transcript was abolished by actinomycin D, but not cycloheximide.	Cycloheximide	85-98	C-X-C motif chemokine ligand 8	Homo sapiens	0-3
19553664-8	2009	When, however, a JNK signal was induced by coadministration of cycloheximide or hydrogen peroxide (H2O2), activated EGFR associated with CD95 and triggered EGFR-mediated CD95-tyrosine phosphorylation and subsequent formation of the death-inducing signaling complex.	Cycloheximide	63-76	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
19553664-8	2009	When, however, a JNK signal was induced by coadministration of cycloheximide or hydrogen peroxide (H2O2), activated EGFR associated with CD95 and triggered EGFR-mediated CD95-tyrosine phosphorylation and subsequent formation of the death-inducing signaling complex.	Cycloheximide	63-76	epidermal growth factor receptor	Rattus norvegicus	116-120
19553664-8	2009	When, however, a JNK signal was induced by coadministration of cycloheximide or hydrogen peroxide (H2O2), activated EGFR associated with CD95 and triggered EGFR-mediated CD95-tyrosine phosphorylation and subsequent formation of the death-inducing signaling complex.	Cycloheximide	63-76	epidermal growth factor receptor	Rattus norvegicus	156-160
19545424-10	2009	Instead, the loss of COX-2 protein, after treatment with cycloheximide to block protein synthesis, was reduced in cells lacking PIN1 in comparison with Control cells, indicating that degradation of the enzyme was reduced.	Cycloheximide	57-70	cytochrome c oxidase II, mitochondrial	Mus musculus	21-26
19578789-9	2009	In the culture of macrophages (Raw264.7), HGF enhanced the LPS-mediated HO-1 induction, and this effect was abolished by cycloheximide, but not by actinomycin-D, thus suggesting that a post-transcriptional pathway is involved in HGF-mediated up-regulation of HO-1.	Cycloheximide	121-134	hepatocyte growth factor	Mus musculus	42-45
19647171-3	2009	We compared the ability of two novel radiolabeled isatins, [18F]WC-IV-3 and [11C]WC-98, to detect caspase-3 activation in a rat model of cycloheximide-induced liver injury.	Cycloheximide	137-150	caspase 3	Rattus norvegicus	98-107
19411256-9	2009	By cycloheximide chase assays, we found that KLF5 decreases MKP-1 protein degradation via activating the ERK signaling.	Cycloheximide	3-16	Kruppel like factor 5	Homo sapiens	45-49
19411256-9	2009	By cycloheximide chase assays, we found that KLF5 decreases MKP-1 protein degradation via activating the ERK signaling.	Cycloheximide	3-16	dual specificity phosphatase 1	Homo sapiens	60-65
19662097-4	2009	METHODOLOGY/PRINCIPAL FINDINGS: Upon onset of apoptosis induced by various kinds of inducers such as NSC606985, etoposide and others, C/EBPalpha expression presented a profound down-regulation in leukemic cell lines and primary cells via induction of protein degradation and inhibition of transcription, as assessed respectively by cycloheximide inhibition test, real-time quantitative RT-PCR and luciferase reporter assay.	Cycloheximide	332-345	CCAAT enhancer binding protein alpha	Homo sapiens	134-144
19414624-4	2009	1,25(OH)(2)D(3) treatment significantly enhanced MRP4 protein expression by increasing protein stability without affecting mRNA expression, as confirmed in cycloheximide experiments.	Cycloheximide	156-169	ATP binding cassette subfamily C member 4	Homo sapiens	49-53
19545424-10	2009	Instead, the loss of COX-2 protein, after treatment with cycloheximide to block protein synthesis, was reduced in cells lacking PIN1 in comparison with Control cells, indicating that degradation of the enzyme was reduced.	Cycloheximide	57-70	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	128-132
19332039-6	2009	The effects of preconditioning on sumo-2/3-ylation following harmful ischemia were blocked by the protein synthesis inhibitor cycloheximide (1.0 muM), a known inhibitor of delayed ischemic tolerance.	Cycloheximide	126-139	small ubiquitin like modifier 2	Homo sapiens	34-40
19151402-7	2009	In contrast, cycloheximide prevented lovastatin from increasing both RhoA and RhoB.	Cycloheximide	13-26	ras homolog family member A	Homo sapiens	69-73
19151402-7	2009	In contrast, cycloheximide prevented lovastatin from increasing both RhoA and RhoB.	Cycloheximide	13-26	ras homolog family member B	Homo sapiens	78-82
19344732-8	2009	After treatment with rat TNF-alpha and cycloheximide in vitro, Ad5F35-SOCS1 infected islets exhibited a lower apoptotic ratio than controls (Ad5F35-EGFP and mock infected islets).	Cycloheximide	39-52	suppressor of cytokine signaling 1	Rattus norvegicus	70-75
19395591-0	2009	Neutralization of IL-10 exacerbates cycloheximide-induced hepatocellular apoptosis and necrosis.	Cycloheximide	36-49	interleukin 10	Rattus norvegicus	18-23
19395591-2	2009	We previously reported that Kupffer cell inactivation causes a reduction of IL-10 production, resulting in the exacerbation of CHX-induced liver injury.	Cycloheximide	127-130	interleukin 10	Rattus norvegicus	76-81
19137541-9	2009	Inhibition of protein synthesis by cycloheximide showed that CLU half-life is less than 2 h. CLU protein products were found poly-ubiquitinated by co-immuniprecipitation.	Cycloheximide	35-48	clusterin	Homo sapiens	61-64
19414763-7	2009	Inhibitors of transcription (actinomycin D), translation (cycloheximide), or membrane translocation (brefeldin A) effectively block the induction of mTGF-beta1, which suggests that induction of mTGF-beta1 by IFN-gamma and/or TNF-alpha occurs through de novo synthesis.	Cycloheximide	58-71	transforming growth factor, beta 1	Mus musculus	149-159
19414763-7	2009	Inhibitors of transcription (actinomycin D), translation (cycloheximide), or membrane translocation (brefeldin A) effectively block the induction of mTGF-beta1, which suggests that induction of mTGF-beta1 by IFN-gamma and/or TNF-alpha occurs through de novo synthesis.	Cycloheximide	58-71	transforming growth factor, beta 1	Mus musculus	194-204
19137541-9	2009	Inhibition of protein synthesis by cycloheximide showed that CLU half-life is less than 2 h. CLU protein products were found poly-ubiquitinated by co-immuniprecipitation.	Cycloheximide	35-48	clusterin	Homo sapiens	93-96
19101987-10	2009	Actinomycin D (a transcription inhibitor) did not modify this effect, whereas cycloheximide (an inhibitor of protein translation) abolished the MMP-2 release.	Cycloheximide	78-91	matrix metallopeptidase 2	Homo sapiens	144-149
19201814-6	2009	Although the increase in EGFR binding was blocked by the protein synthesis inhibitor cycloheximide for LPA, fluticasone, and dexamethasone, only LPA induced a significant increase in EGFR protein expression detected by immunoblotting.	Cycloheximide	85-98	epidermal growth factor receptor	Homo sapiens	25-29
19428567-6	2009	Addition of cycloheximide indicated that the IL-2 effects were independent of de novo protein synthesis and that the HIC gene is a direct target of IL-2.	Cycloheximide	12-25	interleukin 2	Homo sapiens	45-49
19302807-11	2009	In addition, the extracellular LPL mass in cycloheximide (a protein synthesis inhibitor) and fucoidan-treated cells did not change markedly, but LPL shifted significantly from active to inactive form.	Cycloheximide	43-56	lipoprotein lipase	Homo sapiens	31-34
19190257-7	2009	Cycloheximide reduced both aldosterone- and dexamethasone-induced TH mRNA.	Cycloheximide	0-13	tyrosine hydroxylase	Rattus norvegicus	66-68
19439213-4	2009	The cytoprotective effect of IFN-gamma pretreatment was abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	101-114	interferon gamma	Homo sapiens	29-38
19201814-6	2009	Although the increase in EGFR binding was blocked by the protein synthesis inhibitor cycloheximide for LPA, fluticasone, and dexamethasone, only LPA induced a significant increase in EGFR protein expression detected by immunoblotting.	Cycloheximide	85-98	epidermal growth factor receptor	Homo sapiens	183-187
19109222-9	2009	Cycloheximide, a general translational inhibitor, abolished the stimulatory effects of PGF2alpha on HSD11B1 protein expression in endometrial stromal cells, indicating that PGF2alpha increases HSD11B1 protein expression by stimulating a posttranscriptional process rather than a transcriptional mechanism.	Cycloheximide	0-13	hydroxysteroid 11-beta dehydrogenase 1	Bos taurus	100-107
19109222-9	2009	Cycloheximide, a general translational inhibitor, abolished the stimulatory effects of PGF2alpha on HSD11B1 protein expression in endometrial stromal cells, indicating that PGF2alpha increases HSD11B1 protein expression by stimulating a posttranscriptional process rather than a transcriptional mechanism.	Cycloheximide	0-13	hydroxysteroid 11-beta dehydrogenase 1	Bos taurus	193-200
19151744-5	2009	The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay.	Cycloheximide	85-98	BAG cochaperone 1	Homo sapiens	23-28
19097065-5	2009	Moreover, caspase activation induced by DENSPM plus CHX was not prevented by a N(1)-acetylpolyamine oxidase (PAO)/SMO inhibitor, and depletion of all polyamines obtained by specific inhibitors of polyamine biosynthesis did not reproduce DENSPM effects in the presence of CHX.	Cycloheximide	52-55	caspase 9	Homo sapiens	10-17
19097065-5	2009	Moreover, caspase activation induced by DENSPM plus CHX was not prevented by a N(1)-acetylpolyamine oxidase (PAO)/SMO inhibitor, and depletion of all polyamines obtained by specific inhibitors of polyamine biosynthesis did not reproduce DENSPM effects in the presence of CHX.	Cycloheximide	271-274	caspase 9	Homo sapiens	10-17
19006119-4	2009	Indeed, IL-6 increased GLUT-2 mRNA and protein expression as well as 2-DG uptake, which were blocked by actinomycin D (AD, transcription inhibitor) and cycloheximide (CHX, translation inhibitor).	Cycloheximide	152-165	interleukin 6	Gallus gallus	8-12
19006119-4	2009	Indeed, IL-6 increased GLUT-2 mRNA and protein expression as well as 2-DG uptake, which were blocked by actinomycin D (AD, transcription inhibitor) and cycloheximide (CHX, translation inhibitor).	Cycloheximide	152-165	solute carrier family 2 member 2	Gallus gallus	23-29
19006119-4	2009	Indeed, IL-6 increased GLUT-2 mRNA and protein expression as well as 2-DG uptake, which were blocked by actinomycin D (AD, transcription inhibitor) and cycloheximide (CHX, translation inhibitor).	Cycloheximide	167-170	interleukin 6	Gallus gallus	8-12
19006119-4	2009	Indeed, IL-6 increased GLUT-2 mRNA and protein expression as well as 2-DG uptake, which were blocked by actinomycin D (AD, transcription inhibitor) and cycloheximide (CHX, translation inhibitor).	Cycloheximide	167-170	solute carrier family 2 member 2	Gallus gallus	23-29
19118520-7	2009	The TZD-induced REG Ialpha mRNA reduction was abolished by cycloheximide, indicating the necessity of novel protein(s) synthesis.	Cycloheximide	59-72	regenerating family member 1 alpha	Homo sapiens	16-19
19302817-4	2009	KEY FINDINGS: Using the AhR antagonist alpha-napthtoflavone, the translational inhibitor cycloheximide and anti-tumor necrosis factor alpha (TNFalpha) neutralizing antibodies, we demonstrated that Lp(a)-mediated mRNA induction of CCL1 occurs in an AhR-independent manner and requires de novo protein synthesis of TNFalpha.	Cycloheximide	89-102	lipoprotein(a)	Homo sapiens	197-202
19248116-10	2009	Pretreatment of chondrocytes with a JAK-3 inhibitor or with cycloheximide blocked the IL-7-mediated secretion of S100A4, but pretreatment with brefeldin A did not.	Cycloheximide	60-73	interleukin 7	Homo sapiens	86-90
19248116-10	2009	Pretreatment of chondrocytes with a JAK-3 inhibitor or with cycloheximide blocked the IL-7-mediated secretion of S100A4, but pretreatment with brefeldin A did not.	Cycloheximide	60-73	S100 calcium binding protein A4	Homo sapiens	113-119
19873875-6	2009	Using inhibitors of mRNA (actinomycin D) and protein (cycloheximide) synthesis, the strain deficient in Yap1p, a master regulator coordinating yeast adaptive response to oxidative stress, we have found that these enzymes are up-regulated via synthesis of new molecules at transcription and translation levels.	Cycloheximide	54-67	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	104-109
19151744-5	2009	The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay.	Cycloheximide	85-98	BCL2 apoptosis regulator	Homo sapiens	54-59
19151744-11	2009	Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.	Cycloheximide	17-30	BCL2 apoptosis regulator	Homo sapiens	77-82
19151744-11	2009	Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.	Cycloheximide	17-30	BAG cochaperone 1	Homo sapiens	111-116
19151744-11	2009	Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.	Cycloheximide	17-30	nuclear factor kappa B subunit 1	Homo sapiens	117-120
18643838-8	2009	Finally, we found that rosiglitazone increased ATGL mRNA levels in 3T3-L1 adipocytes in the presence of cycloheximide, an inhibitor of protein synthesis, suggesting that rosiglitazone regulation of ATGL occurs at the transcriptional level.	Cycloheximide	104-117	patatin-like phospholipase domain containing 2	Mus musculus	198-202
18925411-12	2009	Blocking protein synthesis with cycloheximide showed that the rapid release of HBD-3 is not dependent on a translational de novo synthesis and is not affected by glucocorticoids.	Cycloheximide	32-45	defensin beta 103B	Homo sapiens	79-84
19016568-6	2009	This increase seen in BRCA2 total and phospho-S3291 protein levels was found to be unaffected with cycloheximide pre-treatment, but decreased following tamoxifen, ICI 182,780 or roscovitine treatment.	Cycloheximide	99-112	BRCA2 DNA repair associated	Homo sapiens	22-27
19158291-4	2009	In the presence of cycloheximide or anisomycin, ephrin-A2, slit-3, and semaphorin3A still induced growth cone collapse and loss of actin filaments, nerve growth factor (NGF) and neurotrophin-3 still induced growth cone protrusion and increased filamentous actin, and sensory growth cones turned toward an NGF source.	Cycloheximide	19-32	ephrin A2	Gallus gallus	48-57
19158291-4	2009	In the presence of cycloheximide or anisomycin, ephrin-A2, slit-3, and semaphorin3A still induced growth cone collapse and loss of actin filaments, nerve growth factor (NGF) and neurotrophin-3 still induced growth cone protrusion and increased filamentous actin, and sensory growth cones turned toward an NGF source.	Cycloheximide	19-32	slit guidance ligand 3	Gallus gallus	59-65
19158291-4	2009	In the presence of cycloheximide or anisomycin, ephrin-A2, slit-3, and semaphorin3A still induced growth cone collapse and loss of actin filaments, nerve growth factor (NGF) and neurotrophin-3 still induced growth cone protrusion and increased filamentous actin, and sensory growth cones turned toward an NGF source.	Cycloheximide	19-32	nerve growth factor	Gallus gallus	148-167
19158291-4	2009	In the presence of cycloheximide or anisomycin, ephrin-A2, slit-3, and semaphorin3A still induced growth cone collapse and loss of actin filaments, nerve growth factor (NGF) and neurotrophin-3 still induced growth cone protrusion and increased filamentous actin, and sensory growth cones turned toward an NGF source.	Cycloheximide	19-32	neurotrophin 3	Gallus gallus	178-192
19158291-4	2009	In the presence of cycloheximide or anisomycin, ephrin-A2, slit-3, and semaphorin3A still induced growth cone collapse and loss of actin filaments, nerve growth factor (NGF) and neurotrophin-3 still induced growth cone protrusion and increased filamentous actin, and sensory growth cones turned toward an NGF source.	Cycloheximide	19-32	nerve growth factor	Gallus gallus	305-308
19115040-3	2009	TREATMENTS: Recombinant human C5a (50 ng/ml) was used in the presence or absence of 10 microg/ml cycloheximide (CHX).	Cycloheximide	97-110	complement C5a receptor 1	Homo sapiens	30-33
18957409-6	2008	A slow growth phenotype was seen for the SET7 deletion strain and the double knock-out when grown in low concentrations of the eukaryotic protein synthesis inhibitor, cycloheximide.	Cycloheximide	167-180	ribosomal lysine N-methyltransferase	Saccharomyces cerevisiae S288C	41-45
19116451-8	2008	Cycloheximide studies demonstrate that troglitazone attenuates Hsp70 translation but not Hsp70 protein stability.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 4	Homo sapiens	63-68
19333544-12	2009	In the presence of actinomycin D or cycloheximide, the amount of PIG11 protein expression did not increase.	Cycloheximide	36-49	tumor protein p53 inducible protein 11	Homo sapiens	65-70
19036901-4	2009	Our experiments revealed FKBP5 as a direct target of the PR, because it exhibited a rapid activation by progestin that was cycloheximide independent and correlated with recruitment of RNA polymerase II to the promoter.	Cycloheximide	123-136	FKBP prolyl isomerase 5	Homo sapiens	25-30
19036901-4	2009	Our experiments revealed FKBP5 as a direct target of the PR, because it exhibited a rapid activation by progestin that was cycloheximide independent and correlated with recruitment of RNA polymerase II to the promoter.	Cycloheximide	123-136	progesterone receptor	Homo sapiens	57-59
19074853-7	2008	Cycloheximide treatment augmented this cyclin D1 protein instability.	Cycloheximide	0-13	cyclin D1	Homo sapiens	39-48
18854426-4	2008	Actinomycin D almost completely abolished the LPS effect, whereas cycloheximide decreased the expression at 12 h, indicating that the LPS-induced ADRP expression was stimulated at the transcriptional level and was also mediated by new protein synthesis.	Cycloheximide	66-79	perilipin 2	Mus musculus	146-150
18842589-2	2008	We describe a novel mutation (S558Y) in transmembrane helix 2 of Pdr5 identified in a screen for suppressors that eliminated Pdr5-mediated cycloheximide hyper-resistance.	Cycloheximide	139-152	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	65-69
18842589-2	2008	We describe a novel mutation (S558Y) in transmembrane helix 2 of Pdr5 identified in a screen for suppressors that eliminated Pdr5-mediated cycloheximide hyper-resistance.	Cycloheximide	139-152	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	125-129
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Cycloheximide	13-26	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	46-56
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Cycloheximide	13-26	mechanistic target of rapamycin kinase	Rattus norvegicus	102-106
18651560-13	2008	Rapamycin or cycloheximide, blocked increased HIF-1alpha levels during re-oxygenation indicating that mTOR-dependent protein synthesis is required for the persistent elevation of HIF-1alpha levels during re-oxygenation.	Cycloheximide	13-26	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	179-189
18721791-5	2008	Cycloheximide decreased the basal p21 level, which was inhibited by CC treatment, supporting the stabilization of p21 by CC.	Cycloheximide	0-13	cyclin dependent kinase inhibitor 1A	Homo sapiens	34-37
19009649-6	2008	Stability of Cyclin D1 was studied by cycloheximide blockade experiments.	Cycloheximide	38-51	cyclin D1	Homo sapiens	13-22
18721791-5	2008	Cycloheximide decreased the basal p21 level, which was inhibited by CC treatment, supporting the stabilization of p21 by CC.	Cycloheximide	0-13	cyclin dependent kinase inhibitor 1A	Homo sapiens	114-117
18622892-8	2008	Pitavastatin induced the expression of TGF-beta, and cycloheximide, a protein synthesis inhibitor, antagonized the increased levels of pitavastatin on Smad3.	Cycloheximide	53-66	SMAD family member 3	Mus musculus	151-156
18974150-4	2008	The proposed method combines a recent map of the insulator protein CCCTC-binding factor (CTCF) with previous ER location studies and expression profiling in the presence of the translation inhibitor cycloheximide, providing evidence that CTCF partitions the human genome into distinct ER-regulatory blocks.	Cycloheximide	199-212	CCCTC-binding factor	Homo sapiens	238-242
19026946-8	2008	The uptake of [(3)H]FLT and [(14)C]FDG decreased rapidly after the initiation of treatment with actinomycin D or cycloheximide.	Cycloheximide	113-126	fms related receptor tyrosine kinase 1	Homo sapiens	20-23
18546202-1	2008	Induction of cell death in HeLa cells with TNF and cycloheximide (CHX) required an adequate ATP supply and was accompanied by decrease in intracellular pH, translocation of Bax, perinuclear clustering of the mitochondria, and cytochrome c release.	Cycloheximide	51-64	BCL2 associated X, apoptosis regulator	Homo sapiens	173-176
18546202-1	2008	Induction of cell death in HeLa cells with TNF and cycloheximide (CHX) required an adequate ATP supply and was accompanied by decrease in intracellular pH, translocation of Bax, perinuclear clustering of the mitochondria, and cytochrome c release.	Cycloheximide	51-64	cytochrome c, somatic	Homo sapiens	226-238
18676622-2	2008	METHODS: PEDF was determined in surgically excised retinal tissue originating from patients with ischemic diabetic retinopathy and in primary guinea pig Muller cell cultures exposed to the protein synthesis inhibitor cycloheximide (CHX) and to hypoxia.	Cycloheximide	217-230	serpin family F member 1	Homo sapiens	9-13
18719002-5	2008	Gastrin-induced mcl-1 expression was inhibited by the transcription inhibitor actinomycin D and by the protein synthesis inhibitor cycloheximide.	Cycloheximide	131-144	gastrin	Homo sapiens	0-7
18708082-8	2008	IL-1beta-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses.	Cycloheximide	89-102	interleukin 1 beta	Canis lupus familiaris	0-8
18708082-8	2008	IL-1beta-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses.	Cycloheximide	89-102	phospholipase A2 group IVA	Canis lupus familiaris	17-22
18719002-5	2008	Gastrin-induced mcl-1 expression was inhibited by the transcription inhibitor actinomycin D and by the protein synthesis inhibitor cycloheximide.	Cycloheximide	131-144	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	16-21
18678651-7	2008	Both Bim and Mcl-1 levels decreased in cycloheximide-induced apoptosis while Bik levels were unchanged, suggesting that apoptosis in siRNA-treated cells is not a direct consequence of loss of mRNA translation.	Cycloheximide	39-52	BCL2-like 11 (apoptosis facilitator)	Mus musculus	5-8
18718443-5	2008	Under basal conditions, treatment with the protein synthesis inhibitor cycloheximide resulted in rapid degradation of PGC-1alpha (t(1/2)=38 min), which was blocked by the proteasome inhibitor epoxomicin, but not the calpain inhibitor calpeptin.	Cycloheximide	71-84	PPARG coactivator 1 alpha	Homo sapiens	118-128
18706402-7	2008	The protein synthesis inhibitor, cycloheximide, blocked the appearance of Mos, blocked MebetaCD-stimulated phosphorylation of MAPK, and inhibited MebetaCD-induced oocyte maturation.	Cycloheximide	33-46	MOS proto-oncogene, serine/threonine kinase L homeolog	Xenopus laevis	74-77
18599551-7	2008	Consistently, the cycloheximide-based protein chase study showed that 5alpha-DHT prolonged HERG protein half-life.	Cycloheximide	18-31	potassium voltage-gated channel subfamily H member 2	Homo sapiens	91-95
18655183-7	2008	Treatment with 100 microM cycloheximide, a protein synthesis inhibitor, replicated the effect of quercetin by inhibiting HIF-1alpha accumulation during hypoxia.	Cycloheximide	26-39	hypoxia inducible factor 1 subunit alpha	Homo sapiens	121-131
18632985-6	2008	p21 was likely a direct target of HDAC4, because HDAC4 down-regulation increased p21 mRNA when protein synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	H3 histone pseudogene 16	Homo sapiens	0-3
18632985-6	2008	p21 was likely a direct target of HDAC4, because HDAC4 down-regulation increased p21 mRNA when protein synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	histone deacetylase 4	Homo sapiens	34-39
18632985-6	2008	p21 was likely a direct target of HDAC4, because HDAC4 down-regulation increased p21 mRNA when protein synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	histone deacetylase 4	Homo sapiens	49-54
18632985-6	2008	p21 was likely a direct target of HDAC4, because HDAC4 down-regulation increased p21 mRNA when protein synthesis was inhibited by cycloheximide.	Cycloheximide	130-143	H3 histone pseudogene 16	Homo sapiens	81-84
18678651-7	2008	Both Bim and Mcl-1 levels decreased in cycloheximide-induced apoptosis while Bik levels were unchanged, suggesting that apoptosis in siRNA-treated cells is not a direct consequence of loss of mRNA translation.	Cycloheximide	39-52	myeloid cell leukemia sequence 1	Mus musculus	13-18
18650263-7	2008	Consistent with posttranscriptional action, knockdown of PIN1 increased the stability of iNOS protein in cycloheximide-treated cells.	Cycloheximide	105-118	peptidyl-prolyl cis/trans isomerase, NIMA-interacting 1	Mus musculus	57-61
18563715-13	2008	Secondly, cycloheximide, a protein synthesis inhibitor, prevented HIF-1 alpha protein increase in serum-deprived PCa cells.	Cycloheximide	10-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	66-77
18421014-5	2008	This decrease in HDAC2 protein expression was reversed by curcumin even in the presence of cycloheximide, a protein synthesis inhibitor.	Cycloheximide	91-104	histone deacetylase 2	Homo sapiens	17-22
18663586-2	2008	We used DNA microarray analysis in combination with a post-translationally regulated BBM:GR protein and cycloheximide to identify target genes that are directly activated by BBM expression in Arabidopsis seedlings.	Cycloheximide	104-117	Integrase-type DNA-binding superfamily protein	Arabidopsis thaliana	174-177
18650263-7	2008	Consistent with posttranscriptional action, knockdown of PIN1 increased the stability of iNOS protein in cycloheximide-treated cells.	Cycloheximide	105-118	nitric oxide synthase 2, inducible	Mus musculus	89-93
18458045-10	2008	Actinomycin D and cycloheximide both inhibited RA-induced PGIS expression.	Cycloheximide	18-31	prostaglandin I2 synthase	Homo sapiens	58-62
18180277-5	2008	Apoptosis of PBMCs was studied by stimulation with TNFalpha in the presence of cycloheximide and annexin V staining.	Cycloheximide	79-92	tumor necrosis factor	Homo sapiens	51-59
18621559-8	2008	The protein synthesis inhibitor cycloheximide had opposing effects in normal vs. CLL malignant B cells: thus, TfR1 and TfR2 mRNA levels were increased in normal B cells, whereas they were unaffected or even suppressed in CLL malignant B cells.	Cycloheximide	32-45	transferrin receptor	Homo sapiens	110-114
18621559-8	2008	The protein synthesis inhibitor cycloheximide had opposing effects in normal vs. CLL malignant B cells: thus, TfR1 and TfR2 mRNA levels were increased in normal B cells, whereas they were unaffected or even suppressed in CLL malignant B cells.	Cycloheximide	32-45	transferrin receptor 2	Homo sapiens	119-123
18718855-5	2008	The OX40L induction on the DNA-damaged activated T cells was inhibited by treatment with either RNA or protein synthesis inhibitors, actinomycin D, or cycloheximide, respectively.	Cycloheximide	151-164	TNF superfamily member 4	Homo sapiens	4-9
18636162-4	2008	Reverse transcription (RT)-polymerase chain reaction (PCR) and heteronuclear PCR assays performed +/- treatment with the protein synthesis inhibitor cycloheximide (CHX) revealed G0S2 induction within 3 h of RA-treatment.	Cycloheximide	149-162	G0/G1 switch 2	Homo sapiens	178-182
18636162-4	2008	Reverse transcription (RT)-polymerase chain reaction (PCR) and heteronuclear PCR assays performed +/- treatment with the protein synthesis inhibitor cycloheximide (CHX) revealed G0S2 induction within 3 h of RA-treatment.	Cycloheximide	164-167	G0/G1 switch 2	Homo sapiens	178-182
18522940-4	2008	Caspase-8 on average was activated 45-600 min after TRAIL/cycloheximide addition.	Cycloheximide	58-71	caspase 8	Homo sapiens	0-9
18534997-5	2008	Cycloheximide solution was used for ODA against tap water.	Cycloheximide	0-13	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	Mus musculus	48-51
18729634-7	2008	BDNF and ERK expression was also down-regulated in animals injected with this dose of cycloheximide.	Cycloheximide	86-99	brain derived neurotrophic factor	Homo sapiens	0-4
18729634-7	2008	BDNF and ERK expression was also down-regulated in animals injected with this dose of cycloheximide.	Cycloheximide	86-99	mitogen-activated protein kinase 1	Homo sapiens	9-12
18690848-3	2008	An increase in NUPR1 expression has been seen with serum starvation and in response to compounds such as cycloheximide, ceramide, and staurosporine.	Cycloheximide	105-118	nuclear protein 1, transcriptional regulator	Homo sapiens	15-20
18636177-8	2008	CRP plus zinc-induced increase in caspase-3 mRNA expression was completely inhibited in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DBR; 10(-6) M), an inhibitor of transcription activity.	Cycloheximide	104-117	C-reactive protein, pentraxin-related	Mus musculus	0-3
18636177-8	2008	CRP plus zinc-induced increase in caspase-3 mRNA expression was completely inhibited in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DBR; 10(-6) M), an inhibitor of transcription activity.	Cycloheximide	104-117	caspase 3	Mus musculus	34-43
18678988-8	2008	IFN-gamma did not affect P2X4-receptor mRNA stability, but increased P2X4-receptor gene transcription in a cycloheximide-insensitive manner.	Cycloheximide	107-120	interferon gamma	Homo sapiens	0-9
18729741-4	2008	Cycloheximide treatment indicated that the augmenting effect of CSC on IL-1alpha, IL-1beta and IL-8, but not IL-6 and CYP1A1, mRNA expression requires de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	71-80
18729741-4	2008	Cycloheximide treatment indicated that the augmenting effect of CSC on IL-1alpha, IL-1beta and IL-8, but not IL-6 and CYP1A1, mRNA expression requires de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	82-90
18729741-4	2008	Cycloheximide treatment indicated that the augmenting effect of CSC on IL-1alpha, IL-1beta and IL-8, but not IL-6 and CYP1A1, mRNA expression requires de novo protein synthesis.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	95-99
19678965-8	2008	Inhibition of protein synthesis with cycloheximide completely abolished reelin immunoreactivity.	Cycloheximide	37-50	reelin	Homo sapiens	72-78
18497737-6	2008	RESULTS: We observed that TNFalpha can induce a caspase-mediated degradation of PPARgamma proteins in the presence of cycloheximide.	Cycloheximide	118-131	tumor necrosis factor	Rattus norvegicus	26-34
18497737-6	2008	RESULTS: We observed that TNFalpha can induce a caspase-mediated degradation of PPARgamma proteins in the presence of cycloheximide.	Cycloheximide	118-131	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	80-89
18497737-9	2008	Use of several specific caspase inhibitors revealed that caspase-1 was activated following treatment with TNFalpha and cycloheximide (CH), and inhibition of caspase-1 blocked the cleavage of PPARgamma proteins in cultured adipocytes.	Cycloheximide	119-132	caspase 1	Rattus norvegicus	57-66
18497737-9	2008	Use of several specific caspase inhibitors revealed that caspase-1 was activated following treatment with TNFalpha and cycloheximide (CH), and inhibition of caspase-1 blocked the cleavage of PPARgamma proteins in cultured adipocytes.	Cycloheximide	119-132	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	191-200
18202854-9	2008	Treatment of PA-1 cells with small interfering RNA (siRNA) directed against TR3, and with cycloheximide or SP600125 (an inhibitor of c-jun N-terminal kinase; JNK), separately, inhibited the VK(2)-induced synthesis of TR3 and apoptosis.	Cycloheximide	90-103	nuclear receptor subfamily 4 group A member 1	Homo sapiens	217-220
18474416-7	2008	Furthermore, the protein synthesis inhibitor cycloheximide decreased Nqo1 mRNA induction, suggesting a role for a labile protein in the transcriptional induction of Nqo1 mRNA by metals.	Cycloheximide	45-58	NAD(P)H dehydrogenase, quinone 1	Mus musculus	69-73
18474416-7	2008	Furthermore, the protein synthesis inhibitor cycloheximide decreased Nqo1 mRNA induction, suggesting a role for a labile protein in the transcriptional induction of Nqo1 mRNA by metals.	Cycloheximide	45-58	NAD(P)H dehydrogenase, quinone 1	Mus musculus	165-169
18450422-4	2008	Cycloheximide decay assays and studies with proteasome inhibitor indicated that Akt1-mediated up-regulation of ERalpha was maintained by inhibiting proteasome-mediated degradation of ERalpha.	Cycloheximide	0-13	AKT serine/threonine kinase 1	Homo sapiens	80-84
18450422-4	2008	Cycloheximide decay assays and studies with proteasome inhibitor indicated that Akt1-mediated up-regulation of ERalpha was maintained by inhibiting proteasome-mediated degradation of ERalpha.	Cycloheximide	0-13	estrogen receptor 1	Homo sapiens	111-118
18571867-11	2008	Local treatment with cycloheximide suppressed the axotomy-induced peripherin-IR-enhancement in severed ends, suggesting the occurrence of intra-axonal peripherin synthesis in vivo.	Cycloheximide	21-34	peripherin	Rattus norvegicus	66-76
18571867-11	2008	Local treatment with cycloheximide suppressed the axotomy-induced peripherin-IR-enhancement in severed ends, suggesting the occurrence of intra-axonal peripherin synthesis in vivo.	Cycloheximide	21-34	peripherin	Rattus norvegicus	151-161
18455888-9	2008	However, the presence of the protein synthesis inhibitor cycloheximide could reverse the repression of Myc, indicating the indirect repression of human NDRG1 by Myc.	Cycloheximide	57-70	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	103-106
18455888-9	2008	However, the presence of the protein synthesis inhibitor cycloheximide could reverse the repression of Myc, indicating the indirect repression of human NDRG1 by Myc.	Cycloheximide	57-70	N-myc downstream regulated 1	Homo sapiens	152-157
18455888-9	2008	However, the presence of the protein synthesis inhibitor cycloheximide could reverse the repression of Myc, indicating the indirect repression of human NDRG1 by Myc.	Cycloheximide	57-70	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	161-164
18231987-5	2008	A short treatment with DENSPM did not reduce cell viability when given alone, but enhanced caspase-3 and -9 activation in chondrocytes exposed to tumor necrosis factor-alpha (TNF) and cycloheximide (CHX).	Cycloheximide	184-197	caspase 3	Homo sapiens	91-107
18231987-5	2008	A short treatment with DENSPM did not reduce cell viability when given alone, but enhanced caspase-3 and -9 activation in chondrocytes exposed to tumor necrosis factor-alpha (TNF) and cycloheximide (CHX).	Cycloheximide	199-202	caspase 3	Homo sapiens	91-107
18336852-9	2008	Moreover, pretreatment with actinomycin D and cycloheximide attenuated TNF-alpha-induced MMP-9 expression.	Cycloheximide	46-59	tumor necrosis factor	Homo sapiens	71-80
18491380-9	2008	The protein synthesis inhibitor cycloheximide completely inhibited upregulation of HGF mRNA induced by maleic acid but superinduced HGF mRNA expression upregulated by 12-O-tetradecanoylphorbol 13-acetate (TPA).	Cycloheximide	32-45	hepatocyte growth factor	Homo sapiens	83-86
18491380-9	2008	The protein synthesis inhibitor cycloheximide completely inhibited upregulation of HGF mRNA induced by maleic acid but superinduced HGF mRNA expression upregulated by 12-O-tetradecanoylphorbol 13-acetate (TPA).	Cycloheximide	32-45	hepatocyte growth factor	Homo sapiens	132-135
18410509-7	2008	The increase in Ha-Ras levels was sensitive to the protein synthesis inhibitor, cycloheximide, suggesting that serum deprivation increases translation of preformed Ha-Ras mRNA.	Cycloheximide	80-93	Harvey rat sarcoma virus oncogene	Mus musculus	16-22
18410509-7	2008	The increase in Ha-Ras levels was sensitive to the protein synthesis inhibitor, cycloheximide, suggesting that serum deprivation increases translation of preformed Ha-Ras mRNA.	Cycloheximide	80-93	Harvey rat sarcoma virus oncogene	Mus musculus	164-170
18638274-7	2008	Interestingly, EGF prevention of apoptosis induced by tumor necrosis factor-alpha in the face of cycloheximide blockade of protein translation occurs via a different set of pathways as the simultaneous inhibition of extracellular signal-regulated kinase, Rac, and PI3K signaling did not eliminate EGF from rescuing fibroblasts in the face of this cytokine.	Cycloheximide	97-110	epidermal growth factor	Homo sapiens	15-18
18465786-1	2008	We were looking by a proteomic approach for new phospho-proteins involved during the early steps of the TNF + cycloheximide (CHX)-induced apoptosis-preceding mitochondrial membrane permeabilization-of endothelial cells (BAEC).	Cycloheximide	110-123	tumor necrosis factor	Homo sapiens	104-107
18465786-1	2008	We were looking by a proteomic approach for new phospho-proteins involved during the early steps of the TNF + cycloheximide (CHX)-induced apoptosis-preceding mitochondrial membrane permeabilization-of endothelial cells (BAEC).	Cycloheximide	125-128	tumor necrosis factor	Homo sapiens	104-107
18502975-10	2008	Further expression analysis through activation of RGA by steroid induction combined with cycloheximide identified eight genes as immediate targets of RGA.	Cycloheximide	89-102	GRAS family transcription factor family protein	Arabidopsis thaliana	150-153
18336852-9	2008	Moreover, pretreatment with actinomycin D and cycloheximide attenuated TNF-alpha-induced MMP-9 expression.	Cycloheximide	46-59	matrix metallopeptidase 9	Homo sapiens	89-94
18474237-5	2008	Cycloheximide or actinomycin D blocked caspase-11 induction, reduced caspase-11 and -3 activation, and attenuated TPEN-induced neuronal apoptosis.	Cycloheximide	0-13	caspase 3	Homo sapiens	69-86
18433744-2	2008	The repression was interfered by dominant negative forms of activin receptor-like kinase 5 (ALK5) and Smad3, and sensitive to cycloheximide, suggesting the involvement of additional protein(s) as well as ALK5 and Smad3 in the repression.	Cycloheximide	126-139	transforming growth factor, beta receptor I	Mus musculus	60-90
18081026-6	2008	Quantitative RT-PCR showed a significant reduction of mutant FTSJ1 mRNA in the patient"s lymphoblast cells, which was restored by treatment with cycloheximide, a potent inhibitor of nonsense-mediated mRNA decay (NMD).	Cycloheximide	145-158	FtsJ RNA 2'-O-methyltransferase 1	Homo sapiens	61-66
18433744-2	2008	The repression was interfered by dominant negative forms of activin receptor-like kinase 5 (ALK5) and Smad3, and sensitive to cycloheximide, suggesting the involvement of additional protein(s) as well as ALK5 and Smad3 in the repression.	Cycloheximide	126-139	transforming growth factor, beta receptor I	Mus musculus	204-208
18433744-2	2008	The repression was interfered by dominant negative forms of activin receptor-like kinase 5 (ALK5) and Smad3, and sensitive to cycloheximide, suggesting the involvement of additional protein(s) as well as ALK5 and Smad3 in the repression.	Cycloheximide	126-139	SMAD family member 3	Mus musculus	213-218
18381927-6	2008	The lipocalin 2 response was blocked by the GC-receptor antagonist RU-486 and was increased further by the protein synthesis blocker cycloheximide.	Cycloheximide	133-146	lipocalin 2	Homo sapiens	4-15
18381294-6	2008	Using cycloheximide and MG132, we demonstrated that the Cyr61-mediated HIF-1alpha up-regulation was through de novo protein synthesis, rather than increased protein stability.	Cycloheximide	6-19	cellular communication network factor 1	Homo sapiens	56-61
18381294-6	2008	Using cycloheximide and MG132, we demonstrated that the Cyr61-mediated HIF-1alpha up-regulation was through de novo protein synthesis, rather than increased protein stability.	Cycloheximide	6-19	hypoxia inducible factor 1 subunit alpha	Homo sapiens	71-81
18359077-6	2008	The QCM-D was able to detect differences in the untreated cellular responses to fibronectin versus serum precoated Ta and PS(ox) substrates, while cycloheximide treatment of the cells produced the same QCM-D response for fibronectin and serum precoatings on each of the materials.	Cycloheximide	147-160	fibronectin 1	Homo sapiens	221-232
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	150-159
18406357-8	2008	Klf5 expression was increased at 1-2 h ( approximately 13-fold) as a second phase response (cycloheximide inhibited the increase).	Cycloheximide	92-105	Kruppel-like factor 5	Rattus norvegicus	0-4
18335505-7	2008	The findings of cycloheximide inhibition and time-course studies are consistent with the hypothesis that the PAX3-FKHR protein acts directly on the MYCN gene at the transcriptional level.	Cycloheximide	16-29	paired box 3	Homo sapiens	109-113
18335505-7	2008	The findings of cycloheximide inhibition and time-course studies are consistent with the hypothesis that the PAX3-FKHR protein acts directly on the MYCN gene at the transcriptional level.	Cycloheximide	16-29	forkhead box O1	Homo sapiens	114-118
18335505-7	2008	The findings of cycloheximide inhibition and time-course studies are consistent with the hypothesis that the PAX3-FKHR protein acts directly on the MYCN gene at the transcriptional level.	Cycloheximide	16-29	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	148-152
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	32-45	nuclear factor kappa B subunit 1	Homo sapiens	182-191
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	32-45	TNF receptor superfamily member 1A	Homo sapiens	219-233
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	32-45	TNF receptor superfamily member 1A	Homo sapiens	235-241
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	47-50	tumor necrosis factor	Homo sapiens	150-159
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	47-50	nuclear factor kappa B subunit 1	Homo sapiens	182-191
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	47-50	TNF receptor superfamily member 1A	Homo sapiens	219-233
18442799-2	2008	The protein synthesis inhibitor cycloheximide (CHX) and its structural derivative acetoxycycloheximide (Ac-CHX) have been recently shown to block the TNF-alpha-induced activation of NF-kappaB via ectodomain shedding of TNF receptor 1 (TNF-R1) in human lung carcinoma A549 cells.	Cycloheximide	47-50	TNF receptor superfamily member 1A	Homo sapiens	235-241
18334598-8	2008	When the HepG2 cells were treated with cycloheximide, a general inhibitor of protein synthesis, the loss of CYP3A4 protein was accelerated by cotreatment with either proteasome or NF-kappaB inhibitors.	Cycloheximide	39-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-114
18485876-1	2008	The inflammatory response of mammalian cells to TNF-alpha can be switched to apoptosis either by cotreatment with a protein synthesis inhibitor, cycloheximide, or Smac mimetic, a small molecule mimic of Smac/Diablo protein.	Cycloheximide	145-158	tumor necrosis factor	Homo sapiens	48-57
18315559-7	2008	The protein synthesis inhibitor cycloheximide blocked apoptosis that was induced by over-expressed shTIF-IA or active form of p53.	Cycloheximide	32-45	tumor protein p53	Homo sapiens	126-129
19031736-2	2008	METHODS: The expression of ID1 was detected by cDNA microarray, cycloheximide inhibition test, real-time RT-PCR and western blot.	Cycloheximide	64-77	inhibitor of DNA binding 1, HLH protein	Homo sapiens	27-30
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	caspase 8	Homo sapiens	23-32
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	caspase 8	Homo sapiens	70-79
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	CASP8 and FADD like apoptosis regulator	Homo sapiens	91-97
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	receptor interacting serine/threonine kinase 1	Homo sapiens	249-254
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	caspase 8	Homo sapiens	70-79
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	receptor interacting serine/threonine kinase 1	Homo sapiens	349-354
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	Fas associated via death domain	Homo sapiens	356-360
18485876-2	2008	Cycloheximide promotes caspase-8 activation by eliminating endogenous caspase-8 inhibitor, c-FLIP, while Smac mimetic does so by triggering autodegradation of cIAP1 and cIAP2 (cIAP1/2), leading to the release of receptor interacting protein kinase (RIPK1) from the activated TNF receptor complex to form a caspase-8-activating complex consisting of RIPK1, FADD, and caspase-8.	Cycloheximide	0-13	caspase 8	Homo sapiens	70-79
18252892-8	2008	Bid-deficient islets were also resistant to apoptosis induced by TNF-alpha plus cycloheximide and were partially resistant to proinflammatory cytokine-induced death.	Cycloheximide	80-93	BH3 interacting domain death agonist	Mus musculus	0-3
18387309-2	2008	The aim of the presented work was to analyze the mechanism of IL-1-induced cytocidal effect in HeLa cells in the presence of cycloheximide (CHX).	Cycloheximide	125-138	interleukin 1 alpha	Homo sapiens	62-66
18387309-2	2008	The aim of the presented work was to analyze the mechanism of IL-1-induced cytocidal effect in HeLa cells in the presence of cycloheximide (CHX).	Cycloheximide	140-143	interleukin 1 alpha	Homo sapiens	62-66
18205807-3	2008	In this work, it is shown that the RPD3 gene encoding the histone deacetylase that functions as a transcriptional corepressor at many promoters and the ROM2 gene coding for the GDP/GTP exchange protein for Rho1p and Rho2p participating in signal transduction pathways are required for PDR5 transcription under cycloheximide-induced and noninduced conditions.	Cycloheximide	310-323	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	35-39
18205807-3	2008	In this work, it is shown that the RPD3 gene encoding the histone deacetylase that functions as a transcriptional corepressor at many promoters and the ROM2 gene coding for the GDP/GTP exchange protein for Rho1p and Rho2p participating in signal transduction pathways are required for PDR5 transcription under cycloheximide-induced and noninduced conditions.	Cycloheximide	310-323	Rho family guanine nucleotide exchange factor ROM2	Saccharomyces cerevisiae S288C	152-156
18205807-3	2008	In this work, it is shown that the RPD3 gene encoding the histone deacetylase that functions as a transcriptional corepressor at many promoters and the ROM2 gene coding for the GDP/GTP exchange protein for Rho1p and Rho2p participating in signal transduction pathways are required for PDR5 transcription under cycloheximide-induced and noninduced conditions.	Cycloheximide	310-323	Rho family GTPase RHO1	Saccharomyces cerevisiae S288C	206-211
18205807-3	2008	In this work, it is shown that the RPD3 gene encoding the histone deacetylase that functions as a transcriptional corepressor at many promoters and the ROM2 gene coding for the GDP/GTP exchange protein for Rho1p and Rho2p participating in signal transduction pathways are required for PDR5 transcription under cycloheximide-induced and noninduced conditions.	Cycloheximide	310-323	Rho family GTPase RHO2	Saccharomyces cerevisiae S288C	216-221
18321792-7	2008	However, we found that inhibition of mRNA translation by either cycloheximide or puromycin in one-cell embryos caused the accumulation of Sam68 in cytoplasmic granules.	Cycloheximide	64-77	KH domain containing, RNA binding, signal transduction associated 1	Mus musculus	138-143
18064628-7	2008	Bim mRNA was upregulated in response to 1 microM Dex; both cycloheximide and the GC receptor antagonist, RU486, prevented Dex-induction of Bim protein, indicating transcriptional regulation involving the GC receptor.	Cycloheximide	59-72	BCL2 like 11	Homo sapiens	139-142
18386821-6	2008	Furthermore, retinoic acid is likely to act directly on BAMBI as induction occurs in the presence of cycloheximide.	Cycloheximide	101-114	BMP and activin membrane bound inhibitor	Homo sapiens	56-61
18196969-4	2008	On the contrary, Atg5-/- MEFs were as sensitive to tumor necrosis factor (TNF)-alpha and cycloheximide as WT cells, and were more sensitive to cell death triggered by amino acid-deprivation than WT MEFs.	Cycloheximide	89-102	autophagy related 5	Mus musculus	17-21
18406487-8	2008	Under the conditions of de novo protein synthesis inhibition with cycloheximide, lactic acid increased the AQP4 expression level.	Cycloheximide	66-79	aquaporin 4	Rattus norvegicus	107-111
18215136-4	2008	Pre-treatment with actinomycin D or cycloheximide blocked the up-regulation of 5alpha-R1 mRNA expression by HGF, indicating that the increased level of 5alpha-R1 mRNA expression is regulated by transcriptional activation and was dependent on de novo protein synthesis.	Cycloheximide	36-49	hepatocyte growth factor	Homo sapiens	108-111
18218673-0	2008	TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species.	Cycloheximide	10-23	tumor necrosis factor	Homo sapiens	0-9
18218673-0	2008	TNF-alpha/cycloheximide-induced apoptosis in intestinal epithelial cells requires Rac1-regulated reactive oxygen species.	Cycloheximide	10-23	Rac family small GTPase 1	Homo sapiens	82-86
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	149-162	Rac family small GTPase 1	Homo sapiens	35-39
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	149-162	mitogen-activated protein kinase 8	Homo sapiens	73-79
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	149-162	tumor necrosis factor	Homo sapiens	138-148
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	164-167	Rac family small GTPase 1	Homo sapiens	35-39
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	164-167	mitogen-activated protein kinase 8	Homo sapiens	73-79
18218673-1	2008	Previously we have shown that both Rac1 and c-Jun NH(2)-terminal kinase (JNK1/2) are key proapoptotic molecules in tumor necrosis factor (TNF)-alpha/cycloheximide (CHX)-induced apoptosis in intestinal epithelial cells, whereas the role of reactive oxygen species (ROS) in apoptosis is unclear.	Cycloheximide	164-167	tumor necrosis factor	Homo sapiens	138-148
18251703-10	2008	Both actinomycin D and cycloheximide prevented this increase in Bim, indicating transcriptional regulation.	Cycloheximide	23-36	BCL2-like 11 (apoptosis facilitator)	Mus musculus	64-67
18327666-7	2008	The stimulatory effects of zinc sulfate on Runx2, OPG, or regucalcin mRNAs were significantly prevented in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (10(-6) M), an inhibitor of transcription activity.	Cycloheximide	123-136	runt related transcription factor 2	Mus musculus	43-48
18327666-7	2008	The stimulatory effects of zinc sulfate on Runx2, OPG, or regucalcin mRNAs were significantly prevented in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (10(-6) M), an inhibitor of transcription activity.	Cycloheximide	123-136	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	50-53
18327666-7	2008	The stimulatory effects of zinc sulfate on Runx2, OPG, or regucalcin mRNAs were significantly prevented in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (10(-6) M), an inhibitor of transcription activity.	Cycloheximide	123-136	regucalcin	Mus musculus	58-68
17955499-4	2008	By using cycloheximide to block the de novo protein synthesis, similar rate of USF2 degradation was found under either normal glucose or high glucose conditions.	Cycloheximide	9-22	upstream transcription factor 2, c-fos interacting	Rattus norvegicus	79-83
18162528-8	2008	CYP24A1 mRNA induction in RPTCs was also inhibited by the protein synthesis inhibitor cycloheximide.	Cycloheximide	86-99	cytochrome P450, family 24, subfamily a, polypeptide 1	Rattus norvegicus	0-7
18439101-6	2008	TNF-alpha-induced JNK phosphorylation was sustained in the presence of cycloheximide, which was accompanied by accelerated neutrophil apoptosis.	Cycloheximide	71-84	tumor necrosis factor	Homo sapiens	0-9
18187554-3	2008	Stimulation of CITED1 mRNA by PTH was transient, peaking at 4 h, concentration dependent, and blocked by actinomycin D but not cycloheximide.	Cycloheximide	127-140	Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1	Mus musculus	15-21
18289527-2	2008	It has been established that the protein synthesis inhibitor cycloheximide (CHX) sensitizes many types of cells to tumor necrosis factor (TNF)-alpha-induced apoptosis, mainly due to its ability to block de novo synthesis of cellular FLICE-inhibitory protein (c-FLIP).	Cycloheximide	61-74	tumor necrosis factor	Homo sapiens	115-148
18289527-2	2008	It has been established that the protein synthesis inhibitor cycloheximide (CHX) sensitizes many types of cells to tumor necrosis factor (TNF)-alpha-induced apoptosis, mainly due to its ability to block de novo synthesis of cellular FLICE-inhibitory protein (c-FLIP).	Cycloheximide	61-74	CASP8 and FADD like apoptosis regulator	Homo sapiens	259-265
18289527-2	2008	It has been established that the protein synthesis inhibitor cycloheximide (CHX) sensitizes many types of cells to tumor necrosis factor (TNF)-alpha-induced apoptosis, mainly due to its ability to block de novo synthesis of cellular FLICE-inhibitory protein (c-FLIP).	Cycloheximide	76-79	tumor necrosis factor	Homo sapiens	115-148
18289527-2	2008	It has been established that the protein synthesis inhibitor cycloheximide (CHX) sensitizes many types of cells to tumor necrosis factor (TNF)-alpha-induced apoptosis, mainly due to its ability to block de novo synthesis of cellular FLICE-inhibitory protein (c-FLIP).	Cycloheximide	76-79	CASP8 and FADD like apoptosis regulator	Homo sapiens	259-265
18289527-3	2008	Nevertheless, we have surprisingly found that CHX, as well as its structural analogue acetoxycycloheximide (Ac-CHX), prevents TNF-alpha-mediated activation of NF-kappaB and caspase-8 in human lung carcinoma A549 cells.	Cycloheximide	46-49	tumor necrosis factor	Homo sapiens	126-135
18289527-3	2008	Nevertheless, we have surprisingly found that CHX, as well as its structural analogue acetoxycycloheximide (Ac-CHX), prevents TNF-alpha-mediated activation of NF-kappaB and caspase-8 in human lung carcinoma A549 cells.	Cycloheximide	46-49	caspase 8	Homo sapiens	173-182
18194670-6	2008	RESULTS: Hepatocytes synthesize and secrete gc-globulin as shown by RT-PCR and [(35)S]-methionine labelling, which could be suppressed by cycloheximide.	Cycloheximide	138-151	GC vitamin D binding protein	Homo sapiens	44-55
18252865-7	2008	Similarly, pretreatment with cycloheximide prevented CCL5 or CXCR4 mRNA expression, consistent with the observation that DAMGO induction of chemokine and chemokine receptor expression requires newly synthesized TGF-beta1 protein.	Cycloheximide	29-42	C-C motif chemokine ligand 5	Homo sapiens	53-57
18252865-7	2008	Similarly, pretreatment with cycloheximide prevented CCL5 or CXCR4 mRNA expression, consistent with the observation that DAMGO induction of chemokine and chemokine receptor expression requires newly synthesized TGF-beta1 protein.	Cycloheximide	29-42	C-X-C motif chemokine receptor 4	Homo sapiens	61-66
18252865-7	2008	Similarly, pretreatment with cycloheximide prevented CCL5 or CXCR4 mRNA expression, consistent with the observation that DAMGO induction of chemokine and chemokine receptor expression requires newly synthesized TGF-beta1 protein.	Cycloheximide	29-42	C-X-C motif chemokine receptor 4	Homo sapiens	154-172
18252865-7	2008	Similarly, pretreatment with cycloheximide prevented CCL5 or CXCR4 mRNA expression, consistent with the observation that DAMGO induction of chemokine and chemokine receptor expression requires newly synthesized TGF-beta1 protein.	Cycloheximide	29-42	transforming growth factor beta 1	Homo sapiens	211-220
18439101-6	2008	TNF-alpha-induced JNK phosphorylation was sustained in the presence of cycloheximide, which was accompanied by accelerated neutrophil apoptosis.	Cycloheximide	71-84	mitogen-activated protein kinase 8	Homo sapiens	18-21
18439101-7	2008	The JNK inhibitors (SP600125 and TAT-TI-JIP(153163)) suppressed neutrophil apoptosis induced by TNF-alpha plus cycloheximide, whereas they attenuated the GM-CSF-mediated antiapoptotic effect on neutrophils.	Cycloheximide	111-124	mitogen-activated protein kinase 8	Homo sapiens	4-7
17617453-3	2008	We analysed programmed cell death pathways of v-myb-transformed BM2 monoblasts induced by arsenic trioxide, cycloheximide and camptothecin with U937 promonocytes as a reference cell line.	Cycloheximide	108-121	MYB proto-oncogene, transcription factor	Homo sapiens	46-51
17916901-4	2008	Using chemical inhibitors of protein synthesis (cycloheximide) and 26S proteosomal degradation (MG-132), we observed that the induction of Nrf2 protein by 3MP-ITC appeared to be post-translationally regulated.	Cycloheximide	48-61	NFE2 like bZIP transcription factor 2	Homo sapiens	139-143
18182057-5	2008	Interestingly, experiments with cycloheximide revealed that relocalization of N-cadherin to the cell surface membrane were independent of protein synthesis.	Cycloheximide	32-45	cadherin 2	Rattus norvegicus	78-88
18339854-9	2008	Measurement of beta-catenin protein stability by cycloheximide treatment showed that Rad6B silencing specifically decreases the stability of high molecular beta-catenin with minimal effect upon the 90-kDa nascent form.	Cycloheximide	49-62	catenin beta 1	Homo sapiens	15-27
18339854-9	2008	Measurement of beta-catenin protein stability by cycloheximide treatment showed that Rad6B silencing specifically decreases the stability of high molecular beta-catenin with minimal effect upon the 90-kDa nascent form.	Cycloheximide	49-62	ubiquitin conjugating enzyme E2 B	Homo sapiens	85-90
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	homeobox A3	Mus musculus	139-144
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	homeobox A5	Mus musculus	146-151
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	growth arrest specific 1	Mus musculus	153-157
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	cytochrome P450, family 26, subfamily a, polypeptide 1	Mus musculus	159-166
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	secreted frizzled-related protein 2	Mus musculus	168-173
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	fructose bisphosphatase 2	Mus musculus	175-179
18164278-8	2008	Genes specifically induced by RA at 6h with the protein synthesis inhibitor cycloheximide in F9 Wt, but not in RARgamma-/- cells, included Hoxa3, Hoxa5, Gas1, Cyp26a1, Sfrp2, Fbp2, and Emp1.	Cycloheximide	76-89	epithelial membrane protein 1	Mus musculus	185-189
18086809-6	2008	Cell viability assays indicated that the p38 mitogen-activated protein kinase (MAPK) inhibitors SB202190 and SB203580 and the general protein synthesis inhibitor cycloheximide inhibited both the LPS and TNF-alpha sensitization of HUVEC to Stx2, while all other inhibitors tested did not inhibit this sensitization.	Cycloheximide	162-175	tumor necrosis factor	Homo sapiens	203-212
18029162-7	2008	The extracellular signal-regulated kinases (ERKs)-1/2 were strongly activated by PMA, while anisomycin activated the c-Jun N-terminal kinase (JNK) and p38 pathways, and cycloheximide activated p38, but emetine had no effect on the stress-activated mitogen-activated protein kinase (MAPK) pathways.	Cycloheximide	169-182	mitogen-activated protein kinase 1	Homo sapiens	193-196
18055878-7	2008	Cotreatment with cycloheximide further suggests a direct transcriptional role for hAhR at the hIGFBP-1 promoter.	Cycloheximide	17-30	insulin like growth factor binding protein 1	Homo sapiens	94-102
18206364-6	2008	Treatment with cycloheximide totally inhibited estrogen effects suggesting that activation of icb-1 gene expression is no ERE-dependent early response but a secondary event requiring protein synthesis.	Cycloheximide	15-28	thymocyte selection associated family member 2	Homo sapiens	94-99
18055878-7	2008	Cotreatment with cycloheximide further suggests a direct transcriptional role for hAhR at the hIGFBP-1 promoter.	Cycloheximide	17-30	aryl hydrocarbon receptor	Homo sapiens	82-86
18029162-8	2008	The involvement of the p38 and JNK pathways in the selective effects of anisomycin and cycloheximide on MMP/TIMP expression was supported by use of pharmacological inhibitors.	Cycloheximide	87-100	mitogen-activated protein kinase 1	Homo sapiens	23-26
18029162-8	2008	The involvement of the p38 and JNK pathways in the selective effects of anisomycin and cycloheximide on MMP/TIMP expression was supported by use of pharmacological inhibitors.	Cycloheximide	87-100	mitogen-activated protein kinase 8	Homo sapiens	31-34
18029162-8	2008	The involvement of the p38 and JNK pathways in the selective effects of anisomycin and cycloheximide on MMP/TIMP expression was supported by use of pharmacological inhibitors.	Cycloheximide	87-100	TIMP metallopeptidase inhibitor 1	Homo sapiens	108-112
18339016-13	2008	Cycloheximide also diminished activation of p38 MAPK and induction of MUC5AC mRNA expression by IL-13.	Cycloheximide	0-13	mitogen-activated protein kinase 14	Mus musculus	44-52
18223147-7	2008	Experiments performed with the protein synthesis inhibitor cycloheximide provided evidence that JAZs, MYC2, and genes encoding several JA biosynthetic enzymes are primary response genes whose expression is derepressed upon COI1-dependent turnover of a labile repressor protein(s).	Cycloheximide	59-72	Basic helix-loop-helix (bHLH) DNA-binding family protein	Arabidopsis thaliana	102-106
18339016-13	2008	Cycloheximide also diminished activation of p38 MAPK and induction of MUC5AC mRNA expression by IL-13.	Cycloheximide	0-13	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	70-76
18223147-7	2008	Experiments performed with the protein synthesis inhibitor cycloheximide provided evidence that JAZs, MYC2, and genes encoding several JA biosynthetic enzymes are primary response genes whose expression is derepressed upon COI1-dependent turnover of a labile repressor protein(s).	Cycloheximide	59-72	RNI-like superfamily protein	Arabidopsis thaliana	223-227
18339016-13	2008	Cycloheximide also diminished activation of p38 MAPK and induction of MUC5AC mRNA expression by IL-13.	Cycloheximide	0-13	interleukin 13	Mus musculus	96-101
18284699-6	2008	At their most effective concentrations, PLCZ1 induced parthenogenetic development at rates similar to those observed using other activation stimuli such as Ionomycin/CHX and Ionomycin/DMAP.	Cycloheximide	166-169	phospholipase C zeta 1	Bos taurus	40-45
17828306-7	2008	The downregulation of DNMT1 expression seems to require de novo protein synthesis, because the apicidin effect is antagonized by cycloheximide treatment.	Cycloheximide	129-142	DNA methyltransferase 1	Homo sapiens	22-27
18157742-4	2008	In contrast to wild type CD45-positive T cells, the CD45-deficient T cell lines are resistant to the induction of DNA fragmentation and chromatin condensation following tributyltin (TBT) or H2O2 exposure, but not to cycloheximide-induced apoptosis.	Cycloheximide	216-229	protein tyrosine phosphatase receptor type C	Homo sapiens	52-56
18202809-4	2008	Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126).	Cycloheximide	119-132	TNF superfamily member 10	Homo sapiens	61-66
18070882-7	2008	Moreover the cycloheximide-induced increase in mTORC1 signaling was significantly attenuated in cells lacking REDD1, showing that REDD1 plays an integral role in the response.	Cycloheximide	13-26	CREB regulated transcription coactivator 1	Mus musculus	47-53
18070882-7	2008	Moreover the cycloheximide-induced increase in mTORC1 signaling was significantly attenuated in cells lacking REDD1, showing that REDD1 plays an integral role in the response.	Cycloheximide	13-26	DNA damage inducible transcript 4	Homo sapiens	110-115
18070882-7	2008	Moreover the cycloheximide-induced increase in mTORC1 signaling was significantly attenuated in cells lacking REDD1, showing that REDD1 plays an integral role in the response.	Cycloheximide	13-26	DNA damage inducible transcript 4	Homo sapiens	130-135
18078929-0	2008	Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide.	Cycloheximide	78-91	Fas cell surface death receptor	Homo sapiens	14-18
18078929-4	2008	It is also known that the protein synthesis inhibitor cycloheximide (CHX) sensitizes Type I cells to CD95-mediated apoptosis, but it remains contradictory whether this effect also occurs in Type II cells.	Cycloheximide	54-67	Fas cell surface death receptor	Homo sapiens	101-105
18078929-4	2008	It is also known that the protein synthesis inhibitor cycloheximide (CHX) sensitizes Type I cells to CD95-mediated apoptosis, but it remains contradictory whether this effect also occurs in Type II cells.	Cycloheximide	69-72	Fas cell surface death receptor	Homo sapiens	101-105
18078929-8	2008	Therefore, CHX treatment is granting the CD95-mediated pathway the ability to bypass the mitochondria requirement to apoptosis, much alike to what is observed in Type I cells.	Cycloheximide	11-14	Fas cell surface death receptor	Homo sapiens	41-45
17989348-6	2008	beta-CDODA-Me repressed AR mRNA transcription, whereas decreased PSA mRNA levels were dependent on protein synthesis and were reversed by cycloheximide.	Cycloheximide	138-151	kallikrein related peptidase 3	Homo sapiens	65-68
18202809-4	2008	Two different approaches were used to sensitize the cells to TRAIL-induced apoptosis: inhibition of protein synthesis (cycloheximide, CHX) and inhibition of the pro-survival MEK/ERK pathway (U0126).	Cycloheximide	134-137	TNF superfamily member 10	Homo sapiens	61-66
18199340-0	2008	Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway.	Cycloheximide	18-31	toll like receptor 3	Homo sapiens	73-77
18039672-3	2008	This also occurred during the induction of E2F1 activity in the presence of cycloheximide, thus indicating that RhoBTB2 is a direct target.	Cycloheximide	76-89	E2F transcription factor 1 L homeolog	Xenopus laevis	43-47
18199340-7	2008	RESULTS: We show that TLR3 are widely expressed on human and murine tumor cell lines, and activation of TLR3 signaling in cancerous cells by poly I:C made Hela cells (human cervical cancer) and MCA38 cells (murine colon cancer) become dose-dependently sensitive to protein synthesis inhibitor cycloheximide (CHX)-induced apoptosis.	Cycloheximide	293-306	toll like receptor 3	Homo sapiens	22-26
18199340-7	2008	RESULTS: We show that TLR3 are widely expressed on human and murine tumor cell lines, and activation of TLR3 signaling in cancerous cells by poly I:C made Hela cells (human cervical cancer) and MCA38 cells (murine colon cancer) become dose-dependently sensitive to protein synthesis inhibitor cycloheximide (CHX)-induced apoptosis.	Cycloheximide	293-306	toll-like receptor 3	Mus musculus	104-108
18199340-7	2008	RESULTS: We show that TLR3 are widely expressed on human and murine tumor cell lines, and activation of TLR3 signaling in cancerous cells by poly I:C made Hela cells (human cervical cancer) and MCA38 cells (murine colon cancer) become dose-dependently sensitive to protein synthesis inhibitor cycloheximide (CHX)-induced apoptosis.	Cycloheximide	308-311	toll like receptor 3	Homo sapiens	22-26
18199340-7	2008	RESULTS: We show that TLR3 are widely expressed on human and murine tumor cell lines, and activation of TLR3 signaling in cancerous cells by poly I:C made Hela cells (human cervical cancer) and MCA38 cells (murine colon cancer) become dose-dependently sensitive to protein synthesis inhibitor cycloheximide (CHX)-induced apoptosis.	Cycloheximide	308-311	toll-like receptor 3	Mus musculus	104-108
18199340-8	2008	Blockade of TLR3 recognition with anti-TLR3 antibody greatly attenuated the proapoptotic effects of poly I:C on tumor cells cultured with CHX.	Cycloheximide	138-141	toll like receptor 3	Homo sapiens	12-16
18199340-8	2008	Blockade of TLR3 recognition with anti-TLR3 antibody greatly attenuated the proapoptotic effects of poly I:C on tumor cells cultured with CHX.	Cycloheximide	138-141	toll like receptor 3	Homo sapiens	39-43
19094210-10	2008	The upregulation of L-PGDS by IL-1beta was blocked by the translational inhibitor cycloheximide, indicating that this effect is indirect, requiring de novo protein synthesis.	Cycloheximide	82-95	prostaglandin D2 synthase	Homo sapiens	20-26
19094210-10	2008	The upregulation of L-PGDS by IL-1beta was blocked by the translational inhibitor cycloheximide, indicating that this effect is indirect, requiring de novo protein synthesis.	Cycloheximide	82-95	interleukin 1 beta	Homo sapiens	30-38
17889962-5	2008	Pretreatment of the cells with the translation inhibitor cycloheximide demonstrated that Tis11B was a primary response gene in this process.	Cycloheximide	57-70	zinc finger protein 36, C3H type-like 1	Mus musculus	89-95
18005266-8	2008	Utilization of catalase, cycloheximide and genistein inhibitors showed that IL-4 induced SOCS3 by a mechanism dependent on a complete NADPH oxidase complex, protein synthesis and tyrosine phosphorylation, but independent of production of reactive oxygen species.	Cycloheximide	25-38	interleukin 4	Homo sapiens	76-80
18005266-8	2008	Utilization of catalase, cycloheximide and genistein inhibitors showed that IL-4 induced SOCS3 by a mechanism dependent on a complete NADPH oxidase complex, protein synthesis and tyrosine phosphorylation, but independent of production of reactive oxygen species.	Cycloheximide	25-38	suppressor of cytokine signaling 3	Homo sapiens	89-94
18504399-7	2008	Actinomycin D and cycloheximide were used to block RNA synthesis and protein synthesis, respectively, in the chasing experiment of the amount of FIP1L1-PDGFRalpha protein.	Cycloheximide	18-31	factor interacting with PAPOLA and CPSF1	Homo sapiens	145-151
18590050-0	2008	Mammalian Rrn3 is required for the formation of a transcription competent preinitiation complex containing RNA polymerase I. Mammalian Rrn3, an essential, polymerase-associated protein, is inactivated when cells are treated with cycloheximide, resulting in the inhibition of transcription by RNA polymerase I.	Cycloheximide	229-242	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	10-14
18590050-0	2008	Mammalian Rrn3 is required for the formation of a transcription competent preinitiation complex containing RNA polymerase I. Mammalian Rrn3, an essential, polymerase-associated protein, is inactivated when cells are treated with cycloheximide, resulting in the inhibition of transcription by RNA polymerase I.	Cycloheximide	229-242	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	135-139
18281744-5	2007	Basal mRNA levels of PPAR-alpha and PGC-1alpha were significantly suppressed upon 20 h treatment with cycloheximide, while those of PPAR-gamma1, -gamma2, and PGC-1beta were elevated.	Cycloheximide	102-115	peroxisome proliferator activated receptor alpha	Homo sapiens	21-31
17977970-8	2008	Stress causes A3A, A3B, A3C, and A3F to colocalize efficiently with Vif(IIIB) and mRNA-PABP1 complexes in stress granules in a manner that is prevented by cycloheximide, an inhibitor of translational elongation.	Cycloheximide	155-168	Vif	Human immunodeficiency virus 1	72-76
17977970-8	2008	Stress causes A3A, A3B, A3C, and A3F to colocalize efficiently with Vif(IIIB) and mRNA-PABP1 complexes in stress granules in a manner that is prevented by cycloheximide, an inhibitor of translational elongation.	Cycloheximide	155-168	poly(A) binding protein cytoplasmic 1 pseudogene 1	Homo sapiens	87-92
18234961-4	2008	The cycloheximide-induced sensitization to Fas-induced apoptosis is associated with a rapid down-regulation of Mcl-1 protein levels, but not that of Bcl-2 or Bcl-xL.	Cycloheximide	4-17	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	111-116
18234969-6	2008	Tyr(845) and Tyr(1068) phosphorylation, in response to HGF, was inhibited by cycloheximide and actinomycin D, consistent with a requirement for DNA transcription and RNA translation.	Cycloheximide	77-90	hepatocyte growth factor	Homo sapiens	55-58
18479958-5	2008	Moreover, galectin-1 increased glucose transporter-1 mRNA and protein expression levels, which were inhibited by a disruption in transcription by actinomycin D and translation by the cycloheximide.	Cycloheximide	183-196	galectin 1	Homo sapiens	10-20
17711404-4	2007	In the present study we show that Cidea is a short-lived protein as measured by cycloheximide-based protein chase experiments in different cell lines or in differentiated brown adipocytes.	Cycloheximide	80-93	cell death inducing DFFA like effector a	Homo sapiens	34-39
18281744-5	2007	Basal mRNA levels of PPAR-alpha and PGC-1alpha were significantly suppressed upon 20 h treatment with cycloheximide, while those of PPAR-gamma1, -gamma2, and PGC-1beta were elevated.	Cycloheximide	102-115	PPARG coactivator 1 alpha	Homo sapiens	36-46
18202547-5	2007	Furthermore, the half-life of AR protein was approximately 4 h in resveratrol-treated AR-positive prostate cancer LNCaP cells, compared to approximately 13 h in control cells, as determined by cycloheximide chase.	Cycloheximide	193-206	androgen receptor	Homo sapiens	30-32
18281744-5	2007	Basal mRNA levels of PPAR-alpha and PGC-1alpha were significantly suppressed upon 20 h treatment with cycloheximide, while those of PPAR-gamma1, -gamma2, and PGC-1beta were elevated.	Cycloheximide	102-115	peroxisome proliferator activated receptor alpha	Homo sapiens	21-25
18281744-6	2007	Cycloheximide also significantly reduced DHEA-induced accumulation of PPAR-alpha, -gamma1, -gamma2, and PGC-1alpha mRNAs, demonstrating the dependence of the DHEA action on de novo protein synthesis.	Cycloheximide	0-13	peroxisome proliferator activated receptor alpha	Homo sapiens	70-98
18281744-6	2007	Cycloheximide also significantly reduced DHEA-induced accumulation of PPAR-alpha, -gamma1, -gamma2, and PGC-1alpha mRNAs, demonstrating the dependence of the DHEA action on de novo protein synthesis.	Cycloheximide	0-13	PPARG coactivator 1 alpha	Homo sapiens	104-114
18030348-7	2007	HeLa cells in which PRAS40 was knocked down were protected against induction of apoptosis by TNFalpha and cycloheximide.	Cycloheximide	106-119	AKT1 substrate 1	Homo sapiens	20-26
17976382-2	2007	Cycloheximide studies revealed a rapid turnover of Nrf3.	Cycloheximide	0-13	NFE2 like bZIP transcription factor 3	Homo sapiens	51-55
18065493-7	2007	We show that TRAIL activates the canonical caspase-dependent pathway, whereas treatment with cycloheximide increases the sensitivity of MG-63 cells to TRAIL and anti-DR5 and can also sensitize hPOB-tert cells to both agents.	Cycloheximide	93-106	TNF superfamily member 10	Homo sapiens	151-156
18065493-7	2007	We show that TRAIL activates the canonical caspase-dependent pathway, whereas treatment with cycloheximide increases the sensitivity of MG-63 cells to TRAIL and anti-DR5 and can also sensitize hPOB-tert cells to both agents.	Cycloheximide	93-106	TNF receptor superfamily member 10b	Homo sapiens	166-169
17937580-8	2007	Prevention of the homocysteine-induced UPR by cycloheximide pretreatment normalized GRP78 expression and ER-Ca(2+) emptying evoked by thapsigargin.	Cycloheximide	46-59	heat shock protein family A (Hsp70) member 5	Homo sapiens	84-89
17950288-2	2007	Apoptosis was induced with an anti-Fas/CD95 antibody in the presence of cycloheximide and no difference was observed between the two genotypes.	Cycloheximide	72-85	Fas cell surface death receptor	Homo sapiens	39-43
21783824-4	2007	Cycloheximide (CHX), an inhibitor of protein synthesis, abolished the DEP-induced effects on ERalpha mRNA expression.	Cycloheximide	0-13	estrogen receptor 1 (alpha)	Mus musculus	93-100
17974960-3	2007	Here, we investigated whether induction of c-Myc by OA or protein synthesis inhibitor cycloheximide contributed to HBC growth inhibition and the mechanisms involved.	Cycloheximide	86-99	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	43-48
17974960-5	2007	However, OA or cycloheximide treatments over 6 or 10 h, respectively, induced c-Myc expression.	Cycloheximide	15-28	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	78-83
17974960-6	2007	Depletion of c-Myc, on the other hand, resulted in enhanced HBC cell viabilities when exposed to OA or cycloheximide, but not by Taxol.	Cycloheximide	103-116	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	13-18
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	interleukin 10	Homo sapiens	27-32
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	interleukin 10	Homo sapiens	62-67
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	interleukin 10	Homo sapiens	62-67
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	Janus kinase 1	Homo sapiens	239-243
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	114-127	tyrosine kinase 2	Homo sapiens	248-252
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	interleukin 10	Homo sapiens	27-32
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	signal transducer and activator of transcription 3	Homo sapiens	41-46
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	interleukin 10	Homo sapiens	62-67
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	interleukin 10	Homo sapiens	62-67
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	Janus kinase 1	Homo sapiens	239-243
17948269-4	2007	Importantly, inhibition of IL-10-induced STAT3 activation and IL-10-suppressive action by a prolonged exposure to cycloheximide (CHX) was observed to occur also in human monocytes and was caused by a defective IL-10-mediated activation of Jak1 and Tyk2 kinases.	Cycloheximide	129-132	tyrosine kinase 2	Homo sapiens	248-252
17948269-5	2007	Taken together, our findings suggest that CHX interferes with the IL-10-mediated intracellular signaling pathway by interrupting events upstream of STAT3 activation.	Cycloheximide	42-45	interleukin 10	Homo sapiens	66-71
17948269-5	2007	Taken together, our findings suggest that CHX interferes with the IL-10-mediated intracellular signaling pathway by interrupting events upstream of STAT3 activation.	Cycloheximide	42-45	signal transducer and activator of transcription 3	Homo sapiens	148-153
21783824-4	2007	Cycloheximide (CHX), an inhibitor of protein synthesis, abolished the DEP-induced effects on ERalpha mRNA expression.	Cycloheximide	15-18	estrogen receptor 1 (alpha)	Mus musculus	93-100
17557191-1	2007	Previous study indicated that beta1,4-galactosyltransferase I (beta1,4GT1) was up-regulated by cycloheximide (CHX) and thus enhanced apoptosis induced by CHX in SMMC-7721 cells.	Cycloheximide	95-108	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	63-73
17804813-9	2007	Furthermore, inhibition of ATF-2 expression prevented the increased resistance of polyamine-deficient cells to apoptosis induced by treatment with tumor necrosis factor-alpha and cycloheximide.	Cycloheximide	179-192	activating transcription factor 2	Homo sapiens	27-32
17711853-5	2007	TIA-1-mediated decay is inhibited by cycloheximide and emetine, drugs that stabilize polysomes, but is unaffected by puromycin, a drug that disassembles polysomes.	Cycloheximide	37-50	TIA1 cytotoxic granule associated RNA binding protein	Homo sapiens	0-5
17627285-6	2007	Inhibition of p21(Cip1/Waf1) protein synthesis with cyclohexamide (CHX) or silencing of p21(Cip1/Waf1) with siRNA, prevented ceramide-mediated G(2) arrest and the late induction of apoptosis.	Cycloheximide	67-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	14-17
17627285-6	2007	Inhibition of p21(Cip1/Waf1) protein synthesis with cyclohexamide (CHX) or silencing of p21(Cip1/Waf1) with siRNA, prevented ceramide-mediated G(2) arrest and the late induction of apoptosis.	Cycloheximide	67-70	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-22
17609434-5	2007	Indeed, under this condition, ERalpha protein was rescued using the proteasome inhibitor MG132 in presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	142-155	estrogen receptor 1	Homo sapiens	30-37
17407140-6	2007	Cycloheximide (Chx) treatment and pulse-chase experiments revealed that overexpression of integrin beta1 prolonged the half-life of p27(Kip1) by inhibiting its degradation.	Cycloheximide	0-13	integrin subunit beta 1	Homo sapiens	90-104
17407140-6	2007	Cycloheximide (Chx) treatment and pulse-chase experiments revealed that overexpression of integrin beta1 prolonged the half-life of p27(Kip1) by inhibiting its degradation.	Cycloheximide	0-13	dynactin subunit 6	Homo sapiens	132-135
17407140-6	2007	Cycloheximide (Chx) treatment and pulse-chase experiments revealed that overexpression of integrin beta1 prolonged the half-life of p27(Kip1) by inhibiting its degradation.	Cycloheximide	15-18	integrin subunit beta 1	Homo sapiens	90-104
17407140-6	2007	Cycloheximide (Chx) treatment and pulse-chase experiments revealed that overexpression of integrin beta1 prolonged the half-life of p27(Kip1) by inhibiting its degradation.	Cycloheximide	15-18	dynactin subunit 6	Homo sapiens	132-135
17666392-4	2007	Accessibility of the fumarase nascent chain to TEV protease under such conditions was prevented by low cycloheximide concentrations, which impede translation.	Cycloheximide	103-116	fumarate hydratase	Homo sapiens	21-29
17516030-2	2007	Our previous study proved that CDK11(p58)-enhanced cycloheximide (CHX)-induced apoptosis in SMMC-7721 hepatocarcinoma cells.	Cycloheximide	51-64	cyclin dependent kinase 11B	Homo sapiens	31-36
17516030-2	2007	Our previous study proved that CDK11(p58)-enhanced cycloheximide (CHX)-induced apoptosis in SMMC-7721 hepatocarcinoma cells.	Cycloheximide	51-64	cyclin dependent kinase 11B	Homo sapiens	37-40
17516030-2	2007	Our previous study proved that CDK11(p58)-enhanced cycloheximide (CHX)-induced apoptosis in SMMC-7721 hepatocarcinoma cells.	Cycloheximide	66-69	cyclin dependent kinase 11B	Homo sapiens	31-36
17516030-2	2007	Our previous study proved that CDK11(p58)-enhanced cycloheximide (CHX)-induced apoptosis in SMMC-7721 hepatocarcinoma cells.	Cycloheximide	66-69	cyclin dependent kinase 11B	Homo sapiens	37-40
17557191-1	2007	Previous study indicated that beta1,4-galactosyltransferase I (beta1,4GT1) was up-regulated by cycloheximide (CHX) and thus enhanced apoptosis induced by CHX in SMMC-7721 cells.	Cycloheximide	110-113	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	63-73
17557191-3	2007	However, the two PI3K inhibitors LY294002 and wortmannin treatment up-regulated beta1,4GT1 through enhancing Sp1 protein expression and consequently increased CHX-induced SMMC-7721 cells apoptosis.	Cycloheximide	159-162	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	Homo sapiens	80-90
17671691-8	2007	Actinomycin D suppressed and cycloheximide augmented CXCL-8 mRNA which was induced by TNF-alpha or not.	Cycloheximide	29-42	C-X-C motif chemokine ligand 8	Homo sapiens	53-59
17652445-5	2007	Although inhibiting protein synthesis with cycloheximide prevented H(2)O(2) from elevating Nrf2 protein level, RNA synthesis inhibition with actinomycin D failed to do so.	Cycloheximide	43-56	NFE2 like bZIP transcription factor 2	Rattus norvegicus	91-95
17938269-2	2007	We previously showed that resistant malignant mesothelioma cells are sensitized to TRAIL-induced apoptosis by diverse toxic insults including chemotherapy, irradiation, or protein translation inhibitors such as cycloheximide.	Cycloheximide	211-224	TNF superfamily member 10	Homo sapiens	83-88
17635918-6	2007	Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification.	Cycloheximide	224-237	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	40-45
17635918-6	2007	Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification.	Cycloheximide	224-237	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
17635918-6	2007	Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification.	Cycloheximide	224-237	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	95-100
17584970-3	2007	The increase in TNF-alpha production was prevented by actinomycin D and cycloheximide, indicating transcriptional activation of TNF-alpha gene.	Cycloheximide	72-85	tumor necrosis factor	Homo sapiens	16-25
17584970-3	2007	The increase in TNF-alpha production was prevented by actinomycin D and cycloheximide, indicating transcriptional activation of TNF-alpha gene.	Cycloheximide	72-85	tumor necrosis factor	Homo sapiens	128-137
17624924-8	2007	Cycloheximide attenuated DHT-mediated repression of CHRM1, suggesting the requirement of new protein synthesis.	Cycloheximide	0-13	cholinergic receptor muscarinic 1	Homo sapiens	52-57
17613518-4	2007	In addition, we find that in comparison with KSR1(-/-) mouse embryonic fibroblasts expressing wild type KSR1 (WT-KSR1), cells expressing a cleavage-resistant KSR1 protein (DEVA-KSR1) exhibit reduced apoptotic signaling in response to tumor necrosis factor-alpha/cycloheximide treatment.	Cycloheximide	262-275	kinase suppressor of ras 1	Mus musculus	172-181
17673310-6	2007	The same treatment caused a rapid increase in PRL-1 expression levels in cultured cells which could be blocked by the protein translation inhibitor, cycloheximide.	Cycloheximide	149-162	protein tyrosine phosphatase 4A1	Homo sapiens	46-51
17671691-8	2007	Actinomycin D suppressed and cycloheximide augmented CXCL-8 mRNA which was induced by TNF-alpha or not.	Cycloheximide	29-42	tumor necrosis factor	Homo sapiens	86-95
17596302-9	2007	In BC-1, a primary effusion lymphoma cell line that is dually infected with EBV and KSHV, CHX blocked EBV BRLF1 lytic gene expression induced by TPA and sodium butyrate; KSHV ORF50 mRNA induced simultaneously in the same cells by the same inducing stimuli was resistant to CHX.	Cycloheximide	90-93	BRLF1	Human gammaherpesvirus 4	106-111
17683115-5	2007	Treatment with the phosphatidylinositol 3-kinase inhibitor (PI3K) wortmaninn, the mammalian target of rapamycin (mTOR) inhibitor rapamycin, and the translation inhibitor cycloheximide blocked the induction of COX-2 protein in response to mannan and PGN, whereas the transcriptional inhibitor actinomycin D did not show a significant effect.	Cycloheximide	170-183	prostaglandin-endoperoxide synthase 2	Homo sapiens	209-214
17596302-9	2007	In BC-1, a primary effusion lymphoma cell line that is dually infected with EBV and KSHV, CHX blocked EBV BRLF1 lytic gene expression induced by TPA and sodium butyrate; KSHV ORF50 mRNA induced simultaneously in the same cells by the same inducing stimuli was resistant to CHX.	Cycloheximide	90-93	ORF50	Human gammaherpesvirus 8	175-180
17673207-7	2007	However, cycloheximide treatment partially blocked the upregulation of IL-21iso mRNA in activated T cells while little affected the IL-21 mRNA expression suggesting that de novo protein synthesis is required for the full expression of IL-21iso transcript.	Cycloheximide	9-22	interleukin 21	Homo sapiens	71-76
17545210-8	2007	However, cycloheximide half-life assay reveals that cdc25A is actually stabilized in arsenite-treated cells.	Cycloheximide	9-22	cell division cycle 25A	Homo sapiens	52-58
17599832-4	2007	The upregulation of hKSR-2 is direct, as it occurs in the presence of cycloheximide, and occurs primarily at the transcriptional level, via activation of vitamin D receptor, which acts as a ligand-activated transcription factor.	Cycloheximide	70-83	kinase suppressor of ras 2	Homo sapiens	20-26
17537394-8	2007	Cycloheximide prevented the insulin-induced decrease of CNT2 mRNA, but had no effect on the CNT1 mRNA level.	Cycloheximide	0-13	solute carrier family 28 member 2	Rattus norvegicus	56-60
17599377-9	2007	Cotreatment of ZR-75 cells with TCDD plus the protein synthesis inhibitor cycloheximide for 6 h enhanced CYP1A1 expression in cells grown under hypoxia and normoxia.	Cycloheximide	74-87	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	105-111
17558433-12	2007	simvastatin (10 microM ) caused a rottlerin (1 microM)-sensitive (cycloheximide (10 microM)-insensitive) increase of PKC-delta protein expression.	Cycloheximide	66-79	protein kinase C delta	Homo sapiens	117-126
17550899-8	2007	Supporting this model, deletion of MGS1, the yeast homolog of WRNIP1, slows the rate of ubiquitin turnover, rendering yeast resistant to cycloheximide.	Cycloheximide	137-150	ssDNA-dependent ATPase MGS1	Saccharomyces cerevisiae S288C	35-39
17641050-5	2007	We found that cells overexpressing the anti-apoptotic protein Bcl-X(L) were resistant to LPS and cycloheximide-induced death and that the proapoptotic Bcl-2 protein Bid was cleaved following treatment with LPS.	Cycloheximide	97-110	BCL2 like 1	Homo sapiens	62-70
17641050-5	2007	We found that cells overexpressing the anti-apoptotic protein Bcl-X(L) were resistant to LPS and cycloheximide-induced death and that the proapoptotic Bcl-2 protein Bid was cleaved following treatment with LPS.	Cycloheximide	97-110	BH3 interacting domain death agonist	Homo sapiens	165-168
17576861-8	2007	Treatment with the protein synthesis inhibitor cycloheximide or RNA interference-mediated knockdown of the Upf1 protein resulted in the restoration of mutant mRNA to levels comparable to that of the wild-type minigene, suggesting that hERG nonsense mutations are subject to nonsense-mediated mRNA decay.	Cycloheximide	47-60	UPF1 RNA helicase and ATPase	Homo sapiens	107-111
17606337-7	2007	The metal-mediated induction of Cyp1a1 mRNA was further potentiated by the protein synthesis inhibitor, cycloheximide and the 26S proteasome inhibitor, MG-132, but completely inhibited by the RNA transcription inhibitor, actinomycin-D, implying a transcriptional regulation of the Cyp1a1 gene by the heavy metals.	Cycloheximide	104-117	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	32-38
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	108-121	caveolin 1	Homo sapiens	35-45
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	108-121	caveolin 1	Homo sapiens	166-176
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	108-121	caveolin 1	Homo sapiens	166-176
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	123-126	caveolin 1	Homo sapiens	35-45
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	123-126	caveolin 1	Homo sapiens	166-176
17537407-4	2007	The actions of glucocorticoid upon caveolin-1 appear indirect acting via intermediary genes as evidenced by cycloheximide (CHX) abolition of Dex-induced increases in caveolin-1 mRNA and by recombinant transfection studies using the caveolin-1 promoter cloned upstream of a reporter gene.	Cycloheximide	123-126	caveolin 1	Homo sapiens	166-176
17576861-8	2007	Treatment with the protein synthesis inhibitor cycloheximide or RNA interference-mediated knockdown of the Upf1 protein resulted in the restoration of mutant mRNA to levels comparable to that of the wild-type minigene, suggesting that hERG nonsense mutations are subject to nonsense-mediated mRNA decay.	Cycloheximide	47-60	ETS transcription factor ERG	Homo sapiens	235-239
17376892-6	2007	Treatment with cycloheximide during CD40 activation prevents up-regulation of those c-FLIP isoforms and sensitizes ALL cells toward CD95-mediated apoptosis.	Cycloheximide	15-28	CD40 molecule	Homo sapiens	36-40
17337591-6	2007	We have also demonstrated that the reduction of I(to) density induced by TNF-alpha was prevented by the selective inducible nitric oxide synthase (iNOS) inhibitor 1400-W, the protein synthesis inhibitor cycloheximide, the antioxidant tocopherol, and the superoxide dismutase mimetic manganese(III) tetrakis (4-benzoic acid) porphyrin.	Cycloheximide	203-216	tumor necrosis factor	Rattus norvegicus	73-82
17376892-6	2007	Treatment with cycloheximide during CD40 activation prevents up-regulation of those c-FLIP isoforms and sensitizes ALL cells toward CD95-mediated apoptosis.	Cycloheximide	15-28	CASP8 and FADD like apoptosis regulator	Homo sapiens	84-90
17376892-6	2007	Treatment with cycloheximide during CD40 activation prevents up-regulation of those c-FLIP isoforms and sensitizes ALL cells toward CD95-mediated apoptosis.	Cycloheximide	15-28	Fas cell surface death receptor	Homo sapiens	132-136
17446180-4	2007	In contrast, inhibition of protein synthesis by cycloheximide enhanced the NE induction of Dio2 expression, suggesting the involvement of a repressor protein.	Cycloheximide	48-61	iodothyronine deiodinase 2	Rattus norvegicus	91-95
17498698-5	2007	Intracerebroventricular injection of argatroban or cycloheximide, both of which prevent thrombin cytotoxicity in vitro, exhibited a significant neuroprotective effect against ICH-induced injury.	Cycloheximide	51-64	coagulation factor II	Rattus norvegicus	88-96
17488973-4	2007	We found that JAK2"s ability to protect mature GHR from rapid degradation measured in the presence of the protein synthesis inhibitor, cycloheximide, depended on the presence of GHR"s Box 1 element and the intact JAK2 FERM (band 4.1/Ezrin/Radixin/Moesin); domain, but not the kinase-like or kinase domains of JAK2.	Cycloheximide	135-148	Janus kinase 2	Homo sapiens	14-18
17606477-3	2007	Administration of recombinant human IL-8 induced a rapid, time-dependent increase in cyclin D1 expression in AIPC cells, a response attenuated by the translation inhibitor cycloheximide but not by the RNA synthesis inhibitor, actinomycin D.	Cycloheximide	172-185	C-X-C motif chemokine ligand 8	Homo sapiens	36-40
17592017-8	2007	Cycloheximide inhibited expression of E-cadherin at 2.8 mM glucose, but not at 16.7 mM, while depolymerization of actin by either cytochalasin B or latrunculin B increased surface E-cadherin at low glucose.	Cycloheximide	0-13	cadherin 1	Rattus norvegicus	38-48
17592017-8	2007	Cycloheximide inhibited expression of E-cadherin at 2.8 mM glucose, but not at 16.7 mM, while depolymerization of actin by either cytochalasin B or latrunculin B increased surface E-cadherin at low glucose.	Cycloheximide	0-13	cadherin 1	Rattus norvegicus	180-190
17488973-4	2007	We found that JAK2"s ability to protect mature GHR from rapid degradation measured in the presence of the protein synthesis inhibitor, cycloheximide, depended on the presence of GHR"s Box 1 element and the intact JAK2 FERM (band 4.1/Ezrin/Radixin/Moesin); domain, but not the kinase-like or kinase domains of JAK2.	Cycloheximide	135-148	growth hormone receptor	Homo sapiens	47-50
17606477-3	2007	Administration of recombinant human IL-8 induced a rapid, time-dependent increase in cyclin D1 expression in AIPC cells, a response attenuated by the translation inhibitor cycloheximide but not by the RNA synthesis inhibitor, actinomycin D.	Cycloheximide	172-185	cyclin D1	Homo sapiens	85-94
17488973-4	2007	We found that JAK2"s ability to protect mature GHR from rapid degradation measured in the presence of the protein synthesis inhibitor, cycloheximide, depended on the presence of GHR"s Box 1 element and the intact JAK2 FERM (band 4.1/Ezrin/Radixin/Moesin); domain, but not the kinase-like or kinase domains of JAK2.	Cycloheximide	135-148	growth hormone receptor	Homo sapiens	178-181
17488973-4	2007	We found that JAK2"s ability to protect mature GHR from rapid degradation measured in the presence of the protein synthesis inhibitor, cycloheximide, depended on the presence of GHR"s Box 1 element and the intact JAK2 FERM (band 4.1/Ezrin/Radixin/Moesin); domain, but not the kinase-like or kinase domains of JAK2.	Cycloheximide	135-148	erythrocyte membrane protein band 4.1	Homo sapiens	224-232
17257889-10	2007	The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	174-187	vascular endothelial growth factor A	Homo sapiens	25-29
17257889-10	2007	The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	174-187	vascular endothelial growth factor A	Homo sapiens	147-151
17360132-9	2007	Incubation of Caco2 cell lines with cycloheximide, a chemical inhibitor of translation that is known to inhibit also NMD, indicates that the apc mRNA isoform that includes exon 1A is degraded by NMD, thereby suggesting that regulated unproductive splicing and NMD degradation could modulate APC protein expression.	Cycloheximide	36-49	APC regulator of WNT signaling pathway	Homo sapiens	141-144
17257889-10	2007	The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	189-192	vascular endothelial growth factor A	Homo sapiens	25-29
17257889-10	2007	The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	189-192	vascular endothelial growth factor A	Homo sapiens	147-151
17360132-9	2007	Incubation of Caco2 cell lines with cycloheximide, a chemical inhibitor of translation that is known to inhibit also NMD, indicates that the apc mRNA isoform that includes exon 1A is degraded by NMD, thereby suggesting that regulated unproductive splicing and NMD degradation could modulate APC protein expression.	Cycloheximide	36-49	APC regulator of WNT signaling pathway	Homo sapiens	291-294
17400304-1	2007	Cycloheximide (CyX), a toxic antibiotic with a unique chemical structure generated by the actinomycete, Streptomyces griseus, has emerged as a primary focus of studies on mammalian bitter taste.	Cycloheximide	0-13	cycloheximide tasting	Mus musculus	15-18
17512555-5	2007	Cycloheximide pre-treatment indicated that FS and activin A expressions appear to be the direct target of BMP-2 and Dex signaling.	Cycloheximide	0-13	follistatin	Mus musculus	43-45
17512555-5	2007	Cycloheximide pre-treatment indicated that FS and activin A expressions appear to be the direct target of BMP-2 and Dex signaling.	Cycloheximide	0-13	inhibin subunit beta A	Rattus norvegicus	50-59
17512555-5	2007	Cycloheximide pre-treatment indicated that FS and activin A expressions appear to be the direct target of BMP-2 and Dex signaling.	Cycloheximide	0-13	bone morphogenetic protein 2	Mus musculus	106-111
17535899-7	2007	Mitochondria depleted of short-lived proteins by cycloheximide (CHX) become resistant to Bax-mediated cytochrome c release.	Cycloheximide	64-67	BCL2 associated X, apoptosis regulator	Homo sapiens	89-92
17535899-7	2007	Mitochondria depleted of short-lived proteins by cycloheximide (CHX) become resistant to Bax-mediated cytochrome c release.	Cycloheximide	64-67	cytochrome c, somatic	Homo sapiens	102-114
17295206-8	2007	Genistein plus zinc-induced increase in caspase-3 mRNA expression was completely inhibited in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB; 10(-6) M), an inhibitor of transcription activity.	Cycloheximide	110-123	caspase 3	Mus musculus	40-49
17311906-7	2007	Treatment of cells with cycloheximide, a protein synthesis inhibitor, revealed rapid turnover of Mcl-1.	Cycloheximide	24-37	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	97-102
17311906-8	2007	In addition, treatment with cycloheximide in the presence or absence of cisplatin demonstrated that cisplatin-induced loss of Mcl-1 results from posttranslational degradation rather than transcriptional inhibition.	Cycloheximide	28-41	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	126-131
17245642-4	2007	To identify the mediator(s) of this necrotic process, a protein synthesis inhibitor (cycloheximide; CHX; 0.33 microg/ml) was used to block cytochrome c release as well as PS exposure and mitochondrial membrane permeability transition pore (MMP) loss.	Cycloheximide	85-98	cytochrome c, somatic	Homo sapiens	139-151
17245642-4	2007	To identify the mediator(s) of this necrotic process, a protein synthesis inhibitor (cycloheximide; CHX; 0.33 microg/ml) was used to block cytochrome c release as well as PS exposure and mitochondrial membrane permeability transition pore (MMP) loss.	Cycloheximide	100-103	cytochrome c, somatic	Homo sapiens	139-151
17264307-9	2007	The effect of IL-4 on SOCS3 protein expression was increased markedly when the proteasome inhibitor MG132 was added to the cultures, but this was inhibited by cycloheximide, suggesting that SOCS3 is de novo-synthesized in response to IL-4.	Cycloheximide	159-172	interleukin 4	Homo sapiens	14-18
17429344-3	2007	Receptor-overexpressing cells were protected against peroxide-induced necrosis and tumor necrosis factor-alpha/cycloheximide-induced apoptosis.	Cycloheximide	111-124	tumor necrosis factor	Mus musculus	83-110
17253962-4	2007	We confirm that the mT2R5, hT2R43 and hT2R47 receptors respond selectively to micromolar concentrations of cycloheximide, aristolochic acid and denatonium respectively.	Cycloheximide	107-120	taste receptor, type 2, member 105	Mus musculus	20-25
17253962-4	2007	We confirm that the mT2R5, hT2R43 and hT2R47 receptors respond selectively to micromolar concentrations of cycloheximide, aristolochic acid and denatonium respectively.	Cycloheximide	107-120	taste 2 receptor member 43	Homo sapiens	27-33
17253962-4	2007	We confirm that the mT2R5, hT2R43 and hT2R47 receptors respond selectively to micromolar concentrations of cycloheximide, aristolochic acid and denatonium respectively.	Cycloheximide	107-120	taste 2 receptor member 30	Homo sapiens	38-44
17331500-5	2007	Stimulation of VEGF expression by TGF-beta2 was blocked by cycloheximide, suggesting that de novo protein synthesis is required.	Cycloheximide	59-72	vascular endothelial growth factor A	Homo sapiens	15-19
17331500-5	2007	Stimulation of VEGF expression by TGF-beta2 was blocked by cycloheximide, suggesting that de novo protein synthesis is required.	Cycloheximide	59-72	transforming growth factor beta 2	Homo sapiens	34-43
17389578-7	2007	Intracellular staining revealed little internal sequestration of CCR1 protein, and CCR1 up-regulation was inhibited by actinomycin D and cycloheximide, indicating that both waves of RSV-CM-induced surface CCR1 expression were dependent on de novo transcription and protein synthesis.	Cycloheximide	137-150	C-C motif chemokine receptor 1	Homo sapiens	83-87
17389578-7	2007	Intracellular staining revealed little internal sequestration of CCR1 protein, and CCR1 up-regulation was inhibited by actinomycin D and cycloheximide, indicating that both waves of RSV-CM-induced surface CCR1 expression were dependent on de novo transcription and protein synthesis.	Cycloheximide	137-150	C-C motif chemokine receptor 1	Homo sapiens	83-87
17146432-6	2007	The HIF-1alpha protein level remained up to 60 min in the presence of 6-MP when de novo protein synthesis was blocked by cycloheximide, suggesting that 6-MP induces stabilization of the HIF-1alpha protein.	Cycloheximide	121-134	hypoxia inducible factor 1 subunit alpha	Homo sapiens	4-14
17173074-4	2007	An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide.	Cycloheximide	140-153	E2F transcription factor 1	Homo sapiens	3-7
17173074-4	2007	An E2F1-estrogen receptor fusion protein activated the endogenous p57 promoter in response to hydroxytamoxifen treatment in the presence of cycloheximide.	Cycloheximide	140-153	cyclin dependent kinase inhibitor 1C	Homo sapiens	66-69
17264307-9	2007	The effect of IL-4 on SOCS3 protein expression was increased markedly when the proteasome inhibitor MG132 was added to the cultures, but this was inhibited by cycloheximide, suggesting that SOCS3 is de novo-synthesized in response to IL-4.	Cycloheximide	159-172	suppressor of cytokine signaling 3	Homo sapiens	22-27
17264307-9	2007	The effect of IL-4 on SOCS3 protein expression was increased markedly when the proteasome inhibitor MG132 was added to the cultures, but this was inhibited by cycloheximide, suggesting that SOCS3 is de novo-synthesized in response to IL-4.	Cycloheximide	159-172	suppressor of cytokine signaling 3	Homo sapiens	190-195
17264307-9	2007	The effect of IL-4 on SOCS3 protein expression was increased markedly when the proteasome inhibitor MG132 was added to the cultures, but this was inhibited by cycloheximide, suggesting that SOCS3 is de novo-synthesized in response to IL-4.	Cycloheximide	159-172	interleukin 4	Homo sapiens	234-238
17316563-0	2007	Internal genomic sequence of human CYP1A1 gene is involved in superinduction of dioxin-induced CYP1A1 transcription by cycloheximide.	Cycloheximide	119-132	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	35-41
17400819-5	2007	The half-life of the TPA-induced Noc mRNA is short, and the inhibition of protein synthesis by cycloheximide prevents Noc mRNA degradation and revealed a 30-fold increase in the transcript levels after 4 h of TPA treatment.	Cycloheximide	95-108	nocturnin	Mus musculus	118-121
17316563-0	2007	Internal genomic sequence of human CYP1A1 gene is involved in superinduction of dioxin-induced CYP1A1 transcription by cycloheximide.	Cycloheximide	119-132	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	95-101
17316563-1	2007	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces CYP1A1 mRNA expression, and co-treatment with the protein synthesis inhibitor, cycloheximide (CHX) magnifies its expression severalfold further.	Cycloheximide	130-143	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	51-57
17316563-3	2007	In the present study, we analyzed the influence of the CYP1A1 internal genomic sequence on CHX-mediated superinduction.	Cycloheximide	91-94	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	55-61
17209135-4	2007	The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126.	Cycloheximide	241-254	elastin	Homo sapiens	17-24
17209135-4	2007	The induction of elastin hnRNA and mRNA expression by TGF-beta was abolished by pretreatments with TGF-beta receptor I inhibitor, global transcription inhibitor actinomycin D, and partially blocked by addition of protein synthesis inhibitor cycloheximide, but was not affected by the p44/42 MAPK inhibitor U0126.	Cycloheximide	241-254	transforming growth factor beta 1	Homo sapiens	54-62
17286758-5	2007	Cycloheximide reduced the UVB-mediated induction of IL-8 by 30-40%, suggesting that new protein synthesis contributed to IL-8 production.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
17482685-6	2007	Indeed, a 4-hydroxytamoxifen activated E2F-1-ER fusion protein induced FOXO expression in the presence of cycloheximide.	Cycloheximide	106-119	E2F transcription factor 1	Rattus norvegicus	39-44
17286758-5	2007	Cycloheximide reduced the UVB-mediated induction of IL-8 by 30-40%, suggesting that new protein synthesis contributed to IL-8 production.	Cycloheximide	0-13	C-X-C motif chemokine ligand 8	Homo sapiens	121-125
17369404-5	2007	Third, TTP can nucleate PB formation on untranslated mRNAs even when other mRNAs are trapped in polysomes by cycloheximide treatment.	Cycloheximide	109-122	ZFP36 ring finger protein	Homo sapiens	7-10
17425429-11	2007	Quantitative analysis of apoptotic cells indicated that a considerable decrease in the apoptotic fraction of cells expressing GPCR, compared with the control cells, was detected after exposure to ActD and cycloheximide.	Cycloheximide	205-218	vomeronasal 1 receptor 17 pseudogene	Homo sapiens	126-130
17240354-3	2007	Pretreatment of cells with cycloheximide, a protein synthesis inhibitor, inhibited the induction of VEGF mRNA by HKLM.	Cycloheximide	27-40	vascular endothelial growth factor A	Mus musculus	100-104
17200126-4	2007	Caspase inhibition and overexpression of Bcl-x(L) blocked cycloheximide-induced apoptosis.	Cycloheximide	58-71	BCL2 like 1	Homo sapiens	41-46
17257628-7	2007	When protein synthesis was blocked by cycloheximide in LPS-activated J774 cells treated with OMA, iNOS protein levels, evaluated by Western blot analysis and (35)S-metabolic labelling, were decreased, suggesting that OMA reduces iNOS biosynthesis and induces an increase in the degradation rate of iNOS protein.	Cycloheximide	38-51	nitric oxide synthase 2, inducible	Mus musculus	98-102
17257628-7	2007	When protein synthesis was blocked by cycloheximide in LPS-activated J774 cells treated with OMA, iNOS protein levels, evaluated by Western blot analysis and (35)S-metabolic labelling, were decreased, suggesting that OMA reduces iNOS biosynthesis and induces an increase in the degradation rate of iNOS protein.	Cycloheximide	38-51	nitric oxide synthase 2, inducible	Mus musculus	229-233
17257628-7	2007	When protein synthesis was blocked by cycloheximide in LPS-activated J774 cells treated with OMA, iNOS protein levels, evaluated by Western blot analysis and (35)S-metabolic labelling, were decreased, suggesting that OMA reduces iNOS biosynthesis and induces an increase in the degradation rate of iNOS protein.	Cycloheximide	38-51	nitric oxide synthase 2, inducible	Mus musculus	229-233
17200126-5	2007	In addition, cycloheximide induced rapid activation of Bak and Bax, which required proteasome activity.	Cycloheximide	13-26	BCL2 antagonist/killer 1	Homo sapiens	55-58
17200126-5	2007	In addition, cycloheximide induced rapid activation of Bak and Bax, which required proteasome activity.	Cycloheximide	13-26	BCL2 associated X, apoptosis regulator	Homo sapiens	63-66
17200126-7	2007	Overexpression of Mcl-1 blocked apoptosis induced by cycloheximide, whereas RNA interference knockdown of Mcl-1 induced apoptosis.	Cycloheximide	53-66	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	18-23
17200126-8	2007	Knockdown of Bim and Bak, downstream targets of Mcl-1, inhibited cycloheximide-induced apoptosis, as did knockdown of Bax.	Cycloheximide	65-78	BCL2 antagonist/killer 1	Homo sapiens	21-24
17200126-8	2007	Knockdown of Bim and Bak, downstream targets of Mcl-1, inhibited cycloheximide-induced apoptosis, as did knockdown of Bax.	Cycloheximide	65-78	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-53
17164311-6	2007	Cycloheximide in cells transfected with luciferase reporter construct, 1.3 kb hNIS gene promoter, stimulated normalized luciferase expression, singly and synergistically with 5-azacytidine, in a dose-dependent, time course-dependent, cell type-specific, and promoter-specific fashion.	Cycloheximide	0-13	solute carrier family 5 member 5	Homo sapiens	78-82
17107344-6	2007	Furthermore, the decreasing effect of IEX-1 on S5a and S1 expression is still seen in the presence of cycloheximide, but not in the presence of actinomycin D, and quantitative real-time PCR revealed lower mRNA levels of S5a and S1 in IEX-1-overexpressing cells, suggesting an interference of IEX-1 with the gene transcription of S5a and S1.	Cycloheximide	102-115	immediate early response 3	Homo sapiens	38-43
17182689-6	2007	Previously, we reported that Nef treatment of primary human monocyte-derived macrophages (MDMs) induces a cycloheximide-independent activation of NF-kappaB and the synthesis and secretion of a set of chemokines/cytokines that activate STAT1 and STAT3.	Cycloheximide	106-119	S100 calcium binding protein B	Homo sapiens	29-32
16967517-8	2007	Pretreatment with a transcription inhibitor actinomycin D or translation inhibitor cycloheximide indicates that E(2) regulates uterine MMP-9 at multiple points, involving transcriptional and posttranscriptional control as well as modulation of inhibitor activities.	Cycloheximide	83-96	matrix metallopeptidase 9	Mus musculus	135-140
16985255-0	2007	Degradation of STAT5 proteins in 3T3-L1 adipocytes is induced by TNF-{alpha} and cycloheximide in a manner independent of STAT5A activation.	Cycloheximide	81-94	signal transducer and activator of transcription 5A	Homo sapiens	15-20
16985255-4	2007	In this study, we demonstrate that TNF-alpha treatment, in the presence of cycloheximide, also results in the rapid turnover of STAT5A and STAT5B in a process that is independent of STAT5 activation by tyrosine phosphorylation.	Cycloheximide	75-88	tumor necrosis factor	Homo sapiens	35-44
16985255-4	2007	In this study, we demonstrate that TNF-alpha treatment, in the presence of cycloheximide, also results in the rapid turnover of STAT5A and STAT5B in a process that is independent of STAT5 activation by tyrosine phosphorylation.	Cycloheximide	75-88	signal transducer and activator of transcription 5A	Homo sapiens	128-134
17435549-4	2007	Exposure of normal intestinal epithelial cells (IEC-6) to the conjugated bile salts taurodeoxycholate (TDCA) and taurochenodeoxycholate (TCDCA) resulted in an increase in resistance to tumor necrosis factor (TNF)-alpha and cycloheximide (CHX)-induced apoptosis, and NF-kappaB activation.	Cycloheximide	223-236	tumor necrosis factor	Homo sapiens	185-218
17435549-4	2007	Exposure of normal intestinal epithelial cells (IEC-6) to the conjugated bile salts taurodeoxycholate (TDCA) and taurochenodeoxycholate (TCDCA) resulted in an increase in resistance to tumor necrosis factor (TNF)-alpha and cycloheximide (CHX)-induced apoptosis, and NF-kappaB activation.	Cycloheximide	238-241	tumor necrosis factor	Homo sapiens	185-218
17266731-6	2007	When overexpressed from the P(GAL1) promoter, the two mutant alleles increased the sensitivity of wild-type cells to cycloheximide and fluconazole and suppressed drug resistance in gain-of-function pdr1 and pdr3 mutant strains.	Cycloheximide	117-130	galactokinase	Saccharomyces cerevisiae S288C	30-34
17266731-6	2007	When overexpressed from the P(GAL1) promoter, the two mutant alleles increased the sensitivity of wild-type cells to cycloheximide and fluconazole and suppressed drug resistance in gain-of-function pdr1 and pdr3 mutant strains.	Cycloheximide	117-130	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	198-202
17266731-6	2007	When overexpressed from the P(GAL1) promoter, the two mutant alleles increased the sensitivity of wild-type cells to cycloheximide and fluconazole and suppressed drug resistance in gain-of-function pdr1 and pdr3 mutant strains.	Cycloheximide	117-130	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	207-211
17304101-3	2007	Using the protein synthesis inhibitor cycloheximide and measuring the expression of CD35 in neutrophils stimulated with IFN-gamma and LPS alone or in combination, we could demonstrate that IFN-gamma enhances TLR4 by de novo protein synthesis, whereas the addition of LPS acts synergistically by enhancing vesicular mobilization to the cell surface.	Cycloheximide	38-51	interferon gamma	Homo sapiens	189-198
17304101-3	2007	Using the protein synthesis inhibitor cycloheximide and measuring the expression of CD35 in neutrophils stimulated with IFN-gamma and LPS alone or in combination, we could demonstrate that IFN-gamma enhances TLR4 by de novo protein synthesis, whereas the addition of LPS acts synergistically by enhancing vesicular mobilization to the cell surface.	Cycloheximide	38-51	toll like receptor 4	Homo sapiens	208-212
17174279-10	2007	The reduction in TH mRNA was blocked by cycloheximide consistent with a protein-dependent mechanism.	Cycloheximide	40-53	tyrosine hydroxylase	Rattus norvegicus	17-19
17140605-5	2007	Cycloheximide inhibited the increase in ATF5 mRNA expression induced by glutamine limitation, indicating that it was dependent on de novo protein synthesis.	Cycloheximide	0-13	activating transcription factor 5	Homo sapiens	40-44
16985255-4	2007	In this study, we demonstrate that TNF-alpha treatment, in the presence of cycloheximide, also results in the rapid turnover of STAT5A and STAT5B in a process that is independent of STAT5 activation by tyrosine phosphorylation.	Cycloheximide	75-88	signal transducer and activator of transcription 5B	Homo sapiens	139-145
16985255-4	2007	In this study, we demonstrate that TNF-alpha treatment, in the presence of cycloheximide, also results in the rapid turnover of STAT5A and STAT5B in a process that is independent of STAT5 activation by tyrosine phosphorylation.	Cycloheximide	75-88	signal transducer and activator of transcription 5A	Homo sapiens	128-133
16985255-6	2007	Initial characterization of the TNF-alpha and cycloheximide-mediated degradation of STAT5 indicates that inhibition of the proteasome stabilizes both forms of STAT5 in the presence of TNF-alpha.	Cycloheximide	46-59	signal transducer and activator of transcription 5A	Homo sapiens	84-89
16985255-6	2007	Initial characterization of the TNF-alpha and cycloheximide-mediated degradation of STAT5 indicates that inhibition of the proteasome stabilizes both forms of STAT5 in the presence of TNF-alpha.	Cycloheximide	46-59	signal transducer and activator of transcription 5A	Homo sapiens	159-164
16985255-6	2007	Initial characterization of the TNF-alpha and cycloheximide-mediated degradation of STAT5 indicates that inhibition of the proteasome stabilizes both forms of STAT5 in the presence of TNF-alpha.	Cycloheximide	46-59	tumor necrosis factor	Homo sapiens	184-193
16985255-7	2007	In addition, the use of an NF-kappaB inhibitor results in the stabilization of STAT5A in the presence of TNF-alpha and cycloheximide, indicating that the degradation of STAT5 proteins under these conditions may involve the NF-kappaB pathway.	Cycloheximide	119-132	signal transducer and activator of transcription 5A	Homo sapiens	79-85
16985255-7	2007	In addition, the use of an NF-kappaB inhibitor results in the stabilization of STAT5A in the presence of TNF-alpha and cycloheximide, indicating that the degradation of STAT5 proteins under these conditions may involve the NF-kappaB pathway.	Cycloheximide	119-132	signal transducer and activator of transcription 5A	Homo sapiens	79-84
17164311-8	2007	Cycloheximide also increased endogenous hNIS mRNA.	Cycloheximide	0-13	solute carrier family 5 member 5	Homo sapiens	40-44
17019530-3	2007	The susceptibility of NSP1 to proteasome degradation was fully reversed in a dose-dependent manner by transfection with the full complement of 11 molecules of translation-competent rotavirus mRNAs, but this effect was abrogated by the protein synthesis inhibitor cycloheximide.	Cycloheximide	263-276	SH2 domain containing 3A	Homo sapiens	22-26
17115938-6	2007	This suppressive effect of EGF on the sensitivity to NaHS was inhibited by cycloheximide, indicating that de novo protein synthesis was required for the suppression of H2S sensitivity.	Cycloheximide	75-88	epidermal growth factor	Homo sapiens	27-30
17082262-7	2007	The net effect contained, however, a component of glucose-induced folding load in the endoplasmic reticulum because coincubation with cycloheximide further amplified the effect of glucose on eIF2alpha dephosphorylation.	Cycloheximide	134-147	eukaryotic translation initiation factor 2A	Homo sapiens	191-200
16978838-6	2007	The mRNA level of MKP-1 is not affected by inhibition of p38, but the expression of MKP-1 is inhibited by treatment of cycloheximide.	Cycloheximide	119-132	dual specificity phosphatase 1	Homo sapiens	84-89
17259394-4	2007	Cycloheximide, but not actinomycin-D, abrogated increased laminin-beta1 synthesis.	Cycloheximide	0-13	laminin subunit beta 1	Homo sapiens	58-71
17283163-8	2007	FAS inhibitor-induced ER stress is activated prior to the detection of caspase 3 and PARP cleavage, primary indicators of cell death, whereas orlistat-induced cell death is rescued by coincubation with the global translation inhibitor cycloheximide.	Cycloheximide	235-248	fatty acid synthase	Homo sapiens	0-3
17283163-8	2007	FAS inhibitor-induced ER stress is activated prior to the detection of caspase 3 and PARP cleavage, primary indicators of cell death, whereas orlistat-induced cell death is rescued by coincubation with the global translation inhibitor cycloheximide.	Cycloheximide	235-248	collagen type XI alpha 2 chain	Homo sapiens	85-89
17178387-4	2007	Employing the protein biosynthesis inhibitor cycloheximide, we demonstrated the involvement of RNase and/or mRNA stabilization protein in ZAP-70, LAT and SLP-76 mRNAs stabilization.	Cycloheximide	45-58	zeta chain of T cell receptor associated protein kinase 70	Homo sapiens	138-144
16957816-5	2007	The lifespan of NMI is longer than 16 h as determined by cycloheximide translation block.	Cycloheximide	57-70	myosin IC	Homo sapiens	16-19
17178387-4	2007	Employing the protein biosynthesis inhibitor cycloheximide, we demonstrated the involvement of RNase and/or mRNA stabilization protein in ZAP-70, LAT and SLP-76 mRNAs stabilization.	Cycloheximide	45-58	linker for activation of T cells	Homo sapiens	146-149
17178387-4	2007	Employing the protein biosynthesis inhibitor cycloheximide, we demonstrated the involvement of RNase and/or mRNA stabilization protein in ZAP-70, LAT and SLP-76 mRNAs stabilization.	Cycloheximide	45-58	lymphocyte cytosolic protein 2	Homo sapiens	154-160
16924669-7	2007	This upregulation could be abrogated by pretreatment with the protein synthesis inhibitor cycloheximide, suggesting that the upregulation of syndecan-4 by FGF2 is not a primary response.	Cycloheximide	90-103	syndecan 4	Rattus norvegicus	141-151
16924669-7	2007	This upregulation could be abrogated by pretreatment with the protein synthesis inhibitor cycloheximide, suggesting that the upregulation of syndecan-4 by FGF2 is not a primary response.	Cycloheximide	90-103	fibroblast growth factor 2	Rattus norvegicus	155-159
16895520-8	2007	Using an endo-exocytosis assay we showed that, after histamine washed out, internalized AQP4 recycled back to the cell surface, even in cells in which de novo protein synthesis was inhibited by cycloheximide.	Cycloheximide	194-207	aquaporin 4	Homo sapiens	88-92
17085545-5	2007	Moreover, NEP activity, measured by hydrolysis of its synthetic substrate (Z-Ala-Ala-Leu-p-nitroanilide), showed a 2.4-fold increase in 5-h incubated versus 2-h incubated tissues, which was completely reversed by cycloheximide (CHX) treatment.	Cycloheximide	213-226	membrane metalloendopeptidase	Homo sapiens	10-13
17085545-5	2007	Moreover, NEP activity, measured by hydrolysis of its synthetic substrate (Z-Ala-Ala-Leu-p-nitroanilide), showed a 2.4-fold increase in 5-h incubated versus 2-h incubated tissues, which was completely reversed by cycloheximide (CHX) treatment.	Cycloheximide	228-231	membrane metalloendopeptidase	Homo sapiens	10-13
16989917-11	2007	Using drug inhibition analysis by a de novo protein synthesis inhibitor (cycloheximide) and a viral DNA replication inhibitor (cytosine arabinofuranoside), RGV DUT was classified as an early (E) viral gene during the in vitro infection.	Cycloheximide	73-86	deoxyuridine triphosphatase	Homo sapiens	160-163
17189831-5	2007	Nrf2 was rapidly degraded in cells treated with cycloheximide under static conditions, but shear stress decreased the rate of Nrf2 degradation.	Cycloheximide	48-61	NFE2 like bZIP transcription factor 2	Homo sapiens	0-4
16971495-7	2007	Chronic regulation (24 h) of NHE3 was blocked completely by prevention of protein synthesis with cycloheximide or actinomycin D and by the glucocorticoid receptor blocker RU486.	Cycloheximide	97-110	solute carrier family 9 member A3	Homo sapiens	29-33
17622750-15	2007	This increase in PPARgamma protein content was almost totally abolished in the presence of 1 microg/ml cycloheximide, but was only marginally reduced by 0.1 microg/ml actinomycin D.	Cycloheximide	103-116	peroxisome proliferator activated receptor gamma	Bos taurus	17-26
17158932-6	2007	SRC-3 shows a time-dependent decay in the presence of cycloheximide which is not apparent for the cytoplasmic mutant.	Cycloheximide	54-67	nuclear receptor coactivator 3	Homo sapiens	0-5
17110078-8	2007	Induction responses to the selenazolidines were also eliminated (most) or reduced (Txnrd1 by 2-methylSCA) by cycloheximide, with the exception of Ugt1a6.	Cycloheximide	109-122	thioredoxin reductase 1	Mus musculus	83-89
17110078-9	2007	The Ugt1a6 mRNA levels in the presence of SCAs and cycloheximide were similar to those with cycloheximide alone, and were almost double those of vehicle-treated cells.	Cycloheximide	51-64	UDP glucuronosyltransferase 1 family, polypeptide A6A	Mus musculus	4-10
17159355-8	2007	The effect of paricalcitol on THBS1 in SMC was blocked by cycloheximide, while its effect on TM and CYP24A1 was not affected, suggesting that the regulation of THBS1 by VDR may be mediated through intermediate factors, but that TM is likely a direct target of VDR.	Cycloheximide	58-71	thrombospondin 1	Homo sapiens	30-35
16949358-3	2007	Cycloheximide pretreatment indicated that Dex signaling immediately increases expressions of the C/EBPs and Dlx5, while expressions of the rest of the genes require de novo protein synthesis.	Cycloheximide	0-13	distal-less homeobox 5	Mus musculus	108-112
17067562-7	2007	Nuclear Stat3 phosphorylation induced by PGE2 is also suppressed by the translation and transcription inhibitors, cycloheximide and actinomycin D, respectively.	Cycloheximide	114-127	signal transducer and activator of transcription 3	Rattus norvegicus	8-13
16888780-5	2007	In the presence of cycloheximide, the selected SCCHN sublines become susceptible to CH-11 Ab, and showed cleavage of caspase-8, suggesting that apoptosis resistance was mediated by an inhibitory protein(s) acting upstream of caspase-8.	Cycloheximide	19-32	caspase 8	Homo sapiens	117-126
16888780-5	2007	In the presence of cycloheximide, the selected SCCHN sublines become susceptible to CH-11 Ab, and showed cleavage of caspase-8, suggesting that apoptosis resistance was mediated by an inhibitory protein(s) acting upstream of caspase-8.	Cycloheximide	19-32	caspase 8	Homo sapiens	225-234
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Cycloheximide	299-312	CD93 molecule	Homo sapiens	45-49
18094537-5	2007	In this study, we examined the modulation of CD93 expression on a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances : an RNA-synthesis inhibitor, actinomycin D (ActD); a DNA topoisomerase I inhibitor, camptothecin (CPT); a protein-synthesis inhibitor, cycloheximide (CHX); a DNA topoisomerase II inhibitor, etoposide (EPS); and a DNA-synthesis inhibitor, mitomycin C (MMC).	Cycloheximide	314-317	CD93 molecule	Homo sapiens	45-49
17097066-2	2006	The selected TRAIL-resistant cells were cross-resistant to TNF-alpha/cycloheximide but remained sensitive to DNA-damage drugs such as oxaliplatin and etoposide.	Cycloheximide	69-82	TNF superfamily member 10	Homo sapiens	13-18
17267405-5	2007	When overexpressed, GFP-Rpm2p does not impact the number and size of P bodies; however, it prevents their disappearance when translation elongation is inhibited by cycloheximide.	Cycloheximide	164-177	ribonuclease P	Saccharomyces cerevisiae S288C	24-29
17070518-6	2006	The inhibitory effect of 2-AP was not mediated by newly synthesized protein because the inhibitory effect of 2-AP on leptin-induced STAT3 activation was not abrogated in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	218-231	signal transducer and activator of transcription 3	Homo sapiens	132-137
17210686-8	2007	The increase in NAT1 mRNA was attenuated by concurrent cycloheximide treatment, suggesting that the effect of R1881 may not be by direct transcriptional activation of NAT1.	Cycloheximide	55-68	N-acetyltransferase 1	Homo sapiens	16-20
17375619-9	2007	Treatment with the chimeric ribozyme significantly reduced the CHX-induced peritoneal thickness, and expression of TGF-beta1, and fibronectin mRNA in peritoneal tissues.	Cycloheximide	63-66	fibronectin 1	Rattus norvegicus	130-141
17157182-5	2006	In the presence of cycloheximide, an inhibitor of protein synthesis, the rates of cell death and MnSOD degradation were accelerated.	Cycloheximide	19-32	superoxide dismutase 2	Homo sapiens	97-102
17050539-4	2006	Disruption of actin stress fibers using any of these redifferentiation stimuli also supported the superinduction of SOX9 by cycloheximide.	Cycloheximide	124-137	SRY-box transcription factor 9	Homo sapiens	116-120
17089002-12	2006	HT-29 cells treatment with actinomycin D or cycloheximide showed that the presence of PPARgamma mRNA including exon A2 was dependent on de novo protein synthesis.	Cycloheximide	44-57	peroxisome proliferator activated receptor gamma	Homo sapiens	86-95
17067731-8	2006	Furthermore, the CHX-treated animals exhibited a significant decrease of phosphorylated Akt/PKB (protein kinase B).	Cycloheximide	17-20	AKT serine/threonine kinase 1	Rattus norvegicus	88-95
17067731-9	2006	These results indicate that the protein synthesis inhibition by CHX induces the CHOP gene through a pathway similar to that of amino acid starvation, and that Akt/PKB inactivation enhances the CHOP-mediated hepatocellular apoptosis.	Cycloheximide	64-67	DNA-damage inducible transcript 3	Rattus norvegicus	80-84
17122584-9	2006	Cycloheximide, an inhibitor for protein synthesis, completely abrogated the induction of HIF-1alpha protein by isoflurane.	Cycloheximide	0-13	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-99
16931628-3	2006	To overcome this problem in vitro, specific NF-kappaB inhibitors or transcription or protein synthesis inhibitors such as actinomycin D and cycloheximide are usually used in combination to increase TNFalpha killing of tumor cells.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	198-206
17067731-2	2006	A previous study showed that the transcriptional level of CHOP was highly increased in rat liver in which hepatocellular apoptosis was induced by cycloheximide (CHX) treatment.	Cycloheximide	146-159	DNA-damage inducible transcript 3	Rattus norvegicus	58-62
17067731-2	2006	A previous study showed that the transcriptional level of CHOP was highly increased in rat liver in which hepatocellular apoptosis was induced by cycloheximide (CHX) treatment.	Cycloheximide	161-164	DNA-damage inducible transcript 3	Rattus norvegicus	58-62
17067731-3	2006	Here, we investigated the relationship between hepatocellular apoptosis and CHOP-mediated apoptotic pathway, and studied the mechanisms of induction of CHOP gene in the liver of rats treated with CHX.	Cycloheximide	196-199	DNA-damage inducible transcript 3	Rattus norvegicus	152-156
17067731-5	2006	In the gene expression assay using quantitative RT-PCR, the genes related to CHOP-mediated apoptosis such as the C/EBPbeta, ATF3 and ATF4 genes were significantly increased corresponding to the induction of hepatocellular apoptosis in rats treated with CHX.	Cycloheximide	253-256	DNA-damage inducible transcript 3	Rattus norvegicus	77-81
17067731-5	2006	In the gene expression assay using quantitative RT-PCR, the genes related to CHOP-mediated apoptosis such as the C/EBPbeta, ATF3 and ATF4 genes were significantly increased corresponding to the induction of hepatocellular apoptosis in rats treated with CHX.	Cycloheximide	253-256	CCAAT/enhancer binding protein beta	Rattus norvegicus	113-122
17067731-5	2006	In the gene expression assay using quantitative RT-PCR, the genes related to CHOP-mediated apoptosis such as the C/EBPbeta, ATF3 and ATF4 genes were significantly increased corresponding to the induction of hepatocellular apoptosis in rats treated with CHX.	Cycloheximide	253-256	activating transcription factor 3	Rattus norvegicus	124-128
17067731-5	2006	In the gene expression assay using quantitative RT-PCR, the genes related to CHOP-mediated apoptosis such as the C/EBPbeta, ATF3 and ATF4 genes were significantly increased corresponding to the induction of hepatocellular apoptosis in rats treated with CHX.	Cycloheximide	253-256	activating transcription factor 4	Rattus norvegicus	133-137
17067731-7	2006	Toxicoproteomics using two-dimensional difference gel electrophoresis and mass spectrometry indicated that GRP78/Bip was inactivated by the CHX treatment.	Cycloheximide	140-143	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	107-112
17067731-7	2006	Toxicoproteomics using two-dimensional difference gel electrophoresis and mass spectrometry indicated that GRP78/Bip was inactivated by the CHX treatment.	Cycloheximide	140-143	heat shock protein family A (Hsp70) member 5	Rattus norvegicus	113-116
17177854-3	2006	Furthermore, treatment with the translation inhibitor cycloheximide could show that entactin-2 is a primary response gene.	Cycloheximide	54-67	nidogen 2	Mus musculus	84-94
17172411-5	2006	Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis.	Cycloheximide	36-49	thymidylate synthetase	Homo sapiens	59-61
16971506-0	2006	Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	89-92
16971506-0	2006	Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	112-115
16971506-12	2006	These results suggest the possibility that kinases that phosphorylate p53 might be affected by CHX administration.	Cycloheximide	95-98	tumor protein p53	Homo sapiens	70-73
16817226-4	2006	Using the prostate cancer cell line LNCaP, Western blot analysis revealed a approximately twofold induction of NKX3.1 protein levels following tRA exposure, with sequential analysis of NKX3.1 protein levels in cycloheximide co-treated cells indicating that tRA does not alter NKX3.1 protein turnover.	Cycloheximide	210-223	NK3 homeobox 1	Homo sapiens	185-191
16817226-4	2006	Using the prostate cancer cell line LNCaP, Western blot analysis revealed a approximately twofold induction of NKX3.1 protein levels following tRA exposure, with sequential analysis of NKX3.1 protein levels in cycloheximide co-treated cells indicating that tRA does not alter NKX3.1 protein turnover.	Cycloheximide	210-223	NK3 homeobox 1	Homo sapiens	185-191
17172411-5	2006	Cotreatment with trichostatin A and cycloheximide restored TS mRNA expression, suggesting that TS mRNA is repressed through new protein synthesis.	Cycloheximide	36-49	thymidylate synthetase	Homo sapiens	95-97
17069807-2	2006	Using ECV304 cells, which can be made TNFalpha-sensitive by cycloheximide (CHX) co-treatment, we evaluated the potential roles of ceramide and phospholipase D (PLD) in TNFalpha-induced apoptosis.	Cycloheximide	60-73	tumor necrosis factor	Homo sapiens	38-46
17064399-6	2006	The effect of cycloheximide, a protein synthesis inhibitor, on RIG-I induction by these stimuli was examined.	Cycloheximide	14-27	DExD/H-box helicase 58	Homo sapiens	63-68
17082775-5	2006	Inhibition of the synthesis of putative trans imprinting factors with cycloheximide led to loss of IGF2 imprinting in normal cultured fibroblasts, suggesting that normal cells produce proteins that act in trans to induce or maintain genomic imprinting.	Cycloheximide	70-83	insulin like growth factor 2	Homo sapiens	99-103
17069807-2	2006	Using ECV304 cells, which can be made TNFalpha-sensitive by cycloheximide (CHX) co-treatment, we evaluated the potential roles of ceramide and phospholipase D (PLD) in TNFalpha-induced apoptosis.	Cycloheximide	75-78	tumor necrosis factor	Homo sapiens	38-46
17197193-11	2006	AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression.	Cycloheximide	47-60	cardiotrophin 1	Homo sapiens	69-73
16732322-5	2006	Further, the upregulation of KSR-1 gene by 1,25D is competed by ZK159222, an antagonist of vitamin D receptor (VDR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that the effect is direct.	Cycloheximide	185-198	kinase suppressor of ras 1	Homo sapiens	29-34
16732322-5	2006	Further, the upregulation of KSR-1 gene by 1,25D is competed by ZK159222, an antagonist of vitamin D receptor (VDR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that the effect is direct.	Cycloheximide	185-198	vitamin D receptor	Homo sapiens	91-109
16822952-5	2006	In CMVEC from mice and newborn pigs, 15 ng/ml TNF-alpha alone, or with 10 microg/ml cycloheximide (CHX) caused apoptosis detected by nuclear translocation of p65 NF-kappaB, caspase-3 activation, DNA fragmentation, cell-cell contact destabilization, and cell detachment.	Cycloheximide	84-97	tumor necrosis factor	Sus scrofa	46-55
16822952-5	2006	In CMVEC from mice and newborn pigs, 15 ng/ml TNF-alpha alone, or with 10 microg/ml cycloheximide (CHX) caused apoptosis detected by nuclear translocation of p65 NF-kappaB, caspase-3 activation, DNA fragmentation, cell-cell contact destabilization, and cell detachment.	Cycloheximide	84-97	caspase 3	Sus scrofa	173-182
16822952-5	2006	In CMVEC from mice and newborn pigs, 15 ng/ml TNF-alpha alone, or with 10 microg/ml cycloheximide (CHX) caused apoptosis detected by nuclear translocation of p65 NF-kappaB, caspase-3 activation, DNA fragmentation, cell-cell contact destabilization, and cell detachment.	Cycloheximide	99-102	tumor necrosis factor	Sus scrofa	46-55
16822952-5	2006	In CMVEC from mice and newborn pigs, 15 ng/ml TNF-alpha alone, or with 10 microg/ml cycloheximide (CHX) caused apoptosis detected by nuclear translocation of p65 NF-kappaB, caspase-3 activation, DNA fragmentation, cell-cell contact destabilization, and cell detachment.	Cycloheximide	99-102	caspase 3	Sus scrofa	173-182
16895761-0	2006	Analysis of cycloheximide-induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide.	Cycloheximide	12-25	annexin A5	Homo sapiens	95-104
17029796-7	2006	Co-treatment of c-pc with 200 microg/ml cycloheximide (CHX), translation inhibitor, resulted in over accumulation of uPA mRNA.	Cycloheximide	40-53	plasminogen activator, urokinase	Homo sapiens	117-120
17029796-7	2006	Co-treatment of c-pc with 200 microg/ml cycloheximide (CHX), translation inhibitor, resulted in over accumulation of uPA mRNA.	Cycloheximide	55-58	plasminogen activator, urokinase	Homo sapiens	117-120
17197193-11	2006	AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression.	Cycloheximide	47-60	interleukin 6	Homo sapiens	82-86
17016628-5	2006	Furthermore, the doxorubicin-induced reduction of Nd1 mRNA expression in NIH3T3 cells was inhibited by treatment of these cells with cycloheximide.	Cycloheximide	133-146	NADH dehydrogenase 1, mitochondrial	Mus musculus	50-53
16887908-8	2006	The stimulatory effects of ghrelin on NPY gene expression were abolished in the presence of cycloheximide, which blocks translation, suggesting that de novo protein synthesis is required for ghrelin action.	Cycloheximide	92-105	ghrelin and obestatin prepropeptide	Rattus norvegicus	27-34
16887908-8	2006	The stimulatory effects of ghrelin on NPY gene expression were abolished in the presence of cycloheximide, which blocks translation, suggesting that de novo protein synthesis is required for ghrelin action.	Cycloheximide	92-105	neuropeptide Y	Rattus norvegicus	38-41
16887908-8	2006	The stimulatory effects of ghrelin on NPY gene expression were abolished in the presence of cycloheximide, which blocks translation, suggesting that de novo protein synthesis is required for ghrelin action.	Cycloheximide	92-105	ghrelin and obestatin prepropeptide	Rattus norvegicus	191-198
16887909-8	2006	Indeed, early-night administration of a protein synthesis inhibitor (cycloheximide) markedly decreased AA-NAT mRNA levels in Syrian hamster.	Cycloheximide	69-82	serotonin N-acetyltransferase	Mesocricetus auratus	103-109
16887909-10	2006	Early-night administration of cycloheximide actually increased AA-NAT mRNA levels toward the late night.	Cycloheximide	30-43	aralkylamine N-acetyltransferase	Rattus norvegicus	63-69
17026526-4	2006	Real-time quantatitive PCR of transcripts in cycloheximide-treated cells showed that all five GR-responsive genes selected from the 1-h time point were primary responsive, whereas all four GR-responsive genes selected from the 3-h time point were downstream responsive.	Cycloheximide	45-58	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	94-96
17026526-4	2006	Real-time quantatitive PCR of transcripts in cycloheximide-treated cells showed that all five GR-responsive genes selected from the 1-h time point were primary responsive, whereas all four GR-responsive genes selected from the 3-h time point were downstream responsive.	Cycloheximide	45-58	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	189-191
17042977-9	2006	Flow cytometry was used to detect apoptotic cells in the HO-1 group and in the control group after induction by recombinant human tumor necrosis factor-alpha (rTNFalpha) and cycloheximide (CHX) for 48 hours.	Cycloheximide	174-187	heme oxygenase 1	Homo sapiens	57-61
16891117-5	2006	Western blot analysis confirmed the presence of activated caspase-3 in the liver and spleen of cycloheximide-treated animals.	Cycloheximide	95-108	caspase 3	Rattus norvegicus	58-67
17018608-8	2006	The induction of ADAM9 by stress can be inhibited by both actinomycin D and cycloheximide through increased gene transcription and protein synthesis.	Cycloheximide	76-89	ADAM metallopeptidase domain 9	Homo sapiens	17-22
17014691-7	2006	In fact, a protein(s) transcribed, later on, as shown by cycloheximide, was responsible for the reversal of the inhibition of Aa-nat transcription.	Cycloheximide	57-70	aralkylamine N-acetyltransferase	Rattus norvegicus	126-132
16814338-9	2006	In the absence of H(2)O(2), BE induces ERKs protein phosphorylation, and HO-1 protein expression induced by BE was blocked by the addition of cycloheximide, actinomycin D, and the ERK inhibitor PD98059.	Cycloheximide	142-155	heme oxygenase 1	Rattus norvegicus	73-77
16814338-9	2006	In the absence of H(2)O(2), BE induces ERKs protein phosphorylation, and HO-1 protein expression induced by BE was blocked by the addition of cycloheximide, actinomycin D, and the ERK inhibitor PD98059.	Cycloheximide	142-155	Eph receptor B1	Rattus norvegicus	39-42
16612578-11	2006	Injection of inhibitor of protein synthesis (Cycloheximide), if administered simultaneously with postconditioning, suppressed beneficial effect of postconditioning and resulted in 50% of CA1 neurons succumbing to neurodegeneration.	Cycloheximide	45-58	carbonic anhydrase 1	Rattus norvegicus	187-190
16612578-12	2006	Although, when Cycloheximide was injected 5 h after postconditioning, this treatment resulted in survival of 90% of CA1 neurons.	Cycloheximide	15-28	carbonic anhydrase 1	Rattus norvegicus	116-119
16786197-1	2006	Our previous studies have shown that overexpression of beta1,4-galactosyltransferase1 (beta1,4GT1) leads to increased apoptosis induced by cycloheximide (CHX) in SMMC-7721 human hepatocarcinoma cells.	Cycloheximide	139-152	beta-1,4-galactosyltransferase 1	Homo sapiens	55-85
16786197-1	2006	Our previous studies have shown that overexpression of beta1,4-galactosyltransferase1 (beta1,4GT1) leads to increased apoptosis induced by cycloheximide (CHX) in SMMC-7721 human hepatocarcinoma cells.	Cycloheximide	139-152	beta-1,4-galactosyltransferase 1	Homo sapiens	87-97
16786197-1	2006	Our previous studies have shown that overexpression of beta1,4-galactosyltransferase1 (beta1,4GT1) leads to increased apoptosis induced by cycloheximide (CHX) in SMMC-7721 human hepatocarcinoma cells.	Cycloheximide	154-157	beta-1,4-galactosyltransferase 1	Homo sapiens	55-85
16786197-1	2006	Our previous studies have shown that overexpression of beta1,4-galactosyltransferase1 (beta1,4GT1) leads to increased apoptosis induced by cycloheximide (CHX) in SMMC-7721 human hepatocarcinoma cells.	Cycloheximide	154-157	beta-1,4-galactosyltransferase 1	Homo sapiens	87-97
16887808-8	2006	For example arsenite, which inhibits 5"-cap-dependent translational initiation, shifted mRNA-A3G-PABP from polysomes into stress granules in a manner that was blocked and reversed by the elongation inhibitor cycloheximide.	Cycloheximide	208-221	apolipoprotein B mRNA editing enzyme catalytic subunit 3G	Homo sapiens	93-96
16925599-8	2006	ZmPPCK2, ZmPPCK3 and ZmPPCK4 are all induced by exposure of tissue to cycloheximide, whereas ZmPPCK1 is not.	Cycloheximide	70-83	phosphoenolpyruvate carboxylase kinase 2	Zea mays	0-7
16925599-8	2006	ZmPPCK2, ZmPPCK3 and ZmPPCK4 are all induced by exposure of tissue to cycloheximide, whereas ZmPPCK1 is not.	Cycloheximide	70-83	phosphoenolpyruvate carboxylase kinase 3	Zea mays	9-16
16925599-8	2006	ZmPPCK2, ZmPPCK3 and ZmPPCK4 are all induced by exposure of tissue to cycloheximide, whereas ZmPPCK1 is not.	Cycloheximide	70-83	phosphoenolpyruvate carboxylase kinase 4	Zea mays	21-28
17172033-4	2006	The effects of pyrrolidine dithiocarbamate (PDTC), an inhibitor of NF-kappaB and of cycloheximide (CHX), a protein synthase inhibitor, on the expression of iNOS and on the activation of NF-kappaB were also investigated in mouse macrophages treated with LAMPs.	Cycloheximide	99-102	nitric oxide synthase 2, inducible	Mus musculus	156-160
16887808-8	2006	For example arsenite, which inhibits 5"-cap-dependent translational initiation, shifted mRNA-A3G-PABP from polysomes into stress granules in a manner that was blocked and reversed by the elongation inhibitor cycloheximide.	Cycloheximide	208-221	poly(A) binding protein cytoplasmic 1	Homo sapiens	97-101
16705092-4	2006	Cycloheximide, actinomycin D, and antibodies against MIP-1alpha and monocyte chemoattractant protein-1 (MCP-1) abolished the stimulation of cell migration by TGF-beta1.	Cycloheximide	0-13	chemokine (C-C motif) ligand 2	Mus musculus	104-109
16876120-4	2006	Resistin gene expression was decreased by TZD in fully differentiated 3T3-L1 adipocytes, which was abolished after treatment of cycloheximide (a protein synthesis inhibitor).	Cycloheximide	128-141	resistin	Homo sapiens	0-8
16705092-4	2006	Cycloheximide, actinomycin D, and antibodies against MIP-1alpha and monocyte chemoattractant protein-1 (MCP-1) abolished the stimulation of cell migration by TGF-beta1.	Cycloheximide	0-13	transforming growth factor, beta 1	Mus musculus	158-167
16835229-4	2006	The results of nuclear run-off assay and cycloheximide treatment consistently indicated that ATDC5 cells acquire the capacity to synthesize BMP-2 mRNA in the nuclei during the differentiation process.	Cycloheximide	41-54	bone morphogenetic protein 2	Mus musculus	140-145
16899713-6	2006	FAK protein stability and mRNA expression were ascertained by cycloheximide decay, RT-PCR, and in situ hybridization in static and migrating Caco-2 cells.	Cycloheximide	62-75	protein tyrosine kinase 2	Homo sapiens	0-3
16951314-6	2006	As little as 1 ng/ml bryostatin-1 induced IFN-gamma and T-bet transcripts within 3 h and protein at 12 h. Treatment of DC with cycloheximide revealed that bryostatin-1-induced T-bet expression requires de novo protein synthesis, but bryostatin-1-induced IFN-gamma expression is independent of protein synthesis.	Cycloheximide	127-140	T-box transcription factor 21	Homo sapiens	176-181
16951370-5	2006	Moreover, IL-17A significantly induced eotaxin-1/CCL11 release and mRNA expression, an effect that was abrogated with cycloheximide and actinomycin D treatment.	Cycloheximide	118-131	interleukin 17A	Homo sapiens	10-16
16951370-5	2006	Moreover, IL-17A significantly induced eotaxin-1/CCL11 release and mRNA expression, an effect that was abrogated with cycloheximide and actinomycin D treatment.	Cycloheximide	118-131	C-C motif chemokine ligand 11	Homo sapiens	39-48
16951370-5	2006	Moreover, IL-17A significantly induced eotaxin-1/CCL11 release and mRNA expression, an effect that was abrogated with cycloheximide and actinomycin D treatment.	Cycloheximide	118-131	C-C motif chemokine ligand 11	Homo sapiens	49-54
16876795-2	2006	Spontaneous neutrophil apoptosis and Mcl-1 degradation were prevented by cyclic AMP (cAMP) agonists (dibutyryl cAMP and prostaglandin E(1)), and the effects of cAMP agonists on neutrophils were highly resistant to cycloheximide, a protein synthesis inhibitor, although slight increase in Mcl-1 mRNA expression was induced by cAMP agonists.	Cycloheximide	214-227	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	37-42
16940541-3	2006	Jurkat cell lines constitutively expressing M-T2 were generated and shown to be resistant to UV irradiation-, etoposide-, and cycloheximide-induced death.	Cycloheximide	126-139	M-T2	Myxoma virus	44-48
16325375-3	2006	Here, we report that overexpression of CKIP-1 in SK-BR-3 breast cancer cells prevents p53 degradation induced by cycloheximide treatment through increase of p53 N-terminal Ser-15 phosphorylation level.	Cycloheximide	113-126	pleckstrin homology domain containing O1	Homo sapiens	39-45
16325375-3	2006	Here, we report that overexpression of CKIP-1 in SK-BR-3 breast cancer cells prevents p53 degradation induced by cycloheximide treatment through increase of p53 N-terminal Ser-15 phosphorylation level.	Cycloheximide	113-126	tumor protein p53	Homo sapiens	86-89
16325375-3	2006	Here, we report that overexpression of CKIP-1 in SK-BR-3 breast cancer cells prevents p53 degradation induced by cycloheximide treatment through increase of p53 N-terminal Ser-15 phosphorylation level.	Cycloheximide	113-126	tumor protein p53	Homo sapiens	157-160
16888033-6	2006	Bryo-1-induced up-regulation of IFN-gammaR2 mRNA levels is not dependent on de novo protein synthesis as shown by cell treatment with the protein-synthesis inhibitor cycloheximide.	Cycloheximide	166-179	interferon gamma receptor 2	Homo sapiens	32-43
16894473-6	2006	Cycloheximide treatment experiment revealed that the half-life of p27 protein was prolonged in integrin beta1A overexpressing cells, indicating that integrin beta(1A) inhibited the degradation of p27 protein.	Cycloheximide	0-13	interferon alpha inducible protein 27	Homo sapiens	66-69
16894473-6	2006	Cycloheximide treatment experiment revealed that the half-life of p27 protein was prolonged in integrin beta1A overexpressing cells, indicating that integrin beta(1A) inhibited the degradation of p27 protein.	Cycloheximide	0-13	interferon alpha inducible protein 27	Homo sapiens	196-199
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	12-25	vascular endothelial growth factor A	Homo sapiens	77-81
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	12-25	bone morphogenetic protein 4	Homo sapiens	116-121
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	12-25	bone morphogenetic protein 4	Homo sapiens	143-148
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	12-25	vascular endothelial growth factor A	Homo sapiens	170-174
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	27-30	vascular endothelial growth factor A	Homo sapiens	77-81
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	27-30	bone morphogenetic protein 4	Homo sapiens	116-121
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	27-30	bone morphogenetic protein 4	Homo sapiens	143-148
16514669-8	2006	Addition of cycloheximide (CHX) or actinomycin-D (ACT) significantly reduced VEGF secretion from cells treated with BMP-4, suggesting that the BMP-4-induced secretion of VEGF requires new RNA and protein synthesis.	Cycloheximide	27-30	vascular endothelial growth factor A	Homo sapiens	170-174
16777145-5	2006	In control experiments, CHX (3 mg/kg) blocked c-Fos protein expression after foot-shock stress and impaired the acquisition of conditioned freezing but did not inhibit spontaneous locomotor activity and sucrose drinking.	Cycloheximide	24-27	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	46-51
16787409-0	2006	Cycloheximide treatment to identify components of the transitional transcriptome in PACAP-induced PC12 cell differentiation.	Cycloheximide	0-13	adenylate cyclase activating polypeptide 1	Rattus norvegicus	84-89
16480751-6	2006	Moreover, acrolein-mediated HO-1 induction is abrogated in the presence of actinomycin D and cycloheximide.	Cycloheximide	93-106	heme oxygenase 1	Homo sapiens	28-32
16495213-5	2006	The altered activity of NHE1 was consistent with an increase of both transcription and translation of the antiporter, as the utilization of actinomycin D and cycloheximide significantly inhibited the upregulation of NHE1 induced by serum withdrawal.	Cycloheximide	158-171	solute carrier family 9 member A1	Rattus norvegicus	24-28
16787641-5	2006	Up-regulation of caspase-3 protein was evident in manganese-treated PC12 cells and was moderate in cisplatin-, rotenone- and A23187-treated cells but was not observed in serum deprivation-, anisomycin-, camptothecin-, cycloheximide- or staurosporine-treated cells in which all treatments induced extensive DNA fragmentation.	Cycloheximide	218-231	caspase 3	Rattus norvegicus	17-26
16675490-4	2006	Pretreatment with a microinjection of actinomycin D or cycloheximide into bilateral RVLM significantly blunted this HSP60 increase, whereas real-time PCR showed progressive augmentation of hsp60 mRNA.	Cycloheximide	55-68	heat shock protein family D (Hsp60) member 1	Rattus norvegicus	116-121
16723184-2	2006	Experiments with cycloheximide suggested that Te repression of TSP1 was dependent on de novo protein synthesis.	Cycloheximide	17-30	thrombospondin 1	Mus musculus	63-67
16675452-10	2006	Pharmacologic inhibition of translation with cycloheximide attenuated Cited2 down-regulation by TGF-beta.	Cycloheximide	45-58	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	Homo sapiens	70-76
16675452-10	2006	Pharmacologic inhibition of translation with cycloheximide attenuated Cited2 down-regulation by TGF-beta.	Cycloheximide	45-58	transforming growth factor beta 1	Homo sapiens	96-104
16495213-5	2006	The altered activity of NHE1 was consistent with an increase of both transcription and translation of the antiporter, as the utilization of actinomycin D and cycloheximide significantly inhibited the upregulation of NHE1 induced by serum withdrawal.	Cycloheximide	158-171	solute carrier family 9 member A1	Rattus norvegicus	216-220
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	345-348	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	18-23
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	345-348	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	89-94
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	345-348	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	101-110
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	350-363	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	18-23
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	350-363	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	89-94
16551274-5	2006	The expression of TRPC1 induced by stable transfection of IEC-6 cells with the wild-type TRPC1 gene (IEC-TRPC1 cells) increased Ca2+ influx after Ca2+ store depletion and repressed NF-kappaB transactivation, which was associated with an increase in susceptibility to apoptosis induced by exposure to TNFalpha (tumour necrosis factor-alpha) plus CHX (cycloheximide) (TNF-alpha/CHX), or STS (staurosporine).	Cycloheximide	350-363	transient receptor potential cation channel, subfamily C, member 1	Rattus norvegicus	101-110
16761962-9	2006	On combined treatment, cycloheximide, AD and SCF displayed additive effects, resulting in a complete disappearance of c-Kit from the cell surface.	Cycloheximide	23-36	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	118-123
16549420-11	2006	The VEGF mRNA expression levels in the neutrophils were higher in the EPF, which was abrogated by cycloheximide, suggesting that the EPF induces the production of VEGF in neutrophils.	Cycloheximide	98-111	vascular endothelial growth factor A	Homo sapiens	4-8
16790802-6	2006	In contrast to intermediate inhibitory effects in nontreated neutrophils, T. gondii induced a complete blockade in LPS-induced surface TNF-alpha expression in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	207-220	tumor necrosis factor	Mus musculus	135-144
16837615-4	2006	In FSH-stimulated cells, the Cyp11a and Hsd17b1 mRNAs had half-lives greater than 12 h. The half-life of Cyp19 mRNA was significantly shorter at 3 h. The addition of the translation inhibitor cycloheximide to FSH-stimulated cells significantly increased Cyp19 mRNA half-life to approximately 12 h. Stimulation of cells with insulin resulted in Cyp19 mRNA half-life that was double (P&lt;0.05) that in FSH-stimulated cells.	Cycloheximide	192-205	cholesterol side-chain cleavage enzyme, mitochondrial	Bos taurus	29-35
16837615-4	2006	In FSH-stimulated cells, the Cyp11a and Hsd17b1 mRNAs had half-lives greater than 12 h. The half-life of Cyp19 mRNA was significantly shorter at 3 h. The addition of the translation inhibitor cycloheximide to FSH-stimulated cells significantly increased Cyp19 mRNA half-life to approximately 12 h. Stimulation of cells with insulin resulted in Cyp19 mRNA half-life that was double (P&lt;0.05) that in FSH-stimulated cells.	Cycloheximide	192-205	hydroxysteroid 17-beta dehydrogenase 1	Bos taurus	40-47
16837615-4	2006	In FSH-stimulated cells, the Cyp11a and Hsd17b1 mRNAs had half-lives greater than 12 h. The half-life of Cyp19 mRNA was significantly shorter at 3 h. The addition of the translation inhibitor cycloheximide to FSH-stimulated cells significantly increased Cyp19 mRNA half-life to approximately 12 h. Stimulation of cells with insulin resulted in Cyp19 mRNA half-life that was double (P&lt;0.05) that in FSH-stimulated cells.	Cycloheximide	192-205	aromatase	Bos taurus	105-110
16549420-11	2006	The VEGF mRNA expression levels in the neutrophils were higher in the EPF, which was abrogated by cycloheximide, suggesting that the EPF induces the production of VEGF in neutrophils.	Cycloheximide	98-111	heat shock protein family E (Hsp10) member 1	Homo sapiens	70-73
16549420-11	2006	The VEGF mRNA expression levels in the neutrophils were higher in the EPF, which was abrogated by cycloheximide, suggesting that the EPF induces the production of VEGF in neutrophils.	Cycloheximide	98-111	heat shock protein family E (Hsp10) member 1	Homo sapiens	133-136
16549420-11	2006	The VEGF mRNA expression levels in the neutrophils were higher in the EPF, which was abrogated by cycloheximide, suggesting that the EPF induces the production of VEGF in neutrophils.	Cycloheximide	98-111	vascular endothelial growth factor A	Homo sapiens	163-167
16720642-5	2006	Cytoplasmic p53 was still observed after the translation activities were blocked by cycloheximide.	Cycloheximide	84-97	tumor protein p53	Homo sapiens	12-15
16514055-6	2006	ATP-induced MMP-9 release was inhibited by the P2X(7) receptor antagonists periodate oxidized ATP and KN-62, or by calcium chelators, as well as by a loss-of-function polymorphism in the P2X(7) receptor, but not by brefeldin A, monensin, or cycloheximide, or by anti-tumor necrosis factor-alpha (TNF-alpha) or anti-interleukin-1beta (IL-1beta) monoclonal antibodies.	Cycloheximide	241-254	matrix metallopeptidase 9	Homo sapiens	12-17
16514055-6	2006	ATP-induced MMP-9 release was inhibited by the P2X(7) receptor antagonists periodate oxidized ATP and KN-62, or by calcium chelators, as well as by a loss-of-function polymorphism in the P2X(7) receptor, but not by brefeldin A, monensin, or cycloheximide, or by anti-tumor necrosis factor-alpha (TNF-alpha) or anti-interleukin-1beta (IL-1beta) monoclonal antibodies.	Cycloheximide	241-254	purinergic receptor P2X 7	Homo sapiens	187-202
16684952-7	2006	HGF was released in its cleaved mature form, and its secretion was completely inhibited in the presence of cycloheximide, indicating a de novo protein synthesis.	Cycloheximide	107-120	hepatocyte growth factor	Homo sapiens	0-3
16541418-8	2006	TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD).	Cycloheximide	95-108	transforming growth factor beta 1	Homo sapiens	0-9
16541418-8	2006	TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD).	Cycloheximide	95-108	C-X-C motif chemokine ligand 8	Homo sapiens	21-25
16541418-8	2006	TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD).	Cycloheximide	110-113	transforming growth factor beta 1	Homo sapiens	0-9
16541418-8	2006	TGF-beta1 stimulated IL-8 expression in dose- and time-dependent manners, which was blocked by cycloheximide (CHX) and actinomycin D (ActD).	Cycloheximide	110-113	C-X-C motif chemokine ligand 8	Homo sapiens	21-25
16464174-3	2006	Pretreatment with actinomycin D or cycloheximide blocked the up-regulation of the NHE3 mRNA by PMA, indicating that the increased level of NHE3 mRNA expression is regulated by transcriptional activation and is dependent on de novo protein synthesis.	Cycloheximide	35-48	solute carrier family 9 member A3	Homo sapiens	82-86
16464174-3	2006	Pretreatment with actinomycin D or cycloheximide blocked the up-regulation of the NHE3 mRNA by PMA, indicating that the increased level of NHE3 mRNA expression is regulated by transcriptional activation and is dependent on de novo protein synthesis.	Cycloheximide	35-48	solute carrier family 9 member A3	Homo sapiens	139-143
16644485-9	2006	Cycloheximide (that is known to activate JNK) enhanced COX-2 expression and its effect was inhibited by SP600125.	Cycloheximide	0-13	mitogen-activated protein kinase 8	Mus musculus	41-44
16704410-4	2006	The induction of heme oxygenase-1 in renal adenocarcinoma cells was blocked by actinomycin D and cycloheximide and was abolished by the phosphatidylinositol 3-kinase inhibitor, LY294002, but not by the inactive analog LY303511.	Cycloheximide	97-110	heme oxygenase 1	Mus musculus	17-33
16478887-6	2006	Plasminogen treatment also markedly reduced internucleosomal DNA fragmentation and reduced levels of active caspase 3, caspase 8, and caspase 9 induced by TNFalpha or by cycloheximide.	Cycloheximide	170-183	plasminogen	Homo sapiens	0-11
16478887-6	2006	Plasminogen treatment also markedly reduced internucleosomal DNA fragmentation and reduced levels of active caspase 3, caspase 8, and caspase 9 induced by TNFalpha or by cycloheximide.	Cycloheximide	170-183	caspase 3	Homo sapiens	108-117
16478887-6	2006	Plasminogen treatment also markedly reduced internucleosomal DNA fragmentation and reduced levels of active caspase 3, caspase 8, and caspase 9 induced by TNFalpha or by cycloheximide.	Cycloheximide	170-183	caspase 8	Homo sapiens	119-128
16478887-6	2006	Plasminogen treatment also markedly reduced internucleosomal DNA fragmentation and reduced levels of active caspase 3, caspase 8, and caspase 9 induced by TNFalpha or by cycloheximide.	Cycloheximide	170-183	caspase 9	Homo sapiens	134-143
16644485-9	2006	Cycloheximide (that is known to activate JNK) enhanced COX-2 expression and its effect was inhibited by SP600125.	Cycloheximide	0-13	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
16753025-13	2006	Pretreatment of MC3T3-E1 cells with cycloheximide showed that the induction of fgf-2 did not require new protein synthesis.	Cycloheximide	36-49	fibroblast growth factor 2	Mus musculus	79-84
16683918-3	2006	Here we use two techniques, biarsenical/tetracysteine (TC) labeling and release from a cycloheximide block, to follow the trafficking of newly synthesized HIV-1 Gag.	Cycloheximide	87-100	Pr55(Gag)	Human immunodeficiency virus 1	161-164
16378625-3	2006	Furthermore, EGCG-mediated HO-1 induction was abrogated in the presence of actinomycin D and cycloheximide, indicating that this upregulation of HO-1 occurred at the transcriptional level.	Cycloheximide	93-106	heme oxygenase 1	Homo sapiens	27-31
16647178-2	2006	Induction of HO-1 protein expression was detected in QUE- but not RUT- or QUI-treated C6 cells, and this was prevented by cycloheximide and actinomycin D.	Cycloheximide	122-135	heme oxygenase 1	Rattus norvegicus	13-17
16650837-6	2006	Inhibition of protein synthesis with cycloheximide resulted in NET disappearance rates from DFO-treated cells greatly exceeding the rate of loss from control cells.	Cycloheximide	37-50	solute carrier family 6 member 2	Rattus norvegicus	63-66
16595663-8	2006	HSS1 chromatin remodeling preceded detectable TNFSF6 mRNA accumulation and was blocked by cycloheximide that also prevented TNFSF6 transcription.	Cycloheximide	90-103	ER membrane protein complex subunit 10	Homo sapiens	0-4
16595663-8	2006	HSS1 chromatin remodeling preceded detectable TNFSF6 mRNA accumulation and was blocked by cycloheximide that also prevented TNFSF6 transcription.	Cycloheximide	90-103	Fas ligand	Homo sapiens	124-130
16405428-11	2006	Oxidized IkappaBalpha persisted intracellularly for up to 6 h. Reversion occurred in the presence of cycloheximide, but was prevented if thioredoxin reductase was inhibited, suggesting that it was due to endogenous methionine sulphoxide reductase activity.	Cycloheximide	101-114	NFKB inhibitor alpha	Homo sapiens	9-21
17147231-0	2006	[The effect of p38 on the cycloheximide-induced HL-60 cell death through mitochondria pathway].	Cycloheximide	26-39	mitogen-activated protein kinase 14	Homo sapiens	15-18
17147231-1	2006	OBJECTIVE: To study the effect of p38 on the cycloheximide (CHX)-induced HL-60 cell death through mitochondria pathway.	Cycloheximide	45-58	mitogen-activated protein kinase 14	Homo sapiens	34-37
17147231-1	2006	OBJECTIVE: To study the effect of p38 on the cycloheximide (CHX)-induced HL-60 cell death through mitochondria pathway.	Cycloheximide	60-63	mitogen-activated protein kinase 14	Homo sapiens	34-37
17147231-12	2006	CONCLUSION: CHX can induce HL-60 cell apoptosis and the cell mitochondria depolarization, and the latter was intensified by inhibition of the p38 pathway.	Cycloheximide	12-15	mitogen-activated protein kinase 14	Homo sapiens	142-145
17147231-13	2006	p38 pathway may related to the cell necrosis in the cycloheximide-induced HL-60 cell apoptosis model.	Cycloheximide	52-65	mitogen-activated protein kinase 14	Homo sapiens	0-3
16378625-3	2006	Furthermore, EGCG-mediated HO-1 induction was abrogated in the presence of actinomycin D and cycloheximide, indicating that this upregulation of HO-1 occurred at the transcriptional level.	Cycloheximide	93-106	heme oxygenase 1	Homo sapiens	145-149
16308312-6	2006	Actinomycin D and cycloheximide inhibited gallic acid-responsive PST-P mRNA expression, indicating that gallic acid is a requirement for transcription and de novo protein synthesis.	Cycloheximide	18-31	sulfotransferase family 1A member 1	Homo sapiens	65-68
16354757-4	2006	These stable WT-FAK-transfected IECs also exhibited increased resistance to apoptosis when they were exposed to TNF-alpha plus cycloheximide (TNF-alpha/CHX).	Cycloheximide	127-140	protein tyrosine kinase 2	Rattus norvegicus	16-19
16354757-4	2006	These stable WT-FAK-transfected IECs also exhibited increased resistance to apoptosis when they were exposed to TNF-alpha plus cycloheximide (TNF-alpha/CHX).	Cycloheximide	127-140	tumor necrosis factor	Rattus norvegicus	142-151
16410451-7	2006	Treatment of HEK-293 and BaF/3 cells with TNF-alpha in the presence of cycloheximide, induced apoptosis in both cases.	Cycloheximide	71-84	tumor necrosis factor	Mus musculus	42-51
16472834-6	2006	Pulse-chase and cycloheximide chase analyses demonstrated that this mediator enhanced unmyristylated Gag degradation.	Cycloheximide	16-29	Pr55(Gag)	Human immunodeficiency virus 1	101-104
16734383-10	2006	The Rac-GTP that increased after N-BP treatment was newly translated, cytoplasmic unprenylated protein, because it was not labeled with [(14)C] mevalonate, and the increase in Rac-GTP was prevented by cycloheximide.	Cycloheximide	201-214	thymoma viral proto-oncogene 1	Mus musculus	4-7
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	Cycloheximide	83-96	insulin	Homo sapiens	4-11
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	Cycloheximide	83-96	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	32-42
16469813-5	2006	Cycloheximide inhibited T(3)-induced SULT2A1 expression, suggesting that regulation was indirect.	Cycloheximide	0-13	sulfotransferase family 2A member 1	Homo sapiens	37-44
16691509-6	2006	Actinomycin D and cycloheximide, inhibitors of transcription and translation, respectively, inhibited PSL-induced tyrosinase activity and its protein expression showing decrease in melanogenesis, correspondingly.	Cycloheximide	18-31	tyrosinase	Mus musculus	114-124
16531089-12	2006	Cycloheximide was shown to inhibit the induction of GVBD and DHP production by IGF-I, b-insulin and HCG.	Cycloheximide	0-13	insulin like growth factor 1	Homo sapiens	79-84
16734383-10	2006	The Rac-GTP that increased after N-BP treatment was newly translated, cytoplasmic unprenylated protein, because it was not labeled with [(14)C] mevalonate, and the increase in Rac-GTP was prevented by cycloheximide.	Cycloheximide	201-214	thymoma viral proto-oncogene 1	Mus musculus	176-179
16719951-1	2006	We have shown that the assembly of lamin-associated polypeptide (LAP) 2beta was detected surrounding the chromatin mass around the time of extrusion of the second polar body (PB) in some fertilized oocytes, but not in most activated oocytes, by using A23187 and cycloheximide (CaA + CH).	Cycloheximide	262-275	thymopoietin	Bos taurus	35-75
16446372-2	2006	AhR-containing murine hepatoma 1c1c7 cultures underwent apoptosis following exposure to tumor necrosis factor-alpha (TNFalpha) + cycloheximide (CHX).	Cycloheximide	129-142	aryl-hydrocarbon receptor	Mus musculus	0-3
16883809-4	2006	With the application of actidione, the transformation rate of NO3(-)-N decreased continuously, and the synthesis of glucosamine was inhibited, while penicillin and streptomycin had no significant effects on them.	Cycloheximide	24-33	NBL1, DAN family BMP antagonist	Homo sapiens	62-65
16446372-2	2006	AhR-containing murine hepatoma 1c1c7 cultures underwent apoptosis following exposure to tumor necrosis factor-alpha (TNFalpha) + cycloheximide (CHX).	Cycloheximide	144-147	aryl-hydrocarbon receptor	Mus musculus	0-3
16585560-6	2006	Cycloheximide, a protein synthesis inhibitor, inhibited both the NO-induced increase in the catalase level and the cytoprotective effect of NO.	Cycloheximide	0-13	catalase	Mus musculus	92-100
16626937-6	2006	However when apoptosis was stimulated with cycloheximide, the schizophrenia group showed an attenuated caspase-3 response.	Cycloheximide	43-56	caspase 3	Homo sapiens	103-112
16325265-5	2006	However, blocking de novo protein synthesis by addition of cycloheximide significantly enhanced apoptosis of bovine endothelial cells by TNF-alpha, LOS or TNF-alpha and LOS in combination.	Cycloheximide	59-72	tumor necrosis factor	Bos taurus	137-146
16325265-5	2006	However, blocking de novo protein synthesis by addition of cycloheximide significantly enhanced apoptosis of bovine endothelial cells by TNF-alpha, LOS or TNF-alpha and LOS in combination.	Cycloheximide	59-72	tumor necrosis factor	Bos taurus	155-164
16704297-4	2006	Here, we demonstrated that the cell death promotion activity of MxA was caspase dependent when cell death was induced by UV irradiation or cycloheximide (CHX).	Cycloheximide	139-152	MX dynamin like GTPase 1	Homo sapiens	64-67
16299053-7	2006	The GSNO-induced increase in PDE4B mRNA levels was blocked by actinomycin D but augmented by cycloheximide.	Cycloheximide	93-106	phosphodiesterase 4B	Rattus norvegicus	29-34
16487927-5	2006	Overexpression of Monad in HEK293 cells potentiated apoptosis and caspase-3 activation induced by tumor necrosis factor-alpha and cycloheximide.	Cycloheximide	130-143	caspase 3	Homo sapiens	66-75
16704297-4	2006	Here, we demonstrated that the cell death promotion activity of MxA was caspase dependent when cell death was induced by UV irradiation or cycloheximide (CHX).	Cycloheximide	154-157	MX dynamin like GTPase 1	Homo sapiens	64-67
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	164-177	signal transducer and activator of transcription 1	Homo sapiens	46-53
16569452-3	2006	In BALB/3T3 cells treated with tumor necrosis factor (TNF)-alpha and cycloheximide, the down-shift in temperature from 37 degrees C to 32 degrees C increased the expression of Cirp and suppressed the apoptosis.	Cycloheximide	69-82	cold inducible RNA binding protein	Mus musculus	176-180
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	164-177	signal transducer and activator of transcription 1	Homo sapiens	222-229
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	164-177	interferon gamma	Homo sapiens	240-249
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	179-182	signal transducer and activator of transcription 1	Homo sapiens	46-53
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	179-182	signal transducer and activator of transcription 1	Homo sapiens	222-229
16581346-5	2006	Janus kinase (JAK)-induced phosphorylation of STAT1/3/6, which acts at translational regulation, seemed to be crucial because chemical inhibition of JAK as well as cycloheximide (CHX) abolished both the phosphorylation of STAT1/3/6 and the IFN-gamma-induced inhibitory effect.	Cycloheximide	179-182	interferon gamma	Homo sapiens	240-249
16426572-5	2006	Moreover, while both genes were up-regulated by TCDD in primary hepatocytes and HepG2 cells, the induction of CYP1A1 and CYP1A2 at the mRNA level was distinguishable, indicated by the marked differences in activation kinetics and the response to the protein synthesis inhibitors, anisomycin and cycloheximide.	Cycloheximide	295-308	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	110-116
16426572-5	2006	Moreover, while both genes were up-regulated by TCDD in primary hepatocytes and HepG2 cells, the induction of CYP1A1 and CYP1A2 at the mRNA level was distinguishable, indicated by the marked differences in activation kinetics and the response to the protein synthesis inhibitors, anisomycin and cycloheximide.	Cycloheximide	295-308	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	121-127
16595503-11	2006	Pretreatment with cycloheximide, a protein synthesis inhibitor, resulted in a marked reduction of L-(11)C-MET uptake and a slight reduction of D-(11)C-MET uptake into protein fractions, whereas no significant changes were detected with L- and D-(11)C-CMT and (18)F-FMT.	Cycloheximide	18-31	met proto-oncogene	Mus musculus	104-109
16595503-11	2006	Pretreatment with cycloheximide, a protein synthesis inhibitor, resulted in a marked reduction of L-(11)C-MET uptake and a slight reduction of D-(11)C-MET uptake into protein fractions, whereas no significant changes were detected with L- and D-(11)C-CMT and (18)F-FMT.	Cycloheximide	18-31	met proto-oncogene	Mus musculus	149-154
16452486-5	2006	Cycloheximide was found to stimulate XOR gene expression in differentiating HC11 mouse mammary epithelial cells.	Cycloheximide	0-13	xanthine dehydrogenase	Mus musculus	37-40
16452486-6	2006	Activation of XOR gene expression by both cycloheximide and inflammatory cytokines suggested that XOR may be regulated by stress-activated protein kinases, the MAPKs.	Cycloheximide	42-55	xanthine dehydrogenase	Mus musculus	14-17
16452486-6	2006	Activation of XOR gene expression by both cycloheximide and inflammatory cytokines suggested that XOR may be regulated by stress-activated protein kinases, the MAPKs.	Cycloheximide	42-55	xanthine dehydrogenase	Mus musculus	98-101
16452486-7	2006	We demonstrate here that XOR was induced in HC11 cells by low dose cycloheximide and that expression was blocked by inhibitors of p38 MAPK.	Cycloheximide	67-80	xanthine dehydrogenase	Mus musculus	25-28
16452486-8	2006	Accumulation of phospho-p38 was stimulated by low dose cycloheximide.	Cycloheximide	55-68	mitogen-activated protein kinase 14	Mus musculus	24-27
16452486-9	2006	Low dose cycloheximide stress promoted phosphorylation and nuclear accumulation of the CCAAT/enhancer-binding protein-beta (C/EBPbeta) transcription factor, which was blocked by inhibition of p38.	Cycloheximide	9-22	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	87-122
16452486-9	2006	Low dose cycloheximide stress promoted phosphorylation and nuclear accumulation of the CCAAT/enhancer-binding protein-beta (C/EBPbeta) transcription factor, which was blocked by inhibition of p38.	Cycloheximide	9-22	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	124-133
16452486-9	2006	Low dose cycloheximide stress promoted phosphorylation and nuclear accumulation of the CCAAT/enhancer-binding protein-beta (C/EBPbeta) transcription factor, which was blocked by inhibition of p38.	Cycloheximide	9-22	mitogen-activated protein kinase 14	Mus musculus	192-195
16452486-10	2006	Furthermore, C/EBPbeta was found to activate the mouse XOR promoter, and XOR promoter-C/EBPbeta protein complexes were induced by low dose cycloheximide stress.	Cycloheximide	139-152	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	13-22
16452486-10	2006	Furthermore, C/EBPbeta was found to activate the mouse XOR promoter, and XOR promoter-C/EBPbeta protein complexes were induced by low dose cycloheximide stress.	Cycloheximide	139-152	xanthine dehydrogenase	Mus musculus	55-58
16452486-10	2006	Furthermore, C/EBPbeta was found to activate the mouse XOR promoter, and XOR promoter-C/EBPbeta protein complexes were induced by low dose cycloheximide stress.	Cycloheximide	139-152	xanthine dehydrogenase	Mus musculus	73-76
16452486-10	2006	Furthermore, C/EBPbeta was found to activate the mouse XOR promoter, and XOR promoter-C/EBPbeta protein complexes were induced by low dose cycloheximide stress.	Cycloheximide	139-152	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	86-95
16479515-7	2006	CXCL-8 mRNA was superinduced by TNF- alpha in the presence of the protein-synthesis inhibitor cycloheximide.	Cycloheximide	94-107	C-X-C motif chemokine ligand 8	Homo sapiens	0-6
16479515-7	2006	CXCL-8 mRNA was superinduced by TNF- alpha in the presence of the protein-synthesis inhibitor cycloheximide.	Cycloheximide	94-107	tumor necrosis factor	Homo sapiens	32-42
16571380-5	2006	The increased SK-1 protein expression is due to stimulated de novo synthesis since cycloheximide inhibited the delayed SK-1 protein upregulation.	Cycloheximide	83-96	sphingosine kinase 1	Homo sapiens	14-18
16571380-5	2006	The increased SK-1 protein expression is due to stimulated de novo synthesis since cycloheximide inhibited the delayed SK-1 protein upregulation.	Cycloheximide	83-96	sphingosine kinase 1	Homo sapiens	119-123
16546987-8	2006	The Mcl-1 turnover was only induced by ssHHT and cycloheximide, but not by daunorubicin and cytosine arabinoside, and could be restored by proteasome inhibitors.	Cycloheximide	49-62	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	4-9
16487253-5	2006	PI-9 was stable for 48 h in the presence of cycloheximide, indicating slow protein turnover.	Cycloheximide	44-57	serpin family B member 9	Homo sapiens	0-4
16479012-7	2006	Actinomycin D, cycloheximide, succinylacetone, and dimethyl-oxalylglycine antagonize IRP2 degradation in response to both FAC and SNP, suggesting a common mechanistic basis.	Cycloheximide	15-28	iron responsive element binding protein 2	Homo sapiens	85-89
16152591-4	2006	The VEGF-D-expressing MCF-7 and MDA-MB-231 lines displayed resistance to apoptosis induced by hypoxia, staurosporin and cycloheximide.	Cycloheximide	120-133	vascular endothelial growth factor D	Homo sapiens	4-10
16754362-5	2006	Preincubation of cells with the protein synthesis inhibitor cycloheximide caused a six-fold decrease in Cx43 accumulation (as assessed by immunofluorescence) at the interfaces of chondrocytes in the aggregate.	Cycloheximide	60-73	gap junction protein alpha 1	Homo sapiens	104-108
16274708-7	2006	Moreover, this endotoxin-induced increase in UGT1A6 expression level was blocked by actinomycin D and cycloheximide, indicating the requirement for RNA and protein synthesis.	Cycloheximide	102-115	UDP glucuronosyltransferase family 1 member A6	Rattus norvegicus	45-51
16546965-8	2006	Pretreatment with cycloheximide showed that active caspase-3 fragments have a high turnover rate in OVCAR3 R350 cells.	Cycloheximide	18-31	caspase 3	Homo sapiens	51-60
16859513-6	2006	The effect of rapamycin on the degradation rate of Skp2 expression was examined in cycloheximide-treated cells and in relationship to the anaphase promoting complex/Cdh1 (APC\C) inhibitor Emi1.	Cycloheximide	83-96	S-phase kinase associated protein 2	Homo sapiens	51-55
16425129-4	2006	The effects of IL-7 and cycloheximide on IL-7R expression by peripheral blood mononuclear cells were examined in vitro.	Cycloheximide	24-37	interleukin 7 receptor	Homo sapiens	41-46
15961274-6	2006	Finally, our experiments utilizing cycloheximide prompt the suggestion that the stability of mRNA or protein also contributes to As2O3- or EGF-induced p21 expression.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	151-154
16330024-7	2006	Stimulation with TNF-alpha protected each cell type from apoptosis induced by TNF-alpha and cycloheximide.	Cycloheximide	92-105	tumor necrosis factor	Homo sapiens	17-26
16283438-7	2006	In contrast, induction of VEGF mRNA by IFNs was blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	91-104	vascular endothelial growth factor A	Homo sapiens	26-30
16283438-8	2006	Interestingly, cycloheximide also blocked IFN-induced activation of the p44/p42 mitogen-activated protein kinase, which was partially required for induction of VEGF by IFNs.	Cycloheximide	15-28	interferon induced protein 44	Homo sapiens	72-75
16283438-8	2006	Interestingly, cycloheximide also blocked IFN-induced activation of the p44/p42 mitogen-activated protein kinase, which was partially required for induction of VEGF by IFNs.	Cycloheximide	15-28	vascular endothelial growth factor A	Homo sapiens	160-164
16543731-5	2006	Actinomycin D and cycloheximide completely blocked the effect of EGF on 2-DG uptake.	Cycloheximide	18-31	epidermal growth factor	Mus musculus	65-68
16613777-6	2006	Cycloheximide (10 microg/ml) reduced Cx43 protein levels to 39% of vehicle (17 mM ethanol) whereas cotreatment of 10 microg/ml cycloheximide with 100 nM rotigaptide reduced Cx43 protein levels to 56% of vehicle.	Cycloheximide	0-13	gap junction protein, alpha 1	Rattus norvegicus	37-41
16613777-6	2006	Cycloheximide (10 microg/ml) reduced Cx43 protein levels to 39% of vehicle (17 mM ethanol) whereas cotreatment of 10 microg/ml cycloheximide with 100 nM rotigaptide reduced Cx43 protein levels to 56% of vehicle.	Cycloheximide	127-140	gap junction protein, alpha 1	Rattus norvegicus	173-177
16687308-5	2006	Interestingly, injection of the protein synthesis inhibitor cycloheximide before, but not after, the c-FOS/c-JUN peak markedly reduces Aanat mRNA levels.	Cycloheximide	60-73	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	101-106
16687308-5	2006	Interestingly, injection of the protein synthesis inhibitor cycloheximide before, but not after, the c-FOS/c-JUN peak markedly reduces Aanat mRNA levels.	Cycloheximide	60-73	aralkylamine N-acetyltransferase	Rattus norvegicus	135-140
16243960-5	2006	The protein synthesis inhibitor cycloheximide significantly inhibited metal-mediated induction of Nqo1 and Gst ya mRNAs, which coincided with a decrease in the nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression, implying the requirement of Nrf2 protein synthesis for the induction of these genes.	Cycloheximide	32-45	NAD(P)H dehydrogenase, quinone 1	Mus musculus	98-102
16243960-6	2006	Furthermore, inhibition of Nrf2 protein degradation by carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132), a 26S proteasome inhibitor, significantly reversed the cycloheximide-mediated inhibition of Nqo1 and Gst ya mRNAs, which coincided with an increase in the expression of Nrf2, confirming that a transcriptional mechanism is involved.	Cycloheximide	160-173	nuclear factor, erythroid derived 2, like 2	Mus musculus	27-31
16243960-5	2006	The protein synthesis inhibitor cycloheximide significantly inhibited metal-mediated induction of Nqo1 and Gst ya mRNAs, which coincided with a decrease in the nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression, implying the requirement of Nrf2 protein synthesis for the induction of these genes.	Cycloheximide	32-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	160-203
16243960-6	2006	Furthermore, inhibition of Nrf2 protein degradation by carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132), a 26S proteasome inhibitor, significantly reversed the cycloheximide-mediated inhibition of Nqo1 and Gst ya mRNAs, which coincided with an increase in the expression of Nrf2, confirming that a transcriptional mechanism is involved.	Cycloheximide	160-173	NAD(P)H dehydrogenase, quinone 1	Mus musculus	197-201
16243960-6	2006	Furthermore, inhibition of Nrf2 protein degradation by carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132), a 26S proteasome inhibitor, significantly reversed the cycloheximide-mediated inhibition of Nqo1 and Gst ya mRNAs, which coincided with an increase in the expression of Nrf2, confirming that a transcriptional mechanism is involved.	Cycloheximide	160-173	nuclear factor, erythroid derived 2, like 2	Mus musculus	274-278
16243960-5	2006	The protein synthesis inhibitor cycloheximide significantly inhibited metal-mediated induction of Nqo1 and Gst ya mRNAs, which coincided with a decrease in the nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression, implying the requirement of Nrf2 protein synthesis for the induction of these genes.	Cycloheximide	32-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	205-209
16243960-5	2006	The protein synthesis inhibitor cycloheximide significantly inhibited metal-mediated induction of Nqo1 and Gst ya mRNAs, which coincided with a decrease in the nuclear factor erythroid 2-related factor 2 (Nrf2) protein expression, implying the requirement of Nrf2 protein synthesis for the induction of these genes.	Cycloheximide	32-45	nuclear factor, erythroid derived 2, like 2	Mus musculus	259-263
16821709-3	2006	Upon short-term preconditioning, both Hsp90 inhibitors conferred cycloheximide-dependent thermal resistance to the yeast cultures, while upon long-term treatment the induction of thermotolerance was confined only to AAG.	Cycloheximide	65-78	Hsp90 family chaperone HSP82	Saccharomyces cerevisiae S288C	38-43
16354693-5	2006	We hypothesized that oxidative and electrophilic stresses induce the nuclear accumulation of Nrf2 by affecting the Keap1-mediated rapid turnover of Nrf2, since such accumulation was diminished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	228-241	NFE2 like bZIP transcription factor 2	Homo sapiens	93-97
16615093-2	2006	Here, we report inhibition of protein synthesis by cycloheximide (CHX) increases induction of Mt1 by approximately five-fold, a phenomenon designated as "superinduction."	Cycloheximide	51-64	metallothionein 1I, pseudogene	Homo sapiens	94-97
16615093-2	2006	Here, we report inhibition of protein synthesis by cycloheximide (CHX) increases induction of Mt1 by approximately five-fold, a phenomenon designated as "superinduction."	Cycloheximide	66-69	metallothionein 1I, pseudogene	Homo sapiens	94-97
16354693-5	2006	We hypothesized that oxidative and electrophilic stresses induce the nuclear accumulation of Nrf2 by affecting the Keap1-mediated rapid turnover of Nrf2, since such accumulation was diminished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	228-241	kelch like ECH associated protein 1	Homo sapiens	115-120
16354693-5	2006	We hypothesized that oxidative and electrophilic stresses induce the nuclear accumulation of Nrf2 by affecting the Keap1-mediated rapid turnover of Nrf2, since such accumulation was diminished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	228-241	NFE2 like bZIP transcription factor 2	Homo sapiens	148-152
16371233-9	2006	The effect of paricalcitol on suppressing PAI-1 in SMC was blocked by cycloheximide, suggesting that protein synthesis was involved.	Cycloheximide	70-83	serpin family E member 1	Homo sapiens	42-47
16388013-11	2006	However, levels of mRNA for PPARgamma were significantly increased in cells treated with cycloheximide (P &lt; 0.05, ANOVA followed by Tukey"s HSD).	Cycloheximide	89-102	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	28-37
16339571-9	2005	Pretreatment with either actinomycin D or cycloheximide abolished TNF-alpha-induced PTX3 expression, indicating the requirement for both transcriptional and translational regulation.	Cycloheximide	42-55	tumor necrosis factor	Homo sapiens	66-75
16302185-6	2005	The induction of gammaGT by TH was blocked by actinomycin D or cycloheximide.	Cycloheximide	63-76	gamma-glutamyltransferase 1	Rattus norvegicus	17-24
16251184-5	2005	The anti-apoptotic effect of Wnt3a was abrogated by inhibitors of canonical Wnt signaling, as well as by inhibitors of MEK, Src, phosphatidylinositol 3-kinase (PI3K), or Akt kinases, or by the addition of cycloheximide to the culture medium.	Cycloheximide	205-218	wingless-type MMTV integration site family, member 3A	Mus musculus	29-34
16251184-5	2005	The anti-apoptotic effect of Wnt3a was abrogated by inhibitors of canonical Wnt signaling, as well as by inhibitors of MEK, Src, phosphatidylinositol 3-kinase (PI3K), or Akt kinases, or by the addition of cycloheximide to the culture medium.	Cycloheximide	205-218	wingless-type MMTV integration site family, member 1	Mus musculus	29-32
16256938-5	2005	However, compared to the suppression of G6Pase expression seen by insulin, the decrease of G6Pase mRNA by LXR activation was delayed and was blocked by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	152-165	glucose-6-phosphatase catalytic subunit 1	Rattus norvegicus	91-97
16357160-7	2005	The translation inhibitor cycloheximide abrogated bortezomib-induced protein aggregation, caspase-4 processing, and all other characteristics of apoptosis.	Cycloheximide	26-39	caspase 4	Homo sapiens	90-99
16339571-9	2005	Pretreatment with either actinomycin D or cycloheximide abolished TNF-alpha-induced PTX3 expression, indicating the requirement for both transcriptional and translational regulation.	Cycloheximide	42-55	pentraxin 3	Homo sapiens	84-88
16204232-4	2005	In the presence of cycloheximide, endogenous apoA-I is substantially phospholipidated intracellularly but acquires some additional lipid after export out of the cell.	Cycloheximide	19-32	apolipoprotein A-I	Mus musculus	45-51
16020653-7	2005	In addition, using cotreatment with actinomycin D or cycloheximide, we observed that 1,25(OH)(2)D(3) regulation of FGF23 gene expression occurs at the transcriptional level, likely via the nuclear vitamin D receptor, and is dependent on synthesis of an intermediary transfactor.	Cycloheximide	53-66	fibroblast growth factor 23	Rattus norvegicus	115-120
16236272-4	2005	The stimulatory effect of NE on phosphorylated MKK3/6 and p38MAPK, but not phosphorylated p42/44MAPK, was blocked by treatment with actinomycin or cycloheximide, indicating a requirement of transcription and translation in activation of the p38MAPK but not the p42/44MAPK pathway.	Cycloheximide	147-160	mitogen activated protein kinase kinase 3	Rattus norvegicus	47-51
16051672-10	2005	To examine whether HIF-1alpha is directly induced, we used the translation inhibitor cycloheximide (CHX).	Cycloheximide	85-98	hypoxia inducible factor 1 subunit alpha	Homo sapiens	19-29
16146692-6	2005	Furthermore iNOS and COX-2 mRNA suppression by 22R-HC was diminished by cellular treatment with cycloheximide.	Cycloheximide	96-109	nitric oxide synthase 2	Homo sapiens	12-16
16146692-6	2005	Furthermore iNOS and COX-2 mRNA suppression by 22R-HC was diminished by cellular treatment with cycloheximide.	Cycloheximide	96-109	prostaglandin-endoperoxide synthase 2	Homo sapiens	21-26
16051672-10	2005	To examine whether HIF-1alpha is directly induced, we used the translation inhibitor cycloheximide (CHX).	Cycloheximide	100-103	hypoxia inducible factor 1 subunit alpha	Homo sapiens	19-29
16081639-9	2005	Cycloheximide chase experiments with metalloprotease, proteasome, and lysosome inhibitors indicated that the enhanced stability of mature GHR conferred by JAK2 is not related to effects on constitutive receptor metalloproteolysis but rather is a result of reduced constitutive endosomal/lysosomal degradation of the mature GHR.	Cycloheximide	0-13	growth hormone receptor	Homo sapiens	138-141
16151015-6	2005	The decay curve of SR-BI protein was markedly retarded in probucol-treated HepG2 cells in the presence of cycloheximide, indicating that probucol may stabilize human SR-BI protein.	Cycloheximide	106-119	scavenger receptor class B member 1	Homo sapiens	19-24
16099857-7	2005	This possibility was also supported by the finding that the inhibitory effect of c-lact on NE-induced aa-nat induction was markedly reduced by cycloheximide, a protein synthesis inhibitor.	Cycloheximide	143-156	aralkylamine N-acetyltransferase	Rattus norvegicus	102-108
16257643-6	2005	Inhibition of nascent protein synthesis by a translation inhibitor, cycloheximide, significantly reduced p22-phox mRNA stability in proliferating but not in confluent CMEC.	Cycloheximide	68-81	cytochrome b-245 alpha chain	Rattus norvegicus	105-113
15913957-5	2005	Treatment of NESK-transfected HeLa cells with TNF-alpha in the presence of cycloheximide or with staurosporine induced proteolytic cleavage of NESK.	Cycloheximide	75-88	Nik related kinase	Homo sapiens	13-17
15913957-5	2005	Treatment of NESK-transfected HeLa cells with TNF-alpha in the presence of cycloheximide or with staurosporine induced proteolytic cleavage of NESK.	Cycloheximide	75-88	tumor necrosis factor	Homo sapiens	46-55
15913957-5	2005	Treatment of NESK-transfected HeLa cells with TNF-alpha in the presence of cycloheximide or with staurosporine induced proteolytic cleavage of NESK.	Cycloheximide	75-88	Nik related kinase	Homo sapiens	143-147
16081639-9	2005	Cycloheximide chase experiments with metalloprotease, proteasome, and lysosome inhibitors indicated that the enhanced stability of mature GHR conferred by JAK2 is not related to effects on constitutive receptor metalloproteolysis but rather is a result of reduced constitutive endosomal/lysosomal degradation of the mature GHR.	Cycloheximide	0-13	Janus kinase 2	Homo sapiens	155-159
16264039-11	2005	Poly(IC)-induced upregulation of IL-4Ralpha was inhibited by treatment with cycloheximide or dexamethasone.	Cycloheximide	76-89	interleukin 4 receptor	Homo sapiens	33-43
16411808-5	2005	tTG mRNA expression levels were increased when apoptosis was induced by tumor necrosis factor-alpha in combination with cycloheximide or by culturing the cells in serum-free culture medium.	Cycloheximide	120-133	transglutaminase 2	Homo sapiens	0-3
16093525-6	2005	The protein synthesis inhibitor, cycloheximide, and 26S proteasome inhibitor, carbobenzoxy-L-leucyl-L-leucyl-leucinal (MG-132), super-induced the metal-mediated induction of Cyp1a1 mRNA.	Cycloheximide	33-46	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	174-180
16358735-6	2005	Treatment of the cells with transcription inhibitor actinomycin D (ActD) in the concentration completely inhibiting activity of DNA-dependent RNA polymerases I and II (RPI and RPII) leads to fast and practically full suppression of exchange GFP-TRF1 (10% of initial fluorescence is restored only) whereas an inhibitor of protein synthesis cycloheximide (CHD) has not effect.	Cycloheximide	339-352	TTAGGG repeat-binding factor 1	Cricetulus griseus	245-249
16234850-7	2005	We examined protein turnover of ALAS2 in the presence of cycloheximide in K562 cells.	Cycloheximide	57-70	5'-aminolevulinate synthase 2	Homo sapiens	32-37
16125142-6	2005	The aldosterone-induced osteopontin mRNA expression was completely blocked by a transcription inhibitor, actinomycin D, and a protein synthesis inhibitor, cycloheximide.	Cycloheximide	155-168	secreted phosphoprotein 1	Rattus norvegicus	24-35
16189006-5	2005	In addition, by Western blotting, U14 was detected at 0 hpi or in the presence of cycloheximide which completely abolished the expression of IE1 protein.	Cycloheximide	82-95	small nucleolar RNA, C/D box 14A	Homo sapiens	34-37
16087364-6	2005	Western blot analysis showed that CHX inhibited both ICAM-1 and ZO-1 expression in the basal cell line.	Cycloheximide	34-37	intercellular adhesion molecule 1	Homo sapiens	53-59
16099423-5	2005	Co-treatment with GA and cycloheximide (CHX), a protein synthesis inhibitor, induced a decrease of half-life of the Chk1 protein to 3h and resulted in Chk1 down-regulation.	Cycloheximide	25-38	checkpoint kinase 1	Homo sapiens	116-120
16099423-5	2005	Co-treatment with GA and cycloheximide (CHX), a protein synthesis inhibitor, induced a decrease of half-life of the Chk1 protein to 3h and resulted in Chk1 down-regulation.	Cycloheximide	25-38	checkpoint kinase 1	Homo sapiens	151-155
16099423-5	2005	Co-treatment with GA and cycloheximide (CHX), a protein synthesis inhibitor, induced a decrease of half-life of the Chk1 protein to 3h and resulted in Chk1 down-regulation.	Cycloheximide	40-43	checkpoint kinase 1	Homo sapiens	116-120
16099423-5	2005	Co-treatment with GA and cycloheximide (CHX), a protein synthesis inhibitor, induced a decrease of half-life of the Chk1 protein to 3h and resulted in Chk1 down-regulation.	Cycloheximide	40-43	checkpoint kinase 1	Homo sapiens	151-155
16135563-5	2005	Caspase activation and 5-LO degradation were blocked by the protein-synthesis inhibitor cycloheximide, and cell-permeable peptide inhibitors of casp-6 and casp-8 prevented 5-LO cleavage.	Cycloheximide	88-101	arachidonate 5-lipoxygenase	Homo sapiens	23-27
16135563-5	2005	Caspase activation and 5-LO degradation were blocked by the protein-synthesis inhibitor cycloheximide, and cell-permeable peptide inhibitors of casp-6 and casp-8 prevented 5-LO cleavage.	Cycloheximide	88-101	arachidonate 5-lipoxygenase	Homo sapiens	172-176
15863444-7	2005	Cycloheximide and actinomycin D abrogated IL-4- and IL-13-dependent CCL26 but not CCL24 secretion.	Cycloheximide	0-13	interleukin 4	Homo sapiens	42-57
15863444-7	2005	Cycloheximide and actinomycin D abrogated IL-4- and IL-13-dependent CCL26 but not CCL24 secretion.	Cycloheximide	0-13	C-C motif chemokine ligand 26	Homo sapiens	68-73
16014622-4	2005	The total turnover time of HAS3 was 4-5 h as judged by the green fluorescent protein signal decay and hyaluronan synthesis inhibition in cycloheximide-treated cells.	Cycloheximide	137-150	hyaluronan synthase 3	Homo sapiens	27-31
15814588-7	2005	Addition of cycloheximide blocked these increases and the downregulation of elastin mRNA by MG-132.	Cycloheximide	12-25	elastin	Homo sapiens	76-83
16087364-6	2005	Western blot analysis showed that CHX inhibited both ICAM-1 and ZO-1 expression in the basal cell line.	Cycloheximide	34-37	tight junction protein 1	Homo sapiens	64-68
16087364-8	2005	IL-4 and IL-13 potentiated CHX-induced apoptosis in basal cells but not in columnar cells, possibly due to low levels of the IL-4 receptor.	Cycloheximide	27-30	interleukin 4	Homo sapiens	0-4
16087364-8	2005	IL-4 and IL-13 potentiated CHX-induced apoptosis in basal cells but not in columnar cells, possibly due to low levels of the IL-4 receptor.	Cycloheximide	27-30	interleukin 13	Homo sapiens	9-14
16133866-8	2005	The most striking anti-apoptotic effect though was obtained by the translational inhibitor cycloheximide, which abolished caspase 8 processing, blocked Bid cleavage and maintained the mitochondrial transmembrane potential.	Cycloheximide	91-104	caspase 8	Homo sapiens	122-131
16350840-6	2005	The addition of protein synthesis inhibitor, cycloheximide (CHX), partially inhibits the induction of type X collagen and MMP-13 mRNA by RA.	Cycloheximide	45-58	matrix metallopeptidase 13	Mus musculus	102-128
16350840-6	2005	The addition of protein synthesis inhibitor, cycloheximide (CHX), partially inhibits the induction of type X collagen and MMP-13 mRNA by RA.	Cycloheximide	60-63	matrix metallopeptidase 13	Mus musculus	102-128
15946695-5	2005	Actinomycin D and cycloheximide completely blocked the effect of ANG II on 2-DG uptake.	Cycloheximide	18-31	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	65-68
16133866-8	2005	The most striking anti-apoptotic effect though was obtained by the translational inhibitor cycloheximide, which abolished caspase 8 processing, blocked Bid cleavage and maintained the mitochondrial transmembrane potential.	Cycloheximide	91-104	BH3 interacting domain death agonist	Homo sapiens	152-155
16034134-5	2005	We found that porcine EC incubated with IL-4 or IL-13, but not with IL-10 or IL-11, became protected from killing by complement and apoptosis induced by TNF-alpha plus cycloheximide.	Cycloheximide	168-181	interleukin 4	Homo sapiens	40-44
16034134-5	2005	We found that porcine EC incubated with IL-4 or IL-13, but not with IL-10 or IL-11, became protected from killing by complement and apoptosis induced by TNF-alpha plus cycloheximide.	Cycloheximide	168-181	interleukin 13	Homo sapiens	48-53
16085794-7	2005	The augmented IL-8 mRNA expression in cord blood was inhibited by actinomycin D but enhanced by cycloheximide, suggesting that IL-8 production is controlled by de novo transcriptional induction as well as posttranscriptional up-regulation of IL-8 by neonatal leukocytes, relating to the development of CLD.	Cycloheximide	96-109	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
15962305-6	2005	Using cycloheximide, we observed that cytoplasmic accumulation of hnRNP-K protein at later time points in the cell cycle occurred with a concomitant decrease in nuclear hnRNP-K protein, suggesting a translocation of nuclear hnRNP-K protein to the cytoplasm.	Cycloheximide	6-19	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	66-73
16033417-6	2005	Administration of cycloheximide blocked Abeta(25-35)-induced increase of DBI gene expression and endozepine accumulation in astrocytes, indicating that protein synthesis is required for DBI gene expression.	Cycloheximide	18-31	amyloid beta precursor protein	Rattus norvegicus	40-45
16033417-6	2005	Administration of cycloheximide blocked Abeta(25-35)-induced increase of DBI gene expression and endozepine accumulation in astrocytes, indicating that protein synthesis is required for DBI gene expression.	Cycloheximide	18-31	diazepam binding inhibitor	Rattus norvegicus	73-76
16033417-6	2005	Administration of cycloheximide blocked Abeta(25-35)-induced increase of DBI gene expression and endozepine accumulation in astrocytes, indicating that protein synthesis is required for DBI gene expression.	Cycloheximide	18-31	diazepam binding inhibitor	Rattus norvegicus	186-189
16085794-7	2005	The augmented IL-8 mRNA expression in cord blood was inhibited by actinomycin D but enhanced by cycloheximide, suggesting that IL-8 production is controlled by de novo transcriptional induction as well as posttranscriptional up-regulation of IL-8 by neonatal leukocytes, relating to the development of CLD.	Cycloheximide	96-109	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
16085794-7	2005	The augmented IL-8 mRNA expression in cord blood was inhibited by actinomycin D but enhanced by cycloheximide, suggesting that IL-8 production is controlled by de novo transcriptional induction as well as posttranscriptional up-regulation of IL-8 by neonatal leukocytes, relating to the development of CLD.	Cycloheximide	96-109	C-X-C motif chemokine ligand 8	Homo sapiens	127-131
16113838-8	2005	However, the induction of TF was abrogated by cycloheximide as well as actinomycin-D, inhibitors or protein- and mRNA-synthesis, respectively, demonstrating that EGF mediates its effect through activation of the TF gene.	Cycloheximide	46-59	coagulation factor III, tissue factor	Homo sapiens	26-28
16113838-8	2005	However, the induction of TF was abrogated by cycloheximide as well as actinomycin-D, inhibitors or protein- and mRNA-synthesis, respectively, demonstrating that EGF mediates its effect through activation of the TF gene.	Cycloheximide	46-59	epidermal growth factor	Homo sapiens	162-165
16113838-8	2005	However, the induction of TF was abrogated by cycloheximide as well as actinomycin-D, inhibitors or protein- and mRNA-synthesis, respectively, demonstrating that EGF mediates its effect through activation of the TF gene.	Cycloheximide	46-59	coagulation factor III, tissue factor	Homo sapiens	212-214
15856013-6	2005	Overexpression of c-IAP2 in normal human oral keratinocyte conferred resistance to tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX)-induced apoptosis, suggesting the increased c-IAP2 expression in HOK16E6E7 may protect the cells from TNF-alpha-mediated cell death.	Cycloheximide	123-136	baculoviral IAP repeat containing 3	Homo sapiens	18-24
15757501-7	2005	Up-regulation of PHGPx mRNA was attenuated by cycloheximide, a protein synthesis inhibitor, and this effect was cancelled by culturing the cells in the conditioned medium of the cultured casein-induced PMNs.	Cycloheximide	46-59	glutathione peroxidase 4	Rattus norvegicus	17-22
15757501-9	2005	Recombinant rat GRO could also induce the up-regulation in the presence of cycloheximide, demonstrating that GRO may play an important role in the PHGPx up-regulation of casein-induced PMNs.	Cycloheximide	75-88	C-X-C motif chemokine ligand 1	Rattus norvegicus	16-19
15757501-9	2005	Recombinant rat GRO could also induce the up-regulation in the presence of cycloheximide, demonstrating that GRO may play an important role in the PHGPx up-regulation of casein-induced PMNs.	Cycloheximide	75-88	C-X-C motif chemokine ligand 1	Rattus norvegicus	109-112
15757501-9	2005	Recombinant rat GRO could also induce the up-regulation in the presence of cycloheximide, demonstrating that GRO may play an important role in the PHGPx up-regulation of casein-induced PMNs.	Cycloheximide	75-88	glutathione peroxidase 4	Rattus norvegicus	147-152
15856013-6	2005	Overexpression of c-IAP2 in normal human oral keratinocyte conferred resistance to tumor necrosis factor-alpha (TNF-alpha)/cycloheximide (CHX)-induced apoptosis, suggesting the increased c-IAP2 expression in HOK16E6E7 may protect the cells from TNF-alpha-mediated cell death.	Cycloheximide	138-141	baculoviral IAP repeat containing 3	Homo sapiens	18-24
15935340-5	2005	XHR1-VP16-GR induced the expression of the ESR genes and XLCL2 as well as Xdelta1, Xngnr1, and XHR1 itself in the presence of DEX even after pretreatment with the protein synthesis inhibitor, cycloheximide.	Cycloheximide	192-205	hairy and enhancer of split 7, gene 1 L homeolog	Xenopus laevis	0-12
15791453-5	2005	Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228.	Cycloheximide	53-66	telomerase reverse transcriptase	Homo sapiens	102-107
15791453-5	2005	Moreover, cotreatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the induction of hTERT transcription by FR901228.	Cycloheximide	68-71	telomerase reverse transcriptase	Homo sapiens	102-107
15845625-4	2005	The negative effect of a high glucose/high insulin setting on IRS-1 protein level was still exerted when protein synthesis was inhibited with cycloheximide.	Cycloheximide	142-155	insulin receptor substrate 1	Rattus norvegicus	62-67
15870696-5	2005	Concomitant treatment with cycloheximide prevented most of these changes in gene expression, including downregulation of ERalpha mRNA, indicating that a limited number of genes signal a hyperacetylated state within cells.	Cycloheximide	27-40	estrogen receptor 1	Homo sapiens	121-128
15870071-3	2005	FGF-1 induced the expression of HO-1 in cultured rat spinal cord astrocytes, which was dependent on FGF receptor activation and prevented by cycloheximide.	Cycloheximide	141-154	fibroblast growth factor 1	Rattus norvegicus	0-5
15870071-3	2005	FGF-1 induced the expression of HO-1 in cultured rat spinal cord astrocytes, which was dependent on FGF receptor activation and prevented by cycloheximide.	Cycloheximide	141-154	heme oxygenase 1	Rattus norvegicus	32-36
15880141-7	2005	The effect of glutamate preincubation on the expression of the three major transporters was studied by Western blotting, showing an increase of approximately 70% in EAAT1 immunoreactivity that was completely blocked by cycloheximide (CEM).	Cycloheximide	219-232	solute carrier family 1 member 3	Homo sapiens	165-170
15880141-7	2005	The effect of glutamate preincubation on the expression of the three major transporters was studied by Western blotting, showing an increase of approximately 70% in EAAT1 immunoreactivity that was completely blocked by cycloheximide (CEM).	Cycloheximide	234-237	solute carrier family 1 member 3	Homo sapiens	165-170
15935340-5	2005	XHR1-VP16-GR induced the expression of the ESR genes and XLCL2 as well as Xdelta1, Xngnr1, and XHR1 itself in the presence of DEX even after pretreatment with the protein synthesis inhibitor, cycloheximide.	Cycloheximide	192-205	hairy and enhancer of split 7, gene 1 L homeolog	Xenopus laevis	0-4
15827295-6	2005	The increase in HSP70 level was significantly blunted on pretreatment with microinjection of the transcription inhibitor actinomycin D or protein synthesis inhibitor cycloheximide into the bilateral RVLM.	Cycloheximide	166-179	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	16-21
15966900-3	2005	In P815 cells, the half-life of endogenous GATA-2 was found to be as short as 30 min after cycloheximide treatment.	Cycloheximide	91-104	GATA binding protein 2	Mus musculus	43-49
15956580-4	2005	Cycloheximide reversal or phosphonoacetic acid treatment of wild-type virus-infected cells as well as infection with the ICP4 mutant vi13 indicated that only the immediate-early class of viral proteins were required for SAPK activation.	Cycloheximide	0-13	mitogen-activated protein kinase 9	Homo sapiens	220-224
16003319-12	2005	Combined treatment with cycloheximide and TRAIL induced cleaved forms of caspases and simultaneously restored the sensitivity to TRAIL-induced apoptosis in the resistant cells.	Cycloheximide	24-37	TNF superfamily member 10	Homo sapiens	129-134
16003319-14	2005	Suppression of FLIP-S by cycloheximide restored sensitivity to TRAIL-induced apoptosis in resistant cancer cells.	Cycloheximide	25-38	TNF superfamily member 10	Homo sapiens	63-68
15876423-2	2005	Results of Western blotting show that QE but not its glycoside rutin (RUT) and quicitrin-induced HO-1 protein expression in a time- and dose-dependent manner, and HO-1 protein induced by QE was blocked by an addition of cycloheximide or actinomycin D.	Cycloheximide	220-233	heme oxygenase 1	Homo sapiens	163-167
15837795-5	2005	17Beta-estradiol repressed TCDD-activated Cyp1a1 and Cyp1b1 gene transcription in MCF-7 cells in the presence of cycloheximide, as determined by reverse transcription/real-time PCR.	Cycloheximide	113-126	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	42-48
15837795-5	2005	17Beta-estradiol repressed TCDD-activated Cyp1a1 and Cyp1b1 gene transcription in MCF-7 cells in the presence of cycloheximide, as determined by reverse transcription/real-time PCR.	Cycloheximide	113-126	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	53-59
15779047-6	2005	Analysis of endogenous gsc, chd, and Xbra transcript distribution in embryos treated with cycloheximide supported this concept.	Cycloheximide	90-103	goosecoid homeobox S homeolog	Xenopus laevis	23-26
15779047-6	2005	Analysis of endogenous gsc, chd, and Xbra transcript distribution in embryos treated with cycloheximide supported this concept.	Cycloheximide	90-103	T-box transcription factor Tr L homeolog	Xenopus laevis	37-41
16077198-0	2005	Cycloheximide-mediated sensitization to TNF-alpha-induced apoptosis in human colorectal cancer cell line COLO 205; role of FLIP and metabolic inhibitors.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	40-49
15919906-8	2005	The stimulation of IRF-7 gene expression by IFN-alpha in glial cell culture was prevented by cycloheximide.	Cycloheximide	93-106	interferon regulatory factor 7	Homo sapiens	19-24
15919906-8	2005	The stimulation of IRF-7 gene expression by IFN-alpha in glial cell culture was prevented by cycloheximide.	Cycloheximide	93-106	interferon alpha 1	Homo sapiens	44-53
15770661-6	2005	Stimulation by TGF-beta and PMA were dependent on protein synthesis and their effects were inhibited by cycloheximide.	Cycloheximide	104-117	transforming growth factor beta 1	Homo sapiens	15-23
15753078-7	2005	When p21 expression was inhibited by cycloheximide, galectin-8 directed the cells toward apoptosis, which involves induction of poly(ADP-ribose) polymerase cleavage.	Cycloheximide	37-50	H3 histone pseudogene 16	Homo sapiens	5-8
15753078-7	2005	When p21 expression was inhibited by cycloheximide, galectin-8 directed the cells toward apoptosis, which involves induction of poly(ADP-ribose) polymerase cleavage.	Cycloheximide	37-50	galectin 8	Homo sapiens	52-62
15870436-6	2005	The half-life of K-cyclin and cyclin D2 proteins was determined by blocking protein synthesis with cycloheximide and measuring proteins in cell lysates by western blot analysis.	Cycloheximide	99-112	cyclin D2	Homo sapiens	30-39
15585589-7	2005	Treatment with cycloheximide, but not with actinomycin D, prevented IGF-I-suppressed Rstn mRNA expression, suggesting that IGF-I destabilizes Rstn mRNA and that IGF-I"s effect requires new protein, but not mRNA, synthesis.	Cycloheximide	15-28	insulin like growth factor 1	Homo sapiens	68-73
15585589-7	2005	Treatment with cycloheximide, but not with actinomycin D, prevented IGF-I-suppressed Rstn mRNA expression, suggesting that IGF-I destabilizes Rstn mRNA and that IGF-I"s effect requires new protein, but not mRNA, synthesis.	Cycloheximide	15-28	resistin	Homo sapiens	85-89
15585589-7	2005	Treatment with cycloheximide, but not with actinomycin D, prevented IGF-I-suppressed Rstn mRNA expression, suggesting that IGF-I destabilizes Rstn mRNA and that IGF-I"s effect requires new protein, but not mRNA, synthesis.	Cycloheximide	15-28	insulin like growth factor 1	Homo sapiens	123-128
15585589-7	2005	Treatment with cycloheximide, but not with actinomycin D, prevented IGF-I-suppressed Rstn mRNA expression, suggesting that IGF-I destabilizes Rstn mRNA and that IGF-I"s effect requires new protein, but not mRNA, synthesis.	Cycloheximide	15-28	resistin	Homo sapiens	142-146
15585589-7	2005	Treatment with cycloheximide, but not with actinomycin D, prevented IGF-I-suppressed Rstn mRNA expression, suggesting that IGF-I destabilizes Rstn mRNA and that IGF-I"s effect requires new protein, but not mRNA, synthesis.	Cycloheximide	15-28	insulin like growth factor 1	Homo sapiens	123-128
16022587-4	2005	In NIH 3T3 and RS485 cells treated with cycloheximide, there were similar rapid drops in IRF-1 protein levels, and the addition of MG132 along with cycloheximide prevented protein loss in both cell lines.	Cycloheximide	40-53	interferon regulatory factor 1	Mus musculus	89-94
15924153-7	2005	Interestingly, cotreatment of Hank-1 with cycloheximide, a protein synthesis inhibitor, markedly sensitized cells to Fas-mediated apoptosis along with caspase 8 activation and c-FLIP(L) (cellular FLICE inhibitory protein long form) downregulation.	Cycloheximide	42-55	caspase 8	Homo sapiens	151-160
15924153-7	2005	Interestingly, cotreatment of Hank-1 with cycloheximide, a protein synthesis inhibitor, markedly sensitized cells to Fas-mediated apoptosis along with caspase 8 activation and c-FLIP(L) (cellular FLICE inhibitory protein long form) downregulation.	Cycloheximide	42-55	CASP8 and FADD like apoptosis regulator	Homo sapiens	176-182
15837527-4	2005	In contrast, the protein synthesis inhibitor cycloheximide increased baseline BNP mRNA levels and abolished the load-induced activation of gene expression.	Cycloheximide	45-58	natriuretic peptide B	Rattus norvegicus	78-81
15930287-8	2005	Instead cycloheximide effectively prevented the increase in HIF-1alpha protein, indicating a stimulatory effect of IL-1beta on HIF-1alpha translation.	Cycloheximide	8-21	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
16077198-3	2005	Nonetheless, co-incubation TNF-alpha (10 ng/ml) with cycloheximide (5 micro g/ml, CHX) caused time-dependent (6, 12, 24 hours) cell death even though, at that concentration cycloheximide did not exert cytotoxic effect unless 24 hour of treatment.	Cycloheximide	53-66	tumor necrosis factor	Homo sapiens	27-36
16077198-3	2005	Nonetheless, co-incubation TNF-alpha (10 ng/ml) with cycloheximide (5 micro g/ml, CHX) caused time-dependent (6, 12, 24 hours) cell death even though, at that concentration cycloheximide did not exert cytotoxic effect unless 24 hour of treatment.	Cycloheximide	173-186	tumor necrosis factor	Homo sapiens	27-36
16077198-6	2005	PKCs inhibitor staurosporine (5 microM) did not influence, whereas cPKC activator PMA (100 microM) prevented TNF-alpha-induced apoptosis in the presence of CHX.	Cycloheximide	156-159	tumor necrosis factor	Homo sapiens	109-118
16077199-0	2005	Position of STAT-1 alpha in cycloheximide-dependent apoptosis triggered by TNF-alpha in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds.	Cycloheximide	28-41	tumor necrosis factor	Homo sapiens	75-84
16077199-6	2005	However, when TNF-alpha (10 ng/ml) has been given along with cycloheximide (5 micro g/ml, CHX) COLO 205 cells died extensively from apoptosis.	Cycloheximide	61-74	tumor necrosis factor	Homo sapiens	14-23
16077199-7	2005	Apparently, cycloheximide sensitized cells to TNF-alpha-induced programmed cell death.	Cycloheximide	12-25	tumor necrosis factor	Homo sapiens	46-55
15897325-7	2005	Four genes showed an increase in expression intensity in the presence of cycloheximide, suggesting a direct effect of E2F1 on gene transcription, whereas one gene was identified as an indirect target.	Cycloheximide	73-86	E2F transcription factor 1	Homo sapiens	118-122
15618453-7	2005	PAF-r protein expression, 35-40% greater in hypoxia, was inhibited by cycloheximide, a protein synthesis inhibitor, suggesting translational regulation.	Cycloheximide	70-83	platelet activating factor receptor	Homo sapiens	0-5
15499571-7	2005	Finally, studies using cycloheximide and monensin showed that upon stimulation with GHRH, an optimal concentration of functional GHRH-R was maintained at the plasma membrane due to de novo synthesis and recycling in pituitary cells and to de novo synthesis solely in hGHRH-R-transfected BHK cells.	Cycloheximide	23-36	somatoliberin	Mesocricetus auratus	84-88
15614529-1	2005	Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), by treatment with cycloheximide (CHX).	Cycloheximide	168-181	TNF superfamily member 10	Homo sapiens	142-147
15614529-1	2005	Human renal carcinoma cells (RCCs) were sensitized to the apoptotic effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), by treatment with cycloheximide (CHX).	Cycloheximide	183-186	TNF superfamily member 10	Homo sapiens	142-147
15614529-2	2005	In contrast to a previous study, a rapid and dramatic decrease in levels of cellular FLICE (Fas-associated death domain-like IL-1beta-converting enzyme) inhibitory protein (cFLIP) following cycloheximide treatment was observed in all RCCs studied.	Cycloheximide	190-203	caspase 8	Homo sapiens	85-90
15614529-2	2005	In contrast to a previous study, a rapid and dramatic decrease in levels of cellular FLICE (Fas-associated death domain-like IL-1beta-converting enzyme) inhibitory protein (cFLIP) following cycloheximide treatment was observed in all RCCs studied.	Cycloheximide	190-203	caspase 8	Homo sapiens	92-151
15614529-2	2005	In contrast to a previous study, a rapid and dramatic decrease in levels of cellular FLICE (Fas-associated death domain-like IL-1beta-converting enzyme) inhibitory protein (cFLIP) following cycloheximide treatment was observed in all RCCs studied.	Cycloheximide	190-203	CASP8 and FADD like apoptosis regulator	Homo sapiens	173-178
15614529-5	2005	Therefore, cycloheximide treatment resulted in an increase in the pro-caspase-8 to cFLIP ratio, which correlated with sensitization to TRAIL-mediated apoptosis.	Cycloheximide	11-24	caspase 8	Homo sapiens	70-79
15614529-5	2005	Therefore, cycloheximide treatment resulted in an increase in the pro-caspase-8 to cFLIP ratio, which correlated with sensitization to TRAIL-mediated apoptosis.	Cycloheximide	11-24	CASP8 and FADD like apoptosis regulator	Homo sapiens	83-88
15614529-5	2005	Therefore, cycloheximide treatment resulted in an increase in the pro-caspase-8 to cFLIP ratio, which correlated with sensitization to TRAIL-mediated apoptosis.	Cycloheximide	11-24	TNF superfamily member 10	Homo sapiens	135-140
15965068-6	2005	Celecoxib-induced HO-1 protein expression was inhibited by actinomycin D and cycloheximide, suggesting that de novo transcription and translation are required in this process.	Cycloheximide	77-90	heme oxygenase 1	Homo sapiens	18-22
15808420-8	2005	TG induced elevated ROS levels and suppressed caspase-3 in apoptotic cells pretreated for 24 h with cycloheximide.	Cycloheximide	100-113	caspase 3	Mus musculus	46-55
15806306-0	2005	IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression.	Cycloheximide	109-122	interferon gamma	Homo sapiens	0-9
15806306-0	2005	IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression.	Cycloheximide	109-122	TNF receptor superfamily member 10a	Homo sapiens	49-52
15806306-0	2005	IFN-gamma/JAK/STAT pathway-induced inhibition of DR4 and DR5 expression on endothelial cells is cancelled by cycloheximide-sensitive mechanism: novel finding of cycloheximide-regulating death receptor expression.	Cycloheximide	109-122	TNF receptor superfamily member 10b	Homo sapiens	57-60
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	56-69	interferon gamma	Homo sapiens	0-9
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	56-69	TNF receptor superfamily member 10a	Homo sapiens	180-183
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	56-69	TNF receptor superfamily member 10b	Homo sapiens	184-187
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	56-69	TNF superfamily member 10	Homo sapiens	210-215
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	71-74	interferon gamma	Homo sapiens	0-9
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	71-74	TNF receptor superfamily member 10a	Homo sapiens	180-183
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	71-74	TNF receptor superfamily member 10b	Homo sapiens	184-187
15806306-6	2005	IFN-gamma/JAK/STAT-induced suppression was regulated by cycloheximide (CHX)-sensitive mechanism since the use of CHX mimicked the action of chemical inhibition of JAK in regard to DR4/DR5 expression as well as TRAIL-mediated endothelial cell apoptosis.	Cycloheximide	71-74	TNF superfamily member 10	Homo sapiens	210-215
15499571-7	2005	Finally, studies using cycloheximide and monensin showed that upon stimulation with GHRH, an optimal concentration of functional GHRH-R was maintained at the plasma membrane due to de novo synthesis and recycling in pituitary cells and to de novo synthesis solely in hGHRH-R-transfected BHK cells.	Cycloheximide	23-36	growth hormone releasing hormone receptor	Rattus norvegicus	129-135
15728246-6	2005	To investigate the mechanism of IFI16 accumulation, cells were incubated for 6 h in the presence of H2O2 or IFN-beta, and then cycloheximide was added to inhibit further protein synthesis.	Cycloheximide	127-140	interferon gamma inducible protein 16	Homo sapiens	32-37
15808886-7	2005	On the other hand, co-incubation with caffei caid and cycloheximide significantly accelerated the Rac1 degradation.	Cycloheximide	54-67	Rac family small GTPase 1	Homo sapiens	98-102
15937643-4	2005	IFN-induced TP mRNA accumulation was not inhibited by the protein synthesis inhibitor cycloheximide, but was strongly blocked by the transcription inhibitor actinomycin D, as well as by transcription factor decoy oligodeoxynucleotides containing the putative IFN response element or the gamma-activated sequence in the TP promoter.	Cycloheximide	86-99	interferon alpha 1	Homo sapiens	0-3
15937643-4	2005	IFN-induced TP mRNA accumulation was not inhibited by the protein synthesis inhibitor cycloheximide, but was strongly blocked by the transcription inhibitor actinomycin D, as well as by transcription factor decoy oligodeoxynucleotides containing the putative IFN response element or the gamma-activated sequence in the TP promoter.	Cycloheximide	86-99	thymidine phosphorylase	Homo sapiens	12-14
15967159-4	2005	Treatment of -Se BAEC with TNFalpha/cyclohexamide (CHX) exhibited elevated levels of apoptosis, which was significantly reduced by the addition of a specific 15-lipoxygenase inhibitor PD146176.	Cycloheximide	51-54	tumor necrosis factor	Bos taurus	27-35
15967159-5	2005	Furthermore, the addition of 15-HPETE to PD146176-treated BAEC, partially restored TNF/CHX-induced apoptosis.	Cycloheximide	87-90	tumor necrosis factor	Bos taurus	83-86
15668985-7	2005	These effects of IGF-1 were abolished by cycloheximide or genistein.	Cycloheximide	41-54	insulin-like growth factor 1	Rattus norvegicus	17-22
15792835-11	2005	The delayed up-regulation of CD13/APN (observed after 72 and/or 96 hrs), required de novo protein synthesis as it could be abrogated by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	136-149	alanyl aminopeptidase, membrane	Homo sapiens	29-33
15792835-11	2005	The delayed up-regulation of CD13/APN (observed after 72 and/or 96 hrs), required de novo protein synthesis as it could be abrogated by cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	136-149	alanyl aminopeptidase, membrane	Homo sapiens	34-37
15735718-7	2005	Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities.	Cycloheximide	43-56	H3 histone pseudogene 16	Homo sapiens	26-29
15735718-7	2005	Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities.	Cycloheximide	43-56	cyclin dependent kinase 4	Homo sapiens	116-120
15735718-7	2005	Conversely, inhibition of p21 induction by cycloheximide or by p21 gene deletion prevents DAP-induced inhibition of Cdk4 and Cdk2 activities.	Cycloheximide	43-56	cyclin dependent kinase 2	Homo sapiens	125-129
15832948-5	2005	Inhibition of translation and de novo protein synthesis by cycloheximide resulted in Hsp70 protein levels diminishing over time in control cells, whereas its level remained constant during CD95 signaling.	Cycloheximide	59-72	heat shock protein family A (Hsp70) member 4	Homo sapiens	85-90
15769481-10	2005	When apoptosis was induced by cicloheximide and TNF-alpha in hepatoblastoma cells, pretreatment with IL-10 was accompanied by a decrease of 38% in apoptosis.	Cycloheximide	30-43	interleukin 10	Rattus norvegicus	101-106
15563689-4	2005	TLR4-activated CD11b expression was cycloheximide sensitive and involved the activation of transcription factors, NF-kappaB and c-Jun/PU.1.	Cycloheximide	36-49	toll-like receptor 4	Mus musculus	0-4
15563689-4	2005	TLR4-activated CD11b expression was cycloheximide sensitive and involved the activation of transcription factors, NF-kappaB and c-Jun/PU.1.	Cycloheximide	36-49	integrin alpha M	Mus musculus	15-20
15563689-4	2005	TLR4-activated CD11b expression was cycloheximide sensitive and involved the activation of transcription factors, NF-kappaB and c-Jun/PU.1.	Cycloheximide	36-49	jun proto-oncogene	Mus musculus	128-133
15563689-4	2005	TLR4-activated CD11b expression was cycloheximide sensitive and involved the activation of transcription factors, NF-kappaB and c-Jun/PU.1.	Cycloheximide	36-49	spleen focus forming virus (SFFV) proviral integration oncogene	Mus musculus	134-138
16076025-8	2005	Our attempt to understand the mechanisms of increased SOD and CAT activities by application of protein synthesis inhibitor cycloheximide showed that this increase was caused by de novo synthesis of enzymes during first hours after ischemia.	Cycloheximide	123-136	superoxide dismutase 1	Rattus norvegicus	54-57
15653751-6	2005	Cell death was only observed in the presence of cycloheximide or after a pulse through CD3 or CD59, correlating with a net reduction in cellular Fas-associated death domain-like IL-1beta-converting enzyme-inhibitory protein long (c-FLIPL) and c-FLIPS expression.	Cycloheximide	48-61	CD59 molecule (CD59 blood group)	Homo sapiens	94-98
15653751-6	2005	Cell death was only observed in the presence of cycloheximide or after a pulse through CD3 or CD59, correlating with a net reduction in cellular Fas-associated death domain-like IL-1beta-converting enzyme-inhibitory protein long (c-FLIPL) and c-FLIPS expression.	Cycloheximide	48-61	CASP8 and FADD like apoptosis regulator	Homo sapiens	230-237
15653751-6	2005	Cell death was only observed in the presence of cycloheximide or after a pulse through CD3 or CD59, correlating with a net reduction in cellular Fas-associated death domain-like IL-1beta-converting enzyme-inhibitory protein long (c-FLIPL) and c-FLIPS expression.	Cycloheximide	48-61	CASP8 and FADD like apoptosis regulator	Homo sapiens	243-250
15809489-4	2005	18F-Annexin V (14.8-51.8 MBq) was administered intravenously to rats after pretreatment with cycloheximide (5 mg/kg) to induce liver apoptosis, and the injected rats were imaged by PET over 2 h. After imaging, rats were dissected and individual organs were weighed and counted.	Cycloheximide	93-106	annexin A5	Rattus norvegicus	4-13
15809489-5	2005	RESULTS: Pretreatment of rats with cycloheximide resulted in a 3- to 9-fold increase in uptake of 18F-annexin V in the liver of treated animals at 2 h, compared with controls.	Cycloheximide	35-48	annexin A5	Rattus norvegicus	102-111
16076025-8	2005	Our attempt to understand the mechanisms of increased SOD and CAT activities by application of protein synthesis inhibitor cycloheximide showed that this increase was caused by de novo synthesis of enzymes during first hours after ischemia.	Cycloheximide	123-136	catalase	Rattus norvegicus	62-65
15608132-6	2005	The protein synthesis inhibitor cycloheximide superinduced the tBHQ-mediated induction of Cyp1a1 mRNA and completely prevented the increase in Cyp1a1 activity, indicating that the induction of enzyme activity by tBHQ is dependent on de novo protein synthesis.	Cycloheximide	32-45	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	90-96
15637055-5	2005	In sharp contrast to cycloheximide-induced Mcl-1 dilapidation, TRAIL did not activate proteasomal degradation of Mcl-1 in Jurkat cells.	Cycloheximide	21-34	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	43-48
15498828-6	2005	IL-8 release was blocked by actinomycin D or cycloheximide, but the inhibitors had no effect on VEGF release, suggesting that IL-8 secretion required de novo synthesis whereas VEGF was secreted from preformed stores.	Cycloheximide	45-58	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
15701621-6	2005	The TNF-alpha increase in MLCK protein expression paralleled the increase in Caco-2 TJ permeability, and the inhibition of the TNF-alpha-induced MLCK expression (by cycloheximide) prevented the increase in Caco-2 TJ permeability, suggesting that MLCK expression may be required for the increase in Caco-2 TJ permeability.	Cycloheximide	165-178	tumor necrosis factor	Homo sapiens	127-136
15701621-6	2005	The TNF-alpha increase in MLCK protein expression paralleled the increase in Caco-2 TJ permeability, and the inhibition of the TNF-alpha-induced MLCK expression (by cycloheximide) prevented the increase in Caco-2 TJ permeability, suggesting that MLCK expression may be required for the increase in Caco-2 TJ permeability.	Cycloheximide	165-178	myosin light chain kinase	Homo sapiens	145-149
15701621-6	2005	The TNF-alpha increase in MLCK protein expression paralleled the increase in Caco-2 TJ permeability, and the inhibition of the TNF-alpha-induced MLCK expression (by cycloheximide) prevented the increase in Caco-2 TJ permeability, suggesting that MLCK expression may be required for the increase in Caco-2 TJ permeability.	Cycloheximide	165-178	myosin light chain kinase	Homo sapiens	145-149
15701621-10	2005	The cycloheximide inhibition of MLCK protein expression prevented the TNF-alpha increase in MLCK activity and Caco-2 TJ permeability.	Cycloheximide	4-17	myosin light chain kinase	Homo sapiens	32-36
15701621-10	2005	The cycloheximide inhibition of MLCK protein expression prevented the TNF-alpha increase in MLCK activity and Caco-2 TJ permeability.	Cycloheximide	4-17	tumor necrosis factor	Homo sapiens	70-79
15701621-10	2005	The cycloheximide inhibition of MLCK protein expression prevented the TNF-alpha increase in MLCK activity and Caco-2 TJ permeability.	Cycloheximide	4-17	myosin light chain kinase	Homo sapiens	92-96
15707993-5	2005	A non-toxic concentration of each enniatin (5 microg/ml, approximately 7.8 microM) strongly inhibited a Pdr5p-mediated efflux of cycloheximide or cerulenin in Pdr5p-overexpressing cells.	Cycloheximide	129-142	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	104-109
15707993-5	2005	A non-toxic concentration of each enniatin (5 microg/ml, approximately 7.8 microM) strongly inhibited a Pdr5p-mediated efflux of cycloheximide or cerulenin in Pdr5p-overexpressing cells.	Cycloheximide	129-142	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	159-164
15608132-6	2005	The protein synthesis inhibitor cycloheximide superinduced the tBHQ-mediated induction of Cyp1a1 mRNA and completely prevented the increase in Cyp1a1 activity, indicating that the induction of enzyme activity by tBHQ is dependent on de novo protein synthesis.	Cycloheximide	32-45	cytochrome P450, family 1, subfamily a, polypeptide 1	Mus musculus	143-149
15722640-5	2005	We further analyzed the IFN-gamma effect, showing that pretreatment with IFN-gamma strongly suppressed IL-5-induced eosinophil shape change, and cycloheximide (CHX) abrogated the suppression by IFN-gamma, suggesting that new protein synthesis is required for the inhibitory effect by this cytokine.	Cycloheximide	160-163	interferon gamma	Homo sapiens	24-33
15881651-5	2005	CycD, emitine, puromycin and anisomycin also enhanced uPA mRNA half-life by three- to five-fold in Beas2B cells treated with DRB, an inhibitor of transcription.	Cycloheximide	0-4	plasminogen activator, urokinase	Homo sapiens	54-57
15714461-5	2005	In addition, the translation inhibitor cycloheximide confirmed that bFGF-induced HIF-1alpha protein expression was due to de novo protein synthesis.	Cycloheximide	39-52	fibroblast growth factor 2	Homo sapiens	68-72
15714461-5	2005	In addition, the translation inhibitor cycloheximide confirmed that bFGF-induced HIF-1alpha protein expression was due to de novo protein synthesis.	Cycloheximide	39-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	81-91
15534876-6	2005	Cycloheximide addition after 4 h-pressure treatment suggested that the half-life of eEF-2 protein was shorter in pressurized cells.	Cycloheximide	0-13	eukaryotic translation elongation factor 2	Homo sapiens	84-89
15574423-5	2005	We found here that this recruitment was dependent on protein synthesis, because a protein synthesis inhibitor, cycloheximide, prevented the accumulation of E-cadherin.	Cycloheximide	111-124	cadherin 1	Canis lupus familiaris	156-166
15596055-6	2005	Studies using cycloheximide to superinduce gene expression indicated transcriptional suppression of syndecan-4 in WC cells.	Cycloheximide	14-27	syndecan 4	Homo sapiens	100-110
15684068-6	2005	In addition, we found that cycloheximide but not Ugi (the specific inhibitor of UNG) inhibited AID-dependent DNA cleavage in the Ig gene during SHM, by using histone H2AX focus formation as a marker of DNA cleavage.	Cycloheximide	27-40	activation induced cytidine deaminase	Homo sapiens	95-98
15629464-4	2005	Deletion of PDE2, similar to ira2 deletion, rendered cells sensitive to freeze-thawing, peroxides, paraquat, cycloheximide, heavy metals, NaCl, heat, or cold shock.	Cycloheximide	109-122	3',5'-cyclic-nucleotide phosphodiesterase PDE2	Saccharomyces cerevisiae S288C	12-16
15454393-9	2005	Using immunohistochemistry, we demonstrate an increase in apical expression of the NaPi-2A transporter in proximal tubules perfused in vitro in Hyp mice even in the presence of bath cycloheximide.	Cycloheximide	182-195	solute carrier family 34 (sodium phosphate), member 1	Mus musculus	83-90
15528219-7	2005	Pre-treatment of cells with caspase-8 or -9 inhibitor, pan caspase inhibitor or cycloheximide totally blocked alpha-santalol-caused caspase-3 activity and cleavage, but only partially reversed apoptotic cell death.	Cycloheximide	80-93	caspase 3	Homo sapiens	132-141
15652337-2	2005	Using myocilin produced in sf9 insect cells, myocilin inhibited spreading of cycloheximide-treated human skin fibroblasts plated on substrates co-coated with myocilin and either fibronectin or its Heparin II domain.	Cycloheximide	77-90	myocilin	Homo sapiens	6-14
15652337-2	2005	Using myocilin produced in sf9 insect cells, myocilin inhibited spreading of cycloheximide-treated human skin fibroblasts plated on substrates co-coated with myocilin and either fibronectin or its Heparin II domain.	Cycloheximide	77-90	myocilin	Homo sapiens	45-53
15652337-2	2005	Using myocilin produced in sf9 insect cells, myocilin inhibited spreading of cycloheximide-treated human skin fibroblasts plated on substrates co-coated with myocilin and either fibronectin or its Heparin II domain.	Cycloheximide	77-90	myocilin	Homo sapiens	45-53
15652337-2	2005	Using myocilin produced in sf9 insect cells, myocilin inhibited spreading of cycloheximide-treated human skin fibroblasts plated on substrates co-coated with myocilin and either fibronectin or its Heparin II domain.	Cycloheximide	77-90	fibronectin 1	Homo sapiens	178-189
15629159-0	2005	Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.	Cycloheximide	100-113	beta-1,4-galactosyltransferase 1	Homo sapiens	18-49
15629159-0	2005	Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.	Cycloheximide	100-113	cyclin dependent kinase 19	Homo sapiens	59-64
15629159-0	2005	Downregulation of beta1,4-galactosyltransferase 1 inhibits CDK11(p58)-mediated apoptosis induced by cycloheximide.	Cycloheximide	100-113	cyclin dependent kinase 11B	Homo sapiens	65-68
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	122-135	beta-1,4-galactosyltransferase 1	Homo sapiens	58-70
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	122-135	cyclin dependent kinase 19	Homo sapiens	81-86
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	122-135	cyclin dependent kinase 11B	Homo sapiens	87-90
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	137-140	beta-1,4-galactosyltransferase 1	Homo sapiens	58-70
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	137-140	cyclin dependent kinase 19	Homo sapiens	81-86
15629159-4	2005	In this study, we demonstrated that ectopically expressed beta1,4-GT 1 increased CDK11(p58)-mediated apoptosis induced by cycloheximide (CHX).	Cycloheximide	137-140	cyclin dependent kinase 11B	Homo sapiens	87-90
15654655-4	2005	Pre-treatment with cycloheximide blocks nuclear labelling for FGF-2 in response to PGF(2alpha).	Cycloheximide	19-32	fibroblast growth factor 2	Homo sapiens	62-67
15627980-7	2005	Transcription inhibitors actinomycin D and 5,6-dichlororibofuranosyl benzimidazole, and the translation inhibitor cycloheximide significantly rescue the accumulation of CIITA mRNA in TPA-treated cells.	Cycloheximide	114-127	class II major histocompatibility complex transactivator	Homo sapiens	169-174
15659748-4	2005	UL78 transcription was activated early after infection, was inhibited by cycloheximide but not by phosphonoacetic acid, and resulted in a 1.7 kb mRNA.	Cycloheximide	73-86	envelope protein UL78	Human betaherpesvirus 5	0-4
15678124-7	2005	The protective effect of OPN was also blocked by the protein synthesis inhibitor cycloheximide, suggesting that the neuroprotective effect of OPN required new protein synthesis.	Cycloheximide	81-94	secreted phosphoprotein 1	Mus musculus	25-28
15678124-7	2005	The protective effect of OPN was also blocked by the protein synthesis inhibitor cycloheximide, suggesting that the neuroprotective effect of OPN required new protein synthesis.	Cycloheximide	81-94	secreted phosphoprotein 1	Mus musculus	142-145
15486049-4	2005	This difference was caused by post-translational regulation; as in the presence of cycloheximide, the rate of degradation of immunodetectable and enzymatically active CYP1B1.4 was distinctly faster than that of CYP1B1.1.	Cycloheximide	83-96	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	167-173
15650164-4	2005	The virus-induced phosphorylation of PERK is blocked by cycloheximide but not by phosphonoacetic acid, suggesting that the accumulation of viral proteins in the ER is essential.	Cycloheximide	56-69	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	37-41
15684389-6	2005	Cells expressing high levels of Nm23-H1 exhibited increased KSR1 degradation in the presence of either cycloheximide or an Hsp90-directed drug currently in clinical trial, 17-allylamino-17-demethoxygeldanamycin (17-AAG).	Cycloheximide	103-116	NME/NM23 nucleoside diphosphate kinase 1	Homo sapiens	32-39
15612946-5	2005	The effect of cycloheximide, a protein synthesis inhibitor, on the IL-1beta-induced expression of RIG-I was examined.	Cycloheximide	14-27	interleukin 1 beta	Homo sapiens	67-75
15612946-5	2005	The effect of cycloheximide, a protein synthesis inhibitor, on the IL-1beta-induced expression of RIG-I was examined.	Cycloheximide	14-27	DExD/H-box helicase 58	Homo sapiens	98-103
15649149-7	2005	Actinomycin D and cycloheximide, inhibitors of transcription and translation, respectively, inhibited PTLF-induction of tyrosinase activity with a corresponding decrease in melanogenesis.	Cycloheximide	18-31	tyrosinase	Mus musculus	120-130
16353668-6	2005	Inhibition of Sf-1 expression by TGF-beta was abolished by cycloheximide, suggesting that the growth factor inhibitory effect requires ongoing protein synthesis.	Cycloheximide	59-72	splicing factor 1	Homo sapiens	14-18
15581603-9	2005	Further, the increase in mRNA was blocked by cycloheximide, indicating a requirement for protein synthesis and an indirect regulation of VDR transcription.	Cycloheximide	45-58	vitamin D (1,25-dihydroxyvitamin D3) receptor	Mus musculus	137-140
15546873-4	2005	The induction of HO-1 by ER stress was blocked by actinomycin D or cycloheximide and was independent of any changes in HO-1 mRNA stability.	Cycloheximide	67-80	heme oxygenase 1	Homo sapiens	17-21
15912208-4	2005	The effect of forskolin was augmented by cycloheximide, suggesting that an inhibitory protein, whose synthesis was inhibited by cycloheximide, could be involved in negative regulation of SF-1 expression.	Cycloheximide	41-54	splicing factor 1	Mus musculus	187-191
15912208-4	2005	The effect of forskolin was augmented by cycloheximide, suggesting that an inhibitory protein, whose synthesis was inhibited by cycloheximide, could be involved in negative regulation of SF-1 expression.	Cycloheximide	128-141	splicing factor 1	Mus musculus	187-191
16121032-10	2005	In keeping with this observation, the protein synthesis inhibitor cycloheximide abolished the stimulatory effect of IL-1 on ATPase-mediated extrusion.	Cycloheximide	66-79	interleukin 1 alpha	Homo sapiens	116-120
16121032-10	2005	In keeping with this observation, the protein synthesis inhibitor cycloheximide abolished the stimulatory effect of IL-1 on ATPase-mediated extrusion.	Cycloheximide	66-79	dynein axonemal heavy chain 8	Homo sapiens	124-130
15987266-0	2005	Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide.	Cycloheximide	110-123	growth associated protein 43	Rattus norvegicus	0-28
15545276-4	2005	Subsequent analysis of strains with a rom2 deletion showed that Rom2p is essential for resistance to a variety of stresses caused by freeze-thawing, oxidants, cycloheximide, NaCl, or cobalt ions.	Cycloheximide	159-172	Rho family guanine nucleotide exchange factor ROM2	Saccharomyces cerevisiae S288C	64-69
15561096-7	2005	We show that coincubation of TPA with the protein synthesis inhibitor cycloheximide or the transcription inhibitor actinomycin D results in synergistic enhancement of the level of activated ERK1/2.	Cycloheximide	70-83	mitogen activated protein kinase 3	Rattus norvegicus	190-196
15531589-6	2005	The up-regulation of RhoB was approximately 15-fold and was based on the de novo synthesis of the GTPase because cycloheximide completely inhibited the toxin A effect.	Cycloheximide	113-126	ras homolog family member B	Homo sapiens	21-25
15358608-10	2005	Cycloheximide, an inhibitor of protein synthesis, enhanced the toxicity of TNF in Ep-SMCs.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	75-78
15763493-4	2005	Membrane stabilisation by tocopherol or prevention of early ALAS induction by cycloheximide prevented both mitochondrial heme accumulation and increase of TDO heme saturation.	Cycloheximide	78-91	5'-aminolevulinate synthase 1	Rattus norvegicus	60-64
15763493-4	2005	Membrane stabilisation by tocopherol or prevention of early ALAS induction by cycloheximide prevented both mitochondrial heme accumulation and increase of TDO heme saturation.	Cycloheximide	78-91	tryptophan 2,3-dioxygenase	Rattus norvegicus	155-158
16353668-6	2005	Inhibition of Sf-1 expression by TGF-beta was abolished by cycloheximide, suggesting that the growth factor inhibitory effect requires ongoing protein synthesis.	Cycloheximide	59-72	transforming growth factor beta 1	Homo sapiens	33-41
15544924-5	2004	HO-1 mRNA induction was abrogated in the presence of actinomycin D and cycloheximide.	Cycloheximide	71-84	heme oxygenase 1	Homo sapiens	0-4
15586228-3	2005	TWEAK alone induced cell death in SW480 cells and induced cell death of HT-29 cells after addition of IFN-gamma, actinomycin D or cycloheximide.	Cycloheximide	130-143	TNF superfamily member 12	Homo sapiens	0-5
15586230-6	2005	The protein synthesis inhibitor cycloheximide markedly increased the TRAIL sensitivity of these cell lines, whereas the CB-specific chemical inhibitor CA-074 markedly reduced the sensitivity of primary OC cells to TRAIL.	Cycloheximide	32-45	TNF superfamily member 10	Homo sapiens	69-74
16293985-4	2005	In these cells, we further show that thrombin-induced VEGF secretion was blocked by cycloheximide and actinomycin D, indicating that de novo protein synthesis is essential for this process.	Cycloheximide	84-97	coagulation factor II, thrombin	Homo sapiens	37-45
16293985-4	2005	In these cells, we further show that thrombin-induced VEGF secretion was blocked by cycloheximide and actinomycin D, indicating that de novo protein synthesis is essential for this process.	Cycloheximide	84-97	vascular endothelial growth factor A	Homo sapiens	54-58
15516693-9	2004	In contrast, the inhibition of protein synthesis by cycloheximide induced transcription from both the hTERT and Xtrp2 genes, indicating that histone deacetylases and labile factors coordinate to silence this chromosomal region.	Cycloheximide	52-65	telomerase reverse transcriptase	Homo sapiens	102-107
15516693-9	2004	In contrast, the inhibition of protein synthesis by cycloheximide induced transcription from both the hTERT and Xtrp2 genes, indicating that histone deacetylases and labile factors coordinate to silence this chromosomal region.	Cycloheximide	52-65	solute carrier family 6 member 18	Homo sapiens	112-117
15330761-3	2004	Pre-treatment with CHX (cycloheximide) followed by PMA led to significantly higher levels of MnSOD mRNA compared with those with either agent alone, suggesting de novo synthesis of an inhibitory protein.	Cycloheximide	19-22	superoxide dismutase 2	Homo sapiens	93-98
15330761-3	2004	Pre-treatment with CHX (cycloheximide) followed by PMA led to significantly higher levels of MnSOD mRNA compared with those with either agent alone, suggesting de novo synthesis of an inhibitory protein.	Cycloheximide	24-37	superoxide dismutase 2	Homo sapiens	93-98
15316935-9	2005	Induction of GADD153 protein by DOC was prevented by either anisomycin or cycloheximide.	Cycloheximide	74-87	DNA damage inducible transcript 3	Homo sapiens	13-20
15489540-8	2005	Actinomycin D as well as cycloheximide abolished the AA-induced reduction of resistin mRNA levels, indicating dependence on de novo transcription and translation.	Cycloheximide	25-38	resistin	Mus musculus	77-85
15322069-6	2004	The effect of TNF-alpha was completely blocked by pretreatment with U-0126 or cycloheximide, but not with SB-203580.	Cycloheximide	78-91	tumor necrosis factor	Rattus norvegicus	14-23
15286033-11	2004	Cycloheximide blocked the LH- or forskolin-induced MMP-19 mRNA expression, demonstrating the requirement for new protein synthesis.	Cycloheximide	0-13	matrix metallopeptidase 19	Rattus norvegicus	51-57
15459750-8	2004	Additionally, coincubation with cycloheximide blocked the mitotic effects of GM-CSF or IL-3, allowing only the apoptotic responses of TNF to persist.	Cycloheximide	32-45	colony stimulating factor 2	Homo sapiens	77-83
15459750-8	2004	Additionally, coincubation with cycloheximide blocked the mitotic effects of GM-CSF or IL-3, allowing only the apoptotic responses of TNF to persist.	Cycloheximide	32-45	interleukin 3	Homo sapiens	87-91
15459750-8	2004	Additionally, coincubation with cycloheximide blocked the mitotic effects of GM-CSF or IL-3, allowing only the apoptotic responses of TNF to persist.	Cycloheximide	32-45	tumor necrosis factor	Homo sapiens	134-137
15465831-2	2004	Here we show that BRE also binds to another death receptor, Fas, and upon overexpression conferred resistance to apoptosis induced by TNF-alpha, anti-Fas agonist antibody, cycloheximide, and a variety of stress-related stimuli.	Cycloheximide	172-185	BRISC and BRCA1 A complex member 2	Homo sapiens	18-21
15659777-4	2004	We demonstrate that exogenous, recombinant, TIMP-1 efficiently prevents apoptosis induced by TNFalpha in cycloheximide-sensitized ECs.	Cycloheximide	105-118	TIMP metallopeptidase inhibitor 1	Homo sapiens	44-50
15659777-4	2004	We demonstrate that exogenous, recombinant, TIMP-1 efficiently prevents apoptosis induced by TNFalpha in cycloheximide-sensitized ECs.	Cycloheximide	105-118	tumor necrosis factor	Homo sapiens	93-101
15358674-3	2004	A GH dose-dependent induction of akr1b7 was demonstrated in cultured primary rat hepatocytes, which was sensitive to cycloheximide.	Cycloheximide	117-130	aldo-keto reductase family 1, member B7	Rattus norvegicus	33-39
15535971-3	2004	The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides.	Cycloheximide	73-86	tumor necrosis factor	Rattus norvegicus	4-13
15371557-7	2004	Experiments with cycloheximide and AhR-deficient B cells indicated that Socs2 mRNA induction is a primary effect that is AhR-dependent.	Cycloheximide	17-30	suppressor of cytokine signaling 2	Mus musculus	72-77
15371557-7	2004	Experiments with cycloheximide and AhR-deficient B cells indicated that Socs2 mRNA induction is a primary effect that is AhR-dependent.	Cycloheximide	17-30	aryl-hydrocarbon receptor	Mus musculus	121-124
15634758-7	2004	Up-regulation of cingulin is reversible and dose dependent and requires de novo protein synthesis and protein kinase activity, because it is inhibited by cycloheximide and by the protein kinase inhibitor H-7.	Cycloheximide	154-167	cingulin	Rattus norvegicus	17-25
15545831-5	2004	The increase in UCH-L1 level was significantly blunted on pretreatment with bilateral microinjection into the RVLM of a transcription inhibitor, actinomycin D (5 nmol), or a translation inhibitor, cycloheximide (20 nmol).	Cycloheximide	197-210	ubiquitin C-terminal hydrolase L1	Rattus norvegicus	16-22
15535971-3	2004	The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides.	Cycloheximide	73-86	tumor necrosis factor	Rattus norvegicus	124-133
15535971-3	2004	The TNF-alpha secretion was abrogated by treatment of RBL-2H3 cells with cycloheximide, indicating the de novo synthesis of TNF-alpha, but not with polymyxin B, excluding the possible TNF-alpha induction by some contaminated lipopolysaccharides.	Cycloheximide	73-86	tumor necrosis factor	Rattus norvegicus	124-133
15522829-6	2004	Treatment with inhibitors (AACOCF(3), staurosporine and cycloheximide) resulted in a sharp decrease in basal and stimulated cPLA(2) activity.	Cycloheximide	56-69	phospholipase A2 group IVA	Bos taurus	124-131
15389870-4	2004	The increase of O-GlcNAc for the 97 kDa protein, which we identified as beta-catenin was partly related to its accumulation during maturation, as was demonstrated by the use of the protein synthesis inhibitor--cycloheximide.	Cycloheximide	208-223	catenin beta 1 L homeolog	Xenopus laevis	72-84
15389877-4	2004	Activation of ERK and Akt by 1,25(OH)2D3 was transient, required a minimal dose of 10(-9) M and could be blocked by actinomycin D and cycloheximide.	Cycloheximide	134-147	mitogen-activated protein kinase 1	Homo sapiens	14-17
15389877-4	2004	Activation of ERK and Akt by 1,25(OH)2D3 was transient, required a minimal dose of 10(-9) M and could be blocked by actinomycin D and cycloheximide.	Cycloheximide	134-147	AKT serine/threonine kinase 1	Homo sapiens	22-25
15467457-4	2004	Treatment of cells with phosphatase inhibitors at concentrations selective for PP2A inhibition prevents CHX and flavopiridol-mediated dephosphorylation of pocket proteins in vivo.	Cycloheximide	104-107	protein phosphatase 2 phosphatase activator	Homo sapiens	79-83
15156195-5	2004	Here, we show that cells essentially lacking expression of hTID1 proteins are protected from cell death in response to multiple stimuli, including cisplatin, tumor necrosis factor alpha/cycloheximide and mitomycin C.	Cycloheximide	186-199	DnaJ heat shock protein family (Hsp40) member A3	Homo sapiens	59-64
15492862-10	2004	The effect of IGF-I (10(-8) M) in increasing the production of albumin in osteoblastic cells was completely prevented in the presence of cycloheximide (10(-7) M), an inhibitor of protein synthesis, or 5, 6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB; 10(-6) M), an inhibitor of transcriptional activity.	Cycloheximide	137-150	insulin-like growth factor 1	Rattus norvegicus	14-19
15666812-5	2004	The Ang II-dependent, but not (Bu)2cAMP-dependent, induction of StAR mRNA was also blocked by AG490 and shown to be sensitive to cycloheximide treatment.	Cycloheximide	129-142	angiogenin	Homo sapiens	4-7
15666812-5	2004	The Ang II-dependent, but not (Bu)2cAMP-dependent, induction of StAR mRNA was also blocked by AG490 and shown to be sensitive to cycloheximide treatment.	Cycloheximide	129-142	steroidogenic acute regulatory protein	Homo sapiens	64-68
15231489-4	2004	However, cycloheximide treatment prolonged the TNF-alpha-induced JNK-1 kinase activity beyond 60 min, suggesting that protein synthesis is required to limit this signaling cascade.	Cycloheximide	9-22	tumor necrosis factor	Homo sapiens	47-56
15231489-4	2004	However, cycloheximide treatment prolonged the TNF-alpha-induced JNK-1 kinase activity beyond 60 min, suggesting that protein synthesis is required to limit this signaling cascade.	Cycloheximide	9-22	mitogen-activated protein kinase 8	Homo sapiens	65-70
15319373-9	2004	Leptin abolished both cycloheximide-induced and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, demonstrated by reduced caspase-3 activity, HSC-TUNEL staining, and DNA fragmentation.	Cycloheximide	22-35	leptin	Homo sapiens	0-6
15281096-9	2004	Pre-treatment of smooth muscle cells with cycloheximide abolished the reduction of PN-1 expression by thrombin.	Cycloheximide	42-55	serpin family E member 2	Rattus norvegicus	83-87
15281096-9	2004	Pre-treatment of smooth muscle cells with cycloheximide abolished the reduction of PN-1 expression by thrombin.	Cycloheximide	42-55	coagulation factor II	Rattus norvegicus	102-110
15525600-5	2004	Blockade of protein synthesis by cycloheximide almost completely inhibited the concomitant induction of FN mRNA by T3, indicating that T3 indirectly regulates FN.	Cycloheximide	33-46	fibronectin 1	Homo sapiens	104-106
15220936-6	2004	Cycloheximide inhibited IFNgamma release in such optimal conditions, confirming the ability of PMN to synthesize IFNgamma.	Cycloheximide	0-13	interferon gamma	Homo sapiens	24-32
15220936-6	2004	Cycloheximide inhibited IFNgamma release in such optimal conditions, confirming the ability of PMN to synthesize IFNgamma.	Cycloheximide	0-13	interferon gamma	Homo sapiens	113-121
15385644-0	2004	Superinduction of CYP1A1 in MCF10A cultures by cycloheximide, anisomycin, and puromycin: a process independent of effects on protein translation and unrelated to suppression of aryl hydrocarbon receptor proteolysis by the proteasome.	Cycloheximide	47-60	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	18-24
15385644-1	2004	Exposure of the human breast epithelial cell line MCF10A to &gt; or = 1 microg/ml cycloheximide (CHX)-induced accumulations of CYP1A1 mRNA 6-fold greater than that achieved with only 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	Cycloheximide	82-95	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	127-133
15385644-1	2004	Exposure of the human breast epithelial cell line MCF10A to &gt; or = 1 microg/ml cycloheximide (CHX)-induced accumulations of CYP1A1 mRNA 6-fold greater than that achieved with only 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	Cycloheximide	97-100	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	127-133
15385644-2	2004	Cotreatment with CHX and TCDD caused superinduction of CYP1A1 with accumulations of CYP1A1 mRNA 30-fold greater than that achieved with only TCDD.	Cycloheximide	17-20	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	55-61
15385644-2	2004	Cotreatment with CHX and TCDD caused superinduction of CYP1A1 with accumulations of CYP1A1 mRNA 30-fold greater than that achieved with only TCDD.	Cycloheximide	17-20	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	84-90
15456846-8	2004	Furthermore, we find that when cells are exposed to cycloheximide or ultraviolet irradiation, Cdc25B partially translocates to the cytoplasm.	Cycloheximide	52-65	cell division cycle 25B	Homo sapiens	94-100
15385644-9	2004	In contrast, CHX or ANS treatment of MCF10A cultures induced AhR loss and enhanced AhR loss in cultures cotreated with TCDD.	Cycloheximide	13-16	aryl hydrocarbon receptor	Homo sapiens	61-64
15470102-6	2004	In wild-type parental or bet1 cells, secretion of alpha-agglutinin also continued after protein synthesis was blocked with cycloheximide.	Cycloheximide	123-136	Bet1p	Saccharomyces cerevisiae S288C	25-29
15385644-9	2004	In contrast, CHX or ANS treatment of MCF10A cultures induced AhR loss and enhanced AhR loss in cultures cotreated with TCDD.	Cycloheximide	13-16	aryl hydrocarbon receptor	Homo sapiens	83-86
15349772-8	2004	Instead, TfR induction was sensitive to cycloheximide and could be induced by treatment with conditioned media from infected human fibroblasts.	Cycloheximide	40-53	transferrin receptor	Homo sapiens	9-12
15251190-4	2004	Peritoneal thioglycollate-exudated macrophages (PEMs) that were induced to die by combined treatment with LPS and cycloheximide (protein synthesis inhibitor) were killed by the treatment with SOD and catalase in the presence of cycloheximide.	Cycloheximide	114-127	catalase	Mus musculus	200-208
15293224-10	2004	After PB1 extrusion, at which time H4K12 had been deacetylated, H4K12 was re-acetylated in the condensed chromosomes by treatment with cycloheximide but not with roscovitine.	Cycloheximide	135-148	polybromo 1	Mus musculus	6-9
15251190-4	2004	Peritoneal thioglycollate-exudated macrophages (PEMs) that were induced to die by combined treatment with LPS and cycloheximide (protein synthesis inhibitor) were killed by the treatment with SOD and catalase in the presence of cycloheximide.	Cycloheximide	228-241	catalase	Mus musculus	200-208
15358832-6	2004	Most of the SLBP in cycloheximide-treated cells is present on polyribosomes as a result of continued synthesis and transport of the histone mRNP to the cytoplasm.	Cycloheximide	20-33	stem-loop binding protein	Homo sapiens	12-16
15353181-5	2004	Treatment with 10 nM E(2) for 7 h in the presence of cycloheximide increased ERalpha, suggesting that E(2) causes a conformational change in the ERalpha protein.	Cycloheximide	53-66	estrogen receptor 1 (alpha)	Mus musculus	77-84
15353181-5	2004	Treatment with 10 nM E(2) for 7 h in the presence of cycloheximide increased ERalpha, suggesting that E(2) causes a conformational change in the ERalpha protein.	Cycloheximide	53-66	estrogen receptor 1 (alpha)	Mus musculus	145-152
15294803-2	2004	Spontaneous cyh2(R)/cyh2(R) mutants resistant to high levels of cycloheximide can be directly isolated from cyh2(S)/cyh2(S) wine yeasts.	Cycloheximide	64-77	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	12-16
15193149-8	2004	The induction of FN was significantly down-regulated in response to the adenosine receptor antagonist alloxazine and was inhibited by cycloheximide.	Cycloheximide	134-147	fibronectin 1	Homo sapiens	17-19
15254973-6	2004	Consistently, EGF inhibited AngII-stimulated formation of inositol phosphates in the presence of cycloheximide but not in the presence of actinomycin D or cytochalasin D.	Cycloheximide	97-110	epidermal growth factor like 1	Rattus norvegicus	14-17
15254973-6	2004	Consistently, EGF inhibited AngII-stimulated formation of inositol phosphates in the presence of cycloheximide but not in the presence of actinomycin D or cytochalasin D.	Cycloheximide	97-110	angiotensinogen	Rattus norvegicus	28-33
15371131-4	2004	RESULTS: The protein synthesis inhibitor cycloheximide (10 microM) blocked both LPS-induced nitrite formation and iNOS protein expression in LSMC.	Cycloheximide	41-54	nitric oxide synthase 2	Rattus norvegicus	114-118
15177944-7	2004	Incubation with either spironolactone (1 microM), glibenclamide (10 microM), RU 486 10 microM, ODQ (10 microM) or cycloheximide (10 microM) significantly reduced the enhancement of CGRP-relaxation produced by aldosterone, while remained unmodified by SQ 22,536.	Cycloheximide	114-127	calcitonin-related polypeptide alpha	Rattus norvegicus	181-185
15219942-6	2004	In resistant M125 cell, both survivin and DcR1 are overexpressed even after CHX treatment, which can explain relative resistance of these cells.	Cycloheximide	76-79	TNF receptor superfamily member 10c	Homo sapiens	42-46
15289288-6	2004	Albumin-induced expression of iNOS protein was inhibited by cycloheximide and NO production was abolished after incubation of the cells with an iNOS inhibitor, N(G)-monomethyl-l-arginine (LNMMA).	Cycloheximide	60-73	nitric oxide synthase 2	Homo sapiens	30-34
15258907-0	2004	Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells.	Cycloheximide	87-100	heme oxygenase 1	Homo sapiens	0-16
15136564-2	2004	c-Fos, a component of the AP-1 transcription factor, is transiently induced by H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide.	Cycloheximide	150-163	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
15294803-2	2004	Spontaneous cyh2(R)/cyh2(R) mutants resistant to high levels of cycloheximide can be directly isolated from cyh2(S)/cyh2(S) wine yeasts.	Cycloheximide	64-77	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	20-24
15294803-2	2004	Spontaneous cyh2(R)/cyh2(R) mutants resistant to high levels of cycloheximide can be directly isolated from cyh2(S)/cyh2(S) wine yeasts.	Cycloheximide	64-77	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	20-24
15294803-2	2004	Spontaneous cyh2(R)/cyh2(R) mutants resistant to high levels of cycloheximide can be directly isolated from cyh2(S)/cyh2(S) wine yeasts.	Cycloheximide	64-77	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	20-24
15297424-6	2004	In cell lines with wild-type p53, treatment with the protein synthesis inhibitor cycloheximide (CHX) together with anti-CD95 overcame the resistance, suggesting the presence of a labile inhibiting protein.	Cycloheximide	81-94	tumor protein p53	Homo sapiens	29-32
15217807-5	2004	Marked increase in these mRNA levels by TGFbeta1 was inhibited by c-Src-tyrosine kinase inhibitors and protein synthesis inhibitor cycloheximide.	Cycloheximide	131-144	transforming growth factor, beta 1	Mus musculus	40-48
15316656-0	2004	beta2-integrins mediate a novel form of chemoresistance in cycloheximide-induced U937 apoptosis.	Cycloheximide	59-72	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5
15297424-6	2004	In cell lines with wild-type p53, treatment with the protein synthesis inhibitor cycloheximide (CHX) together with anti-CD95 overcame the resistance, suggesting the presence of a labile inhibiting protein.	Cycloheximide	96-99	tumor protein p53	Homo sapiens	29-32
15158594-3	2004	Detection of the UL54 transcript in infected cells by reverse transcription-polymerase chain reaction (RT-PCR) demonstrated that the UL54 gene belonged to the early kinetic class based on sensitivity to cycloheximide and insensitivity to phosphonoacetic acid (PAA).	Cycloheximide	203-216	multifunctional expression regulator	Suid alphaherpesvirus 1	17-21
15326561-4	2004	Although the increase by insulin in these cells was inhibited by treatment with actinomycin D, this was enhanced by treatment with cycloheximide.	Cycloheximide	131-144	insulin	Homo sapiens	25-32
15287883-7	2004	The delayed increase in NCX activity by IFN-gamma for 24 h was blocked by the protein synthesis inhibitor cycloheximide and actinomycin D.	Cycloheximide	106-119	solute carrier family 8 member A1	Rattus norvegicus	24-27
15287883-7	2004	The delayed increase in NCX activity by IFN-gamma for 24 h was blocked by the protein synthesis inhibitor cycloheximide and actinomycin D.	Cycloheximide	106-119	interferon gamma	Rattus norvegicus	40-49
15158594-3	2004	Detection of the UL54 transcript in infected cells by reverse transcription-polymerase chain reaction (RT-PCR) demonstrated that the UL54 gene belonged to the early kinetic class based on sensitivity to cycloheximide and insensitivity to phosphonoacetic acid (PAA).	Cycloheximide	203-216	multifunctional expression regulator	Suid alphaherpesvirus 1	133-137
15181190-2	2004	We have shown that recombinant human IL-8/CXCL8 (rhIL-8/CXCL8) protects cultured IEC against tumor necrosis factor (TNF)-alpha and cycloheximide-induced cytotoxicity.	Cycloheximide	131-144	C-X-C motif chemokine ligand 8	Homo sapiens	37-41
15184910-7	2004	In the presence of cycloheximide, CXCR4 and PAX3 are still inducible, supporting the hypothesis that these genes are direct transcriptional targets of PAX3-FKHR.	Cycloheximide	19-32	C-X-C motif chemokine receptor 4	Homo sapiens	34-39
15184910-7	2004	In the presence of cycloheximide, CXCR4 and PAX3 are still inducible, supporting the hypothesis that these genes are direct transcriptional targets of PAX3-FKHR.	Cycloheximide	19-32	paired box 3	Homo sapiens	44-48
15184910-7	2004	In the presence of cycloheximide, CXCR4 and PAX3 are still inducible, supporting the hypothesis that these genes are direct transcriptional targets of PAX3-FKHR.	Cycloheximide	19-32	paired box 3	Homo sapiens	151-155
15184910-7	2004	In the presence of cycloheximide, CXCR4 and PAX3 are still inducible, supporting the hypothesis that these genes are direct transcriptional targets of PAX3-FKHR.	Cycloheximide	19-32	forkhead box O1	Homo sapiens	156-160
15181190-2	2004	We have shown that recombinant human IL-8/CXCL8 (rhIL-8/CXCL8) protects cultured IEC against tumor necrosis factor (TNF)-alpha and cycloheximide-induced cytotoxicity.	Cycloheximide	131-144	C-X-C motif chemokine ligand 8	Homo sapiens	42-47
15181190-2	2004	We have shown that recombinant human IL-8/CXCL8 (rhIL-8/CXCL8) protects cultured IEC against tumor necrosis factor (TNF)-alpha and cycloheximide-induced cytotoxicity.	Cycloheximide	131-144	C-X-C motif chemokine ligand 8	Homo sapiens	56-61
14976143-8	2004	In an attempt to determine the mechanism by which these gene expressions occurred, we detected the inhibition of protein synthesis by cycloheximide, which up-regulated the expression of thyroperoxidase and thyroglobulin mRNA in HDACI-treated cells and down-regulated that of sodium/iodide symporter mRNA.	Cycloheximide	134-147	thyroid peroxidase	Homo sapiens	186-201
15193999-7	2004	The effect of FK960 on c-Fos was inhibited by PD98059 (10microM), an ERK kinase inhibitor, and cycloheximide (1microg/ml), a transcription inhibitor, and the effect of FK960 on CREB phosphorylation was blocked by PD98059.	Cycloheximide	95-108	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	23-28
15193999-8	2004	The effect of FK960 on GDNF mRNA expression was attenuated by PD98059, curcumin (10microM), an activator protein-1 inhibitor, cycloheximide and actinomycin D (10microg/ml).	Cycloheximide	126-139	glial cell derived neurotrophic factor	Rattus norvegicus	23-27
15094781-6	2004	TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner.	Cycloheximide	101-114	TNF superfamily member 10	Homo sapiens	0-5
15094781-6	2004	TRAIL-induced cell death could be further enhanced by cotreatment of IGR-N91-C8 and SH-EP cells with cycloheximide or subtoxic concentrations of chemotherapeutic drugs in a caspase-dependent manner.	Cycloheximide	101-114	caspase 8	Homo sapiens	173-180
15192330-6	2004	Of note, sensitisation of the Jurkat cells to TRAIL was shown to depend on new protein synthesis, since no enhancement of apoptosis was observed when cells were exposed to both TRAIL and the protein synthesis inhibitor cycloheximide.	Cycloheximide	219-232	TNF superfamily member 10	Homo sapiens	46-51
15256743-0	2004	Dual effects of cycloheximide on U937 apoptosis induced by its combination with VP-16.	Cycloheximide	16-29	host cell factor C1	Homo sapiens	80-85
15256743-2	2004	The presence of CHX markedly prevented VP-16-induced apoptosis, suggesting that in this process de novo protein synthesis is required.	Cycloheximide	16-19	host cell factor C1	Homo sapiens	39-44
15256743-5	2004	In particular, VP-16 even promoted CHX-induced apoptosis, but did not alter its selection of cell types.	Cycloheximide	35-38	host cell factor C1	Homo sapiens	15-20
15202020-8	2004	The effect of zinc sulfate (10(-4) M) in inhibiting RANKL-induced osteoclast-like cell formation was completely abolished in the presence of cycloheximide (10(-7) M), an inhibitor of translation in protein synthesis, or 5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole (DRB; 10(-6) M), an inhibitor of transcription.	Cycloheximide	141-154	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	52-57
15247382-6	2004	A total of 125 bp of the CBF2 promoter, which has previously been shown to be sufficient for cold-, mechanical-, and cycloheximide-induced expression, was also sufficient for ABA-induced expression.	Cycloheximide	117-130	C-repeat/DRE binding factor 2	Arabidopsis thaliana	25-29
15266023-3	2004	Using flow cytometry analyses, TNFalpha enhanced CD38 expression in a manner that was time-(0-24 h), concentration-(0.1-40 ng/ml), and protein synthesis-(cycloheximide blockade) dependent.	Cycloheximide	154-167	tumor necrosis factor	Homo sapiens	31-39
15266023-3	2004	Using flow cytometry analyses, TNFalpha enhanced CD38 expression in a manner that was time-(0-24 h), concentration-(0.1-40 ng/ml), and protein synthesis-(cycloheximide blockade) dependent.	Cycloheximide	154-167	CD38 molecule	Homo sapiens	49-53
15140889-6	2004	However, the protein level of ABCA1 increased, and the rate of its decay in the presence of cycloheximide was slower in the probucol-treated cells.	Cycloheximide	92-105	ATP binding cassette subfamily A member 1	Homo sapiens	30-35
15138068-5	2004	These increases reflect enhanced synthesis of the DHFR-TS enzyme, rather than liberation of a latent activity, as they were completely abolished if cultures were pre-incubated with cycloheximide to block de novo protein synthesis.	Cycloheximide	181-194	dihydrofolate reductase	Homo sapiens	50-54
15224149-7	2004	Verapamil (10 micromol/L), a Ca(2+) channel blocker, and cycloheximide (50 microg/ml), a protein synthesis inhibitor, reduced the immunostaining of c-Myb, and also lowered hCG-induced testosterone secretion in isolated rat Leydig cells.	Cycloheximide	57-70	hypertrichosis 2 (generalised, congenital)	Homo sapiens	172-175
14976143-8	2004	In an attempt to determine the mechanism by which these gene expressions occurred, we detected the inhibition of protein synthesis by cycloheximide, which up-regulated the expression of thyroperoxidase and thyroglobulin mRNA in HDACI-treated cells and down-regulated that of sodium/iodide symporter mRNA.	Cycloheximide	134-147	thyroglobulin	Homo sapiens	206-219
15173890-4	2004	Interestingly, transcription of IFN-gamma but not that of IL-4 was sensitive to cycloheximide treatment, indicating the intrinsic involvement of de novo protein synthesis for IFN-gamma production by NKT cells.	Cycloheximide	80-93	interferon gamma	Homo sapiens	32-41
15007540-9	2004	Incubation of ETs with cycloheximide prior to heat shock reduced the ability of the OE to recover from heat shock at 37 degrees C. Thus the OE of the rat nasal cavity expresses HSP72, and this protein appears to play an important role in the ability of the tissue to withstand hyperthermia.	Cycloheximide	23-36	heat shock protein family A (Hsp70) member 1A	Rattus norvegicus	177-182
15173890-4	2004	Interestingly, transcription of IFN-gamma but not that of IL-4 was sensitive to cycloheximide treatment, indicating the intrinsic involvement of de novo protein synthesis for IFN-gamma production by NKT cells.	Cycloheximide	80-93	interferon gamma	Homo sapiens	175-184
15153524-7	2004	Whereas inhibition of Bax targeting to the mitochondria and inhibition of caspase activation by G-CSF were dependent on protein synthesis, Bid truncation and redistribution were prevented by G-CSF regardless of the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	259-272	BCL2 associated X, apoptosis regulator	Homo sapiens	22-25
15209417-9	2004	Increases in PS1 expression upon treatment with RA and TPA were blocked by treatment with cycloheximide, indicating a role of de-novo protein synthesis in this effect.	Cycloheximide	90-103	presenilin 1	Homo sapiens	13-16
15171706-5	2004	Northern blot analysis of estradiol-treated MCF-7 cells showed rapid and robust induction of Egr3, and addition of cycloheximide or ICI 182,780 suggested that Egr3 is the bona fide target for the estrogen receptor alpha (ERalpha).	Cycloheximide	115-128	early growth response 3	Homo sapiens	159-163
15118344-4	2004	In Hela cells, the induction of Mn-SOD mRNA by YS 51 was in a time- and dose-dependent manner and the expression of Mn-SOD mRNA was increased to a maximum of 4-fold in 9 h. Enhancement of Mn-SOD mRNA by YS 51 was completely abolished by actinomycin D but not cycloheximide, suggesting that the induction of Mn-SOD mRNA byYS 51 is independent of new protein synthesis.	Cycloheximide	259-272	superoxide dismutase 2	Homo sapiens	32-38
15118344-4	2004	In Hela cells, the induction of Mn-SOD mRNA by YS 51 was in a time- and dose-dependent manner and the expression of Mn-SOD mRNA was increased to a maximum of 4-fold in 9 h. Enhancement of Mn-SOD mRNA by YS 51 was completely abolished by actinomycin D but not cycloheximide, suggesting that the induction of Mn-SOD mRNA byYS 51 is independent of new protein synthesis.	Cycloheximide	259-272	superoxide dismutase 2	Homo sapiens	116-122
15118344-4	2004	In Hela cells, the induction of Mn-SOD mRNA by YS 51 was in a time- and dose-dependent manner and the expression of Mn-SOD mRNA was increased to a maximum of 4-fold in 9 h. Enhancement of Mn-SOD mRNA by YS 51 was completely abolished by actinomycin D but not cycloheximide, suggesting that the induction of Mn-SOD mRNA byYS 51 is independent of new protein synthesis.	Cycloheximide	259-272	superoxide dismutase 2	Homo sapiens	116-122
15118344-4	2004	In Hela cells, the induction of Mn-SOD mRNA by YS 51 was in a time- and dose-dependent manner and the expression of Mn-SOD mRNA was increased to a maximum of 4-fold in 9 h. Enhancement of Mn-SOD mRNA by YS 51 was completely abolished by actinomycin D but not cycloheximide, suggesting that the induction of Mn-SOD mRNA byYS 51 is independent of new protein synthesis.	Cycloheximide	259-272	superoxide dismutase 2	Homo sapiens	116-122
15075199-6	2004	Decreased levels of c-IAP2 and XIAP proteins by inactivation of NF-kappaB through AdIkappaBSR infection or treatment with the specific inhibitor Smac also overcame the resistance of polyamine-depleted cells to apoptosis induced by the combination of tumor necrosis factor (TNF)-alpha and cycloheximide (CHX).	Cycloheximide	288-301	X-linked inhibitor of apoptosis	Rattus norvegicus	31-35
15039451-0	2004	A Gcn4p homolog is essential for the induction of a ribosomal protein L41 variant responsible for cycloheximide resistance in the yeast Candida maltosa.	Cycloheximide	98-111	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	2-7
15039451-7	2004	The C-GCN4-depleted mutant was unable to grow in a nutrient medium containing CYH and did not express L41-Q genes.	Cycloheximide	78-81	amino acid starvation-responsive transcription factor GCN4	Saccharomyces cerevisiae S288C	6-10
15024023-6	2004	This activated Akt was associated with both decreased levels of active caspase-3 and increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis.	Cycloheximide	137-150	AKT serine/threonine kinase 1	Homo sapiens	15-18
15024023-6	2004	This activated Akt was associated with both decreased levels of active caspase-3 and increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis.	Cycloheximide	137-150	tumor necrosis factor	Homo sapiens	109-136
15024023-7	2004	Inactivation of Akt by either treatment with LY294002 or ectopic expression of a dominant negative Akt mutant (DNMAkt) not only enhanced the caspase-3 activation in polyamine-deficient cells but also prevented the increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis.	Cycloheximide	266-279	AKT serine/threonine kinase 1	Homo sapiens	16-19
15024023-7	2004	Inactivation of Akt by either treatment with LY294002 or ectopic expression of a dominant negative Akt mutant (DNMAkt) not only enhanced the caspase-3 activation in polyamine-deficient cells but also prevented the increased resistance to tumor necrosis factor-alpha/cycloheximide-induced apoptosis.	Cycloheximide	266-279	AKT serine/threonine kinase 1	Homo sapiens	99-102
15010466-8	2004	In both LPS-treated RAW 264.7 macrophages and fetal calf serum-treated mouse embryonic fibroblasts, TTP protein was stable after induction, with minimal degradation occurring for several hours after treatment of the cells with cycloheximide.	Cycloheximide	227-240	zinc finger protein 36	Mus musculus	100-103
15075199-6	2004	Decreased levels of c-IAP2 and XIAP proteins by inactivation of NF-kappaB through AdIkappaBSR infection or treatment with the specific inhibitor Smac also overcame the resistance of polyamine-depleted cells to apoptosis induced by the combination of tumor necrosis factor (TNF)-alpha and cycloheximide (CHX).	Cycloheximide	303-306	X-linked inhibitor of apoptosis	Rattus norvegicus	31-35
14731112-5	2004	Actinomycin D and cycloheximide inhibited MG132-responsive HO-1 protein expression, indicating a requirement for transcription and de novo protein synthesis.	Cycloheximide	18-31	heme oxygenase 1	Homo sapiens	59-63
15102798-9	2004	Induction of MMP-1 and -3 following MAPK and JAK/STAT activation was cycloheximide sensitive, suggesting synthesis of intermediary proteins is required.	Cycloheximide	69-82	matrix metallopeptidase 1	Homo sapiens	13-18
15141306-7	2004	Combinatorial disruptions of the tricalbin genes revealed that tcb2 single mutants or tcb1, tcb3 double mutants have an altered vacuole morphology and are hypersensitive to cycloheximide.	Cycloheximide	173-186	tricalbin	Saccharomyces cerevisiae S288C	33-42
15141306-7	2004	Combinatorial disruptions of the tricalbin genes revealed that tcb2 single mutants or tcb1, tcb3 double mutants have an altered vacuole morphology and are hypersensitive to cycloheximide.	Cycloheximide	173-186	tricalbin	Saccharomyces cerevisiae S288C	63-67
15141306-7	2004	Combinatorial disruptions of the tricalbin genes revealed that tcb2 single mutants or tcb1, tcb3 double mutants have an altered vacuole morphology and are hypersensitive to cycloheximide.	Cycloheximide	173-186	tricalbin	Saccharomyces cerevisiae S288C	86-90
15141306-8	2004	A screen for single-copy suppressors of the cycloheximide sensitivity of tricalbin mutants yielded RSP5, which encodes a C2-domain-containing, ubiquitin-conjugating ligase essential for receptor-mediated and fluid phase endocytosis.	Cycloheximide	44-57	tricalbin	Saccharomyces cerevisiae S288C	73-82
15141306-8	2004	A screen for single-copy suppressors of the cycloheximide sensitivity of tricalbin mutants yielded RSP5, which encodes a C2-domain-containing, ubiquitin-conjugating ligase essential for receptor-mediated and fluid phase endocytosis.	Cycloheximide	44-57	NEDD4 family E3 ubiquitin-protein ligase	Saccharomyces cerevisiae S288C	99-103
15366422-7	2004	A significant increase in NBC1 mRNA expression level was observed at 6 h and maintained for 24 h. Total NBC1 protein increased at 12 to 24 h with 10% CO2 incubation and this effect was blocked by cycloheximide.	Cycloheximide	196-209	solute carrier family 4 member 4	Homo sapiens	26-30
14982947-7	2004	Addition of cycloheximide demonstrates that IL-15 delays apoptosis via de novo synthesis of intracellular proteins and that it increases myeloid cell differentiation factor-1 stability.	Cycloheximide	12-25	interleukin 15	Homo sapiens	44-49
15366422-7	2004	A significant increase in NBC1 mRNA expression level was observed at 6 h and maintained for 24 h. Total NBC1 protein increased at 12 to 24 h with 10% CO2 incubation and this effect was blocked by cycloheximide.	Cycloheximide	196-209	solute carrier family 4 member 4	Homo sapiens	104-108
17200614-7	2004	We checked the stress-inducible transcription factor, nuclear factor kappa B (NF-kappaB), which was persistently activated by cycloheximide but not by other agents after 24 hours indicating no role of NFkappaB in the RNase L-induction.	Cycloheximide	126-139	nuclear factor kappa B subunit 1	Homo sapiens	54-76
15125768-5	2004	Treatment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms that CYCD3;1 is normally a highly unstable protein, with a half-life of approximately 7 min on CHX treatment.	Cycloheximide	78-91	CYCLIN D3;1	Arabidopsis thaliana	112-117
15125768-5	2004	Treatment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms that CYCD3;1 is normally a highly unstable protein, with a half-life of approximately 7 min on CHX treatment.	Cycloheximide	93-96	CYCLIN D3;1	Arabidopsis thaliana	112-117
15125768-5	2004	Treatment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms that CYCD3;1 is normally a highly unstable protein, with a half-life of approximately 7 min on CHX treatment.	Cycloheximide	202-205	CYCLIN D3;1	Arabidopsis thaliana	112-117
17200614-7	2004	We checked the stress-inducible transcription factor, nuclear factor kappa B (NF-kappaB), which was persistently activated by cycloheximide but not by other agents after 24 hours indicating no role of NFkappaB in the RNase L-induction.	Cycloheximide	126-139	nuclear factor kappa B subunit 1	Homo sapiens	78-87
14681202-6	2004	Protein synthesis inhibitor cycloheximide (CHX) inhibited FSH- or PMA-induced oocyte meiotic resumption, but not the MAPK activation in cumulus cells.	Cycloheximide	28-41	peroneal muscular atrophy	Mus musculus	66-69
15067079-6	2004	Enhanced macrophage-inflammatory protein 1 alpha production may contribute to the prolonged down-regulation of CCR1 cell surface expression observed in response to the TLR2 agonist, as preventing chemokine generation with the protein synthesis inhibitor cycloheximide, or CCR1 signaling with the receptor antagonist UCB35625, abolished TLR2- and TLR4-induced CCR1 down-modulation.	Cycloheximide	254-267	C-C motif chemokine receptor 1	Homo sapiens	9-48
14981545-5	2004	The increase in RAD6 protein expression observed in ADR-treated cells is dependent upon transcription and de novo protein synthesis, as addition of actinomycin D and cycloheximide eliminated the induction effects.	Cycloheximide	166-179	E2 ubiquitin-conjugating protein RAD6	Saccharomyces cerevisiae S288C	16-20
14644748-4	2004	ANG II (&gt;2 h; &gt;10(-9) M) inhibited alpha-MG uptake in a time- and concentration-dependent manner and decreased the protein level of Na+-glucose cotransporters, the expression of which was abrogated by both actinomycin D and cycloheximide exposure.	Cycloheximide	230-243	angiogenin	Oryctolagus cuniculus	0-3
15087236-3	2004	We found that the bitter compound cycloheximide induces phosphorylation of extracellular signal-regulated kinases1 and 2 (ERK 1/2) and inhibits cAMP accumulation in HEK293 cells expressing the mouse bitter T2R(5) receptor.	Cycloheximide	34-47	mitogen-activated protein kinase 1	Homo sapiens	75-120
15087236-3	2004	We found that the bitter compound cycloheximide induces phosphorylation of extracellular signal-regulated kinases1 and 2 (ERK 1/2) and inhibits cAMP accumulation in HEK293 cells expressing the mouse bitter T2R(5) receptor.	Cycloheximide	34-47	mitogen-activated protein kinase 3	Homo sapiens	122-129
15013845-11	2004	Moreover, the inhibitory effect of beta-cryptoxanthin on RANKL plus M-CSF-, PTH-, or TNFalpha-induced osteoclast-like cell formation was not observed in the presence of cycloheximide (10(-7)M), an inhibitor of protein synthesis at translational process, or 5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole (10(-6)M), an inhibitor of transcription.	Cycloheximide	169-182	tumor necrosis factor	Mus musculus	85-93
14681202-6	2004	Protein synthesis inhibitor cycloheximide (CHX) inhibited FSH- or PMA-induced oocyte meiotic resumption, but not the MAPK activation in cumulus cells.	Cycloheximide	43-46	peroneal muscular atrophy	Mus musculus	66-69
15078986-9	2004	De novo protein synthesis was required for initiation of apoptosis in that the protein synthesis inhibitor, cycloheximide, inhibited SBHA-induced conformational changes in Bax as well as changes in mitochondrial membrane permeability and activation of caspase-3.	Cycloheximide	108-121	BCL2 associated X, apoptosis regulator	Homo sapiens	172-175
15039304-2	2004	Previous reports have demonstrated that LPS induced apoptosis in a murine macrophage-like cell line, J744.1, as well as in peritoneal macrophages from C3H/HeN mice in the presence of cycloheximide (CHX).	Cycloheximide	183-196	toll-like receptor 4	Mus musculus	40-43
15039304-2	2004	Previous reports have demonstrated that LPS induced apoptosis in a murine macrophage-like cell line, J744.1, as well as in peritoneal macrophages from C3H/HeN mice in the presence of cycloheximide (CHX).	Cycloheximide	198-201	toll-like receptor 4	Mus musculus	40-43
15037583-4	2004	Annexin V staining was also used to determine the capacity of either cycloheximide or interferon-beta to enhance TRAIL-induced apoptosis.	Cycloheximide	69-82	TNF superfamily member 10	Homo sapiens	113-118
15037583-7	2004	Cycloheximide exerted a profound effect in enhancing TRAIL-induced apoptosis in all but two of the uveal melanoma cell lines and in all three of the metastases cell lines.	Cycloheximide	0-13	TNF superfamily member 10	Homo sapiens	53-58
15034930-0	2004	Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-kappaB in cultured caco-2 cells.	Cycloheximide	26-39	interleukin 6	Homo sapiens	18-22
15034930-0	2004	Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-kappaB in cultured caco-2 cells.	Cycloheximide	26-39	mitogen-activated protein kinase 14	Homo sapiens	106-109
15034930-0	2004	Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-kappaB in cultured caco-2 cells.	Cycloheximide	26-39	nuclear factor kappa B subunit 1	Homo sapiens	125-134
15034930-6	2004	Treatment of Caco-2 cells with cycloheximide (10 microg/ml) increased IL-6 mRNA and protein levels in IL-1beta-treated cells and this was associated with increased mRNA stabilization.	Cycloheximide	31-44	interleukin 6	Homo sapiens	70-74
15034930-6	2004	Treatment of Caco-2 cells with cycloheximide (10 microg/ml) increased IL-6 mRNA and protein levels in IL-1beta-treated cells and this was associated with increased mRNA stabilization.	Cycloheximide	31-44	interleukin 1 beta	Homo sapiens	102-110
15034930-7	2004	In addition, cycloheximide suppressed IkappaBalpha resynthesis and prolonged p38MAP kinase activation and these changes were associated with sustained activation of the transcription factor NF-kappaB.	Cycloheximide	13-26	NFKB inhibitor alpha	Homo sapiens	38-50
15034930-7	2004	In addition, cycloheximide suppressed IkappaBalpha resynthesis and prolonged p38MAP kinase activation and these changes were associated with sustained activation of the transcription factor NF-kappaB.	Cycloheximide	13-26	mitogen-activated protein kinase 14	Homo sapiens	77-80
15034930-7	2004	In addition, cycloheximide suppressed IkappaBalpha resynthesis and prolonged p38MAP kinase activation and these changes were associated with sustained activation of the transcription factor NF-kappaB.	Cycloheximide	13-26	nuclear factor kappa B subunit 1	Homo sapiens	190-199
15034930-9	2004	Our results suggest that superinduction of IL-6 by cycloheximide in enterocytes results from both increased mRNA stabilization and upregulated transcriptional activity mediated by prolonged activation of the p38 MAP kinase and NF-kappaB.	Cycloheximide	51-64	interleukin 6	Homo sapiens	43-47
15034930-9	2004	Our results suggest that superinduction of IL-6 by cycloheximide in enterocytes results from both increased mRNA stabilization and upregulated transcriptional activity mediated by prolonged activation of the p38 MAP kinase and NF-kappaB.	Cycloheximide	51-64	mitogen-activated protein kinase 14	Homo sapiens	208-222
15034930-9	2004	Our results suggest that superinduction of IL-6 by cycloheximide in enterocytes results from both increased mRNA stabilization and upregulated transcriptional activity mediated by prolonged activation of the p38 MAP kinase and NF-kappaB.	Cycloheximide	51-64	nuclear factor kappa B subunit 1	Homo sapiens	227-236
15078986-9	2004	De novo protein synthesis was required for initiation of apoptosis in that the protein synthesis inhibitor, cycloheximide, inhibited SBHA-induced conformational changes in Bax as well as changes in mitochondrial membrane permeability and activation of caspase-3.	Cycloheximide	108-121	caspase 3	Homo sapiens	252-261
15037783-4	2004	The monocytic cell line, THP-1, was treated with cycloheximide and endotoxin to enrich for ARE-mediated gene expression followed by the RT procedure.	Cycloheximide	49-62	GLI family zinc finger 2	Homo sapiens	25-30
15081542-8	2004	CXCL10-induced up-regulation of CXCR3 expression in the three cell lines was inhibited by cycloheximide, indicating that de novo protein synthesis is required for this process.	Cycloheximide	90-103	C-X-C motif chemokine ligand 10	Homo sapiens	0-6
15072547-6	2004	Cycloheximide treatment studies indicated first that estrogen affected the transcript levels of ABCC3 and ABCC5 through dissimilar pathways, and secondly that protein synthesis was needed for modulation of the expression of the CCNA2 and TACC1 genes by estrogens.	Cycloheximide	0-13	ATP binding cassette subfamily C member 3	Homo sapiens	96-101
15072547-6	2004	Cycloheximide treatment studies indicated first that estrogen affected the transcript levels of ABCC3 and ABCC5 through dissimilar pathways, and secondly that protein synthesis was needed for modulation of the expression of the CCNA2 and TACC1 genes by estrogens.	Cycloheximide	0-13	ATP binding cassette subfamily C member 5	Homo sapiens	106-111
15072547-6	2004	Cycloheximide treatment studies indicated first that estrogen affected the transcript levels of ABCC3 and ABCC5 through dissimilar pathways, and secondly that protein synthesis was needed for modulation of the expression of the CCNA2 and TACC1 genes by estrogens.	Cycloheximide	0-13	cyclin A2	Homo sapiens	228-233
15072547-6	2004	Cycloheximide treatment studies indicated first that estrogen affected the transcript levels of ABCC3 and ABCC5 through dissimilar pathways, and secondly that protein synthesis was needed for modulation of the expression of the CCNA2 and TACC1 genes by estrogens.	Cycloheximide	0-13	transforming acidic coiled-coil containing protein 1	Homo sapiens	238-243
15061970-5	2004	Pretreatment with transcription inhibitor actinomycin D and translation inhibitor cycloheximide repressed cytoplasmic AR protein leves to 46% and 12% (means) of the androgen treatment control level respectively.	Cycloheximide	82-95	androgen receptor	Rattus norvegicus	118-120
15469694-7	2004	In addition, the co-treatment of TNF-alpha and cycloheximide decreased the protein level of tTGase and cell viability in the RA-treated cells, supporting the role of tTGase in the protection of cell death.	Cycloheximide	47-60	transglutaminase 2	Homo sapiens	92-98
15469694-7	2004	In addition, the co-treatment of TNF-alpha and cycloheximide decreased the protein level of tTGase and cell viability in the RA-treated cells, supporting the role of tTGase in the protection of cell death.	Cycloheximide	47-60	transglutaminase 2	Homo sapiens	166-172
15081542-8	2004	CXCL10-induced up-regulation of CXCR3 expression in the three cell lines was inhibited by cycloheximide, indicating that de novo protein synthesis is required for this process.	Cycloheximide	90-103	C-X-C motif chemokine receptor 3	Homo sapiens	32-37
14563673-2	2004	We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK.	Cycloheximide	57-70	tumor necrosis factor	Rattus norvegicus	47-56
14749039-7	2004	Semi-quantitative RT-PCR and Southern blotting showed that insulin also increased P-LAP mRNA, which was abrogated by prior exposure to cycloheximide.	Cycloheximide	135-148	insulin	Homo sapiens	59-66
14749039-7	2004	Semi-quantitative RT-PCR and Southern blotting showed that insulin also increased P-LAP mRNA, which was abrogated by prior exposure to cycloheximide.	Cycloheximide	135-148	leucyl and cystinyl aminopeptidase	Homo sapiens	82-87
15003278-5	2004	The half-life of the two forms of the androgen receptor was approximately 6 h, as determined by cycloheximide chase.	Cycloheximide	96-109	androgen receptor	Homo sapiens	38-55
14630716-2	2004	We have previously shown that cytokine-induced iNOS expression is cycloheximide (CHX) sensitive and requires nuclear factor-kappa B (NF-kappa B) activation.	Cycloheximide	66-79	nitric oxide synthase 2	Rattus norvegicus	47-51
14630716-2	2004	We have previously shown that cytokine-induced iNOS expression is cycloheximide (CHX) sensitive and requires nuclear factor-kappa B (NF-kappa B) activation.	Cycloheximide	81-84	nitric oxide synthase 2	Rattus norvegicus	47-51
15009193-6	2004	In addition, we show that in the presence of cycloheximide or diazaborine PDR5 can be activated by additional transcription factors beside Pdr1p and Pdr3p.	Cycloheximide	45-58	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	149-154
15009193-6	2004	In addition, we show that in the presence of cycloheximide or diazaborine PDR5 can be activated by additional transcription factors beside Pdr1p and Pdr3p.	Cycloheximide	45-58	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	74-78
15009193-6	2004	In addition, we show that in the presence of cycloheximide or diazaborine PDR5 can be activated by additional transcription factors beside Pdr1p and Pdr3p.	Cycloheximide	45-58	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	139-144
14563673-2	2004	We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK.	Cycloheximide	57-70	mitogen-activated protein kinase 8	Rattus norvegicus	203-206
14563673-2	2004	We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK.	Cycloheximide	72-75	tumor necrosis factor	Rattus norvegicus	47-56
14563673-2	2004	We have recently reported that protection from TNF-alpha/cycloheximide (CHX)-induced apoptosis in epithelial cells depleted of polyamines is mediated through the inactivation of a proapoptotic mediator, JNK.	Cycloheximide	72-75	mitogen-activated protein kinase 8	Rattus norvegicus	203-206
15047883-4	2004	Cycloheximide repressed the -S induction of SULTR1;1, but enhanced the basal mRNA level of SULTR1;1 under sulfur replete (+S) condition.	Cycloheximide	0-13	sulfate transporter 1;1	Arabidopsis thaliana	91-99
15007258-13	2004	In all the experiments, exposure to CHX abolished caspase-3 activity and Hsp60 synthesis.	Cycloheximide	36-39	caspase-3	Cavia porcellus	50-59
15047883-4	2004	Cycloheximide repressed the -S induction of SULTR1;1, but enhanced the basal mRNA level of SULTR1;1 under sulfur replete (+S) condition.	Cycloheximide	0-13	sulfate transporter 1;1	Arabidopsis thaliana	44-52
15009675-8	2004	Both up-regulation of ferritin content by iron application and up-regulation of TfR content by DFX were prevented by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	149-162	transferrin receptor	Rattus norvegicus	80-83
15009675-8	2004	Both up-regulation of ferritin content by iron application and up-regulation of TfR content by DFX were prevented by the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	164-167	transferrin receptor	Rattus norvegicus	80-83
14996278-4	2004	The effect of indomethacin, dexamethasone, or cycloheximide (CHX) on the IL-1beta-induced expression of MMP-1 was examined.	Cycloheximide	46-59	interleukin 1 beta	Homo sapiens	73-81
14996278-4	2004	The effect of indomethacin, dexamethasone, or cycloheximide (CHX) on the IL-1beta-induced expression of MMP-1 was examined.	Cycloheximide	46-59	matrix metallopeptidase 1	Homo sapiens	104-109
14996278-4	2004	The effect of indomethacin, dexamethasone, or cycloheximide (CHX) on the IL-1beta-induced expression of MMP-1 was examined.	Cycloheximide	61-64	interleukin 1 beta	Homo sapiens	73-81
14996278-4	2004	The effect of indomethacin, dexamethasone, or cycloheximide (CHX) on the IL-1beta-induced expression of MMP-1 was examined.	Cycloheximide	61-64	matrix metallopeptidase 1	Homo sapiens	104-109
14660677-3	2004	We show here that subsequent transcription of the cyclin D2 gene occurs by a delayed, cycloheximide-sensitive mechanism, which implies the involvement of additional regulatory mechanisms.	Cycloheximide	86-99	cyclin D2	Homo sapiens	50-59
14691455-4	2004	NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide.	Cycloheximide	94-107	MYCN proto-oncogene, bHLH transcription factor	Homo sapiens	26-31
14607841-6	2004	Cycloheximide and pulse-chase experiments revealed that the decreased expression levels of [L166P]DJ-1 were because of accelerated protein turnover.	Cycloheximide	0-13	Parkinsonism associated deglycase	Homo sapiens	98-102
14660677-6	2004	Instead, we found that Stat5 activates the phosphatidylinositol 3-kinase (PI3 kinase) pathway by a delayed, cycloheximide-sensitive mechanism and that PI3 kinase activity is essential for the induction of cyclin D2 by Stat5.	Cycloheximide	108-121	signal transducer and activator of transcription 5A	Homo sapiens	23-28
14743437-8	2004	In addition, the increase in astroglial gammaGT activity after application of TNFalpha was prevented completely by the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	163-176	gamma-glutamyltransferase 1	Rattus norvegicus	40-47
14743437-8	2004	In addition, the increase in astroglial gammaGT activity after application of TNFalpha was prevented completely by the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	163-176	tumor necrosis factor	Rattus norvegicus	78-86
14623896-7	2004	Studies with cycloheximide treatment showed that protein synthesis induced in the first 24 h after IFN-gamma treatment was required for apoptosis under these conditions.	Cycloheximide	13-26	interferon gamma	Homo sapiens	99-108
15143625-2	2004	Here we report that t-ACPD, a metabotropic glutamate receptor (mGluR) agonist, produced small increases in CaBP-IR which was potentiated by a mGluR antagonist The increase in CaBPIR was not due to de novo protein synthesis because the translational inhibitors (cycloheximide and emetine) or transciptional inhibitors (actinomycine-D and a-amanitine), did not prevent the EAA enhanced CaBP-IR.	Cycloheximide	261-274	S100 calcium binding protein G	Rattus norvegicus	107-111
14734658-8	2004	Finally, in three types of non-neurosecretory cells (CV-1, adenocarcinoma TS/A and a clone of PC12 incompetent for secretion) the transfected chromogranin A accumulated mostly in the Golgi/transGolgi area and was released rapidly from resting cells (constitutive secretion) as revealed by both immunofluorescence during cycloheximide treatment and pulse-chase experiments.	Cycloheximide	320-333	chromogranin A	Rattus norvegicus	142-156
14764712-0	2004	Calcium and its role in the nuclear translocation and activation of cytosolic phospholipase A2 in cells rendered sensitive to TNF-induced apoptosis by cycloheximide.	Cycloheximide	151-164	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	68-94
14764712-0	2004	Calcium and its role in the nuclear translocation and activation of cytosolic phospholipase A2 in cells rendered sensitive to TNF-induced apoptosis by cycloheximide.	Cycloheximide	151-164	tumor necrosis factor	Mus musculus	126-129
14769821-8	2004	Cycloheximide prevented up-regulation of eNOS protein, indicating that post-translational stabilization of eNOS is not involved.	Cycloheximide	0-13	nitric oxide synthase 3	Bos taurus	41-45
14975243-1	2004	The chemokine RANTES is secreted rapidly after activation of human CD8+ T cells, with a cycloheximide-resistant burst during the first hour.	Cycloheximide	88-101	C-C motif chemokine ligand 5	Homo sapiens	14-20
14762791-5	2004	Cycloheximide, an inhibitor of protein translation, induced a microtubule- and p38(MAP) kinase-dependent decrease of Golgi-associated BSEP, accompanied by a more than 2-fold increase in BSEP-positive pseudocanaliculi.	Cycloheximide	0-13	mitogen-activated protein kinase 14	Homo sapiens	79-94
14762791-5	2004	Cycloheximide, an inhibitor of protein translation, induced a microtubule- and p38(MAP) kinase-dependent decrease of Golgi-associated BSEP, accompanied by a more than 2-fold increase in BSEP-positive pseudocanaliculi.	Cycloheximide	0-13	ATP binding cassette subfamily B member 11	Homo sapiens	134-138
14762791-5	2004	Cycloheximide, an inhibitor of protein translation, induced a microtubule- and p38(MAP) kinase-dependent decrease of Golgi-associated BSEP, accompanied by a more than 2-fold increase in BSEP-positive pseudocanaliculi.	Cycloheximide	0-13	ATP binding cassette subfamily B member 11	Homo sapiens	186-190
15009103-9	2004	The addition of cycloheximide to the cell cultures strongly inhibited the increase of VEGF proteins in TGF-beta1-stimulated NHFs.	Cycloheximide	16-29	vascular endothelial growth factor A	Homo sapiens	86-90
15009103-9	2004	The addition of cycloheximide to the cell cultures strongly inhibited the increase of VEGF proteins in TGF-beta1-stimulated NHFs.	Cycloheximide	16-29	transforming growth factor beta 1	Homo sapiens	103-112
14643888-8	2004	In addition, we observed that both TGF-beta1-induced apoptosis and PARP degradation in AML-12 cells can be completely blocked by inhibiting the protein synthesis with cycloheximide.	Cycloheximide	167-180	transforming growth factor, beta 1	Mus musculus	35-44
14643888-8	2004	In addition, we observed that both TGF-beta1-induced apoptosis and PARP degradation in AML-12 cells can be completely blocked by inhibiting the protein synthesis with cycloheximide.	Cycloheximide	167-180	poly (ADP-ribose) polymerase family, member 1	Mus musculus	67-71
14975243-3	2004	In contrast, secretion of other chemokines and interferon-gamma by these cells was sensitive to cycloheximide and detectable only after a lag.	Cycloheximide	96-109	interferon gamma	Homo sapiens	47-63
14603531-8	2004	Additionally, analysis utilizing protein synthesis inhibitor cycloheximide demonstrated that pHi mediated inhibition of COX-2 mRNA expression requires de novo protein synthesis of regulatory protein(s).	Cycloheximide	61-74	glucose-6-phosphate isomerase	Homo sapiens	93-96
14603531-8	2004	Additionally, analysis utilizing protein synthesis inhibitor cycloheximide demonstrated that pHi mediated inhibition of COX-2 mRNA expression requires de novo protein synthesis of regulatory protein(s).	Cycloheximide	61-74	prostaglandin-endoperoxide synthase 2	Homo sapiens	120-125
14592538-4	2004	We show here that inhibitory concentrations of cycloheximide (CHX) and anisomycin (ANISO) differentially affect BESpm-induced SSAT activity in 2008 and in C13* cells in a concentration-dependent manner and allow resistant cells to reach activation levels comparable to those of the sensitive cells.	Cycloheximide	47-60	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	126-130
14743399-4	2004	We found that treatment with cycloheximide, a protein synthesis inhibitor, remarkably increased CD40 mRNA levels by semi-quantitative RT-PCR.	Cycloheximide	29-42	CD40 antigen	Mus musculus	96-100
14743399-6	2004	After treatment with cycloheximide, and further cultivation in fresh medium, CD40 protein levels were found to increase by flow cytometry.	Cycloheximide	21-34	CD40 antigen	Mus musculus	77-81
14966463-7	2004	The response to IL-1beta was consistent in the total cell and nuclear extracts and was significantly reduced by pretreatment with actinomycin D or cycloheximide.	Cycloheximide	147-160	interleukin 1 beta	Homo sapiens	16-24
14717847-8	2004	Tyrosinase activation by quercetin was blocked by actinomycin-D or by cycloheximide demonstrating that its actions in stimulating melanogenesis may involve both transcriptional and translational events.	Cycloheximide	70-83	tyrosinase	Homo sapiens	0-10
14697509-5	2004	Analysis of expression difference between them and IFN signal factors, CaSTAT1 and CaIRF7, indicated that their transcriptions were mediated possibly through JAK-STAT signal pathway, which was further supported by the induction analysis in UV-inactivated GCHV infected, IFN-treated and untreated cells in the presence or absence of cycloheximide (CHX), a potent inhibitor of protein synthesis.	Cycloheximide	332-345	interferon alpha 1	Homo sapiens	51-54
14697509-5	2004	Analysis of expression difference between them and IFN signal factors, CaSTAT1 and CaIRF7, indicated that their transcriptions were mediated possibly through JAK-STAT signal pathway, which was further supported by the induction analysis in UV-inactivated GCHV infected, IFN-treated and untreated cells in the presence or absence of cycloheximide (CHX), a potent inhibitor of protein synthesis.	Cycloheximide	332-345	interferon alpha 1	Homo sapiens	270-273
14697509-5	2004	Analysis of expression difference between them and IFN signal factors, CaSTAT1 and CaIRF7, indicated that their transcriptions were mediated possibly through JAK-STAT signal pathway, which was further supported by the induction analysis in UV-inactivated GCHV infected, IFN-treated and untreated cells in the presence or absence of cycloheximide (CHX), a potent inhibitor of protein synthesis.	Cycloheximide	347-350	interferon alpha 1	Homo sapiens	51-54
14697509-5	2004	Analysis of expression difference between them and IFN signal factors, CaSTAT1 and CaIRF7, indicated that their transcriptions were mediated possibly through JAK-STAT signal pathway, which was further supported by the induction analysis in UV-inactivated GCHV infected, IFN-treated and untreated cells in the presence or absence of cycloheximide (CHX), a potent inhibitor of protein synthesis.	Cycloheximide	347-350	interferon alpha 1	Homo sapiens	270-273
15512768-4	2004	In contrast, aprotinin, cycloheximide, staurosporine, H7, and Go6976 could suppress MMP-2 secretion in all tissue cultures and also decrease MMP-9 production in all synovial and some meniscal cultures.	Cycloheximide	24-37	matrix metallopeptidase 2	Homo sapiens	84-89
15512768-4	2004	In contrast, aprotinin, cycloheximide, staurosporine, H7, and Go6976 could suppress MMP-2 secretion in all tissue cultures and also decrease MMP-9 production in all synovial and some meniscal cultures.	Cycloheximide	24-37	matrix metallopeptidase 9	Homo sapiens	141-146
14743399-7	2004	Additionally, we found that cycloheximide treatment appeared to downregulate the Bcl-xL mRNA level but not the Bax mRNA level by RNase protection assay.	Cycloheximide	28-41	BCL2-like 1	Mus musculus	81-87
14743399-8	2004	Because the upregulation of CD40 mRNA and the downregulation of Bcl-xL correlated with CT26 cell death, our results suggest that chemotherapeutic agents, including cycloheximide, may exert their synergistic effects on the TNF family treatment of cancer cells by regulating the mRNA levels of apoptosis-related genes.	Cycloheximide	164-177	CD40 antigen	Mus musculus	28-32
14743399-8	2004	Because the upregulation of CD40 mRNA and the downregulation of Bcl-xL correlated with CT26 cell death, our results suggest that chemotherapeutic agents, including cycloheximide, may exert their synergistic effects on the TNF family treatment of cancer cells by regulating the mRNA levels of apoptosis-related genes.	Cycloheximide	164-177	BCL2-like 1	Mus musculus	64-70
14758339-12	2004	Cycloheximide inhibited LEI synthesis and protected cells against apoptosis.	Cycloheximide	0-13	serpin family B member 1	Homo sapiens	24-27
15062559-5	2004	However, this up-regulation was inhibited by cycloheximide, indicating that GADD45gamma induction by androgens requires new protein synthesis.	Cycloheximide	45-58	growth arrest and DNA damage inducible gamma	Homo sapiens	76-87
15062560-5	2004	GA accelerated relocalization of GR in the cytoplasm even when reimport of GR into the nucleus was inhibited by okadaic acid or when novel GR synthesis was inhibited by cycloheximide.	Cycloheximide	169-182	nuclear receptor subfamily 3 group C member 1	Homo sapiens	33-35
14510636-3	2004	Inhibition of protein synthesis with CHX (cycloheximide) completely blocks induction of NQO1 by TCDD as well as the basal expression and induction by phenolic antioxidant tBHQ (2-t-butylbenzene-1,4-diol), implicating a labile factor in NQO1 mRNA expression.	Cycloheximide	37-40	NAD(P)H dehydrogenase, quinone 1	Mus musculus	88-92
14510636-3	2004	Inhibition of protein synthesis with CHX (cycloheximide) completely blocks induction of NQO1 by TCDD as well as the basal expression and induction by phenolic antioxidant tBHQ (2-t-butylbenzene-1,4-diol), implicating a labile factor in NQO1 mRNA expression.	Cycloheximide	37-40	NAD(P)H dehydrogenase, quinone 1	Mus musculus	236-240
14510636-3	2004	Inhibition of protein synthesis with CHX (cycloheximide) completely blocks induction of NQO1 by TCDD as well as the basal expression and induction by phenolic antioxidant tBHQ (2-t-butylbenzene-1,4-diol), implicating a labile factor in NQO1 mRNA expression.	Cycloheximide	42-55	NAD(P)H dehydrogenase, quinone 1	Mus musculus	88-92
14510636-3	2004	Inhibition of protein synthesis with CHX (cycloheximide) completely blocks induction of NQO1 by TCDD as well as the basal expression and induction by phenolic antioxidant tBHQ (2-t-butylbenzene-1,4-diol), implicating a labile factor in NQO1 mRNA expression.	Cycloheximide	42-55	NAD(P)H dehydrogenase, quinone 1	Mus musculus	236-240
14592538-4	2004	We show here that inhibitory concentrations of cycloheximide (CHX) and anisomycin (ANISO) differentially affect BESpm-induced SSAT activity in 2008 and in C13* cells in a concentration-dependent manner and allow resistant cells to reach activation levels comparable to those of the sensitive cells.	Cycloheximide	62-65	spermidine/spermine N1-acetyltransferase 1	Homo sapiens	126-130
14584042-5	2004	The induction of Glvr-2 mRNA by Pi was inhibited in the presence of cycloheximide (CHX).	Cycloheximide	68-81	solute carrier family 20 member 2	Rattus norvegicus	17-23
14584042-5	2004	The induction of Glvr-2 mRNA by Pi was inhibited in the presence of cycloheximide (CHX).	Cycloheximide	83-86	solute carrier family 20 member 2	Rattus norvegicus	17-23
14671092-7	2004	Cycloheximide block-and-release experiments clearly demonstrated that even in the presence of enough amounts of the BZLF1 protein, purvalanol A blocked expression of lytic viral proteins at transcription level.	Cycloheximide	0-13	protein Zta	Human gammaherpesvirus 4	116-121
14999519-7	2004	The induction of OPG mRNA expression by stretching was inhibited in the presence of indomethacin or genistein, whereas TIMP-1 mRNA expression induced by stretching was inhibited by the addition of cycloheximide, suggesting that tensile stress regulates cyclooxygenase activities, tyrosine phosphorylation, and de novo protein synthesis in PDL cells through the induction of OPG and TIMP-1 mRNA expression.	Cycloheximide	197-210	TIMP metallopeptidase inhibitor 1	Homo sapiens	119-125
14999519-7	2004	The induction of OPG mRNA expression by stretching was inhibited in the presence of indomethacin or genistein, whereas TIMP-1 mRNA expression induced by stretching was inhibited by the addition of cycloheximide, suggesting that tensile stress regulates cyclooxygenase activities, tyrosine phosphorylation, and de novo protein synthesis in PDL cells through the induction of OPG and TIMP-1 mRNA expression.	Cycloheximide	197-210	TNF receptor superfamily member 11b	Homo sapiens	374-377
14999519-7	2004	The induction of OPG mRNA expression by stretching was inhibited in the presence of indomethacin or genistein, whereas TIMP-1 mRNA expression induced by stretching was inhibited by the addition of cycloheximide, suggesting that tensile stress regulates cyclooxygenase activities, tyrosine phosphorylation, and de novo protein synthesis in PDL cells through the induction of OPG and TIMP-1 mRNA expression.	Cycloheximide	197-210	TIMP metallopeptidase inhibitor 1	Homo sapiens	382-388
14746834-6	2004	This IGF-2-induced glutamine transport activity was attenuated by actinomycin-D or cycloheximide.	Cycloheximide	83-96	insulin-like growth factor 2	Rattus norvegicus	5-10
14709150-6	2004	Actinomycin D and cycloheximide completely blocked the effect of ACTH on HO-1 mRNA expression whereas mRNA stability was not affected by ACTH.	Cycloheximide	18-31	pro-opiomelanocortin-alpha	Mus musculus	65-69
14709150-6	2004	Actinomycin D and cycloheximide completely blocked the effect of ACTH on HO-1 mRNA expression whereas mRNA stability was not affected by ACTH.	Cycloheximide	18-31	heme oxygenase 1	Mus musculus	73-77
14688367-11	2004	FLIP-caspase-8 balance seems tightly regulated in fibroblasts by extracellular factors that determine their susceptibility to Fas- or Fas-CHX-induced apoptosis.	Cycloheximide	138-141	caspase 8	Homo sapiens	5-14
15004651-7	2004	IGF-1 at a concentration of 10 ng/ml significantly reduced the level of apoptosis induced by puromycin, emetine, or cycloheximide.	Cycloheximide	116-129	insulin like growth factor 1	Homo sapiens	0-5
14630082-2	2004	In this study, we demonstrated that a potent NF-kappaB inhibitor, Nalpha-tosyl-L-lysinyl chloromethyl ketone (TLCK), inhibits apoptosis of THP-1 cells triggered by etoposide (VP16), and actinomycin D (ACT D) or cycloheximide inhibits apoptosis.	Cycloheximide	211-224	nuclear factor kappa B subunit 1	Homo sapiens	45-54
14681852-3	2004	These events, which are actinomycin- and cycloheximide-sensitive, occur only in activated, but not nonactivated, CD4(+) and CD8(+) lymphocytes.	Cycloheximide	41-54	CD4 molecule	Homo sapiens	113-116
14681852-3	2004	These events, which are actinomycin- and cycloheximide-sensitive, occur only in activated, but not nonactivated, CD4(+) and CD8(+) lymphocytes.	Cycloheximide	41-54	CD8a molecule	Homo sapiens	124-127
14690445-2	2003	We report that uninfected Sf9 cells readily undergo apoptosis and show increased phosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eIF2alpha) in the presence of agents such as UVB light, etoposide, high concentrations of cycloheximide, and EGTA.	Cycloheximide	243-256	eukaryotic translation initiation factor 2A	Homo sapiens	153-162
15633612-3	2004	We found that low dose H2O2 induced increased FAK production in pulmonary microvascular endothelial cells, which could be blocked by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	133-146	protein tyrosine kinase 2	Homo sapiens	46-49
15633612-3	2004	We found that low dose H2O2 induced increased FAK production in pulmonary microvascular endothelial cells, which could be blocked by cycloheximide (CHX), a protein synthesis inhibitor.	Cycloheximide	148-151	protein tyrosine kinase 2	Homo sapiens	46-49
14690445-3	2003	In contrast, tunicamycin, A23187, and low concentrations of cycloheximide promoted eIF2alpha phosphorylation in Sf9 cells but without apoptosis.	Cycloheximide	60-73	eukaryotic translation initiation factor 2A	Homo sapiens	83-92
14632785-10	2003	Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX).	Cycloheximide	123-136	TNF superfamily member 10	Homo sapiens	35-40
12890646-3	2003	We found that cycloheximide blocked IL-1beta-induced downregulation of elastin mRNA but did not inhibit IL-1beta-induced translocation of p65 into the nucleus.	Cycloheximide	14-27	elastin	Rattus norvegicus	71-78
15033719-1	2003	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in most tumor cells, a process sometimes potentiated by chemotherapeutic drugs or cycloheximide (CHX).	Cycloheximide	176-189	TNF superfamily member 10	Homo sapiens	0-55
15033719-1	2003	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in most tumor cells, a process sometimes potentiated by chemotherapeutic drugs or cycloheximide (CHX).	Cycloheximide	176-189	TNF superfamily member 10	Homo sapiens	57-62
14632785-10	2003	Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX).	Cycloheximide	123-136	caspase 8	Homo sapiens	57-66
14632785-10	2003	Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX).	Cycloheximide	138-141	TNF superfamily member 10	Homo sapiens	35-40
14632785-10	2003	Interestingly, in some cell lines, TRAIL sensitivity and caspase-8 activity was enhanced or restored with the treatment of cycloheximide (CHX).	Cycloheximide	138-141	caspase 8	Homo sapiens	57-66
14632785-11	2003	In addition, X-linked inhibitor of apoptosis (XIAP) levels decreased significantly and rapidly following treatment with CHX.	Cycloheximide	120-123	X-linked inhibitor of apoptosis	Homo sapiens	13-44
14632785-11	2003	In addition, X-linked inhibitor of apoptosis (XIAP) levels decreased significantly and rapidly following treatment with CHX.	Cycloheximide	120-123	X-linked inhibitor of apoptosis	Homo sapiens	46-50
14632785-12	2003	Down-regulation of XIAP may be responsible for enhancement or restoration of TRAIL sensitivity after CHX treatment in B-lymphocytic leukaemia cells.	Cycloheximide	101-104	X-linked inhibitor of apoptosis	Homo sapiens	19-23
14632785-12	2003	Down-regulation of XIAP may be responsible for enhancement or restoration of TRAIL sensitivity after CHX treatment in B-lymphocytic leukaemia cells.	Cycloheximide	101-104	TNF superfamily member 10	Homo sapiens	77-82
14624478-5	2003	RT-PCR and cycloheximide inhibition studies confirmed that MMP was synthesized by P0 HUVE.	Cycloheximide	11-24	matrix metallopeptidase 9	Homo sapiens	59-62
14681550-5	2003	Using staurosporine, TNF-alpha plus cycloheximide, and gamma-radiations, we observed that ACH-2 were more sensitive to programmed cell death than A301, while U1 were less sensitive than U937.	Cycloheximide	36-49	acyl-CoA thioesterase 1	Homo sapiens	90-95
14665469-7	2003	The mislocalized DeltaF774 mutant Cdr1p could be rescued to the plasma membrane as a functional transporter by growth in the presence of a Cdr1p substrate, cycloheximide.	Cycloheximide	156-169	cerebellar degeneration related protein 1	Homo sapiens	34-39
14665469-7	2003	The mislocalized DeltaF774 mutant Cdr1p could be rescued to the plasma membrane as a functional transporter by growth in the presence of a Cdr1p substrate, cycloheximide.	Cycloheximide	156-169	cerebellar degeneration related protein 1	Homo sapiens	139-144
14645681-2	2003	Proenkephalin (PEnk) gene activation after depolarization of chromaffin cells with 40 mM KCl was blocked by the voltage-sensitive calcium-channel blocker methoxyverapamil (D600) (30 microM) and by calcineurin inhibition with 100 nM cyclosporin A or ascomycin but not by inhibiting new protein synthesis with 0.5 microg/ml cycloheximide.	Cycloheximide	322-335	proenkephalin	Homo sapiens	0-13
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	120-133	ubiquitin	Saccharomyces cerevisiae S288C	20-29
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	120-133	ubiquitin	Saccharomyces cerevisiae S288C	135-144
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	120-133	ubiquitin	Saccharomyces cerevisiae S288C	135-144
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	182-195	ubiquitin	Saccharomyces cerevisiae S288C	20-29
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	182-195	ubiquitin	Saccharomyces cerevisiae S288C	135-144
14645527-2	2003	Here we report that ubiquitin levels are critical for the survival of Saccharomyces cerevisiae cells in the presence of cycloheximide: ubiquitin overexpression confers resistance to cycloheximide, while a reduced ubiquitin level confers sensitivity.	Cycloheximide	182-195	ubiquitin	Saccharomyces cerevisiae S288C	135-144
14662022-6	2003	Treatment with the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 or with the protein synthesis inhibitor cycloheximide induced a suppression of constitutive Akt activation in SNU-216 cells and a concomitant decrease in the expression of FLIP(S).	Cycloheximide	115-128	AKT serine/threonine kinase 1	Homo sapiens	167-170
14662022-8	2003	As a result, LY294002 or cycloheximide significantly enhanced TRAIL-induced apoptosis.	Cycloheximide	25-38	TNF superfamily member 10	Homo sapiens	62-67
14645681-2	2003	Proenkephalin (PEnk) gene activation after depolarization of chromaffin cells with 40 mM KCl was blocked by the voltage-sensitive calcium-channel blocker methoxyverapamil (D600) (30 microM) and by calcineurin inhibition with 100 nM cyclosporin A or ascomycin but not by inhibiting new protein synthesis with 0.5 microg/ml cycloheximide.	Cycloheximide	322-335	proenkephalin	Homo sapiens	15-19
14645681-3	2003	KCl-induced elevation of PEnk mRNA was distinct from activation of the PEnk gene by either cAMP or protein kinase C. Twenty-five micromolar forskolin- and 100 nM phorbol 12-myristate 13-acetate-induced elevations of PEnk mRNA were cycloheximide-sensitive and were not blocked by cyclosporin A or ascomycin.	Cycloheximide	231-244	proenkephalin	Homo sapiens	25-29
14673498-7	2003	Oleate, however, increased ABCA1 turnover when protein synthesis was blocked by cycloheximide.	Cycloheximide	80-93	ATP binding cassette subfamily A member 1	Homo sapiens	27-32
14751030-9	2003	In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not.	Cycloheximide	121-134	two pore segment channel 1	Homo sapiens	8-13
14751030-11	2003	In conclusion, TRAIL in combination with troglitazone, paclitaxel, and cycloheximide induces apoptosis in thyroid cancer cells at suboptimal concentrations that cannot be achieved using TRAIL alone.	Cycloheximide	71-84	TNF superfamily member 10	Homo sapiens	15-20
14751030-9	2003	In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not.	Cycloheximide	121-134	TNF superfamily member 10	Homo sapiens	15-20
14751030-11	2003	In conclusion, TRAIL in combination with troglitazone, paclitaxel, and cycloheximide induces apoptosis in thyroid cancer cells at suboptimal concentrations that cannot be achieved using TRAIL alone.	Cycloheximide	71-84	TNF superfamily member 10	Homo sapiens	186-191
14751030-9	2003	In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not.	Cycloheximide	121-134	TNF superfamily member 10	Homo sapiens	45-50
14751030-9	2003	In both TPC-1 (TRAIL-sensitive) and FTC-133 (TRAIL-resistant) thyroid cancer cell lines, pretreatment with troglitazone, cycloheximide, and paclitaxel enhanced TRAIL-induced cell death significantly but pretreatment with geldanamycin did not.	Cycloheximide	121-134	TNF superfamily member 10	Homo sapiens	45-50
14636649-2	2003	In 32Dcl3 cells, C/EBPalpha-ER rapidly induces the PU.1 and C/EBPalpha RNAs even in the presence of cycloheximide, suggesting that these are direct C/EBPalpha genetic targets.	Cycloheximide	100-113	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	17-27
14599741-5	2003	The results show that in both cellular conditions, the inhibition of UV-dependent de novo protein synthesis by cycloheximide impairs the excision repair of the transcriptionally active GAL10 and URA3 genes, with a greater effect on the non-transcribed strands.	Cycloheximide	111-124	bifunctional UDP-glucose 4-epimerase/aldose 1-epimerase	Saccharomyces cerevisiae S288C	185-190
14599741-5	2003	The results show that in both cellular conditions, the inhibition of UV-dependent de novo protein synthesis by cycloheximide impairs the excision repair of the transcriptionally active GAL10 and URA3 genes, with a greater effect on the non-transcribed strands.	Cycloheximide	111-124	orotidine-5'-phosphate decarboxylase	Saccharomyces cerevisiae S288C	195-199
14597412-6	2003	In agreement with previous studies, low levels of cycloheximide increase the proportions and sizes of polysomes in absorbance profiles, and increase the proportions and sizes of polysomes translating four 5" TOP mRNA species including the Rpl32 mRNA in 8-day seminiferous tubules.	Cycloheximide	50-63	ribosomal protein L32	Mus musculus	239-244
12869386-5	2003	Significant apoptosis was observed when CHX was given along with TNF-alpha, as indicated by a significant increase in the detachment of cells, caspase-3 activity, and DNA fragmentation.	Cycloheximide	40-43	tumor necrosis factor	Rattus norvegicus	65-74
12869386-5	2003	Significant apoptosis was observed when CHX was given along with TNF-alpha, as indicated by a significant increase in the detachment of cells, caspase-3 activity, and DNA fragmentation.	Cycloheximide	40-43	caspase 3	Rattus norvegicus	143-152
14645527-3	2003	Consistent with these findings, ubiquitin is unstable in yeast (t(1/2) = 2 h) and is rapidly depleted upon cycloheximide treatment.	Cycloheximide	107-120	ubiquitin	Saccharomyces cerevisiae S288C	32-41
14645527-4	2003	Cycloheximide does not noticeably enhance ubiquitin turnover, but serves principally to block ubiquitin synthesis.	Cycloheximide	0-13	ubiquitin	Saccharomyces cerevisiae S288C	94-103
14645527-5	2003	Cycloheximide also induces UBI4, the polyubiquitin gene.	Cycloheximide	0-13	ubiquitin	Saccharomyces cerevisiae S288C	27-31
14645527-6	2003	The cycloheximide-resistant phenotype of ubiquitin overexpressors is also characteristic of partial-loss-of-function proteasome mutants.	Cycloheximide	4-17	ubiquitin	Saccharomyces cerevisiae S288C	41-50
14645527-7	2003	Ubiquitin is stabilized in these mutants, which may account for their cycloheximide resistance.	Cycloheximide	70-83	ubiquitin	Saccharomyces cerevisiae S288C	0-9
14645527-8	2003	Previous studies have reported that ubiquitin is destabilized in the absence of Ubp6, a proteasome-associated deubiquitinating enzyme, and that ubp6 mutants are hypersensitive to cycloheximide.	Cycloheximide	179-192	ubiquitin	Saccharomyces cerevisiae S288C	36-45
14645527-8	2003	Previous studies have reported that ubiquitin is destabilized in the absence of Ubp6, a proteasome-associated deubiquitinating enzyme, and that ubp6 mutants are hypersensitive to cycloheximide.	Cycloheximide	179-192	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	144-148
14645527-9	2003	Consistent with the model that cycloheximide-treated cells are ubiquitin deficient, the cycloheximide sensitivity of ubp6 mutants can be rescued either by ubiquitin overexpression or by mutations in proteasome subunit genes.	Cycloheximide	31-44	ubiquitin	Saccharomyces cerevisiae S288C	63-72
14645527-9	2003	Consistent with the model that cycloheximide-treated cells are ubiquitin deficient, the cycloheximide sensitivity of ubp6 mutants can be rescued either by ubiquitin overexpression or by mutations in proteasome subunit genes.	Cycloheximide	31-44	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	117-121
14645527-9	2003	Consistent with the model that cycloheximide-treated cells are ubiquitin deficient, the cycloheximide sensitivity of ubp6 mutants can be rescued either by ubiquitin overexpression or by mutations in proteasome subunit genes.	Cycloheximide	88-101	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	117-121
14645527-9	2003	Consistent with the model that cycloheximide-treated cells are ubiquitin deficient, the cycloheximide sensitivity of ubp6 mutants can be rescued either by ubiquitin overexpression or by mutations in proteasome subunit genes.	Cycloheximide	88-101	ubiquitin	Saccharomyces cerevisiae S288C	155-164
12923199-4	2003	In Madin-Darby canine kidney cells at steady state and after treatment with cycloheximide or temperature blocks, E-cadherin and beta-catenin localized to the Golgi complex, but p120ctn was found only at the basolateral plasma membrane.	Cycloheximide	76-89	cadherin 1	Canis lupus familiaris	113-123
12923199-4	2003	In Madin-Darby canine kidney cells at steady state and after treatment with cycloheximide or temperature blocks, E-cadherin and beta-catenin localized to the Golgi complex, but p120ctn was found only at the basolateral plasma membrane.	Cycloheximide	76-89	catenin beta 1	Canis lupus familiaris	128-140
12869419-10	2003	Our experiments demonstrated: (i) that the elevated WAF1 mRNA expression after Fe chelation was due to increased transcription and also to a post-transcriptional mechanism that was sensitive to cycloheximide; and (ii) that Fe-chelation increased WAF1 expression through a p53-independent pathway.	Cycloheximide	194-207	cyclin dependent kinase inhibitor 1A	Homo sapiens	52-56
14515361-12	2003	The data suggest that the ratio of Bcl-2/Bad in astrocytes following ActD and CHX treatment does not decrease as much in untreated cells during ischemia.	Cycloheximide	78-81	BCL2 apoptosis regulator	Homo sapiens	35-40
12871956-9	2003	Indeed, PBX-2 level drastically decreased after 3 h of cycloheximide treatment in control but not in PREP-1-overexpressing cells and the proteasome inhibitor MG132 prevented PBX-2 decay in control cells.	Cycloheximide	55-68	PBX homeobox 2	Homo sapiens	8-13
12773314-7	2003	Elimination of SGLT1 synthesis by incubation of cells with cycloheximide did not significantly reduce the size of the intracellular SGLT1 pool.	Cycloheximide	59-72	solute carrier family 5 member 1	Homo sapiens	15-20
14515361-0	2003	Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia.	Cycloheximide	0-13	BCL2 apoptosis regulator	Homo sapiens	55-60
14515361-0	2003	Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia.	Cycloheximide	0-13	BCL2 associated X, apoptosis regulator	Homo sapiens	62-65
14515361-0	2003	Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice gene expression in astrocytes under in vitro ischemia.	Cycloheximide	0-13	carboxylesterase 2	Homo sapiens	71-74
12882979-6	2003	Consistent with this, we found that TL1A significantly increased the production of c-IAP2, a known NF-kappaB-dependent anti-apoptotic protein, and that the NF-kappaB inhibitor or cycloheximide prevented its synthesis.	Cycloheximide	179-192	baculoviral IAP repeat containing 3	Homo sapiens	83-89
12941295-13	2003	Treatment with cycloheximide, at doses that inhibit protein synthesis without affecting cell viability, also induced Mcl-1 protein decay.	Cycloheximide	15-28	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	117-122
14500682-5	2003	Cycloheximide as well as sodium cromoglycate blocked the Der f-induced IL-4 production, indicating a de novo protein synthesis process.	Cycloheximide	0-13	interleukin 4	Mus musculus	71-75
12963046-4	2003	A cycloheximide experiment indicated that Osx expression by BMP-2 requires new protein synthesis.	Cycloheximide	2-15	bone morphogenetic protein 2	Mus musculus	60-65
12951045-6	2003	Results of treatments with the protein synthesis inhibitor cycloheximide and the pure antiestrogen ICI182,780 suggest that these PK pathways modulate WISP-2 gene expression via different molecular mechanisms than those for pS2.	Cycloheximide	59-72	cellular communication network factor 5	Homo sapiens	150-156
12951045-6	2003	Results of treatments with the protein synthesis inhibitor cycloheximide and the pure antiestrogen ICI182,780 suggest that these PK pathways modulate WISP-2 gene expression via different molecular mechanisms than those for pS2.	Cycloheximide	59-72	trefoil factor 1	Homo sapiens	223-226
12951046-2	2003	In our previous study, we first reported that beta1,4GT1 was associated with cycloheximide-induced apoptosis in human hepatocarcinoma cells.	Cycloheximide	77-90	beta-1,4-galactosyltransferase 1	Homo sapiens	46-56
14622206-9	2003	Whereas, IL-1 receptor antagonist and cycloheximide inhibited IL-1beta-evoked secretion of SP-like immunoreactivity (SP-li), actinomycin D decreased it significantly but did not entirely abolish it.	Cycloheximide	38-51	interleukin 1 beta	Rattus norvegicus	62-70
12956869-4	2003	Depletion of Gag from this region by cycloheximide treatment, coupled with the presence of ribosomal clusters that are in close vicinity to the assembling capsids, suggests that the dominant N-terminal cytoplasmic targeting-retention signal functions in a cotranslational manner.	Cycloheximide	37-50	Pr78	Mason-Pfizer monkey virus	13-16
12842877-6	2003	Loss of YNL323W/LEM3 does not confer resistance to N-nitroquinilone N-oxide or ketoconazole and actually increases sensitivity to cycloheximide.	Cycloheximide	130-143	Lem3p	Saccharomyces cerevisiae S288C	16-20
12902026-3	2003	Pre-treatment with cycloheximide (a protein synthesis inhibitor; 200 mg/kg) intraperitoneally prevented the expression of CaMK II and phosphorylation of CaMK II induced by KA.	Cycloheximide	19-32	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	122-129
14517093-5	2003	Interestingly, a 10-kb UL57 transcript accumulated in cycloheximide-treated infected cells, even though other early transcripts were not detectable.	Cycloheximide	54-67	single-stranded DNA-binding protein	Human betaherpesvirus 5	23-27
14519412-11	2003	The CRH-induced increase of plasma catecholamines was also reduced either by cycloheximide (an inhibitor of protein synthesis) [107 nmol (30 microg)/animal, i.c.v.]	Cycloheximide	77-90	corticotropin releasing hormone	Rattus norvegicus	4-7
12902026-3	2003	Pre-treatment with cycloheximide (a protein synthesis inhibitor; 200 mg/kg) intraperitoneally prevented the expression of CaMK II and phosphorylation of CaMK II induced by KA.	Cycloheximide	19-32	calcium/calmodulin-dependent protein kinase II gamma	Mus musculus	153-160
12815054-7	2003	Cycloheximide treatment indicated that Dlx5 was immediately induced by BMP signaling, while Runx2 required de novo protein synthesis.	Cycloheximide	0-13	distal-less homeobox 5	Mus musculus	39-43
14667141-9	2003	Upregulation of osteocalcin was reduced when cycloheximide was added to E2, suggesting the presence of intermediates in the enhancement of osteocalcin gene transcription.	Cycloheximide	45-58	bone gamma-carboxyglutamate protein	Rattus norvegicus	16-27
12934082-2	2003	We here report that CD95L-induced cell death is inhibited by sulfasalazine (SS) in all of four human glioma cell lines, both in the absence and presence of cycloheximide (CHX).	Cycloheximide	156-169	Fas ligand	Homo sapiens	20-25
12934082-2	2003	We here report that CD95L-induced cell death is inhibited by sulfasalazine (SS) in all of four human glioma cell lines, both in the absence and presence of cycloheximide (CHX).	Cycloheximide	171-174	Fas ligand	Homo sapiens	20-25
14667141-9	2003	Upregulation of osteocalcin was reduced when cycloheximide was added to E2, suggesting the presence of intermediates in the enhancement of osteocalcin gene transcription.	Cycloheximide	45-58	bone gamma-carboxyglutamate protein	Rattus norvegicus	139-150
12949251-7	2003	Induction of endogenous PU.1 RNA by C/EBPalpha-estradiol receptor (ER) in the presence of cycloheximide is obviated by mutation of the C/EBPalpha DNA-binding domain, and chromosomal immunoprecipitation demonstrated specific interaction of C/EBPalpha and C/EBPalpha-ER with the PU.1 promoter.	Cycloheximide	90-103	Spi-1 proto-oncogene	Homo sapiens	24-28
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	207-220	tumor protein p53	Homo sapiens	51-54
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	207-220	tumor protein p53	Homo sapiens	59-62
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	207-220	tumor protein p53	Homo sapiens	59-62
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	222-224	tumor protein p53	Homo sapiens	51-54
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	222-224	tumor protein p53	Homo sapiens	59-62
12891704-10	2003	Renaturation of temperature sensitive A135V mutant p53 (ts-p53) was found to alter the sensitivity of p53 mRNA translation, but not bulk mRNA translation, to the translocation-specific elongation inhibitor, cycloheximide (Cx).	Cycloheximide	222-224	tumor protein p53	Homo sapiens	59-62
12938225-3	2003	Furthermore, following overexpression of a human Fas:FLICE construct, which directly induces caspase activation in a death-inducing signaling complex-independent manner, cells could not be protected through BCR stimulation.Co-incubation with cycloheximide partially reversed protection from apoptosis and increased Fas-stimulated initiator and effector caspase activation, suggesting new protein synthesis is necessary to induce protection upstream of caspase activation.	Cycloheximide	242-255	caspase 8	Homo sapiens	53-58
12949251-7	2003	Induction of endogenous PU.1 RNA by C/EBPalpha-estradiol receptor (ER) in the presence of cycloheximide is obviated by mutation of the C/EBPalpha DNA-binding domain, and chromosomal immunoprecipitation demonstrated specific interaction of C/EBPalpha and C/EBPalpha-ER with the PU.1 promoter.	Cycloheximide	90-103	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	36-46
12950455-8	2003	Application of cycloheximide, a protein synthesis inhibitor, prevented the enhancement of MCT2 IR, while the mRNA synthesis inhibitor actinomycin D also blocked the effect of NA on MCT2 IR levels.	Cycloheximide	15-28	solute carrier family 16 (monocarboxylic acid transporters), member 7	Mus musculus	90-94
12923263-6	2003	Inhibiting translation with cycloheximide stabilized nonsense-containing beta-globin mRNA, resulting in a fivefold increase in its steady-state level.	Cycloheximide	28-41	hemoglobin subunit beta	Homo sapiens	73-84
12805413-4	2003	Induction of FGFR1 was independent of mRNA half-life and abolished by actinomycin D and cycloheximide, indicating the involvement of an intermediary protein.	Cycloheximide	88-101	fibroblast growth factor receptor 1	Mus musculus	13-18
12783871-7	2003	Pretreatment of cells with cycloheximide blocked the cpt-cAMP-mediated increase of AQP5 mRNA, indicating that de novo protein synthesis is essential for increased AQP5 transcription.	Cycloheximide	27-40	aquaporin 5	Mus musculus	83-87
14519770-5	2003	To test this, we analysed the effect of translation inhibitor cycloheximide on the CGS1 mRNA decay.	Cycloheximide	62-75	Pyridoxal phosphate (PLP)-dependent transferases superfamily protein	Arabidopsis thaliana	83-87
14519770-7	2003	Simultaneous addition of actinomycin D and cycloheximide stabilized CGS1 mRNA both in the presence and absence of Met, as essentially no decrease of CGS1 mRNA was observed.	Cycloheximide	43-56	Pyridoxal phosphate (PLP)-dependent transferases superfamily protein	Arabidopsis thaliana	68-72
14519770-8	2003	Moreover, cycloheximide treatment inhibited production of the truncated CGS1 RNA species, a possible degradation intermediate.	Cycloheximide	10-23	Pyridoxal phosphate (PLP)-dependent transferases superfamily protein	Arabidopsis thaliana	72-76
12970474-5	2003	In continuous light or in the presence of metabolizable sugars in the dark, cytosolic G6PDH activity increased 6-fold within 24 h. Cycloheximide incubation demonstrated that enhanced cytosolic G6PDH activity depends on de novo protein synthesis.	Cycloheximide	131-144	glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform	Solanum tuberosum	86-91
12970474-5	2003	In continuous light or in the presence of metabolizable sugars in the dark, cytosolic G6PDH activity increased 6-fold within 24 h. Cycloheximide incubation demonstrated that enhanced cytosolic G6PDH activity depends on de novo protein synthesis.	Cycloheximide	131-144	glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform	Solanum tuberosum	193-198
12783871-7	2003	Pretreatment of cells with cycloheximide blocked the cpt-cAMP-mediated increase of AQP5 mRNA, indicating that de novo protein synthesis is essential for increased AQP5 transcription.	Cycloheximide	27-40	aquaporin 5	Mus musculus	163-167
12828986-7	2003	The induction of RGD-CAP mRNA, meanwhile, was completely inhibited by cycloheximide which is an inhibitor of protein synthesis.	Cycloheximide	70-83	transforming growth factor beta induced	Homo sapiens	17-24
12835381-8	2003	We demonstrate that this Boz activity is independent of that of other zygotic genes, because it also occurs when translation of zygotic genes is suppressed by cycloheximide (CHX).	Cycloheximide	159-172	dharma	Danio rerio	25-28
12835381-8	2003	We demonstrate that this Boz activity is independent of that of other zygotic genes, because it also occurs when translation of zygotic genes is suppressed by cycloheximide (CHX).	Cycloheximide	174-177	dharma	Danio rerio	25-28
12884026-3	2003	Using cell-culture systems we tested active compounds for their ability to induce apoptosis in Bcl-X(L)-overexpressing MCF7 cells and increase the sensitivities of the cells to apoptosis-inducing drugs [vincristine sulphate, dexamethasone, cycloheximide and 6alpha-methylprednisolone (MP)].	Cycloheximide	240-253	BCL2 like 1	Homo sapiens	95-102
12865654-9	2003	In contrast, HO-1 induction upon oxidative stress was attenuated in HepG2 cells by cycloheximide and dexamethasone.	Cycloheximide	83-96	heme oxygenase 1	Homo sapiens	13-17
12851419-4	2003	FGF-1-induced ET-AR expression was inhibited by FGF-receptor inhibitor PD-166866, MEK inhibitor U-0126, transcription inhibitor actinomycin D, and translation inhibitor cycloheximide.	Cycloheximide	169-182	fibroblast growth factor 1	Rattus norvegicus	0-5
12851419-4	2003	FGF-1-induced ET-AR expression was inhibited by FGF-receptor inhibitor PD-166866, MEK inhibitor U-0126, transcription inhibitor actinomycin D, and translation inhibitor cycloheximide.	Cycloheximide	169-182	endothelin receptor type A	Rattus norvegicus	14-19
12897156-7	2003	The protein synthesis inhibitor cycloheximide and the proteasome inhibitor MG132 block E2-mediated decrease in GR protein levels, suggesting that estrogen agonists down regulate the GR via the proteasomal degradation pathway.	Cycloheximide	32-45	nuclear receptor subfamily 3 group C member 1	Homo sapiens	111-113
12897156-7	2003	The protein synthesis inhibitor cycloheximide and the proteasome inhibitor MG132 block E2-mediated decrease in GR protein levels, suggesting that estrogen agonists down regulate the GR via the proteasomal degradation pathway.	Cycloheximide	32-45	nuclear receptor subfamily 3 group C member 1	Homo sapiens	182-184
12869656-6	2003	In contrast, cells treated with tumor necrosis factor alpha plus cycloheximide (TNFalpha + CHX) first appeared in the early apoptotic fraction and then accumulated in the necrotic/late apoptotic fraction.	Cycloheximide	65-78	tumor necrosis factor	Homo sapiens	80-88
12869656-7	2003	Both C2-ceramide and TNFalpha + CHX increased caspase 8- and 3-like activities in cytosolic extracts; however, treatment of cells with the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected NB16 cells from TNFalpha + CHX-induced cell death but did not prevent C2-ceramide cytotoxicity.	Cycloheximide	32-35	tumor necrosis factor	Homo sapiens	21-29
12869656-7	2003	Both C2-ceramide and TNFalpha + CHX increased caspase 8- and 3-like activities in cytosolic extracts; however, treatment of cells with the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected NB16 cells from TNFalpha + CHX-induced cell death but did not prevent C2-ceramide cytotoxicity.	Cycloheximide	32-35	caspase 8	Homo sapiens	46-55
12869656-7	2003	Both C2-ceramide and TNFalpha + CHX increased caspase 8- and 3-like activities in cytosolic extracts; however, treatment of cells with the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected NB16 cells from TNFalpha + CHX-induced cell death but did not prevent C2-ceramide cytotoxicity.	Cycloheximide	32-35	tumor necrosis factor	Homo sapiens	249-257
12869656-7	2003	Both C2-ceramide and TNFalpha + CHX increased caspase 8- and 3-like activities in cytosolic extracts; however, treatment of cells with the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected NB16 cells from TNFalpha + CHX-induced cell death but did not prevent C2-ceramide cytotoxicity.	Cycloheximide	260-263	tumor necrosis factor	Homo sapiens	21-29
12879014-8	2003	This PI3K-inhibitable, JNK-induced death response was not impeded, but actually accelerated, by cycloheximide.	Cycloheximide	96-109	mitogen-activated protein kinase 8	Homo sapiens	23-26
12865931-8	2003	The protein synthesis inhibitor cycloheximide decreased FLICE-like inhibitory protein levels in all cell lines, and the TRAIL-resistant cell lines Caco-2 and Colo320 became sensitive for TRAIL.	Cycloheximide	32-45	TNF superfamily member 10	Homo sapiens	187-192
12859969-8	2003	Furthermore, annexin I-stimulated insulin secretion was inhibited by cycloheximide but not by actinomycin D.	Cycloheximide	69-82	annexin A1	Mus musculus	13-22
12867890-3	2003	Cycloheximide, a compound that prevents new protein synthesis was used to inhibit inducible heat shock protein 70 (Hsp70) production during heat stress.	Cycloheximide	0-13	heat shock 70 kDa protein 1B	Bos taurus	92-113
12730225-8	2003	Upon forskolin withdrawal or after cycloheximide addition, this CDK4 phosphoform unexpectedly persisted in p27 complexes devoid of cyclin D3 but it disappeared from the more labile cyclin D3 complexes.	Cycloheximide	35-48	cyclin dependent kinase 4	Canis lupus familiaris	64-68
12730225-8	2003	Upon forskolin withdrawal or after cycloheximide addition, this CDK4 phosphoform unexpectedly persisted in p27 complexes devoid of cyclin D3 but it disappeared from the more labile cyclin D3 complexes.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1B	Canis lupus familiaris	107-110
12730225-8	2003	Upon forskolin withdrawal or after cycloheximide addition, this CDK4 phosphoform unexpectedly persisted in p27 complexes devoid of cyclin D3 but it disappeared from the more labile cyclin D3 complexes.	Cycloheximide	35-48	cyclin D3	Canis lupus familiaris	131-140
12867890-3	2003	Cycloheximide, a compound that prevents new protein synthesis was used to inhibit inducible heat shock protein 70 (Hsp70) production during heat stress.	Cycloheximide	0-13	heat shock 70 kDa protein 1B	Bos taurus	115-120
12867890-4	2003	Cycloheximide was also used to verify that the induction of Hsp70 takes place in lenses during heat stress.	Cycloheximide	0-13	heat shock 70 kDa protein 1B	Bos taurus	60-65
12818375-7	2003	Cycloheximide prevented the YC-1-enhanced TNF alpha formation, implying that new protein synthesis was required.	Cycloheximide	0-13	glutathione S-transferase alpha 1	Rattus norvegicus	28-32
12623786-9	2003	Chase experiments with the use of cycloheximide revealed that 15d-PGJ2 and shear stress both inhibited the proteolytic degradation of c-IAP1 protein.	Cycloheximide	34-47	baculoviral IAP repeat containing 2	Homo sapiens	134-140
12818375-7	2003	Cycloheximide prevented the YC-1-enhanced TNF alpha formation, implying that new protein synthesis was required.	Cycloheximide	0-13	tumor necrosis factor	Rattus norvegicus	42-51
14681037-2	2003	We have used a combination of cell surface biotinylation, immunofluorescence microscopy, and scrape-load dye transfer assays to investigate the effect of the protein synthesis inhibitor cycloheximide on connexin43 and connexin32 after their transport to the plasmalemma.	Cycloheximide	186-199	gap junction protein alpha 1	Homo sapiens	203-213
12767051-2	2003	LTC(4) S activity in rat basophilic leukemia-1 (RBL-1) cells increased after culture in the presence of retinoic acid (RA) analogues, which was inhibited by cycloheximide or actinomycin D (ACD).	Cycloheximide	157-170	leukotriene C4 synthase	Rattus norvegicus	0-8
12851530-7	2003	This release of MMP-9 was significantly inhibited by cycloheximide (95%) and by the specific inhibitors of protein tyrosine kinase, genistein (70 +/- 3.0%, P = 0.00027 and 67 +/- 1.0%, P = 0.00005) and mitogen-activated protein (MAP)-kinase, PD98059 (56 +/- 2.0%, P = 0.0001 and 62 +/- 1.0%, P = 0.00003) in A375 and J82 cells, respectively.	Cycloheximide	53-66	matrix metallopeptidase 9	Homo sapiens	16-21
12894851-3	2003	This increase in CXCR4 expression level was inhibited by the addition of brefeldin A, actinomycin D, or cycloheximide.	Cycloheximide	104-117	C-X-C motif chemokine receptor 4	Homo sapiens	17-22
14681037-2	2003	We have used a combination of cell surface biotinylation, immunofluorescence microscopy, and scrape-load dye transfer assays to investigate the effect of the protein synthesis inhibitor cycloheximide on connexin43 and connexin32 after their transport to the plasmalemma.	Cycloheximide	186-199	gap junction protein beta 1	Homo sapiens	218-228
12690110-4	2003	The up-regulation of p21Cip1 transcription is prevented by cycloheximide, indicating the requirement of intermediate protein(s), which, in turn, regulate gene expression.	Cycloheximide	59-72	cyclin dependent kinase inhibitor 1A	Homo sapiens	21-28
12861043-6	2003	Actually, cFLIP expression was decreased in ActD or CHX treatment.	Cycloheximide	52-55	CASP8 and FADD like apoptosis regulator	Homo sapiens	10-15
12788213-5	2003	The morphological damage induced by KA (0.1microg) in the hippocampus was markedly concentrated in the CA3 pyramidal neurons and cycloheximide effectively prevented the KA-induced pyramidal cell death in CA3 hippocampal region.	Cycloheximide	129-142	carbonic anhydrase 3	Mus musculus	204-207
12788213-7	2003	Cycloheximide attenuated the increased p-ERK, p-JNK1, and p-CaMK II levels induced by KA.	Cycloheximide	0-13	eukaryotic translation initiation factor 2 alpha kinase 3	Mus musculus	39-44
12788213-7	2003	Cycloheximide attenuated the increased p-ERK, p-JNK1, and p-CaMK II levels induced by KA.	Cycloheximide	0-13	mitogen-activated protein kinase 8	Mus musculus	48-52
12788213-7	2003	Cycloheximide attenuated the increased p-ERK, p-JNK1, and p-CaMK II levels induced by KA.	Cycloheximide	0-13	calcium/calmodulin-dependent protein kinase II, beta	Mus musculus	60-67
12788213-8	2003	Furthermore, cycloheximide inhibited the increased c-Fos and c-Jun protein expression levels induced by KA in the hippocampus.	Cycloheximide	13-26	FBJ osteosarcoma oncogene	Mus musculus	51-56
12788213-8	2003	Furthermore, cycloheximide inhibited the increased c-Fos and c-Jun protein expression levels induced by KA in the hippocampus.	Cycloheximide	13-26	jun proto-oncogene	Mus musculus	61-66
12763636-5	2003	Blockade of translation (cycloheximide) but not transcription (actinomycin D) prevented the postprandial rise in HDC activity.	Cycloheximide	25-38	histidine decarboxylase	Rattus norvegicus	113-116
12770614-5	2003	In addition, phosphorylations of MAPKs (ERK 1/2, p38, JNK 1/2) were increased by LT. LT-induced iNOS mRNA level was inhibited by PD98059 (MEK 1/2 inhibitor), SB203580 (p38 inhibitor), and cycloheximide (a protein synthesis blocker), indicating that the phosphorylation of ERK 1/2 and p38, and on-going protein synthesis are necessary for LT-induced iNOS expression.	Cycloheximide	188-201	nitric oxide synthase 2	Homo sapiens	96-100
12770614-5	2003	In addition, phosphorylations of MAPKs (ERK 1/2, p38, JNK 1/2) were increased by LT. LT-induced iNOS mRNA level was inhibited by PD98059 (MEK 1/2 inhibitor), SB203580 (p38 inhibitor), and cycloheximide (a protein synthesis blocker), indicating that the phosphorylation of ERK 1/2 and p38, and on-going protein synthesis are necessary for LT-induced iNOS expression.	Cycloheximide	188-201	mitogen-activated protein kinase kinase 1	Homo sapiens	138-145
12821942-6	2003	The cleavage of PML-RARalpha is blocked by RARalpha antagonist Ro-41-5253 and cycloheximide and therefore requires a RARalpha transactivation-dependent pathway.	Cycloheximide	78-91	PML nuclear body scaffold	Homo sapiens	16-19
12821942-6	2003	The cleavage of PML-RARalpha is blocked by RARalpha antagonist Ro-41-5253 and cycloheximide and therefore requires a RARalpha transactivation-dependent pathway.	Cycloheximide	78-91	retinoic acid receptor alpha	Homo sapiens	20-28
12663669-1	2003	In the presence of cycloheximide, tumor necrosis factor or interleukin-1 initiates caspase activation, loss of mitochondrial membrane potential (DeltaPsi), DNA degradation, and nuclear condensation and fragmentation characteristic of apoptotic cell death in human vascular endothelial cells (EC).	Cycloheximide	19-32	tumor necrosis factor	Homo sapiens	34-55
12777630-5	2003	N-myc transcription is induced in the presence of the protein synthesis inhibitor cycloheximide, so it appears to be a direct target of Shh.	Cycloheximide	82-95	v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived	Mus musculus	0-5
12777630-5	2003	N-myc transcription is induced in the presence of the protein synthesis inhibitor cycloheximide, so it appears to be a direct target of Shh.	Cycloheximide	82-95	sonic hedgehog	Mus musculus	136-139
12663665-3	2003	However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis.	Cycloheximide	53-66	chromobox 8	Homo sapiens	173-176
12663669-4	2003	Cycloheximide but not LY294002 decreases expression of c-FLIP (cellular FLICE inhibitory protein), an inhibitor of caspase-8 activation.	Cycloheximide	0-13	CASP8 and FADD like apoptosis regulator	Homo sapiens	55-61
12663665-3	2003	However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis.	Cycloheximide	53-66	chromobox 8	Homo sapiens	187-190
12663669-4	2003	Cycloheximide but not LY294002 decreases expression of c-FLIP (cellular FLICE inhibitory protein), an inhibitor of caspase-8 activation.	Cycloheximide	0-13	CASP8 and FADD like apoptosis regulator	Homo sapiens	63-96
12663665-3	2003	However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis.	Cycloheximide	53-66	TNF superfamily member 10	Homo sapiens	205-210
12663669-4	2003	Cycloheximide but not LY294002 decreases expression of c-FLIP (cellular FLICE inhibitory protein), an inhibitor of caspase-8 activation.	Cycloheximide	0-13	caspase 8	Homo sapiens	115-124
12663669-5	2003	The caspase inhibitor zVADfmk completely blocks caspase activation, DNA degradation, and nuclear fragmentation in both cases but only prevents loss of DeltaPsi and cell death for cytokine plus cycloheximide treatment.	Cycloheximide	193-206	caspase 8	Homo sapiens	4-11
12824943-8	2003	Cycloheximide (10 microM) prevented histamine-induced stimulation of PDE4.	Cycloheximide	0-13	phosphodiesterase 4A	Homo sapiens	69-73
12824820-10	2003	In the HepG2-CYP3A4 line, incubation with cycloheximide caused a decrease in fentanyl metabolism secondary to a decrease in CYP3A4 levels; this decrease was prevented by coincubation of cycloheximide with ethanol.	Cycloheximide	42-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
12824820-10	2003	In the HepG2-CYP3A4 line, incubation with cycloheximide caused a decrease in fentanyl metabolism secondary to a decrease in CYP3A4 levels; this decrease was prevented by coincubation of cycloheximide with ethanol.	Cycloheximide	42-55	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
12824820-10	2003	In the HepG2-CYP3A4 line, incubation with cycloheximide caused a decrease in fentanyl metabolism secondary to a decrease in CYP3A4 levels; this decrease was prevented by coincubation of cycloheximide with ethanol.	Cycloheximide	186-199	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
12824820-10	2003	In the HepG2-CYP3A4 line, incubation with cycloheximide caused a decrease in fentanyl metabolism secondary to a decrease in CYP3A4 levels; this decrease was prevented by coincubation of cycloheximide with ethanol.	Cycloheximide	186-199	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
12808024-6	2003	Experiments with actinomycin D and cycloheximide also pointed to a transcriptional and translational process in facilitating the TNF-alpha response.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	129-138
12718447-6	2003	Both activation of caspase-3 and significant recovery of viability following pretreatment with cycloheximide were shown in RPS9-AS cells treated with H2O2.	Cycloheximide	95-108	caspase 3	Rattus norvegicus	19-28
12718447-6	2003	Both activation of caspase-3 and significant recovery of viability following pretreatment with cycloheximide were shown in RPS9-AS cells treated with H2O2.	Cycloheximide	95-108	ribosomal protein S9	Rattus norvegicus	123-127
12825835-5	2003	Cell death was induced in 1321N1 astrocytoma cells permanently expressing the rat P2Y6 receptor by exposure to TNFalpha in the presence of cycloheximide.	Cycloheximide	139-152	pyrimidinergic receptor P2Y6	Homo sapiens	82-95
12869540-4	2003	In both cell lines, cycloheximide, an inhibitor of protein synthesis, augmented the gene expression of the p450s except CYP2B1.	Cycloheximide	20-33	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	120-126
12648514-6	2003	Cycloheximide prevented protection, indicating that GM-CSF might induce synthesis of antiapoptotic proteins.	Cycloheximide	0-13	colony stimulating factor 2	Homo sapiens	52-58
12668682-3	2003	In cycloheximide-treated BALB/MK2 keratinocytes we found that C/EBPalpha is a short-lived protein with a half-life of approximately 1 h. Treatment with proteasome inhibitors, MG-132 or lactacystin, blocked the degradation of the C/EBPalpha protein.	Cycloheximide	3-16	MAP kinase-activated protein kinase 2	Mus musculus	30-33
12668682-3	2003	In cycloheximide-treated BALB/MK2 keratinocytes we found that C/EBPalpha is a short-lived protein with a half-life of approximately 1 h. Treatment with proteasome inhibitors, MG-132 or lactacystin, blocked the degradation of the C/EBPalpha protein.	Cycloheximide	3-16	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	62-72
12646579-5	2003	TGF-beta 1 induced ADAMTS-2 mRNA approximately 8-fold in MG-63 osteosarcoma cells in a dose- and time-dependent, cycloheximide-inhibitable manner, which appeared to operate at the transcriptional level.	Cycloheximide	113-126	transforming growth factor beta 1	Homo sapiens	0-10
12646579-5	2003	TGF-beta 1 induced ADAMTS-2 mRNA approximately 8-fold in MG-63 osteosarcoma cells in a dose- and time-dependent, cycloheximide-inhibitable manner, which appeared to operate at the transcriptional level.	Cycloheximide	113-126	ADAM metallopeptidase with thrombospondin type 1 motif 2	Homo sapiens	19-27
12611887-5	2003	Furthermore, trans-activation of cyclin D3 by ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appears direct.	Cycloheximide	117-130	E2F transcription factor 1 L homeolog	Xenopus laevis	49-53
12801486-12	2003	T4-induced Tgase activity was suppressed with cycloheximide and protein kinase C inhibitors.	Cycloheximide	46-59	coagulation factor XIII A chain	Homo sapiens	11-16
12642589-6	2003	Treatment of cells with the protein synthesis inhibitor, cycloheximide, or the specific p38 MAP kinase inhibitor, SB203580, blocked the induction of HO-1 and suppression of LPS-induced I kappa B degradation mediated by 15d-PGJ2.	Cycloheximide	57-70	heme oxygenase 1	Mus musculus	149-153
12710934-7	2003	Cycloheximide-pilocarpine-treated animals, in contrast, had CGRP and neo-Timm staining similar to controls.	Cycloheximide	0-13	calcitonin-related polypeptide alpha	Rattus norvegicus	60-64
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	Cycloheximide	111-124	CCAAT enhancer binding protein beta	Homo sapiens	152-162
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	Cycloheximide	111-124	interleukin 6	Homo sapiens	167-171
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	Cycloheximide	111-124	interferon gamma	Homo sapiens	175-184
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	Cycloheximide	111-124	mitogen-activated protein kinase kinase 1	Homo sapiens	198-202
12853299-5	2003	However, inhibition of protein synthesis by cycloheximide abolished the mRNA stabilizing effect of ethanol on NR1 mRNA, thus suggesting de novo protein synthesis is crucial for the action of ethanol on NR1 mRNA stabilization.	Cycloheximide	44-57	glutamate ionotropic receptor NMDA type subunit 1	Homo sapiens	110-113
12697668-8	2003	Pretreatment of the cells with inhibitors of RNA transcription, actinomycin D, or protein translation, cycloheximide, significantly suppressed R1881-induced pro-MMP-2 expression in LNCaP cells, indicating that androgen stimulates pro-MMP-2 gene expression.	Cycloheximide	103-116	matrix metallopeptidase 2	Homo sapiens	161-166
12710934-8	2003	Cycloheximide might protect hilar CGRP-positive cells during SE and, by allowing those cells to retain their normal axonal projection, prevent mossy fiber sprouting.	Cycloheximide	0-13	calcitonin-related polypeptide alpha	Rattus norvegicus	34-38
12710934-11	2003	We suggest that cycloheximide prevents SE-induced mossy fiber sprouting by preventing the loss of hilar CGRP-positive cells (putative mossy cells).	Cycloheximide	16-29	calcitonin-related polypeptide alpha	Rattus norvegicus	104-108
12727987-4	2003	The proteolysis inhibitors insulin, cycloheximide, and puromycin impede ER alpha, but not ER beta, turnover.	Cycloheximide	36-49	estrogen receptor 1	Homo sapiens	72-80
12682920-6	2003	Interestingly, ebselen addition completely prevented caspase activation in cycloheximide-treated Sp2/O-Ag14 cells, indicating that this antioxidant interferes with the apoptotic machinery.	Cycloheximide	75-88	Sp2 transcription factor	Mus musculus	97-100
12694384-2	2003	In this study, we determined effects of lowered temperature or of exposure to the protein synthesis inhibitor cycloheximide (CHX) on cell surface expression of homomeric alpha7-nAChR in transfected SH-EP1 human epithelial cells.	Cycloheximide	110-123	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	177-182
12800980-3	2003	This glucocorticoid-induced decrease in CDK2 mRNA expression could be suppressed by cycloheximide treatment.	Cycloheximide	84-97	cyclin dependent kinase 2	Homo sapiens	40-44
12694384-2	2003	In this study, we determined effects of lowered temperature or of exposure to the protein synthesis inhibitor cycloheximide (CHX) on cell surface expression of homomeric alpha7-nAChR in transfected SH-EP1 human epithelial cells.	Cycloheximide	125-128	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	177-182
12770726-2	2003	In the rat ovary, the preovulatory surge of LH induces NGFI-B expression in granulosa cells of preovulatory follicles, reaching a peak within 1 h and declining to control levels at 6 h. The LH-stimulated NGFI-B expression is abolished by alpha-amanitin, but superinduced by cycloheximide.	Cycloheximide	274-287	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	55-61
12769863-5	2003	Accelerated turnover via this pathway required Upf1p and was blocked by the translation inhibitor cycloheximide.	Cycloheximide	98-111	ATP-dependent RNA helicase NAM7	Saccharomyces cerevisiae S288C	47-52
12770726-2	2003	In the rat ovary, the preovulatory surge of LH induces NGFI-B expression in granulosa cells of preovulatory follicles, reaching a peak within 1 h and declining to control levels at 6 h. The LH-stimulated NGFI-B expression is abolished by alpha-amanitin, but superinduced by cycloheximide.	Cycloheximide	274-287	nuclear receptor subfamily 4 group A member 1	Homo sapiens	204-210
12694807-3	2003	Stimulation of neutrophils by TNF-alpha increased the levels of HSP27 in the presence, but not in the absence, of cycloheximide.	Cycloheximide	114-127	tumor necrosis factor	Homo sapiens	30-39
12582163-4	2003	This abnormality was caused by a single-nucleotide deletion at position +1489 of the TAP-1 gene and was corrected by cycloheximide, which inhibits RNA degradation.	Cycloheximide	117-130	transporter 1, ATP binding cassette subfamily B member	Homo sapiens	85-90
12695118-5	2003	Co-incubation of L10A cells with TSA and cycloheximide (CHX) abrogated the up-regulation of Blimp-1 expression, indicating that TSA-activated Blimp-1 expression required synthesis of a transcriptional activator.	Cycloheximide	41-54	PR domain containing 1, with ZNF domain	Mus musculus	92-99
12695118-5	2003	Co-incubation of L10A cells with TSA and cycloheximide (CHX) abrogated the up-regulation of Blimp-1 expression, indicating that TSA-activated Blimp-1 expression required synthesis of a transcriptional activator.	Cycloheximide	41-54	PR domain containing 1, with ZNF domain	Mus musculus	142-149
12695118-5	2003	Co-incubation of L10A cells with TSA and cycloheximide (CHX) abrogated the up-regulation of Blimp-1 expression, indicating that TSA-activated Blimp-1 expression required synthesis of a transcriptional activator.	Cycloheximide	56-59	PR domain containing 1, with ZNF domain	Mus musculus	92-99
12695118-5	2003	Co-incubation of L10A cells with TSA and cycloheximide (CHX) abrogated the up-regulation of Blimp-1 expression, indicating that TSA-activated Blimp-1 expression required synthesis of a transcriptional activator.	Cycloheximide	56-59	PR domain containing 1, with ZNF domain	Mus musculus	142-149
12695118-6	2003	In contrast, mad expression was increased in L10A cells cultured with TSA and cycloheximide or cycloheximide alone, suggesting mad expression may occur independent of Blimp-1 expression and is regulated by a labile, HDAC associated transcriptional repressor.	Cycloheximide	78-91	PR domain containing 1, with ZNF domain	Mus musculus	167-174
12695118-6	2003	In contrast, mad expression was increased in L10A cells cultured with TSA and cycloheximide or cycloheximide alone, suggesting mad expression may occur independent of Blimp-1 expression and is regulated by a labile, HDAC associated transcriptional repressor.	Cycloheximide	95-108	PR domain containing 1, with ZNF domain	Mus musculus	167-174
12694807-4	2003	Reverse transcription-polymerase chain reaction (RT-PCR) experiments showed that TNF-alpha also induced HSP27 mRNA in the presence of cycloheximide.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	81-90
12694807-4	2003	Reverse transcription-polymerase chain reaction (RT-PCR) experiments showed that TNF-alpha also induced HSP27 mRNA in the presence of cycloheximide.	Cycloheximide	134-147	heat shock protein family B (small) member 1	Homo sapiens	104-109
12694807-7	2003	The accumulation of HSP27 induced by TNF-alpha plus cycloheximide was also suppressed by pretreatment with a specific protein kinase C (PKC) inhibitor.	Cycloheximide	52-65	heat shock protein family B (small) member 1	Homo sapiens	20-25
12647290-11	2003	The BMP enhancement of the osterix gene expression in chondrocytes was blocked in the presence of a protein synthesis inhibitor, cycloheximide, while it was still observed in the presence of 5,6-dichloro-1-beta D-ribofuranosylbenzimidazol (DRB) suggesting the involvement of post-transcriptional events, which require new protein synthesis.	Cycloheximide	129-142	Sp7 transcription factor 7	Mus musculus	27-34
12814781-6	2003	Cycloheximide completely attenuated release of the IGFBPs, indicating dependency on new synthesis of the proteins.	Cycloheximide	0-13	insulin like growth factor binding protein 2	Bos taurus	51-57
12718765-6	2003	Upregulation of B7-1 and B7-2 was cycloheximide inhibitable and was a consequence of CD40 activation.	Cycloheximide	34-47	CD80 molecule	Homo sapiens	16-29
12684839-6	2003	Wild-type cells harboring hNedd4 grew better at elevated temperature and on media containing cycloheximide.	Cycloheximide	93-106	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	26-32
12684839-8	2003	Our results show that hNedd4 affects cell growth, endocytosis and cycloheximide tolerance of yeast cells.	Cycloheximide	66-79	NEDD4 E3 ubiquitin protein ligase	Homo sapiens	22-28
12505861-3	2003	Cycloheximide (CHX) superinduced the GC-stimulated alpha-ENaC expression in a dose-dependent manner, but had no effect on basal or aldosterone-stimulated alpha-ENaC expression, whereas anisomycin inhibited basal and corticosteroid-stimulated alpha-ENaC expression.	Cycloheximide	0-13	sodium channel epithelial 1 subunit alpha	Canis lupus familiaris	51-61
12505861-3	2003	Cycloheximide (CHX) superinduced the GC-stimulated alpha-ENaC expression in a dose-dependent manner, but had no effect on basal or aldosterone-stimulated alpha-ENaC expression, whereas anisomycin inhibited basal and corticosteroid-stimulated alpha-ENaC expression.	Cycloheximide	15-18	sodium channel epithelial 1 subunit alpha	Canis lupus familiaris	51-61
12505861-5	2003	CHX had no effect on alpha-ENaC mRNA half-life, confirming that its effect was via an increase in alpha-ENaC transcription.	Cycloheximide	0-3	sodium channel epithelial 1 subunit alpha	Canis lupus familiaris	98-108
12505861-8	2003	These data confirm a model in which CHX activates p38 in Madin-Darby canine kidney-C7 cells to increase alpha-ENaC gene transcription in a GC-dependent manner.	Cycloheximide	36-39	sodium channel epithelial 1 subunit alpha	Canis lupus familiaris	104-114
12608905-8	2003	Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	168-181	matrix metallopeptidase 3	Homo sapiens	13-18
12639923-6	2003	The ACTH-mediated mRNA increase was blunted by actinomycin D and enhanced by cycloheximide.	Cycloheximide	77-90	pro-opiomelanocortin-alpha	Mus musculus	4-8
12608905-8	2003	Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	168-181	fibroblast growth factor 2	Homo sapiens	46-50
12608905-8	2003	Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	168-181	matrix metallopeptidase 3	Homo sapiens	119-124
12608905-8	2003	Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	168-181	matrix metallopeptidase 3	Homo sapiens	119-124
12608905-8	2003	Induction of MMP-3 after the stimulation with bFGF was observed as early as 12 h with maximal at 24 h. Thereafter, the MMP-3 mRNA level gradually decreased until 72 h. Cycloheximide blocked the induction of MMP-3 by bFGF, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	168-181	fibroblast growth factor 2	Homo sapiens	216-220
12733826-8	2003	The Ang II induced increase of hAT1R density was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	94-107	angiogenin	Homo sapiens	4-7
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	0-13	CORT	Gallus gallus	28-32
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	0-13	growth hormone	Gallus gallus	46-48
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	0-13	CORT	Gallus gallus	116-120
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	0-13	growth hormone	Gallus gallus	134-136
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	15-18	CORT	Gallus gallus	28-32
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	15-18	growth hormone	Gallus gallus	46-48
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	15-18	CORT	Gallus gallus	116-120
12706289-8	2003	Cycloheximide (CHX) blocked CORT induction of GH mRNA, indicating that synthesis of some protein(s) is required for CORT induction of GH gene expression.	Cycloheximide	15-18	growth hormone	Gallus gallus	134-136
12569581-8	2003	Cycloheximide blocked the suppression of hTERT mRNA induced by FR901228, and the inhibition of hTERT mRNA by FR901228 required newly synthesized proteins.	Cycloheximide	0-13	telomerase reverse transcriptase	Homo sapiens	41-46
12514186-10	2003	Actinomycin D and cycloheximide inhibited Shh-induced capillary morphogenesis.	Cycloheximide	18-31	sonic hedgehog	Mus musculus	42-45
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	Cycloheximide	118-131	activation induced cytidine deaminase	Homo sapiens	187-190
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	Cycloheximide	118-131	activation induced cytidine deaminase	Homo sapiens	205-208
12591955-5	2003	When such transfectants were treated with an estrogen analogue, 4-hydroxytamoxifen (OHT), CSR was induced within 1 h. Cycloheximide or puromycin drastically suppressed OHT-induced CSR in AID-ER expressing AID-/- B cells when added 1 h before OHT but not after OHT, suggesting that de novo protein synthesis is required for an event downstream to AID expression in CSR.	Cycloheximide	118-131	activation induced cytidine deaminase	Homo sapiens	205-208
12733826-8	2003	The Ang II induced increase of hAT1R density was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	94-107	angiotensin II receptor type 1	Homo sapiens	31-36
12581864-4	2003	Both types of stimulus increased the GLUT1 protein content in a cycloheximide (CHX)-sensitive manner, and the glucose transport rate was elevated by 3- to 4-fold after 48 h under both experimental conditions.	Cycloheximide	64-77	solute carrier family 2 member 1	Bos taurus	37-42
12554354-5	2003	The IL-3-induced expression of CD13 was decreased in the presence of the protein-synthesis inhibitor cycloheximide (-8.8%).	Cycloheximide	101-114	interleukin 3	Homo sapiens	4-8
12554354-5	2003	The IL-3-induced expression of CD13 was decreased in the presence of the protein-synthesis inhibitor cycloheximide (-8.8%).	Cycloheximide	101-114	alanyl aminopeptidase, membrane	Homo sapiens	31-35
12581864-4	2003	Both types of stimulus increased the GLUT1 protein content in a cycloheximide (CHX)-sensitive manner, and the glucose transport rate was elevated by 3- to 4-fold after 48 h under both experimental conditions.	Cycloheximide	79-82	solute carrier family 2 member 1	Bos taurus	37-42
12642232-5	2003	In contrast, cycloheximide, a protein synthesis inhibitor, was found to decrease the total SOD activity.	Cycloheximide	13-26	superoxide dismutase 2	Rattus norvegicus	91-94
12446695-5	2003	Treatment of HepG2 cells with cycloheximide resulted in the loss of Nrf2 within 30 min.	Cycloheximide	30-43	NFE2 like bZIP transcription factor 2	Homo sapiens	68-72
12459556-6	2003	The decay of tyrosine-phosphorylated Stat6 was similar in the presence or absence of either cycloheximide or actinomycin D.	Cycloheximide	92-105	signal transducer and activator of transcription 6	Homo sapiens	37-42
12642232-7	2003	Injection of isoproterenol after cycloheximide treatment resulted in the recovery of the total SOD activity.	Cycloheximide	33-46	superoxide dismutase 2	Rattus norvegicus	95-98
12802426-1	2003	Accumulation of c-fos gene locus DNA in the nuclear matrix of hepatocyte nuclei was observed during induction of c-fos with cycloheximide.	Cycloheximide	124-137	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
12802426-1	2003	Accumulation of c-fos gene locus DNA in the nuclear matrix of hepatocyte nuclei was observed during induction of c-fos with cycloheximide.	Cycloheximide	124-137	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	113-118
12520520-4	2003	CHX treatment reduced total vitamin D receptor (VDR) protein levels in cells, but reintroduction of VDR and/or retinoid X receptor protein into cells by transfection did not reduce the inhibition by CHX.	Cycloheximide	0-3	vitamin D receptor	Rattus norvegicus	28-46
12596040-1	2003	The protein synthesis inhibitor cycloheximide (Chx) suppresses prolactin-induced beta-casein gene expression in the mammary epithelial cell line COMMA-D. As the mechanism underlying this effect is unclear, the effects of protein synthesis inhibitors on interactions of transcription factors with the beta-casein promoter were examined.	Cycloheximide	32-45	prolactin	Mus musculus	63-72
12596040-1	2003	The protein synthesis inhibitor cycloheximide (Chx) suppresses prolactin-induced beta-casein gene expression in the mammary epithelial cell line COMMA-D. As the mechanism underlying this effect is unclear, the effects of protein synthesis inhibitors on interactions of transcription factors with the beta-casein promoter were examined.	Cycloheximide	32-45	casein beta	Mus musculus	81-92
12596040-1	2003	The protein synthesis inhibitor cycloheximide (Chx) suppresses prolactin-induced beta-casein gene expression in the mammary epithelial cell line COMMA-D. As the mechanism underlying this effect is unclear, the effects of protein synthesis inhibitors on interactions of transcription factors with the beta-casein promoter were examined.	Cycloheximide	47-50	prolactin	Mus musculus	63-72
12596040-1	2003	The protein synthesis inhibitor cycloheximide (Chx) suppresses prolactin-induced beta-casein gene expression in the mammary epithelial cell line COMMA-D. As the mechanism underlying this effect is unclear, the effects of protein synthesis inhibitors on interactions of transcription factors with the beta-casein promoter were examined.	Cycloheximide	47-50	casein beta	Mus musculus	81-92
12596040-1	2003	The protein synthesis inhibitor cycloheximide (Chx) suppresses prolactin-induced beta-casein gene expression in the mammary epithelial cell line COMMA-D. As the mechanism underlying this effect is unclear, the effects of protein synthesis inhibitors on interactions of transcription factors with the beta-casein promoter were examined.	Cycloheximide	47-50	casein beta	Mus musculus	300-311
12494458-4	2003	Cells were treated with TNF-alpha in the presence of cyclohexamide (CHX) to rapidly induce apoptosis.	Cycloheximide	68-71	tumor necrosis factor	Rattus norvegicus	24-33
12520520-4	2003	CHX treatment reduced total vitamin D receptor (VDR) protein levels in cells, but reintroduction of VDR and/or retinoid X receptor protein into cells by transfection did not reduce the inhibition by CHX.	Cycloheximide	0-3	vitamin D receptor	Rattus norvegicus	48-51
12569180-9	2003	Semi-quantitative RT-PCR and Southern blot analysis showed that IL-1beta also increased P-LAP mRNA, which was abrogated by prior exposure to cycloheximide.	Cycloheximide	141-154	interleukin 1 beta	Homo sapiens	64-72
12627322-8	2003	Cycloheximide, a protein synthesis inhibitor, completely blocked insulin-induced reduction of resistin mRNA.	Cycloheximide	0-13	insulin	Homo sapiens	65-72
12627322-8	2003	Cycloheximide, a protein synthesis inhibitor, completely blocked insulin-induced reduction of resistin mRNA.	Cycloheximide	0-13	resistin	Homo sapiens	94-102
12569180-9	2003	Semi-quantitative RT-PCR and Southern blot analysis showed that IL-1beta also increased P-LAP mRNA, which was abrogated by prior exposure to cycloheximide.	Cycloheximide	141-154	leucyl and cystinyl aminopeptidase	Homo sapiens	88-93
12557277-3	2003	Disruption of PDH1 in a cgcdr1::ura3 strain increased susceptibility to rhodamine 6G, cycloheximide and chloramphenicol, and also increased rhodamine 6G accumulation, all properties of pdr5 null mutants.	Cycloheximide	86-99	putative 2-methylcitrate dehydratase	Saccharomyces cerevisiae S288C	14-18
12592338-12	2003	Both the cell permeable NF-kappaB inhibitor SN50 and cycloheximide lowered cFLIP(L)expression and restored sentivity of AR cells to TRAIL.	Cycloheximide	53-66	TNF superfamily member 10	Homo sapiens	132-137
12589068-6	2003	Surface CD14 was more rapidly internalized after GA treatment (2-3 h) than after incubation with cycloheximide.	Cycloheximide	97-110	CD14 antigen	Mus musculus	8-12
12566244-2	2003	We reported previously that staurosporine, cycloheximide, actinomycin D, as well as more physiological apoptotic agents (lactosylceramide, 15d-PGJ(2)) increase prostaglandin release in parallel with induction of apoptosis in WISH and amnion epithelial cells.	Cycloheximide	43-56	NCK interacting protein with SH3 domain	Homo sapiens	225-229
12557277-4	2003	Overexpression of PDH1 in S. cerevisiae complemented the pdr5 mutation by reversing susceptibility to rhodamine 6G, chloramphenicol and cycloheximide, as well as by decreasing rhodamine 6G intracellular concentration.	Cycloheximide	136-149	putative 2-methylcitrate dehydratase	Saccharomyces cerevisiae S288C	18-22
12557277-4	2003	Overexpression of PDH1 in S. cerevisiae complemented the pdr5 mutation by reversing susceptibility to rhodamine 6G, chloramphenicol and cycloheximide, as well as by decreasing rhodamine 6G intracellular concentration.	Cycloheximide	136-149	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	57-61
12557277-7	2003	Abundance of PDH1 and CgCDR1 mRNA in C. glabrata was increased by rhodamine 6G, cycloheximide and oligomycin, properties in common with PDR5.	Cycloheximide	80-93	putative 2-methylcitrate dehydratase	Saccharomyces cerevisiae S288C	13-17
12441344-7	2003	Cycloheximide inhibited cadmium-stimulated Nrf2 expression and DNA binding activity and attenuated HO-1 mRNA accumulation.	Cycloheximide	0-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	43-47
12441344-7	2003	Cycloheximide inhibited cadmium-stimulated Nrf2 expression and DNA binding activity and attenuated HO-1 mRNA accumulation.	Cycloheximide	0-13	heme oxygenase 1	Mus musculus	99-103
12411429-5	2003	Wild type cells transformed with the PDR1(R821H) allele or a PDR1 dominant allele (PDR1-3) showed the low iron growth defect as well as increased resistance to drugs such as cycloheximide and oligomycin.	Cycloheximide	174-187	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	37-41
12433929-8	2003	Furthermore, the EF2-dependent translocation was inhibited by 50% at 2.5 microm of the translocation inhibitor cycloheximide in the L41 mutant compared with 1.2 microm in the wild type.	Cycloheximide	111-124	elongation factor 2	Saccharomyces cerevisiae S288C	17-20
12670444-7	2003	The up-regulation of c-Fos, GATA-1 and NF-E2 protein by PDGF was inhibited by actinomycin D and cycloheximide, suggesting that mRNA and protein synthesis might be involved in the mechanism.	Cycloheximide	96-109	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	21-26
12670444-7	2003	The up-regulation of c-Fos, GATA-1 and NF-E2 protein by PDGF was inhibited by actinomycin D and cycloheximide, suggesting that mRNA and protein synthesis might be involved in the mechanism.	Cycloheximide	96-109	GATA binding protein 1	Homo sapiens	28-34
12670444-7	2003	The up-regulation of c-Fos, GATA-1 and NF-E2 protein by PDGF was inhibited by actinomycin D and cycloheximide, suggesting that mRNA and protein synthesis might be involved in the mechanism.	Cycloheximide	96-109	nuclear factor, erythroid 2	Homo sapiens	39-44
12411429-5	2003	Wild type cells transformed with the PDR1(R821H) allele or a PDR1 dominant allele (PDR1-3) showed the low iron growth defect as well as increased resistance to drugs such as cycloheximide and oligomycin.	Cycloheximide	174-187	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	61-65
12411429-5	2003	Wild type cells transformed with the PDR1(R821H) allele or a PDR1 dominant allele (PDR1-3) showed the low iron growth defect as well as increased resistance to drugs such as cycloheximide and oligomycin.	Cycloheximide	174-187	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	61-65
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	dynactin subunit 6	Homo sapiens	17-20
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	cyclin dependent kinase inhibitor 1B	Homo sapiens	21-25
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	paired box 3	Homo sapiens	37-41
12409292-8	2003	Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro.	Cycloheximide	179-192	catenin (cadherin associated protein), beta 1	Mus musculus	145-157
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	forkhead box O1	Homo sapiens	42-46
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	dynactin subunit 6	Homo sapiens	80-83
12401804-5	2003	The reduction in p27(Kip1) levels by PAX3-FKHR resulted from destabilization of p27(Kip1) as shown by cycloheximide treatment and in vivo pulse-chase labeling experiments.	Cycloheximide	102-115	cyclin dependent kinase inhibitor 1B	Homo sapiens	84-88
12737047-9	2003	Cycloheximide or actinomycin D completely blocked the stimulatory effect of both GH and IGF-I on P4 production but did not reduce basal progesterone secretion suggesting involvement of gene transcription and translation in the GH and IGF-I action on luteal cells.	Cycloheximide	0-13	growth hormone	Mus musculus	81-83
12737047-9	2003	Cycloheximide or actinomycin D completely blocked the stimulatory effect of both GH and IGF-I on P4 production but did not reduce basal progesterone secretion suggesting involvement of gene transcription and translation in the GH and IGF-I action on luteal cells.	Cycloheximide	0-13	insulin-like growth factor 1	Mus musculus	88-93
12737047-9	2003	Cycloheximide or actinomycin D completely blocked the stimulatory effect of both GH and IGF-I on P4 production but did not reduce basal progesterone secretion suggesting involvement of gene transcription and translation in the GH and IGF-I action on luteal cells.	Cycloheximide	0-13	growth hormone	Mus musculus	227-229
12737047-9	2003	Cycloheximide or actinomycin D completely blocked the stimulatory effect of both GH and IGF-I on P4 production but did not reduce basal progesterone secretion suggesting involvement of gene transcription and translation in the GH and IGF-I action on luteal cells.	Cycloheximide	0-13	insulin-like growth factor 1	Mus musculus	234-239
12534561-9	2003	Extracellular release of mMCP-1 was significantly inhibited ( approximately 40%) by cycloheximide and by the Golgi-disrupting agent brefeldin A, indicating both continuous protein synthesis and transportation via the Golgi complex are required for optimal mMCP-1 secretion.	Cycloheximide	84-97	chemokine (C-C motif) ligand 2	Mus musculus	25-31
12393619-4	2003	We report here that broad-spectrum caspase inhibitors effectively attenuated apoptosis induced in human neutrophils by incubation with agonistic anti-Fas antibody or by coincubation with tumor necrosis factor-alpha (TNF-alpha) and cycloheximide ex vivo.	Cycloheximide	231-244	tumor necrosis factor	Homo sapiens	216-225
12364326-5	2002	Cycloheximide did not block the effects of PTH on RANKL but did inhibit the suppression of OPG mRNA.	Cycloheximide	0-13	TNF receptor superfamily member 11b	Homo sapiens	91-94
12488327-11	2003	As an example, cycloheximide blocked the beta-tubulin mRNA expression, whereas it increased tropomyosin-4 (TM4) mRNA.	Cycloheximide	15-28	tropomyosin 4	Rattus norvegicus	92-105
12488327-11	2003	As an example, cycloheximide blocked the beta-tubulin mRNA expression, whereas it increased tropomyosin-4 (TM4) mRNA.	Cycloheximide	15-28	tropomyosin 4	Rattus norvegicus	107-110
12619892-2	2003	In this study, the mRNA level of beta 1,4GT1 was found to increase greatly during the 7721 hepatocarcinoma cells apoptosis induced by cycloheximide.	Cycloheximide	134-147	beta-1,4-galactosyltransferase 1	Homo sapiens	33-44
12619892-4	2003	Further study showed that the 7721 hepatocarcinoma cells transiently transfected with beta 1,4GT1 were more susceptible to the apoptosis induced by cycloheximide.	Cycloheximide	148-161	beta-1,4-galactosyltransferase 1	Homo sapiens	86-97
12881020-9	2003	Treatment with actinomycin D and cycloheximide demonstrated that the increase in BRCA2 mRNA was not blocked by cycloheximide, indicating that de novo protein synthesis was required in MDA-MB-23, although de novo synthesis was not required in MCF10a for the genistein.	Cycloheximide	33-46	BRCA2 DNA repair associated	Homo sapiens	81-86
12558136-6	2003	Subsequent studies revealed that LPS induced de novo synthesis of CD14: the increase of surface expression could be inhibited by cycloheximide and by interfering with a known LPS-induced signaling event, the translocation of NFkappaB.	Cycloheximide	129-142	CD14 molecule	Homo sapiens	66-70
12397080-2	2002	Depletion of the DIAP1 protein in Drosophila S2 cells or the Sf-IAP protein in Spodoptera frugiperda Sf21 cells by RNA interference (RNAi) or cycloheximide treatment resulted in rapid and widespread caspase-dependent apoptosis.	Cycloheximide	142-155	Death-associated inhibitor of apoptosis 1	Drosophila melanogaster	17-22
12374805-3	2002	Moreover, UV-induced NPM/B23 expression was super-induced by cycloheximide (20 microg/ml), which was characteristic of immediate-early gene response.	Cycloheximide	61-74	nucleophosmin 1	Homo sapiens	21-24
12374805-3	2002	Moreover, UV-induced NPM/B23 expression was super-induced by cycloheximide (20 microg/ml), which was characteristic of immediate-early gene response.	Cycloheximide	61-74	nucleophosmin 1	Homo sapiens	25-28
12384470-6	2002	Cortisol pretreatment significantly increased the rate of eNOS protein degradation in the presence of cycloheximide.	Cycloheximide	102-115	nitric oxide synthase 3	Bos taurus	58-62
12488957-9	2002	However, treatment with an inhibitor of protein synthesis (cycloheximide) or with an enzyme (PI-PLC) that can remove TRAIL-R3 from the islet-cell membrane was able to increase the susceptibility of TRAIL-resistant primary islet cells to the TRAIL death pathway.	Cycloheximide	59-72	TNF receptor superfamily member 10c	Homo sapiens	117-125
12488957-9	2002	However, treatment with an inhibitor of protein synthesis (cycloheximide) or with an enzyme (PI-PLC) that can remove TRAIL-R3 from the islet-cell membrane was able to increase the susceptibility of TRAIL-resistant primary islet cells to the TRAIL death pathway.	Cycloheximide	59-72	TNF superfamily member 10	Homo sapiens	117-122
12488957-9	2002	However, treatment with an inhibitor of protein synthesis (cycloheximide) or with an enzyme (PI-PLC) that can remove TRAIL-R3 from the islet-cell membrane was able to increase the susceptibility of TRAIL-resistant primary islet cells to the TRAIL death pathway.	Cycloheximide	59-72	TNF superfamily member 10	Homo sapiens	198-203
12376324-3	2002	sgk1 mRNA was increased in these epithelia by GCs, and this was inhibited by actinomycin D and superinduced by cycloheximide, consistent with a transcriptional effect that did not require protein synthesis.	Cycloheximide	111-124	serum/glucocorticoid regulated kinase 1	Homo sapiens	0-4
12482503-6	2002	Turnover of E2A proteins was assessed following cycloheximide treatment.	Cycloheximide	48-61	transcription factor 3	Mus musculus	12-15
12472684-10	2002	Auxin induction of Aux/IAA genes in the presence of cycloheximide can be repressed by DEX treatment, showing that the repression of transcription of the Aux/IAAs by the iaa1 mutant protein is primary.	Cycloheximide	52-65	indole-3-acetic acid inducible	Arabidopsis thaliana	169-173
12421978-8	2002	IL-2-induced steroid insensitivity in HT-2 cells appears to be a signaling event as the effects of IL-2 on nuclear translocation of the GCR occurred within 30 min even in the presence of cycloheximide.	Cycloheximide	187-200	interleukin 2	Mus musculus	0-4
12421978-8	2002	IL-2-induced steroid insensitivity in HT-2 cells appears to be a signaling event as the effects of IL-2 on nuclear translocation of the GCR occurred within 30 min even in the presence of cycloheximide.	Cycloheximide	187-200	interleukin 2	Mus musculus	99-103
12421978-8	2002	IL-2-induced steroid insensitivity in HT-2 cells appears to be a signaling event as the effects of IL-2 on nuclear translocation of the GCR occurred within 30 min even in the presence of cycloheximide.	Cycloheximide	187-200	nuclear receptor subfamily 3, group C, member 1	Mus musculus	136-139
12417306-3	2002	However, soluble myc-hApg5 was degraded during apoptosis induced by staurosporine or TNFalpha/cycloheximide whilst expression of soluble p45ASP was stabilised.	Cycloheximide	94-107	autophagy related 5	Homo sapiens	21-26
12376363-5	2002	Actinomycin D and cycloheximide inhibited TGF-beta1-responsive HO-1 mRNA expression, indicating a requirement for transcription and de novo protein synthesis.	Cycloheximide	18-31	transforming growth factor beta 1	Homo sapiens	42-51
12376363-5	2002	Actinomycin D and cycloheximide inhibited TGF-beta1-responsive HO-1 mRNA expression, indicating a requirement for transcription and de novo protein synthesis.	Cycloheximide	18-31	heme oxygenase 1	Homo sapiens	63-67
12390868-5	2002	The coordinate induction of P synthesis and StAR gene expression by mEGF was effectively inhibited by cycloheximide, indicating a requirement for de novo protein synthesis.	Cycloheximide	102-115	steroidogenic acute regulatory protein	Mus musculus	44-48
12117412-4	2002	Recombinant uPA induced the release of MMP9/gelatinase B, as detected by zymography and Western blotting, and this release was abolished by actinomycin D and cycloheximide (inhibitors of DNA transcription and protein synthesis) and partially suppressed by monensin (an inhibitor of secretion).	Cycloheximide	158-171	plasminogen activator, urokinase	Homo sapiens	12-15
12117412-4	2002	Recombinant uPA induced the release of MMP9/gelatinase B, as detected by zymography and Western blotting, and this release was abolished by actinomycin D and cycloheximide (inhibitors of DNA transcription and protein synthesis) and partially suppressed by monensin (an inhibitor of secretion).	Cycloheximide	158-171	matrix metallopeptidase 9	Homo sapiens	39-43
12588051-8	2002	Blockade of protein synthesis with cycloheximide as well as abrogation of mitogen-activated protein kinase (MAPK) activity with PD98059 or U0126 also prevented the TZD-induced increase in UCP2 mRNA.	Cycloheximide	35-48	uncoupling protein 2	Homo sapiens	188-192
12414531-6	2002	With rat AMs, C5a generation was time-dependent and was blocked if AMs were pretreated with inhibitors of transcription or protein synthesis (actinomycin D or cycloheximide).	Cycloheximide	159-172	complement C5	Rattus norvegicus	14-17
12385002-5	2002	Results from the treatment of HMEC with cycloheximide and actinomycin D indicated that the regulation of the IL-1beta gene by RA occurred at the transcriptional level and that the IL-1beta gene is a direct, downstream target gene of RA.	Cycloheximide	40-53	interleukin 1 beta	Homo sapiens	109-117
12209935-6	2002	Comparative studies with neutrophils adherent under static conditions demonstrated time-dependent activation of caspases in TNF-alpha/cycloheximide-induced apoptosis, for which caspase-3 also was implicated.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	124-133
12209935-6	2002	Comparative studies with neutrophils adherent under static conditions demonstrated time-dependent activation of caspases in TNF-alpha/cycloheximide-induced apoptosis, for which caspase-3 also was implicated.	Cycloheximide	134-147	caspase 3	Homo sapiens	177-186
12202477-6	2002	p21 protein levels increased in cultured primary hepatocytes treated with the proteasome inhibitor MG132 and cycloheximide, indicating that p21 expression is regulated at the level of protein stability in liver cells.	Cycloheximide	109-122	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	0-3
12202477-6	2002	p21 protein levels increased in cultured primary hepatocytes treated with the proteasome inhibitor MG132 and cycloheximide, indicating that p21 expression is regulated at the level of protein stability in liver cells.	Cycloheximide	109-122	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	140-143
12385002-5	2002	Results from the treatment of HMEC with cycloheximide and actinomycin D indicated that the regulation of the IL-1beta gene by RA occurred at the transcriptional level and that the IL-1beta gene is a direct, downstream target gene of RA.	Cycloheximide	40-53	interleukin 1 beta	Homo sapiens	180-188
12186872-9	2002	Whereas Ang II was without effect on SF-1 expression, forskolin significantly increased SF-1 protein and mRNA levels in a cycloheximide-sensitive manner (to 167.4 +/- 16.6 and 173.1 +/- 25.1% of controls after 6 h, respectively, p &lt; 0.01).	Cycloheximide	122-135	splicing factor 1	Bos taurus	88-92
12421372-2	2002	This cell death can be blocked by genetic deletion of Bax, a member of the pro-apoptotic Bcl-2 family, cycloheximide an inhibitor of macromolecular synthesis or expression of dominant-negative c-jun.	Cycloheximide	103-116	BCL2 associated X, apoptosis regulator	Homo sapiens	54-57
12421372-2	2002	This cell death can be blocked by genetic deletion of Bax, a member of the pro-apoptotic Bcl-2 family, cycloheximide an inhibitor of macromolecular synthesis or expression of dominant-negative c-jun.	Cycloheximide	103-116	BCL2 apoptosis regulator	Homo sapiens	89-94
12370804-5	2002	Interestingly, cycloheximide inhibition experiments revealed that secondary protein synthesis was necessary to induce AIB1 expression by antiestrogens and retinoids.	Cycloheximide	15-28	HEAT repeat containing 6	Homo sapiens	118-122
12370398-7	2002	The expression of PAR-2 on the cell surface was promoted by PR3, and inhibited by cytochalasin B, but not by cycloheximide.	Cycloheximide	109-122	F2R like trypsin receptor 1	Homo sapiens	18-23
12370400-9	2002	Cycloheximide blocked the increase in mRNA at 6 h in both conditions, but also blocked the increase at 24 h with TGF-beta1 plus IL-13.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	113-122
12370400-9	2002	Cycloheximide blocked the increase in mRNA at 6 h in both conditions, but also blocked the increase at 24 h with TGF-beta1 plus IL-13.	Cycloheximide	0-13	interleukin 13	Homo sapiens	128-133
12393267-5	2002	On the other hand, the protein synthesis inhibitor cycloheximide (10 microg/ml) produced a decrease in the rate of receptor degradation, t(1/2)=22 h indicated that the rate of MOR turnover was attenuated almost 2-fold following the inhibition of protein synthesis.	Cycloheximide	51-64	opioid receptor, mu 1	Mus musculus	176-179
12393267-6	2002	Furthermore, when N2A cells were exposed to a combination of DAMGO and cycloheximide, the t(1/2) was 9.7 h. These data provided the first evidence that MOR is down-regulated during agonist stimulation and that the turnover rate of MOR is sum of both accelerated receptor degradation and decreased receptor biosynthesis.	Cycloheximide	71-84	opioid receptor, mu 1	Mus musculus	152-155
12393267-6	2002	Furthermore, when N2A cells were exposed to a combination of DAMGO and cycloheximide, the t(1/2) was 9.7 h. These data provided the first evidence that MOR is down-regulated during agonist stimulation and that the turnover rate of MOR is sum of both accelerated receptor degradation and decreased receptor biosynthesis.	Cycloheximide	71-84	opioid receptor, mu 1	Mus musculus	231-234
12225948-7	2002	Dexamethasone and cycloheximide prevented COX-2 induction.	Cycloheximide	18-31	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	42-47
12239085-8	2002	Time-course studies and suppression of TGF-beta-induced VEGF production by cycloheximide suggest that TGF-beta induces de novo synthesis of VEGF in folliculostellate cells, which is completely blocked by dexamethasone.	Cycloheximide	75-88	transforming growth factor, beta 1	Mus musculus	39-47
12420142-2	2002	Transformation of the S. cerevisiae Delta pdr1 Delta pdr3 mutant strain, hypersensitive to drugs, with isolated plasmids resulted in resistance to cycloheximide and fluconazole.	Cycloheximide	147-160	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	42-46
12420142-2	2002	Transformation of the S. cerevisiae Delta pdr1 Delta pdr3 mutant strain, hypersensitive to drugs, with isolated plasmids resulted in resistance to cycloheximide and fluconazole.	Cycloheximide	147-160	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	53-57
12084011-6	2002	Cycloheximide, the protein synthesis inhibitor, induced PAEC apoptosis more slowly than staurosporine, but did not induce FAK dephosphorylation or rapid focal adhesion disruption, and instead caused a slower loss of focal adhesions and a marked increase in FAK proteolysis.	Cycloheximide	0-13	protein tyrosine kinase 2	Homo sapiens	257-260
12239085-8	2002	Time-course studies and suppression of TGF-beta-induced VEGF production by cycloheximide suggest that TGF-beta induces de novo synthesis of VEGF in folliculostellate cells, which is completely blocked by dexamethasone.	Cycloheximide	75-88	vascular endothelial growth factor A	Mus musculus	56-60
12239085-8	2002	Time-course studies and suppression of TGF-beta-induced VEGF production by cycloheximide suggest that TGF-beta induces de novo synthesis of VEGF in folliculostellate cells, which is completely blocked by dexamethasone.	Cycloheximide	75-88	transforming growth factor, beta 1	Mus musculus	102-110
12239085-8	2002	Time-course studies and suppression of TGF-beta-induced VEGF production by cycloheximide suggest that TGF-beta induces de novo synthesis of VEGF in folliculostellate cells, which is completely blocked by dexamethasone.	Cycloheximide	75-88	vascular endothelial growth factor A	Mus musculus	140-144
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	50-63	early growth response 1	Rattus norvegicus	123-128
12084011-8	2002	Cycloheximide induces apoptosis through a pathway involving FAK proteolysis without dephosphorylation.	Cycloheximide	0-13	protein tyrosine kinase 2	Homo sapiens	60-63
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	50-63	phospholipase C, gamma 1	Rattus norvegicus	146-155
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	50-63	early growth response 1	Rattus norvegicus	243-248
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	50-63	phospholipase C, gamma 1	Rattus norvegicus	266-275
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	65-68	early growth response 1	Rattus norvegicus	123-128
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	65-68	phospholipase C, gamma 1	Rattus norvegicus	146-155
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	65-68	early growth response 1	Rattus norvegicus	243-248
12374773-7	2002	Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgamma1-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells.	Cycloheximide	65-68	phospholipase C, gamma 1	Rattus norvegicus	266-275
12270129-7	2002	Treatment of the cultures with cycloheximide revealed that PLD1 and 2 proteins had biological half-lives of 2-3 days (PLD2) and 4-6 days (PLD1), respectively.	Cycloheximide	31-44	phospholipase D1	Homo sapiens	59-69
12683216-4	2002	Based on the inhibitory effect of cycloheximide, actinomycin-D we may suggest that PMA and LPS could upregulate IL-8 receptor in monocytes through denovo protein synthesis.	Cycloheximide	34-47	C-X-C motif chemokine ligand 8	Homo sapiens	112-116
12460542-7	2002	DNA damage-induced death of cells expressing mutant PS1 was attenuated by inhibitors of calpains I and II, by an intracellular Ca(2+) chelator, by the protein synthesis inhibitor cycloheximide, and by a broad-spectrum caspase inhibitor, but not by an inhibitor of caspase-1.	Cycloheximide	179-192	presenilin 1	Rattus norvegicus	52-55
12140283-3	2002	In PANC-1 cells, TGF-beta1 dramatically stimulated BGN mRNA accumulation through a BGN transcription-independent, cycloheximide-sensitive mechanism and strongly increased the synthesis and release of the proteoglycan form of BGN.	Cycloheximide	114-127	transforming growth factor beta 1	Homo sapiens	17-26
12270129-7	2002	Treatment of the cultures with cycloheximide revealed that PLD1 and 2 proteins had biological half-lives of 2-3 days (PLD2) and 4-6 days (PLD1), respectively.	Cycloheximide	31-44	phospholipase D2	Homo sapiens	118-122
12270129-7	2002	Treatment of the cultures with cycloheximide revealed that PLD1 and 2 proteins had biological half-lives of 2-3 days (PLD2) and 4-6 days (PLD1), respectively.	Cycloheximide	31-44	phospholipase D1	Homo sapiens	59-63
12350235-8	2002	Both sGC activity and beta1 subunit levels decreased more rapidly in chromaffin cells exposed to NO than in cells exposed to the protein synthesis inhibitor, cycloheximide, suggesting that NO decreases beta1 subunit stability.	Cycloheximide	158-171	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	202-207
12181122-3	2002	Thrombin stimulated the accumulation of HSP27 dose dependently between 0.01 and 1 U/ml and cycloheximide reduced the accumulation.	Cycloheximide	91-104	coagulation factor II, thrombin	Homo sapiens	0-8
12181122-3	2002	Thrombin stimulated the accumulation of HSP27 dose dependently between 0.01 and 1 U/ml and cycloheximide reduced the accumulation.	Cycloheximide	91-104	heat shock protein family B (small) member 1	Homo sapiens	40-45
12511984-0	2002	Cycloheximide prevents inhibition of expression of immediate early gene c-fos in paraventricular nuclei of rat hypothalamus produced by delta sleep-inducing peptide.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	72-77
12557470-0	2002	The effect of cycloheximide on butyrylcholinesterase activity in vivo.	Cycloheximide	14-27	butyrylcholinesterase	Rattus norvegicus	31-52
12557470-1	2002	The paper describes the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver, white adipose tissue, heart, and brain of rats intraperitoneally administered a single non-lethal dose of cycloheximide (2.0 mg/kg body weight; CHM).	Cycloheximide	209-222	butyrylcholinesterase	Rattus norvegicus	46-67
12557470-1	2002	The paper describes the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver, white adipose tissue, heart, and brain of rats intraperitoneally administered a single non-lethal dose of cycloheximide (2.0 mg/kg body weight; CHM).	Cycloheximide	209-222	butyrylcholinesterase	Rattus norvegicus	69-74
12511984-1	2002	We studied expression of the immediate early gene c-fos in hypothalamic paraventricular nuclei in rats with different prognostic resistance to emotional stress receiving delta-sleep-inducing peptide after intracerebroventricular administration of cycloheximide.	Cycloheximide	247-260	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	50-55
12181447-8	2002	The half-life of iNOS mRNA after LPS treatment was 5 h 40 min, and dexamethasone reduced it to 3 h. The increased degradation of iNOS mRNA was reversed by a protein synthesis inhibitor cycloheximide.	Cycloheximide	185-198	nitric oxide synthase 2, inducible	Mus musculus	17-21
12205052-6	2002	Also, the release of VEGF was blocked by cycloheximide.	Cycloheximide	41-54	vascular endothelial growth factor A	Mus musculus	21-25
12365717-10	2002	By treating the cells, galactosamine and cycloheximide also lowered the apoptosis-inducing activity and decreased TNF-alpha and IL-2 productions.	Cycloheximide	41-54	tumor necrosis factor	Mus musculus	114-123
12365717-10	2002	By treating the cells, galactosamine and cycloheximide also lowered the apoptosis-inducing activity and decreased TNF-alpha and IL-2 productions.	Cycloheximide	41-54	interleukin 2	Mus musculus	128-132
12396717-6	2002	Conversely, cotreatment of cells with a protein synthesis inhibitor, cycloheximide, and H(2)O(2) drastically shortened the half-life of p21.	Cycloheximide	69-82	cyclin dependent kinase inhibitor 1A	Homo sapiens	136-139
12181447-8	2002	The half-life of iNOS mRNA after LPS treatment was 5 h 40 min, and dexamethasone reduced it to 3 h. The increased degradation of iNOS mRNA was reversed by a protein synthesis inhibitor cycloheximide.	Cycloheximide	185-198	nitric oxide synthase 2, inducible	Mus musculus	129-133
12055194-5	2002	Malondialdehyde treatment induced an increase in the cellular levels of col1a1 mRNA that was abrogated by pretreating cells with cycloheximide, p-hydroxymercuribenzoate, pyridoxal 5"-phosphate, and mithramycin.	Cycloheximide	129-142	collagen type I alpha 1 chain	Rattus norvegicus	72-78
12147270-7	2002	Inhibition of protein synthesis by cycloheximide enhances the induction of TiPARP in the presence of an AhR agonist.	Cycloheximide	35-48	TCDD-inducible poly(ADP-ribose) polymerase	Mus musculus	75-81
12147270-7	2002	Inhibition of protein synthesis by cycloheximide enhances the induction of TiPARP in the presence of an AhR agonist.	Cycloheximide	35-48	aryl-hydrocarbon receptor	Mus musculus	104-107
12169274-6	2002	The reduction of procollagen alpha1(I) and alpha1(III) mRNA steady-state levels by TSA did not require de novo protein synthesis, while the effect of TSA on alpha-SMA mRNA steady-state levels was cycloheximide-sensitive.	Cycloheximide	196-209	actin gamma 2, smooth muscle	Rattus norvegicus	157-166
12163389-4	2002	We found that the emergence of resistance to Apo2L/TRAIL, after prolonged incubation with this cytokine, was associated with increased levels of FLICE inhibitory protein (FLIP), and was overcome by cycloheximide and bisindolylmaleimide, that specifically down-regulated FLIP expression, as well as by transfection of a FLIP anti-sense oligonucleotide.	Cycloheximide	198-211	TNF superfamily member 10	Homo sapiens	45-50
12176960-4	2002	OPN mRNA induction by FGF-1 was completely inhibited by either actinomycin D or cycloheximide, selective inhibitors of RNA polymerase and protein synthesis, respectively.	Cycloheximide	80-93	secreted phosphoprotein 1	Rattus norvegicus	0-3
12176960-4	2002	OPN mRNA induction by FGF-1 was completely inhibited by either actinomycin D or cycloheximide, selective inhibitors of RNA polymerase and protein synthesis, respectively.	Cycloheximide	80-93	fibroblast growth factor 1	Rattus norvegicus	22-27
12163389-4	2002	We found that the emergence of resistance to Apo2L/TRAIL, after prolonged incubation with this cytokine, was associated with increased levels of FLICE inhibitory protein (FLIP), and was overcome by cycloheximide and bisindolylmaleimide, that specifically down-regulated FLIP expression, as well as by transfection of a FLIP anti-sense oligonucleotide.	Cycloheximide	198-211	TNF superfamily member 10	Homo sapiens	51-56
12212968-4	2002	The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated.	Cycloheximide	151-164	caspase 8	Homo sapiens	208-224
12135878-6	2002	TNFalpha alone failed to induce granulosa cell death but significantly increased the apoptotic cell number in the presence of cycloheximide.	Cycloheximide	126-139	tumor necrosis factor	Rattus norvegicus	0-8
12163468-9	2002	Nevertheless, cycloheximide treatment prevented BDNF-mediated apoptosis.	Cycloheximide	14-27	brain derived neurotrophic factor	Mus musculus	48-52
12212968-4	2002	The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated.	Cycloheximide	151-164	BCL2 like 1	Homo sapiens	359-365
12212968-4	2002	The administration of agonistic anti-Fas antibody (CH-11) or cycloheximide alone did not induce apoptosis, whereas the co-administration of CH-11 with cycloheximide induced apoptosis in WI-38 cells, in which caspase-8 and -3, but not -9, were activated, and X chromosome-linked inhibitor of apoptosis (ILP) and FLICE-like inhibitor protein (FLIP(L)), but not bcl-xL and bcl-2, were remarkably down regulated.	Cycloheximide	151-164	BCL2 apoptosis regulator	Homo sapiens	370-375
12153521-11	2002	However, in the presence of cycloheximide, there was a slow reduction of IkappaBalpha and IkappaBbeta, which disappeared almost completely at 4 hr.	Cycloheximide	28-41	NFKB inhibitor alpha	Rattus norvegicus	73-85
12363040-3	2002	HL-60 cells do not normally express detectable amounts of NEP/CD10 on their surface or intracytoplasmically, but upon jaspamide treatment, CD10 was synthesized de novo, its expression being inhibited by cycloheximide pretreatment.	Cycloheximide	203-216	membrane metalloendopeptidase	Homo sapiens	139-143
12143039-4	2002	Hepatoma cells treated with TNF and cycloheximide undergo apoptosis, which is proceeded by a strong activation of JNK.	Cycloheximide	36-49	mitogen-activated protein kinase 9	Homo sapiens	114-117
12153521-11	2002	However, in the presence of cycloheximide, there was a slow reduction of IkappaBalpha and IkappaBbeta, which disappeared almost completely at 4 hr.	Cycloheximide	28-41	NFKB inhibitor beta	Rattus norvegicus	90-101
12162503-6	2002	In cells treated with cycloheximide (CHX), perinuclear staining for OPN and BSP was lost, but iOPN staining was retained within cell processes.	Cycloheximide	22-35	secreted phosphoprotein 1	Rattus norvegicus	68-71
12716463-4	2002	To analyze the mechanism of p53 accumulation by E2, the stability of p53, ERalpha and MDM2 proteins was analyzed in the presence of cycloheximide under an E2-supplemented or -depleted condition.	Cycloheximide	132-145	tumor protein p53	Homo sapiens	69-72
12716463-4	2002	To analyze the mechanism of p53 accumulation by E2, the stability of p53, ERalpha and MDM2 proteins was analyzed in the presence of cycloheximide under an E2-supplemented or -depleted condition.	Cycloheximide	132-145	MDM2 proto-oncogene	Homo sapiens	86-90
12162503-6	2002	In cells treated with cycloheximide (CHX), perinuclear staining for OPN and BSP was lost, but iOPN staining was retained within cell processes.	Cycloheximide	22-35	integrin-binding sialoprotein	Rattus norvegicus	76-79
12162503-6	2002	In cells treated with cycloheximide (CHX), perinuclear staining for OPN and BSP was lost, but iOPN staining was retained within cell processes.	Cycloheximide	37-40	secreted phosphoprotein 1	Rattus norvegicus	68-71
12162503-6	2002	In cells treated with cycloheximide (CHX), perinuclear staining for OPN and BSP was lost, but iOPN staining was retained within cell processes.	Cycloheximide	37-40	integrin-binding sialoprotein	Rattus norvegicus	76-79
11978789-2	2002	We now demonstrate that GLP-2, in a cycloheximide-insensitive manner, enhanced survival in baby hamster kidney cells stably transfected with the rat GLP-2R; reduced mitochondrial cytochrome c efflux; and attenuated the caspase-dependent cleavage of Akt, poly(ADP-ribose) polymerase, and beta-catenin following inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002.	Cycloheximide	36-49	mast cell protease 10	Rattus norvegicus	24-29
12149134-2	2002	RESULTS: In a yeast t-degron (ubiquitin-argDHFR(ts))- phosphoglycerate mutase (GPM1) fusion strain, increasing periods of exposure to the non-permissive temperature 37 degrees C, even in the presence of cycloheximide, gave decreasing function, as assessed at 23 degrees C in vivo by glucose metabolism and confirmed by immunoblot.	Cycloheximide	203-216	phosphoglycerate mutase	Saccharomyces cerevisiae S288C	54-77
12149134-2	2002	RESULTS: In a yeast t-degron (ubiquitin-argDHFR(ts))- phosphoglycerate mutase (GPM1) fusion strain, increasing periods of exposure to the non-permissive temperature 37 degrees C, even in the presence of cycloheximide, gave decreasing function, as assessed at 23 degrees C in vivo by glucose metabolism and confirmed by immunoblot.	Cycloheximide	203-216	phosphoglycerate mutase GPM1	Saccharomyces cerevisiae S288C	79-83
12117555-6	2002	In addition, pretreating the cells with an inhibitor of protein synthesis, cycloheximide, inhibited the increase in AQP9 mRNA induced by dbcAMP, but not the decrease in AQP5 mRNA.	Cycloheximide	75-88	aquaporin 9	Rattus norvegicus	116-120
12015311-2	2002	The mouse homologue of yeast Rrn3, a polymerase-associated transcription initiation factor, can complement extracts from cycloheximide-treated mammalian cells.	Cycloheximide	121-134	rDNA-binding RNA polymerase I transcriptional factor	Saccharomyces cerevisiae S288C	29-33
12015311-3	2002	Cycloheximide inhibits the phosphorylation of Rrn3 and causes its dissociation from RNA polymerase I.	Cycloheximide	0-13	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	46-50
12015311-4	2002	Rrn3 interacts with the rpa43 subunit of RNA polymerase I, and treatment with cycloheximide inhibits the formation of a Rrn3.rpa43 complex in vivo.	Cycloheximide	78-91	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	120-124
12115434-9	2002	The level of Bcl-X(L) expressed after ZnSO(4) induction was sufficient to prevent apoptosis experimentally induced by cycloheximide and allowed 4G1.D9 cells to grow at higher densities and remain viable for prolonged periods in suboptimal culture conditions.	Cycloheximide	118-131	BCL2-like 1	Mus musculus	13-21
11980899-7	2002	Studies using cycloheximide and antisense oligonucleotides to IRF-1 indicate a direct role of IRF-1 in activating 2-5 AS.	Cycloheximide	14-27	interferon regulatory factor 1	Homo sapiens	94-99
12055072-8	2002	Cycloheximide blocked TNF-alpha-mediated antiapoptotic signaling, suggesting protein synthesis is required.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	22-31
12111350-8	2002	Cycloheximide (10 micro M) induced a blockade of adrenaline-induced stimulation of PDE4.	Cycloheximide	0-13	phosphodiesterase 4A	Homo sapiens	83-87
12063295-5	2002	NF-kappa B may be a common mediator of various stimuli that increase B(1)R gene transcription in the rabbit aorta, including tissue isolation, but cycloheximide also stabilizes B(1)R mRNA.	Cycloheximide	147-160	B1 bradykinin receptor	Oryctolagus cuniculus	177-182
12163132-7	2002	In addition, experiments using cycloheximide treatment, that blocks nascent protein synthesis, indicated that estrogen withdrawal affected the transcript levels of LXR(alpha) and IL-1ra through dissimilar pathways.	Cycloheximide	31-44	interleukin 1 receptor antagonist	Homo sapiens	179-185
12110442-10	2002	Cycloheximide, an inhibitor for protein synthesis, inhibited PTH-stimulated RANKL mRNA expression by 60% without altering the effect of PTH on OPG mRNA expression.	Cycloheximide	0-13	parathyroid hormone	Mus musculus	61-64
12110442-10	2002	Cycloheximide, an inhibitor for protein synthesis, inhibited PTH-stimulated RANKL mRNA expression by 60% without altering the effect of PTH on OPG mRNA expression.	Cycloheximide	0-13	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	76-81
12136286-12	2002	TRAIL failed to kill RPE cells in vitro, but showed a strong synergistic killing effect when coincubated with protein (cycloheximide) or RNA (actinomycin D) synthesis inhibitor.	Cycloheximide	119-132	TNF superfamily member 10	Homo sapiens	0-5
12111005-6	2002	Cycloheximide (CHX) treatment resulted in increased PAI-1 mRNA induction, indicating that this response to TCDD is a direct effect on transcription and not a secondary effect mediated by other TCDD-induced proteins.	Cycloheximide	0-13	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	52-57
12111005-6	2002	Cycloheximide (CHX) treatment resulted in increased PAI-1 mRNA induction, indicating that this response to TCDD is a direct effect on transcription and not a secondary effect mediated by other TCDD-induced proteins.	Cycloheximide	15-18	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	52-57
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	plasminogen activator, urokinase receptor	Homo sapiens	59-63
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	118-127
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Homo sapiens	131-140
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	plasminogen activator, urokinase receptor	Homo sapiens	172-176
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	202-211
12070711-4	2002	Cycloheximide, a protein synthesis inhibitor, also induced uPAR mRNA accumulation either alone or in combination with IFN-alpha or IFN-gamma, suggesting that the effect on uPAR mRNA levels activated by IFN-alpha or IFN-gamma does not require de novo protein synthesis.	Cycloheximide	0-13	interferon gamma	Homo sapiens	215-224
12052876-10	2002	However, the Delta fes1 mutant showed increased cycloheximide sensitivity and a general translational defect, suggesting that Fes1p acts during protein translation, a process in which Ssa1p and Ydj1p are known to be involved.	Cycloheximide	48-61	Fes1p	Saccharomyces cerevisiae S288C	19-23
12052876-10	2002	However, the Delta fes1 mutant showed increased cycloheximide sensitivity and a general translational defect, suggesting that Fes1p acts during protein translation, a process in which Ssa1p and Ydj1p are known to be involved.	Cycloheximide	48-61	Fes1p	Saccharomyces cerevisiae S288C	126-131
12137744-5	2002	The inhibitors SB203580, PD98059, SN50, cycloheximide and D-ribofuranosylbenzimidazole each reduced the basal and TNFalpha-stimulated secretion of IL-1beta and also reduced IL-6 secretion with the exception of SN50.	Cycloheximide	40-53	tumor necrosis factor	Homo sapiens	114-122
12087245-10	2002	Furthermore, by using actinomycin D and cycloheximide, the authors demonstrated that the rhPDGF-BB-induced VEGF mRNA expression was transcriptionally mediate and not dependent on de novo protein synthesis.	Cycloheximide	40-53	vascular endothelial growth factor A	Rattus norvegicus	107-111
12137744-5	2002	The inhibitors SB203580, PD98059, SN50, cycloheximide and D-ribofuranosylbenzimidazole each reduced the basal and TNFalpha-stimulated secretion of IL-1beta and also reduced IL-6 secretion with the exception of SN50.	Cycloheximide	40-53	interleukin 1 beta	Homo sapiens	147-155
12137744-5	2002	The inhibitors SB203580, PD98059, SN50, cycloheximide and D-ribofuranosylbenzimidazole each reduced the basal and TNFalpha-stimulated secretion of IL-1beta and also reduced IL-6 secretion with the exception of SN50.	Cycloheximide	40-53	interleukin 6	Homo sapiens	173-177
12082077-5	2002	Treatment of cells with cycloheximide caused a similar imbalance in the accumulation of COX subunits, and enhanced mRNA for Lon and Yme1, the latter another mitochondrial ATP-dependent protease.	Cycloheximide	24-37	lon peptidase 1, mitochondrial	Rattus norvegicus	124-127
12112229-0	2002	The SCR1 gene from Schwanniomyces occidentalis encodes a highly hydrophobic polypeptide, which confers ribosomal resistance to cycloheximide.	Cycloheximide	127-140	SCR1	Saccharomyces cerevisiae S288C	4-8
12112229-1	2002	In Saccharomyces cerevisiae, the SCR1 gene from Schwanniomyces occidentalis is known to induce ribosomal resistance to cycloheximide (cyh).	Cycloheximide	119-132	SCR1	Saccharomyces cerevisiae S288C	33-37
12112229-1	2002	In Saccharomyces cerevisiae, the SCR1 gene from Schwanniomyces occidentalis is known to induce ribosomal resistance to cycloheximide (cyh).	Cycloheximide	134-137	SCR1	Saccharomyces cerevisiae S288C	33-37
12112229-9	2002	However, SCR1 only conferred resistance to cyh but not to benomyl or methotrexate.	Cycloheximide	43-46	SCR1	Saccharomyces cerevisiae S288C	9-13
12112229-12	2002	It is proposed that the ribosomes of yeast cells expressing SCR1 undergo a conformational change during their interaction with the ER, which lowers their affinity for cyh-binding.	Cycloheximide	167-170	SCR1	Saccharomyces cerevisiae S288C	60-64
11997671-3	2002	We recently showed that activation of the CC chemokine 9 receptor (CCR9), a thymus-specific chemokine receptor, led to potent cFLIP(L)-independent resistance to cycloheximide-induced apoptosis and modest resistance to Fas-mediated apoptosis possibly via activation of multiple signaling components involving Akt and glycogen synthase kinase 3beta.	Cycloheximide	161-174	C-C motif chemokine receptor 9	Homo sapiens	67-71
12080469-5	2002	However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of c-myc, suggesting that selective stress conditions are required to increase c-myc protein stability.	Cycloheximide	70-83	tumor necrosis factor	Homo sapiens	58-67
12080469-5	2002	However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of c-myc, suggesting that selective stress conditions are required to increase c-myc protein stability.	Cycloheximide	70-83	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	129-134
12080469-5	2002	However, in combination with tumor necrosis factor-alpha (TNF-alpha), cycloheximide efficiently increases steady-state levels of c-myc, suggesting that selective stress conditions are required to increase c-myc protein stability.	Cycloheximide	70-83	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	205-210
12065413-6	2002	In addition, blocking synthesis of inducible p53 by cycloheximide did not abrogate apoptosis, suggesting that the latent population of p53 is sufficient for executing the apoptotic program.	Cycloheximide	52-65	transformation related protein 53, pseudogene	Mus musculus	45-48
12036874-3	2002	The induction of HO-1 expression by serum was inhibited by actinomycin D or cycloheximide.	Cycloheximide	76-89	heme oxygenase 1	Homo sapiens	17-21
11943786-2	2002	For example, Pdr1p and Pdr3p activate multidrug resistance genes by binding to pleiotropic drug response elements (PDREs) found in promoters of target genes such as PDR5, encoding a drug efflux pump involved in resistance to cycloheximide.	Cycloheximide	225-238	drug-responsive transcription factor PDR1	Saccharomyces cerevisiae S288C	13-18
11943786-2	2002	For example, Pdr1p and Pdr3p activate multidrug resistance genes by binding to pleiotropic drug response elements (PDREs) found in promoters of target genes such as PDR5, encoding a drug efflux pump involved in resistance to cycloheximide.	Cycloheximide	225-238	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	23-28
11943786-2	2002	For example, Pdr1p and Pdr3p activate multidrug resistance genes by binding to pleiotropic drug response elements (PDREs) found in promoters of target genes such as PDR5, encoding a drug efflux pump involved in resistance to cycloheximide.	Cycloheximide	225-238	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	165-169
11943786-8	2002	For example, cycloheximide sensitivity of a Deltastb5 strain was correlated with decreased RNA levels and promoter activity of the PDR5 gene.	Cycloheximide	13-26	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	131-135
11997671-3	2002	We recently showed that activation of the CC chemokine 9 receptor (CCR9), a thymus-specific chemokine receptor, led to potent cFLIP(L)-independent resistance to cycloheximide-induced apoptosis and modest resistance to Fas-mediated apoptosis possibly via activation of multiple signaling components involving Akt and glycogen synthase kinase 3beta.	Cycloheximide	161-174	C-X-C motif chemokine receptor 4	Homo sapiens	92-110
12040025-4	2002	In the presence of cycloheximide, AVP up-regulates the expression of MEF2, but not of myogenin, indicating that the synthesis of a protein intermediate is not necessary for MEF2 induction.	Cycloheximide	19-32	arginine vasopressin	Mus musculus	34-37
12021290-9	2002	Based on enzyme profile and cycloheximide effects on pollen germination and activity, it is hypothesized that the gene encoding alpha4-Fuc-T could be regulated late during pollen development.	Cycloheximide	28-41	glycoprotein 3-alpha-L-fucosyltransferase A-like	Nicotiana tabacum	135-140
11991986-6	2002	Importantly, the cycloheximide requirement for TVB-dependent cell death was overcome by the expression of a transdominant form of I kappa B-alpha, and downregulation of NF-kappa B by the immunomodulator pyrrolidinedithiocarbamate enhanced the cytopathogenicity of ALV-B.	Cycloheximide	17-30	NFKB inhibitor alpha	Homo sapiens	130-145
11991986-6	2002	Importantly, the cycloheximide requirement for TVB-dependent cell death was overcome by the expression of a transdominant form of I kappa B-alpha, and downregulation of NF-kappa B by the immunomodulator pyrrolidinedithiocarbamate enhanced the cytopathogenicity of ALV-B.	Cycloheximide	17-30	nuclear factor kappa B subunit 1	Homo sapiens	169-179
12021180-5	2002	Cycloheximide treatment, at a dose able to profoundly inhibit protein synthesis in FRTL-5 cells, obliterated the decrease in the level of the inhibitory subunit I kappa B alpha produced by thapsigargin and tunicamycin.	Cycloheximide	0-13	NFKB inhibitor alpha	Rattus norvegicus	161-176
12113554-11	2002	In addition, H7, staurosporine, cycloheximide and TGF-beta could suppress MMP-2 production.	Cycloheximide	32-45	matrix metallopeptidase 2	Homo sapiens	74-79
12095698-5	2002	Upon formation of a deletion over the active CAN1-CYH2 genes, a cell becomes resistant to both canavanine and cycloheximide.	Cycloheximide	110-123	ribosomal 60S subunit protein L28	Saccharomyces cerevisiae S288C	50-54
12093154-6	2002	T3 increases msi-1 mRNA level in an actinomycin D-sensitive, cycloheximide-resistant fashion without affecting its half-life, which suggests a transcriptional effect.	Cycloheximide	61-74	musashi RNA-binding protein 1	Mus musculus	13-18
12297009-4	2002	Inhibition of translation using cycloheximide greatly enhanced the apoptotic effect of TNF-alpha.	Cycloheximide	32-45	tumor necrosis factor	Rattus norvegicus	87-96
12091715-5	2002	Cycloheximide inhibited SAMDC activity in parallel with pollen germination at 25 degrees C, whereas actinomycin D had no effect on either of them, indicating that enhanced SAMDC activity is associated with de novo protein synthesis.	Cycloheximide	0-13	S-adenosylmethionine decarboxylase	Solanum lycopersicum	24-29
12091715-5	2002	Cycloheximide inhibited SAMDC activity in parallel with pollen germination at 25 degrees C, whereas actinomycin D had no effect on either of them, indicating that enhanced SAMDC activity is associated with de novo protein synthesis.	Cycloheximide	0-13	S-adenosylmethionine decarboxylase	Solanum lycopersicum	172-177
12085986-5	2002	Seven of ten HCC cell lines showed resistance to TRAIL-induced apoptosis and five of seven TRAIL-resistant cell lines became sensitive to TRAIL by co-treatment with cycloheximide.	Cycloheximide	165-178	TNF superfamily member 10	Homo sapiens	91-96
12085986-5	2002	Seven of ten HCC cell lines showed resistance to TRAIL-induced apoptosis and five of seven TRAIL-resistant cell lines became sensitive to TRAIL by co-treatment with cycloheximide.	Cycloheximide	165-178	TNF superfamily member 10	Homo sapiens	91-96
12095698-5	2002	Upon formation of a deletion over the active CAN1-CYH2 genes, a cell becomes resistant to both canavanine and cycloheximide.	Cycloheximide	110-123	arginine permease CAN1	Saccharomyces cerevisiae S288C	45-49
11901146-8	2002	Furthermore, in the rat hepatoma cell line FTO2B, LXR-dependent transcription of the ABCG5/G8 genes was cycloheximide-resistant, indicating that these genes are directly regulated by LXRs.	Cycloheximide	104-117	nuclear receptor subfamily 1, group H, member 2	Mus musculus	50-53
11901146-8	2002	Furthermore, in the rat hepatoma cell line FTO2B, LXR-dependent transcription of the ABCG5/G8 genes was cycloheximide-resistant, indicating that these genes are directly regulated by LXRs.	Cycloheximide	104-117	ATP binding cassette subfamily G member 5	Rattus norvegicus	85-90
11882665-7	2002	A Deltardr1 strain has increased resistance to cycloheximide, as expected from the overexpression of PDR5.	Cycloheximide	47-60	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	101-105
12085214-4	2002	Protein degradation induced by proteolysis-inducing factor was completely attenuated in the presence of cycloheximide (1 microM), suggesting a requirement for new protein synthesis.	Cycloheximide	104-117	dermcidin	Homo sapiens	31-58
11977986-4	2002	However, cycloheximide-treated oocytes underwent GVBD following injection of constitutively active mitogen-activated protein kinase (MAPK) kinase 2 (MEK2), p33(Ringo), or Delta 90 cyclin B.	Cycloheximide	9-22	mitogen-activated protein kinase 1	Xenopus tropicalis	99-131
11977986-4	2002	However, cycloheximide-treated oocytes underwent GVBD following injection of constitutively active mitogen-activated protein kinase (MAPK) kinase 2 (MEK2), p33(Ringo), or Delta 90 cyclin B.	Cycloheximide	9-22	mitogen-activated protein kinase 1	Xenopus tropicalis	133-137
11977986-4	2002	However, cycloheximide-treated oocytes underwent GVBD following injection of constitutively active mitogen-activated protein kinase (MAPK) kinase 2 (MEK2), p33(Ringo), or Delta 90 cyclin B.	Cycloheximide	9-22	lymphotoxin beta	Xenopus tropicalis	156-159
12126649-6	2002	Cycloheximide, a protein synthesis inhibitor, enhanced the stimulatory effect of IL-1beta.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	81-89
11864976-2	2002	Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability.	Cycloheximide	53-66	cytochrome c, somatic	Homo sapiens	139-151
11864976-4	2002	The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	162-175	tumor protein p53	Homo sapiens	18-21
11864976-4	2002	The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.	Cycloheximide	162-175	BCL2 associated X, apoptosis regulator	Homo sapiens	94-97
11959686-5	2002	Culture with inhibitors of translation (cycloheximide) or transcription (actinomycin-D) abrogated the induction of leptin following TNF-alpha.	Cycloheximide	40-53	leptin	Mus musculus	115-121
11839765-13	2002	Unlike the apoptosis induced by TNF-alpha, which occurs only with inhibition of new protein synthesis, apoptosis induced by inhibitors of HMG-CoA reductase, geranylgeranyltransferase, or RhoA kinase was blocked by cycloheximide.	Cycloheximide	214-227	ras homolog family member A	Homo sapiens	187-191
11959686-5	2002	Culture with inhibitors of translation (cycloheximide) or transcription (actinomycin-D) abrogated the induction of leptin following TNF-alpha.	Cycloheximide	40-53	tumor necrosis factor	Mus musculus	132-141
12065901-7	2002	Cycloheximide blocked the HGF-induced increase in alpha2 integrin mRNA expression.	Cycloheximide	0-13	hepatocyte growth factor	Canis lupus familiaris	26-29
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Cycloheximide	125-138	interleukin 6	Mus musculus	56-60
11970911-5	2002	Exposure of myotubes to H(2)O(2) increased steady-state IL-6 mRNA levels, and pretreatment of myotubes with actinomycin D or cycloheximide abolished the ROS-induced IL-6 production.	Cycloheximide	125-138	interleukin 6	Mus musculus	165-169
11996904-13	2002	MOB cells pretreated with 3 microg/mL cycloheximide produced sustained RGS-2 mRNA levels 2 h after 10 nmol/L PTH treatment.	Cycloheximide	38-51	regulator of G-protein signaling 2	Mus musculus	71-76
11996904-13	2002	MOB cells pretreated with 3 microg/mL cycloheximide produced sustained RGS-2 mRNA levels 2 h after 10 nmol/L PTH treatment.	Cycloheximide	38-51	parathyroid hormone	Mus musculus	109-112
11973615-5	2002	Resistance of the mutant Jurkat cells was specific for FasL killing, since the mutant clones were sensitive to other apoptotic stimuli such as cycloheximide and staurosporine.	Cycloheximide	143-156	Fas ligand	Homo sapiens	55-59
11969260-4	2002	In situ hybridization analysis reveals that the induction of ectopic XMyf5 expression in the dorsal mesoderm occurs within 45 min and is not blocked by the protein synthesis inhibitor cycloheximide.	Cycloheximide	184-197	myogenic factor 5 S homeolog	Xenopus laevis	69-74
11969260-5	2002	By contrast, the induction of XMyoD is observed after 2 h of lithium treatment and the normal expression pattern of XMyoD is blocked by cycloheximide.	Cycloheximide	136-149	myogenic differentiation 1 L homeolog	Xenopus laevis	30-35
11969260-5	2002	By contrast, the induction of XMyoD is observed after 2 h of lithium treatment and the normal expression pattern of XMyoD is blocked by cycloheximide.	Cycloheximide	136-149	myogenic differentiation 1 L homeolog	Xenopus laevis	116-121
11940647-4	2002	Both total and nuclear Nrf2 levels increased rapidly and persistently after treatment with D3T but could be blocked by cotreatment with cycloheximide.	Cycloheximide	136-149	nuclear factor, erythroid derived 2, like 2	Mus musculus	23-27
12006651-2	2002	Herein, we show that human Cdc6 is rapidly destroyed by a p53-independent, proteasome-, and ubiquitin-dependent pathway during early stages of programmed cell death induced by the DNA-damaging drug adozelesin, or by a separate caspase-dependent pathway in cells undergoing apoptosis through an extrinsic pathway induced by tumor necrosis factor-alpha and cycloheximide.	Cycloheximide	355-368	cell division cycle 6	Homo sapiens	27-31
12006651-2	2002	Herein, we show that human Cdc6 is rapidly destroyed by a p53-independent, proteasome-, and ubiquitin-dependent pathway during early stages of programmed cell death induced by the DNA-damaging drug adozelesin, or by a separate caspase-dependent pathway in cells undergoing apoptosis through an extrinsic pathway induced by tumor necrosis factor-alpha and cycloheximide.	Cycloheximide	355-368	tumor protein p53	Homo sapiens	58-61
11827962-12	2002	A super-repressor adenovirus (AdIkappaBalphaSR) that constitutively sequesters IkappaB in the cytoplasm as well as cycloheximide or actinomycin D inhibited Tat- or TNF-mediated kappaB translocation and E-selectin up-regulation.	Cycloheximide	115-128	tyrosine aminotransferase	Homo sapiens	156-159
11929766-10	2002	One requisite activity may be activation of the C/EBPepsilon gene by C/EBPalpha, as either C/EBPalpha-ER or C/EBPbeta-ER rapidly elevated C/EBPepsilon RNA in 32D cl3 cells in the presence of cycloheximide but not actinomycin D.	Cycloheximide	191-204	CCAAT/enhancer binding protein (C/EBP), epsilon	Mus musculus	48-60
11929766-10	2002	One requisite activity may be activation of the C/EBPepsilon gene by C/EBPalpha, as either C/EBPalpha-ER or C/EBPbeta-ER rapidly elevated C/EBPepsilon RNA in 32D cl3 cells in the presence of cycloheximide but not actinomycin D.	Cycloheximide	191-204	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	69-79
11929766-10	2002	One requisite activity may be activation of the C/EBPepsilon gene by C/EBPalpha, as either C/EBPalpha-ER or C/EBPbeta-ER rapidly elevated C/EBPepsilon RNA in 32D cl3 cells in the presence of cycloheximide but not actinomycin D.	Cycloheximide	191-204	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	108-117
11809775-6	2002	When protein synthesis was inhibited with cycloheximide, LPL activity and protein mass decreased rapidly and in parallel with half-lives of around 2 h, and the effect of refeeding was blocked.	Cycloheximide	42-55	lipoprotein lipase	Rattus norvegicus	57-60
12007784-6	2002	Furthermore, insulin induced ubiquitous PFK-2 protein levels, that were evident after a lag of 3 h and could be inhibited by incubation with cycloheximide.	Cycloheximide	141-154	insulin	Homo sapiens	13-20
12054658-9	2002	Cycloheximide prevented the OxLDL-induced increase in p21, Rb, and HypoP-Rb, whereas okadaic acid had no effect.	Cycloheximide	0-13	cyclin dependent kinase inhibitor 1A	Homo sapiens	54-57
12007784-6	2002	Furthermore, insulin induced ubiquitous PFK-2 protein levels, that were evident after a lag of 3 h and could be inhibited by incubation with cycloheximide.	Cycloheximide	141-154	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	Homo sapiens	40-45
11940097-6	2002	Noggin transcripts were induced by the addition of recombinant activin A, and activin A was inhibited by activin antibody except in the presence of cycloheximide (CHX).	Cycloheximide	163-166	noggin	Homo sapiens	0-6
11961137-4	2002	A maximum of 4.5-fold induction of AR mRNA by MG was accompanied by elevated enzyme activity and protein levels and was completely abolished in the presence of cycloheximide or actinomycin D.	Cycloheximide	160-173	aldo-keto reductase family 1 member B1	Rattus norvegicus	35-37
11959806-12	2002	Furthermore, treatment with the protein synthesis inhibitor cycloheximide produced a time-dependent increase in secretin receptor responsiveness.	Cycloheximide	60-73	secretin receptor	Mus musculus	112-129
12073095-6	2002	Surprisingly, the PDR2-2-mediated hyperresistance to chloramphenicol, anisomycin, and cycloheximide requires the function of the UBP6 gene and at least one other gene product.	Cycloheximide	86-99	Yrr1p	Saccharomyces cerevisiae S288C	18-22
12073095-6	2002	Surprisingly, the PDR2-2-mediated hyperresistance to chloramphenicol, anisomycin, and cycloheximide requires the function of the UBP6 gene and at least one other gene product.	Cycloheximide	86-99	ubiquitin-specific protease UBP6	Saccharomyces cerevisiae S288C	129-133
11796725-4	2002	TIMP-1 demonstrated a consistent, significant, and dose-dependent antiapoptotic effect for HSC activated in tissue culture and stimulated to undergo apoptosis by serum deprivation, cycloheximide exposure, and nerve growth factor stimulation.	Cycloheximide	181-194	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6
12021551-7	2002	In addition, the neurokinin (NK) receptor antagonists (spantide, FK224 and FK888) and protein synthesis inhibitor (cycloheximide) inhibited SP production by 30-40% of control response.	Cycloheximide	115-128	tachykinin precursor 1	Homo sapiens	140-142
11918738-4	2002	METHODS: Apoptosis was induced in wild type, p27Kip1 (p27) -/- and p21Cip1/Waf1 (p21) -/- mouse MC by survival factor withdrawal, actinomycin D, ultraviolet (UV)-B irradiation and cycloheximide in the presence or absence of insulin (1 micromol/L) or insulin-like growth factor-I (IGF-I; 100 ng/mL).	Cycloheximide	180-193	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	67-74
11918738-4	2002	METHODS: Apoptosis was induced in wild type, p27Kip1 (p27) -/- and p21Cip1/Waf1 (p21) -/- mouse MC by survival factor withdrawal, actinomycin D, ultraviolet (UV)-B irradiation and cycloheximide in the presence or absence of insulin (1 micromol/L) or insulin-like growth factor-I (IGF-I; 100 ng/mL).	Cycloheximide	180-193	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	67-70
11918738-6	2002	RESULTS: Insulin and IGF-I inhibited wild-type MC apoptosis induced by survival factor withdrawal, actinomycin D, ultraviolet-B irradiation and cycloheximide and in p27 -/- MC when apoptosis was induced by survival factor withdrawal.	Cycloheximide	144-157	insulin-like growth factor 1	Mus musculus	21-26
11920574-3	2002	TSP-1 in T lymphocytes has a high turnover as shown by the fact that brefeldin and monensin rapidly increase while cycloheximide tend to decrease the cellular TSP-1 content.	Cycloheximide	115-128	thrombospondin 1	Homo sapiens	0-5
11920574-3	2002	TSP-1 in T lymphocytes has a high turnover as shown by the fact that brefeldin and monensin rapidly increase while cycloheximide tend to decrease the cellular TSP-1 content.	Cycloheximide	115-128	thrombospondin 1	Homo sapiens	159-164
11912247-6	2002	For example, exposure to 1 ng/ml TGF-beta1 for 15 h increased uptake approximately twofold, a response that was attenuated by cycloheximide.	Cycloheximide	126-139	transforming growth factor beta 1	Homo sapiens	33-42
11781314-3	2002	A maximal induction of 10-fold was obtained when hepatocytes were exposed to 400 nm insulin for 24 h. Cycloheximide, a potent inhibitor of protein synthesis, prevented induction of LXRalpha mRNA expression by insulin, indicating that the induction is dependent on de novo synthesis of proteins.	Cycloheximide	102-115	nuclear receptor subfamily 1, group H, member 3	Mus musculus	181-189
11943214-6	2002	Chemotactic activity of Lkn-1 was inhibited by the treatment of cycloheximide and actinomycin D suggesting that newly synthesized proteins are needed for chemotaxis.	Cycloheximide	64-77	C-C motif chemokine ligand 15	Homo sapiens	24-29
11948395-10	2002	This was prevented by cycloheximide, suggesting that any stabilizing action of CP-31398 would have to be on newly synthesized p53.	Cycloheximide	22-35	tumor protein p53	Homo sapiens	126-129
11877293-5	2002	Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels.	Cycloheximide	237-250	CASP8 and FADD like apoptosis regulator	Homo sapiens	72-96
11779863-2	2002	Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K).	Cycloheximide	16-29	insulin receptor substrate 1	Homo sapiens	82-87
11779863-2	2002	Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K).	Cycloheximide	16-29	insulin receptor substrate 2	Homo sapiens	92-97
11779863-2	2002	Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K).	Cycloheximide	16-29	insulin receptor	Homo sapiens	142-158
11779863-2	2002	Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K).	Cycloheximide	16-29	insulin	Homo sapiens	142-149
11779863-2	2002	Similar to TNF, cycloheximide and anisomycin stimulated serine phosphorylation of IRS-1 and IRS-2, reduced their ability to interact with the insulin receptor, inhibited the insulin-induced tyrosine phosphorylation of IRS proteins, and diminished their association with phosphatidylinositol 3-kinase (PI3K).	Cycloheximide	16-29	isoleucyl-tRNA synthetase 1	Homo sapiens	82-85
11782473-5	2002	PPARalpha activators-induced up-regulation of UCP2 mRNA was not due to increased mRNA stability and required cycloheximide-sensitive short term turnover protein(s).	Cycloheximide	109-122	peroxisome proliferator activated receptor alpha	Mus musculus	0-9
11782473-5	2002	PPARalpha activators-induced up-regulation of UCP2 mRNA was not due to increased mRNA stability and required cycloheximide-sensitive short term turnover protein(s).	Cycloheximide	109-122	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	46-50
11877293-5	2002	Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels.	Cycloheximide	237-250	TNF superfamily member 10	Homo sapiens	151-156
11877293-5	2002	Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels.	Cycloheximide	237-250	baculoviral IAP repeat containing 3	Homo sapiens	353-394
11877293-5	2002	Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels.	Cycloheximide	237-250	baculoviral IAP repeat containing 3	Homo sapiens	396-402
11877293-5	2002	Higher levels of expression for various apoptosis inhibitors, including FLICE-inhibitory protein (FLIP), and lower procaspase-8 levels were present in TRAIL-resistant cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the protein kinase C (PKC) inhibitor bisindolylmaleimide (BIM), which both lowered FLIP and cellular inhibitor of apoptosis protein-2 (cIAP-2) protein levels.	Cycloheximide	252-255	TNF superfamily member 10	Homo sapiens	151-156
12002481-7	2002	Lastly, genetic analyses by using AhR- or Arnt-defective variant cells demonstrate that superinduction by cycloheximide requires the transcription activation (TA) domain of AhR, implicating the TA domain in the control of AhR turnover by ADPF.	Cycloheximide	106-119	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	42-46
11912154-12	2002	The protein synthesis inhibitor cycloheximide also has a cytotoxicity-protective effect against topoisomerase II inhibitor/E2F-1-induced apoptosis and suggests that new protein synthesis is required for this process.	Cycloheximide	32-45	E2F transcription factor 1	Homo sapiens	123-128
11870092-8	2002	The use of cycloheximide, a protein synthesis inhibitor, suggested that PACAP requires an intermediary protein to decrease uPA-mRNA, but not to induce tPA-mRNA.	Cycloheximide	11-24	adenylate cyclase activating polypeptide 1	Rattus norvegicus	72-77
11870092-8	2002	The use of cycloheximide, a protein synthesis inhibitor, suggested that PACAP requires an intermediary protein to decrease uPA-mRNA, but not to induce tPA-mRNA.	Cycloheximide	11-24	plasminogen activator, urokinase	Rattus norvegicus	123-126
11835269-9	2002	Experiments performed with cycloheximide, a translation inhibitor, revealed a translation peak later than 24 h after thrombin stimulation.	Cycloheximide	27-40	coagulation factor II, thrombin	Bos taurus	117-125
11888922-3	2002	Furthermore, we showed that sensitization with pRL1a MAP was inhibited by the addition of chloroquine, cycloheximide, and brefeldin A to the culture, but not by the addition of inhibitors for lysosomal proteases or proteasome.	Cycloheximide	103-116	protein tyrosine phosphatase 4a1	Mus musculus	47-51
11888922-5	2002	Inhibition of sensitization by the addition of cycloheximide and brefeldin A to the culture indicated the requirement of newly generated MHC class I antigen molecules and the involvement of transport of the peptide MHC class I complex from the endoplasmic reticulum to the Golgi.	Cycloheximide	47-60	H2-T3-like	Mus musculus	137-156
12002481-6	2002	Analyses of nuclear AhR demonstrated that cycloheximide increases nuclear AhR protein and functional AhR/Arnt DNA-binding complex, resulting in superinduction of CYP1A1.	Cycloheximide	42-55	aryl hydrocarbon receptor	Homo sapiens	20-23
12002481-6	2002	Analyses of nuclear AhR demonstrated that cycloheximide increases nuclear AhR protein and functional AhR/Arnt DNA-binding complex, resulting in superinduction of CYP1A1.	Cycloheximide	42-55	aryl hydrocarbon receptor	Homo sapiens	74-77
12002481-6	2002	Analyses of nuclear AhR demonstrated that cycloheximide increases nuclear AhR protein and functional AhR/Arnt DNA-binding complex, resulting in superinduction of CYP1A1.	Cycloheximide	42-55	aryl hydrocarbon receptor	Homo sapiens	74-77
12002481-6	2002	Analyses of nuclear AhR demonstrated that cycloheximide increases nuclear AhR protein and functional AhR/Arnt DNA-binding complex, resulting in superinduction of CYP1A1.	Cycloheximide	42-55	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	105-109
12002481-7	2002	Lastly, genetic analyses by using AhR- or Arnt-defective variant cells demonstrate that superinduction by cycloheximide requires the transcription activation (TA) domain of AhR, implicating the TA domain in the control of AhR turnover by ADPF.	Cycloheximide	106-119	aryl hydrocarbon receptor	Homo sapiens	173-176
12002481-6	2002	Analyses of nuclear AhR demonstrated that cycloheximide increases nuclear AhR protein and functional AhR/Arnt DNA-binding complex, resulting in superinduction of CYP1A1.	Cycloheximide	42-55	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	162-168
12002481-7	2002	Lastly, genetic analyses by using AhR- or Arnt-defective variant cells demonstrate that superinduction by cycloheximide requires the transcription activation (TA) domain of AhR, implicating the TA domain in the control of AhR turnover by ADPF.	Cycloheximide	106-119	aryl hydrocarbon receptor	Homo sapiens	34-37
12002481-7	2002	Lastly, genetic analyses by using AhR- or Arnt-defective variant cells demonstrate that superinduction by cycloheximide requires the transcription activation (TA) domain of AhR, implicating the TA domain in the control of AhR turnover by ADPF.	Cycloheximide	106-119	aryl hydrocarbon receptor	Homo sapiens	173-176
11861504-12	2002	The reduction of GATA-1 mRNA by cAMP can be prevented when a translational inhibitor, cycloheximide, is added.	Cycloheximide	86-99	GATA binding protein 1	Mus musculus	17-23
11822881-3	2002	Cycloheximide downregulated the expression of FLIP (L) and markedly sensitized EL-4 cells to FasL-induced apoptosis.	Cycloheximide	0-13	Fas ligand (TNF superfamily, member 6)	Mus musculus	93-97
11861541-8	2002	Agonist-dependent induction of PGHS-2 mRNA was not dependent on new protein synthesis (coincubation with cycloheximide; 10 microg/ml) but was blocked by transcription inhibitor actinomycin D (5 microg/ml), suggesting that PGHS-2 acts an immediate early-response gene in prostatic epithelial cells.	Cycloheximide	105-118	prostaglandin-endoperoxide synthase 2	Homo sapiens	31-37
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	23-27
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	100-104
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	signal transducer and activator of transcription 6	Mus musculus	190-195
11859138-6	2002	Second, the ability of IL-4 to potentiate LPS-stimulated cytokine production appears to require new IL-4-stimulated gene expression, because it is time dependent, requires the activation of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-4 pretreatment period.	Cycloheximide	258-271	interleukin 4	Mus musculus	100-104
11675381-8	2002	Interestingly, tissue-, light-, and cycloheximide-dependent expressions of the two isoforms of ferrochelatase were similar to those of two glutamyl-tRNA reductase isoforms involved in the early step of tetrapyrrole biosynthesis, suggesting the existence of distinctly controlled tetrapyrrole biosynthetic pathways in photosynthetic and nonphotosynthetic tissues.	Cycloheximide	36-49	ferrochelatase-2, chloroplastic-like	Cucumis sativus	95-109
11726647-5	2002	Although previous studies suggested that ERK-1/2 activation was downstream of many cell death-inducing signals in HT22 cells, we show here that cycloheximide, the Z-vad caspase inhibitor, and a nonlethal heat shock protect against glutamate- and MG132-induced toxicity without diminishing ERK-1/2 activation.	Cycloheximide	144-157	mitogen-activated protein kinase 3	Mus musculus	41-48
11726647-5	2002	Although previous studies suggested that ERK-1/2 activation was downstream of many cell death-inducing signals in HT22 cells, we show here that cycloheximide, the Z-vad caspase inhibitor, and a nonlethal heat shock protect against glutamate- and MG132-induced toxicity without diminishing ERK-1/2 activation.	Cycloheximide	144-157	mitogen-activated protein kinase 3	Mus musculus	289-296
11804937-11	2002	The effects of hCG and activin on maturational competence of oocytes could be significantly inhibited by actinomycin D (1 microg/ml) and completely blocked by cycloheximide (1 microg/ml), suggesting that the hCG and activin-induced acquisition of oocyte maturational competence involves de novo protein synthesis at both the transcriptional and translational levels.	Cycloheximide	159-172	chorionic gonadotropin subunit beta 5	Homo sapiens	15-18
11850832-6	2002	The protein synthesis inhibitor cycloheximide significantly enhanced TRAIL toxicity toward PrEC as measured by tetrazolium conversion but had little or no effect on other TRAIL-induced apoptotic responses.	Cycloheximide	32-45	TNF superfamily member 10	Homo sapiens	69-74
11850832-7	2002	Although cycloheximide did not further accelerate the processing of caspases 3 and 8, it significantly enhanced cleavage of the caspase 3 substrate gelsolin, indicating that in PrEC a protein(s) with a short half-life may inhibit the activity of the executioner caspases toward specific substrates.	Cycloheximide	9-22	caspase 3	Homo sapiens	128-137
11850832-7	2002	Although cycloheximide did not further accelerate the processing of caspases 3 and 8, it significantly enhanced cleavage of the caspase 3 substrate gelsolin, indicating that in PrEC a protein(s) with a short half-life may inhibit the activity of the executioner caspases toward specific substrates.	Cycloheximide	9-22	gelsolin	Homo sapiens	148-156
11741998-8	2002	Unsaturated fatty acids, however, increased ABCA1 turnover when protein synthesis was blocked by cycloheximide.	Cycloheximide	97-110	ATP binding cassette subfamily A member 1	Homo sapiens	44-49
11804877-5	2002	Pretreatment with cycloheximide, a protein synthesis inhibitor, prevented the at-RA-mediated induction of VEGF mRNA expression.	Cycloheximide	18-31	vascular endothelial growth factor A	Homo sapiens	106-110
11804937-11	2002	The effects of hCG and activin on maturational competence of oocytes could be significantly inhibited by actinomycin D (1 microg/ml) and completely blocked by cycloheximide (1 microg/ml), suggesting that the hCG and activin-induced acquisition of oocyte maturational competence involves de novo protein synthesis at both the transcriptional and translational levels.	Cycloheximide	159-172	chorionic gonadotropin subunit beta 5	Homo sapiens	208-211
11796507-4	2002	Cycloheximide and a blocking antibody against IFN did not alter the Poly (IC)-mediated inhibition of IGF-I mRNA, but prevented IFN from reducing IGF-I mRNA.	Cycloheximide	0-13	insulin-like growth factor 1	Rattus norvegicus	145-150
11830526-8	2002	The kinetics of AIbZIP mRNA up-regulation and the results of experiments with cycloheximide suggest that AIbZIP may be a delayed response gene.	Cycloheximide	78-91	cAMP responsive element binding protein 3 like 4	Homo sapiens	105-111
11818405-9	2002	Administration of cycloheximide at night decreased retinal AA-NAT activity in darkness and enhanced the effect of light.	Cycloheximide	18-31	aralkylamine N-acetyltransferase	Gallus gallus	59-65
11813164-5	2002	In addition, cycloheximide similarly renders TNF-alpha pro-apoptotic, suggesting that NF-kappaB activation controls the production of a protein(s) that protects eosinophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	45-54
11813164-5	2002	In addition, cycloheximide similarly renders TNF-alpha pro-apoptotic, suggesting that NF-kappaB activation controls the production of a protein(s) that protects eosinophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	nuclear factor kappa B subunit 1	Homo sapiens	86-95
11813164-5	2002	In addition, cycloheximide similarly renders TNF-alpha pro-apoptotic, suggesting that NF-kappaB activation controls the production of a protein(s) that protects eosinophils from the cytotoxic effects of TNF-alpha.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	203-212
11895476-7	2002	The effects of actinomycin D, cycloheximide and 5,6-dichloro-beta-d-ribofuranosyl-benzimidazole on Nrap expression and distribution in cultured cells suggest that Nrap is associated with the pre-rRNA transcript.	Cycloheximide	30-43	nebulin related anchoring protein	Homo sapiens	99-103
11895476-7	2002	The effects of actinomycin D, cycloheximide and 5,6-dichloro-beta-d-ribofuranosyl-benzimidazole on Nrap expression and distribution in cultured cells suggest that Nrap is associated with the pre-rRNA transcript.	Cycloheximide	30-43	nebulin related anchoring protein	Homo sapiens	163-167
11779361-2	2002	MATERIALS AND METHODS: MOLT-4 cells pretreated with 0.5 microg/ml cycloheximide for 1h were exposed to 7.5Gy of X-rays.	Cycloheximide	66-79	transmembrane protein 132D	Homo sapiens	23-27
11779361-5	2002	Cycloheximide also inhibited the activation of caspases and AP-1, the expression of Fas, the formation of DISC and the release of cytochrome-C, but not the activation of SAPK/JNK in X-irradiated MOLT-4 cells.	Cycloheximide	0-13	caspase 8	Homo sapiens	47-55
11779361-5	2002	Cycloheximide also inhibited the activation of caspases and AP-1, the expression of Fas, the formation of DISC and the release of cytochrome-C, but not the activation of SAPK/JNK in X-irradiated MOLT-4 cells.	Cycloheximide	0-13	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	60-64
11779361-5	2002	Cycloheximide also inhibited the activation of caspases and AP-1, the expression of Fas, the formation of DISC and the release of cytochrome-C, but not the activation of SAPK/JNK in X-irradiated MOLT-4 cells.	Cycloheximide	0-13	transmembrane protein 132D	Homo sapiens	195-199
11796528-9	2002	Actinomycin D blockade of transcription in luteinized granulosa cells resulted in reduced NPC-1 mRNA and provided a half-life estimate of 20 h. Cycloheximide treatment increased NPC-1 transcript abundance in excess of 5-fold over 24 h. Treatment of luteinized granulosa cells with 1 mM (Bu)(2)cAMP increased the abundance of the NPC-1 message by 2- to 4-fold.	Cycloheximide	144-157	NPC intracellular cholesterol transporter 1	Sus scrofa	90-95
11796528-9	2002	Actinomycin D blockade of transcription in luteinized granulosa cells resulted in reduced NPC-1 mRNA and provided a half-life estimate of 20 h. Cycloheximide treatment increased NPC-1 transcript abundance in excess of 5-fold over 24 h. Treatment of luteinized granulosa cells with 1 mM (Bu)(2)cAMP increased the abundance of the NPC-1 message by 2- to 4-fold.	Cycloheximide	144-157	NPC intracellular cholesterol transporter 1	Sus scrofa	178-183
11796528-9	2002	Actinomycin D blockade of transcription in luteinized granulosa cells resulted in reduced NPC-1 mRNA and provided a half-life estimate of 20 h. Cycloheximide treatment increased NPC-1 transcript abundance in excess of 5-fold over 24 h. Treatment of luteinized granulosa cells with 1 mM (Bu)(2)cAMP increased the abundance of the NPC-1 message by 2- to 4-fold.	Cycloheximide	144-157	NPC intracellular cholesterol transporter 1	Sus scrofa	178-183
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P&lt;0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P&lt;0.05 for cycloheximide, P&lt;0.001 for PD98059).	Cycloheximide	95-108	urocortin	Rattus norvegicus	0-9
11830332-6	2002	RESULTS: The expression of the NGFI-B family genes were recognized within 30 min after ischemia-reperfusion in rat liver, which was augmented by cycloheximide injection.	Cycloheximide	145-158	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	31-37
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P&lt;0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P&lt;0.05 for cycloheximide, P&lt;0.001 for PD98059).	Cycloheximide	95-108	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	23-28
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P&lt;0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P&lt;0.05 for cycloheximide, P&lt;0.001 for PD98059).	Cycloheximide	190-203	urocortin	Rattus norvegicus	0-9
11834446-7	2002	Urocortin induction of hsp90 was inhibited by the MEK1/2 inhibitor PD98059 (P&lt;0.001) and by cycloheximide, and both inhibitors abrogate urocortin-mediated cardioprotection (P&lt;0.05 for cycloheximide, P&lt;0.001 for PD98059).	Cycloheximide	190-203	heat shock protein 90 alpha family class A member 1	Rattus norvegicus	23-28
11842162-12	2002	The gravity- and IAA-stimulated increase in Ivr2 transcripts was sensitive to the protein synthesis inhibitor, cycloheximide.	Cycloheximide	111-124	invertase 2	Zea mays	44-48
11849390-7	2002	RESULTS: TNF-alpha with cycloheximide for three hours caused apoptosis in 87% PMN compared to 2% in untreated controls (N=18; P &lt; 0.01).	Cycloheximide	24-37	tumor necrosis factor	Homo sapiens	9-18
11849390-11	2002	Blocking caspase-3 activity prevented apoptosis in TNF-alpha with cycloheximide-treated cells (83% to 2%) and prevented compromised respiratory burst in response to ANCA.	Cycloheximide	66-79	caspase 3	Homo sapiens	9-18
11849390-11	2002	Blocking caspase-3 activity prevented apoptosis in TNF-alpha with cycloheximide-treated cells (83% to 2%) and prevented compromised respiratory burst in response to ANCA.	Cycloheximide	66-79	tumor necrosis factor	Homo sapiens	51-60
11698395-7	2002	The addition of cycloheximide greatly inhibited activation of caspase-3 by apicidin by interfering with cleavage of procaspase-3 and DNA fragmentation, suggesting that apicidin-induced apoptosis was dependent on de novo protein synthesis.	Cycloheximide	16-29	caspase 3	Homo sapiens	62-71
11698395-7	2002	The addition of cycloheximide greatly inhibited activation of caspase-3 by apicidin by interfering with cleavage of procaspase-3 and DNA fragmentation, suggesting that apicidin-induced apoptosis was dependent on de novo protein synthesis.	Cycloheximide	16-29	caspase 3	Homo sapiens	116-128
11777967-3	2002	Although the TWEAK-induced cell death in Kym-1 cells was indirectly mediated by TNF-alpha and was inhibited by cycloheximide, the TWEAK-induced cell death in HSC3 cells or IFN-gamma-treated HT-29 cells was not inhibited by anti-TNF-alpha mAb or cycloheximide, suggesting a direct triggering of cell death via TWEAK receptor in the latter cell lines.	Cycloheximide	111-124	TNF superfamily member 12	Homo sapiens	13-18
11781253-5	2002	These G-CSF effects were inhibited by cycloheximide.	Cycloheximide	38-51	colony stimulating factor 3	Homo sapiens	6-11
11754479-0	2002	Use of a YAP1 overexpression cassette conferring specific resistance to cerulenin and cycloheximide as an efficient selectable marker in the yeast Saccharomyces cerevisiae.	Cycloheximide	86-99	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	9-13
11754479-4	2002	Yeast cells containing PGKp-YAP1 were resistant to cycloheximide, a protein synthesis inhibitor, and also to cerulenin, a fatty acid synthesis inhibitor, but not to other drugs tested.	Cycloheximide	51-64	DNA-binding transcription factor YAP1	Saccharomyces cerevisiae S288C	28-32
11777967-3	2002	Although the TWEAK-induced cell death in Kym-1 cells was indirectly mediated by TNF-alpha and was inhibited by cycloheximide, the TWEAK-induced cell death in HSC3 cells or IFN-gamma-treated HT-29 cells was not inhibited by anti-TNF-alpha mAb or cycloheximide, suggesting a direct triggering of cell death via TWEAK receptor in the latter cell lines.	Cycloheximide	245-258	TNF superfamily member 12	Homo sapiens	13-18
11777967-3	2002	Although the TWEAK-induced cell death in Kym-1 cells was indirectly mediated by TNF-alpha and was inhibited by cycloheximide, the TWEAK-induced cell death in HSC3 cells or IFN-gamma-treated HT-29 cells was not inhibited by anti-TNF-alpha mAb or cycloheximide, suggesting a direct triggering of cell death via TWEAK receptor in the latter cell lines.	Cycloheximide	245-258	TNF superfamily member 12	Homo sapiens	130-135
12297723-7	2002	CHX induced a transient and CD95L a delayed activation of c-Jun-N-terminal kinase (JNK), but when added together initial JNK activation was enhanced and prolonged.	Cycloheximide	0-3	Fas ligand	Rattus norvegicus	28-33
11741820-6	2002	EGFR upregulation was blocked by cycloheximide and actinomycin D, suggesting that LPA influences transcriptional regulation of EGFR expression.	Cycloheximide	33-46	epidermal growth factor receptor	Homo sapiens	0-4
11741820-6	2002	EGFR upregulation was blocked by cycloheximide and actinomycin D, suggesting that LPA influences transcriptional regulation of EGFR expression.	Cycloheximide	33-46	epidermal growth factor receptor	Homo sapiens	127-131
12077556-7	2002	Cycloheximide, but not actinomycin D, increased the phosphorylation of p54 JNK in HepG2 cells.	Cycloheximide	0-13	mitogen-activated protein kinase 8	Homo sapiens	75-78
12297723-11	2002	CONCLUSION: Sensitization of HSC towards CD95L-induced apoptosis by cycloheximide is accompanied by a JNK-dependent CD95 membrane targeting, which, however, has little impact for the apoptotic response.	Cycloheximide	68-81	Fas ligand	Rattus norvegicus	41-46
12297723-7	2002	CHX induced a transient and CD95L a delayed activation of c-Jun-N-terminal kinase (JNK), but when added together initial JNK activation was enhanced and prolonged.	Cycloheximide	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	58-81
12297723-7	2002	CHX induced a transient and CD95L a delayed activation of c-Jun-N-terminal kinase (JNK), but when added together initial JNK activation was enhanced and prolonged.	Cycloheximide	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	83-86
12297723-7	2002	CHX induced a transient and CD95L a delayed activation of c-Jun-N-terminal kinase (JNK), but when added together initial JNK activation was enhanced and prolonged.	Cycloheximide	0-3	mitogen-activated protein kinase 8	Rattus norvegicus	121-124
11803202-9	2002	cAMP or glucagon significantly increased NHE3 protein abundance in the surface membrane when incubated with cycloheximide for 24 h. CONCLUSIONS: Glucagon acutely inhibits but chronically activates NHE3 activity in OKP cells via a PKA-dependent pathway.	Cycloheximide	108-121	solute carrier family 9 member A3	Rattus norvegicus	41-45
11782381-7	2002	Inhibition of de novo protein synthesis by cycloheximide treatment showed a similar half-life of Rad51 protein in normal and tumor cells.	Cycloheximide	43-56	RAD51 recombinase	Homo sapiens	97-102
11751590-5	2002	Both actinomycin D and cycloheximide completely blocked the effect of EGF/TGFalpha, indicating that the promotion of oocyte maturation by EGF/TGFalpha requires de novo mRNA transcription and protein synthesis.	Cycloheximide	23-36	epidermal growth factor	Danio rerio	70-82
11751590-5	2002	Both actinomycin D and cycloheximide completely blocked the effect of EGF/TGFalpha, indicating that the promotion of oocyte maturation by EGF/TGFalpha requires de novo mRNA transcription and protein synthesis.	Cycloheximide	23-36	transforming growth factor, alpha	Danio rerio	74-82
12391545-6	2002	VEGF secretion was inhibited by cycloheximide (85%) and the specific inhibitors of protein tyrosine kinase, genistein (71+/-0.74 and 55+/-4.90%) and mitogen-activated protein (MAP)-kinase, PD098059 (82+/-2.0 and 59+/-6.7%) in A375 and J82 cells respectively.	Cycloheximide	32-45	vascular endothelial growth factor A	Homo sapiens	0-4
11835405-7	2002	Irrespective of STAT1 status, TNF induced cytotoxic effects in the presence of cycloheximide (CHX) in both cell types.	Cycloheximide	79-92	tumor necrosis factor	Homo sapiens	30-33
11787064-9	2002	EGF and bFGF were able both to cooperate with cycloheximide, an inhibitor of protein synthesis, to augment the expression of SAMDC mRNA.	Cycloheximide	46-59	epidermal growth factor	Homo sapiens	0-3
11787064-9	2002	EGF and bFGF were able both to cooperate with cycloheximide, an inhibitor of protein synthesis, to augment the expression of SAMDC mRNA.	Cycloheximide	46-59	fibroblast growth factor 2	Homo sapiens	8-12
11787064-9	2002	EGF and bFGF were able both to cooperate with cycloheximide, an inhibitor of protein synthesis, to augment the expression of SAMDC mRNA.	Cycloheximide	46-59	adenosylmethionine decarboxylase 1	Homo sapiens	125-130
11835405-7	2002	Irrespective of STAT1 status, TNF induced cytotoxic effects in the presence of cycloheximide (CHX) in both cell types.	Cycloheximide	94-97	tumor necrosis factor	Homo sapiens	30-33
11967994-4	2002	Early G1-phase activation of cdk3 was downregulated by treatment of cells with MG132, an inhibitor of the proteasome, and by the protein synthesis inhibitor cycloheximide.	Cycloheximide	157-170	cyclin-dependent kinase 3	Cricetulus griseus	29-33
11786386-6	2002	Up-regulation of p21 was resistant to cycloheximide but not to actinomycin D, suggesting that it occurred at the transcriptional level.	Cycloheximide	38-51	cyclin dependent kinase inhibitor 1A	Homo sapiens	17-20
11716780-5	2001	The TGF-beta 1-mediated l-proline uptake was inhibited by cycloheximide or actinomycin D.	Cycloheximide	58-71	transforming growth factor beta 1	Homo sapiens	4-14
11810026-5	2002	Cycloheximide causes accumulation of human Cyr61 RNA in the absence of growth factors, and EGF prevents decay of transcripts in actinomycin-D-treated cells, which suggests that induction by growth factors may partially involve mRNA stabilization.	Cycloheximide	0-13	cellular communication network factor 1	Homo sapiens	43-48
11750069-4	2001	In contrast to c-fos, a representative neuronal activation-related immediate-early gene that was induced within 1 h after PTZ administration, induction of the NDRF gene expression reached a maximum level at 7-8 h after PTZ injection and was inhibited by pretreatment with cycloheximide and MK801.	Cycloheximide	272-285	neurogenic differentiation 2	Mus musculus	159-163
11598137-4	2001	Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TRO, RSG, and rottlerin shortened the half-life of p21(Cip1) protein.	Cycloheximide	54-67	KRAS proto-oncogene, GTPase	Rattus norvegicus	131-134
11598137-4	2001	Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TRO, RSG, and rottlerin shortened the half-life of p21(Cip1) protein.	Cycloheximide	54-67	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	135-139
11726619-7	2001	Treatment of TM cells with the protein synthesis inhibitor cycloheximide abolished the Dex induction, suggesting an indirect effect of the GR on MYOC expression.	Cycloheximide	59-72	nuclear receptor subfamily 3 group C member 1	Homo sapiens	139-141
11784055-7	2001	Inhibition of global protein translation with cycloheximide also inhibits amino acid-dependent signals, suggesting that mTOR regulates the translation of proteins required for trophoblast differentiation.	Cycloheximide	46-59	mechanistic target of rapamycin kinase	Mus musculus	120-124
11726619-7	2001	Treatment of TM cells with the protein synthesis inhibitor cycloheximide abolished the Dex induction, suggesting an indirect effect of the GR on MYOC expression.	Cycloheximide	59-72	myocilin	Homo sapiens	145-149
11792826-7	2001	By using proteasome inhibitors, it was shown that the cycloheximide-dependent increase in functional pore size was due to the inhibition of protein synthesis, consistent with the fact that p53 is a short-lived protein, and requires the activity of at least two different factors.	Cycloheximide	54-67	transformation related protein 53, pseudogene	Mus musculus	189-192
11748592-10	2001	Experiments using cycloheximide to inhibit protein synthesis demonstrated that recycling of the PTHR-GFP back to the plasma membrane was complete within 1-2 h of ligand removal and was partially blocked by pretreatment with cytochalasin D, but not nocodazole.	Cycloheximide	18-31	parathyroid hormone 1 receptor	Homo sapiens	96-100
11726273-3	2001	Phosphorylation is effectively inhibited in the presence of actinomycin D or cycloheximide, which restore cell viability to the same level as control cells not expressing Bcl-2.	Cycloheximide	77-90	BCL2 apoptosis regulator	Homo sapiens	171-176
11811586-5	2001	However, unlike proliferating cells, no cellular death occurred in the predominantly non-proliferating cells after the treatment of agonistic anti-CD95 antibody with cycloheximide, pretreated with interferon-gamma.	Cycloheximide	166-179	Fas cell surface death receptor	Homo sapiens	147-151
11714826-5	2001	An active 18-kDa form of IL-18 was detected in lysate and supernatant of the cells only after the above treatment and the induction was inhibited by cycloheximide and by serine proteinase inhibitors.	Cycloheximide	149-162	interleukin 18	Homo sapiens	25-30
11737592-6	2001	HO-1 overexpressing cells were markedly resistant to apoptosis induced by TNFalpha/cycloheximide or staurosporine as assessed by the caspase-3 activity assay.	Cycloheximide	83-96	heme oxygenase 1	Sus scrofa	0-4
11811586-5	2001	However, unlike proliferating cells, no cellular death occurred in the predominantly non-proliferating cells after the treatment of agonistic anti-CD95 antibody with cycloheximide, pretreated with interferon-gamma.	Cycloheximide	166-179	interferon gamma	Homo sapiens	197-213
11737592-10	2001	The pharmacologic inducer of HO-1, hemin, increased expression of p21 in wild-type cells and decreased apoptosis provoked by TNF-alpha/cycloheximide.	Cycloheximide	135-148	heme oxygenase 1	Sus scrofa	29-33
11553613-9	2001	However, actinomycin D and cycloheximide increased basal KCC1 mRNA in an additive manner, suggesting different mechanisms of action for both drugs.	Cycloheximide	27-40	solute carrier family 12 member 4	Rattus norvegicus	57-61
11728456-4	2001	uPA effect occurs also in the presence of the transcriptional inhibitor dichloro-ribobenzimidazole, whereas it is abolished by the protein synthesis inhibitor cycloheximide.	Cycloheximide	159-172	plasminogen activator, urokinase	Homo sapiens	0-3
11716080-8	2001	After an 8-day culture period TGF-beta, CD, H7, and Go6976 were found to depress MMP-2 production.	Cycloheximide	40-42	matrix metallopeptidase 2	Homo sapiens	81-86
11641060-7	2001	In contrast, the Ca2+-switch from low to normal caused a prominent increase of BPAG1, both in cytosolic and membrane-associated forms after 4 h, that was inhibited both with H7 and cycloheximide (an inhibitor of protein synthesis) at 70 microM, suggesting a role for PKC and BPAG1 synthesis in these Ca2+-induced effects.	Cycloheximide	181-194	dystonin	Homo sapiens	79-84
11641060-7	2001	In contrast, the Ca2+-switch from low to normal caused a prominent increase of BPAG1, both in cytosolic and membrane-associated forms after 4 h, that was inhibited both with H7 and cycloheximide (an inhibitor of protein synthesis) at 70 microM, suggesting a role for PKC and BPAG1 synthesis in these Ca2+-induced effects.	Cycloheximide	181-194	dystonin	Homo sapiens	275-280
11700024-5	2001	Unexpectedly, the fall of apM1 mRNA was prevented by the addition of actinomycin D, an inhibitor of transcription, or cycloheximide, an inhibitor of protein synthesis, and by reducing the amount of adipose tissue cultured per dish, thereby suggesting that a newly synthesized factor released by adipose tissue destabilizes apM1 mRNA.	Cycloheximide	118-131	adiponectin, C1Q and collagen domain containing	Homo sapiens	26-30
11709159-4	2001	LTF occurred without transcription, but the translation inhibitors cycloheximide and anisomycin, or local presynaptic injection of mRNA cap analog m7GpppG, impaired LTF expression.	Cycloheximide	67-80	lactotransferrin	Homo sapiens	165-168
11696451-7	2001	Insulin-induced increase in TGF-beta1 concentration was not abrogated by actinomycin D, however, stimulation by insulin, in the presence of cycloheximide led to a dose-dependent decrease in TGF-beta1 production.	Cycloheximide	140-153	insulin	Homo sapiens	0-7
11696451-7	2001	Insulin-induced increase in TGF-beta1 concentration was not abrogated by actinomycin D, however, stimulation by insulin, in the presence of cycloheximide led to a dose-dependent decrease in TGF-beta1 production.	Cycloheximide	140-153	insulin	Homo sapiens	112-119
11696451-7	2001	Insulin-induced increase in TGF-beta1 concentration was not abrogated by actinomycin D, however, stimulation by insulin, in the presence of cycloheximide led to a dose-dependent decrease in TGF-beta1 production.	Cycloheximide	140-153	transforming growth factor beta 1	Homo sapiens	190-199
11551821-2	2001	First identified in 1990 when intraperitoneal injection of the protein synthesis inhibitor cycloheximide activated a 54 kDa protein kinase, the JNK MAPKs have now taken on a prominent role in signal transduction.	Cycloheximide	91-104	mitogen-activated protein kinase 8	Homo sapiens	144-147
11710520-7	2001	Inhibition of protein synthesis by cycloheximide strongly enhanced the EA4-dependent Cyp1a1 mRNA expression.	Cycloheximide	35-48	erythrocyte antigen 4	Mus musculus	71-74
11738558-8	2001	Inhibition of protein synthesis by cycloheximide (CHI) injection demonstrated that delayed and lasting increase of the AR binding after T injection partially depended on the stimulated protein synthesis.	Cycloheximide	35-48	androgen receptor	Rattus norvegicus	119-121
11691580-8	2001	The CD-induced up-regulation of gene expression was largely repressed by blocking protein synthesis by cycloheximide for all the MMPs, by inhibiting the tyrosine-kinases of the src family by herbimycin A for all MMPs, except MMP-2, and by inhibiting the TPA-inducible PKC isoforms by bisindoyl maleimide for all MMPs, except MMP-14.	Cycloheximide	103-116	matrix metallopeptidase 1	Homo sapiens	129-133
11774033-3	2001	Inhibition of protein synthesis with cycloheximide blocked IL-1beta-mediated induction of matrilysin mRNA suggesting that synthesis of one or more additional factors is required for IL-1beta-induced promatrilysin protein expression.	Cycloheximide	37-50	interleukin 1 beta	Homo sapiens	59-67
11774033-3	2001	Inhibition of protein synthesis with cycloheximide blocked IL-1beta-mediated induction of matrilysin mRNA suggesting that synthesis of one or more additional factors is required for IL-1beta-induced promatrilysin protein expression.	Cycloheximide	37-50	matrix metallopeptidase 7	Homo sapiens	90-100
11710520-7	2001	Inhibition of protein synthesis by cycloheximide strongly enhanced the EA4-dependent Cyp1a1 mRNA expression.	Cycloheximide	35-48	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	85-91
11673761-5	2001	RESULTS: Pretreatment of primary cultures of rat brown fat cells with micromolar concentrations of NA or the NO-donor S-nitroso-N-acetylpenicillamine (SNAP) induced the expression of HSP70 mRNA and protein, which was associated with cytoprotection against TNF-alpha plus CHX-induced apoptosis.	Cycloheximide	271-274	heat shock protein family A (Hsp70) member 4	Homo sapiens	183-188
11758940-5	2001	The purified inhibitor (molecular weight = 1,193 by FAB-MS) inhibited a Pdr5-mediated efflux of cycloheximide and cerulenin.	Cycloheximide	96-109	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	72-76
11461904-9	2001	Treatment of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to TRAIL.	Cycloheximide	34-47	TNF superfamily member 10	Homo sapiens	108-113
11591736-7	2001	Inhibition of protein synthesis using cycloheximide or actinomycin reversed the antiapoptotic effect of sPLA(2).	Cycloheximide	38-51	phospholipase A2 group IIA	Homo sapiens	104-111
11533151-4	2001	RID inhibits TRAIL-induced apoptosis when cells are sensitized to TRAIL either by adenovirus infection or treatment with cycloheximide.	Cycloheximide	121-134	TNF superfamily member 10	Homo sapiens	13-18
11682609-3	2001	As shown in this study, apoptosis in human-derived HL-60 and U937 cells induced by treatment with actinomycin D or TNF-alpha in combination with cycloheximide, respectively, was indeed dose-dependently downregulated by prior infection with T. gondii, as determined by DNA fragmentation assays.	Cycloheximide	145-158	tumor necrosis factor	Homo sapiens	115-124
11533151-4	2001	RID inhibits TRAIL-induced apoptosis when cells are sensitized to TRAIL either by adenovirus infection or treatment with cycloheximide.	Cycloheximide	121-134	TNF superfamily member 10	Homo sapiens	66-71
11533154-2	2001	The level of ISG54-specific RNA in human fetal lung (HFL) or human foreskin (BJ) fibroblasts increased substantially after infection with either virus in the presence of cycloheximide.	Cycloheximide	170-183	interferon induced protein with tetratricopeptide repeats 2	Homo sapiens	13-18
11533154-4	2001	A DNA-binding complex that recognized an interferon-responsive sequence motif was induced upon infection with HSV-1 or HCMV in the presence of cycloheximide, and the complex was shown to contain the cell proteins interferon response factor 3 (IRF-3) and CREB-binding protein.	Cycloheximide	143-156	interferon regulatory factor 3	Homo sapiens	243-248
11495721-8	2001	The enhancing effects of TNF-alpha and PDGF-BB were attenuated by PD98059 (an inhibitor of activation of MAPK kinase, MEK) and cycloheximide (an inhibitor of protein synthesis), suggesting that TNF-alpha may share a common signalling pathway with PDGF-BB via protein(s) synthesis in TSMCs.	Cycloheximide	127-140	tumor necrosis factor	Canis lupus familiaris	25-34
11597171-8	2001	Cycloheximide (an inhibitor of protein synthesis), pyrrolidine dithiocarbamate (PDTC; an NF-kappa B inhibitor) and genistein (an inhibitor of tyrosine protein kinases) inhibited cytokine-induced NO production, while dexamethasone, diaminohydroxypyrimidine (DAHP; an inhibitor of tetrahydrobiopterin synthesis) and PD 98059 (p42/44 MAP kinase inhibitor) had no effect.	Cycloheximide	0-13	cyclin dependent kinase 20	Homo sapiens	324-327
11593415-12	2001	Inhibition of protein synthesis by cycloheximide also causes LNCap cells sensitive to TRAIL.	Cycloheximide	35-48	TNF superfamily member 10	Homo sapiens	86-91
11516172-3	2001	The rapid disappearance of CYP1A1 mRNA after 5 h of suspension was unaffected by the addition of TCDD but was prevented by the inclusion of the protein synthesis inhibitor cycloheximide.	Cycloheximide	172-185	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	27-33
11551508-5	2001	Consistent with the dependence of NMD on translation, the NMD of CBP80-bound mRNA is blocked by cycloheximide or suppressor tRNA.	Cycloheximide	96-109	nuclear cap binding protein subunit 1	Homo sapiens	65-70
11495721-8	2001	The enhancing effects of TNF-alpha and PDGF-BB were attenuated by PD98059 (an inhibitor of activation of MAPK kinase, MEK) and cycloheximide (an inhibitor of protein synthesis), suggesting that TNF-alpha may share a common signalling pathway with PDGF-BB via protein(s) synthesis in TSMCs.	Cycloheximide	127-140	tumor necrosis factor	Canis lupus familiaris	194-203
11518513-6	2001	In addition, VegT activates Sox17alpha in the presence of cycloheximide or a Nodal antagonist, suggesting that Sox17alpha is an immediate-early target of VegT in vegetal blastomeres.	Cycloheximide	58-71	vegt protein S homeolog	Xenopus laevis	13-17
11531942-7	2001	IL-8 mRNA accumulation was detected by Northern blot analysis within 2 h of stimulation by the immune complexes and was enhanced by the addition of cycloheximide.	Cycloheximide	148-161	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
11572089-9	2001	To determine whether the observed alteration was due to the direct effect of estrogen, protein synthesis was inhibited by cycloheximide (CHX) during stimulation by estradiol, Estrogen-mediated upregulation of PGDS was completely abolished by a concurrent treatment with CHX, suggesting that its activation requires the participation of some newly synthesized factor(s).	Cycloheximide	122-135	prostaglandin D2 synthase 21kDa (brain)	Gallus gallus	209-213
11572089-9	2001	To determine whether the observed alteration was due to the direct effect of estrogen, protein synthesis was inhibited by cycloheximide (CHX) during stimulation by estradiol, Estrogen-mediated upregulation of PGDS was completely abolished by a concurrent treatment with CHX, suggesting that its activation requires the participation of some newly synthesized factor(s).	Cycloheximide	137-140	prostaglandin D2 synthase 21kDa (brain)	Gallus gallus	209-213
11572089-9	2001	To determine whether the observed alteration was due to the direct effect of estrogen, protein synthesis was inhibited by cycloheximide (CHX) during stimulation by estradiol, Estrogen-mediated upregulation of PGDS was completely abolished by a concurrent treatment with CHX, suggesting that its activation requires the participation of some newly synthesized factor(s).	Cycloheximide	270-273	prostaglandin D2 synthase 21kDa (brain)	Gallus gallus	209-213
11518513-6	2001	In addition, VegT activates Sox17alpha in the presence of cycloheximide or a Nodal antagonist, suggesting that Sox17alpha is an immediate-early target of VegT in vegetal blastomeres.	Cycloheximide	58-71	SRY-box 17 alpha L homeolog	Xenopus laevis	28-38
11518513-6	2001	In addition, VegT activates Sox17alpha in the presence of cycloheximide or a Nodal antagonist, suggesting that Sox17alpha is an immediate-early target of VegT in vegetal blastomeres.	Cycloheximide	58-71	SRY-box 17 alpha L homeolog	Xenopus laevis	111-121
11509750-6	2001	Cycloheximide elicited a dose-dependent increase in c-myc mRNA levels in NHBE and A549 cells, but did not alter expression of the housekeeping gene beta-actin.	Cycloheximide	0-13	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	52-57
11559366-11	2001	In U2OS cells stably expressing an E2F1-estrogen receptor chimeric protein that could be activated by tamoxifen, PAI-1 gene transcription was markedly reduced by tamoxifen even in the presence of cycloheximide.	Cycloheximide	196-209	E2F transcription factor 1	Homo sapiens	35-39
11559366-11	2001	In U2OS cells stably expressing an E2F1-estrogen receptor chimeric protein that could be activated by tamoxifen, PAI-1 gene transcription was markedly reduced by tamoxifen even in the presence of cycloheximide.	Cycloheximide	196-209	serpin family E member 1	Homo sapiens	113-118
11519044-1	2001	When cervical carcinoma cells were monitored for apoptotic signals, HPV18(+) lines were found to be highly sensitive to agonistic CD95 antibodies or recombinant CD95 ligands after co-exposure with CHX (CD95(S)).	Cycloheximide	197-200	Fas cell surface death receptor	Homo sapiens	130-134
11519044-1	2001	When cervical carcinoma cells were monitored for apoptotic signals, HPV18(+) lines were found to be highly sensitive to agonistic CD95 antibodies or recombinant CD95 ligands after co-exposure with CHX (CD95(S)).	Cycloheximide	197-200	Fas cell surface death receptor	Homo sapiens	161-165
11519044-1	2001	When cervical carcinoma cells were monitored for apoptotic signals, HPV18(+) lines were found to be highly sensitive to agonistic CD95 antibodies or recombinant CD95 ligands after co-exposure with CHX (CD95(S)).	Cycloheximide	197-200	Fas cell surface death receptor	Homo sapiens	161-165
11514053-5	2001	Cycloheximide caused a partial inhibition of R1881-induced SPAK expression which suggests that androgen induction of SPAK expression may require synthesis of additional proteins.	Cycloheximide	0-13	serine/threonine kinase 39	Homo sapiens	59-63
11514053-5	2001	Cycloheximide caused a partial inhibition of R1881-induced SPAK expression which suggests that androgen induction of SPAK expression may require synthesis of additional proteins.	Cycloheximide	0-13	serine/threonine kinase 39	Homo sapiens	117-121
11549696-5	2001	A maximal stimulation of the basal level up to 192% was found with 10 nmol/liter insulin after 24 h. Actinomycin D and cycloheximide abolished this effect, providing evidence that active RNA and protein synthesis are involved in insulin"s action.	Cycloheximide	119-132	insulin	Homo sapiens	81-88
11596109-7	2001	We show that, increased and more sustained TCR/CD3-mediated [Ca(2+)](i) response was also observed in 100 nM Dex-treated cells in the presence of actinomycin D or cycloheximide suggesting that cellular transcription and/or de novo protein synthesis are not required for the induction.	Cycloheximide	163-176	T cell receptor beta variable 20/OR9-2 (non-functional)	Homo sapiens	43-46
11502362-4	2001	The increase in Isl-1 mRNA levels upon NGF addition was rapid and occurred even in the presence of cycloheximide.	Cycloheximide	99-112	ISL LIM homeobox 1	Rattus norvegicus	16-21
11502362-4	2001	The increase in Isl-1 mRNA levels upon NGF addition was rapid and occurred even in the presence of cycloheximide.	Cycloheximide	99-112	nerve growth factor	Rattus norvegicus	39-42
11476570-5	2001	MAPK activity was reduced in ectoderm expressing a constitutively active BMP-4 receptor, or ectoderm treated with BMP-4 protein in the presence or absence of cycloheximide.	Cycloheximide	158-171	mitogen-activated protein kinase 1 S homeolog	Xenopus laevis	0-4
11561718-6	2001	Cycloheximide (CHX) caused a superinduction of the FSK- or PMA-induced c-fos mRNA level.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
11561718-6	2001	Cycloheximide (CHX) caused a superinduction of the FSK- or PMA-induced c-fos mRNA level.	Cycloheximide	15-18	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
11425850-8	2001	MG132 or lactacystin (10 microm), inhibitors of the proteasome pathway by which D2 is degraded, increase both D2 activity and (75)Se-p31 3-4-fold and prevent the loss of D2 activity during cycloheximide or substrate (T(4)) exposure.	Cycloheximide	189-202	iodothyronine deiodinase 2	Homo sapiens	80-82
11493434-0	2001	Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction.	Cycloheximide	35-48	CASP8 and FADD like apoptosis regulator	Homo sapiens	12-18
11493434-6	2001	When MOLT4 cells, which expressed Fas as well as CXCR4, were stimulated with cycloheximide (CHX), an agonistic anti-Fas antibody, or a combination of these, the cells rapidly underwent apoptosis.	Cycloheximide	77-90	C-X-C motif chemokine receptor 4	Homo sapiens	49-54
11509022-7	2001	Similarly, cycloheximide decreased ethanol-induced AP-1 transcriptional activation.	Cycloheximide	11-24	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	51-55
11459803-7	2001	Cycloheximide prevents the synthesis and the secretagogue-mediated secretion of leptin.	Cycloheximide	0-13	leptin	Rattus norvegicus	80-86
11487528-4	2001	The COX-2 induction was dependent on a de novo synthesis since cycloheximide, an inhibitor of protein synthesis, blocked the enzyme expression.	Cycloheximide	63-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	4-9
11502212-0	2001	Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.	Cycloheximide	131-144	protein tyrosine kinase 2	Homo sapiens	0-21
11521188-0	2001	Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells.	Cycloheximide	37-50	cyclin dependent kinase inhibitor 1A	Homo sapiens	18-21
11521188-0	2001	Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells.	Cycloheximide	37-50	Fas cell surface death receptor	Homo sapiens	76-80
11521188-2	2001	CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX).	Cycloheximide	172-185	Fas ligand	Homo sapiens	0-11
11521188-2	2001	CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX).	Cycloheximide	187-190	Fas ligand	Homo sapiens	0-11
11521188-2	2001	CD95 ligand (CD95L) induced mitochondrial cytochrome c release and processing of caspases 3, 7, 8 and 9 in LN-18 cells in the absence of an inhibitor of protein synthesis, cycloheximide (CHX).	Cycloheximide	187-190	Fas ligand	Homo sapiens	13-18
11521188-9	2001	These data place potentiating effects of CHX (i) to the activation of caspase 8 at the receptor in LN-229 cells as well as (ii) to a down-stream target at least in LN-18 cells, but probably both cell lines, that may be identical with p21Waf/Cip1.	Cycloheximide	41-44	caspase 8	Homo sapiens	70-79
11521188-9	2001	These data place potentiating effects of CHX (i) to the activation of caspase 8 at the receptor in LN-229 cells as well as (ii) to a down-stream target at least in LN-18 cells, but probably both cell lines, that may be identical with p21Waf/Cip1.	Cycloheximide	41-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	241-245
11502212-0	2001	Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.	Cycloheximide	131-144	tumor necrosis factor	Homo sapiens	103-130
11502212-0	2001	Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.	Cycloheximide	131-144	protein tyrosine kinase 2 beta	Homo sapiens	177-193
11665859-6	2001	Notably, the AMPH-generated increases in mGluR5 protein and mRNA were completely blocked by the pretreatment with cycloheximide and actinomycin D, respectively.	Cycloheximide	114-127	glutamate receptor, ionotropic, kainate 1	Mus musculus	41-47
11502212-1	2001	Most cell lines are resistant to tumor necrosis factor-alpha (TNF-alpha) cytotoxicity and require cotreatment of TNF-alpha with cycloheximide (Chx) to undergo apoptosis.	Cycloheximide	143-146	tumor necrosis factor	Homo sapiens	113-122
11502212-4	2001	PKB levels decreased during TNF-alpha/Chx-induced apoptosis.	Cycloheximide	38-41	protein tyrosine kinase 2 beta	Homo sapiens	0-3
11461775-7	2001	In fact, protein synthesis inhibitor cycloheximide (CHX) prevented the stimulation of AP-1 nuclear binding due to PMA and ascorbate plus PMA.	Cycloheximide	37-50	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
11461775-7	2001	In fact, protein synthesis inhibitor cycloheximide (CHX) prevented the stimulation of AP-1 nuclear binding due to PMA and ascorbate plus PMA.	Cycloheximide	52-55	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	86-90
11455027-11	2001	The protein synthesis inhibitors cycloheximide and puromycin fully restored CYP1A1 mRNA expression to c33 cells, supporting the notion that NMD degrades CYP1A1 mRNA in this strain.	Cycloheximide	33-46	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	76-82
11455027-11	2001	The protein synthesis inhibitors cycloheximide and puromycin fully restored CYP1A1 mRNA expression to c33 cells, supporting the notion that NMD degrades CYP1A1 mRNA in this strain.	Cycloheximide	33-46	CD82 molecule	Homo sapiens	102-105
11463813-5	2001	Resistance to either FasL- or TNF-induced apoptosis is overcome when cells are incubated in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	140-153	Fas ligand	Homo sapiens	21-25
11463813-5	2001	Resistance to either FasL- or TNF-induced apoptosis is overcome when cells are incubated in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	140-153	tumor necrosis factor	Homo sapiens	30-33
11453647-6	2001	Experiments using metabolic labeling and cycloheximide treatment revealed that zinc increased PS1-CTF by elevating the de novo synthesis of PS1.	Cycloheximide	41-54	presenilin 1	Mus musculus	94-97
11515543-5	2001	The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively.	Cycloheximide	104-117	C-5 sterol desaturase	Saccharomyces cerevisiae S288C	47-51
11368875-5	2001	Phorbol ester markedly stimulated PSCA gene expression in a cycloheximide- and actinomycin-inhibitable manner after a lag phase of 10 h, indicating that transcription of the PSCA gene is regulated by protein kinase C and a newly synthesized protein.	Cycloheximide	60-73	prostate stem cell antigen	Homo sapiens	34-38
11368875-5	2001	Phorbol ester markedly stimulated PSCA gene expression in a cycloheximide- and actinomycin-inhibitable manner after a lag phase of 10 h, indicating that transcription of the PSCA gene is regulated by protein kinase C and a newly synthesized protein.	Cycloheximide	60-73	prostate stem cell antigen	Homo sapiens	174-178
11306562-8	2001	Our results further show that in addition to the heavy metals zinc and cadmium, heat shock, hydrogen peroxide, low extracellular pH (pH 6.0), inhibition of protein synthesis by cycloheximide, and serum induce nuclear accumulation of MTF-1.	Cycloheximide	177-190	metal regulatory transcription factor 1	Homo sapiens	233-238
11470516-4	2001	The drug sensitivity of the strains deleted for these genes revealed that TPO1, a gene previously found to be involved in spermidine resistance and vacuolar polyamine transport, is a determinant of multidrug transporter since it also mediates growth resistance to cycloheximide and quinidine.	Cycloheximide	264-277	Tpo1p	Saccharomyces cerevisiae S288C	74-78
11515543-5	2001	The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively.	Cycloheximide	104-117	C-5 sterol desaturase	Saccharomyces cerevisiae S288C	52-56
11515543-5	2001	The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively.	Cycloheximide	104-117	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	63-67
11515543-5	2001	The sensitivity of the indicator strain (delta syr1/erg3 delta pdr5 delta snq2) to the Pdr5 substrates, cycloheximide and cerulenin, was increased 16-fold and 4-fold against wild type, respectively.	Cycloheximide	104-117	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	87-91
11515543-6	2001	The screening system is mainly based on the growth inhibition of the PDR5-overexpressed indicator strain with the combination of a sample and cycloheximide or cerulenin.	Cycloheximide	142-155	ATP-binding cassette multidrug transporter PDR5	Saccharomyces cerevisiae S288C	69-73
11516624-7	2001	In addition, the effect of ET-1 on GLUT1 mRNA accumulation was inhibited by PD98059 and cycloheximide, implying that a trans-activation was involved.	Cycloheximide	88-101	endothelin 1	Homo sapiens	27-31
11416032-9	2001	Upon fractionation of commercial ATA by size exclusion chromatography, we found that fractions that enhanced the intensity of tyrosyl-phosphorylated IRS-1/IRS-2 also increased the survival of MCF-7 cells in the presence of cycloheximide, whereas fractions devoid of IRS phosphorylation activity had no survival ability.	Cycloheximide	223-236	insulin receptor substrate 1	Homo sapiens	149-154
11516624-7	2001	In addition, the effect of ET-1 on GLUT1 mRNA accumulation was inhibited by PD98059 and cycloheximide, implying that a trans-activation was involved.	Cycloheximide	88-101	solute carrier family 2 member 1	Homo sapiens	35-40
11416032-2	2001	Previously we have shown that ATA, similar to insulin-like growth factor I (IGF-I), protected MCF-7 cells against apoptotic death induced by the protein synthesis inhibitor cycloheximide.	Cycloheximide	173-186	insulin like growth factor 1	Homo sapiens	76-81
11416027-8	2001	LH-stimulated NGFI-B expression in preovulatory follicles was abolished by alpha-amanitin, but was superinduced by cycloheximide.	Cycloheximide	115-128	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	14-20
11416032-9	2001	Upon fractionation of commercial ATA by size exclusion chromatography, we found that fractions that enhanced the intensity of tyrosyl-phosphorylated IRS-1/IRS-2 also increased the survival of MCF-7 cells in the presence of cycloheximide, whereas fractions devoid of IRS phosphorylation activity had no survival ability.	Cycloheximide	223-236	insulin receptor substrate 2	Homo sapiens	155-160
11416032-9	2001	Upon fractionation of commercial ATA by size exclusion chromatography, we found that fractions that enhanced the intensity of tyrosyl-phosphorylated IRS-1/IRS-2 also increased the survival of MCF-7 cells in the presence of cycloheximide, whereas fractions devoid of IRS phosphorylation activity had no survival ability.	Cycloheximide	223-236	isoleucyl-tRNA synthetase 1	Homo sapiens	149-152
11478515-4	2001	Viral induction of vig-2 was blocked by cycloheximide (CHX), indicating its dependency on a newly synthesised intermediate protein.	Cycloheximide	40-53	VIG-2 protein	Oncorhynchus mykiss	19-24
11478515-4	2001	Viral induction of vig-2 was blocked by cycloheximide (CHX), indicating its dependency on a newly synthesised intermediate protein.	Cycloheximide	55-58	VIG-2 protein	Oncorhynchus mykiss	19-24
11422744-15	2001	In contrast, the later glucose-stimulated induction of TSG-6 mRNA was abrogated by the addition of cycloheximide.	Cycloheximide	99-112	TNF alpha induced protein 6	Homo sapiens	55-60
11435497-5	2001	Cycloheximide, monodansylcadaverine, and cytochalasin B all blocked TNF-alpha release from macrophages stimulated with LTA or poly I:C, whereas monensin only nominally reduced TNF-alpha production.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	68-77
11435497-5	2001	Cycloheximide, monodansylcadaverine, and cytochalasin B all blocked TNF-alpha release from macrophages stimulated with LTA or poly I:C, whereas monensin only nominally reduced TNF-alpha production.	Cycloheximide	0-13	tumor necrosis factor	Mus musculus	176-185
11418676-8	2001	Characteristic of an immediate early gene, pretreatment of mice with the protein synthesis inhibitor cycloheximide before either two-thirds hepatectomy or CCl(4) injection led to Crg-2 superinduction.	Cycloheximide	101-114	chemokine (C-X-C motif) ligand 10	Mus musculus	179-184
11530283-9	2001	Cells pretreated with cycloheximide (1 microg/ml) showed induced TGF alpha mRNA in response to E(2) or 4-OHT but TGF alpha mRNA induction was blocked by actinomycin D (1 microg/ml).	Cycloheximide	22-35	transforming growth factor alpha	Homo sapiens	65-74
12035527-4	2001	Cycloheximide also decreases alpha-2-macroglobulin activity in serum and liver and trypsin-, elastaseinhibitory activity of alpha-1-proteinase inhibitor in all investigated organs.	Cycloheximide	0-13	alpha-2-macroglobulin	Rattus norvegicus	29-50
11530283-9	2001	Cells pretreated with cycloheximide (1 microg/ml) showed induced TGF alpha mRNA in response to E(2) or 4-OHT but TGF alpha mRNA induction was blocked by actinomycin D (1 microg/ml).	Cycloheximide	22-35	transforming growth factor alpha	Homo sapiens	113-122
11681714-8	2001	The effect of MK-7 in increasing protein content, alkaline phosphatase activity, and osteocalcin production in the cells was completely blocked by cycloheximide.	Cycloheximide	147-160	bone gamma-carboxyglutamate protein 2	Mus musculus	85-96
12035527-4	2001	Cycloheximide also decreases alpha-2-macroglobulin activity in serum and liver and trypsin-, elastaseinhibitory activity of alpha-1-proteinase inhibitor in all investigated organs.	Cycloheximide	0-13	serpin family A member 1	Rattus norvegicus	124-152
11294857-6	2001	Hypoxia-induced Akt activation can be prevented by treatment with cycloheximide or actinomycin D, suggesting that de novo protein synthesis is required.	Cycloheximide	66-79	AKT serine/threonine kinase 1	Rattus norvegicus	16-19
11306585-3	2001	We report that pho23 mutants like rpd3, sin3, and sap30 are hypersensitive to cycloheximide and heat shock and exhibit enhanced silencing of rDNA, telomeric, and HMR loci, suggesting that these genes are functionally related.	Cycloheximide	78-91	Pho23p	Saccharomyces cerevisiae S288C	15-20
11306585-3	2001	We report that pho23 mutants like rpd3, sin3, and sap30 are hypersensitive to cycloheximide and heat shock and exhibit enhanced silencing of rDNA, telomeric, and HMR loci, suggesting that these genes are functionally related.	Cycloheximide	78-91	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	34-38
11306585-3	2001	We report that pho23 mutants like rpd3, sin3, and sap30 are hypersensitive to cycloheximide and heat shock and exhibit enhanced silencing of rDNA, telomeric, and HMR loci, suggesting that these genes are functionally related.	Cycloheximide	78-91	transcriptional regulator SIN3	Saccharomyces cerevisiae S288C	40-44
11306585-3	2001	We report that pho23 mutants like rpd3, sin3, and sap30 are hypersensitive to cycloheximide and heat shock and exhibit enhanced silencing of rDNA, telomeric, and HMR loci, suggesting that these genes are functionally related.	Cycloheximide	78-91	Sap30p	Saccharomyces cerevisiae S288C	50-55
11439339-3	2001	Cells were exposed to TRAIL in the presence of cycloheximide which acted as a sensitizer.	Cycloheximide	47-60	TNF superfamily member 10	Homo sapiens	22-27
11382404-3	2001	The blocking of protein synthesis by cycloheximide (CHX) evokes a further increase of C2 ceramide-induced proENK mRNA and phospho-CREB level, while C2 ceramide-induced increases of AP-1 protein levels were reduced by CHX.	Cycloheximide	37-50	proenkephalin	Rattus norvegicus	106-112
11382404-3	2001	The blocking of protein synthesis by cycloheximide (CHX) evokes a further increase of C2 ceramide-induced proENK mRNA and phospho-CREB level, while C2 ceramide-induced increases of AP-1 protein levels were reduced by CHX.	Cycloheximide	37-50	cAMP responsive element binding protein 1	Rattus norvegicus	130-134
11382404-3	2001	The blocking of protein synthesis by cycloheximide (CHX) evokes a further increase of C2 ceramide-induced proENK mRNA and phospho-CREB level, while C2 ceramide-induced increases of AP-1 protein levels were reduced by CHX.	Cycloheximide	52-55	proenkephalin	Rattus norvegicus	106-112
11382404-3	2001	The blocking of protein synthesis by cycloheximide (CHX) evokes a further increase of C2 ceramide-induced proENK mRNA and phospho-CREB level, while C2 ceramide-induced increases of AP-1 protein levels were reduced by CHX.	Cycloheximide	52-55	cAMP responsive element binding protein 1	Rattus norvegicus	130-134
11444904-7	2001	Cycloheximide treatment diminished the effect of proteasome inhibitors on ISG induction, implicating an IFN/dsRNA-induced protein in this activity.	Cycloheximide	0-13	interferon alpha 1	Homo sapiens	104-107
11357057-18	2001	Inhibition of protein synthesis with cycloheximide increased basal levels of CYP17 mRNA levels and blocked the induction observed by PP2.	Cycloheximide	37-50	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	77-82
11395571-6	2001	Moreover, RA-VII still decreased cyclin D1 protein in the presence of cycloheximide.	Cycloheximide	70-83	cyclin D1	Homo sapiens	33-42
11356667-11	2001	We extended these findings by examining whether the LH-induced down-regulation of the ERbeta mRNA is cycloheximide-sensitive.	Cycloheximide	101-114	estrogen receptor 2	Rattus norvegicus	86-92
11356667-12	2001	When granulosa cells were cultured in the presence of cycloheximide, a protein synthesis inhibitor, the inhibitory effects of hCG, FSK, and TPA on ERbeta mRNA levels were abolished.	Cycloheximide	54-67	hypertrichosis 2 (generalised, congenital)	Homo sapiens	126-129
11356667-12	2001	When granulosa cells were cultured in the presence of cycloheximide, a protein synthesis inhibitor, the inhibitory effects of hCG, FSK, and TPA on ERbeta mRNA levels were abolished.	Cycloheximide	54-67	estrogen receptor 2	Rattus norvegicus	147-153
11356667-14	2001	Taken together, our results demonstrate that LH decreases ERbeta mRNA expression, predominantly at the posttranscriptional level, in a cycloheximide-sensitive manner.	Cycloheximide	135-148	estrogen receptor 2	Rattus norvegicus	58-64
11387233-5	2001	In differentiated T37i cells, insulin induced leptin release ( approximately 0.25 ng/10(6) cells/h) in a concentration-dependent manner (EC50=0.1 nM), and this was totally suppressed by beta3-adrenergic ligand, thiazolidinedione, cycloheximide, or actinomycin D.	Cycloheximide	230-243	leptin	Mus musculus	46-52
11374877-5	2001	However, an increase in hr mRNA, but not in inv mRNA, was seen in cells treated with the protein synthesis inhibitor cycloheximide, suggesting that new protein synthesis is involved in the suppression of hr transcription or in the degradation of hr mRNA in the steady state.	Cycloheximide	117-130	lysine demethylase and nuclear receptor corepressor	Mus musculus	24-26
11374877-5	2001	However, an increase in hr mRNA, but not in inv mRNA, was seen in cells treated with the protein synthesis inhibitor cycloheximide, suggesting that new protein synthesis is involved in the suppression of hr transcription or in the degradation of hr mRNA in the steady state.	Cycloheximide	117-130	lysine demethylase and nuclear receptor corepressor	Mus musculus	204-206
11374877-5	2001	However, an increase in hr mRNA, but not in inv mRNA, was seen in cells treated with the protein synthesis inhibitor cycloheximide, suggesting that new protein synthesis is involved in the suppression of hr transcription or in the degradation of hr mRNA in the steady state.	Cycloheximide	117-130	lysine demethylase and nuclear receptor corepressor	Mus musculus	204-206
11352510-6	2001	Dexamethasone and actinomycin D completely suppressed not only the interleukin-1 beta-induced cyclooxygenase-2 mRNA expression, but also the bradykinin-induced cyclooxygenase-2 mRNA expression in the interleukin-1 beta-primed fibroblasts, although cycloheximide did not inhibit the effects of interleukin-1 beta and bradykinin.	Cycloheximide	248-261	interleukin 1 beta	Homo sapiens	67-85
11352510-6	2001	Dexamethasone and actinomycin D completely suppressed not only the interleukin-1 beta-induced cyclooxygenase-2 mRNA expression, but also the bradykinin-induced cyclooxygenase-2 mRNA expression in the interleukin-1 beta-primed fibroblasts, although cycloheximide did not inhibit the effects of interleukin-1 beta and bradykinin.	Cycloheximide	248-261	kininogen 1	Homo sapiens	141-151
11352510-6	2001	Dexamethasone and actinomycin D completely suppressed not only the interleukin-1 beta-induced cyclooxygenase-2 mRNA expression, but also the bradykinin-induced cyclooxygenase-2 mRNA expression in the interleukin-1 beta-primed fibroblasts, although cycloheximide did not inhibit the effects of interleukin-1 beta and bradykinin.	Cycloheximide	248-261	prostaglandin-endoperoxide synthase 2	Homo sapiens	160-176
11356868-6	2001	Actinomycin D and cycloheximide experiments have revealed that, despite the presence of the mRNA-destabilizing AU-rich motif, transcriptional activation is a main determinant for selective Homer 1a mRNA induction.	Cycloheximide	18-31	homer scaffold protein 1	Homo sapiens	189-197
11357057-18	2001	Inhibition of protein synthesis with cycloheximide increased basal levels of CYP17 mRNA levels and blocked the induction observed by PP2.	Cycloheximide	37-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
11359904-0	2001	NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.	Cycloheximide	39-52	nuclear factor kappa B subunit 1	Homo sapiens	0-9
11380820-7	2001	Both cycloheximide (20 micromol/L) and nocodazole (20 micromol/L) blocked the hypertonic up-regulation of BGT1.	Cycloheximide	5-18	solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12	Mus musculus	106-110
11380820-10	2001	Hypertonic activation of BGT1 transport was detected in an isolated membrane fraction and was blocked by cycloheximide but not by nocodazole.	Cycloheximide	105-118	solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12	Mus musculus	25-29
11453113-6	2001	Stimulation of collagenase-2 mRNA expression by IL-1beta was prevented by pretreatment with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	92-105	matrix metallopeptidase 8	Homo sapiens	15-28
11453113-6	2001	Stimulation of collagenase-2 mRNA expression by IL-1beta was prevented by pretreatment with cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	92-105	interleukin 1 beta	Homo sapiens	48-56
11359904-6	2001	SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX).	Cycloheximide	168-181	TNF superfamily member 10	Homo sapiens	39-76
11359904-6	2001	SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX).	Cycloheximide	168-181	TNF superfamily member 10	Homo sapiens	78-83
11359904-6	2001	SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX).	Cycloheximide	168-181	tumor necrosis factor	Homo sapiens	39-42
11359904-6	2001	SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX).	Cycloheximide	183-186	TNF superfamily member 10	Homo sapiens	39-76
11359904-6	2001	SV80 cells normally show resistance to TNF-related apoptosis-inducing ligand (TRAIL) and TNF, as apoptosis can be induced only in the presence of low concentrations of cycloheximide (CHX).	Cycloheximide	183-186	TNF superfamily member 10	Homo sapiens	78-83
11359904-0	2001	NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.	Cycloheximide	39-52	CASP8 and FADD like apoptosis regulator	Homo sapiens	30-35
11359904-8	2001	Western blot analysis further revealed that cFLIP, but not TRAF1, A20, and cIAP2, expression levels rapidly decrease upon CHX treatment.	Cycloheximide	122-125	CASP8 and FADD like apoptosis regulator	Homo sapiens	44-49
11359904-8	2001	Western blot analysis further revealed that cFLIP, but not TRAF1, A20, and cIAP2, expression levels rapidly decrease upon CHX treatment.	Cycloheximide	122-125	TNF alpha induced protein 3	Homo sapiens	66-69
11327701-4	2001	Insulin administration to diabetic rats induces Delta6 desaturase mRNA eightfold within 24 h. The effect of insulin on the Delta6 desaturase mRNA was inhibited 70% with dibutyryl-cAMP and theophylline administration and 90% by cycloheximide administration.	Cycloheximide	227-240	fatty acid desaturase 2	Rattus norvegicus	54-65
11406201-7	2001	TACE enzymatic activity from OGD-exposed slices was significantly inhibited by cycloheximide, suggesting that de novo synthesis of TACE contributes to TNF-alpha release after ischaemia.	Cycloheximide	79-92	ADAM metallopeptidase domain 17	Rattus norvegicus	0-4
11406201-7	2001	TACE enzymatic activity from OGD-exposed slices was significantly inhibited by cycloheximide, suggesting that de novo synthesis of TACE contributes to TNF-alpha release after ischaemia.	Cycloheximide	79-92	ADAM metallopeptidase domain 17	Rattus norvegicus	131-135
11406201-7	2001	TACE enzymatic activity from OGD-exposed slices was significantly inhibited by cycloheximide, suggesting that de novo synthesis of TACE contributes to TNF-alpha release after ischaemia.	Cycloheximide	79-92	tumor necrosis factor	Rattus norvegicus	151-160
11278665-7	2001	However, when the cells were sensitized with cycloheximide, which is sufficient to sensitize the cells also to apoptosis by TNF-R1 stimulation, we noticed that adenovirus-mediated expression of constitutively active MKK1 could rescue the cells from apoptosis induced by the respective receptors by preventing caspase-8 activation.	Cycloheximide	45-58	TNF receptor superfamily member 1A	Homo sapiens	124-130
11278665-7	2001	However, when the cells were sensitized with cycloheximide, which is sufficient to sensitize the cells also to apoptosis by TNF-R1 stimulation, we noticed that adenovirus-mediated expression of constitutively active MKK1 could rescue the cells from apoptosis induced by the respective receptors by preventing caspase-8 activation.	Cycloheximide	45-58	mitogen-activated protein kinase kinase 1	Homo sapiens	216-220
11278665-7	2001	However, when the cells were sensitized with cycloheximide, which is sufficient to sensitize the cells also to apoptosis by TNF-R1 stimulation, we noticed that adenovirus-mediated expression of constitutively active MKK1 could rescue the cells from apoptosis induced by the respective receptors by preventing caspase-8 activation.	Cycloheximide	45-58	caspase 8	Homo sapiens	309-318
11327734-4	2001	In addition, all the LOT genes, except for LOT1/FBA1, were induced by a low concentration of cycloheximide.	Cycloheximide	93-106	fructose-bisphosphate aldolase FBA1	Saccharomyces cerevisiae S288C	43-47
11327734-4	2001	In addition, all the LOT genes, except for LOT1/FBA1, were induced by a low concentration of cycloheximide.	Cycloheximide	93-106	fructose-bisphosphate aldolase FBA1	Saccharomyces cerevisiae S288C	48-52
11408585-5	2001	Inhibition of the MAPK pathway in the extract by the MEK1 inhibitor U0126 delayed, but did not prevent, activation of the Plx1 pathway, and inhibition of Mos synthesis by cycloheximide had a similar effect, suggesting that MAPK activation is the only relevant function of Mos.	Cycloheximide	171-184	MOS proto-oncogene, serine/threonine kinase L homeolog	Xenopus laevis	154-157
11385144-9	2001	Using the protein synthesis inhibitor cycloheximide, we demonstrated that meconium directly induced iNOS in macrophages.	Cycloheximide	38-51	nitric oxide synthase 2	Rattus norvegicus	100-104
11279137-3	2001	We have identified two known endothelial anti-apoptotic proteins, c-FLIP and Mcl-1, the expression of which is decreased markedly in the presence of cycloheximide.	Cycloheximide	149-162	CASP8 and FADD like apoptosis regulator	Homo sapiens	66-72
11279137-3	2001	We have identified two known endothelial anti-apoptotic proteins, c-FLIP and Mcl-1, the expression of which is decreased markedly in the presence of cycloheximide.	Cycloheximide	149-162	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	77-82
11327701-4	2001	Insulin administration to diabetic rats induces Delta6 desaturase mRNA eightfold within 24 h. The effect of insulin on the Delta6 desaturase mRNA was inhibited 70% with dibutyryl-cAMP and theophylline administration and 90% by cycloheximide administration.	Cycloheximide	227-240	fatty acid desaturase 2	Rattus norvegicus	129-140
11294760-6	2001	The cytoprotective effect of ET-1 was abolished by pretreatment with cycloheximide or staurosporine.	Cycloheximide	69-82	endothelin 1	Rattus norvegicus	29-33
11334620-8	2001	In contrast, the chronic phase is associated with an induction of ata2 gene expression as evidenced from the increase in the steady-state levels of ATA2 mRNA, restoration of the intracellular pool of ATA2 protein, and blockade of the induction by cycloheximide and actinomycin D.	Cycloheximide	247-260	solute carrier family 38, member 2	Rattus norvegicus	66-70
11392499-9	2001	Furthermore, apoptosis was suppressed by cycloheximide in THP-1 cells, suggesting that newly synthesized proteins may be essential for apoptotic events.	Cycloheximide	41-54	GLI family zinc finger 2	Homo sapiens	58-63
11350835-4	2001	The observed augmentation of FSK-stimulated cAMP formation by IL-1beta was completely abrogated by pretreatment with an IL-1 receptor antagonist or cycloheximide, demonstrating that the effect is mediated via the IL-1 receptor 1 (IL-1R1) and that de novo protein synthesis is required.	Cycloheximide	148-161	interleukin 1 beta	Homo sapiens	62-70
11350835-4	2001	The observed augmentation of FSK-stimulated cAMP formation by IL-1beta was completely abrogated by pretreatment with an IL-1 receptor antagonist or cycloheximide, demonstrating that the effect is mediated via the IL-1 receptor 1 (IL-1R1) and that de novo protein synthesis is required.	Cycloheximide	148-161	interleukin 1 receptor type 1	Homo sapiens	213-228
11309811-4	2001	METHODS: Apoptosis of human MCF-7, U-937, or HL-60 cells was induced by camptothecin (CPT) or tumor necrosis factor-alpha (TNF-alpha) combined with cycloheximide (CHX).	Cycloheximide	163-166	tumor necrosis factor	Homo sapiens	123-132
11348878-5	2001	The downregulation of eNOS by nLDL was abrogated by cycloheximide, an inhibitor of protein synthesis, and by N-acetyl-leucyl-leucyl-norleucinal, a protease inhibitor that reduces the catabolism of sterol regulatory element binding proteins.	Cycloheximide	52-65	nitric oxide synthase 3	Homo sapiens	22-26
11358522-8	2001	Chase analysis of beta-catenin in Wnt-3A-stimulated cells following cycloheximide treatment revealed that PS1 mutation enhanced the generation of the higher molecular mass form of beta-catenin, most likely, ubiquitinated beta-catenin.	Cycloheximide	68-81	presenilin 1	Homo sapiens	106-109
11316763-7	2001	Cycloheximide treatment induced fra-2 expression, and actinomycin D inhibited basal and PTHrP-induced expression.	Cycloheximide	0-13	fos-like antigen 2	Mus musculus	32-37
11316763-7	2001	Cycloheximide treatment induced fra-2 expression, and actinomycin D inhibited basal and PTHrP-induced expression.	Cycloheximide	0-13	parathyroid hormone-like peptide	Mus musculus	88-93
11432727-11	2001	A similar redistribution of gelsolin immunore-activity was observed after induction of apoptosis by cycloheximide, but not after initiation of necrosis by hydrogen peroxide.	Cycloheximide	100-113	gelsolin	Mus musculus	28-36
11333363-6	2001	In another subset of animals treated with cycloheximide, a general protein synthesis inhibitor, the late phase of cytochrome c redistribution was inhibited, whereas most hippocampal CA1 neurons never regained mitochondrial cytochrome c. Examination of neuronal survival revealed that ischemic preconditioning prevents, whereas cycloheximide only delays, ischemic hippocampal CA1 neuronal death.	Cycloheximide	42-55	carbonic anhydrase 1	Rattus norvegicus	182-185
11287623-9	2001	However, unlike immediate-early Raf targets such as heparin binding epidermal growth factor and Mdm2, beta3-integrin mRNA was induced by Raf in a manner that was cycloheximide sensitive.	Cycloheximide	162-175	zinc fingers and homeoboxes 2	Homo sapiens	137-140
11429161-5	2001	The recombinant porcine FasL expressed by recombinant baculovirus containing the whole coding sequences of porcine FasL showed cytotoxic effect and induced apoptosis in porcine renal tubular cell line PK-15 cells sensitized by cycloheximide (CHX), which was confirmed by MTT assay, DNA fragmentation assay, and TUNEL staining, respectively.	Cycloheximide	227-240	Fas ligand	Sus scrofa	24-28
11429161-5	2001	The recombinant porcine FasL expressed by recombinant baculovirus containing the whole coding sequences of porcine FasL showed cytotoxic effect and induced apoptosis in porcine renal tubular cell line PK-15 cells sensitized by cycloheximide (CHX), which was confirmed by MTT assay, DNA fragmentation assay, and TUNEL staining, respectively.	Cycloheximide	227-240	Fas ligand	Sus scrofa	115-119
11429161-5	2001	The recombinant porcine FasL expressed by recombinant baculovirus containing the whole coding sequences of porcine FasL showed cytotoxic effect and induced apoptosis in porcine renal tubular cell line PK-15 cells sensitized by cycloheximide (CHX), which was confirmed by MTT assay, DNA fragmentation assay, and TUNEL staining, respectively.	Cycloheximide	242-245	Fas ligand	Sus scrofa	24-28
11429161-5	2001	The recombinant porcine FasL expressed by recombinant baculovirus containing the whole coding sequences of porcine FasL showed cytotoxic effect and induced apoptosis in porcine renal tubular cell line PK-15 cells sensitized by cycloheximide (CHX), which was confirmed by MTT assay, DNA fragmentation assay, and TUNEL staining, respectively.	Cycloheximide	242-245	Fas ligand	Sus scrofa	115-119
11311405-6	2001	The effect of IL-1beta was completely abolished when we treated cells with inhibitor of mitogen-activated protein kinases (MAPKs) (PD98059) (25 microM), phospholipase A(2) inhibitor mepacrine (30 microM) and protein synthesis inhibitor cycloheximide (CHX) (10 microg/ml).	Cycloheximide	236-249	interleukin 1 beta	Rattus norvegicus	14-22
11311405-6	2001	The effect of IL-1beta was completely abolished when we treated cells with inhibitor of mitogen-activated protein kinases (MAPKs) (PD98059) (25 microM), phospholipase A(2) inhibitor mepacrine (30 microM) and protein synthesis inhibitor cycloheximide (CHX) (10 microg/ml).	Cycloheximide	251-254	interleukin 1 beta	Rattus norvegicus	14-22
11335106-1	2001	Recombinant rat interleukin (IL)-5-induced prolongation of rat eosinophil survival in culture was inhibited in a concentration-dependent manner by the protein synthesis inhibitor cycloheximide, the DNA-dependent RNA synthesis inhibitor actinomycin D, and the tyrosine kinase inhibitor herbimycin A when examined 96 h after incubation.	Cycloheximide	179-192	interleukin 5	Rattus norvegicus	16-34
11281644-5	2001	RA at more than 10(-8) M induced the expression of Ihh and Patched 1 (Ptc1) within 3 h, before it increased the type X collagen mRNA level at 6-24 h. Cycloheximide blocked the up-regulation of Ihh by RA, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	150-163	indian hedgehog protein	Oryctolagus cuniculus	51-54
11355693-3	2001	KA increased proenkephalin mRNA expression in rat hippocampus, which was decreased by pre-administration with cycloheximide (CHX, a protein synthesis inhibitor).	Cycloheximide	110-123	proenkephalin	Rattus norvegicus	13-26
11368167-4	2001	Exposure of HO-1-expressing hepatocytes to cycloheximide unraveled a hyperosmotic acceleration of HO-1 degradation which was counteracted by betaine and the proteolysis inhibitor MG-132.	Cycloheximide	43-56	heme oxygenase 1	Rattus norvegicus	12-16
11334998-7	2001	Inhibitors of transcription (actinomycin D) or of translation (cycloheximide) eliminated all the increase in DA+DOPAC contents elicited by these compounds, indicating that de novo transcription and translation were required for increased expression of the TH and other related enzymes.	Cycloheximide	63-76	tyrosine hydroxylase	Homo sapiens	256-258
11402317-2	2001	A human lung cancer cell line that expresses the temperature sensitive murine p53 was utilized to quantitate mRNA levels of various genes at different time points after shifting the temperature to 32 degrees C. Inhibition of protein synthesis by cycloheximide (CHX) was used to distinguish between primary and secondary target genes regulated by p53.	Cycloheximide	246-259	transformation related protein 53, pseudogene	Mus musculus	78-81
11368167-4	2001	Exposure of HO-1-expressing hepatocytes to cycloheximide unraveled a hyperosmotic acceleration of HO-1 degradation which was counteracted by betaine and the proteolysis inhibitor MG-132.	Cycloheximide	43-56	heme oxygenase 1	Rattus norvegicus	98-102
11281644-5	2001	RA at more than 10(-8) M induced the expression of Ihh and Patched 1 (Ptc1) within 3 h, before it increased the type X collagen mRNA level at 6-24 h. Cycloheximide blocked the up-regulation of Ihh by RA, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	150-163	protein patched homolog 1	Oryctolagus cuniculus	59-68
11281644-5	2001	RA at more than 10(-8) M induced the expression of Ihh and Patched 1 (Ptc1) within 3 h, before it increased the type X collagen mRNA level at 6-24 h. Cycloheximide blocked the up-regulation of Ihh by RA, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	150-163	protein patched homolog 1	Oryctolagus cuniculus	70-74
11281644-5	2001	RA at more than 10(-8) M induced the expression of Ihh and Patched 1 (Ptc1) within 3 h, before it increased the type X collagen mRNA level at 6-24 h. Cycloheximide blocked the up-regulation of Ihh by RA, indicating the requirement of de novo protein synthesis for this stimulation.	Cycloheximide	150-163	indian hedgehog protein	Oryctolagus cuniculus	193-196
11313933-3	2001	This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage.	Cycloheximide	76-89	caspase 3	Homo sapiens	138-147
11278364-7	2001	By contrast, functional phosphorylation of 4E-BP1 induced by injection of cycloheximide or growth factors was partially reversed by the drug.	Cycloheximide	74-87	eukaryotic translation initiation factor 4E binding protein 1	Rattus norvegicus	43-49
11400163-6	2001	IL-1beta- or PMA-stimulated hyaluronan synthesis was blocked by the protein synthesis inhibitor, cycloheximide.	Cycloheximide	97-110	interleukin 1 beta	Homo sapiens	0-8
11313933-3	2001	This fragmentation was inhibited by the caspase inhibitor, z-VAD-fmk and by cycloheximide, which also prevented proteolytic activation of caspase-3 and poly(ADP-ribose)polymerase cleavage.	Cycloheximide	76-89	poly(ADP-ribose) polymerase 1	Homo sapiens	152-178
11245595-1	2001	In a previous study, it was found that exposure to tumor necrosis factor-alpha (TNF-alpha) potentiated the electrophysiological response to carbachol in a time-dependent and cycloheximide-sensitive manner.	Cycloheximide	174-187	tumor necrosis factor	Homo sapiens	51-78
11245595-1	2001	In a previous study, it was found that exposure to tumor necrosis factor-alpha (TNF-alpha) potentiated the electrophysiological response to carbachol in a time-dependent and cycloheximide-sensitive manner.	Cycloheximide	174-187	tumor necrosis factor	Homo sapiens	80-89
11124951-7	2001	Interestingly, treating the hepatocytes with the translational inhibitor, cycloheximide, prevented the PUFA-dependent decay of SREBP-1.	Cycloheximide	74-87	sterol regulatory element binding transcription factor 1	Rattus norvegicus	127-134
11399512-7	2001	Evidence in support of this notion includes (1) TNF-induced apoptosis only in A375-R8, but not A375-6 cells; (2) cycloheximide enabled TNF to induce apoptosis even in A375-6 cells; and (3) somatic hybrid cells between A375-6 and A375-R8 cells are resistant to TNF-induced apoptosis.	Cycloheximide	113-126	tumor necrosis factor	Homo sapiens	135-138
11399512-7	2001	Evidence in support of this notion includes (1) TNF-induced apoptosis only in A375-R8, but not A375-6 cells; (2) cycloheximide enabled TNF to induce apoptosis even in A375-6 cells; and (3) somatic hybrid cells between A375-6 and A375-R8 cells are resistant to TNF-induced apoptosis.	Cycloheximide	113-126	tumor necrosis factor	Homo sapiens	135-138
11259523-3	2001	The acute addition of BK (10-100 nM) to HEK 293 cells stably expressing B2R-GFP in the presence of cycloheximide was rapidly followed by translocation of the surface receptors into the cells, with essentially complete recycling of the surface receptors in 1 to 3 h (confocal microscopy, cell fractionation).	Cycloheximide	99-112	B2 bradykinin receptor	Oryctolagus cuniculus	72-75
11259624-10	2001	This increase was associated with a decrease of CYP2E1 turnover by salicylate in the presence of cycloheximide.	Cycloheximide	97-110	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	48-54
11453539-5	2001	The DNA binding of Ets-1 protein was enhanced by the initial 4-hour bFGF treatment and the subsequent 8-hour cycloheximide treatment.	Cycloheximide	109-122	ETS proto-oncogene 1, transcription factor	Homo sapiens	19-24
11453539-6	2001	When TGF-beta replaced cycloheximide in the subsequent 8-hour treatment, TGF-beta inhibited this bFGF-enhanced DNA-Ets complex formation.	Cycloheximide	23-36	transforming growth factor beta 1	Homo sapiens	73-81
11453539-6	2001	When TGF-beta replaced cycloheximide in the subsequent 8-hour treatment, TGF-beta inhibited this bFGF-enhanced DNA-Ets complex formation.	Cycloheximide	23-36	fibroblast growth factor 2	Homo sapiens	97-101
11453539-7	2001	When TGF-beta and cycloheximide were simultaneously added in the subsequent 8-hour treatment, the inhibitory effect of TGF-beta on bFGF-enhanced DNA-Ets complex formation was completely abolished.	Cycloheximide	18-31	transforming growth factor beta 1	Homo sapiens	119-127
11453539-7	2001	When TGF-beta and cycloheximide were simultaneously added in the subsequent 8-hour treatment, the inhibitory effect of TGF-beta on bFGF-enhanced DNA-Ets complex formation was completely abolished.	Cycloheximide	18-31	fibroblast growth factor 2	Homo sapiens	131-135
11414630-10	2001	This increase in TF expression and PCA of intact cells incubated with Hb was significantly inhibited by cycloheximide at a concentration of 10 microg/ml (P &lt; 0.01).	Cycloheximide	104-117	coagulation factor III, tissue factor	Homo sapiens	17-19
11247901-9	2001	Serum deprivation and culture in the presence of 50 microM cycloheximide was associated with an increase in HSC apoptosis which was significantly inhibited by addition of 10 ng/ml and 100 ng/ml IGF-1, respectively (0.05&gt;p, n=5).	Cycloheximide	59-72	insulin-like growth factor 1	Rattus norvegicus	194-199
11258956-7	2001	We also provide two independent lines of evidence suggesting that caveolin-1 is a direct target of Myc: (i) the effect of Myc activation on caveolin-1 expression is independent of new protein synthesis, as revealed through the use of cycloheximide; and (ii) Myc-mediated repression of the caveolin-1 promoter is dependent on an intact INR sequence.	Cycloheximide	234-247	caveolin 1, caveolae protein	Mus musculus	66-76
11295234-3	2001	The inhibition of protein synthesis by cycloheximide (CHX; 15 microM) also increased proENK mRNA level in PTX-treated cells (5.2-fold), but not in CTX-stimulated cells.	Cycloheximide	39-52	proenkephalin	Rattus norvegicus	85-91
11295234-3	2001	The inhibition of protein synthesis by cycloheximide (CHX; 15 microM) also increased proENK mRNA level in PTX-treated cells (5.2-fold), but not in CTX-stimulated cells.	Cycloheximide	54-57	proenkephalin	Rattus norvegicus	85-91
11295234-9	2001	These results suggest that the elevation of phosphorylation of CREB rather than AP-1 level may be involved in CTX-induced and CHX-dependent-PTX-induced increase of proENK mRNA level.	Cycloheximide	126-129	cAMP responsive element binding protein 1	Rattus norvegicus	63-67
11295234-9	2001	These results suggest that the elevation of phosphorylation of CREB rather than AP-1 level may be involved in CTX-induced and CHX-dependent-PTX-induced increase of proENK mRNA level.	Cycloheximide	126-129	proenkephalin	Rattus norvegicus	164-170
11292320-4	2001	The U937(M) cells, however, were sensitive to the cytotoxic action of TNF both in the presence and absence of cycloheximide.	Cycloheximide	110-123	tumor necrosis factor	Homo sapiens	70-73
11258956-7	2001	We also provide two independent lines of evidence suggesting that caveolin-1 is a direct target of Myc: (i) the effect of Myc activation on caveolin-1 expression is independent of new protein synthesis, as revealed through the use of cycloheximide; and (ii) Myc-mediated repression of the caveolin-1 promoter is dependent on an intact INR sequence.	Cycloheximide	234-247	myelocytomatosis oncogene	Mus musculus	99-102
11171124-9	2001	The enhancing effects of IL-1beta and PDGF-BB on Ins(X)P accumulation, Ca2+ mobilization and B(max) were attenuated by PD98059 [an inhibitor of activation of mitogen-activated protein kinase (MAPK) kinase, MEK] and cycloheximide (an inhibitor of protein synthesis), suggesting that IL-1beta may share a common signalling pathway with PDGF-BB via protein synthesis.	Cycloheximide	215-228	interleukin 1 beta	Canis lupus familiaris	25-33
11223427-8	2001	The reduced expression of eNOS protein by TNF-alpha was also prevented by coincubation with cycloheximide.	Cycloheximide	92-105	nitric oxide synthase 3	Bos taurus	26-30
11223427-8	2001	The reduced expression of eNOS protein by TNF-alpha was also prevented by coincubation with cycloheximide.	Cycloheximide	92-105	tumor necrosis factor	Bos taurus	42-51
11223427-9	2001	In addition cycloheximide inhibited the binding activity of the cytosolic proteins to 3"-UTR of eNOS mRNA, suggesting the inducible character of the mentioned-cytosolic proteins.	Cycloheximide	12-25	nitric oxide synthase 3	Bos taurus	96-100
11113123-3	2001	Administration of cAMP or taurocholate to rats increased amounts of SPGP, MDR1, and MDR2 in the bile canalicular membrane by 3-fold; these effects abated after 6 h and were insensitive to prior treatment of rats with cycloheximide.	Cycloheximide	217-230	ATP binding cassette subfamily B member 11	Rattus norvegicus	68-72
11291750-7	2001	The glucocorticoid receptor antagonist RU-38486, administered intracerebroventricularly at the dose of 1 ng/mouse, was also able to block dexamethasone effects on clonidine-induced antinociception and locomotor hypoactivity, whereas both cycloheximide and RU-38486 per se did not influence pain sensitivity or locomotor activity.	Cycloheximide	238-251	nuclear receptor subfamily 3, group C, member 1	Mus musculus	4-27
11282560-8	2001	However, 24P3 gene induction was slow, reaching a plateau from 36 to 72 hours after stimulation and was inhibited if cells were treated with cycloheximide during the first 8 hours of IL-9 stimulation, suggesting an indirect induction requiring new protein synthesis.	Cycloheximide	141-154	lipocalin 2	Mus musculus	9-13
11282560-8	2001	However, 24P3 gene induction was slow, reaching a plateau from 36 to 72 hours after stimulation and was inhibited if cells were treated with cycloheximide during the first 8 hours of IL-9 stimulation, suggesting an indirect induction requiring new protein synthesis.	Cycloheximide	141-154	interleukin 9	Mus musculus	183-187
11238378-3	2001	The repression of Ntc12 was observed even when indirect effects were blocked by cycloheximide.	Cycloheximide	80-93	gibberellin 20 oxidase 1-like	Nicotiana tabacum	18-23
11260269-7	2001	Treatment with cycloheximide or vanadate prolonged the increased expression of SGK by FGF, concomitant with a more prolonged activation of ERKs.	Cycloheximide	15-28	serum/glucocorticoid regulated kinase 1	Mus musculus	79-82
11207318-5	2001	A protein synthesis inhibitor, cycloheximide, rather enhanced the LPS-mediated increase of ODF mRNA, and both a neutralizing Ab of TNF-alpha and a specific inhibitor of PGE synthesis failed to block the ODF mRNA increase by native LPS.	Cycloheximide	31-44	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	91-94
11252166-8	2001	Results from cycloheximide and actinomycin D studies suggest the existence of a labile repressor protein(s) that destabilizes the pool of Cnn1 mRNA and/or silences transcription of the Cnn1 locus.	Cycloheximide	13-26	calponin 1	Mus musculus	138-142
11252166-8	2001	Results from cycloheximide and actinomycin D studies suggest the existence of a labile repressor protein(s) that destabilizes the pool of Cnn1 mRNA and/or silences transcription of the Cnn1 locus.	Cycloheximide	13-26	calponin 1	Mus musculus	185-189
11226410-2	2001	We have found that treatment of A431 cells with tumor necrosis factor-alpha in the presence of cycloheximide resulted in the cleavage of epidermal growth factor receptor (EGFR) as well as the activation of caspase-3.	Cycloheximide	95-108	tumor necrosis factor	Homo sapiens	48-75
11331038-6	2001	Cycloheximide (CHX) alone increased both gp130 and IL-6 transcripts in the BMSC.	Cycloheximide	0-13	interleukin 6 cytokine family signal transducer	Homo sapiens	41-46
11331038-6	2001	Cycloheximide (CHX) alone increased both gp130 and IL-6 transcripts in the BMSC.	Cycloheximide	0-13	interleukin 6	Homo sapiens	51-55
11331038-6	2001	Cycloheximide (CHX) alone increased both gp130 and IL-6 transcripts in the BMSC.	Cycloheximide	15-18	interleukin 6 cytokine family signal transducer	Homo sapiens	41-46
11331038-6	2001	Cycloheximide (CHX) alone increased both gp130 and IL-6 transcripts in the BMSC.	Cycloheximide	15-18	interleukin 6	Homo sapiens	51-55
11226410-2	2001	We have found that treatment of A431 cells with tumor necrosis factor-alpha in the presence of cycloheximide resulted in the cleavage of epidermal growth factor receptor (EGFR) as well as the activation of caspase-3.	Cycloheximide	95-108	epidermal growth factor receptor	Homo sapiens	137-169
11226410-2	2001	We have found that treatment of A431 cells with tumor necrosis factor-alpha in the presence of cycloheximide resulted in the cleavage of epidermal growth factor receptor (EGFR) as well as the activation of caspase-3.	Cycloheximide	95-108	epidermal growth factor receptor	Homo sapiens	171-175
11226410-2	2001	We have found that treatment of A431 cells with tumor necrosis factor-alpha in the presence of cycloheximide resulted in the cleavage of epidermal growth factor receptor (EGFR) as well as the activation of caspase-3.	Cycloheximide	95-108	caspase 3	Homo sapiens	206-215
11179193-4	2001	CYP51 mRNA levels decrease in nLDL-treated cells in a dose- and time-dependent manner (9-fold after 24 hours with 180 mg of LDL cholesterol per deciliter), an effect that is blocked by cycloheximide.	Cycloheximide	185-198	cytochrome P450 family 51 subfamily A member 1	Sus scrofa	0-5
11368346-5	2001	Actinomycin D or cycloheximide treatment of cells drastically reduced alpha2M*-induced cPLA2 synthesis.	Cycloheximide	17-30	alpha-2-macroglobulin	Homo sapiens	70-77
11368346-5	2001	Actinomycin D or cycloheximide treatment of cells drastically reduced alpha2M*-induced cPLA2 synthesis.	Cycloheximide	17-30	phospholipase A2 group IVA	Homo sapiens	87-92
11179193-4	2001	CYP51 mRNA levels decrease in nLDL-treated cells in a dose- and time-dependent manner (9-fold after 24 hours with 180 mg of LDL cholesterol per deciliter), an effect that is blocked by cycloheximide.	Cycloheximide	185-198	LDL	Sus scrofa	31-34
11221830-3	2001	The teniposide-induced increase of cytochrome c was inhibited by cycloheximide, indicating new protein synthesis.	Cycloheximide	65-78	cytochrome c, somatic	Homo sapiens	35-47
11741524-0	2001	Cycloheximide blocks TGF-beta1-induced apoptosis in murine hepatocytes.	Cycloheximide	0-13	transforming growth factor, beta 1	Mus musculus	21-30
11741524-8	2001	TGF-beta1-induced apoptosis in AML12 cells was completely blocked in the presence of cycloheximide.	Cycloheximide	85-98	transforming growth factor, beta 1	Mus musculus	0-9
11741524-9	2001	The inhibitory effect of cycloheximide was accompanied with down-regulation of Tak1 expression and TGF-beta1-induced PAI-1 expression.	Cycloheximide	25-38	mitogen-activated protein kinase kinase kinase 7	Mus musculus	79-83
11741524-9	2001	The inhibitory effect of cycloheximide was accompanied with down-regulation of Tak1 expression and TGF-beta1-induced PAI-1 expression.	Cycloheximide	25-38	transforming growth factor, beta 1	Mus musculus	99-108
11741524-9	2001	The inhibitory effect of cycloheximide was accompanied with down-regulation of Tak1 expression and TGF-beta1-induced PAI-1 expression.	Cycloheximide	25-38	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	117-122
11165054-4	2001	The number of vasoactive intestinal polypeptide (VIP) binding sites was reduced 66% upon treatment with E(2) for 72 h. After cycloheximide pretreatment, the E(2) mediated mRNA reduction was attenuated from 50% to 25% after 24 h suggesting the effect to be at least partly independent of protein synthesis.	Cycloheximide	125-138	vasoactive intestinal peptide	Homo sapiens	14-47
11165054-4	2001	The number of vasoactive intestinal polypeptide (VIP) binding sites was reduced 66% upon treatment with E(2) for 72 h. After cycloheximide pretreatment, the E(2) mediated mRNA reduction was attenuated from 50% to 25% after 24 h suggesting the effect to be at least partly independent of protein synthesis.	Cycloheximide	125-138	vasoactive intestinal peptide	Homo sapiens	49-52
11208575-6	2001	The protein synthesis blocker cycloheximide prevented the hypothalamic CRH content elevation after stress.	Cycloheximide	30-43	corticotropin releasing hormone	Rattus norvegicus	71-74
11159850-13	2001	Cycloheximide treatment of stably transfected HK293 cells demonstrated that the UGT2B17 protein is more labile than the other enzymes; the protein levels decrease after 1 h of treatment, whereas other UGT2B proteins were stable for at least 12 h. Treatment of stable cells with actinomycin D reveals that UGT2B transcripts are stable for 12 h, except for the UGT2B4 transcript, which was decreased by 50% after the 12-h incubation period.	Cycloheximide	0-13	UDP glucuronosyltransferase family 2 member B17	Homo sapiens	80-87
11159850-13	2001	Cycloheximide treatment of stably transfected HK293 cells demonstrated that the UGT2B17 protein is more labile than the other enzymes; the protein levels decrease after 1 h of treatment, whereas other UGT2B proteins were stable for at least 12 h. Treatment of stable cells with actinomycin D reveals that UGT2B transcripts are stable for 12 h, except for the UGT2B4 transcript, which was decreased by 50% after the 12-h incubation period.	Cycloheximide	0-13	UDP glucuronosyltransferase family 2 member B4	Homo sapiens	359-365
11168841-7	2001	The effects of cycloheximide and actinomycin on vasopressin and oxytocin release suggest that ongoing protein synthesis is required for stimulation of hormone release.	Cycloheximide	15-28	arginine vasopressin	Homo sapiens	48-59
11135429-10	2001	Treatment with either actinomycin D or cycloheximide efficiently blocked the induction of K23 mRNA by NaBu/TSA.	Cycloheximide	39-52	keratin 23	Homo sapiens	90-93
11204422-6	2001	De novo protein synthesis was essential for the induction because cycloheximide (CHX) decreased the effect of 1alpha,25(OH)2D3 on the MMP-13 mRNA level.	Cycloheximide	66-79	matrix metallopeptidase 13	Mus musculus	134-140
11204422-6	2001	De novo protein synthesis was essential for the induction because cycloheximide (CHX) decreased the effect of 1alpha,25(OH)2D3 on the MMP-13 mRNA level.	Cycloheximide	81-84	matrix metallopeptidase 13	Mus musculus	134-140
11168841-1	2001	The effects of cycloheximide and actinomycin on 8-bromo-cAMP (8-Br-cAMP) stimulated vasopressin and oxytocin release from the posterior pituitary and vasopressin mRNA content of the supraoptic nucleus were studied with perifused explants of the hypothalamo-neurohypophyseal system.	Cycloheximide	15-28	arginine vasopressin	Homo sapiens	84-95
11168841-1	2001	The effects of cycloheximide and actinomycin on 8-bromo-cAMP (8-Br-cAMP) stimulated vasopressin and oxytocin release from the posterior pituitary and vasopressin mRNA content of the supraoptic nucleus were studied with perifused explants of the hypothalamo-neurohypophyseal system.	Cycloheximide	15-28	arginine vasopressin	Homo sapiens	150-161
11093178-7	2001	The MDM, but not the PMN elicited radiolabel release, was inhibited by the protein synthesis inhibitor cycloheximide, as was the increase in PNB activity.	Cycloheximide	103-116	secreted LY6/PLAUR domain containing 1	Homo sapiens	4-7
11168841-8	2001	Since the posterior pituitary hormone stores are not depleted with a stimulus for release that is even more potent than cAMP, it is possible that cycloheximide and actinomycin depleted smaller pools of the peptides such as those responsible for intranuclear vasopressin and oxytocin release.	Cycloheximide	146-159	arginine vasopressin	Homo sapiens	258-269
11168841-4	2001	Vasopressin mRNA content was not changed by 8-Br-cAMP in the absence or presence of cycloheximide, but it was significantly decreased by simultaneous exposure to 8-Br-cAMP and actinomycin.	Cycloheximide	84-97	arginine vasopressin	Homo sapiens	0-11
11162606-1	2001	While MCF-7 and BT-20 cells were responsive to TNF without any metabolic inhibitors, CAMA-1 and SKBR-3 cells responded to TNF in the presence of cycloheximide; MDA-MB-231 and Hs578t cells were resistant to TNF even in the presence of cycloheximide.	Cycloheximide	145-158	tumor necrosis factor	Homo sapiens	122-125
11162606-1	2001	While MCF-7 and BT-20 cells were responsive to TNF without any metabolic inhibitors, CAMA-1 and SKBR-3 cells responded to TNF in the presence of cycloheximide; MDA-MB-231 and Hs578t cells were resistant to TNF even in the presence of cycloheximide.	Cycloheximide	145-158	tumor necrosis factor	Homo sapiens	122-125
11162595-3	2001	The increase in ET-1 peptide was inhibited by cycloheximide or actinomycin D whereas only cycloheximide decreased basal ET-1 release.	Cycloheximide	46-59	endothelin 1	Bos taurus	16-20
11162606-1	2001	While MCF-7 and BT-20 cells were responsive to TNF without any metabolic inhibitors, CAMA-1 and SKBR-3 cells responded to TNF in the presence of cycloheximide; MDA-MB-231 and Hs578t cells were resistant to TNF even in the presence of cycloheximide.	Cycloheximide	234-247	tumor necrosis factor	Homo sapiens	122-125
11162595-3	2001	The increase in ET-1 peptide was inhibited by cycloheximide or actinomycin D whereas only cycloheximide decreased basal ET-1 release.	Cycloheximide	90-103	endothelin 1	Bos taurus	120-124
11162606-1	2001	While MCF-7 and BT-20 cells were responsive to TNF without any metabolic inhibitors, CAMA-1 and SKBR-3 cells responded to TNF in the presence of cycloheximide; MDA-MB-231 and Hs578t cells were resistant to TNF even in the presence of cycloheximide.	Cycloheximide	234-247	tumor necrosis factor	Homo sapiens	122-125
11162606-2	2001	Bisindolylmaleimide (BIM), an inhibitor of PKC, either alone (MCF-7 and BT-20) or in combination with cycloheximide enhanced sensitivity of these cells to TNF.	Cycloheximide	102-115	tumor necrosis factor	Homo sapiens	155-158
11299730-3	2001	Co-treatment of these cells with actinomycin D or cycloheximide enhances TNF-alpha induced apoptosis, suggesting that some TNF-alpha-derived signals can augment apoptosis.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	73-82
11212279-6	2001	Up-regulation of DR4 and DR5 was not preceded by the induction of their mRNA levels but was inhibited by cotreatment with cycloheximide.	Cycloheximide	122-135	TNF receptor superfamily member 10a	Homo sapiens	17-20
11212279-6	2001	Up-regulation of DR4 and DR5 was not preceded by the induction of their mRNA levels but was inhibited by cotreatment with cycloheximide.	Cycloheximide	122-135	TNF receptor superfamily member 10b	Homo sapiens	25-28
11120970-2	2001	The JGCDR1 and JGCaMDR1 yeasts demonstrated markedly diminished susceptibility to the azole antifungals, terbinafine and cycloheximide, while that to amphotericin B was unchanged.	Cycloheximide	121-134	GTPase-activating protein MDR1	Saccharomyces cerevisiae S288C	15-23
11299730-3	2001	Co-treatment of these cells with actinomycin D or cycloheximide enhances TNF-alpha induced apoptosis, suggesting that some TNF-alpha-derived signals can augment apoptosis.	Cycloheximide	50-63	tumor necrosis factor	Homo sapiens	123-132
11120603-7	2001	CDC2 kinase activation was inhibited by cycloheximide.	Cycloheximide	40-53	cyclin dependent kinase 1	Homo sapiens	0-4
11196194-5	2001	Heregulin-beta1 also induced the expression of uPAR mRNA and protein in an actinomycin D-sensitive manner and cycloheximide superinduced the uPAR mRNA.	Cycloheximide	110-123	plasminogen activator, urokinase receptor	Homo sapiens	141-145
11748914-2	2001	The effect of TNF-alpha-induced apoptosis was exacerbated by the hypoxanthine-xanthine oxidase (HX/XO) system and cycloheximide (CHX), but alleviated by superoxide dismutase (SOD), suggesting that TNF-alpha-induced apoptosis may be due to oxidative stress, and independent of protein synthesis.	Cycloheximide	114-127	tumor necrosis factor	Homo sapiens	14-23
11748914-2	2001	The effect of TNF-alpha-induced apoptosis was exacerbated by the hypoxanthine-xanthine oxidase (HX/XO) system and cycloheximide (CHX), but alleviated by superoxide dismutase (SOD), suggesting that TNF-alpha-induced apoptosis may be due to oxidative stress, and independent of protein synthesis.	Cycloheximide	129-132	tumor necrosis factor	Homo sapiens	14-23
11145587-7	2001	Both actinomycin and cycloheximide prevented the IL-6 induction of IGFBP-4 mRNA suggesting that the IL-6 effect on IGFBP-4 gene occurs probably at the transcriptional level and needs an ongoing protein synthesis.	Cycloheximide	21-34	interleukin 6	Rattus norvegicus	49-53
11145587-7	2001	Both actinomycin and cycloheximide prevented the IL-6 induction of IGFBP-4 mRNA suggesting that the IL-6 effect on IGFBP-4 gene occurs probably at the transcriptional level and needs an ongoing protein synthesis.	Cycloheximide	21-34	insulin-like growth factor binding protein 4	Rattus norvegicus	67-74
11145587-7	2001	Both actinomycin and cycloheximide prevented the IL-6 induction of IGFBP-4 mRNA suggesting that the IL-6 effect on IGFBP-4 gene occurs probably at the transcriptional level and needs an ongoing protein synthesis.	Cycloheximide	21-34	interleukin 6	Rattus norvegicus	100-104
11145587-7	2001	Both actinomycin and cycloheximide prevented the IL-6 induction of IGFBP-4 mRNA suggesting that the IL-6 effect on IGFBP-4 gene occurs probably at the transcriptional level and needs an ongoing protein synthesis.	Cycloheximide	21-34	insulin-like growth factor binding protein 4	Rattus norvegicus	115-122
11235918-8	2001	In NR3 cells, alterations in ODC and in SAMDC gene expression was an event requiring de novo protein synthesis, whereas in highly malignant C2 cells, protein synthesis inhibition following cycloheximide treatment in cooperation with PMA resulted in an augmentation of both ODC and SAMDC gene expression.	Cycloheximide	189-202	ornithine decarboxylase, structural 1	Mus musculus	273-276
11235918-8	2001	In NR3 cells, alterations in ODC and in SAMDC gene expression was an event requiring de novo protein synthesis, whereas in highly malignant C2 cells, protein synthesis inhibition following cycloheximide treatment in cooperation with PMA resulted in an augmentation of both ODC and SAMDC gene expression.	Cycloheximide	189-202	S-adenosylmethionine decarboxylase 1	Mus musculus	281-286
11448101-6	2001	HMBA induces c-fos and represses cycloheximide-induced c-jun and fra-1 expression.	Cycloheximide	33-46	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
11448101-6	2001	HMBA induces c-fos and represses cycloheximide-induced c-jun and fra-1 expression.	Cycloheximide	33-46	FOS like 1, AP-1 transcription factor subunit	Homo sapiens	65-70
11525244-5	2001	The use of cycloheximide to inhibit protein synthesis revealed that in comparison to MCF-7 cells cultured at 37 degrees C, those exposed to heat stress (42 degrees C for 3 hours) displayed an elevated rate of degradation of both CyP40 and FKBP52 proteins.	Cycloheximide	11-24	peptidylprolyl isomerase D	Homo sapiens	229-234
11120603-8	2001	Furthermore, cycloheximide inhibited activation of CDK2:cyclin A, which normally precedes CDC2 kinase activation in caffeine-treated cells.	Cycloheximide	13-26	cyclin dependent kinase 2	Homo sapiens	51-55
11120603-8	2001	Furthermore, cycloheximide inhibited activation of CDK2:cyclin A, which normally precedes CDC2 kinase activation in caffeine-treated cells.	Cycloheximide	13-26	cyclin A2	Homo sapiens	56-64
11120603-8	2001	Furthermore, cycloheximide inhibited activation of CDK2:cyclin A, which normally precedes CDC2 kinase activation in caffeine-treated cells.	Cycloheximide	13-26	cyclin dependent kinase 1	Homo sapiens	90-94
11455586-7	2001	Furthermore, cycloheximide treatment of malignant C3 cells resulted in elevated SAMDC mRNA levels.	Cycloheximide	13-26	S-adenosylmethionine decarboxylase 1	Mus musculus	80-85
11329613-7	2001	Actually, cycloheximide alone was able to induce hepatoma cell BEL7404 to death that could also be inhibited by over-expressing Bcl-2.	Cycloheximide	10-23	BCL2 apoptosis regulator	Homo sapiens	128-133
11455586-8	2001	Treatment of malignant C3 cells with both cycloheximide and forskolin together resulted in a further additive elevation in SAMDC message levels.	Cycloheximide	42-55	S-adenosylmethionine decarboxylase 1	Mus musculus	123-128
11455586-9	2001	Cycloheximide treatment alone was found to affect the half-life of SAMDC mRNA through a mechanism of post-transcriptional stabilization.	Cycloheximide	0-13	S-adenosylmethionine decarboxylase 1	Mus musculus	67-72
11309649-6	2001	Treatment with either actinomycin D (Act D;10 :g/ml) or cycloheximide (CHX; 10 :g/ml) decreased FLIP expression levels in all three cell lines.	Cycloheximide	56-69	visual system homeobox 2	Homo sapiens	71-78
11329625-8	2001	Treatment of osteoblast cultures with cycloheximide markedly reduces the level of cIF2 message indicating that novel protein synthesis is required for its expression.	Cycloheximide	38-51	eukaryotic translation initiation factor 5B	Gallus gallus	82-86
11139773-3	2001	The induction of 3betaHSD II mRNA did not occur until 6 h after the growth factor treatment and was completely abolished in the presence of a protein synthesis inhibitor, cycloheximide (CHX), suggesting that the induction required de novo protein synthesis.	Cycloheximide	171-184	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	Homo sapiens	17-28
11139773-3	2001	The induction of 3betaHSD II mRNA did not occur until 6 h after the growth factor treatment and was completely abolished in the presence of a protein synthesis inhibitor, cycloheximide (CHX), suggesting that the induction required de novo protein synthesis.	Cycloheximide	186-189	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	Homo sapiens	17-28
11139773-7	2001	The PD98059-mediated induction of the 3betaHSD II mRNA was completely blocked by the CHX treatment.	Cycloheximide	85-88	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	Homo sapiens	38-49
11500944-6	2001	Inhibition of protein synthesis by cycloheximide depleted the cells from leptin, but not from angiotensinogen for up to 6 h. Insulin increased leptin secretion (+75%) and cell content (+70 %), without affecting angiotensinogen.	Cycloheximide	35-48	leptin	Rattus norvegicus	73-79
11500944-8	2001	The presence of brefeldin A led to a specific rise in leptin cell content, an effect inhibited by cycloheximide and enhanced by insulin (+80%).	Cycloheximide	98-111	leptin	Rattus norvegicus	54-60
11216854-5	2001	In this study, the protein synthesis inhibitor cycloheximide was used as a tool to understand Pgp gene expression and regulation in animal tissues.	Cycloheximide	47-60	ATP binding cassette subfamily B member 1	Homo sapiens	94-97
11204269-8	2001	Tracking a bolus of TNF-alpha over time in cycloheximide-treated cells confirmed that uncleaved TNF-alpha is first transported to the cell surface and subsequently endocytosed.	Cycloheximide	43-56	tumor necrosis factor	Mus musculus	20-29
11204269-8	2001	Tracking a bolus of TNF-alpha over time in cycloheximide-treated cells confirmed that uncleaved TNF-alpha is first transported to the cell surface and subsequently endocytosed.	Cycloheximide	43-56	tumor necrosis factor	Mus musculus	96-105
11216854-0	2001	Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated.	Cycloheximide	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	13-27
11216854-7	2001	The results showed that cycloheximide significantly induced class II Pgp expression in all tissues examined.	Cycloheximide	24-37	ATP binding cassette subfamily B member 1	Homo sapiens	69-72
11216854-0	2001	Induction of P-glycoprotein mRNA transcripts by cycloheximide in animal tissues: evidence that class I Pgp is transcriptionally regulated whereas class II Pgp is post-transcriptionally regulated.	Cycloheximide	48-61	ATP binding cassette subfamily B member 1	Homo sapiens	103-106
11216854-9	2001	In contrast, the relatively modest increase in class I Pgp expression by cycloheximide was found to be mainly due to increased transcriptional activity.	Cycloheximide	73-86	ATP binding cassette subfamily B member 1	Homo sapiens	55-58
11216854-10	2001	On the other hand, cycloheximide induced class III Pgp expression in some tissues while caused decay of class III Pgp mRNA in other tissues.	Cycloheximide	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	51-54
11216854-10	2001	On the other hand, cycloheximide induced class III Pgp expression in some tissues while caused decay of class III Pgp mRNA in other tissues.	Cycloheximide	19-32	ATP binding cassette subfamily B member 1	Homo sapiens	114-117
11216854-11	2001	The transcriptional and post-transcriptional mechanisms exerted by cycloheximide on Pgp genes are discussed.	Cycloheximide	67-80	ATP binding cassette subfamily B member 1	Homo sapiens	84-87
12053189-1	2001	To explore the role of FAK in TNF-alpha/cycloheximide-induced apoptos is of human hepatocellular carcinoma cell line SMMC-7721, the FAK antisense plasmid was constructed and transfected into SMMC-7721 cells.	Cycloheximide	40-53	protein tyrosine kinase 2	Homo sapiens	23-26
12053189-0	2001	Role of FAK in TNF-alpha/Cycloheximide-induced Apoptosis of SMMC-7721 Cells.	Cycloheximide	25-38	protein tyrosine kinase 2	Homo sapiens	8-11
12053189-5	2001	PKB was decreased during TNF-alpha/cycloheximide-induced apoptosis.	Cycloheximide	35-48	AKT serine/threonine kinase 1	Homo sapiens	0-3
12053189-1	2001	To explore the role of FAK in TNF-alpha/cycloheximide-induced apoptos is of human hepatocellular carcinoma cell line SMMC-7721, the FAK antisense plasmid was constructed and transfected into SMMC-7721 cells.	Cycloheximide	40-53	protein tyrosine kinase 2	Homo sapiens	132-135
12053189-7	2001	When FAK was 60% reduced as a result of the transfection of SMMC-7721 cells with FAK antisense construct, the percentage of TNF-alpha/cycloheximide-induced apoptosis was enhanced at lower dose of TNF-alpha but decreased at higher dose of TNF-alpha, compared with the control.	Cycloheximide	134-147	protein tyrosine kinase 2	Homo sapiens	5-8
12053189-7	2001	When FAK was 60% reduced as a result of the transfection of SMMC-7721 cells with FAK antisense construct, the percentage of TNF-alpha/cycloheximide-induced apoptosis was enhanced at lower dose of TNF-alpha but decreased at higher dose of TNF-alpha, compared with the control.	Cycloheximide	134-147	protein tyrosine kinase 2	Homo sapiens	81-84
12053189-7	2001	When FAK was 60% reduced as a result of the transfection of SMMC-7721 cells with FAK antisense construct, the percentage of TNF-alpha/cycloheximide-induced apoptosis was enhanced at lower dose of TNF-alpha but decreased at higher dose of TNF-alpha, compared with the control.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	124-133
12053189-7	2001	When FAK was 60% reduced as a result of the transfection of SMMC-7721 cells with FAK antisense construct, the percentage of TNF-alpha/cycloheximide-induced apoptosis was enhanced at lower dose of TNF-alpha but decreased at higher dose of TNF-alpha, compared with the control.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	196-205
11204570-4	2001	The LPS-induced expression of VEGF was inhibited by cycloheximide pretreatment, which suggested that synthesis of certain factor(s) is required for the LPS activity.	Cycloheximide	52-65	vascular endothelial growth factor A	Homo sapiens	30-34
12053189-7	2001	When FAK was 60% reduced as a result of the transfection of SMMC-7721 cells with FAK antisense construct, the percentage of TNF-alpha/cycloheximide-induced apoptosis was enhanced at lower dose of TNF-alpha but decreased at higher dose of TNF-alpha, compared with the control.	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	196-205
12053189-9	2001	Therefore, FAK regulated TNF-alpha/cycloheximide-induced apoptosis in a biphase manner.	Cycloheximide	35-48	protein tyrosine kinase 2	Homo sapiens	11-14
12053189-9	2001	Therefore, FAK regulated TNF-alpha/cycloheximide-induced apoptosis in a biphase manner.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	25-34
11018038-5	2000	TGF-beta1 treatment in conjunction with actinomycin D or cycloheximide demonstrated that induction of HO-1 mRNA requires de novo transcription and, in part, protein synthesis.	Cycloheximide	57-70	heme oxygenase 1	Homo sapiens	102-106
11106802-0	2000	Intravenous injection of cycloheximide induces apoptosis and up-regulates p53 and Fas receptor expression in the rat liver in vivo.	Cycloheximide	25-38	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	74-77
11016947-6	2000	Induction of apoptosis in HeLa cells by tumor necrosis factor alpha plus cycloheximide evoked the conversion of full-length epitope-tagged PKCzeta to two catalytic domain polypeptides and increased PKCzeta activity.	Cycloheximide	73-86	protein kinase C zeta	Homo sapiens	139-146
11016947-6	2000	Induction of apoptosis in HeLa cells by tumor necrosis factor alpha plus cycloheximide evoked the conversion of full-length epitope-tagged PKCzeta to two catalytic domain polypeptides and increased PKCzeta activity.	Cycloheximide	73-86	protein kinase C zeta	Homo sapiens	198-205
11106802-0	2000	Intravenous injection of cycloheximide induces apoptosis and up-regulates p53 and Fas receptor expression in the rat liver in vivo.	Cycloheximide	25-38	Fas cell surface death receptor	Rattus norvegicus	82-94
11106802-7	2000	Rats injected with a single intravenous dose of CHX, however, provide a simple and useful model for investigating the apoptotic machinery and the molecular mechanism of transcriptional up-regulation of p53 and Fas receptor in hepatocytes.	Cycloheximide	48-51	Wistar clone pR53P1 p53 pseudogene	Rattus norvegicus	202-205
11106802-7	2000	Rats injected with a single intravenous dose of CHX, however, provide a simple and useful model for investigating the apoptotic machinery and the molecular mechanism of transcriptional up-regulation of p53 and Fas receptor in hepatocytes.	Cycloheximide	48-51	Fas cell surface death receptor	Rattus norvegicus	210-222
11226825-5	2000	Use of cycloheximide to block protein synthesis strongly induced c-jun mRNA, suggesting that there had been relief from a labile protein repressor of transcription.	Cycloheximide	7-20	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	65-70
11226825-7	2000	The high induction by cycloheximide obscured simple interpretation of elevated c-jun mRNA levels after concomitant administration of cycloheximide and dexamethasone.	Cycloheximide	22-35	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	79-84
11226825-7	2000	The high induction by cycloheximide obscured simple interpretation of elevated c-jun mRNA levels after concomitant administration of cycloheximide and dexamethasone.	Cycloheximide	133-146	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	79-84
11077046-3	2000	Here we report that these cells can be rendered sensitive to TNFalpha killing by treatment with the translational inhibitor cycloheximide, suggesting the existence of proteins that can suppress the death stimulus induced by the cytokine.	Cycloheximide	124-137	tumor necrosis factor	Homo sapiens	61-69
11095735-3	2000	Members of the Mnn9p-containing complexes were incorporated into COPII vesicles made in vitro from endoplasmic reticulum (ER) membranes isolated from cycloheximide-treated cells.	Cycloheximide	150-163	mannosyltransferase complex subunit MNN9	Saccharomyces cerevisiae S288C	15-20
11076803-3	2000	Sepharose-immobilized IL-8 stimulated a sevenfold increase in IL-8 production within 2 h. IL-8 induced the expression of its own message, and IL-8 biosynthesis was inhibited by cycloheximide and actinomycin D, indicating de novo RNA and protein synthesis.	Cycloheximide	177-190	C-X-C motif chemokine ligand 8	Homo sapiens	22-26
11076803-3	2000	Sepharose-immobilized IL-8 stimulated a sevenfold increase in IL-8 production within 2 h. IL-8 induced the expression of its own message, and IL-8 biosynthesis was inhibited by cycloheximide and actinomycin D, indicating de novo RNA and protein synthesis.	Cycloheximide	177-190	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
11076803-3	2000	Sepharose-immobilized IL-8 stimulated a sevenfold increase in IL-8 production within 2 h. IL-8 induced the expression of its own message, and IL-8 biosynthesis was inhibited by cycloheximide and actinomycin D, indicating de novo RNA and protein synthesis.	Cycloheximide	177-190	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
11076803-3	2000	Sepharose-immobilized IL-8 stimulated a sevenfold increase in IL-8 production within 2 h. IL-8 induced the expression of its own message, and IL-8 biosynthesis was inhibited by cycloheximide and actinomycin D, indicating de novo RNA and protein synthesis.	Cycloheximide	177-190	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
11112151-5	2000	Treatment with cycloheximide to inhibit translation, and with dexamethasone or actinomycin D to inhibit transcription, linked the effect of PGE(2) to the transcriptional level of COX-2 mRNA rather than to a potential effect on protein and/or mRNA stabilization.	Cycloheximide	15-28	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	179-184
11124986-9	2000	Because reduction of NADE expression with cycloheximide or NADE antisense oligonucleotides attenuated zinc-induced neuronal death, NADE appears to contribute to p75(NTR)-induced cortical neuronal death as shown in other cells.	Cycloheximide	42-55	brain expressed X-linked 3	Rattus norvegicus	21-25
11187905-7	2000	Furthermore, protein synthesis inhibition by cycloheximide restored sensitivity to CD95-mediated apoptosis and allowed activation of both caspase-8 and caspase-3 in BR97 cells.	Cycloheximide	45-58	Fas cell surface death receptor	Homo sapiens	83-87
11122013-8	2000	Co-incubation with metabolic inhibitors, actinomycin D and cycloheximide, revealed that the early induction of TGF-beta1 mRNA by 1,25(OH)2D3 is dependent on de novo RNA synthesis, but not on RNA stabilization or protein synthesis.	Cycloheximide	59-72	transforming growth factor beta 1	Homo sapiens	111-120
11122185-6	2000	Genomic protein synthesis, sodium-hydrogen exchanger (NHE) and protein kinase C (PKC) activity were inhibited with cycloheximide, ethylisopropylamiloride and chelerythrine chloride respectively.	Cycloheximide	115-128	solute carrier family 9 member C1	Homo sapiens	54-57
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-114
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	115-119
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	146-149
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	35-48	cyclin dependent kinase inhibitor 1A	Homo sapiens	150-154
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	35-48	tumor necrosis factor	Homo sapiens	163-172
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	50-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	111-114
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	50-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	115-119
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	50-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	146-149
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	50-53	cyclin dependent kinase inhibitor 1A	Homo sapiens	150-154
11097743-4	2000	Further experiments suggested that cycloheximide (CHX), a protein synthesis inhibitor, increased the levels of p21(WAF1)mRNA and the induction of p21(WAF1)mRNA by TNF-alpha did not require new protein synthesis.	Cycloheximide	50-53	tumor necrosis factor	Homo sapiens	163-172
11191208-4	2000	After in vitro mutagenesis of the PDR3 gene six single amino acid substitutions were identified and resulted in resistance to cycloheximide, sulfomethuron methyl, 4-nitroquinoline oxide, fluconazole, mucidin, chloramphenicol and oligomycin.	Cycloheximide	126-139	drug-responsive transcription factor PDR3	Saccharomyces cerevisiae S288C	34-38
11108276-4	2000	Interestingly, ET-1 stimulated 2-DOG uptake at 6 h, not at 20 min, was almost completely blocked by the protein-synthesis inhibitor, cycloheximide and the RNA-synthesis inhibitor, actinomycin D, suggesting that the short-term (20 min) and long-term (6 h) effects of ET-1 involve distinct mechanisms.	Cycloheximide	133-146	endothelin 1	Canis lupus familiaris	15-19
11080176-6	2000	Inhibition of translation with cycloheximide did not stabilize GLT-1 but partially attenuated the degradation of GLAST mRNA.	Cycloheximide	31-44	solute carrier family 1 member 3	Homo sapiens	113-118
11080184-8	2000	The present study demonstrates that cortical neurons exposed to haloperidol undergo apoptosis depending on activation of p38 mitogen-activated protein kinase and c-Jun-NH(2)-terminal protein kinase sensitive to cycloheximide and insulin.	Cycloheximide	211-224	mitogen-activated protein kinase 14	Homo sapiens	121-124
11187905-7	2000	Furthermore, protein synthesis inhibition by cycloheximide restored sensitivity to CD95-mediated apoptosis and allowed activation of both caspase-8 and caspase-3 in BR97 cells.	Cycloheximide	45-58	caspase 8	Homo sapiens	138-147
11187905-7	2000	Furthermore, protein synthesis inhibition by cycloheximide restored sensitivity to CD95-mediated apoptosis and allowed activation of both caspase-8 and caspase-3 in BR97 cells.	Cycloheximide	45-58	caspase 3	Homo sapiens	152-161
11138844-5	2000	Cycloheximide inhibited TGF-beta1-mediated reduction of beta2-adrenoceptor mRNA and protein, whilst alone caused induction of beta2-adrenoceptor mRNA without any effect on receptor number.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	24-33
11093754-7	2000	The effect of NOC-18 on HIF-1 activity was blocked by cycloheximide, consistent with a post-transcriptional effect.	Cycloheximide	54-67	hypoxia inducible factor 1 subunit alpha	Homo sapiens	24-29
11074007-5	2000	We demonstrated that HRG stimulation of human breast cancer cells and normal breast epithelial cells induces the expression of Rab3A protein and mRNA in a cycloheximide-independent manner.	Cycloheximide	155-168	RAB3A, member RAS oncogene family	Homo sapiens	127-132
11138844-5	2000	Cycloheximide inhibited TGF-beta1-mediated reduction of beta2-adrenoceptor mRNA and protein, whilst alone caused induction of beta2-adrenoceptor mRNA without any effect on receptor number.	Cycloheximide	0-13	adrenoceptor beta 2	Homo sapiens	56-74
11058790-7	2000	Cycloheximide abolished only the GFAP response to ethanol.	Cycloheximide	0-13	glial fibrillary acidic protein	Homo sapiens	33-37
11202433-1	2000	Cycloheximide, an inhibitor of cytoplasmic translation, induced a rapid reduction of 70-80% in levels of mRNA for the chloroplast elongation factor Tu (tufA) in asynchronously growing Chlamydomonas.	Cycloheximide	0-13	eukaryotic translation elongation factor 1 alpha 1	Homo sapiens	130-150
11202433-3	2000	Confirmatory evidence that the inhibition of chloroplast transcription was mainly due to blocking cytoplasmic translation was obtained with the cycloheximide-resistant mutant act1, and by using another translation inhibitor, anisomycin.	Cycloheximide	144-157	TRAF3 interacting protein 2	Homo sapiens	175-179
10964918-5	2000	Cycloheximide inhibited the sterol-stimulated degradation of HMGR concomitantly with a marked reduction in polyubiquitination of the enzyme.	Cycloheximide	0-13	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	61-65
11045978-7	2000	Cycloheximide inhibited the increase in HO-1 mRNA in response to hemin.	Cycloheximide	0-13	heme oxygenase 1	Rattus norvegicus	40-44
11103799-6	2000	Treatment with cycloheximide indicated that ER directly controls GREB1 expression.	Cycloheximide	15-28	estrogen receptor 1	Homo sapiens	44-46
11103799-6	2000	Treatment with cycloheximide indicated that ER directly controls GREB1 expression.	Cycloheximide	15-28	growth regulating estrogen receptor binding 1	Homo sapiens	65-70
11067899-5	2000	The inhibitory effects of IFN-gamma/alpha on the IL-4R mRNA expression require a lag period of about 8 h, and are sensitive to cycloheximide treatment, which suggests that the suppressive effect of IFNs on IL-4R gene expression is a secondary response requiring de novo synthesis of IFN-induced factors.	Cycloheximide	127-140	interferon gamma	Homo sapiens	26-35
11067899-5	2000	The inhibitory effects of IFN-gamma/alpha on the IL-4R mRNA expression require a lag period of about 8 h, and are sensitive to cycloheximide treatment, which suggests that the suppressive effect of IFNs on IL-4R gene expression is a secondary response requiring de novo synthesis of IFN-induced factors.	Cycloheximide	127-140	interleukin 4 receptor	Homo sapiens	49-54
11067899-5	2000	The inhibitory effects of IFN-gamma/alpha on the IL-4R mRNA expression require a lag period of about 8 h, and are sensitive to cycloheximide treatment, which suggests that the suppressive effect of IFNs on IL-4R gene expression is a secondary response requiring de novo synthesis of IFN-induced factors.	Cycloheximide	127-140	interleukin 4 receptor	Homo sapiens	206-211
10930408-4	2000	Cyclic stretch induced an increase in vascular fibronectin mRNA levels that was inhibited by actinomycin D and CV11974, an angiotensin II type 1 receptor antagonist; cycloheximide and PD123319, an angiotensin II type 2 receptor antagonist, did not affect the induction.	Cycloheximide	166-179	fibronectin 1	Homo sapiens	47-58
11068016-3	2000	After pretreatment of neutrophils with cycloheximide or actinomycin D, TNF-alpha produced morphologically typical apoptosis in a time- and concentration-dependent manner.	Cycloheximide	39-52	tumor necrosis factor	Homo sapiens	71-80
11068016-5	2000	Caspase-3 activation by TNF-alpha was significantly enhanced by pretreatment with both cycloheximide and pyrrolidine dithiocarbamate.	Cycloheximide	87-100	caspase 3	Homo sapiens	0-9
11068016-5	2000	Caspase-3 activation by TNF-alpha was significantly enhanced by pretreatment with both cycloheximide and pyrrolidine dithiocarbamate.	Cycloheximide	87-100	tumor necrosis factor	Homo sapiens	24-33
11153595-7	2000	In addition, treatment of cells with cycloheximide, an inhibitor of protein synthesis, inhibited the NAC-mediated IL-1beta release.	Cycloheximide	37-50	X-linked Kx blood group	Homo sapiens	101-104
11153595-7	2000	In addition, treatment of cells with cycloheximide, an inhibitor of protein synthesis, inhibited the NAC-mediated IL-1beta release.	Cycloheximide	37-50	interleukin 1 beta	Homo sapiens	114-122
11032871-7	2000	Treatment with cycloheximide caused increases in adrenomedullin mRNA levels in both normoxic and hypoxic states, raising the possibility that some protein(s) may act as a suppressor of adrenomedullin gene expression in T98G cells.	Cycloheximide	15-28	adrenomedullin	Homo sapiens	49-63
11032871-7	2000	Treatment with cycloheximide caused increases in adrenomedullin mRNA levels in both normoxic and hypoxic states, raising the possibility that some protein(s) may act as a suppressor of adrenomedullin gene expression in T98G cells.	Cycloheximide	15-28	adrenomedullin	Homo sapiens	185-199
11120388-9	2000	CX prevented the effects of both RA and ethanol on GAP-43 mRNA.	Cycloheximide	0-2	growth associated protein 43	Homo sapiens	51-57
11032726-0	2000	E-73, an acetoxyl analogue of cycloheximide, blocks the tumor necrosis factor-induced NF-kappaB signaling pathway.	Cycloheximide	30-43	nuclear factor kappa B subunit 1	Homo sapiens	86-95
11120388-5	2000	With cycloheximide (CX), RA still stimulated RAR beta mRNA, but the effect of ethanol was abolished.	Cycloheximide	20-22	retinoic acid receptor beta	Homo sapiens	45-53
11225246-11	2000	The protein synthesis inhibitor cycloheximide inhibited the production of syndecan-1.	Cycloheximide	32-45	syndecan 1	Homo sapiens	74-84
11032726-2	2000	We have found that E-73, an acetoxyl analogue of cycloheximide, specifically blocks TNF-induced ICAM-1 expression even at concentrations unable to affect protein synthesis.	Cycloheximide	49-62	tumor necrosis factor	Homo sapiens	84-87
11032726-2	2000	We have found that E-73, an acetoxyl analogue of cycloheximide, specifically blocks TNF-induced ICAM-1 expression even at concentrations unable to affect protein synthesis.	Cycloheximide	49-62	intercellular adhesion molecule 1	Homo sapiens	96-102
11032726-3	2000	By contrast, cycloheximide inhibited both TNF- and IL-1-induced ICAM-1 expression primarily due to the blockage of protein synthesis.	Cycloheximide	13-26	tumor necrosis factor	Homo sapiens	42-45
11032726-3	2000	By contrast, cycloheximide inhibited both TNF- and IL-1-induced ICAM-1 expression primarily due to the blockage of protein synthesis.	Cycloheximide	13-26	intercellular adhesion molecule 1	Homo sapiens	64-70
11003574-8	2000	LXA(4)-induced TF activity was dose dependent, cycloheximide sensitive, and associated with increased TF mRNA levels.	Cycloheximide	47-60	coagulation factor III, tissue factor	Homo sapiens	15-17
11040356-3	2000	The stimulated prostaglandin E(2) production was abolished in the presence of indomethacin (1 microM) or cycloheximide (2 microM), suggesting that the increased production of prostaglandin E(2) by LPS reflects the inducible synthesis of prostaglandin E(2) by COX-2.	Cycloheximide	105-118	prostaglandin-endoperoxide synthase 2	Mus musculus	259-264
11001757-6	2000	Actinomycin D, cycloheximide, and thiocyanate abolished the PRL effect on NIS accumulation, whereas perchlorate was without effect.	Cycloheximide	15-28	prolactin	Mus musculus	60-63
11029375-6	2000	COX-2 messenger RNA was upregulated in LPS-treated lungs, and inhibition of transcription with actinomycin D or of protein biosynthesis with cycloheximide protected against LPS-induced VHR but not AHR.	Cycloheximide	141-154	toll-like receptor 4	Mus musculus	173-176
11014236-9	2000	Protein synthesis inhibition with cycloheximide markedly induced Rev-erbalpha mRNA levels; however, this induction was reduced by dexamethasone supplementation in both rat and human primary hepatocytes.	Cycloheximide	34-47	nuclear receptor subfamily 1, group D, member 1	Rattus norvegicus	65-77
11004677-10	2000	While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL.	Cycloheximide	57-70	TNF superfamily member 10	Homo sapiens	100-105
11004677-10	2000	While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL.	Cycloheximide	57-70	TNF superfamily member 10	Homo sapiens	109-114
11004677-10	2000	While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL.	Cycloheximide	57-70	TNF superfamily member 10	Homo sapiens	109-114
11004677-10	2000	While macromolecule synthesis inhibitors (actinomycin D, cycloheximide) augmented susceptibility to TRAIL in TRAIL-responsive cell lines, these agents did not render TRAIL-resistant cell lines susceptible to TRAIL.	Cycloheximide	57-70	TNF superfamily member 10	Homo sapiens	109-114
11093245-5	2000	Experiments with exogenous administration of Ec, cycloheximide, and actinomycin D suggest a complex interplay of factors affecting catalase expression.	Cycloheximide	49-62	Catalase	Drosophila melanogaster	131-139
11093245-6	2000	In cultured third instar larvae, superinduction of catalase occurred in the presence of both Ec and cycloheximide.	Cycloheximide	100-113	Catalase	Drosophila melanogaster	51-59
11036837-8	2000	During priming, PR3 mRNA appears in PMN at 2 h, peaks at 6 h, and has disappeared at 12 h. By comparison, in primed PBMC, PR3 mRNA appears at 6 h, peaks at 12 h, and disappears at 24 h. Immunoprecipitation of metabolically labeled PR3 revealed new synthesis of PR3 by both cell types, a process that was inhibited by cycloheximide.	Cycloheximide	317-330	proteinase 3	Homo sapiens	16-19
11002287-12	2000	Consistently with this hypothesis, a major pool of MAP1B HC is rapidly degraded after blocking protein synthesis with cycloheximide, whereas LC1 levels remain constant even after 24 hr of cycloheximide treatment.	Cycloheximide	118-131	microtubule-associated protein 1B	Rattus norvegicus	51-56
10987821-5	2000	Nevertheless, in all cases, induction of the GPDH gene requires adrenal steroids and new protein synthesis, as the induction was blocked in adrenalectomized rats and by cycloheximide treatment, respectively.	Cycloheximide	169-182	glycerol-3-phosphate dehydrogenase 1	Rattus norvegicus	45-49
11027537-6	2000	Cycloheximide prevented the OxLDL-induced augmentation in both p53 binding activity and intracellular level.	Cycloheximide	0-13	tumor protein p53	Homo sapiens	63-66
11015728-6	2000	yEGFP3- Cln2(PEST) had a markedly shorter half-life (t(1/2)) than yEGFP3; inhibition of protein synthesis with cycloheximide lead to a rapid decline in GFP content and fluorescence (t(1/2) approximately 30 min) in cells expressing yEGFP3-Cln2(PEST), whereas these parameters were quite stable in yEGFP3-expressing cells (t(1/2) approximately 7 h).	Cycloheximide	111-124	cyclin CLN2	Saccharomyces cerevisiae S288C	8-12
11015728-6	2000	yEGFP3- Cln2(PEST) had a markedly shorter half-life (t(1/2)) than yEGFP3; inhibition of protein synthesis with cycloheximide lead to a rapid decline in GFP content and fluorescence (t(1/2) approximately 30 min) in cells expressing yEGFP3-Cln2(PEST), whereas these parameters were quite stable in yEGFP3-expressing cells (t(1/2) approximately 7 h).	Cycloheximide	111-124	cyclin CLN2	Saccharomyces cerevisiae S288C	238-242
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Cycloheximide	16-29	cyclin dependent kinase 1	Homo sapiens	75-79
10956385-4	2000	The addition of cycloheximide inhibited the paclitaxel-induced increase in cdc2 protein level, further indicating that paclitaxel stimulates cdc2 synthesis.	Cycloheximide	16-29	cyclin dependent kinase 1	Homo sapiens	141-145
10975829-9	2000	Cycloheximide abrogated PAI-1 mRNA expression, suggesting that transcription of the PAI-1 gene requires de novo synthesis of early gene products, including transcription factors.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	24-29
10979965-8	2000	Secretion of IL-8 reached a plateau level in less than 24 hours, was inhibited by cycloheximide, and required the presence of HrHRF throughout the culture period.	Cycloheximide	82-95	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
10960843-9	2000	Cycloheximide and specific oligonucleotides to HSP 72 blocked the increased expression of HSP 72 and the resistance to apoptosis.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 1A	Homo sapiens	47-53
10960843-9	2000	Cycloheximide and specific oligonucleotides to HSP 72 blocked the increased expression of HSP 72 and the resistance to apoptosis.	Cycloheximide	0-13	heat shock protein family A (Hsp70) member 1A	Homo sapiens	90-96
10975829-9	2000	Cycloheximide abrogated PAI-1 mRNA expression, suggesting that transcription of the PAI-1 gene requires de novo synthesis of early gene products, including transcription factors.	Cycloheximide	0-13	serpin family E member 1	Homo sapiens	84-89
10998247-6	2000	To induce the cellular reactivity with apoA-I, the incubation with dBcAMP required at least 6 h. Actinomycin D, cycloheximide, puromycin, and brefeldin A suppressed both the induction of apoA-I-mediated lipid release and the apoA-I specific binding to the cells.	Cycloheximide	112-125	apolipoprotein A-I	Mus musculus	39-45
11018479-0	2000	GDP-fucose: beta-galactoside alpha1,2-fucosyltransferase, MFUT-II, and not MFUT-I or -III, is induced in a restricted region of the digestive tract of germ-free mice by host-microbe interactions and cycloheximide.	Cycloheximide	199-212	fucosyltransferase 1	Mus musculus	12-56
11018481-6	2000	Even greater effects on specificity of PtdSer synthesis, movement to CFMV and inhibition by z-VAD-fmk were observed in apoptotic cells induced by UV irradiation or tumor necrosis factor-alpha/cycloheximide treatment.	Cycloheximide	192-205	tumor necrosis factor	Homo sapiens	164-191
10998247-6	2000	To induce the cellular reactivity with apoA-I, the incubation with dBcAMP required at least 6 h. Actinomycin D, cycloheximide, puromycin, and brefeldin A suppressed both the induction of apoA-I-mediated lipid release and the apoA-I specific binding to the cells.	Cycloheximide	112-125	apolipoprotein A-I	Mus musculus	187-193
10998247-6	2000	To induce the cellular reactivity with apoA-I, the incubation with dBcAMP required at least 6 h. Actinomycin D, cycloheximide, puromycin, and brefeldin A suppressed both the induction of apoA-I-mediated lipid release and the apoA-I specific binding to the cells.	Cycloheximide	112-125	apolipoprotein A-I	Mus musculus	187-193
11054088-2	2000	Transient overexpression of HSP72 was achieved using an adenoviral vector (Advhsp72) and apoptosis was induced by heat shock, tumour necrosis factor (TNF)-alpha with cycloheximide (CHX), lipopolysaccharide (LPS) with TNF-alpha and verocytotoxin (VT).	Cycloheximide	181-184	heat shock protein family A (Hsp70) member 1A	Homo sapiens	28-33
11131645-6	2000	Furthermore, our data explained why application of low concentrations of cycloheximide can sensitize cells for apoptosis induction by TNF-alpha.	Cycloheximide	73-86	tumor necrosis factor	Homo sapiens	134-143
10960082-4	2000	The stimulatory action of IL-1beta on PGE(2) production was totally abolished by NS-398, a specific inhibitor of cyclo-oxygenase-2 activity, as well as by the protein synthesis inhibitor cycloheximide, and the glucocorticoid dexamethasone.	Cycloheximide	187-200	interleukin 1 beta	Mus musculus	26-34
10969831-3	2000	To directly test this hypothesis, we examined the effects of 2 substances-brefeldin A (BFA) and cycloheximide (CHX)-that are predicted to selectively block constitutive secretion on the release of IAPP-like immunoreactivity (IAPP-LI) and immunoreactive insulin (IRI) from neonatal rat islet cell monolayer cultures.	Cycloheximide	96-109	islet amyloid polypeptide	Rattus norvegicus	197-201
10971474-8	2000	The mechanisms which regulate COX-2 mRNA expression were studied using inhibitors of translation (Actinomycin D) and transcription (Cicloheximide).	Cycloheximide	132-145	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	30-35
11054088-2	2000	Transient overexpression of HSP72 was achieved using an adenoviral vector (Advhsp72) and apoptosis was induced by heat shock, tumour necrosis factor (TNF)-alpha with cycloheximide (CHX), lipopolysaccharide (LPS) with TNF-alpha and verocytotoxin (VT).	Cycloheximide	166-179	heat shock protein family A (Hsp70) member 1A	Homo sapiens	28-33
10969831-3	2000	To directly test this hypothesis, we examined the effects of 2 substances-brefeldin A (BFA) and cycloheximide (CHX)-that are predicted to selectively block constitutive secretion on the release of IAPP-like immunoreactivity (IAPP-LI) and immunoreactive insulin (IRI) from neonatal rat islet cell monolayer cultures.	Cycloheximide	111-114	islet amyloid polypeptide	Rattus norvegicus	197-201
11043401-5	2000	Moreover, the induction of MMP-1, MMP-3 and MMP-9 mRNA expression was observed in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	98-111	matrix metallopeptidase 1	Homo sapiens	27-32
11043401-5	2000	Moreover, the induction of MMP-1, MMP-3 and MMP-9 mRNA expression was observed in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	98-111	matrix metallopeptidase 3	Homo sapiens	34-39
11043401-5	2000	Moreover, the induction of MMP-1, MMP-3 and MMP-9 mRNA expression was observed in the presence of cycloheximide, an inhibitor of protein synthesis.	Cycloheximide	98-111	matrix metallopeptidase 9	Homo sapiens	44-49
10954422-12	2000	The ratio of the two splice variants of CLK1 can be altered by treatment with cycloheximide.	Cycloheximide	78-91	CDC-like kinase 1	Rattus norvegicus	40-44
10956420-6	2000	The cytochrome C release was completely blocked by the addition of cycloheximide or actinomycin D.	Cycloheximide	67-80	cytochrome c, somatic	Homo sapiens	4-16
11035283-15	2000	Treatment with cycloheximide produced dose-dependent inhibition of the ability of IL-1 to up-regulate IL-6 transcripts; the maximal inhibitory effect was 89%.	Cycloheximide	15-28	interleukin 6	Rattus norvegicus	102-106
10964761-6	2000	Cotreatment with PDTC and curcumin reduced particle-elicited IL-8 response, whereas cycloheximide caused enhancement of IL-8 mRNA expression in both the quartz- and TiO(2)-treated cells.	Cycloheximide	84-97	C-X-C motif chemokine ligand 8	Homo sapiens	120-124
10964681-2	2000	The translational blocker, cycloheximide, decreased the abundance of IGFBP-5 mRNA to undetectable levels, suggesting that IGFBP-5 mRNA integrity is linked to protein synthesis.	Cycloheximide	27-40	insulin-like growth factor binding protein 5	Rattus norvegicus	69-76
10980416-4	2000	The effects of PTH, which were abrogated by cycloheximide (28 microg/ml), did not alter the stability of the BSP mRNA.	Cycloheximide	44-57	parathyroid hormone	Rattus norvegicus	15-18
10942596-7	2000	The protein synthesis inhibitor, cycloheximide, also increased NPC1 mRNA levels, augmenting the progesterone-induced increase in NPC1 mRNA abundance.	Cycloheximide	33-46	NPC intracellular cholesterol transporter 1	Homo sapiens	63-67
10942596-7	2000	The protein synthesis inhibitor, cycloheximide, also increased NPC1 mRNA levels, augmenting the progesterone-induced increase in NPC1 mRNA abundance.	Cycloheximide	33-46	NPC intracellular cholesterol transporter 1	Homo sapiens	129-133
10942603-5	2000	Apoptosis of HL-60 cells was induced by DNA topoisomerase I inhibitor camptothecin (CPT) or tumor necrosis factor-alpha combined with cycloheximide (TNF-alpha + CHX).	Cycloheximide	134-147	tumor necrosis factor	Homo sapiens	149-158
10964681-2	2000	The translational blocker, cycloheximide, decreased the abundance of IGFBP-5 mRNA to undetectable levels, suggesting that IGFBP-5 mRNA integrity is linked to protein synthesis.	Cycloheximide	27-40	insulin-like growth factor binding protein 5	Rattus norvegicus	122-129
10964681-4	2000	Anisomycin, emetine, and puromycin abolished IGFBP-5 mRNA as seen with cycloheximide.	Cycloheximide	71-84	insulin-like growth factor binding protein 5	Rattus norvegicus	45-52
10964681-5	2000	Cycloheximide had a dose- and time-dependent effect on IGFBP-5 mRNA.	Cycloheximide	0-13	insulin-like growth factor binding protein 5	Rattus norvegicus	55-62
10964681-13	2000	This region binds RISM cytoplasmic proteins, and may mediate the dramatic effect of cycloheximide on IGFBP-5 abundance.	Cycloheximide	84-97	insulin-like growth factor binding protein 5	Rattus norvegicus	101-108
10931534-9	2000	In addition, cycloheximide worked synergistically with TRAIL/Apo-2L to induce apoptosis in glioma cells.	Cycloheximide	13-26	TNF superfamily member 10	Homo sapiens	61-67
10926555-6	2000	Inhibition of new protein synthesis by cycloheximide blocked the increase in Galpha(i-2) protein induced by TNF-alpha.	Cycloheximide	39-52	succinate-CoA ligase GDP/ADP-forming subunit alpha	Homo sapiens	77-87
10823821-1	2000	In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX).	Cycloheximide	202-215	nuclear factor kappa B subunit 1	Homo sapiens	65-74
10823821-1	2000	In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX).	Cycloheximide	202-215	TNF superfamily member 10	Homo sapiens	100-105
10823821-1	2000	In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX).	Cycloheximide	217-220	nuclear factor kappa B subunit 1	Homo sapiens	65-74
10823821-1	2000	In HeLa cells, induction of apoptosis and nuclear factor kappaB (NF-kappaB) activation initiated by TRAIL/Apo2L or the agonistic Apo1/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX).	Cycloheximide	217-220	TNF superfamily member 10	Homo sapiens	100-105
10945619-10	2000	One medullary carcinoma cell line was resistant to Fas-and TRAIL-induced apoptosis, even in the presence of cycloheximide, and to transfection of constitutively active caspase-8, suggesting a different regulation of the apoptotic pathway.	Cycloheximide	108-121	TNF superfamily member 10	Homo sapiens	59-64
10926555-6	2000	Inhibition of new protein synthesis by cycloheximide blocked the increase in Galpha(i-2) protein induced by TNF-alpha.	Cycloheximide	39-52	tumor necrosis factor	Homo sapiens	108-117
11265758-2	2000	In mammals, growth-dependent regulation of RNA polymerase I (Pol I) transcription is mediated by TIF-IA, an essential initiation factor that is active in extracts from growing but not starved or cycloheximide-treated mammalian cells.	Cycloheximide	195-208	RRN3 homolog, RNA polymerase I transcription factor	Homo sapiens	97-103
10955723-6	2000	The staurosporine-induced DNA ladder formation was accompanied by an increase in caspase-3 activity in both lines which, however, was considerably lower in Jurkat JM cells after gemcitabine or cycloheximide exposure.	Cycloheximide	193-206	caspase 3	Homo sapiens	81-90
10948078-8	2000	Pretreatment with cycloheximide superinduced cPLA(2) and PGHS-2 mRNA expression but almost completely inhibited PGHS-1.	Cycloheximide	18-31	phospholipase A2 group IVA	Homo sapiens	45-52
10896788-9	2000	Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts.	Cycloheximide	0-13	SMAD family member 3	Homo sapiens	42-47
10896788-9	2000	Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	100-109
10896788-9	2000	Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts.	Cycloheximide	0-13	SMAD family member 7	Homo sapiens	123-128
10896788-9	2000	Cycloheximide prevented the inhibition of Smad3, but not the induction of Smad7, mRNA expression by TGF-beta1, identifying Smad7 as an immediate-early gene target of TGF-beta in fibroblasts.	Cycloheximide	0-13	transforming growth factor beta 1	Homo sapiens	100-108
11126569-7	2000	Cycloheximide (at 35 microM) abolishes the increase of Mvp1, and L seeds are turned into E seeds, which develop normally when the inhibitor is applied for a short time during imbibition.	Cycloheximide	0-13	GDSL-like Lipase/Acylhydrolase superfamily protein	Arabidopsis thaliana	55-59
10948078-8	2000	Pretreatment with cycloheximide superinduced cPLA(2) and PGHS-2 mRNA expression but almost completely inhibited PGHS-1.	Cycloheximide	18-31	prostaglandin-endoperoxide synthase 2	Homo sapiens	57-63
10948078-8	2000	Pretreatment with cycloheximide superinduced cPLA(2) and PGHS-2 mRNA expression but almost completely inhibited PGHS-1.	Cycloheximide	18-31	prostaglandin-endoperoxide synthase 1	Homo sapiens	112-118
10948078-9	2000	Pretreatment with EGTA had effects similar to pretreatment with cycloheximide in the case of cPLA(2) and PGHS-1 but did not affect PGHS-2.	Cycloheximide	64-77	phospholipase A2 group IVA	Homo sapiens	93-100
10937564-2	2000	The aim of this study was to further investigate the mechanisms of IFNgamma-, Fas-, and cycloheximide (CHX)-induced programmed cell death, with special attention to the role of transcriptional factors NF-kappaB and STAT1.	Cycloheximide	103-106	nuclear factor kappa B subunit 1	Homo sapiens	201-210
10899924-6	2000	The BDNF-accelerated death of cortical neurons was inhibited by the addition of actinomycin D or cycloheximide.	Cycloheximide	97-110	brain derived neurotrophic factor	Homo sapiens	4-8
10936029-6	2000	The enhanced induction of CD154 following CD3 stimulation depended on protein synthesis, since was abolished when the cells were stimulated via CD3 in the presence of cycloheximide.	Cycloheximide	167-180	CD40 ligand	Homo sapiens	26-31
10937564-2	2000	The aim of this study was to further investigate the mechanisms of IFNgamma-, Fas-, and cycloheximide (CHX)-induced programmed cell death, with special attention to the role of transcriptional factors NF-kappaB and STAT1.	Cycloheximide	103-106	signal transducer and activator of transcription 1	Homo sapiens	215-220
10891489-7	2000	HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.	Cycloheximide	131-144	high mobility group AT-hook 1	Homo sapiens	0-7
10891489-7	2000	HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.	Cycloheximide	131-144	high mobility group AT-hook 1	Homo sapiens	162-169
10937564-14	2000	EMSA revealed that NF-kappaB was activated after IFNgamma and anti-Fas ab treatments and inhibited after CHX treatment.	Cycloheximide	105-108	nuclear factor kappa B subunit 1	Homo sapiens	19-28
10891489-7	2000	HMG-I/Y expression is stimulated by c-Myc in a Myc-estradiol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating that HMG-I/Y is a direct c-Myc target gene.	Cycloheximide	131-144	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	182-187
10937564-16	2000	STAT1-binding activity persisted after CHX treatment.	Cycloheximide	39-42	signal transducer and activator of transcription 1	Homo sapiens	0-5
10908304-6	2000	Moreover, the effect of dexamethasone on PXR mRNA accumulation seems to be through direct action on the glucocorticoid receptor (GR) because the addition of cycloheximide has no effect, and dexamethasone does not affect the degradation of PXR mRNA.	Cycloheximide	157-170	nuclear receptor subfamily 3 group C member 1	Homo sapiens	129-131
10947155-5	2000	Cycloheximide (10 microM) prevented the transcriptional down-regulation of Cox-2 mRNA and to a lesser extent, TNFalpha mRNA, in LPS-tolerant cells.	Cycloheximide	0-13	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	75-80
10947155-5	2000	Cycloheximide (10 microM) prevented the transcriptional down-regulation of Cox-2 mRNA and to a lesser extent, TNFalpha mRNA, in LPS-tolerant cells.	Cycloheximide	0-13	tumor necrosis factor	Homo sapiens	110-118
10947155-10	2000	However, cycloheximide augmented both Cox-2 and TNFalpha mRNA expression in this group.	Cycloheximide	9-22	tumor necrosis factor	Homo sapiens	48-56
10947155-10	2000	However, cycloheximide augmented both Cox-2 and TNFalpha mRNA expression in this group.	Cycloheximide	9-22	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	38-43
10989280-4	2000	Cycloheximide effect is additive to the tyrosine phosphatase inhibitor orthovanadate since these two stimuli induced sustained ERK activation respectively through inhibition of the translation and activity of MAPK phosphatase-1 (MKP-1).	Cycloheximide	0-13	mitogen-activated protein kinase 1	Mus musculus	127-130
10899001-8	2000	Altering segmental identity in embryos by perturbing the activity of Thylacine 1 and the Notch pathway, or by treatment with a protein synthesis inhibitor, cycloheximide, leads to the predicted changes in the segmental expression of PAPC.	Cycloheximide	156-169	protocadherin 8 S homeolog	Xenopus laevis	233-237
10961349-4	2000	By pretreating with cycloheximide prior to irradiation, we observed a decrease in the protein half-life, from 3.5 h to 53 min, suggesting that a decrease in protein half-life may cause the lower levels of BRCA1 after irradiation.	Cycloheximide	20-33	BRCA1 DNA repair associated	Homo sapiens	205-210
10924699-0	2000	Regulation of c-fos gene expression by lipopolysaccharide and cycloheximide in C6 rat glioma cells.	Cycloheximide	62-75	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	14-19
10924699-4	2000	Cycloheximide (CHX, 20 microM), a protein synthesis inhibitor, alone caused increases of c-fos and c-jun mRNA levels.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-94
10924699-4	2000	Cycloheximide (CHX, 20 microM), a protein synthesis inhibitor, alone caused increases of c-fos and c-jun mRNA levels.	Cycloheximide	15-18	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	89-94
10807932-9	2000	Treatment of cells with SB203580 after inhibition of transcription by actinomycin D decreased the half-life of IL-1beta-induced PDGF-Ralpha mRNA from &gt;4 to approximately 1.5 h. Moreover, pretreatment of cells with cycloheximide blocked induction of PDGF-Ralpha mRNA by IL-1beta, suggesting that de novo protein synthesis was required for PDGF-Ralpha mRNA stabilization.	Cycloheximide	217-230	interleukin 1 beta	Rattus norvegicus	111-119
10919673-3	2000	Here, we report that metabolic inhibitors such as cycloheximide (CHX) or actinomycin D (ActD) sensitize for CD95-induced apoptosis by strongly down-regulating FLIP and RIP expression.	Cycloheximide	50-63	Fas cell surface death receptor	Homo sapiens	108-112
10919673-3	2000	Here, we report that metabolic inhibitors such as cycloheximide (CHX) or actinomycin D (ActD) sensitize for CD95-induced apoptosis by strongly down-regulating FLIP and RIP expression.	Cycloheximide	50-63	receptor interacting serine/threonine kinase 1	Homo sapiens	168-171
10919673-3	2000	Here, we report that metabolic inhibitors such as cycloheximide (CHX) or actinomycin D (ActD) sensitize for CD95-induced apoptosis by strongly down-regulating FLIP and RIP expression.	Cycloheximide	65-68	Fas cell surface death receptor	Homo sapiens	108-112
10919673-3	2000	Here, we report that metabolic inhibitors such as cycloheximide (CHX) or actinomycin D (ActD) sensitize for CD95-induced apoptosis by strongly down-regulating FLIP and RIP expression.	Cycloheximide	65-68	receptor interacting serine/threonine kinase 1	Homo sapiens	168-171
10919673-9	2000	Pretreatment with CHX or ActD sensitized for subsequent CD95 stimulation compared with cells without pretreatment.	Cycloheximide	18-21	Fas cell surface death receptor	Homo sapiens	56-60
10918593-3	2000	The tumoricidal effect of TRAIL was further enhanced by CHX, suggesting the presence of CHX-sensitive inhibitor(s) of apoptosis in these thyroid cancer cell lines.	Cycloheximide	56-59	TNF superfamily member 10	Homo sapiens	26-31
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Cycloheximide	84-97	interleukin 6	Homo sapiens	11-15
10873159-7	2000	Release of IL-6 elicited by TNF-alpha was significantly inhibited by dexamethasone, cycloheximide, and nordihydroguaiaretic acid (NDGA).	Cycloheximide	84-97	tumor necrosis factor	Homo sapiens	28-37
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	54-67	interferon gamma	Mus musculus	161-164
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	54-67	interferon gamma	Mus musculus	168-171
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	54-67	tumor necrosis factor	Mus musculus	174-177
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	54-67	tumor necrosis factor	Mus musculus	261-264
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	69-71	interferon gamma	Mus musculus	161-164
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	69-71	interferon gamma	Mus musculus	168-171
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	69-71	tumor necrosis factor	Mus musculus	174-177
10859241-9	2000	CL cells treated with the protein synthesis inhibitor cycloheximide (CX) were killed by Fas mAb in the absence of cytokine pretreatment (34%); pretreatment with IFN or IFN + TNF further potentiated killing (62% and 96%, respectively), whereas pretreatment with TNF had no effect (42%).	Cycloheximide	69-71	tumor necrosis factor	Mus musculus	261-264
10989280-0	2000	Cycloheximide-induced cPLA(2) activation is via the MKP-1 down-regulation and ERK activation.	Cycloheximide	0-13	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	22-29
10989280-0	2000	Cycloheximide-induced cPLA(2) activation is via the MKP-1 down-regulation and ERK activation.	Cycloheximide	0-13	dual specificity phosphatase 1	Mus musculus	52-57
10989280-0	2000	Cycloheximide-induced cPLA(2) activation is via the MKP-1 down-regulation and ERK activation.	Cycloheximide	0-13	mitogen-activated protein kinase 1	Mus musculus	78-81
10989280-2	2000	In this study, we found that the protein synthesis inhibitor cycloheximide can potentiate thapsigargin-induced arachidonic acid (AA) release concomitant with ERK phosphorylation from murine RAW 264.7 macrophages.	Cycloheximide	61-74	mitogen-activated protein kinase 1	Mus musculus	158-161
10989280-4	2000	Cycloheximide effect is additive to the tyrosine phosphatase inhibitor orthovanadate since these two stimuli induced sustained ERK activation respectively through inhibition of the translation and activity of MAPK phosphatase-1 (MKP-1).	Cycloheximide	0-13	dual specificity phosphatase 1	Mus musculus	209-227
10989280-4	2000	Cycloheximide effect is additive to the tyrosine phosphatase inhibitor orthovanadate since these two stimuli induced sustained ERK activation respectively through inhibition of the translation and activity of MAPK phosphatase-1 (MKP-1).	Cycloheximide	0-13	dual specificity phosphatase 1	Mus musculus	229-234
10866818-7	2000	The induction of TIMP-1 mRNA by ATRA and bFGF was greatly diminished by cycloheximide and therefore required new protein synthesis.	Cycloheximide	72-85	TIMP metallopeptidase inhibitor 1	Homo sapiens	17-23
10866818-7	2000	The induction of TIMP-1 mRNA by ATRA and bFGF was greatly diminished by cycloheximide and therefore required new protein synthesis.	Cycloheximide	72-85	fibroblast growth factor 2	Homo sapiens	41-45
10873576-3	2000	TNF-alpha-resistant NCI-H157 cells became sensitized to TNF-alpha by prior treatment with cycloheximide, suggesting the presence of newly synthesized antiapoptotic protein(s).	Cycloheximide	90-103	tumor necrosis factor	Homo sapiens	0-9
10901171-5	2000	Cycloheximide (CHX) increased c-fos and c-jun mRNA levels.	Cycloheximide	0-13	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-35
10901171-5	2000	Cycloheximide (CHX) increased c-fos and c-jun mRNA levels.	Cycloheximide	15-18	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-35
10901171-6	2000	CHX caused a super-induction of CTX-induced c-fos mRNA level.	Cycloheximide	0-3	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	44-49
10816606-7	2000	Inhibition of the de novo synthesis of NF-IL-6 by cycloheximide or an antisense oligonucleotide reduced the enhancement of NF-IL-6 binding to the CAAT box and inhibited stimulation of IL-6 transcription by forskolin.	Cycloheximide	50-63	CCAAT enhancer binding protein beta	Homo sapiens	39-46
10816606-7	2000	Inhibition of the de novo synthesis of NF-IL-6 by cycloheximide or an antisense oligonucleotide reduced the enhancement of NF-IL-6 binding to the CAAT box and inhibited stimulation of IL-6 transcription by forskolin.	Cycloheximide	50-63	CCAAT enhancer binding protein beta	Homo sapiens	123-130
10816606-7	2000	Inhibition of the de novo synthesis of NF-IL-6 by cycloheximide or an antisense oligonucleotide reduced the enhancement of NF-IL-6 binding to the CAAT box and inhibited stimulation of IL-6 transcription by forskolin.	Cycloheximide	50-63	interleukin 6	Homo sapiens	42-46
10873576-3	2000	TNF-alpha-resistant NCI-H157 cells became sensitized to TNF-alpha by prior treatment with cycloheximide, suggesting the presence of newly synthesized antiapoptotic protein(s).	Cycloheximide	90-103	tumor necrosis factor	Homo sapiens	56-65
10925144-5	2000	In cell extracts, the concentration of immunoreactive VIP was elevated four-fold upon PACAP stimulation for 8 h, and it remained elevated during the next 40 h. In conditioned medium, a stable 20-fold VIP increase was seen after 8-24 h. Experiments with the translational inhibitor cycloheximide showed a direct effect of PACAP on the VIP mRNA level, and nuclear run-on assays revealed a three- to four-fold enhancement of the VIP gene transcription rate after PACAP stimulation.	Cycloheximide	281-294	vasoactive intestinal peptide	Homo sapiens	54-57
10764744-1	2000	The sensitivity of HepG2 cells overexpressing catalase in either the cytosolic or mitochondrial compartment to tumor necrosis factor-alpha (TNF-alpha) and cycloheximide was studied.	Cycloheximide	155-168	catalase	Homo sapiens	46-54
10764744-8	2000	TNF-alpha plus cycloheximide increased ATP levels, with higher levels in C33 and mC5 cells compared with Hp cells.	Cycloheximide	15-28	hemolytic complement	Mus musculus	81-84
10871865-4	2000	We observe that p27KIP1 is down-regulated following exposure to a variety of apoptotic stimuli including an agonistic anti-Fas antibody, cycloheximide and etoposide.	Cycloheximide	137-150	cyclin dependent kinase inhibitor 1B	Homo sapiens	16-23
10854851-3	2000	On the other hand, the effect of TSH on the abundance of ERp29 mRNA started within 6 h and peaked at 8 h. Actinomycin D strongly blocked this effect while cycloheximide did not.	Cycloheximide	155-168	endoplasmic reticulum protein 29	Rattus norvegicus	57-62
10871865-7	2000	In contrast, the loss of p27KIP1 in cells exposed to cycloheximide and etoposide occurs in the absence of caspase-8 or any Z-VAD-fmk- or Boc-D-fmk-sensitive caspase activities.	Cycloheximide	53-66	cyclin dependent kinase inhibitor 1B	Homo sapiens	25-32
10777716-4	2000	Products of the two COL5A1 alleles were approximately equal after the addition of cycloheximide to the fibroblast cultures.	Cycloheximide	82-95	collagen type V alpha 1 chain	Homo sapiens	20-26
10844120-5	2000	Cycloheximide prevented interleukin-1 beta-mediated increases in B(1) and B(2) binding, but not mRNA suggesting that de novo synthesis of a transcriptional activator was unnecessary.	Cycloheximide	0-13	interleukin 1 beta	Homo sapiens	24-42
10835336-9	2000	Cycloheximide pretreatment suggested that hypoxia-induced downregulation of IL-1beta expression did not require de novo protein synthesis.	Cycloheximide	0-13	interleukin 1 beta	Mus musculus	76-84
10843740-6	2000	LPS-induced TNF-alpha production from alveolar epithelial cells was blocked not only by cycloheximide, an inhibitor of protein translation, but also by actinomycin D, an inhibitor of gene transcription.	Cycloheximide	88-101	tumor necrosis factor	Rattus norvegicus	12-21
10822279-4	2000	Here, we show that BID is cleaved in response to multiple death-inducing stimuli (staurosporine, UV radiation, cycloheximide, etoposide).	Cycloheximide	111-124	BH3 interacting domain death agonist	Homo sapiens	19-22
10864887-10	2000	Activation of caspase 3-like activity by flurbiprofen was slow (&gt;6 h incubation needed) and was inhibited by cycloheximide.	Cycloheximide	112-125	caspase-3	Cavia porcellus	14-23
10942104-6	2000	Inhibition of the nonsense-mediated decay mechanism by cycloheximide resulted in the stabilization of mutant elastin mRNA.	Cycloheximide	55-68	elastin	Homo sapiens	109-116
11180837-5	2000	Since activation is also observed in activin A treated animal cap explants in the presence of cycloheximide, XFD-4/4" genes represent direct targets of activin signaling.	Cycloheximide	94-107	inhibin subunit beta A L homeolog	Xenopus laevis	37-46
11180837-5	2000	Since activation is also observed in activin A treated animal cap explants in the presence of cycloheximide, XFD-4/4" genes represent direct targets of activin signaling.	Cycloheximide	94-107	forkhead box C2 L homeolog	Xenopus laevis	109-114
10835036-9	2000	PAR-1 resensitisation occurs via new PAR-1 synthesis since resensitisation was inhibited by cycloheximide and brefeldin A.	Cycloheximide	92-105	coagulation factor II (thrombin) receptor	Rattus norvegicus	37-42
10825388-0	2000	Cycloheximide increases proenkephalin and tyrosine hydroxylase gene expression in rat adrenal medulla.	Cycloheximide	0-13	tyrosine hydroxylase	Rattus norvegicus	42-62
10835036-9	2000	PAR-1 resensitisation occurs via new PAR-1 synthesis since resensitisation was inhibited by cycloheximide and brefeldin A.	Cycloheximide	92-105	coagulation factor II (thrombin) receptor	Rattus norvegicus	0-5
10825388-1	2000	The effect of cycloheximide (CHX; 5 mg/kg) on proenkephalin (proENK) and tyrosine hydroxylase (TH) mRNA expression in rat central and peripheral nervous systems was studied.	Cycloheximide	29-32	tyrosine hydroxylase	Rattus norvegicus	73-93
10825388-1	2000	The effect of cycloheximide (CHX; 5 mg/kg) on proenkephalin (proENK) and tyrosine hydroxylase (TH) mRNA expression in rat central and peripheral nervous systems was studied.	Cycloheximide	29-32	tyrosine hydroxylase	Rattus norvegicus	95-97
11032754-5	2000	The GPHalpha gene could be induced by NaBtr in the JEG-3 parent only when they were simultaneously treated with cycloheximide (CHX).	Cycloheximide	112-125	glycoprotein hormones, alpha polypeptide	Homo sapiens	4-12
10882039-6	2000	Inhibition of COX-2 induction by dexamethasone was abrogated by cycloheximide, an inhibitor of translation, indicating dependence on de novo protein synthesis.	Cycloheximide	64-77	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	14-19
11032754-5	2000	The GPHalpha gene could be induced by NaBtr in the JEG-3 parent only when they were simultaneously treated with cycloheximide (CHX).	Cycloheximide	127-130	glycoprotein hormones, alpha polypeptide	Homo sapiens	4-12
10896254-7	2000	Cycloheximide treatment of HUVEC slightly inhibited the IL-1alpha-induced expression of VEGF mRNA, and IL-1alpha may mediate, at least in part, VEGF expression in response to IL-1alpha.	Cycloheximide	0-13	interleukin 1 alpha	Homo sapiens	56-65
10896254-7	2000	Cycloheximide treatment of HUVEC slightly inhibited the IL-1alpha-induced expression of VEGF mRNA, and IL-1alpha may mediate, at least in part, VEGF expression in response to IL-1alpha.	Cycloheximide	0-13	vascular endothelial growth factor A	Homo sapiens	88-92
10896254-7	2000	Cycloheximide treatment of HUVEC slightly inhibited the IL-1alpha-induced expression of VEGF mRNA, and IL-1alpha may mediate, at least in part, VEGF expression in response to IL-1alpha.	Cycloheximide	0-13	vascular endothelial growth factor A	Homo sapiens	144-148
10788444-3	2000	Treatment with TNFalpha and cycloheximide (TNFalpha/CHX) induced mitochondrial cytochrome c release, increased the steady-state reduction of cytochrome b, and decreased the steady-state reduction of cytochromes cc(1) and aa(3).	Cycloheximide	28-41	tumor necrosis factor	Mus musculus	43-51
10748050-7	2000	Recovery of receptor expression was inhibited by cycloheximide, indicating that augmented VEGF receptor mRNAs, and not receptor recycling from a cytoplasmic pool, restored responsiveness.	Cycloheximide	49-62	vascular endothelial growth factor A	Homo sapiens	90-94
10801327-2	2000	The extent to which insulin induces this response is potentiated by cycloheximide and blocked by pretreatment with rapamycin.	Cycloheximide	68-81	Insulin-like receptor	Drosophila melanogaster	20-27
10844602-8	2000	The inhibitors of gene transcription (actinomycin D) and of protein synthesis (cycloheximide) did not affect the short-term effect of CORTI on NHE activity, but inhibited the long-term effect of CORTI on NHE activity.	Cycloheximide	79-92	solute carrier family 9 member A1	Rattus norvegicus	204-207
10809776-5	2000	Estrogen-activated prolactin gene expression was also inhibited by cycloheximide, suggesting that some form of protein synthesis is involved in ER.Pit-1 complex formation and subsequent prolactin gene activation.	Cycloheximide	67-80	prolactin	Rattus norvegicus	19-28
10809776-5	2000	Estrogen-activated prolactin gene expression was also inhibited by cycloheximide, suggesting that some form of protein synthesis is involved in ER.Pit-1 complex formation and subsequent prolactin gene activation.	Cycloheximide	67-80	POU class 1 homeobox 1	Rattus norvegicus	147-152
10809776-5	2000	Estrogen-activated prolactin gene expression was also inhibited by cycloheximide, suggesting that some form of protein synthesis is involved in ER.Pit-1 complex formation and subsequent prolactin gene activation.	Cycloheximide	67-80	prolactin	Rattus norvegicus	186-195
10788444-3	2000	Treatment with TNFalpha and cycloheximide (TNFalpha/CHX) induced mitochondrial cytochrome c release, increased the steady-state reduction of cytochrome b, and decreased the steady-state reduction of cytochromes cc(1) and aa(3).	Cycloheximide	28-41	cytochrome b, mitochondrial	Mus musculus	141-153
10794675-3	2000	Previously we have shown that postinduction normalization of SMIT mRNA levels and myo-inositol accumulation following removal of hyperosmotic stress is inhibited by actinomycin D and cycloheximide, suggesting that normalization requires RNA transcription and protein synthesis.	Cycloheximide	183-196	solute carrier family 5 member 3	Homo sapiens	61-65
10814841-7	2000	Induction of hMTH-1 gene expression was prevented by addition of actinomycin D and cycloheximide.	Cycloheximide	83-96	nudix hydrolase 1	Homo sapiens	13-19
10812056-6	2000	Transcriptional and translational inhibitors such as actinomycin D, cycloheximide, and dexamethasone also suppressed the interleukin-1beta-induced prostaglandin E(2) release and the bradykinin-induced prostaglandin E(2) release in interleukin-1beta-pretreated human gingival fibroblasts.	Cycloheximide	68-81	interleukin 1 beta	Homo sapiens	121-138
10812056-6	2000	Transcriptional and translational inhibitors such as actinomycin D, cycloheximide, and dexamethasone also suppressed the interleukin-1beta-induced prostaglandin E(2) release and the bradykinin-induced prostaglandin E(2) release in interleukin-1beta-pretreated human gingival fibroblasts.	Cycloheximide	68-81	kininogen 1	Homo sapiens	182-192
10812056-6	2000	Transcriptional and translational inhibitors such as actinomycin D, cycloheximide, and dexamethasone also suppressed the interleukin-1beta-induced prostaglandin E(2) release and the bradykinin-induced prostaglandin E(2) release in interleukin-1beta-pretreated human gingival fibroblasts.	Cycloheximide	68-81	interleukin 1 beta	Homo sapiens	231-248
10704940-9	2000	It was also found that cycloheximide reversed the growth inhibition induced by panaxydol and partially abrogated the increase in p27(KIP1) expression.	Cycloheximide	23-36	interferon alpha inducible protein 27	Homo sapiens	129-132
10704940-9	2000	It was also found that cycloheximide reversed the growth inhibition induced by panaxydol and partially abrogated the increase in p27(KIP1) expression.	Cycloheximide	23-36	cyclin dependent kinase inhibitor 1B	Homo sapiens	133-137
10872747-13	2000	The increase in HO-1 mRNA was inhibited by actinomycin D and cycloheximide, but not by NAC, and was not mimicked by the lipophilic cGMP analogue, 8-bromo-cGMP, suggesting that NO-mediated induction required de novo RNA and protein synthesis and was unrelated to cGMP and redox signaling.	Cycloheximide	61-74	heme oxygenase 1	Homo sapiens	16-20
10811114-3	2000	Treatment of PC-3 and DU145 cells with TRAIL caused a rapid apoptotic cell death, whereas tumor necrosis factor-alpha (TNF-alpha) is ineffective unless in the presence of the protein synthesis inhibitor cycloheximide.	Cycloheximide	203-216	TNF superfamily member 10	Homo sapiens	39-44
10797535-10	2000	Cycloheximide had a dual action on PPARgamma expression in RPE cells: it enhanced expression under basal conditions but repressed expression induced by ROS phagocytosis.	Cycloheximide	0-13	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	35-44
10937621-8	2000	Treatment of the cells with camptothecin or tumor necrosis factor-alpha plus cycloheximide significantly inhibited COL2A1 transcriptional activity.	Cycloheximide	77-90	collagen type II alpha 1 chain	Homo sapiens	115-121
10867506-2	2000	The IL-5-induced prolongation of eosinophil survival was dose-dependently inhibited by the protein synthesis inhibitor cycloheximide, the DNA-dependent RNA synthesis inhibitor actinomycin D, and the tyrosine kinase inhibitor herbimycin A.	Cycloheximide	119-132	interleukin 5	Rattus norvegicus	4-8
10787437-1	2000	Transcription of the LDL receptor gene is markedly enhanced in the Jurkat T cell line by stimulation with the combination of the phorbol ester phorbol 12-myristate 13-acetate (PMA) and the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	217-230	low density lipoprotein receptor	Homo sapiens	21-33
10787437-1	2000	Transcription of the LDL receptor gene is markedly enhanced in the Jurkat T cell line by stimulation with the combination of the phorbol ester phorbol 12-myristate 13-acetate (PMA) and the protein synthesis inhibitor cycloheximide (CHX).	Cycloheximide	232-235	low density lipoprotein receptor	Homo sapiens	21-33
10737967-6	2000	Consistent with this, immunoblot analysis revealed that CENP-E level remained high during meiosis I/meiosis II (MI/MII) transition and that some of CENP-E survived through the transition even in cycloheximide-treated oocytes in which cyclin B1 was completely degraded.	Cycloheximide	195-208	centromere protein E	Sus scrofa	56-62
10737967-6	2000	Consistent with this, immunoblot analysis revealed that CENP-E level remained high during meiosis I/meiosis II (MI/MII) transition and that some of CENP-E survived through the transition even in cycloheximide-treated oocytes in which cyclin B1 was completely degraded.	Cycloheximide	195-208	centromere protein E	Sus scrofa	148-154
10737967-6	2000	Consistent with this, immunoblot analysis revealed that CENP-E level remained high during meiosis I/meiosis II (MI/MII) transition and that some of CENP-E survived through the transition even in cycloheximide-treated oocytes in which cyclin B1 was completely degraded.	Cycloheximide	195-208	cyclin B1	Sus scrofa	234-243
10757810-6	2000	In at least five cases, the TGF-beta-induced upregulation was found to be cycloheximide resistant, suggesting the roles of the genes in the TGF-beta-induced primary responses.	Cycloheximide	74-87	transforming growth factor beta 1	Homo sapiens	28-36
10757810-6	2000	In at least five cases, the TGF-beta-induced upregulation was found to be cycloheximide resistant, suggesting the roles of the genes in the TGF-beta-induced primary responses.	Cycloheximide	74-87	transforming growth factor beta 1	Homo sapiens	140-148
10928547-10	2000	However, when catalase was inactivated by the application of 3-amino-1,2,4-triazole or depleted by prolonged exposure to cycloheximide a strong photoinactivation of glycolate oxidase was also seen in leaves.	Cycloheximide	121-134	hydroxyacid oxidase 2	Homo sapiens	165-182
10857586-7	2000	After 4 h, 43% of the oocytes were activated, and the percentage increased to 97% after 6 h. Pig cyclin B1 disappeared in the oocytes at 6 h after insemination in both cycloheximide-containing and cycloheximide-free media.	Cycloheximide	168-181	cyclin B1	Sus scrofa	97-106
10857586-7	2000	After 4 h, 43% of the oocytes were activated, and the percentage increased to 97% after 6 h. Pig cyclin B1 disappeared in the oocytes at 6 h after insemination in both cycloheximide-containing and cycloheximide-free media.	Cycloheximide	197-210	cyclin B1	Sus scrofa	97-106
10830777-5	2000	Interestingly, cycloheximide prevented C2-ceramide-induced DNA fragmentation, indicating that ceramide-induced apoptosis in PC3 and DU145 requires new protein synthesis.	Cycloheximide	15-28	proprotein convertase subtilisin/kexin type 1	Homo sapiens	124-127
10777545-8	2000	Cycloheximide, which activates SAPK, while inhibiting protein synthesis, stabilized endogenous ATF2.	Cycloheximide	0-13	mitogen-activated protein kinase 9	Homo sapiens	31-35
10857586-9	2000	At 8 h after insemination ERK 2 changed to the fast-migrating inactive form in the oocytes cultured in both cycloheximide-containing and cycloheximide-free media, although the shift-down was not complete.	Cycloheximide	108-121	mitogen-activated protein kinase 1	Sus scrofa	26-31
10857586-9	2000	At 8 h after insemination ERK 2 changed to the fast-migrating inactive form in the oocytes cultured in both cycloheximide-containing and cycloheximide-free media, although the shift-down was not complete.	Cycloheximide	137-150	mitogen-activated protein kinase 1	Sus scrofa	26-31
10777545-8	2000	Cycloheximide, which activates SAPK, while inhibiting protein synthesis, stabilized endogenous ATF2.	Cycloheximide	0-13	activating transcription factor 2	Homo sapiens	95-99
10777545-9	2000	However, treatment of cells with the high dose of SB203580, which inhibits JNK and p38 kinase, resulted in efficient degradation of ATF2 in cells exposed to cycloheximide.	Cycloheximide	157-170	mitogen-activated protein kinase 9	Homo sapiens	75-78
10777545-9	2000	However, treatment of cells with the high dose of SB203580, which inhibits JNK and p38 kinase, resulted in efficient degradation of ATF2 in cells exposed to cycloheximide.	Cycloheximide	157-170	mitogen-activated protein kinase 14	Homo sapiens	83-86
10777561-8	2000	Furthermore, cycloheximide is shown to increase the accumulation of the TCDD-activated AhR and the functional AhR x Arnt complex in nucleus.	Cycloheximide	13-26	aryl hydrocarbon receptor	Homo sapiens	87-90
10777545-9	2000	However, treatment of cells with the high dose of SB203580, which inhibits JNK and p38 kinase, resulted in efficient degradation of ATF2 in cells exposed to cycloheximide.	Cycloheximide	157-170	activating transcription factor 2	Homo sapiens	132-136
10777561-1	2000	Regulation of 2,3,7, 8-tetrachlorodibenzo-p-dioxin-induced degradation of Ah receptor by cycloheximide.	Cycloheximide	89-102	aryl hydrocarbon receptor	Homo sapiens	74-85
10777561-2	2000	Cycloheximide superinduces the transcription of CYP1A1 in the presence of an agonist for the Ah receptor (AhR).	Cycloheximide	0-13	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	48-54
10777561-2	2000	Cycloheximide superinduces the transcription of CYP1A1 in the presence of an agonist for the Ah receptor (AhR).	Cycloheximide	0-13	aryl hydrocarbon receptor	Homo sapiens	93-104
10777561-2	2000	Cycloheximide superinduces the transcription of CYP1A1 in the presence of an agonist for the Ah receptor (AhR).	Cycloheximide	0-13	aryl hydrocarbon receptor	Homo sapiens	106-109
10777561-4	2000	Whereas 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of AhR, induces a rapid reduction of the AhR protein, cycloheximide blocks the down-regulation of steady state AhR.	Cycloheximide	124-137	aryl hydrocarbon receptor	Homo sapiens	73-76
10777561-8	2000	Furthermore, cycloheximide is shown to increase the accumulation of the TCDD-activated AhR and the functional AhR x Arnt complex in nucleus.	Cycloheximide	13-26	aryl hydrocarbon receptor	Homo sapiens	110-113
10777561-4	2000	Whereas 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of AhR, induces a rapid reduction of the AhR protein, cycloheximide blocks the down-regulation of steady state AhR.	Cycloheximide	124-137	aryl hydrocarbon receptor	Homo sapiens	111-114
10777561-9	2000	Collectively, our results reveal a mechanism of superinduction by cycloheximide by enhancing the stability of agonist-activated AhR.	Cycloheximide	66-79	aryl hydrocarbon receptor	Homo sapiens	128-131
10777561-4	2000	Whereas 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of AhR, induces a rapid reduction of the AhR protein, cycloheximide blocks the down-regulation of steady state AhR.	Cycloheximide	124-137	aryl hydrocarbon receptor	Homo sapiens	111-114
10777561-10	2000	The finding that inhibition of protein synthesis blocks the TCDD-induced AhR turnover implicates a cycloheximide-sensitive, labile factor (designated as AhR degradation promoting factor, or ADPF) in controlling the removal of agonist-activated AhR in nucleus.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	73-76
10777561-5	2000	Analyses of the turnover of AhR reveal that cycloheximide blocks the shortening of the half-life of AhR by TCDD.	Cycloheximide	44-57	aryl hydrocarbon receptor	Homo sapiens	28-31
10777561-10	2000	The finding that inhibition of protein synthesis blocks the TCDD-induced AhR turnover implicates a cycloheximide-sensitive, labile factor (designated as AhR degradation promoting factor, or ADPF) in controlling the removal of agonist-activated AhR in nucleus.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	153-156
10777561-5	2000	Analyses of the turnover of AhR reveal that cycloheximide blocks the shortening of the half-life of AhR by TCDD.	Cycloheximide	44-57	aryl hydrocarbon receptor	Homo sapiens	100-103
10777561-6	2000	Blocking of the TCDD-induced AhR degradation requires inhibition of protein synthesis, because (a) cycloheximide inhibits protein synthesis at the concentration at which it causes superinduction and inhibition of AhR degradation; and (b) puromycin, an inhibitor of protein synthesis by mimicking aminoacyl-tRNA, also blocks the TCDD-induced AhR degradation.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	29-32
10777561-10	2000	The finding that inhibition of protein synthesis blocks the TCDD-induced AhR turnover implicates a cycloheximide-sensitive, labile factor (designated as AhR degradation promoting factor, or ADPF) in controlling the removal of agonist-activated AhR in nucleus.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	153-156
10777561-6	2000	Blocking of the TCDD-induced AhR degradation requires inhibition of protein synthesis, because (a) cycloheximide inhibits protein synthesis at the concentration at which it causes superinduction and inhibition of AhR degradation; and (b) puromycin, an inhibitor of protein synthesis by mimicking aminoacyl-tRNA, also blocks the TCDD-induced AhR degradation.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	213-216
10822373-5	2000	This inhibitory effect of IL-1beta was evident when cells were treated with protein synthesis inhibitors such as cycloheximide (CHX).	Cycloheximide	113-126	interleukin 1 beta	Homo sapiens	26-34
10834301-5	2000	Co-treatment of cycloheximide (10(-5) M), a protein synthesis inhibitor, or actinomycin D (10(-7) M), an RNA synthesis inhibitor with LPS inhibited the development of relaxing ability in response to L-arginine, indicating iNOS induction by LPS.	Cycloheximide	16-29	nitric oxide synthase 2	Rattus norvegicus	222-226
10822373-5	2000	This inhibitory effect of IL-1beta was evident when cells were treated with protein synthesis inhibitors such as cycloheximide (CHX).	Cycloheximide	128-131	interleukin 1 beta	Homo sapiens	26-34
10777561-6	2000	Blocking of the TCDD-induced AhR degradation requires inhibition of protein synthesis, because (a) cycloheximide inhibits protein synthesis at the concentration at which it causes superinduction and inhibition of AhR degradation; and (b) puromycin, an inhibitor of protein synthesis by mimicking aminoacyl-tRNA, also blocks the TCDD-induced AhR degradation.	Cycloheximide	99-112	aryl hydrocarbon receptor	Homo sapiens	213-216
10781822-5	2000	Treatment of PC12 cells with actinomycin D or cycloheximide completely abolishes the NGF-induced elevation of SM.	Cycloheximide	46-59	nerve growth factor	Rattus norvegicus	85-88
10749718-5	2000	Surprisingly, inhibition of E-selectin expression with the general protein synthesis inhibitor cycloheximide induced P-selectin expression 4 h after thrombin stimulation.	Cycloheximide	95-108	selectin E	Homo sapiens	28-38
11232241-6	2000	One pathway induced by H-7, actinomycin D or cycloheximide is calmodulin-dependent (pathway H), and another induced by A23187 is calmodulin-independent (pathway A).	Cycloheximide	45-58	Calmodulin	Drosophila melanogaster	62-72
10749718-5	2000	Surprisingly, inhibition of E-selectin expression with the general protein synthesis inhibitor cycloheximide induced P-selectin expression 4 h after thrombin stimulation.	Cycloheximide	95-108	selectin P	Homo sapiens	117-127
10749718-5	2000	Surprisingly, inhibition of E-selectin expression with the general protein synthesis inhibitor cycloheximide induced P-selectin expression 4 h after thrombin stimulation.	Cycloheximide	95-108	coagulation factor II, thrombin	Homo sapiens	149-157
10749718-6	2000	Cycloheximide and thrombin (4 h) induced sufficient P-selectin-dependent rolling to recruit as many neutrophils as were recruited with 4 h of stimulation with thrombin alone.	Cycloheximide	0-13	selectin P	Homo sapiens	52-62
10749718-6	2000	Cycloheximide and thrombin (4 h) induced sufficient P-selectin-dependent rolling to recruit as many neutrophils as were recruited with 4 h of stimulation with thrombin alone.	Cycloheximide	0-13	coagulation factor II, thrombin	Homo sapiens	159-167
10749718-8	2000	Treatment of endothelium with tumor necrosis factor-alpha (an E-selectin inducer) and cycloheximide also eliminated E-selectin expression but, much like thrombin, induced P-selectin expression and neutrophil recruitment.	Cycloheximide	86-99	selectin E	Homo sapiens	116-126
10749718-8	2000	Treatment of endothelium with tumor necrosis factor-alpha (an E-selectin inducer) and cycloheximide also eliminated E-selectin expression but, much like thrombin, induced P-selectin expression and neutrophil recruitment.	Cycloheximide	86-99	coagulation factor II, thrombin	Homo sapiens	153-161
10749718-8	2000	Treatment of endothelium with tumor necrosis factor-alpha (an E-selectin inducer) and cycloheximide also eliminated E-selectin expression but, much like thrombin, induced P-selectin expression and neutrophil recruitment.	Cycloheximide	86-99	selectin P	Homo sapiens	171-181
10792504-5	2000	The PMA-induced MCP-3 mRNA increase was almost abrogated when cells were pretreated with cycloheximide (CHX).	Cycloheximide	89-102	C-C motif chemokine ligand 7	Homo sapiens	16-21
10792504-5	2000	The PMA-induced MCP-3 mRNA increase was almost abrogated when cells were pretreated with cycloheximide (CHX).	Cycloheximide	104-107	C-C motif chemokine ligand 7	Homo sapiens	16-21
10727516-6	2000	Induction of AR mRNA by SNAP was completely abolished by actinomycin D or cycloheximide, but unaffected by guanylate cyclase inhibitors or genistein, a tyrosine kinase inhibitor.	Cycloheximide	74-87	aldo-keto reductase family 1 member B1	Rattus norvegicus	13-15
10792507-10	2000	The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA.	Cycloheximide	55-68	interferon gamma	Homo sapiens	14-23
10792507-10	2000	The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA.	Cycloheximide	55-68	C-C motif chemokine ligand 5	Homo sapiens	27-33
10792507-10	2000	The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA.	Cycloheximide	55-68	interferon gamma	Homo sapiens	86-95
10792507-10	2000	The effect of IFN-gamma on RANTES mRNA was reversed by cycloheximide, suggesting that IFN-gamma may act by increasing the rate of translation of RANTES mRNA.	Cycloheximide	55-68	C-C motif chemokine ligand 5	Homo sapiens	145-151
10938866-4	2000	Cycloheximide-treatment strongly reduced the enhancement of beta-amylase activity.	Cycloheximide	0-13	beta-amylase	Cucumis sativus	60-72
10725732-4	2000	NF-kappa B activation was rapid and was not inhibited by a protein synthesis inhibitor cycloheximide, suggesting that these bacteria could directly activate NF-kappa B.	Cycloheximide	87-100	nuclear factor kappa B subunit 1	Homo sapiens	0-10
10725732-7	2000	STAT1 and STAT3 activation and ISGF3 complex formation were inhibited by cycloheximide or by neutralization with IFN-alpha/beta-specific Abs.	Cycloheximide	73-86	signal transducer and activator of transcription 1	Homo sapiens	0-5
10725732-7	2000	STAT1 and STAT3 activation and ISGF3 complex formation were inhibited by cycloheximide or by neutralization with IFN-alpha/beta-specific Abs.	Cycloheximide	73-86	signal transducer and activator of transcription 3	Homo sapiens	10-15
10725732-7	2000	STAT1 and STAT3 activation and ISGF3 complex formation were inhibited by cycloheximide or by neutralization with IFN-alpha/beta-specific Abs.	Cycloheximide	73-86	signal transducer and activator of transcription 1	Homo sapiens	31-36
10762717-4	2000	As well as AP-1 proteins and their DNA-binding activities, proENK mRNA level induced by AA was reduced by the pretreatment with 15 microM of cycloheximide (CHX; 1.6-fold).	Cycloheximide	141-154	proenkephalin	Homo sapiens	59-65
10762717-4	2000	As well as AP-1 proteins and their DNA-binding activities, proENK mRNA level induced by AA was reduced by the pretreatment with 15 microM of cycloheximide (CHX; 1.6-fold).	Cycloheximide	156-159	proenkephalin	Homo sapiens	59-65
10722850-3	2000	An erg4 mutant strain exhibited pleiotropic defects such as hypersensitivity to divalent cations and a number of drugs such as cycloheximide, miconazole, 4-nitroquinoline, fluconazole, and sodium dodecyl sulfate.	Cycloheximide	127-140	delta(24(24(1)))-sterol reductase	Saccharomyces cerevisiae S288C	3-7
10713678-7	2000	We show that induction of terminal differentiation of HO-1 cells with IFN-beta+MEZ dramatically increases the half-life of mda-7 mRNA while treatment with cycloheximide results in detectable mda-7 mRNA in control and inducer treated cells.	Cycloheximide	155-168	interleukin 24	Homo sapiens	191-196
10761935-5	2000	Mice strains deficient in their ability to detect cycloheximide have amino acid substitutions in the mT2R-5 gene; these changes render the receptor significantly less responsive to cycloheximide.	Cycloheximide	50-63	taste receptor, type 2, member 105	Mus musculus	101-107
10761935-5	2000	Mice strains deficient in their ability to detect cycloheximide have amino acid substitutions in the mT2R-5 gene; these changes render the receptor significantly less responsive to cycloheximide.	Cycloheximide	181-194	taste receptor, type 2, member 105	Mus musculus	101-107
10692470-7	2000	However, G492S GLAST exhibited a marked decrease in activity after the addition of cycloheximide, while the wild type showed no significant change, indicating that G492S GLAST was unstable compared with the wild-type transporter.	Cycloheximide	83-96	solute carrier family 1 member 3	Canis lupus familiaris	15-20
10692470-7	2000	However, G492S GLAST exhibited a marked decrease in activity after the addition of cycloheximide, while the wild type showed no significant change, indicating that G492S GLAST was unstable compared with the wild-type transporter.	Cycloheximide	83-96	solute carrier family 1 member 3	Canis lupus familiaris	170-175
10722866-2	2000	Treatment of confluent L929 cells with cAMP analogues -dibutyryl-cAMP (db-cAMP) or 8-Cl-cAMP caused dose-dependent augmentation of inducible NO synthase (iNOS)-mediated NO production, which has been abrogated by inhibition of protein synthesis with cycloheximide or addition of selective iNOS inhibitor aminoguanidine.	Cycloheximide	249-262	nitric oxide synthase 2, inducible	Mus musculus	154-158
10705380-7	2000	We also show that zygotically activated Xretpos transcripts are restricted to ventro-posterior specific regions and induced by UV-irradiation and BMP-4 overexpression in cycloheximide-dependent way.	Cycloheximide	170-183	bone morphogenetic protein 4 L homeolog	Xenopus laevis	146-151
10722866-2	2000	Treatment of confluent L929 cells with cAMP analogues -dibutyryl-cAMP (db-cAMP) or 8-Cl-cAMP caused dose-dependent augmentation of inducible NO synthase (iNOS)-mediated NO production, which has been abrogated by inhibition of protein synthesis with cycloheximide or addition of selective iNOS inhibitor aminoguanidine.	Cycloheximide	249-262	nitric oxide synthase 2, inducible	Mus musculus	131-152
10819297-4	2000	The effect of CGA, but not of CPB, GE and TTB, was abolished by cycloheximide.	Cycloheximide	64-77	chromogranin A	Bos taurus	14-17